PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	FitzGerald, MJ; Arsura, M; Bellas, RE; Yang, W; Wu, M; Chin, L; Mann, KK; DePinho, RA; Sonenshein, GE				FitzGerald, MJ; Arsura, M; Bellas, RE; Yang, W; Wu, M; Chin, L; Mann, KK; DePinho, RA; Sonenshein, GE			Differential effects of the widely expressed dMax splice variant of Max on E-box vs initiator element-mediated regulation by c-Myc	ONCOGENE			English	Article						Max; Myc; Mad/Mxi; apoptosis; proliferation	HELIX-LOOP-HELIX; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; NEOPLASTIC TRANSFORMATION; GROWTH-FACTOR; CELL-GROWTH; B-CELLS; S-PHASE; HLA-A	dMax, a naturally occurring splice variant of the Myc binding protein Mas, lacks the DNA binding basic region and helix 1 of the Helix-Loop-Helix domain; dMax interacts with c-Myc in vitro and in vivo, and inhibits E-bos Myc site driven transcription in transient transfection assays, Here we have investigated the expression, function and interactions of dMax, RT/PCR analyses detected dmax mRNA in multiple tissues of the developing, newborn and adult mouse. Functionally, dMax reduced the ability of c-Myc to cooperate,vith the progression factor A-Myb to promote S phase entry of quiescent smooth muscle cells. In contrast, dMax failed to ablate inhibition of initiator element (Inr)-mediated transcription by c-Myc in Jurkat T cells. In in vitro protein:protein association assays, dMax interacted with c-Myc, N-Myc, L-Myc, Mad1, Mxi1, Mad3 and Mad4, but not,vith itself or wild-type Max, These interactions required an intact leucine zipper. Inhibition of E-box-mediated transactivation by induction of dMax overexpression resulted in apoptosis of WEHI 231 B cells. Thus, dMax is a widely expressed, naturally occurring protein, with the capacity to bind most members of the Myc/Max superfamily; dMax has little effect on Inr-mediated repression by c-Myc, but can significantly decrease E-bos-mediated events promoting proliferation and cell survival.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Dermatol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Boston University; Boston University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Sonenshein, GE (corresponding author), Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.			DePinho, Ronald/0000-0002-5625-577X	NCI NIH HHS [CA36355, T32-CA64070] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA064070, R01CA036355] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ARSURA M, 1995, MOL CELL BIOL, V15, P6702; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bello-Fernandez C, 1992, Curr Top Microbiol Immunol, V182, P445; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CROUCH DH, 1993, ONCOGENE, V8, P1849; DAVIS LJ, 1993, ONCOGENE, V8, P125; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GROSSCHEDL R, 1980, P NATL ACAD SCI-BIOL, V77, P1432, DOI 10.1073/pnas.77.3.1432; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HARDIN JA, 1992, TOXICOL APPL PHARM, V117, P155, DOI 10.1016/0041-008X(92)90232-H; Hatton KS, 1996, MOL CELL BIOL, V16, P1794; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HINOSHITA F, 1992, TOXICOLOGY, V73, P203, DOI 10.1016/0300-483X(92)90103-L; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOLLER BH, 1985, J IMMUNOL, V134, P2727; LARSSON LG, 1994, ONCOGENE, V9, P1247; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; ManzanoWinkler B, 1996, J BIOL CHEM, V271, P12076, DOI 10.1074/jbc.271.20.12076; Marhamati DJ, 1997, MOL CELL BIOL, V17, P2448, DOI 10.1128/MCB.17.5.2448; MATTHEWS JA, 1985, ANAL BIOCHEM, V151, P205, DOI 10.1016/0003-2697(85)90073-9; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; REDDY CD, 1992, ONCOGENE, V7, P2085; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SEMSEI I, 1989, ONCOGENE, V4, P465; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; TIBENSKY D, 1990, IMMUNOGENETICS, V32, P210, DOI 10.1007/BF02114976; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; Wu M, 1996, MOL CELL BIOL, V16, P5015; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	62	14	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2489	2498		10.1038/sj.onc.1202611	http://dx.doi.org/10.1038/sj.onc.1202611			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229200				2022-12-28	WOS:000079703300009
J	Kawazoe, N; Watabe, M; Masuda, Y; Nakajo, S; Nakaya, K				Kawazoe, N; Watabe, M; Masuda, Y; Nakajo, S; Nakaya, K			Tiam1 is involved in the regulation of bufalin-induced apoptosis in human leukemia cells	ONCOGENE			English	Article						bufalin; apoptosis; Tiam1; leukemia	JNK/SAPK SIGNALING PATHWAY; PLECKSTRIN HOMOLOGY DOMAIN; HL-60 CELLS; KINASE ACTIVATION; ANTICANCER DRUGS; MAMMALIAN-CELLS; U937 CELLS; G-PROTEIN; DEATH; RAC	Bufalin, a component of the Chinese medicine chan'su, induces apoptosis in various lines of human tumor cells, such as leukemia HL60 and U937 cells, by altering the expression of apoptosis-related genes, for example, bcl-2 and c-myc. In this study, we characterized a gene that is involved in bufalin-induced apoptosis by the differential display (DD) technique, The partial nucleotide sequence of one of the differentially expressed clones obtained after treatment with bufalin was identical to that of the human gene for Tiam1, When U937 cells mere treated with 10(-7) M bufalin, expression of both Tiam1 mRNA and the protein was induced 1 h after the start of the treatment, The increase of Tiam1 mRNA was transient but the level of Tiam1 protein continued to increase at least for 6 h, In addition, the activities of Rad and p21-activated kinase (PAK) were also stimulated by bufalin treatment. To evaluate the role of Tiam1 in the apoptotic process, we examined the effects of the expression of sense and antisense RNA for Tiam1 in U937 cells, Apoptosis was strongly induced by bufalin in cells that expressed sense RNA for Tiam1 as compared to apoptosis in control cells treated with bufalin only, Cells expressing antisense RNA for Tiam1 were significantly more resistant than the control bufalin-treated cells to induction of DNA fragmentation in response to bufalin, Moreover, sense transformants had elevated activities of PAK and c-Jun NH2-terminal kinase (JNK). These results suggest that Tiam1 might play a critical role in bufalin-induced apoptosis through the activation of Rac1, PAK, and JNK pathway.	Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Shinagawa Ku, Tokyo 1428555, Japan	Showa University	Nakaya, K (corresponding author), Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.							BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BHALLA K, 1993, LEUKEMIA, V7, P563; Butterfield L, 1997, J BIOL CHEM, V272, P10110; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; DIDSBURY JR, 1987, FEBS LETT, V219, P259, DOI 10.1016/0014-5793(87)81228-0; Franklin CC, 1995, ONCOGENE, V11, P2365; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN JH, 1993, J BIOL CHEM, V268, P25009; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; JING YK, 1994, JPN J CANCER RES, V85, P645, DOI 10.1111/j.1349-7006.1994.tb02408.x; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MANIATIS T, 1982, MOL CLONING LABORATO, P188; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MASUDA Y, 1995, LEUKEMIA RES, V19, P549, DOI 10.1016/0145-2126(95)00031-I; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOGUCHI K, 1995, JPN J CANCER RES, V86, P217, DOI 10.1111/j.1349-7006.1995.tb03042.x; NUMAZAWA S, 1994, J CELL PHYSIOL, V160, P113, DOI 10.1002/jcp.1041600114; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; ONISHI Y, 1993, BIOCHIM BIOPHYS ACTA, V1175, P147, DOI 10.1016/0167-4889(93)90017-J; PIERCE GB, 1989, P NATL ACAD SCI USA, V86, P3654, DOI 10.1073/pnas.86.10.3654; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WALKER PR, 1991, CANCER RES, V51, P1078; Watabe M, 1996, J BIOL CHEM, V271, P14067, DOI 10.1074/jbc.271.24.14067; Watabe M, 1998, ONCOGENE, V16, P779, DOI 10.1038/sj.onc.1201592; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHANG L, 1991, BIOCHEM BIOPH RES CO, V178, P686, DOI 10.1016/0006-291X(91)90162-Z	56	97	105	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2413	2421		10.1038/sj.onc.1202555	http://dx.doi.org/10.1038/sj.onc.1202555			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229192				2022-12-28	WOS:000079703300001
J	Strathdee, G; MacKean, MJ; Illand, M; Brown, R				Strathdee, G; MacKean, MJ; Illand, M; Brown, R			A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer	ONCOGENE			English	Article						mismatch repair; methylation; cisplatin; drug resistance; ovarian cancer	DNA MISMATCH REPAIR; NONPOLYPOSIS COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; TUMOR-CELLS; HMSH2 GENE; CISPLATIN; HYPERMETHYLATION; NEOPLASMS; MUTATION	Experimental evidence from several sources has identified a link between mismatch repair deficiency and cytotoxic drug resistance, Selection for cisplatin resistance in the human ovarian cancer cell line A2780, results in loss of expression of the mismatch repair protein hMLH1 in most (90%) of the resultant cisplatin-resistant cell lines, Here me demonstrate that the cisplatin sensitive parental cell line displays methylation of the promoter of only one hMLH1 allele, but that the resistant cell lines all exhibit hyper-methylation of the promoters of both hMLH1 alleles, Full methylation of all sites tested was found to be invariably associated with loss of hMLH1 expression, whereas a partial increase in methylation appears compatible with either loss or maintenance of expression, In addition treatment of two of the resistant cell lines with 5-azacytidine, a known inhibitor of methylation, results in re-expression of hMLH1, Clonogenic assays demonstrate that the 5-azacytidine treated cells show increased sensitivity to cisplatin, Furthermore, 12.5% (3/24) of ovarian tumours show hypermethylation of the hMLH1 promoter, Expression of hMLH1 is absent in the tumours that are hypermethylated, while all the unmethylated tumours still express the protein, This analysis suggests that methylation of the hMLH1 promoter may be a common mechanism for loss of hMLH1 expression, and possibly for cisplatin-resistance, in ovarian cancer.	Univ Glasgow, CRC, Dept Med Oncol, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; University of Glasgow	Brown, R (corresponding author), Univ Glasgow, CRC, Dept Med Oncol, Beatson Labs, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.			Strathdee, Gordon/0000-0001-9681-8429				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Aebi S, 1996, CANCER RES, V56, P3087; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; Fink D, 1996, CANCER RES, V56, P4881; Fink D, 1998, CLIN CANCER RES, V4, P1; Fink D, 1997, INT J ONCOL, V11, P539; FROST P, 1990, CANCER RES, V50, P4572; Fujita M, 1995, INT J CANCER, V64, P361, DOI 10.1002/ijc.2910640602; Hatta Y, 1997, INT J ONCOL, V11, P465; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Kane MF, 1997, CANCER RES, V57, P808; Kaye SB, 1996, ANN ONCOL, V7, P9; KING BL, 1995, BRIT J CANCER, V72, P376, DOI 10.1038/bjc.1995.341; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; NEIJT JP, 1997, TXB MED ONCOLOGY, P87; NYCE J, 1989, CANCER RES, V49, P5829; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Reitmair AH, 1996, CANCER RES, V56, P3842; Thibodeau SN, 1996, CANCER RES, V56, P4836; Zingg JM, 1997, CARCINOGENESIS, V18, P869, DOI 10.1093/carcin/18.5.869	25	290	312	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2335	2341		10.1038/sj.onc.1202540	http://dx.doi.org/10.1038/sj.onc.1202540			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327053				2022-12-28	WOS:000079595500005
J	Mayer, T; Meyer, M; Janning, A; Schiedel, AC; Barnekow, A				Mayer, T; Meyer, M; Janning, A; Schiedel, AC; Barnekow, A			A mutant form of the rho protein can restore stress fibers and adhesion plaques in v-src transformed fibroblasts	ONCOGENE			English	Article						rho proteins; transformed fibroblasts; v-src	ROUS-SARCOMA VIRUS; INTRACELLULAR-LOCALIZATION; ACTIN CYTOSKELETON; TYROSINE KINASES; ONCOGENE PRODUCT; CELLS; PHOSPHORYLATION; GTPASES; FAMILY; SIGNAL	The organization of polymerized actin in the mammalian cell is regulated by several members of the rho family. Three rho proteins, cdc42, rac and rho act in a cascade to organize the intracellular actin cytoskeleton. Rho proteins are involved in the formation of actin stress fibers and adhesion plaques in fibroblasts. During transformation of mammalian cells by oncogenes the cytoskeleton is rearranged and stress fibers and adhesion plaques are disintegrated. In this paper we investigate the function of the rho protein in RR1022 rat fibroblasts transformed by the Rous sarcoma virus. Two activated mutants of the rho protein, rho G14V and rho Q63L, and a dominant negative mutant, rho N117I, were stably transfected into RR1022 cells. The resulting cell lines were analysed for the organization of polymerized actin and adhesion plaques. Cells expressing rho Q63L, but not rho wt, rho G14V or rho N117I, showed an altered morphology. These cells displayed a flat, fibroblast like shape when compared with the RR1022 ancestor cells. Immunofluorescence analyses revealed that actin stress fibers and adhesion plaques were rearranged in these cells. We conclude from these data that an active rho protein can restore elements of the actin cytoskeleton in transformed cells by overriding the tyrosine kinase phosphorylation induced by the pp60(v-src).	Muenster Univ, Dept Expt Tumorbiol, D-48149 Muenster, Germany		Mayer, T (corresponding author), Muenster Univ, Dept Expt Tumorbiol, Badestr 9, D-48149 Muenster, Germany.			Mayer, Thomas/0000-0001-6954-2287; Schiedel, Anke/0000-0002-8114-3139				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARNEKOW A, 1984, MOL CELL BIOL, V4, P1179, DOI 10.1128/MCB.4.6.1179; BARNEKOW A, 1987, COMP BIOCHEM PHYS B, V87, P663, DOI 10.1016/0305-0491(87)90371-3; BARNEKOW A, 1991, BEHRING I MITT, V8, P67; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; DECLUE JE, 1987, MOL CELL BIOL, V7, P371, DOI 10.1128/MCB.7.1.371; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRAME MC, 1994, MOL BIOL CELL, V5, P1177, DOI 10.1091/mbc.5.11.1177; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HORVATH AR, 1990, ONCOGENE, V5, P1349; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; KELLIE S, 1986, J CELL SCI, V82, P129; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Leung T, 1996, MOL CELL BIOL, V16, P5313; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIDLEY AJ, 1994, EMBO J, V13, P2610; ROHRSCHNEIDER L, 1985, MOL CELL BIOL, V5, P3097, DOI 10.1128/MCB.5.11.3097; SCHIEDEL AC, 1995, FEBS LETT, V376, P113, DOI 10.1016/0014-5793(95)01258-0; Seabra MC, 1996, J BIOL CHEM, V271, P14398, DOI 10.1074/jbc.271.24.14398; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; STOKER AW, 1986, J VIROL, V58, P876, DOI 10.1128/JVI.58.3.876-883.1986; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TROULIARIS S, 1995, J VIROL, V69, P6010, DOI 10.1128/JVI.69.10.6010-6020.1995; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WYKE AW, 1993, CELL GROWTH DIFFER, V4, P671; WYKE AW, 1995, CELL GROWTH DIFFER, V6, P1225	50	35	36	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2117	2128		10.1038/sj.onc.1202537	http://dx.doi.org/10.1038/sj.onc.1202537			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321736				2022-12-28	WOS:000079346200009
J	Englaro, W; Bahadoran, P; Bertolotto, C; Busca, R; Derijard, B; Livolsi, A; Peyron, JF; Ortonne, JP; Ballotti, R				Englaro, W; Bahadoran, P; Bertolotto, C; Busca, R; Derijard, B; Livolsi, A; Peyron, JF; Ortonne, JP; Ballotti, R			Tumor necrosis factor alpha-mediated inhibition of melanogenesis is dependent on nuclear factor kappa B activation	ONCOGENE			English	Article						TNF alpha; inhibition of melanogenesis; tyrosinase; NF kappa B; melanoma cells	MELANOCYTE-STIMULATING HORMONE; TYROSINASE ACTIVITY; ULTRAVIOLET-LIGHT; PROTEIN-KINASES; CELL-DEATH; PHOSPHORYLATION; DEGRADATION; KERATINOCYTES; TRANSCRIPTION; CYTOKINES	Melanogenesis is a physiological process resulting in the synthesis of melanin pigments which play a crucial protective role against skin photocarcinogenesis. lit vivo, solar ultraviolet light triggers the secretion of numerous keratinocyte-derived factors that are implicated in the regulation of melanogenesis. Among these, tumor necrosis factor alpha. (TNF alpha), a cytokine implicated in the pro-inflammatory response, down-regulates pigment synthesis in vitro. In this report, we aimed to determine the molecular mechanisms by which this cytokine inhibits melanogenesis in B16 melanoma cells. First, we show that TNF alpha inhibits the activity and protein expression of tyrosinase which is the key enzyme of melanogenesis, Further, we demonstrate that this effect is subsequent to a down-regulation of the tyrosinase promoter activity in both basal and cAMP-induced melanogenesis, Finally, we present evidence indicating that the inhibitory effect of TNF alpha on melanogenesis is dependent on nuclear factor kappa B (NF kappa B) activation. Indeed, overexpression of this transcription factor in B16 cells is sufficient to inhibit tyrosinase promoter activity, Furthermore, a mutant of inhibitory kappa B (I kappa B), that prevents NF kappa B activation, is able to revert the effect of TNF alpha on the tyrosinase promoter activity. Taken together, our results clarify the mechanisms by which TNF alpha inhibits pigmentation and point out the key role of NF kappa B in the regulation of melanogenesis.	Fac Med, INSERM, U385, F-06107 Nice 2, France; Fac Med, CJF 9605, F-06107 Nice, France; Fac Sci, Ctr Biochim, CNRS, UMR 134, F-06018 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Ballotti, R (corresponding author), Fac Med, INSERM, U385, Ave Valombrose, F-06107 Nice 2, France.		Jean-Francois, Peyron/AAA-9496-2022; Peyron, Jean-Francois/M-5682-2016; Bertolotto, Corine/AAF-6634-2021; BALLOTTI, Robert/F-8825-2013; Bertolotto-Ballotti, Corine/O-2155-2016	Jean-Francois, Peyron/0000-0001-6113-916X; Peyron, Jean-Francois/0000-0001-6113-916X; Bertolotto, Corine/0000-0001-6971-7753; Bahadoran, Philippe/0000-0002-2481-0556; BALLOTTI, Robert/0000-0002-7322-4908				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bennicelli J L, 1993, Exp Dermatol, V2, P186, DOI 10.1111/j.1600-0625.1993.tb00031.x; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HUNT G, 1994, J CELL SCI, V107, P205; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KOCK A, 1990, J EXP MED, V172, P1609, DOI 10.1084/jem.172.6.1609; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEVINE N, 1991, JAMA-J AM MED ASSOC, V266, P2730, DOI 10.1001/jama.266.19.2730; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MartinezEsparza M, 1997, J BIOL CHEM, V272, P3967, DOI 10.1074/jbc.272.7.3967; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; OKEEFE E, 1974, P NATL ACAD SCI USA, V71, P2500, DOI 10.1073/pnas.71.6.2500; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OXHOLM A, 1988, BRIT J DERMATOL, V118, P369, DOI 10.1111/j.1365-2133.1988.tb02430.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SWOPE VB, 1991, J INVEST DERMATOL, V96, P180, DOI 10.1111/1523-1747.ep12460991; SWOPE VB, 1989, J IMMUNOL, V142, P1943; TAKAHASHI H, 1992, J INVEST DERMATOL, V98, P481, DOI 10.1111/1523-1747.ep12499862; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5	33	56	59	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1553	1559		10.1038/sj.onc.1202446	http://dx.doi.org/10.1038/sj.onc.1202446			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102625				2022-12-28	WOS:000078770700005
J	Saxena, A; Shriml, LM; Dean, M; Ali, IU				Saxena, A; Shriml, LM; Dean, M; Ali, IU			Comparative molecular genetic profiles of anaplastic astrocytomas glioblastomas multiforme and their subsequent recurrences	ONCOGENE			English	Article						malignant gliomas; recurrence; genetic profiles	TUMOR-SUPPRESSOR GENE; MALIGNANT BRAIN-TUMORS; GROWTH-FACTOR RECEPTOR; TISSUE INHIBITOR; GELATINASE-A; P53; GLIOMAS; PROGRESSION; EXPRESSION; MUTATION	Malignant glial tumors (anaplastic astrocytomas and glioblastomas multiforme) arise mostly either from the progression of low grade precursor lesions or rapidly in a de novo fashion and contain distinct genetic alterations. There is, however, a third subset of malignant gliomas in which genetic lesions remain to be identified, Following surgical resection, all gliomas appear to have an inherent tendency to recur, Comparative molecular analysis of ten primary malignant gliomas (three anaplastic astrocytomas and seven glioblastomas multiforme) with their recurrences identified two distinct subgroups of recurrent tumors. In one group, primary tumors harbored genetic aberrations frequently associated with linear progression or ne novo formation pathways of glial tumorigenesis and maintained their genetic profiles upon recurrence. In the other subset with no detectable known genetic mutations at first presentation, the recurrent tumors sustained specific abnormalities associated with pathways of linear progression or ne novo formation. These included loss of genes on chromosomes 17 and 10, mutations in the p53 gene, homozygous deletion of the DMBTA1 and p16 and/or p15 genes and amplification and/or overexpression of CDK4 and alpha form of the PDGF receptor. Recurrent tumors from both groups also displayed an abnormal expression profile of the metalloproteinase, gel A, and its inhibitor, TIMP-2, consistent with their highly invasive behavior, Delineation of the molecular differences between malignant glioblastomas and their subsequent recurrences may have important implications for the development of rational clinical approaches for this neoplasm that remains refractory to existing therapeutic modalities.	NCI, Chemoprevent Branch, NIH, Bethesda, MD 20892 USA; NINCDS, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; NCI, Lab Genom Divers, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ali, IU (corresponding author), NCI, Chemoprevent Branch, NIH, Bethesda, MD 20892 USA.		Dean, Michael C/G-8172-2012; Dean, Michael/R-7501-2019	Dean, Michael C/0000-0003-2234-0631; 	NATIONAL CANCER INSTITUTE [ZIABC005652, Z01BC005652] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERKMAN RA, 1992, J NEUROSURG, V77, P432, DOI 10.3171/jns.1992.77.3.0432; Berns EMJJ, 1998, BRIT J CANCER, V77, P1130, DOI 10.1038/bjc.1998.187; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; CHO Y, 1994, SCIENCE, V265, P1994; Erber R, 1998, ONCOGENE, V16, P1671, DOI 10.1038/sj.onc.1201690; FLEMING TP, 1992, CANCER RES, V52, P4550; GUTIERREZ MI, 1994, HUM MOL GENET, V3, P2247, DOI 10.1093/hmg/3.12.2247; HAYASHI Y, 1991, BIOCHEM BIOPH RES CO, V180, P1145, DOI 10.1016/S0006-291X(05)81186-6; Hermanson M, 1996, CANCER RES, V56, P164; KERN SE, 1991, ONCOGENE, V6, P131; Kleihues P, 1993, HISTOLOGICAL TYPING; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Louis DN, 1997, BRAIN PATHOL, V7, P755, DOI 10.1111/j.1750-3639.1997.tb01062.x; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; MIKKELSEN T, 1995, J NEUROSURG, V83, P285, DOI 10.3171/jns.1995.83.2.0285; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; MORSE RP, 1994, J NEURO-ONCOL, V21, P151, DOI 10.1007/BF01052899; NAKAGAWA T, 1994, J NEUROSURG, V81, P69, DOI 10.3171/jns.1994.81.1.0069; NEMETH JA, 1993, EXP CELL RES, V207, P376, DOI 10.1006/excr.1993.1204; PRUCHON E, 1994, CANCER GENET CYTOGEN, V76, P85, DOI 10.1016/0165-4608(94)90454-5; RAJAN B, 1994, EUR J CANCER, V30A, P1809, DOI 10.1016/0959-8049(94)00248-4; Reifenberger J, 1996, J NEUROPATH EXP NEUR, V55, P822, DOI 10.1097/00005072-199607000-00007; RITTER AM, 1994, NEUROSURGERY, V35, P192, DOI 10.1227/00006123-199408000-00003; ROLLEY N, 1995, ONCOGENE, V11, P763; Rosenberg JE, 1996, ONCOGENE, V13, P2483; SAXENA A, 1995, INT J ONCOL, V7, P469; Saxena A, 1996, ONCOGENE, V13, P661; SAXENA A, 1992, CANCER RES, V52, P6716; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; VONDEIMLING A, 1993, BRAIN PATHOL, V3, P19; Yamamoto M, 1996, CANCER RES, V56, P384; YAMAMOTO M, 1994, J NEURO-ONCOL, V22, P139, DOI 10.1007/BF01052889; YONG WH, 1995, J NEUROPATH EXP NEUR, V54, P622, DOI 10.1097/00005072-199509000-00002	35	31	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1385	1390		10.1038/sj.onc.1202440	http://dx.doi.org/10.1038/sj.onc.1202440			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022821				2022-12-28	WOS:000078510900015
J	Ljungman, M; Zhang, FF; Chen, F; Rainbow, AJ; McKay, BC				Ljungman, M; Zhang, FF; Chen, F; Rainbow, AJ; McKay, BC			Inhibition of RNA polymerase II as a trigger for the p53 response	ONCOGENE			English	Article						transcription; p53; p21(WAF1); apoptosis	WILD-TYPE P53; DNA-DAMAGING AGENTS; TRANSCRIPTIONALLY ACTIVE P53; CYCLE CHECKPOINT PATHWAY; SUPPRESSOR PROTEIN P53; CELL-CYCLE; IN-VIVO; TUMOR-SUPPRESSOR; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION	The mechanisms by which the p53 response is triggered following exposure to DNA-damaging agents have not yet been clearly elucidated. We and others have previously suggested that blockage of RNA polymerase II may be the trigger for induction of the p53 response following exposure to ultraviolet light. Here we report on the correlation between inhibition of mRNA synthesis and the induction of p53, p21(WAF1) and apoptosis in diploid human fibroblasts treated with either UV light, cisplatin or the RNA synthesis inhibitors actinomycin D, DRB, H7 and alpha-amanitin. Exposure to ionizing radiation or the proteasome inhibitor LLnL, however, induced p53 and p21(WAF1) without affecting mRNA synthesis. Importantly, induction of p53 by the RNA synthesis or proteasome inhibitors did not correlate with the induction of DNA strand breaks. Furthermore, cisplatin-induced accumulation of active p53 in repair-deficient XP-A cells occurred despite the lack of DNA strand break induction. Our results suggest that the induction of the p53 response by certain toxic agents is not triggered by DNA strand breaks but rather, may be linked to inhibition of mRNA synthesis either directly by the poisoning of RNA polymerase II or indirectly by the induction of elongation-blocking DNA lesions.	Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Canc Biol, Ann Arbor, MI 48109 USA; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada	University of Michigan System; University of Michigan; McMaster University	Ljungman, M (corresponding author), Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Canc Biol, Ann Arbor, MI 48109 USA.		McKay, Bruce C/I-4081-2013	McKay, Bruce C/0000-0002-7921-1331				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AHNSTROM G, 1981, MEASUREMENT STRAND B, P403; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; CANMAN CE, 1994, CANCER RES, V54, P5054; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Chung DH, 1998, RADIAT RES, V149, P187, DOI 10.2307/3579929; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CORDA Y, 1993, BIOCHEMISTRY-US, V32, P8582, DOI 10.1021/bi00084a027; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; Dumaz N, 1997, MOL CARCINOGEN, V20, P340, DOI 10.1002/(SICI)1098-2744(199712)20:4<340::AID-MC3>3.0.CO;2-N; EASTMAN A, 1986, BIOCHEMISTRY-US, V25, P3912, DOI 10.1021/bi00361a026; EGYHAZI E, 1976, NATURE, V262, P319, DOI 10.1038/262319a0; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; ERIXON K, 1979, MUTAT RES, V59, P257, DOI 10.1016/0027-5107(79)90164-7; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FERGUSON LR, 1994, ENVIRON MOL MUTAGEN, V24, P245, DOI 10.1002/em.2850240402; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; GIARDINA C, 1993, J BIOL CHEM, V268, P23806; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gonen H, 1997, FEBS LETT, V406, P17, DOI 10.1016/S0014-5793(97)00225-1; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JARVIS WD, 1994, CANCER RES, V54, P1707; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kastan MB, 1996, BIOESSAYS, V18, P617, DOI 10.1002/bies.950180804; KHANNA KK, 1993, ONCOGENE, V8, P3307; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; KUWANO M, 1973, EXP CELL RES, V82, P454, DOI 10.1016/0014-4827(73)90365-0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liu M, 1998, CANCER RES, V58, P1723; Ljungman M, 1996, BBA-GENE STRUCT EXPR, V1307, P171, DOI 10.1016/0167-4781(96)00037-1; Ljungman M, 1996, ONCOGENE, V13, P823; LJUNGMAN M, 1995, NUCLEIC ACIDS RES, V23, P1782, DOI 10.1093/nar/23.10.1782; Loignon M, 1997, CANCER RES, V57, P3390; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUCHNIK AN, 1988, NUCLEIC ACIDS RES, V16, P5175, DOI 10.1093/nar/16.11.5175; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATSUMOTO H, 1994, CANCER LETT, V87, P39, DOI 10.1016/0304-3835(94)90407-3; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; McKay BC, 1997, CARCINOGENESIS, V18, P245, DOI 10.1093/carcin/18.2.245; MELLO JA, 1995, BIOCHEMISTRY-US, V34, P14783, DOI 10.1021/bi00045a020; Mukhopadhyay T, 1997, ONCOGENE, V14, P379, DOI 10.1038/sj.onc.1200835; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nguyen VT, 1996, NUCLEIC ACIDS RES, V24, P2924, DOI 10.1093/nar/24.15.2924; Ohnishi T, 1998, ONCOGENE, V16, P1507, DOI 10.1038/sj.onc.1201663; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; Plaumann B, 1996, ONCOGENE, V13, P1605; Poon RYC, 1998, ONCOGENE, V16, P1333, DOI 10.1038/sj.onc.1201897; RODI CP, 1989, J CELL PHYSIOL, V141, P346, DOI 10.1002/jcp.1041410216; SAUERBIER W, 1978, ANNU REV GENET, V12, P329, DOI 10.1146/annurev.ge.12.120178.001553; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEHGAL PB, 1976, CELL, V9, P473, DOI 10.1016/0092-8674(76)90092-1; SELBY CP, 1990, J BIOL CHEM, V265, P21330; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; SMITH ML, 1995, ONCOGENE, V10, P1053; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; TISHLER RB, 1993, CANCER RES, V53, P2212; TISHLER RB, 1995, CANCER RES, V55, P6021; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805	91	243	243	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					583	592		10.1038/sj.onc.1202356	http://dx.doi.org/10.1038/sj.onc.1202356			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989808				2022-12-28	WOS:000078394400003
J	Lu, WG; Mayer, BJ				Lu, WG; Mayer, BJ			Mechanism of activation of Pak1 kinase by membrane localization	ONCOGENE			English	Article						Pak kinase; Nck; SH2/SH3 adaptors; Cdc42; Rac; signal transduction	P21-ACTIVATED PROTEIN-KINASES; ACTIN STRESS FIBERS; RHO-FAMILY GTPASES; ADAPTER PROTEIN; BINDING-PROTEIN; CELL-CYCLE; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; XENOPUS OOCYTES; FOCAL COMPLEXES	Pak kinases are a family of serine/threonine protein kinases homologous to Ste20p of yeast. Paks can be activated in vivo and in vitro by binding to GTP-bound Cdc42 and Rad, members of the Rho family of small GTPases implicated in regulating the organization of the actin cytoskeleton. We have previously reported that the SH2/SH3-containing adaptor protein Nck binds Pak kinase through its second SH3 domain. Pak1 can be targeted to the membrane by Nck in response to tyrosine phosphorylation, and membrane association of Pak1 is sufficient to increase its specific activity. The mechanism whereby Pak is activated by membrane localization, however, is unknown, We show here that expression of three proteins that inhibit Rho-family GTPases by different mechanisms (RhoGDI, Bcr and D57Y Cdc42) all block the activation of Pak by a membrane-targeted Nck SH3 domain, demonstrating that the in vivo activation of Pak1 induced by membrane localization is dependent on Rho-family GTPases. This implies that Pak activity can be regulated in cells both by the level of GTP loading of various Rho-family GTPases and the local concentration of Pak relative to these GTPases. Our data also suggest the existence of Rho-family GTPases in addition to Cdc42 and Rad that can activate Pak on membranes.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Mayer, BJ (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp, 320 Longwood Ave, Boston, MA 02115 USA.							BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Cullen BR, 1996, CURR BIOL, V6, P1557, DOI 10.1016/S0960-9822(02)70770-7; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Faure S, 1997, EMBO J, V16, P5550, DOI 10.1093/emboj/16.18.5550; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Harden N, 1996, MOL CELL BIOL, V16, P1896; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; HU G, 1995, MOL CELL BIOL, V15, P1169; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; JUNG V, 1994, MOL CELL BIOL, V14, P3707, DOI 10.1128/MCB.14.6.3707; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Lu XB, 1996, CURR BIOL, V6, P1677, DOI 10.1016/S0960-9822(02)70792-6; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nunn MF, 1996, J VIROL, V70, P6157, DOI 10.1128/JVI.70.9.6157-6161.1996; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sawai ET, 1996, CURR BIOL, V6, P1519, DOI 10.1016/S0960-9822(96)00757-9; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	66	69	69	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					797	806		10.1038/sj.onc.1202361	http://dx.doi.org/10.1038/sj.onc.1202361			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989831				2022-12-28	WOS:000078394400026
J	Dragovich, T; Rudin, CM; Thompson, CB				Dragovich, T; Rudin, CM; Thompson, CB			Signal transduction pathways that regulate cell survival and cell death	ONCOGENE			English	Article						signal transduction; bcl-2 proteins; caspases; death receptors	NF-KAPPA-B; TRAF-INTERACTING PROTEIN; CYTOCHROME-C; DNA-DAMAGE; GENE CED-3; APOPTOSIS; BCL-2; BCL-X(L); BAX; ACTIVATION	Apoptosis or programmed cell death (PCD) is a physiological process critical for organ development, tissue homeostasis and elimination of defective or potentially dangerous cells in complex organisms. Apoptosis permits cell death without a concomitant inflammatory response in the surrounding tissues. The process of apoptosis depends on the reception of multiple extracellular and intracellular signals, integration and amplification of these signals by second messengers and finally, activation of the death effector proteases, Defects in control of apoptotic pathways may contribute to a variety of diseases including cancer, autoimmune and neurodegenerative conditions and AIDS, While many components of the regulatory network controlling apoptosis have been defined, the mechanisms of action and patterns of interaction of these factors remain controversial. This article summarizes some of the known aspects of signaling pathways involved in apoptosis.	Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago; Howard Hughes Medical Institute; University of Chicago; University of Chicago	Thompson, CB (corresponding author), Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA.		Rudin, Charles/R-2530-2019	Rudin, Charles/0000-0001-5204-3465; Dragovich, Tomislav/0000-0002-1569-2172				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Aplin AE, 1998, PHARMACOL REV, V50, P197; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Casiano CA, 1996, J EXP MED, V184, P765, DOI 10.1084/jem.184.2.765; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; KASTAN MB, 1997, NEW ENGL J MED, V333, P662; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1993, BLOOD, V81, P151; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RATHMEL JC, 1998, IN PRESS ANN REV IMM; Rathmell JC, 1996, CELL, V87, P319, DOI 10.1016/S0092-8674(00)81349-5; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wyllie A, 1997, NATURE, V389, P237, DOI 10.1038/38405; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	62	163	171	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 24	1998	17	25					3207	3213		10.1038/sj.onc.1202587	http://dx.doi.org/10.1038/sj.onc.1202587			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916983				2022-12-28	WOS:000078048200002
J	Ghebranious, N; Donehower, LA				Ghebranious, N; Donehower, LA			Mouse models in tumor suppression	ONCOGENE			English	Review						tumor suppressors; knockout mice; cancer models; inherited cancer syndromes	WILD-TYPE P53; CELL-CYCLE CONTROL; RETINOBLASTOMA SUSCEPTIBILITY GENE; MULTIPLE INTESTINAL NEOPLASIA; OVARIAN-CANCER FAMILIES; ZINC FINGER GENE; BREAST-CANCER; POLYPOSIS-COLI; APC GENE; P53-DEFICIENT MICE	Genetic lesions found in tumors are often targeted to the negative growth regulatory tumor suppressor genes. Much of our understanding of tumor suppressor gene function is derived from experimental manipulations in cultured cells. Recently, however, the generation of mice with germ line tumor suppressor gene mutations through gene targeting in embryonic stem cells has provided another dimension by allowing experimental studies of tumor suppressor function in an organismal context. Novel insights into the role of tumor suppressors in development, differentiation, cell cycle control, and tumor suppression have been obtained from the studies on these 'knockout' mice, In addition, such mice may serve as disease models for humans with inherited cancer predisposition syndromes, Perhaps the greatest advantage of many of the mouse tumor suppressor models is that they facilitate study of the roles of tumor suppressor gene loss in tumor initiation and progression in vivo. Moreover, derivation of primary cells from tumor suppressor-deficient mice has provided an important resource for in vitro studies on the role of targeted genes in cell cycle regulation, DNA damage response, regulation of apoptotic pathways, and preservation of genomic stability. In this review, we discuss some of the mechanistic insights provided by tumor suppressor-deficient mice and their utility as models for human cancer syndromes.	Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Donehower, LA (corresponding author), Baylor Coll Med, Div Mol Virol, 1 Baylor Plaza, Houston, TX 77030 USA.							ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BADER JL, 1978, J PEDIATR-US, V92, P925, DOI 10.1016/S0022-3476(78)80362-X; BAIRD PN, 1992, ONCOGENE, V7, P2141; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bedell MA, 1997, GENE DEV, V11, P11, DOI 10.1101/gad.11.1.11; Bilger A, 1996, SEMIN CANCER BIOL, V7, P249, DOI 10.1006/scbi.1996.0033; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BOOKSTEIN R, 1988, P NATL ACAD SCI USA, V85, P2210, DOI 10.1073/pnas.85.7.2210; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; BULOW S, 1987, DAN MED BULL, V34, P1; Cairns P, 1997, CANCER RES, V57, P4997; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CannonAlbright LA, 1996, SEMIN ONCOL, V23, P1; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Cichowski K, 1996, SEMIN CANCER BIOL, V7, P291, DOI 10.1006/scbi.1996.0037; CLARKE AR, 1995, ONCOGENE, V11, P1913; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; COLLINS N, 1995, ONCOGENE, V10, P1673; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; COUCH FJ, 1998, GENETIC BASIS HUMAN, P537; COWELL JK, 1991, ONCOGENE, V6, P595; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DAVIS LM, 1991, GENOMICS, V10, P588, DOI 10.1016/0888-7543(91)90440-P; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DELSAL G, 1995, MOL CELL BIOL, V15, P7152; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; DIETRICH WF, 1995, P NATL ACAD SCI USA, V92, P10849, DOI 10.1073/pnas.92.24.10849; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; DURO D, 1995, ONCOGENE, V11, P21; EASTON D, 1993, CANCER SURV, V18, P1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ENG C, 1994, J MED GENET, V31, P458, DOI 10.1136/jmg.31.6.458; ENG C, 1998, GENETIC BASIS HUMAN, P519; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; Friedman LS, 1998, CANCER RES, V58, P1338; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FRITH CH, 1981, J NATL CANCER I, V66, P703; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Gnarra JR, 1996, BBA-REV CANCER, V1242, P201, DOI 10.1016/0304-419X(95)00012-5; Gnarra JR, 1997, P NATL ACAD SCI USA, V94, P9102, DOI 10.1073/pnas.94.17.9102; Goggins M, 1996, CANCER RES, V56, P5360; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; GONDO Y, 1994, BIOCHEM BIOPH RES CO, V202, P830, DOI 10.1006/bbrc.1994.2005; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GUTMANN DH, 1998, GENETIC BASIS HUMAN, P423; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1995, CANCER RES, V55, P1146; Hope D G, 1981, Adv Neurol, V29, P33; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HU NP, 1994, ONCOGENE, V9, P1021; HUFF V, 1991, AM J HUM GENET, V48, P997; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; HUYNH DP, 1994, DEV BIOL, V161, P538, DOI 10.1006/dbio.1994.1052; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Jacks T, 1996, ANNU REV GENET, V30, P603, DOI 10.1146/annurev.genet.30.1.603; James C. David, 1996, Current Opinion in Oncology, V8, P188; JEN J, 1994, CANCER RES, V54, P6353; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; Johannsson O, 1996, AM J HUM GENET, V58, P441; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; Kaelin WG, 1998, J INTERN MED, V243, P535; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAMB A, 1998, GENETIC BASIS HUMAN, P507; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; KIRBY ML, 1993, DEV DYNAM, V198, P296, DOI 10.1002/aja.1001980407; KNUDSON A, 1991, CANCER RES, V51, P5435; KNUDSON AG, 1985, CANCER RES, V45, P1437; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVY DB, 1994, CANCER RES, V54, P5953; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Lin SCJ, 1996, SEMIN CANCER BIOL, V7, P279, DOI 10.1006/scbi.1996.0036; LINEHAN WM, 1998, GENETIC BASIS HUMAN, P455; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; LIU L, 1995, ONCOGENE, V11, P405; LIVINGSTONE LR, 1992, CELL, V70, P605; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; LUONGO C, 1994, CANCER RES, V54, P5947; MACCOLLIN M, 1998, GENETIC BASIS HUMAN, P492; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; MAO L, 1995, CANCER RES, V55, P2995; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; MCCLATCHEY AI, 1997, GENE DEV, V11, P1250; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moll UM, 1998, CRIT REV ORAL BIOL M, V9, P23, DOI 10.1177/10454411980090010101; MORRIS JF, 1991, ONCOGENE, V6, P2339; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; NEWSHAM I, 1998, GENETICS BASIS HUMAN, P392; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Pan WJ, 1998, CARCINOGENESIS, V19, P765, DOI 10.1093/carcin/19.5.765; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; PURDIE CA, 1994, ONCOGENE, V9, P603; QUELLE DE, 1995, CELL, V83, P993; Rasheed BKA, 1997, CANCER RES, V57, P4187; Rhei E, 1997, CANCER RES, V57, P3657; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SCHUTTE M, 1995, P NATL ACAD SCI USA, V92, P5950, DOI 10.1073/pnas.92.13.5950; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Serova O, 1996, AM J HUM GENET, V58, P42; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shoemaker AR, 1998, P NATL ACAD SCI USA, V95, P10826, DOI 10.1073/pnas.95.18.10826; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; STEVENS LC, 1954, P NATL ACAD SCI USA, V40, P1080, DOI 10.1073/pnas.40.11.1080; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Stratton MR, 1996, CURR OPIN GENET DEV, V6, P93, DOI 10.1016/S0959-437X(96)90017-9; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tashiro H, 1997, CANCER RES, V57, P3935; Taverna D, 1998, CANCER RES, V58, P848; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; TSUKADA T, 1993, ONCOGENE, V8, P3313; VANHEYNINGEN V, 1990, P NATL ACAD SCI USA, V87, P5383, DOI 10.1073/pnas.87.14.5383; Varley JM, 1997, CANCER RES, V57, P3245; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Venkatachalam S, 1998, MUTAT RES-FUND MOL M, V400, P391, DOI 10.1016/S0027-5107(98)00018-9; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WINDLE JJ, 1990, NATURE, V343, P665, DOI 10.1038/343665a0; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; Yin L, 1998, HEPATOLOGY, V27, P73, DOI 10.1002/hep.510270113; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; ZONANA J, 1976, J PEDIATR-US, V89, P600, DOI 10.1016/S0022-3476(76)80397-6	242	61	64	1	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 24	1998	17	25					3385	3400		10.1038/sj.onc.1202573	http://dx.doi.org/10.1038/sj.onc.1202573			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9917000				2022-12-28	WOS:000078048200019
J	Liebermann, DA; Hoffman, B				Liebermann, DA; Hoffman, B			MyD genes in negative growth control	ONCOGENE			English	Review						MyD genes; growth arrest; apoptosis; myeloid differentiation; IRF-1; fos	NF-KAPPA-B; PRIMARY RESPONSE GENE; PROGRAMMED CELL-DEATH; MYELOID-LEUKEMIA CELLS; HERPES-SIMPLEX VIRUS; REGULATORY FACTOR-I; ACTIVATED PROTEIN-KINASE; SWINE FEVER VIRUS; RECEPTOR ACCESSORY PROTEIN; SIGNAL-TRANSDUCTION PATHWAY	Two interrelated cellular processes are invoked simultaneously upon induction of differentiation, the regulated progression of cells through successive stages of cell differentiation and growth inhibition which ultimately leads to growth arrest. In tissues with rapid cell turnover terminally differentiated cells undergo programmed cell death. Terminal differentiation, thus, represents one form of negative growth control. It was surmised that the molecular engine which drives the differentiation process forward requires induction of positive regulators of terminal cell differentiation, to be found among differentiation primary response genes, as well as suppression of negative regulators, which correspond to genes which control cellular growth. This line of thought has prompted the isolation of myeloid differentiation primary response (MyD) genes activated in the absence of de novo protein synthesis, upon IL-6 induced terminal differentiation of murine MI myeloblastic leukemia cells, where the cells growth arrest and ultimately undergo programmed cell death. As delineated in this review many of the genes identified as MyD genes, including both known genes [IRF-1, (AP-1) Fos/Jun.EGR-1] and novel ones (MyD88, MyD116, MyD118), turned out to play a role in negative growth control, including growth suppression and apoptosis, in many cell types, of both hematopoietic and non hematopoietic origins.	Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Dept Biochem, Sch Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liebermann, DA (corresponding author), Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, 3307 N Broad St, Philadelphia, PA 19140 USA.							ABDOLLAHI A, 1991, ONCOGENE, V6, P165; ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; Ahmed MM, 1997, J BIOL CHEM, V272, P33056, DOI 10.1074/jbc.272.52.33056; Aizawa S, 1997, J BIOL CHEM, V272, P2042; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brown SM, 1997, J VIROL, V71, P9442, DOI 10.1128/JVI.71.12.9442-9449.1997; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dinkel A, 1997, J IMMUNOL, V159, P2678; Distel R J, 1990, Adv Cancer Res, V55, P37, DOI 10.1016/S0065-230X(08)60467-4; DIXON LK, 1994, J GEN VIROL, V75, P1655, DOI 10.1099/0022-1317-75-7-1655; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; ELDON E, 1994, DEVELOPMENT, V120, P885; ELIOT HE, 1995, ANTICANCER RES, V15, P729; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; FUNATO T, 1992, ADV ENZYME REGUL, V32, P195; Gajate C, 1996, BIOCHEM BIOPH RES CO, V218, P267, DOI 10.1006/bbrc.1996.0047; GALINDO RL, 1995, DEVELOPMENT, V121, P2209; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goodenough S, 1997, EXP NEUROL, V145, P451, DOI 10.1006/exnr.1997.6471; Grant S, 1996, CELL GROWTH DIFFER, V7, P603; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; Guillouf C, 1998, INT J ONCOL, V13, P107; GUNJI H, 1991, CANCER RES, V51, P741; HALL PA, 1995, ONCOGENE, V10, P2427; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; Hardiman G, 1996, ONCOGENE, V13, P2467; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; He B, 1996, J VIROL, V70, P84, DOI 10.1128/JVI.70.1.84-90.1996; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; HERRLICH P, 1994, ADV ENZYME REGUL, V34, P381, DOI 10.1016/0065-2571(94)90024-8; Hoey T, 1997, SCIENCE, V278, P1578, DOI 10.1126/science.278.5343.1578; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; Horiuchi M, 1997, J BIOL CHEM, V272, P11952, DOI 10.1074/jbc.272.18.11952; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; HULTMARK D, 1994, BIOCHEM BIOPH RES CO, V199, P144, DOI 10.1006/bbrc.1994.1206; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; ITOH N, 1993, J BIOL CHEM, V268, P10932; Jacobs-Helber SM, 1998, MOL CELL BIOL, V18, P3699, DOI 10.1128/MCB.18.7.3699; Jaunin F, 1998, EXP CELL RES, V243, P67, DOI 10.1006/excr.1998.4131; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kanangat S, 1996, VIROLOGY, V219, P295, DOI 10.1006/viro.1996.0250; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1998, CANCER J SCI AM, V4, pS92; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Korherr C, 1997, EUR J IMMUNOL, V27, P262, DOI 10.1002/eji.1830270139; KREIPE H, 1986, DIFFERENTIATION, V33, P56, DOI 10.1111/j.1432-0436.1986.tb00410.x; Krishnaraju K, 1998, BLOOD, V92, P1957, DOI 10.1182/blood.V92.6.1957.418k24_1957_1966; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; Krishnaraju K, 1997, BLOOD, V90, P1840, DOI 10.1182/blood.V90.5.1840; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Lallemand C, 1997, J BIOL CHEM, V272, P29801, DOI 10.1074/jbc.272.47.29801; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LETSOU A, 1993, EMBO J, V12, P3449, DOI 10.1002/j.1460-2075.1993.tb06019.x; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Liebermann DA, 1998, INT J ONCOL, V12, P685; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; Lord EM., 1991, FLOWERING NEWSLETTER, V11, P4; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1990, ONCOGENE, V5, P1095; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Lovenberg TW, 1996, J NEUROIMMUNOL, V70, P113, DOI 10.1016/S0165-5728(96)00047-1; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MCGEOCH DJ, 1991, NATURE, V353, P609, DOI 10.1038/353609b0; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MESNER PW, 1995, J NEUROSCI, V15, P7357; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; Muthukkumar S, 1997, J BIOL CHEM, V272, P27987, DOI 10.1074/jbc.272.44.27987; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Norris JL, 1996, GENE DEV, V10, P862, DOI 10.1101/gad.10.7.862; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; PANTERNE B, 1992, ONCOGENE, V7, P2341; Parker JE, 1997, PLANT CELL, V9, P879, DOI 10.1105/tpc.9.6.879; Parnet P, 1996, J BIOL CHEM, V271, P3967; Preston GA, 1996, MOL CELL BIOL, V16, P211; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RITKE MK, 1994, MOL PHARMACOL, V46, P605; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; RUBIN E, 1992, CANCER RES, V52, P878; RUBIN E, 1991, MOL PHARMACOL, V39, P697; SALEEM A, 1995, CELL GROWTH DIFFER, V6, P1651; Sato T, 1997, BLOOD, V90, P4749, DOI 10.1182/blood.V90.12.4749.4749_4749_4758; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; SQUIER MKT, 1995, J LEUKOCYTE BIOL, V57, P2, DOI 10.1002/jlb.57.1.2; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; SUSSMAN MD, 1992, J VIROL, V66, P5586, DOI 10.1128/JVI.66.9.5586-5589.1992; Tamura T, 1996, BIOCHEM BIOPH RES CO, V229, P21, DOI 10.1006/bbrc.1996.1752; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Vairapandi M, 1996, ONCOGENE, V12, P2579; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VYDELINGUM S, 1993, J GEN VIROL, V74, P2125, DOI 10.1099/0022-1317-74-10-2125; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGATA M, 1994, GENE, V139, P223, DOI 10.1016/0378-1119(94)90760-9; YANAGISAWA K, 1993, FEBS LETT, V318, P83, DOI 10.1016/0014-5793(93)81333-U; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zsak L, 1996, J VIROL, V70, P8865, DOI 10.1128/JVI.70.12.8865-8871.1996	164	68	71	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 24	1998	17	25					3319	3329		10.1038/sj.onc.1202574	http://dx.doi.org/10.1038/sj.onc.1202574			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916994				2022-12-28	WOS:000078048200013
J	Reed, JC				Reed, JC			Bcl-2 family proteins	ONCOGENE			English	Review						Bcl-2; Bax; apoptosis; chemoresistance	PROGRAMMED CELL-DEATH; MITOCHONDRIAL PERMEABILITY TRANSITION; P53-MEDIATED TRANSCRIPTIONAL REPRESSION; SURVIVAL-PROMOTING PROTEINS; DOMAIN-CONTAINING PROTEIN; YEAST 2-HYBRID SYSTEM; PORE-FORMING DOMAIN; CYTOCHROME-C; CAENORHABDITIS-ELEGANS; MAMMALIAN-CELLS	Bcl-2 family proteins serve as critical regulators of pathways involved in apoptosis, acting to either inhibit or promote cell death. Altered expression of these proteins occurs commonly in human cancers, contributing to neoplastic cell expansion by suppressing programmed cell death and extending tumor cell life span. Moreover, because chemotherapeutic drugs typically exert their cytotoxic actions by inducing apoptosis, the ultimate efficacy of most anticancer drugs can be heavily influenced by the relative levels and state of activation of members of the Bcl-2 family. The question of how Bcl-2 family proteins function remains debatable, but new findings are shaping our impressions of these multifunctional proteins and revealing the details of how these proteins participate in the regulation of cell life and death.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; Brunet CL, 1998, CELL DEATH DIFFER, V5, P107, DOI 10.1038/sj.cdd.4400334; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; CHEN G, 1998, IN PRESS J BIOL CHEM; CHEN Q, 1998, IN PRESS BLOOD; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; CRAMER WA, 1992, FEMS MICROBIOL IMMUN, V105, P71; CRAMER WA, 1995, ANNU REV BIOPH BIOM, V24, P611, DOI 10.1146/annurev.biophys.24.1.611; CRUZREYES J, 1995, GENE, V158, P171, DOI 10.1016/0378-1119(95)00159-4; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEJONG D, 1994, CANCER RES, V54, P256; delPeso L, 1997, SCIENCE, V278, P687; DELPESO L, 1998, IN PRESS J BIOL CHEM; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Diaz JL, 1997, J BIOL CHEM, V272, P11350; DONOVAN JJ, 1982, NATURE, V298, P669, DOI 10.1038/298669a0; Duche D, 1996, J BIOL CHEM, V271, P15401, DOI 10.1074/jbc.271.26.15401; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; FINUCANE DM, 1998, IN PRESS J BIOL CHEM; Garland JM, 1998, BLOOD, V92, P1235, DOI 10.1182/blood.V92.4.1235.416k18_1235_1246; GOPING IS, 1998, IN PRESS J CELL BIOL; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Han JH, 1998, MOL CELL BIOL, V18, P6052, DOI 10.1128/MCB.18.10.6052; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Hengartner MO, 1998, NATURE, V391, P441, DOI 10.1038/35036; Hirsch T, 1997, BIOSCIENCE REP, V17, P67, DOI 10.1023/A:1027339418683; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Ink B, 1997, MOL CELL BIOL, V17, P2468, DOI 10.1128/MCB.17.5.2468; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; INOHARA N, 1998, IN PRESS J BIOL CHEM; Irmler M, 1997, FEBS LETT, V406, P189, DOI 10.1016/S0014-5793(97)00271-8; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Jurgensmeier JM, 1997, MOL BIOL CELL, V8, P325; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kitada S, 1998, AM J PATHOL, V152, P51; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; KURSCHNER C, 1995, MOL BRAIN RES, V30, P165, DOI 10.1016/0169-328X(95)00013-I; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; Longo VD, 1997, J CELL BIOL, V137, P1581, DOI 10.1083/jcb.137.7.1581; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; MATSUSHIMA M, 1997, IN PRESS GENES CHROM; MATSUYAMA S, 1998, IN PRESS J BIOL CHEM; McCarthy JV, 1998, J BIOL CHEM, V273, P24009, DOI 10.1074/jbc.273.37.24009; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P5829, DOI 10.1021/bi00476a026; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Ohta T, 1997, J BIOL CHEM, V272, P23111, DOI 10.1074/jbc.272.37.23111; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; PARKER MW, 1992, J MOL BIOL, V224, P639, DOI 10.1016/0022-2836(92)90550-4; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1990, CANCER RES, V50, P6565; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shimizu S, 1996, ONCOGENE, V13, P21; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; Simonen M, 1997, EUR J BIOCHEM, V249, P85, DOI 10.1111/j.1432-1033.1997.t01-1-00085.x; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Simonian PL, 1996, J BIOL CHEM, V271, P32073, DOI 10.1074/jbc.271.50.32073; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; SUSIN SA, 1998, IN PRESS J EXP MED; Takayama S, 1998, CANCER RES, V58, P3116; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Tao WK, 1997, J BIOL CHEM, V272, P15547, DOI 10.1074/jbc.272.24.15547; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zha HB, 1997, J BIOL CHEM, V272, P31482, DOI 10.1074/jbc.272.50.31482; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	156	896	943	2	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 24	1998	17	25					3225	3236		10.1038/sj.onc.1202591	http://dx.doi.org/10.1038/sj.onc.1202591			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916985				2022-12-28	WOS:000078048200004
J	Liu, SK; McGlade, CJ				Liu, SK; McGlade, CJ			Gads is a novel SH2 and SH3 domain-containing adaptor protein that binds to tyrosine-phosphorylated Shc	ONCOGENE			English	Article						adaptor protein; SH2 domain; SH3 domain; Shc; Bcr-Abl	NUCLEOTIDE EXCHANGE FACTOR; EPIDERMAL GROWTH-FACTOR; C-CBL PROTOONCOGENE; SIGNAL TRANSDUCTION; HEMATOPOIETIC-CELLS; RAS PATHWAY; GRB2; RECEPTOR; TRANSFORMATION; KINASE	Shc proteins are important substrates of receptor and cytoplasmic tyrosine kinases that couple activated receptors to downstream signaling enzymes. Phosphorylation of Shc tyrosine residues 239 and 317 leads to recruitment of the Grb2-Sos complex, thus linking Shc phosphorylation to Ras activation. We have used phosphorylated peptides corresponding to the regions spanning tyrosine 239/240 and 317 of Shc in an expression library screen to identify additional downstream targets of Shc. Here we report the identification of Gads, a novel adaptor protein most similar to Grb2 and Grap that contains amino and carboxy terminal SH3 domains flanking a central SH2 domain and a 120 amino acid unique region. Gads is most highly expressed in the thymus and spleen of adult animals and in human leukemic cell lines, The binding specificity of the Gads SH2 domain is similar to Grb2 and mediates the interaction of Gads with Shc, Bcr-Abl and c-kit, Gads does not interact with Sos, Cbl or Sam68, although the isolated carboxy terminal Gads SH3 domain is able to bind these molecules in vitro. Our results suggest that the unique structure of Gads regulates its interaction with downstream SH3 domain-binding proteins and that Gads may function to couple tyrosine-phosphorylated proteins such as Shc, Bcr-Abl and activated receptor tyrosine kinases to downstream effectors distinct from Sos and Ras.	Univ Toronto, Ontario Canc Inst, AMGEN Inst, Dept Med Biophys, Toronto, ON M5G 2C1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	McGlade, CJ (corresponding author), Univ Toronto, Ontario Canc Inst, AMGEN Inst, Dept Med Biophys, 60 Univ Ave,Suite 706, Toronto, ON M5G 2C1, Canada.			Liu, Stanley/0000-0001-6851-0857				Anafi M, 1996, J BIOL CHEM, V271, P21365, DOI 10.1074/jbc.271.35.21365; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALDARI CT, 1995, ONCOGENE, V10, P1141; Benson DA, 1998, NUCLEIC ACIDS RES, V26, P1, DOI 10.1093/nar/26.1.1; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CROWE AJ, 1994, ONCOGENE, V9, P537; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; Gotoh A, 1997, Curr Opin Hematol, V4, P3; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; LI N, 1993, NATURE, V363, P88; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PULL L, 1994, EMBO J, V13, P764; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	46	95	97	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 17	1998	17	24					3073	3082		10.1038/sj.onc.1202337	http://dx.doi.org/10.1038/sj.onc.1202337			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872323				2022-12-28	WOS:000077517400001
J	Amundson, SA; Zhan, Q; Penn, LZ; Fornace, AJ				Amundson, SA; Zhan, Q; Penn, LZ; Fornace, AJ			Myc suppresses induction of the growth arrest genes gadd34, gadd45, and gadd153 by DNA-damaging agents	ONCOGENE			English	Article						gadd45; myc; transcriptional repression	C-MYC; REPRESSES TRANSCRIPTION; INDUCED APOPTOSIS; RAT FIBROBLASTS; CELL-GROWTH; P53; ACTIVATION; PROMOTER; RADIATION; PATHWAY	The growth arrest and DNA damage inducible (gadd) genes are induced by various genotoxic and nongenotoxic stresses such as serum starvation, ultraviolet irradiation and treatment with alkylating agents. Their coordinate induction is a growth arrest signal which may play an important role in the response of cells to DNA damage. Conversely, c-myc is a strong proliferative signal, and overexpression of Myc is frequently observed in cancer cells, We have found that ectopic expression of v-myc in RAT-I cells results in an attenuated induction of the three major gadd transcripts by methyl methanesulfonate (MMS), and almost completely blocks the response to ultraviolet (UV) radiation. Myc acts in part by reducing the stress-responsiveness of the gadd45 promoter, as a c-myc expression vector strongly suppressed activation of gadd-reporter constructs. This activity of Myc localizes to a recently described CC-rich binding site within the gadd45 promoter. These results indicate that a coordinate down-regulation of the gadd gene response is one mechanism by which Myc can circumvent growth arrest and contribute to the neoplastic phenotype.	NCI, NIH, Bethesda, MD 20892 USA; Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Toronto; University Toronto Affiliates; University Health Network Toronto	Fornace, AJ (corresponding author), NCI, NIH, 37 Convent Dr,Bldg,37 Room 5C09, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; Penn, Linda/0000-0001-8133-5459				AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Chen CH, 1996, ONCOGENE, V13, P1659; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; HERMEKING H, 1995, ONCOGENE, V11, P1409; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; JACKMAN J, 1994, CANCER RES, V54, P5656; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PRABHAKAR NR, 1995, BRAIN RES, V697, P266, DOI 10.1016/0006-8993(95)00994-2; WANG ZY, 1995, ONCOGENE, V10, P1243; Yu K, 1997, CELL GROWTH DIFFER, V8, P731; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	28	77	80	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2149	2154		10.1038/sj.onc.1202136	http://dx.doi.org/10.1038/sj.onc.1202136			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811446				2022-12-28	WOS:000076698200001
J	Tsubakimoto, K; Matsumoto, K; Abe, H; Ishii, J; Amano, M; Kaibuchi, K; Endo, T				Tsubakimoto, K; Matsumoto, K; Abe, H; Ishii, J; Amano, M; Kaibuchi, K; Endo, T			Small GTPase RhoD suppresses cell migration and cytokinesis	ONCOGENE			English	Article						small GTPase; Rho family; actin cytoskeleton; cell motility; cytokinesis	ACTIN STRESS FIBERS; PROTO-ONCOGENE PRODUCT; FOCAL ADHESIONS; BINDING PROTEIN; REGULATED EXPRESSION; HEMATOPOIETIC-CELLS; SMOOTH-MUSCLE; IN-VIVO; KINASE; GENE	Rho family small GTPases regulate organization of the actin cytoskeleton, Among them, RhoA plays essential roles in the formation of the actin stress fibers, the associated focal adhesions, and the contractile rings necessary for cytokinesis, Recently, RhoD, a novel member of Rho family has been identified. The amino acid sequences of its effector domain is distinct from those of the other Rho family proteins, suggesting its unique cellular functions. Introduction of the constitutively active form of RhoD(G26V) into fibroblasts by microinjection or transfection resulted in disassembly of the actin stress fibers and the focal adhesions, whereas the dominant negative form of RhoD(G26V) did not affect these structures. The degree of cell migration assessed by the phagokinetic tracks on a substrate covered with gold particles was diminished by the expression of RhoD(G26V) but not by RhoD(T31K). Thus, cytoskeletal alterations including the loss of stress fibers and focal adhesions by RhoD seems to lead to the retardation of cell migration. Transfection of RhoD(G26V) cDNA into cultured cells also induced multinucleation, Moreover, RhoD(G26V) microinjected into fertilized eggs and embryos of Xenopus laevis caused cleavage arrest only in the injected cells, and the uncleaved cells contained multiple nuclei. These results imply that RhoD does not affect nuclear division but can interfere with cytokinesis presumably by preventing the formation of the actin-based contractile ring. Enhancement of the stress fibers by RhoA or RhoA-activating lysophosphatidic acid was reversed by the transfection of RhoD cDNA, Accordingly, the cellular functions of RhoD are likely to be antagonistic to those of RhoA.	Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan; Nara Inst Sci & Technol, Div Signal Transduct, Nara 6300101, Japan	Chiba University; Nara Institute of Science & Technology	Endo, T (corresponding author), Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan.		Amano, Mutsuki/M-4820-2014	Amano, Mutsuki/0000-0002-0662-1524				AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; AMANO T, 1972, P NATL ACAD SCI USA, V69, P258, DOI 10.1073/pnas.69.1.258; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; del Peso L, 1997, ONCOGENE, V15, P3047; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Dutartre H, 1996, J CELL SCI, V109, P367; ENDO T, 1982, BIOCHEM BIOPH RES CO, V107, P1467, DOI 10.1016/S0006-291X(82)80164-2; Endo T, 1996, J BIOL CHEM, V271, P27855, DOI 10.1074/jbc.271.44.27855; Endo T, 1998, J CELL SCI, V111, P1081; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Foster R, 1996, MOL CELL BIOL, V16, P2689; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leung T, 1996, MOL CELL BIOL, V16, P5313; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; MANSER E, 1995, METHOD ENZYMOL, V256, P130; Marks PW, 1996, GENOMICS, V38, P13, DOI 10.1006/geno.1996.0586; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MOLL J, 1991, ONCOGENE, V6, P863; MORII N, 1995, METHOD ENZYMOL, V256, P196; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Nakamura T, 1996, BIOCHEM BIOPH RES CO, V226, P688, DOI 10.1006/bbrc.1996.1415; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1991, NEW BIOL, V3, P372; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; SEGADE F, 1995, J IMMUNOL, V154, P2384; SELF AJ, 1993, ONCOGENE, V8, P655; SHIRSAT NV, 1990, ONCOGENE, V5, P769; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	64	49	53	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2431	2440		10.1038/sj.onc.1202604	http://dx.doi.org/10.1038/sj.onc.1202604			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229194	Bronze			2022-12-28	WOS:000079703300003
J	Swanton, E; Savory, P; Cosulich, S; Clarke, P; Woodman, P				Swanton, E; Savory, P; Cosulich, S; Clarke, P; Woodman, P			Bcl-2 regulates a caspase-3/caspase-2 apoptotic cascade in cytosolic extracts	ONCOGENE			English	Article						ICH-1; caspase cleavage; cytochrome c; dATP	CELL-FREE SYSTEM; CYTOCHROME-C; INITIATES APOPTOSIS; DEATH DOMAIN; GRANZYME-B; PROTEIN; ACTIVATION; PROTEASES; CASPASES; INTERACTS	Apoptosis is accompanied by the activation of a number of apoptotic proteases (caspases) which selectively cleave specific cellular substrates. Caspases themselves are zymogens which are activated by proteolysis. It is widely believed that 'initiator' caspases are recruited to and activated within apoptotic signalling complexes, and then cleave and activate downstream 'effector' caspases, While activation of the effector caspase, caspase-3, has indeed been observed as distal to activation of several different initiator caspases, evidence for a further downstream proteolytic cascade is limited. In particular, there is little evidence that cellular levels of caspase-3 that are activated via one pathway are sufficient to cleave and activate other initiator caspases, To address this issue, the ability of caspase-3, activated upon addition to cytosolic extracts of cytochrome c, to cause cleavage of caspase-2 was investigated. It was demonstrated that cleavage of caspase-2 follows, and is dependent upon, activation of caspase-3, Moreover, the activation of both caspases was inhibited by Bcl-2, Together, these data indicate that Bcl-2 can protect cells from apoptosis by acting at a point downstream from release of mitochondrial cytochrome c, thereby preventing a caspase-3 dependent proteolytic cascade.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Woodman, P (corresponding author), Univ Manchester, Sch Biol Sci, Oxford Rd, Manchester M13 9PT, Lancs, England.		Clarke, Paul R./AAA-6803-2020; Clarke, Paul R/B-1684-2009	Swanton, Eileithyia/0000-0002-3299-4228; Clarke, Paul R/0000-0003-3525-2622				BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Pan GH, 1998, FEBS LETT, V426, P151, DOI 10.1016/S0014-5793(98)00330-5; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Polverino AJ, 1997, J BIOL CHEM, V272, P7013, DOI 10.1074/jbc.272.11.7013; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	29	97	128	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1781	1787		10.1038/sj.onc.1202490	http://dx.doi.org/10.1038/sj.onc.1202490			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086332				2022-12-28	WOS:000079090000001
J	Eymin, B; Haugg, M; Droin, N; Sordet, O; Dimanche-Boitrel, MT; Solary, E				Eymin, B; Haugg, M; Droin, N; Sordet, O; Dimanche-Boitrel, MT; Solary, E			p27(Kip1) induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells	ONCOGENE			English	Article						p27(Kip1); drug resistance; apoptosis; caspases; cytochrome c	ANTICANCER AGENTS; TOPOISOMERASE-II; CYCLE ARREST; MITOCHONDRIA; PROTEASE; CASPASES; DEATH; BCL-2; INHIBITORS; ETOPOSIDE	The cyclin-dependent kinase inhibitor p27(Kip1) has been implicated as a drug resistance factor in tumor cells grown as spheroids or confluent monolayers. Here, we show that p27(Kip1) overexpression also induces resistance to drug-induced apoptosis and cytotoxicity in human leukemic cells growing in suspension, The anti-apoptotic effect of p27(Kip1) is not restricted to DNA-damaging agents but extends to the tubulin poison vinblastin, agonistic anti-Fas antibodies and macromolecule synthesis inhibitors. To further identify at which level this protein interferes with the cell death pathway, we investigated its influence on caspase activation and mitochondrial changes. Exposure df mock-transfected U937 cells to 50 mu M etoposide activates procaspase-3 and the long isoform of procaspase-2 and induces mitochondrial potential decrease and cytochrome c release from mitochondria to the cytosol, All these events are prevented by p27(KiP1) overexpression. p27(Kip1) does not modulate BcL-2, BcL-X-L, Mel-1 and Bar protein level in leukemic cells but suppresses Mel-1 expression decrease observed in mock-transfected U937 cells undergoing etoposide-induced cell death. We conclude that p27(Kip1) prevents cell death upstream of the final pathway common to many apoptotic stimuli that involves cytochrome c release from mitochondria and activation of downstream caspases.	Fac Med & Pharm, CJF,Lab Oncohematol & Pharmacol, INSERM 94-08, Grp Biol & Therapie Canc JE515, F-21033 Dijon, France; CHU Le Bocoge, F-21033 Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Solary, E (corresponding author), Fac Med & Pharm, CJF,Lab Oncohematol & Pharmacol, INSERM 9408, Grp Biol & Therapie Canc JE515, 7 Blvd Jeanne Arc, F-21033 Dijon, France.		Sordet, Olivier/M-3271-2014; Droin, Nathalie M/Y-5506-2018; eymin, beatrice/U-4670-2019; Dimanche-Boitrel, Marie-Therese M/I-4642-2015; Eymin, Beatrice/M-1962-2013	Sordet, Olivier/0000-0001-6027-4925; Droin, Nathalie M/0000-0002-6099-5324; eymin, beatrice/0000-0002-7311-3810; Eymin, Beatrice/0000-0002-7311-3810; Dimanche-Boitrel, Marie-Therese/0000-0002-8038-7780; Solary, Eric/0000-0002-8629-1341				BERTRAND R, 1995, DRUG DEVELOP RES, V34, P138, DOI 10.1002/ddr.430340206; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; DIMANCHEBOITREL MT, 1998, IN PRESS INT J CANC; DROIN N, 1998, IN PRESS ONCOGENE; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; Eymin B, 1997, CANCER RES, V57, P686; EYMIN B, 1995, INT J CANCER, V63, P268, DOI 10.1002/ijc.2910630221; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Katayose Y, 1997, CANCER RES, V57, P5441; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038/sj.onc.1201585; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SOLARY E, 1993, BLOOD, V81, P1359; Solary E, 1998, CELL BIOL TOXICOL, V14, P121, DOI 10.1023/A:1007481921502; StCroix B, 1996, NAT MED, V2, P1204; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang W, 1995, CLIN CANCER RES, V1, P1051	41	84	87	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1411	1418		10.1038/sj.onc.1202437	http://dx.doi.org/10.1038/sj.onc.1202437			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050878				2022-12-28	WOS:000078651600003
J	Rickert, P; Corden, JL; Lees, E				Rickert, P; Corden, JL; Lees, E			Cyclin C CDK8 and cyclin H CDK7 p36 are biochemically distinct CTD kinases	ONCOGENE			English	Article						cyclin C; CDK8; CTD; RNA polymerase II	RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; TRANSCRIPTION FACTOR TFIIH; PRE-MESSENGER-RNA; LARGEST SUBUNIT; PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; ACTIVATING KINASE; REPEAT DOMAIN; DEPENDENT KINASES	Phosphorylation of the carboxyl-terminal domain (CTD) of RNA polymerase IT is important for basal transcriptional processes in vivo and for cell viability. Several kinases, including certain cyclin-dependent kinases, can phosphorylate this substrate in vitro. It has been proposed that differential CTD phosphorylation by different kinases may regulate distinct transcriptional processes. We have found that two of these kinases, cyclin C/CDK8 and cyclin H/CDK7/p36, can specifically phosphorylate distinct residues in recombinant CTD substrates, This difference in specificity may be largely due to their varying ability to phosphorylate lysine-substituted heptapeptide repeats within the CTD, since they phosphorylate the same residue in CTD consensus heptapeptide repeats. Furthermore, this substrate specificity is reflected in vivo where cyclin C/CDK8 and cyclin H/CDK7/p36 can differentially phosphorylate an endogenous RNA polymerase II substrate, Several small-molecule kinase inhibitors have different specificities for these related kinases, indicating that these enzymes have diverse active-site conformations. These results suggest that cyclin C/CDK8 and cyclin H/CDK7/p36 are physically distinct enzymes that may have unique roles in transcriptional regulation mediated by their phosphorylation of specific sites on RNA polymerase II.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signaling, Palo Alto, CA 94304 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21209 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Stanford University; Johns Hopkins University	Lees, E (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signaling, 901 Calif Ave, Palo Alto, CA 94304 USA.							ABRAHAM RT, 1995, BIOL CELL, V83, P105, DOI 10.1016/0248-4900(96)81298-6; AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; Baskaran R, 1997, J BIOL CHEM, V272, P18905, DOI 10.1074/jbc.272.30.18905; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Bellier S, 1997, MOL CELL BIOL, V17, P1434, DOI 10.1128/MCB.17.3.1434; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CAGAS PM, 1995, PROTEINS, V21, P149, DOI 10.1002/prot.340210209; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; CHAPMAN AB, 1994, J BIOL CHEM, V269, P4754; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CISEK LJ, 1991, METHOD ENZYMOL, V200, P301; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORDEN JL, 1993, CURR OPIN GENET DEV, V3, P213, DOI 10.1016/0959-437X(93)90025-K; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; DAHMUS ME, 1981, J BIOL CHEM, V256, P3332; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; Dubois MF, 1997, NUCLEIC ACIDS RES, V25, P694, DOI 10.1093/nar/25.4.694; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; DUBOIS MF, 1994, EMBO J, V13, P4787, DOI 10.1002/j.1460-2075.1994.tb06804.x; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Gebara MM, 1997, J CELL BIOCHEM, V64, P390; GIESECKE H, 1991, BIOCHEM BIOPH RES CO, V180, P1350, DOI 10.1016/S0006-291X(05)81344-0; GLAB N, 1994, FEBS LETT, V353, P207, DOI 10.1016/0014-5793(94)01035-8; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; JIANG Y, 1994, NUCLEIC ACIDS RES, V22, P4958, DOI 10.1093/nar/22.23.4958; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; KUCHIN S, 1995, P NATL ACAD SCI USA, V92, P4006, DOI 10.1073/pnas.92.9.4006; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; Lee JM, 1997, J BIOL CHEM, V272, P10990; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; MISTELI T, 1995, J CELL SCI, V108, P2715; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; PAYNE JM, 1993, J BIOL CHEM, V268, P80; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; RICE SA, 1994, J VIROL, V68, P988, DOI 10.1128/JVI.68.2.988-1001.1994; Rickert P, 1996, ONCOGENE, V12, P2631; RICKERT P, 1997, THESIS STANFORD U; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SAMBROOK J, CLONIONG LAB MANUAL; SCHULZEGAHMEN U, 1995, PROTEINS, V22, P378, DOI 10.1002/prot.340220408; SEHGAL PB, 1976, CELL, V9, P473, DOI 10.1016/0092-8674(76)90092-1; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Shilatifard A, 1997, CURR OPIN GENET DEV, V7, P199, DOI 10.1016/S0959-437X(97)80129-3; SIMON M, 1986, EMBO J, V5, P2697, DOI 10.1002/j.1460-2075.1986.tb04553.x; Song CZ, 1996, BIOCHEM BIOPH RES CO, V229, P810, DOI 10.1006/bbrc.1996.1885; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; STEVENS A, 1989, BIOCHEM BIOPH RES CO, V159, P508, DOI 10.1016/0006-291X(89)90022-3; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587; VENETIANER A, 1995, EUR J BIOCHEM, V233, P83, DOI 10.1111/j.1432-1033.1995.083_1.x; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WEST ML, 1995, GENETICS, V140, P1223; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; Yuryev A, 1996, GENETICS, V143, P661; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	82	96	99	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					1093	1102		10.1038/sj.onc.1202399	http://dx.doi.org/10.1038/sj.onc.1202399			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023686				2022-12-28	WOS:000078510600027
J	Salvucci, M; Lemoine, A; Saffroy, R; Azoulay, D; Lepere, B; Gaillard, S; Bismuth, H; Reynes, R; Debuire, B				Salvucci, M; Lemoine, A; Saffroy, R; Azoulay, D; Lepere, B; Gaillard, S; Bismuth, H; Reynes, R; Debuire, B			Microsatellite instability in European hepatocellular carcinoma	ONCOGENE			English	Article						transforming growth factor (TGF beta) type II; receptor (RII) gene; cirrhosis; clinicopathological characteristics; recurrent disease; prognostic factor	II RECEPTOR GENE; GENOMIC INSTABILITY; COLORECTAL-CANCER; LIVER-TRANSPLANTATION; ULCERATIVE-COLITIS; MUTATION COMMON; BREAST-CANCER; HEPATITIS; REPEATS; ADENOCARCINOMA	Genetic instability has been detected in many types of cancers but poorly investigated in hepatocellular carcinoma (HCC). We have studied the incidence of microsatellite instability (MI) at eight highly polymorphic microsatellite markers and the poly A tract BAT26 and tested for mutations at two sites of repetitive sequence (poly-A nucleotides 709-718 and GT repeat-nucleotides 1931-1936) in the Transforming Growth Factor beta (TGF beta) type II receptor (RII) gene, in a group of 46 European HCCs and the surrounding nontumour tissue. This analysis showed that 63% of HCCs exhibit MI in at least one chromosome locus and 41% in two or more loci. No mutations of the TGF beta RII gene were found in the MI positive tumours. No correlation was found with clinicopathological characteristics of the tumours such as cirrhosis, etiology, number of nodules, Edmondson's grade and vascular invasion. However, in patients who had a rearranged D16S402 microsatellite in their tumour, the recurrent disease and the number of nodules were significantly higher than in the others (P<0.005 and P<0.02, respectively). We propose to consider D16S402 rearrangement in HCC as a prognostic factor to identify patients presenting a higher risk of recurrence.	Hop Paul Brousse, Dept Biochem, F-94804 Villejuif, France; Hop Paul Brousse, Hepatobiliary Surg & Liver Transplant Res Unit, F-94804 Villejuif, France; Hop Paul Brousse, Dept Pathol, F-94804 Villejuif, France; Fac Med Paris Sud, CEA, CNRS, UMR 217, Fontenay Aux Roses, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Debuire, B (corresponding author), Hop Paul Brousse, Dept Biochem, 14 Ave Paul Vaillant Couturier, F-94804 Villejuif, France.		Azoulay, Daniel/Q-7887-2018	SAFFROY, RAPHAEL/0000-0002-9878-3669				Abe T, 1996, EUR J SURG ONCOL, V22, P474, DOI 10.1016/S0748-7983(96)92824-3; AKASHI Y, 1991, HEPATOLOGY, V14, P262, DOI 10.1016/0270-9139(91)91413-U; ARZIMANOGLOU IA, 1996, CARCINOGENESIS, V47, P1799; BISMUTH H, 1993, ANN SURG, V218, P145, DOI 10.1097/00000658-199308000-00005; Boige V, 1997, CANCER RES, V57, P1986; BOURDON JC, 1995, GASTROENTEROLOGY, V108, P1176, DOI 10.1016/0016-5085(95)90217-1; BRENTNALL TA, 1995, CANCER RES, V55, P4264; Brentnall TA, 1996, CANCER RES, V56, P1237; Chung YJ, 1996, CANCER RES, V56, P4662; DeMarchis L, 1997, CLIN CANCER RES, V3, P241; DUGGAN BD, 1994, J NATL CANCER I, V86, P1216, DOI 10.1093/jnci/86.16.1216; FERAY C, 1994, HEPATOLOGY, V20, P1137, DOI 10.1016/0270-9139(94)90748-X; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; HANN HJ, 1993, CANCER RES, V53, P5087; HOANG JM, 1996, CANCER RES, V53, P300; HONCHEL R, 1994, CANCER RES, V54, P1159; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kaneko H, 1996, LEUKEMIA, V10, P1696; Kaplanski C, 1997, INT J CANCER, V72, P248, DOI 10.1002/(SICI)1097-0215(19970717)72:2<248::AID-IJC8>3.0.CO;2-R; Lemoine A, 1997, ANN SURG, V226, P43, DOI 10.1097/00000658-199707000-00006; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOTHE RA, 1993, CANCER RES, V53, P5849; LU SL, 1995, BIOCHEM BIOPH RES CO, V216, P452, DOI 10.1006/bbrc.1995.2644; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MELTZER SJ, 1994, CANCER RES, V54, P3379; MERLO A, 1994, CANCER RES, V54, P2098; MYEROFF LL, 1995, CANCER RES, V55, P5545; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; PARSONS R, 1995, CANCER RES, V55, P5548; Paulson TG, 1996, CANCER RES, V56, P4021; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; RHYU MG, 1994, ONCOGENE, V9, P29; Salvucci M, 1996, ONCOGENE, V13, P2681; SAMUEL D, 1995, HEPATOLOGY, V21, P333, DOI 10.1016/0270-9139(95)90089-6; SHRIDHAR V, 1994, CANCER RES, V54, P2084; Souza RF, 1997, GASTROENTEROLOGY, V112, P40, DOI 10.1016/S0016-5085(97)70217-8; Takenoshita S, 1997, CARCINOGENESIS, V18, P1427, DOI 10.1093/carcin/18.7.1427; TAMURA G, 1995, CANCER RES, V55, P1933; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Togo G, 1996, CANCER RES, V56, P5620; UCHIDA T, 1994, CANCER RES, V54, P3682; Vincent F, 1996, BIOCHEM BIOPH RES CO, V223, P561, DOI 10.1006/bbrc.1996.0934; WADA C, 1994, BLOOD, V83, P3449, DOI 10.1182/blood.V83.12.3449.bloodjournal83123449; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; Yeh SH, 1996, GASTROENTEROLOGY, V110, P184, DOI 10.1053/gast.1996.v110.pm8536855; Zhu JG, 1996, ONCOGENE, V12, P1417	46	66	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					181	187		10.1038/sj.onc.1202279	http://dx.doi.org/10.1038/sj.onc.1202279			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926933				2022-12-28	WOS:000078166000020
J	Varadhachary, AS; Salgame, P				Varadhachary, AS; Salgame, P			CD95 mediated T cell apoptosis and its relevance to immune deviation	ONCOGENE			English	Article						T cells; CD95; immune; deviation	ACTIVATION-INDUCED CELL; TUMOR-NECROSIS-FACTOR; B7-2 COSTIMULATORY MOLECULES; PROTEIN-TYROSINE-PHOSPHATASE; SIGNALING COMPLEX DISC; FAS-INDUCED APOPTOSIS; DIFFERENTIAL ABILITY; MONOCLONAL-ANTIBODY; FUNCTIONAL SUBSETS; DEATH DOMAIN	The CD95/CD95L pair plays a manifold role in regulating life and death in the function of the immune system, Examples include CD95/CD95L acting as cytotoxic CD8+ T cell effector molecules, or functioning on CD4+ T helper cells to maintain peripheral tolerance or reestablishing homeostasis, Current understanding of the CD95 signaling pathway reveals several potential regulatory targets, acting both receptor proximally and distally, that can terminate or amplify the receptor's signal, The important and possibly nonredundant role of CD95 is highlighted both in how deficiencies in functional CD95 or its ligand manifest themselves in autoimmune syndromes, and how uncontrolled cell death results in insufficient, or inappropriate immune responses against immune challenge. This review examines CD95-mediated signal transduction, and the effect preferential apoptosis of T helper cell subsets has on immune system biasing.	Temple Univ, Dept Microbiol & Immunol, Sch Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Salgame, P (corresponding author), Temple Univ, Dept Microbiol & Immunol, Sch Med, Philadelphia, PA 19140 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055972] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 55972] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKBAR AN, 1993, J EXP MED, V178, P427, DOI 10.1084/jem.178.2.427; AMEISEN JC, 1994, IMMUNOL REV, V142, P9, DOI 10.1111/j.1600-065X.1994.tb00882.x; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; BLOOM BR, 1992, ANNU REV IMMUNOL, V10, P453, DOI 10.1146/annurev.iy.10.040192.002321; BOISE LH, 1995, CURR OPIN IMMUNOL, V7, P620, DOI 10.1016/0952-7915(95)80067-0; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CHAN J, 1994, IMMUNE MECH PROTECTI, pCH24; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CHIU VK, 1995, J IMMUNOL, V154, P2023; CLERICI M, 1993, SCIENCE, V262, P1721, DOI 10.1126/science.7903123; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; GAJEWSKI TF, 1990, J IMMUNOL, V144, P4110; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1997, P NATL ACAD SCI USA, V94, P5986, DOI 10.1073/pnas.94.12.5986; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; IRLMER M, 1997, NATURE, V388, P461; ITOH N, 1993, J BIOL CHEM, V268, P10932; JAATTELA M, 1995, ONCOGENE, V10, P2297; JANEWAY CA, 1988, IMMUNOL REV, V101, P39, DOI 10.1111/j.1600-065X.1988.tb00732.x; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Ledru E, 1998, J IMMUNOL, V160, P3194; Lee RK, 1996, INT IMMUNOL, V8, P991, DOI 10.1093/intimm/8.7.991; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; MEMON SA, 1995, J IMMUNOL, V155, P4644; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NOVAK TJ, 1990, P NATL ACAD SCI USA, V87, P9353, DOI 10.1073/pnas.87.23.9353; Okura T, 1996, J IMMUNOL, V157, P4277; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; PFEIFFER C, 1991, IMMUNOL REV, V123, P65, DOI 10.1111/j.1600-065X.1991.tb00606.x; POWRIE F, 1993, EUR J IMMUNOL, V23, P3043, DOI 10.1002/eji.1830231147; RAMSDELL F, 1994, INT IMMUNOL, V6, P1545, DOI 10.1093/intimm/6.10.1545; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; SALGAME P, 1992, CHEM IMMUNOL, V54, P44; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCAFFIDI C, 1998, IN PRESS J BIOL CHEM; Scott P, 1998, IMMUNOL RES, V17, P229, DOI 10.1007/BF02786447; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; STADECKER MJ, 1994, IMMUNOL TODAY, V15, P571, DOI 10.1016/0167-5699(94)90219-4; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; SU X, 1995, IMMUNITY, V2, P353, DOI 10.1016/1074-7613(95)90143-4; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; SWAIN SL, 1990, J IMMUNOL, V145, P3796; Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817; Takayama H, 1995, ADV IMMUNOL, V60, P289, DOI 10.1016/S0065-2776(08)60588-X; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Trinchieri G, 1998, IMMUNOL RES, V17, P269, DOI 10.1007/BF02786451; Van Parijs L, 1998, SCIENCE, V280, P243; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; vanParijs L, 1996, CURR OPIN IMMUNOL, V8, P355, DOI 10.1016/S0952-7915(96)80125-7; Varadhachary AS, 1997, P NATL ACAD SCI USA, V94, P5778, DOI 10.1073/pnas.94.11.5778; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VILLANUEVA POF, 1994, J IMMUNOL, V153, P5190; WEAVER CT, 1988, P NATL ACAD SCI USA, V85, P8181, DOI 10.1073/pnas.85.21.8181; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837	98	21	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 24	1998	17	25					3271	3276		10.1038/sj.onc.1202572	http://dx.doi.org/10.1038/sj.onc.1202572			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916989				2022-12-28	WOS:000078048200008
J	Tanimoto, A; Chen, H; Kao, CY; Moran, E; Sasaguri, Y; Padmanabhan, R				Tanimoto, A; Chen, H; Kao, CY; Moran, E; Sasaguri, Y; Padmanabhan, R			Transactivation of the human cdc2 promoter by adenovirus E1A in cycling cells is mediated by induction of a 110-kDa CCAAT-box-binding factor	ONCOGENE			English	Article						cell cycle control; p34(cdc2) kinase; cell proliferation	RETINOBLASTOMA GENE-PRODUCT; IMR-90 DIPLOID FIBROBLASTS; TUMOR-SUPPRESSOR PROTEIN; E2F TRANSCRIPTION FACTOR; FISSION YEAST; DNA-REPLICATION; MAMMALIAN-CELLS; NF-Y; DEPENDENT KINASES; GROWTH SUPPRESSOR	Cyclin-dependent protein kinases (Cdks) are key regulatory proteins of the eukaryotic cell cycle. Cdc2 is expressed in late G1/S phase and functions in the G2 to M phase transition. Adenovirus E1A proteins are known to induce the expression of p34(cdc)2 and DNA synthesis in normal quiescent cells. In this study, mutational analysis of the human cdc2 promoter revealed that transactivation of the promoter by the E1A proteins in cycling cells is mediated through the two CCAAT box binding motifs. A 110-kDa protein (CBF/cdc2) was identified in nuclear extracts from monkey kidney (CV-1) cells stably expressing E1A as well as from adenovirus-transformed human 293 cells, Further, we show that this E1A-inducible CBF/cdc2 is related to the CBF which was shown to activate the heat shock protein 70 promoter. Analyses of the functional domain(s) of E1A required for the induction of the CBF and transactivation of the cdc2 promoter in these conditions revealed that E1A mutants which were defective in binding the pRB family of proteins or the cellular p300 protein were still active in assays measuring the induction of the CBF and transactivation of the cdc2 promoter, albeit with reduced efficiencies. But the E1A mutant which lost both functional domains was inactive in these assays. These results suggest that E1A has redundant functional domains for the induction of the 110-kDa CBF and activation of human cdc2 gene expression.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Univ Occupat & Environm Hlth, Dept Pathol & Cell Biol, Yahatanishi Ku, Kitakyushu, Fukuoka 807, Japan	University of Kansas; University of Kansas Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Occupational & Environmental Health - Japan	Padmanabhan, R (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.				NATIONAL CANCER INSTITUTE [R01CA055330] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BECK GR, 1998, HUMAN TUMOR VIRUSES; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chen HF, 1996, J BIOL CHEM, V271, P13959, DOI 10.1074/jbc.271.24.13959; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; Cress WD, 1996, CURR TOP MICROBIOL, V208, P63; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DRAETTA G, 1988, ONCOGENE, V2, P553; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GOOD L, 1995, J CELL PHYSIOL, V163, P636, DOI 10.1002/jcp.1041630326; Gopalakrishnan S, 1997, CELL GROWTH DIFFER, V8, P541; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRANA X, 1995, ONCOGENE, V11, P211; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HUGGETT AC, 1991, CANCER RES, V51, P5929; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KINGSTON RE, 1991, STABLE TRANSFER GENE; Kramer A, 1997, CANCER RES, V57, P5117; KREK W, 1989, EMBO J, V8, P3071, DOI 10.1002/j.1460-2075.1989.tb08458.x; KU DH, 1993, J BIOL CHEM, V268, P2255; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LUM LSY, 1992, MOL CELL BIOL, V12, P2599, DOI 10.1128/MCB.12.6.2599; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P16574; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; MYMRYK JS, 1994, VIRUS RES, V33, P89, DOI 10.1016/0168-1702(94)90019-1; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NEVINS JR, 1992, SCIENCE, V258, P424; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PANG JH, 1993, J BIOL CHEM, V268, P2909; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; QUINLAN MP, 1994, ONCOGENE, V9, P2639; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; REED SI, 1985, COLD SPRING HARB SYM, V50, P627, DOI 10.1101/SQB.1985.050.01.076; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Scolnick DM, 1997, CANCER RES, V57, P3693; SHENK T, 1991, ADV CANCER RES, V57, P47; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1995, J VIROL, V69, P7917, DOI 10.1128/JVI.69.12.7917-7924.1995; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WU CL, 1995, MOL CELL BIOL, V15, P2536; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0	88	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	1998	17	24					3103	3114		10.1038/sj.onc.1202236	http://dx.doi.org/10.1038/sj.onc.1202236			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872326				2022-12-28	WOS:000077517400004
J	Wagner, KU; Dierisseau, P; Rucker, EB; Robinson, GW; Hennighausen, L				Wagner, KU; Dierisseau, P; Rucker, EB; Robinson, GW; Hennighausen, L			Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: Common types of shorter transcripts are true alternative splice variants	ONCOGENE			English	Article						TSG101 protein; mice; human; genomic DNA; pseudogene; mammary gland	HUMAN BREAST-CANCER; MAMMARY-GLAND; PROTEIN; IDENTIFICATION; CHROMOSOME-11; TUMORIGENESIS; FAMILY; INT3	The functional inactivation of the tumor susceptibility gene tsg101 in mouse NIH3T3 cells leads to cell transformation and the formation of metastatic tumors in nude mice. We cloned, mapped and sequenced the mouse tsg101 gene and further identified a processed pseudogene that is 98% identical to the tsg101 cDNA. Based on Northern blot analysis, tsg101 is expressed ubiquitously in mouse tissues. A comparison of the coding region of the mouse tsg101 gene with the human TSG101 cDNA revealed that both the mouse and human gene encode ten additional highly conserved amino acids at the N-terminus. Based on the mouse tsg101 genomic structure, we predicted four additional introns within the human TSG101 gene. Their location was confirmed using PCR and sequencing analysis. The presence of these so far unidentified introns now explains published data on aberrantly spliced mRNA products that were frequently observed in primary breast tumors. We show that a majority of shorter TSG101 transcripts are not the result of aberrant splicing events, but represent a fraction of true alternative splice variants. Finally, we examined tsg101 expression patterns during different stages of mammary gland development and in different transgenic mouse models for breast tumorigenesis.	NIDDKD, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hennighausen, L (corresponding author), NIDDKD, Lab Genet & Physiol, NIH, Bldg 8,Room 101, Bethesda, MD 20892 USA.		Robinson, Gertraud/I-2136-2012; Wagner, Kay-Uwe/B-6044-2009	Wagner, Kay-Uwe/0000-0002-5081-0226; Hennighausen, Lothar/0000-0001-8319-9841	FDA HHS [369VFDK013712] Funding Source: Medline	FDA HHS		Aki T, 1997, J BIOCHEM, V122, P271; ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Gallahan D, 1996, CANCER RES, V56, P1775; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Hampl M, 1998, BIOCHEM BIOPH RES CO, V248, P753, DOI 10.1006/bbrc.1998.9038; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Li ML, 1996, CELL GROWTH DIFFER, V7, P3; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; Ozon S, 1997, EUR J BIOCHEM, V248, P794, DOI 10.1111/j.1432-1033.1997.t01-2-00794.x; Ponting CP, 1997, J MOL MED-JMM, V75, P467; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; SANDGREN EP, 1995, CANCER RES, V55, P3915; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; Sun ZJ, 1997, ONCOGENE, V15, P3121, DOI 10.1038/sj.onc.1201521; TZENG YJ, 1993, ONCOGENE, V8, P1965; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wang Q, 1998, ONCOGENE, V16, P677, DOI 10.1038/sj.onc.1201563; Watanabe M, 1998, BIOCHEM BIOPH RES CO, V245, P900, DOI 10.1006/bbrc.1998.8547; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; Zhong Q, 1997, CANCER RES, V57, P4225	27	35	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2761	2770		10.1038/sj.onc.1202529	http://dx.doi.org/10.1038/sj.onc.1202529			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840940				2022-12-28	WOS:000077146700009
J	Bogenmann, E; Peterson, S; Maekawa, K; Matsushima, H				Bogenmann, E; Peterson, S; Maekawa, K; Matsushima, H			Regulation of NGF responsiveness in human neuroblastoma	ONCOGENE			English	Article						neuroblastoma; trkA; differentiation	NERVE GROWTH-FACTOR; HUMAN NEURO-BLASTOMA; RETINOIC ACID; CELL-LINE; NEUROTROPHIN RECEPTOR; TRK PROTOONCOGENE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; HIGH-AFFINITY	Functional nerve growth factor (NGF) responsiveness was investigated in human neuroblastoma (NB) cell lines in vitro and retinoic acid (RA) was found to transcriptionally enhance expression of the trkA, but not the trkB gene in GOTO cells, while the reverse was found in HTLA230 NE cells. Ciliary neurotrophic factor (CNTF) specifically induced trkA gene transcription in both cell lines. Transcriptional activation of the trkA gene increased total trkA protein and surface bound receptor, which was tyrosine phosphorylated upon NGF stimulation inducing immediate early response gene transcription (i.e. c-fos, Egr-1). Newly synthesized trkA protein had a molecular weight of 110 kDa and was post-translationally modified. Rapid down regulation of the receptor protein occurred upon NGF stimulation, despite the presence of high levels of trkA mRNA, due to an increased rate of receptor degradation. Transient DNA synthesis and cell proliferation upon NGF treatment occurred in GOTO cells with elevated trkA expression. In contrast, NGF induced neuronal differentiation in HTLA230 cells expressing the endogenous trkA receptor gene, despite the lack of p75 expression. Hence, transcriptional activation of trkA gene expression can be achieved by different signal pathways in human NE cells, but NGF can act either as mitogen or inducer of cell differentiation, depending on the tumor from which cells are derived.	Childrens Hosp Los Angeles, Div Hematol Oncol, Los Angeles, CA 90027 USA; Jikei Univ, Sch Med, Inst DNA Med, Dept Pediat,Minato Ku, Tokyo 105, Japan; Jikei Univ, Sch Med, Inst DNA Med, Dept Gene Therapy,Minato Ku, Tokyo 105, Japan	Children's Hospital Los Angeles; Jikei University; Jikei University	Bogenmann, E (corresponding author), Childrens Hosp Los Angeles, Div Hematol Oncol, 4650 Sunset Blvd, Los Angeles, CA 90027 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034940] Funding Source: NIH RePORTER; NINDS NIH HHS [1R01NS34940] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARBACID M, 1993, ONCOGENE, V8, P2033; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BASU T, 1994, ONCOGENE, V9, P3483; BIRREN SJ, 1992, SCIENCE, V257, P395, DOI 10.1126/science.1321502; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BOGENMANN E, 1995, ONCOGENE, V10, P1915; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; Davis S, 1993, CURR OPIN CELL BIOL, V5, P281, DOI 10.1016/0955-0674(93)90117-9; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HOLTZMAN DM, 1992, NEURON, V9, P465, DOI 10.1016/0896-6273(92)90184-F; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IP NY, 1994, NEURON, V13, P443, DOI 10.1016/0896-6273(94)90359-X; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KUMAR S, 1993, MOL BRAIN RES, V17, P163, DOI 10.1016/0169-328X(93)90086-5; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LUCARELLI E, 1995, J BIOL CHEM, V270, P24725, DOI 10.1074/jbc.270.42.24725; MATSUMOTO K, 1995, CANCER RES, V55, P1798; MATSUSHIMA H, 1992, INT J CANCER, V51, P250, DOI 10.1002/ijc.2910510214; MATSUSHIMA H, 1992, INT J CANCER, V51, P727, DOI 10.1002/ijc.2910510511; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MATSUSHIMA H, 1990, MOL CELL BIOL, V10, P5015, DOI 10.1128/MCB.10.9.5015; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; PLEASURE SJ, 1990, P NATL ACAD SCI USA, V87, P8496, DOI 10.1073/pnas.87.21.8496; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; SCHEIBE RJ, 1992, J BIOL CHEM, V267, P17611; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1982, ANN INTERN MED, V97, P873, DOI 10.7326/0003-4819-97-6-873; Seeger Robert C., 1993, P2172; SEKIGUCHI M, 1979, JPN J EXP MED, V49, P67; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; TAHIRA T, 1991, ONCOGENE, V6, P2333; TAIJI M, 1992, MOL CELL BIOL, V12, P2193, DOI 10.1128/MCB.12.5.2193; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Torres M, 1996, ONCOGENE, V12, P77; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VERDI JM, 1994, NEURON, V13, P1359, DOI 10.1016/0896-6273(94)90421-9; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WYATT S, 1995, J CELL BIOL, V130, P1435, DOI 10.1083/jcb.130.6.1435	64	23	27	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2367	2376		10.1038/sj.onc.1202160	http://dx.doi.org/10.1038/sj.onc.1202160			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811468				2022-12-28	WOS:000076723300011
J	Sun, GQ; Sharma, AK; Budde, RJA				Sun, GQ; Sharma, AK; Budde, RJA			Autophosphorylation of Src and Yes blocks their inactivation by Csk phosphorylation	ONCOGENE			English	Article						Src and Yes regulation; Csk; protein tyrosine phosphatase 1B; autophosphorylation	PROTEIN-TYROSINE KINASE; HUMAN COLORECTAL-CANCER; C-SRC; EXPRESSION SYSTEM; PP60(C-SRC) ACTIVITY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; HUMAN-PLACENTA; PP60C-SRC; PURIFICATION	Csk phosphorylates Src family protein tyrosine kinases on a tyrosine residue near their C-terminus and down-regulates their activity. We previously observed that this regulation requires a stoichiometric ratio of Csk:Src in a time-independent manner. In this report we examined this unusual kinetic behavior and found it to be caused by Src autophosphorylation, First, pre-incubation of Src with ATP-Mg led to time-dependent autophosphorylation of Src, activation of its kinase activity and loss of its ability to be inactivated by Csk, However, the autophosphorylated Src can still be phosphorylated by Csk. The SH2 binding site for phospho-Tyr of this hyperactive and doubly phosphorylated form of Src is not accessible. Second, dephosphorylation of autophosphorylated Src by protein tyrosine phosphatase 1B allowed Src to be inactivated by Csk, Third, protein tyrosine phosphatase 1B preferentially dephosphorylates the Src autophosphorylation site and allows for Src regulation by Csk, Finally, Yes, another member of the Src family, was also only partially inactivated when a sub-stoichiometric amount of Csk was used. Mutation of the tyrosine autophosphorylation site of Yes to a phenylalanine resulted in a mutant Yes enzyme that can be fully inactivated by a sub-stoichiometric amount of Csk in a time-dependent manner. These results demonstrate that Csk phosphorylation inactivates Src and Yes only when they are not previously autophosphorylated and Src autophosphorylation can block the inactivation by Csk phosphorylation, This conclusion suggests a dynamic model for the regulation of the Src family protein tyrosine kinases, which is discussed in the context of previously reported observations on the regulation of Src family protein tyrosine kinases.	Univ Texas, MD Anderson Cancer Ctr, Dept Neurooncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Budde, RJA (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Neurooncol, Box 316, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P30CA016672, U19CA053617, U01CA053617] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA53617] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; BOLEN JB, 1987, ONCOGENE RES, V1, P149; Bougeret C, 1996, J BIOL CHEM, V271, P7465, DOI 10.1074/jbc.271.13.7465; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BUDDE RJA, 1993, PREP BIOCHEM, V23, P493, DOI 10.1080/10826069308544572; Chappel J, 1997, J CELL BIOCHEM, V67, P432, DOI 10.1002/(SICI)1097-4644(19971215)67:4<432::AID-JCB2>3.0.CO;2-T; Chedin M, 1997, CARCINOGENESIS, V18, P1463, DOI 10.1093/carcin/18.8.1463; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; Hardwick JS, 1997, J BIOL CHEM, V272, P25429, DOI 10.1074/jbc.272.41.25429; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOVE R, 1989, ONCOGENE RES, V5, P49; JULLIEN P, 1994, EUR J BIOCHEM, V224, P589, DOI 10.1111/j.1432-1033.1994.00589.x; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOEGL M, 1994, BIOCHEM J, V302, P737, DOI 10.1042/bj3020737; Levitzki A, 1996, ANTI-CANCER DRUG DES, V11, P175; Li SL, 1996, CELL BIOL INT, V20, P723; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; OETKEN C, 1994, ONCOGENE, V9, P1625; OKADA M, 1989, J BIOL CHEM, V264, P20886; OSUSKY M, 1995, J BIOL CHEM, V270, P25729, DOI 10.1074/jbc.270.43.25729; RUZZENE M, 1994, J BIOL CHEM, V269, P15885; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; Sambrook J, 1989, MOL CLONING; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SMITH JA, 1993, MOL CELL BIOCHEM, V128, P51, DOI 10.1007/BF01076757; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; STOVER DR, 1994, J BIOL CHEM, V269, P26885; Sun GQ, 1997, BIOCHEMISTRY-US, V36, P2139, DOI 10.1021/bi962291n; Sun GQ, 1997, ARCH BIOCHEM BIOPHYS, V345, P135, DOI 10.1006/abbi.1997.0236; SUN GQ, 1995, ANAL BIOCHEM, V231, P458, DOI 10.1006/abio.1995.0081; Sun GQ, 1997, ARCH BIOCHEM BIOPHYS, V343, P194, DOI 10.1006/abbi.1997.0156; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TONKS NK, 1991, METHOD ENZYMOL, V201, P427; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; WATANABE N, 1995, JPN J CLIN ONCOL, V25, P5; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	48	74	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1587	1595		10.1038/sj.onc.1202076	http://dx.doi.org/10.1038/sj.onc.1202076			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794236				2022-12-28	WOS:000076089900011
J	Murakami, H; Iwashita, T; Asai, N; Iwata, Y; Narumiya, S; Takahashi, M				Murakami, H; Iwashita, T; Asai, N; Iwata, Y; Narumiya, S; Takahashi, M			Rho-dependent and -independent tyrosine phosphorylation of focal adhesion kinase, paxillin and p130(Cas) mediated by Ret kinase	ONCOGENE			English	Article						Ret; GDNF; focal adhesion kinase; paxillin; p130(Cas)	MEN 2B MUTATIONS; NEUROTROPHIC FACTOR; GROWTH-FACTOR; TRANSFORMING ACTIVITY; BIOLOGICAL PROPERTIES; DOPAMINERGIC-NEURONS; CELL-ADHESION; MOTOR-NEURONS; IN-VIVO; GDNF	Glial cell line-derived neurotrophic factor (GDNF) signals through a unique receptor system that includes Ret receptor tyrosine kinase and a glycosyl-phosphatidylinositol-linked cell surface protein. In the present study, we have identified several proteins in neuroblastoma cells that are phosphorylated on tyrosine in response to GDNF, The phosphorylated proteins include focal adhesion kinase (FAK), paxillin and Crk-associated substrate, p130(Cas), all of which are known to be associated with focal adhesions. Of these, paxillin and p130(Cas) interacted with Crk proteins in GDNF-treated neuroblastoma cells. GDNF also induced reorganization of the actin cytoskelton, Tyrosine phosphorylation of FAK, paxillin and p130(Cas) was inhibited by cytochalasin D or two specific inhibitors of phosphatidylinositol-3' kinase (PI-3' kinase), wortmannin and LY294002, indicating that their tyrosine phosphorylation depends on the formation of actin stress fiber and activation of PI-3' kinase. In addition, phosphorylation of FAK but not of paxillin and p130(Cas) was markedly impaired by the Clostridium botulinum C3 exoenzyme that specifically ADP-ribosylates and inactivates Rho, These results suggested the presence of Rho-dependent and -independent signaling pathways downstream of PI-3' kinase that mediate tyrosine phosphorylation of FAK, paxillin and p130(Cas) through Pet kinase.	Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 466, Japan; Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 606, Japan	Nagoya University; Kyoto University	Takahashi, M (corresponding author), Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 466, Japan.		TAKAHASHI, Masahide/I-7244-2014; ASAI, Naoya/I-7377-2014; Takahashi, Masahide/AAN-4770-2020	Takahashi, Masahide/0000-0002-2803-2683				Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; Bocciardi R, 1997, ONCOGENE, V15, P2257, DOI 10.1038/sj.onc.1201413; BORELLO MG, 1995, ONCOGENE, V11, P2419; BORRELLO MA, 1993, ONCOGENE, V9, P1661; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945-053X(97)90008-1; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; Ito S, 1997, CANCER RES, V57, P2870; Iwashita T, 1996, ONCOGENE, V12, P481; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JIAN X, 1991, NATURE, V352, P73; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Nozaki C, 1998, ONCOGENE, V16, P293, DOI 10.1038/sj.onc.1201548; Ohiwa M, 1997, BIOCHEM BIOPH RES CO, V237, P747, DOI 10.1006/bbrc.1997.7225; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Sasaki T, 1996, BIOCHEM J, V315, P1035, DOI 10.1042/bj3151035; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	45	66	67	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					1975	1982		10.1038/sj.onc.1202514	http://dx.doi.org/10.1038/sj.onc.1202514			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208419				2022-12-28	WOS:000079191300007
J	North, S; Espanel, X; Bantignies, F; Viollet, B; Vallet, V; Jalinot, P; Brun, G; Gillet, G				North, S; Espanel, X; Bantignies, F; Viollet, B; Vallet, V; Jalinot, P; Brun, G; Gillet, G			Regulation of cdc2 gene expression by the upstream stimulatory factors (USFs)	ONCOGENE			English	Article						cell cycle; differentiation; retina; cdc2; USF	TRANSCRIPTION FACTOR USF; HELIX-LOOP-HELIX; CELL-CYCLE REGULATION; MAMMALIAN-CELLS; IN-VIVO; PROMOTER; REGION; ACTIVATION; REPRESSION; IDENTIFICATION	cdc2 gene expression is under the control of multiple factors. Although E2F/DP proteins have been reported to play a central role, they cannot account for all aspects of the fine modulation of cdc2 gene expression during cell cycle and embryonic development. To characterize the transcription factors that control cdc2 gene expression during nerve cell differentiation in avians, we have previously cloned the quail cdc2 gene promoter region. We had identified an octamer (CAGGTGGC) containing an E-box, which has important activity in regulating cdc2 transcription. Using lit vivo genomic footprinting experiments, we show here that this motif, currently named TG, is the target of binding proteins at different stages of neuroretina development, confirming its importance as a regulatory response element for cdc2 gene expression. A subset of Helix-Loop-Helix family of transcription factors, known as Upstream Stimulatory Factors (USFs) specifically bind to this sequence as dimers, Moreover, our results indicate that USFs transactivate the promoter of cdc2 via the IG motif, These data may help to better understand the mechanisms that control cell division in differentiating nerve cells.	CNRS, Inst Biol & Chim Prot, UPR 412, F-69367 Lyon 07, France; CHU Cochin Port Royal, INSERM, U129, Unite Rech Genet & Pathol Mol, F-75014 Paris, France; Ecole Normale Super Lyon, UMR CNRS 49, Res Grp, Mol & Cellular Biol Lab, F-69364 Lyon 07, France; Ecole Normale Super Lyon, UMR CNRS 49, F-69364 Lyon 07, France	Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Ecole Normale Superieure de Lyon (ENS de LYON); Ecole Normale Superieure de Lyon (ENS de LYON)	Gillet, G (corresponding author), CNRS, Inst Biol & Chim Prot, UPR 412, 7 Passage Vercors, F-69367 Lyon 07, France.		Viollet, Benoit/O-6927-2017; gillet, germain/A-9095-2013; Viollet, Benoit/N-2397-2019	Viollet, Benoit/0000-0002-0121-0224; Viollet, Benoit/0000-0002-0121-0224; GILLET, Germain/0000-0002-1514-327X				BORN TL, 1994, MOL CELL BIOL, V14, P5710, DOI 10.1128/MCB.14.9.5710; Breen GAM, 1997, J BIOL CHEM, V272, P10538; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; Espanel X, 1997, INT J DEV BIOL, V41, P469; ESPINAS ML, 1994, MOL CELL BIOL, V14, P4116, DOI 10.1128/MCB.14.6.4116; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Ghosh AK, 1997, ONCOGENE, V14, P589, DOI 10.1038/sj.onc.1200866; GILLET G, 1993, ONCOGENE, V8, P565; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Kastner A, 1998, CELL GROWTH DIFFER, V9, P857; Kenny JJ, 1997, VIROLOGY, V230, P381, DOI 10.1006/viro.1997.8501; KU DH, 1993, J BIOL CHEM, V268, P2255; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; North S, 1996, CELL GROWTH DIFFER, V7, P339; NURSE P, 1993, PHILOS T ROY SOC B, V341, P449, DOI 10.1098/rstb.1993.0127; OUTRAM SV, 1994, J BIOL CHEM, V269, P26525; Rippe RA, 1997, J BIOL CHEM, V272, P1753, DOI 10.1074/jbc.272.3.1753; SARDET C, 1997, E2FS RETINOBLASTOMA; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHIMIZU M, 1995, MOL CELL BIOL, V15, P2882; SHIMIZU T, 1995, CANCER RES, V55, P228; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SUGARMAN JL, 1995, MOL CELL BIOL, V15, P3282; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; WEN SC, 1995, EXP CELL RES, V217, P8, DOI 10.1006/excr.1995.1057; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	39	26	26	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					1945	1955		10.1038/sj.onc.1202506	http://dx.doi.org/10.1038/sj.onc.1202506			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208416				2022-12-28	WOS:000079191300004
J	Ahmad, N; Gupta, S; Mukhtar, H				Ahmad, N; Gupta, S; Mukhtar, H			Involvement of retinoblastoma (Rb) and E2F transcription factors during photodynamic therapy of human epidermoid carcinoma cells A431	ONCOGENE			English	Article						photodynamic therapy; cell cycle; retinoblastoma (pRb); E2F	MOUSE LYMPHOMA-CELLS; CYCLE PROGRESSION; INDUCED ABLATION; CANCER-CELLS; NITRIC-OXIDE; APOPTOSIS; INDUCTION; PROTEINS; KINASE; PHOTOSENSITIZERS	Photodynamic therapy (PDT), a promising new therapeutic modality for the management of a variety of solid malignancies and many non-malignant diseases, is a bimodal therapy using a porphyrin based photosensitizing chemical and visible light. The proper understanding of the mechanism of PDT-mediated cancer cell-kill may result in improving the efficacy of this treatment modality. Earlier we have shown (PI oc. Natl, Acad. Sci, USA; 95: 6977-6982, 1998) that silicon phthalocyanine (Pc4)-PDT results in an induction of the cyclin kinase inhibitor WAF1/CIP1/p21 which, by inhibiting cyclins (E and DI) and cyclin dependent kinases (cdk2 and cdk6), results in a G0/G1-phase arrest followed by apoptosis in human epidermoid carcinoma cells A431. We have also demonstrated the generation of nitric oxide during PDT-mediated apoptosis (Cancer Res.; 58: 1785-1788, 1998), Retinoblastoma (pRb) and E2F family transcription factors are important proteins, which regulate the G1-->S transition in the cell cycle. Here, we pro, ide evidence for the involvement of pRb-E2F/DP machinery as an important contributor of PDT-mediated cell cycle arrest and apoptosis, Western blot analysis demonstrated a decrease in the hyper-phosphorylated form of pRb at 3, 6 and 12 h post-PDT with a relative increase in hypo-phosphorylated pRb, Western blot analysis also revealed that PDT-caused decrease in phosphorylation of pRb occurs at serine-780, The ELISA data demonstrated a time dependent accumulation of hypo-phosphorylated pRb by PDT, This response was accompanied with down-regulation in the protein expression of all five E2F (1-5) family transcription factors, and their heterodimeric partners DP1 and DP2, These results suggest that Pc4-PDT of A431 cells results in a down regulation of hyper-phosphorylated pRb protein with a relative increase in hypo-phosphorylated pRb that, in turn, compromises with the availability of free E2F, We suggest that these events result in a stoppage of the cell cycle progression at G1-->S transition thereby leading to a G0/G1 phase arrest and a subsequent apoptotic cell death, These data provide an evidence for the involvement of pRb-E2F/DP machinery in PDT-mediated cell cycle arrest leading to apoptosis.	Case Western Reserve Univ, Dept Dermatol, Cleveland, OH 44106 USA	Case Western Reserve University	Mukhtar, H (corresponding author), Case Western Reserve Univ, Dept Dermatol, 11100 Euclid Ave, Cleveland, OH 44106 USA.			Gupta, Sanjay/0000-0002-9492-3249	NCI NIH HHS [P30 CA 43703, R01 CA51802, P01 CA 48735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703, P01CA048735, R01CA051802] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AGARWAL ML, 1993, CANCER RES, V53, P5897; AGARWAL ML, 1991, CANCER RES, V51, P5993; Agarwal R, 1996, PHOTOCHEM PHOTOBIOL, V63, P547, DOI 10.1111/j.1751-1097.1996.tb03082.x; Ahmad N, 1998, P NATL ACAD SCI USA, V95, P6977, DOI 10.1073/pnas.95.12.6977; BenHur E, 1997, PHOTOCHEM PHOTOBIOL, V65, P456, DOI 10.1111/j.1751-1097.1997.tb08589.x; Bowen C, 1998, CANCER RES, V58, P3275; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; Goldberg Y, 1996, ONCOGENE, V12, P893; Gomer CJ, 1996, CANCER RES, V56, P2355; GOMER CJ, 1991, PHOTOCHEM PHOTOBIOL, V54, P1093, DOI 10.1111/j.1751-1097.1991.tb02133.x; Granville DJ, 1997, CELL DEATH DIFFER, V4, P623, DOI 10.1038/sj.cdd.4400286; Gupta S, 1998, CANCER RES, V58, P1785; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Ishida A, 1997, J BIOL CHEM, V272, P10050; Kasten MM, 1998, CELL DEATH DIFFER, V5, P132, DOI 10.1038/sj.cdd.4400323; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Linke SP, 1997, ONCOGENE, V15, P337, DOI 10.1038/sj.onc.1201200; LUNA MC, 1994, CANCER RES, V54, P1374; Luo Y, 1996, PHOTOCHEM PHOTOBIOL, V63, P528, DOI 10.1111/j.1751-1097.1996.tb03079.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; PASS HI, 1993, JNCI-J NATL CANCER I, V85, P443, DOI 10.1093/jnci/85.6.443; RYTER SW, 1993, PHOTOCHEM PHOTOBIOL, V58, P753, DOI 10.1111/j.1751-1097.1993.tb04964.x; Separovic D, 1997, CANCER RES, V57, P1717; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Tao JS, 1996, J BIOL CHEM, V271, P27107, DOI 10.1074/jbc.271.43.27107; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; TOM R, 1997, J NATL CANCER I, V89, P112; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; ZAIDI SIA, 1993, PHOTOCHEM PHOTOBIOL, V58, P771, DOI 10.1111/j.1751-1097.1993.tb04969.x	41	28	33	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1891	1896		10.1038/sj.onc.1202493	http://dx.doi.org/10.1038/sj.onc.1202493			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086343				2022-12-28	WOS:000079090000012
J	Schreiber, M; Muller, WJ; Singh, G; Graham, FL				Schreiber, M; Muller, WJ; Singh, G; Graham, FL			Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1/CIP1) and p27(KIP1) in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity	ONCOGENE			English	Article						adenovirus; gene therapy; cyclin dependent kinase inhibitors; cell growth; apoptosis	RETINOBLASTOMA GENE-PRODUCT; D-DEPENDENT KINASES; WILD-TYPE P53; MICE LACKING; POLY(ADP-RIBOSE) POLYMERASE; MOLECULAR CONTROLS; SUPPRESSOR GENES; MAMMALIAN-CELLS; LEUKEMIA-CELLS; IN-VIVO	Cell cycle regulatory proteins are important candidates for therapeutic tumour suppressors. Adenovirus vectors were constructed to overexpress cyclin kinase inhibitors p16(INK4A), p18(INK4C), p19(ISK4D), P21(WAF1/CIP1) and p(27KIP1) under the control of the murine cytomegalovirus immediate early gene promoter, These vectors directed the efficient expression of each of the cyclin kinase inhibitors and induced growth arrest, inhibited DNA synthesis, and prevented phosphorylation of the retinoblastoma protein (pRb) in cell lines expressing functional pRb, In pRb-deficient cells, expression of the cyclin kinase inhibitors was not effective in inhibiting DNA replication or growth arrest, Interestingly, three of the cyclin kinase inhibitors, p16, p18 and p27 were found to induce apoptotic death in transduced HeLa and A549 cells. When the vectors were tested for their ability to inhibit tumorigenicity in a polyomavirus middle T antigen model of murine breast carcinoma, expression of the cyclin kinase inhibitors resulted in a delay in tumour formation that varied from several weeks for the p19 expressing vector to greater than 25 weeks for the p27 expressing vector. When tumours were injected directly with the adenovirus vectors expressing the cyclin kinase inhibitors, only treatment with the vector expressing p16 resulted in a delay in tumour growth.	McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Pathol, Hamilton, ON L8S 4K1, Canada	McMaster University; McMaster University	Graham, FL (corresponding author), McMaster Univ, Dept Biol, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.		Singh, Gurmit/C-6744-2014					Adachi M, 1997, BLOOD, V90, P126; Addison CL, 1997, J GEN VIROL, V78, P1653, DOI 10.1099/0022-1317-78-7-1653; ADDISON CL, 1995, P NATL ACAD SCI USA, V92, P8522, DOI 10.1073/pnas.92.18.8522; Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; BACCHETTI S, 1993, INT J ONCOL, V3, P781; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHOW VTK, 1993, CANCER LETT, V73, P141, DOI 10.1016/0304-3835(93)90256-9; Cox LS, 1997, J PATHOL, V183, P134, DOI 10.1002/(SICI)1096-9896(199710)183:2<134::AID-PATH960>3.0.CO;2-D; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EASTHAM JA, 1995, CANCER RES, V55, P5151; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gotoh A, 1997, J UROLOGY, V158, P636, DOI 10.1016/S0022-5347(01)64574-9; GRANA X, 1995, ONCOGENE, V11, P211; Hamada K, 1996, CANCER RES, V56, P3047; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HITT M, 1995, METH MOL G, V7, P13; Hitt M. M., 1994, CELL BIOL LAB HDB, V1, P479; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; JIN XM, 1995, CANCER RES, V55, P3250; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; Katayose Y, 1997, CANCER RES, V57, P5441; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kawakami K, 1996, BIOCHEM BIOPH RES CO, V219, P778, DOI 10.1006/bbrc.1996.0310; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038/sj.onc.1201585; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; Mayol X, 1997, Prog Cell Cycle Res, V3, P157; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morse L, 1997, IMMUNITY, V6, P47, DOI 10.1016/S1074-7613(00)80241-1; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Ohno T, 1997, GENE THER, V4, P361, DOI 10.1038/sj.gt.3300403; OMalley BW, 1996, CANCER RES, V56, P1737; Putzer BM, 1998, HUM GENE THER, V9, P707, DOI 10.1089/hum.1998.9.5-707; Sambrook J., 2002, MOL CLONING LAB MANU; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; Schwaller J, 1997, LEUKEMIA, V11, P54, DOI 10.1038/sj.leu.2400522; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SGONC R, 1994, TRENDS GENET, V10, P41, DOI 10.1016/0168-9525(94)90140-6; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Terada Y, 1997, J AM SOC NEPHROL, V8, P51; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Urashima M, 1997, BLOOD, V90, P4106, DOI 10.1182/blood.V90.10.4106; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; WARNEFORD S, 1991, CELL GROWTH DIFFER, V2, P439; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xiong Y, 1996, Biochim Biophys Acta, V1288, P01; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250	70	136	142	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	1999	18	9					1663	1676		10.1038/sj.onc.1202466	http://dx.doi.org/10.1038/sj.onc.1202466			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208428				2022-12-28	WOS:000079025000002
J	Tahara, H; Yasui, W; Tahara, E; Fujimoto, J; Ito, K; Tamai, K; Nakayama, J; Ishikawa, F; Tahara, E; Ide, T				Tahara, H; Yasui, W; Tahara, E; Fujimoto, J; Ito, K; Tamai, K; Nakayama, J; Ishikawa, F; Tahara, E; Ide, T			Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections	ONCOGENE			English	Article						telomerase; in situ detection; hTERT; immuno-histochemistry; colorectal carcinoma	MAMMALIAN TELOMERASE; SUBUNIT GENE; CELLS; PROTEIN; CANCER; RNA; EXPRESSION; STOMACH	Human telomerase is expressed in germ tissues and in the majority of primary tumors. Cell renewal tissues and some pre-cancerous tissues also have weak telomerase activity, Yet, neither the exact location and frequency of telomerase-positive cells nor the changes in telomerase expression during differentiation or carcinogenesis of individual cells are known. This paper reports on the expression of hTERT (telomerase reverse transcriptase) protein in tumor and non-tumor colorectal tissues by Western blotting and tissue sections by immunohistochemistry using antibodies raised against partial peptides of hTERT, Though telomerase activity and hTERT expression at both mRNA and protein levels were generally higher in tumor part than in non-tumor part, these two were not always correlated: expression of hTERT did not always give rise to high telomerase activity. Colonic carcinoma cell nuclei were stained with anti-hTERT antibodies but not with antigen-preabsorbed antibodies. In normal mucosa, hTERT protein was expressed, though weaker than in carcinoma, in all colonic crypt epithelial cells except those at the tip; the expressing-cell distribution was much wider than that of Ki-67 positive cells which were located at the bottom of the crypt, Isolated crypt contained a significant level of hTERT protein revealed by Western blotting, while having very weak telomerase activity. Telomerase activity was detected in epithelial cells only at the bottom half of the crypt, Specific hTERT-staining was positive in tissue lymphocytes but negative in almost all other stromal cells. It is of interest to see whether a significant level of hTERT expression with low telomerase activity is characteristic of physiologically regenerating tissues containing stem cells, In situ detection of the hTERT protein mill permit further analysis of cancer diagnosis and stem cell differentiation.	Hiroshima Univ, Sch Med, Dept Cellular & Mol Biol, Hiroshima 734, Japan; Hiroshima Univ, Sch Med, Dept Pathol 1, Hiroshima 734, Japan; Tokyo Inst Technol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 226, Japan; Med & Biol Labs Co Ltd, Nagano, Japan	Hiroshima University; Hiroshima University; Tokyo Institute of Technology	Ide, T (corresponding author), Hiroshima Univ, Sch Med, Dept Cellular & Mol Biol, Kasumi 1-2-3, Hiroshima 734, Japan.		Tamai, Katsuyuki/F-4743-2013; Ishikawa, Fuyuki/AAU-4056-2021; Nakayama, Jun-ichi/C-6003-2011	Tamai, Katsuyuki/0000-0003-4094-3911; Ishikawa, Fuyuki/0000-0002-5580-2305; Nakayama, Jun-ichi/0000-0002-5597-8239				Avilion AA, 1996, CANCER RES, V56, P645; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Hiyama E, 1996, INT J ONCOL, V9, P453; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Kuniyasu H, 1997, JPN J CANCER RES, V88, P103, DOI 10.1111/j.1349-7006.1997.tb00353.x; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Ohyashiki K, 1997, CANCER RES, V57, P2100; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Tahara H, 1995, CLIN CANCER RES, V1, P1245; Yasui W, 1996, J PATHOL, V180, P122, DOI 10.1002/(SICI)1096-9896(199610)180:2<122::AID-PATH647>3.0.CO;2-C	20	151	170	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1561	1567		10.1038/sj.onc.1202458	http://dx.doi.org/10.1038/sj.onc.1202458			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102626				2022-12-28	WOS:000078770700006
J	Greenberg, RA; O'Hagan, RC; Deng, HY; Xiao, QR; Hann, SR; Adams, RR; Lichtsteiner, S; Chin, L; Morin, GB; DePinho, RA				Greenberg, RA; O'Hagan, RC; Deng, HY; Xiao, QR; Hann, SR; Adams, RR; Lichtsteiner, S; Chin, L; Morin, GB; DePinho, RA			Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation	ONCOGENE			English	Article						Myc; telomerase; TERT; transformation	CATALYTIC SUBUNIT GENE; ORNITHINE DECARBOXYLASE; IMMORTAL CELLS; TUMOR-CELLS; EXPRESSION; SENESCENCE; PROTEIN; DIFFERENTIATION; FIBROBLASTS; ACTIVATION	The telomerase reverse transcriptase component (TERT) is not expressed in most primary somatic human cells and tissues, but is upregulated in the majority of immortalized cell lines and tumors. Here, we identify the c-Myc transcription factor as a direct mediator of telomerase activation in primary human fibroblasts through its ability to specifically induce TERT gene expression. Through the use of a hormone inducible form of c-Myc (c-MSc-ER), we demonstrate that MSc-induced activation of the hTERT promoter requires an evolutionarily conserved E-box and that c-Myc-ER-induced accumulation of hTERT mRNA takes place in the absence of de novo protein synthesis. These findings demonstrate that the TERT gene is a direct transcriptional target of c-Myc, Since telomerase activation frequently correlates with immortalization and telomerase functions to stabilize telomers in cycling cells, we tested whether Myc-induced activation of TERT gene expression represents an important mechanism through which c-Myc acts to immortalize cells. Employing the rat embryo fibroblast cooperation assay, we show that TERT is unable to substitute for c-Myc in the transformation of primary rodent fibroblasts, suggesting that the transforming activities of Myc extend beyond its ability to activate TERT gene expression and hence telomerase activity.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Harvard Univ, Sch Med, Dept Med Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Geron Corp, Menlo Park, CA 94025 USA	Harvard University; Dana-Farber Cancer Institute; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Vanderbilt University; Geron Corporation	DePinho, RA (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.		Morin, Gregg B/E-9123-2012	Morin, Gregg B/0000-0001-8949-4374; DePinho, Ronald/0000-0002-5625-577X	NEI NIH HHS [R01EY09300] Funding Source: Medline; NICHD NIH HHS [R01HD28317] Funding Source: Medline; NIGMS NIH HHS [5T32GM07491] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028317] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BISHOP JM, 1991, COLD SH Q B, V56, P99; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Fujimoto K, 1997, BIOCHEM BIOPH RES CO, V241, P775, DOI 10.1006/bbrc.1997.7806; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WRIGHT WE, 1995, TRENDS CELL BIOL, V5, P293, DOI 10.1016/S0962-8924(00)89044-3; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446	39	342	375	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1219	1226		10.1038/sj.onc.1202669	http://dx.doi.org/10.1038/sj.onc.1202669			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022128				2022-12-28	WOS:000078510700011
J	Uchida, H; Downing, JR; Miyazaki, Y; Frank, R; Zhang, J; Nimer, SD				Uchida, H; Downing, JR; Miyazaki, Y; Frank, R; Zhang, J; Nimer, SD			Three distinct domains in TEL-AML1 are required for transcriptional repression of the IL-3 promoter	ONCOGENE			English	Article						transcription; repression; TEL-AML1	ACUTE LYMPHOBLASTIC-LEUKEMIA; COLONY-STIMULATING FACTOR; ACUTE LYMPHOCYTIC-LEUKEMIA; FETAL LIVER HEMATOPOIESIS; T(8-21) FUSION PROTEIN; ACUTE MYELOID-LEUKEMIA; HUMAN RECOMBINANT IL-3; CORE BINDING-FACTOR; MYELOPROLIFERATIVE DISORDERS; CHROMOSOMAL TRANSLOCATION	A cytogenetically cryptic (12;21) translocation is the most common molecular abnormality identified in childhood acute lymphoblastic leukemia (ALL), and it generates a chimeric TEL-AML1 protein. Fusion of the Helix-Loop-Helix (HLH) (also called the pointed) domain of TEL to AML1 has been suggested to convert AML1 from a transcriptional activator to a repressor. To define the structural features of this chimeric protein required for repression, we analysed the transcriptional activity of a series of TEL-AML1 mutants on the AML1-responsive interleukin-3 (IL-3) promoter, potentially relevant gene target. Our results demonstrate that TEL-AML1 represses basal IL-3 promoter activity in lymphoid cells, and deletion mutant analysis identified three distinct domains of TEL-AML1 that are required for repression; the HLH (pointed) motif contained in the TEL portion of TEL-AML1, and both the runt homology domain (Rhd) and the 74 amino acids downstream of the Rhd that are present in the AML1 portion of the fusion protein. Although AML1B (and a shorter AML1 isoform, AML1A) have transcriptional activating activity on the IL-3 promoter, fusion of the AML1 gene to the TEL gene generates a repressor of IL-3 expression. Consistent with this activity, freshly isolated human ALL cells that contain TEL-AML1 do not express IL-3.	Mem Sloan Kettering Canc Ctr, Lab Mol Aspects Hematopoiesis, New York, NY 10021 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38109 USA	Memorial Sloan Kettering Cancer Center; St Jude Children's Research Hospital	Nimer, SD (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Mol Aspects Hematopoiesis, 1275 York Ave, New York, NY 10021 USA.		Downing, James R./N-8102-2018		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK052208, R01DK052208, R01DK043025] Funding Source: NIH RePORTER; NCI NIH HHS [CA 70388] Funding Source: Medline; NIDDK NIH HHS [DK 52208, DK43025] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguiar RCT, 1996, BRIT J HAEMATOL, V95, P673, DOI 10.1046/j.1365-2141.1996.d01-1946.x; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; BUIJS A, 1995, ONCOGENE, V10, P1511; CANN AJ, 1988, ONCOGENE, V3, P123; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ERICKSON P, 1992, BLOOD, V80, P1825; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Frank R, 1995, ONCOGENE, V11, P2667; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GRIMALDI JC, 1989, BLOOD, V73, P2081; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; KINASHI T, 1988, P NATL ACAD SCI USA, V85, P4473, DOI 10.1073/pnas.85.12.4473; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; LENNY N, 1995, ONCOGENE, V11, P1761; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; McLean TW, 1996, BLOOD, V88, P4252; MEEKER TC, 1990, BLOOD, V76, P285; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYATAKE S, 1985, EMBO J, V4, P2561, DOI 10.1002/j.1460-2075.1985.tb03971.x; Miyazaki Y, 1996, ONCOGENE, V13, P1721; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; NIMER SD, 1995, STEM CELLS, V13, P324, DOI 10.1002/stem.5530130402; NUCIFORA G, 1995, BLOOD, V86, P1; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peeters P, 1997, CANCER RES, V57, P564; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Raynaud S, 1996, LEUKEMIA, V10, P1529; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; ROGERS SY, 1994, EXP HEMATOL, V22, P593; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Shih LY, 1996, LEUKEMIA, V10, P1456; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; TADMORI W, 1989, J IMMUNOL, V142, P1950; Uchida H, 1997, J IMMUNOL, V158, P2251; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WOLIN M, 1993, ONCOGENE, V8, P1905; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; XIA X, 1992, J IMMUNOL, V148, P491; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0; Yonemura Y, 1996, P NATL ACAD SCI USA, V93, P4040, DOI 10.1073/pnas.93.9.4040; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zent CS, 1996, P NATL ACAD SCI USA, V93, P1044, DOI 10.1073/pnas.93.3.1044; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	54	49	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					1015	1022		10.1038/sj.onc.1202383	http://dx.doi.org/10.1038/sj.onc.1202383			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023677				2022-12-28	WOS:000078510600018
J	Sementchenko, VI; Schweinfest, CW; Papas, TS; Watson, DK				Sementchenko, VI; Schweinfest, CW; Papas, TS; Watson, DK			ETS2 function is required to maintain the transformed state of human prostate cancer cells	ONCOGENE			English	Article						ETS; transcription factor; prostate cancer; oncogene; epithelial cancer	DNA-BINDING DOMAIN; TRANSCRIPTION FACTORS; EXPRESSION; GENES; PROTOONCOGENE; PROMOTER; ACTIVATION; METASTASIS; CARCINOMA; ELEMENTS	The contribution of the ETS2 transcription factor to the transformed state in prostate cancer cells has been assessed. Northern blot analysis easily detects ETS2 in DU145 and PC3, high grade human prostate cell lines, but ETS2 is not present in lower grade LNCaP cells. Stable transfection of PC3 and DU145 prostate cell lines with an antisense ETS2 vector or with a dominant negative ETS2 mutant significantly reduced the ability of DU145 and PC3 cells to form large colonies in soft agar. Thus, the presence of ETS2 is positively correlated with a more transformed phenotype and blockage of ETS2 function can reduce transformed properties of prostate cancer cells.	Med Univ S Carolina, Hollings Canc Ctr, Ctr Mol & Struct Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Watson, DK (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Ctr Mol & Struct Biol, 171 Ashley Ave, Charleston, SC 29425 USA.							ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BHAT NK, 1992, HYBRIDOMA, V11, P277, DOI 10.1089/hyb.1992.11.277; BOSTWICK DG, 1992, CANCER, V70, P291, DOI 10.1002/1097-0142(19920701)70:1+<291::AID-CNCR2820701317>3.0.CO;2-4; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; CARTER HB, 1990, PROSTATE, V16, P39; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GALANG CK, 1994, ONCOGENE, V9, P2913; Gambarotta G, 1996, ONCOGENE, V13, P1911; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Isaacs JT, 1997, AM J PATHOL, V150, P1511; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Liu AY, 1997, PROSTATE, V30, P145, DOI 10.1002/(SICI)1097-0045(19970215)30:3<145::AID-PROS1>3.0.CO;2-L; MOHLER JL, 1992, CANCER, V69, P511, DOI 10.1002/1097-0142(19920115)69:2<511::AID-CNCR2820690239>3.0.CO;2-3; MOSTOFI FK, 1992, CANCER, V70, P235, DOI 10.1002/1097-0142(19920701)70:1+<235::AID-CNCR2820701311>3.0.CO;2-G; NERLOV C, 1991, ONCOGENE, V6, P1583; Papas Takis S., 1997, Leukemia (Basingstoke), V11, P557; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PISTERS LL, 1995, J UROLOGY, V154, P293, DOI 10.1016/S0022-5347(01)67297-5; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; Simpson S, 1997, ONCOGENE, V14, P2149, DOI 10.1038/sj.onc.1201058; Wasilenko WJ, 1996, INT J CANCER, V68, P259, DOI 10.1002/(SICI)1097-0215(19961009)68:2<259::AID-IJC20>3.0.CO;2-4; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WEN SC, 1995, EXP CELL RES, V217, P8, DOI 10.1006/excr.1995.1057; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; ZHAU HYE, 1992, MOL CARCINOGEN, V5, P320, DOI 10.1002/mc.2940050413; Zhau HYE, 1996, PROSTATE, V28, P73	36	61	72	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 3	1998	17	22					2883	2888		10.1038/sj.onc.1202220	http://dx.doi.org/10.1038/sj.onc.1202220			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879994				2022-12-28	WOS:000077286400008
J	Schmidt, T; Karsunky, H; Gau, E; Zevnik, B; Elsasser, HP; Moroy, T				Schmidt, T; Karsunky, H; Gau, E; Zevnik, B; Elsasser, HP; Moroy, T			Zinc finger protein GFI-1 has low oncogenic potential but cooperates strongly with pim and myc genes in T-cell lymphomagenesis	ONCOGENE			English	Article						oncogene cooperation; zinc finger	E-MU-MYC; TRANSGENIC MICE; N-MYC; C-MYC; ACTIVATION; TUMORS	The gfi-1 gene encodes a zinc finger containing protein that is specifically expressed in T-lymphocytes and is a frequent target of proviral insertion in T-cell lymphoma provoked by infection with MoMuLV-a non acute transforming retrovirus. Expression of a gfi-1 transgene targeted to T-cells by the lck proximal promoter provokes a reduction of peripheral CD4 and CD8 positive T-cells but nevertheless weakly predisposes transgenic animals for the development of T-cell lymphoma. Forced coexpression of the serine/threonine kinase Pim-1 can partially restore normal T-cell numbers in double pim-1/gfi-1 transgenic mice. Moreover, the combinatorial expression of Pim-1 and Gfi-1 leads to accelerated development of T-cell lymphoma with a mean latency period of 114 days. A similar accelerated rate of lymphoma development was observed when lck-gfi-1 mice were crossed with mice that carry a L-myc gene targeted to be expressed at high levels in T-cells. The results show that gfi-1 can act with low activity as a dominant oncogene when overexpressed but also demonstrate that it is most efficient only in the presence of a cooperative partner protein as for example Pim-1 or L-Myc. In addition, the results suggest that Pim-1 and Gfi-1 are acting synergistically in both T-cell lymphomagenesis and T-cell development.	Univ Essen Gesamthsch Klinikum, Inst Zellbiol Tumourforsch, IFZ, D-45122 Essen, Germany; Univ Marburg, Inst Zytobiol & Zytopathol, D-35033 Marburg, Germany	University of Duisburg Essen; Philipps University Marburg	Moroy, T (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Zellbiol Tumourforsch, IFZ, Virchowstr 173, D-45122 Essen, Germany.		Moroy, Tarik/D-9923-2011; Zevnik, Branko/AAB-7853-2020	Zevnik, Branko/0000-0001-7845-9522				BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HOGAN B, 1986, MANIPULATION MOUSE E; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; MOROY T, 1991, ONCOGENE, V6, P1941; Sambrook J., 2002, MOL CLONING LAB MANU; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; Schmidt T, 1996, NUCLEIC ACIDS RES, V24, P2528, DOI 10.1093/nar/24.13.2528; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Zornig M, 1996, ONCOGENE, V12, P1789	15	98	100	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2661	2667		10.1038/sj.onc.1202191	http://dx.doi.org/10.1038/sj.onc.1202191			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840930				2022-12-28	WOS:000077058900014
J	Hajitou, A; Baramova, EN; Bajou, K; Noe, V; Bruyneel, E; Mareel, M; Collette, J; Foidart, JM; Calberg-Bacq, CM				Hajitou, A; Baramova, EN; Bajou, K; Noe, V; Bruyneel, E; Mareel, M; Collette, J; Foidart, JM; Calberg-Bacq, CM			FGF-3 and FGF-4 elicit distinct oncogenic properties in mouse mammary myoepithelial cells	ONCOGENE			English	Article						FGF-3; FGF-4; mammary tumors; myoepithelial cells	FIBROBLAST GROWTH-FACTOR; E-CADHERIN EXPRESSION; SMOOTH-MUSCLE ACTIN; HUMAN BREAST-CANCER; TRANSGENIC MICE; TUMOR VIRUS; PROVIRAL INSERTION; FACTOR FAMILY; NUDE-MICE; IN-VITRO	Fibroblast Growth Factors 3 (FGF-3) and 4 (FGF-4) mere compared for the effects they each exert on EF43 mouse cells. This non-transformed mammary cell line appears to be myoepithelial mainly because it expresses cc-smooth muscle actin, The EF43 cells were infected with similar vectors that carry either the short fgf-3 sequence (the product of which goes into the secretory pathway), fgf-4 or the selection gene only as control, In syngeneic animals, EF43,fgf-3 cells were tumorigenic only when orthotopically implanted whereas EF43.fgf-4 cells invariably gave rise to aggressive tumors. However, both tumor types were metastatic as evidenced by the blue micrometastases observed when the implanted cells expressed lacZ. In vitro, the FGF-3 producing cells were strongly invasive in matrigel coated chambers whereas the EF43.fgf-4 cells only were invasive in type I-collagen gels, Interestingly, FGF-3 production greatly stimulated the synthesis of pro-MMP-9 (Matrix Metalloprotease-9) and, to a lesser extent, that of pro-MMP-2, FGF-3 also up-regulated the production of plasminogen activators. In contrast, FGF-4 had no effect on these secretions and the medium conditioned by the EF43.fgf-4 cells displayed the largest plasminogen activator-inhibitor activity, These results show that FGF-3 and FGF-4 have distinct mechanisms of action on myoepithelial cells.	Univ Liege, Lab Fundamental Virol & Immunol, Inst Pathol, B-4000 Liege, Belgium; Univ Liege, Inst Pathol, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; Univ Liege, Inst Pathol, Med Chem Lab, B-4000 Liege, Belgium; State Univ Ghent, Expt Cancerol Lab, B-9000 Ghent, Belgium	University of Liege; University of Liege; University of Liege; Ghent University	Calberg-Bacq, CM (corresponding author), Univ Liege, Lab Fundamental Virol & Immunol, Inst Pathol, B23, B-4000 Liege, Belgium.			Hajitou, Amin/0000-0003-1119-5686; Bajou, Khalid/0000-0002-5529-9228				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ADAMS LM, 1987, CANCER RES, V47, P4425; ANDERSSON LA, 1994, EXP CELL RES, V219, P389; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; Bansal GS, 1997, BRIT J CANCER, V75, P1567, DOI 10.1038/bjc.1997.269; BARAMOVA EN, 1994, ANTICANCER RES, V14, P841; BARRACLOUGH R, 1990, J CELL PHYSIOL, V144, P333, DOI 10.1002/jcp.1041440220; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BRACKE ME, 1993, BRIT J CANCER, V68, P282, DOI 10.1038/bjc.1993.329; Deroanne CF, 1997, CANCER RES, V57, P5590; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DIMANCHEBOITREL MT, 1994, INT J CANCER, V56, P512, DOI 10.1002/ijc.2910560410; FERNIG DG, 1990, J CELL PHYSIOL, V142, P108, DOI 10.1002/jcp.1041420114; FERNIG DG, 1995, INTERCELLULAR SIGNAL, P336; FOIDART JM, 1980, LAB INVEST, V42, P336; FRANKE WW, 1980, J CELL BIOL, V84, P633, DOI 10.1083/jcb.84.3.633; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; GOMM JJ, 1991, CANCER RES, V51, P4685; GUGLIOTTA P, 1988, J HISTOCHEM CYTOCHEM, V36, P659, DOI 10.1177/36.6.3367051; GUNZBURG WH, 1988, CARCINOGENESIS, V9, P1849, DOI 10.1093/carcin/9.10.1849; HAJITOU A, 1995, INT J CANCER, V63, P702, DOI 10.1002/ijc.2910630516; Jaakkola P, 1997, MOL CELL BIOL, V17, P3210, DOI 10.1128/MCB.17.6.3210; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; Kapoun AM, 1997, ONCOGENE, V14, P2985, DOI 10.1038/sj.onc.1201146; KE Y, 1993, J CELL SCI, V100, P135; Kitsberg DI, 1996, ONCOGENE, V13, P2507; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LEPRINCE P, 1989, ANAL BIOCHEM, V177, P341, DOI 10.1016/0003-2697(89)90063-8; LIN WC, 1990, CANCER RES, V50, P2808; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MAREEL M M, 1981, Invasion and Metastasis, V1, P195; MAREEL MM, 1991, INT J CANCER, V47, P922, DOI 10.1002/ijc.2910470623; MATHIEU M, 1995, J BIOL CHEM, V270, P24197, DOI 10.1074/jbc.270.41.24197; MCLESKEY SW, 1993, CANCER RES, V53, P2168; Miyake H, 1996, CANCER RES, V56, P2440; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; MURAKAMI A, 1990, CELL GROWTH DIFFER, V1, P225; NAVARRO P, 1993, J CELL SCI, V105, P923; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; RIES C, 1995, BIOL CHEM H-S, V376, P345; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; SATO H, 1992, ONCOGENE, V7, P77; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; SMALLEY M, 1995, INTERCELLULAR SIGNALLING IN THE MAMMARY GLAND, P99; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; Spieker N, 1995, EUR J CELL BIOL, V68, P427; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; TANAKA H, 1993, BIOCHEM BIOPH RES CO, V190, P732, DOI 10.1006/bbrc.1993.1110; VAKAET L, 1991, INVAS METAST, V11, P249; vanHengel J, 1997, J CELL BIOL, V137, P1103, DOI 10.1083/jcb.137.5.1103; VERMEULEN SJ, 1995, BRIT J CANCER, V72, P1447, DOI 10.1038/bjc.1995.528; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Warburton MJ, 1996, EXP CELL RES, V228, P76, DOI 10.1006/excr.1996.0301; Wiedlocha A, 1996, MOL CELL BIOL, V16, P270; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918	63	27	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2059	2071		10.1038/sj.onc.1202126	http://dx.doi.org/10.1038/sj.onc.1202126			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798677				2022-12-28	WOS:000076540900005
J	Barnard, D; Diaz, B; Clawson, D; Marshall, M				Barnard, D; Diaz, B; Clawson, D; Marshall, M			Oncogenes, growth factors and phorbol esters regulate Raf-1 through common mechanisms	ONCOGENE			English	Article						oncogene; Ras; Raf; PKC; Src; EGF	ACTIVATED PROTEIN-KINASE; CELL-CYCLE ARREST; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; IN-VITRO; RAS; C-RAF-1; DOMAIN; IDENTIFICATION; ASSOCIATION	We have uniformly examined the regulatory steps required by oncogenic Ras, Src, EGF and phorbol 12-myristate 13-acetate (PMA) to activate Raf-1. Specifically, we determined the role of Ras binding and the phosphorylation of serines 338/339, tyrosines 340/341 and the activation loop (491-508) in response to these stimuli in COS-7 cells. An intact Ras binding domain was found to be essential for Raf-1 kinase activation by each stimulus, including PMA, Brief treatment of COS-7 cells with PMA was found to rapidly promote accumulation of the active, GTP-bound form of Ras. Furthermore, loss of the serine 338/339 and tyrosine 340/341 phosphorylation sites also blocked Raf-1 activation by all stimuli tested. Loss of the serine 497 and serine 499 PKC alpha phosphorylation sites failed to significantly reduce Raf-1 activation by any stimulus including PMA. Alanine substitution of all other potential phosphorylation sites within the Raf-1 activation loop had little or no effect on kinase regulation by Ras[V12] or vSrc although some mutants were less responsive to PMA. These results suggest that in mammalian cells, Raf-1 can be regulated by a variety of different stimuli through a common mechanism involving association with Ras-GTP and multiple phosphorylations of the amino-terminal region of the catalytic domain. Phosphorylation of the activation loop does not appear to be a significant mechanism of Raf-1 kinase regulation in COS-7 cells.	Indiana Univ, Sch Med, Dept Med, Div Hematol & Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Marshall, M (corresponding author), Indiana Univ, Sch Med, Dept Med, Div Hematol & Oncol, 1044 W Walnut St, Indianapolis, IN 46202 USA.							Arai H, 1996, MOL PHARMACOL, V50, P522; Barnard D, 1995, ONCOGENE, V10, P1283; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Ferrier AF, 1997, J BIOL CHEM, V272, P2136; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MORRISON DK, 1995, MOL REPROD DEV, V42, P507, DOI 10.1002/mrd.1080420420; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Rommel C, 1996, ONCOGENE, V12, P609; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; TRAVERSE S, 1993, ONCOGENE, V8, P3175; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	45	65	67	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1539	1547		10.1038/sj.onc.1202061	http://dx.doi.org/10.1038/sj.onc.1202061			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794231				2022-12-28	WOS:000076089900006
J	Sun, SY; Yue, P; Wu, GS; El-Deiry, WS; Shroot, B; Hong, WK; Lotan, R				Sun, SY; Yue, P; Wu, GS; El-Deiry, WS; Shroot, B; Hong, WK; Lotan, R			Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells	ONCOGENE			English	Article						retinoids; CD437; lung cancer; p53; apoptosis	P53 GENE-MUTATIONS; GROWTH ARREST; IN-VIVO; CANCER; DEATH; ACID; INDUCTION; LINES; PATHWAY; IDENTIFICATION	The novel synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) has been shown to induce apoptosis in various tumor cell lines including human non-small cell lung carcinoma (NSCLC) cells, which are resistant to the natural all-trans retinoic acid and to many synthetic receptor-selective retinoids, Although the mechanism of this effect was not elucidated, it was found to be independent of nuclear retinoid receptors, In the present study, we analysed the mechanisms by which CD437 induces apoptosis in two human NSCLC cell lines: H460 with wild-type p53 and H1792 with mutant p53. Both cell lines underwent apoptosis after exposure to CD437, although the cell line with wild-type p53 (H460) was more sensitive to the induction of apoptosis, CD437 increased the activity of caspase in both cell lines, however, the effect was much more pronounced in the H460 cells, The caspase inhibitors (Z-DEVD-FMK and Z-VAD-FMK) suppressed CD437-induced CPP32-like caspase activation and apoptosis in both cell lines, CD437 induced the expression of the p53 gene and its target genes, p21, Bas, and Killer/DR5, only in the H460 cells. These results suggest that CD437-induced apoptosis is more extensive in NSCLC cells that express wild-type p53, possibly due to the involvement of the p53 regulated genes Killer/DR5, and Bar although CD437 can also induce apoptosis by means of a p53-independent mechanism. Both pathways of CD437-induced apoptosis appear to involve activation of CPP32-like caspase.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Galderma Res & Dev, Sophia Antipolis, France	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Howard Hughes Medical Institute; University of Pennsylvania; Galderma R&D SNC	Sun, SY (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd,Box 108, Houston, TX 77030 USA.		El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266	NATIONAL CANCER INSTITUTE [U19CA068437] Funding Source: NIH RePORTER; NCI NIH HHS [U19 CA68437] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi H, 1998, AM J RESP CELL MOL, V18, P323, DOI 10.1165/ajrcmb.18.3.2974; Benner S E, 1995, Oncology (Williston Park), V9, P205; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN YQ, 1995, CANCER RES, V55, P4536; DE LUCA LM, 1991, FASEB J, V5, P2924; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FAN SJ, 1994, CANCER RES, V54, P5824; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GomezManzano C, 1997, J NATL CANCER I, V89, P1036, DOI 10.1093/jnci/89.14.1036; HARPER JW, 1993, CELL, V75, P805; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEHMANN JM, 1991, CANCER RES, V51, P4804; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU S, 1994, P AM ASSOC CANC RES, V35, pA1517; MARTIN SJ, 1995, CRIT REV ONCOL HEMAT, V18, P137, DOI 10.1016/1040-8428(94)00124-C; MICHIELI P, 1994, CANCER RES, V54, P3391; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MIYASHITA T, 1995, CELL, V80, P293; Nagy L, 1998, CELL DEATH DIFFER, V5, P11, DOI 10.1038/sj.cdd.4400337; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Oridate N, 1997, INT J CANCER, V70, P484, DOI 10.1002/(SICI)1097-0215(19970207)70:4<484::AID-IJC21>3.0.CO;2-E; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Schadendorf D, 1996, J CELL BIOL, V135, P1889, DOI 10.1083/jcb.135.6.1889; SHAO ZM, 1995, ONCOGENE, V11, P493; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Shimamura A, 1996, CLIN CANCER RES, V2, P435; Sun SY, 1997, J CELL PHYSIOL, V173, P279, DOI 10.1002/(SICI)1097-4652(199711)173:2<279::AID-JCP36>3.0.CO;2-8; Sun SY, 1997, CANCER RES, V57, P4931; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zou CP, 1998, CLIN CANCER RES, V4, P1345	39	113	115	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	1999	18	14					2357	2365		10.1038/sj.onc.1202543	http://dx.doi.org/10.1038/sj.onc.1202543			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327056				2022-12-28	WOS:000079595500008
J	Graham, SM; Oldham, SM; Martin, CB; Drugan, JK; Zohn, IE; Campbell, S; Der, CJ				Graham, SM; Oldham, SM; Martin, CB; Drugan, JK; Zohn, IE; Campbell, S; Der, CJ			TC21 and Ras share indistinguishable transforming and differentiating activities	ONCOGENE			English	Article						Ras-related; JNK; PC12 pheochromocytoma cells; C2 myoblasts	ACTIVATED PROTEIN-KINASE; NUCLEOTIDE DISSOCIATION STIMULATOR; KAPPA-B ACTIVATION; NIH 3T3 CELLS; R-RAS; ONCOGENIC RAS; HA-RAS; INDEPENDENT PATHWAYS; PLASMA-MEMBRANE; FAMILY MEMBERS	Constitutively activated mutants of the Ras-related protein TC21/R-Ras2 cause tumorigenic transformation of NIH3T3 cells. However, unlike Ras, TC21 fails to bind to and activate the Raf-1 serine-threonine kinase, Thus, whereas Ras transformation is critically dependent on Raf-1 TC21 activity is promoted by activation of Raf-independent signaling pathways. In the present study, we have further compared the functions of Ras and TC21, First we determined the basis for the inability of TC21 to activate Raf-1, Whereas Ras can interact with the two distinct Ras-binding sequences in NH2-terminus of Raf-2, designated RBS1 and Raf-Cys, TC21 could only bind Raf-Cys, Thus, the inability of TC21 to bind to RBS1 may prevent it from promoting the translocation of Raf-1 to the plasma membrane. Second, we found that TC21 is an activator of the JNK and p38, but not ERK, mitogen-activated protein kinase cascades and that TC21 transforming activity was dependent on Rac function. Thus, like Ras, TC21 may activate a Rac/JNK pathway, Third, we determined if TC21 could cause the same biological consequences as Ras in three distinct cell types. Like Ras, activated TC21 caused transformation of RIE-1 rat intestinal epithelial cells and terminal differentiation of PC12 pheochromocytoma cells. Finally, activated TC21 blocked serum starvation-induced differentiation of C2 myoblasts, whereas dominant negative TC21 greatly accelerated this differentiation process. Therefore, TC21 and Ras share indistinguishable biological activities in all cell types that we have evaluated. These results support the importance of Raf-independent pathways in mediating the actions of Ras and TC21.	Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Der, CJ (corresponding author), Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA.			Zohn, Irene/0000-0001-7688-682X; campbell, sharon/0000-0003-0311-409X; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA070308, R29CA064569, R01CA042978] Funding Source: NIH RePORTER; NCI NIH HHS [CA64569, CA70308, CA42978] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1992, CANCER BIOL, V3, P199; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CAMPBELL SL, 1998, IN PRESS ONCOGENE; CAMPBELLBURK SL, 1995, METHOD ENZYMOL, V255, P3; CARBONI JM, 1995, ONCOGENE, V10, P1905; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; Clark GJ, 1996, ONCOGENE, V12, P169; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX AD, 1994, ONCOGENE, V9, P3281; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GHOSH S, 1994, J BIOL CHEM, V269, P30785; Graham SM, 1996, MOL CELL BIOL, V16, P6132; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HILL CS, 1993, CELL, V73, P385; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KONG YF, 1995, MOL CELL BIOL, V15, P5205; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MILLER AF, 1993, BIOCHEMISTRY-US, V32, P7367, DOI 10.1021/bi00080a006; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; OLDHAM SM, 1998, IN PRESS ONCOGENE; OLSEN EN, 1987, MOL CELL BIOL, V7, P2104; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; REY I, 1994, ONCOGENE, V9, P685; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SAEZ R, 1994, ONCOGENE, V9, P2977; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; VANAELST L, 1994, COLD SPRING HARB SYM, V59, P181, DOI 10.1101/SQB.1994.059.01.022; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WESTWICK JK, 1995, METHOD ENZYMOL, V255, P342; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1996, ONCOGENE, V13, P353; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	94	51	54	2	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2107	2116		10.1038/sj.onc.1202517	http://dx.doi.org/10.1038/sj.onc.1202517			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321735				2022-12-28	WOS:000079346200008
J	Prasad, GL; Masuelli, L; Raj, MHG; Harindranath, N				Prasad, GL; Masuelli, L; Raj, MHG; Harindranath, N			Suppression of src-induced transformed phenotype by expression of tropomyosin-1	ONCOGENE			English	Article						tropomyosin; src; oncogenes; transformation; tumor suppression; cytoskeleton	MAMMARY EPITHELIAL-CELLS; PROTEIN-TYROSINE KINASES; EPIDERMAL GROWTH-FACTOR; RAT FIBROBLASTS; C-SRC; CDNA; ACTIN; ORGANIZATION; CYTOSKELETON; ONCOGENE	Suppression of high M-r tropomyosins (TMs) is a common feature of transformed cells. Previous work from this laboratory has demonstrated that the isoform 1 of TM, TM1, acts as an anti-oncogene in ras-transformed murine fibroblasts. In this study, we have investigated whether TM1 is a ras-specific suppressor, or a general suppressor protein of the cellular transformation. V-src transformed fibroblasts, which express decreased TM1, were transduced with a full-length cDNA to overexpress TM1. Both the control and the transduced cells expressed v-src kinase at comparable levels. TM1 expressing (src-T1) cells grew at a lower rate in monolayer, exhibited well spread, flat morphology than the control cells. Enhanced expression of TM1 resulted in improved microfilamental architecture. More significantly, src-T1 cells completely failed to grow under anchorage independent conditions. These data demonstrate that TM1 is as an anti-oncogene of functionally diverse oncogenes, and it is a class II tumor suppressor protein.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19104 USA; Univ La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy; Louisiana State Univ, Med Ctr, Dept Obgyn & Biochem, New Orleans, LA 70112 USA; US FDA, CBER, Div Hematol Prod, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Sapienza University Rome; Louisiana State University System; US Food & Drug Administration (FDA)	Prasad, GL (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19104 USA.		Masuelli, Laura/AGW-4259-2022	MASUELLI, Laura/0000-0001-8174-8034				BHATTACHARYA B, 1988, ONCOGENE RES, V3, P51; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; Braverman RH, 1996, ONCOGENE, V13, P537; BUTTON E, 1995, CELL MOTIL CYTOSKEL, V30, P247, DOI 10.1002/cm.970300402; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; COOPER HL, 1987, CANCER RES, V47, P4493; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Gusella JF, 1996, CURR OPIN GENET DEV, V6, P87, DOI 10.1016/S0959-437X(96)90016-7; JAMMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111; JANCSO A, 1991, J BIOL CHEM, V266, P5891; KELLIE S, 1993, SYM SOC EXP BIOL, V47, P267; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEHRER SS, 1991, BIOCHEMISTRY-US, V30, P5682, DOI 10.1021/bi00237a007; LEONARDI CL, 1982, BIOCHIM BIOPHYS ACTA, V720, P154, DOI 10.1016/0167-4889(82)90007-6; Lin J J, 1997, Int Rev Cytol, V170, P1, DOI 10.1016/S0074-7696(08)61619-8; LIN JJC, 1985, J CELL BIOL, V100, P692, DOI 10.1083/jcb.100.3.692; Masuda A, 1996, ONCOGENE, V12, P2081; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MULLAUER L, 1993, ONCOGENE, V8, P2531; NIGG EA, 1986, VIROLOGY, V151, P50, DOI 10.1016/0042-6822(86)90103-0; OKAMURA H, 1994, ONCOGENE, V9, P2293; OZAKI T, 1993, P NATL ACAD SCI USA, V90, P2593, DOI 10.1073/pnas.90.7.2593; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; PRASAD GL, 1994, EUR J BIOCHEM, V224, P1, DOI 10.1111/j.1432-1033.1994.tb19988.x; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; PRASAD GL, 1991, BIOCHEM BIOPH RES CO, V177, P1068, DOI 10.1016/0006-291X(91)90647-P; SCHAFER R, 1994, REV PHYSL BIOCH PHAR, V124, P30; Sers C, 1997, J CELL BIOL, V136, P935, DOI 10.1083/jcb.136.4.935; SHRIVER K, 1981, J CELL BIOL, V89, P525, DOI 10.1083/jcb.89.3.525; SUPERTIFURGA G, 1995, FEBS LETT, V369, P62, DOI 10.1016/0014-5793(95)00636-N; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; VANDEKERCKHOVE J, 1990, CURR OPIN CELL BIOL, V2, P241; Wang DZM, 1997, CANCER RES, V57, P2478; Wang FL, 1996, CANCER RES, V56, P3634; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; YAMASHIRO S, 1994, ADV EXP MED BIOL, V358, P113	45	52	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					2027	2031		10.1038/sj.onc.1202264	http://dx.doi.org/10.1038/sj.onc.1202264			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208425				2022-12-28	WOS:000079191300013
J	Falchetti, ML; Falcone, G; D'Ambrosio, E; Verna, R; Alema, S; Levi, A				Falchetti, ML; Falcone, G; D'Ambrosio, E; Verna, R; Alema, S; Levi, A			Induction of telomerase activity in v-myc-transformed avian cells	ONCOGENE			English	Article						telomerase; v-Myc; v-Src; transformation; TRAP	DIFFERENTIATION PROGRAM; MYOGENIC CELLS; IMMORTAL CELLS; STEM-CELLS; ONCOGENES; CANCER; TRANSCRIPTION; PROTEIN; LINES; GENE	Telomerase activity is detectable in the majority of tumors or immortalized cell lines, but is repressed in most normal human somatic cells. It is generally assumed that reactivation of telomerase prevents the erosion of chromosome ends which occurs in cycling cells and, hence, hinders cellular replicative senescence. Here, we show that the expression of v-Myc oncoprotein by retroviral infection of telomerase-negative embryonal quail myoblasts and chicken neuroretina cells is sufficient for reactivating telomerase activity, earlier than telomere shortening could occur. Furthermore, the use of a conditional v-Myc-estrogen receptor protein (v-MycER) causes estrogen-dependent expression of detectable levels of telomerase activity in recently infected chick embryo fibroblasts and neuroretina cells. We conclude that the high levels of telomerase activity in v-Myc-expressing avian cells are not the mere consequence of transformation or of a differentiative block, since v-Src tyrosine kinase, which prevents terminal differentiation and promotes cell transformation, fails to induce telomerase activity.	Univ Roma La Sapienza, Ist Neurobiol, Rome, Italy; Univ Roma La Sapienza, Ist Biol Cellulare, Rome, Italy; Univ Roma La Sapienza, CNR, Ist Med Sperimentale, Rome, Italy; Univ Roma La Sapienza, Dipartimento Med Sperimentale, Rome, Italy	Sapienza University Rome; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Sapienza University Rome	Levi, A (corresponding author), Univ Roma La Sapienza, Ist Neurobiol, Rome, Italy.		falchetti, maria laura/AAA-5586-2019; Falcone, Germana/A-3735-2016	Alema, Stefano/0000-0002-9869-6354; VERNA, Roberto/0000-0002-1869-3912; Falcone, Germana/0000-0002-3508-7623				ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Belair CD, 1997, P NATL ACAD SCI USA, V94, P13677, DOI 10.1073/pnas.94.25.13677; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; BISTER K, 1987, ONCOGENE, V1, P97; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOETTIGER D, 1989, CURR TOP MICROBIOL, V147, P31; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CASALBORE P, 1987, NATURE, V326, P188, DOI 10.1038/326188a0; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELANGE T, 1995, TELOMERES, P265; Falchetti ML, 1998, NUCLEIC ACIDS RES, V26, P862, DOI 10.1093/nar/26.3.862; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Fujimoto K, 1997, BIOCHEM BIOPH RES CO, V241, P775, DOI 10.1006/bbrc.1997.7806; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Greaves M, 1996, TRENDS GENET, V12, P127, DOI 10.1016/0168-9525(96)30016-4; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLEY CB, 1995, TELOMERES, P247; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; Holt SE, 1996, MOL CELL BIOL, V16, P2932; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; LEJNINE S, 1995, P NATL ACAD SCI USA, V92, P2393, DOI 10.1073/pnas.92.6.2393; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Lustig AJ, 1997, TRENDS CELL BIOL, V7, P299, DOI 10.1016/S0962-8924(97)01110-0; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Pain B, 1996, DEVELOPMENT, V122, P2339; POLLERBERG GE, 1995, J NEUROSCI RES, V41, P427, DOI 10.1002/jnr.490410402; RAMSAY G, 1980, NATURE, V288, P170, DOI 10.1038/288170a0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Stoppler H, 1997, J BIOL CHEM, V272, P13332, DOI 10.1074/jbc.272.20.13332; Strahl C, 1996, MOL CELL BIOL, V16, P53; Tahara H, 1995, CLIN CANCER RES, V1, P1245; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; VOJTA PJ, 1995, BBA-REV CANCER, V1242, P29, DOI 10.1016/0304-419X(95)00002-W; WEINBERG RA, 1989, CANCER RES, V49, P3713; WHITAKER NJ, 1995, ONCOGENE, V11, P971	49	23	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	1999	18	7					1515	1519		10.1038/sj.onc.1202438	http://dx.doi.org/10.1038/sj.onc.1202438			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050888				2022-12-28	WOS:000078651600013
J	Harhaj, EW; Good, LF; Xiao, GT; Sun, SC				Harhaj, EW; Good, LF; Xiao, GT; Sun, SC			Gene expression profiles in HTLV-I-immortalized T cells: deregulated expression of genes involved in apoptosis regulation	ONCOGENE			English	Article						HTLV-I; adult T-cell leukemia; T-cell immortalization; gene array; gene expression profile	VIRUS TYPE-I; TRANSCRIPTION FACTOR YB-1; NF-KAPPA-B; LEUKEMIA-VIRUS; TAX-PROTEIN; MOLECULAR-CLONING; SIGNALING COMPLEX; BINDING PROTEIN; INFECTED-CELLS; FAS-LIGAND	Human T-cell leukemia virus type I (HTLV-I) is the etiologic agent of adult T-cell leukemia, an acute and often fatal T-cell malignancy. A key step in HTLV-I-induced leukemigenesis is induction of abnormal T-cell growth and survival. Unlike antigen-stimulated T cells, which cease proliferation after a finite number of cell division, HTLV-I-infected T cells proliferate indefinitely (immortalized), thus facilitating occurrence of secondary genetic changes leading to malignant transformation. To explore the molecular basis of HTLV-I-induced abnormal T-cell survival, we compared the gene expression profiles of normal and HTLV-I-immortalized T cells using 'gene array'. These studies revealed a strikingly altered expression pattern of a large number of genes along with HTLV-I-mediated T-cell immortalization. Interestingly, many of these deregulated genes are involved in the control of programmed cell death or apoptosis. These findings indicate that disruption of the cellular apoptosis-regulatory network may play a role in the HTLV-I-mediated oncogenesis.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, 500 Univ Dr, Hershey, PA 17033 USA.				NCI NIH HHS [R01 CA68471-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi Tsuyoshi, 1997, Leukemia (Basingstoke), V11, P25; ALEXANDRE C, 1991, ONCOGENE, V6, P543; Arai M, 1998, AIDS RES HUM RETROV, V14, P261, DOI 10.1089/aid.1998.14.261; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; BAUM PR, 1994, EMBO J, V13, P3992, DOI 10.1002/j.1460-2075.1994.tb06715.x; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; BROWNING JL, 1995, J IMMUNOL, V154, P33; Butscher WG, 1998, J BIOL CHEM, V273, P552, DOI 10.1074/jbc.273.1.552; Chenchik A, 1998, CLONTECHNIQUES, V13, P16; COPELAND KFT, 1994, AIDS RES HUM RETROV, V10, P1259, DOI 10.1089/aid.1994.10.1259; Crepieux P, 1997, MOL CELL BIOL, V17, P7375, DOI 10.1128/MCB.17.12.7375; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Dick T, 1996, MOL CELL BIOL, V16, P1966; DORMAN DM, 1992, J BIOL CHEM, V267, P1279; Eischen CM, 1997, J IMMUNOL, V159, P1135; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; Fujii J, 1996, NEPHROL DIAL TRANSPL, V11, P34; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GonzalezGarcia A, 1997, J IMMUNOL, V158, P4104; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; HINTZEN RQ, 1994, IMMUNOL TODAY, V15, P307, DOI 10.1016/0167-5699(94)90077-9; Imura A, 1996, J EXP MED, V183, P2185, DOI 10.1084/jem.183.5.2185; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KASHANCHI F, 1994, J VIROL, V68, P561, DOI 10.1128/JVI.68.1.561-565.1994; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Kishi S, 1997, J EXP MED, V186, P57, DOI 10.1084/jem.186.1.57; KOEFFLER HP, 1984, BLOOD, V64, P482; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; LI CCH, 1993, J VIROL, V67, P4205, DOI 10.1128/JVI.67.7.4205-4213.1993; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; MALEFYT RD, 1990, J IMMUNOL, V145, P2297; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; Mena MA, 1997, J NEUROCHEM, V69, P21; MERL S, 1984, BLOOD, V64, P967; MIGITA K, 1995, IMMUNOLOGY, V85, P550; MIURA K, 1992, BIOCHEM BIOPH RES CO, V187, P375, DOI 10.1016/S0006-291X(05)81503-7; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; MIYOSHI I, 1981, GANN, V72, P978; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; Ohga T, 1996, CANCER RES, V56, P4224; Ohtani K, 1998, J BIOL CHEM, V273, P14119, DOI 10.1074/jbc.273.23.14119; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PERSAUD D, 1995, J VIROL, V69, P6297, DOI 10.1128/JVI.69.10.6297-6303.1995; Petricoin EF, 1997, NATURE, V390, P629, DOI 10.1038/37648; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; PROSPERI MT, 1993, J BIOL CHEM, V268, P11050; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; SAGGIORO D, 1991, AIDS RES HUM RETROV, V7, P571, DOI 10.1089/aid.1991.7.571; SAURI H, 1995, BIOCHEM BIOPH RES CO, V208, P964, DOI 10.1006/bbrc.1995.1428; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SODROSKI J, 1992, BIOCHIM BIOPHYS ACTA, V1114, P19, DOI 10.1016/0304-419X(92)90003-H; SUGIMOTO A, 1995, EMBO J, V14, P4434, DOI 10.1002/j.1460-2075.1995.tb00122.x; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; Tsushima H, 1997, CELL GROWTH DIFFER, V8, P1317; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VanSnick J, 1996, J IMMUNOL, V157, P2570; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Ware CF, 1996, J CELL BIOCHEM, V60, P47, DOI 10.1002/(SICI)1097-4644(19960101)60:1<47::AID-JCB8>3.3.CO;2-H; Weiss Arthur, 1993, P467; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; YOSHIDA M, 1995, J CANCER RES CLIN, V121, P521, DOI 10.1007/BF01197764; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	84	75	76	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1341	1349		10.1038/sj.onc.1202405	http://dx.doi.org/10.1038/sj.onc.1202405			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022816				2022-12-28	WOS:000078510900010
J	Skourides, PA; Perera, SA; Ren, RB				Skourides, PA; Perera, SA; Ren, RB			Polarized distribution of Bcr-Abl in migrating myeloid cells and co-localization of Bcr-Abl and its target proteins	ONCOGENE			English	Article						chronic myelogenous leukemia; Bcr-Abl; phosphorylation; Grb2; Shc; Cbl	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE; PHILADELPHIA-CHROMOSOME; TRANSGENIC MICE; SIGNAL-TRANSDUCTION; INTEGRIN FUNCTION; ADAPTER PROTEIN; LYMPHOID-CELLS; V-ABL; ONCOGENE	Bcr-Abl plays a critical role in the pathogenesis of Philadelphia chromosome-positive leukemia. Although a large number of substrates and interacting proteins of Bcr-Abl have been identified, it remains unclear whether Bcr-Abl assembles multi-protein complexes and if it does where these complexes are within cells. We have investigated the localization of Bcr-Abl in 32D myeloid cells attached to the extracellular matrix. We have found that Bcr-Abl displays a polarized distribution, colocalizing with a subset of filamentous actin at trailing portions of migrating 32D cells, and localizes on the cortical F-actin and on vesicle-like structures in resting 32D cells. Deletion of the actin binding domain of Bcr-Abl (Bcr-Abl-AD) dramatically enhances the localization of Bcr-Abl on the vesicle-like structures. These distinct localization patterns of Bcr-Abl and Bcr-Abl-AD enabled us to examine the localization of Bcr-Abl substrate and interacting proteins in relation to Bcr-Abl. We found that a subset of biochemically defined target proteins of Bcr-Abl redistributed and co-localized with Bcr-Abl on F-actin and on vesicle-like structures. The co-localization of signaling proteins with Bcr-Abl at its sites of localization supports the idea that Bcr-Abl forms a multi-protein signaling complex, while the polarized distribution and vesicle-like localization of Bcr-Abl may play a role in leukemogenesis.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA; Brandeis Univ, Dept Biol, Waltham, MA 02254 USA	Brandeis University; Brandeis University	Ren, RB (corresponding author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, MS 029, Waltham, MA 02254 USA.			Skourides, Paris/0000-0003-3502-5729	NCI NIH HHS [CA68008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; Bouton AH, 1997, HYBRIDOMA, V16, P403, DOI 10.1089/hyb.1997.16.403; Cortes JE, 1996, AM J MED, V100, P555, DOI 10.1016/S0002-9343(96)00061-7; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; Enright H, 1996, Curr Opin Hematol, V3, P303; Goldman J M, 1997, Curr Opin Hematol, V4, P277; Gotoh A, 1997, Curr Opin Hematol, V4, P3; Hariharan I K, 1988, Oncogene Res, V3, P387; HARIHARAN IK, 1989, MOL CELL BIOL, V9, P2798, DOI 10.1128/MCB.9.7.2798; HAWLEY RG, 1994, GENE THER, V1, P136; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KELLIHER MA, 1993, ONCOGENE, V8, P1249; LANEUVILLE P, 1991, ONCOGENE, V6, P275; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lester LB, 1997, RECENT PROG HORM RES, V52, P409; Liu JX, 1996, MOL CELL BIOL, V16, P998; LIU JX, 1993, ONCOGENE, V8, P101; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; McWhirter JR, 1997, ONCOGENE, V15, P1625, DOI 10.1038/sj.onc.1201342; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PULL L, 1994, EMBO J, V13, P764; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Sawyers CL, 1997, BAILLIERE CLIN HAEM, V10, P223, DOI 10.1016/S0950-3536(97)80004-2; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; Wu Y, 1998, ONCOGENE, V16, P141, DOI 10.1038/sj.onc.1201524; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079; ZHANG X, 1998, IN PRESS BLOOD	60	29	30	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1165	1176		10.1038/sj.onc.1202407	http://dx.doi.org/10.1038/sj.onc.1202407			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022122				2022-12-28	WOS:000078510700005
J	Qiu, GF; Ahmed, M; Sells, SF; Mohiuddin, M; Weinstein, MH; Rangnekar, VM				Qiu, GF; Ahmed, M; Sells, SF; Mohiuddin, M; Weinstein, MH; Rangnekar, VM			Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4	ONCOGENE			English	Article						Par-4; Bcl-2; apoptosis; prostate	PROTEIN-KINASE-C; CELL-DEATH; APOPTOSIS; CANCER; ISOFORMS; FAMILY	Par-4 is a widely expressed protein that sensitizes both prostatic and non-prostatic cells to apoptosis, Constitutive- or regulated- overexpression of Par-4 caused a reduction in the levels of the anti-apoptotic protein Bcl-2, Replenishment of Bcl-2 levels abrogated susceptibility to Par-4-dependent apoptosis, suggesting that Par-4-mediated apoptosis requires downmodulation of Bcl-2 levels. The inverse correlation between Par-4 and Bcl-2 expression was recapitulated in human prostate tumors, Par-4 but not Bcl-2 was detected in the secretory epithelium of benign prostatic tumors and in primary and metastatic prostate cancers that are apt to undergo apoptosis, Moreover, xenografts of human, androgen-dependent CWR22 tumors showed Par-4 but not Bcl-2 expression. By contrast, androgen-independent CWR22R tumors derived from the CWR22 xenografts showed mutually exclusive expression patterns of Par-4 and Bcl-2, These findings suggest a mechanism by which Par-4 may sensitize prostate tumor cells to apoptosis.	Univ Kentucky, Dept Surg, Div Urol, Lexington, KY 40536 USA; Univ Kentucky, Dept Radiat Med, Lexington, KY 40536 USA; Univ Kentucky, Dept Pathol, Lexington, KY 40536 USA; Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40536 USA; Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky	Rangnekar, VM (corresponding author), Univ Kentucky, Dept Surg, Div Urol, Lexington, KY 40536 USA.				NATIONAL CANCER INSTITUTE [R01CA060872] Funding Source: NIH RePORTER; NCI NIH HHS [CA60872] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIHARA M, 1995, CANCER-AM CANCER SOC, V75, P522, DOI 10.1002/1097-0142(19950115)75:2<522::AID-CNCR2820750215>3.0.CO;2-W; Beham A, 1997, ONCOGENE, V15, P2767, DOI 10.1038/sj.onc.1201464; Berges RR, 1995, CLIN CANCER RES, V1, P473; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; Bromberg Jacqueline, 1993, Current Opinion in Oncology, V5, P546, DOI 10.1097/00001622-199305000-00017; CARTER HB, 1990, PROSTATE, V16, P39; COLOMBEL M, 1993, AM J PATHOL, V143, P390; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Ishibashi Y, 1998, BIOCHEM BIOPH RES CO, V243, P609, DOI 10.1006/bbrc.1998.8145; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Krajewska M, 1996, AM J PATHOL, V148, P1567; MCCOLLOUGH DL, 1988, DIAGNOSIS MANAGEMENT, P405; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; NAGABHUSHAN M, 1996, CANCER RES, V56, P6049; RAFFO A, 1990, CANCER RES, V55, P4438; Rangnekar VM, 1998, APOPTOSIS, V3, P61, DOI 10.1023/A:1009666705875; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; StClair EG, 1997, J BIOL CHEM, V272, P29347; Tu HC, 1996, INT J CANCER, V69, P357, DOI 10.1002/(SICI)1097-0215(19961021)69:5<357::AID-IJC1>3.0.CO;2-4; WHEELER TM, 1994, J CELL BIOCHEM, P202; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	30	72	74	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					623	631		10.1038/sj.onc.1202344	http://dx.doi.org/10.1038/sj.onc.1202344			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989812				2022-12-28	WOS:000078394400007
J	Scotlandi, K; Manara, MC; Serra, M; Benini, S; Maurici, D; Caputo, A; De Giovanni, C; Lollini, PL; Nanni, P; Picci, P; Campanacci, M; Baldini, N				Scotlandi, K; Manara, MC; Serra, M; Benini, S; Maurici, D; Caputo, A; De Giovanni, C; Lollini, PL; Nanni, P; Picci, P; Campanacci, M; Baldini, N			The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells	ONCOGENE			English	Article						MDR1 gene; tumorigenicity; metastasis; osteosarcoma; P-glycoprotein	MULTIDRUG-RESISTANCE; TUMOR PROGRESSION; COMPLEMENTARY-DNA; MDR PROTEIN; GENE; ESTABLISHMENT; AMPLIFICATION; BEHAVIOR; GROWTH; LINES	The relationship between P-glycoprotein expression and malignancy is controversial. We have recently found that, in osteosarcoma, multidrug resistance (MDR) is associated with a less aggressive behavior, both in vitro and in clinical settings. In this study, we evaluated whether P-glycoprotein overexpression has a cause-effect relationship with the reduced metastatic potential of MDR cells, or rather reflects a more complex phenotype, MDR1 gene-transfected osteosarcoma cell clones, showing different levels of P-glycoprotein expression, were analysed for their in vitro characteristics and their tumorigenic and metastatic ability in athymic mice. Apart from the different levels of P-glycoprotein, no significant change in the expression of surface antigens or in the differentiative features were observed in the MDR1 gene transfectants compared to the parental cell lines or control clones, obtained by transfection with neo gene alone. In contrast to controls, however, MDR1 transfectants showed a significantly lower ability to grow in semi-solid medium and were completely unable to grow and give lung metastases in athymic mice. These findings indicate that P-glycoprotein overexpression is causally associated with a low malignant potential of osteosarcoma cells, and open new insights on the role and functions of P-glycoprotein activity.	Istituti Ortopedici Rizzoli, Lab Ricerca Oncol, I-40136 Bologna, Italy; Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, I-44100 Ferrara, Italy; Univ Bologna, Ist Cancerol, I-40126 Bologna, Italy	University of Ferrara; University of Bologna	Baldini, N (corresponding author), Istituti Ortopedici Rizzoli, Lab Ricerca Oncol, I-40136 Bologna, Italy.		Caputo, Antonella/ABE-7851-2020; Serra, Massimo/J-4878-2016; De Giovanni, Carla/B-1312-2009; Baldini, Nicola/J-4806-2016; Lollini, Pier Luigi/A-7644-2008; Scotlandi, Katia/J-9009-2016; Manara, Maria Cristina/K-3366-2018; Picci, Piero/J-5979-2016; BENINI, STEFANIA/D-1804-2019	Caputo, Antonella/0000-0002-1241-0299; Serra, Massimo/0000-0003-0742-1177; Baldini, Nicola/0000-0003-2228-3833; Lollini, Pier Luigi/0000-0003-1702-4108; Scotlandi, Katia/0000-0001-6114-9499; Manara, Maria Cristina/0000-0001-5686-720X; DE GIOVANNI, CARLA/0000-0003-4388-4988; Nanni, Patrizia/0000-0001-5319-0803; Picci, Piero/0000-0002-8519-4101; BENINI, STEFANIA/0000-0003-0958-9088				Baldini N, 1997, NAT MED, V3, P378, DOI 10.1038/nm0497-378; BALDINI N, 1995, NEW ENGL J MED, V333, P1380, DOI 10.1056/NEJM199511233332103; BASHIR I, 1994, INT J CANCER, V57, P719, DOI 10.1002/ijc.2910570519; BENARD J, 1989, INT J CANCER, V43, P471, DOI 10.1002/ijc.2910430322; BIEDLER JL, 1994, CANCER METAST REV, V13, P191, DOI 10.1007/BF00689636; BIEDLER JL, 1975, J NATL CANCER I, V55, P671, DOI 10.1093/jnci/55.3.671; BRADLEY G, 1992, CANCER RES, V52, P5154; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; CHAN HSL, 1990, J CLIN ONCOL, V8, P689, DOI 10.1200/JCO.1990.8.4.689; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; Chan HSL, 1997, J NATL CANCER I, V89, P1706, DOI 10.1093/jnci/89.22.1706; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HABU S, 1981, J IMMUNOL, V127, P34; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hoffman MM, 1996, J GEN PHYSIOL, V108, P295, DOI 10.1085/jgp.108.4.295; Kerbel R. S., 1993, P583; LINCKE CR, 1990, CANCER RES, V50, P1779; MIRSKI SEL, 1987, CANCER RES, V47, P2594; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; PINEDO HM, 1995, NEW ENGL J MED, V333, P1417, DOI 10.1056/NEJM199511233332111; RIORDAN JR, 1989, SCIENCE, V245, P1066; RODAN SB, 1987, CANCER RES, V47, P4961; Roepe PD, 1996, J BIOENERG BIOMEMBR, V28, P541, DOI 10.1007/BF02110444; Scotlandi K, 1996, CANCER RES, V56, P2434; SERRA M, 1993, ANTICANCER RES, V13, P323; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004	31	31	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					739	746		10.1038/sj.onc.1202330	http://dx.doi.org/10.1038/sj.onc.1202330			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989824				2022-12-28	WOS:000078394400019
J	Nishida, K; Kaziro, Y; Satoh, T				Nishida, K; Kaziro, Y; Satoh, T			Anti-apoptotic function of Rac in hematopoietic cells	ONCOGENE			English	Article						Akt; apoptosis; p38 mitogen-activated protein kinase; phosphatidylinositol 3-kinase; Rac	ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; COLONY-STIMULATING FACTOR; SIGNALING PATHWAY; JUN KINASE; B-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIN POLYMERIZATION; SELECTIVE ACTIVATION; CYTOKINE DEPRIVATION	The small GTP-binding protein Rac plays a pivotal role in the regulation of diverse physiological events including reorganization of the actin cytoskeleton, cell cycle progression, and transformation. Here we show an anti-apoptotic effect of Rac in interleukin-3-dependent murine hematopoietic BaF3 cells. Activated Rac(G12V), when ectopically expressed in BaF3 cells, rendered the cells resistant to apoptosis upon interleukin-3 deprivation, while activated mutants of Rho and Cdc42 displayed no significant anti-apoptotic effect. In contrast to activated Ras, which also supports cell survival in the absence of interleukin-3, Rac required fetal bovine serum for the prevention of cell death. The involvement of phosphatidylinositol 3-kinase downstream of Rac was demonstrated by the inhibition of Rac-induced cell survival by wortmannin and LY294002 and the presence of phosphatidylinositol kinase activity in the Rac immunoprecipitate, Furthermore, the serine/threonine kinase Akt was stimulated by activated Rac and fetal bovine serum in a synergistic manner. Rac-induced Akt activation was mediated by phosphorylation of threonine-308 and serine-473, In addition to the phosphatidylinositol 3-kinase/Akt pathway, the p38 mitogen-activated protein kinase pathway was crucial for Rac-dependent survival, whereas p38 mitogen-activated protein kinase was not implicated in Ras-induced anti-apoptotic signaling. These findings provide evidence for the involvement of Rac in survival signaling of hematopoietic cells.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Satoh, T (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.		Satoh, Takaya/K-2628-2014	Nishida, Kazuhiko/0000-0001-8825-8441				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu R, 1997, BIOCHEM BIOPH RES CO, V234, P611, DOI 10.1006/bbrc.1997.6643; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nagata Y, 1997, BLOOD, V89, P2664, DOI 10.1182/blood.V89.8.2664; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ohta T, 1997, J BIOL CHEM, V272, P23111, DOI 10.1074/jbc.272.37.23111; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Suzuki J, 1997, ONCOGENE, V15, P1689, DOI 10.1038/sj.onc.1201333; Tago K, 1998, J BIOCHEM-TOKYO, V123, P659; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	74	81	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					407	415		10.1038/sj.onc.1202301	http://dx.doi.org/10.1038/sj.onc.1202301			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927197				2022-12-28	WOS:000078166500013
J	Voorhoeve, PM; Hijmans, EM; Bernards, R				Voorhoeve, PM; Hijmans, EM; Bernards, R			Functional interaction between a novel protein phosphatase 2A regulatory subunit, PR59, and the retinoblastoma-related p107 protein	ONCOGENE			English	Article						cell cycle; p107; protein phosphatase 2A; retinoblastoma protein	SERINE THREONINE PHOSPHATASES; CYCLIN-DEPENDENT KINASES; DNA-BINDING ACTIVITY; CELL-PROLIFERATION; CATALYTIC SUBUNIT; GENE FAMILY; IN-VIVO; E2F; COMPLEXES; CDK2	The proteins of the retinoblastoma family are potent inhibitors of cell cycle progression. It is well documented that their growth-inhibitory activity can be abolished by phosphorylation on serine and threonine residues by cyclin dependent kinases, In contrast, very little is known about the dephosphorylation of retinoblastoma-family proteins. We report here the isolation, by virtue of its ability to associate,vith p107, of a novel Protein Phosphatase 2A (PP2A) regulatory subunit, named PR59, PR59 shares sequence homology with a known regulatory subunit of PP2A, PR72, but differs from PR72 in its expression pattern and its functional properties. We show that PR59 co-immunoprecipitates with the PP2A catalytic subunit, indicating that PR59 is a genuine component of PP2A hole-enzymes. In vivo, PR59 associates specifically with p107, but not with pRb, Elevated expression of PR59 results in dephosphorylation of p107, but not of pRb, and inhibits cell proliferation by causing cells to accumulate in G1, These data support a model in which the distinct PP2A regulatory subunits act to target the PP2A catalytic subunit to specific substrates and suggest a role for PP2A in regulation of p107.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, 121 Plesmanlaan, NL-1066 CX Amsterdam, Netherlands.			Bernards, Rene/0000-0001-8677-3423				Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Bernards R, 1997, BBA-REV CANCER, V1333, pM33, DOI 10.1016/S0304-419X(97)00027-9; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN PTW, 1990, FEBS LETT, V268, P355, DOI 10.1016/0014-5793(90)81285-V; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAVRE B, 1994, J BIOL CHEM, V269, P16331; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARPER JW, 1993, CELL, V75, P805; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HONKANAN RE, 1994, TOXICON, V32, P339, DOI 10.1016/0041-0101(94)90086-8; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1995, ADV PROT PHOSPHATASE, V9, P195; KITAGAWA M, 1995, ONCOGENE, V10, P229; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nelson DA, 1997, ONCOGENE, V14, P2407, DOI 10.1038/sj.onc.1201081; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; RADULESCU RT, 1995, MED HYPOTHESES, V44, P28, DOI 10.1016/0306-9877(95)90297-X; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STONE SR, 1988, NUCLEIC ACIDS RES, V16, P11365, DOI 10.1093/nar/16.23.11365; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; Tung HYL, 1997, FEBS LETT, V401, P197, DOI 10.1016/S0014-5793(96)01470-6; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Virshup DM, 1993, ADV PROTEIN PHOSPHAT, V7, P271; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Zolnierowicz S, 1996, BIOCHEM J, V317, P187, DOI 10.1042/bj3170187	57	87	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					515	524		10.1038/sj.onc.1202316	http://dx.doi.org/10.1038/sj.onc.1202316			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927208	Green Published			2022-12-28	WOS:000078166500024
J	Zhan, QM; Kontny, U; Iglesias, M; Alamo, I; Yu, K; Hollander, MC; Woodworth, CD; Fornace, AJ				Zhan, QM; Kontny, U; Iglesias, M; Alamo, I; Yu, K; Hollander, MC; Woodworth, CD; Fornace, AJ			Inhibitory effect of Bcl-2 on p53-mediated transactivation following genotoxic stress	ONCOGENE			English	Article						BCL-2; GADD45; p21(CIPI/WAF1); p53; apoptosis; ionizing radiation; methylmethane sulfonate; UV radiation	PROGRAMMED CELL-DEATH; DNA-DAMAGING AGENTS; NUCLEAR ANTIGEN; GENE-EXPRESSION; P53; PROTEIN; APOPTOSIS; INDUCTION; GROWTH; GADD45	In the cellular response to genotoxic stress, cell cycle checkpoint and apoptosis are considered to be two of the major biological events in maintaining genomic stability. The tumor suppressor p53 has been shown to play critical roles in these stress-induced cellular responses at least in part through the activation of its down-stream genes, such as p21(ClPl/WAFl), GADD45 and BAX. In addition, p53 has been found to down-regulate the expression of BCL-2, which is able to block apoptosis induced by both p53-dependent and independent signaling events. In this report,,ve have found that increased expression of Bcl-2 protein in the human Burkitt's lymphoma WMN cell line suppressed apoptosis induced by different DNA-damaging agents. The induction of p53-regulated genes including GADDIS, p21(ClPl/WAFl) and BAX by genotoxic stress was substantially reduced in cells expressing high levels of Bcl-2 protein. Furthermore, Bcl-2 protein was shown to specifically suppress the p53-mediated transactivation of p21(ClPl/WAFl) and PG13-CAT, which is a typical p53-binding-site reporter construct, Similarly, the inhibitory effect of Bcl-2 protein was seen in a GADD45 promoter reporter construct after treatment with methylmethane sulfonate or UV-radiation, These results indicate that in addition to its apoptosis-suppressing activity, Bcl-2 protein is able to inhibit transactivation of p53-regulated genes, which function in multiple important cellular responses to genotoxic stress, including the control of cell cycle checkpoints, cell growth suppression and DNA repair.	NCI, Biol Chem Lab, Bethesda, MD 20892 USA; NCI, Div Basic Sci, Biol Lab, Bethesda, MD 20892 USA; NCI, Pediat Oncol Branch, Div Clin Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhan, QM (corresponding author), NCI, Biol Chem Lab, Room 5CO9,Bldg 37, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HALDAR S, 1994, CANCER RES, V54, P2095; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; HOLLANDER MC, 1989, CANCER RES, V49, P1687; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LAROCCA RV, 1990, J STEROID BIOCHEM, V37, P893, DOI 10.1016/0960-0760(90)90439-R; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; MICHIELI P, 1994, CANCER RES, V54, P3391; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1995, CELL, V80, P293; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OCONNOR PM, 1993, CANCER RES, V53, P4776; OCONNOR PM, 1991, CANCER RES, V51, P6550; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1992, CELL, V70, P526; WOODWORTH CD, 1992, ONCOGENE, V7, P619; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHAN QM, 1995, INT J ONCOL, V6, P937	46	45	56	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					297	304		10.1038/sj.onc.1202310	http://dx.doi.org/10.1038/sj.onc.1202310			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927186				2022-12-28	WOS:000078166500002
J	Chen, ZH; Seimiya, H; Naito, M; Mashima, T; Kizaki, A; Dan, S; Imaizumi, M; Ichijo, H; Miyazono, K; Tsuruo, T				Chen, ZH; Seimiya, H; Naito, M; Mashima, T; Kizaki, A; Dan, S; Imaizumi, M; Ichijo, H; Miyazono, K; Tsuruo, T			ASK1 mediates apoptotic cell death induced by genotoxic stress	ONCOGENE			English	Article						ASK1; apoptosis; kinase cascades; genotoxic stress	ACTIVATED PROTEIN-KINASE; CHEMOTHERAPY-INDUCED APOPTOSIS; CERAMIDE-INDUCED APOPTOSIS; LEUKEMIA U937 CELLS; C-JUN; JNK ACTIVATION; POLY(ADP-RIBOSE) POLYMERASE; SIGNALING PATHWAY; GAMMA-RADIATION; TNF RECEPTOR-1	Genotoxic stress-induced apoptosis is mediated by caspase family proteases as triggered by other stimuli. In this study, we found that the DNA-damaging agent cisplatin (cDDP) activated MAP kinase kinase kinase ASK1 and subsequent downstream subgroups of MAP kinase kinase, SEK1 (or MKK4) and MKK3/MKK6, which in turn activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK) and p38 MAP kinase prior to caspase family protease activation and the onset of apoptosis in human ovarian carcinoma (OVCAR-3) and human kidney (293T) cells. As reported previously, benzyloxy carbonyl-Asp-CH2OC(O)-2, 6-dichlorobenzene (Z-Asp), a preferential inhibitor of caspase family proteases, blocked the apoptosis of OVCAR-3 cells induced by the genotoxic stress cDDP. Z-Asp, however, did not inhibit ASK1 activation and the subsequent kinase cascades. Overexpression of kinase-negative ASK1 (K709R), which inhibited ASK1 activation and the downstream MKK3-p38 and MKK4-JNK1 pathways, also suppressed the caspase protease activation and apoptosis induced by cDDP. These results indicate that the ASK1 pathway is involved in genotoxic stress-induced apoptosis and mediates apoptosis at a step upstream of caspase protease activation.	Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, Tokyo 113, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 170, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, Tokyo 113, Japan.			Ichijo, Hidenori/0000-0002-5005-6438; Seimiya, Hiroyuki/0000-0003-3314-9736				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dong JA, 1997, ONCOGENE, V15, P639, DOI 10.1038/sj.onc.1201237; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; MEYN RE, 1994, CANCER CHEMOTH PHARM, V33, P410, DOI 10.1007/BF00686270; MEYN RE, 1995, ANTI-CANCER DRUG, V6, P443, DOI 10.1097/00001813-199506000-00013; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; SEARLE J, 1975, J PATHOL, V116, P129, DOI 10.1002/path.1711160302; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Teng DHF, 1997, CANCER RES, V57, P4177; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	49	157	162	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					173	180		10.1038/sj.onc.1202276	http://dx.doi.org/10.1038/sj.onc.1202276			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926932				2022-12-28	WOS:000078166000019
J	Notterman, D; Young, S; Wainger, B; Levine, AJ				Notterman, D; Young, S; Wainger, B; Levine, AJ			Prevention of mammalian DNA reduplication, following the release from the mitotic spindle checkpoint, requires p53 protein, but not p53-mediated transcriptional activity	ONCOGENE			English	Article						p53; p21; G(2)/M; DNA; transactivation; nocodazole	CELL-CYCLE ARREST; WILD-TYPE P53; GROWTH SUPPRESSION; G(1) ARREST; ACTIVATION; APOPTOSIS; LACKING; DOMAIN; P21; IDENTIFICATION	The tumor suppressor p53 has been identified as a component of a mitotic spindle checkpoint. When exposed to a spindle-disrupting drug such as nocodazole, fibroblasts derived from mice having wild-type p53 are blocked with a 4N content of DNA, Conversely, fibroblasts from p53-deficient mice become polyploid, To learn if transcriptional activation of downstream genes by p53 plays a role in this putative checkpoint, three cell lines mere exposed to nocodazole, In one line, p53 protein is not expressed, while the other two cell lines over-express p53, In one of these two lines, the N-terminal transactivation domain is wild-type and in the second, this region contains a mutation that eliminates the ability of the protein to act as a transcription factor. Incubation with nocodazole of cells containing wild-type p53 results in accumulation of both 2N and 4N populations of cells. Under the same conditions, cells containing a transactivation-deficient mutant of p53 accumulate a 4N population of cells, but not a 2N population of cells. Cells entirely deficient in p53 protein become hyperdiploid, and display 8N to 16N DNA content. In all three cell lines, nocodazole elicited an initial increase in mitotic cells, but within 24 h the mitotic index returned to baseline. Expression patterns of cyclins B and D indicated that following entry into mitosis, the cells returned to a G(1) state but with 4N DNA content. Subsequent re-duplication of DNA beyond 4N is prevented in cells containing either wild-type or transcriptionally inactive p53 protein. In cells entirely lacking p53 protein, DNA is re-duplicated (without an intervening mitosis) and the cells become hyperdiploid. These experiments indicate that p53 does not participate in the transient mitotic arrest that follows spindle disruption, but is essential to prevent subsequent reduplication of DNA and the resulting hyperdiploid state. This function is intact in a mutant that is transcriptionally inactive.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Levine, AJ (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Wainger, Brian/L-7553-2017					BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DARBRE A, 1986, PRACTICAL PROTEIN CH, P227; DELSAL G, 1995, MOL CELL BIOL, V15, P7152; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Leonardo A, 1997, CANCER RES, V57, P1013; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; Starostik P, 1996, MOL CELL BIOL, V16, P3606; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335	33	53	53	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2743	2751		10.1038/sj.onc.1202210	http://dx.doi.org/10.1038/sj.onc.1202210			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840938				2022-12-28	WOS:000077146700007
J	Chew, YP; Ellis, M; Wilkie, S; Mittnacht, S				Chew, YP; Ellis, M; Wilkie, S; Mittnacht, S			pRB phosphorylation mutants reveal role of pRB in regulating S phase completion by a mechanism independent of E2F	ONCOGENE			English	Article						retinoblastoma protein; pRB; E2F; phosphorylation; checkpoint control; cell cycle	RETINOBLASTOMA-SUSCEPTIBILITY GENE; CELL-CYCLE CONTROL; RESTRICTION POINT; PROTEIN; PRODUCT; BINDING; EXPRESSION; TRANSCRIPTION; APOPTOSIS; RB	Progression of cells into S phase is controlled by the retinoblastoma protein (pRB) and relies on the functional inactivation of this tumour suppressor in late G1 via protein phosphorylation. We provide evidence here that, besides controlling entry of cells into S phase, pRB can operate to inhibit S phase completion. Differential arrays of phosphorylation appear to regulate these different events, suggesting that cycle progression at these two stages of the cell cycle may be achieved via activation of distinct downstream pRB effector pathways. In agreement with this hypothesis, pRB's ability to prevent S phase entry, but not its ability to inhibit S phase completion, correlates with repression of E2F-regulated promoters. Furthermore, ectopic expression of E2F or the E2F-regulated cyclin E gene promote S phase entry in cells expressing phosphorylation-defective pRB but neither is sufficient to trigger completion of S phase. Our findings raise the possibility that pRB, in addition to its web-established role in controlling a checkpoint in late G1, could be involved in the control of a further checkpoint operating during S phase and that implementation of this checkpoint relies on an as yet unidentified PRE effector distinct from E2F.	Inst Canc Res, Chester Beatty Labs, CRC Ctr Cell & Mol Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Mittnacht, S (corresponding author), Inst Canc Res, Chester Beatty Labs, CRC Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.							ABRAHAM SE, 1992, MOL BIOL CELL, V3, P655, DOI 10.1091/mbc.3.6.655; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Amellem O, 1996, EXP CELL RES, V227, P106, DOI 10.1006/excr.1996.0255; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DelSal G, 1996, CRIT REV ONCOGENESIS, V7, P127, DOI 10.1615/CritRevOncog.v7.i1-2.80; GAUTSCHI JR, 1973, J MOL BIOL, V80, P393, DOI 10.1016/0022-2836(73)90411-7; Geng Y, 1996, ONCOGENE, V12, P1173; HAAPAJARVI T, 1995, ONCOGENE, V11, P151; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Iliakis G, 1997, SEMIN ONCOL, V24, P602; JOHNSON AF, 1993, ECOSYSTEMS WORLD, V2, P365; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; Linke SP, 1997, ONCOGENE, V15, P337, DOI 10.1038/sj.onc.1201200; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MITTNACHT S, 1991, COLD SPRING HARB SYM, V56, P197; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YAVUZER U, 1995, ONCOGENE, V10, P123; Zarkowska T, 1997, ONCOGENE, V14, P249, DOI 10.1038/sj.onc.1200824; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	44	74	74	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2177	2186		10.1038/sj.onc.1202443	http://dx.doi.org/10.1038/sj.onc.1202443			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811449				2022-12-28	WOS:000076698200004
J	Jian, YC; Schmidt-Grimminger, DC; Chien, WM; Wu, X; Broker, TR; Chow, LT				Jian, YC; Schmidt-Grimminger, DC; Chien, WM; Wu, X; Broker, TR; Chow, LT			Post-transcriptional induction of p21cip1 protein by human papillomavirus E7 inhibits unscheduled DNA synthesis reactivated in differentiated keratinocytes	ONCOGENE			English	Article						HPV E7 protein; p21cip1 protein induction; post-transcription regulation; inhibition of DNA synthesis	CYCLIN-DEPENDENT KINASES; CELL NUCLEAR ANTIGEN; P21(WAF1/CIP1) EXPRESSION; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; UP-REGULATION; REPLICATION; P53; P21; PROLIFERATION	Productive infection by human papillomaviruses (HPVs) occurs only in differentiated squamous epithelial cells in papillomas, condylomata, and low grade intraepithelial neoplasias, Host DNA replication is reactivated in a fraction of terminally differentiated keratinocytes in benign human lesions and in organotypic raft cultures of primary human keratinocytes (PHKs) transduced with retroviruses expressing HPV-18 E7 oncogene from its native upstream regulatory region (URR), Thus the natural function of E7 protein, which inactivates pRB family proteins, is to induce host genes essential to support viral DNA replication in post-mitotic cells, Using this raft culture model system, we show that HPV-18 URR-E7 induces the universal cyclin-dependent kinase inhibitor p21cip1 protein in a fraction of differentiated PHKs, Induction is mediated by posttranscriptional mechanisms independent of p53, Double immunofluorescence studies demonstrate that, in raft cultures and in laryngeal papillomas, p21cip1 induction and reactivated host DIVA synthesis take place in a mutually exclusive manner in PCNA-positive, differentiated keratinocytes, We suggest that p21cip1 induction effectively blocks unscheduled DNA synthesis reactivated by E7, These results begin to explain the inverse relationship between p21cip1 induction and HPV activities previously observed in a spectrum of benign lesions regardless of HPV types present.	Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chow, LT (corresponding author), Univ Alabama, Dept Biochem & Mol Genet, 1918 Univ Blvd,Room 508, Birmingham, AL 35294 USA.				NCI NIH HHS [CA36200, T32 CA09467] Funding Source: Medline; NIAID NIH HHS [AI34674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009467, R01CA036200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034674] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BLANTON RA, 1992, CELL GROWTH DIFFER, V3, P791; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; Chow Louise T., 1997, P267; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DEMETER LM, 1994, HUM PATHOL, V25, P343, DOI 10.1016/0046-8177(94)90141-4; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Fuchs E, 1990, CURR OPIN CELL BIOL, V2, P1028, DOI 10.1016/0955-0674(90)90152-5; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Harper JW, 1997, CANCER SURV, V29, P91; HEALY E, 1995, J INVEST DERMATOL, V105, P274, DOI 10.1111/1523-1747.ep12318430; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Inohara S, 1996, BRIT J DERMATOL, V135, P717; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; KUO SR, 1994, J BIOL CHEM, V269, P24058; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; Matsuta M, 1997, J DERMATOL SCI, V14, P233, DOI 10.1016/S0923-1811(96)00579-8; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Palazzo JP, 1997, HUM PATHOL, V28, P60, DOI 10.1016/S0046-8177(97)90280-X; PARKER JN, 1997, CELL GROWTH DIFFER, V8, P75; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; Ruesch MN, 1997, J VIROL, V71, P5570, DOI 10.1128/JVI.71.7.5570-5578.1997; Scheffner M, 1994, Curr Top Microbiol Immunol, V186, P83; Schmidt-Grimminger DC, 1998, AM J PATHOL, V152, P1015; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHEVCHUK MM, 1982, CANCER, V49, P489, DOI 10.1002/1097-0142(19820201)49:3<489::AID-CNCR2820490316>3.0.CO;2-U; Steenbergen RDM, 1998, J VIROL, V72, P749, DOI 10.1128/JVI.72.1.749-757.1998; STOLER MH, 1986, HUM PATHOL, V17, P1250, DOI 10.1016/S0046-8177(86)80569-X; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; Tiainen M, 1996, MOL CELL BIOL, V16, P5302; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; VOUSDEN KH, 1994, ADV CANCER RES, V64, P1, DOI 10.1016/S0065-230X(08)60833-7; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WILSON JL, 1992, CELL GROWTH DIFFER, V3, P471; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; Zeng YX, 1996, ONCOGENE, V12, P1557; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; Zhao W, 1997, J VIROL, V71, P8832, DOI 10.1128/JVI.71.11.8832-8840.1997; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	60	56	58	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2027	2038		10.1038/sj.onc.1202142	http://dx.doi.org/10.1038/sj.onc.1202142			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798674				2022-12-28	WOS:000076540900002
J	Helbing, CC; Wellington, CL; Gogela-Spehar, M; Cheng, T; Pinchbeck, GG; Johnston, RN				Helbing, CC; Wellington, CL; Gogela-Spehar, M; Cheng, T; Pinchbeck, GG; Johnston, RN			Quiescence versus apoptosis: Myc abundance determines pathway of exit from the cell cycle	ONCOGENE			English	Article						apoptosis; c-Myc; cdk2; cell cycle control; quiescence; tetracycline	DEPENDENT PROTEIN-KINASES; C-MYC; GENE-EXPRESSION; RETINOBLASTOMA PROTEIN; TUMOR-SUPPRESSOR; MAMMALIAN-CELLS; DNA-REPLICATION; MESSENGER-RNA; GROWTH; FIBROBLASTS	When exposed to diverse growth conditions in vitro, cells can respond by entering states of proliferation, quiescence, differentiation or apoptosis, While the choices among these states can be influenced by proto-oncogene expression, how these disparate outcomes are achieved remains poorly understood. To address these issues, we have generated rodent fibroblast cell lines that harbor a human c-myc gene under the control of a tetracycline-regulated promoter, When Myc-induced cells are deprived of serum growth factors, they rapidly become apoptotic with the onset of apoptosis preceded by a large, transient increase in cdk2 kinase activity that is associated with the induction of cdc25A phosphatase and the later accumulation of p27(Kip1) kinase inhibitor, Surprisingly, serum starvation in the absence of myc overexpression, (which leads to quiescence instead of apoptosis) also causes a marked transient elevation in cdk2 kinase activity, an induction of cdc25A and a delayed increase in p27(Kip1), Transient elevations in cdk2 kinase activity and cdc25A abundance are required for cell cycle progression, but it is evident that these changes also precede entry to either apoptosis or quiescence in serum-starved cells. These findings suggest that the pathways to both quiescence and apoptosis share regulatory machinery with cell cycle control mechanisms. In addition, the abundance of MSc protein can be critical in the choices among these cellular states.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary	Johnston, RN (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.		Johnston, Randal/B-9247-2009	Helbing, Caren/0000-0002-8861-1070				ASKEW DS, 1991, ONCOGENE, V6, P1915; BARRETT JF, 1995, J BIOL CHEM, V270, P15923, DOI 10.1074/jbc.270.27.15923; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; Cleveland J L, 1988, Oncogene Res, V3, P357; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FREEMAN RS, 1994, NEURON, V12, P3443; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GIBSON AW, 1995, EXP CELL RES, V218, P351, DOI 10.1006/excr.1995.1166; GIBSON AW, 1992, BIOCHEM CELL BIOL, V70, P998, DOI 10.1139/o92-143; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HASS R, 1994, CRIT REV ONCOGENESIS, V5, P359, DOI 10.1615/CritRevOncog.v5.i4.20; HAYASHI K, 1987, NUCLEIC ACIDS RES, V15, P6419, DOI 10.1093/nar/15.16.6419; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Helbing C, 1996, DEV GENET, V18, P223, DOI 10.1002/(SICI)1520-6408(1996)18:3<223::AID-DVG3>3.3.CO;2-T; Helbing CC, 1997, CANCER RES, V57, P1255; HINDS PW, 1995, CURR OPIN GENET DEV, V5, P79, DOI 10.1016/S0959-437X(95)90057-8; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOUGE G, 1995, MOL CELL BIOL, V15, P2051; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LEE WH, 1995, ANN NY ACAD SCI, V752, P432, DOI 10.1111/j.1749-6632.1995.tb17453.x; Lemaitre JM, 1996, ADV CANCER RES, V70, P95, DOI 10.1016/S0065-230X(08)60873-8; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Mueller Rolf, 1993, Biochimica et Biophysica Acta, V1155, P151; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Packham G, 1997, ONCOGENE, V15, P1219, DOI 10.1038/sj.onc.1201273; PANDEY S, 1995, J CELL BIOCHEM, V58, P135, DOI 10.1002/jcb.240580203; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; Pusch O, 1997, ONCOGENE, V15, P649, DOI 10.1038/sj.onc.1201236; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RASSOW J, 1995, TRENDS CELL BIOL, V5, P207, DOI 10.1016/S0962-8924(00)89001-7; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Sakamuro D, 1995, ONCOGENE, V11, P2411; Sambrook J., 2002, MOL CLONING LAB MANU; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SOLOMON DLC, 1995, ONCOGENE, V11, P1893; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI LH, 1993, ONCOGENE, V8, P1593; VONWEIZSACKER F, 1986, EMBO J, V5, P1521, DOI 10.1002/j.1460-2075.1986.tb04392.x; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WATERS CM, 1991, ONCOGENE, V6, P797; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	77	22	22	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 24	1998	17	12					1491	1501		10.1038/sj.onc.1202241	http://dx.doi.org/10.1038/sj.onc.1202241			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794226				2022-12-28	WOS:000076089900001
J	Valentinis, B; Morrione, A; Peruzzi, F; Prisco, M; Reiss, K; Baserga, R				Valentinis, B; Morrione, A; Peruzzi, F; Prisco, M; Reiss, K; Baserga, R			Anti-apoptotic signaling of the IGF-I receptor in fibroblasts following loss of matrix adhesion	ONCOGENE			English	Article						anchorage-independence; apoptosis; IGI-I receptor; ras; Akt	GROWTH-FACTOR-I; BREAST-CANCER CELLS; ANCHORAGE-INDEPENDENT GROWTH; ACTIVATED PROTEIN-KINASE; RAS-TRANSFORMED CELLS; MYC-INDUCED APOPTOSIS; ANTISENSE RNA; TUMOR-CELLS; PHOSPHATIDYLINOSITOL 3'-KINASE; HEMATOPOIETIC-CELLS	The type 1 insulin-like growth factor receptor (IGF-IR) is known to protect cells from a variety of apoptotic injuries. In several instances, the anti-apoptotic effect of the wild type IGF-IR is more evident under conditions of anchorage-independence than in cells in monolayer cultures. We have investigated IGF-IR signaling in cells in anoikis, a form of apoptosis that occurs when cells are denied attachment to the extra-cellular matrix. IGF-I protects mouse embryo fibroblasts (MEF) from anoikis caused by withdrawal of growth factors. Survival is dependent on the concentration of TGF-I and a sufficient number of functional IGF-I receptors. In this model, IGF-I protection correlates best,vith ras activation and cell-to-cell aggregation, while PI3-kinase, Akt and MAP kinases seem to play a lesser, alternative role.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.		Peruzzi, Francesca/M-9804-2014		NATIONAL CANCER INSTITUTE [R01CA053484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033694] Funding Source: NIH RePORTER; NCI NIH HHS [CA 53484] Funding Source: Medline; NIGMS NIH HHS [GM33694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON SA, 1968, SCIENCE, V162, P1024, DOI 10.1126/science.162.3857.1024; Baserga R, 1997, EXP CELL RES, V236, P1, DOI 10.1006/excr.1997.3732; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; CLARK S, 1991, BIOCHEM J, V276, P27, DOI 10.1042/bj2760027; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; Craparo A, 1997, J BIOL CHEM, V272, P11663; DAmbrosio C, 1997, CANCER RES, V57, P3264; DAmbrosio C, 1996, CANCER RES, V56, P4013; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Day ML, 1997, J BIOL CHEM, V272, P8125, DOI 10.1074/jbc.272.13.8125; Dews M, 1997, RECEPT SIGNAL TRANS, V7, P231; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Dunn SE, 1998, CANCER RES, V58, P3353; Dunn SE, 1997, CANCER RES, V57, P2687; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; GunnMoore FJ, 1997, BIOCHEM J, V324, P365, DOI 10.1042/bj3240365; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hsing AY, 1996, CANCER RES, V56, P5146; Jung YK, 1996, J BIOL CHEM, V271, P5112; KATO H, 1993, J BIOL CHEM, V268, P2655; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kawada M, 1997, BIOCHEM BIOPH RES CO, V231, P735, DOI 10.1006/bbrc.1997.6179; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kuzumaki T, 1996, BBA-MOL CELL RES, V1310, P185, DOI 10.1016/0167-4889(95)00166-2; Lebowitz PF, 1997, CANCER RES, V57, P708; Lee CT, 1996, CANCER RES, V56, P3038; Lin TH, 1997, J BIOL CHEM, V272, P8849; LONG L, 1995, CANCER RES, V55, P1006; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; McGill G, 1997, J CELL BIOL, V138, P901, DOI 10.1083/jcb.138.4.901; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1355, DOI 10.1210/en.138.3.1355; Parrizas M, 1997, J BIOL CHEM, V272, P154; Pass HI, 1996, CANCER RES, V56, P4044; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; PRISCO M, IN PRESS HORMONES ME; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Reiss K, 1998, EXP CELL RES, V242, P361, DOI 10.1006/excr.1998.4113; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rininsland F, 1997, P NATL ACAD SCI USA, V94, P5854, DOI 10.1073/pnas.94.11.5854; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Singleton JR, 1996, CANCER RES, V56, P4522; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Turner BC, 1997, CANCER RES, V57, P3079; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Valentinis B, 1996, BIOCHEM BIOPH RES CO, V224, P362, DOI 10.1006/bbrc.1996.1034; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; Wu YL, 1996, J CELL PHYSIOL, V168, P499, DOI 10.1002/(SICI)1097-4652(199609)168:3<499::AID-JCP2>3.0.CO;2-K; Zamorano J, 1996, J IMMUNOL, V157, P4926; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	71	79	79	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1827	1836		10.1038/sj.onc.1202471	http://dx.doi.org/10.1038/sj.onc.1202471			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086337				2022-12-28	WOS:000079090000006
J	Sala, A; Saitta, B; De Luca, P; Cervellera, MN; Casella, I; Lewis, RE; Watson, R; Peschle, C				Sala, A; Saitta, B; De Luca, P; Cervellera, MN; Casella, I; Lewis, RE; Watson, R; Peschle, C			B-MYB transactivates its own promoter through SP1-binding sites	ONCOGENE			English	Article						B-MYB; cell-cycle; promoter; SP1; transcription	V-MYB; A-MYB; CONSTITUTIVE EXPRESSION; TRANSCRIPTION FACTOR; ACTIVATION; CELLS; SP1; FAMILY; GENE; DIFFERENTIATION	B-MYB is an ubiquitous protein required for mammalian cell growth. In this report we show that B-MYB transactivates its own promoter through a 120 bp segment proximal to the transcription start site. The B-MYB-responsive element does not contain myb-binding sites and gel-shift analysis shows that SP1, but not B-MYB, protein contained in SAOS2 cell extracts binds to the 120 bp B-myb promoter fragment. B-MYB-dependent transactivation is cooperatively increased in the presence of SP1, but not SP3 overexpression, When the SP1 elements of the B-myb promoter are transferred in front of a heterologous promoter, an increased response to B-MYB results. In contrast, c-MYB, the prototype member of the Myb family, is not able to activate the luciferase construct containing the SP1 elements. With the use of an SP1-GAL4 fusion protein, we have determined that the cooperative activation occurs through the domain A of SP1, These observations suggest that B-MYB functions as a coactivator of SP1, and that diverse combinations of myb and SP1 sites may dictate the responsiveness of myb-target genes to the various members of the myb family.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Mol Pharmacol & Pathol, I-66030 Santa Maria Imbaro, CH, Italy; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Immunol Microbiol, Philadelphia, PA 19107 USA; Dept Reumatol, Philadelphia, PA 19107 USA; Univ Naples Federico II, Dept Genet Mol & Gen Biol, I-80134 Naples, Italy; Univ Nebraska, Med Ctr, Eppley Canc Inst, Omaha, NE 68198 USA; St Marys Hosp, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Ist Super Sanita, Lab Ematol Oncol, I-00161 Rome, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Jefferson University; University of Naples Federico II; University of Nebraska System; University of Nebraska Medical Center; Imperial College London; Ludwig Institute for Cancer Research; Istituto Superiore di Sanita (ISS)	Sala, A (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Mol Pharmacol & Pathol, Via Nazl, I-66030 Santa Maria Imbaro, CH, Italy.		De Luca, Pasquale/AAL-5673-2021; Lewis, Robert E./H-3404-2019; sala, arturo/C-4959-2008	De Luca, Pasquale/0000-0003-4289-6784; Sala, Arturo/0000-0002-2841-7866; Casella, Ida/0000-0002-3358-4976				ARSURA M, 1992, BLOOD, V79, P2708; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BIES J, 1995, CANCER RES, V55, P501; Bies J, 1996, ONCOGENE, V12, P355; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; ENGELKE U, 1995, VIROLOGY, V208, P467, DOI 10.1006/viro.1995.1177; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GOLAY J, 1994, ONCOGENE, V9, P2469; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kamano H, 1997, ONCOGENE, V14, P1223, DOI 10.1038/sj.onc.1200945; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1992, ONCOGENE, V7, P1885; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Marhamati DJ, 1996, J BIOL CHEM, V271, P3359; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; TASHIRO S, 1995, ONCOGENE, V10, P1699; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	38	40	40	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1333	1339		10.1038/sj.onc.1202421	http://dx.doi.org/10.1038/sj.onc.1202421			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022815				2022-12-28	WOS:000078510900009
J	Chen, P; Gatei, M; O'Connell, MJ; Khanna, KK; Bugg, SJ; Hogg, A; Scott, SP; Hobson, K; Lavin, MF				Chen, P; Gatei, M; O'Connell, MJ; Khanna, KK; Bugg, SJ; Hogg, A; Scott, SP; Hobson, K; Lavin, MF			Chk1 complements the G2/M checkpoint defect and radiosensitivity of ataxia-telangiectasia cells	ONCOGENE			English	Article						ataxia-telangiectasia; chk1; radiosensitivity; G2/M checkpoint; cell cycle	DNA-DAMAGE CHECKPOINT; IONIZING-RADIATION; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; WEE1 KINASE; P53 PROTEIN; ATM; GENE; PATHWAY; PHOSPHORYLATION	Cells from patients with the human genetic disorder ataxia-telangiectasia (A-T) are defective in the activation of cell cycle checkpoints in response to ionizing radiation damage. In order to understand the role of ATM in checkpoint control we investigated whether Schizosaccaromyces pombe chk1, a protein kinase implicated in controlling the G2 DNA damage checkpoint, might alter the radiosensitive phenotype in A-T cells. The fission yeast chk1 gene was cloned into an EBV-based vector under the control of a metallothionein promoter and transfected into A-T lymphoblastoid cells, Induction of chk1 enhanced the survival of an A-T cell line in response to radiation exposure as determined by cell viability and reduction of radiation-induced chromosome aberrations. This can be accounted for at least in part by the restoration of the G2 checkpoint to chk1 expressing cells. There was no evidence that chk1 expression corrected either the G1/S checkpoint or radioresistant DNA synthesis in S phase in these cells. These results suggest that chk1 when overexpressed acts downstream from ATM to restore the G2 checkpoint in these cells and correct the radiosensitive phenotype, These data allow us to dissociate individual checkpoint events and relate them to the radiosensitive phenotype in A-T cells.	Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Peter MacCallum Res Inst, E Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Genet, Parkville, Vic 3052, Australia; Univ Queensland, Royal Brisbane Hosp, Dept Surg, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Peter Maccallum Cancer Center; University of Melbourne; Royal Brisbane & Women's Hospital; University of Queensland	Lavin, MF (corresponding author), Queensland Inst Med Res, PO Royal Brisbane Hosp, Brisbane, Qld 4029, Australia.		Hobson, Keith/Q-9306-2019; Lavin, Martin F/F-5961-2014; Khanna, Kum Kum/I-1747-2013	Lavin, Martin F/0000-0002-5940-4769; Khanna, Kum Kum/0000-0001-8650-5381				ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; BADIE C, 1995, CANCER RES, V55, P1232; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BATES PR, 1985, INT J RADIAT BIOL, V47, P713, DOI 10.1080/09553008514550951; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; CANMAN CE, 1994, CANCER RES, V54, P5054; Chen P, 1996, INT J RADIAT BIOL, V69, P385, DOI 10.1080/095530096145940; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Flaggs G, 1997, CURR BIOL, V7, P977, DOI 10.1016/S0960-9822(06)00417-9; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GOTOFF SP, 1967, AM J DIS CHILD, V114, P617, DOI 10.1001/archpedi.1967.02090270073006; Honda R, 1997, BIOCHEM BIOPH RES CO, V230, P262, DOI 10.1006/bbrc.1996.5933; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; KONIG K, 1980, RADIAT ENVIRON BIOPH, V18, P257, DOI 10.1007/BF01324268; LAVIN MF, 1995, TRENDS BIOCHEM SCI, V20, P382, DOI 10.1016/S0968-0004(00)89083-0; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEEPER DB, 1972, RADIAT RES, V50, P410; LEHMANN AR, 1986, INT J RADIAT BIOL, V49, P639; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MORGAN JL, 1968, AM J DIS CHILD, V116, P557, DOI 10.1001/archpedi.1968.02100020561022; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; OGG S, 1994, J BIOL CHEM, V269, P30461; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SEDGWICK RP, 1991, HEREDITARY NEUROPATH, P347; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; VOUSDEN KH, 1993, J GEN VIROL, V74, P803, DOI 10.1099/0022-1317-74-5-803; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; Westphal CH, 1997, CURR BIOL, V7, pR789, DOI 10.1016/S0960-9822(06)00406-4; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021	58	40	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					249	256		10.1038/sj.onc.1202257	http://dx.doi.org/10.1038/sj.onc.1202257			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926940				2022-12-28	WOS:000078166000027
J	Lorentz, O; Cadoret, A; Duluc, I; Capeau, J; Gespach, C; Cherqui, G; Freund, JN				Lorentz, O; Cadoret, A; Duluc, I; Capeau, J; Gespach, C; Cherqui, G; Freund, JN			Downregulation of the colon tumour-suppressor homeobox gene Cdx-2 by oncogenic ras	ONCOGENE			English	Article						caco-2; HT-29 cells; protein kinase c; MEK1-MAP kinase; AP-1; Jun/Fos	MIDDLE-T-ONCOGENES; PASSAGE RODENT CELLS; KINASE-C-ALPHA; EPITHELIAL-CELLS; CACO-2 CELLS; COLORECTAL CARCINOGENESIS; MALIGNANT TRANSFORMATION; INTESTINAL EPITHELIUM; NEGATIVE REGULATION; PROTEIN EXPRESSION	Constitutive activation of the ras proto-oncogene is a frequent and early event in colon cancers, but the downstream nuclear targets are not fully understood. The Cdx-1 and Cdx-2 homeobox genes play crucial roles in intestinal cell proliferation and differentiation, In addition, Cdx-2 is a colonic tumour-suppressor gene, whereas Cdx-1 has oncogenic potential. Here, we show that constitutive activation of ras alters Cdx-1 and Cdx-2 expression in human colonic Caco-2 and HT-29 cells that harbour a normal ras proto-oncogene. Oncogenic ras downregulates Cdx-2 through activation of the PKC pathway and a decline in activity of the Cdx-2 promoter AP-1 site, This decline results from a PKC-dependent decrease in the relative expression of c-Jun, an activator of Cdx-2 transcription, compared to c-Fos, an inhibitor of Cdx-2. Unlike Cdx-2, Cdx-1 is upregulated by oncogenic ras and this effect is mediated by activation of the MEK1 pathway. These results indicate that oncogenic ras activation has opposite effects on Cdx-1 and Cdx-2 expression through distinct signalling pathways and they provide the first evidence for a functional link between ras activation and the downregulation of the Cdx-2 tumour-suppressor gene in colon cancer cells.	INSERM, U381, F-67200 Strasbourg, France; INSERM, U402, F-75571 Paris, France; INSERM, U482, F-75571 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Freund, JN (corresponding author), INSERM, U381, 3 Ave Moliere, F-67200 Strasbourg, France.		Duluc, Isabelle/O-1972-2017; Cadoret, Axelle/L-2529-2017; Freund, Jean-Noel/R-4383-2016; DULUC, Isabelle/AAA-7062-2022	Duluc, Isabelle/0000-0001-8396-6385; Cadoret, Axelle/0000-0002-4283-6864; Freund, Jean-Noel/0000-0002-0971-3774; DULUC, Isabelle/0000-0001-8396-6385				BaronDelage S, 1996, AM J PHYSIOL-GASTR L, V270, pG314, DOI 10.1152/ajpgi.1996.270.2.G314; BARONDELAGE S, 1994, J BIOL CHEM, V269, P18686; Cadoret A, 1997, ONCOGENE, V14, P1589, DOI 10.1038/sj.onc.1200992; CHANTRET I, 1994, J CELL SCI, V107, P213; CHASTRE E, 1993, GASTROENTEROLOGY, V105, P1776, DOI 10.1016/0016-5085(93)91076-T; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; DAVIDSON LA, 1995, J NUTR, V125, P49; DELAGE S, 1993, CANCER RES, V53, P2762; Duluc I, 1997, J CELL SCI, V110, P1317; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; EE HC, 1995, AM J PATHOL, V147, P586; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINKENZELLER G, 1992, CELL SIGNAL, V4, P163, DOI 10.1016/0898-6568(92)90080-R; FOSTER E, 1994, BIOTECHNIQUES, V16, P18; FREUND JN, 1992, FEBS LETT, V314, P163, DOI 10.1016/0014-5793(92)80965-J; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HU YL, 1993, J BIOL CHEM, V268, P27214; Ilyas M, 1996, HISTOPATHOLOGY, V28, P389, DOI 10.1046/j.1365-2559.1996.339381.x; JAMES R, 1991, J BIOL CHEM, V266, P3246; JAMES R, 1994, J BIOL CHEM, V269, P15229; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; Peddanna N, 1995, ANTICANCER RES, V15, P2055; PINTO M, 1983, BIOL CELL, V47, P323; PINTO M, 1982, BIOL CELL, V44, P193; ROUSSET M, 1980, JNCI-J NATL CANCER I, V65, P885; Sambrook J., 2002, MOL CLONING LAB MANU; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; SPANDIDOS DA, 1986, J GEN VIROL, V67, P793, DOI 10.1099/0022-1317-67-4-793; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STOPERA SA, 1992, CARCINOGENESIS, V13, P573, DOI 10.1093/carcin/13.4.573; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; Velazquez OC, 1996, JPEN-PARENTER ENTER, V20, P243, DOI 10.1177/0148607196020004243; Vider BZ, 1997, BIOCHEM BIOPH RES CO, V232, P742, DOI 10.1006/bbrc.1997.6364	39	76	78	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					87	92		10.1038/sj.onc.1202280	http://dx.doi.org/10.1038/sj.onc.1202280			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926923				2022-12-28	WOS:000078166000010
J	Timmermann, S; Hinds, PW; Munger, K				Timmermann, S; Hinds, PW; Munger, K			Re-expression of endogenous p16(ink4a) in oral squamous cell carcinoma lines by 5-aza-2 '-deoxycytidine treatment induces a senescence-like state	ONCOGENE			English	Article						cdk inhibitor; retinoblastoma protein; promoter methylation	CYCLIN-DEPENDENT KINASE-6; TUMOR-SUPPRESSOR GENE; RETINOBLASTOMA PROTEIN; CDKN2 GENE; DNA METHYLTRANSFERASE; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; HEAD; NECK; AMPLIFICATION	We have previously reported that a set of oral squamous cell carcinoma lines express specifically elevated cdk6 activity. One of the cell lines, SCC4, contains a cdk6 amplification and expresses functional p16(ink4a), the other cell lines express undetectable levels of p16(ink4a), despite a lack of coding-region mutations. Two of the cell lines, SCC15 and SCC40 have a hypermethylated p16(ink4A) promoter and a third cell line, SCC9, has a mutation in the p16(ink4a) promoter. Using the demethylation agent 5-aza-2'-deoxycytidine, we showed that the p16(ink4a) protein was re-expressed after a 5-day treatment with this chemical, One cell line, SCC15 espressed high levels of p16(ink4a). In this line, cdk6 activity was decreased after 5-aza-2'deoxycytidine treatment, and the hypophosphorylated, growth suppressive form of the retinoblastoma tumor suppressor protein PRE was detected. Expression of p16(ink4a) persisted, even after the drug was removed and the cells espressed senescence-associated beta-galactosidase activity. Ectopic expression of p16(ink4a) with a recombinant retrovirus in this cell line also induced a similar senescence-like phenotype, Hence, it was possible to restore a functional pRB pathway in an oral squamous cell carcinoma line by inducing re-expression of endogenous p16(ink4a) in response to treatment with a demethylating agent.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Canc Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.			Munger, Karl/0000-0003-3288-9935	NIDCR NIH HHS [1 PO1 DE12467-01] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012467] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABELE R, 1987, EUR J CANCER CLIN ON, V23, P1921, DOI 10.1016/0277-5379(87)90060-5; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bender CM, 1998, CANCER RES, V58, P95; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; Costello JF, 1997, CANCER RES, V57, P1250; CREUSOT F, 1982, J BIOL CHEM, V257, P2041; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fernandez-Martinez J A, 1995, Bull Group Int Rech Sci Stomatol Odontol, V38, P11; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Gonzalez MV, 1997, J CLIN PATHOL, V50, P509, DOI 10.1136/jcp.50.6.509; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HE J, 1995, CANCER RES, V55, P4833; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KATO J, 1993, GENE DEV, V7, P331; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; Loughran D, 1996, J MANAGE ENG, V12, P13; LYDIATT WM, 1995, GENE CHROMOSOME CANC, V13, P94, DOI 10.1002/gcc.2870130204; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MICHALOWSKY LA, 1987, MOL CELL BIOL, V7, P3076, DOI 10.1128/MCB.7.9.3076; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIN BM, 1994, ORAL ONCOL, V30B, P338, DOI 10.1016/0964-1955(94)90036-1; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; OTTERSON GA, 1995, ONCOGENE, V11, P1211; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; Reed AL, 1996, CANCER RES, V56, P3630; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Schwoebel A, 1997, J PERINAT NEONAT NUR, V11, P78, DOI 10.1097/00005237-199712000-00009; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SONODA Y, 1995, ONCOGENE, V11, P2145; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; Timmermann S, 1997, CELL GROWTH DIFFER, V8, P361; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Willemze R, 1997, LEUKEMIA S1, V11, P24; ZHANG SY, 1994, CANCER RES, V54, P5050	55	66	69	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3445	3453		10.1038/sj.onc.1202244	http://dx.doi.org/10.1038/sj.onc.1202244			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030668				2022-12-28	WOS:000078086200005
J	Levy-Strumpf, N; Kimchi, A				Levy-Strumpf, N; Kimchi, A			Death associated proteins (DAPs): from gene identification to the analysis of their apoptotic and tumor suppressive functions	ONCOGENE			English	Article						apoptosis; DAP-kinase; cathepsin D; interferon-gamma; metastasis; functional gene cloning	PROGRAMMED CELL-DEATH; INITIATION-FACTOR 4G; INTERFERON-GAMMA; KINASE; EXPRESSION; MEDIATOR	The process of apoptosis (programmed cell death) has become the subject of intensive and extensive research over the past few years. Various approaches are being used to identify and study genes which function as positive mediators of apoptosis, Here, we address a novel approach of gene cloning aimed at isolating intracellular death promoting genes by utilizing a functional screen. This method, called TKO, was based on transfection of cells with an anti-sense cDNA library, followed by the selection of transfectants which survived in the continuous presence of a killing cytokine - interferon-gamma. It led to the identification of five novel apoptotic genes and to the finding that a known protease-cathepsin D, is actively recruited to the death process. The five novel apoptotic genes (named DAP genes for: Death Associated Proteins) code for proteins which display a diverse spectrum of biochemical activities. The List comprises a novel type of calcium/calmodulin-regulated kinase which carries ankyrin repeats and a death domain (DAP-kinase), a nucleotide-binding protein (DAP-3), a small proline-rich cytoplasmic protein (DAP-1), and a novel homolog of the eIF4G translation initiation factor (DAP-5), Extensive studies proved that these genes are critical for mediating cell death initiated by interferon-gamma, and in some of the tested cases also cell death induced by Fas/APO-1, TNF-alpha, and a detachment from extracellular matrix. Moreover, one of these genes, DAP-kinase, was recently found to display strong tumor suppressive activities, coupling the control of apoptosis to metastasis. The advantage of functional approaches of gene cloning is that they select the relevant rate limiting genes along the death pathways in a complete unbiased manner. As a consequence, novel targets and unpredicted mechanisms emerged, A few examples illustrating this important point will be discussed, One relates to the calcium/calmodulin-dependent DAP-kinase, which is localized to the actin microfilaments. It was found that the correct localization of DAP-kinase to the microfilament network was critical for the execution of the apoptotic process, and more specifically for the disruption of the stress fibers-a typical hallmark of apoptosis, Another important breakthrough step in our understanding of apoptotic processes relates to the identification and analysis of the DAP-5 gene. The structure/ function features of this novel translation regulator resemble the proteolytically cleaved eIF4G which appears in cells upon infection with some RNA viruses and which directs cap-independent translation, Thus, the rescue of DAP-5 highlighted the importance of regulation of protein translation in certain apoptotic systems, Finally, the isolation of cathespin D by our method suggests that lysosomal proteases are recruited during apoptosis, in addition to the well known caspase family of proteases, and that a unique pattern of regulation affecting the processing of this protease takes place. The major challenge now is to analyse how these diverse DAP gene activities constitute biochemical pathway(s) leading to programmed cell death, and what is their functional position with respect to other known positive mediators and suppressors of apoptosis such as the Bcl2 and caspase family members.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Kimchi, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.			Levy-Strumpf, Naomi/0000-0002-5454-8800				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FEINSTEIN E, 1995, GENOMICS, V29, P305, DOI 10.1006/geno.1995.1255; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Imataka H, 1997, EMBO J, V16, P817, DOI 10.1093/emboj/16.4.817; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; KISSIL J, 1999, IN PRESS EMBO J; KISSIL JL, 1995, J BIOL CHEM, V270, P27932, DOI 10.1074/jbc.270.46.27932; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; Kissil JL, 1997, CYTOGENET CELL GENET, V77, P252, DOI 10.1159/000134587; KOGEL D, 1998, IN PRESS ONCOGENE, V17; Laird PW, 1997, MOL MED TODAY, V3, P223, DOI 10.1016/S1357-4310(97)01019-8; LevyStrumpf N, 1997, MOL CELL BIOL, V17, P1615, DOI 10.1128/MCB.17.3.1615; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yamanaka S, 1997, GENE DEV, V11, P321, DOI 10.1101/gad.11.3.321	33	107	112	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 24	1998	17	25					3331	3340		10.1038/sj.onc.1202588	http://dx.doi.org/10.1038/sj.onc.1202588			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916995				2022-12-28	WOS:000078048200014
J	Denissenko, MF; Koudriakova, TB; Smith, L; O'Connor, TR; Riggs, AD; Pfeifer, GP				Denissenko, MF; Koudriakova, TB; Smith, L; O'Connor, TR; Riggs, AD; Pfeifer, GP			The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B-1 adducts	ONCOGENE			English	Article						aflatoxin B-1; p53 gene; hepatocellular carcinoma	TUMOR-SUPPRESSOR GENE; POLYMERASE CHAIN-REACTION; RAT-LIVER; DNA-DAMAGE; NUCLEOTIDE RESOLUTION; PYRIMIDINE DIMERS; FORMED INVIVO; LOW-FREQUENCY; CANCER; REPAIR	Sequence-dependent formation and lack of repair of polycyclic aromatic hydrocarbon-induced DNA adducts correlates well with the positions of p53 mutational hotspots in smoking-related lung cancers (Denissenko et al. 1996, 1998). The mycotoxin aflatoxin B-1 (AFB(1)) is considered to be a major causative agent in hepatocellular carcinoma (HCC) in regions with presumed high food contamination by AFB(1). A unique mutational hotspot, a G to T transversion at the third base of codon 249 of the p53 gene is observed in these tumors. To test whether a selectivity of AFB(1) adduct formation is related to this peculiar mutational spectrum, we have mapped AFB(1)-DNA adducts at nucleotide resolution using ligation-mediated PCR and terminal transferase-dependent PCR. Human HepG2 cells were exposed to AFB(1) metabolically activated in the presence of rat liver microsomes. Significant adduct formation was seen at the third base of codon 249. However, this was not the major site of AFB(1) adducts and strong adduction was also observed at codons 226, 243, 244, 245 and 248 in exon 7 of the p53 gene and at several codons in exon 8. The damage at codon 249 does not consist of a unique abasic site or ring-opened aflatoxin B-1 adduct but rather is consistent with the principal N7-guanine adduct of AFB1. Time course experiments indicate that, under the conditions used. AFB(1) adducts are not removed in a strand-selective manner and adduct removal from the third base of codon 249 proceeds at a relatively fast rate (50% in 7 h). The incomplete correspondence between sites of persistent AFB(1) damage and the specific codon 249 mutation suggests that AFB(1) may not be involved in mutation of this site or that additional mechanisms such as parallel infection with hepatitis B virus may be required for selection of codon 249 mutants in HCC.	City Hope Natl Med Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA; Ohio State Univ, Dept Pharmacol, Columbus, OH 43210 USA	City of Hope; Beckman Research Institute of City of Hope; University System of Ohio; Ohio State University	Pfeifer, GP (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA.			Riggs, Arthur/0000-0002-8184-5288; O'Connor, Timothy/0000-0001-5848-3592	NATIONAL CANCER INSTITUTE [P01CA069449, R01CA065652] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA65652, P01CA69449] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284; Bailey EA, 1996, P NATL ACAD SCI USA, V93, P1535, DOI 10.1073/pnas.93.4.1535; BENASUTTI M, 1988, BIOCHEMISTRY-US, V27, P472, DOI 10.1021/bi00401a068; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; Busby Jr W. F., 1984, CHEM CARCINOGENS, V182, P945; CHALLEN C, 1992, HEPATOLOGY, V16, P1362, DOI 10.1002/hep.1840160610; CHETSANGA CJ, 1983, CARCINOGENESIS, V4, P997, DOI 10.1093/carcin/4.8.997; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROY RG, 1981, CANCER RES, V41, P197; CROY RG, 1978, P NATL ACAD SCI USA, V75, P1745, DOI 10.1073/pnas.75.4.1745; DANDREA AD, 1978, P NATL ACAD SCI USA, V75, P4120, DOI 10.1073/pnas.75.9.4120; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Denissenko MF, 1998, ONCOGENE, V16, P1241, DOI 10.1038/sj.onc.1201647; Denissenko MF, 1997, P NATL ACAD SCI USA, V94, P3893, DOI 10.1073/pnas.94.8.3893; DUFLOT A, 1994, CARCINOGENESIS, V15, P1353, DOI 10.1093/carcin/15.7.1353; EATON DL, 1994, ANNU REV PHARMACOL, V34, P135, DOI 10.1146/annurev.pa.34.040194.001031; EISENSTADT E, 1982, P NATL ACAD SCI-BIOL, V79, P1945, DOI 10.1073/pnas.79.6.1945; ESSIGMANN JM, 1977, P NATL ACAD SCI USA, V74, P1870, DOI 10.1073/pnas.74.5.1870; ESSIGMANN JM, 1982, DRUG METAB REV, V13, P581, DOI 10.3109/03602538209011088; FUJIMOTO Y, 1992, CANCER RES, V52, P1044; Greenblatt MS, 1997, CANCER RES, V57, P426; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HAYWARD NK, 1991, NATURE, V352, P764, DOI 10.1038/352764a0; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HULLA JE, 1993, CANCER RES, V53, P9; HUSSAIN SP, 1994, ONCOGENE, V9, P2277; Iatsimirskaia E, 1997, CLIN PHARMACOL THER, V61, P554, DOI 10.1016/S0009-9236(97)90135-1; IRVIN TR, 1985, CANCER RES, V45, P3497; Johnson WW, 1996, J AM CHEM SOC, V118, P8213, DOI 10.1021/ja960525k; Kobertz WR, 1997, P NATL ACAD SCI USA, V94, P9579, DOI 10.1073/pnas.94.18.9579; Komura J, 1998, NUCLEIC ACIDS RES, V26, P1807, DOI 10.1093/nar/26.7.1807; Koudriakova T, 1996, J PHARMACOL EXP THER, V279, P1300; KRESS S, 1992, CANCER RES, V52, P3220; Lasky T, 1997, ENVIRON HEALTH PERSP, V105, P392, DOI 10.2307/3433335; LEADON SA, 1981, CANCER RES, V41, P5125; LIN JK, 1977, CANCER RES, V37, P4430; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MUENCH KF, 1983, P NATL ACAD SCI-BIOL, V80, P6, DOI 10.1073/pnas.80.1.6; MURAKAMI Y, 1991, CANCER RES, V51, P5520; ODA T, 1992, CANCER RES, V52, P6358; OLEYKOWSKI CA, 1993, J BIOL CHEM, V268, P7990; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; PUISIEUX A, 1991, CANCER RES, V51, P6185; REFOLO LM, 1985, P NATL ACAD SCI USA, V82, P3096, DOI 10.1073/pnas.82.10.3096; RIVKINA MB, 1994, CANCER RES, V54, P5430; RODRIGUEZ H, 1995, J BIOL CHEM, V270, P17633, DOI 10.1074/jbc.270.29.17633; ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G; SARASIN AR, 1977, CANCER RES, V37, P1786; Shen HM, 1996, MUTAT RES-REV GENET, V366, P23, DOI 10.1016/S0165-1110(96)90005-6; Tommasi S, 1997, CANCER RES, V57, P4727; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; Tornaletti Silvia, 1996, P199; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	59	81	81	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	1998	17	23					3007	3014		10.1038/sj.onc.1202214	http://dx.doi.org/10.1038/sj.onc.1202214			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881702				2022-12-28	WOS:000077427800007
J	Li, YW; Bhuiyan, M; Mohammad, RM; Sarkar, FH				Li, YW; Bhuiyan, M; Mohammad, RM; Sarkar, FH			Induction of apoptosis in breast cancer cells by TPA	ONCOGENE			English	Article						apoptosis; breast cancer; TPA	POLY(ADP-RIBOSE) POLYMERASE; GROWTH ARREST; P53; EXPRESSION; PROTEINASE; MATRIX; DEATH; CYCLOOXYGENASE-2; IDENTIFICATION; SUPPRESSION	Bcl-2, Fax and p53 gene products have been linked to programmed cell death pathways. p21(WAF1) has been shown to mediate p53-induced cell cycle arrest and to inhibit cyclin-dependent kinase activity. We have analysed the expression of these genes and apoptosis induced by 12-O-tetradecanoyl-phorbol-13-acetate (TPA) in several human breast cancer cell line. We found up-regulation of p2l(WAF1) and Bax expressions, however, the expressions of p53 and Bcl-2 genes remained unchanged in TPA-treated cells. Furthermore, DNA ladder formation and PARP cleavage were observed after treatment for 24 h, indicating apoptotic cell death. Flow cytometry with 7-amino actinomycin D staining showed that the number of apoptotic cells increased with longer treatment of TPA. From these results, we conclude that TPA is not only a tumor promoter, but also induces apoptosis in breast cancer cells. TPA-induced apoptosis appears to be mediated through a p53-independent pathway, and the up-regulation of p21(WAF1) and Bax may be the molecular mechanisms by which TPA induces apoptosis.	Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Internal Med, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University	Sarkar, FH (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst, Detroit, MI 48201 USA.							AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CHIARUGI V, 1994, CELL MOL BIOL RES, V40, P603; CORNELIUS LA, 1995, J INVEST DERMATOL, V105, P170, DOI 10.1111/1523-1747.ep12317080; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Findley HW, 1997, BLOOD, V89, P2986, DOI 10.1182/blood.V89.8.2986; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; HARPER JW, 1993, CELL, V75, P241; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Huang P, 1997, CANCER RES, V57, P3407; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KAPILA S, 1995, J DENT RES, V74, P1328, DOI 10.1177/00220345950740061301; KARGMAN SL, 1995, CANCER RES, V55, P2556; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kitada S, 1996, ONCOGENE, V12, P187; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lund LR, 1996, DEVELOPMENT, V122, P181; MIYASHITA T, 1995, CELL, V80, P293; Mohammad RM, 1998, CLIN CANCER RES, V4, P445; Parker S. L., 1996, CA CANC J CLIN, V65, P5; Philpott NJ, 1996, BLOOD, V87, P2244, DOI 10.1182/blood.V87.6.2244.bloodjournal8762244; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Quarrie LH, 1996, J CELL PHYSIOL, V168, P559, DOI 10.1002/(SICI)1097-4652(199609)168:3<559::AID-JCP8>3.0.CO;2-O; RAWDANOWICZ TJ, 1994, J CLIN ENDOCR METAB, V79, P530, DOI 10.1210/jc.79.2.530; Reddy BS, 1996, CANCER RES, V56, P4566; Salomons GS, 1997, INT J CANCER, V71, P959, DOI 10.1002/(SICI)1097-0215(19970611)71:6<959::AID-IJC9>3.0.CO;2-X; SANO H, 1995, CANCER RES, V55, P3785; SEDLAK ML, 1995, P NATL ACAD SCI USA, V92, P7934; Sundareshan P, 1997, CANCER LETT, V113, P17, DOI 10.1016/S0304-3835(96)04552-1; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	33	28	36	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 3	1998	17	22					2915	2920		10.1038/sj.onc.1202218	http://dx.doi.org/10.1038/sj.onc.1202218			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879997				2022-12-28	WOS:000077286400011
J	Vanacker, JM; Bonnelye, E; Delmarre, C; Laudet, V				Vanacker, JM; Bonnelye, E; Delmarre, C; Laudet, V			Activation of the thyroid hormone receptor alpha gene promoter by the orphan nuclear receptor ERR alpha	ONCOGENE			English	Article						nuclear receptors; ERR alpha; thyroid hormone; transcription factor cross-talk	ESTROGEN-RELATED RECEPTOR; STEROIDOGENIC FACTOR-I; EXPRESSION; DIFFERENTIATION; IDENTIFICATION; TRANSCRIPTION; PROTEIN; CELLS; TRANSACTIVATION; REGULATOR	The superfamily of nuclear receptors comprises transcription factors that depend on a ligand for their activity, In addition, the superfamily includes a number of orphan receptors, for which no ligand is known. We report here that the orphan receptor estrogen receptor related alpha receptor (ERR alpha) stimulates the expression of the thyroid hormone receptor alpha (TR alpha) gene promoter. We characterized a responsive site that is both necessary and sufficient for ERR alpha-induced transactivation. In addition, we show that both TR alpha and ERR alpha are coexpressed in embryonic intestine, brown fat and heart as well as in the adult gonads, In the testis, expression of both receptors can be found in the seminiferous tubes where it is totally restricted to spermatocytes I. Altogether this suggests that TRa is an in vivo target of ERR alpha.	Inst Pasteur, Inst Biol, UMR 319, CNRS, F-59019 Lille, France; Ecole Normale Super Lyon, CNRS, UMR 49, F-69364 Lyon 07, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)	Vanacker, JM (corresponding author), Univ Toronto, Dept Anat & Cell Biol, Toronto, ON M5S 1A8, Canada.		Bonnelye, Edith/AAT-9134-2021					Baas D, 1997, GLIA, V19, P324, DOI 10.1002/(SICI)1098-1136(199704)19:4<324::AID-GLIA5>3.0.CO;2-X; Bonnelye E, 1997, MOL ENDOCRINOL, V11, P905, DOI 10.1210/me.11.7.905; Bonnelye E, 1997, MECH DEVELOP, V65, P71, DOI 10.1016/S0925-4773(97)00059-2; BOSHART M, 1992, GENE, V110, P123; BRITTO JM, 1994, ENDOCRINOLOGY, V134, P169, DOI 10.1210/en.134.1.169; CARNAC G, 1993, ONCOGENE, V8, P3103; Chassande O, 1997, MOL ENDOCRINOL, V11, P1278, DOI 10.1210/me.11.9.1278; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; Fraichard A, 1997, EMBO J, V16, P4412, DOI 10.1093/emboj/16.14.4412; FRANCAVILLA S, 1992, J ENDOCRINOL INVEST, V15, P240; GANDRILLON O, 1994, ONCOGENE, V9, P749; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; IKEDA Y, 1994, MOL ENDOCRINOL, V8, P654, DOI 10.1210/me.8.5.654; JANNINI EA, 1994, MOL ENDOCRINOL, V8, P89, DOI 10.1210/me.8.1.89; Johnston SD, 1997, MOL ENDOCRINOL, V11, P342, DOI 10.1210/me.11.3.342; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAUDET V, 1993, ONCOGENE, V8, P975; LAZAR J, 1994, J BIOL CHEM, V269, P20352; LAZAR MA, 1990, J BIOL CHEM, V265, P12859; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; Parker KL, 1996, TRENDS ENDOCRIN MET, V7, P203, DOI 10.1016/1043-2760(96)00105-1; QUEVA C, 1992, DEVELOPMENT, V114, P125; SAKURAI A, 1992, BIOCHEM BIOPH RES CO, V185, P78, DOI 10.1016/S0006-291X(05)80957-X; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SATO K, 1987, ENDOCRINOLOGY, V120, P1873, DOI 10.1210/endo-120-5-1873; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SHIIO Y, 1993, ONCOGENE, V8, P2059; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; STRAIT KA, 1991, P NATL ACAD SCI USA, V88, P3887, DOI 10.1073/pnas.88.9.3887; Vanacker JM, 1996, J VIROL, V70, P2369, DOI 10.1128/JVI.70.4.2369-2377.1996; VANACKER JM, 1993, J VIROL, V67, P7668, DOI 10.1128/JVI.67.12.7668-7672.1993; VARGA F, 1994, FEBS LETT, V345, P67, DOI 10.1016/0014-5793(94)00442-0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILEY SR, 1993, GENE DEV, V7, P2206, DOI 10.1101/gad.7.11.2206; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; Yang NY, 1996, J BIOL CHEM, V271, P5795, DOI 10.1074/jbc.271.10.5795	39	63	65	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2429	2435		10.1038/sj.onc.1202167	http://dx.doi.org/10.1038/sj.onc.1202167			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824153				2022-12-28	WOS:000076927300002
J	Izzo, JG; Papadimitrakopoulou, VA; Li, XQ; Ibarguen, H; Lee, JS; Ro, JY; El-Naggar, A; Hong, WK; Hittelman, WN				Izzo, JG; Papadimitrakopoulou, VA; Li, XQ; Ibarguen, H; Lee, JS; Ro, JY; El-Naggar, A; Hong, WK; Hittelman, WN			Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification	ONCOGENE			English	Article						cyclin D1; tumorigenesis; dysregulated expression; amplification; FISH; immunohistochemistry	SQUAMOUS-CELL CARCINOMAS; CHROMOSOME 11Q13 REGION; G1 PHASE PROGRESSION; PREMALIGNANT LESIONS; INSITU HYBRIDIZATION; TUMOR PROGRESSION; AMPLIFIED REGION; CANCER; OVEREXPRESSION; PROTEIN	Cyclin D1 proto-oncogene is a key regulator of the mammalian cell-cycle acting at the restriction point in late G1, Amplification of the cyclin D1 locus, located on chromosome 11q13, as well as cyclin D1 protein overexpression have been reported in several human malignancies. The purpose of this study was to evaluate cyclin D1 gene copy status and protein expression during the multistep process of head and neck tumorigenesis, using a combination of fluorescence in situ hybridization and immunohistochemistry techniques. From 29 selected patients presenting with head and neck squamous carcinoma and whose tumor cytospins had been previously screened for presence (16 cases) or absence (13 cases) of amplification at the 11q13 band, we analysed 46 paraffin-embedded tissue specimens that demonstrated, besides the primary tumor, the presence of contiguous adjacent normal tissue and/or premalignant lesions. Of the 16 amplified cases, nine demonstrated a continuous progression from premalignant to invasive carcinoma and seven (77.7%) of these cases showed cyclin D1 gene amplification in premalignant lesions prior to development of invasive carcinoma. Increased cyclin D1 protein expression was observed in all 16 amplified tumors' and five of the 13 (38.4%) nonamplified tumors. Interestingly, dysregulated cyclin D1 expression was also found in the premalignant lesions adjacent to all 16 amplified tumors, and it appeared to precede cyclin D1 gene amplification. In contrast no dysregulated expression was detected in the premalignant lesions of the non-amplified tumors. In conclusion, these findings provide strong evidence for early dysregulation of cyclin D1 expression during the tumorigenesis process and suggest that dysregulated increased expression precedes and possibly enables gene amplification.	Univ Texas, MD Anderson Canc Ctr, Dept Clin Invest, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Hittelman, WN (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Clin Invest, 1515 holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA-16672, CA-52051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052051, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ALMASAN A, 1995, CANCER METAST REV, V14, P59, DOI 10.1007/BF00690212; Arber N, 1996, CANCER EPIDEM BIOMAR, V5, P457; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; BARTKOVA J, 1995, CANCER RES, V55, P949; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BERENSON JR, 1989, ONCOGENE, V4, P1111; BOHR VA, 1988, J CELL SCI, V91, P175; BOYLE JO, 1993, CANCER RES, V53, P4477; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; BROOKES S, 1993, GENE CHROMOSOME CANC, V6, P222, DOI 10.1002/gcc.2870060406; Califano J, 1996, CANCER RES, V56, P2488; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; COWAN JM, 1992, J NATL CANCER I, V84, P793, DOI 10.1093/jnci/84.10.793; ELNAGGAR AK, 1995, CYTOMETRY, V21, P47, DOI 10.1002/cyto.990210110; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; Farber E, 1996, ADV CANCER RES, V70, P21, DOI 10.1016/S0065-230X(08)60870-2; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; HINDS PW, 1994, P NATL ACAD SCI USA, V87, P6281; Izzo J., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P361; JARES P, 1994, CANCER RES, V54, P4813; JIAN W, 1993, ONCOGENE, V8, P2159; JUNIEN C, 1992, GENOMICS, V12, P620, DOI 10.1016/0888-7543(92)90461-Z; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; KUO MT, 1994, MOL CELL BIOL, V14, P5202, DOI 10.1128/MCB.14.8.5202; LAMMIE GA, 1991, ONCOGENE, V6, P439; LESE CM, 1995, GENE CHROMOSOME CANC, V12, P288, DOI 10.1002/gcc.2870120409; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1995, ONCOGENE, V10, P2125; LUTZ S, 1992, J PATHOL, V167, P279, DOI 10.1002/path.1711670304; Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682; MICHALIDES R, 1995, CANCER RES, V55, P975; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; NAWROZ H, 1994, CANCER RES, V54, P1152; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Roh H. J., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P117; SAUTER G, 1995, INT J CANCER, V64, P99, DOI 10.1002/ijc.2910640205; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SCHUURING E, 1992, ONCOGENE, V7, P355; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIN DM, 1994, CANCER RES, V54, P3153; SHIN DM, 1993, J NATL CANCER I, V85, P971, DOI 10.1093/jnci/85.12.971; SHIN DM, 1994, CANCER RES, V54, P321; SODER AI, 1995, CANCER RES, V55, P5030; SOMERS KD, 1990, ONCOGENE, V5, P915; TAINSKY MA, 1995, CANCER METAST REV, V14, P43, DOI 10.1007/BF00690210; TAM SW, 1994, ONCOGENE, V9, P2663; TANIGAMI A, 1992, GENOMICS, V13, P21, DOI 10.1016/0888-7543(92)90196-Y; TLSTY TD, 1993, COLD SPRING HARB SYM, V58, P645, DOI 10.1101/SQB.1993.058.01.072; Uchimaru K, 1996, JPN J CANCER RES, V87, P459, DOI 10.1111/j.1349-7006.1996.tb00246.x; Uhlman DL, 1996, CANCER RES, V56, P2199; VORAVUD N, 1993, CANCER RES, V53, P2874; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Zhou P, 1996, CANCER RES, V56, P36	55	103	109	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2313	2322		10.1038/sj.onc.1202153	http://dx.doi.org/10.1038/sj.onc.1202153			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811462				2022-12-28	WOS:000076723300005
J	Arvand, A; Bastians, H; Welford, SM; Thompson, AD; Ruderman, JV; Denny, CT				Arvand, A; Bastians, H; Welford, SM; Thompson, AD; Ruderman, JV; Denny, CT			EWS/FLI1 up regulates mE2-C, a cyclin-selective ubiquitin conjugating enzyme involved in cyclin B destruction	ONCOGENE			English	Article						Ewing's sarcoma; EWS/FLI1; RDA; cell cycle; transformation; E2-C	EWINGS-SARCOMA; DNA-BINDING; FUSION GENE; TRANSCRIPTIONAL ACTIVATOR; SACCHAROMYCES-CEREVISIAE; SISTER CHROMATIDS; PROTEIN; TRANSLOCATION; PROTEOLYSIS; SEPARATION	The EWS/FLI1 fusion gene found in Ewing's sarcoma and primitive neuroectodermal tumor, is able to transform certain cell lines by acting as an aberrant transcription factor, The ability of EWS/FLI1 to modulate gene expression in cells transformed and resistant to transformation by EWS/FLI1, was assessed by Representational Difference Analysis (RDA), We found that the cyclin selective ubiquitin conjugase murine E2-C, was up regulated in NIH3T3 cells transformed by EWS/FLI1 but not in a nontransformed NIH3T3 clone expressing EWS/FLI1, We also found that mn-C is upregulated in NIH3T3 cells transformed by other genes including activated cdc42, v-ABL and c-myc, We demonstrated that expression of mn-C in both the EWS/FLI1 transformed and parent NIH3T3 lines varies with the cell cycle. Finally, dominant-negative mE2-C, created by changing a catalytic cysteine to serine, inhibits the in vitro ubiquitination and degradation of cyclin B in human HeLa cell extracts. These data suggest that part of the biologic effect of EWS/FLI1 could be, to transcriptionally modulate genes involved in cell cycle regulation.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Calif Los Angeles, Dept Expt Pathol Lab Med, Los Angeles, CA USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Div Hematol Oncol,Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Denny, CT (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.				NCI NIH HHS [CA09056, CA32737] Funding Source: Medline; NIGMS NIH HHS [GM07185] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA032737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BRAUN BS, 1997, THESIS; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; LESSNICK SL, 1995, ONCOGENE, V10, P423; LESSNICK SL, 1994, THESIS; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; OHNO T, 1993, CANCER RES, V53, P5859; ORMEROD MG, 1996, FLOW CYTOMETRY PRACT, P75; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; RON D, 1995, P NATL ACAD SCI USA, V92, P2016; Segade F, 1995, LIFE SCI, V58, P277, DOI 10.1016/0024-3205(95)02288-0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stratmann R, 1996, CELL, V84, P25, DOI 10.1016/S0092-8674(00)80990-3; Thompson AD, 1996, ONCOGENE, V13, P2649; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4	31	75	82	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2039	2045		10.1038/sj.onc.1202129	http://dx.doi.org/10.1038/sj.onc.1202129			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798675				2022-12-28	WOS:000076540900003
J	von Brevern, M; Hollstein, MC; Risk, JM; Garde, J; Bennett, WP; Harris, CC; Muehlbauer, KR; Field, JK				von Brevern, M; Hollstein, MC; Risk, JM; Garde, J; Bennett, WP; Harris, CC; Muehlbauer, KR; Field, JK			Loss of heterozygosity in sporadic oesophageal tumors in the tylosis oesophageal cancer (TOC) gene region of chromosome 17q	ONCOGENE			English	Article						tylosis; loss of heterozygosity; oesophageal cancer	ESOPHAGEAL CANCER; PALMOPLANTAR KERATODERMA; P53 GENE; CARCINOMA; ALLELOTYPE; MUTATIONS	From the genotyping of UK and US tylotic families with a high risk of oesophageal cancer we have previously localized the tylosis-associated cancer susceptibility gene (TOC gene, tylosis oesophageal cancer gene) to a 1 cM region on the long arm of chromosome 17 (Kelsell et al,, 1996), In the present study we investigated loss of heterozygosity (LOH) patterns of 35 sporadic squamous cell carcinomas of the oesophagus using six polymorphic microsatellite markers encompassing this locus. Twenty-four of the 35 cases (69%) revealed LOH at one or more loci. Deletion was most frequently observed with the marker D17S801 (64% LOH, informative cases), which shows significant linkage to the TOC locus. The LOH analysis in sporadic oesophageal cancer we report here is thus consistent with the hypothesis that the tylosis oesophageal cancer susceptibility gene is also involved in the pathogenesis of a proportion of sporadic squamous cell carcinomas of the oesophagus.	Univ Liverpool, Dept Clin Dent Sci, Mol Genet & Oncol Grp, Liverpool L69 3BX, Merseyside, England; Deutsch Krebsforschungszentrum, German Canc Res Ctr, D-69120 Heidelberg, Germany; NCI, Human Carcinogenesis Lab, Bethesda, MD 20892 USA; Roy Castle Int Ctr Lung Canc Res, Liverpool L3 4TA, Merseyside, England	University of Liverpool; Helmholtz Association; German Cancer Research Center (DKFZ); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Field, JK (corresponding author), Univ Liverpool, Dept Clin Dent Sci, Mol Genet & Oncol Grp, Liverpool L69 3BX, Merseyside, England.		Field, John K./AAD-5674-2020	Field, John K./0000-0003-3951-6365				AOKI T, 1994, GENE CHROMOSOME CANC, V10, P177, DOI 10.1002/gcc.2870100305; BENNETT WP, 1991, ONCOGENE, V6, P1779; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Ellis A, 1994, Eur J Cancer B Oral Oncol, V30B, P102, DOI 10.1016/0964-1955(94)90061-2; HENNIES HC, 1995, GENOMICS, V29, P537, DOI 10.1006/geno.1995.9971; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; *J HOPK U, 1990, GDBTM HUM GEN DAT VE; Kelsell DP, 1996, HUM MOL GENET, V5, P857, DOI 10.1093/hmg/5.6.857; Montesano R, 1996, INT J CANCER, V69, P225, DOI 10.1002/(SICI)1097-0215(19960621)69:3<225::AID-IJC13>3.0.CO;2-6; MORI T, 1994, CANCER RES, V54, P1638; MUNOZ N, 1994, EUR J GASTROEN HEPAT, V6, P649, DOI 10.1097/00042737-199408000-00002; RISK JM, 1994, NAT GENET, V8, P319, DOI 10.1038/ng1294-319; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; Stevens HP, 1996, ARCH DERMATOL, V132, P640, DOI 10.1001/archderm.132.6.640; TOMATIS L, 1990, IARC SCI PUBLICATION, V100; vonBrevern MC, 1996, CANCER RES, V56, P4917	17	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2101	2105		10.1038/sj.onc.1202139	http://dx.doi.org/10.1038/sj.onc.1202139			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798681				2022-12-28	WOS:000076540900009
J	Mai, M; Qian, CP; Yokomizo, A; Tindall, DJ; Bostwick, D; Polychronakos, C; Smith, DI; Liu, WG				Mai, M; Qian, CP; Yokomizo, A; Tindall, DJ; Bostwick, D; Polychronakos, C; Smith, DI; Liu, WG			Loss of imprinting and allele switching of p73 in renal cell carcinoma	ONCOGENE			English	Article						p73; imprinting; allelic expression; renal cell carcinoma	TUMOR-SUPPRESSOR; WILMS-TUMOR; CANCER; GENE; EXPRESSION; P53; NEUROBLASTOMA; METHYLATION; H19	p73, a protein that has substantial structural and functional similarity to p53, has recently been identified. It was found to be monoallelically expressed in all cell lines and normal individuals tested, To elucidate its role in cancer development and as a potential imprinted tumor suppressor, we investigated the allele-specific expression of the human p73 gene in 28 cases of renal cell carcinoma and its imprinting status in fetal pancreatic and thymic tissues. Of 12 informative pairs of renal cell carcinoma and matched normal tissues identified by StyI restriction fragment length polymorphism (RFLP) in exon 2, p73 showed monoallelic expression in 11 out of 12 normal tissues but biallelic expression in 8/12 and switched allele expression in 2/12 of the matched corresponding cancers. An imprinting study of the p73 gene in two families using a newly identified exonic BanI RFLP indicated that expression of p73 was limited to the maternal allele in RNA from fetal pancreas and thymus, demonstrating that p73 is imprinted in at least these two tissues. These findings strongly suggest that loss of imprinting or switching of allelic expression of the p73 gene is associated with the development of renal cell carcinoma.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Urol Res, Rochester, MN 55905 USA; McGill Univ, Dept Pediat, Div Endocrinol, Montreal, PQ H3H 1P3, Canada	Mayo Clinic; Mayo Clinic; McGill University	Liu, WG (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA.		Polychronakos, Constantin/B-8151-2008	Polychronakos, Constantin/0000-0002-7624-6635	NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Dickman S, 1997, SCIENCE, V277, P1605, DOI 10.1126/science.277.5332.1605; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; Hibi K, 1996, CANCER RES, V56, P480; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; McBride G, 1997, J NATL CANCER I, V89, P1256; Oda H, 1998, INT J CANCER, V75, P343, DOI 10.1002/(SICI)1097-0215(19980130)75:3<343::AID-IJC3>3.0.CO;2-2; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5; Rachmilewitz J, 1996, ONCOGENE, V13, P1687; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; Svensson K, 1998, DEVELOPMENT, V125, P61; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; Thompson JS, 1996, CANCER RES, V56, P5723; Tycko B, 1997, MUTAT RES-REV MUTAT, V386, P131, DOI 10.1016/S1383-5742(96)00049-X; VERSTEEG R, 1995, EUR J CANCER, V31A, P538, DOI 10.1016/0959-8049(95)00037-J; Watanabe D, 1996, GENES CELLS, V1, P795, DOI 10.1046/j.1365-2443.1996.d01-276.x; ZHANG YH, 1993, AM J HUM GENET, V53, P113	18	75	79	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1739	1741		10.1038/sj.onc.1202099	http://dx.doi.org/10.1038/sj.onc.1202099			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796703				2022-12-28	WOS:000076200100012
J	Maeda, A; Scharenberg, AM; Tsukada, S; Bolen, JB; Kinet, JP; Kurosaki, T				Maeda, A; Scharenberg, AM; Tsukada, S; Bolen, JB; Kinet, JP; Kurosaki, T			Paired immunoglobulin-like receptor B (PIR-B) inhibits BCR-induced activation of Syk and Btk by SHP-1	ONCOGENE			English	Article						PIR-B; ITIM; SHP-1; SHP-2; tyrosine phosphorylation	CELL ANTIGEN RECEPTOR; TYROSINE-PHOSPHATASE SHP-1; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-2; CA2+ MOBILIZATION; DISTINCT PATHWAYS; KINASE LYN; INVOLVEMENT; LYMPHOCYTES; REQUIREMENT	Coligation of paired immunoglobulin-like receptor B (PIR-B) with B cell antigen receptor (BCR) blocks antigen-induced B cell activation. This inhibition is mediated in part by recruitment of SHP-1 and SHP-2 to the phosphorylated ITIMs in the cytoplasmic domain of PIR-B; however the molecular target(s) of these phosphatases remain elusive. Here,ve show that PIR-B ligation inhibits the BCR-induced tyrosine phosphorylation of Ig alpha/Ig beta, Syk, Btk and phospholipase C (PLC)-gamma 2 Overexpression of a catalgtically inactive form of SHP-1 prevents the PIR-B-mediated inhibition: of tyrosine phosphorylation of Syk, Btk, and PLC-gamma 2. Dephosphorylation of Syk and Btk mediated by SHP-1 leads to a decrease of their kinase activity, which in turn inhibits tyrosine phosphorylation of PLC-gamma 2. Furthermore, we define a requirement for Lan in mediating tyrosine phosphorylation of PIR-B, Based on these results, we propose a model of PIR-B-mediated inhibitory signaling in which coligation of PIR-B and BCR results in phosphorylation of ITIMs by Lyn, subsequent recruitment of SHP-1, and a resulting inhibition of the BCR-induced inositol 1,4,5-trisphosphate generation by dephosphorylation of Syk and Btk.	Kansai Med Univ, Dept Mol Genet, Inst Liver Res, Moriguchi, Osaka 5708506, Japan; Beth Israel Hosp, Lab Allergy & Immunol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Hoechst Marion Roussel, Bridgewater, NJ 08807 USA	Kansai Medical University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kurosaki, T (corresponding author), Kansai Med Univ, Dept Mol Genet, Inst Liver Res, Moriguchi, Osaka 5708506, Japan.		Maeda, Akito/AAX-6252-2020; Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X; Maeda, Akito/0000-0001-8776-9135				BABA Y, IN PRESS BLOOD; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; Blery M, 1998, P NATL ACAD SCI USA, V95, P2446, DOI 10.1073/pnas.95.5.2446; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gupta N, 1997, J EXP MED, V186, P473, DOI 10.1084/jem.186.3.473; Hayami K, 1997, J BIOL CHEM, V272, P7320, DOI 10.1074/jbc.272.11.7320; Hippen KL, 1997, IMMUNITY, V7, P49, DOI 10.1016/S1074-7613(00)80509-9; Kubagawa H, 1997, P NATL ACAD SCI USA, V94, P5261, DOI 10.1073/pnas.94.10.5261; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; Maeda A, 1998, J EXP MED, V187, P1355, DOI 10.1084/jem.187.8.1355; Nadler MJS, 1997, J BIOL CHEM, V272, P20038, DOI 10.1074/jbc.272.32.20038; Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; ORourke L, 1997, CURR OPIN IMMUNOL, V9, P324, DOI 10.1016/S0952-7915(97)80077-5; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; Wang JY, 1996, J EXP MED, V184, P831, DOI 10.1084/jem.184.3.831; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	34	118	122	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2291	2297		10.1038/sj.onc.1202552	http://dx.doi.org/10.1038/sj.onc.1202552			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327049	Bronze			2022-12-28	WOS:000079595500001
J	Russell, A; Thompson, MA; Hendley, J; Trute, L; Armes, J; Germain, D				Russell, A; Thompson, MA; Hendley, J; Trute, L; Armes, J; Germain, D			Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer	ONCOGENE			English	Article						D-type cyclin; breast cancer; proteolysis; SCF	CELL-CYCLE; ESTROGEN-RECEPTOR; EXPRESSION; GENE; DEGRADATION; PROTEIN; D2; DIFFERENTIATION; UBIQUITINATION; AMPLIFICATION	D-type cyclins are important cell cycle regulators that promote cellular proliferation in response to growth factors by inactivation of the retinoblastoma protein (Rb), Cyclin D1 has been shown to be overexpressed in several cancer types and to act as an oncogene in breast cancers. As D-type cyclins are rate limiting for progression into S phase, the level at which they accumulate must be carefully regulated. Several mechanisms leading to overexpression of cyclin D1 have been reported including amplification, translocation and stabilization of the mRNA, Here, we present data showing elevated cyclin D1 protein in breast cancer samples in the absence of elevated mRNA level. Further, we found that in these cases, cyclin D3 protein also accumulates and that the coordinate increase in cyclin D1 and D3 occurs in 15% (7/47) of breast cancers. In addition we show that blocking the activity of the 26S proteosome results in the accumulation of cyclin D1 and D3, that both D-type cyclins are abiquitinated and associate with Cul-1, a component of the SCF ubiquitin Ligase complex. Finally, we show that the coordinated elevation of cyclin D1 and D3 is also observed in the breast cell line MCF-7 and demonstrate that the degradation of cyclin D1 and D3 is deficient in this cell line. These results indicate that cyclin D1 and cyclin D3 share a common mechanism of degradation and we propose that the coordinate increase of D-type cyclins observed in primary breast cancers reflects a defect in their proteolysis.	Peter MacCallum Canc Inst, Trescowthick Res Lab, Melbourne, Vic 3000, Australia	Peter Maccallum Cancer Center	Germain, D (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Lab, Locked Bag 1,Abeckett St, Melbourne, Vic 3000, Australia.		Armes, Jane/D-6396-2012	Armes, Jane/0000-0002-2215-0347				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; GILLETT C, 1994, CANCER RES, V54, P1812; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HERBER B, 1994, ONCOGENE, V9, P1295; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sweeney KJ, 1997, ONCOGENE, V14, P1329, DOI 10.1038/sj.onc.1200951; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welcker M, 1996, ONCOGENE, V13, P419; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	41	115	121	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	1999	18	11					1983	1991		10.1038/sj.onc.1202511	http://dx.doi.org/10.1038/sj.onc.1202511			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208420				2022-12-28	WOS:000079191300008
J	Moskaluk, CA; Tian, Q; Marshall, CR; Rumpel, CA; Franquemont, DW; Frierson, HF				Moskaluk, CA; Tian, Q; Marshall, CR; Rumpel, CA; Franquemont, DW; Frierson, HF			Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors	ONCOGENE			English	Article						c-kit; oncogene; gene mutation; sarcoma; gastrointestinal tract	RECEPTOR TYROSINE KINASE; CELL GROWTH-FACTOR; INTERSTITIAL-CELLS; ELECTRICAL RHYTHMICITY; TISSUES; CAJAL; EXPRESSION; PROTEIN; LIGAND; INTESTINE	The c-kit gene encodes a transmembrane receptor kinase (KIT) which is expressed in the majority of human gastrointestinal stromal tumors (GISTs), a subtype of gastrointestinal mesenchymal neoplasms. A previous study identified mutations in the juxtamembrane (JR I) domain of c-X-it in five of six GISTs (Science 279: 577, 1998), To better define the frequency and spectrum of c-kit gene mutations in mesenchymal neoplasms of the GI tract that had been characterized for KIT protein expression, we examined archived tissue samples for mutations in the JM domain by PCR amplification and DNA sequencing. c-kit JM domain mutations were found in nine of 56 mesenchymal tumors (46 GISTs, eight leiomyomas, two leiomyosarcomas) and occurred exclusively in GISTs (21%), Seven of the nine mutations consisted of intragenic deletions of one to 19 codons, There was one insertion mutation that added 12 codons and one missense mutation (Val560Asp), None of the mutations disrupted the downstream reading frame of the gene, The single missense mutation (Val560Asp) is very similar to the only other missense mutation reported in GISTs (Val599Asp). Of the 46 GISTs, 43,were strongly positive for KIT protein expression and negative for diffuse expression of desmin, Neither KIT expression nor gene mutations,were found in gastrointestinal leiomyomas or leiomyosarcomas. We conclude that mutation of the c-kit JM domain does not occur in gastrointestinal mesenchymal neoplasms,vith well developed-smooth muscle differentiation, and is restricted to GISTs, However, since these mutations are only found in a minority of GISTs, further investigation into the mechanisms of c-kit gene activation in this group of neoplasms is warranted.	Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Penrose Hosp, Dept Pathol, Colorado Springs, CO 80907 USA	University of Virginia; University of Virginia	Moskaluk, CA (corresponding author), Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA.				NATIONAL CANCER INSTITUTE [K08CA074431] Funding Source: NIH RePORTER; NCI NIH HHS [5K08CA74431-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arber DA, 1998, HUM PATHOL, V29, P498, DOI 10.1016/S0046-8177(98)90066-1; BRIZZI MF, 1994, J BIOL CHEM, V269, P31680; FRANQUEMONT DW, 1992, AM J SURG PATHOL, V16, P947, DOI 10.1097/00000478-199210000-00004; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; HJERMSTAD BM, 1987, AM J SURG PATHOL, V11, P383, DOI 10.1097/00000478-198705000-00007; HORIE K, 1993, HUM REPROD, V8, P1955, DOI 10.1093/oxfordjournals.humrep.a137967; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; Isozaki K, 1997, AM J GASTROENTEROL, V92, P332; Kenny SE, 1998, J PEDIATR SURG, V33, P130, DOI 10.1016/S0022-3468(98)90379-7; Kindblom LG, 1998, AM J PATHOL, V152, P1259; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kluppel M, 1998, DEV DYNAM, V211, P60; LAMMIE A, 1994, J HISTOCHEM CYTOCHEM, V42, P1417, DOI 10.1177/42.11.7523489; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; MATSUDA R, 1993, AM J PATHOL, V142, P339; MIETTINEN M, 1995, AM J SURG PATHOL, V19, P207, DOI 10.1097/00000478-199502000-00009; Moskaluk CA, 1997, AM J PATHOL, V150, P1547; Sanders KM, 1996, GASTROENTEROLOGY, V111, P492, DOI 10.1053/gast.1996.v111.pm8690216; SARLOMORIKALA M, 1998, IN PRESS MOD PATHOL; SAUL SH, 1987, AM J SURG PATHOL, V11, P464, DOI 10.1097/00000478-198706000-00007; Torihashi S, 1997, GASTROENTEROLOGY, V112, P144, DOI 10.1016/S0016-5085(97)70229-4; Tsujimura T, 1996, BLOOD, V87, P273; TSUURA Y, 1994, VIRCHOWS ARCH, V424, P135; VANDENBARK GR, 1992, ONCOGENE, V7, P1259; Vanderwinden JM, 1996, GASTROENTEROLOGY, V111, P901, DOI 10.1016/S0016-5085(96)70057-4; Vanderwinden JM, 1996, GASTROENTEROLOGY, V111, P279, DOI 10.1053/gast.1996.v111.pm8690192; Vliagoftis H, 1997, J ALLERGY CLIN IMMUN, V100, P435, DOI 10.1016/S0091-6749(97)70131-3; WARD SM, 1994, J PHYSIOL-LONDON, V480, P91, DOI 10.1113/jphysiol.1994.sp020343; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x	30	147	160	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1897	1902		10.1038/sj.onc.1202496	http://dx.doi.org/10.1038/sj.onc.1202496			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086344				2022-12-28	WOS:000079090000013
J	Philips, A; Huet, X; Plet, A; Rech, J; Vie, A; Blanchard, JM				Philips, A; Huet, X; Plet, A; Rech, J; Vie, A; Blanchard, JM			Anchorage-dependent expression of cyclin A in primary cells requires a negative DNA regulatory element and a functional Rb	ONCOGENE			English	Article						cyclin A; Rb; adhesion; primary cells	CCAAT-BINDING PROTEIN; A GENE-EXPRESSION; RETINOBLASTOMA PROTEIN; TRANSCRIPTIONAL REPRESSION; INDEPENDENT GROWTH; DOWN-REGULATION; NUDE MICE; RAS; PROGRESSION; TUMORIGENICITY	Many cells, when cultured in suspension, fail to express cyclin A, a regulatory component of cell cycle kinases cdc2 and cdk2 and as a consequence, do not enter S phase, However, many cell type-specific differences are disclosed between not only normal and transformed cells, but also between cell lines whose proliferation is strictly anchorage-dependent, These apparent discrepancies are seen in established cell lines most probably because of adaptative events that have occurred during cell culture, We have therefore used primary cells to understand how cyclin A transcription is controlled by cell anchorage properties, To this aim, we have used embryonic fibroblasts from either wild type, Rb(-/-) or p107(-/-)/p130(-/-) mice and tested the effect of an ectopic expression of Rb mutants. In the experiments reported here, we show that anchorage-dependent expression of cyclin A (i) is reflected by the irt vivo occupancy of a negative DNA regulatory element previously shown to be instrumental in the down regulation of cyclin A transcription in quiescent cells (Cell Cycle Responsive Element: CCRE) (ii) requires a functional Rb but neither p107 nor p130 (iii) mutation of the CCRE abolishes both adhesion-dependent regulation and response to Rb.	Inst Mol Genet, CNRS, UMR 5535, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Blanchard, JM (corresponding author), Inst Mol Genet, CNRS, UMR 5535, 1919 Route Mende, F-34293 Montpellier 5, France.		PHILIPS, Alexandre/AAB-6047-2020					Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; BARLAT I, 1995, ONCOGENE, V11, P1309; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; BOS JL, 1989, CANCER RES, V49, P4682; Carstens CP, 1996, EXP CELL RES, V229, P86, DOI 10.1006/excr.1996.0346; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; COLBURN NH, 1978, CANCER RES, V38, P624; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; Downward J, 1997, CURR BIOL, V7, P258; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GIRARD F, 1991, CELL, V67, P1; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Huet X, 1996, MOL CELL BIOL, V16, P3789; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kang JS, 1996, MOL CELL BIOL, V16, P3370; Kramer A, 1996, J BIOL CHEM, V271, P6579; Kramer A, 1997, CANCER RES, V57, P5117; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PAGANO M, 1992, EMBO J, V88, P1039; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Philips A, 1998, ONCOGENE, V16, P1373, DOI 10.1038/sj.onc.1201655; Plet A, 1997, ONCOGENE, V14, P2575, DOI 10.1038/sj.onc.1201103; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; SARDET C, 1997, ONCOGENES TRANSCRIPT, V2, P1; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Schulze A, 1996, MOL CELL BIOL, V16, P4632; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	50	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1819	1825		10.1038/sj.onc.1202530	http://dx.doi.org/10.1038/sj.onc.1202530			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086336				2022-12-28	WOS:000079090000005
J	Buess, M; Engler, O; Hirsch, HH; Moroni, C				Buess, M; Engler, O; Hirsch, HH; Moroni, C			Search for oncogenic regulators in an autocrine tumor model using differential display PCR: Identification of novel candidate genes including the calcium channel mtrp6	ONCOGENE			English	Article						mast cells; serine protease; ras; mRNA fingerprinting; differential cloning	INTERLEUKIN-3 MESSENGER-RNA; 3' UNTRANSLATED REGION; MAST-CELLS; MOLECULAR-CLONING; GM-CSF; EXPRESSION; ENTRY; TRP; TRANSFORMATION; ACTIVATION	A hemopoietic multistep tumor model, in which IL-3 dependent PB-3c mast cells, following expression of v-H-ras progress in vivo to IL-3 producing autocrine tumors has previously been established. Central for this oncogenic progression is a recessive step, which is reversible by cell fusion and leads to stabilization of IL-3 mRNA with concomitant activation of the autocrine loop. Comparing the IL-3 dependent PB-3c and the IL-3 autocrine V2D1 tumor cells with differential display PCR revealed 12 differentially expressed genes of which eight were upregulated and four downregulated in the tumor. They included four proteases (mouse mast cell protease 2, granzyme B, pepsinogen F and serine protease 1) and two metabolic enzymes (adenine phosphoribosyltransferase and fructose1,6-bisphosphatase). For validation, expression of the identified genes was tested in independent PB-3c precursor clones and their tumor derivatives. Expression of an endogenous retroviral IAP element and three unknown transcripts were consistently upregulated in all tumor lines. In somatic cell hybrids, two of these unknown cDNAs showed a dominant and one a recessive expression pattern. One transcript, expressed in the precursor but downregulated in the tumor cells, was cloned and identified as the murine calcium channel mtrp6.	Univ Basel, Inst Med Microbiol, CH-4003 Basel, Switzerland	University of Basel	Moroni, C (corresponding author), Univ Basel, Inst Med Microbiol, Peterspl 10, CH-4003 Basel, Switzerland.			Hirsch, Hans H./0000-0003-0883-0423				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BALL PE, 1983, DIFFERENTIATION, V24, P74, DOI 10.1111/j.1432-0436.1983.tb01305.x; Banholzer R, 1997, MOL CELL BIOL, V17, P3254, DOI 10.1128/MCB.17.6.3254; BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4272, DOI 10.1093/nar/21.18.4272; BERTIOLI DJ, 1995, NUCLEIC ACIDS RES, V23, P4520, DOI 10.1093/nar/23.21.4520; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; BRUNET JF, 1986, NATURE, V322, P268, DOI 10.1038/322268a0; BRUNET JF, 1987, J IMMUNOL, V138, P4102; Buess M, 1997, NUCLEIC ACIDS RES, V25, P2233, DOI 10.1093/nar/25.11.2233; BURNAY MM, 1994, ENDOCRINOLOGY, V135, P751, DOI 10.1210/en.135.2.751; Chenchik A, 1996, BIOTECHNIQUES, V21, P526; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; DIAMANTIS ID, 1989, P NATL ACAD SCI USA, V86, P9299, DOI 10.1073/pnas.86.23.9299; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HAWLEY RG, 1984, MOL CELL BIOL, V4, P2565, DOI 10.1128/MCB.4.12.2565; HIRSCH HH, 1993, J EXP MED, V178, P403, DOI 10.1084/jem.178.2.403; HIRSCH HH, 1995, J BIOL CHEM, V270, P20629, DOI 10.1074/jbc.270.35.20629; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1995, CURR OPIN IMMUNOL, V7, P274, DOI 10.1016/0952-7915(95)80015-8; LIANG P, 1992, CANCER RES, V52, P6966; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; Mirza H, 1997, BLOOD, V90, P3914, DOI 10.1182/blood.V90.10.3914; NAIR APK, 1992, ONCOGENE, V7, P1963; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; NAIR APK, 1994, NATURE, V369, P239, DOI 10.1038/369239a0; NOMURA M, 1994, FEBS LETT, V348, P201, DOI 10.1016/0014-5793(94)00608-3; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; SAGER R, 1993, FASEB J, V7, P964, DOI 10.1096/fasebj.7.10.8344495; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TURKER MS, 1993, J MOL EVOL, V36, P31, DOI 10.1007/BF02407304; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	43	19	24	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1487	1494		10.1038/sj.onc.1202445	http://dx.doi.org/10.1038/sj.onc.1202445			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050885	Bronze			2022-12-28	WOS:000078651600010
J	Yeyati, PL; Shaknovich, R; Boterashvili, S; Li, J; Ball, HJ; Waxman, S; Nason-Burchenal, K; Dmitrovsky, E; Zelent, A; Licht, JD				Yeyati, PL; Shaknovich, R; Boterashvili, S; Li, J; Ball, HJ; Waxman, S; Nason-Burchenal, K; Dmitrovsky, E; Zelent, A; Licht, JD			Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A	ONCOGENE			English	Article						PLZF; acute promyelocytic leukemia; cell cycle; cyclin A	ACUTE PROMYELOCYTIC LEUKEMIA; ACID RECEPTOR-ALPHA; EMBRYONAL CARCINOMA-CELLS; ZINC-FINGER GENE; RETINOIC ACID; RAR-ALPHA; DNA-BINDING; S-PHASE; TRANSCRIPTIONAL PROPERTIES; MAMMALIAN FIBROBLASTS	The PLZF gene was identified by its fusion with the RAR alpha locus in a therapy resistant form of acute promyelocytic leukemia (APL) associated with the t(11;17)(q23;q21) translocation, Here we describe PLZF as a negative regulator of cell cycle progression ultimately leading to growth suppression, PLZF can bind and repress the cyclin A2 promoter while expression of cyclin A2 reverts the growth suppressed phenotype of myeloid cells expressing PLZF, In contrast RAR alpha-PLZF, a fusion protein generated in t(11;17)(q23;q21)APL activates cyclin A2 transcription and allows expression of cyclin A in anchorage-deprived NIH3T3 cells. Therefore, cyclin A2 is a candidate target gene for PLZF and inhibition of cyclin A expression may contribute to the growth suppressive properties of PLZF, Deregulation of cyclin A2 by RAR alpha-PLZF may represent an oncogenic mechanism of this chimeric protein and contribute to the aggressive clinical phenotype of t(11;17)(q23;q21)-associated APL.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Brookdale Ctr Dev & Mol Biol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Inst Canc Res, Leukaemia Res Fund Ctr, London SW3 6JB, England; Mem Sloan Kettering Canc Ctr, Mol Med Lab, New York, NY 10021 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Memorial Sloan Kettering Cancer Center	Licht, JD (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.		Ball, Helen J/A-4242-2010; Zelent, Arthur/B-3532-2009; Licht, Jonathan/L-4239-2019	Ball, Helen J/0000-0003-3733-9748; Zelent, Arthur/0000-0002-7968-9888; Licht, Jonathan/0000-0002-3942-1369	NATIONAL CANCER INSTITUTE [R01CA062275, R01CA059936] Funding Source: NIH RePORTER; NCI NIH HHS [CA62275, CA59936] Funding Source: Medline; NIGMS NIH HHS [GM0707280-17] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1988, MOL REPROD DEV; AVANTAGGIATO V, 1995, J NEUROSCI, V15, P4927; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Desdouets C, 1996, FEBS LETT, V385, P34, DOI 10.1016/0014-5793(96)00330-4; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; EAVES CJ, 1991, BLOOD, V78, P110; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GRIGNANI F, 1994, BLOOD, V83, P10; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grimwade D, 1997, BLOOD, V90, P4876; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUIDEZ F, 1994, LEUKEMIA, V8, P312; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Huet X, 1996, MOL CELL BIOL, V16, P3789; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KREIDER BL, 1990, MOL CELL BIOL, V10, P4846, DOI 10.1128/MCB.10.9.4846; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LANOTTE M, 1991, BLOOD, V77, P1080; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Licht JD, 1996, ONCOGENE, V12, P323; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Meyyappan M, 1998, MOL CELL BIOL, V18, P3163, DOI 10.1128/MCB.18.6.3163; MOASSER MM, 1995, ONCOGENE, V10, P1537; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OTSUKA H, 1976, J CELL PHYSIOL, V87, P213, DOI 10.1002/jcp.1040870209; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pandolfi PP, 1996, HAEMATOLOGICA, V81, P472; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; SCHMID I, 1991, CYTOMETRY, V12, P279, DOI 10.1002/cyto.990120312; SCHUSTERSEWC H, 1992, LETOPIS, V1, P9; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	57	154	156	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					925	934		10.1038/sj.onc.1202375	http://dx.doi.org/10.1038/sj.onc.1202375			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023668				2022-12-28	WOS:000078510600009
J	Hartmann, BL; Geley, S; Loffler, M; Hattmannstorfer, R; Strasser-Wozak, EMC; Auer, B; Kofler, R				Hartmann, BL; Geley, S; Loffler, M; Hattmannstorfer, R; Strasser-Wozak, EMC; Auer, B; Kofler, R			Bcl-2 interferes with the execution phase, but not upstream events, in glucocorticoid-induced leukemia apoptosis	ONCOGENE			English	Article						glucocorticoid; apoptosis; bcl-2; leukemia; tetracycline-regulated gene expression	POLY(ADP-RIBOSE) POLYMERASE CLEAVAGE; FAMILY PROTEASE INHIBITORS; CERAMIDE-INDUCED APOPTOSIS; LINE CCRF-CEM; CELL-DEATH; CYTOCHROME-C; REGULATED APOPTOSIS; THYMOCYTE APOPTOSIS; REPRESSIVE FUNCTION; DNA FRAGMENTATION	Due to their growth arrest- and apoptosis-inducing ability, glucocorticoids (GC) are widely used in the therapy of various lymphoid malignancies. Cell death is associated with activation of members of the interleukin-1 beta-converting enzyme (ICE) protease/caspase family and, is presumably prevented by the anti-apoptotic protein Bcl-2. To further address the role of Bcl-2 in CC-mediated cytotoxicity, we generated subclones of the GC-sensitive human T-cell acute lymphoblastic leukemia line CCRF-CEM, in which transgenic Bcl-2 expression is regulated by tetracycline. Up to about 48 h, exogenous Bcl-2 almost completely protected these cells from apoptosis, digestion of poly-ADP ribose polymerase (PARP) and generation of Asp-Glu-Val-Asp cleaving (DEVDase) activity. However, when the cells were cultured for another 24 h in the continuous presence of GC, they underwent massive apoptosis that was associated with DEVDase activity and PARP cleavage. Bcl-2 did not markedly affect GC-mediated growth arrest, thereby separating the anti-proliferative from the apoptosis-inducing effect of GC. Moreover, Bcl-2 did not prevent the dramatic reduction in the levels of several mRNAs observed during GC treatment, including the transgenic Bcl-2 mRNA. Thus, Bcl-2 can be placed upstream of effector caspase activation, but downstream of other GC-regulated events, such as growth arrest and the potentially critical repression of steady state levels of multiple mRNA.	Univ Innsbruck, Inst Gen & Expt Pathol, Div Mol Pathophysiol, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Biochem, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck	Kofler, R (corresponding author), Univ Innsbruck, Inst Gen & Expt Pathol, Div Mol Pathophysiol, A-6020 Innsbruck, Austria.							ADELMAN NE, 1983, J EXP MED, V158, P1350, DOI 10.1084/jem.158.4.1350; ALNEMRI ES, 1992, CANCER RES, V52, P491; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; ASHRAF J, 1993, MOL ENDOCRINOL, V7, P631, DOI 10.1210/me.7.5.631; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Benson RSP, 1998, CELL DEATH DIFFER, V5, P432, DOI 10.1038/sj.cdd.4400366; Boulakia CA, 1996, ONCOGENE, V12, P529; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brunet CL, 1998, CELL DEATH DIFFER, V5, P107, DOI 10.1038/sj.cdd.4400334; CARONLESLIE LAM, 1994, FASEB J, V8, P639, DOI 10.1096/fasebj.8.9.8005391; Chapman MS, 1996, MOL ENDOCRINOL, V10, P967, DOI 10.1210/me.10.8.967; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; Decaudin D, 1997, CANCER RES, V57, P62; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EVANSSTORMS RB, 1995, J STEROID BIOCHEM, V53, P1, DOI 10.1016/0960-0760(95)00034-W; Geley S, 1997, FEBS LETT, V402, P36, DOI 10.1016/S0014-5793(96)01496-2; Geley S, 1997, ONCOGENE, V15, P2429, DOI 10.1038/sj.onc.1201399; Geley S, 1996, REV PHYSIOL BIOCH P, V128, P1; Geley S, 1996, CANCER RES, V56, P5033; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hala M, 1996, INT J CANCER, V68, P663, DOI 10.1002/(SICI)1097-0215(19961127)68:5<663::AID-IJC17>3.0.CO;2-2; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Ibrado AM, 1996, CANCER RES, V56, P4743; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Melkova Z, 1997, FEBS LETT, V403, P273, DOI 10.1016/S0014-5793(97)00065-3; MEMON SA, 1995, J IMMUNOL, V155, P4644; Messmer UK, 1996, FEBS LETT, V384, P162; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIYASHITA T, 1993, BLOOD, V81, P151; Miyashita T, 1997, BIOCHEM BIOPH RES CO, V233, P781, DOI 10.1006/bbrc.1997.6559; MIYASHITA T, 1992, CANCER RES, V52, P5407; Monney L, 1996, BIOCHEM BIOPH RES CO, V221, P340, DOI 10.1006/bbrc.1996.0597; Moreno MB, 1996, J IMMUNOL, V157, P3845; MORIMOTO C, 1985, J IMMUNOL, V134, P3762; NEAMATI N, 1995, J IMMUNOL, V154, P3788; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NORMAN MR, 1977, CANCER RES, V37, P3785; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; POWERS JH, 1993, CANCER RES, V53, P4059; Robertson NM, 1997, CANCER RES, V57, P43; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SCHWARTZMAN RA, 1994, INT ARCH ALLERGY IMM, V105, P347, DOI 10.1159/000236781; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SGONC R, 1994, INT ARCH ALLERGY IMM, V105, P327, DOI 10.1159/000236777; Shimizu S, 1996, ONCOGENE, V12, P2251; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; STRASSERWOZAK EMC, 1995, CANCER RES, V55, P348; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; THOMPSON EB, 1994, MOL ENDOCRINOL, V8, P665, DOI 10.1210/me.8.6.665; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; THULASI R, 1993, J BIOL CHEM, V268, P18306; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; Urashima M, 1997, BLOOD, V90, P279; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUH YS, 1989, J BIOL CHEM, V264, P10904; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZHIVOTOVSKY B, 1995, EXP CELL RES, V221, P404, DOI 10.1006/excr.1995.1391; Zhou F, 1996, MOL ENDOCRINOL, V10, P306, DOI 10.1210/me.10.3.306; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	77	48	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					713	719		10.1038/sj.onc.1202339	http://dx.doi.org/10.1038/sj.onc.1202339			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989821				2022-12-28	WOS:000078394400016
J	Martincic, D; Koury, MJ; Gale, K; Whitlock, JA				Martincic, D; Koury, MJ; Gale, K; Whitlock, JA			Detection of mutations by automated fluorescence/RNA-based dideoxy fingerprinting (ARddF)	ONCOGENE			English	Article						dideoxyfingerprinting (ddF); mutation detection; p53 gene; automated sequencing	SEVERE COMBINED IMMUNODEFICIENCY; P53 GENE; DNA; DDF; POLYMORPHISMS; SEQUENCE	Dideoxy fingerprinting (ddF) is a hybrid technique which combines aspects of single strand conformational polymorphism (SSCP) and dideoxy sequencing to detect the presence of single base changes in a defined fragment of nucleic acid, ddF is no more technically demanding than SSCP, yet it is more sensitive in detecting point mutations. We describe here the adaptation of conventional ddF to an automated sequencing system using fluorescent Cy5 labeled primers. We show that automated RNA-based ddF (ARddF) has several advantages over conventional radioisotope-based ddF, including: (1) analysis of larger nucleic acid fragments (up to 10(3) bp), due to the ability to continuously analyse and compile sequencing information; (2) greater reliability for distinguishing mutant sequences from wild type sequences (particularly when the mutation leads to gain or loss of a dideoxy termination segment); (3) the use of fluorescent labeled primers, making ARddF less hazardous than methods requiring radionucleotides, The use of ARddF in conjunction with new methods for isolating RNA from nine small number of cells facilitates mutational analysis of small tissue biopsies and other limited samples, and will allow more widespread application of mutational screening in the setting of clinical diagnostic laboratories.	Vanderbilt Univ, Sch Med, Dept Pediat, Div Pediat Hematol Oncol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Internal Med, Div Hematol, Nashville, TN 37232 USA; Vet Adm Med Ctr, Nashville, TN 37232 USA; Amersham Pharm Biotech, Piscataway, NJ 08854 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Martincic, D (corresponding author), Vanderbilt Univ, Sch Med, Dept Pediat, Div Pediat Hematol Oncol, 221 Kirkland Hall, Nashville, TN 37232 USA.			Whitlock, James/0000-0002-7887-0634	NCI NIH HHS [1P30CA68485] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLASZYK H, 1995, BIOTECHNIQUES, V18, P256; Chen HL, 1997, MOL MED TODAY, V3, P160, DOI 10.1016/S1357-4310(97)01003-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVID YB, 1988, ONCOGENE, V3, P179; Durocher F, 1996, J MED GENET, V33, P814, DOI 10.1136/jmg.33.10.814; GROMPE M, 1993, NAT GENET, V5, P111, DOI 10.1038/ng1093-111; Hamada M, 1996, J CANCER RES CLIN, V122, P360, DOI 10.1007/BF01220804; Koury MJ, 1997, BLOOD, V90, P4054, DOI 10.1182/blood.V90.10.4054; LIU Q, 1995, BIOTECHNIQUES, V18, P470; LIU Q, 1992, HUM MOL GENET, V5, P107; Martincic D, 1996, ONCOGENE, V13, P2039; MARTINCIC D, 1998, IN PRESS BLOOD; Miyata I, 1997, ENDOCR J, V44, P149, DOI 10.1507/endocrj.44.149; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; Olsen LS, 1996, PHARMACOL TOXICOL, V78, P364, DOI 10.1111/j.1600-0773.1996.tb00220.x; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; *PHARM BIOT, 1996, ALF EXPR DNA SEQ US; Puck JM, 1997, BLOOD, V89, P1968; Puck JM, 1997, HUM GENET, V99, P628, DOI 10.1007/s004390050418; QUIANG L, 1995, AM J MED GENET, V60, P165; QUIANG L, 1994, PCR METH APPL, V4, P97; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1992, NUCLEIC ACIDS RES, V20, P871, DOI 10.1093/nar/20.4.871; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; Scriver C.R., 1995, METABOLIC MOL BASES, P1; Sobell JL, 1997, AM J MED GENET, V74, P44, DOI 10.1002/(SICI)1096-8628(19970221)74:1<44::AID-AJMG10>3.0.CO;2-R; STOFLET ES, 1988, SCIENCE, V239, P491, DOI 10.1126/science.3340835; WENDLING F, 1981, P NATL ACAD SCI-BIOL, V78, P3614, DOI 10.1073/pnas.78.6.3614; ZAHURAK M, 1996, J NATL CANCER I, V88, P1580; ZHANG WW, 1995, HUM GENE THER, V6, P155, DOI 10.1089/hum.1995.6.2-155	31	6	8	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					617	621		10.1038/sj.onc.1202295	http://dx.doi.org/10.1038/sj.onc.1202295			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989811				2022-12-28	WOS:000078394400006
J	Porte, D; Tuckermann, J; Becker, M; Baumann, B; Teurich, S; Higgins, T; Owen, MJ; Schorpp-Kistner, M; Angel, P				Porte, D; Tuckermann, J; Becker, M; Baumann, B; Teurich, S; Higgins, T; Owen, MJ; Schorpp-Kistner, M; Angel, P			Both AP-1 and Cbfa1-like factors are required for the induction of interstitial collagenase by parathyroid hormone	ONCOGENE			English	Article						AP-1; collagenase; parathyroid hormone; osteoblast; Cbfa; bone development; Runt	ACUTE MYELOID-LEUKEMIA; HUMAN MATRIX METALLOPROTEINASE; RAT OSTEOBLASTIC CELLS; C-FOS GENE; TARGETED DISRUPTION; POLYOMAVIRUS ENHANCER; MOLECULAR-CLONING; PROMOTER ACTIVITY; OSTEOCALCIN GENE; MESSENGER-RNA	PTH is a major regulator of calcium homeostasis by mobilizing calcium through bone resorption, We show that the expression of collagenase-3 (MMP-13), a member of the family of matrix metalloproteinases, required for the cleavage of collagens in the bone, is increased upon PTH injection in mice. A cis-acting element in the collagenase-3 promoter was identified which, together with AP-1, is required for induction by PTH, This element contains CCACA motifs which are required for binding of the 65 kDa osteoblast-specific splice variant of Cbfa1. Introduction of mutations in this binding site that interfere with protein interaction also eliminates PTH inducibilty and transactivation by Cbfa/Runt proteins, While DNA binding activity of AP-1 is increased upon PTH treatment, high basal level of Cbfa/ Runt binding activity is detectable in untreated cells which is not further increased by PTH, suggesting that AP-1 and Cbfa1 contribute to transcriptional activation through different mechanisms, In agreement with the critical role of both proteins defined in tissue culture cells, expression of collagenase-3 is reduced in mice lacking c-fos and is completely absent in cbfa1(-/-)embryos. These data provide the first evidence for a critical role of Cbfa1, a major regulator of bone de development, in PTH-dependent processes such as bone resorption.	Deutsch Krebsforschungszentrum, Abt Signaltransdukt & Wachstumskontrolle, D-69120 Heidelberg, Germany; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; Imperial Canc Res Fund, Lincolns Inn Fields, London WC2A 3PX, England	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Karlsruhe Institute of Technology; Cancer Research UK	Angel, P (corresponding author), Deutsch Krebsforschungszentrum, Abt Signaltransdukt & Wachstumskontrolle, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Piris, Miguel A/AAP-1445-2020	Piris, Miguel A/0000-0001-5839-3634				ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V124, P1107, DOI 10.1210/endo-124-3-1107; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAE SC, 1993, ONCOGENE, V8, P809; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOHISY JC, 1992, MOL ENDOCRINOL, V6, P1834, DOI 10.1210/me.6.11.1834; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Evans DB, 1996, J BONE MINER RES, V11, P1066; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; GACK S, 1994, J BIOL CHEM, V269, P10363; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HEATH JK, 1984, BIOCHIM BIOPHYS ACTA, V802, P151, DOI 10.1016/0304-4165(84)90046-1; HENRIET P, 1992, FEBS LETT, V310, P175, DOI 10.1016/0014-5793(92)81323-E; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kronenberg Henry M., 1996, P68; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MATTOT V, 1995, J CELL SCI, V108, P529; MINDEN A, 1997, BIOCHIM BIOPHYS ACTA, V1333, pF85; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pearman AT, 1996, J BIOL CHEM, V271, P25715, DOI 10.1074/jbc.271.41.25715; Pendas AM, 1997, J BIOL CHEM, V272, P4281, DOI 10.1074/jbc.272.7.4281; Pollock JH, 1996, J BONE MINER RES, V11, P754; QUINN CO, 1990, J BIOL CHEM, V265, P22342; Rajakumar RA, 1996, MOL ENDOCRINOL, V10, P867, DOI 10.1210/me.10.7.867; SATAKE M, 1988, ONCOGENE, V3, P69; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SCHORPP M, 1995, BIOCHEM J, V308, P211, DOI 10.1042/bj3080211; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SCOTT DK, 1992, MOL ENDOCRINOL, V6, P2153, DOI 10.1210/me.6.12.2153; SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Yang RJ, 1996, J BIOL CHEM, V271, P29839, DOI 10.1074/jbc.271.47.29839; Yu XP, 1997, ENDOCRINOLOGY, V138, P3085, DOI 10.1210/en.138.8.3085; Zaiman AL, 1996, J VIROL, V70, P5618, DOI 10.1128/JVI.70.8.5618-5629.1996	54	131	133	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					667	678		10.1038/sj.onc.1202333	http://dx.doi.org/10.1038/sj.onc.1202333			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989817				2022-12-28	WOS:000078394400012
J	Ye, DW; Mendelsohn, J; Fan, Z				Ye, DW; Mendelsohn, J; Fan, Z			Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225	ONCOGENE			English	Article						EGF receptor; HER2; mAb; p27(Kip1); CDK; cell cycle	MONOCLONAL-ANTIBODY; BREAST-CANCER; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; CARCINOMA-CELLS; OVARIAN-CANCER; G(1) ARREST; NEU; HETERODIMERIZATION; P27(KIP1)	Overexpression of epidermal growth factor (EGF) receptor and HER2 (p185(neu)) may both contribute to the growth of human cancers. A humanized anti-HER2 monoclonal antibody (mAb) 4D5 and a human-mouse chimeric anti-EGF receptor mAb C225 are currently being investigated in clinical trials for their anti-tumor activities. In the present study, we have examined the effect of concurrent treatment of OVCA 420 human ovarian cancer cells with mAb C225 and mAb 4D5, Exposure of OVCA420 cells to saturating concentrations of C225 (20 nM) for 7 days resulted in 40-50% growth inhibition, and exposure to 20 nM mAb 4D5 also resulted in 30-40% growth inhibition. The growth inhibition of OVCA420 cells by mAb C225 or 4D5 was associated with an increased G1 cell population; an increased level of a cyclin-dependent kinase (CDK) inhibitor p27(Kip1) with increased association of p27(Kip1) with CDK2, CDK4 and CDK6; and decreased activities of these CDKs, Combination treatment with concurrent exposure to mAbs C225 and 4D5 resulted in additive anti-proliferative effects on these cells, which was accompanied by enhanced G1 cell distribution, a greater increase in the levels of p27(Kip1) and a greater decrease in the activities of CDK kinases, The anti-proliferative effects and related changes in cell cycle regulators induced by mAb 4D5, mAb C225 or the combination of the two mAbs could be reversed by concurrent exposure to exogenous EGF, Our data suggest the potential fruitful cooperation of anti-EGF receptor mAb and anti-HER2 mAb in the treatment of human cancers stimulated by EGF receptor and HER2 signals.	Univ Texas, MD Anderson Cancer Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Cancer Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA68425, CA42060] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA042060, R01CA042060, P50CA068425] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BOS M, 1996, P AN M AM SOC CLIN, V15, P443; Chou J. L., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P10; COBLEIGH MA, 1998, P AN M AM SOC CLIN, V17, pA97; DIVGI CR, 1991, J NATL CANCER I, V83, P97, DOI 10.1093/jnci/83.2.97; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; FALCEY J, 1997, P AN M AM SOC CLIN, V16, pA383; Fan Z, 1997, CLIN CANCER RES, V3, P1943; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FAN Z, 1994, J BIOL CHEM, V269, P27595; FAN Z, 1993, J BIOL CHEM, V268, P21073; Fan Zhen, 1998, Current Opinion in Oncology, V10, P67, DOI 10.1097/00001622-199801000-00011; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Goldstein NI, 1995, CLIN CANCER RES, V1, P1311; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; JARDINES L, 1993, PATHOBIOLOGY, V61, P268, DOI 10.1159/000163805; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; Mendelsohn J, 1990, Semin Cancer Biol, V1, P339; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PEGRAM M, 1995, P AN M AM SOC CLIN, V14, P106; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; Peng D, 1996, CANCER RES, V56, P3666; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Prewett M, 1996, J IMMUNOTHER, V19, P419, DOI 10.1097/00002371-199611000-00006; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHOTT S, 1990, STAT HLTH PROFESSION, P151; SLAMON D, 1998, P AN M AM SOC CLIN, V17, pA98; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; Wu XP, 1996, ONCOGENE, V12, P1397	39	123	155	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					731	738		10.1038/sj.onc.1202319	http://dx.doi.org/10.1038/sj.onc.1202319			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989823				2022-12-28	WOS:000078394400018
J	Biswas, T; Ramana, CV; Srinivasan, G; Boldogh, I; Hazra, TK; Chen, ZP; Tano, K; Thompson, EB; Mitra, S				Biswas, T; Ramana, CV; Srinivasan, G; Boldogh, I; Hazra, TK; Chen, ZP; Tano, K; Thompson, EB; Mitra, S			Activation of human O-6-methylguanine-DNA methyltransferase gene by glucocorticoid hormone	ONCOGENE			English	Article						CNU; DNA damage; DNA repair; glucocorticoid; gene regulation	O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE ACTIVITY; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; PROGESTERONE-RECEPTOR; NEGATIVE REGULATION; NUCLEAR RECEPTORS; MAMMALIAN-CELLS; CROSS-LINKING; TUMOR CELLS; CPG ISLAND; DNA	O-6-methylguanine-DNA methyltransferase (MGMT), a ubiquitous DNA repair protein, removes the mutagenic DNA adduct O-6-alkylguanine, which is synthesized both endogenously and after exposure to alkylnitrosamines and alkylating antitumor drugs such as 2-chloroethyl-N-nitrosourea (CNU), The MGMT gene is highly regulated in mammalian cells and its overexpression, observed in many types of tumor cells, is often associated with cellular resistance to CNU, Dexamethasone, a synthetic glucocorticoid hormone, was found to increase MGMT expression in HeLa S3 cells, concomitant with their increased resistance to CNU, Two putative glucocorticoid responsive elements (GREs) were identified in the human MGMT (hMGMT) promoter. Transient expression of the luciferase reporter gene driven by an hMGMT promoter fragment containing these GREs was activated by dexamethasone. DNase I footprinting assays demonstrated the binding of glucocorticoid receptor to these sequences. In vitro transcription experiment showed that these DNA sequences are functional in glucocorticoid receptor signal-mediated activation of transcription. These results suggest glucocorticoid-mediated induction of the MGMT gene contributes to high level expression of MGMT.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Immunol & Microbiol, Galveston, TX 77555 USA; Kyoto Univ, Reactor Inst, Osaka 59004, Japan	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Kyoto University	Mitra, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA.			chilakamarti, ramana/0000-0002-5153-8252	NATIONAL CANCER INSTITUTE [R01CA031721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007572] Funding Source: NIH RePORTER; NCI NIH HHS [CA 31721] Funding Source: Medline; NIEHS NIH HHS [ES 07572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAGCHI MK, 1990, J BIOL CHEM, V265, P5129; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOWMAN LH, 1981, NUCLEIC ACIDS RES, V9, P4951, DOI 10.1093/nar/9.19.4951; BRENT TP, 1985, P NATL ACAD SCI USA, V82, P2985, DOI 10.1073/pnas.82.9.2985; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAMBROSIO SM, 1987, CANCER RES, V47, P51; DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EADIE JS, 1984, NATURE, V308, P201, DOI 10.1038/308201a0; ERICKSON LC, 1980, NATURE, V288, P727, DOI 10.1038/288727a0; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; FRITZ G, 1991, MOL CELL BIOL, V11, P4660, DOI 10.1128/MCB.11.9.4660; Grombacher T, 1996, CARCINOGENESIS, V17, P2329, DOI 10.1093/carcin/17.11.2329; HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P6163, DOI 10.1093/nar/19.22.6163; Heiss JD, 1996, J CLIN INVEST, V98, P1400, DOI 10.1172/JCI118927; Izumi T, 1996, BIOCHEMISTRY-US, V35, P14679, DOI 10.1021/bi961995u; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; Kokkinakis DM, 1997, CANCER RES, V57, P5360; LEBLANC B, 1994, DNA PROTEIN INTERACT, P1; Levin Victor A., 1997, P2022; Liu LL, 1996, CANCER RES, V56, P1880; LUDLUM DB, 1990, MUTAT RES, V233, P117, DOI 10.1016/0027-5107(90)90156-X; McEwan IJ, 1995, MUTAT RES-FUND MOL M, V333, P15, DOI 10.1016/0027-5107(95)00126-3; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; MYRNES B, 1984, CARCINOGENESIS, V5, P1061, DOI 10.1093/carcin/5.8.1061; NAKATSU Y, 1993, MUTAT RES, V293, P119, DOI 10.1016/0921-8777(93)90063-M; Patel SA, 1997, MOL CELL BIOL, V17, P5813, DOI 10.1128/MCB.17.10.5813; PEGG AE, 1995, BIOCHEM PHARMACOL, V50, P1141, DOI 10.1016/0006-2952(95)00249-Y; PEGG AE, 1990, CANCER RES, V50, P6119; PIEPER RO, 1990, CANCER COMMUN, V2, P13, DOI 10.3727/095535490820874812; ROBINS P, 1983, NUCLEIC ACIDS RES, V11, P7743, DOI 10.1093/nar/11.22.7743; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SAGHER D, 1989, CANCER RES, V49, P5339; SALMON SE, 1989, CANC PRINCIPLES PRAC, P2344; SCHOLD SC, 1989, J NEUROSURG, V70, P573, DOI 10.3171/jns.1989.70.4.0573; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Singer B., 1983, MOL BIOL MUTAGENS CA; SNOW ET, 1984, J BIOL CHEM, V259, P8095; TANO K, 1990, P NATL ACAD SCI USA, V87, P686, DOI 10.1073/pnas.87.2.686; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TSAI SY, 1990, J BIOL CHEM, V265, P17055; WASHINGTON WJ, 1989, MECH AGEING DEV, V48, P43, DOI 10.1016/0047-6374(89)90024-9; Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612; YAROSH DB, 1984, MUTAT RES, V131, P27, DOI 10.1016/0167-8817(84)90044-0; YUNG W K A, 1990, Current Opinion in Oncology, V2, P673	46	66	69	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					525	532		10.1038/sj.onc.1202320	http://dx.doi.org/10.1038/sj.onc.1202320			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927209				2022-12-28	WOS:000078166500025
J	Grand, RJA; Turnell, AS; Mason, GGF; Wang, WL; Milner, AE; Mymryk, JS; Rookes, SM; Rivett, AJ; Gallimore, PH				Grand, RJA; Turnell, AS; Mason, GGF; Wang, WL; Milner, AE; Mymryk, JS; Rookes, SM; Rivett, AJ; Gallimore, PH			Adenovirus early region 1A protein binds to mammalian SUG1-a regulatory component of the proteasome	ONCOGENE			English	Article						adenovirus; adenovirus 12; E1A; SUG1; proteasome; Trip 1	WILD-TYPE P53; E1A PROTEIN; TRANSCRIPTIONAL MEDIATOR; TUMOR-SUPPRESSOR; EPITHELIAL-CELLS; 26-S PROTEASOME; DNA-SYNTHESIS; ACTIVATION; APOPTOSIS; SUBUNIT	Adenovirus early region 1A (Ad E1A) is a multifunctional protein which is essential for adenovirus-mediated transformation and oncogenesis, Whilst E1A is generally considered to exert its influence on recipient cells through regulation of transcription it also increases the le, el of cellular p53 by increasing the protein half-life. With this in, view, we have investigated the relationship of Ad E1A to the proteasome, which is normally responsible for degradation of p53, Here we have shown that both Ad5 and Ad12 EIA 12S and 13S proteins can be co-immunoprecipitated with proteasomes and that the larger Ad12 E1A protein binds strongly to at least three components of the 26S but not 20S proteasome, One of these interacting species has been identified as mammalian SUG1, a proteasome regulatory component which also plays a role in the cell as a mediator of transcription, In vitro assays have demonstrated a direct interaction between Ad12 E1A 13S protein and mouse SUG1, Following infection of human cells with Ad5 wt and Ad5 mutants with lesions in the E1A gene it has been shown that human SUG1 can be co-immunoprecipitated with full-length E1A and with E1A carrying a deletion in conserved region 1 which is the region considered to be responsible for increased expression of p53, We have concluded therefore that Ad E1A binds strongly to SUG1 but that this interaction is not responsible for inhibition of proteasome activity, This is consistent with the observation that purified Ad12 E1A inhibits the activity of the purified 20S but not 26S proteasomes, We have also demonstrated that SUG1 can be co-immunoprecipitated with SV40 T and therefore,ve suggest that this may represent a common interaction of transforming proteins of DNA tumour viruses.	Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England; Univ Western Ontario, Dept Oncol, London, ON N6A 4L6, Canada	University of Birmingham; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; University of Bristol; Western University (University of Western Ontario)	Grand, RJA (corresponding author), Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAYLEY ST, 1994, INT J ONCOL, V5, P425; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; BOULLATA IJ, 1991, MUSLIM WORLD, V81, P299; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fraser RA, 1997, J BIOL CHEM, V272, P7122, DOI 10.1074/jbc.272.11.7122; GALLIMORE PH, 1985, CANCER RES, V45, P2670; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; Grand RJA, 1998, VIROLOGY, V244, P330, DOI 10.1006/viro.1998.9102; Grand RJA, 1998, VIROLOGY, V244, P230, DOI 10.1006/viro.1998.9081; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Grand RJA, 1996, VIROLOGY, V218, P23, DOI 10.1006/viro.1996.0162; GRAND RJA, 1984, J GEN VIROL, V65, P2149, DOI 10.1099/0022-1317-65-12-2149; GRAND RJA, 1993, VIROLOGY, V193, P579, DOI 10.1006/viro.1993.1166; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; JONES N, 1995, CURR TOP MICROBIOL, V199, P59; KRISTENSEN P, 1994, BIOCHEM BIOPH RES CO, V205, P1785, DOI 10.1006/bbrc.1994.2876; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MARUYAMA K, 1987, ONCOGENE, V1, P361; MASON GGF, 1998, IN PRESS FEBS LETT; MORAN E, 1994, SEMIN VIROL, V5, P327, DOI 10.1006/smvy.1994.1037; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MYMRYK JS, 1993, J GEN VIROL, V74, P2131, DOI 10.1099/0022-1317-74-10-2131; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; PARASKEVA C, 1982, J GEN VIROL, V58, P73, DOI 10.1099/0022-1317-58-1-73; PETERS JM, 1994, J BIOL CHEM, V269, P7709; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reidlinger J, 1997, J BIOL CHEM, V272, P24899, DOI 10.1074/jbc.272.40.24899; RIVETT AJ, 1994, METHOD ENZYMOL, V244, P331; RIVETT AJ, 1993, BIOCHEM J, V291, P1; RIVETT AJ, 1991, BIOCHEM J, V278, P171, DOI 10.1042/bj2780171; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Seeger M, 1997, J BIOL CHEM, V272, P8145, DOI 10.1074/jbc.272.13.8145; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; VOMBAUR E, 1995, EMBO J, V15, P110; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WILLIAMS J, 1995, CURR TOP MICROBIOL, V199, P149; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	53	33	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					449	458		10.1038/sj.onc.1202304	http://dx.doi.org/10.1038/sj.onc.1202304			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927201				2022-12-28	WOS:000078166500017
J	Krynska, B; Otte, J; Franks, R; Khalili, K; Croul, S				Krynska, B; Otte, J; Franks, R; Khalili, K; Croul, S			Human ubiquitous JCV(CY) T-antigen gene induces brain tumors in experimental animals	ONCOGENE			English	Article						human virus; brain tumors; transgenic mice	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; JC VIRUS-DNA; HUMAN NEUROTROPIC POLYOMAVIRUS; HUMAN PAPOVAVIRUS JC; TRANSGENIC MICE; EARLY PROTEIN; BK-VIRUS; TISSUE; URINE; EXPRESSION	JCV is a papovavirus which is widespread in the human population. The prototype Mad-1 variant of JCV induces a fatal demyelinating disease of the central nervous system (CNS) called Progressive Multifocal Leukoencephalopathy (PML) in immunosuppressed individuals. The unique tropism of JCV (Mad-l) to the CNS is attributed to the tissue-specific regulation of the viral early promoter which is responsible for the production of the viral regulatory protein, T-antigen, The archetype form of this virus, JCV(CY), which has been repeatedly isolated from the urine of PML and non-PML individuals, is distinct from JCV(Mad-1) in the structural organization of the regulatory sequence. To characterize the tissue specific expression of JCV(CY) and to investigate its potential in inducing disease, transgenic mice containing the early region of JCV(CY) were generated. Some of these mice between 9-13 months of age exhibited signs of illness as manifested by paralysis of rear limbs, hunched posture, and poor grooming. Neuropathological examination indicated no sign of hypomyelination of the brain, but surprisingly, revealed the presence of primitive tumors originating from the cerebellum and the surrounding brain stem. The tumor masses also infiltrated the surrounding tissue. Results from RNA and protein studies revealed a high level of T-antigen mRNA expression in hindbrains of clinically normal and affected transgenic mice. However, higher levels of T-antigen RNA and protein were detected in brains of the animals exhibiting severe illness. The close resemblance of JCV(CY) induced tumor in transgenic mice to the human medulloblastoma/primitive neuroectodermal tumor (PNETs) in location, histologic appearance, and expression of marker proteins strongly suggests the utility of this novel animal model for the study of human brain tumors.	Allegheny Univ Hlth Sci, Ctr Neurovirol & Neurooncol, Philadelphia, PA 19102 USA; Univ Illinois, Coll Med, Dept Genet, Chicago, IL 60612 USA; Allegheny Univ Hlth Sci, Dept Pathol & Lab Med, Philadelphia, PA 19102 USA	Drexel University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Drexel University	Khalili, K (corresponding author), Allegheny Univ Hlth Sci, Ctr Neurovirol & Neurooncol, Broad & Vine,MS 406, Philadelphia, PA 19102 USA.			Croul, Sidney/0000-0002-2224-5485				ARTHUR RR, 1989, PROG MED VIROL, V36, P42; ARTHUR RR, 1989, J CLIN MICROBIOL, V27, P1174, DOI 10.1128/JCM.27.6.1174-1179.1989; ASTROM KE, 1958, BRAIN, V81, P93, DOI 10.1093/brain/81.1.93; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; CASTAIGNE P, 1974, REV NEUROL-FRANCE, V130, P379; COLEMAN DV, 1980, J INFECT DIS, V142, P1, DOI 10.1093/infdis/142.1.1; DORRIES K, 1994, VIROLOGY, V198, P59, DOI 10.1006/viro.1994.1008; EGAN JD, 1980, TRANSPLANTATION, V29, P84, DOI 10.1097/00007890-198001000-00021; FEIGENBAUM L, 1992, J VIROL, V66, P1176, DOI 10.1128/JVI.66.2.1176-1182.1992; Franks RR, 1996, ONCOGENE, V12, P2573; FRIDQUE RJ, 1992, MOL NEUROVIROLOGY, P25; FRISQUE RJ, 1980, J VIROL, V35, P265, DOI 10.1128/JVI.35.1.265-269.1980; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; FUNG KM, 1995, J NEUROPATH EXP NEUR, V54, P285, DOI 10.1097/00005072-199505000-00001; GARDNER SD, 1984, J CLIN PATHOL, V37, P578, DOI 10.1136/jcp.37.5.578; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; HO K, 1980, ACTA NEUROPATHOL, V52, P81, DOI 10.1007/BF00687233; ISHAQ M, 1994, P NATL ACAD SCI USA, V91, P8283, DOI 10.1073/pnas.91.17.8283; Krynska B, 1997, J CELL BIOCHEM, V67, P223, DOI 10.1002/(SICI)1097-4644(19971101)67:2<223::AID-JCB7>3.0.CO;2-Z; LIBERSKI PP, 1982, NEUROPATOL POL, V20, P3; LOEBER G, 1988, J VIROL, V62, P1730, DOI 10.1128/JVI.62.5.1730-1735.1988; Matsushima T, 1997, NEUROLOGY, V48, P279, DOI 10.1212/WNL.48.1.279; MYERS C, 1989, J VIROL, V63, P4445, DOI 10.1128/JVI.63.10.4445-4449.1989; OHASHI T, 1978, J NEUROPATH EXP NEUR, V37, P667, DOI 10.1097/00005072-197809000-00301; PADGETT BL, 1971, LANCET, V1, P1257; RAJ GV, 1995, INT J ONCOL, V7, P801; RAJ GV, 1995, VIROLOGY, V213, P283, DOI 10.1006/viro.1995.0001; Rencic A, 1996, P NATL ACAD SCI USA, V93, P7352, DOI 10.1073/pnas.93.14.7352; RHEIN GMZ, 1965, SCIENCE, V148, P1477, DOI 10.1126/science.148.3676.1477; SIMA AAF, 1983, ANN NEUROL, V14, P183, DOI 10.1002/ana.410140205; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; SURI C, 1993, J NEUROSCI, V13, P1280; TORNATORE C, 1992, ANN NEUROL, V31, P454, DOI 10.1002/ana.410310426; Vago L, 1996, J ACQ IMMUN DEF SYND, V12, P139, DOI 10.1097/00042560-199606010-00006; VARAKIS J, 1978, CANCER RES, V38, P1718; WALKER DL, 1973, SCIENCE, V181, P674, DOI 10.1126/science.181.4100.674; WEINER LP, 1972, NEW ENGL J MED, V286, P385, DOI 10.1056/NEJM197202242860801; WHITE FA, 1992, J VIROL, V66, P5726, DOI 10.1128/JVI.66.10.5726-5734.1992; YOGO Y, 1991, J VIROL, V65, P2422, DOI 10.1128/JVI.65.5.2422-2428.1991; ZURHEIN GM, 1983, POLYOMAVIRUSES HUMAN, P205; ZURHEIN GM, 1987, CANC CAMPAIGN EXPT N, V10, P19; ZURHEIN GM, 1975, P 7 INT C NEUR, V1, P479	43	85	89	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					39	46		10.1038/sj.onc.1202278	http://dx.doi.org/10.1038/sj.onc.1202278			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926918	Bronze			2022-12-28	WOS:000078166000005
J	Nevels, M; Spruss, T; Wolf, H; Dobner, T				Nevels, M; Spruss, T; Wolf, H; Dobner, T			The adenovirus E4orf6 protein contributes to malignant transformation by antagonizing E1A-induced accumulation of the tumor suppressor protein p53	ONCOGENE			English	Article						DNA tumor virus; viral oncogene	TRANSCRIPTIONAL ACTIVATION; 55-KILODALTON PROTEIN; MONOCLONAL-ANTIBODIES; INFECTED-CELLS; E1B PROTEINS; 5 DNA; APOPTOSIS; GENE; BINDING; ANTIGEN	The adenovirus type 5 (Ad5) E4orf6 protein promotes focus formation of primary baby rat kidney (BRK) cells in cooperation with Ad5 E1 proteins. This activity is most likely related to the ability of the E4orf6 protein to bind to p53 and modulate its tumor suppressor functions. In this study we report that transformed BRK cells that stably express E40rf6 in addition to E1A and E1B (ABS cells) displayed multiple additional properties commonly associated with a high grade of oncogenic transformation compared to cells expressing only E1A and E1B (AB cells). These properties included morphological alterations, markedly enhanced growth rates and growth to much higher saturation densities. Following injection into nude mice ABS-derived tumors exhibited accelerated growth and, based on histopathological criteria, proofed to be much more malignant compared to tumors generated by AB cells. Interestingly, these highly transformed properties of ABS cells correlated with a dramatic reduction of p53 steady-state levels which inversely correlated with E40rf6 expression. From these results we conclude that expression of the Ad5 E40rf6 protein (i) confers additional transformed in vitro properties to primary rat cells expressing the Ad5 Fl proteins, and (ii) increases the tumorigenic and malignant potential of these cells in vivo. Our data suggest that the Ad5 E40rf6 protein enhances the intrinsic ability of E1-transformed rat cells to grow in a neoplastic state by completely inactivating p53 tumor suppressor function in combination with the E1A and E1B proteins.	Univ Regensburg, Inst Med Mikrobiol & Hyg, D-93053 Regensburg, Germany	University of Regensburg	Dobner, T (corresponding author), Univ Regensburg, Inst Med Mikrobiol & Hyg, D-93053 Regensburg, Germany.		Nevels, Michael M/J-4783-2014	Nevels, Michael M/0000-0002-7115-407X				BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BERNARDS R, 1986, VIROLOGY, V150, P126, DOI 10.1016/0042-6822(86)90272-2; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1984, ADENOVIRUSES, P339; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Logan J, 1984, CANCER CELL, V2, P527; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MCLORIE W, 1991, J GEN VIROL, V72, P1467, DOI 10.1099/0022-1317-72-6-1467; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; MORAN E, 1994, SEMIN VIROL, V5, P327, DOI 10.1006/smvy.1994.1037; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; NEVINS JR, 1996, FIELDS VIROLOGY, V1, P301; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Rubenwolf S, 1997, J VIROL, V71, P1115, DOI 10.1128/JVI.71.2.1115-1123.1997; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHENK T, 1996, FIELDS VIROLOGY, V2, P2111; SHIROKI K, 1981, J VIROL, V38, P1048, DOI 10.1128/JVI.38.3.1048-1054.1981; Spruss T, 1996, CONTR ONCOL, V51, P12; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TOOZE J, 1981, COLD SPRING HARBOR, P943; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; WHITE E, 1994, SEMIN VIROL, V5, P341, DOI 10.1006/smvy.1994.1038; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAJDEL MEB, 1988, ONCOGENE, V2, P579; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0	55	39	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					9	17		10.1038/sj.onc.1202284	http://dx.doi.org/10.1038/sj.onc.1202284			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926915				2022-12-28	WOS:000078166000002
J	Bergmann, A; Agapite, J; Steller, H				Bergmann, A; Agapite, J; Steller, H			Mechanisms and control of programmed cell death in invertebrates	ONCOGENE			English	Review						C-elegans; Drosophila; apoptosis; programmed cell death; ced genes	APOPTOSIS INHIBITORY PROTEIN; DROSOPHILA EYE DEVELOPMENT; CAENORHABDITIS-ELEGANS; CYTOCHROME-C; TYROSINE KINASE; GENETIC-CONTROL; NERVOUS-SYSTEM; BCL-2; REAPER; CED-4	Apoptosis is a morphologically distinct form of programmed cell death that plays important roles in development, tissue homeostasis and a wide variety of diseases, including cancer, AIDS, stroke, myopathies and various neurodegenerative disorders (see Thompson (1995) for review). It is now clear that apoptosis occurs by activating an intrinsic cell suicide program which is constitutively expressed in most animal cells, and that key components of this program have been conserved in evolution from worms to insects to man. Genetic studies of programmed cell death in experimentally highly accessible invertebrate model systems have provided important clues about the molecular nature of the death program, and the intracellular mechanisms that control its activation. This review summarizes some of the key findings in this area, but also touches on some of the many unresolved questions and challenges that remain.	MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Steller, H (corresponding author), MIT, Howard Hughes Med Inst, Dept Biol, 77 Massachusetts ave,Bldg 68-430, Cambridge, MA 02139 USA.							ABRAMS JM, 1993, DEVELOPMENT, V117, P29; AGAPITE J, 1997, MOL CELLULAR APPROAC, P264; Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BAKSHI A, 1985, CELL, V41, P889; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BOS JL, 1989, CANCER RES, V49, P4682; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CAMPOS AR, 1992, DEVELOPMENT, V114, P355; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; Chen P, 1996, J BIOL CHEM, V271, P25735, DOI 10.1074/jbc.271.42.25735; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Davidson FF, 1998, NATURE, V391, P587, DOI 10.1038/35385; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dickson BJ, 1996, GENETICS, V142, P163; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, DEVELOPMENT, V112, P591; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Evans EK, 1997, EMBO J, V16, P7372, DOI 10.1093/emboj/16.24.7372; Foley K, 1998, DEVELOPMENT, V125, P1075; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; Gregory-Evans K, 1998, TRENDS GENET, V14, P103, DOI 10.1016/S0168-9525(98)01402-4; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOFFMAN B, 1994, ONCOGENE, V9, P1807; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jiang CG, 1997, DEVELOPMENT, V124, P4673; Karim FD, 1996, GENETICS, V143, P315; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KNOWLES BA, 1994, TRENDS GENET, V10, P235, DOI 10.1016/0168-9525(94)90170-8; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KURADA P, 1995, NEURON, V14, P571, DOI 10.1016/0896-6273(95)90313-5; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; LAMBLIN AF, 1998, IN PRESS; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; MacCorkle RA, 1998, P NATL ACAD SCI USA, V95, P3655, DOI 10.1073/pnas.95.7.3655; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; McCall K, 1998, SCIENCE, V279, P230, DOI 10.1126/science.279.5348.230; McCall K, 1997, TRENDS GENET, V13, P222, DOI 10.1016/S0168-9525(97)01126-8; McCarthy JV, 1998, J BIOL CHEM, V273, P24009, DOI 10.1074/jbc.273.37.24009; McNabb SL, 1997, NEURON, V19, P813, DOI 10.1016/S0896-6273(00)80963-0; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; Miller DT, 1998, DEVELOPMENT, V125, P2327; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nordstrom W, 1996, DEV BIOL, V180, P213, DOI 10.1006/dbio.1996.0296; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Ottilie S, 1997, CELL DEATH DIFFER, V4, P526, DOI 10.1038/sj.cdd.4400288; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Robinow S, 1997, DEV BIOL, V190, P206, DOI 10.1006/dbio.1997.8696; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sawamoto K, 1998, CELL DEATH DIFFER, V5, P262, DOI 10.1038/sj.cdd.4400342; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SELLECK SB, 1991, NEURON, V6, P83, DOI 10.1016/0896-6273(91)90124-I; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STELLER H, 1987, CELL, V50, P1139, DOI 10.1016/0092-8674(87)90180-2; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STELLER H, 1994, NEURON, V13, P1269, DOI 10.1016/0896-6273(94)90413-8; Steller H, 1998, P NATL ACAD SCI USA, V95, P5421, DOI 10.1073/pnas.95.10.5421; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Thress K, 1998, EMBO J, V17, P6135, DOI 10.1093/emboj/17.21.6135; TRUMAN JW, 1992, J NEUROBIOL, V23, P1295, DOI 10.1002/neu.480230917; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Vucic D, 1997, MOL CELL BIOL, V17, P667, DOI 10.1128/MCB.17.2.667; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhou L, 1997, P NATL ACAD SCI USA, V94, P5131, DOI 10.1073/pnas.94.10.5131; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	130	106	110	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 24	1998	17	25					3215	3223		10.1038/sj.onc.1202586	http://dx.doi.org/10.1038/sj.onc.1202586			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916984				2022-12-28	WOS:000078048200003
J	Muschel, RJ; Soto, DE; McKenna, WG; Bernhard, EJ				Muschel, RJ; Soto, DE; McKenna, WG; Bernhard, EJ			Radiosensitization and apoptosis	ONCOGENE			English	Review						radiation; X-rays; cell cycle; radiosensitization; apoptosis	RADIATION-INDUCED APOPTOSIS; WILD-TYPE P53; TUMOR-CELL LINES; FARNESYL TRANSFERASE INHIBITORS; P53-DEPENDENT G(1) ARREST; IRRADIATED MURINE TUMORS; HUMAN-SKIN FIBROBLASTS; S-PHASE PROGRESSION; HELA-CELLS; H-RAS	The toxicity of radiation to living tissues was discovered soon after the discovery of radioactivity itself and this toxicity is the basis for cancer therapy with radiation. Although this mode of therapy is often effective, its success is far from assured. One major difficulty in the implementation of radiotherapy is that normal tissues are also sensitive to killing by radiation so that treatment is often limited by the tolerance of normal tissues for radiation, Thus methods that sensitize tumor cells while sparing normal tissues could potentially lead to greater success with radiation as a therapy. Oncogenes are frequently altered in tumors, but are not in normal tissue making them potential targets for altering radiosensitivity and apoptosis in tumors.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Muschel, RJ (corresponding author), Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.		BERNHARD, ERIC/HIU-0025-2022					Badie B, 1998, J NEURO-ONCOL, V37, P217, DOI 10.1023/A:1005924925149; Barratt RA, 1998, CANCER RES, V58, P2639; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Barth H, 1996, CANCER RES, V56, P2268; BAYREUTHER K, 1988, P NATL ACAD SCI USA, V85, P5112, DOI 10.1073/pnas.85.14.5112; Bernhard EJ, 1996, CANCER RES, V56, P1727; Bernhard EJ, 1996, INT J RADIAT BIOL, V69, P575, DOI 10.1080/095530096145580; Bernhard EJ, 1998, CANCER RES, V58, P1754; Bowen C, 1998, CANCER RES, V58, P3275; Bristow RG, 1996, RADIOTHER ONCOL, V40, P197, DOI 10.1016/0167-8140(96)01806-3; Bristow RG, 1998, ONCOGENE, V16, P1789, DOI 10.1038/sj.onc.1201935; BUSSE PM, 1978, RADIAT RES, V76, P292, DOI 10.2307/3574780; Chang EH, 1997, ARCH OTOLARYNGOL, V123, P507; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; DAVIS MA, 1995, INT J RADIAT BIOL, V67, P509, DOI 10.1080/09553009514550621; DeWeese TL, 1997, INT J RADIAT ONCOL, V37, P145, DOI 10.1016/S0360-3016(96)00448-8; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; FAN SJ, 1995, CANCER RES, V55, P1649; Gallardo D, 1996, CANCER RES, V56, P4891; Gelb MH, 1998, CURR OPIN CHEM BIOL, V2, P40, DOI 10.1016/S1367-5931(98)80034-3; Geng L, 1998, RADIAT RES, V150, P31, DOI 10.2307/3579642; Gibbs JB, 1997, CURR OPIN CHEM BIOL, V1, P197, DOI 10.1016/S1367-5931(97)80010-5; Gjerset RA, 1995, MOL CARCINOGEN, V14, P275, DOI 10.1002/mc.2940140408; Gregoire V, 1997, BRIT J CANCER, V76, P1315, DOI 10.1038/bjc.1997.554; Guo M, 1997, RADIAT RES, V147, P295, DOI 10.2307/3579336; HaasKogan DA, 1996, INT J RADIAT ONCOL, V36, P95, DOI 10.1016/S0360-3016(96)00244-1; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HarmsRingdahl M, 1996, MUTAT RES-REV GENET, V366, P171, DOI 10.1016/S0165-1110(96)90038-X; Hasegawa M, 1997, RADIAT RES, V147, P457, DOI 10.2307/3579503; HENDRY JH, 1982, INT J RADIAT BIOL, V42, P611, DOI 10.1080/09553008214551591; Hendry JH, 1996, INT J RADIAT BIOL, V70, P677, DOI 10.1080/095530096144563; Hendry JH, 1997, RADIAT RES, V148, P254, DOI 10.2307/3579610; HURWITZ C, 1969, BIOPHYS J, V9, P607, DOI 10.1016/S0006-3495(69)86407-6; IJIRI K, 1983, BRIT J CANCER, V47, P175, DOI 10.1038/bjc.1983.25; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; LANG FF, 1963, J NEUROSURG, V125, P98; Lara PC, 1996, INT J RADIAT BIOL, V70, P683, DOI 10.1080/095530096144572; Lawrence TS, 1996, INT J RADIAT BIOL, V70, P273, DOI 10.1080/095530096145003; Lawrence TS, 1996, CANCER RES, V56, P3203; Lebowitz PF, 1997, CANCER RES, V57, P708; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; LING CC, 1989, RADIAT RES, V120, P267, DOI 10.2307/3577713; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; McGinn CJ, 1996, J NATL CANCER I, V88, P1193, DOI 10.1093/jnci/88.17.1193; MCKENNA WG, 1990, CANCER RES, V50, P97; McKenna WG, 1996, ONCOGENE, V12, P237; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Meyn R E, 1997, Oncology (Williston Park), V11, P349; Meyn R.E., 1997, ONCOLOGY WILLISTON P, V11, P356; Meyn R.E., 1997, ONCOLOGY WILLISTON P, V11, P361; Meyn R.E., 1997, ONCOLOGY WILLISTON P, V11, P365; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; Milner AE, 1997, ONCOGENE, V15, P1815, DOI 10.1038/sj.onc.1201355; O'Rourke DM, 1998, P NATL ACAD SCI USA, V95, P10842, DOI 10.1073/pnas.95.18.10842; Ogawa N, 1997, INT J CANCER, V73, P367, DOI 10.1002/(SICI)1097-0215(19971104)73:3<367::AID-IJC11>3.0.CO;2-A; OHYAMA H, 1985, RADIAT RES, V101, P123, DOI 10.2307/3576309; Pirollo KF, 1997, ONCOGENE, V14, P1735, DOI 10.1038/sj.onc.1201116; POWELL SN, 1995, CANCER RES, V55, P1643; Prendergast GC, 1996, CANCER RES, V56, P2626; RADFORD IR, 1991, INT J RADIAT BIOL, V59, P1353, DOI 10.1080/09553009114551221; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P217, DOI 10.1080/09553009414550251; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Rodemann HP, 1996, KIDNEY INT, V49, pS32; RODEMANN HP, 1991, SCANNING MICROSCOPY, V5, P1135; RODEMANN HP, 1991, SCANNING MICROSCOPY, V5, P1142; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Rupnow BA, 1998, CANCER RES, V58, P1779; RUSSELL KJ, 1995, CANCER RES, V55, P1639; SAMID D, 1991, RADIAT RES, V126, P244, DOI 10.2307/3577825; Sebti Said, 1997, Current Opinion in Oncology, V9, P557, DOI 10.1097/00001622-199711000-00011; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Shewach DS, 1996, INVEST NEW DRUG, V14, P257, DOI 10.1007/BF00194528; SINCLAIR WK, 1964, RADIAT RES, V21, P584, DOI 10.2307/3571653; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; STEPHENS LC, 1993, RADIAT RES, V135, P75, DOI 10.2307/3578399; STEPHENS LC, 1991, RADIAT RES, V127, P308, DOI 10.2307/3577946; Sun JZ, 1998, ONCOGENE, V16, P1467, DOI 10.1038/sj.onc.1201656; TAUCHI H, 1994, INT J RADIAT BIOL, V65, P449, DOI 10.1080/09553009414550521; THOMPSON LH, 1967, INT J RADIAT BIOL RE, V13, P391; THOMPSON LH, 1969, INT J RADIAT BIOL RE, V15, P347, DOI 10.1080/09553006914550571; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; TSANG NM, 1995, ONCOGENE, V10, P2403; TSANG NM, 1994, RADIAT RES, V140, P172, DOI 10.2307/3578900; VanHouten N, 1997, INT IMMUNOL, V9, P945, DOI 10.1093/intimm/9.7.945; Vidair CA, 1996, CANCER RES, V56, P4116; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Wang L, 1996, RADIAT RES, V146, P259, DOI 10.2307/3579455; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Wouters BG, 1997, CANCER RES, V57, P4703; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAMADA T, 1988, INT J RADIAT BIOL, V53, P65, DOI 10.1080/09553008814550431; YIN DX, 1995, CANCER RES, V55, P4922; Yount GL, 1996, CANCER RES, V56, P500	103	48	56	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 24	1998	17	25					3359	3363		10.1038/sj.onc.1202580	http://dx.doi.org/10.1038/sj.onc.1202580			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916998	Bronze			2022-12-28	WOS:000078048200017
J	Jeffers, M; Koochekpour, S; Fiscella, M; Sathyanarayana, BK; Vande Woude, GF				Jeffers, M; Koochekpour, S; Fiscella, M; Sathyanarayana, BK; Vande Woude, GF			Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor	ONCOGENE			English	Article						Met; oncogene; signaling	HEPATOCYTE GROWTH-FACTOR; GRB2 BINDING-SITE; SCATTER FACTOR; EPITHELIAL-CELLS; TRANSFORMING ACTIVITY; FACTOR/SCATTER FACTOR; CARBOXY-TERMINUS; PROTOONCOGENE; MUTATIONS; GENE	The Met tyrosine kinase receptor has been implicated in human cancer. Here we have examined the signaling requirements of three oncogenic forms of this molecule: wild type Met in response to ligand/autocrine stimulation, Met which has been mutationally activated, and Tpr-Met (a constitutively active truncated Met fusion protein). Previous studies have demonstrated the importance of a Grb2 binding site, and of specific tyrosine residues (i.e. Y8,9 and Y14,15) for Met function, and we have now explored the relevance of these and other sites for oncogenic Met signaling. Following substitution of various intracellular tyrosines for phenylalanine, we find that the transforming activity of each Met oncogene is dependent upon tyrosines Y8,9 and Y14,15, in addition to two novel tyrosines (Y6 and Y10) not previously implicated in Met signaling. Tyrosines Y6 and Y10 influence a variety of Met-mediated responses both in vitro (transformation, mitogenicity and invasion), and in vivo (tumorigenicity and metastasis). We also show that Tpr-Met is much more dependent on its Grb2 binding site for biological activity than are the other oncogenic forms of the Met receptor. Thus, although the three Met oncogenes examined are similar in their dependency on a number of specific tyrosines for activity, the signaling strategy employed by Tpr-Met can be differentiated from that of the other two.	NCI, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Vande Woude, GF (corresponding author), NCI, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, POB B, Ft Detrick, MD 21702 USA.			KOOCHEKPOUR, SHAHRIAR/0000-0001-6649-5788				ALBINI A, 1987, CANCER RES, V47, P3239; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; Higashio K, 1993, EXS, V65, P351; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Iwashita T, 1996, ONCOGENE, V12, P481; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, CELL GROWTH DIFFER, V7, P1805; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jeffers M, 1996, ONCOGENE, V13, P853; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; KANDA H, 1993, ONCOGENE, V8, P3047; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Sambrook J., 2002, MOL CLONING LAB MANU; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145	62	35	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2691	2700		10.1038/sj.onc.1202209	http://dx.doi.org/10.1038/sj.onc.1202209			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840933				2022-12-28	WOS:000077146700002
J	Lauper, N; Beck, ARP; Cariou, S; Richman, L; Hofmann, K; Reith, W; Slingerland, JM; Amati, B				Lauper, N; Beck, ARP; Cariou, S; Richman, L; Hofmann, K; Reith, W; Slingerland, JM; Amati, B			Cyclin E2: a novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle	ONCOGENE			English	Article						cyclin e2; cyclin E; CDK2; p27(Kip1)	DEPENDENT KINASE INHIBITOR; UBIQUITIN-PROTEASOME PATHWAY; GROWTH-FACTOR-BETA; PROTEIN-KINASE; C-MYC; P27(KIP1); ACTIVATION; ARREST; PROGRESSION; P21	We report here the cloning and characterization of human and mouse cyclin E2, which define a new subfamily within the vertebrate E-type cyclins, while all previously identified family-members belong to the cyclin El subfamily. Cyclin E2/CKD2 and cyclin E/CDK2 complexes phosphorylate histone H1 in vitro with similar specific activities and both are inhibited by p27(Kip1). Cyclin E2 mRNA levels in human cells oscillate throughout the cell cycle and peak at the G1/S boundary, in parallel with the cyclin E mRNA. In cells, cyclin E2 is complexed with CDK2, p27 and p21. Like cyclin E, cyclin E2 is an unstable protein in vivo and is stabilized by proteasome inhibitors. Cyclin E2-associated kinase activity rises in late G1 and peaks very close to cyclin E activity. In two malignantly transformed cell lines, cyclin E2 activity is sustained throughout S phase, while cyclin E activity has already declined and cyclin A activity is only beginning to rise. We speculate that cyclin E2 is not simply redundant with cyclin E, but may regulate distinct rate-limiting pathway(s) in G1-S control.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Geneva, Sch Med, CMU, Dept Genet & Microbiol, CH-1211 Geneva, Switzerland	Swiss Institute Experimental Cancer Research; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Geneva	Amati, B (corresponding author), Swiss Inst Expt Canc Res, 155 Ch Boveresses, CH-1066 Epalinges, Switzerland.		Hofmann, Kay/D-6714-2011; Amati, Bruno/AAM-3418-2020	Hofmann, Kay/0000-0002-2289-9083; Amati, Bruno/0000-0002-2958-1799				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; BRAUN K, 1998, IN PRESS ONCOGENE, V16; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hancock DC, 1998, METH MOL B, V80, P15; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lilly MA, 1996, GENE DEV, V10, P2514, DOI 10.1101/gad.10.19.2514; LUKAS J, 1994, ONCOGENE, V9, P707; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Solomon M J, 1998, Results Probl Cell Differ, V22, P79; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x	49	121	128	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2637	2643		10.1038/sj.onc.1202477	http://dx.doi.org/10.1038/sj.onc.1202477			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840927				2022-12-28	WOS:000077058900011
J	Menjo, M; Kaneko, Y; Ogata, E; Ikeda, K; Nakanishi, M				Menjo, M; Kaneko, Y; Ogata, E; Ikeda, K; Nakanishi, M			Critical role for p27(Kip1) in cell cycle arrest after androgen depletion in mouse mammary carcinoma cells (SC-3)	ONCOGENE			English	Article						androgen; cancer; endocrine therapy; cell cycle; p27(Kip1) Cdk inhibitor	HUMAN BREAST-CANCER; DEPENDENT KINASE-ACTIVITY; GROWTH-FACTOR; INHIBITOR P27(KIP1); ESTROGEN-RECEPTOR; G1 PHASE; EXPRESSION; D1; ACTIVATION; PROGRESSION	The molecular mechanisms underlying androgen-regulated cancer growth and the frequent development of refractoriness to endocrine therapy remain unknown. In this study functional and quantitative alterations in cell cycle regulators after androgen depletion were examined in androgen-dependent mouse mammary carcinoma cells (SC-3) as a model system to clarify the initial response of cancer cells to anti-androgen therapy. FAGS analysis of SC-3 cells cultured with or without 10(-7) M testosterone revealed that suppression of cell growth after hormone withdrawal was due to G1 arrest. Although cyclin D1/Cdk4 activity decreased along with a reduced level of cyclin D1 protein, this was a later event (48-72 h) than the G1 arrest (24 h). Taken together with the results that constitutive expression of cyclin D1 in SC-3 cells did not overcome the growth suppression following androgen depletion, the existence of an alternative pathway(s) causing G1 arrest was suggested. Cyclin E/Cdk2 and cyclin A/Cdk2 activities decreased significantly at 24 h without apparent changes in the amounts of Cdk2, cyclin E or cyclin A. Among various Cdk inhibitors (CKIs) examined, p27(Kip1) was upregulated at both mRNA and protein levels at 24 h after androgen depletion. In addition, immunoprecipitation-Western analysis showed that the amount of p27(Kip1) associated with Cdk2 complexes increased as early as 24 h. These results suggest that p27(Kip1) CKI is a critical target in the initial response of cancer cells to androgen depletion and plays a key role in Cdk2 inactivation through association with the kinase complex, leading to cell cycle arrest.	Natl Inst Longev Sci, Dept Geriatr Res, Aichi 4748522, Japan; Japanese Fdn Canc Res, Inst Canc, Tokyo 170, Japan	Japanese Foundation for Cancer Research	Nakanishi, M (corresponding author), Natl Inst Longev Sci, Dept Geriatr Res, 36-3 Gengo, Aichi 4748522, Japan.							Altucci L, 1996, ONCOGENE, V12, P2315; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Goldhirsch A, 1996, SEMIN ONCOL, V23, P494; HENDERSON BE, 1993, SCIENCE, V259, P633, DOI 10.1126/science.8381558; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Liu Y, 1996, CANCER RES, V56, P31; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Lu S, 1997, CANCER RES, V57, P4511; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MINESITA T, 1965, CANCER RES, V25, P1168; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; NOGUCHI S, 1987, CANCER RES, V47, P263; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	41	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2619	2627		10.1038/sj.onc.1202193	http://dx.doi.org/10.1038/sj.onc.1202193			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840925				2022-12-28	WOS:000077058900009
J	Pelton, PD; Sherman, LS; Rizvi, TA; Marchionni, MA; Wood, P; Friedman, RA; Ratner, N				Pelton, PD; Sherman, LS; Rizvi, TA; Marchionni, MA; Wood, P; Friedman, RA; Ratner, N			Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells	ONCOGENE			English	Article						merlin; schwannomin; actin; Rho; Rac; C3 transferase; adenovirus	NEUROFIBROMATOSIS-2 TUMOR-SUPPRESSOR; NERVE SHEATH TUMORS; ERM FAMILY MEMBERS; FIBRILLARY ACIDIC-PROTEIN; ACTIN-BASED CYTOSKELETONS; GERM-LINE MUTATIONS; PERIPHERAL-NERVE; GENE-PRODUCT; FOCAL ADHESIONS; TYPE-2 GENE	Schwannomas are peripheral nerve tumors that typically have mutations in the NF2 tumor suppressor gene. We compared cultured schwannoma cells with Schwann cells from normal human peripheral nerves (NHSC). Both cell types expressed specific antigenic markers, interacted with neurons, and proliferated in response to glial growth factor, confirming their identity as Schwann cells. Schwannoma cells frequently had elevated basal proliferation compared to NHSC. Schwannoma cells also showed spread areas 5-7-fold greater than NHSC, aberrant membrane ruffling and numerous, frequently disorganized stress fibers. Dominant negative Rac inhibited schwannoma cell ruffling but had no apparent effect on NHSC. Schwannoma cell stress fibers were inhibited by C3 transferase, tyrphostin A25, or dominant negative RhoA. These data suggest that the Rho and Rac pathways are abnormally activated in schwannoma cells. Levels of ezrin and moesin, proteins related to the NF2 gene product, merlin, were unchanged in schwannoma cells compared to NHSC. Our findings demonstrate for the first time that cell proliferation and actin organization are aberrant in schwannoma cells. Because NF2 is mutant in most or all human schwannomas, we postulate that loss of NF2 contributes to the cell growth and cytoskeletal dysfunction reported here.	Univ Cincinnati, Coll Med, Dept Otolaryngol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Univ Miami, Miami Project, Miami, FL 33136 USA; Cambridge Neurosci, Cambridge, MA 02139 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Miami	Ratner, N (corresponding author), Univ Cincinnati, Coll Med, Dept Otolaryngol, Cincinnati, OH 45267 USA.			RATNER, NANCY/0000-0001-5030-9354	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028840] Funding Source: NIH RePORTER; NINDS NIH HHS [NS10133, NS10297, NS28840] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; BARON P, 1991, ACTA NEUROPATHOL, V81, P491, DOI 10.1007/BF00310128; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BROCKES JP, 1986, ANN NEUROL, V20, P317, DOI 10.1002/ana.410200308; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; CRAVIOTO H, 1969, ACTA NEUROPATHOL, V12, P141, DOI 10.1007/BF00692502; CRAVIOTO H, 1969, ACTA NEUROPATHOL, V12, P116, DOI 10.1007/BF00692501; DARDENNE AJ, 1984, J CLIN PATHOL, V37, P895, DOI 10.1136/jcp.37.8.895; DENBAKKER MA, 1995, ONCOGENE, V10, P757; DENBAKKER MA, 1995, AM J PATHOL, V147, P1339; EINHEBER S, 1993, J CELL BIOL, V123, P1223, DOI 10.1083/jcb.123.5.1223; ERLANDSON RA, 1982, CANCER, V49, P273, DOI 10.1002/1097-0142(19820115)49:2<273::AID-CNCR2820490213>3.0.CO;2-R; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FELTRI ML, 1994, DEVELOPMENT, V120, P1287; FernandezValle C, 1997, J NEUROSCI, V17, P241, DOI 10.1523/JNEUROSCI.17-01-00241.1997; FERNANDEZVALLE C, 1994, J NEUROBIOL, V25, P1207, DOI 10.1002/neu.480251004; FRANCK Z, 1993, J CELL SCI, V105, P219; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hitotsumatsu T, 1997, ACTA NEUROPATHOL, V93, P225, DOI 10.1007/s004010050608; Huynh DP, 1996, ONCOGENE, V13, P73; Huynh DP, 1997, J NEUROPATH EXP NEUR, V56, P382, DOI 10.1097/00005072-199704000-00007; JAAKKOLA S, 1993, J NEUROCYTOL, V22, P215, DOI 10.1007/BF01246360; JAASKELAINEN J, 1994, J NEUROSURG, V80, P541, DOI 10.3171/jns.1994.80.3.0541; Jacoby LB, 1996, GENE CHROMOSOME CANC, V17, P45, DOI 10.1002/(SICI)1098-2264(199609)17:1<45::AID-GCC7>3.0.CO;2-2; JACOBY LB, 1994, HUM MOL GENET, V3, P413, DOI 10.1093/hmg/3.3.413; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JOHNSON MD, 1988, ARCH PATHOL LAB MED, V112, P155; KAWAHARA E, 1988, AM J SURG PATHOL, V12, P115, DOI 10.1097/00000478-198802000-00004; KLEITMAN N, 1991, CULTURING NERVE CELL, P251; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LEVI ADO, 1995, J NEUROSCI, V15, P1329; LUTCHMAN M, 1995, CANCER RES, V55, P2270; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARKWELL MA, 1978, ANAL BIOCHEM, V82, P206; McCartney BM, 1996, J CELL BIOL, V133, P843, DOI 10.1083/jcb.133.4.843; MCCOMB RD, 1985, J NEUROPATH EXP NEUR, V44, P242, DOI 10.1097/00005072-198505000-00003; MCGARVEY ML, 1984, DEV BIOL, V105, P18, DOI 10.1016/0012-1606(84)90257-4; MEREL P, 1995, GENE CHROMOSOME CANC, V12, P117, DOI 10.1002/gcc.2870120206; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; MORRISSEY TK, 1991, J NEUROSCI, V11, P2433; NANCE WE, 1993, ARCH NEUROL-CHICAGO, V45, P575; NOBES CD, 1995, J CELL SCI, V108, P225; Parry DM, 1996, AM J HUM GENET, V59, P529; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Raabe TD, 1996, J NEUROSCI RES, V46, P263; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rosenbaum C, 1997, EXP NEUROL, V148, P604, DOI 10.1006/exnr.1997.6696; Rosenbaum T, 1997, NEUROSCIENTIST, V3, P412, DOI 10.1177/107385849700300614; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUTKOWSKI JL, 1992, ANN NEUROL, V31, P580, DOI 10.1002/ana.410310603; SAINZ J, 1994, HUM MOL GENET, V3, P885, DOI 10.1093/hmg/3.6.885; SALZER JL, 1980, J CELL BIOL, V84, P767, DOI 10.1083/jcb.84.3.767; Scherer SS, 1996, J NEUROSCI RES, V46, P595, DOI 10.1002/(SICI)1097-4547(19961201)46:5<595::AID-JNR8>3.3.CO;2-2; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; SOBEL RA, 1993, J NEUROPATH EXP NEUR, V52, P106, DOI 10.1097/00005072-199303000-00002; StemmerRachamimov AO, 1997, AM J PATHOL, V151, P1649; TAKAISHI K, 1995, ONCOGENE, V11, P39; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TIKOO A, 1994, J BIOL CHEM, V269, P1; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; WECHSLER W., 1965, BEITR PATHOL ANAT ALLG PATHOL, V132, P319; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; YONEMURA S, 1993, J CELL BIOL, V120, P437, DOI 10.1083/jcb.120.2.437	82	103	120	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2195	2209		10.1038/sj.onc.1202141	http://dx.doi.org/10.1038/sj.onc.1202141			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811451				2022-12-28	WOS:000076698200006
J	Hatakeyama, S; Osawa, M; Omine, M; Ishikawa, F				Hatakeyama, S; Osawa, M; Omine, M; Ishikawa, F			JTB: A novel membrane protein gene at 1q21 rearranged in a jumping translocation	ONCOGENE			English	Article						jumping translocation; JTB; leukemia	COMPARATIVE GENOMIC HYBRIDIZATION; GAINS; LIPOSARCOMAS; LYMPHOMA; FAMILY; LOSSES; CANCER	1q21 is frequently involved in different types of translocation in many types of cancers. Jumping translocation (JT) is an unbalanced translocation that comprises amplified chromosomal segments jumping to various telomeres. In this study, we identified a novel gene human JTB (Jumping Translocation Breakpoint) at 1q21, which fused with the telomeric repeats of acceptor telomeres in a case of JT. hJTB (human JTB) encodes a trans-membrane protein that is highly conserved among divergent eukaryotic species. JT results in a hJTB truncation, which potentially produces an hJTB product devoid of the trans-membrane domain. hJTB is located in a gene-rich region at 1q21, called EDC (Epidermal Differentiation Complex). This is the first report identifying the gene involved in unbalanced translocations at 1q21.	Tokyo Inst Technol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Kirin Pharmaceut Res Lab, Takasaki, Gumma 3701202, Japan; Showa Univ, Fujigaoka Hosp, Div Hematol, Aoba Ku, Yokohama, Kanagawa 2270043, Japan	Tokyo Institute of Technology; Showa University	Ishikawa, F (corresponding author), Tokyo Inst Technol, Dept Life Sci, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.		Ishikawa, Fuyuki/AAU-4056-2021; Hatakeyama, Shinji/I-8873-2019	Ishikawa, Fuyuki/0000-0002-5580-2305; Hatakeyama, Shinji/0000-0002-0166-2773				Armengol G, 1997, BRIT J CANCER, V75, P1403, DOI 10.1038/bjc.1997.242; BERNHEIM A, 1988, CANCER GENET CYTOGEN, V32, P67, DOI 10.1016/0165-4608(88)90313-5; Flint J, 1997, NAT GENET, V15, P252, DOI 10.1038/ng0397-252; Gronwald J, 1997, CANCER RES, V57, P481; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; Hatakeyama S, 1998, BLOOD, V91, P1514, DOI 10.1182/blood.V91.5.1514.1514_1514_1519; Ishikawa F, 1997, BIOCHEM BIOPH RES CO, V230, P1, DOI 10.1006/bbrc.1996.5928; Lioumi M, 1998, GENOMICS, V49, P200, DOI 10.1006/geno.1998.5234; Marenholz I, 1996, GENOMICS, V37, P295, DOI 10.1006/geno.1996.0563; OFFIT K, 1991, BLOOD, V77, P1508; SALTMAN D, 1993, CHROMOSOMA, V102, P121, DOI 10.1007/BF00356029; SHIPPEY C A, 1990, Genes Chromosomes and Cancer, V2, P14, DOI 10.1002/gcc.2870020104; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; Szymanska J, 1996, GENE CHROMOSOME CANC, V15, P89, DOI 10.1002/(SICI)1098-2264(199602)15:2<89::AID-GCC2>3.0.CO;2-#; Szymanska J, 1997, CANCER GENET CYTOGEN, V99, P14, DOI 10.1016/S0165-4608(96)00436-0; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4	16	38	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2085	2090		10.1038/sj.onc.1202510	http://dx.doi.org/10.1038/sj.onc.1202510			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321732				2022-12-28	WOS:000079346200005
J	Frank, RC; Sun, X; Berguido, FJ; Jakubowiak, A; Nimer, SD				Frank, RC; Sun, X; Berguido, FJ; Jakubowiak, A; Nimer, SD			The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1	ONCOGENE			English	Article						AML1/ETO; transformation; AP-1	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; FETAL LIVER HEMATOPOIESIS; DNA-BINDING; TRANSCRIPTION FACTOR; C-JUN; CHIMERIC ONCOPROTEIN; RETINOIC ACID; GENE	The 8;21 translocation is the most common cytogenetic abnormality in human acute myelogenous leukemia, joining the AML1 gene on chromosome 21, to the ETO gene on chromosome 8, forming the AML1/ETO fusion gene, The AML1/ETO fusion protein has been shown to function mainly as a transcriptional repressor of AML1 target genes and to block AML1 function in vitro and in vivo. However, AML1/ETO can also activate the BCL-2 promoter and cause enhanced hematopoietic progenitor self-renewal in vitro, suggesting gain-of-functions unique to the fusion protein. We used NIH3T3 cells to determine the transforming capacity of AML1/ETO, and to further characterize its mechanism of action. Expression of AML1/ETO in NIH3T3 cells caused cell-type specific cell death, and cellular transformation, characterized by phenotypic changes, anchorage-independent growth, and tumor formation in nude mice, In contrast, neither expression of AML1A, AML1B or ETO altered the normal growth pattern of the cells, To investigate the mechanism of transformation by AML1/ETO, we analysed the levels of activated, phosphorylated c-Jun (ser63) and other constituents of the AP-1 complex, in the presence of various AML1/ETO related proteins. Expression of AML1/ETO increased the level of c-Jun-P (ser63), and activated AP-1 dependent transcription, which was inhibited by expression of a dominant-negative c-Jun protein. Mutational analysis revealed that the runt homology domain (RHD) and a C-terminal transcriptional repression domain in AML1/ETO are required for transformation, activation of c-Jun and increased AP-1 activity, These results establish the transforming potential of the t(8;21) fusion protein and link this gain-of-function property to modulation of AP-1 activity.	Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, New York, NY 10021 USA; Sloan Kettering Inst, Lab Mol Aspects Hematopoiesis, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Nimer, SD (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, 1275 York Ave,H-701,Box 575, New York, NY 10021 USA.				NCI NIH HHS [K08 CA70388, CA09207] Funding Source: Medline; NIDDK NIH HHS [DK 43025] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA070388, T32CA009207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043025] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASKEW DS, 1991, ONCOGENE, V6, P1915; ASOU H, 1991, BLOOD, V77, P2031; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BROWN PH, 1993, ONCOGENE, V8, P877; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; Darley RL, 1997, J EXP MED, V185, P1337, DOI 10.1084/jem.185.7.1337; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; DOWNING JR, 1993, BLOOD, V81, P2860; ERICKSON P, 1992, BLOOD, V80, P1825; Erickson PF, 1996, BLOOD, V88, P1813; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEINSTEIN PG, 1995, GENETICS, V140, P573; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; Frank R, 1995, ONCOGENE, V11, P2667; Golling G, 1996, MOL CELL BIOL, V16, P932; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; KURIE JM, 1993, DIFFERENTIATION, V54, P115; Kurokawa M, 1996, ONCOGENE, V12, P883; KUROKAWA M, 1995, ONCOGENE, V11, P833; LENNY N, 1995, ONCOGENE, V11, P1761; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; MANDANAS RA, 1993, BLOOD, V82, P1838; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Sawyers CL, 1997, LANCET, V349, P196, DOI 10.1016/S0140-6736(96)07535-6; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Smith KS, 1997, ONCOGENE, V14, P2917, DOI 10.1038/sj.onc.1201249; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Uchida H, 1997, J IMMUNOL, V158, P2251; Wang J., 1997, Blood, V90, p245A; Wang JX, 1997, CANCER RES, V57, P2951; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; YOSHIHARA T, 1995, MOL CELL BIOL, V15, P3247	64	41	44	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	1999	18	9					1701	1710		10.1038/sj.onc.1202459	http://dx.doi.org/10.1038/sj.onc.1202459			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208431				2022-12-28	WOS:000079025000005
J	Li, L; Peterson, CA; Kanter-Smoler, G; Wei, YF; Ramagli, LS; Sunnerhagen, P; Siciliano, MJ; Legerski, RJ				Li, L; Peterson, CA; Kanter-Smoler, G; Wei, YF; Ramagli, LS; Sunnerhagen, P; Siciliano, MJ; Legerski, RJ			hRAD17, a structural homolog of the Schizosaccharomyces pombe RAD17 cell cycle checkpoint gene, stimulates p53 accumulation	ONCOGENE			English	Article						cell cycle checkpoint; DNA damage; p53; fission yeast S-Pombe; RAD17; human homolog	DNA-DAMAGE CHECKPOINT; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; S-PHASE; PROTEIN-KINASE; BUDDING YEAST; ATAXIA-TELANGIECTASIA; ACCESSORY PROTEINS; REPAIR; REPLICATION	The RAD17 gene product of S. Pombe is an essential component of the checkpoint control pathway which responds to both DNA damage and disruption of replication. We have identified a human cDNA that encodes a polypeptide which is structurally conserved with the S, Pombe Rad17 protein. The human gene, designated hRAD17, predicts an encoded protein of 590 amino acids and a molecular weight of 69 kD. Amino acid sequence alignment revealed that hRad17 has 28.3% and 52.5% similarity with the S. Pombe Rad17 protein, and 21.8% identity and 45.8% similarity to the budding yeast cell cycle checkpoint protein, Rad 24. When introduced into the S. Pombe rad17 mutant, hRAD17 was able to partially revert its hydroxyurea and ionizing radiation hypersensitivity, but not its UV hypersensitivity. Permanent overexpression of the kRAD17 gene in human fibrosarcoma cells resulted in p53 activation and a significant reduction of S- and G2/M-phase cells accompanied by an accumulation of the G1-phase population, suggesting that hRAD17 may have a role in cell cycle checkpoint control, Immunostaining of HT-1080 cells transiently transfected with a hRAD17 construct confirmed the nuclear accumulation of p53, which mimics the induction caused by DNA damage. Using FISH analysis, we have mapped the hRAD17 locus to human chromosome 5q11.2.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Gothenburg, Dept Biol Mol, Lundberg Lab, SE-40530 Gothenburg, Sweden; Human Genome Sci Inc, Rockville, MD 20850 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Gothenburg; GlaxoSmithKline; Human Genome Sciences Inc	Legerski, RJ (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Genet, Houston, TX 77030 USA.		Sunnerhagen, Per/G-1696-2012	Sunnerhagen, Per/0000-0002-0967-8729	NATIONAL CANCER INSTITUTE [R01CA076172, R29CA076172, P01CA034936, R01CA052461] Funding Source: NIH RePORTER; NCI NIH HHS [CA76172, CA52461, CA34936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; Barrett MT, 1996, ONCOGENE, V13, P1867; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; CARR AM, 1995, SEMIN CELL BIOL, V6, P65, DOI 10.1016/1043-4682(95)90002-0; DAHLKVIST A, 1995, MOL GEN GENET, V246, P316, DOI 10.1007/BF00288604; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOWARD DL, 1998, GENE DEV, V12, P382; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Lydall D, 1997, MOL GEN GENET, V256, P638, DOI 10.1007/s004380050612; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; McAlear MA, 1996, GENETICS, V142, P65; MIURA I, 1992, CANCER RES, V52, P1322; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; PAN ZQ, 1993, P NATL ACAD SCI USA, V90, P6, DOI 10.1073/pnas.90.1.6; Parker AE, 1998, J BIOL CHEM, V273, P18340, DOI 10.1074/jbc.273.29.18340; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; Plug AW, 1997, NAT GENET, V17, P457, DOI 10.1038/ng1297-457; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; SIEDE W, 1994, GENETICS, V138, P271; STALLINGS RL, 1988, AM J HUM GENET, V43, P144; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; Sugimoto K, 1996, P NATL ACAD SCI USA, V93, P7048, DOI 10.1073/pnas.93.14.7048; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	56	21	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	1999	18	9					1689	1699		10.1038/sj.onc.1202469	http://dx.doi.org/10.1038/sj.onc.1202469			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208430				2022-12-28	WOS:000079025000004
J	Benedict, WF; Lerner, SP; Zhou, J; Shen, XH; Tokunaga, H; Czerniak, B				Benedict, WF; Lerner, SP; Zhou, J; Shen, XH; Tokunaga, H; Czerniak, B			Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer	ONCOGENE			English	Article						bladder cancer; RB; p16; prognosis	ALTERED EXPRESSION; RB PROTEIN; PRB ALTERATIONS; CELL-CARCINOMA; HIGH-FREQUENCY; GENE-PRODUCT; LUNG CANCERS; TUMORS; INACTIVATION; MUTATIONS	Recent studies have shown that patients whose bladder cancer exhibit overexpression of RB protein as measured by immunohistochemical analysis do equally poorly as those with loss of RB function. We hypothesized that loss of p16 protein function could be related to RB overexpression, since p16 can induce transcriptional downregulation of RB and its loss may lead to aberrant RB regulation. Conversely, loss of RB function has been associated with high p16 protein expression in several other tumor types, In the present study RB negative bladder tumors also exhibited strong nuclear p16 staining while each tumor with strong, homogeneous RB nuclear staining were p16 negative, supporting our hypothesis. To expand on these immunohistochemical studies additional cases were selected in which the status of the p16 encoding gene had been determined at the molecular level. Absent p16 and high RB protein expression was found in the tumors having loss of heterozygosity within 9p21 and a structural change (mutation or deletion) of the remaining p16 encoding gene allele, confirming the staining results. These results strongly support the hypothesis that the RB nuclear overexpression recently associated with poor prognosis in bladder cancer is also associated with toss of p16 function and implies that loss of p16 function could be equally deleterious as RB loss in bladder and likely other cancers.	Univ Texas, MD Anderson Cancer Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Benedict, WF (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Genitourinary Med Oncol, 1515 Holcombe Blvd,Box 13, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R29CA066723, R01CA054672, R01CA066723] Funding Source: NIH RePORTER; NCI NIH HHS [CA54672, CA66723] Funding Source: Medline; NEI NIH HHS [EY06195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BENEDICT WF, 1990, J CLIN INVEST, V85, P988, DOI 10.1172/JCI114575; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; Chaturvedi V, 1997, ONCOGENE, V14, P2059, DOI 10.1038/sj.onc.1201044; CORDONCARDO C, 1992, J NATL CANCER I, V84, P1251, DOI 10.1093/jnci/84.16.1251; CordonCardo C, 1997, CANCER RES, V57, P1217; Cote RJ, 1998, CANCER RES, V58, P1090; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Fang XJ, 1998, ONCOGENE, V16, P1, DOI 10.1038/sj.onc.1201525; Grossman HB, 1998, CLIN CANCER RES, V4, P829; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; ISHIKAWA J, 1991, CANCER RES, V51, P5376; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kratzke RA, 1996, CANCER RES, V56, P3415; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PACKENHAM JP, 1995, MOL CARCINOGEN, V14, P147, DOI 10.1002/mc.2940140303; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Reed AL, 1996, CANCER RES, V56, P3630; Sakaguchi M, 1996, INT J CANCER, V65, P442, DOI 10.1002/(SICI)1097-0215(19960208)65:4<442::AID-IJC8>3.0.CO;2-X; SHAPIRO GI, 1995, CANCER RES, V55, P505; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; WILLIAMSON MP, 1995, HUM MOL GENET, V4, P1569, DOI 10.1093/hmg/4.9.1569; Wong DJ, 1997, CANCER RES, V57, P2619; Xu HJ, 1996, CLIN CANCER RES, V2, P1169; XU HJ, 1993, INT J CANCER, V53, P781, DOI 10.1002/ijc.2910530513; XU HJ, 1989, ONCOGENE, V4, P807; XU HJ, 1991, ONCOGENE, V6, P1139; YEAGER T, 1995, CANCER RES, V55, P493; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	35	105	108	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1197	1203		10.1038/sj.onc.1202452	http://dx.doi.org/10.1038/sj.onc.1202452			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022125	Bronze			2022-12-28	WOS:000078510700008
J	Koken, MHM; Daniel, MT; Gianni, M; Zelent, A; Licht, J; Buzyn, A; Minard, P; Degos, L; Varet, B; de The, H				Koken, MHM; Daniel, MT; Gianni, M; Zelent, A; Licht, J; Buzyn, A; Minard, P; Degos, L; Varet, B; de The, H			Retinoic acid, but not arsenic trioxide, degrades the PLZF/RAR alpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient	ONCOGENE			English	Article						nuclear dot; leukaemia; degradation; PML; t(15;17); translocation	ACUTE PROMYELOCYTIC LEUKEMIA; PML GROWTH-SUPPRESSOR; RECEPTOR-ALPHA; T(15-17) TRANSLOCATION; NUCLEAR-BODIES; DNA-BINDING; CELLS; ONCOPROTEIN; GENE; EXPRESSION	Primary blasts of a t(11;17)(q23;q21) acute promyelocytic leukaemia (APL) patient were analysed with respect to retinoic acid (RA) and arsenic trioxide (As2O3) sensitivity as well as PLZF/RAR alpha status. Although RA induced partial monocytic differentiation ex vivo, but not in vivo, As203 failed to induce apoptosis in culture, contrasting with t(15;17) APL and arguing against the clinical use of As203 in t(11;17)(q23;q21) APL. Prior to cell culture, PLZF/RAR alpha was found to exactly co-localize with PML onto PML nuclear bodies. However upon cell culture, it quickly shifted towards microspeckles, its localization found in transfection experiments. Arsenic trioxide, known to induce aggregation of PML nuclear bodies, left the microspeckled PLZF/RAR alpha localization completely unaffected. RA treatment led to PLZF/RARa degradation. However, this complete PLZF/RAR alpha degradation was not accompanied by differentiation or apoptosis, which could suggest a contribution of the reciprocal RAR alpha/PLZF fusion product in leukaemogenesis or the existence of irreversible changes induced by the chimera.	Hop St Louis, Lab Associe Comite Paris Ligue Contre Canc, CNRS, UPR 90 51, F-75010 Paris, France; Hop St Louis, Serv Clin Malad Sang, Paris, France; Hop Necker Enfants Malad, Hematol Serv, Paris, France; Hop Moulins, Serv Med Interne, Moulins, France; Hop St Louis, Hematol Serv, Paris, France; Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England; CUNY, Mt Sinai Med Ctr, New York, NY USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Koken, MHM (corresponding author), Hop St Louis, Lab Associe Comite Paris Ligue Contre Canc, CNRS, UPR 90 51, 1 Av Claude Vellefaux, F-75010 Paris, France.		koken, marcel/N-1349-2019; Licht, Jonathan/L-4239-2019; Zelent, Arthur/B-3532-2009; Gianni, Maurizio/ABG-6322-2020; koken, marcel/J-8154-2012; Minard, Philippe/GRS-4797-2022	Gianni, Maurizio/0000-0002-6945-708X; koken, marcel/0000-0002-0839-0125; Minard, Philippe/0000-0002-3256-528X; Licht, Jonathan/0000-0002-3942-1369; Zelent, Arthur/0000-0002-7968-9888				BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Chen GQ, 1997, BLOOD, V89, P3345; Chen GQ, 1996, BLOOD, V88, P1052; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DANIEL MT, 1993, BLOOD, V82, P1858; DEGOS L, 1993, LEUKEMIA, V7, P766; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He L. Z., 1997, Blood, V90, p320A; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Quignon F, 1997, BBA-REV CANCER, V1333, pM53, DOI 10.1016/S0304-419X(97)00025-5; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; Stadler M, 1995, ONCOGENE, V11, P2565; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Yeyati P. L., 1997, Blood, V90, p245A; Yoshida H, 1996, CANCER RES, V56, P2945; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	40	82	84	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1113	1118		10.1038/sj.onc.1202414	http://dx.doi.org/10.1038/sj.onc.1202414			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023688				2022-12-28	WOS:000078510600029
J	Sexl, V; Diehl, JA; Sherr, CJ; Ashmun, R; Beach, D; Roussel, MF				Sexl, V; Diehl, JA; Sherr, CJ; Ashmun, R; Beach, D; Roussel, MF			A rate limiting function of cdc25A for S phase entry inversely correlates with tyrosine dephosphorylation of Cdk2	ONCOGENE			English	Article						cdc25; cyclin-dependent kinases; colony-stimulating factor-1 receptor; cell cycle; tyrosine phosphatase; p27(Kip1) inhibitor	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; RETINOBLASTOMA PROTEIN; G1 PHASE; PROTEASOME PATHWAY; ACTIVATING KINASE; DNA-REPLICATION; GROWTH-FACTOR; C-MYC; PHOSPHORYLATION	The cdc25A phosphatase removes inhibitory phosphates from threonine-14 and tyrosine-15 of cyclin dependent kinase-2 (cdk2) in vitro, and it is therefore widely assumed that cdc25A positively regulates cyclin E- and A-associated cdk2 activity at the G1 to S phase transition of the mammalian cell division cycle. Human cdc25A was introduced into mouse NIH3T3 fibroblasts co-expressing a form of the colony-stimulating factor-1 (CSF-1) receptor that is partially defective in transducing mitogenic signals. Cdc25A enabled these cells to form colonies in semisolid medium containing serum plus human recombinant CSF-1 in a manner reminiscent of cells rescued by c-myc. However, cdc25A-rescued cells could not proliferate in chemically defined medium containing CSF-1 and continued to require c-myc function for S phase entry. When contact-inhibited cells overexpressing cdc25A were dispersed and stimulated to synchronously enter the cell division cycle, they entered S phase 2-3 h earlier than their parental untransfected counterparts. Shortening of G1 phase temporally correlated with more rapid degradation of the cdk inhibitor p27(Kip1) and with premature activation of cyclin A-dependent cdk2. Paradoxically, tyrosine phosphorylation of cdk2 increased considerably as cells entered S phase, and cdc25A overexpression potentiated rather than diminished this effect. At face value, these results are inconsistent with the hypothesis that cdc25A acts directly on cdk2 to activate its S phase promoting function.	St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Expt Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA; Inst Child Hlth, London WC1N 1EH, England	St Jude Children's Research Hospital; St Jude Children's Research Hospital; Howard Hughes Medical Institute; St Jude Children's Research Hospital; University of London; University College London	Roussel, MF (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38105 USA.		Sherr, Charles J/N-8074-2018; Roussel, Martine F/F-1469-2016; Sexl, Veronika/B-8657-2016	Sherr, Charles J/0000-0002-5516-6206; Roussel, Martine F/0000-0002-1740-8139; Sexl, Veronika/0000-0001-9363-0412	NCI NIH HHS [CA-21765, CA-56819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA056819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P21; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Eckstein J., 1997, BIOCHIM BIOPHYS ACTA, V1332, P53; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOFFMANN T, 1993, BONE MARROW TRANSPL, V12, P1; Iavarone A, 1997, NATURE, V387, P417; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KARN J, 1989, ONCOGENE, V4, P773; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; NAGATA A, 1991, NEW BIOL, V3, P959; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; Saha P, 1997, MOL CELL BIOL, V17, P4338, DOI 10.1128/MCB.17.8.4338; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SANDHU K, 1990, P NATL ACAD SCI USA, V87, P5139; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xu X, 1996, J BIOL CHEM, V271, P5118	68	87	88	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					573	582		10.1038/sj.onc.1202362	http://dx.doi.org/10.1038/sj.onc.1202362			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989807				2022-12-28	WOS:000078394400002
J	Qing, J; Wei, D; Maher, VM; McCormick, JJ				Qing, J; Wei, D; Maher, VM; McCormick, JJ			Cloning and characterization of a novel gene encoding a putative transmembrane protein with altered expression in some human transformed and tumor-derived cell lines	ONCOGENE			English	Article						differential display; cell transformation; gene expression	EUKARYOTIC MESSENGER-RNAS; MALIGNANT TRANSFORMATION; DIFFERENTIAL DISPLAY; HUMAN FIBROBLASTS; CARCINOGENESIS; RECEPTOR; GROWTH; MODEL; STRAIN	Identification and characterization of genes expressed in normal cells and decreased in their malignant counterparts is an important method for detecting candidate tumor suppressors. Using differential display of mRNAs from nontumorigenic infinite life span human fibroblast cell strain MSU-1.1 and an isogenic fibrosarcoma-derived cell line, 6A/SB1, which was derived from chemical carcinogen transformed MSU-1.1 cells, we identified a no, el gene, ST7, showing sixfold lower expression in 6A/SB1 cells compared with parental MSU-1.1 cells. Molecular cloning of a near full-length cDNA revealed that the no, el gene encodes a putative transmembrane protein composed of 859 amino acids: the 492 N-terminal amino acids including a fivefold cysteine-rich repeat of 40 amino acids homologous to the ligand binding repeat of the known low density Lipoprotein receptor, a 24 hydrophobic amino acid stretch spanning the plasma membrane, and a C-terminal domain of 343 residues, ST7 is located on human chromosome 8, band q22.2-23.1, the same locus as the genes involved in acute myeloid leukemia and a locus of high polymorphism in cancer biopsies. The ST7 gene is widely expressed in normal human tissues and is particularly abundant in human heart and skeletal muscle. Northern analysis of 15 tumor cell lines derived from patients and 16 cell lines established from tumors formed in athymic mice by MSU-1.1 cells transformed in culture by various methods showed that 16 of the 31 cell lines ha,le low or undetectable levels of ST7 mRNA. Furthermore, Western blotting analysis using a specific anti-peptide antibody demonstrated that the level of ST7 protein is high in normal fibroblasts and low in 12 sarcoma-derived cell lines tested. Altered expression of ST7 appears to occur at both the transcriptional and post-transcriptional levels. These studies are a first step in characterizing a novel putative receptor protein, whose expression is downregulated in some malignantly transformed cells, and which may play an important role in the transformation process of these cells.	Michigan State Univ, Dept Microbiol, Carcinogenesis Lab, E Lansing, MI 48824 USA; Michigan State Univ, Ctr Canc, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	McCormick, JJ (corresponding author), Michigan State Univ, Dept Microbiol, Carcinogenesis Lab, FST Bldg, E Lansing, MI 48824 USA.				NCI NIH HHS [CA60907] Funding Source: Medline; NIA NIH HHS [AG11026] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011026] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; CHO KR, 1995, CURR OPIN GENET DEV, V5, P72, DOI 10.1016/S0959-437X(95)90056-X; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; FARBER E, 1984, CANCER RES, V44, P4217; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1996, BIOCHIM BIOPHYS ACTA, V1288, P17; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURUYA T, 1989, CANCER GENET CYTOGEN, V43, P131, DOI 10.1016/0165-4608(89)90136-2; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MCCORMICK JJ, 1994, RISK ANAL, V14, P257, DOI 10.1111/j.1539-6924.1994.tb00240.x; Miyazaki S, 1997, GENOMICS, V46, P155, DOI 10.1006/geno.1997.4996; MORGAN TL, 1991, EXP CELL RES, V197, P125, DOI 10.1016/0014-4827(91)90489-H; PARK NH, 1995, ONCOGENE, V10, P2145; Peto R, 1977, ORIGINS HUMAN CANC C, P1403; Qing J, 1997, ONCOGENE, V15, P2159, DOI 10.1038/sj.onc.1201385; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Reinhold DS, 1996, INT J RADIAT BIOL, V69, P707, DOI 10.1080/095530096145454; REZNIKOFF CA, 1993, SEMIN CANCER BIOL, V4, P143; RHIM JS, 1994, P NATL ACAD SCI USA, V91, P11874, DOI 10.1073/pnas.91.25.11874; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; Sambrook J., 2002, MOL CLONING LAB MANU; SHABTAI F, 1988, CANCER GENET CYTOGEN, V31, P113, DOI 10.1016/0165-4608(88)90018-0; STANLEY KK, 1985, EMBO J, V4, P375, DOI 10.1002/j.1460-2075.1985.tb03639.x; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; STONER GD, 1991, CANCER RES, V51, P365; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; YANG DJ, 1992, P NATL ACAD SCI USA, V89, P2237, DOI 10.1073/pnas.89.6.2237	33	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					335	342		10.1038/sj.onc.1202290	http://dx.doi.org/10.1038/sj.onc.1202290			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927190				2022-12-28	WOS:000078166500006
J	Reichert, M; Eick, D				Reichert, M; Eick, D			Analysis of cell cycle arrest in adipocyte differentiation	ONCOGENE			English	Article						3T3-L1 cells; differentiation; adipocytes; cell cycle; Rb; SV40 large T antigen	LARGE T-ANTIGEN; BINDING-PROTEIN-ALPHA; MYC-INDUCED APOPTOSIS; LARGE TUMOR-ANTIGEN; SV40 LARGE-T; C-MYC; DNA-REPLICATION; C/EBP-ALPHA; DEPENDENT KINASES; TRANSCRIPTIONAL REGULATION	Confluent 3T3-L1 preadipocytes differentiate to adipocytes in the presence of insulin, dexamethasone, and isobutylmethylxanthine (IDI), A transient increase of DNA synthesis is induced in 3T3-L1 cells 18 h after addition of IDI, followed by an arrest in the G1 phase of the cell cycle. Growth arrested cells express the protooncogene oncogene c-myc and gene for the CCAAT/enhancer binding protein (C/EBP alpha) between day 2 and 5, While c-Myc is strongly implicated in cell proliferation, C/EBP alpha is a differentiation-specific transcription factor with antiproliferative, activity. Here we have characterized the cell cycle arrest in differentiating 3T3-L1 cells. Arrested cells express the Cdk inhibitors p21 and p27, but, at the same time, show hyperphosphorylation of Rb and expression of the E2F-regulated thymidine kinase gene. The addition of new serum to arrested cells resulted in cyclin A expression and Cdk2 activity, but not in DNA synthesis, Simian virus 40 large tumor antigen (LTAg) is a potent mitogen, The mutant LTAg-K1, deficient in binding of pocket proteins and unable to induce DNA synthesis in serum-starved 3T3-L1 cells, efficiently induced DNA synthesis in differentiating 3T3-L1 cells. This indicates that pocket proteins are probably not in,ol,ed in the control of the cell cycle arrest during 3T3-L1 cell differentiation. Our data suggest that the differentiation-specific cell cycle block in 3T3-L1 cells is resistant to high levels of c-Myc, inactivation of pocket proteins, upregulation of cyclin A levels, and Cdk2 activation, but can be abolished by a function of LTAg that is independent of binding to pocket proteins.	GSF Forschungszentrum Umwelt & Gesundheit, Inst Klin Mol Biol & Tumorgenet, D-81377 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Eick, D (corresponding author), GSF Forschungszentrum Umwelt & Gesundheit, Inst Klin Mol Biol & Tumorgenet, Marchioninistr 25, D-81377 Munich, Germany.							BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Constance CM, 1996, MOL CELL BIOL, V16, P3878; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Fajas L, 1998, CURR OPIN CELL BIOL, V10, P165, DOI 10.1016/S0955-0674(98)80138-5; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; GRANA X, 1995, ONCOGENE, V11, P211; GRATZNER HG, 1985, CYTOMETRY, V6, P563, DOI 10.1002/cyto.990060610; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; KIESS M, 1995, ONCOGENE, V10, P159; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LESAGE F, 1994, NUCLEIC ACIDS RES, V22, P3685, DOI 10.1093/nar/22.18.3685; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MEUTH M, 1974, CELL, V3, P367, DOI 10.1016/0092-8674(74)90052-X; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; OHKUBO Y, 1994, EXP CELL RES, V214, P270, DOI 10.1006/excr.1994.1258; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER MD, 1987, MOL CELL BIOL, V7, P1973, DOI 10.1128/MCB.7.5.1973; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WOLF DA, 1995, ONCOGENE, V10, P2067; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	51	100	101	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					459	466		10.1038/sj.onc.1202308	http://dx.doi.org/10.1038/sj.onc.1202308			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927202				2022-12-28	WOS:000078166500018
J	Xu, Y; Krishnan, A; Wan, XS; Majima, H; Yeh, CC; Ludewig, G; Kasarskis, EJ; St Clair, DK				Xu, Y; Krishnan, A; Wan, XS; Majima, H; Yeh, CC; Ludewig, G; Kasarskis, EJ; St Clair, DK			Mutations in the promoter reveal a cause for the reduced expression of the human manganese superoxide dismutase gene in cancer cells	ONCOGENE			English	Article						tumor suppressor gene; mutation; promoter; transcription factors; MnSOD; reactive oxygen species	TRANSCRIPTION FACTOR; MALIGNANT PHENOTYPE; BINDING PROTEINS; TRANSGENIC MICE; DNA-BINDING; ACTIVATION; SP1; SUPPRESSION; OVEREXPRESSION; SITES	Manganese superoxide dismutase (MnSOD) has been shown to play an important role in preventing the development of cancer. MnSOD activity is reduced in many transformed cells and tumor tissues. We previously showed that the reduced level of MnSOD activity in cancer cells was not due to a defect in the primary structure of MnSOD protein, but rather was due to defects in gene expression. To elucidate the cause for the reduced expression of human MnSOD in cancer, we investigated the nucleotide sequence in the regulatory region of the MnSOD gene in a normal human cell line and various human tumor cell lines. A DNA fragment spanning 3.4 kb 5' flanking region of the MnSOD gene isolated from a normal human genomic DNA library was used to determine the DNA sequence of MnSOD promoter. PCR primers were used for amplification of the 3.4 kb 5' flanking region of the human MnSOD gene in cancer cells. Sequence analysis identified three heterozygous mutations in the proximal region of the promoter in five human tumor cell lines; These mutations, clustered around the GC-rich region of the human MnSOD promoter, change the binding pattern of AP-2 and lead to a reduction in transcription activity using a luciferase reporter assay system. These results suggest that the reduced level of MnSOD expression in some tumor cells is, at least in part, due to a defect in the DNA sequence of the promoter region.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	St Clair, DK (corresponding author), Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA.		Majima, Hideyuki J./K-3778-2019; Ludewig, Gabriele/A-2745-2008	Ludewig, Gabriele/0000-0003-2385-7720	NCI NIH HHS [CA 59835, CA 49797] Funding Source: Medline; NHLBI NIH HHS [HL 03544] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA049797, R01CA049797, R01CA059835] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K02HL003544] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amstad PA, 1997, CARCINOGENESIS, V18, P479, DOI 10.1093/carcin/18.3.479; Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dharmavaram RM, 1997, J BIOL CHEM, V272, P26918, DOI 10.1074/jbc.272.43.26918; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FLAMAN JM, 1994, NUCLEIC ACIDS RES, V22, P3259, DOI 10.1093/nar/22.15.3259; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; Halliwell B., 1989, FREE RADICAL BIO MED, P86; HO YS, 1991, AM J RESP CELL MOL, V4, P278, DOI 10.1165/ajrcmb/4.3.278; IKEDA K, 1993, GENE, V136, P341; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; JONES PL, 1995, GENE, V153, P155, DOI 10.1016/0378-1119(94)00666-G; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; Keller JN, 1998, J NEUROSCI, V18, P687; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LI JJ, 1995, ONCOGENE, V10, P1989; Li M, 1997, ONCOGENE, V15, P1535, DOI 10.1038/sj.onc.1201325; LopezRodriguez C, 1997, J BIOL CHEM, V272, P29120, DOI 10.1074/jbc.272.46.29120; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MEYRICK B, 1994, AM J RESP CELL MOL, V10, P113, DOI 10.1165/ajrcmb.10.1.8292376; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Moffat GJ, 1996, J BIOL CHEM, V271, P1054, DOI 10.1074/jbc.271.2.1054; OBERLEY LW, 1979, CANCER RES, V39, P1141; OBERLEY LW, 1984, J THEOR BIOL, V106, P403, DOI 10.1016/0022-5193(84)90038-9; OBERLEY LW, 1989, FREE RADICAL BIO MED, V6, P379, DOI 10.1016/0891-5849(89)90083-X; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; SAFFORD SE, 1994, CANCER RES, V54, P4261; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; StClair DK, 1997, ONCOL REP, V4, P753; STCLAIR DK, 1994, FREE RADICAL BIO MED, V16, P275, DOI 10.1016/0891-5849(94)90153-8; StClair DK, 1996, ONCOL REP, V3, P429; STCLAIR DK, 1992, MOL CARCINOGEN, V6, P238, DOI 10.1002/mc.2940060404; STCLAIR DK, 1991, CANCER RES, V51, P939; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; Tang W, 1997, J BIOL CHEM, V272, P13146, DOI 10.1074/jbc.272.20.13146; THOMSEN DR, 1984, P NATL ACAD SCI-BIOL, V81, P659, DOI 10.1073/pnas.81.3.659; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; URANO M, 1995, CANCER RES, V55, P2490; WAN XS, 1994, DNA CELL BIOL, V13, P1127, DOI 10.1089/dna.1994.13.1127; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WISPE JR, 1992, J BIOL CHEM, V267, P23937; Yen HC, 1996, J CLIN INVEST, V98, P1253, DOI 10.1172/JCI118909; YEN HC, 1997, J BIOMED LAB SCI, V9, P40; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852	53	107	117	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					93	102		10.1038/sj.onc.1202265	http://dx.doi.org/10.1038/sj.onc.1202265			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926924				2022-12-28	WOS:000078166000011
J	Reichel, M; Gillert, E; Nilson, I; Siegler, G; Greil, J; Fey, GH; Marschalek, R				Reichel, M; Gillert, E; Nilson, I; Siegler, G; Greil, J; Fey, GH; Marschalek, R			Fine structure of translocation breakpoints in leukemic blasts with chromosomal translocation t(4;11): the DNA damage-repair model of translocation	ONCOGENE			English	Article						ALL-1/MLL/HRX gene; AF4/FEL gene; chromosomal translocation t(4 ; 11); recombination	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; TOPOISOMERASE-II INHIBITORS; CLUSTER REGION; ALL-1 GENE; HOMOLOGOUS RECOMBINATION; 11Q23 TRANSLOCATIONS; CELL-LINE; EXON/INTRON STRUCTURE; DROSOPHILA-TRITHORAX	Chromosomal translocations t(4;11) are regularly associated with a specific type of acute leukemias and probably initiate the development of this disease. It has been proposed by others, that these translocations are mediated by recombinases of the immune system. The breakpoints on both derivative chromosomes for three t(4;11) leukemia-derived cell lines and primary blasts from two patients have been analysed here in detail. The results revealed that: (a) multiple double- or single-stranded DNA breaks must have occured near the translocation breakpoints on both participating chromosomes; and (b) DNA fragments flanked by these breaks must have either been deleted, inverted or duplicated during the translocation process. We found no evidence for the involvement of specific target sequences and recombinases of the immune system. Similar characteristic features were observed by re-interpretation of published t(6;11) and t(9;22) translocation data. Therefore we present a new model for the generation of these translocations which poses, that these translocations are reciprocal but not balanced at the fine structure level and that the DNA damage-repair machinery is likely involved in producing the final structure of the translocation breakpoint.	Univ Erlangen Nurnberg, Chair Genet, D-91058 Erlangen, Germany; Univ Erlangen Nurnberg, Childrens Hosp, D-91054 Erlangen, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg	Marschalek, R (corresponding author), Univ Erlangen Nurnberg, Chair Genet, Staudtstr 15, D-91058 Erlangen, Germany.		Siegler, Gabriele/AAE-4614-2019; Marschalek, Rolf/D-3404-2011	Marschalek, Rolf/0000-0003-4870-3445; Reichel, Martin/0000-0001-7886-2784				ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; Aplan PD, 1996, BLOOD, V87, P2649, DOI 10.1182/blood.V87.7.2649.bloodjournal8772649; BAER R, 1987, CELL, V50, P97, DOI 10.1016/0092-8674(87)90666-0; BAER R, 1985, CELL, V43, P705, DOI 10.1016/0092-8674(85)90243-0; BERNARD OA, 1995, LEUKEMIA, V9, P1487; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; CHEN CS, 1993, BLOOD, V82, P1080; CIMINO G, 1993, BLOOD, V82, P544; COFFIN JM, 1992, DEV BIOLOGICALS, V76, P141; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DOMER PH, 1995, LEUKEMIA, V9, P1305; FELIX CA, 1993, CANCER RES, V53, P2954; GARCIA IS, 1991, ONCOGENE, V6, P577; GILLSUPER H, 1997, GENES CHROMOSOM CANC, V20, P185; GILLSUPER HJ, 1993, BLOOD, V82, P3705; GREIL J, 1994, BRIT J HAEMATOL, V86, P275, DOI 10.1111/j.1365-2141.1994.tb04726.x; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1994, CANCER RES, V54, P2327; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; HARRIMAN W, 1993, ANNU REV IMMUNOL, V11, P361, DOI 10.1146/annurev.iy.11.040193.002045; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; HUNGER SP, 1993, BLOOD, V81, P3197; IIDA S, 1992, LEUKEMIA RES, V16, P1155, DOI 10.1016/0145-2126(92)90113-L; KANEKO Y, 1986, BLOOD, V67, P484; KATZ F, 1988, BLOOD, V71, P1438; LAITINEN J, 1994, BIOTECHNIQUES, V17, P316; LANGE B, 1987, BLOOD, V70, P192; LITZ CE, 1993, BLOOD, V81, P1567; Marschalek R, 1997, LEUKEMIA LYMPHOMA, V27, P417, DOI 10.3109/10428199709058308; MARSCHALEK R, 1995, BRIT J HAEMATOL, V90, P308, DOI 10.1111/j.1365-2141.1995.tb05151.x; MURNANE JP, 1990, NUCLEIC ACIDS RES, V18, P2733, DOI 10.1093/nar/18.9.2733; Nilson I, 1996, BRIT J HAEMATOL, V93, P966, DOI 10.1046/j.1365-2141.1996.d01-1748.x; Nilson I, 1997, BRIT J HAEMATOL, V98, P157, DOI 10.1046/j.1365-2141.1997.1522966.x; PEDERSENBJERGAARD J, 1992, LEUKEMIA RES, V16, P733, DOI 10.1016/0145-2126(92)90150-6; PLESNER P, 1987, P NATL ACAD SCI USA, V84, P1936, DOI 10.1073/pnas.84.7.1936; PUI CH, 1990, BLOOD, V76, P1449; PUI CH, 1991, BLOOD, V77, P440; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; PUI CH, 1987, BLOOD, V69, P1289; PUI CH, 1990, LANCET, V336, P417, DOI 10.1016/0140-6736(90)91956-B; RABITTS TH, 1994, NATURE, V372, P143; Rasio D, 1996, CANCER RES, V56, P1766; ROTH DB, 1991, NUCLEIC ACIDS RES, V19, P7201, DOI 10.1093/nar/19.25.7201; SCHICHMAN SA, 1994, CANCER RES, V54, P4277; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; So CW, 1997, CANCER RES, V57, P117; Stanulla M, 1997, LEUKEMIA, V11, P490, DOI 10.1038/sj.leu.2400632; Stanulla M, 1997, MOL CELL BIOL, V17, P4070, DOI 10.1128/MCB.17.7.4070; Strout MP, 1998, P NATL ACAD SCI USA, V95, P2390, DOI 10.1073/pnas.95.5.2390; Strout MP, 1996, GENE CHROMOSOME CANC, V16, P204, DOI 10.1002/(SICI)1098-2264(199607)16:3<204::AID-GCC8>3.0.CO;2-2; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANDERPOEL SZ, 1991, P NATL ACAD SCI USA, V88, P10735; Varmus H., 1989, MOBILE DNA; ZHANG JG, 1995, BRIT J HAEMATOL, V90, P138, DOI 10.1111/j.1365-2141.1995.tb03392.x	56	86	89	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	1998	17	23					3035	3044		10.1038/sj.onc.1202229	http://dx.doi.org/10.1038/sj.onc.1202229			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881706				2022-12-28	WOS:000077427800011
J	Zariwala, M; Liu, JD; Xiong, Y				Zariwala, M; Liu, JD; Xiong, Y			Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3, is induced by viral oncoproteins	ONCOGENE			English	Article						cyclin E2; CDK; G1 cell cycle control; cell transformation	CELL-CYCLE; DEPENDENT KINASES; PHASE-TRANSITION; RETINOBLASTOMA-PROTEIN; E GENE; G(1); TRANSFORMATION; TRANSCRIPTION; FIBROBLASTS; INHIBITION	G1 cyclin E controls the initiation of DNA synthesis by activating CDK2, and abnormally high levels of cyclin E expression have frequently been observed in human cancers. We have isolated a novel human cyclin, cyclin E2, that contains significant homology to cyclin E. Cyclin E2 specifically interacts with CDK inhibitors of the CIP/KIP family and activates both CDK2 and CDK3. The expression of cyclin E2 mRNA oscillates periodically throughout the cell cycle, peaking at the G1/S transition, and exhibits a pattern of tissue specificity distinct from that of cyclin El. Cyclin E2 encodes a short lived protein whose turnover is most likely governed by the proteasome pathway and is regulated by phosphorylation on a conserved Thr-392 residue. Expression of the viral E6 oncoprotein in normal human fibroblasts increases the steady state level of cyclin E2, but not cyclin El, while expression of the E7 oncoprotein upregulates both. These data suggest that the expression of these two G1 E-type cyclins may be similarly regulated by the pRb function, but distinctly by the p53 activity.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Xiong, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	yxiong@unc.edu			NCI NIH HHS [CA65572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Botz J, 1996, MOL CELL BIOL, V16, P3401; Chevalier S, 1996, J CELL SCI, V109, P1173; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dou QP, 1996, NAT MED, V2, P254, DOI 10.1038/nm0396-254a; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; Geng Y, 1996, ONCOGENE, V12, P1173; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALL M, 1996, CANCER RES, V68, P1173; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; Howe JA, 1996, P NATL ACAD SCI USA, V93, P2060, DOI 10.1073/pnas.93.5.2060; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JENKINS CW, 1995, CELL CYCLE MAT METHO, P250; KEYOMARSI K, 1994, CANCER RES, V54, P380; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI Y, 1994, ONCOGENE, V9, P2261; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Mumberg D, 1997, NUCLEIC ACIDS RES, V25, P2098, DOI 10.1093/nar/25.11.2098; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; Phelps DE, 1997, METHOD ENZYMOL, V283, P194; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SEWING A, 1994, J CELL SCI, V107, P581; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	50	89	96	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2787	2798		10.1038/sj.onc.1202505	http://dx.doi.org/10.1038/sj.onc.1202505			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840943				2022-12-28	WOS:000077146700012
J	Sheikh, MS; Antinore, MJ; Huang, Y; Fornace, AJ				Sheikh, MS; Antinore, MJ; Huang, Y; Fornace, AJ			Ultraviolet-irradiation-induced apoptosis is mediated via ligand independent activation of tumor necrosis factor receptor 1	ONCOGENE			English	Article						UV; TNF alpha; caspase cascade; DNA damage	KAPPA-B ACTIVATION; RADIATION-INDUCED APOPTOSIS; DOMAIN-CONTAINING RECEPTOR; BREAST-CARCINOMA CELLS; DEATH DOMAIN; CYSTEINE PROTEASES; CD95 FAS/APO-1; PROTEIN; LIGHT; TRAIL	Ultraviolet (UV)-irradiation has been shown to induce jun N-terminal kinase activity via aggregation-mediated activation of tumor necrosis factor receptor 1 (TNFR1) but the role of TNFR1 in mediating UV-induced apoptosis has not been explored. Using p53-null cells, me demonstrate that UV-stimulated ligand independent activation of TNFR1 plays a major role in mediating the apoptotic effects of UV-irradiation. UV-irradiation and TNF alpha acted in a synergistic manner to induce apoptosis, UV-irradiation stimulated the aggregation-mediated activation of TNFR1 which was coupled with activation of caspase 8, the most proximal caspase in TNF alpha signaling pathway, CrmA and the dominant negative versions of FADD, caspase 8 and caspase 10, that block the apoptotic axis of TNFR1 at different levels, also independently inhibited the UV-induced apoptosis, The engagement of the membrane initiated events was specific for UV-irradiation since neither CrmA nor the dominant negative FADD, caspase 8 or caspase 10 blocked the ionizing radiation-induced apoptosis, Cisplatin and melphalan, the UV-mimetic agents known to elicit UV-type DNA damage, also induced apoptosis but differed from UV in that both of the former agents engaged the caspase cascade at a level distal to FADD. Consistent with these findings cisplatin also did not stimulate TNFR1 aggregation. Together these results indicate that DNA damage pel se was not sufficient to activate the membrane TNFR1. Based on our results we propose that the plasma membrane initiated events play a predominant role in mediating UV-irradiation-induced apoptosis and that UV-irradiation appears to engage the apoptotic axis of TNFR1 and perhaps those of other membrane death receptors to transduce its apoptotic signals.	NCI, Div Basic Sci, NIH, Bethesda, MD 20892 USA; NIA, Biol Chem Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Sheikh, MS (corresponding author), NCI, Div Basic Sci, NIH, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; BATES S, 1996, CURRENT OPIN GENET D, V6, P1; Brash DE, 1996, J INVEST DERMATOL S, V1, P136; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; FAN SJ, 1995, CANCER RES, V55, P1649; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Friedberg ECW GC, 1995, DNA REPAIR MUTAGENES, P19; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Keane MM, 1996, CANCER RES, V56, P4791; KOCK A, 1990, J EXP MED, V172, P1609, DOI 10.1084/jem.172.6.1609; KONDO S, 1995, CANCER RES, V55, P6166; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; MARTIN SJ, 1991, INT J RADIAT BIOL, V59, P1001, DOI 10.1080/09553009114550891; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; SCHWARZ A, 1995, J INVEST DERMATOL, V102, P422; Sheikh MS, 1996, CELL GROWTH DIFFER, V7, P1599; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Tobin D, 1998, P NATL ACAD SCI USA, V95, P565, DOI 10.1073/pnas.95.2.565; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	38	110	114	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2555	2563		10.1038/sj.onc.1202292	http://dx.doi.org/10.1038/sj.onc.1202292			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840918				2022-12-28	WOS:000077058900002
J	Tsatsanis, C; Patriotis, C; Tsichlis, PN				Tsatsanis, C; Patriotis, C; Tsichlis, PN			Tpl-2 induces IL-2 expression in T-cell lines by triggering multiple signaling pathways that activate NFAT and NF-kappa B	ONCOGENE			English	Article						Tpl-2; NF kappa B; nuclear factor of activated T cells; interleukin 2	PROTEIN-KINASE; TRANSCRIPTION FACTORS; NUCLEAR FACTOR; INTERLEUKIN-2 ENHANCER; CYCLOSPORINE-A; CALCINEURIN; PHOSPHORYLATION; FAMILY; ALPHA; RECEPTOR	The Tpl-2 kinase activates the nuclear factor of activated T cells (NFAT) and induces IL-2 expression in T-cell lines. Here we show that the activation of the IL-2 promoter by Tpl-2 is inhibited by mutant signaling molecules that inhibit the mitogen-activated protein kinase (MAPK) or the calcineurin/NFAT pathways and is promoted by combinations of signaling molecules that activate these pathways, We, therefore, conclude that signals generated by the convergence of the MAPK and the calcineurin/NFAT pathway are necessary and sufficient for the activation of the IL-2 promoter by Tpl-2. The activation of both the IL-2 promoter and an NEAT-driven minimal promoter were shown to depend on signals transduced by Raf1. However, it was only the IL-2 promoter whose activation by Tpl-2 was fully blocked by the dominant negative mutant MEK1S218/222A and the MEK1/MEK2 inhibitor PD098059, Since the activation of NEAT is MAPK-dependent these findings suggested that the activation of MAPK by Tpl-2 is either independent or only partially dependent on MEK1 and MEK2, In addition, they suggested that the activation of the IL-2 promoter is under the control of not only NFAT but also a second factor whose activation is MEK-dependent. Experiments in COS-1 and EL-4 cells confirmed both hypotheses and revealed that the second factor activated by Tpl-2 is NF-kappa B, While the activation of the IL-2 promoter and an NEAT-driven minimal promoter by Tpl-2 was fully blocked by the dominant negative mutant NFAT Delta 418, it was only partially blocked by the calcineurin inhibitor cyclosporin A suggesting that the Tpl-2-mediated NFAT activation is under the control of a combination of calcineurin-dependent and independent pathways. Both pathways were fully blocked by Bcl-2 or Bcl-X-L.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Tsichlis, PN (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA.		Tsatsanis, Christos/AAM-9362-2020	Tsatsanis, Christos/0000-0003-1214-4151	NCI NIH HHS [CA38047, CA06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038047, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Ballester A, 1997, J IMMUNOL, V159, P1613; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BIGNON C, 1993, BIOTECHNIQUES, V15, P243; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Erny KM, 1996, ONCOGENE, V13, P2015; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; FRUMAN DA, 1995, MOL CELL BIOL, V15, P3857; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; Ghosh P, 1996, J BIOL CHEM, V271, P7700, DOI 10.1074/jbc.271.13.7700; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Luo C, 1996, MOL CELL BIOL, V16, P3955; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; PANG L, 1995, BIOCHEM J, V307, P513, DOI 10.1042/bj3070513; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; Tsatsanis C, 1998, P NATL ACAD SCI USA, V95, P3827, DOI 10.1073/pnas.95.7.3827; YAN MH, 1994, NATURE, V372, P798; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	52	67	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	1998	17	20					2609	2618		10.1038/sj.onc.1202460	http://dx.doi.org/10.1038/sj.onc.1202460			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840924				2022-12-28	WOS:000077058900008
J	Piovesan, B; Pennell, N; Berinstein, NL				Piovesan, B; Pennell, N; Berinstein, NL			Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity	ONCOGENE			English	Article						apoptosis; mutated p53; cisplatin; lymphoblastoid cell lines	WILD-TYPE P53; CHRONIC LYMPHOCYTIC-LEUKEMIA; TUMOR-SUPPRESSOR GENE; DNA-DAMAGING AGENTS; HUMAN B-CELLS; THYMOCYTE APOPTOSIS; UV IRRADIATION; IN-VIVO; MUTATIONS; LYMPHOMA	Human lymphoblastoid cells were transfected with expression vectors containing p53 cDNA mutated at either codon 135 or 246. The cells were subjected to cisplatin treatment or gamma-radiation and observed for changes in the cell cycle arrest and apoptosis, We found that compared to the parental cell line, cells overexpressing mutant p53 (either 246(val) or 135(ser)) exhibited decreased apoptosis in response to gamma-radiation or cisplatin as measured by: propidium iodide (PI) staining of the cellular DNA (cell cycle analysis) and decrease in PARP (poly ADP-ribose polymerase) cleavage as detected by Western blotting. Interestingly the cells expressing mutant p53(135(ser)) protein were less resistant to cisplatin-induced apoptosis than the p53(246(val))-bearing cell line. A significant decrease in the G1/S arrest assayed by bromodeoxyuridine and PI staining (cell cycle/proliferation assay) was also observed in response to irradiation and cisplatin in cell lines expressing either of the mutant p53 constructs. A lower basal level and reduced magnitude of protein induction of the cell cycle inhibitor p21/Waf1 was seen both after cisplatin and gamma-radiation treatment in the mutant p53 expressing lymphoblastoid variant when compared to the wild type p53 parental cell line but induction of the p53 regulator MDM2 was comparable in both. No increase in basal levels of Bc12 protein in wild type or mutant p53 expressing cells was observed in response to cisplatin or irradiation. Unexpectedly, following cisplatin treatment we observed an increase in mutant and wild type p53 RNA steady state levels in addition to increased levels of p53 protein. These results suggest that irradiation or cisplatin treatment may not only stabilize wild type p53 protein but also may increase the steady state p53 RNA levels. Finally these results indicate that both irradiation and cisplatin should be used with caution in the treatment of lymphoid tumors bearing mutations of p53.	Univ Toronto, Dept Med, Toronto, ON M4N 3M5, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M4N 3M5, Canada; Toronto Sunnybrook Reg Canc Ctr, Toronto, ON M4N 3M5, Canada	University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Berinstein, NL (corresponding author), Univ Toronto, Dept Med, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.			Pennell, Nancy/0000-0002-1556-3506				ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; EASTMAN A, 1985, BIOCHEMISTRY-US, V24, P5027, DOI 10.1021/bi00340a011; EASTMAN A, 1987, PHARMACOL THERAPEUT, V34, P155, DOI 10.1016/0163-7258(87)90009-X; FAN SJ, 1995, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; FARRUGIA MM, 1994, BLOOD, V83, P191; FUJIWARA T, 1994, CANCER RES, V54, P2287; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; Hawkins DS, 1996, CANCER RES, V56, P892; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang TS, 1996, ONCOGENE, V13, P625; KASTAN MB, 1991, CANCER RES, V51, P6304; Kondo S, 1996, ONCOGENE, V13, P1279; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LI CCH, 1995, LEUKEMIA, V9, P650; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORMEROD MG, 1994, BRIT J CANCER, V69, P93, DOI 10.1038/bjc.1994.14; PEACOCK JW, 1995, MOL CELL BIOL, V15, P1446; Perego P, 1996, CANCER RES, V56, P556; Pocard M, 1996, ONCOGENE, V12, P875; Roberts J J, 1979, Prog Nucleic Acid Res Mol Biol, V22, P71, DOI 10.1016/S0079-6603(08)60799-0; RODRIGUEZ MA, 1995, J CLIN ONCOL, V13, P1734, DOI 10.1200/JCO.1995.13.7.1734; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SLINGERLAND JM, 1991, J CELL PHYSIOL, V148, P391, DOI 10.1002/jcp.1041480309; SUGIMOTO K, 1991, BLOOD, V77, P1153; TWEEDDALE ME, 1987, BLOOD, V69, P1307; VAZIRI H, 1997, EMBO J, V16, P6818; VELASQUEZ WS, 1988, BLOOD, V71, P117; VOELKERDING KV, 1995, ONCOGENE, V10, P515; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Zhang N, 1996, ONCOGENE, V13, P655; ZINZANI PL, 1994, AM J HEMATOL, V47, P301, DOI 10.1002/ajh.2830470410	45	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2339	2350		10.1038/sj.onc.1202147	http://dx.doi.org/10.1038/sj.onc.1202147			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811465				2022-12-28	WOS:000076723300008
J	Scheele, JS; Pilz, RB; von Lintig, FC; Boss, GR				Scheele, JS; Pilz, RB; von Lintig, FC; Boss, GR			Deficient post-translational processing of Rap 1A in variant HL-60 cells	ONCOGENE			English	Article						Rap 1A; HL-60 cells; post-translational processing	DEPENDENT PROTEIN-KINASE; GTP-BINDING PROTEINS; PROMYELOCYTIC LEUKEMIA-CELLS; INDUCED DIFFERENTIATION; HUMAN-PLATELETS; GRANULOCYTIC DIFFERENTIATION; PHOSPHORYLATION SITE; CARBOXYL METHYLATION; SIGNAL TRANSDUCTION; KINETIC MECHANISM	Variant HL-60 cells resistant to differentiation induced by nitroprusside and cGMP analogs have normal guanylate cyclase and cGMP-dependent protein kinase (G-kinase) activity (J, Biol. Chem. 269, 32155-32161, 1994). We found decreased phosphorylation of a low molecular weight protein (pp23) in the variant cells and by co-migration on two-dimensional polyacrylamide gels, phosphopeptide mapping, immunoprecipitation and immunoblotting, we showed that pp23 was one of three post-translationally modified forms of Rap 1A expressed in HL-60 cells. Using an in vitro transcription/ translation system, rye studied each of the posttranslational processing steps of Rap 1A and we showed that pp23 represented fully processed Rap 1A. By immunoprecipitation, immunoblotting and S-35-methionine/cysteine incorporation, we showed that the variant cells were deficient in pp23, and thus in fully processed Rap 1A, but that these cells did express normal amounts of completely unprocessed Rap 1A and geranylgeranylated Rap 1A; the lack of Rap 1A processing beyond geranylgeranylation in the variant cells was not secondary to a change in Rap 1A's amino acid sequence, The variant cells had normal carboxyl methyltransferase activity suggesting they are deficient in proteolytic cleavage of Rap 1A, The deficient post-translational processing of Rap 1A had no effect on Rap 1A's subcellular distribution and we found no evidence for altered post-translational processing of H-Ras.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biochem & Chem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Boss, GR (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.			Boss, Gerry/0000-0002-9758-8714	NIGMS NIH HHS [GM49360] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049360] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI M, 1992, ONCOGENE, V7, P323; ALTSCHULER D, 1993, J BIOL CHEM, V268, P7527; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; BOKOCH GM, 1991, SCIENCE, V254, P1794, DOI 10.1126/science.1763330; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOS JL, 1984, NUCLEIC ACIDS RES, V12, P9155, DOI 10.1093/nar/12.23.9155; BOSS GR, 1989, P NATL ACAD SCI USA, V86, P7174, DOI 10.1073/pnas.86.18.7174; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; CHAPLINSKI TJ, 1982, J CLIN INVEST, V70, P953, DOI 10.1172/JCI110707; Chen YL, 1996, BIOCHEMISTRY-US, V35, P3227, DOI 10.1021/bi952529s; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; CORBIN JD, 1990, ADV SEC MESS PHOSPH, V24, P411; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; FISCHER TH, 1991, FEBS LETT, V283, P173, DOI 10.1016/0014-5793(91)80581-M; GALLAGHER R, 1979, BLOOD, V54, P713; GLASS DB, 1980, ANNU REV PHARMACOL, V20, P363, DOI 10.1146/annurev.pa.20.040180.002051; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; HANCOCK JF, 1995, METHOD ENZYMOL, V255, P60; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; HATA Y, 1991, J BIOL CHEM, V266, P6571; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLINZ FJ, 1992, EUR J BIOCHEM, V207, P207, DOI 10.1111/j.1432-1033.1992.tb17039.x; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; MA YT, 1993, FEBS LETT, V332, P105, DOI 10.1016/0014-5793(93)80493-E; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; MIURA Y, 1992, FEBS LETT, V297, P171, DOI 10.1016/0014-5793(92)80353-I; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PILZ RB, 1992, J BIOL CHEM, V267, P16161; PILZ RB, 1994, J BIOL CHEM, V269, P32155; PILZ RB, 1990, J BIOL CHEM, V265, P8880; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SCHEELE JS, 1994, J BIOL CHEM, V269, P18599; SCHEELE JS, 1998, IN PRESS MOL CELL BI; SHI YQ, 1992, J BIOL CHEM, V267, P9547; STUDZINSKI GP, 1987, LAB INVEST, V56, P499; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VOLKER C, 1990, Methods (Orlando), V1, P283, DOI 10.1016/S1046-2023(05)80329-9; VOLKER C, 1991, J BIOL CHEM, V266, P21515; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; ZHANG FL, 1994, J BIOL CHEM, V269, P23465	57	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	1998	17	17					2211	2223		10.1038/sj.onc.1202137	http://dx.doi.org/10.1038/sj.onc.1202137			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811452				2022-12-28	WOS:000076698200007
J	Suzuki, R; Sakamoto, H; Yasukawa, H; Masuhara, M; Wakioka, T; Sasaki, A; Yuge, K; Komiya, S; Inoue, A; Yoshimura, A				Suzuki, R; Sakamoto, H; Yasukawa, H; Masuhara, M; Wakioka, T; Sasaki, A; Yuge, K; Komiya, S; Inoue, A; Yoshimura, A			CIS3 and JAB have different regulatory roles in interleukin-6 mediated differentiation and STAT3 activation in M1 leukemia cells	ONCOGENE			English	Article						interleukin 6; STAT; JAK; tyrosine kinase; regulation	GROWTH ARREST; TRANSCRIPTIONAL ACTIVATION; TERMINAL DIFFERENTIATION; INHIBITORY FACTOR; DNA-DAMAGE; C-MYC; RECEPTOR; PATHWAYS; PROTEIN; FAMILY	We have reported JAK-signaling modulators, CIS1 (cytokine-inducible SH2 protein-1), CIS3 and JAB (JAK2 binding protein), which are structurally related. In M1 myeloid leukemia cells, CIS3 was induced by neither interleukin 6 (IL6) nor interferon gamma (IFN gamma), while JAB was induced strongly by IFN gamma and slightly by IL6 and leukemia inhibitory factor (ILF), Forced expression of CIS3 and JAB in Mi cells prevented IL6- or LIF-induced growth arrest and differentiation, even when their expression levels were comparable to endogenous ones in several cell lines such as HEL, UT-7, IFN gamma-treated Mi, and CTLL2 cells, Pretreatment of parental Mi cells with IFN gamma but not IFN beta resulted in suppression of LIF-induced STAT3 activation and differentiation, further supporting that physiological level of JAB is sufficient to inhibit LIF-signaling. However, unlike JAB, CIS3 did not inhibit IFN gamma-induced growth arrest, suggesting a difference in cytokine specificity between CIS3 and JAB. CIS3 inhibited STAT3 activation with slower kinetics than JAB and allowed rapid c-fos induction and partial Fc gamma RI expression in response to IL6, In 293 cells, CIS3 as well as JAB bound to JAK2 tyrosine kinase domain (JH1), and inhibited its kinase activity, however, the effect of CIS3 an tyrosine kinase activity was weaker than that of JAB, indicating that CIS3 possesses lower affinity to JAK kinases than JAB, These findings suggest that CIS3 is a weaker inhibitor than JAB against JAK signaling, and JAB and CIS3 possess different regulatory roles in cytokine signaling.	Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan; Kurume Univ, Fac Med, Dept Internal Med 3, Kurume, Fukuoka 8300011, Japan	Kurume University; Kurume University	Yoshimura, A (corresponding author), Kurume Univ, Inst Life Sci, Aikawa Machi 2432-3, Kurume, Fukuoka 8390861, Japan.			Sasaki, Atsuo/0000-0003-2963-4501				ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Minamoto S, 1997, BIOCHEM BIOPH RES CO, V237, P79, DOI 10.1006/bbrc.1997.7080; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Narimatsu M, 1997, BIOCHEM BIOPH RES CO, V238, P764, DOI 10.1006/bbrc.1997.7387; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; Sengupta TK, 1996, P NATL ACAD SCI USA, V93, P9499, DOI 10.1073/pnas.93.18.9499; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; XU LX, 1994, INT IMMUNOL, V6, P515, DOI 10.1093/intimm/6.4.515; YAMAMURA Y, 1992, EMBO J, V11, P4909, DOI 10.1002/j.1460-2075.1992.tb05597.x; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	26	77	79	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2271	2278		10.1038/sj.onc.1202143	http://dx.doi.org/10.1038/sj.onc.1202143			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811457				2022-12-28	WOS:000076698200012
J	Cobellis, G; Missero, C; Di Lauro, R				Cobellis, G; Missero, C; Di Lauro, R			Concomitant activation of MEK-1 and Rac-1 increases the proliferative potential of thyroid epithelial cells, without affecting their differentiation	ONCOGENE			English	Article						thyroid; Rac; MEK; Ras; differentiation; transformation	MAP KINASE KINASE; ACTIN STRESS FIBERS; PROTEIN-KINASE; MAMMALIAN-CELLS; THYROGLOBULIN PROMOTER; SIGNAL-TRANSDUCTION; RAS TRANSFORMATION; CYCLE PROGRESSION; GENE-EXPRESSION; CDC42 GTPASES	Activating point mutations in the Ras oncogene occur in a large number of human tumors, especially of epithelial origin. In thyroid follicular cells, ectopic expression of oncogenic H-Ras results in growth factor-independent proliferation, loss of differentiation and tumor formation in nude mice. In fibroblasts concomitant activation of the MAP kinase cascade and the small GTPase Rac-1 leads to full malignant transformation. We have tested the effects of these key downstream mediators of Pas in thyroid epithelial cells, by stably expressing either a constitutively active form of MEK-1 (MEKDelta N3/S218E/S222D), a constitutively active form of Rac-1 (Val12-Rac), or both. While the activation of one molecule or the other results in a weak phenotype, concomitant activation of both MEK-1 and Rac-1 in thyroid cells leads to growth factor-independent proliferation, morphological transformation and anchorage-independent growth. However, in contrast to Pas-transformed thyroid cells, the ones expressing the constitutively active forms of MEK-1 and Rac-1 maintain their differentiate phenotype and fail to form tumors when injected into nude mice. Thus, in thyroid epithelial cells, concomitant activation of MEK-1 and Rac-1 can reproduce only a subset of the Ras-induced effects and is not sufficient to cause full malignant transformation. Significantly, Pas-mediated increased proliferation and loss of differentiation can be dissociated in these cells.	Staz Zool Anton Dohrn, I-80121 Naples, Italy	Stazione Zoologica Anton Dohrn di Napoli	Di Lauro, R (corresponding author), Staz Zool Anton Dohrn, I-80121 Naples, Italy.		Di Lauro, Roberto/A-2746-2012	Di Lauro, Roberto/0000-0001-9493-3036; Cobellis, Gilda/0000-0003-2687-2272; Missero, Caterina/0000-0003-0905-5123	Telethon [E.0406] Funding Source: Medline	Telethon(Fondazione Telethon)		AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; ALBLAS J, 1993, J BIOL CHEM, V268, P22235; AMBESIIMPIOMBAT.FS, 1982, COLD SPRING HARBOR C, V9, P483; AVVEDIMENTO VE, 1985, EUR J BIOCHEM, V149, P467, DOI 10.1111/j.1432-1033.1985.tb08948.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAMANTE G, 1994, BBA-GENE STRUCT EXPR, V1218, P255, DOI 10.1016/0167-4781(94)90176-7; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; FARID NR, 1994, ENDOCR REV, V15, P202, DOI 10.1210/er.15.2.202; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KONG YF, 1995, MOL CELL BIOL, V15, P5205; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LANGECARTER CA, 1995, METH ENZIMOL, V255; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEMOINE NR, 1990, ONCOGENE, V5, P1833; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARIAIS R, 1993, CELL, V73, P391; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Mascia A, 1997, BBA-GENE STRUCT EXPR, V1354, P171, DOI 10.1016/S0167-4781(97)00127-9; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MISSERO C, 1997, IN PRESS MOL CELL EN; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rochefort P, 1996, ONCOGENE, V12, P111; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SAUREZ HG, 1990, ONCOGENE, V5, P565; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE P, 1993, NATURE, V36, P352; WESTWICK JK, 1995, METH ENZIMOL; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YAMAMOTO M, 1993, J BIOL CHEM, V268, P21509; Zannini M, 1997, EMBO J, V16, P3185, DOI 10.1093/emboj/16.11.3185; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	76	25	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2047	2057		10.1038/sj.onc.1202130	http://dx.doi.org/10.1038/sj.onc.1202130			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798676				2022-12-28	WOS:000076540900004
J	Somerville, RPT; Shoshan, Y; Eng, C; Barnett, G; Miller, D; Cowell, JK				Somerville, RPT; Shoshan, Y; Eng, C; Barnett, G; Miller, D; Cowell, JK			Molecular analysis of two putative tumour suppressor genes, PTEN and DMBT, which have been implicated in glioblastoma multiforme disease progression	ONCOGENE			English	Article						glioma; PTEN; DMBT; mutation; tumour suppressor; 10q24-26	GERMLINE MUTATIONS; HUMAN GLIOMAS; HEREDITARY RETINOBLASTOMA; BRAIN-TUMORS; CHROMOSOME-10; HETEROZYGOSITY; PHOSPHATASE; REGIONS; LOCI	The transition from low grade astrocytoma to glioblastoma multiforme is almost always accompanied by the loss of genetic markers from chromosome 10. Recently two genes, PTEN/MMAC1/TEP1 and DMBT, have been isolated from chromosome 10q. We have analysed these two genes for mutations in 21 primary glioblastomas, An exon by exon screen of the PTEN gene using SSCP failed to identify any mutations in this tumour series, In contrast, 38% of tumours showed intragenic homozygous deletions in the DMBT gene, The fact that the majority of gliomas do not carry mutations in either of these genes suggests that there may still be other genes on chromosome 10 which are important in the development of glioblastoma multiforme.	Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurosurg, Cleveland, OH 44195 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Somerville, RPT (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, 9500 Euclid Ave,NC30, Cleveland, OH 44195 USA.			Eng, Charis/0000-0002-3693-5145; Cowell, John/0000-0002-2079-5950				Albarosa R, 1996, AM J HUM GENET, V58, P1260; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BIGNER SH, 1988, CANCER RES, V48, P405; BIGNER SH, 1990, CANCER GENET CYTOGEN, V47, P141, DOI 10.1016/0165-4608(90)90024-5; CHERNOVA O, 1998, IN PRESS CANC GENET; Cowell John K., 1994, European Journal of Human Genetics, V2, P281; DAVIS A, 1993, HUM MOL GENET, V2, P2093, DOI 10.1093/hmg/2.12.2093; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; HOGG A, 1992, ONCOGENE, V7, P1444; JAMES CD, 1988, CANCER RES, V48, P5546; KARLBOM AE, 1993, HUM GENET, V92, P169; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Li DM, 1997, CANCER RES, V57, P2124; LI J, 1997, SCIENCE, V275, P1945; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LIU ZX, 1995, GENE CHROMOSOME CANC, V14, P277, DOI 10.1002/gcc.2870140406; Louis David N., 1997, P2013; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; RANSOM DT, 1992, GENE CHROMOSOME CANC, V5, P357, DOI 10.1002/gcc.2870050412; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; Rasheed BKA, 1997, CANCER RES, V57, P4187; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; WANG SI, 1997, CANCER RES, V57, P4138	28	64	64	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1755	1757		10.1038/sj.onc.1202066	http://dx.doi.org/10.1038/sj.onc.1202066			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796706				2022-12-28	WOS:000076200100015
J	Yanagisawa, K; Osada, H; Masuda, A; Kondo, M; Saito, T; Yatabe, Y; Takagi, K; Takahashi, T; Takahashi, T				Yanagisawa, K; Osada, H; Masuda, A; Kondo, M; Saito, T; Yatabe, Y; Takagi, K; Takahashi, T; Takahashi, T			Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGF-beta in human normal lung epithelial cells	ONCOGENE			English	Article						Smad; TGF-beta; apoptosis; down-regulation; lung	TRANSFORMING-GROWTH-FACTOR; MAD-RELATED PROTEIN; IN-VIVO ALTERATIONS; SIGNAL-TRANSDUCTION; RECEPTOR; 18Q21; GENES; SUPERFAMILY; CANCERS; DPC4	Small family members are essential intracellular signaling components of the transforming growth factor-beta (TGF-beta) superfamily involved in a range of biological activities, Two highly homologous molecules, Smad2 and Smad3, have so far been identified as receptor-activated Smads for TGF-beta signaling and have become the focus of intensive studies, However, no definite differences in regulation or function have been established between these TGF-beta signaling molecules. In the present study, we show that the expression of Smad3, but not its close relative, Smad2, is down-regulated by TGF-beta mediated signals themselves in human lung epithelial cells. This down-regulation of Smad3 by TGF-beta treatment did not appear to result from shortening of the half-life of Smad3 mRNA, Constitutive expression of Smad3 in the presence of TGF-beta induced apoptotic cell death, with an adverse effect on the cell growth of human lung epithelial cells, Apoptotic cell death could also be induced by forced expression of Smad2 in the presence of TGF-beta, but less efficiently than by that of Smad3. These findings clearly define the distinctions between Smad2 and Smad3 for the first time in that a qualitative difference was observed with regard to the regulation of their expression in response to TGF-beta, while Smad2 and Smad3 appeared to have quantitatively different capabilities regarding the induction of apoptotic cell death in human lung epithelial cells.	Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr, Res Inst, Immunol Lab, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr, Res Inst, Pathophysiol Unit, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr Hosp, Dept Pathol & Clin Labs, Chikusa Ku, Nagoya, Aichi 464, Japan; Nagoya Univ, Sch Med, Showa Ku, Nagoya, Aichi 466, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Nagoya University	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, Nagoya, Aichi 464, Japan.		Yanagisawa, Kiyoshi/I-7263-2014; Osada, Hiroyuki/AAY-6254-2020; Kondo, Masashi/I-7378-2014; Takahashi, Takashi/I-7262-2014; YATABE, Yasushi/J-6461-2014	Takahashi, Takashi/0000-0003-0615-7001; YATABE, Yasushi/0000-0003-1788-559X				Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Masuda A, 1997, CANCER RES, V57, P4898; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; Nagatake M, 1996, CANCER RES, V56, P2718; Ookawa K, 1997, ONCOGENE, V14, P1389, DOI 10.1038/sj.onc.1200976; REDDEL RR, 1988, CANCER RES, V48, P1904; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Uchida K, 1996, CANCER RES, V56, P5583; Wrana J, 1997, NATURE, V388, P28, DOI 10.1038/40290; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	26	140	150	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1743	1747		10.1038/sj.onc.1202052	http://dx.doi.org/10.1038/sj.onc.1202052			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796704				2022-12-28	WOS:000076200100013
J	Groysman, M; Nagano, M; Shaanan, B; Katzav, S				Groysman, M; Nagano, M; Shaanan, B; Katzav, S			Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation	ONCOGENE			English	Article						vav; SH3; Zyxin; hnRNP-K	AMINO-ACID SUBSTITUTIONS; TYROSINE KINASE-ACTIVITY; PROLINE-RICH PEPTIDES; GTP EXCHANGE FACTOR; PROTOONCOGENE PRODUCT; C-SRC; SIGNAL-TRANSDUCTION; T-CELL; BINDING-PROTEIN; GENE	The vav proto-oncogene encodes a protein with multiple modulae domains that enable it to function as a mediator, linking tyrosine signaling to downstream events in hematopoietic cells, Circumstantial evidence suggests that protein-protein interactions exerted by two of these domains, the Src homology 2 (SH2) and the Src homology 3 (SH3), play an important role in the regulation of Vav activity, To study the relevance of the SH3 domain for the function of vav as a transforming gene, we have created several mutations in the SH3 domain located at its carboxy region. Substitution of the non-conserved aspartic acid 797 (to asparagine, D797N) retained the transforming potential of the vav oncogene, whereas substitutions of five highly conserved amino-acids: alanine 789 (to asparagine, A789N), leucine 801 (to arginine, L801R), tryptophan 821 (to arginine, W821R), glycine 830 (to valine, G830V) and valine 837 (to glutamic acid, V837E) greatly reduced its transforming potential. The mutant proteins resemble Vav in many biochemical properties; however, while the transforming mutant protein (D797N) associates with several unidentified proteins in a manner similar to that of Vav, the non-transforming mutant Vav proteins react very poorly with these proteins, Among the known Vav-interacting proteins, hnRNP-K associates with all mutant proteins except A789N and V837E whereas binding of Zyxin to any of the mutant proteins is not affected. Taken together, our results clearly demonstrate that the SH3 domain has a positive effect on vav activity and is needed for vav transformation, The vavSH3C associating protein(s) that are crucial for its activity as a transforming gene have probably not Set been identified.	Hebrew Univ Jerusalem, Hadassah Med Sch, Hubert H Humphrey Ctr Expt Med & Canc Res, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Katzav, S (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Hubert H Humphrey Ctr Expt Med & Canc Res, IL-91120 Jerusalem, Israel.		Shaanan, Boaz/F-1202-2012	Shaanan, Boaz/0000-0001-8925-4362; Sherman, Maya/0000-0002-7421-9844				ADAMS JM, 1992, ONCOGENE, V7, P611; BOUGSKI MS, 1993, NATURE, V366, P643; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GALLAND F, 1992, ONCOGENE, V7, P585; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENSKE EP, 1995, ANN HUM GENET, V59, P25, DOI 10.1111/j.1469-1809.1995.tb01603.x; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; Hiroaki H, 1996, J BIOMOL NMR, V8, P105; Hobert O, 1996, MOL CELL BIOL, V16, P3066; Hobert O, 1996, ONCOGENE, V12, P1577; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON PK, 1993, ONCOGENE, V8, P1943; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; Katzav S, 1995, CRIT REV ONCOGENESIS, V6, P87; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1993, ONCOGENE, V8, P1757; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; Morton CJ, 1996, STRUCTURE, V4, P705, DOI 10.1016/S0969-2126(96)00076-7; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Romero F, 1996, MOL CELL BIOL, V16, P37; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; Wittekind M, 1997, J MOL BIOL, V267, P933, DOI 10.1006/jmbi.1996.0886; WU J, 1995, MOL CELL BIOL, V15, P4337; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; ZMUIDZINAS A, 1995, EMBO J, V14, P1	59	27	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1597	1606		10.1038/sj.onc.1202074	http://dx.doi.org/10.1038/sj.onc.1202074			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794237				2022-12-28	WOS:000076089900012
J	Carroll, PE; Okuda, M; Horn, HF; Biddinger, P; Stambrook, PJ; Gleich, LL; Li, YQ; Tarapore, P; Fukasawa, K				Carroll, PE; Okuda, M; Horn, HF; Biddinger, P; Stambrook, PJ; Gleich, LL; Li, YQ; Tarapore, P; Fukasawa, K			Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression	ONCOGENE			English	Article						chromosome instability; p53; Mdm2; human cancer; centrosome hyperamplification	WILD-TYPE P53; TUMOR-SUPPRESSOR GENE; GENOMIC INSTABILITY; P53-DEFICIENT MICE; GAMMA-TUBULIN; BARRETTS-ESOPHAGUS; BREAST-CANCER; PROTEIN; AMPLIFICATION; CELLS	We have previously reported that loss of p53 tumor suppressor protein results in centrosome hyperamplification, which leads to aberrant mitosis and chromosome instability, Since p53 is either deleted or mutated in human cancers at a high frequency, we investigated whether human cancers showed centrosome hyperamplification, Screening of advanced stage breast ductal carcinomas and squamous cell carcinomas of the head and neck (SCCHN) revealed that centrosome hyperamplification is frequent in both tumor types, Moreover, through the analyses of p53 in SCCHN samples by direct sequencing and by loss-of-heterozygosity test, we found that p53 mutations correlated with occurrence of centrosome hyperamplification. However, in some cases, me observed centrosome hyperamplification in tumors that retained wild-type p53, These tumors contained high levels of Mdm2, Since Mdm2 can inactivate p53 through physical association, we investigated whether Mdm2 overexpression induced centrosome hyperamplification, We found that Mdm2 overexpression, like loss of p53, induced centrosome hyperamplification and chromosome instability in cultured cells.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Otolaryngol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, POB 670521, Cincinnati, OH 45267 USA.		Tarapore, Pheruza/A-8876-2013	Tarapore, Pheruza/0000-0003-0911-3661; Okuda, Masaru/0000-0003-4690-8244; Horn, Henning/0000-0002-5885-8996				BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; BLOUNT PL, 1994, CANCER RES, V54, P2292; Bornens Michel, 1992, P1; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; CAHILLYSYNDER L, 1987, GENET, V13, P234; CARDER P, 1993, ONCOGENE, V8, P1397; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHENG KC, 1993, ADV CANCER RES, V60, P121; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELLEDGE RM, 1994, BREAST CANCER RES TR, V32, P39, DOI 10.1007/BF00666204; EYFJORD JE, 1995, CANCER RES, V55, P646; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GAPANY M, 1993, CANCER DETECT PREV, V17, P379; Gleich LL, 1996, LARYNGOSCOPE, V106, P1378, DOI 10.1097/00005537-199611000-00013; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Harlow E., 1988, ANTIBODIES LAB MANUA; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, ONCOGENE, V8, P2457; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; KONDOLEON S, 1987, NUCLEIC ACIDS RES, V15, P10605, DOI 10.1093/nar/15.24.10605; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LADANYI M, 1993, CANCER RES, V53, P16; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1997, J CELL BIOCHEM, V64, P343; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OSHIMURA M, 1986, ENVIRON MUTAGEN, V8, P129, DOI 10.1002/em.2860080112; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PAVELIC ZP, 1994, ANTICANCER RES, V14, P2259; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; PURDIE CA, 1994, ONCOGENE, V9, P603; RaybaudDiogene H, 1996, ORAL ONCOL, V32B, P143; REID BJ, 1992, GASTROENTEROLOGY, V102, P1212; Smith Martin L., 1995, Current Opinion in Oncology, V7, P69; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; Vandre D.D., 1989, MITOSIS MOL MECHANIS, P39; VISSING H, 1987, NUCLEIC ACIDS RES, V15, P1363, DOI 10.1093/nar/15.4.1363; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	58	221	229	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					1935	1944		10.1038/sj.onc.1202515	http://dx.doi.org/10.1038/sj.onc.1202515			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208415				2022-12-28	WOS:000079191300003
J	Zwicker, J; Korner, K; Muller, R				Zwicker, J; Korner, K; Muller, R			The SV40 large T oncoprotein disrupts DNA-binding of the cell cycle-regulated transcriptional repressor CDF	ONCOGENE			English	Article						cell cycle; repression; transcriptional regulation; viral oncoproteins; SV40; cyclin A; cdc25C	CDC25C TRANSCRIPTION; GENE; PROTEIN; EXPRESSION; ANTIGEN; E2F; MODULATION; PATHWAY; PRODUCT; ELEMENT	A hallmark of neoplastic transformation by DNA tumor viruses is the deregulation of cell cycle genes. At least in some genes, this deregulation appears to be due to the oncoprotein-mediated disruption of complexes between E2F and pocket proteins and the ensuing generation of transcriptionally active free E2F. In the present study, we have analysed the effect of the SV40 large T oncoprotein (SV-LT) on the function of a different cell cycle-regulated transcriptional repressor, CDF, which is the principal regulator of the cdc25C, cyclin A and cdc2 genes, As shown by genomic footprinting of sorted G(1) and G(2) cell populations, transformation by SV-LT completely abrogated protection of the CDF binding site (CDE-CHR) in the cdc25C promoter. In agreement with this observation, expression of the SV-LT in fibroblasts led to a dramatic up-regulation of the cdc25C promoter in cells synchronized in G(0). These findings indicate that the oncoprotein-mediated dissociation of the CDF repressor protein from its cognate DNA-binding site is a major mechanism in virus-induced transcriptional deregulation.	Univ Marburg, IMT, D-35033 Marburg, Germany	Philipps University Marburg	Muller, R (corresponding author), Univ Marburg, IMT, Emil Mannkopff Str 2, D-35033 Marburg, Germany.		Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				Boyer SN, 1996, CANCER RES, V56, P4620; BUCHOU T, 1993, ONCOGENE, V8, P1765; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; NEVINS JR, 1992, SCIENCE, V258, P424; OSHIMA J, 1993, ONCOGENE, V8, P2987; SCHUERMANN M, 1990, NUCLEIC ACIDS RES, V18, P4945, DOI 10.1093/nar/18.16.4945; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SPITKOVSKY D, 1994, J VIROL, V68, P2206, DOI 10.1128/JVI.68.4.2206-2214.1994; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	19	6	6	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					2023	2025		10.1038/sj.onc.1202063	http://dx.doi.org/10.1038/sj.onc.1202063			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208424				2022-12-28	WOS:000079191300012
J	Lian, ZR; Pan, JB; Liu, J; Zhang, SM; Zhu, MH; Arbuthnot, P; Kew, M; Feitelson, MA				Lian, ZR; Pan, JB; Liu, J; Zhang, SM; Zhu, MH; Arbuthnot, P; Kew, M; Feitelson, MA			The translation initiation factor, hu-Sui1 may be a target of hepatitis B X antigen in hepatocarcinogenesis	ONCOGENE			English	Article						translation initiation; hepatitis B X antigen; Sui1; hepatocellular carcinoma	VIRUS HBX PROTEIN; HEPATOCELLULAR-CARCINOMA; LIVER-CANCER; DNA-BINDING; TRANSACTIVATION FUNCTION; REPLICATIVE SENESCENCE; CELLULAR SENESCENCE; INTEGRATED STATE; CARRIER PATIENTS; GENE PRODUCT(S)	The role of hepatitis B virus X antigen in the development of hepatocellular carcinoma was explored by stably transfecting HepG2 cells with an X antigen expression vector, and identifying the differences in gene expression that distinguish X positive from X negative cells by subtractive PCR, One differentially expressed gene, the human homolog of sdl (hu-sui1), encodes a translation initiation factor whose expression was suppressed by X antigen in HepG2 cells. Hu-Sui1 was also expressed in nontumor liver but not in tumor cells from patients with hepatocellular carcinoma. Introduction of hu-sui1 into HepG2 cells inhibited cell growth in culture, in soft agar, and partially inhibited tumor formation in nude mice. Hence, the suppression of hu-sui1 by X antigen may result in the abrogation of negative growth regulation and contribute to the development of hepatocellular carcinoma.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ Witwatersrand, Dept Med, Mol Hepatol Res Unit, Johannesburg, South Africa; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Fourth Mil Med Coll, Dept Pathol, Xian, Shanxi, Peoples R China	Jefferson University; University of Witwatersrand; Jefferson University; Air Force Military Medical University	Feitelson, MA (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Room 222 Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.		Arbuthnot, Patrick Brian/B-8163-2009; Lian, Zhaorui/AAW-2379-2020		NCI NIH HHS [CA66971, CA48656] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA048656, R01CA048656, R01CA066971] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; AUTUNOVIC J, 1993, CELL MOL BIOL RES, V39, P463; Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Benson DA, 1997, NUCLEIC ACIDS RES, V25, P1, DOI 10.1093/nar/25.1.1; Bond J, 1996, ONCOGENE, V13, P2097; CEPKO CL, 1992, TRANSDUCTION GENES U; CHEN JY, 1988, HEPATOLOGY, V8, P518, DOI 10.1002/hep.1840080315; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Cui Y, 1998, MOL CELL BIOL, V18, P1506, DOI 10.1128/MCB.18.3.1506; DANOS O, 1991, METHOD MOL BIOL, V8, P17; DUAN LX, 1995, HUM GENE THER, V6, P561; FEITELSON MA, 1988, J MED VIROL, V24, P121, DOI 10.1002/jmv.1890240202; FEITELSON MA, 1990, GASTROENTEROLOGY, V98, P1071, DOI 10.1016/0016-5085(90)90035-Y; FEITELSON MA, 1990, VIROLOGY, V177, P357, DOI 10.1016/0042-6822(90)90491-9; FEITELSON MA, 1986, HEPATOLOGY, V6, P191, DOI 10.1002/hep.1840060207; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FEITELSON MA, 1990, VIROLOGY, V177, P367, DOI 10.1016/0042-6822(90)90492-A; FIELDS C, 1994, BIOCHEM BIOPH RES CO, V198, P288, DOI 10.1006/bbrc.1994.1040; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; Henkler F, 1996, J VIRAL HEPATITIS, V3, P109, DOI 10.1111/j.1365-2893.1996.tb00001.x; HENSLER PJ, 1995, AM J PATHOL, V147, P1; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HORIIKE N, 1991, J INFECT DIS, V164, P1104, DOI 10.1093/infdis/164.6.1104; KASTAN MB, 1991, CANCER RES, V51, P6304; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOIKE K, 1994, HEPATOLOGY, V19, P810, DOI 10.1002/hep.1840190403; KOIKE K, 1994, J CLIN INVEST, V94, P44, DOI 10.1172/JCI117343; KWEE L, 1992, J VIROL, V66, P4382, DOI 10.1128/JVI.66.7.4382-4389.1992; Kyrpides NC, 1998, P NATL ACAD SCI USA, V95, P224, DOI 10.1073/pnas.95.1.224; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Luber B, 1996, ONCOGENE, V12, P1597; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MARAKAMI S, 1994, J BIOL CHEM, V269, P15118; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; Ozer A, 1996, GASTROENTEROLOGY, V110, P1519, DOI 10.1053/gast.1996.v110.pm8613059; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; ROBINSON WS, 1982, VIRAL HEPATITIS, P57; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; RUNKEL L, 1993, VIROLOGY, V197, P529, DOI 10.1006/viro.1993.1626; SEEGER C, 1991, J VIROL, V65, P1673, DOI 10.1128/JVI.65.4.1673-1679.1991; SEIFER M, 1991, J HEPATOL, V13, P61, DOI DOI 10.1016/0168-8278(91)90026-8; SHAFRITZ DA, 1981, NEW ENGL J MED, V305, P1067, DOI 10.1056/NEJM198110293051807; Shantz LM, 1996, CANCER RES, V56, P5136; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Sun BS, 1998, HEPATOLOGY, V27, P228, DOI 10.1002/hep.510270135; Szmuness W, 1978, Prog Med Virol, V24, P40; TAKADA S, 1994, VIROLOGY, V205, P503, DOI 10.1006/viro.1994.1671; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; TAKADA S, 1995, J CANCER RES CLIN, V121, P593, DOI 10.1007/BF01197776; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; TWU JS, 1989, J VIROL, V63, P2857, DOI 10.1128/JVI.63.6.2857-2860.1989; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; VALENZUELA P, 1980, ANIMAL VIRUS GENETIC, P57; VILE R, 1991, VIRAL VECTORS GENE E, V8, P1; WANG WL, 1991, CANCER RES, V51, P4971; WANG WL, 1991, HEPATOLOGY, V14, P29, DOI 10.1002/hep.1840140106; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248; ZAHM P, 1988, ONCOGENE, V3, P169; ZHOU YZ, 1987, J NATL CANCER I, V79, P223; ZHU MH, 1993, INT J CANCER, V55, P571, DOI 10.1002/ijc.2910550409	81	55	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	1999	18	9					1677	1687		10.1038/sj.onc.1202470	http://dx.doi.org/10.1038/sj.onc.1202470			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208429				2022-12-28	WOS:000079025000003
J	Kubota, S; Copeland, TD; Pomerantz, RJ				Kubota, S; Copeland, TD; Pomerantz, RJ			Nuclear and nucleolar targeting of human ribosomal protein S25: Common features shared with HIV-1 regulatory proteins	ONCOGENE			English	Article						ribosome; protein; nuclear targeting; rev; HIV-1	IMMUNODEFICIENCY-VIRUS TYPE-1; REV TRANS-ACTIVATOR; GENE-EXPRESSION; MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; FUNCTIONAL-ANALYSIS; VISNA VIRUS; I REX; LOCALIZATION; SEQUENCE	The nuclear and nucleolar targeting properties of human ribosomal protein S25 (RPS25) were analysed by the expression of epitope-tagged RPS25 cDNAs in Cos-l cells. The tagged RPS25 was localized to the cell nucleus, with a strong predominance in the nucleolus. At the amino terminus of RPS25, two stretches of highly basic residues juxtapose. This configuration shares common features with the nucleolar targeting signals (NOS) of lentiviral RNA-binding transactivators, including human immunodeficiency viruses' (HIV) Rev proteins. Deletion and site-directed mutational analyses demonstrated that the first NOS-like stretch is dispensable for both nuclear and nucleolar localization of RPS25, and that the nuclear targeting signal is located within the second NOS-like stretch. It has also been suggested that a set of continuous basic residues and the total number of basic residues should be required for nucleolar targeting. Signal-mediated nuclear/nucleolar targeting was further characterized by the construction and expression of a variety of chimeric constructs, utilizing three different backbones with RPS25 cDNA fragments. Immunofluorescence analyses demonstrated a 17 residue peptide of RPS25 as a potential nuclear/nucleolar targeting signal. The identified peptide signal may belong to a putative subclass of NOS, characterized by compact structure, together with lentiviral RNA binding transactivators.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Dorrance H Hamilton Labs, Div Infect Dis,Ctr Human Virol, Philadelphia, PA 19107 USA; NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Ft Detrick, MD 21702 USA	Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Pomerantz, RJ (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Dorrance H Hamilton Labs, Div Infect Dis,Ctr Human Virol, Philadelphia, PA 19107 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036552] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36552] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI Y, 1992, J BIOL CHEM, V267, P21977; AGRAWAL MG, 1987, J BIOL CHEM, V262, P4868; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; ALONI R, 1992, MOL CELL BIOL, V12, P2203, DOI 10.1128/MCB.12.5.2203; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DANG CV, 1989, J BIOL CHEM, V264, P18019; ENG FJ, 1991, CELL, V65, P797, DOI 10.1016/0092-8674(91)90387-E; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; GOLDFARB DS, 1997, CURR BIOL, V7, P1213; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GRITZ L, 1985, MOL CELL BIOL, V5, P3436, DOI 10.1128/MCB.5.12.3436; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; IMAI T, 1994, GENOMICS, V20, P142, DOI 10.1006/geno.1994.1145; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436; KUBOTA S, 1991, J VIROL, V65, P2452, DOI 10.1128/JVI.65.5.2452-2456.1991; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; Kubota S, 1996, J VIROL, V70, P1282, DOI 10.1128/JVI.70.2.1282-1287.1996; LI H, 1995, J MOL BIOL, V250, P447, DOI 10.1006/jmbi.1995.0389; LI ML, 1991, GENE, V107, P329, DOI 10.1016/0378-1119(91)90335-9; MAGER WH, 1988, BIOCHIM BIOPHYS ACTA, V949, P1, DOI 10.1016/0167-4781(88)90048-6; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MartinNieto J, 1997, J CELL SCI, V110, P955; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; Michael WM, 1996, J BIOL CHEM, V271, P11571, DOI 10.1074/jbc.271.19.11571; MORELAND RB, 1985, P NATL ACAD SCI USA, V82, P6561, DOI 10.1073/pnas.82.19.6561; NOSAKA T, 1993, EXP CELL RES, V209, P89, DOI 10.1006/excr.1993.1289; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; RICHARD N, 1994, VIROLOGY, V204, P123, DOI 10.1006/viro.1994.1516; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Russo G, 1997, J BIOL CHEM, V272, P5229, DOI 10.1074/jbc.272.8.5229; SCHMIDT C, 1995, MOL BIOL CELL, V6, P1875, DOI 10.1091/mbc.6.12.1875; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; SCHOBORG RV, 1994, VIROLOGY, V202, P485, DOI 10.1006/viro.1994.1367; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SIOMI H, 1990, J VIROL, V64, P1803, DOI 10.1128/JVI.64.4.1803-1807.1990; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; SOLLNERWEBB B, 1991, TRENDS BIOCHEM SCI, V16, P58, DOI 10.1016/0968-0004(91)90025-Q; SOMMERVILLE J, 1986, TRENDS BIOCHEM SCI, V11, P438, DOI 10.1016/0968-0004(86)90242-2; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; TANG CK, 1990, BIOCHEMISTRY-US, V29, P4434, DOI 10.1021/bi00470a025; TASHEVA ES, 1995, GENE DEV, V9, P304, DOI 10.1101/gad.9.3.304; TILEY LS, 1991, J VIROL, V65, P3877, DOI 10.1128/JVI.65.7.3877-3881.1991; Warner JR, 1990, CURR OPIN CELL BIOL, V2, P521, DOI 10.1016/0955-0674(90)90137-4; YAN C, 1993, J CELL BIOL, V123, P1081, DOI 10.1083/jcb.123.5.1081; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	51	36	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1503	1514		10.1038/sj.onc.1202429	http://dx.doi.org/10.1038/sj.onc.1202429			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050887				2022-12-28	WOS:000078651600012
J	Dan, S; Naito, M; Seimiya, H; Kizaki, A; Mashima, T; Tsuruo, T				Dan, S; Naito, M; Seimiya, H; Kizaki, A; Mashima, T; Tsuruo, T			Activation of c-Abl tyrosine kinase requires caspase activation and is not involved in JNK/SAPK activation during apoptosis of human monocytic leukemia U937 cells	ONCOGENE			English	Article						c-Abl; JNK1/SAPK; caspase; apoptosis	DEPENDENT PROTEIN-KINASE; DNA-DAMAGE; IONIZING-RADIATION; CELLULAR-RESPONSE; STRESS-RESPONSE; P53; 1-BETA-D-ARABINOFURANOSYLCYTOSINE; PHOSPHORYLATION; RESISTANCE; SUBSTRATE	Genotoxic stress triggers the activation of several sensor molecules, such as p53, JNK1/SAPK and c-Abl, and occasionally promotes the cells to apoptosis, We previously reported that JNK1/SAPK regulates genotoxic stress-induced apoptosis in p53-negative U937 cells by activating caspases, c-Abl is expected to act upstream of JNK1/SAPK activation upon treatment with genotoxic stressors, but its involvement in apoptosis development is still unclear. We herein investigated the kinase activities of c-Abl and JNK1/SAPK during apoptosis elicited by genotoxic anticancer drugs and tumor necrosis factor (TNF) in U937 cells and their apoptosis-resistant variant UK711 cells. We found that the activation of JNK1/SAPK and c-Abl correlated well with apoptosis development in these cell lines. Unexpectedly, however, the JNK1/SAPK activation preceded the c-Abl activation. Moreover, the caspase inhibitor Z-Asp suppressed c-Abl activation and the onset of apoptosis but not the JNK1/SAPK activation. Interestingly, c-Abl tyrosine kinase inhibition by CGP 57148 reduced apoptosis without interfering with JNK1/SAPK activation. These results indicate that c-Abl acts not upstream of JNK1/SAPK but downstream of caspases during the development of p53-independent apoptosis and is possibly involved in accelerating execution of the cell death pathway.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.			Seimiya, Hiroyuki/0000-0003-3314-9736				Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Buchdunger E, 1996, CANCER RES, V56, P100; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; GUNJI H, 1991, CANCER RES, V51, P741; Han ZY, 1996, J BIOL CHEM, V271, P25035, DOI 10.1074/jbc.271.40.25035; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; KASTAN MB, 1991, CANCER RES, V51, P6304; KATAOKA S, 1994, EXP CELL RES, V215, P199, DOI 10.1006/excr.1994.1332; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; McConnell KR, 1997, J IMMUNOL, V158, P2083; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Teraoka H, 1996, FEBS LETT, V393, P1, DOI 10.1016/0014-5793(96)00842-3; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	32	26	27	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1277	1283		10.1038/sj.onc.1202423	http://dx.doi.org/10.1038/sj.onc.1202423			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022809				2022-12-28	WOS:000078510900003
J	Cook, J; Krishnan, S; Ananth, S; Sells, SF; Shi, Y; Walther, MM; Linehan, WM; Sukhatme, VP; Weinstein, MH; Rangnekar, VM				Cook, J; Krishnan, S; Ananth, S; Sells, SF; Shi, Y; Walther, MM; Linehan, WM; Sukhatme, VP; Weinstein, MH; Rangnekar, VM			Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma	ONCOGENE			English	Article						Par-4; renal cell carcinoma; apoptosis	TUMOR-SUPPRESSOR GENE; VONHIPPEL-LINDAU DISEASE; KINASE-C; MUTATIONS; CANCER; IDENTIFICATION; PHENOTYPE; ISOFORMS; TISSUES; PRODUCT	Par-4 is a widely expressed leucine zipper protein that confers sensitization to apoptosis induced by exogenous insults. Because the expression of genes that promote apoptosis may be down-regulated during tumorigenesis, we sought to examine the expression of Par-4 in human tumors, We present here evidence that Par-4 protein levels were severely decreased in human renal cell carcinoma specimens relative to normal tubular cells, Replenishment of Par-4 protein levels in renal cell carcinoma cell lines conferred sensitivity to apoptosis, Because apoptosis may serve as a defense mechanism against malignant transformation or progression, decreased expression of Par-4 may contribute to the pathophysiology of renal cell carcinoma.	Univ Kentucky, Dept Surg, Div Urol, Lexington, KY 40536 USA; Univ Kentucky, Dept Pathol, Lexington, KY 40536 USA; Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40536 USA; Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA; Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA USA; NCI, Urol Oncol Sect, NIH, Bethesda, MD 20892 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rangnekar, VM (corresponding author), Univ Kentucky, Dept Surg, Div Urol, Combs Res Bldg,Room 303,800 Rose St, Lexington, KY 40536 USA.		Sukhatme, Vikas/W-2776-2019		NATIONAL CANCER INSTITUTE [R01CA068258, R01CA060872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044921] Funding Source: NIH RePORTER; NCI NIH HHS [CA68258, CA60872] Funding Source: Medline; NIDDK NIH HHS [DK44921] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GUO Q, 1998, IN PRESS NAT MED; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; Pan HC, 1997, CANCER SURV, V29, P305; QIU G, IN PRESS ONCOGENE; Rangnekar VM, 1998, APOPTOSIS, V3, P61, DOI 10.1023/A:1009666705875; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; WALTHER MM, 1995, J UROLOGY, V154, P278, DOI 10.1016/S0022-5347(01)67294-X; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WYLLIE AH, 1992, CANCER METAST REV, V11, P95, DOI 10.1007/BF00048057	20	87	88	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	1999	18	5					1205	1208		10.1038/sj.onc.1202416	http://dx.doi.org/10.1038/sj.onc.1202416			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022126				2022-12-28	WOS:000078510700009
J	Ess, KC; Witte, DP; Bascomb, CP; Aronow, BJ				Ess, KC; Witte, DP; Bascomb, CP; Aronow, BJ			Diverse developing mouse lineages exhibit high-level c-Myb expression in immature cells and loss of expression upon differentiation	ONCOGENE			English	Article						in situ hybridization; transcription factor; repression; anti-differentiation; development; stem cell; embryogenesis	ADENOSINE-DEAMINASE GENE; LOCUS-CONTROL REGION; B-MYB; A-MYB; TRANSGENIC MICE; HAIR FOLLICLE; TERMINAL DIFFERENTIATION; TRANSCRIPTION FACTORS; LUNG MORPHOGENESIS; GUT EPITHELIUM	The c-myb gene encodes a sequence specific transactivator that is required for fetal hematopoiesis, but its potential role in other tissues is less clear because of the early fetal demise of mice with targeted deletions of the c-myb gene and incomplete of knowledge about c-myb's expression pattern. In the hematopoietic system, c-Myb protein acts on target genes whose expression is restricted to individual lineages, despite Myb's presence and role in multiple immature lineages. This suggests that c-Myb actions within different cell type-specific contexts are strongly affected by combinatorial interactions, To consider the possibility of similar c-Myb actions could extend into non-hematopoietic systems in other cell and tissue compartments, we characterized c-myb expression in developing and adult mice using in situ hybridization and correlated this with stage-specific differentiation and mitotic activity, Diverse tissues exhibited strong c-myb expression during development, notably tooth buds, the thyroid primordium, developing trachea and proximal branching airway epithelium, hair follicles, hematopoietic cells, and gastrointestinal crypt epithelial cells, The latter three of these all maintained high expression into adulthood, but with characteristic restriction to immature cell lineages prior to their terminal differentiation. In all sites, during fetal and adult stages, loss of c-Myb expression correlated strikingly with the initiation of terminal differentiation, but not the loss of mitotic activity. Based on these data, we hypothesize that c-Myb's function during cellular differentiation is both an activator of immature gene expression and a suppressor of terminal differentiation in diverse lineages.	Univ Cincinnati, Childrens Hosp Res Fdn, Div Med & Mol Genet, Cincinnati, OH 45229 USA; Univ Cincinnati, Childrens Hosp Res Fdn, Dept Pathol, Cincinnati, OH 45229 USA; Miami Valley Lab, Div Corp Res, Cincinnati, OH 45061 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Aronow, BJ (corresponding author), Univ Cincinnati, Childrens Hosp Res Fdn, Div Med & Mol Genet, Cincinnati, OH 45229 USA.		Aronow, Bruce J/F-8438-2012		NHLBI NIH HHS [HL07527] Funding Source: Medline; NIDDK NIH HHS [DK47022] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047022] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; ARONOW BJ, 1995, MOL CELL BIOL, V15, P1123; ARONOW BJ, 1992, MOL CELL BIOL, V12, P4170, DOI 10.1128/MCB.12.9.4170; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BARLETTA C, 1992, European Journal of Gynaecological Oncology, V13, P53; Bellon T, 1997, BLOOD, V90, P1828, DOI 10.1182/blood.V90.5.1828; Bellusci S, 1996, DEVELOPMENT, V122, P1693; Bellusci S, 1997, DEVELOPMENT, V124, P53; BEPLER G, 1989, ONCOGENE, V4, P45; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; CHANDRASENA G, 1992, CELL MOL BIOL, V38, P243; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; CUDDIHY AE, 1993, MOL CELL BIOL, V13, P3505, DOI 10.1128/MCB.13.6.3505; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DESBIENS X, 1991, DEVELOPMENT, V111, P699; ESS KC, 1995, MOL CELL BIOL, V15, P5707; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOODLAD RA, 1992, VIRCHOWS ARCH B, V61, P415, DOI 10.1007/BF02890445; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HIJIYA N, 1994, P NATL ACAD SCI USA, V91, P4499, DOI 10.1073/pnas.91.10.4499; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HSIANG YHH, 1995, J IMMUNOL, V154, P5195; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; KIEFER PE, 1987, CANCER RES, V47, P6236; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; Kollar EJ, 1983, EPITHELIAL MESENCHYM, P27; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; LAM EWF, 1992, ONCOGENE, V7, P1885; Latham KE, 1996, ONCOGENE, V13, P1161; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; MACKENZIE A, 1992, DEVELOPMENT, V115, P403; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; MCDERMOTT FT, 1976, VIRCHOWS ARCH B, V22, P353; MIZUGUCHI G, 1995, J BIOL CHEM, V270, P9384, DOI 10.1074/jbc.270.16.9384; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MUKHOPADHYAYA R, 1992, J VIROL, V66, P6035, DOI 10.1128/JVI.66.10.6035-6044.1992; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NASONBURCHENAL K, 1993, P NATL ACAD SCI USA, V90, P1619, DOI 10.1073/pnas.90.4.1619; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Oh IH, 1997, J BIOL CHEM, V272, P21432, DOI 10.1074/jbc.272.34.21432; Postigo AA, 1997, EMBO J, V16, P3924, DOI 10.1093/emboj/16.13.3924; QUEVA C, 1992, DEVELOPMENT, V114, P125; Rosenthal MA, 1996, CELL GROWTH DIFFER, V7, P961; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; SEIBERG M, 1995, J INVEST DERMATOL, V104, P78, DOI 10.1111/1523-1747.ep12613555; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; Sitzmann J, 1996, ONCOGENE, V12, P1889; STENN KS, 1994, J INVEST DERMATOL, V103, P107, DOI 10.1111/1523-1747.ep12391844; TASHIRO S, 1995, ONCOGENE, V10, P1699; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; Thompson MA, 1997, ONCOGENE, V14, P1715, DOI 10.1038/sj.onc.1201007; TORELLI G, 1987, CANCER RES, V47, P5266; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; Tung J, 1997, AM J PHYSIOL-GASTR L, V273, pG83, DOI 10.1152/ajpgi.1997.273.1.G83; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; Wallrapp C, 1997, CANCER RES, V57, P3135; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; WILSON C, 1994, DIFFERENTIATION, V55, P127, DOI 10.1046/j.1432-0436.1994.5520127.x; WITTE DP, 1991, J CELL BIOL, V115, P179, DOI 10.1083/jcb.115.1.179; WOLFF L, 1991, J VIROL, V65, P3607, DOI 10.1128/JVI.65.7.3607-3616.1991; Zannini M, 1997, EMBO J, V16, P3185, DOI 10.1093/emboj/16.11.3185; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	71	43	45	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1103	1111		10.1038/sj.onc.1202387	http://dx.doi.org/10.1038/sj.onc.1202387			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023687				2022-12-28	WOS:000078510600028
J	Bottger, V; Bottger, A; Garcia-Echeverria, C; Ramos, YFM; van der Eb, AJ; Jochemsen, AG; Lane, DP				Bottger, V; Bottger, A; Garcia-Echeverria, C; Ramos, YFM; van der Eb, AJ; Jochemsen, AG; Lane, DP			Comparative study of the p53-mdm2 and p53-MDMX interfaces	ONCOGENE			English	Article						p53; mdm2; MDMX; phage display; phosphorylated peptides	DEPENDENT PROTEIN-KINASE; WILD-TYPE P53; DNA-DAMAGE; MONOCLONAL-ANTIBODIES; PHAGE DISPLAY; MDM2 BINDING; IMMUNOCHEMICAL ANALYSIS; TRANSACTIVATION DOMAIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE	Mdm2 and MDMX are two structurally related p53-binding proteins which show the highest level of sequence similarity in the N-terminal p53-binding domains, Apart from its ability to inhibit p53 mediated transcription, a feature it shares with mdm2, very little is known about the physiological functions of MDMX, It is clearly distinct from mdm2 since its expression appears not to be regulated by p53 and it cannot compensate for lack of mdm2 in early development. We present data on the structural similarity between the p53 binding pockets of mdm2 and MDMX using p53- and phage-selected peptides, From the results we conclude that our recently devised innovative approach to reverse the mdm2-mediated inhibition of p53's transactivation function in vivo would probably target MDMX as well. Strategies for selectively targeting mdm2 and MDMX are suggested and a possible mechanism for regulating the p53-mdm2/MDMX interactions by protein phosphorylation is discussed.	Univ Dundee, Canc Res Campaign Labs, Dundee DD1 4HN, Scotland; Leiden Univ, Med Ctr, Dept Mol Cell Biol, Mol Carcinogenesis Lab, NL-2300 RA Leiden, Netherlands; Novartis Pharma AG, Oncol Res, CH-4002 Basel, Switzerland	University of Dundee; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Novartis	Bottger, V (corresponding author), Univ Dundee, Canc Res Campaign Labs, Dundee DD1 4HN, Scotland.		Ramos, Yolande F. M./C-3774-2018; Lane, David P/C-4920-2008	Ramos, Yolande F. M./0000-0003-1459-413X; Lane, David/0000-0003-0551-3545; Bottger, Angelika/0000-0003-3273-9558				BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARTEK J, 1993, J PATHOL, V169, P27, DOI 10.1002/path.1711690106; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; BOTTGER V, 1995, J MOL BIOL, V247, P932, DOI 10.1006/jmbi.1995.0191; Bottger V, 1996, ONCOGENE, V13, P2141; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHAN S, 1987, MOL CELL PROBE, V1, P73, DOI 10.1016/0890-8508(87)90008-9; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; GARCIAECHEVERRI.C, 1995, LETT PEPT SCI, V2, P369; GARCIAECHEVERRIA C, 1995, LETT PEPT SCI, V2, P93, DOI 10.1007/BF00128503; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Knippschild U, 1996, ONCOGENE, V13, P1387; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LUNA RMD, 1995, NATURE, V378, P203; Mayo LD, 1997, CANCER RES, V57, P5013; MCCAFFERTY J, 1994, APPL BIOCHEM BIOTECH, V47, P157, DOI 10.1007/BF02787932; Meek DW, 1997, BIOCHEM SOC T, V25, P416, DOI 10.1042/bst0250416; MICHEEL B, 1994, J IMMUNOL METHODS, V171, P103, DOI 10.1016/0022-1759(94)90233-X; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MILNE DM, 1992, ONCOGENE, V7, P1361; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Rathmell WK, 1997, CANCER RES, V57, P68; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A	37	157	160	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					189	199		10.1038/sj.onc.1202281	http://dx.doi.org/10.1038/sj.onc.1202281			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926934				2022-12-28	WOS:000078166000021
J	Watts, RG; Huang, CS; Young, MR; Li, JJ; Dong, ZG; Pennie, WD; Colburn, NH				Watts, RG; Huang, CS; Young, MR; Li, JJ; Dong, ZG; Pennie, WD; Colburn, NH			Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation	ONCOGENE			English	Article						MAP kinases; transcription factors; tumor promotion; neoplastic transformation	ACTIVATED PROTEIN-KINASE; SERUM RESPONSE ELEMENT; PROMOTER-INDUCED TRANSFORMATION; SIGNAL-REGULATED KINASES; GROWTH-FACTOR RECEPTOR; C-FOS EXPRESSION; TERNARY COMPLEX; MAP KINASE; JB6 CELLS; S6 KINASE	The mitogen activated protein (MAP) kinases or extracellular signal-regulated kinases (Erks) are activated in response to Ras expression or exposure to tumor promoters or to growth factors, and have been implicated in AP-I transactivation in some models. We have shown that tumor promoter induced activation of the transcription factor AP-1 is required for induced neoplastic transformation in the Balb/C JB6 cell model. Jun and Fos family protein levels have been found not to be limiting for AP-l response. The present study asks whether activation of Erks1 and 2 is required for AP-1 transactivation and transformation of JB6 cells and whether Erks might be targeted for cancer prevention. Expression of either of two different dominant negative kinase inactive Erk2 mutants in transformation sensitive (P+) JB6 cells substantially inhibited the tumor promoter induced activation of Erks1 and 2 and of AP-I measured by a collagenase-luciferase reporter. Multiple mutant Erk2 expressing clonal lines were also rendered non-responsive to induced neoplastic transformation. These observations, together with our recent finding attributing AP-1 non-responsiveness to Erk deficiency in a clonal line of transformation resistant (P-) cells, argue for a requirement for Erks1 and/or 2 activation in AP-1 transactivation in the mouse JB6 neoplastic progression model, and suggest the utility of Erks as a prevention target.	NCI, Frederick Canc Res & Dev Ctr, Lab Biochem Pathol, Frederick, MD 21702 USA; Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Minnesota System	Colburn, NH (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Lab Biochem Pathol, Bldg 560, Frederick, MD 21702 USA.			Li, Jian Jian/0000-0003-3694-9675; Huang, Chuanshu/0000-0003-4133-5096				AHN NG, 1990, J BIOL CHEM, V265, P11495; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, CELL, V5, P62; BENARI ET, 1992, MOL CARCINOGEN, V5, P62, DOI 10.1002/mc.2940050111; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BERNSTEIN LR, 1991, ENVIRON HEALTH PERSP, V93, P111, DOI 10.2307/3431178; Buttice G, 1996, ONCOGENE, V13, P2297; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; GRUDA MC, 1994, ONCOGENE, V9, P2537; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; LEE RM, 1992, J BIOL CHEM, V267, P1088; Li JJ, 1996, CANCER RES, V56, P483; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Strahl T, 1996, P NATL ACAD SCI USA, V93, P11563, DOI 10.1073/pnas.93.21.11563; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKASHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TRIESMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WATTS RG, 1995, MOL CARCINOGEN, V13, P27, DOI 10.1002/mc.2940130106; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	45	103	105	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3493	3498		10.1038/sj.onc.1202259	http://dx.doi.org/10.1038/sj.onc.1202259			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030673				2022-12-28	WOS:000078086200010
J	Liu, WH; Yung, BYM				Liu, WH; Yung, BYM			Mortalization of human promyelocytic leukemia HL-60 cells to be more susceptible to sodium butyrate induced apoptosis and inhibition of telomerase activity by down-regulation of nucleophosmin/B23	ONCOGENE			English	Article						nucleophosmin/B23; apoptosis; telomerase activity	NUCLEOLAR PHOSPHOPROTEIN B23; HELA-CELLS; RNA-SYNTHESIS; PROTEIN B23; HUMAN FIBROBLASTS; IMMORTAL CELLS; ACTINOMYCIN-D; NUMATRIN B23; TRANSLOCATION; GROWTH	Vanadate (10 mu M), a potent inhibitor of tyrosine phosphatase, added simultaneously potentiated BuONa-induced (1 mM) apoptosis, The steady-state level of nucleophosmin/B23 mRNA and the total cellular nucleophosmin/B23 protein decreased during the BuONa/vanadate-induced apoptosis. Stabilization and promotor transcriptional activity assays indicate that the decrease in nucleophosmin/B23 mRNA in BuONa/vanadate-treated HL-60 cells was transcriptionally regulated. A decline in telomerase activity was observed in HL-60 cells treated with BuONa/vanadate for 24-96 h. There was virtually no decline of nucleophosmin/B23 mRNA nor the telomerase activities during the growth arrest by serum-starvation. The decrease in nucleophosmin/B23 mRNA expression and telomerase activity in HL-60 cells subsequent to BuONa/vanadate treatment can thus be attributed to cellular apoptosis rather than the growth arrest induced by BuONa/vanadate. Nucleophosmin/BW antisense oligomer treatment significantly potentiated BuONa-induced apoptosis and inhibition of telomerase activity. Results of this study suggest that nucleophosmin/B23 is one of the key elements in the down-regulation of nucleolar function for cellular apoptosis and mortalization.	Chang Gung Univ, Coll Med, Dept Pharmacol, Canc Biochem Lab, Tao Yuan 333, Taiwan	Chang Gung University	Yung, BYM (corresponding author), Chang Gung Univ, Coll Med, Dept Pharmacol, Canc Biochem Lab, 259 Wen Hwa 1st Rd, Tao Yuan 333, Taiwan.			Yung, Benjamin Yat Ming/0000-0003-0093-3196				Albanell J, 1996, CANCER RES, V56, P1503; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BERNHARD W, 1968, ULTRASTRUCT BIOL, V3, P81; Bestilny LJ, 1996, CANCER RES, V56, P3796; BUSCH H, 1963, CANCER RES, V23, P313; CALABRESSE C, 1993, BIOCHEM BIOPH RES CO, V195, P31, DOI 10.1006/bbrc.1993.2005; CHAN PK, 1989, CANCER RES, V49, P3271; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Chang ST, 1996, BIOCHEM BIOPH RES CO, V221, P594, DOI 10.1006/bbrc.1996.0641; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CHOU YH, 1995, BIOCHEM BIOPH RES CO, V217, P313, DOI 10.1006/bbrc.1995.2779; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; FEUERSTEIN N, 1988, J CELL BIOL, V107, P1629, DOI 10.1083/jcb.107.5.1629; FEUERSTEIN N, 1987, J IMMUNOL, V139, P1818; FONAGY A, 1992, CANCER RES, V52, P5250; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HIYAMA E, 1995, CANCER RES, V55, P3258; Hsu CY, 1998, ONCOGENE, V16, P915, DOI 10.1038/sj.onc.1201615; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI XZ, 1989, BIOCHEM BIOPH RES CO, V163, P72, DOI 10.1016/0006-291X(89)92100-1; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; PATTERSON SD, 1995, J BIOL CHEM, V270, P9429, DOI 10.1074/jbc.270.16.9429; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; PRESTAYKO AW, 1974, BIOCHEMISTRY-US, V13, P1945, DOI 10.1021/bi00706a026; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; WU MH, 1995, BIOCHEM J, V305, P987, DOI 10.1042/bj3050987; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YonedaKato N, 1996, ONCOGENE, V12, P265; YUNG BY, 1990, CANCER RES, V50, P5987; YUNG BYM, 1990, INT J CANCER, V46, P272, DOI 10.1002/ijc.2910460222; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8; YUNG BYM, 1986, CANCER RES, V46, P922; YUNG BYM, 1992, INT J CANCER, V52, P317, DOI 10.1002/ijc.2910520227	46	51	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	1998	17	23					3055	3064		10.1038/sj.onc.1202234	http://dx.doi.org/10.1038/sj.onc.1202234			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881708				2022-12-28	WOS:000077427800013
J	Pochampally, R; Fodera, B; Chen, LH; Shao, WJ; Levine, EA; Chen, JD				Pochampally, R; Fodera, B; Chen, LH; Shao, WJ; Levine, EA; Chen, JD			A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells	ONCOGENE			English	Article						MDM2; p53; oncogene; tumor suppressor; apoptosis; caspase; isoform	WILD-TYPE P53; SOFT-TISSUE SARCOMAS; PROTEOLYTIC CLEAVAGE; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; P53-BINDING PROTEIN; ONCOGENE; ONCOPROTEIN; EXPRESSION; GENE	The MDM2 oncogene product is a regulator of the p53 tumor suppressor. MDM2 is cleaved by Caspase 3 (CPP32) during apoptosis after aspartic acid-361, generating a 60 kd fragment. Here we report that human tumor cell lines often express high levels of a 60 kd MDM2 isoform (p60) in the absence of apoptosis. We demonstrate that p60 is a product of caspase cleavage of full length MDM2 after residue 361. The protease that cleaves MDM2 in non-apoptotic cells appears to be distinct from the apoptosis-specific Caspase 3, since Caspase 3 substrate poly(ADP-ribose) polymerase (PARP) is not cleaved in cells producing p60. The p60 form of MDM2 is a significant fraction of the p53-bound MDM2 protein in certain tumor cells, suggesting that it functions in the regulation of p53. p60 is also detected in breast tumors overexpressing MDM2. These observations suggest that MDM2 is regulated by caspase processing in non-apoptotic cells, and may account for the MDM2 proteins of similar mobility seen in tumors and other cell lines.	Louisiana State Univ, Med Ctr, Dept Microbiol, New Orleans, LA 70112 USA; Louisiana State Univ, Med Ctr, Stanley S Scott Canc Ctr, Dept Surg, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University System	Chen, JD (corresponding author), Louisiana State Univ, Med Ctr, Dept Microbiol, 1901 Perdido St, New Orleans, LA 70112 USA.			Pochampally, Radhika/0000-0002-4263-0364	NCI NIH HHS [CA72915] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072915] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; BuesoRamos CE, 1996, BREAST CANCER RES TR, V37, P179, DOI 10.1007/BF01806499; BUESORAMOS CE, 1993, BLOOD, V82, P2617; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; CORDONCARDO C, 1994, CANCER RES, V54, P794; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Gorgoulis VG, 1996, J PATHOL, V180, P129; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Landers JE, 1997, CANCER RES, V57, P3562; LANDERS JE, 1994, ONCOGENE, V9, P2745; LEACH FS, 1993, CANCER RES, V53, P2231; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SHEIKH MS, 1993, CANCER RES, V53, P3226; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; TAKAHASHI K, 1993, MOL CARCINOGEN, V8, P58, DOI 10.1002/mc.2940080112; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	41	60	60	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2629	2636		10.1038/sj.onc.1202206	http://dx.doi.org/10.1038/sj.onc.1202206			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840926				2022-12-28	WOS:000077058900010
J	Higuchi, M; Proske, RJ; Yeh, ETH				Higuchi, M; Proske, RJ; Yeh, ETH			Inhibition of mitochondrial respiratory chain complex I by TNF results in cytochrome c release, membrane permeability transition, and apoptosis	ONCOGENE			English	Article						reactive oxygen species; caspases; apoptosis; necrosis; cytochrome	TUMOR-NECROSIS-FACTOR; MANGANOUS SUPEROXIDE-DISMUTASE; FAS-MEDIATED APOPTOSIS; CYTO-TOXICITY; ELECTRON-TRANSPORT; CELL-LINES; GENERATION; PROTEASE; BCL-2; INDUCTION	Mitochondria have been shown to play a key role in apoptosis induction. However, the sequence of changes that occur in the mitochondria in the initial step of apoptosis has not been clearly elucidated, Here, we showed that mitochondrial respiratory chain (MRC) complex I was inhibited during the early phase of TNF- or serum withdrawal apoptosis, The importance of complex I inhibition in apoptosis is also supported by the observation that rotenone, an inhibitor of complex I but not that of other complexes, could induce apoptosis in a manner comparable to TNF, We hypothesized that inhibition of complex I could affect electron flow through other complexes leading to cytochrome c release by an antioxidant-sensitive pathway and caspase 3 activation followed by the induction of membrane permeability transition (MPT). This hypothesis is supported by the following observations: (1) TNF and rotenone induced MPT and cytochrome c release; (2) TNF-induced complex I inhibition was observed prior to cytochrome c release and MPT induction; (3) MPT induction was inhibited by a caspase 3 inhibitor, z-DEVD-CH2F, and an antioxidant pyrrolidine dithiocarbamate (PDTC), whereas cytochrome c release was only inhibited by PDTC, Thus, these results suggest that MRC complex I plays a key role in apoptosis signalings.	Univ Texas, Hlth Sci Ctr, Inst Mol Med Prevent Human Dis, Res Ctr Cardiovasc Dis, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Div Mol Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Higuchi, M (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Mol Med Prevent Human Dis, Res Ctr Cardiovasc Dis, 2121 W Holcombe, Houston, TX 77030 USA.							Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; GABAI VL, 1992, TISSUE CELL, V24, P171, DOI 10.1016/0040-8166(92)90090-T; GRANGER DL, 1982, J CELL BIOL, V95, P527, DOI 10.1083/jcb.95.2.527; Guidarelli A, 1996, BIOCHEM J, V317, P371, DOI 10.1042/bj3170371; HARTLEY A, 1994, J NEUROCHEM, V63, P1987; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; HIGUCHI M, 1995, J IMMUNOL METHODS, V178, P173, DOI 10.1016/0022-1759(94)00254-T; HIGUCHI M, 1992, J IMMUNOTHER, V12, P41, DOI 10.1097/00002371-199207000-00005; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KSENZENKO M, 1983, FEBS LETT, V155, P19, DOI 10.1016/0014-5793(83)80200-2; KULL FC, 1981, CANCER RES, V41, P4885; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MACHO A, 1995, BLOOD, V86, P2481; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; PASTORINO JG, 1995, ARCH BIOCHEM BIOPHYS, V318, P175, DOI 10.1006/abbi.1995.1218; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; RICHTER C, 1993, FEBS LETT, V325, P104, DOI 10.1016/0014-5793(93)81423-W; RUTKA JT, 1988, INT J CANCER, V41, P573, DOI 10.1002/ijc.2910410417; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; SOUSSI B, 1990, BIOCHEM J, V265, P227, DOI 10.1042/bj2650227; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Tang DG, 1998, BIOCHEM BIOPH RES CO, V242, P380, DOI 10.1006/bbrc.1997.7969; TAYLOR DE, 1995, ARCH BIOCHEM BIOPHYS, V316, P70, DOI 10.1006/abbi.1995.1011; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	42	108	111	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2515	2524		10.1038/sj.onc.1202485	http://dx.doi.org/10.1038/sj.onc.1202485			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824162				2022-12-28	WOS:000076927300011
J	Lanoix, J; Mullick, A; He, YL; Brave, R; Skup, D				Lanoix, J; Mullick, A; He, YL; Brave, R; Skup, D			Wild-type egr1/Krox24 promotes and dominant-negative mutants inhibit, pluripotent differentiation of p19 embryonal carcinoma cells	ONCOGENE			English	Article						EC cells; differentiation; Krox24; egr1; transcription factors	BINDING TRANSCRIPTION FACTOR; ACID RECEPTORS RARS; RETINOIC ACID; GENE-EXPRESSION; PROTO-ONCOGENE; C-FOS; NEUROECTODERMAL DIFFERENTIATION; MICE LACKING; FACTOR EGR-1; NGFI-A	The zinc-finger transcription factor Krox24 was analysed for its role in differentiation in P19 embryonal carcinoma cells. Reciprocal dominant negative mutants consisting of Krox24 deleted for a crucial region of the zinc-finger domain (Delta Krox24) or of the zinc-finger region alone (Delta Krox24Zf) abolished the activation of transcription by Krox24 in P19 cells. Expression of Krox24 led to spontaneous differentiation of P19 cells in a lineage-independent fashion. Krox24 transfected populations, as well as individual clones randomly picked from them, displayed a nide array of diverse morphologies and expressed markers characteristic of a variety of differentiated cells. The dominant negative mutants blacked differentiation of P19 cells, We conclude that expression of Krox24 is sufficient for pluripotent differentiation of embryonal carcinoma cells, and that expression of Krox24 or other egr family members is essential to this process.	Univ Montreal, Inst Canc Montreal, Ctr Rech Louis Charles Simard, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Bristol Myers Squibb Pharmaceut Res Inst, Dept Oncol, Princeton, NJ 08543 USA	Universite de Montreal; Universite de Montreal; Bristol-Myers Squibb	Skup, D (corresponding author), Univ Montreal, Inst Canc Montreal, Ctr Rech Louis Charles Simard, 1560 Sherbrooke E, Montreal, PQ H2L 4M1, Canada.							BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2846, DOI 10.1128/MCB.13.5.2846; BERARD J, 1994, EMBO J, V13, P5570, DOI 10.1002/j.1460-2075.1994.tb06894.x; BERG RW, 1990, DEV BIOL, V138, P123, DOI 10.1016/0012-1606(90)90182-I; BERNSTEIN SH, 1991, CELL GROWTH DIFFER, V2, P273; BRULET P, 1980, P NATL ACAD SCI-BIOL, V77, P4113, DOI 10.1073/pnas.77.7.4113; CARMAN JA, 1995, DNA CELL BIOL, V14, P581, DOI 10.1089/dna.1995.14.581; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; DARLAND T, 1991, ONCOGENE, V6, P1367; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDWARDS SA, 1991, DEV BIOL, V148, P165, DOI 10.1016/0012-1606(91)90327-Y; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; HERDEGEN T, 1991, J COMP NEUROL, V313, P178, DOI 10.1002/cne.903130113; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; LANOIX J, 1991, CELL GROWTH DIFFER, V2, P391; LEE SL, 1995, J BIOL CHEM, V270, P9971, DOI 10.1074/jbc.270.17.9971; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; Levi G, 1996, DEVELOPMENT, V122, P113; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LUO JM, 1995, MECH DEVELOP, V53, P61, DOI 10.1016/0925-4773(95)00424-6; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCCOY C, 1995, MOL CELL BIOL, V15, P6100; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; MENDELSOHN C, 1994, DEV BIOL, V166, P246, DOI 10.1006/dbio.1994.1311; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PETERSOHN D, 1995, J BIOL CHEM, V270, P24361, DOI 10.1074/jbc.270.41.24361; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; PRINCE VE, 1991, J VIROL, V65, P1801; ROSSANT J, 1982, J EMBRYOL EXP MORPH, V70, P99; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SCHUURING E, 1989, MOL CELL BIOL, V9, P1357, DOI 10.1128/MCB.9.3.1357; SEYFERT VL, 1990, SCIENCE, V250, P797, DOI 10.1126/science.2237429; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STARNAUD R, 1989, ONCOGENE, V4, P1077; STARNAUD R, 1993, MOL CELL BIOL, V13, P1590, DOI 10.1128/MCB.13.3.1590; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; THIEL G, 1994, J BIOL CHEM, V269, P15294; Topilko P, 1998, MOL ENDOCRINOL, V12, P107, DOI 10.1210/mend.12.1.0049; VIDRICAIRE G, 1994, DEVELOPMENT, V120, P115	60	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2495	2504		10.1038/sj.onc.1202166	http://dx.doi.org/10.1038/sj.onc.1202166			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824160				2022-12-28	WOS:000076927300009
J	Smilenov, LB; Mellado, W; Rao, PH; Sawant, SG; Umbricht, CB; Sukumar, S; Pandita, TK				Smilenov, LB; Mellado, W; Rao, PH; Sawant, SG; Umbricht, CB; Sukumar, S; Pandita, TK			Molecular cloning and chromosomal localization of Chinese hamster telomeric protein chTRF1. Its potential role in chromosomal instability	ONCOGENE			English	Article						chTRF1; identity; localization	END ASSOCIATIONS; CELLS; TRF1; SEQUENCES; TELOBOX; LENGTH; YEAST	Chinese hamster cells frequently have altered karyotypes, To investigate the basis of recent observations that karyotypic alterations are related to telomeric fusions, we asked whether these alterations are due to lack of telomere repeat binding factor/s, Further, Chinese hamster chromosomes contain large blocks of interstitial telomeric repeats, which are preferentially involved in chromosome breakage and exchange, rendering it an interesting model for such studies. Here, we report on the cloning and the chromosomal localization of the Chinese hamster telomere repeat binding factor, chTRF1, The sequence analysis revealed, similar to human TRF1 (hTRF1), an N-terminal acidic domain, a TRF1 specific DNA binding motif and a C-terminal Myb type domain, Unlike mouse TRF1 (mTRF1), chTRF1 shows 97.5% identity to hTRF1, chTRF1 gene was localized on the long arm of chromosome 5. In vitro translation of chTRF1 resulted in protein product similar in molecular weight to hTRF1, Immunostaining of Chinese hamster ovary cells (CHO) with anti-TRF1 antibody revealed punctate nuclear staining. At metaphase, antibodies failed to detect TRF1 on most of the chromosome ends and the interstitial telomeric repeat bands. These studies suggest that chTRF1 does not bind the interstitial telomeric repeats, and its presence at the metaphase chromosome ends is limited. The later could be a factor contributing to frequent karyotypic alterations observed in Chinese hamster cells.	Columbia Univ Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Johns Hopkins Univ, Ctr Oncol, Baltimore, MD 21205 USA	Columbia University; Memorial Sloan Kettering Cancer Center; Johns Hopkins University; Johns Hopkins Medicine	Pandita, TK (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Radiol Res, 630 W 168th St, New York, NY 10032 USA.		Pandita, Tej K/AAM-9188-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER; NINDS NIH HHS [NS34746] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Bilaud T, 1996, NUCLEIC ACIDS RES, V24, P1294, DOI 10.1093/nar/24.7.1294; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOUFFLER S, 1993, GENE CHROMOSOME CANC, V6, P98, DOI 10.1002/gcc.2870060206; Bouffler SD, 1996, MUTAT RES-REV GENET, V366, P129, DOI 10.1016/S0165-1110(96)90033-0; Broccoli D, 1997, HUM MOL GENET, V6, P69, DOI 10.1093/hmg/6.1.69; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DEAVEN LL, 1973, CHROMOSOMA, V41, P129, DOI 10.1007/BF00319690; FARR C, 1991, P NATL ACAD SCI USA, V88, P7006, DOI 10.1073/pnas.88.16.7006; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KAO FT, 1969, J CELL PHYSIOL, V74, P245, DOI 10.1002/jcp.1040740305; KATINKA MD, 1992, EMBO J, V11, P725, DOI 10.1002/j.1460-2075.1992.tb05105.x; LEJNINE S, 1995, P NATL ACAD SCI USA, V92, P2393, DOI 10.1073/pnas.92.6.2393; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MEYNE J, 1989, P NATL ACAD SCI USA, V86, P7049, DOI 10.1073/pnas.86.18.7049; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; Pandita TK, 1996, ONCOGENE, V13, P1423; PANDITA TK, 1995, CYTOGENET CELL GENET, V68, P95, DOI 10.1159/000133899; RAO PH, 1993, GENOMICS, V16, P426, DOI 10.1006/geno.1993.1206; SHEN M, 1997, P NATL ACAD SCI USA, V98, P13618; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; TOMMERUP H, 1994, MOL CELL BIOL, V14, P5777, DOI 10.1128/MCB.14.9.5777; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Zakian VA, 1996, TRENDS CELL BIOL, V6, P29, DOI 10.1016/0962-8924(96)81035-X; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	30	19	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2137	2142		10.1038/sj.onc.1202138	http://dx.doi.org/10.1038/sj.onc.1202138			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798685				2022-12-28	WOS:000076540900013
J	Iben, S; Royer-Pokora, B				Iben, S; Royer-Pokora, B			Analysis of native WT1 protein from frozen human kidney and Wilms' tumors	ONCOGENE			English	Article						Wilms' tumor; WT1 protein; gelfiltration	DNA-BINDING; GENE WT1; TRANSCRIPTION; PHOSPHORYLATION; LOCALIZATION; INITIATION; EXPRESSION; INHIBITION; PRODUCT; P53	The Wilms' tumor susceptibility gene, WT1, is altered in a subset of Wilms' tumors and encodes a transcription factor with four zinc fingers. Here we describe the isolation of native WT1 protein from frozen normal human kidney and Wilms' tumor samples. Through size exclusion chromatography and Western blot analysis we determined the elution pattern of WT1, The majority of WT1 from adult kidney and Wilms' tumor specimens was found to elute at a size of approximately 120 kDa, consistent with a WT1 homodimer and some WT1 protein was also found in a higher molecular weight complex, In 14 week fetal kidney the majority of the WT1 protein eluted at a size of 80 kDa, suggesting that at this developmental stage the WT1 protein is not present as a homodimer, The identity of complexing partners can now be studied using this approach.	Univ Dusseldorf, Inst Human Genet & Anthropol, D-40001 Dusseldorf, Germany; Univ Heidelberg, Inst Human Genet & Anthropol, D-69120 Heidelberg, Germany	Heinrich Heine University Dusseldorf; Ruprecht Karls University Heidelberg	Royer-Pokora, B (corresponding author), Univ Dusseldorf, Inst Human Genet & Anthropol, Postfach 101007, D-40001 Dusseldorf, Germany.			Royer-Pokora, Brigitte/0000-0001-5114-7801				BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BRENNER B, 1992, ONCOGENE, V7, P1431; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUBB GR, 1994, LAB INVEST, V71, P472; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MOFFETT P, 1995, P NATL ACAD SCI USA, V92, P11105, DOI 10.1073/pnas.92.24.11105; MUNDLOS S, 1993, DEVELOPMENT, V119, P1329; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Renshaw J, 1997, GENE CHROMOSOME CANC, V19, P256, DOI 10.1002/(SICI)1098-2264(199708)19:4<256::AID-GCC8>3.0.CO;2-W; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; Sakamoto Y, 1997, ONCOGENE, V15, P2001, DOI 10.1038/sj.onc.1201391; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; Schumacher V, 1997, P NATL ACAD SCI USA, V94, P3972, DOI 10.1073/pnas.94.8.3972; Wang ZY, 1996, J BIOL CHEM, V271, P24811, DOI 10.1074/jbc.271.40.24811; Ye Y, 1996, EMBO J, V15, P5606, DOI 10.1002/j.1460-2075.1996.tb00945.x	26	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2533	2536		10.1038/sj.onc.1202618	http://dx.doi.org/10.1038/sj.onc.1202618			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229205				2022-12-28	WOS:000079703300014
J	Metcalfe, S; Weeds, A; Okorokov, AL; Milner, J; Cockman, M; Pope, B				Metcalfe, S; Weeds, A; Okorokov, AL; Milner, J; Cockman, M; Pope, B			Wild-type p53 protein shows calcium-dependent binding to F-actin	ONCOGENE			English	Article						p53; actin; calcium	TUMOR-SUPPRESSOR P53; MUTANT P53; DISRUPTION; CLEAVAGE; CELLS	Nuclear localization of p53 is required for p53 to detect and respond to DNA strand abnormalities and breaks following DNA damage. This leads to activation of the tumour suppressive functions of p53 resulting in either cell cycle arrest and DNA repair; or apoptosis, Critical functional changes in DNA which require strand breaks, including gene rearrangement, may transiently mimic DNA damage: here it is important not to trigger a p53 response. The fine control of p53 in these different circumstances is unknown but may include transient sequestering of p53 in the cytoplasm, Reversible nuclear-cytoplasmic shuttling is an intrinsic property of p53 (Middeler et al,, 1997) associated with cell cycle-related changes in p53's subcellular distribution, Takahashi and Suzuki (1994) described p53 inactivation by shuttling to the cytoplasm and Katsumoto et al, (1995) found wildtype p53 to be closely associated,vith cytoplasmic actin filaments during DNA synthesis. Here we show that, in the presence of free calcium ions, p53 binds directly to F-actin with a dissocation constant of about 10 mu M. Thus, part of the regulatory machinery in normal cell cycling may involve p53-actin interactions regulated by calcium fluxes and the dynamic turnover of F-actin.	Addenbrookes Hosp, Dept Surg, Cambridge CB2 2QQ, England; MRC, Mol Biol Lab, Cambridge CB2 2QQ, England; Univ York, YCRC P53 Lab, York YO1 5DD, N Yorkshire, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; MRC Laboratory Molecular Biology; University of York - UK	Metcalfe, S (corresponding author), Addenbrookes Hosp, Dept Surg, Hills Rd,Box 202, Cambridge CB2 2QQ, England.		Cockman, Matthew/V-9619-2019	Cockman, Matthew/0000-0002-3310-4821; Okorokov, Andrei/0000-0003-2477-3254				Ayscough KR, 1998, CURR OPIN CELL BIOL, V10, P102, DOI 10.1016/S0955-0674(98)80092-6; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; FOURIE AM, 1997, J BIOL CHEM, V272, P1947; GANNON JV, 1991, NATURE, V349, P802; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Guenal I, 1997, J CELL SCI, V110, P489; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; Katsumoto T, 1995, BIOL CELL, V84, P167, DOI 10.1016/0248-4900(96)89426-3; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; Maki CG, 1996, CANCER RES, V56, P2649; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; Molinari M, 1996, ONCOGENE, V13, P2077; POPE B, 1994, FEBS LETT, V338, P58, DOI 10.1016/0014-5793(94)80116-9; Pope BJ, 1997, BIOCHEMISTRY-US, V36, P15848, DOI 10.1021/bi972192p; Rubtsova SN, 1998, FEBS LETT, V430, P353, DOI 10.1016/S0014-5793(98)00692-9; TAKAHASHI K, 1994, ONCOGENE, V9, P183; TAYLOR RS, 1976, BIOCHEM J, V159, P301, DOI 10.1042/bj1590301; WAY M, 1992, J CELL BIOL, V116, P1135, DOI 10.1083/jcb.116.5.1135; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517	22	39	39	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2351	2355		10.1038/sj.onc.1202559	http://dx.doi.org/10.1038/sj.onc.1202559			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327055				2022-12-28	WOS:000079595500007
J	Klesse, LJ; Meyers, KA; Marshall, CJ; Parada, LF				Klesse, LJ; Meyers, KA; Marshall, CJ; Parada, LF			Nerve growth factor induces survival and differentiation through two distinct signaling cascades in PC12 cells	ONCOGENE			English	Article						PC12 cells; nerve growth factor; map kinase; phosphatidylinositol 3-kinase	ADENOVIRUS-MEDIATED TRANSFER; TRK PROTOONCOGENE PRODUCT; TYROSINE KINASE-ACTIVITY; RAT SYMPATHETIC NEURONS; PHOSPHATIDYLINOSITOL 3-KINASE; PHEOCHROMOCYTOMA CELLS; PHOSPHOINOSITIDE 3-KINASE; NEUROTROPHIN RECEPTORS; AKT PROTOONCOGENE; BINDING-SITES	Nerve growth factor induces differentiation and survival of rat PC12 pheochromocytoma cells. The activation of the erk cascade has been implicated in transducing the multitude of signals induced by NGF. In order to explore the role of this signaling cascade in NGF mediated survival, differentiation and proliferation, we generated recombinant adenoviruses which express the intermediates of the erk cascade in their wild type, dominant negative and constitutively activated forms. We show that differentiation of PC12 cells requires activity of the ras/erk pathway, whereas inhibition of this pathway had no effect on survival or proliferation. Constitutively active forms of ras, raf and mek induced PC12 cell differentiation, while dominant interfering forms inhibited differentiation. Survival of PC12 cells in serum-free medium did not require activity of the ras/erk pathway. Instead, PI3 Kinase signaling was necessary for PC12 cell survival. Interestingly, constitutively activated versions of raf and mek were able to promote survival, but again this was dependent on activation of PI3 Kinase. Therefore, at least two distinct signaling pathways are required in PC12 cells for mediation of NGF functions.	Univ Texas, SW Med Ctr, Ctr Dev Biol, Dallas, TX 75235 USA; Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Parada, LF (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Parada, luis F/B-9400-2014	Klesse, Laura/0000-0003-1323-7720	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034296] Funding Source: NIH RePORTER; NINDS NIH HHS [R0I NS 34296] Funding Source: Medline; PHS HHS [T326M08203] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BORASIO GD, 1993, J CELL BIOL, V121, P665, DOI 10.1083/jcb.121.3.665; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EDWARDS SN, 1994, J CELL BIOL, V124, P537, DOI 10.1083/jcb.124.4.537; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Jackson TR, 1996, J CELL SCI, V109, P289; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Nakamura T, 1996, ONCOGENE, V13, P1111; Nobes CD, 1996, NEUROSCIENCE, V70, P1067, DOI 10.1016/0306-4522(95)00420-3; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; Rinkenberger JL, 1997, CURR OPIN GENET DEV, V7, P589, DOI 10.1016/S0959-437X(97)80004-4; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Snider WD, 1996, PHILOS T ROY SOC B, V351, P395, DOI 10.1098/rstb.1996.0034; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SZEBERENYI J, 1992, ONCOGENE, V7, P2105; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TISCHLER AS, 1975, NATURE, V258, P341, DOI 10.1038/258341a0; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOGEL KS, 1995, CELL, V82, P733, DOI 10.1016/0092-8674(95)90470-0; Wang JK, 1996, ONCOGENE, V13, P721; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yan CYI, 1998, J NEUROSCI, V18, P4042; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	72	181	186	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	1999	18	12					2055	2068		10.1038/sj.onc.1202524	http://dx.doi.org/10.1038/sj.onc.1202524			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321730				2022-12-28	WOS:000079346200003
J	Ugolini, F; Adelaide, J; Charafe-Jauffret, E; Nguyen, C; Jacquemier, J; Jordan, B; Birnbaum, D; Pebusque, MJ				Ugolini, F; Adelaide, J; Charafe-Jauffret, E; Nguyen, C; Jacquemier, J; Jordan, B; Birnbaum, D; Pebusque, MJ			Differential expression assay of chromosome arm 8p genes identifies Frizzled-related (FRP1/FRZB) and Fibroblast Growth Factor Receptor 1 (FGFR1) as candidate breast cancer genes	ONCOGENE			English	Article						amplification; breast cancer; tumor suppressor gene; oncogene; FGFR1; FRP1/FRZB; cDNA array; gene expression; chromosome 8	HUMAN GENOME; SUSCEPTIBILITY GENE; DNA AMPLIFICATION; FACTOR HEREGULIN; LINKAGE ANALYSIS; SEQUENCE TAGS; MAP; FAMILY; CELLS; HETEROZYGOSITY	Deletions and amplifications are frequent alterations of the short arm of chromosome 8 associated with various types of cancers, including breast cancers. This indicates the likely presence of tumor suppressor genes and oncogenes, In the present study, we have used the expressed sequence tag (EST) map of 8p11-21 to assemble a set of available cDNAs representing genes from this region. DNA arrays were prepared for expression analysis and search for genes potentially involved in breast cancer, Underexpresion in tumoral breast cells (versus normal breast) was observed for 15 transcripts, Among these, the Frizzled-related gene FRP1/FRZB, was turned off in 78% of breast carcinomas, suggesting that the lack of its product may be associated with malignant transformation, Overexpression in tumoral breast cells was observed for 13 genes. The FGFR1 gene, that encodes a tyrosine kinase receptor for members of the fibroblast growth factor family, was identified as a good candidate for one amplification unit, Taken together, our results demonstrate that such a strategy can rapidly identify genes with an altered pattern of expression and provide candidate genes for malignancies.	INSERM U119, Oncol Mol Lab, F-13009 Marseille, France; Inst J Paoli I Calmettes, Lab Biol Tumeurs, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Anatomopathol, F-13009 Marseille, France; Ctr Immunol Marseille Luminy, TAGC, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Pebusque, MJ (corresponding author), INSERM U119, Oncol Mol Lab, 27 Bd Lei Roure, F-13009 Marseille, France.		ADELAIDE, José JA/O-4390-2017; Nguyen, Catherine/M-4119-2016; Charafe-Jauffret, emmanuelle/P-6009-2017	ADELAIDE, José JA/0000-0003-4364-9857; Nguyen, Catherine/0000-0001-9376-6360; Birnbaum, Daniel/0000-0001-7920-9883; Charafe-Jauffret, emmanuelle/0000-0002-0286-1299				ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S; Anbazhagan R, 1998, AM J PATHOL, V152, P815; Bacus SS, 1996, ONCOGENE, V12, P2535; Barlund M, 1997, GENE CHROMOSOME CANC, V20, P372, DOI 10.1002/(SICI)1098-2264(199712)20:4<372::AID-GCC8>3.0.CO;2-Z; Bernard K, 1996, NUCLEIC ACIDS RES, V24, P1435, DOI 10.1093/nar/24.8.1435; Chaffanet M, 1998, ONCOGENE, V16, P945, DOI 10.1038/sj.onc.1201601; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Courjal F, 1997, CANCER RES, V57, P4360; Dale TC, 1996, CANCER RES, V56, P4320; DIB A, 1995, ONCOGENE, V10, P995; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; Granjeaud S, 1996, GENET ANAL-BIOMOL E, V12, P151, DOI 10.1016/1050-3862(95)00128-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOULGATTE R, 1995, GENOME RES, V5, P272, DOI 10.1101/gr.5.3.272; Imbert A, 1996, GENOMICS, V32, P29, DOI 10.1006/geno.1996.0073; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Jordan BR, 1998, J BIOCHEM-TOKYO, V124, P251, DOI 10.1093/oxfordjournals.jbchem.a022104; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Leach RJ, 1996, CYTOGENET CELL GENET, V75, P71, DOI 10.1159/000134460; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lyne JC, 1997, CANCER J SCI AM, V3, P21; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Miller G, 1997, GENOME RES, V7, P1027, DOI 10.1101/gr.7.10.1027; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Pennisi E, 1998, SCIENCE, V281, P1438, DOI 10.1126/science.281.5382.1438; Pennisi E, 1998, SCIENCE, V279, P1445; Popovici C, 1998, P NATL ACAD SCI USA, V95, P5712, DOI 10.1073/pnas.95.10.5712; POPOVICI C, 1999, IN PRESS BLOOD; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Rocha D, 1997, IMMUNOGENETICS, V46, P142, DOI 10.1007/s002510050253; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Schwab M, 1998, BIOESSAYS, V20, P473, DOI 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.3.CO;2-N; Seitz S, 1997, ONCOGENE, V14, P741, DOI 10.1038/sj.onc.1200881; Tanner MM, 1996, CANCER RES, V56, P3441; Theillet C, 1998, NAT MED, V4, P767, DOI 10.1038/nm0798-767; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Van Hul W, 1998, GENOMICS, V47, P230, DOI 10.1006/geno.1997.5101; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; WILLIAMSON AR, 1995, J NIH RES, V7, P61; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4; Zorn AM, 1997, CURR BIOL, V7, pR501, DOI 10.1016/S0960-9822(06)00248-X; ZUKERBERG LR, 1995, MODERN PATHOL, V8, P560	54	112	123	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	1999	18	10					1903	1910		10.1038/sj.onc.1202739	http://dx.doi.org/10.1038/sj.onc.1202739			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086345				2022-12-28	WOS:000079090000014
J	Arriola, EL; Lopez, AR; Chresta, CM				Arriola, EL; Lopez, AR; Chresta, CM			Differential regulation of p21(waf-1/cip-1) and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop	ONCOGENE			English	Article						testicular neoplasms; p53; Mdm2; etoposide; apoptosis	WILD-TYPE P53; CYCLE CHECKPOINT PATHWAY; HUMAN TESTICULAR-TUMORS; GERM-CELL TUMORS; INDUCED APOPTOSIS; TRANSCRIPTIONAL ACTIVITY; ONCOPROTEIN MDM2; UV-RADIATION; DNA-DAMAGE; IN-VIVO	The Mdm2 protein is frequently overexpressed in human non-seminomatous germ cell tumours and transitional carcinoma of the bladder where it may contribute to tolerance of wtp53. Mdm2 forms an autoregulatory feedback loop with p53; the Mdm2 gene is responsive to transactivation by p53 and once synthesized the Mdm2 protein terminates the p53 response, We show here that the topoisomerase poison etoposide, like ultra violet irradiation, inhibits Mdm2 synthesis. Cytotoxic concentrations of etoposide (IC90 for >3 h) result in inhibition of Mdm2 induction at both the RNA and protein level. Rapid apoptosis ensues, Global transcription is not inhibited: p21(saf-1/cip-1) and GADD45 expression increase in a dose dependent manner. Inhibition of Mdm2 synthesis depends on the continuous presence of etoposide, suggesting the DNA damage may prevent transcription. Downregulation of Mdm2 transcript occurs in cells expressing HPV16-E6 suggesting that inhibition of Mdm2 transcription is p53-independent, When cells are treated with a pulse (1 h) of etoposide and reincubated in drug free medium, Mdm2 synthesis commences immediately after damage is repaired (3 h) and the p53 response is attenuated, Induction of apoptosis and loss of clonogenicity are 3-5-fold lower under pulse treatment conditions. This is the first observation of inhibition of Mdm2 transcription following treatment with topoisomerase (topo II) poisons, a feature that may be useful in tumour types where p53 is tolerated by overexpression of Mdm2.	Univ Manchester, Sch Biol Sci, CRC, Mol & Cellular Pharmacol Res Grp, Manchester M13 9PT, Lancs, England	University of Manchester	Chresta, CM (corresponding author), Univ Manchester, Sch Biol Sci, CRC, Mol & Cellular Pharmacol Res Grp, B-38,Stopford Bldg, Manchester M13 9PT, Lancs, England.		Lopez, Andrea/GQQ-3059-2022					BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARBARESCHI M, 1995, UROL RES, V22, P349, DOI 10.1007/BF00296873; BERTRAND R, 1991, CANCER RES, V51, P6280; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; CANMAN CE, 1994, CANCER RES, V54, P5054; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; Chresta CM, 1996, CANCER RES, V56, P1834; CORDONCARDO C, 1994, CANCER RES, V54, P794; De Jong S., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P638; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FLEISCHHACKER M, 1994, MODERN PATHOL, V7, P435; Guillou L, 1996, AM J PATHOL, V149, P1221; Haines DS, 1997, LEUKEMIA LYMPHOMA, V26, P227, DOI 10.3109/10428199709051772; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Knippschild U, 1996, ONCOGENE, V13, P1387; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; KOHN KW, 1976, BIOCHEMISTRY-US, V15, P4629, DOI 10.1021/bi00666a013; KONDO S, 1995, ONCOGENE, V10, P2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Landers JE, 1997, CANCER RES, V57, P3562; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LIANES P, 1994, J NATL CANCER I, V86, P1325, DOI 10.1093/jnci/86.17.1325; Ljungman M, 1996, ONCOGENE, V13, P823; Lu X, 1996, ONCOGENE, V13, P413; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUNA RMD, 1995, NATURE, V378, P203; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; RIEGER KM, 1995, BRIT J CANCER, V72, P683, DOI 10.1038/bjc.1995.394; RIOU G, 1995, MOL CARCINOGEN, V12, P124, DOI 10.1002/mc.2940120303; RIOU JF, 1993, FEBS LETT, V334, P369, DOI 10.1016/0014-5793(93)80714-6; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; WEINBERG R, 1993, NEURON, V11, P191, DOI 10.1016/0896-6273(93)90177-S; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Xiao G, 1998, ONCOGENE, V16, P1171, DOI 10.1038/sj.onc.1201631; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; [No title captured]	56	52	53	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					1081	1091		10.1038/sj.onc.1202391	http://dx.doi.org/10.1038/sj.onc.1202391			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023685				2022-12-28	WOS:000078510600026
J	Duncan, EL; Reddel, RR				Duncan, EL; Reddel, RR			Downregulation of metallothionein-IIA expression occurs at immortalization	ONCOGENE			English	Article						metallothionein-IIA; immortalization; senescence; SV40	FRAUMENI SYNDROME FIBROBLASTS; HUMAN-DIPLOID FIBROBLASTS; GENE-EXPRESSION; MESSENGER-RNA; HUMAN-CELLS; P16(INK4) EXPRESSION; TELOMERASE ACTIVITY; EPITHELIAL-CELLS; INDUCTION; ZINC	Metallothioneins (MTs) may modulate a variety of cellular processes by regulating the activity of zinc-binding proteins, These proteins have been implicated in cell growth regulation, and their expression is abnormal in some tumors. In particular, MT-IIA is expressed 27-fold less in human colorectal tumors and tumor cell lines compared with normal tissue (Zhang et al,, 1997), Here we demonstrate that MT-IIA downregulation occurs when human cells become immortal, a key event in tumorigenesis, After immortalization MT-IIA expression remains inducible but the basal activity of the MT-IIA promoter is decreased, MT-IIA downregulation at immortalization is one of the most common immortalization-related changes identified to date, suggesting that MT-IIA has a role in this process.	Childrens Med Res Inst, Sydney, NSW 2145, Australia	Children's Medical Research Institute - Australia; University of Sydney	Reddel, RR (corresponding author), Childrens Med Res Inst, Locked Bag 23, Wentworthville, NSW 2145, Australia.		Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107				ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DESILVA R, 1993, CELL MOL BIOL RES, V39, P101; DESILVA R, 1994, EXP CELL RES, V213, P418, DOI 10.1006/excr.1994.1218; Duncan EL, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1263; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GONCHAROVA EI, 1994, CANCER RES, V54, P5318; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HEGUY A, 1986, MOL CELL BIOL, V6, P2149, DOI 10.1128/MCB.6.6.2149; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; JAHROUDI N, 1990, J BIOL CHEM, V265, P6506; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; KARIN M, 1983, P NATL ACAD SCI-BIOL, V80, P4040, DOI 10.1073/pnas.80.13.4040; KARIN M, 1987, MOL CELL BIOL, V7, P606, DOI 10.1128/MCB.7.2.606; KARIN M, 1982, NATURE, V299, P797, DOI 10.1038/299797a0; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KARIN M, 1981, EUR J BIOCHEM, V118, P527, DOI 10.1111/j.1432-1033.1981.tb05551.x; Lechner J F, 1985, J TISSUE CULT METHOD, V9, P43; LECHNER JF, 1985, P NATL ACAD SCI USA, V82, P3884, DOI 10.1073/pnas.82.11.3884; LI Y, 1994, CANCER RES, V54, P6078; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LUCE MC, 1993, EXP GERONTOL, V28, P17, DOI 10.1016/0531-5565(93)90017-8; MACLEAN K, 1994, ONCOGENE, V9, P719; Noble JR, 1996, ONCOGENE, V13, P1259; OFNER D, 1994, VIRCHOWS ARCH, V425, P491; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; SCHMIDT CJ, 1986, P NATL ACAD SCI USA, V83, P3346, DOI 10.1073/pnas.83.10.3346; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; STENNARD FA, 1994, BBA-GENE STRUCT EXPR, V1218, P357, DOI 10.1016/0167-4781(94)90189-9; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; UDOM AO, 1980, BIOCHEM J, V187, P329, DOI 10.1042/bj1870329; VALLEE BL, 1995, NEUROCHEM INT, V27, P23, DOI 10.1016/0197-0186(94)00165-Q; Waalkes MP, 1996, J PHARMACOL EXP THER, V277, P1026; WEST AK, 1990, GENOMICS, V8, P513, DOI 10.1016/0888-7543(90)90038-V; WILSON VL, 1983, SCIENCE, V220, P1054; ZENG J, 1991, FEBS LETT, V279, P310, DOI 10.1016/0014-5793(91)80175-3; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	42	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					897	903		10.1038/sj.onc.1202370	http://dx.doi.org/10.1038/sj.onc.1202370			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023665				2022-12-28	WOS:000078510600006
J	Tomizawa, Y; Kohno, T; Fujita, T; Kiyama, M; Saito, R; Noguchi, M; Matsuno, Y; Hirohashi, S; Yamaguchi, N; Nakajima, T; Yokota, J				Tomizawa, Y; Kohno, T; Fujita, T; Kiyama, M; Saito, R; Noguchi, M; Matsuno, Y; Hirohashi, S; Yamaguchi, N; Nakajima, T; Yokota, J			Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma	ONCOGENE			English	Article						stage I NSCLC; p53 mutation; p53 expression; prognosis	TUMOR-SUPPRESSOR GENE; PROGNOSTIC-SIGNIFICANCE; POOR-PROGNOSIS; BREAST-CANCER; MUTANT P53; MUTATIONS; HETEROZYGOSITY; EXPRESSION; 17P13.3; TP53	The association of p53 abnormalities with the prognosis of patients,vith non-small cell lung carcinoma (NSCLC) has been extensively investigated to date, however, this association is still controversial, Therefore, we investigated the prognostic significance of p53 mutations through exons 2 to 11 and p53 protein expression in 103 cases of stage I NSCLC, p53 mutations were detected in 49 of 103 (48%) tumors, Two separate mutations were detected in four tumors giving a total of 53 unique mutations in 49 tumors. Ten (19%) of mutations occurred outside exons 5-8, Positive immunohistochemical staining of p53 protein was detected in 41 of 103 (40%) tumors. The concordance rate between mutations and protein overexpression,vas only 69%, p53 mutations, but not expression, were significantly associated with a shortened survival of patients (P < 0.001), Furthermore, we investigated the correlation between the types of p53 mutations and prognosis. p53 missense mutations rather than null mutations were associated with poor prognosis (P < 0.001 in missense mutations and P = 0.243 in null mutations), These results indicated that p53 mutations, in particular missense mutations, rather than p53 expression could be a useful molecular marker for the prognosis of patients with surgically resected stage I NSCLC.	Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Canc Informat & Epidemiol Div, Chuo Ku, Tokyo 1040045, Japan; Gunma Univ, Sch Med, Dept Pathol 2, Gunma 3718511, Japan; Hitachi Ltd, Adv Res Lab, Hatoyama, Saitama 3500395, Japan; Gunma Univ, Sch Med, Dept Internal Med 1, Gunma 3718511, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Gunma University; Hitachi Limited; Gunma University	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1 Tsukiji, Tokyo 1040045, Japan.							BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BODNER SM, 1992, ONCOGENE, V7, P743; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; CARBONE DP, 1994, CHEST, V106, pS377, DOI 10.1378/chest.106.6.377S; Casey G, 1996, ONCOGENE, V13, P1971; CHIBA I, 1990, ONCOGENE, V5, P1603; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CORNELIS RS, 1994, CANCER RES, V54, P4200; deAnta JM, 1997, ONCOGENE, V15, P2951, DOI 10.1038/sj.onc.1201475; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FONG KM, 1995, CANCER RES, V55, P4268; Fukuyama Y, 1997, BRIT J CANCER, V75, P1125, DOI 10.1038/bjc.1997.194; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIO Y, 1993, CANCER RES, V53, P1; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISOBE T, 1994, JPN J CANCER RES, V85, P1240, DOI 10.1111/j.1349-7006.1994.tb02936.x; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; Kiyama M, 1996, BIOTECHNIQUES, V21, P710; LOHMANN D, 1993, DIAGN MOL PATHOL, V2, P36, DOI 10.1097/00019606-199300020-00006; MINNA JD, 1991, HARRISONS PRINCIPLES, P1102; Mitsudomi T, 1995, Ann Oncol, V6 Suppl 3, pS9; MITSUDOMI T, 1993, JNCI-J NATL CANCER I, V85, P2018, DOI 10.1093/jnci/85.24.2018; MOORE DF, 1996, LUNG CANC PRINCIPLES, P481; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Ohno A, 1997, INT J ONCOL, V10, P521; OKAMOTO A, 1991, CANCER RES, V51, P5632; OKAMOTO A, 1991, CANCER RES, V51, P5157; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Sakamoto T, 1996, GYNECOL ONCOL, V63, P173, DOI 10.1006/gyno.1996.0302; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; Schultz DC, 1996, CANCER RES, V56, P1997; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THOMPSON AM, 1992, INT J CANCER, V50, P528, DOI 10.1002/ijc.2910500405; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; *WHO, 1981, HIST TYP LUNG TUM, V1; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488	43	72	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1007	1014		10.1038/sj.onc.1202384	http://dx.doi.org/10.1038/sj.onc.1202384			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023676				2022-12-28	WOS:000078510600017
J	Liew, CT; Li, HM; Lo, KW; Leow, CK; Chan, JYH; Hin, LY; Lau, WY; Lai, PBS; Lim, BK; Huang, J; Leung, WT; Wu, S; Lee, JCK				Liew, CT; Li, HM; Lo, KW; Leow, CK; Chan, JYH; Hin, LY; Lau, WY; Lai, PBS; Lim, BK; Huang, J; Leung, WT; Wu, S; Lee, JCK			High frequency of p16(INK4A) gene alterations in hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; p16; hypermethylation; homozygous deletion; mutation	HOMOZYGOUS DELETIONS; DNA METHYLATION; MUTATIONS; INACTIVATION; INHIBITION; MDM2	The tumor suppressor gene p16 (CDKN2/MTS-1/INK4A) is an important component of the cell cycle and inactivation of the gene has been found in a variety of human cancers. In order to investigate the role of p16 gene in the tumorigenesis of hepatocellular carcinoma (HCC), 48 cases of HCC were analysed for p16 alterations by: methylation-specific PCR (MSP) to determine the methylation status of the p16 promoter region; comparative multiplex PCR to detect homozygous deletion; PCR-SSCP and DNA sequencing analysis to identify mutation of the p16 gene. We found high frequency of hypermethylation of the 5' CpG island of the p16 gene in 30 of 48 cases (62.5%) of HCC tumors. Moreover, homozygous deletion at p16 region were present in five of 48 cases (10.4%); and missense mutation were detected in three of 48 cases (6.3%), The overall frequency of p16 alterations, including homozygous deletion, mutation and hypermethylation, in HCC tumors was 70.8% (34 of 48 cases), These findings suggest that: (a) the inactivation of the p16 is a frequent event in HCC; (b) the p16 gene is inactivated by multiple mechanisms including homozygous deletion, promoter hypermethylation and point mutation; (c) the most common somatic alteration of the p16 gene in HCC is de novo hypermethylation of the 5' CpG island; and (d) in contrast to other studies, high frequency of genomic alterations are not uncommon in the 9p21 of the p16 gene. Our results strongly suggest that the p16 gene plays an important role in the pathogenesis of HCC.	Prince Wales Hosp, Chinese Univ Hong Kong, Fac Med, Dept Anat & Cellular Pathol, Shatin, Peoples R China; Prince Wales Hosp, Chinese Univ Hong Kong, Fac Med, Dept Surg, Shatin, Peoples R China; Prince Wales Hosp, Chinese Univ Hong Kong, Fac Med, Dept Clin Oncol, Shatin, Peoples R China; Prince Wales Hosp, Chinese Univ Hong Kong, Fac Med, Dept Obstet & Gynecol, Shatin, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital	Liew, CT (corresponding author), Prince Wales Hosp, Chinese Univ Hong Kong, Fac Med, Dept Anat & Cellular Pathol, Shatin, Peoples R China.		Hin, Lin Yee/B-1204-2009; Lai, Paul BS/K-8556-2015	Hin, Lin Yee/0000-0002-6125-4632; Lai, Paul BS/0000-0002-9469-6728; Lo, Kwok Wai/0000-0002-3488-6124				Baylin SB, 1998, ADV CANCER RES, V72, P141; Biden K, 1997, HEPATOLOGY, V25, P593, DOI 10.1002/hep.510250317; CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Chaubert P, 1997, HEPATOLOGY, V25, P1376, DOI 10.1002/hep.510250613; GERBER MA, 1992, AM J PATHOL, V141, P1271; HERMAN JG, 1995, CANCER RES, V55, P4525; *HONG KONG HOSP AU, 1998, CANC INC MORT HONG K; Hui AM, 1996, HEPATOLOGY, V24, P575, DOI 10.1002/hep.510240319; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kita R, 1996, INT J CANCER, V67, P176, DOI 10.1002/(SICI)1097-0215(19960717)67:2<176::AID-IJC4>3.0.CO;2-Q; MARX J, 1994, SCIENCE, V264, P1846, DOI 10.1126/science.8009205; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MISCHIATI C, 1993, BIOTECHNIQUES, V15, P146; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Qin LX, 1996, ONCOL REP, V3, P405; Reed AL, 1996, CANCER RES, V56, P3630; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; TOMIMATSU M, 1993, CANCER, V72, P683, DOI 10.1002/1097-0142(19930801)72:3<683::AID-CNCR2820720310>3.0.CO;2-C; WEISING K, 1991, ELECTROPHORESIS, V12, P159, DOI 10.1002/elps.1150120211; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	27	156	170	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					789	795		10.1038/sj.onc.1202359	http://dx.doi.org/10.1038/sj.onc.1202359			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989830				2022-12-28	WOS:000078394400025
J	Pupa, SM; Howard, CM; Invernizzi, AM; De Vecchi, R; Giani, C; Claudio, PP; Colnaghi, MI; Giordano, A; Menard, S				Pupa, SM; Howard, CM; Invernizzi, AM; De Vecchi, R; Giani, C; Claudio, PP; Colnaghi, MI; Giordano, A; Menard, S			Ectopic expression of pRb2/p130 suppresses the tumorigenicity of the c-erbB-2-overexpressing SKOV3 tumor cell line	ONCOGENE			English	Article						Rb2; oncosuppressor; c-erbB-2; oncogene; ovary carcinoma; tumorigenicity	RETINOBLASTOMA-SUSCEPTIBILITY GENE; TRANSCRIPTIONAL REPRESSION; NEU PROTOONCOGENE; FAMILY MEMBERS; PROTEIN FAMILY; RB2/P130 GENE; CYCLE; PRODUCT; ONCOGENE; E1A	We investigated the in vitro and in vivo effects of the ectopic expression of the pRb2/p130 cell cycle regulator on c-erbB-2-associated tumorigenicity. SKOV3 ovarian cancer cells, which display c-erbB-2 gene amplification and oncoprotein (p185(HER2)) overexpression, were stably transfected with a plasmid containing the coding sequence for human wild-type pRb2/p130 (wtRb2), or with pcDNA3 empty vector. Three wtRb2-transfected clones (cl. 24, cl. 19, cl. 100) and one empty vector-transfected clone (cl, mock) were randomly picked and further analysed, Western blot analysis revealed high levels of pRb2/p130 in the three clones compared to mock cells. Levels of p185(HER2) and the extent of its tyrosine phosphorylation were similar in all transfectant clones, as were levels of pRb1 and p107, In anchorage-independent growth assays, the number of colonies from wtRb2 clone-transfectants was about 90% less than that arising from mock cells (P < 0.001). Tumor take rates of the three wtRb2-transfected clones xenografted in nu/nu mice were much lower than those of mock cells, and tumor volume was decreased by 80% (P < 0.001). A mutant version of pRb2/p130 deleted of the pocket region (mut-Rb2) was also transfected into SKOV3 cells and studied in parallel with the wtRb2-transfected and pcDNA empty vector-transfected bulk populations. mut-Rb2 transfected cells showed no inhibition of in vitro colony formation and were fully tumorigenic. Together, these findings indicate that Rb2 acts as a tumor suppressor gene in vivo and in vitro in SKOV3 cells and that the intact pocket region is required for the suppressor activity.	Ist Nazl Tumori, Div Expt Oncol E, I-20133 Milan, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Sbarro Inst Canc Res & Mol Med, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Fondazione IRCCS Istituto Nazionale Tumori Milan; Jefferson University	Menard, S (corresponding author), Ist Nazl Tumori, Div Expt Oncol E, Via Venezian 1, I-20133 Milan, Italy.		menard, sylvie mm/C-7940-2011; Giordano, Antonio/F-1927-2010; Claudio, Pier Paolo/AAW-7282-2021; Pupa, Serenella/K-6388-2016	Giordano, Antonio/0000-0002-5959-016X; Claudio, Pier Paolo/0000-0001-7790-1622; Pupa, Serenella/0000-0002-4592-6830; Howard, Candace/0000-0001-6537-3551	NATIONAL CANCER INSTITUTE [R01CA060999] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA60999-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Baldi A, 1996, P NATL ACAD SCI USA, V93, P4629, DOI 10.1073/pnas.93.10.4629; Baldi A, 1997, CLIN CANCER RES, V3, P1691; BALDI A, 1996, CLIN CANCER RES, V2, P1; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FRISCH SM, 1995, CANCER RES, V55, P5551; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; KERN JA, 1994, J CLIN INVEST, V93, P516, DOI 10.1172/JCI117001; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; MATIN A, 1994, ONCOGENE, V9, P1333; MAYOL X, 1993, ONCOGENE, V8, P2561; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Susini T, 1998, J CLIN ONCOL, V16, P1085, DOI 10.1200/JCO.1998.16.3.1085; TAGLIABUE E, 1991, INT J CANCER, V47, P933, DOI 10.1002/ijc.2910470625; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; YEUNG RS, 1993, ONCOGENE, V8, P3465; YU DH, 1994, CELL GROWTH DIFFER, V5, P431; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1992, J BIOL CHEM, V267, P10203; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	31	21	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					651	656		10.1038/sj.onc.1202363	http://dx.doi.org/10.1038/sj.onc.1202363			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989815				2022-12-28	WOS:000078394400010
J	Velasco, JA; Avila, MA; Notario, V				Velasco, JA; Avila, MA; Notario, V			The product of the cph oncogene is a truncated, nucleotide-binding protein that enhances cellular survival to stress	ONCOGENE			English	Article						chemical carcinogenesis; Syrian hamster embryo cells; oncogenic activation; nucleotide-binding proteins; stress survival	HAMSTER-EMBRYO FIBROBLASTS; MULTISTEP CARCINOGENESIS; RIBONUCLEOTIDE REDUCTASE; SEQUENCE SIMILARITY; SIGNAL-TRANSDUCTION; EXCHANGE ACTIVITY; MAMMALIAN-CELLS; GROWTH-FACTOR; P53 GENE; RAS	Cph was isolated from neoplastic Syrian hamster embryo fibroblasts initiated by 3-methylcholanthrene (MCA), and was shown to be a single copy gene in the hamster genome, conserved from yeast to human cells, expressed in fetal cells and most adult tissues, and acting synergistically with H-ras in the transformation of murine NIH3T3 fibroblasts, We have now isolated Syrian hamster full-length cDNAs for the cph oncogene and proto-oncogene, Nucleotide sequence analysis revealed that cph was activated in MCA-treated cells by a point-mutational deletion at codon 214, which caused a shift in the normal open reading frame (ORF) and brought a translation termination codon 33 amino acids downstream. While proto-cph encodes a protein (pcph) of 469 amino acids, cpk encodes a truncated protein (cph) of 246 amino acids with a new, hydrophobic C-terminus, Similar mechanisms activated cph in other MCA-treated Syrian hamster cells. The cph and proto-cph proteins have partial sequence homology with two protein families: GDP/GTP exchange factors and nucleotide phosphohydrolases. In vitro translated, gel-purified cph proteins did not catalyze nucleotide exchange for H-ras, but were able to bind nucleotide phosphates, in particular ribonucleotide diphosphates such as UDP and GDP, Steady-state levels of cph mRNA increased 6.7-fold in hamster neoplastic cells, relative to a 2.2-fold increase in normal cells, when they were subjected to a nutritional stress such as serum deprivation, Moreover, cph-transformed NIH3T3 cells showed increased survival to various forms of stress (serum starvation, hyperthermia, ionizing radiation), strongly suggesting that cph participates in cellular mechanisms of response to stress.	Georgetown Univ, Med Ctr, Dept Radiat Med, Washington, DC 20007 USA	Georgetown University	Notario, V (corresponding author), Georgetown Univ, Med Ctr, Dept Radiat Med, Washington, DC 20007 USA.		/AFP-0764-2022; /AAB-6461-2022; Avila, Matias A/Y-6342-2019	Avila, Matias A/0000-0001-6570-3557	NCI NIH HHS [CA64472, P30-CA-51008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064472, P30CA051008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; ALBOR A, 1994, MOL CARCINOGEN, V11, P176, DOI 10.1002/mc.2940110309; ALBOR A, 1994, CANCER RES, V54, P4502; AVILA MA, 1995, ONCOGENE, V10, P963; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERWALD Y, 1965, J NATL CANCER I, V35, P641; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOREK C, 1987, P NATL ACAD SCI USA, V84, P794, DOI 10.1073/pnas.84.3.794; BOS JL, 1989, CANCER RES, V49, P4682; BOYD JA, 1990, PHARMACOL THERAPEUT, V46, P469, DOI 10.1016/0163-7258(90)90028-Z; BRENNER DG, 1989, P NATL ACAD SCI USA, V86, P5517, DOI 10.1073/pnas.86.14.5517; Broach JR, 1997, CURR OPIN GENET DEV, V7, P1, DOI 10.1016/S0959-437X(97)80102-5; BROOKS BJ, 1987, ADV VIRAL ONCOL, V7, P155; BUSTELO XR, 1994, ONCOGENE, V9, P2405; CHAN AML, 1994, ONCOGENE, V9, P1057; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIPAOLO J A, 1986, Toxicologic Pathology, V14, P417; DIPAOLO JA, 1969, SCIENCE, V165, P917, DOI 10.1126/science.165.3896.917; DIPAOLO JA, 1969, J NATL CANCER I, V42, P867; DIPAOLO JA, 1971, NATURE-NEW BIOL, V230, P240, DOI 10.1038/newbio230240a0; DIPAOLO JA, 1983, J NATL CANCER I, V70, P3; FARBER E, 1984, CANCER RES, V44, P4217; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GILMER TM, 1988, MOL CARCINOGEN, V1, P180, DOI 10.1002/mc.2940010306; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GUSTINCICH S, 1993, CELL GROWTH DIFFER, V4, P753; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HARRIS CC, 1991, CANCER RES, V51, pS5023; HART MJ, 1994, J BIOL CHEM, V269, P62; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Leonardsen L, 1996, ONCOGENE, V13, P2177; Lih CJ, 1996, P NATL ACAD SCI USA, V93, P4617, DOI 10.1073/pnas.93.10.4617; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NOTARIO V, 1990, ONCOGENE, V5, P1425; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1991, NEW BIOL, V3, P372; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCOVASSI AI, 1984, J BIOL CHEM, V259, P973; SELF AJ, 1995, METHOD ENZYMOL, V256, P67; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SODERMAN K, 1986, ANAL BIOCHEM, V152, P89, DOI 10.1016/0003-2697(86)90124-7; STEVENS CW, 1995, RAD ONCOL INVEST, V2, P212; TOKSOZ D, 1994, ONCOGENE, V9, P621; Velasco JA, 1998, MOL CARCINOGEN, V21, P156, DOI 10.1002/(SICI)1098-2744(199803)21:3<156::AID-MC2>3.0.CO;2-K; Velasco JA, 1996, ONCOGENE, V12, P2713; VELASCO JA, 1993, GENE, V137, P179, DOI 10.1016/0378-1119(93)90004-M; VELASCO JA, 1994, ONCOGENE, V9, P2065; WEINBERG RA, 1989, CANCER RES, V49, P3713; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77	69	24	25	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					689	701		10.1038/sj.onc.1202324	http://dx.doi.org/10.1038/sj.onc.1202324			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989819				2022-12-28	WOS:000078394400014
J	Bird, KJ; Semus, HL; Ruddell, A				Bird, KJ; Semus, HL; Ruddell, A			Resistance to avian leukosis virus lymphomagenesis occurs subsequent to proviral c-myc integration	ONCOGENE			English	Article						c-myc; c-erbB; lymphoma; tumor resistance; avian leukosis virus	REPEAT-ENHANCED TRANSCRIPTION; INDUCED ERYTHROBLASTOSIS; LYMPHOID LEUKOSIS; PROMOTER INSERTION; ERBB ACTIVATION; EGF-RECEPTOR; CELLS; INDUCTION; CHICKENS; MICE	Most chicken strains are highly susceptible to avian leukosis virus (ALV) induction of bursal lymphoma, involving proviral integration within the c-myc protoncogene, while certain strains are genetically resistant to lymphomagenesis, A nested PCR assay was developed to analyse the appearance of proviral c-myc integrations after ALV infection of lymphoma-susceptible birds, and to determine whether these integrations arise in lymphoma-resistant birds. Proviral c-myc integrations are detected in bursa and other tissues from 6 day-old lymphoma-susceptible birds infected as embryos, The abundance of bursal cells carrying these integrations increases roughly 40-fold by 35 days of age, indicating that these cells hyperproliferate within the bursal environment. Bursal cells with proviral c-myc integrations also arise soon after infection of lymphoma-resistant embryos. However, these cells expand much more slowly than cells from lymphoma-susceptible birds. Both strains show the same rate of viral infection, so that resistance to lymphomagenesis occurs at a step subsequent to proviral c-myc integration. Proviral c-erbB gene integrations arise at the same frequency in bursa and other tissues of both strains, and they do not increase in abundance during development. These findings indicate that the mechanism of resistance to lymphomagenesis involves specific inhibition of cells with proviral c-myc integrations within the bursa.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA; Univ Rochester, Dept Microbiol & Immunol, Rochester, NY USA	Fred Hutchinson Cancer Center; University of Rochester	Ruddell, A (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N,Mailstop C2-023,POB 19024, Seattle, WA 98104 USA.			Ruddell, Alanna/0000-0002-0195-5576	NCI NIH HHS [R01 CA68328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABA TW, 1984, J VIROL, V51, P123, DOI 10.1128/JVI.51.1.123-130.1984; BACON L, 1979, POULTRY SCI, V58, P1033; BACON LD, 1986, IMMUNOGENETICS, V23, P213, DOI 10.1007/BF00373015; BACON LD, 1981, POULTRY SCI, V60, P1132, DOI 10.3382/ps.0601132; BELLI B, 1995, J VIROL, V69, P5138, DOI 10.1128/JVI.69.8.5138-5141.1995; Bowers WJ, 1996, J VIROL, V70, P3051, DOI 10.1128/JVI.70.5.3051-3059.1996; BOWERS WJ, 1994, LEUKEMIA, V8, pS211; BURMESTER BR, 1960, J NATL CANCER I, V24, P1423; CALLAGHAN T, 1993, ONCOGENE, V8, P2939; CLURMAN BE, 1989, MOL CELL BIOL, V9, P2657, DOI 10.1128/MCB.9.6.2657; COOPER MD, 1968, JNCI-J NATL CANCER I, V41, P373; Curristin SM, 1997, J VIROL, V71, P5972, DOI 10.1128/JVI.71.8.5972-5981.1997; ESCOT C, 1993, ONCOGENE, V8, P969; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWERT DL, 1988, ADV VET SCI COMP MED, V32, P37; FLAMANT F, 1987, VIROLOGY, V160, P301, DOI 10.1016/0042-6822(87)90079-1; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; FUNG YKT, 1982, VIROLOGY, V119, P411; Gong M, 1998, J VIROL, V72, P5517, DOI 10.1128/JVI.72.7.5517-5525.1998; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HENRIKSSON M, 1996, ADV CANCER RES, V68, P110; HIHARA H, 1980, AVIAN DIS, V24, P971, DOI 10.2307/1589971; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; Kung H J, 1991, Curr Top Microbiol Immunol, V171, P1; LINIAL M, 1985, P NATL ACAD SCI USA, V82, P53, DOI 10.1073/pnas.82.1.53; MAAS HJL, 1982, AVIAN PATHOL, V11, P309, DOI 10.1080/03079458208436103; MILES BD, 1985, J VIROL, V54, P295, DOI 10.1128/JVI.54.2.295-303.1985; Muller JR, 1996, CANCER RES, V56, P419; Muller JR, 1997, BLOOD, V89, P291, DOI 10.1182/blood.V89.1.291.291_291_296; NASONBURCHENAL K, 1993, P NATL ACAD SCI USA, V90, P1619, DOI 10.1073/pnas.90.4.1619; Neiman P. E., 1980, Viruses in naturally occurring cancers. Book A, P519; NEIMAN PE, 1994, ADV IMMUNOL, V56, P467, DOI 10.1016/S0065-2776(08)60457-5; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; PELICCI PG, 1986, J EXP MED, V164, P2049, DOI 10.1084/jem.164.6.2049; PETERSON RD, 1966, JNCI-J NATL CANCER I, V36, P585, DOI 10.1093/jnci/36.4.585; PINK JRL, 1985, IMMUNOLOGICAL METHOD, V3, P385; PURCHASE HG, 1977, NATURE, V270, P61, DOI 10.1038/270061a0; RAINES MA, 1985, P NATL ACAD SCI USA, V82, P2287, DOI 10.1073/pnas.82.8.2287; ROBINSON HL, 1986, J VIROL, V57, P28, DOI 10.1128/JVI.57.1.28-36.1986; RUDDELL A, 1988, J VIROL, V62, P2728, DOI 10.1128/JVI.62.8.2728-2735.1988; SHIH CK, 1984, P NATL ACAD SCI-BIOL, V81, P4697, DOI 10.1073/pnas.81.15.4697; SMITH CD, 1994, J VIROL, V68, P6232, DOI 10.1128/JVI.68.10.6232-6242.1994; SMITH EJ, 1979, AVIAN DIS, V23, P698, DOI 10.2307/1589746; Tam W, 1997, MOL CELL BIOL, V17, P1490, DOI 10.1128/MCB.17.3.1490; WURM FM, 1986, P NATL ACAD SCI USA, V83, P5414, DOI 10.1073/pnas.83.15.5414	45	3	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					201	209		10.1038/sj.onc.1202283	http://dx.doi.org/10.1038/sj.onc.1202283			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926935				2022-12-28	WOS:000078166000022
J	Nunez, G; Benedict, MA; Hu, YM; Inohara, N				Nunez, G; Benedict, MA; Hu, YM; Inohara, N			Caspases: the proteases of the apoptotic pathway	ONCOGENE			English	Review						apoptosis; Bcl-2; caspase; cell death; protease	INTERLEUKIN-1-BETA CONVERTING-ENZYME; DOMAIN-CONTAINING PROTEIN; PROGRAMMED CELL-DEATH; FAS-INDUCED APOPTOSIS; CYTOCHROME-C; SIGNALING COMPLEX; CED-3/ICE-LIKE PROTEASE; NEGATIVE SELECTION; NEURONAL APOPTOSIS; INHIBITORY PROTEIN	Apoptosis, a morphologically defined form of physiological cell death, is implemented by a death machinery whose executionary arm is a family of cysteine proteases called caspases. These death proteases are part of a proteolytic caspase cascade that is activated by diverse apoptotic stimuli from outside and inside of the cell. The cell death machinery is evolutionarily conserved and composed of caspases and their regulatory components that include activators and repressors. These key components of the death machinery are linked to signaling pathways that are activated by either ligation of death receptors expressed at the cell surface or intracellular death signals. Caspases are normally present in the cell as proenzymes that require limited proteolysis for activation of enzymatic activity. Recent studies suggest that the basic mechanism of caspase activation is conserved in evolution. Binding of initiator caspase precursors to activator molecules appears to promote procaspase oligomerization and autoactivation. Enzymatic activation of initiator caspases leads to proteolytic activation of downstream (effector) caspases and cleavage of a number of vital proteins, resulting in the orderly demise and removal of the cell.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.		Nuñez, Gabriel/A-7160-2014		NCI NIH HHS [K04 CA64421-01, CA64556] Funding Source: Medline; PHS HHS [T32A107413-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064556, K04CA064421] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Bertin J, 1996, J VIROL, V70, P6251, DOI 10.1128/JVI.70.9.6251-6259.1996; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Brockstedt E, 1998, J BIOL CHEM, V273, P28057, DOI 10.1074/jbc.273.43.28057; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Clayton LK, 1997, EMBO J, V16, P2282, DOI 10.1093/emboj/16.9.2282; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; del Peso L, 1998, J BIOL CHEM, V273, P33495, DOI 10.1074/jbc.273.50.33495; delPeso L, 1997, SCIENCE, V278, P687; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Flygare J, 1998, FEBS LETT, V427, P247, DOI 10.1016/S0014-5793(98)00433-5; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JAATTELA M, 1995, ONCOGENE, V10, P2297; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacCorkle RA, 1998, P NATL ACAD SCI USA, V95, P3655, DOI 10.1073/pnas.95.7.3655; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Rheaume E, 1997, EMBO J, V16, P6346, DOI 10.1093/emboj/16.21.6346; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Schneider TJ, 1997, J IMMUNOL, V159, P4834; Schwab BL, 1998, EXP CELL RES, V238, P415, DOI 10.1006/excr.1997.3850; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shimizu S, 1996, ONCOGENE, V12, P2251; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Ubeda M, 1997, J BIOL CHEM, V272, P19562, DOI 10.1074/jbc.272.31.19562; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	129	879	946	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 24	1998	17	25					3237	3245		10.1038/sj.onc.1202581	http://dx.doi.org/10.1038/sj.onc.1202581			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916986				2022-12-28	WOS:000078048200005
J	Razavi, R; Ramos, JC; Yehia, G; Schlotter, F; Molina, CA				Razavi, R; Ramos, JC; Yehia, G; Schlotter, F; Molina, CA			ICER-II gamma is a tumor suppressor that mediates the antiproliferative activity of cAMP	ONCOGENE			English	Article						cAMP; ICER-II gamma; tumor suppressor; CREM	ELEMENT-BINDING-PROTEINS; TRANSCRIPTION FACTORS; GENE-EXPRESSION; CELL-CYCLE; KINASE; ACTIVATION; INHIBITION; PATHWAY; CREM; FIBROBLASTS	The second messenger cAMP inhibits the proliferation of most cell types. The nuclear response of cAMP is mediated by transcription factors like the cAMP-Responsive Element Modulator (CREM) gene. One of the products of the CREM gene, the transcriptional repressor Inducible cAMP Early Repressor-II gamma (ICER-II gamma), is induced by cAMP. ICER-II gamma blocks cells at the G2/M boundary of the cell cycle. Here we show that ICER-II gamma, dramatically inhibits the growth and DNA synthesis of mouse pituitary tumor cells and human choriocarcinoma cells. This alteration in cell growth is coupled with reduced ability of these cells to grow in an anchorage-independent manner and to form tumors in mice. These data demonstrate that ICER-II gamma is a tumor suppressor gene product mediating the antiproliferative activity of cAMP.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Obstet & Gynecol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Molina, CA (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Obstet & Gynecol, Newark, NJ 07103 USA.				NCI NIH HHS [R29 CA69316] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069316] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; Lamas M, 1997, MOL ENDOCRINOL, V11, P1425, DOI 10.1210/me.11.10.1425; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MOLINA CA, 1997, CELL DEATH REPROD PH, V15, P182; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; VALLEJO M, 1994, J NEUROENDOCRINOL, V6, P587, DOI 10.1111/j.1365-2826.1994.tb00623.x; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	17	33	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	1998	17	23					3015	3019		10.1038/sj.onc.1202225	http://dx.doi.org/10.1038/sj.onc.1202225			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881703				2022-12-28	WOS:000077427800008
J	Wang, XJ; Ohnishi, K; Takahashi, A; Ohnishi, T				Wang, XJ; Ohnishi, K; Takahashi, A; Ohnishi, T			Poly(ADP-ribosyl)ation is required for p53-dependent signal transduction induced by radiation	ONCOGENE			English	Article						p53; WAF1; signal transduction; PARP; 3AB	WILD-TYPE P53; HUMAN GLIOBLASTOMA CELLS; DNA-BINDING FUNCTION; GAMMA-IRRADIATION; ADP-RIBOSYLATION; GROWTH ARREST; PROTEIN; POLYMERASE; INDUCTION; APOPTOSIS	p53 and poly(ADP-ribose) polymerase (PARP) are both DNA damage recognition proteins and can be functionally activated by DNA strand breaks. To understand the functional interaction between these two proteins, the effects of a PARP inhibitor, 3-aminobenzamide (3AB), on the p53 pathway were investigated in human glioblastoma cells with different p53 status. Consistent with previous studies, irradiation with gamma-rays induced both p53 and WAF1 accumulation in A-172 cells (wtp53) but not in T98G cells (mp53). However, the presence of 3AB but not its analog suppressed radiation-induced accumulation of wtp53 and the expression of WAF1 and MDM2. Similar results were also obtained from U87MG, another human glioblastoma cell line with wtp53 status. Northern blotting analysis showed that 3AB inhibited the gamma-ray-induced WAF1 gene expression. Moreover, 3AB but not its analog inhibited irradiation-induced activation of sequence-specific DNA binding of wtp53 as detected using P-32-labeled or biotin-labeled p53 consensus sequence (p53CON). However, immunoblotting with an anti-poly(ADP-ribose) antibody showed that p53 proteins of the p53CON-bound fraction did not contain poly(ADP-ribose) (PAR). These findings suggested that poly(ADP-ribosyl)ation is required for rapid accumulation of p53, activation of p53 sequence-specific DNA binding and its transcriptional activity after DNA damage.	Nara Med Univ, Dept Biol, Kashihara, Nara 6348521, Japan	Nara Medical University	Ohnishi, T (corresponding author), Nara Med Univ, Dept Biol, Kashihara, Nara 6348521, Japan.			Takahashi, Akihisa/0000-0002-9960-2153				Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Aoki H, 1998, MOL CARCINOGEN, V21, P171, DOI 10.1002/(SICI)1098-2744(199803)21:3<171::AID-MC4>3.0.CO;2-P; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DING RC, 1994, CANCER RES, V54, P4627; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUCHS B, 1995, ONCOGENE, V10, P789; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; Hall PA, 1996, J PATHOL, V180, P1; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JUNG JM, 1995, CELL GROWTH DIFFER, V6, P909; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUPPER JH, 1995, MOL CELL BIOL, V15, P3154; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MATSUMOTO H, 1994, CANCER LETT, V87, P39, DOI 10.1016/0304-3835(94)90407-3; McDonald E, 1996, CANCER RES, V56, P2250; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; Ohnishi K, 1998, EXP CELL RES, V238, P399, DOI 10.1006/excr.1997.3842; Ohnishi T, 1998, ONCOGENE, V16, P1507, DOI 10.1038/sj.onc.1201663; Ohnishi T, 1996, J BIOL CHEM, V271, P14510, DOI 10.1074/jbc.271.24.14510; Ohtsubo T, 1997, CANCER RES, V57, P3910; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; SHALL S, 1994, MOL CELL BIOCHEM, V138, P71, DOI 10.1007/BF00928445; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SIMONIN F, 1993, J BIOL CHEM, V268, P13454; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VanGool L, 1997, EUR J BIOCHEM, V244, P15; Wang XJ, 1997, J RADIAT RES, V38, P179, DOI 10.1269/jrr.38.179; Wang XJ, 1997, EXP CELL RES, V237, P186, DOI 10.1006/excr.1997.3780; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WesierskaGadek J, 1996, BIOCHEM BIOPH RES CO, V224, P96, DOI 10.1006/bbrc.1996.0990; WHITACRE CM, 1995, CANCER RES, V55, P3697; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	48	72	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	1998	17	22					2819	2825		10.1038/sj.onc.1202216	http://dx.doi.org/10.1038/sj.onc.1202216			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879988				2022-12-28	WOS:000077286400002
J	Bates, S; Ryan, KM; Phillips, AC; Vousden, KH				Bates, S; Ryan, KM; Phillips, AC; Vousden, KH			Cell cycle arrest and DNA endoreduplication following p21(Waf1/Cip1) expression	ONCOGENE			English	Article						p21(Waf1/Cip1); cell cycle arrest; cyclin dependent kinase; endoreduplication; senescence	DEPENDENT-KINASE INHIBITOR; P53-MEDIATED G(1) ARREST; HUMAN CANCER-CELLS; WILD-TYPE P53; S-PHASE; RETINOBLASTOMA PROTEIN; HUMAN FIBROBLASTS; CDK INHIBITORS; GROWTH ARREST; IN-VIVO	p21(Waf1/Cip1) is a major transcriptional target of p53 and has been shown to be one of the principal mediators of the p53 induced G1 cell cycle arrest. We show that in addition to the G1 block, p21(Waf1/Cip1) can also contribute to a delay in G2 and expression of p21(Waf1/Cip1) gives rise to cell cycle profiles essentially indistinguishable from those obtained following p53 expression. Arrest of cells in G2 likely reflects an inability to induce cyclin B1/cdc2 kinase activity in the presence of p21(Waf1/Cip1), although the inefficient association of p21(Waf1/cip1) and cyclin B1 suggests that the mechanism of inhibition is indirect. Cells released from an S-phase block were not retarded in their ability to progress through S-phase by the presence of p21(Waf1/Cip1), despite efficient inhibition of cyclin E, A and B1 dependent kinase activity, suggesting that p2l(Waf1/Cip1) is inefficient at inhibiting replicative DNA synthesis in vivo. Interestingly, significant numbers of cells released from the p21(Waf1/Cip1) activated G2 block undergo endoreduplication, passing through another S-phase before undergoing mitosis, This supports a function of the mitotic kinases in both entry into mitosis, and also in preventing re-replication of DNA following S-phase and suggests a role for p21(Waf1/Cip1) in coupling DNA synthesis and mitosis, Unlike p53, which induces apoptosis in these cells, extended expression of p21(Waf1/Cip1) resulted in the expression of a senescent-like phenotype in these p53 null, pRB null tumor cells.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Vousden, KH (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Bldg 560,Room 22-96,W 7th St, Frederick, MD 21702 USA.			Ryan, Kevin M./0000-0002-1059-9681				ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756-3282(95)00183-E; BATES S, 1994, ONCOGENE, V9, P1633; BATES S, 1996, CURRENT OPIN GENET D, V6, P1; BOND JA, 1995, CANCER RES, V55, P2404; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; HALL M, 1995, ONCOGENE, V11, P1581; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hickman ES, 1997, J VIROL, V71, P3710, DOI 10.1128/JVI.71.5.3710-3718.1997; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEVEDAKOU EN, 1995, CANCER RES, V55, P2500; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Linke SP, 1997, ONCOGENE, V15, P337, DOI 10.1038/sj.onc.1201200; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; McDonald E, 1996, CANCER RES, V56, P2250; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SHEIKH MS, 1995, ONCOGENE, V11, P1899; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; Stern B, 1996, TRENDS GENET, V12, P345; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XIONG Y, 1992, CELL, V71, P504; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	62	145	149	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1691	1703		10.1038/sj.onc.1202104	http://dx.doi.org/10.1038/sj.onc.1202104			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796698				2022-12-28	WOS:000076200100007
J	Derrington, EA; Dufay, N; Rudkin, BB; Belin, MF				Derrington, EA; Dufay, N; Rudkin, BB; Belin, MF			Human primitive neuroectodermal tumour cells behave as multipotent neural precursors in response to FGF2	ONCOGENE			English	Article						medulloblastoma; stem cells; FGF; proliferation; differentiation; signal transduction	CENTRAL-NERVOUS-SYSTEM; FIBROBLAST GROWTH-FACTOR; STEM-CELLS; HUMAN MEDULLOBLASTOMA; SIGNAL-TRANSDUCTION; PROGENITOR CELLS; FACTOR RECEPTORS; CEREBRAL-CORTEX; HUMAN HOMOLOG; BRAIN-TUMORS	Primitive neuroectodermal tumours (PNET) are thought to derive from the malignant transformation of pluripotent CNS precursors although this hypothesis has yet to be tested in vitro. Here we show that cells of a human PNET cell line 'Dev' express functional fibroblast growth factor (FGF) receptors (FGFR) and respond to FGF2 as multipotent CNS precursors. FGF2 induces tyrosine phosphorylation of FGFR-1 and FGFR-2 and many cellular substrates including MAP kinases and stimulates proliferation. Cells detach from plastic substrates and proliferate to form large clusters of undifferentiated cells. After adhesion to polylysine, cells migrate out from the clusters and differentiate. The majority of differentiated cells express neuronal phenotypes but distinct subpopulations express oligodendrocytic and astrocytic markers. Mature neural differentiation markers are not otherwise detected in Del cells in defined medium. Identical results were obtained with 12 monoclonal subclones as well as the parent cell line, confirming that Dev cells are multipotent, This extends evidence that multipotent CNS precursors are the cellular substrate from which certain PNET develop and shows that FGF2 is a potent proliferation and differentiation inducer for PNET cells in vitro, suggesting that FGF2 may also modulate the evolution of PNET in vivo. Finally our results suggest that PNET cell lines may provide models to elucidate the biology of human multipotent CNS precursors.	Lyon Neurol Hosp, Dept Neuropathol, INSERM U433, F-69003 Lyon, France; Ecole Normale Super Lyon, Differentiat & Cell Cycle Grp, Biol Cellulaire & Mol Lab, UMR 49, F-69364 Lyon 07, France	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); Ecole Normale Superieure de Lyon (ENS de LYON)	Derrington, EA (corresponding author), Lyon Neurol Hosp, Dept Neuropathol, INSERM U433, Bvd Pinel, F-69003 Lyon, France.		Derrington, Ed/G-9478-2017	RUDKIN, Brian B./0000-0003-3700-1982				BIEGEL JA, 1989, GENE CHROMOSOME CANC, V1, P139, DOI 10.1002/gcc.2870010206; BIGNER SH, 1988, CANCER GENET CYTOGEN, V30, P91, DOI 10.1016/0165-4608(88)90096-9; Billon N, 1996, ONCOGENE, V13, P2047; Burnett ME, 1997, CANCER GENET CYTOGEN, V97, P25, DOI 10.1016/S0165-4608(96)00319-6; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; Dubois PM, 1996, J IMMUNOL, V156, P1356; DUFAY N, 1994, EUR J NEUROSCI, V6, P1633, DOI 10.1111/j.1460-9568.1994.tb00554.x; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; GHOSH A, 1995, NEURON, V15, P1; GIRAUDON P, 1993, NEUROSCIENCE, V52, P1069, DOI 10.1016/0306-4522(93)90553-R; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; Gritti A, 1996, J NEUROSCI, V16, P1091; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KILPATRICK TJ, 1993, NEURON, V10, P255, DOI 10.1016/0896-6273(93)90316-J; KILPATRICK TJ, 1995, J NEUROSCI, V15, P3653; Kleihues P, 1993, HISTOLOGICAL TYPING; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; MCKAY R, 1993, CR ACAD SCI III-VIE, V316, P1452; MIYAKE A, 1995, MOL BRAIN RES, V31, P95, DOI 10.1016/0169-328X(95)00039-U; PACKER RJ, 1984, J NEUROSURG, V61, P296, DOI 10.3171/jns.1984.61.2.0296; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; PIETSCH T, 1994, CANCER RES, V54, P3278; Qian XM, 1997, NEURON, V18, P81, DOI 10.1016/S0896-6273(01)80048-9; REID CB, 1995, NEURON, V15, P299, DOI 10.1016/0896-6273(95)90035-7; Rorke LB, 1997, BRAIN PATHOL, V7, P765, DOI 10.1111/j.1750-3639.1997.tb01063.x; Schutz BR, 1996, GENE CHROMOSOME CANC, V16, P196; SHAOUL E, 1995, ONCOGENE, V10, P1553; Smits A, 1996, LAB INVEST, V74, P188; Stemple DL, 1997, NEURON, V18, P1, DOI 10.1016/S0896-6273(01)80018-0; TOHYAMA T, 1992, LAB INVEST, V66, P303; TROJANOWSKI JQ, 1994, MOL CHEM NEUROPATHOL, V21, P219, DOI 10.1007/BF02815352; VALTZ NLM, 1991, NEW BIOL, V3, P364; VESCOVI AL, 1993, NEURON, V11, P951, DOI 10.1016/0896-6273(93)90124-A; Weiner HL, 1996, PEDIATR NEUROSURG, V25, P64, DOI 10.1159/000121099; WILLIAMS BP, 1995, NEURON, V14, P1181, DOI 10.1016/0896-6273(95)90265-1	40	14	16	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1663	1672		10.1038/sj.onc.1202025	http://dx.doi.org/10.1038/sj.onc.1202025			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796695				2022-12-28	WOS:000076200100004
J	Sato, M; Morii, E; Komori, T; Kawahata, H; Sugimoto, M; Terai, K; Shimizu, H; Yasui, T; Ogihara, H; Yasui, N; Ochi, T; Kitamura, Y; Ito, Y; Nomura, S				Sato, M; Morii, E; Komori, T; Kawahata, H; Sugimoto, M; Terai, K; Shimizu, H; Yasui, T; Ogihara, H; Yasui, N; Ochi, T; Kitamura, Y; Ito, Y; Nomura, S			Transcriptional regulation of osteopontin gene in vivo by PEBP2 alpha A/CBFA1 and ETS1 in the skeletal tissues	ONCOGENE			English	Article						osteopontin; PEBP2 alpha A/CBFA1; ETS1; synergistic transactivation; osteogenesis	LEUKEMIA-VIRUS ENHANCERS; CORE-BINDING-FACTOR; GM-CSF PROMOTER; RUNT DOMAIN; MESSENGER-RNA; RESPONSE ELEMENT; RECEPTOR-DELTA; BONE-FORMATION; NUCLEAR FACTOR; IN-VIVO	Osteopontin (Opn) and polyoma enhancer-binding protein (PEBP) 2 alpha A/core binding factor (CBFA) 1 have been suggested to play important roles in ossification, The overlapping localization of opn and PEBP2 alpha A/CBFA1 mRNA, and the marked decrease of opn mRNA expression in PEBP2 alpha A knockout mice, indicated that the transcription of opn gene was controlled by PEBP2 alpha A. In the present study, we determined the direct regulation of PEBP2 alpha A on the opn promoter activity, Opn promoter activity was markedly enhanced by PEBP2 alpha A and ETS1 in a synergistic manner, The synergistic effect was diminished when either the PEBP2 alpha A or ETS1 binding site was mutated, or the spatial arrangement of these sites was mutated by a 4-nt insertion. The distance between these sites was important for transactivation but not protein-DNA binding. The direct interaction between PEBP2 alpha A and ETS1 was depended on protein-DNA binding. These results suggested that the specific spatial arrangement of both sites and direct interaction between PEBP2 alpha A and ETS1, were essential for promoter function. Furthermore, endogenous opn mRNA was decreased with the introduction of dominant negative PEBP2 alpha A to MC3T3/E1 cells expressing endogenous PEBP2 alpha A, ETS1 and opn, These findings suggest that PEBP2 alpha A and ETS1 cooperate iii vivo to regulate expression of the opn gene in the skeletal tissue, Cell type-specific regulation of Opn gene expression will also be discussed.	Osaka Univ, Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Orthopaed Surg, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Med 3, Suita, Osaka 5650871, Japan; Nagoya City Univ, Sch Med, Dept Urol, Nagoya, Aichi 4678601, Japan; Kyoto Univ, Sch Med, Inst Virus Res, Dept Viral Oncol, Kyoto 6068397, Japan	Osaka University; Osaka University; Osaka University; Nagoya City University; Kyoto University	Nomura, S (corresponding author), Osaka Univ, Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan.		YASUI, Takahiro/E-6401-2018	YASUI, Takahiro/0000-0003-2197-2477				AUBIN JE, 1996, J BONE MINER RES, V11, pS102; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BROWN LF, 1994, AM J PATHOL, V145, P610; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Frank R, 1995, ONCOGENE, V11, P2667; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; HALLBERG B, 1992, NUCLEIC ACIDS RES, V20, P6495, DOI 10.1093/nar/20.24.6495; HIRAKAWA K, 1994, J BONE MINER RES, V9, P1551; HIROTA S, 1995, LAB INVEST, V72, P64; HIROTA S, 1993, AM J PATHOL, V143, P1003; HSIANG YHH, 1993, J IMMUNOL, V150, P3905; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KOHRI K, 1993, J BIOL CHEM, V268, P15180; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NAKASE T, 1994, BONE MINER, V26, P109, DOI 10.1016/S0169-6009(08)80056-6; Nimer SD, 1996, BLOOD, V87, P3694, DOI 10.1182/blood.V87.9.3694.bloodjournal8793694; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Oates AJ, 1996, ONCOGENE, V13, P97; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; PAGANO M, 1992, ONCOGENE, V7, P1681; PATARCA R, 1989, J EXP MED, V170, P145, DOI 10.1084/jem.170.1.145; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SATO M, IN PRESS J BONE MINE; SINGH RP, 1991, J EXP MED, V171, P1931; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TAKEMURA T, 1994, HEARING RES, V79, P99, DOI 10.1016/0378-5955(94)90131-7; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WARGNIER A, 1995, P NATL ACAD SCI USA, V92, P6930, DOI 10.1073/pnas.92.15.6930; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; WIJMENGA C, 1995, GENOMICS, V26, P611, DOI 10.1016/0888-7543(95)80185-O; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; YAMADA T, 1995, EUR J IMMUNOL, V25, P2710, DOI 10.1002/eji.1830250947; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	57	183	185	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 24	1998	17	12					1517	1525		10.1038/sj.onc.1202064	http://dx.doi.org/10.1038/sj.onc.1202064			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794229				2022-12-28	WOS:000076089900004
J	Smith, PD; Crossland, S; Parker, G; Osin, P; Brooks, L; Waller, J; Philp, E; Crompton, MR; Gusterson, BA; Allday, MJ; Crook, T				Smith, PD; Crossland, S; Parker, G; Osin, P; Brooks, L; Waller, J; Philp, E; Crompton, MR; Gusterson, BA; Allday, MJ; Crook, T			Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	ONCOGENE			English	Article						p53; novel; mutation; breast; BRCA-1; BRCA-2	CELL-CYCLE ARREST; TRANSCRIPTIONAL ACTIVATION; P53-DEPENDENT APOPTOSIS; DNA-REPAIR; CANCER; BREAST; GENE; MUTATION; MDM2; P21(WAF1/CIP1)	Inheritance of germ-line mutant alleles of BRCA1 and BRCA2 confers a markedly increased risk of breast cancer and we have previously reported a higher incidence of p53 mutations in these tumours than in grade matched sporadic tumours, We have now characterized these p53 mutants, The results of these studies identify a novel class of p53 mutants previously undescribed in human cancer Set with multiple occurrences in BRCA-associated tumours which retain a profile of p53-dependent activities in terms of transactivation, growth suppression and apoptosis induction which is close or equal to wild-type. However, these mutants fail to suppress transformation and exhibit gain of function transforming activity in rat embryo fibroblasts, These mutants therefore fall into a novel category of p53 mutants which dissociate transformation suppression from other wild-type functions. The rarity of these mutants in human cancer and their multiple occurrence in BRCA-associated breast tumours suggests that these novel p53 mutants are selected during malignant progression in the unique genetic background of BRCA1- and BRCA2-associated tumours.	Inst Canc Res, Haddow Labs, Sutton SM2 5NG, Surrey, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Sect Virol & Cell Biol, London W2 1PG, England; London Sch Hyg & Trop Med, Div Clin Sci, London W1, England; Inst Canc Res, Toby Robins Breast Canc Res Ctr, London SW3 6JB, England	University of London; Institute of Cancer Research - UK; Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; University of London; London School of Hygiene & Tropical Medicine; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Crook, T (corresponding author), Inst Canc Res, Haddow Labs, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.		gusterson, barry a/D-3752-2009		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; COLLINS N, 1995, ONCOGENE, V10, P1673; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Crook T, 1998, ONCOGENE, V16, P1429, DOI 10.1038/sj.onc.1201699; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakhani SR, 1997, LANCET, V349, P1505; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LUDWIG T, 1997, GENE DEV, V11, P1126; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIYASHITA T, 1995, CELL, V80, P293; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Parker GA, 1996, ONCOGENE, V13, P2541; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SMITH AP, 1992, HDB HUMAN PERFORMANC, V2, P2; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	39	82	87	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2451	2459		10.1038/sj.onc.1202565	http://dx.doi.org/10.1038/sj.onc.1202565			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229196				2022-12-28	WOS:000079703300005
J	Ettenberg, SA; Keane, MM; Nau, MM; Frankel, M; Wang, LM; Pierce, JH; Lipkowitz, S				Ettenberg, SA; Keane, MM; Nau, MM; Frankel, M; Wang, LM; Pierce, JH; Lipkowitz, S			cbl-b inhibits epidermal growth factor receptor signaling	ONCOGENE			English	Article						cbl proteins; EGF receptor; signal transduction	PROTEIN-COUPLED RECEPTORS; PROTOONCOGENE C-CBL; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; V-CBL; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; T-CELLS; KINASE; ACTIVATION	The role of cbl-b in signaling by the epidermal growth factor receptor (EGFR),vas studied and compared with c-cbl, We demonstrate in vivo, that chl-b, like c-cbl, is phosphorylated and recruited to the EGFR upon EGF stimulation and both cbl proteins can bind to the Grb2 adaptor protein, To investigate the functional role of chi proteins in EGFR signaling, we transfected cbl-b or c-cbl into 32D cells overexpressing the EGFR (32D/EGFR), This cell line is absolutely dependent on exogenous IL-3 or EGF for sustained growth. 32D/EGFR cells overexpressing cbl-b showed markedly inhibited growth in EGF compared to c-cbl transfectants and vector controls, This growth inhibition by cbl-b was the result of a dramatic increase in the number of cells undergoing apoptosis, Consistent with this finding, chl-b overexpression markedly decreased the amplitude and duration of AKT activation upon EGF stimulation compared to either vector controls or c-cbl overexpressing cells. In addition, the duration of EGF mediated MAP kinase and Jun kinase activation in cells overespressing cbl-b is shortened. These data demonstrate that cbl-b inhibits EGF-induced cell growth and that cbl-b and c-cbl have distinct roles in EGF mediated signaling.	USN Hosp, NCI, Med Branch, Dept Genet, Bethesda, MD 20889 USA; Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; NCI, Mol & Cellular Biol Lab, Div Basic Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lipkowitz, S (corresponding author), USN Hosp, NCI, Med Branch, Dept Genet, Bethesda, MD 20889 USA.				NATIONAL CANCER INSTITUTE [ZIASC007263, Z01SC007263] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; Andoniou CE, 1996, ONCOGENE, V12, P1981; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BENSASSON SA, 1995, METHOD CELL BIOL, V46, P29; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CRESPO P, 1994, J BIOL CHEM, V269, P21103; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; IHLE JN, 1981, J IMMUNOL, V126, P2184; IHLE JN, 1982, J IMMUNOL, V129, P2431; JONGEWARD GD, 1995, GENETICS, V139, P1553; KEANE MM, 1995, ONCOGENE, V10, P2367; Khwaja A, 1996, ONCOGENE, V12, P2491; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Levkowitz G, 1996, ONCOGENE, V12, P1117; Liu YC, 1997, J BIOL CHEM, V272, P168; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Odai H, 1995, JPN J CANCER RES, V86, P1119, DOI 10.1111/j.1349-7006.1995.tb03303.x; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; PRYSTOWSKY MB, 1982, J IMMUNOL, V129, P2337; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	46	101	111	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1855	1866		10.1038/sj.onc.1202499	http://dx.doi.org/10.1038/sj.onc.1202499			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086340				2022-12-28	WOS:000079090000009
J	de Lera, TL; Folgueira, L; Martin, AG; Dargemont, C; Pedraza, MA; Bermejo, M; Bonay, P; Fresno, M; Alcami, J				de Lera, TL; Folgueira, L; Martin, AG; Dargemont, C; Pedraza, MA; Bermejo, M; Bonay, P; Fresno, M; Alcami, J			Expression of I kappa B alpha in the nucleus of human peripheral blood T lymphocytes	ONCOGENE			English	Article						IKB alpha; NF-kappa B; nuclear; T lymphocytes	TUMOR-NECROSIS-FACTOR; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; REL ONCOGENE; C-REL; P50; PROTEIN; SUBUNIT; SIGNAL; PHOSPHORYLATION	According to current models the inhibitory capacity of I kappa B alpha would be mediated through the retention of Rel/NF-kappa B proteins in the cytosol. However, I kappa B alpha has also been detected in the nucleus of cell lines and when overexpressed by transient transfection. To gain better insight into the potential role of nuclear I kappa B alpha in a physiological context we have analysed its presence in the nucleus of human peripheral blood T lymphocytes (PBL). We demonstrate the nuclear localization of I kappa B alpha in PBL by different techniques: Western blot, indirect immunofluorescence and electron microscopy. Low levels of nuclear I kappa B alpha were detected in resting cells whereas a superinduction was obtained after PMA activation. The nuclear pool of I kappa B alpha showed a higher stability than cytosolic I kappa B alpha and was partially independent of the resynthesis of the protein. Unexpectedly, the presence of nuclear I kappa B alpha did not inhibit NF-kappa B binding to DNA and this phenomenon was not due to the presence of I kappa B beta at the nuclear level. Immunoprecipitation experiments failed to demonstrate an association between nuclear I kappa B alpha and NF-kappa B proteins. Our results demonstrate that in resting and PMA-activated human PBL, I kappa B alpha is present in the nucleus in an apparently inactive form unable to disrupt NF-kappa B binding from DNA.	Hosp 12 Octubre, Ctr Invest, Microbiol Serv, E-28041 Madrid, Spain; Inst Curie, CNRS, UMR 144, Lab Transport Nucleocytoplasm, F-75231 Paris, France; Univ Autonoma Madrid, Ctr Biol Mol, E-28049 Madrid, Spain	Hospital Universitario 12 de Octubre; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Autonomous University of Madrid	Alcami, J (corresponding author), Hosp 12 Octubre, Ctr Invest, Microbiol Serv, E-28041 Madrid, Spain.		Folgueira, Lola/C-7958-2016; Alcami, Pepe/T-2242-2018	Folgueira, Lola/0000-0002-3730-015X; Alcami, Pepe/0000-0003-0023-7377; Fresno Escudero, Manuel/0000-0002-9223-5477; Bermejo, Mercedes/0000-0001-9909-8578				ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; BACHELERIE F, 1991, NATURE, V350, P709, DOI 10.1038/350709a0; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; Chen BK, 1997, J VIROL, V71, P5495, DOI 10.1128/JVI.71.7.5495-5504.1997; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; LAI JH, 1994, J BIOL CHEM, V269, P30077; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; MATTHEWS JR, 1993, NUCLEIC ACIDS RES, V21, P4516, DOI 10.1093/nar/21.19.4516; MOORE NC, 1995, J IMMUNOL, V155, P4653; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PIMENTELMUINOS FX, 1995, EUR J IMMUNOL, V25, P179, DOI 10.1002/eji.1830250130; PIMENTELMUINOS FX, 1994, J BIOL CHEM, V269, P24424; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; Suyang H, 1996, MOL CELL BIOL, V16, P5444; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413	49	23	23	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1581	1588		10.1038/sj.onc.1202455	http://dx.doi.org/10.1038/sj.onc.1202455			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102628				2022-12-28	WOS:000078770700008
J	Matsubara, K; Kishida, S; Matsuura, Y; Kitayama, H; Noda, M; Kikuchi, A				Matsubara, K; Kishida, S; Matsuura, Y; Kitayama, H; Noda, M; Kikuchi, A			Plasma membrane recruitment of RalGDS is critical for Ras-dependent Ral activation	ONCOGENE			English	Article						intracellular localization; post-translational modification; RalGDS; Ras; Rap	NUCLEOTIDE DISSOCIATION STIMULATOR; GTP-BINDING PROTEINS; C-FOS PROMOTER; SIGNAL-TRANSDUCTION; EUKARYOTIC CELLS; EXCHANGE FACTOR; GOLGI-COMPLEX; H-RAS; R-RAS; TRANSFORMATION	In COS cells, Ral GDP dissociation stimulator (RalGDS)-induced Ral activation was stimulated by Ras(G12V) or a Rap1/Ras chimera in which the IV-terminal region of Rap1 was ligated to the C-terminal region of Ras but not by Rap1(G12V) or a Ras/Rap1 chimera in which the IV-terminal region of Ras was ligated to the C-terminal region of Rap1, although RalGDS interacted with these small GTP-binding proteins, When Ras(G12V), Ral and the Rap1/Ras chimera were individually expressed in NIH3T3 cells, they localized to the plasma membrane. Rap1(Q63E) and the Ras/Rap1 chimera were detected in the perinuclear region, When RalGDS was expressed alone, it was abundant in the cytoplasm, When coexpressed with Ras(G12V) or the Rap1/Ras chimera, RalGDS was detected at the plasma membrane, whereas when coexpressed with Rap1(Q63E) or the Ras/Rap1 chimera, RalGDS was observed in the perinuclear region. RalGDS which was targeted to the plasma membrane by the addition of Ras farnesylation site (RaLGDS-CAAX) activated Ral in the absence of Ras(G12V). Although RalGDS did not stimulate the dissociation of GDP from Ral in the absence of the GTP-bound form of Ras in a reconstitution assay using the liposomes, RalGDS-CAAX could stimulate it without Pas, Ras(G12V) activated Raf-1 when they were coexpressed in Sf9 cells, whereas Ras(G12V) did not affect the RalGDS activity, These results indicate that Pas recruits RalGDS to the plasma membrane and that the translocated RalGDS induces the activation of Ral, but that Rap1 does not activate Pal due to distinct subcellular localization.	Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Natl Inst Infect Dis, Dept Virol 2, Shinjyuku Ku, Tokyo 1628640, Japan; Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto 6068501, Japan	Hiroshima University; National Institute of Infectious Diseases (NIID); Kyoto University	Kikuchi, A (corresponding author), Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.			kishida, shosei/0000-0003-0405-851X				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BERGER G, 1994, BRIT J HAEMATOL, V88, P372, DOI 10.1111/j.1365-2141.1994.tb05033.x; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; KITAYAMA H, 1990, JPN J CANCER RES, V81, P445, DOI 10.1111/j.1349-7006.1990.tb02589.x; KITAYAMA H, 1993, KREV 1 RELATED GENES; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LopezBarahona M, 1996, ONCOGENE, V12, P463; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Murai H, 1997, J BIOL CHEM, V272, P10483; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; PIZON V, 1994, J CELL SCI, V107, P1661; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Summers MD, 1987, MANUAL METHODS BACUL; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P1; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	43	70	72	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1303	1312		10.1038/sj.onc.1202425	http://dx.doi.org/10.1038/sj.onc.1202425			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022812				2022-12-28	WOS:000078510900006
J	Morimoto, AM; Berson, AE; Fujii, GH; Teng, DHF; Tavtigian, SV; Bookstein, R; Steck, PA; Bolen, JB				Morimoto, AM; Berson, AE; Fujii, GH; Teng, DHF; Tavtigian, SV; Bookstein, R; Steck, PA; Bolen, JB			Phenotypic analysis of human glioma cells expressing the MMAC1 tumor suppressor phosphatase	ONCOGENE			English	Article						MMAC1/PTEN; tumor suppressor; phosphatase	GERMLINE MUTATIONS; GENE; PTEN; PROTEINS; BREAST; CANCER	MMAC1, also known as PTEN or TEP-1, was recently identified as a gene commonly mutated in a variety of human neoplasias, Sequence analysis revealed that MMAC1 harbored sequences similar to those found in several protein phosphatases, Subsequent studies demonstrated that MMAC1 possessed in vitro enzymatic activity similar to that exhibited by dual specificity phosphatases, To characterize the potential cellular functions of MMAC1, we expressed wild-type and several mutant variants of MMAC1 in the human glioma cell line, U373, that lacks endogenous expression. While expression of wild-type MMAC1 in these cells significantly reduced their growth rate and saturation density, expression of enzymatically inactive MMAC1 significantly enhanced growth in soft agar, Our observations indicate that while wild-type MMAC1 exhibits activities compatible with its proposed role as a tumor suppressor, cellular expression of MMAC1 containing mutations in the catalytic domain may yield protein products that enhance transformation characteristics.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signaling, Palo Alto, CA 94304 USA; Myriad Genet Inc, Salt Lake City, UT 84108 USA; Canji Inc, San Diego, CA 92121 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Neurooncol, Houston, TX 77030 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Myriad Genetics, Inc; University of Texas System; UTMD Anderson Cancer Center	Morimoto, AM (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signaling, Palo Alto, CA 94304 USA.							BAKER BW, 1992, NUCLEIC ACIDS RES, V20, P5234, DOI 10.1093/nar/20.19.5234; Cheney IW, 1998, CANCER RES, V58, P2331; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Guldberg P, 1997, CANCER RES, V57, P3660; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Onishi M, 1996, EXP HEMATOL, V24, P324; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Teng DHF, 1997, CANCER RES, V57, P5221	21	31	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1261	1266		10.1038/sj.onc.1202441	http://dx.doi.org/10.1038/sj.onc.1202441			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022807				2022-12-28	WOS:000078510900001
J	Hurd, C; Dinda, S; Khattree, N; Moudgil, VK				Hurd, C; Dinda, S; Khattree, N; Moudgil, VK			Estrogen-dependent and independent activation of the P1 promoter of the p53 gene in transiently transfected breast cancer cells	ONCOGENE			English	Article						breast cancer; tumor suppressors; p53; estrogen; antiestrogens; tamoxifen	TUMOR-SUPPRESSOR P53; C-MYC; TRANSCRIPTIONAL REPRESSION; INDUCED APOPTOSIS; RETINOBLASTOMA; PROTEIN; EXPRESSION; PRODUCT; PHOSPHORYLATION; FIBROBLASTS	Loss of p53 function by mutational inactivation is the most common marker of the cancerous phenotype, Previous studies from our laboratory have demonstrated 17 beta estradiol (E-2) induction of p53 protein expression in breast cancer cells. Although direct effects of E-2 on the expression of p53 gene are not known, the steroid is a potent regulator of c-Myc transcription. In the present studies, we have examined the ability of E-2 and antiestrogens to regulate the P1 promoter of the p53 gene which contains a c-Myc responsive element, Estrogen receptor (ER)-positive T47D and MCF-7 cells were transiently transfected with the P1CAT reporter plasmid and levels of CAT activity in response to serum, E-2 and antiestrogens were monitored. Factors in serum were noted to be the dominant inducers of chloramphenicol acetyltransferase (CAT) expression in MCF-7 cells. The levels of CAT were drastically reduced when cells were maintained in serum free medium (SFM). However, a subtle ER-mediated induction of CAT expression was detectable when MCF-7 cells, cultured in SFM, were treated with E-2, In serum-stimulated T47D cells, the CAT expression was minimal. The full ER antagonist, ICI 182 780 (ICI) had no effect. Treatment with E-2 or 4-hydroxy tamoxifen (OHT) resulted in P1CAT induction; OHT was more effective than E-2. Consistent with c-Myc regulation of the P1 promoter, E-2 stimulated endogenous c-Myc in both cell lines. Two forms of c-Myc were expressed independent of E-2 stimuli. The expression of a third more rapidly migrating form was E-2-dependent and ER-mediated since it was blocked by the full ER antagonist, ICI, but not by the ER agonist/antagonist OHT, These data demonstrate both ER-mediated and ER-independent regulation of c-Myc and the P1 promoter of the p53 gene, and show differential effects of the two classes of antiestrogens in their ability to induce the P1 promoter of the p53 gene in breast cancer cells.	Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA; Oakland Univ, Ctr Biomed Res, Rochester, MI 48309 USA	Oakland University; Oakland University	Moudgil, VK (corresponding author), Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020893] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 20893] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altucci L, 1996, ONCOGENE, V12, P2315; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DUBIK D, 1988, J BIOL CHEM, V263, P12705; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HURD C, 1995, J BIOL CHEM, V270, P28507, DOI 10.1074/jbc.270.48.28507; Hurd C, 1997, ONCOGENE, V15, P991, DOI 10.1038/sj.onc.1201233; Hurd C, 1998, HANDBK PHYS, V1, P383; Kang Y, 1996, J NATL CANCER I, V88, P279, DOI 10.1093/jnci/88.5.279; KODALI S, 1994, BIOCHEM BIOPH RES CO, V202, P1413, DOI 10.1006/bbrc.1994.2088; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lukas J, 1996, MOL CELL BIOL, V16, P6917; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; REISMAN D, 1988, P NATL ACAD SCI USA, V85, P5146, DOI 10.1073/pnas.85.14.5146; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; WU HY, 1994, J BIOL CHEM, V269, P20067	26	33	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1067	1072		10.1038/sj.onc.1202398	http://dx.doi.org/10.1038/sj.onc.1202398			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023683				2022-12-28	WOS:000078510600024
J	Kishida, M; Koyama, S; Kishida, S; Matsubara, K; Nakashima, S; Higano, K; Takada, R; Takada, S; Kikuchi, A				Kishida, M; Koyama, S; Kishida, S; Matsubara, K; Nakashima, S; Higano, K; Takada, R; Takada, S; Kikuchi, A			Axin prevents Wnt-3a-induced accumulation of beta-catenin	ONCOGENE			English	Article						Axin; Wnt; beta-catenin; APC; GSK-3 beta	GLYCOGEN-SYNTHASE KINASE-3; MOUSE FUSED LOCUS; INT-1 PROTOONCOGENE; SIGNALING PATHWAY; XENOPUS EMBRYOS; MAMMALIAN-CELLS; WNT GENES; PROTEIN; COMPLEX; APC	When Axin, a negative regulator of the Wnt signaling pathway, was expressed in COS cells, it coeluted with glycogen synthase kinase-3 beta (GSK-3 beta), beta-catenin, and adenomatous polyposis coli protein (APC) in a high molecular weight fraction on gel filtration column chromatography. In this fraction, GSK-3 beta, beta-catenin, and APC were co-precipitated with Axin. Although beta-catenin was detected in the high molecular weight fraction in L cells on gel filtration column chromatography, addition of conditioned medium expressing Wnt-3a to the cells increased beta-catenin in the low molecular weight fraction. However, Wnt-3a-dependent accumulation of beta-catenin was greatly inhibited in L cells stably expressing Axin, Axin also suppressed Wnt-3a-dependent activation of Tcf-4 which binds to beta-catenin and acts as a transcription factor. These results suggest that Axin forms a complex with GSK-3 beta, beta-catenin, and APC, resulting in the stimulation of the degradation of beta-catenin and that Wnt-3a induces the dissociation of beta-catenin from the Axin complex and accumulates beta-catenin.	Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Kyoto Univ, Fac Sci, Ctr Mol & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Hiroshima University; Kyoto University	Kikuchi, A (corresponding author), Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.			kishida, shosei/0000-0003-0405-851X; Takada, Shinji/0000-0003-4125-6056; Takada, Ritsuko/0000-0002-1615-056X				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; GLUECKSOHNSCHOENHEIMER S, 1949, J EXP ZOOL, V110, P47, DOI 10.1002/jez.1401100105; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeya M, 1997, NATURE, V389, P966, DOI 10.1038/40146; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; JACOBSCOHEN RJ, 1984, GENET RES, V43, P43, DOI 10.1017/S0016672300025702; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PARR BA, 1993, DEVELOPMENT, V119, P247; PERRY WL, 1995, GENETICS, V141, P321; PIERCE SB, 1995, DEVELOPMENT, V121, P755; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451; Reed SC, 1937, GENETICS, V22, P1; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; SHIBAMOTO S, 1999, IN PRESS GENES CELLS; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; Stewart DB, 1997, J BIOL CHEM, V272, P29652, DOI 10.1074/jbc.272.47.29652; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; YOST C, 1996, GENE DEV, V10, P143; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	47	116	120	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					979	985		10.1038/sj.onc.1202388	http://dx.doi.org/10.1038/sj.onc.1202388			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023673				2022-12-28	WOS:000078510600014
J	Hummel, JL; Wells, RA; Dube, ID; Licht, JD; Kamel-Reid, S				Hummel, JL; Wells, RA; Dube, ID; Licht, JD; Kamel-Reid, S			Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia	ONCOGENE			English	Article						APL; NPM-RAR alpha; PLZF; subcellular localization	ACID RECEPTOR-ALPHA; MITOTIC APPARATUS PROTEIN; POLYMERASE CHAIN-REACTION; NON-HODGKINS-LYMPHOMA; ZINC FINGER GENE; PML-RAR-ALPHA; RETINOIC ACID; DNA-BINDING; MOLECULAR CHARACTERIZATION; T(15-17) TRANSLOCATION	Greater than 95% of acute promyelocytic leukemia (APL) cases are associated with the expression of PML-RAR alpha. This chimeric protein has been strongly implicated in APL pathogenesis because of its interactions with growth suppressors (PML), retinoid signaling molecules (RXR alpha), and nuclear hormone transcriptional co-repressors (N-CoR and SMRT), A small number of variant APL translocations have also been shown to involve rearrangements that fuse RAR alpha to partner genes other than PML, namely PLZF, NPM, and NuMA. We describe the molecular characterization of a t(5;17)(q35;q21) variant translocation involving the NPM gene, identified in a pediatric case of APL, RT-PCR, cloning, and sequence studies identified NPM as the RAR alpha partner on chromosome 5, and both NPM-RAR alpha and RAR alpha-NPM fusion mRNAs were expressed in this patient. We further explored the effects of the NPM-RAR alpha chimeric protein on the subcellular localization of PML, RXR alpha, NPM, and PLZF using immunofluorescent confocal microscopy. While PML remained localized to its normal 10-20 nuclear bodies, NPM nucleolar localization was disrupted and PLZF expression was upregulated in a microspeckled pattern in patient leukemic bone marrow cells, We also observed nuclear co-localization of NPM, RXRa, and NPM-RAR alpha in these cells. Our data support the hypothesis that while deregulation of both the retinoid signaling pathway and RAR alpha partner proteins are molecular consequences of APL translocations, APL pathogenesis is not dependent on disruption of PML nuclear bodies.	Toronto Hosp, Princess Margaret Hosp, Ontario Canc Inst, Canc Cytogenet & Mol Oncol Program, Toronto, ON M5G 2M9, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada; Sunnybrook Hlth Sci Ctr, Lab Med, Toronto, ON M4N 3M5, Canada; Harvard Univ, Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat, Boston, MA 02115 USA; CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Mol Biol, New York, NY 10029 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Kamel-Reid, S (corresponding author), Toronto Hosp, Princess Margaret Hosp, Ontario Canc Inst, Canc Cytogenet & Mol Oncol Program, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.		Licht, Jonathan/L-4239-2019; Licht, Jonathan/AAL-9184-2020	Licht, Jonathan/0000-0002-3942-1369; Kamel-Reid, Suzanne/0000-0002-4386-0292	NCI NIH HHS [R01 CA 59936] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Borden KLB, 1997, FEBS LETT, V418, P30, DOI 10.1016/S0014-5793(97)01344-6; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BORROW J, 1992, BRIT J HAEMATOL, V82, P529, DOI 10.1111/j.1365-2141.1992.tb06463.x; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CASTAIGNE S, 1992, BLOOD, V79, P3110; CHAN PK, 1990, BIOCHEM J, V270, P549, DOI 10.1042/bj2700549; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DANIEL MT, 1993, BLOOD, V82, P1858; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P271, DOI 10.1007/BF01538965; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1994, BLOOD, V83, P10; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; Grimwade D, 1997, BLOOD, V90, P4876; Grimwade D, 1996, BRIT J HAEMATOL, V94, P557; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; HERRERA JE, 1995, NUCLEIC ACIDS RES, V23, P3974, DOI 10.1093/nar/23.19.3974; Herrera JE, 1996, BIOCHEMISTRY-US, V35, P2668, DOI 10.1021/bi9523320; HILLSTEAD LF, 1957, ACTA MED SCAND, V69, P189; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KANG YJ, 1974, J BIOL CHEM, V249, P5580; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Li YP, 1996, EUR J BIOCHEM, V237, P153, DOI 10.1111/j.1432-1033.1996.0153n.x; Licht JD, 1996, ONCOGENE, V12, P323; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; LYDERSEN BK, 1980, CELL, V22, P489, DOI 10.1016/0092-8674(80)90359-1; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NORWOOD TH, 1976, SOMAT CELL GENET, V2, P263, DOI 10.1007/BF01538964; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Redner RL, 1997, LEUKEMIA, V11, P1014, DOI 10.1038/sj.leu.2400661; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPARKS CA, 1993, GENOMICS, V17, P222, DOI 10.1006/geno.1993.1307; WANG DR, 1994, J BIOL CHEM, V269, P30994; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wells RA, 1996, LEUKEMIA, V10, P735; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; YonedaKato N, 1996, ONCOGENE, V12, P265; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	66	44	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					633	641		10.1038/sj.onc.1202357	http://dx.doi.org/10.1038/sj.onc.1202357			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989813				2022-12-28	WOS:000078394400008
J	Voorhoeve, PM; Watson, RJ; Farlie, PG; Bernards, R; Lam, EWF				Voorhoeve, PM; Watson, RJ; Farlie, PG; Bernards, R; Lam, EWF			Rapid dephosphorylation of p107 following UV irradiation	ONCOGENE			English	Article						E2F; p107; G1 arrest; PP2A; UV response	RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; THREONINE PROTEIN PHOSPHATASES; CELL-CYCLE CONTROL; GROWTH SUPPRESSION; IN-VIVO; SUSCEPTIBILITY GENE; CATALYTIC SUBUNIT; CANCER CELL; FAMILY	In response to UV irradiation, mouse NIH3T3 fibroblasts transiently arrest predominantly in the G1 phase of the cell cycle. Here, we investigate the role of the retinoblastoma-related pocket proteins in this biological process. We report here that UV induces an increase in p107/E2F complexes, shown previously to be repressors of E2F-dependent transcriptional activity. Several lines of evidence indicate that the increase of p107/E2F complexes following UV irradiation is a consequence of rapid dephosphorylation of p107. First, UV-mediated p107 dephosphorylation could be abolished by pretreatment of NIH3T3 fibroblasts with the serine/threonine phosphatase inhibitors calyculin A and okadaic acid. Second, alteration of protein phosphatase 2A holoenzyme composition by over-expression of specific B subunits interfered with UV-mediated dephosphorylation of p107, Consistent with this, p107 could be dephosphorylated in vitro with PP2A, Moreover, dephosphorylation of p107 was shown to be independent of the activity of p53 and p21, as it occurred also in UV-treated p53-null as well as p21-null mouse fibroblasts. We observed a close correlation between the UV dosages required for G1 cell cycle arrest and p107 dephosphorylation. Our data suggest a model in which UV radiation-induced cell cycle arrest depends, at least in part, on the induction of a PP2A-like phosphatase that acts on p107.	Imperial Coll Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Imperial Coll Sch Med, Dept Med Microbiol, London W2 1PG, England; Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands	Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; Netherlands Cancer Institute	Lam, EWF (corresponding author), Imperial Coll Sch Med, Ludwig Inst Canc Res, Norfolk Pl, London W2 1PG, England.		Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576; Bernards, Rene/0000-0001-8677-3423				BACHRACH U, 1975, P NATL ACAD SCI USA, V72, P3087, DOI 10.1073/pnas.72.8.3087; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CIMENT G, 1978, SCIENCE, V202, P765, DOI 10.1126/science.213832; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HATAKEYAMA M, 1994, COLD SPRING HARB SYM, V59, P1; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HONKANAN RE, 1994, TOXICON, V32, P339, DOI 10.1016/0041-0101(94)90086-8; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KATO J, 1993, GENE DEV, V7, P331; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MAYOL X, 1995, ONCOGENE, V11, P801; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Nelson DA, 1997, ONCOGENE, V14, P2407, DOI 10.1038/sj.onc.1201081; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; NEVINS JR, 1992, SCIENCE, V258, P424; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; RONAI ZA, 1990, CELL BIOL TOXICOL, V6, P105, DOI 10.1007/BF00135030; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STONE SR, 1988, NUCLEIC ACIDS RES, V16, P11365, DOI 10.1093/nar/16.23.11365; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; van der Eb A J, 1980, Methods Enzymol, V65, P826; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; WU CL, 1995, MOL CELL BIOL, V15, P2536; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZHANG YH, 1995, ONCOGENE, V10, P2085; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZHU LG, 1995, MOL CELL BIOL, V15, P3552	66	38	39	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					679	688		10.1038/sj.onc.1202289	http://dx.doi.org/10.1038/sj.onc.1202289			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989818	Green Published			2022-12-28	WOS:000078394400013
J	Liu, JH; Wei, S; Burnette, PK; Gamero, AM; Hutton, M; Djeu, JY				Liu, JH; Wei, S; Burnette, PK; Gamero, AM; Hutton, M; Djeu, JY			Functional association of TGF-beta receptor II with cyclin B	ONCOGENE			English	Article						transforming growth factor receptor; cyclin B; cdc-2; cell cycle control	GROWTH-FACTOR-BETA; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; DEPENDENT KINASE; PROTEIN-KINASE; HUMAN WEE1; PHOSPHORYLATION; INHIBITION; G1; ACTIVATION	Utilizing the cytoplasmic tail of Transforming Growth Factor Receptor Type II (TGF beta RII) as bait in a yeast two hybrid system, we have identified human cyclin B2 as a direct physical partner of TGF beta RII. Analysis of deletion mutants of glutathione-S-transferase (GST)-cyclin B2 mapped its binding domain for TGF beta RII to the C-terminal and revealed a negative regulatory region immediately upstream of the cyclin box. Using recombinant proteins, Cdc2 was demonstrated to indirectly interact with TGF beta RII via cyclin B2. This interaction was reproduced in THP-1 monocytic cells, where TGF beta treatment markedly enhanced the ability of cyclin B2 and, correspondingly, Cdc2 from TGF beta-treated THP-1 cells, to bind the GST-TGF beta RII fusion protein. More importantly, TGF beta RII co-precipitated with cyclin B2 in TGF beta-treated THP-1 cells. TGF beta treatment also caused threonine phosphorylation of Cdc2 in the TGF beta RII-cyclin B2-Cdc2 complex in THP1 cells, in parallel with down regulation of Cdc2 function as measured by histone H1 kinase activity. Cyclin B1 had the same capacity to bind TGF beta RII and mediate indirect Cdc2 binding. These results suggest an alternative mechanism that cell cycle arrest in the G1/S phase caused by TGF beta may, in part, be due to inactivation of cyclin B/Cdc2 kinase, which is needed for entry into the G2/M phase.	Univ S Florida, Dept Biochem & Mol Biol, H Lee Moffit Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA; Mayo Clin, Jacksonville, FL 32224 USA	State University System of Florida; University of South Florida; Mayo Clinic	Djeu, JY (corresponding author), Univ S Florida, Dept Biochem & Mol Biol, H Lee Moffit Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA.				NCI NIH HHS [R01-CA63724] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063724] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE PR, 1994, CUR BIOL, V5, P40; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GUARENTE L, 1993, P NATL ACAD SCI USA, V90, P1639, DOI 10.1073/pnas.90.5.1639; HARPER JW, 1993, CELL, V75, P805; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Lock Leslie F., 1994, Trends in Cell Biology, V4, P404, DOI 10.1016/0962-8924(94)90054-X; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; Moore DD, 1995, GLOB MOB SURV; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RAVITZ MJ, 1995, CANCER RES, V55, P1413; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	39	37	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					269	275		10.1038/sj.onc.1202263	http://dx.doi.org/10.1038/sj.onc.1202263			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926943				2022-12-28	WOS:000078166000030
J	Peters, UR; Hasse, U; Oppliger, E; Tschan, M; Ong, ST; Rassool, FV; Borisch, B; Tobler, A; Fey, MF				Peters, UR; Hasse, U; Oppliger, E; Tschan, M; Ong, ST; Rassool, FV; Borisch, B; Tobler, A; Fey, MF			Aberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemia	ONCOGENE			English	Article						FHIT; FRA3B; leukaemia; lymphoma	TUMOR-SUPPRESSOR LOCUS; RENAL-CELL CARCINOMA; COMMON FRAGILE SITE; LUNG-CANCER; HOMOZYGOUS DELETIONS; BREAST CARCINOMAS; FRA3B REGION; SHORT ARM; GENE; 3P14.2	Alterations of the recently cloned fragile histidine triad (FHIT) gene at chromosome 3p14.2 are frequent in a variety of solid tumours and cancer cell lines. Based on these findings, FHIT has been proposed as a putative tumour-suppressor gene. We evaluated the mRNA expression of the FHIT gene in samples from 55 patients with various haematological malignancies (21 AML, 8 CML, 10 CLL, seven low-grade and nine high-grade Non-Hodgkin's lymphomas), in a panel of 16 leukaemia cell lines, in normal mature haematopoietic cells of both myeloid and lymphoid lineage, as well as in CD34(+) haematopoietic progenitor cells. Aberrant FHIT mRNA transcripts were observed in 14/16 (88%) leukaemia cell lines, 43/55 (78%) primary haematological neoplasms, but also in 17/22 (77%) normal controls. 1/16 (6%) cell lines and 7/55 (13%) neoplasms did not express and FHIT mRNA. cDNA sequencing revealed exonic deletions, small DNA insertions and combinations of both. Analysis of genomic DNA showed gene deletions in two myeloid leukaemia cell lines. In contrast to all normal types of haematopoietic cells, FHIT protein was clearly reduced or absent in 8/18 (44%) neoplastic samples tested. Our data indicate that whilst aberrant FHIT mRNA transcripts are seen both in normal and malignant cells, lack of FHIT protein is restricted to leukaemia. Absent FHIT protein expression might contribute to leukaemogenesis.	Univ Bern, Dept Clin Res, Bern, Switzerland; Univ Bern, Inst Med Oncol, Bern, Switzerland; Univ Bern, Cent Haematol Lab, Bern, Switzerland; Inselspital Bern, CH-3010 Bern, Switzerland; Univ Geneva, Dept Pathol, CH-1211 Geneva 4, Switzerland; Univ Chicago, Med Ctr, Sect Haematol Oncol, Chicago, IL 60637 USA	University of Bern; University of Bern; University of Bern; University of Geneva; University of Chicago; University of Chicago Medical Center	Fey, MF (corresponding author), Univ Bern, Dept Clin Res, Bern, Switzerland.		Borisch, Bettina/AAG-8212-2019; Oppliger Leibundgut, Elisabeth/AGG-5030-2022	Borisch, Bettina/0000-0002-9902-324X; Tschan, Mario P./0000-0001-5897-3647; Ong, S. Tiong/0000-0001-9460-3483; Oppliger Leibundgut, Elisabeth/0000-0002-6652-4160				Ahmadian M, 1997, CANCER RES, V57, P3664; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; Carapeti M., 1996, Blood, V88, p578A; Druck T, 1997, CANCER RES, V57, P504; Fong KM, 1997, CANCER RES, V57, P2256; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Gemma A, 1997, CANCER RES, V57, P1435; Greenspan DL, 1997, CANCER RES, V57, P4692; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Hayashi S, 1997, CANCER RES, V57, P1981; Inoue H, 1997, P NATL ACAD SCI USA, V94, P14584, DOI 10.1073/pnas.94.26.14584; Kastury K, 1996, CANCER RES, V56, P978; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; Le Beau MM, 1998, GENE CHROMOSOME CANC, V21, P281, DOI 10.1002/(SICI)1098-2264(199804)21:4<281::AID-GCC1>3.0.CO;2-V; LEBEAU MM, 1984, NATURE, V308, P607, DOI 10.1038/308607a0; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; Lin PM, 1997, BRIT J HAEMATOL, V99, P612, DOI 10.1046/j.1365-2141.1997.4223235.x; Mao L, 1998, J NATL CANCER I, V90, P412, DOI 10.1093/jnci/90.6.412; Mao L, 1996, CANCER RES, V56, P5128; Michael D, 1997, ONCOGENE, V15, P1653; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Ong ST, 1997, GENE CHROMOSOME CANC, V20, P16, DOI 10.1002/(SICI)1098-2264(199709)20:1<16::AID-GCC3>3.0.CO;2-C; Otterson GA, 1998, J NATL CANCER I, V90, P426, DOI 10.1093/jnci/90.6.426; Panagopoulos I, 1997, GENE CHROMOSOME CANC, V19, P215, DOI 10.1002/(SICI)1098-2264(199708)19:4<215::AID-GCC2>3.0.CO;2-#; Rassool FV, 1996, GENOMICS, V35, P109, DOI 10.1006/geno.1996.0329; SANCHEZ Y, 1994, P NATL ACAD SCI USA, V91, P3383, DOI 10.1073/pnas.91.8.3383; Schwaller J, 1997, BRIT J HAEMATOL, V99, P896, DOI 10.1046/j.1365-2141.1997.4863289.x; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sozzi G, 1997, CANCER RES, V57, P5207; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Sugimoto K, 1997, STEM CELLS, V15, P223, DOI 10.1002/stem.150223; Thiagalingam S, 1996, CANCER RES, V56, P2936; Uguccioni M, 1996, J EXP MED, V183, P2379, DOI 10.1084/jem.183.5.2379; vandenBerg A, 1997, GENE CHROMOSOME CANC, V19, P220, DOI 10.1002/(SICI)1098-2264(199708)19:4<220::AID-GCC3>3.0.CO;2-Z; Wang L, 1998, ONCOGENE, V16, P635, DOI 10.1038/sj.onc.1201576; Yeung R. S., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P422; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; Zimonjic DB, 1997, CANCER RES, V57, P1166	42	21	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					79	85		10.1038/sj.onc.1202256	http://dx.doi.org/10.1038/sj.onc.1202256			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926922				2022-12-28	WOS:000078166000009
J	Salgia, R; Li, JL; Ewaniuk, DS; Wang, YB; Sattler, M; Chen, WC; Richards, W; Pisick, E; Shapiro, GI; Rollins, BJ; Chen, LB; Griffin, JD; Sugarbaker, DJ				Salgia, R; Li, JL; Ewaniuk, DS; Wang, YB; Sattler, M; Chen, WC; Richards, W; Pisick, E; Shapiro, GI; Rollins, BJ; Chen, LB; Griffin, JD; Sugarbaker, DJ			Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility	ONCOGENE			English	Article						paxillin; lung cancer; cell motility	ROUS-SARCOMA VIRUS; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; KINASE; P210(BCR/ABL); CYTOSKELETON; FIBROBLASTS; BINDING; FORMS	Lung cancer can lead to abnormalities of the actin cytoskeleton structure which may be important in transformation. In this study, we have investigated the expression of the cytoskeletal associated protein paxillin in lung cancer, Paxillin is a 68 kDa focal adhesion protein, with four tandem LIM domains at the C-terminus, involved in growth factor receptor, integrin and oncogenic signaling such as v-src, BCR/ABL, and E6 of the papilloma virus. In non-small cell lung cancer (NSCLC) cell lines, paxillin localized to the focal adhesions. The possible role of paxillin in lung cancer cells was assessed by overexpressing green fluorescence protein (GFP)-paxillin construct in two separate NSCLC cell lines (Calu-1 and H661), Over the course of 48 h, GFP-paxillin consistently caused the cells to become round and to decrease cell motility as compared to normal controls, GFP-N-terminus paxillin, or GFP-LIM transfected cells. Because some lung cancers may be quite aggressive and metastasize quickly, which may be related to the cytoskeleton, we determined the expression of paxillin in NSCLC and small cell lung cancer (SCLC) cell lines and patient tumor tissues. Expression of paxillin in NSCLC and SCLC cell lines were determined by Northern blot and Western blot analysis. The expression of paxillin was consistently low in SCLC cell lines, whereas there was paxillin expression in NSCLC cell lines. There was a variability of expression of paxillin in NSCLC tumor tissue as compared to normal lung tissue. In contrast, by immunohistochemistry, we show that there was no detectable expression of paxillin in 5/5 SCLC patients. This data suggests that absence or low level of paxillin protein expression may cause certain lung cancers, such as SCLC, to be more motile and possibly more aggressive.	Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Cellular & Mol Biol, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Neoplast Dis Mechanisms, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Thorac Oncol & Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Salgia, R (corresponding author), Dana Farber Canc Inst, Div Hematol Oncol, 44 Binney St, Boston, MA 02115 USA.		Li, Jian-Liang/AAE-9315-2019; Li, J L/E-6100-2018	Li, Jian-Liang/0000-0002-6487-081X; Li, J L/0000-0002-6487-081X	NATIONAL CANCER INSTITUTE [R29CA075348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER; NCI NIH HHS [CA75348] Funding Source: Medline; NIDDK NIH HHS [DK50654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMBROS VR, 1975, P NATL ACAD SCI USA, V72, P3144, DOI 10.1073/pnas.72.8.3144; BERNAL SD, 1983, CANCER RES, V43, P1798; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BOCKHOLT SM, 1995, CELL ADHES COMMUN, V3, P91, DOI 10.3109/15419069509081279; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARBONE D, 1996, LUNG CANC PRINCIPLES, P107; Charlesworth A, 1996, ONCOGENE, V12, P1337; COLL JL, 1995, P NATL ACAD SCI USA, V92, P9161, DOI 10.1073/pnas.92.20.9161; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; KERN JA, 1993, CLIN CHEST MED, V14, P31; Lauffenburger DA, 1996, NATURE, V383, P390, DOI 10.1038/383390a0; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; Mazaki Y, 1997, J BIOL CHEM, V272, P7437, DOI 10.1074/jbc.272.11.7437; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; PRINS J, 1993, ANTICANCER RES, V13, P1373; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; SALGIA R, 1995, ONCOGENE, V11, P1149; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SHAPIRO GI, 1995, CANCER RES, V55, P505; Sidransky D, 1996, ANNU REV MED, V47, P285; SLEBOS RJC, 1992, J NATL CANCER I MONO, V13, P23; Strauss GM, 1997, HEMATOL ONCOL CLIN N, V11, P409, DOI 10.1016/S0889-8588(05)70441-X; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; TURNER CE, 1994, J CELL SCI, V107, P1583; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; Weisberg E, 1997, CRIT REV ONCOGENESIS, V8, P343, DOI 10.1615/CritRevOncog.v8.i4.40; YAMAGUCHI R, 1994, FEBS LETT, V356, P114, DOI 10.1016/0014-5793(94)01246-6	39	75	79	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					67	77		10.1038/sj.onc.1202273	http://dx.doi.org/10.1038/sj.onc.1202273			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926921				2022-12-28	WOS:000078166000008
J	LaCasse, EC; Baird, S; Korneluk, RG; MacKenzie, AE				LaCasse, EC; Baird, S; Korneluk, RG; MacKenzie, AE			The inhibitors of apoptosis (IAPs) and their emerging role in cancer	ONCOGENE			English	Review						inhibitor of apoptosis; IAP; programmed cell death; BIR; RING finger; CARD; NAIP; survivin; NF-kappa B; caspase	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; SPINAL MUSCULAR-ATROPHY; PROGRAMMED CELL-DEATH; MANGANESE SUPEROXIDE-DISMUTASE; RECEPTOR-ASSOCIATED FACTORS; SWINE FEVER VIRUS; X-LINKED IAP; BACULOVIRUS INHIBITOR; ZINC-FINGER	The inhibitor of apoptosis protein family has been characterized over the past 5 years, initially in baculovirus and more recently in metazoans, The IAPs are a widely expressed gene family of apoptotic inhibitors from both phylogenic and physiologic points of view. The diversity of triggers against which the IAPs suppress apoptosis is greater than that observed for any other family of apoptotic inhibitors including the bcl-2 family. The central mechanisms of IAP apoptotic suppression appear to be through direct caspase and pro-caspase inhibition (primarily caspase 3 and 7) and modulation of and by the transcription factor NF-kappa B, Although evidence for a direct oncogenic role for the IAPs has yet to be delineated, a number of lines of evidence point towards this class of protein playing a role in oncogenesis, The strongest evidence for IAP involvement in cancer is seen in the IAP called survivin, Although not observed in adult differentiated tissue, survivin is present in most transformed cell lines and cancers tested to date. Survivin has been shown to inhibit caspase directly and apoptosis in general, moreover survivin protein levels correlate inversely with 5 year survival rates in colorectal cancer. Recent data has also implicated survivin in cell cycle control, The second line of evidence for IAP involvement in cancer comes from their emerging role as mediators and regulators of the anti-apoptotic activity of v-Rel and NF-kappa B transcription factor families. The IAPs have been shown to be induced by NF-kappa B or v-Rel in multiple cell lines and conversely, HIAP1 and HIAP2 have been shown to activate NF-kappa B possibly forming a positive feed-back loop, Overall a picture consistent with an IAP role in tumour progression rather than tumour initiation is emerging making the IAPs an attractive therapeutic target.	Childrens Hosp Eastern Ontario, Res Inst, Apoptogen Inc, Ottawa, ON K1H 8L1, Canada; Univ Ottawa, Dept Pediat, Ottawa, ON K1N 6N5, Canada; Childrens Hosp Eastern Ontario, Solange Gauthier Karsh Mol Genet Lab, Ottawa, ON K1H 8L1, Canada	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario	MacKenzie, AE (corresponding author), Childrens Hosp Eastern Ontario, Res Inst, Apoptogen Inc, Suite R306,401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.							Adida C, 1998, LANCET, V351, P882, DOI 10.1016/S0140-6736(05)70294-4; Adida C, 1998, AM J PATHOL, V152, P43; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Antoku K, 1997, LEUKEMIA, V11, P1665, DOI 10.1038/sj.leu.2400805; Banyer JL, 1998, MAMM GENOME, V9, P235, DOI 10.1007/s003359900732; Barge RMY, 1997, FEBS LETT, V409, P207, DOI 10.1016/S0014-5793(97)00507-3; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Chacon MR, 1995, VIROLOGY, V214, P670, DOI 10.1006/viro.1995.0083; Chen QF, 1998, GENOMICS, V48, P121, DOI 10.1006/geno.1997.5141; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; Clem RJ, 1996, CELL DEATH DIFFER, V3, P9; Craxton A, 1998, J IMMUNOL, V161, P3225; CROCKER S, 1999, IN PRESS ADENOVIRAL; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Digby MR, 1996, DNA CELL BIOL, V15, P981, DOI 10.1089/dna.1996.15.981; Dorstyn L, 1997, CELL DEATH DIFFER, V4, P570, DOI 10.1038/sj.cdd.4400281; Dubowitz V., 1995, MUSCLE DISORDERS CHI; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; EichholtzWirth H, 1997, BRIT J CANCER, V76, P1322, DOI 10.1038/bjc.1997.555; Farahani R, 1997, GENOMICS, V42, P514, DOI 10.1006/geno.1997.4742; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Fulda S, 1998, INT J CANCER, V76, P105; Gilmore TD, 1996, ONCOGENE, V13, P1367; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; Hacker G, 1996, Behring Inst Mitt, P118; Harvey AJ, 1997, MOL CELL BIOL, V17, P2835, DOI 10.1128/MCB.17.5.2835; Harvey AJ, 1997, CELL DEATH DIFFER, V4, P733, DOI 10.1038/sj.cdd.4400294; Hauser HP, 1998, J CELL BIOL, V141, P1415, DOI 10.1083/jcb.141.6.1415; Hawkins CJ, 1998, CELL DEATH DIFFER, V5, P569, DOI 10.1038/sj.cdd.4400389; Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Hu ZH, 1998, VIRUS RES, V55, P71, DOI 10.1016/S0168-1702(98)00029-X; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Johnson AL, 1998, BIOL REPROD, V58, P414, DOI 10.1095/biolreprod58.2.414; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; KAWASAKI H, 1998, IN PRESS CANC RES; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; Keller JN, 1998, J NEUROSCI, V18, P687; Krohn AJ, 1998, J NEUROSCI, V18, P8186; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LI F, 1998, IN PRESS NATURE; Li J, 1998, ENDOCRINOLOGY, V139, P1321, DOI 10.1210/en.139.3.1321; Liston P, 1997, GENOMICS, V46, P495, DOI 10.1006/geno.1997.5059; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Los M, 1997, BLOOD, V90, P3118, DOI 10.1182/blood.V90.8.3118; Lu CD, 1998, CANCER RES, V58, P1808; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; MacKenzie AE, 1998, AM J HUM GENET, V62, P485, DOI 10.1086/301723; Manji GA, 1997, J VIROL, V71, P4509, DOI 10.1128/JVI.71.6.4509-4516.1997; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Martinez-Lorenzo MJ, 1998, INT J CANCER, V75, P473, DOI 10.1002/(SICI)1097-0215(19980130)75:3<473::AID-IJC23>3.0.CO;2-8; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; McCarthy JV, 1998, J BIOL CHEM, V273, P24009, DOI 10.1074/jbc.273.37.24009; McLachlin JR, 1997, IN VITRO CELL DEV-AN, V33, P575, DOI 10.1007/s11626-997-0101-7; Messineo C, 1998, BLOOD, V91, P2443, DOI 10.1182/blood.V91.7.2443.2443_2443_2451; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Neilan JG, 1997, VIROLOGY, V230, P252, DOI 10.1006/viro.1997.8481; Nicholl JK, 1996, CHROMOSOME RES, V4, P81, DOI 10.1007/BF02254951; Oeda E, 1998, J BIOL CHEM, V273, P9353, DOI 10.1074/jbc.273.16.9353; Orth R, 1997, J BIOL CHEM, V272, P8841; Prikhodko EA, 1996, J VIROL, V70, P7116, DOI 10.1128/JVI.70.10.7116-7124.1996; Qi XM, 1997, ONCOGENE, V15, P1207, DOI 10.1038/sj.onc.1201290; RajcanSeparovic E, 1996, CYTOGENET CELL GENET, V75, P243, DOI 10.1159/000134493; RajcanSeparovic E, 1996, GENOMICS, V37, P404, DOI 10.1006/geno.1996.0579; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Resnicoff M, 1998, J BIOL CHEM, V273, P10376, DOI 10.1074/jbc.273.17.10376; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Sanna MG, 1998, P NATL ACAD SCI USA, V95, P6015, DOI 10.1073/pnas.95.11.6015; Scharf JM, 1996, GENOMICS, V38, P405, DOI 10.1006/geno.1996.0644; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Seshagiri S, 1997, P NATL ACAD SCI USA, V94, P13606, DOI 10.1073/pnas.94.25.13606; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; SIMONS M, 1998, IN PRESS J NEUROCHEM; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Srikanth S, 1998, CANCER RES, V58, P834; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Stehlik C, 1998, BIOCHEM BIOPH RES CO, V243, P827, DOI 10.1006/bbrc.1998.8185; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; TAMM I, 1998, IN PRESS CANC RES; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Vitte-Mony I, 1997, APOPTOSIS, V2, P501, DOI 10.1023/A:1026434514183; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Vucic D, 1997, MOL CELL BIOL, V17, P667, DOI 10.1128/MCB.17.2.667; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wen LP, 1997, AM J PHYSIOL-LUNG C, V273, pL921, DOI 10.1152/ajplung.1997.273.5.L921; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997-997; Xu DG, 1997, J COMP NEUROL, V382, P247; YAMAGUCHI K, 1998, IN PRESS EMBO J; Yaraghi Z, 1998, GENOMICS, V51, P107, DOI 10.1006/geno.1998.5378; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; YOUNG SS, 1998, IN PRESS MAMM GENOME; Zong WX, 1997, ONCOGENE, V15, P971, DOI 10.1038/sj.onc.1201266	122	882	975	2	66	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 24	1998	17	25					3247	3259		10.1038/sj.onc.1202569	http://dx.doi.org/10.1038/sj.onc.1202569			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916987				2022-12-28	WOS:000078048200006
J	Pestov, DG; Grzeszkiewicz, TM; Lau, LF				Pestov, DG; Grzeszkiewicz, TM; Lau, LF			Isolation of growth suppressors from a cDNA expression library	ONCOGENE			English	Article						inducible vector; Rb; 3T3 cells	UBIQUITIN-CONJUGATING ENZYMES; G-PROTEIN; CRYSTAL-STRUCTURE; DEGRADATION; SYSTEM; CHECKPOINTS; REPRESSOR; IDENTIFICATION; PROTEOLYSIS; SEQUENCES	We describe an experimental procedure for the isolation of growth inhibitory sequences from a complex cDNA library, This approach first takes advantage of the SETGAP technique (selectable expression of transient growth arrest phenotype) to enrich for growth inhibitory sequences, followed by a screening procedure to identify individual cDNAs that inhibit cell proliferation. Here we provide a detailed description of the experimental protocol and report the characterization of two cDNA sequences isolated id our initial screen of a mouse cDNA Library. One of these cDNAs encodes the mouse ubiquitin-conjugation enzyme UbcM2, The other encodes a truncated form of a novel WD40 repeat protein, named Bop1, which is conserved from yeast to human. Together, these results demonstrate a new approach for the isolation of growth suppressors from cDNA libraries, and identify a previously unknown gene likely to be involved in growth control.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lau, LF (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.			Lau, Lester/0000-0002-4364-2914; Pestov, Dimitri/0000-0002-1425-9879	NATIONAL CANCER INSTITUTE [R01CA052220] Funding Source: NIH RePORTER; NCI NIH HHS [CA52220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; Bej Asim K., 1994, P219; Bonaldo MDF, 1996, GENOME RES, V6, P791, DOI 10.1101/gr.6.9.791; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; KALUZ S, 1992, NUCLEIC ACIDS RES, V20, P4369, DOI 10.1093/nar/20.16.4369; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LIU HP, 1992, GENETICS, V132, P665; LOO DT, 1989, CELL GROWTH CELL DIV, P17; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; Maki CG, 1996, CANCER RES, V56, P2649; Matuschewski K, 1996, J BIOL CHEM, V271, P2789, DOI 10.1074/jbc.271.5.2789; Nagase T, 1995, DNA Res, V2, P167, DOI 10.1093/dnares/2.4.167; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; Nicholas KB, 1997, EMBNEW NEWS, V4, P14; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PESTOV DG, 1994, P NATL ACAD SCI USA, V91, P12549, DOI 10.1073/pnas.91.26.12549; Pietrokovski S, 1996, NUCLEIC ACIDS RES, V24, P197, DOI 10.1093/nar/24.1.197; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shiyanov P, 1997, MOL BIOL CELL, V8, P1815, DOI 10.1091/mbc.8.9.1815; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TODARO GJ, 1965, J CELL COMPAR PHYSL, V66, P325, DOI 10.1002/jcp.1030660310; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1	42	33	37	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 17	1998	17	24					3187	3197		10.1038/sj.onc.1202260	http://dx.doi.org/10.1038/sj.onc.1202260			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872334				2022-12-28	WOS:000077517400012
J	Date, K; Matsumoto, K; Kuba, K; Shimura, H; Tanaka, M; Nakamura, T				Date, K; Matsumoto, K; Kuba, K; Shimura, H; Tanaka, M; Nakamura, T			Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor	ONCOGENE			English	Article						c-Met; hepatocyte growth factor; HGF-antagonist; tumor invasion; tumor-stromal interactions	SCATTER FACTOR EXPRESSION; HUMAN PANCREATIC-CANCER; C-MET; TYROSINE PHOSPHORYLATION; FACTOR/SCATTER FACTOR; RECEPTOR EXPRESSION; MOLECULAR-CLONING; EPITHELIAL-CELLS; CARCINOMA-CELLS; BREAST-CANCER	Invasion of various carcinoma cells follows their interaction with stromal cells. Hepatocyte growth factor (HGF), four-kringle-containing growth factor, is a mesenchymal or stromal-derived mediator which affects the growth and the invasiveness of carcinoma cells. We now have evidence that a four-kringle-containing antagonist for HGF, HGF/NK4 inhibits invasion of tumors in vivo, as well as in vitro. HGF/NK4 competitively inhibited the binding of HGF to Met/HGF receptors on GB-d1 human gallbladder carcinoma cells. HGF induced invasion of the cells through Matrigel basement membrane components and into collagen gels, but HGF-induced invasion was inhibited by HGF/NK4. Invasion of GB-d1 cells was induced by co-cultivation with stromal fibroblasts, which mimics tumor-stromal interaction, but it was almost completely suppressed by HGF/NK4. Likewise, invasive growth induced by HGF in collagen gels in GB-d1 cells, HuCC-T1 human cholangiocarcinoma cells, and ME-180 human uterus cervical carcinoma cells was also strongly inhibited by HGF/NK4. When GB-d1 cells were implanted subcutaneously into nude mouse, tumor cells invaded muscular tissue, but the infusion of HGF/NK4 inhibited this invasion. Furthermore, HGF/NK4 increased apoptotic cell death of GB-d1 cells and inhibited tumor growth in vivo. These results indicate that HGF/NK4 may inhibit growth and invasion of carcinoma cells, as mediated by HGF during tumor-stromal interactions. We propose that there is a unique therapeutic potential for HGF/NK4 to prevent tumor invasion and perhaps even metastasis.	Osaka Univ, Sch Med, Biomed Res Ctr, Dept Oncol,Div Biochem, Osaka 5650871, Japan; Kyushu Univ, Fac Med, Dept Surg 1, Fukuoka 8120054, Japan	Osaka University; Kyushu University	Nakamura, T (corresponding author), Osaka Univ, Sch Med, Biomed Res Ctr, Dept Oncol,Div Biochem, Osaka 5650871, Japan.		MATSUMOTO, Kunio/D-8441-2015	MATSUMOTO, Kunio/0000-0002-6532-4482				BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; Date K, 1997, FEBS LETT, V420, P1, DOI 10.1016/S0014-5793(97)01475-0; DIRENZO MF, 1995, CANCER RES, V55, P1129; EBERT M, 1994, CANCER RES, V54, P5775; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GREY AM, 1989, P NATL ACAD SCI USA, V86, P2438, DOI 10.1073/pnas.86.7.2438; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HUMPHREY PA, 1995, AM J PATHOL, V147, P386; Inoue T, 1997, JPN J CANCER RES, V88, P152, DOI 10.1111/j.1349-7006.1997.tb00360.x; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; JIANG WG, 1993, CLIN EXP METASTAS, V11, P235, DOI 10.1007/BF00121166; JIANG WG, 1993, BRIT J SURG, V80, P1368, DOI 10.1002/bjs.1800801104; Lamszus K, 1997, LAB INVEST, V76, P339; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; Matsumoto K, 1996, CANCER CHEMOTH PHARM, V38, pS42, DOI 10.1007/s002800051037; Matsumoto K, 1996, JPN J CANCER RES, V87, P702, DOI 10.1111/j.1349-7006.1996.tb00281.x; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; Matsumoto K, 1997, BIOCHEM BIOPH RES CO, V239, P639, DOI 10.1006/bbrc.1997.7517; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; Nagy J, 1996, SURG ONCOL, V5, P15, DOI 10.1016/S0960-7404(96)80017-X; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nakamura T, 1997, CANCER RES, V57, P3305; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; Natali PG, 1996, INT J CANCER, V69, P212, DOI 10.1002/(SICI)1097-0215(19960621)69:3<212::AID-IJC11>3.0.CO;2-9; OKIGAKI M, 1992, BIOCHEMISTRY-US, V31, P9555, DOI 10.1021/bi00155a007; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROSEN EM, 1994, J CELL BIOL, V127, P225, DOI 10.1083/jcb.127.1.225; Rosen EM, 1996, INT J CANCER, V67, P248, DOI 10.1002/(SICI)1097-0215(19960717)67:2<248::AID-IJC16>3.0.CO;2-7; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; SEKI T, 1990, BIOCHEM BIOPH RES CO, V172, P321, DOI 10.1016/S0006-291X(05)80212-8; SESLAR SP, 1993, CANCER RES, V53, P1233; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SHIMURA H, 1995, JPN J CANCER RES, V86, P662, DOI 10.1111/j.1349-7006.1995.tb02450.x; SILVAGNO F, 1995, ARTERIOSCL THROM VAS, V15, P1857, DOI 10.1161/01.ATV.15.11.1857; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; TAKAISHI K, 1994, ONCOGENE, V9, P273; VANDENHOOFF A, 1988, ADV CANCER RES, V50, P159, DOI 10.1016/S0065-230X(08)60437-6; VASSALLI JD, 1984, J EXP MED, V159, P1653, DOI 10.1084/jem.159.6.1653; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Yamamoto S, 1997, JPN J CANCER RES, V88, P564, DOI 10.1111/j.1349-7006.1997.tb00420.x; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; [No title captured]	52	162	185	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	1998	17	23					3045	3054		10.1038/sj.onc.1202231	http://dx.doi.org/10.1038/sj.onc.1202231			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881707				2022-12-28	WOS:000077427800012
J	Thomas, M; Banks, L				Thomas, M; Banks, L			Inhibition of Bak-induced apoptosis by HPV-18 E6	ONCOGENE			English	Article						HPV; apoptosis; Bak; ubiquitin	HUMAN PAPILLOMAVIRUS TYPE-16; PROGRAMMED CELL-DEATH; P53 DNA-BINDING; UBIQUITIN-PROTEIN LIGASE; IN-VIVO; MEDIATED DEGRADATION; TRANSFORMED-CELLS; ANGELMAN SYNDROME; OLIGOMERIC STATE; BCL-2 HOMOLOG	Human papillomavirus (HPV) E6 proteins inhibit apoptosis in both p53-dependent and p53-independent manners. A key point in apoptosis is the regulation provided by the Bcl-2 family; and in differentiating keratinocytes, in which HPV replicates, the Bak protein is highly expressed. We show that HPV-18 E6 will inhibit Bak-induced apoptosis and this is mediated by an interaction between the E6 and Bak proteins resulting in degradation of the Bak protein in vivo. We also show that Bak protein interacts with the ubiquitin ligase, E6AP, and that a mutant of Bak defective in E6AP binding is overexpressed in comparison with wild type. These studies suggest that Bak is probably the first naturally occurring target of E6AP to be identified.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.							ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; FADOK VA, 1992, J IMMUNOL, V148, P2207; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; GARDIOL D, 1998, IN PRESS J GEN VIROL; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GROSSMAN SR, 1989, J VIROL, V63, P366, DOI 10.1128/JVI.63.1.366-374.1989; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KANDA T, 1991, VIROLOGY, V185, P536, DOI 10.1016/0042-6822(91)90523-E; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Krajewski S, 1996, CANCER RES, V56, P2849; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PIM D, 1994, ONCOGENE, V9, P1869; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; Steller MA, 1996, CANCER RES, V56, P5087; TANAKA S, 1993, J BIOL CHEM, V268, P10920; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; THOMAS M, 1995, ONCOGENE, V10, P261; Thomas M, 1996, ONCOGENE, V13, P265; Thomas M, 1996, ONCOGENE, V13, P471; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	55	224	236	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	1998	17	23					2943	2954		10.1038/sj.onc.1202223	http://dx.doi.org/10.1038/sj.onc.1202223			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881696				2022-12-28	WOS:000077427800001
J	Hartl, M; Bister, K				Hartl, M; Bister, K			Structure and transcriptional regulation of BKJ, a novel AP-1 target gene activated during jun- or fos-induced fibroblast transformation	ONCOGENE			English	Article						cell transformation; oncogenes; transcription factor AP-1; keratin; cell differentiation	AVIAN KERATIN GENES; C-JUN; DNA-BINDING; V-JUN; CELL-TRANSFORMATION; EMBRYO FIBROBLASTS; RNA-POLYMERASE; BASIC REGION; EXPRESSION; PROTEIN	The BKJ gene was originally identified based on its specific transcriptional activation in jun-transformed avian fibroblasts. We now show that BKJ is a direct transcriptional target of the AP-1 transcription factor components Jun and Fos. The complete structural organization of the quail BKJ gene was determined by nucleotide sequence analysis and transcriptional mapping. The gene contains three exons with the coding region confined to the third exon. A major mRNA species of 0.8 kb and a minor one of 1.3 kb are produced by variable usage of two transcriptional initiation sites. The BKJ promoter region contains two authentic AP-1 binding sites. By transactivation of reporter gene constructs and direct binding of Jun recombinant protein, the proximal AP-T element was shown to be essential for BKJ promoter activation. Using polyclonal antiserum directed against recombinant BKJ protein, the activation of BKJ in jun-transformed avian fibroblasts was also demonstrated at the protein level. BKJ is a novel gene related to the avian beta-keratin gene family whose members display highly specific expression patterns during embryogenesis and epidermal development. Activation of BKJ in fibroblasts by retroviral or deregulated cellular jun or fos alleles may contribute to cell transformation.	Univ Innsbruck, Inst Biochem, A-6020 Innsbruck, Austria	University of Innsbruck	Hartl, M (corresponding author), Univ Innsbruck, Inst Biochem, Peter Mayr Str 1A, A-6020 Innsbruck, Austria.		Bister, Klaus/AFA-9400-2022; Hartl, Markus/O-4655-2014	Hartl, Markus/0000-0001-7447-5920; Bister, Klaus/0000-0001-6545-5653				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BISTER K, 1987, ONCOGENE, V1, P97; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BRUN G, 1989, NUCLEIC ACIDS RES, V17, P6393, DOI 10.1093/nar/17.15.6393; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; Crittenden L, 1995, Trends Genet, P33; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Gao MH, 1996, CANCER RES, V56, P4229; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hadman M, 1996, ONCOGENE, V12, P135; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HARTL M, 1995, VIROLOGY, V207, P321, DOI 10.1006/viro.1995.1086; HARTL M, 1991, ONCOGENE, V6, P1623; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; Jefferies D, 1998, BBA-GENE STRUCT EXPR, V1396, P237, DOI 10.1016/S0167-4781(97)00234-0; JURDIC P, 1995, ONCOGENE, V11, P1699; KERKHOFF E, 1991, ONCOGENE, V6, P93; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Martin ML, 1996, MOL CELL BIOL, V16, P2110; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; MOLDERS H, 1987, ONCOGENE, V1, P377; MORGAN IM, 1993, ONCOGENE, V8, P1135; MORGAN IM, 1992, ONCOGENE, V7, P1119; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHIZAWA M, 1987, J VIROL, V61, P3733, DOI 10.1128/JVI.61.12.3733-3740.1987; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; Oshima RG, 1996, CANCER METAST REV, V15, P445, DOI 10.1007/BF00054012; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; PAPOULAS O, 1992, J BIOL CHEM, V267, P10470; PATSCHINSKY T, 1986, J VIROL, V59, P341, DOI 10.1128/JVI.59.2.341-353.1986; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PRESLAND RB, 1989, J MOL BIOL, V209, P549, DOI 10.1016/0022-2836(89)90593-7; PRESLAND RB, 1989, J MOL BIOL, V209, P561, DOI 10.1016/0022-2836(89)90594-9; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TIKHONENKO AT, 1992, J VIROL, V66, P946, DOI 10.1128/JVI.66.2.946-955.1992; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; Weiskirchen R, 1997, GENOMICS, V44, P83, DOI 10.1006/geno.1997.4855; WEISKIRCHEN R, 1993, GENE, V128, P269, DOI 10.1016/0378-1119(93)90573-L; WEISKIRCHEN R, 1993, ONCOGENE, V8, P2317; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WONG WY, 1992, ONCOGENE, V7, P2077	64	21	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 3	1998	17	22					2901	2913		10.1038/sj.onc.1202219	http://dx.doi.org/10.1038/sj.onc.1202219			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879996				2022-12-28	WOS:000077286400010
J	Mangano, R; Piddini, E; Carramusa, L; Duhig, T; Feo, S; Fried, M				Mangano, R; Piddini, E; Carramusa, L; Duhig, T; Feo, S; Fried, M			Chimeric amplicons containing the c-myc gene in HL60 cells	ONCOGENE			English	Article						HL60 chimeric amplicon; fiber-FISH; MYC amplification; amplicon organization; illegitimate recombination; inverted and direct repeats	HUMAN BREAST-CANCER; HUMAN NEUROBLASTOMA; FRAGILE SITES; AMPLIFICATION; ONCOGENE; EXPRESSION; DNA; DIFFERENTIATION; PROLIFERATION; SEQUENCES	The major amplicon present in HL60 cells is chimeric in nature being composed of 70 kb of DNA sequence derived from the MYC locus linked to 80 kb of novel DNA sequence derived from a non contiguous region located telomeric to the c-myc gene at 8q24 (Feo et al,, 1996), Here we show by fluorescence in situ hybridization (FISH) that these coamplified sequences, MCR (Myc Coamplified Region), are derived from a locus located 3-4 Mb telomeric to the c-myc gene in the q24.2-24.3 region of chromosome 8. Genomic cloning and Southern blot analysis indicate the arrangement of chimeric amplicons are in tandem arrays, Analysis of the DNA sequences at the juncture of the MYC locus and the NICR suggest that these non syntenic regions were joined by nonhomologous recombination events, Visualization of the organization of the amplified DNA by fiber-FISH analysis illustrates we have cloned the complete amplicon, This is the first complete mammalian amplicon to be cloned and have its structure visualized. In addition to the major class of tandemly repeated amplicons, a second class of amplicons was detected by fiber-FISH in which the extent of the MCR component is about twice the size of the MCR component in the major amplicon, These longer amplicons most likely contain inverted repeats of MCR and MYC region sequences. Whether the amplicons contain mixtures of these two types of structures or separate amplicons only contain one type of structure has not yet been resolved. Properties of the MCR sequences responsible for retention in the chimeric HL60 amplicons upon long term passage are discussed.	Imperial Canc Res Fund, London WC2A 3PX, England; Univ Palermo, Dipartimento Biol Cellulare & Sviluppo, I-90123 Palermo, Italy; Univ Palermo, Ctr Oncobiol Sperimentale, I-90123 Palermo, Italy	Cancer Research UK; University of Palermo; University of Palermo	Fried, M (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Feo, Salvatore/C-1333-2012	Feo, Salvatore/0000-0003-3877-2906; Piddini, Eugenia/0000-0003-3901-076X				AKIYAMA K, 1994, NUCLEIC ACIDS RES, V22, P187, DOI 10.1093/nar/22.2.187; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COLLINS SJ, 1987, BLOOD, V70, P1233; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; Elkahloun AG, 1996, GENE CHROMOSOME CANC, V17, P205, DOI 10.1002/(SICI)1098-2264(199612)17:4<205::AID-GCC2>3.3.CO;2-#; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P820, DOI 10.1073/pnas.80.3.820; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; Feo S, 1996, ONCOGENE, V13, P1521; FEO S, 1994, ONCOGENE, V9, P955; FORD M, 1986, CELL, V45, P425, DOI 10.1016/0092-8674(86)90328-4; Forozan F, 1997, TRENDS GENET, V13, P405, DOI 10.1016/S0168-9525(97)01244-4; FRIED M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P143, DOI 10.1016/0167-4781(91)90095-4; GAUWERKY CE, 1993, SEMIN CANCER BIOL, V4, P333; HECHT F, 1990, CANCER GENET CYTOGEN, V44, P37, DOI 10.1016/0165-4608(90)90195-G; Heiskanen M, 1996, GENET ANAL-BIOMOL E, V12, P179, DOI 10.1016/1050-3862(95)00134-4; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; Korn Bernhard, 1992, Human Molecular Genetics, V1, P235, DOI 10.1093/hmg/1.4.235; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; SCHNEIDER SS, 1992, MOL CELL BIOL, V12, P5563, DOI 10.1128/MCB.12.12.5563; SHTIVELMAN E, 1989, MOL CELL BIOL, V9, P1148, DOI 10.1128/MCB.9.3.1148; TAKAHASHI E, 1991, CYTOGENET CELL GENET, V57, P109, DOI 10.1159/000133124; Tanner MM, 1996, CANCER RES, V56, P3441; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375	27	15	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2771	2777		10.1038/sj.onc.1202434	http://dx.doi.org/10.1038/sj.onc.1202434			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840941				2022-12-28	WOS:000077146700010
J	Kuo, ML; Shen, SC; Yang, CH; Chuang, SE; Cheng, AL; Huang, TS				Kuo, ML; Shen, SC; Yang, CH; Chuang, SE; Cheng, AL; Huang, TS			Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity	ONCOGENE			English	Article						Bcl-2; apoptosis; GL331; poly(ADP-ribose)polymerase	NICOTINAMIDE ADENINE-DINUCLEOTIDE; INTERLEUKIN-1-BETA CONVERTING-ENZYME; PROGRAMMED CELL-DEATH; CHINESE-HAMSTER CELLS; LEUKEMIA HL-60 CELLS; MITOCHONDRIAL PERMEABILITY; DNA FRAGMENTATION; ADP-RIBOSYLATION; POLYMERASE; ACTIVATION	Poly (ADP-ribose) polymerase (PARP), a nuclear enzyme responsible for DNA strand breaks, has been recently suggested to be crucial for apoptosis induced by a number chemotherapeutic drugs, In this study, we demonstrated that the PARP activity could be evidently elevated with a peak at 6 h when HL-60 cells were treated with a new anticancer drug GL331, Coincident with the peak of PARP activity, an apparent DNA fragmentation and apoptotic morphology were observed in cells treated with GL331. The subsequent apoptotic DNA fragmentation induced by GL331 could be completely blocked by transfecting cells with anti-sense PARP retroviral vector or by treating cells with PARP inhibitor, 3-aminobenzamide (3-AB). This blocking effect thus suggests that activation of PARP was critically involved in GL331-induced apoptosis, The fact that Bcl-2 has been found to antagonize cell death induced by a wide variety of agents, accounts for why we examined whether if Bcl-2 could antagonize GL331 effects, Interestingly, ectopic overexpression of Bcl-2 in either HL-60 or U937 cells caused in resistance towards GL331-elicited DNA fragmentation and cytotoxic effect. Additionally, Bcl-2 also attenuated the poly(ADP-ribosyl)ation of PARP itself as well as Histone H1 at the early period of drug treatment. However, Bcl-2 did not influence the extent of DNA strand breaks induced by GL331 in either control or Bcl-2-overexpressing cells. In addition, analysis of basal PARP activity in control and several Bcl-2 overexpressing clones revealed that Bcl-2 down-regulated PARP activity under the condition without DNA damages, Above findings suggest that poly(ADP-ribosyl)ation of nuclear targets is important for apoptosis induced by DNA-reactive anticancer drugs.	Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Ctr Canc Res, Dept Oncol, Taipei, Taiwan; Natl Hlth Res Inst, Canc Res Div, Cooperat Lab, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Health Research Institutes - Taiwan	Kuo, ML (corresponding author), Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei, Taiwan.		Chuang, Shuang-En/D-2080-2010; Huang, Tze-Sing/E-3667-2010; Kuo, Min-Liang/C-4872-2009; Huang, Tze-Sing/C-9361-2013	Huang, Tze-Sing/0000-0001-8736-4330; KUO, MIN-LIANG/0000-0002-7139-0144; Yang, James Chih-Hsin/0000-0002-5586-5138; Cheng, Ann-Lii/0000-0002-9152-6512				ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; BENJAMIN RC, 1980, J BIOL CHEM, V255, P493; Bhatia M, 1996, CELL GROWTH DIFFER, V7, P91; CHU G, 1994, J BIOL CHEM, V269, P787; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Eymin B, 1997, CANCER RES, V57, P686; Fabianek RA, 1997, J BIOL CHEM, V272, P4467, DOI 10.1074/jbc.272.7.4467; FAIRBAIRN LJ, 1994, MOL CARCINOGEN, V11, P49, DOI 10.1002/mc.2940110109; FERRO AM, 1984, J BIOL CHEM, V259, P547; FRITZ G, 1994, MUTAT RES, V308, P127, DOI 10.1016/0027-5107(94)90147-3; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HAHN GM, 1973, RADIAT RES, V55, P280, DOI 10.2307/3573683; Huang TS, 1996, CANCER LETT, V110, P77, DOI 10.1016/S0304-3835(96)04464-3; HUANG TS, 1997, CANCER RES, V57, P2914; Hyde H, 1997, BLOOD, V89, P2453, DOI 10.1182/blood.V89.7.2453; Ibrado AM, 1996, CANCER RES, V56, P4743; IKEJIMA M, 1987, J BIOL CHEM, V262, P17641; Jacobson MD, 1997, CURR BIOL, V7, pR277, DOI 10.1016/S0960-9822(06)00136-9; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kuo ML, 1996, BBA-MOL BASIS DIS, V1317, P95, DOI 10.1016/S0925-4439(96)00032-4; Kyprianou N, 1997, INT J CANCER, V70, P341, DOI 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Marchetti P, 1996, J IMMUNOL, V157, P4830; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MASUTANI M, 1995, BIOCHIMIE, V77, P462, DOI 10.1016/0300-9084(96)88161-2; MEISTERERNST M, 1997, P NATL ACAD SCI USA, V75, P12; MEMON SA, 1995, J IMMUNOL, V155, P4644; MIYASHITA T, 1993, BLOOD, V81, P151; MIZUMOTO K, 1994, MOL PHARMACOL, V46, P890; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SCOVASSI AI, 1984, J BIOL CHEM, V259, P973; Shah GM, 1996, BIOCHEM BIOPH RES CO, V229, P838, DOI 10.1006/bbrc.1996.1889; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; SIMS JL, 1983, BIOCHEMISTRY-US, V22, P5188, DOI 10.1021/bi00291a019; Sokolove PM, 1996, J BIOENERG BIOMEMBR, V28, P199, DOI 10.1007/BF02110651; SOLVEIG WSA, 1984, CARCINGOENESIS, V5, P319; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Takahashi T, 1996, J BIOCHEM-TOKYO, V119, P256; TANAKA Y, 1994, EXP CELL RES, V213, P242, DOI 10.1006/excr.1994.1196; TANIZAWA A, 1989, EXP CELL RES, V185, P237, DOI 10.1016/0014-4827(89)90052-9; TANUMA SI, 1985, ARCH BIOCHEM BIOPHYS, V237, P38, DOI 10.1016/0003-9861(85)90251-6; TSENG A, 1987, P NATL ACAD SCI USA, V84, P1107, DOI 10.1073/pnas.84.4.1107; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; VAN GL, 1997, EUR J BIOCHEM, V244, P15; Venkatachalam S, 1997, ONCOGENE, V14, P801, DOI 10.1038/sj.onc.1200890; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1990, J MED CHEM, V33, P2660, DOI 10.1021/jm00171a050; WHITACRE CM, 1995, CANCER RES, V55, P3697; Wright SC, 1996, J EXP MED, V183, P463, DOI 10.1084/jem.183.2.463; Yoon YS, 1996, J BIOL CHEM, V271, P9129, DOI 10.1074/jbc.271.15.9129; YOSHIHARA K, 1985, BIOCHEM BIOPH RES CO, V128, P61, DOI 10.1016/0006-291X(85)91644-4; ZEREZ CR, 1987, BLOOD, V69, P999	61	35	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	1998	17	17					2225	2234		10.1038/sj.onc.1202133	http://dx.doi.org/10.1038/sj.onc.1202133			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811453				2022-12-28	WOS:000076698200008
J	Saito, T; Schlegel, R; Andresson, T; Yuge, L; Yamamoto, M; Yamasaki, H				Saito, T; Schlegel, R; Andresson, T; Yuge, L; Yamamoto, M; Yamasaki, H			Induction of cell transformation by mutated 16K vacuolar H+-ATPase (ductin) is accompanied by down-regulation of gap junctional intercellular communication and translocation of connexin 43 in NIH3T3 cells	ONCOGENE			English	Article						gap junction; connexins; 16 K protein; ductin; cell transformation	GROWTH-CONTROL; E5 ONCOPROTEIN; POTENTIAL ROLE; PROTON PUMP; HELA-CELLS; SRC GENE; PROTEIN; CHANNEL; COMPONENT; CARCINOGENESIS	The 16 K subunit of the vacuolar H+-ATPase (ductin) has been suggested to also play a role in gap junction channels. Since mutated 16 K subunits have transforming ability when transfected into NIH3T3 cells and since aberrant gap junctional intercellular communication (GJIC) is a hallmark of cancer cells, we hypothesized that mutated 16 K subunits might transform these cells via alteration of GJIC, When GJIC was measured by the dye-transfer assay, NIH3T3 cells transfected with the mutant 16 K protein genes (deletion of the fourth transmembrane domain or a point mutation at codon 143 from glutamic acid to arginine) showed significantly lower levels of GJIC than those transfected with the vector alone or with the wild-type 16 K subunit gene. GJIC levels of NIH3T3 cells transformed by v-ras and v-src were not significantly decreased, suggesting that low GJIC levels are not necessarily the result of cell transformation pel se. NIH3T3 cells express Cx 43 as a major connexin gene. Although cells transfected with mutated 16 K subunits showed a level of Cx 43 protein expression similar to non-transfectants, their Cx43 protein was localized aberrantly, i.e. intracytoplasmically, These results indicate that mutant 16 K subunits with transforming ability translocate Cx43 proteins, thus inhibiting GJIC of NIH3T3 cells.	Int Agcy Res Canc, Unit Multistage Carcinogenesis, F-69372 Lyon 08, France; Georgetown Univ, Sch Med, Dept Pathol, Washington, DC 20007 USA; Hiroshima Univ, Sch Med, Inst Hlth Sci, Minami Ku, Hiroshima 734, Japan; Hiroshima Univ, Sch Med, Dept Anat, Minami Ku, Hiroshima 734, Japan	World Health Organization; International Agency for Research on Cancer (IARC); Georgetown University; Hiroshima University; Hiroshima University	Yamasaki, H (corresponding author), Sapporo Med Univ, Sch Med, Dept Obstet & Gynaecol, Chuo Ku, S1,W16, Sapporo, Hokkaido 060, Japan.				NCI NIH HHS [R01/CA40534] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040534] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRESSON T, 1995, J BIOL CHEM, V270, P6830, DOI 10.1074/jbc.270.12.6830; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P191, DOI 10.1007/BF01871629; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Beyer E C, 1993, Int Rev Cytol, V137C, P1; BIGNAMI M, 1988, MOL CARCINOGEN, V1, P67, DOI 10.1002/mc.2940010113; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; CHANG CC, 1985, P NATL ACAD SCI USA, V82, P5360, DOI 10.1073/pnas.82.16.5360; deFeijter AW, 1996, MOL CARCINOGEN, V16, P203, DOI 10.1002/(SICI)1098-2744(199608)16:4<203::AID-MC4>3.3.CO;2-F; DuflotDancer A, 1997, ONCOGENE, V15, P2151, DOI 10.1038/sj.onc.1201393; DUNLOP J, 1995, EMBO J, V14, P3609, DOI 10.1002/j.1460-2075.1995.tb00030.x; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; FINBOW ME, 1993, J CELL SCI, V106, P463; FINBOW ME, 1984, EMBO J, V3, P2271, DOI 10.1002/j.1460-2075.1984.tb02125.x; FINBOW ME, 1983, EMBO J, V2, P1479, DOI 10.1002/j.1460-2075.1983.tb01611.x; FINBOW ME, 1995, BIOESSAYS, V17, P247, DOI 10.1002/bies.950170311; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; GOLDSTEIN DJ, 1992, J VIROL, V66, P405, DOI 10.1128/JVI.66.1.405-413.1992; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; HARIKUMAR P, 1983, J BIOL CHEM, V258, P403; JONGEN WMF, 1991, J CELL BIOL, V114, P545, DOI 10.1083/jcb.114.3.545; KAESTNER KH, 1988, J BIOL CHEM, V263, P1282; Krutovskikh V, 1997, HISTOL HISTOPATHOL, V12, P761; KRUTOVSKIKH V, 1994, INT J CANCER, V56, P87; KRUTOVSKIKH VA, 1995, LAB INVEST, V72, P571; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KUMAR NM, 1995, J CELL SCI, V108, P3725; LEITCH B, 1990, EXP CELL RES, V190, P218, DOI 10.1016/0014-4827(90)90189-H; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; LOO LWM, 1995, J BIOL CHEM, V270, P12751, DOI 10.1074/jbc.270.21.12751; MARQUEZSTERLING N, 1991, EUR J CELL BIOL, V56, P19; MERCHENTHALER I, 1989, J HISTOCHEM CYTOCHEM, V37, P1563, DOI 10.1177/37.10.2674275; MESNIL M, 1995, CANCER RES, V55, P629; MESNIL M, 1994, CELL ADHES COMMUN, V2, P377, DOI 10.3109/15419069409004449; MORIYAMA Y, 1986, BIOCHIM BIOPHYS ACTA, V854, P102, DOI 10.1016/0005-2736(86)90069-6; NELSON N, 1992, J EXP BIOL, V172, P19; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; Sakaguchi T, 1996, J CELL BIOL, V133, P733, DOI 10.1083/jcb.133.4.733; SCHMID S, 1989, J CELL BIOL, V108, P1291, DOI 10.1083/jcb.108.4.1291; SUN SZ, 1987, J BIOL CHEM, V262, P14790; TROSKO JE, 1983, J AM COLL TOXICOL, V2, P5, DOI 10.3109/10915818309140689; XU HX, 1994, J BIOL CHEM, V269, P22875; Yamasaki H, 1996, MUTAT RES-REV GENET, V365, P91, DOI 10.1016/S0165-1110(96)90014-7; YAMASAKI H, 1990, CARCINOGENESIS, V11, P1051, DOI 10.1093/carcin/11.7.1051; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Yeager M, 1996, CURR OPIN STRUC BIOL, V6, P183, DOI 10.1016/S0959-440X(96)80073-X	49	44	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1673	1680		10.1038/sj.onc.1202092	http://dx.doi.org/10.1038/sj.onc.1202092			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796696				2022-12-28	WOS:000076200100005
J	Coccia, EM; Del Russo, N; Stellacci, E; Orsatti, R; Benedetti, E; Marziali, G; Hiscott, J; Battistini, A				Coccia, EM; Del Russo, N; Stellacci, E; Orsatti, R; Benedetti, E; Marziali, G; Hiscott, J; Battistini, A			Activation and repression of the 2-5A synthetase and p21 gene promoters by IRF-1 and IRF-2	ONCOGENE			English	Article						interferon regulatory factors; cell growth; p21 (WAF1/CP1); 2-5A synthetase	REGULATORY FACTOR-I; INTERFERON-INDUCIBLE GENES; TRANSCRIPTION FACTOR IRF-1; CELL-GROWTH INHIBITION; PROTEIN-KINASE; DNA-DAMAGE; P21(WAF1/CIP1) EXPRESSION; CONSTITUTIVE EXPRESSION; LEUKEMIA-CELLS; INDUCTION	The Interferon Regulatory Factors-1 and -2 (IRF-1 and IRF-2) were originally identified as transcriptional regulators of the interferon (IFN) and IFN-stimulated genes, These factors also modulate immune response and play a role in cell growth regulation, In this study we analysed the effect of the ectopic expression of IRF-1 and IRF-2 on the regulation of two potential IRF target genes involved in cell growth regulation, 2-5A synthetase and p21 (WAF/CP1), both of which contain consensus binding sites for IRF family members within their promoters. Following ectopic expression, IRF-1 transactivated 2-5A synthetase and p21 genes, an effect that was counterbalanced by concomitant ectopic expression of IRF-2, These effects were mediated by direct binding of IRF to the gene promoters. A construct expressing an IRF-2 antisense (FRI-2) was able to revert the inhibitory effect of IRF-2 on the IRF-1 transactivation, IRF-1 also induced expression of its homologous repressor IRF-2 as indicated by EMSA analysis using an IRF-E probe from the IRF-2 promoter; and by cotransfection of IRF-1 together with an IRF-2 promoter CAT construct, Therefore, the induction of IRF-1 by IFNs or other stimuli acts as a transactivator of genes involved in cell growth regulation, as web as of its own repressor IRF-2, thus providing autoinhibitory regulation of IRF-1 activated genes.	Ist Super Sanita, Virol Lab, I-00161 Rome, Italy; Ist Super Sanita, Immunol Lab, I-00161 Rome, Italy; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Lady Davis Institute; McGill University	Battistini, A (corresponding author), Ist Super Sanita, Virol Lab, Viale Regina Elena 299, I-00161 Rome, Italy.		Coccia, Eliana M/B-4752-2013; BATTISTINI, ANGELA/C-2944-2016; Marziali, Giovanna/J-9808-2016; stellacci, emilia/J-2747-2014	Coccia, Eliana M/0000-0002-1606-2949; Marziali, Giovanna/0000-0001-7450-1017; stellacci, emilia/0000-0003-0415-3285				BATTISTINI A, 1991, BLOOD, V78, P2098, DOI 10.1182/blood.V78.8.2098.bloodjournal7882098; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; CHIN IE, 1996, SCIENCE, V272, P729; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; COCCIA EM, 1995, VIROLOGY, V211, P113, DOI 10.1006/viro.1995.1384; COCCIA EM, 1991, J VIROL, V65, P2081, DOI 10.1128/JVI.65.4.2081-2087.1991; COCCIA EM, 1988, J INTERFERON RES, V7, P113; Demaeyer E., 1988, INTERFERONS OTHER RE; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HIRAMA T, 1995, BLOOD, V86, P841; HISCOTT J, 1995, SEMIN VIROL, V6, P161, DOI 10.1006/smvy.1995.0021; HOVANESSIAN AG, 1991, J INTERFERON RES, V11, P199, DOI 10.1089/jir.1991.11.199; JACOBSEN H, 1983, P NATL ACAD SCI-BIOL, V80, P4954, DOI 10.1073/pnas.80.16.4954; JIANG HP, 1994, ONCOGENE, V9, P3397; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LIN RT, 1994, J BIOL CHEM, V269, P17542; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NGUYEN H, 1995, ONCOGENE, V11, P537; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; OZAWA H, 1996, NATURE, V382, P816; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; REIS LF, 1994, EMBO J, V11, P185; RUFFNER H, 1993, P NATL ACAD SCI USA, V90, P11503, DOI 10.1073/pnas.90.24.11503; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; VILCEK J, 1994, FIELDS VIROLOGY, P717; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WELLS V, 1985, EXP CELL RES, V159, P27, DOI 10.1016/S0014-4827(85)80034-3; WILLIAMS BRG, 1985, 2 5A SYSTEM; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; YAMAMOTO H, 1994, ONCOGENE, V9, P1423; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHANG W, 1995, CANCER RES, V55, P668	61	58	58	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2129	2137		10.1038/sj.onc.1202536	http://dx.doi.org/10.1038/sj.onc.1202536			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321737				2022-12-28	WOS:000079346200010
J	Furukawa, Y; Iwase, S; Kikuchi, J; Nakamura, M; Yamada, H; Matsuda, M				Furukawa, Y; Iwase, S; Kikuchi, J; Nakamura, M; Yamada, H; Matsuda, M			Transcriptional repression of the E2F-1 gene by interferon-alpha is mediated through induction of E2F-4/pRB and E2F-4/p130 complexes	ONCOGENE			English	Article						interferon; transcription; E2F-1; E2F-4; pRB; p130	CELL-CYCLE REGULATION; SENSITIVE HEMATOPOIETIC-CELLS; DNA-BINDING ACTIVITY; GROWTH-FACTOR-BETA; RETINOBLASTOMA PROTEIN; IN-VIVO; INTERLEUKIN-6 SUPPRESS; CDC2 GENE; EXPRESSION; ACTIVATION	E2F is a heterodimeric transcription factor composed of one of five E2F subunits (E2F-1 to E2F-5) and a DP subunit, E2F regulates the expression of several growth-promoting genes, and thus, can be a target of antiproliferative action of interferons (IFNs), In this study, me investigated the mechanisms whereby IFN-alpha suppresses transcription of the E2F-1 gene. Transfection studies revealed that E2F-1 promoter was functionally divided into two parts: upstream activation sequences (UAS) and a downstream negative-regulatory element (E2F-binding sites). When cells were proliferating, transcription of the E2F-1 gene was primarily driven by the UAS, while E2F sites were not involved in activation. IFN-alpha markedly reduced E2F-1 promoter activity, but introduction of non-binding mutation at the E2F sites completely abrogated the inhibition. Free E2F-1 was found to be the predominant species bound to the E2F sites in proliferating cells. IFN-alpha induced upregulation of E2F-4 along with dephosphorylation of PRE and p130, which resulted in the formation of E2F-4/pRB and E2F-4/p130 complexes on the E2F-1 promoter, These complexes function as transcriptional repressors to inhibit E2F-1 mRNA expression. Our findings indicate that E2F-4 is a critical regulator of E2F-1, which offer an excellent paradigm for understanding functional diversity within the E2F family.	Jichi Med Sch, Ctr Mol Med, Div Mol Hemopoiesis, Minamimaki, Tochigi 3290498, Japan; Jichi Med Sch, Dept Hematol, Minami Kawachi, Tochigi 3290498, Japan; Hitachi Ltd, Katsuta Res Lab, Katsuta, Ibaraki 312, Japan; Jikei Univ, Sch Med, DNA Res Inst, Dept Internal Med,Aoto, Tokyo 105, Japan; Jikei Univ, Sch Med, DNA Res Inst, Dept Genet, Tokyo 105, Japan	Jichi Medical University; Jichi Medical University; Hitachi Limited; Jikei University; Jikei University	Furukawa, Y (corresponding author), Jichi Med Sch, Ctr Mol Med, Div Mol Hemopoiesis, 3311-1 Yakushiji, Minamimaki, Tochigi 3290498, Japan.		Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Cress WD, 1996, MOL CELL BIOL, V16, P2119; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; Einhorn S, 1996, J INTERF CYTOK RES, V16, P275, DOI 10.1089/jir.1996.16.275; FURUKAWA Y, 1992, J BIOL CHEM, V267, P17121; Furukawa Y, 1996, J BIOL CHEM, V271, P28469, DOI 10.1074/jbc.271.45.28469; FURUKAWA Y, 1994, J BIOL CHEM, V269, P26249; Geng Y, 1996, ONCOGENE, V12, P1173; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HUBER HE, 1994, J BIOL CHEM, V269, P6999; Iwase S, 1997, J BIOL CHEM, V272, P12406, DOI 10.1074/jbc.272.19.12406; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KITAGAWA M, 1995, ONCOGENE, V10, P229; Kramer A, 1996, J BIOL CHEM, V271, P6579; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; Li JM, 1997, P NATL ACAD SCI USA, V94, P4948, DOI 10.1073/pnas.94.10.4948; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; Moberg K, 1996, MOL CELL BIOL, V16, P1436; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Selleri C, 1996, BLOOD, V87, P4149, DOI 10.1182/blood.V87.10.4149.bloodjournal87104149; SEN GC, 1992, J BIOL CHEM, V267, P5017; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; THOMAS NSB, 1988, J BIOL CHEM, V264, P13697; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Williams CD, 1997, BRIT J HAEMATOL, V96, P688, DOI 10.1046/j.1365-2141.1997.d01-2086.x; Williams CD, 1997, BLOOD, V90, P194; XU JH, 1994, MOL CELL BIOL, V14, P8018, DOI 10.1128/MCB.14.12.8018; YAMADA H, 1994, MOL CELL BIOCHEM, V136, P117, DOI 10.1007/BF00926071; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	54	36	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	1999	18	11					2003	2014		10.1038/sj.onc.1202500	http://dx.doi.org/10.1038/sj.onc.1202500			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208422				2022-12-28	WOS:000079191300010
J	Ritchie, A; Braun, SE; He, J; Broxmeyer, HE				Ritchie, A; Braun, SE; He, J; Broxmeyer, HE			Thrombopoietin-induced conformational change in p53 lies downstream of the p44/p42 mitogen activated protein kinase cascade in the human growth factor-dependent cell line M07e	ONCOGENE			English	Article						MAPK; p53 conformation; thrombopoietin; apoptosis; M07e	WILD-TYPE P53; FACTOR RECEPTOR SUPERFAMILY; TUMOR-SUPPRESSOR PROTEIN; MPL CYTOPLASMIC DOMAIN; C-KIT LIGAND; TYROSINE-PHOSPHORYLATION; HEMATOPOIETIC-CELLS; MEGAKARYOCYTIC DIFFERENTIATION; SHC PHOSPHORYLATION; SIGNALING MOLECULES	Thrombopoietin is a cytokine with potent megakaryocytopoietic and thrombopoietic activities in who. Wild-type p53 is a conformationally flexible, anti-oncogenic transcription factor that plays a principal role in mediating growth factor withdrawal-induced apoptosis in factor-dependent hematopoietic cells. We recently reported that Tpo induces a conformational change in and functional inactivation of p53, coincident with its anti-apoptotic effects, in the human factor-dependent cell line M07e. In an effort to identify potential signaling cascades through which Tpo illicits these effects on p53, we report here that treating M07e cells with MAPK kinase inhibitor PD98059 dramatically suppressed Tpo-induced conformational change in p53 as well as Tpo-enhanced viability in M07e cells in a p53-dependent manner. Furthermore, the expression of constitutively active Raf1 in M07e cells induced conformational change in p53 independent of Tpo stimulation. Inhibition of the JAK/STAT pathway revealed that JAK/STAT signaling plays an insignificant role in conformational modulation of p53 and apoptosis suppression. Inhibition of phosphatidylinositol-3 kinase did not have a significant effect on p53 conformation but did have a weak but significant effect on Tpo-enhanced viability. Cytokine-induced activation of the MAPK pathway and the subsequent functional neutralization of p53, may be an event by which apoptosis is commonly suppressed in hematopoiesis.	Indiana Univ, Sch Med, Dept Microbiol Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med Hematol Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46208 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Broxmeyer, HE (corresponding author), Indiana Univ, Sch Med, Dept Microbiol Immunol, Indianapolis, IN 46202 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054037, R01HL056416] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053674] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 54037, R01 HL 56416] Funding Source: Medline; NIDDK NIH HHS [R01 DK 53674] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; Alexander WS, 1996, EMBO J, V15, P6531, DOI 10.1002/j.1460-2075.1996.tb01044.x; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; BACON CM, 1995, FEBS LETT, V370, P63, DOI 10.1016/0014-5793(95)00796-C; BI S, 1993, LEUKEMIA, V7, P1840; BLANDINO G, 1995, ONCOGENE, V10, P731; Brizzi MF, 1996, ONCOGENE, V13, P2067; BROUDY VC, 1995, BLOOD, V85, P1719, DOI 10.1182/blood.V85.7.1719.bloodjournal8571719; CarverMoore K, 1996, BLOOD, V88, P803; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; CohenSolal K, 1997, THROMB HAEMOSTASIS, V78, P37; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Dorsch M, 1997, J EXP MED, V186, P1947, DOI 10.1084/jem.186.12.1947; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gotoh A, 1997, ANN HEMATOL, V75, P207, DOI 10.1007/s002770050344; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HENDRIE PC, 1991, EXP HEMATOL, V19, P1031; KAUSHANSKY K, 1995, P NATL ACAD SCI USA, V92, P3234, DOI 10.1073/pnas.92.8.3234; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Melemed AS, 1997, BLOOD, V90, P3462, DOI 10.1182/blood.V90.9.3462; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1990, ONCOGENE, V5, P1683; MIYASHITA T, 1995, CELL, V80, P293; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morita H, 1996, FEBS LETT, V395, P228, DOI 10.1016/0014-5793(96)01047-2; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; Nagata Y, 1995, FEBS LETT, V377, P497, DOI 10.1016/0014-5793(95)01386-5; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Parrizas M, 1997, J BIOL CHEM, V272, P154; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PICKSLEY SM, 1992, ONCOGENE, V7, P1649; Porteu F, 1996, MOL CELL BIOL, V16, P2473; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Ramsfjell V, 1997, J IMMUNOL, V158, P5169; Reid S, 1996, J IMMUNOL METHODS, V192, P43, DOI 10.1016/0022-1759(96)00004-X; Ritchie A, 1997, BLOOD, V90, P4394; Ritchie A, 1996, STEM CELLS, V14, P330, DOI 10.1002/stem.140330; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; Sattler M, 1997, J CELL PHYSIOL, V171, P28; Sitnicka E, 1996, BLOOD, V87, P4998, DOI 10.1182/blood.V87.12.4998.bloodjournal87124998; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Takahira H, 1997, BLOOD, V89, P1574, DOI 10.1182/blood.V89.5.1574.1574_1574_1584; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; TORTOLANI PJ, 1995, BLOOD, V85, P3444, DOI 10.1182/blood.V85.12.3444.bloodjournal85123444; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMADA M, 1995, BIOCHEM BIOPH RES CO, V217, P230, DOI 10.1006/bbrc.1995.2768; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zauli G, 1997, BLOOD, V89, P883, DOI 10.1182/blood.V89.3.883; ZERRAHN J, 1992, ONCOGENE, V7, P1371; ZHANG W, 1992, ONCOGENE, V7, P1645; ZHANG W, 1994, LEUKEMIA LYMPHOMA, V14, P251, DOI 10.3109/10428199409049675; ZHU YM, 1994, BRIT J CANCER, V69, P468, DOI 10.1038/bjc.1994.85	70	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	1999	18	7					1465	1477		10.1038/sj.onc.1202439	http://dx.doi.org/10.1038/sj.onc.1202439			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050883				2022-12-28	WOS:000078651600008
J	Ghorbel, MT; Seugnet, I; Hadj-Sahraoui, N; Topilko, P; Levi, G; Demeneix, B				Ghorbel, MT; Seugnet, I; Hadj-Sahraoui, N; Topilko, P; Levi, G; Demeneix, B			Thyroid hormone effects on Krox-24 transcription in the post-natal mouse brain are developmentally regulated but are not correlated with mitosis	ONCOGENE			English	Article						non viral gene transfer; polyethylenimine; thyroid hormone; Krox-24; mouse; central nervous system	A GENE-EXPRESSION; NGFI-A; GROWTH-FACTORS; RAT-BRAIN; IN-VIVO; DIFFERENTIATION; RECEPTOR; CELLS; POLYETHYLENIMINE; PROLIFERATION	Krox-24 (NGFI-A, Egr-1) is an immediate-early gene encoding a zinc finger transcription factor. As Krox-24 is expressed in brain areas showing post-natal neurogenesis during a thyroid hormone (T-3)-sensitive period, we followed T-3 effects on Krox-24 expression in newborn mice. We analysed whether regulation was associated,vith changes in mitotic activity in the subventricular zone and the cerebellum, In vivo T-3-dependent Krox-24 transcription was studied by polyethylenimine-based gene transfer. T-3 increased transcription from the Krox-24 promoter in both areas studied at post-natal day 2, but was without effect at day 6, An intact thyroid hormone response element (TRE) in the Krox-24 promoter was necessary for these inductions. These stage-dependent effects were also seen in endogenous Krox-24 mRNA levels: activation at day 2 and no effect at day 6, Moreover, similar results were obtained by examining beta-galactosidase expression in heterozygous mice in which one allele of the Krox-24 gene was disrupted with an in-frame Lac-Z insertion. However, bromodeoxyuridine incorporation showed mitosis to continue through to day 6. We conclude first, that T-3 activates Krox-24 transcription during early post-natal mitosis but that this effect is extinguished as development proceeds and second, loss of T-3-dependent Krox-24 expression is not correlated with loss of mitotic activity.	Museum Natl Hist Nat, Lab Physiol Gen & Comparee, CNRS, URA 90, F-75231 Paris 5, France; Ecole Normale Super, INSERM, U368, F-75230 Paris, France; IST, CBA, Mol Biol Lab, Genoa, Italy	Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Demeneix, B (corresponding author), Museum Natl Hist Nat, Lab Physiol Gen & Comparee, CNRS, URA 90, F-75231 Paris 5, France.		Levi, Giovanni/B-4416-2013	Levi, Giovanni/0000-0002-7041-6787				Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; DEMENEIX BA, 1978, GEN COMP ENDOCR, V35, P77, DOI 10.1016/0016-6480(78)90170-3; FORREST D, 1994, SEMIN CANCER BIOL, V5, P167; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Ghorbel M, 1997, NEUROSCI LETT, V231, P127, DOI 10.1016/S0304-3940(97)00541-7; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GUISSOUMA H, IN PRESS FASEB J; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; Lebel JM, 1994, CURR OPIN ENDOCRINOL, V1, P167; Lee SL, 1996, MOL CELL BIOL, V16, P4566; LEE SL, 1995, J BIOL CHEM, V270, P9971, DOI 10.1074/jbc.270.17.9971; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEZOUALCH F, 1992, MOL ENDOCRINOL, V6, P1797, DOI 10.1210/me.6.11.1797; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; MELLSTROM B, 1994, ENDOCRINOLOGY, V135, P583, DOI 10.1210/en.135.2.583; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NICHOLSO.JL, 1972, BRAIN RES, V44, P13, DOI 10.1016/0006-8993(72)90362-9; PIPAON C, 1992, J BIOL CHEM, V267, P21, DOI 10.1016/S0021-9258(18)48449-9; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROHRER H, 1990, EUR J NEUROSCI, V2, P1005, DOI 10.1111/j.1460-9568.1990.tb00013.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Topilko P, 1998, MOL ENDOCRINOL, V12, P107, DOI 10.1210/mend.12.1.0049; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	33	21	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					917	924		10.1038/sj.onc.1202378	http://dx.doi.org/10.1038/sj.onc.1202378			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023667	Bronze			2022-12-28	WOS:000078510600008
J	Perez, M; Haschke, B; Donato, NJ				Perez, M; Haschke, B; Donato, NJ			Differential expression and translocation of protein tyrosine phosphatase 1B-related proteins in ME-180 tumor cells expressing apoptotic sensitivity and resistance to tumor necrosis factor: potential interaction with epidermal growth factor receptor	ONCOGENE			English	Article						apoptosis; protein tyrosine; phosphate; TNF	FAS-MEDIATED APOPTOSIS; MANGANOUS SUPEROXIDE-DISMUTASE; RADIATION-INDUCED APOPTOSIS; KAPPA-B ACTIVATION; CARCINOMA-CELLS; FACTOR-ALPHA; TRANSCRIPTION FACTOR; CELLULAR-RESISTANCE; SIGNAL-TRANSDUCTION; GAMMA-RADIATION	Tumor necrosis factor (TNF)-induced apoptosis can be inhibited by overexpression of specific tyrosine kinases or activation of tyrosine kinase cascades, suggesting potential antagonism between apoptotic and tyrosine kinase signaling processes. In this report, the effects of TNF on EGF receptor tyrosine phosphorylation in ME-180 cell variants selected for apoptotic sensitivity (Sen) or resistance (Res) to TNF, previously shown to differentially express EGFr, were examined, Prior to the onset of apoptosis, TNF caused a significant reduction in the level of EGFr tyrosine phosphorylation in Sen cells but mediated only limited suppression of EGFr tyrosine phosphorylation in apoptotically resistant Res cells, In vitro incubation of cellular membranes with TNF derived from Sen cells stimulated a resident protein tyrosine phosphatase (PTP) activity which was able to dephosphorylate EGFr or tyrosine phosphopeptides mimicking an EGFr autophosphorylation site, In membrane preparations, PTP1B complexed with tyrosine phosphorylated EGFr and this association was disrupted by TNF through an apparent stimulation of PTP activity and turnover of phosphotyrosine, Intrinsic enzymatic activity of PTP1B was 2-3-fold higher in Sen versus Res cell lysates and a family of PTP1B-related proteins with altered C-termini was found to be highly expressed in Sen cells but absent or expressed at reduced levels in Res cells, Cytoplasmic extracts of Sen cells contained PTP1B-like proteins and TNF incubation resulted in the time dependent accumulation of PTP1B-like proteins in Sen cells but did not effect these proteins in Res cells, Together, these results suggest that specific changes in expression and subcellular distribution of phosphotyrosine modulatory proteins may play a role in conveying intrinsic apoptotic sensitivity to TNF in some tumor cell types.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy & Drug Carriers, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Donato, NJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy & Drug Carriers, Box 44,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA073018, R29CA048906, R01CA048906] Funding Source: NIH RePORTER; NCI NIH HHS [CA48906, CA73018] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGGARWAL BB, 1994, FEBS LETT, V345, P219, DOI 10.1016/0014-5793(94)00441-2; Atherton E., 1990, SOLID PHASE PEPTIDE; Bandyopadhyay D, 1997, J BIOL CHEM, V272, P1639, DOI 10.1074/jbc.272.3.1639; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Byon JCH, 1997, P SOC EXP BIOL MED, V216, P1; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; CHANG DJ, 1992, BIOCHEM BIOPH RES CO, V188, P538, DOI 10.1016/0006-291X(92)91089-9; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DONATO NJ, 1992, CELL GROWTH DIFFER, V3, P259; DONATO NJ, 1993, CELL GROWTH DIFFER, V4, P411; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; DOWD DR, 1995, ADV SEC MESS PHOSPH, V30, P255; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; EASTMAN A, 1995, SEMIN CANCER BIOL, V6, P45, DOI 10.1006/scbi.1995.0006; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; FREEMAN BA, 1982, LAB INVEST, V47, P412; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GarciaLloret MI, 1996, J CELL PHYSIOL, V167, P324, DOI 10.1002/(SICI)1097-4652(199605)167:2<324::AID-JCP17>3.0.CO;2-7; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HUDZIAK RM, 1988, P NATL ACAD SCI USA, V85, P5102, DOI 10.1073/pnas.85.14.5102; JAATTELA M, 1995, ONCOGENE, V10, P2297; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lumelsky NL, 1996, CANCER RES, V56, P3909; MAEGAWA H, 1995, J BIOL CHEM, V270, P7724, DOI 10.1074/jbc.270.13.7724; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; MIGITA K, 1995, IMMUNOLOGY, V85, P550; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; NISHIKAWA K, 1994, LYMPHOKINE CYTOK RES, V13, P37; Perez M, 1996, J INTERF CYTOK RES, V16, P307, DOI 10.1089/jir.1996.16.307; Rock MT, 1997, J BIOL CHEM, V272, P33377, DOI 10.1074/jbc.272.52.33377; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SCHIEVEN GL, 1995, J BIOL CHEM, V270, P20824, DOI 10.1074/jbc.270.35.20824; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHEPARD HM, 1988, J CLIN IMMUNOL, V8, P333, DOI 10.1007/BF00917148; Shifrin VI, 1997, J BIOL CHEM, V272, P2957, DOI 10.1074/jbc.272.5.2957; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; SU X, 1995, IMMUNITY, V2, P353, DOI 10.1016/1074-7613(95)90143-4; SUGARMAN BJ, 1987, CANCER RES, V47, P781; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TILLY JL, 1992, MOL ENDOCRINOL, V6, P1942, DOI 10.1210/me.6.11.1942; TONKS NK, 1988, J BIOL CHEM, V263, P6722; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; WARREN S, 1993, LYMPHOKINE CYTOK RES, V12, P75; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; Wu YL, 1996, J CELL PHYSIOL, V168, P499, DOI 10.1002/(SICI)1097-4652(199609)168:3<499::AID-JCP2>3.0.CO;2-K; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868; ZHAI YF, 1993, CANCER RES, V53, P2272; ZIMMERMAN RJ, 1989, CANCER RES, V49, P164	76	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					967	978		10.1038/sj.onc.1202368	http://dx.doi.org/10.1038/sj.onc.1202368			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023672				2022-12-28	WOS:000078510600013
J	de Fromentel, CC; Gruel, N; Venot, C; Debussche, L; Conseiller, E; Dureuil, C; Teillaud, JL; Tocque, B; Bracco, L				de Fromentel, CC; Gruel, N; Venot, C; Debussche, L; Conseiller, E; Dureuil, C; Teillaud, JL; Tocque, B; Bracco, L			Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments	ONCOGENE			English	Article						p53; scFv; intracellular immunization; gene therapy	DNA-BINDING FUNCTION; C-TERMINAL DOMAIN; ACTIVATION FUNCTION; GROWTH SUPPRESSION; INDUCED APOPTOSIS; PROTEIN; INDUCTION; DAMAGE; INVOLVEMENT; SEQUENCE	We report here the production and the properties of single chain Fv fragments (scFvs) derived from the anti-p53 monoclonal antibodies PAb421 and 11D3, 11D3 is a newly generated monoclonal antibody which exhibits properties very comparable to those of PAb421, The scFvs PAb421 and 11D3 are able to stably associate with p53 and to restore the DNA binding activity of some p53 mutants in vitro. When expressed in p53(-/-) human tumour cells, the scFv421 is essentially localized in the cytoplasm in the absence of p53, and in the nucleus when exogenous p53 is present, Thus, p53 is also able to stably associate with an anti-p53 scFv in cells. Cotransfection of p53(-/-) human tumour cells with expression vectors encoding the His273 p53 mutant and either scFv leads to restoration of the p53 mutant deficient transcriptional activity. These data demonstrate that, in human tumour cells, these scFvs are able to restore a function essential for the tumour suppressor activity of p53 and may represent a novel class of molecules for p53-based cancer therapy.	Rhone Poulenc Rorer SA, Gene Med Dept, F-94403 Vitry, France; Inst Curie, Lab Biotechnol Anticorps, F-75005 Paris, France; Inst Curie, U255, INSERM, F-75005 Paris, France	Sanofi-Aventis; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	de Fromentel, CC (corresponding author), Inst Cochin Genet Mol, INSERM, U380, 22 Rue Mechain, F-75014 Paris, France.		de Fromentel, Claude Caron/Y-9715-2019	de Fromentel, Claude Caron/0000-0001-7566-3958; Teillaud, Jean-Luc/0000-0003-4442-9565				ABARZUA P, 1995, CANCER RES, V55, P3490; Abarzua P, 1996, ONCOGENE, V13, P2477; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; BYK G, 1995, Patent No. 01865; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cochet O, 1998, CANCER RES, V58, P1170; EIZENBERG O, 1995, EMBO J, V14, P1136, DOI 10.1002/j.1460-2075.1995.tb07097.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GUILLOUF C, 1995, ONCOGENE, V10, P2263; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jannot CB, 1997, BIOCHEM BIOPH RES CO, V230, P242, DOI 10.1006/bbrc.1996.5930; Kabat EA, 1991, SEQUENCES PROTEINS I; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEGROS Y, 1994, ONCOGENE, V9, P2071; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Marasco WA, 1997, GENE THER, V4, P11, DOI 10.1038/sj.gt.3300346; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MIYASHITA T, 1995, CELL, V80, P293; Nieba L, 1997, PROTEIN ENG, V10, P435, DOI 10.1093/protein/10.4.435; NIEWOLIK D, 1995, ONCOGENE, V10, P881; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PARK DJ, 1994, ONCOGENE, V9, P1899; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RICHARDSON JH, 1995, P NATL ACAD SCI USA, V92, P3137, DOI 10.1073/pnas.92.8.3137; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SMITH ML, 1995, ONCOGENE, V10, P1053; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	49	65	71	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					551	557		10.1038/sj.onc.1202338	http://dx.doi.org/10.1038/sj.onc.1202338			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927212				2022-12-28	WOS:000078166500028
J	Hosono, S; Luo, X; Hyink, DP; Schnapp, LM; Wilson, PD; Burrow, CR; Reddy, JC; Atweh, GF; Licht, JD				Hosono, S; Luo, X; Hyink, DP; Schnapp, LM; Wilson, PD; Burrow, CR; Reddy, JC; Atweh, GF; Licht, JD			WT1 expression induces features of renal epithelial differentiation in mesenchymal fibroblasts	ONCOGENE			English	Article						WT1; Wilms'; differentiation; epithelium	WILMS-TUMOR GENE; MICE LACKING GDNF; GROWTH-FACTOR-I; KIDNEY DEVELOPMENT; SUPPRESSOR WT1; TRANSCRIPTIONAL ACTIVATION; BASEMENT-MEMBRANE; PROTO-ONCOGENE; CELL-ADHESION; RECEPTOR GENE	The WT1 tumor suppressor gene, implicated in hereditofamilial and sporadic Wilms' tumor, is required for normal renal development and is up-regulated during the mesenchymal-epithelial transition. NIH3T3 fibroblasts overexpressing WT1 were less proliferative, larger in size and more firmly attached to tissue culture plastic, suggesting an alteration of their state of differentiation. These cells were studied in vivo by subcutaneous injection into nude mice, The resulting tumors exhibited epithelioid histopathology and formed desmosome-like structures. Molecular analyses of these WT1 expressing fibroblasts grown in culture and in nude mice revealed significant alterations in the expression of many kidney epithelial markers. These studies indicate that WT1 expression can initiate features of a program of epithelial differentiation consistent with a prominent role for WT1 in the mesenchymal epithelial transition that occurs during renal development. Through this work we identified a number of novel target genes for the WT1 transcription factor, including uvomorulin, integrin alpha 8 and perlecan, and suggest that WT1 may activate the IGF-II gene, also implicated in the development of Wilms' tumor.	CUNY Mt Sinai Sch Med, Brookdale Ctr Dev & Mol Biol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Licht, JD (corresponding author), CUNY Mt Sinai Sch Med, Brookdale Ctr Dev & Mol Biol, Box 1126, New York, NY 10029 USA.		Licht, Jonathan/L-4239-2019; Hyink, Deborah/AAT-6821-2021	Hyink, Deborah/0000-0001-5820-4995; Licht, Jonathan/0000-0002-3942-1369	NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054184] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA59936] Funding Source: Medline; NHLBI NIH HHS [R01 HL54184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGREZ M, 1994, J CELL BIOL, V127, P547, DOI 10.1083/jcb.127.2.547; ALBELDA SM, 1993, LAB INVEST, V68, P4; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Cook DM, 1996, ONCOGENE, V13, P1789; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; GABBIANI G, 1972, CANCER-AM CANCER SOC, V30, P486, DOI 10.1002/1097-0142(197208)30:2<486::AID-CNCR2820300229>3.0.CO;2-F; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GERALD WL, 1992, AM J PATHOL, V140, P1031; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOODYER P, 1995, ONCOGENE, V10, P1125; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HASTIE ND, 1994, ANNU REV GENET, V28, P523; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; Hewitt SM, 1996, ANTICANCER RES, V16, P621; HIRVONEN H, 1989, J CELL BIOL, V108, P1093, DOI 10.1083/jcb.108.3.1093; HUFF V, 1992, CANCER RES, V52, P6117; HUFF V, 1993, BIOCHIM BIOPHYS ACTA, V1155, P295, DOI 10.1016/0304-419X(93)90011-Z; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Iozzo RV, 1997, J BIOL CHEM, V272, P5219, DOI 10.1074/jbc.272.8.5219; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Johnstone RW, 1998, J BIOL CHEM, V273, P10880, DOI 10.1074/jbc.273.18.10880; KLYMKOWSKY MW, 1989, CELL MOTIL CYTOSKEL, V14, P309, DOI 10.1002/cm.970140302; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Little M, 1997, HUM MUTAT, V9, P209, DOI 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2; LUO XN, 1995, ONCOGENE, V11, P743; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MACHINAMI R, 1982, VIRCHOWS ARCH A, V397, P109, DOI 10.1007/BF00430898; MAW MA, 1992, CANCER RES, V52, P3094; Menke AL, 1996, ONCOGENE, V12, P537; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; Miyamoto N, 1997, DEVELOPMENT, V124, P1653; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Muller U, 1997, CELL, V88, P603, DOI 10.1016/S0092-8674(00)81903-0; NICHOLS KE, 1995, CANCER RES, V55, P4540; OOSTERWEGEL M, 1992, DEV IMMUNOL, V3, P1, DOI 10.1155/1992/27903; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; PritchardJones K, 1997, LEUKEMIA LYMPHOMA, V27, P207, DOI 10.3109/10428199709059677; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; ROGERS SA, 1991, J CELL BIOL, V113, P1447, DOI 10.1083/jcb.113.6.1447; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; RUBIN H, 1993, DIFFERENTIATION, V53, P123, DOI 10.1111/j.1432-0436.1993.tb00652.x; RYAN G, 1995, DEVELOPMENT, V121, P867; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SANTOS E, 1983, P NATL ACAD SCI-BIOL, V80, P4679, DOI 10.1073/pnas.80.15.4679; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHNAPP LM, 1995, J CELL SCI, V108, P537; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Torban E, 1998, BBA-MOL CELL RES, V1401, P53, DOI 10.1016/S0167-4889(97)00119-5; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; VANDENBORN J, 1992, KIDNEY INT, V41, P115, DOI 10.1038/ki.1992.15; vandenHeuvel LPWJ, 1995, NEPHROL DIAL TRANSPL, V10, P2205, DOI 10.1093/ndt/10.12.2205; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; WAHRMAN MZ, 1985, TUMOUR BIOL, V6, P41; WANG ZY, 1992, J BIOL CHEM, V267, P21999; Ward A, 1995, GENE, V167, P239, DOI 10.1016/0378-1119(95)00645-1; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; WERNER H, 1995, MOL CELL BIOL, V15, P3516; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; YURCHENCO PD, 1987, J CELL BIOL, V105, P2559, DOI 10.1083/jcb.105.6.2559	73	42	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					417	427		10.1038/sj.onc.1202311	http://dx.doi.org/10.1038/sj.onc.1202311			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927198				2022-12-28	WOS:000078166500014
J	Chai, YL; Cui, JQ; Shao, NS; Reddy, ESP; Rao, VN				Chai, YL; Cui, JQ; Shao, NS; Reddy, ESP; Rao, VN			The second BRCT domain of BRCA-1 proteins interacts with p53 and stimulates transcription from the p21(WAF1/CIP1) promoter	ONCOGENE			English	Article						BRCA1; BRCA1a; BRCA1b; p53; p21(WAF1/CIP1); BRCT domain; CBP/p300	OVARIAN-CANCER INCIDENCE; CELL-CYCLE; GENE BRCA1; BREAST; EXPRESSION; GROWTH; ACTIVATION; INDUCTION; TISSUES; REGION	Inherited mutations in the breast and ovarian cancer susceptibility gene BRCA1 are associated with high risk for developing breast and ovarian cancers. Several studies link BRCA1 to transcriptional regulation, DNA repair, apoptosis and growth/tumor suppression. BRCA1 associates with p53 and stimulates transcription in both p53 dependent and p53-independent manners. BRCA1 splice variants BRCA1a (p110) and BRCA1b (p100) associates with CBP/p300 co-activators. Here we show that BRCA1a and BRCA1b proteins stimulate p53-dependent transcription from the p21(WAF1/CIP1) promoter. In addition, the C-terminal second BRCA1 (BRCT) domain is sufficient for p53 mediated transactivation of the p21 promoter. Previous studies emphasized the importance of the BRCT domain, which shows homology with p53 binding protein (53BP1), in transcriptional activation, growth inhibition and tumor suppression. Our findings demonstrate an additional function for this domain in protein-protein interaction and co-activation of p53. We also found that BRCA1a and BRCA1b proteins interact with p53 in vitro and in vivo. The p53 interaction domain of BRCA1a/1b maps, in vitro, to the second BRCT domain (aa 1760-1863). The BRCT domain binds to the central domain of p53 which is required for sequence specific DNA binding. These results demonstrate for the first time the presence of a second p53 interaction domain in BRCA1 proteins and suggests that BRCA1a and BRCA1b proteins, like BRCA1, function as p53 co-activators. This BRCT domain also binds in vitro to CBP. These results suggest that one of the mechanisms by which BRCA1 proteins function is through recruitment of CBP/p300 associated HAT/FAT activity for acetylation of p53 to specific promoters resulting in transcriptional activation.	Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, Philadelphia, PA 19102 USA	Drexel University	Rao, VN (corresponding author), Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, MS 481,New Coll Bldg,Broad & Vine St, Philadelphia, PA 19102 USA.				NCI NIH HHS [CA57322, CA50507, CA58642] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050507, R01CA057322, R01CA058642] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Cui JQ, 1998, ONCOL REP, V5, P585; Cui JQ, 1998, ONCOL REP, V5, P591; EASTON DF, 1995, AM J HUM GENET, V56, P265; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FORD D, 1995, AM J HUM GENET, V57, P1457; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Rao VN, 1996, ONCOGENE, V12, P523; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Szabo CI, 1996, HUM MOL GENET, V5, P1289, DOI 10.1093/hmg/5.9.1289; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; WU CJ, 1996, NAT GENET, V14, P430; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	33	154	157	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					263	268		10.1038/sj.onc.1202323	http://dx.doi.org/10.1038/sj.onc.1202323			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926942				2022-12-28	WOS:000078166000029
J	Wimmer, K; Zhu, XX; Lamb, BJ; Kuick, R; Ambros, PF; Kovar, H; Thoraval, D; Motyka, S; Alberts, JR; Hanash, SM				Wimmer, K; Zhu, XX; Lamb, BJ; Kuick, R; Ambros, PF; Kovar, H; Thoraval, D; Motyka, S; Alberts, JR; Hanash, SM			Co-amplification of a novel gene, NAG, with the N-myc gene in neuroblastoma	ONCOGENE			English	Article						gene amplification; neuroblastoma; N-myc amplicon	HUMAN NEURO-BLASTOMA; DEAD BOX GENE; DNA-SEQUENCES; CELL-LINES; ORNITHINE DECARBOXYLASE; SINGLE-COPY; EXPRESSION; COAMPLIFICATION; CHROMOSOMES; FRAGMENTS	Substantial evidence implicates amplification of the N-myc gene with aggressive tumor growth and poor outcome in neuroblastoma. However some evidence suggests that this gene alone is not the sole determinant of outcome in N-myc amplified tumors. We have searched for genes that co-amplify with N-myc in neuroblastoma by means of two-dimensional analysis of genomic restriction digests. Using this approach, we have identified and cloned a novel genomic fragment which is co-amplified with N-myc in neuroblastomas, This fragment was mapped in close vicinity to N-myc on chromosome arm 2p24, It was amplified in 5/8 N-myc amplified neuroblastoma cell lines and in 9/13 N-myc amplified tumors. Using a PCR-based approach we isolated a 4.5 kb c-DNA sequence that is partly contained in the genomic fragment, The open reading frame of the cDNA encodes a predicted protein of 1353 amino acids (aa), The homology of the predicted protein, which we designated NAG (neuroblastoma amplified gene), to a C, elegans protein of as yet unknown function, and its ubiquious expression suggest that NAG may serve an essential function, By Northern blot analysis we showed that amplification of the cloned gene correlates with over-expression in neuroblastoma cell lines. Amplification and consequent over-expression of NAG may, therefore, contribute to the phenotype of a subset of neuroblastomas.	Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria	University of Michigan System; University of Michigan; Saint Anna Children's Hospital	Wimmer, K (corresponding author), Univ Vienna, Dept Med Biol, Wahringerstr 10, A-1090 Vienna, Austria.		Ambros, Peter/AAA-1266-2021	Ambros, Peter/0000-0002-5507-7211; Zhu, Charles/0000-0003-2922-0042; Kovar, Heinrich/0000-0001-6873-9109	NCI NIH HHS [CA-26803] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA026803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA K, 1991, NUCLEIC ACIDS RES, V19, P6887, DOI 10.1093/nar/19.24.6887; AKIYAMA K, 1994, NUCLEIC ACIDS RES, V25, P157; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ambros IM, 1997, EUR J CANCER, V33, P2043, DOI 10.1016/S0959-8049(97)00204-9; AMLER LC, 1995, ONCOGENE, V10, P1095; AMLER LC, 1992, ONCOGENE, V7, P807; Amler LC, 1996, GENE CHROMOSOME CANC, V15, P134, DOI 10.1002/(SICI)1098-2264(199602)15:2<134::AID-GCC9>3.0.CO;2-4; ASAKAWA J, 1994, P NATL ACAD SCI USA, V91, P9052, DOI 10.1073/pnas.91.19.9052; BIEDLER JL, 1973, CANCER RES, V33, P2643; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHN SL, 1995, CANCER RES, V55, P721; DEBERNARDI B, 1995, J CLIN ONCOL, V13, P884, DOI 10.1200/JCO.1995.13.4.884; DRETZEN G, 1981, ANAL BIOCHEM, V112, P295, DOI 10.1016/0003-2697(81)90296-7; George RE, 1996, ONCOGENE, V12, P1583; GIRVITZ SC, 1980, ANAL BIOCHEM, V106, P492, DOI 10.1016/0003-2697(80)90553-9; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; Hiemstra J L, 1994, Prog Clin Biol Res, V385, P51; HIYAMA E, 1991, J PEDIATR SURG, V26, P838, DOI 10.1016/0022-3468(91)90151-I; KANDA N, 1983, P NATL ACAD SCI-BIOL, V80, P4069, DOI 10.1073/pnas.80.13.4069; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kuick R, 1996, GENETICS, V144, P307; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Lutz W, 1997, ONCOGENE, V15, P303, DOI 10.1038/sj.onc.1201195; MANOHAR CF, 1995, GENE CHROMOSOME CANC, V14, P196, DOI 10.1002/gcc.2870140307; NISEN PD, 1988, J NATL CANCER I, V80, P1633, DOI 10.1093/jnci/80.20.1633; Pandita A, 1997, GENE CHROMOSOME CANC, V20, P243, DOI 10.1002/(SICI)1098-2264(199711)20:3<243::AID-GCC4>3.0.CO;2-2; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; Schweizer D, 1994, Methods Mol Biol, V29, P97; SHILOH Y, 1986, CANCER RES, V46, P5297; Sivak LE, 1997, ONCOGENE, V15, P1937, DOI 10.1038/sj.onc.1201363; SLAVC I, 1990, CANCER RES, V50, P1459; SQUIRE JA, 1995, ONCOGENE, V10, P1417; Thoraval D, 1996, GENE CHROMOSOME CANC, V17, P234, DOI 10.1002/(SICI)1098-2264(199612)17:4<234::AID-GCC5>3.0.CO;2-4; Thoraval D, 1996, P NATL ACAD SCI USA, V93, P4442, DOI 10.1073/pnas.93.9.4442; TONIN PN, 1989, ONCOGENE, V4, P1117; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Wimmer K, 1997, BIOCHEM SOC T, V25, P262, DOI 10.1042/bst0250262	40	59	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					233	238		10.1038/sj.onc.1202287	http://dx.doi.org/10.1038/sj.onc.1202287			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926938				2022-12-28	WOS:000078166000025
J	Morrison, EE; Wardleworth, BN; Askham, JM; Markham, AF; Meredith, DM				Morrison, EE; Wardleworth, BN; Askham, JM; Markham, AF; Meredith, DM			EB1, a protein which interacts with the APC tumour suppressor, is associated with the microtubule cytoskeleton throughout the cell cycle	ONCOGENE			English	Article						EB1; APC; microtubules; mitosis; cancer	ADENOMATOUS POLYPOSIS; BETA-CATENIN; IN-VITRO; DYNAMICS; BINDING; GENE; EXPRESSION; MUTATIONS; MIGRATION; HOMOLOG	The characteristics of the adenomatous polyposis coli (APC) associated protein EB1 were examined in mammalian cells. By immunocytochemistry EB1 was shown to be closely associated with the microtubule cytoskeleton throughout the cell cycle, In interphase cells EB1 was associated with microtubules along their full length but was often particularly concentrated at their tips, During early mitosis, EB1 was localized to separating centrosomes and associated microtubules, while at metaphase it was associated with the spindle poles and associated microtubules. During cytokinesis EB1 was strongly associated with the midbody microtubules, Treatment with nocodazole caused a diffuse redistribution of EB1 immunoreactivity, whereas treatment with cytochalasin D had no effect. Interestingly, treatment with taxol abolished the EB1 association with microtubules, In nocodazole washout experiments EB1 rapidly became associated with the centrosome and repolymerizing microtubules. In taxol wash-out experiments EB1 rapidly re-associated with the microtubule cytoskeleton, resembling untreated control cells within 10 min, Immunostaining of SW480 cells, which contain truncated APC incapable of interaction with EEL, showed that the association of EB1 with microtubules throughout the cell cycle was not dependent upon an interaction with APC. These results suggest a role for EB1 in the control of microtubule dynamics in mammalian cells.	Univ Leeds, St James Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Morrison, EE (corresponding author), Univ Leeds, St James Hosp, Mol Med Unit, Clin Sci Bldg, Leeds LS9 7TF, W Yorkshire, England.							Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; GRODEN J, 1993, AM J HUM GENET, V52, P263; Gumbiner BM, 1997, CURR BIOL, V7, pR443, DOI 10.1016/S0960-9822(06)00214-4; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; JORDAN MA, 1992, J CELL SCI, V102, P401; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LEVY DB, 1994, CANCER RES, V54, P5953; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Morrison EE, 1997, NEUROSCI LETT, V235, P129, DOI 10.1016/S0304-3940(97)00739-8; Morrison EE, 1997, NEUROSCIENCE, V81, P553, DOI 10.1016/S0306-4522(97)00099-7; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Pollack AL, 1997, J CELL BIOL, V137, P1651, DOI 10.1083/jcb.137.7.1651; Renner C, 1997, J IMMUNOL, V159, P1276; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; SMITH KJ, 1994, CANCER RES, V54, P3672; SU LK, 1995, CANCER RES, V55, P2972; SU LK, 1998, P AM ASS CANC RES, V39; Trzepacz C, 1997, J BIOL CHEM, V272, P21681, DOI 10.1074/jbc.272.35.21681; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; Zhang KZ, 1996, P NATL ACAD SCI USA, V93, P4504, DOI 10.1073/pnas.93.9.4504	24	191	194	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 31	1998	17	26					3471	3477		10.1038/sj.onc.1202247	http://dx.doi.org/10.1038/sj.onc.1202247			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030671				2022-12-28	WOS:000078086200008
J	Valge-Archer, V; Forster, A; Rabbitts, TH				Valge-Archer, V; Forster, A; Rabbitts, TH			The LMO1 and LDB1 proteins interact in human T cell acute Leukaemia with the chromosomal translocation t(11;14)(p15;q11)	ONCOGENE			English	Article						leukaemia; dimerization; tumours; chromosomal translocation; transcription	MESSENGER-RNAS; LIM; RHOMBOTIN; ONCOGENE; LEUKEMIA; EXPRESSION; COMPLEX; MOTIF; TTG-1; TAL1	The ectopic expression of LMO1 or LMO2 in T cell acute leukaemias resulting from chromosomal translocations t(11;14)(p15;q11) or t(11;14)(p13;q11) respectively in a causal factor in tumorigenesis. LMO1 has been found as a heterodimer with a 46 Kd protein in a T cell Line derived from a childhood T-acute leukaemia. This 46 Kd protein is the LIM-binding protein LDB1/NLI, The latter is a phosphoprotein and binds to LMO1 in its phosphorylated state and essentially all the LMO1 and LDB1 protein in the T cell line is part of the complex. Therefore, the LMO1-LDB1 interaction is likely to be involved in tumorigenesis after LMO1 is ectopically expressed following chromosomal translocation in T cells prior to development of acute leukaemias.	MRC, Mol Biol Lab, Div Prot & Nucleic Acid Chem, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Rabbitts, TH (corresponding author), MRC, Mol Biol Lab, Div Prot & Nucleic Acid Chem, Hills Rd, Cambridge CB2 2QH, England.		Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1991, ONCOGENE, V6, P695; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; Grutz GG, 1998, EMBO J, V17, P4594, DOI 10.1093/emboj/17.16.4594; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145	17	27	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	1998	17	24					3199	3202		10.1038/sj.onc.1202353	http://dx.doi.org/10.1038/sj.onc.1202353			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872335				2022-12-28	WOS:000077517400013
J	Deng, J; Xia, WY; Hung, MC				Deng, J; Xia, WY; Hung, MC			Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo	ONCOGENE			English	Article						tumor suppression; apoptosis; adenovirus 5 E1A; murine melanoma	PROGRAMMED CELL-DEATH; NECROSIS-FACTOR-ALPHA; E1A GENE-PRODUCTS; TRANSCRIPTIONAL REPRESSION; ULTRAVIOLET-RADIATION; MURINE MELANOMA; BREAST-CANCER; SOLID TUMORS; RAT-CELLS; EXPRESSION	Disruption of apoptotic pathways is a major factor in the multistep process of tumorigenesis, whereas induction of apoptosis can be important for tumor suppression and cancer therapy. The adenovirus type 5 E1A gene provides a useful tool to study the function of tumor suppression and apoptosis. E1A has been shown to induce apoptosis in different systems in vitro . However, this activity has not been well characterized in vivo. Therefore, the effect of this activity and the link to the in vivo biological function are not clear. To answer these questions, we introduced E1A into murine melanoma cells and characterized the biological features both in vitro and in vivo. Expression of the EIA gene does not affect the proliferation rate of tumor cells in vitro, but inhibits tumor growth in vivo. The in vitro analysis indicated that the E1A-expressing tumor cells are sensitive to serum depletion-induced apoptosis. Importantly, E1A-mediated apoptosis was also identified in vivo, suggesting this activity contributed to the tumor suppressive function. The in vivo apoptotic pattern was unique: most of the apoptotic cells were around the periphery of the tumors, implicating the interaction of these cells with stress stimuli irt vivo. In addition, E1A also rendered the tumor cells susceptible to the cytotoxicity of other anticancer agents, a feature useful for improving the efficacy of cancer therapy. The results provide a functional link between in vitro activity and in vivo effects.	Univ Texas, Md Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [R01 CA58880] Funding Source: Medline; PHS HHS [16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058880] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; Boulakia CA, 1996, ONCOGENE, V12, P529; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; Chang JY, 1996, ONCOGENE, V13, P1405; Chang JY, 1997, ONCOGENE, V14, P561, DOI 10.1038/sj.onc.1200861; Chen H, 1997, ONCOGENE, V14, P1965, DOI 10.1038/sj.onc.1201030; Chen H, 1997, J BIOL CHEM, V272, P6101, DOI 10.1074/jbc.272.10.6101; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; CHEN PW, 1993, J IMMUNOL, V151, P244; CHU G, 1994, J BIOL CHEM, V269, P787; COOK JL, 1989, J IMMUNOL, V142, P4527; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DESOIZE B, 1994, ANTICANCER RES, V14, P2291; Donawho CK, 1996, J IMMUNOL, V157, P781; DUERKSENHUGHES P, 1989, J IMMUNOL, V143, P4193; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FRISCH SM, 1995, CANCER RES, V55, P5551; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Glinsky GV, 1996, CANCER LETT, V101, P43, DOI 10.1016/0304-3835(96)04112-2; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUTMAN M, 1995, CANCER RES, V55, P2470; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; Jansen B, 1997, CANCER RES, V57, P362; KERBEL RS, 1994, INVAS METAST, V14, P50; KRIPKE ML, 1979, JNCI-J NATL CANCER I, V63, P541, DOI 10.1093/jnci/63.3.541; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MYMRYK JS, 1994, ONCOGENE, V9, P1187; Mymryk JS, 1996, ONCOGENE, V13, P1581; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; PERIS K, 1991, ARCH DERMATOL RES, V283, P500, DOI 10.1007/BF00371922; PIERCEALL WE, 1992, CANCER RES, V52, P3946; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SANCHEZPRIETO R, 1995, ONCOGENE, V11, P675; SanchezPrieto R, 1996, ONCOGENE, V13, P1083; SHIH IM, 1993, J INVEST DERMATOL, V100, P196; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; SMETS LA, 1994, ANTI-CANCER DRUG, V5, P3, DOI 10.1097/00001813-199402000-00001; TEODORO JG, 1995, ONCOGENE, V11, P467; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TRENT JC, 1996, EMBO J, V15, P4459; TSUJI Y, 1993, J IMMUNOL, V150, P1897; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Wu JX, 1996, ANTICANCER RES, V16, P2233; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZHANG YJ, 1995, ONCOGENE, V10, P1947	58	62	67	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2167	2175		10.1038/sj.onc.1202148	http://dx.doi.org/10.1038/sj.onc.1202148			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811448				2022-12-28	WOS:000076698200003
J	Rodriguez-Puebla, ML; LaCava, M; Gimenez-Conti, IB; Johnson, DG; Conti, CJ				Rodriguez-Puebla, ML; LaCava, M; Gimenez-Conti, IB; Johnson, DG; Conti, CJ			Deregulated expression of cell-cycle proteins during premalignant progression in SENCAR mouse skin	ONCOGENE			English	Article						cyclins; cell-cycle; tumor progression; papilloma; squamous cell carcinoma	RETINOBLASTOMA GENE-PRODUCT; DEPENDENT KINASE INHIBITORS; E2F TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR GENE; HARVEY-RAS ONCOGENE; D-CDK COMPLEXES; GROWTH SUPPRESSION; SQUAMOUS-CELL; ALTERED EXPRESSION; TRANSGENIC MICE	It is now evident that several genes encoding regulatory activities that control the mammalian cell cycle, particularly some that control the progression of quiescent cells through G1 and into S phase, are targets for alterations that underlie the development of neoplasms. Here, we made a sequential study of alterations in cell cycle protein expression and complex formation among cyclin, cyclin dependent kinases (CDKs) and CDK inhibitors (CKIs) during premalignant progression in SENCAR mouse skin tumors. Changes in the level of expression were observed in positive (cyclin DI, D2, and E2F family members) and negative regulators (p16(Ink4a), p57(Kip2)) Of the cell cycle. Also, we observed the formation of cyclin/CDK/CKI complexes. The amounts of these proteins and complexes increased substantially at specific times during promotion but not during malignant conversion to carcinomas. These data show that deregulation of growth control occurs in benign tumors and that subsequent mutations not involved cell-cycle regulation are probably necessary to induce invasive behavior.	Univ Texas, Md Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Conti, CJ (corresponding author), Univ Texas, Md Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA.			Johnson, David/0000-0002-6223-1790	NCI NIH HHS [CA 57596, CA 42157, CA 16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA042157, P01CA057596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1989, MOL CARCINOGEN, V2, P22, DOI 10.1002/mc.2940020104; ALDAZ CM, 1987, P NATL ACAD SCI USA, V84, P2029, DOI 10.1073/pnas.84.7.2029; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BARTKOVA J, 1995, CANCER RES, V55, P949; BARTKOVA J, 1995, ONCOGENE, V10, P775; BATES S, 1994, ONCOGENE, V9, P1633; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BIANCHI AB, 1991, P NATL ACAD SCI USA, V88, P7590, DOI 10.1073/pnas.88.17.7590; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BURNS FJ, 1978, CARCINOGENESIS, V2, P91; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FUKUDA M, 1978, CELL TISSUE KINET, V11, P611, DOI 10.1111/j.1365-2184.1978.tb00834.x; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HIRAMA T, 1995, BLOOD, V86, P841; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jadayel DM, 1997, LEUKEMIA, V11, P64, DOI 10.1038/sj.leu.2400555; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KOIKE M, 1994, BIOCHEM BIOPH RES CO, V201, P673, DOI 10.1006/bbrc.1994.1753; LAMMIE GA, 1991, ONCOGENE, V6, P439; Lilischkis R, 1996, INT J CANCER, V66, P249, DOI 10.1002/(SICI)1097-0215(19960410)66:2<249::AID-IJC19>3.0.CO;2-7; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MITSUNAGA SI, 1995, CARCINOGENESIS, V16, P1629, DOI 10.1093/carcin/16.7.1629; MOOLGAVKAR SH, 1981, J NATL CANCER I, V66, P1037, DOI 10.1093/jnci/66.6.1037; MORI T, 1994, CANCER RES, V54, P3396; MUSGROVE EA, 1995, INT J CANCER, V63, P584, DOI 10.1002/ijc.2910630420; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POTTER VR, 1981, CARCINOGENESIS, V2, P1375, DOI 10.1093/carcin/2.12.1375; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Rodriguez-Puebla ML, 1998, CELL GROWTH DIFFER, V9, P31; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SGAMBATO A, 1995, CARCINOGENESIS, V16, P2193, DOI 10.1093/carcin/16.9.2193; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLAGA T J, 1989, P1; Taniguchi T, 1997, ONCOGENE, V14, P1201, DOI 10.1038/sj.onc.1200934; TENNENBAUM T, 1992, CANCER RES, V52, P2966; VAN DJ, 1991, AM J PATHOL, V138, P1165; Wang A, 1996, J CANCER RES CLIN, V122, P122, DOI 10.1007/BF01226270; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Weinberg WC, 1997, ONCOGENE, V15, P685, DOI 10.1038/sj.onc.1201230; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; Xiong Y, 1996, Biochim Biophys Acta, V1288, P01; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YUSPA SH, 1990, ENVIRON HEALTH PERSP, V88, P193; Zhang SY, 1997, MOL CARCINOGEN, V18, P142, DOI 10.1002/(SICI)1098-2744(199703)18:3<142::AID-MC3>3.3.CO;2-J; ZHANG SY, 1994, CANCER RES, V54, P5050	72	32	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	1998	17	17					2251	2258		10.1038/sj.onc.1202131	http://dx.doi.org/10.1038/sj.onc.1202131			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811455				2022-12-28	WOS:000076698200010
J	Asso-Bonnet, M; Feuillard, J; Ferreira, V; Bissieres, P; Tarantino, N; Korner, M; Raphael, M				Asso-Bonnet, M; Feuillard, J; Ferreira, V; Bissieres, P; Tarantino, N; Korner, M; Raphael, M			Relationship between I kappa B alpha constitutive expression, TNF alpha synthesis, and apoptosis in EBV-infected lymphoblastoid cells	ONCOGENE			English	Article						NF-kappa B; I kappa B alpha; EBV; TNF alpha	TUMOR-NECROSIS-FACTOR; SIGNAL-BINDING-PROTEIN; VIRUS TRANSFORMING PROTEIN; RBP-J-KAPPA; T-CELL; V-REL; RETICULOENDOTHELIOSIS VIRUS; TRANSCRIPTION FACTOR; LYMPHOMA PATIENTS; GENE-EXPRESSION	In order to understand the role of NF-KB in EBV transformation we have established stably transfected I kappa B alpha: into lymphoblastoid cells. Two clones were obtained in which the loss of NF-kappa B binding activity correlated with the constitutive expression of the transgenic I kappa B alpha. Protein latency expression was determined by immunocytochemistry. Expression of surface markers, intracytoplasmic content of cytokines cell cycle analysis after BrdU incorporation and DNA staining with propidium iodide were studied by flow cytometry, Percentage of apoptotic cells was determined by in-situ labelling of DNA strand breaks, No significative changes in EBV latency nor in cell surface marker expression was found. In contrast, intracytoplasmic TNF alpha levels were strongly reduced in transfected clones. Furthermore, 30% of I kappa B alpha transfected cells were apoptotic after 8 h of TNF alpha treatment. This correlated with a strong reduction of BrdU incorporation after 24 h of TNF alpha treatment, No effect was seen with non transfected cells or with cells transfected with a control plasmid, Our results suggest that the TNF: gene could be one of the targets of NF-kappa B in EBV infected cells and that NF-kappa B protects EBV-infected cells from apoptosis induced by TNF alpha, which may favour the proliferative effect of this cytokine.	Hop Avicenne, Serv Hematol Biol, F-93009 Bobigny, France; Hop La Pitie Salpetriere, URA 625, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Feuillard, J (corresponding author), Hop Avicenne, Serv Hematol Biol, F-93009 Bobigny, France.		Feuillard, Jean/O-8587-2016	Feuillard, Jean/0000-0001-6223-2454				ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Coral S, 1997, CELL GROWTH DIFFER, V8, P581; CORDINGLEY FT, 1988, LANCET, V1, P969; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; Ferreira V, 1998, J BIOL CHEM, V273, P592, DOI 10.1074/jbc.273.1.592; FEUILLARD J, 1995, INT IMMUNOL, V7, P121, DOI 10.1093/intimm/7.1.121; FEUILLARD J, 1991, CYTOKINE, V3, P257, DOI 10.1016/1043-4666(91)90025-9; GOLDFELD AE, 1991, J EXP MED, V174, P73, DOI 10.1084/jem.174.1.73; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GRILLI M, 1993, INT REV CYTOL, V143, P1; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; Houldsworth J, 1996, BLOOD, V87, P25; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; HUEN DS, 1995, ONCOGENE, V10, P549; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; JELINEK DF, 1987, J IMMUNOL, V139, P2970; Jochems G J, 1991, Hum Antibodies Hybridomas, V2, P57; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KEHRL JH, 1987, J EXP MED, V166, P786, DOI 10.1084/jem.166.3.786; KIEFF E, 1990, EPSTEINBARR VIRUS IT; Klein SC, 1996, LEUKEMIA RES, V20, P633, DOI 10.1016/0145-2126(96)00029-X; KORNER M, 1990, BIOCHEM J, V265, P547, DOI 10.1042/bj2650547; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Macia J, 1996, LEUKEMIA LYMPHOMA, V20, P481, DOI 10.3109/10428199609052433; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Osnes LTN, 1996, THROMB HAEMOSTASIS, V76, P970; PICKER LJ, 1995, BLOOD, V86, P1408, DOI 10.1182/blood.V86.4.1408.bloodjournal8641408; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; Rothenberger S, 1997, ONCOGENE, V14, P2123, DOI 10.1038/sj.onc.1201032; Salles G, 1996, BRIT J HAEMATOL, V93, P352, DOI 10.1046/j.1365-2141.1996.5181059.x; Shackelford RE, 1997, MOL PHARMACOL, V52, P421, DOI 10.1124/mol.52.3.421; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; Sugano N, 1997, J EXP MED, V186, P731, DOI 10.1084/jem.186.5.731; SUNG SSJ, 1988, J EXP MED, V168, P1539, DOI 10.1084/jem.168.5.1539; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Waltzer L, 1995, NUCLEIC ACIDS RES, V23, P4939, DOI 10.1093/nar/23.24.4939; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Warzocha K, 1997, J CLIN ONCOL, V15, P499, DOI 10.1200/JCO.1997.15.2.499; Warzocha Krzysztof, 1997, Leukemia (Basingstoke), V11, P441; WU F, 1988, J VIROL, V62, P218, DOI 10.1128/JVI.62.1.218-225.1988; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; ZIMBERSTROBL U, 1994, EMBO J, V13, P4973, DOI 10.1002/j.1460-2075.1994.tb06824.x	63	22	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 24	1998	17	12					1607	1615		10.1038/sj.onc.1202365	http://dx.doi.org/10.1038/sj.onc.1202365			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794238				2022-12-28	WOS:000076089900013
J	Liang, SH; Clarke, MF				Liang, SH; Clarke, MF			The nuclear import of p53 is determined by the presence of a basic domain and its relative position to the nuclear localization signal	ONCOGENE			English	Article						p53; nuclear localization; tumor suppressor gene 5	STRUCTURAL ASPECTS; GENE EVOLUTION; CELL-CYCLE; PROTEIN; ACCUMULATION; TRAFFICKING; RECEPTOR; SEQUENCE; LOCATION; MYC	It has been reported that Lysine-305 is needed for the nuclear import of the p53 protein (Liang et al., 1998). In the present study, further mutagenesis analyses were carried out between Lys-305 and the major nuclear localization signal (NLS I) of p53. It was found that a single mutation of Arg-306 resulted in the defect of p53 nuclear import. This effect is the same as that of Lys-305 mutation. Other mutations between Arg-306 and NLS I have no effect on the nuclear import of p53. However, deletions of more than two amino acids between this region abolished the transport of p53 into the nucleus. These results indicate that a basic domain other than the well defined NLS is required for the nuclear import of p53. A spacer between this basic domain and NLS I is necessary for the entrance of p53 into the cell nucleus.	Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Clarke, MF (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, 4310 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.				NATIONAL CANCER INSTITUTE [R55CA067140, R01CA067140] Funding Source: NIH RePORTER; NCI NIH HHS [CA67140] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSARI S, 1995, AM J PATHOL, V147, P790; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; DANG CV, 1989, J BIOL CHEM, V264, P18019; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HOLSTEIN M, 1991, SCIENCE, V253, P49; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; SOUSSI T, 1990, ONCOGENE, V5, P945; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X	21	44	46	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2163	2166		10.1038/sj.onc.1202350	http://dx.doi.org/10.1038/sj.onc.1202350			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321742	Bronze			2022-12-28	WOS:000079346200015
J	Shaughnessy, JD; Largaespada, DA; Tian, EM; Fletcher, CF; Cho, BC; Vyas, P; Jenkins, NA; Copeland, NG				Shaughnessy, JD; Largaespada, DA; Tian, EM; Fletcher, CF; Cho, BC; Vyas, P; Jenkins, NA; Copeland, NG			Mrvil, a common MRV integration site in BXH2 myeloid leukemias, encodes a protein with homology to a lymphoid-restricted membrane protein Jaw1	ONCOGENE			English	Article						myeloid leukemia model; retroviral insertional mutagenesis; common sites of integration	C-MPL LIGAND; VIRUS; GENE; EXPRESSION; MICE; MEGAKARYOCYTOPOIESIS; CHROMOSOME-11; SEQUENCES; T(7-11)(P15-P15); TRANSLOCATION	Ecotropic MuLVs induce myeloid leukemia in BXH2 mice by insertional mutagenesis of cellular protooncogenes or tumor suppressor genes, Disease genes can thus be identified by viral tagging as common sites of viral integration in BXH2 leukemias. Previous studies showed that a frequent common integration site in BXH2 leukemias is the NJ1 tumor suppressor gene. Unexpectedly, about half of the viral integrations at Nf1 represented a previously undiscovered defective nonecotropic virus, termed MRV, Because other common integration sites in BXH2 leukemias encoding protooncogenes contain ecotropic rather than MRV viruses, it has been speculated that MRV viruses may selectively target tumor suppressor genes. To determine if this were the case, 21 MRV-positive BXH2 leukemias were screened for new MRV common integration sites. One new site, Mrvi1 was identified that was disrupted by MRV in two of the leukemias. Ecotropic virus did not disrupt Mrvi1 in 205 ecotropic virus-positive leukemias, suggesting that Mrvi1 is specifically targeted by MRV, Mrvi1 encodes a novel protein with homology to Jaw1, a lymphoid restricted type II membrane protein that localizes to the endoplasmic reticulum, MRV integration occurs at the 5' end of the gene between two differentially used promoters. Within hematopoietic cells, Mrvi1 expression is restricted to megakaryocytes and some myeloid leukemias, Like Jaw1, which is downregulated during lymphoid differentiation, Mrv1 is do downregulated during monocytic differentiation of BXH2 leukemias, Taken together, these data suggest that MRV integration at Mrvi1 induces myeloid leukemia by altering the expression of a gene important for myeloid cell growth and/or differentiation. Experiments are in progress to test whether Mrvi1 is a tumor suppressor gene.	Univ Arkansas Med Sci, Dept Med, Div Hematol & Oncol, Little Rock, AR 72205 USA; Univ Minnesota, Ctr Canc, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; NCI, Mammalian Genet Lab, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Thomas Jefferson Univ, Inst Canc, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Childrens Hosp, Dept Hematol & Oncol, Boston, MA 02115 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Jefferson University; Harvard University; Boston Children's Hospital	Shaughnessy, JD (corresponding author), Univ Arkansas Med Sci, Dept Med, Div Hematol & Oncol, Little Rock, AR 72205 USA.		Vyas, Paresh/B-5708-2009; Largaespada, David/C-9832-2014	Vyas, Paresh/0000-0003-3931-0914; 				ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; Baffa R, 1996, CANCER RES, V56, P268; BEDIGIAN HG, 1984, J VIROL, V51, P586, DOI 10.1128/JVI.51.3.586-594.1984; BEDIGIAN HG, 1981, J VIROL, V39, P632, DOI 10.1128/JVI.39.2.632-640.1981; BEDIGIAN HG, 1993, J VIROL, V67, P6105, DOI 10.1128/JVI.67.10.6105-6109.1993; BEHRENS TW, 1994, J IMMUNOL, V153, P682; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BUCHBERG AM, 1990, MOL CELL BIOL, V10, P4658, DOI 10.1128/MCB.10.9.4658; CHATTOPDAHYAY SK, 1989, P NATL ACAD SCI USA, V486, P3862; CHO BC, 1995, J VIROL, V69, P7138, DOI 10.1128/JVI.69.11.7138-7146.1995; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; COPELAND NG, 1991, TRENDS GENET, V7, P44; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JENKINS NA, 1982, J VIROL, V42, P379, DOI 10.1128/JVI.42.2.379-388.1982; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LARGAESPADA DA, 1995, J VIROL, V69, P5095, DOI 10.1128/JVI.69.8.5095-5102.1995; LOH WE, 1992, P NATL ACAD SCI USA, V89, P1755, DOI 10.1073/pnas.89.5.1755; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCAFFERY CA, 1986, EMBO J, V5, P3167, DOI 10.1002/j.1460-2075.1986.tb04625.x; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; METHIA N, 1993, BLOOD, V82, P1395; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Mostert MC, 1998, ONCOGENE, V16, P2617, DOI 10.1038/sj.onc.1201787; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J., 2002, MOL CLONING LAB MANU; SHANNON KM, 1994, NEW ENGL J MED, V330, P579; Shaughnessy JD, 1997, GENOMICS, V39, P192, DOI 10.1006/geno.1996.4502; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; SUEDHOF TC, 1989, SCIENCE, V245, P1474; TESSAROLLO L, 1995, METHOD ENZYMOL, V254, P419; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; TSAO SGS, 1983, ANAL BIOCHEM, V131, P365, DOI 10.1016/0003-2697(83)90185-9; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0; WENDLING F, 1986, VIROLOGY, V149, P242, DOI 10.1016/0042-6822(86)90125-X	47	36	38	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2069	2084						16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321731				2022-12-28	WOS:000079346200004
J	di Iasio, MG; Calin, G; Tibiletti, MG; Vorechovsky, I; Benediktsson, KP; Taramelli, R; Barbanti-Brodano, G; Negrini, M				di Iasio, MG; Calin, G; Tibiletti, MG; Vorechovsky, I; Benediktsson, KP; Taramelli, R; Barbanti-Brodano, G; Negrini, M			Refinement of the LOH region 1 at 11q23.1 deleted in human breast carcinomas and sublocalization of 11 expressed sequence tags within the refined region	ONCOGENE			English	Article						LOH at 11q23; breast cancer	ATAXIA-TELANGIECTASIA; CERVICAL-CARCINOMA; OVARIAN-CANCER; MALIGNANT-MELANOMA; ATM MUTATIONS; CHROMOSOME-II; LONG ARM; HETEROZYGOSITY; GENE; TUMORS	Loss of constitutive heterozygosity at 11q23 has been detected in various human solid tumors. Here, we described the analysis of a series of normal and tumor pairs from 110 breast carcinomas for the presence of loss of heterozygosity at 11q23 loci. The overall frequency of LOH was 48%, confirming the importance of deletions at 11q23 in breast tumorigenesis. Previously, we have identified two independent regions of LOH at 11q23, the LOH region 1 at 11q23.1 and the LOH region 2 at 11q23.3. The most telomeric region was recently refined between loci D11S1345 and D11S1316, a region of about 1 Mb. However, the LOH region 1, most centromeric, was still not finely refined: the boundaries were defined by loci D11S2000 and D11S897, separated by about 8 Mb. Here, me refined its boundaries between loci D11S1347 and D11S927, a region of about 2 Mb. We have mapped 11 expressed sequence tags (ESTs) within this region and excluded another 20. This study represents a further step toward the identification of the putative tumor suppressor gene found within the LOH region 1 at 11q23.1.	Univ Ferrara, Dept Mol & Diagnost Med, I-44100 Ferrara, Italy; Univ Pavia, Dept Clin & Biol Sci, I-21100 Varese, Italy; Huddinge Hosp, Dept Surg, S-14157 Huddinge, Sweden; Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; Univ Varese, Dept Struct & Funct Biol, I-21110 Varese, Italy	University of Ferrara; University of Pavia; Karolinska Institutet; University of Insubria	Negrini, M (corresponding author), Univ Ferrara, Dept Expt & Diagnost Med, Microbiol Sect, Via Luigi Borsari 46, I-44100 Ferrara, Italy.		Calin, George/E-9390-2011; Negrini, Massimo/J-2377-2016	Negrini, Massimo/0000-0002-0007-1920; Calin, George/0000-0001-6704-5615				Arai Y, 1996, GENOMICS, V35, P196, DOI 10.1006/geno.1996.0339; BETHWAITE PB, 1995, BRIT J CANCER, V71, P814, DOI 10.1038/bjc.1995.157; CARTER SL, 1994, CANCER RES, V54, P6270; Dahiya R, 1997, INT J CANCER, V72, P283, DOI 10.1002/(SICI)1097-0215(19970717)72:2<283::AID-IJC14>3.0.CO;2-H; Davis M, 1996, CANCER RES, V56, P741; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; FOULKES WD, 1993, BRIT J CANCER, V67, P268, DOI 10.1038/bjc.1993.51; Gabra H, 1996, CANCER RES, V56, P950; GUSTAFSON CE, 1994, BRIT J CANCER, V70, P395, DOI 10.1038/bjc.1994.315; HAMPTON GM, 1994, CANCER RES, V54, P4586; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HERBST RA, 1995, CANCER RES, V55, P2494; Hui ABY, 1996, CANCER RES, V56, P3225; IIZUKA M, 1995, GENE CHROMOSOME CANC, V13, P40; KELDYSH PL, 1993, GENE CHROMOSOME CANC, V6, P45, DOI 10.1002/gcc.2870060109; Kerangueven F, 1997, ONCOGENE, V14, P339, DOI 10.1038/sj.onc.1200818; Laake K, 1997, GENE CHROMOSOME CANC, V18, P175, DOI 10.1002/(SICI)1098-2264(199703)18:3<175::AID-GCC4>3.0.CO;2-Z; LOU WE, 1992, P NATL ACAD SCI USA, V89, P1755; Monaco C, 1997, GENOMICS, V46, P217, DOI 10.1006/geno.1997.5036; NEGRINI M, 1994, CANCER RES, V54, P1331; NEGRINI M, 1995, CANCER RES, V55, P3003; RASIO D, 1995, CANCER RES, V55, P3988; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SRIVATSAN ES, 1991, AM J HUM GENET, V49, P868; STILGENBAUER S, 1997, NAT MED, V3, P1115; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Tomlinson IPM, 1996, J PATHOL, V180, P38, DOI 10.1002/(SICI)1096-9896(199609)180:1<38::AID-PATH638>3.0.CO;2-C; TOMLINSON IPM, 1993, GENE CHROMOSOME CANC, V7, P169, DOI 10.1002/gcc.2870070310; Visser M, 1997, ONCOGENE, V15, P1309, DOI 10.1038/sj.onc.1201302; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; Vorechovsky I, 1996, CANCER RES, V56, P4130; Vorechovsky I, 1996, CANCER RES, V56, P2726; WINQVIST R, 1995, CANCER RES, V55, P2660	33	27	27	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1635	1638		10.1038/sj.onc.1202453	http://dx.doi.org/10.1038/sj.onc.1202453			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102634				2022-12-28	WOS:000078770700014
J	Dougher, M; Terman, BI				Dougher, M; Terman, BI			Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization	ONCOGENE			English	Article						VEGF; KDR receptor; autophosphorylation; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; TYROSINE KINASE; SIGNAL-TRANSDUCTION; INSULIN-RECEPTOR; CELLS; IDENTIFICATION; EXPRESSION; SITES; PHOSPHORYLATION	We have previously reported the identification of four autophosphorylation sites on the KDR VEGF receptor. Two of these sites (tyrosines 951 and 996) are located in the receptor's kinase insert domain, and two (tyrosines 1054 and 1059) are located in the catalytic domain. In order to clarify the functional significance of these sites, we made DNA constructs in which tyrosine codons were replaced with those for phenylalanine, and expressed the DNA constructs in 293 cells. VEGF binding to cells expressing the native receptor led to a rapid increase in receptor and PLC gamma phosphorylation, and a slower increase in the phosphorylation of p(125)FAK and paxillin. VEGF binding to KDR(Y951F) and KDR(Y996F) expressing cells resulted in phosphorylation of all cellular substrates tested, although the level of PLC gamma phosphorylation was decreased for KDR(Y996F). The decreased level of PLC gamma phosphorylation was not because PLC gamma-containing SH2 domains bind to the Y996 autophosphorylation site. We conclude that there exists receptor autophosphorylation sites not previously identified which allow for signaling via PLC gamma, as well as p(125)FAK and paxillin. VEGF binding to cells expressing KDR mutated at both tyrosine's 1054 and 1059 activated receptor autophosphorylation but at a level which was only 10% of that seen for cells expressing native receptor. Tyrosine phosphorylation of cell signaling proteins was not observed in KDR(Y1054,1059) expressing cells. Utilizing an in vitro assay which directly measures receptor catalytic activity allowed us to determine that the tyrosine kinase activity of the native receptor was significantly greater than that for the double mutant. We conclude from this result that VEGF-induced autophosphorylation at tyrosines 1054 and 1059 is a required step for allowing maximal KDR kinase activity. Maximal rates of receptor kinase activity is required for VEGF-induced receptor internalization, as internalization was delayed in the KDR(Y1054,1059F) expressing cells when compared to cells expressing native receptor.	Wyeth Ayerst Oncol Res, Pearl River, NY 10965 USA	Pfizer	Terman, BI (corresponding author), Wyeth Ayerst Oncol Res, Bldg 200-4623, Pearl River, NY 10965 USA.							Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; BROWN LF, 1993, AM J PATHOL, V143, P1255; Broxmeyer HE, 1995, INT J HEMATOL, V62, P203; CULLINANBOVE K, 1993, ENDOCRINOLOGY, V133, P829, DOI 10.1210/en.133.2.829; CUNNINGHAM SA, 1997, BIOCHEM BIOPH RES CO, V240, P35; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dougher AM, 1997, GROWTH FACTORS, V14, P257, DOI 10.3109/08977199709021524; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; DVORAK HF, 1995, AM J PATHOL, V146, P1029; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1991, J NATL CANCER I, V82, P4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GARNER A, 1994, DYNAMIC APPROACH, P1625; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LONGATI P, 1994, ONCOGENE, V9, P3457; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; WILEY HS, 1991, J BIOL CHEM, V266, P11083	45	151	166	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1619	1627		10.1038/sj.onc.1202478	http://dx.doi.org/10.1038/sj.onc.1202478			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102632				2022-12-28	WOS:000078770700012
J	Wan, MH; Sun, T; Vyas, R; Zheng, JP; Granada, E; Dubeau, L				Wan, MH; Sun, T; Vyas, R; Zheng, JP; Granada, E; Dubeau, L			Suppression of tumorigenicity in human ovarian cancer cell lines is controlled by a 2 cM fragment in chromosomal region 6q24-q25	ONCOGENE			English	Article						tumor suppressor; chromosome 6; ovarian cancer; chromosome transfer	ACUTE LYMPHOBLASTIC-LEUKEMIA; COMMONLY DELETED REGION; KARYOTYPIC ANALYSIS; FREQUENT LOSS; HUMAN GENOME; LONG ARM; 6Q; HETEROZYGOSITY; CARCINOMAS; TUMORS	Multiple distinct regions of chromosome 6 are frequently affected by losses of heterozygosity in primary human ovarian carcinomas. We introduced a normal human chromosome 6 into HEY and SKOV-3 ovarian carcinoma cell lines using microcell-mediated chromosome transfer techniques to further investigate the role of this chromosome in ovarian tumorigenesis, The exogenous chromosome was stably propagated in the recipient cells based on fluorescence in situ hybridization (FISH) analyses with a chromosome 6 painting probe. The tumorigenicity of HEY and SKOV-3 cells was completely suppressed after transfer of chromosome 6, but not after transfer of a chromosome 11q13-qter fragment used as control. Using 46 polymorphic microsatellite markers, the region bounded by D6S1649 and D6S1564 was found to be commonly deleted in HEY: chromosome 6 tumorigenic revertant clones. The boundaries of the commonly deleted region could be further narrowed down to a 2 cM (based on the Whitehead genetic map) or 0.36 megabase (based on gdb mapping data) region between D6S1637 and D6S1564 after transferring the exogenous chromosome from revertants into mouse L cells and performing allelic deletion mapping studies against this mouse background. We conclude that this region contains a tumor suppressor gene important for the control of ovarian tumor development.	Univ So Calif, Sch Med, Dept Pathol, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Urol, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Dubeau, L (corresponding author), Univ So Calif, Sch Med, Dept Pathol, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA.				NATIONAL CANCER INSTITUTE [R01CA051167] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA51167] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; BUICK RN, 1985, CANCER RES, V45, P3668; CLIBY W, 1993, CANCER RES, V53, P2393; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Cooney KA, 1996, CANCER RES, V56, P4150; Deger RB, 1997, CANCER GENET CYTOGEN, V96, P166, DOI 10.1016/S0165-4608(96)00327-5; DEVILEE P, 1991, ONCOGENE, V6, P1705; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; EHLEN T, 1990, ONCOGENE, V5, P219; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; Gerard B, 1997, LEUKEMIA, V11, P228, DOI 10.1038/sj.leu.2400566; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; LEE JH, 1990, CANCER RES, V50, P2724; LUGO TG, 1987, MOL CELL BIOL, V7, P2814, DOI 10.1128/MCB.7.8.2814; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; MERLO A, 1994, CANCER RES, V54, P2322; NEGRINI M, 1994, CANCER RES, V54, P1331; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; ORPHANOS V, 1994, GENOMICS, V20, P301, DOI 10.1006/geno.1994.1172; SAHA V, 1995, GENE CHROMOSOME CANC, V14, P220, DOI 10.1002/gcc.2870140311; SAITO S, 1992, CANCER RES, V52, P5815; Saito S, 1996, CANCER RES, V56, P5586; Sandhu AK, 1996, ONCOGENE, V12, P247; SHEER D, 1987, CANCER GENET CYTOGEN, V26, P339, DOI 10.1016/0165-4608(87)90068-9; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; Tibiletti MG, 1996, CANCER RES, V56, P4493; Tibiletti MG, 1997, BRIT J CANCER, V75, P1831, DOI 10.1038/bjc.1997.312; Tibiletti MG, 1998, ONCOGENE, V16, P1639, DOI 10.1038/sj.onc.1201654; TRENT JM, 1981, CANCER GENET CYTOGEN, V3, P279, DOI 10.1016/0165-4608(81)90037-6; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; VOLTZ A, 1994, GENOMICS, V21, P464; WAKE N, 1980, CANCER RES, V40, P4512; WALKER GJ, 1994, INT J CANCER, V58, P203, DOI 10.1002/ijc.2910580210; Wan M, 1996, BRIT J CANCER, V73, P1398, DOI 10.1038/bjc.1996.265; WAN MH, 1994, INT J ONCOL, V5, P1043; WELCH DR, 1994, ONCOGENE, V9, P255; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V11, P91, DOI 10.1016/0165-4608(84)90102-X	39	41	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1545	1551		10.1038/sj.onc.1202476	http://dx.doi.org/10.1038/sj.onc.1202476			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102624				2022-12-28	WOS:000078770700004
J	Sun, SC; Maggirwar, SB; Harhaj, EW; Uhlik, M				Sun, SC; Maggirwar, SB; Harhaj, EW; Uhlik, M			Binding of c-Rel to STAT5 target sequences in HTLV-I-transformed T cells	ONCOGENE			English	Article						HTLV-I; c-Rel; STAT; T-cell transformation; NF-kappa B	NF-KAPPA-B; VIRUS TYPE-I; LEUKEMIA-LYMPHOMA VIRUS; LONG TERMINAL REPEAT; JAK-3 JANUS KINASE; TAX PROTEIN; TRANSCRIPTIONAL ACTIVATION; CONSTITUTIVE ACTIVATION; SIGNAL; PHOSPHORYLATION	The type I human T-cell leukemia virus (HTLV-I) induces abnormal growth and subsequent transformation of T cells, which is associated with the development of an acute T-cell malignancy termed adult T-cell leukemia, A characteristic of HTLV-I-transformed T cells is the constitutive nuclear expression of NF-kappa B/Rel family of transcription factors, which appears to be essential for the growth of these transformed cells. Although NF-kappa B/Rel factors are known to induce the expression of T-cell growth factor interleukin (IL)-2, it is unclear how they participate in the IL-2-independent growth of HTLV-1-transformed cells, In this study, we show that certain NF-kappa B/Rel members, predominantly c-Rel, interact with enhancer sequences for STAT5, a key transcription factor mediating IL-2-induced T-cell proliferation. Reporter gene assays reveal that the binding of c-Rel to the STAT5 site present in the Fc gamma 1 gene leads to potent transactivation of this enhancer. Binding of c-Rel to the Fc gamma R1 STAT site also occurs in human peripheral blood T cells immortalized with HTLV-I in vitro and is correlated with enhanced levels of proliferation of these cells. These results raise the possibility that NF-kappa B/Rel may participate in the growth control of HTLV-I-transformed T cells by regulating genes driven by both kappa B and certain STAT enhancers.	Penn State Univ, Coll Med, Hershey Med Ctr, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Hershey Med Ctr, Dept Microbiol & Immunol, POB 850, Hershey, PA 17033 USA.				NCI NIH HHS [1 R01 CA68471-03, 5 T32 CA 6039-5] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOERRE S, 1993, P NATL ACAD SCI USA, V90, P1023, DOI 10.1073/pnas.90.3.1023; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GAZDAR AF, 1980, BLOOD, V55, P409; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; HOLLSBERG P, 1992, J IMMUNOL, V148, P3256; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KOEFFLER HP, 1984, BLOOD, V64, P482; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LI CCH, 1993, J VIROL, V67, P4205, DOI 10.1128/JVI.67.7.4205-4213.1993; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; MERL S, 1984, BLOOD, V64, P967; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MIYOSHI I, 1981, GANN, V72, P978; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Mulloy JC, 1998, J VIROL, V72, P4408, DOI 10.1128/JVI.72.5.4408-4412.1998; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; PERSAUD D, 1995, J VIROL, V69, P6297, DOI 10.1128/JVI.69.10.6297-6303.1995; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Ressler S, 1996, FEMS MICROBIOL LETT, V140, P99, DOI 10.1016/0378-1097(96)00166-8; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SODROSKI J, 1992, BIOCHIM BIOPHYS ACTA, V1114, P19, DOI 10.1016/0304-419X(92)90003-H; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YOSHIDA M, 1995, J CANCER RES CLIN, V121, P521, DOI 10.1007/BF01197764; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	52	13	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1401	1409		10.1038/sj.onc.1202430	http://dx.doi.org/10.1038/sj.onc.1202430			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050877				2022-12-28	WOS:000078651600002
J	Davis, JN; Williams, BJ; Herron, JT; Galiano, FJ; Meyers, S				Davis, JN; Williams, BJ; Herron, JT; Galiano, FJ; Meyers, S			ETO-2, a new member of the ETO-family of nuclear proteins	ONCOGENE			English	Article						ETO family; MTG8; (8;21) translocation; nuclear; dimerization	ACUTE MYELOID-LEUKEMIA; DROSOPHILA SEGMENTATION GENE; T(8-21) FUSION PROTEIN; CORE-BINDING FACTOR; TRANSCRIPTIONAL REGULATION; MOLECULAR-CLONING; AML1 GENE; CELL-LINE; RUNT; IDENTIFICATION	The t(8;21) is associated with 12-15% of acute myelogenous leukemias of the M2 subtype, the translocation results in the fusion of two genes, AML1 (CBFA2) on chromosome 21 and ETO (MTG8) on chromosome 8, AML1 encodes a DNA binding factor; the ETO protein product is less well characterized, but is thought to be a transcription factor. Here we describe the isolation and characterization of ETO-2, a murine cDNA that encodes a new member of the ETO family of proteins. ETO-2 is 75% identical to murine ETO and shares very high sequence identities over four regions of the protein with ETO (domain I-III and zinc-finger). Northern analysis identifies ETO-2 transcripts in many of the murine tissues analysed and in the developing mouse embryo. ETO-2 is also expressed in myeloid and erythroid cell lines. We confirmed the nuclear localization of ETO-2 and demonstrated that domain III and the zinc-finger region are not required for nuclear localization. We further showed that a region within ETO, containing domain II, mediates dimerization among family members. This region is conserved in the oncoprotein AML-1/ETO. The recent identification of another ETO-like protein, myeloid translocation gene-related protein 1, together with the data presented here, demonstrates that at least three ETO proteins exist with the potential to form dimers in the cell nucleus.	Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Louisiana State Univ, Med Ctr, Dept Urol, Shreveport, LA 71130 USA; Louisiana State Univ, Med Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Meyers, S (corresponding author), Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA.				NATIONAL CANCER INSTITUTE [R29CA076186] Funding Source: NIH RePORTER; NCI NIH HHS [R29-CA76186] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1993, HEMATOL PATHOL, V7, P1; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DICKSTEIN R, 1996, CELL, V87, P137; ERICKSON P, 1992, BLOOD, V80, P1825; ERICKSON PF, 1994, CANCER RES, V54, P1782; Erickson PF, 1996, BLOOD, V88, P1813; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEINSTEIN PG, 1995, GENETICS, V140, P573; Frank R, 1995, ONCOGENE, V11, P2667; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Hiebert SW, 1996, CURR TOP MICROBIOL, V211, P253; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Hwang I, 1997, J IMMUNOL, V158, P1165; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; KOZU T, 1993, BLOOD, V82, P1270; Kozu Tomoko, 1997, Leukemia (Basingstoke), V11, P297; LEE JC, 1982, J IMMUNOL, V128, P2393; LENNY N, 1995, ONCOGENE, V11, P1761; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MELNIKOVA IN, 1993, J VIROL, V67, P2408, DOI 10.1128/JVI.67.4.2408-2411.1993; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; ROWLEY JD, 1984, CANCER RES, V44, P3159; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137	44	35	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1375	1383		10.1038/sj.onc.1202412	http://dx.doi.org/10.1038/sj.onc.1202412			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022820				2022-12-28	WOS:000078510900014
J	Haapasalo, A; Saarelainen, T; Moshnyakov, M; Arumae, U; Kiema, TR; Saarma, M; Wong, G; Castren, E				Haapasalo, A; Saarelainen, T; Moshnyakov, M; Arumae, U; Kiema, TR; Saarma, M; Wong, G; Castren, E			Expression of the naturally occurring truncated trkB neurotrophin receptor induces outgrowth of filopodia and processes in neuroblastoma cells	ONCOGENE			English	Article						trkB; BDNF; NT-4; N2a; neuroblastoma	NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; AFFINITY NGF RECEPTOR; DIFFERENTIAL RESPONSE; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; TISSUE DISTRIBUTION; RETINOIC ACID; BRAIN; ENCODES	We have investigated the effects of the truncated trkB receptor isoform T1 (trkB.T1) by transient transfection into mouse N2a neuroblastoma cells. We observed that expression of trkB.T1 leads to a striking change in cell morphology characterized by outgrowth of filopodia and processes. A similar morphological response was also observed in SH-SY5Y human neuroblastoma cells and NIH3T3 fibroblasts transfected with trkB.T1. N2a cells lack endogenous expression of trkB isoforms, but express barely detectable amounts of its ligands, brainderived neurotrophic factor (BDNF) and neurotrophin-4 (NT-4). The morphological change was ligand-independent, since addition of exogenous BDNF or NT-4 or blockade of endogenous trkB ligands did not influence this response. Filopodia and process outgrowth was significantly suppressed when full-length trkB.TK + was cotransfected together with trkS.T1 and this inhibitory effect was blocked by tyrosine kinase inhibitor K252a. Transfection of trkB.T1 deletion mutants showed that the morphological response is dependent on the extracellular, but not the intracellular domain of the receptor. Our results suggest a novel ligand-independent role for truncated trkB in the regulation of cellular morphology.	Univ Kuopio, AI Vir Tanen Inst, Mol Pharmacol Lab, Kuopio 70100, Finland; Univ Kuopio, Dept Psychiat, Kuopio 70100, Finland; Univ Helsinki, Inst Biotechnol, Helsinki 00014, Finland	University of Eastern Finland; University of Eastern Finland; University of Helsinki	Castren, E (corresponding author), Univ Kuopio, AI Vir Tanen Inst, Mol Pharmacol Lab, POB 1627, Kuopio 70100, Finland.		Castrén, Eero/A-4618-2010; Arumäe, Urmas/E-8290-2016	Arumäe, Urmas/0000-0003-3658-6464; Haapasalo, Annakaisa/0000-0003-0959-2957; Castren, Eero/0000-0002-1402-2791				ARMANINI MP, 1995, EUR J NEUROSCI, V7, P1403, DOI 10.1111/j.1460-9568.1995.tb01132.x; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARIK S, 1995, METH NEUROSCI, V26, P309; Baxter GT, 1997, J NEUROSCI, V17, P2683; BECK KD, 1993, J NEUROSCI, V13, P4001; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BIFFO S, 1995, DEVELOPMENT, V121, P2461; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Eide FF, 1996, J NEUROSCI, V16, P3123; EIDE FF, 1993, EXP NEUROL, V121, P200, DOI 10.1006/exnr.1993.1087; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; FRISEN J, 1993, P NATL ACAD SCI USA, V90, P4971, DOI 10.1073/pnas.90.11.4971; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAMBALLE F, 1991, CELL, V66, P968; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Lucarelli E, 1994, Prog Clin Biol Res, V385, P185; LUCARELLI E, 1995, J BIOL CHEM, V270, P24725, DOI 10.1074/jbc.270.42.24725; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MATSUMOTO K, 1995, CANCER RES, V55, P1798; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Ninkina N, 1996, EMBO J, V15, P6385, DOI 10.1002/j.1460-2075.1996.tb01029.x; PASTOR R, 1994, ONCOGENE, V9, P1081; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; Rubio N, 1997, EUR J NEUROSCI, V9, P1847, DOI 10.1111/j.1460-9568.1997.tb00751.x; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SEEDS NW, 1970, P NATL ACAD SCI USA, V66, P160, DOI 10.1073/pnas.66.1.160; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; SKENE JHP, 1986, SCIENCE, V233, P783, DOI 10.1126/science.3738509; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; TANNAHILL L, 1995, EUR J NEUROSCI, V7, P1424, DOI 10.1111/j.1460-9568.1995.tb01136.x; TOMA JG, 1997, NEURAL NOTES, V111, P20; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VAUGHAN VC, 1979, NELSON TXB PEDIAT, P1444; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; Yamashiro DJ, 1996, ONCOGENE, V12, P37; Zhou H, 1997, J NEUROSCI RES, V49, P281, DOI 10.1002/(SICI)1097-4547(19970801)49:3<281::AID-JNR3>3.0.CO;2-8	54	57	57	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1285	1296		10.1038/sj.onc.1202401	http://dx.doi.org/10.1038/sj.onc.1202401			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022810				2022-12-28	WOS:000078510900004
J	Suzuki, A; Tsutomi, Y; Miura, M; Akahane, K				Suzuki, A; Tsutomi, Y; Miura, M; Akahane, K			Caspase 3 inactivation to suppress Fas-mediated apoptosis: identification of binding domain with p21 and ILP and inactivation machinery by p21	ONCOGENE			English	Article						Fas; caspase 3; p21; ILP; serineproteinase	CELL-DEATH; ICE/CED-3 PROTEASE; INVOLVEMENT; INHIBITION; ACTIVATION; RECEPTOR; COMPLEX; KINASE; PCNA; CDK	The death mediator caspase acts as the dominant regulator during cell death induction. The CPP32 subfamily, including caspase 3 (CPP32/Yama/Apopain), is essential for the cell death signaling, We recently reported that activation of caspase 3 is regulated by complex formation with p21 or ILP, In the present study, we investigated the binding domain with p21 and ILP to further characterize the caspase 3 inactivation machinery, Our results show that caspase 3 contains p21 binding domain in the N-terminus and ILP binding domain in the active site, Further, the caspase 3 binding domain in p21 was independent of the Cdk- or PCNA-binding domain. We also found caspase 3 protection by p21 from the p3-site cleavage serineproteinase contributes to the suppression machinery. Here, we propose the caspase 3 inactivation system by p21 and ILP as new essential system in the regulation of cell death.	Daiichi Pharmaceut Co Ltd, Drug Safety Res Lab, Tokyo R&D Ctr, Edogawa Ku, Tokyo 134, Japan; Osaka Univ, Sch Med, Dept Neuroanat, Ctr Biomed Res, Suita, Osaka 565, Japan; Daiichi Pharmaceut Co Ltd, New Prod Res Lab 4, Tokyo R&D Ctr, Edogawa Ku, Tokyo 134, Japan	Daiichi Sankyo Company Limited; Osaka University; Daiichi Sankyo Company Limited	Suzuki, A (corresponding author), Daiichi Pharmaceut Co Ltd, Drug Safety Res Lab, Tokyo R&D Ctr, Edogawa Ku, 16-13 Kitakasai 1 Chome, Tokyo 134, Japan.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Hasegawa J, 1996, CANCER RES, V56, P1713; LI Y, 1994, ONCOGENE, V9, P2261; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MIYAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P852, DOI 10.1016/0006-291X(92)91705-U; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Suzuki A, 1997, EXP CELL RES, V233, P48, DOI 10.1006/excr.1997.3546; Suzuki A, 1997, EXP CELL RES, V233, P41, DOI 10.1006/excr.1997.3498; SUZUKI A, 1998, IN PRESS ONCOGENE; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	23	133	137	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1239	1244		10.1038/sj.onc.1202409	http://dx.doi.org/10.1038/sj.onc.1202409			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022130				2022-12-28	WOS:000078510700013
J	Yin, XY; Grove, L; Datta, NS; Long, MW; Prochownik, EV				Yin, XY; Grove, L; Datta, NS; Long, MW; Prochownik, EV			C-myc overexpression and p53 loss cooperate to promote genomic instability	ONCOGENE			English	Article						c-myc; p53; tetraploidy; genomic instability	HUMAN-PAPILLOMAVIRUS TYPE-16; LYMPHOMA CELL-LINES; WILD-TYPE P53; NORMAL HUMAN FIBROBLASTS; DNA-DAMAGE; S-PHASE; GROWTH-FACTOR; CYCLE CONTROL; EMBRYO FIBROBLASTS; EPITHELIAL-CELLS	p53 monitors genomic integrity at the G1 and G2/M cell cycle checkpoints. Cells lacking p53 may show gene amplification as well as the polyploidy or aneuploidy typical of many tumors. The pathways through which this develops, however, are not well defined. We demonstrate here that the combination of p53 inactivation and c-myc overexpression in diploid cells markedly accelerates the spontaneous development of tetraploidy. This is not seen with either N-myc or L-myc. Tetraploidy is accompanied by significantly higher levels of cyclin B and its associated cdc2 kinase activity, Mitotic spindle poisons accelerate the appearance of tetraploidy in cells either lacking functional p53 or overexpressing c-myc whereas the combination is additive. Restoration of p53 function in cells overexpressing c-myc causing rapid apoptosis, indicating that cells yet to become tetraploid have nonetheless suffered irreversible genomic and/or mitotic spindle damage. In the face of normal p53 function, such damage would either be repaired or trigger apoptotis. We propose that loss of p53 and overexpression of c-myc permits the emergence and survival of cells with increasingly severe damage and the eventual development of tetraploidy.	Childrens Hosp Pittsburgh, Dept Pediat, Hematol Oncol Sect, Pittsburgh, PA 15213 USA; Univ Michigan, Med Ctr, Dept Pediat, Hematol Oncol Sect, Ann Arbor, MI 48109 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA USA; Univ Pittsburgh, Pittsburgh Canc Inst, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Dept Pediat, Hematol Oncol Sect, Pittsburgh, PA 15213 USA.				NHLBI NIH HHS [HL33741] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BALLERINI P, 1993, BLOOD, V81, P166; BANKS L, 1990, ONCOGENE, V5, P833; Barbosa MS, 1996, CRIT REV ONCOGENESIS, V7, P1; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; Berns EMJJ, 1996, GENE CHROMOSOME CANC, V16, P170, DOI 10.1002/(SICI)1098-2264(199607)16:3<170::AID-GCC3>3.0.CO;2-W; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BLANDINO G, 1995, ONCOGENE, V10, P731; BLOUNT PL, 1994, CANCER RES, V54, P2292; CARDER P, 1993, ONCOGENE, V8, P1397; Coursen JD, 1997, EXP CELL RES, V235, P245, DOI 10.1006/excr.1997.3670; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Datta NS, 1996, MOL BIOL CELL, V7, P209, DOI 10.1091/mbc.7.2.209; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; Farthing Alan J., 1994, Trends in Microbiology, V2, P170, DOI 10.1016/0966-842X(94)90667-X; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, ONCOGENE, V8, P2457; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUIBREGTSE JM, 1994, COLD SPRING HARB SYM, V59, P237, DOI 10.1101/SQB.1994.059.01.028; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KARN J, 1989, ONCOGENE, V4, P773; KASTAN MB, 1991, CANCER RES, V51, P6304; Kaufmann WK, 1997, CELL GROWTH DIFFER, V8, P1105; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; Langlands K, 1997, ANAL BIOCHEM, V249, P250, DOI 10.1006/abio.1997.2184; LEVINE DS, 1991, P NATL ACAD SCI USA, V88, P6427, DOI 10.1073/pnas.88.15.6427; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MA A, 1993, ONCOGENE, V8, P1093; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nesbit CE, 1998, BLOOD, V92, P1003; NESBIT CE, 1998, IN PRESS CELL GROWTH; OCONNOR PM, 1993, CANCER RES, V53, P4776; Oda D, 1996, CARCINOGENESIS, V17, P2003, DOI 10.1093/carcin/17.9.2003; Pellegata NS, 1996, P NATL ACAD SCI USA, V93, P15209, DOI 10.1073/pnas.93.26.15209; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; PURDIE CA, 1994, ONCOGENE, V9, P603; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WALKER DH, 1995, CELL GROWTH DIFFER, V6, P1053; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WIMAN KG, 1991, ONCOGENE, V6, P1633; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	66	115	121	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1177	1184		10.1038/sj.onc.1202410	http://dx.doi.org/10.1038/sj.onc.1202410			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022123				2022-12-28	WOS:000078510700006
J	Ferrier, R; Nougarede, R; Doucet, S; Kahn-Perles, B; Imbert, J; Mathieu-Mahul, D				Ferrier, R; Nougarede, R; Doucet, S; Kahn-Perles, B; Imbert, J; Mathieu-Mahul, D			Physical interaction of the bHLH LYL1 protein and NF-kappa B1 p105	ONCOGENE			English	Article						bHLH; LYL1; NF-kappa b	NF-KAPPA-B; T-CELL LEUKEMIA; LOOP-HELIX PROTEINS; ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING PROPERTIES; SCL GENE-PRODUCT; TRANSGENIC MICE; ERYTHROID-DIFFERENTIATION; HEMATOPOIETIC LINEAGES; ENHANCER-BINDING	The LYL1 gene was first identified upon the molecular characterization of the t(7;9)(q35;p13) translocation associated with some human T-cell acute leukemias (T-ALLs), In adult tissues, LYL1 expression is restricted to hematopoietic cells with the notable exclusion of the T cell lineage. LYL1 encodes a basic helix-loop-helix (bHLH) protein highly related to TAL-1, whose activation is also associated with a high proportion of human T-ALLs. A yeast two-hybrid system was used to identify proteins that specifically interact with LYL1 and might mediate its activities. We found that p105, the precursor of NF-kappa B1 p50, was the major LYL1-interacting protein in this system. The association between LYL1 and p105 was confirmed both in vitro and in vivo in mammalian cells. Biochemical studies indicated that the interaction was mediated by the bHLH motif of LYL1 and the ankyrin-like motifs of p105. Ectopic expression of LYL1 in a human T cell line caused a significant decrease in NF-kappa B-dependent transcription, associated with a reduced level of NF-kappa B1 proteins.	Inst Genet Mol, UMR 5535, F-34293 Montpellier, France; Inst J Paoli I Calmettes, INSERM, U119, F-13009 Marseille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC)	Mathieu-Mahul, D (corresponding author), Inst Genet Mol, UMR 5535, 1919 Route Mende, F-34293 Montpellier, France.		Imbert, Jean/G-3248-2013; Imbert, Jean/AAG-1165-2020; Mathieu, Daniele/G-6092-2012; Kahn-Perlès, Brigitte/M-3513-2016	Imbert, Jean/0000-0002-0478-9593; Imbert, Jean/0000-0002-0478-9593; Kahn-Perlès, Brigitte/0000-0001-5673-5901				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baichwal V. R., 1997, CURR BIOL, V7, P94; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1991, ONCOGENE, V6, P1477; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; Condorelli GL, 1997, MOL CELL BIOL, V17, P2954, DOI 10.1128/MCB.17.5.2954; Condorelli GL, 1996, CANCER RES, V56, P5113; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINCH E, 1995, ADDICT RES, V3, P63, DOI 10.3109/16066359509005223; FUJIMOTO K, 1995, GENE, V165, P183, DOI 10.1016/0378-1119(95)00507-3; Gilmore TD, 1996, ONCOGENE, V13, P1367; GOLDFARB AN, 1992, BLOOD, V80, P2658; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; KALLIANPUR AR, 1994, BLOOD, V83, P1200; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KLEIN ES, 1993, GENE DEV, V7, P55, DOI 10.1101/gad.7.1.55; LEROYVIARD K, 1995, EMBO J, V14, P2341, DOI 10.1002/j.1460-2075.1995.tb07229.x; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; Mahajan MA, 1996, ONCOGENE, V12, P2343; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; Miyamoto A, 1996, MOL CELL BIOL, V16, P2394; MOUTHON MA, 1993, BLOOD, V81, P647; MUNOZ E, 1994, J VIROL, V68, P8035; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Ono Y, 1997, J BIOL CHEM, V272, P4576, DOI 10.1074/jbc.272.7.4576; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; PULFORD K, 1995, BLOOD, V85, P675, DOI 10.1182/blood.V85.3.675.bloodjournal853675; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VISVADER J, 1991, ONCOGENE, V6, P187; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; XIA Y, 1994, ONCOGENE, V9, P1437; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416	62	31	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					995	1005		10.1038/sj.onc.1202374	http://dx.doi.org/10.1038/sj.onc.1202374			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023675				2022-12-28	WOS:000078510600016
J	Yan, DH; Wen, Y; Spohn, B; Choubey, D; Gutterman, JU; Hung, MC				Yan, DH; Wen, Y; Spohn, B; Choubey, D; Gutterman, JU; Hung, MC			Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202	ONCOGENE			English	Article						p202; interferon-inducible protein; prostate cancer; PC-3; growth retardation; anchorage-independent growth	TUMOR-NECROSIS-FACTOR; CARCINOMA; TRANSCRIPTION; INHIBITION; EXPRESSION; ALPHA; LINES; GENE; DIFFERENTIATION; INTERLEUKIN-2	Interferons (IFNs) can exert cytostatic and immunomodulatory effects on carcinoma cells. In particular, growth inhibition of human prostate carcinoma by IFNs has been demonstrated both in vitro and in vivo. p202 is a 52 kd nuclear phosphoprotein known to be induced by IFNs. In this report, we showed that the expression of p202 was associated with an anti-proliferative effect on human prostate cancer cells. More importantly, cells that expressed p202 showed reduced ability to grow in soft-agar, indicating a loss of transformation phenotype. Our data suggest that p202 is a growth inhibitor gene in prostate cancer cells and its expression may also suppress transformation phenotype of prostate cancer cells.	Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Mol Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, 1515 Holcombe Blvd,Box 79, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021; Choubey, Divaker/A-4771-2008	Hung, Mien-Chie/0000-0003-4317-4740; 	NATIONAL CANCER INSTITUTE [R29CA069031, R01CA058880] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58880, CA69031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALKWILL FR, 1989, LANCET, V1, P1060; CARRENO V, 1987, LANCET, V2, P1086; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1993, J INTERFERON RES, V13, P43, DOI 10.1089/jir.1993.13.43; Choubey D, 1997, ONCOGENE, V15, P291, DOI 10.1038/sj.onc.1201184; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Choubey D, 1996, BIOCHEM BIOPH RES CO, V221, P396, DOI 10.1006/bbrc.1996.0607; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; DAWSON MJ, 1995, IMMUNOGENETICS, V41, P40, DOI 10.1007/BF00188431; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; FIDLER IJ, 1987, CANCER RES, V47, P2020; FIGLIN RA, 1993, SEMIN ONCOL, V20, P11; FRAKER DL, 1994, MELANOMA RES, V4, P27; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; KAIGHN ME, 1979, INVEST UROL, V17, P16; Lembo D, 1995, J BIOL REG HOMEOS AG, V9, P42; Lembo M, 1998, ONCOGENE, V16, P1543, DOI 10.1038/sj.onc.1201677; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Min W, 1996, MOL CELL BIOL, V16, P359; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; SEN GC, 1992, J BIOL CHEM, V267, P5017; SICA G, 1989, UROL RES, V17, P111; Sokoloff MH, 1996, CANCER-AM CANCER SOC, V77, P1862; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; TRAPANI JA, 1994, IMMUNOGENETICS, V40, P415; VANMOORSELAAR RJA, 1991, PROSTATE, V18, P331, DOI 10.1002/pros.2990180407; vonEschenbach A, 1997, CA-CANCER J CLIN, V47, P261, DOI 10.3322/canjclin.47.5.261; YU DH, 1993, CANCER RES, V53, P891	30	35	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					807	811		10.1038/sj.onc.1202369	http://dx.doi.org/10.1038/sj.onc.1202369			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989832				2022-12-28	WOS:000078394400027
J	Adnane, J; Shao, ZH; Robbins, PD				Adnane, J; Shao, ZH; Robbins, PD			Cyclin D1 associates with the TBP-associated factor TAF(II)250 to regulate Sp1-mediated transcription	ONCOGENE			English	Article						cyclin D1; Sp1; Rb; TAF(II)250	CDK-ACTIVATING KINASE; RETINOBLASTOMA PROTEIN; G1 CYCLINS; DIFFERENTIAL REGULATION; GROWTH SUPPRESSION; ESTROGEN-RECEPTOR; CELL-LINE; GENE; BINDING; E2F	We have previously shown that Sp1-mediated transcription is stimulated by Rb and repressed by cyclin D1. The stimulation of Sp1 transcriptional activity by Rb iis conferred, in part, through a direct interaction with the TBP-associated factor TAF(II)250. Here we investigated the mechanism(s) through which cyclin D1 represses Sp1. We examined the ability of cyclin D1 to regulate transcription mediated by Gal4-Sp1 fusion proteins, which contain the Gal4 DNA-binding domain and Spl trans-activation domain(s). The domain of Spl sufficient to confer repression by cyclin D1 was mapped to a region important for interaction with TAF(II)110. We further demonstrate that TAF(II)250-cyclin D1 complexes can be immunoprecipitated from mammalian and baculovirus-infected insect cells and that recombinant GST-TAF(II)250 (amino acids 1-434) associates with cyclin D1 in vitro. Moreover, the overexpression of Rb or CDK4 reduced the level of TAF(II)250-cyclin D1 complex. The amino terminus of cyclin D1 (amino acids 1-100) was sufficient for association with TAF(II)250 and for repressing Spl-mediated transcription. Taken together, the results suggest that cyclin D1 may regulate transcription by interacting directly or indirectly with TAF(II)250.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Robbins, PD (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA.				NCI NIH HHS [CA55227] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055227] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHEN PL, 1995, CELL GROWTH DIFFER, V6, P199; CROSS F, 1995, TRENDS GENET, V11, P209, DOI 10.1016/S0168-9525(00)89047-2; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAYASHIDA T, 1994, GENE, V141, P267; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; KATO J, 1993, GENE DEV, V7, P331; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KUCHIN S, 1995, P NATL ACAD SCI USA, V92, P4006, DOI 10.1073/pnas.92.9.4006; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Malik S, 1998, P NATL ACAD SCI USA, V95, P2192, DOI 10.1073/pnas.95.5.2192; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; RUPPERT S, 1995, GENE DEV, V9, P2747, DOI 10.1101/gad.9.22.2747; Rushton JJ, 1997, CELL GROWTH DIFFER, V8, P1099; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; SEKIGUCHI T, 1995, EXP CELL RES, V218, P490, DOI 10.1006/excr.1995.1183; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; Shao ZH, 1997, ONCOGENE, V15, P385, DOI 10.1038/sj.onc.1201204; SHAO ZH, 1995, ONCOGENE, V10, P221; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SIEGERT J, 1998, UNPUB MOL CELL BIOL; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; SMITH EJ, 1995, MOL CELL BIOL, V15, P338, DOI 10.1128/MCB.15.1.338; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	49	55	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					239	247		10.1038/sj.onc.1202297	http://dx.doi.org/10.1038/sj.onc.1202297			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926939	Bronze			2022-12-28	WOS:000078166000026
J	Chen, YC; Freund, R; Listerud, M; Wang, Z; Talmage, DA				Chen, YC; Freund, R; Listerud, M; Wang, Z; Talmage, DA			Retinoic acid inhibits transformation by preventing phosphatidylinositol 3-kinase dependent activation of the c-fos promoter	ONCOGENE			English	Article						vitamin A; retinoic acid; Jun kinase; polyoma virus	MIDDLE-T-ANTIGEN; JUN TRANSCRIPTIONAL ACTIVITY; JNK/SAPK SIGNALING PATHWAY; SERUM RESPONSE ELEMENT; POLYOMA-VIRUS MUTANT; SIZED TUMOR-ANTIGEN; PROTEIN-KINASE-C; PP70 S6 KINASE; TYROSINE PHOSPHORYLATION; RAT FIBROBLASTS	Retinoic acid inhibits transformation of cells by polyoma virus middle T oncoprotein. Inhibition of transformation results from a retinoic acid-dependent failure of cells to fully express the c-fos proto-oncogene. Retinoic acid prevents transactivation of the c-fos promoter by disrupting signaling between tyrosine kinases at the plasma membrane and trans-acting factors at the c-fos promoter. We used complementary genetic, biochemical and molecular approaches to demonstrate that: (1) phosphatidylinositol 3-kinase signaling is the principle mechanism of polyoma virus middle T oncoprotein activation of c-fos expression; (2) middle T/phosphatidylinositol 3-kinase transactivation of the c-fos promoter and transformation of cells requires activation of both the small GTP-binding protein Rac and Jun N-terminal kinase; (3) retinoic acid inhibits activation of Jun N- terminal kinase, thereby preventing c-fos transactivation and transformation; and (4) middle T activation of c-fos transcription requires both the serum response element and the promoter proximal cyclic AMP response element. These studies identify a novel target through which retinoids prevent oncogenic transformation.	Columbia Univ, Inst Human Nutr, New York, NY 10032 USA; Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	Columbia University; University System of Maryland; University of Maryland Baltimore	Talmage, DA (corresponding author), Columbia Univ, Inst Human Nutr, New York, NY 10032 USA.			Talmage, David/0000-0003-4627-3007	NCI NIH HHS [CA63111] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA063111] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTO AS, 1908, CELL, V92, P475; Bronson R, 1997, P NATL ACAD SCI USA, V94, P7954, DOI 10.1073/pnas.94.15.7954; BUSAM KJ, 1992, J BIOL CHEM, V267, P19971; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; CARMICHAEL G, 1984, P NATL ACAD SCI-BIOL, V81, P679, DOI 10.1073/pnas.81.3.679; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; Crespo P, 1996, ONCOGENE, V13, P455; Dahl J, 1996, MOL CELL BIOL, V16, P2728; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Fisher GJ, 1998, J CLIN INVEST, V101, P1432, DOI 10.1172/JCI2153; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franklin CC, 1995, ONCOGENE, V11, P2365; FREUND R, 1992, AM J PATHOL, V141, P1409; FREUND R, 1992, VIROLOGY, V191, P716, DOI 10.1016/0042-6822(92)90247-M; GLENN GM, 1993, J VIROL, V67, P1945, DOI 10.1128/JVI.67.4.1945-1952.1993; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HARVEY R, 1984, MOL CELL BIOL, V4, P1334, DOI 10.1128/MCB.4.7.1334; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JANKNECHT R, 1995, ONCOGENE, V10, P1209; Janknecht R, 1996, ONCOGENE, V12, P1961; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Khuri FR, 1996, CELL GROWTH DIFFER, V7, P595; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LING LE, 1992, J VIROL, V66, P1702, DOI 10.1128/JVI.66.3.1702-1708.1992; Mangelsdorf David J., 1994, P319; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; Meili R, 1998, ONCOGENE, V16, P903, DOI 10.1038/sj.onc.1201605; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RAMEH LE, 1991, ONCOGENE, V6, P1049; RAPTIS L, 1991, J VIROL, V65, P5203, DOI 10.1128/JVI.65.10.5203-5210.1991; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SCHAFFHAUSEN B, 1981, J VIROL, V40, P184, DOI 10.1128/JVI.40.1.184-196.1981; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; Soprano DR, 1996, ONCOGENE, V12, P577; SRINIVAS S, 1994, P NATL ACAD SCI USA, V91, P10064, DOI 10.1073/pnas.91.21.10064; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TALMAGE DA, 1994, ONCOGENE, V9, P3557; TALMAGE DA, 1992, ONCOGENE, V7, P1837; TALMAGE DA, 1988, MOL CELL BIOL, V8, P2309, DOI 10.1128/MCB.8.6.2309; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; URICH M, 1995, J BIOL CHEM, V270, P29286, DOI 10.1074/jbc.270.49.29286; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Xu X, 1996, ONCOGENE, V13, P135; Yi XD, 1997, J VIROL, V71, P6279, DOI 10.1128/JVI.71.9.6279-6286.1997; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210	68	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					139	148		10.1038/sj.onc.1202272	http://dx.doi.org/10.1038/sj.onc.1202272			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926928				2022-12-28	WOS:000078166000015
J	Regev, A; Cohen, S; Cohen, E; Bar-Am, I; Lavi, S				Regev, A; Cohen, S; Cohen, E; Bar-Am, I; Lavi, S			Telomeric repeats on small polydisperse circular DNA (spcDNA) and genomic instability	ONCOGENE			English	Article						genomic instability; spcDNA; telomeres; mutator phenotype; two dimensional electrophoresis; cancer	GENE AMPLIFICATION; CHROMOSOMAL-ABERRATIONS; HUMAN-CELLS; SEQUENCES; RECOMBINATION; INVOLVEMENT; RESISTANCE; EXCISION; FAMILY; VIRUS	Small polydisperse circular DNA (spcDNA) is a heterogeneous population of extrachromosomal circular molecules present in a large variety of eukaryotic cells. Elevated amounts of total spcDNA are related to endogenous and induced genomic instability in rodent and human cells, We suggested spcDNA as a novel marker for genomic instability, and speculated that spcDNA might serve as a mutator, In this study, we examine the presence of telomeric sequences on spcDNA, We report for the first time the appearance of telomeric repeats in spcDNA molecules (tel-spcDNA) in rodent and human cells. Restriction enzyme analysis indicates that tel-spcDNA molecules harbor mostly, if not exclusively, telomeric repeats, In rodent cells, tel-spcDNA levels are higher in transformed than in normal cells and are enhanced by treatment with carcinogen, Tel-spcDNA is also detected in some human tumors and cell lines, but not in others. We suggest, that its levels in human cells may be primarily related to the amount of the chromosomal telomeric sequences. Tel-spcDNA may serve as a unique mutator, through specific mechanisms related to the telomeric repeats, which distinguish it from the total heterogeneous spcDNA population. It may affect telomere dynamics and genomic instability by clastogenic events, alterations of telomere size and sequestration of telomeric proteins.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel	Tel Aviv University	Lavi, S (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel.							Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; Balajee AS, 1996, MUTAT RES-FUND MOL M, V372, P163, DOI 10.1016/S0027-5107(96)00136-4; BARAM I, 1992, GENE CHROMOSOME CANC, V4, P314, DOI 10.1002/gcc.2870040407; Bassham S, 1998, MOL CELL BIOL, V18, P269, DOI 10.1128/MCB.18.1.269; BERTONI L, 1994, GENOMICS, V24, P53, DOI 10.1006/geno.1994.1581; Bouffler SD, 1996, MUTAT RES-REV GENET, V366, P129, DOI 10.1016/S0165-1110(96)90033-0; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BRITTEN RJ, 1968, SCIENCE, V161, P529, DOI 10.1126/science.161.3841.529; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cohen S, 1997, ONCOGENE, V14, P977, DOI 10.1038/sj.onc.1200917; Cohen S, 1996, MOL CELL BIOL, V16, P2002; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DENIS N, 1991, ONCOGENE, V6, P1453; Friedman SL, 1997, ONCOGENE, V15, P63, DOI 10.1038/sj.onc.1201149; GAUBATZ JW, 1990, MUTAT RES, V237, P271, DOI 10.1016/0921-8734(90)90009-G; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JONES RS, 1985, NUCLEIC ACIDS RES, V13, P1027, DOI 10.1093/nar/13.3.1027; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; KIYAMA R, 1987, J MOL BIOL, V198, P589, DOI 10.1016/0022-2836(87)90202-6; LAVI S, 1981, P NATL ACAD SCI-BIOL, V78, P6144, DOI 10.1073/pnas.78.10.6144; Mirabella A, 1997, EMBO J, V16, P523, DOI 10.1093/emboj/16.3.523; Ohki R, 1995, NUCLEIC ACIDS RES, V23, P4971, DOI 10.1093/nar/23.24.4971; OKUMURA K, 1987, NUCLEIC ACIDS RES, V15, P7477, DOI 10.1093/nar/15.18.7477; PANDITA TK, 1995, CYTOGENET CELL GENET, V68, P95, DOI 10.1159/000133899; RENAULT S, 1993, GENOME, V36, P244, DOI 10.1139/g93-034; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; SUNNERHAGEN P, 1989, SOMAT CELL MOLEC GEN, V15, P61, DOI 10.1007/BF01534670; WELLS RA, 1990, GENOMICS, V8, P699, DOI 10.1016/0888-7543(90)90257-U; WINOCOUR E, 1992, VIROLOGY, V190, P316, DOI 10.1016/0042-6822(92)91218-J	31	57	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3455	3461		10.1038/sj.onc.1202250	http://dx.doi.org/10.1038/sj.onc.1202250			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030669				2022-12-28	WOS:000078086200006
J	Tran, Y; Benbatoul, K; Gorse, K; Rempel, S; Futreal, A; Green, M; Newsham, I				Tran, Y; Benbatoul, K; Gorse, K; Rempel, S; Futreal, A; Green, M; Newsham, I			Novel regions of allelic deletion on chromosome 18p in tumors of the lung, brain and breast	ONCOGENE			English	Article						loss of heterozygosity; chromosome 18p; Non-small cell lung cancer; breast cancer; glioblastoma	MICROSATELLITE INSTABILITY; COMMON REGION; HETEROZYGOSITY; CANCER; CARCINOMAS; ABNORMALITIES; PROGRESSION; SEQUENCES; LOCUS; PANEL	Lung cancer is now the number one cause of cancer death for both men and women. An age-adjusted analysis over the past 25 gears shows that in women specifically, lung cancer incidence is on the rise. It is estimated that 10-20 genetic events including the alteration of oncogenes and tumor suppressor genes will have occurred by the time a lung tumor becomes clinically evident. In an effort to identify regions containing novel cancer genes, chromosome 18p11, a band not previously implicated in disease, was examined for loss of heterozygosity (LOH). In this study, 50 matched normal and NSCLC tumor samples were examined using sis 18p11 and one 18q12.3 PCR-based polymorphic markers. In addition, LOH was examined in 29 glioblastoma pairs and 14 paired breast carcinomas. This analysis has revealed potentially two regions of LOH in 18p11 in up to 38% of the tumor samples examined, The regions of LOH identified included a 2 cm area between markers D18S59 and D18S476, and a more proximal, 25 cm region of intermediate frequency between D18S452 and D18S453, These results provide evidence for the presence of one or more potential tumor suppressor genes on the short arm of chromosome 18 which may be involved in NSCLC, brain tumors and possibly breast carcinomas as well.	Univ Calif San Diego, Dept Med, Theodore Gildred Canc Ctr, La Jolla, CA 92093 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA; Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; Duke Univ, Dept Surg, Durham, NC 27710 USA; Med Univ S Carolina, Med Ctr, Hollings Canc Ctr, Charleston, SC 29425 USA	University of California System; University of California San Diego; Virginia Commonwealth University; Henry Ford Health System; Henry Ford Hospital; Duke University; Medical University of South Carolina	Newsham, I (corresponding author), Univ Calif San Diego, Dept Med, Theodore Gildred Canc Ctr, La Jolla, CA 92093 USA.				NATIONAL CANCER INSTITUTE [P20CA066215, R29CA077730, P30CA023100] Funding Source: NIH RePORTER; NCI NIH HHS [R29-CA77730-02, 5-P30-CA23100-13, 1 P20-CA66215-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI J, 1995, GENE CHROMOSOME CANC, V14, P301, DOI 10.1002/gcc.2870140409; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; BUETOW KH, 1994, NAT GENET, V6, P391, DOI 10.1038/ng0494-391; CENTER R, 1993, GENE CHROMOSOME CANC, V7, P47, DOI 10.1002/gcc.2870070108; FONG KM, 1995, CANCER RES, V55, P4268; FONG KM, 1995, CANCER RES, V55, P220; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAMPTON GM, 1994, CANCER RES, V54, P4586; HUANG THM, 1995, DIAGN MOL PATHOL, V4, P6672; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; KISHIMOTO Y, 1995, JNCI-J NATL CANCER I, V87, P1224, DOI 10.1093/jnci/87.16.1224; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; LUKEIS R, 1993, GENE CHROMOSOME CANC, V8, P262, DOI 10.1002/gcc.2870080409; MERLENS F, 1997, CANCER RES, V57, P2765; Nagatake M, 1996, CANCER RES, V56, P1886; Nagatake M, 1996, CANCER RES, V56, P2718; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; RABBITTS P, 1989, GENE CHROMOSOME CANC, V1, P95, DOI 10.1002/gcc.2870010115; RASIO D, 1995, CANCER RES, V55, P3988; REMPEL SA, 1993, CANCER RES, V53, P2386; ROJAS K, 1995, GENOMICS, V25, P329, DOI 10.1016/0888-7543(95)80153-D; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; SHRIDHAR V, 1994, CANCER RES, V54, P2084; TESTA JR, 1992, CANCER RES, V52, pS2702; TESTA JR, 1994, GENE CHROMOSOME CANC, V11, P178, DOI 10.1002/gcc.2870110307; Tran YK, 1996, CANCER RES, V56, P2916; WINQVIST R, 1995, CANCER RES, V55, P2660; Zhu JG, 1996, ONCOGENE, V12, P1417	29	46	50	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3499	3505		10.1038/sj.onc.1202258	http://dx.doi.org/10.1038/sj.onc.1202258			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030674				2022-12-28	WOS:000078086200011
J	Joers, A; Kristjuhan, A; Kadaja, L; Maimets, T				Joers, A; Kristjuhan, A; Kadaja, L; Maimets, T			Tumour associated mutants of p53 can inhibit transcriptional activity of p53 without heterooligomerization	ONCOGENE			English	Article						p53; transcription; oligomerization	WILD-TYPE P53; DNA-BINDING FUNCTION; PROTEIN-KINASE-C; MONOCLONAL-ANTIBODIES; REPRESSION FUNCTIONS; SUPPRESSOR PROTEIN; ACTIVATION DOMAINS; TYROSINE KINASE; GENE-EXPRESSION; GROWTH	Tumour suppressor protein p53 is the most frequent target of mutations occurring in different types of human cancers. Most of these are point mutations clustered in certain 'hot spots'. Because p53 is a tetramer in solution, it can form heterooligomers when both wild-type and mutant forms of p53 are expressed in the same cell. Inactivation of wt p53 by heterooligomerization has been proposed as a mechanism for dominant negative effect of mutant protein. In this paper we show that other mechanisms can also be involved in the inhibition of transcriptional activity of wt p53 by mutant proteins. In addition to suppressing the wt p53 activity, mutant proteins are also able to suppress the activity of p53 protein unable to oligomerize. Either N- or C-terminus of mutant p53 are needed for this activity. The suppression of transcriptional activity described is restricted to p53-dependent promoters and no effect is seen with the promoter not containing p53 binding site. Point mutants also inhibit the growth suppressing activity of monomeric p53. Our data allow to propose the existence of a cofactor specifically needed for p53-dependent transcription. Depletion of this cofactor could be an alternative mechanism of inactivation of wt p53 by its point mutants.	Tartu State Univ, Inst Mol & Cell Biol, Dept Cell Biol, EE-2400 Tartu, Estonia	University of Tartu	Maimets, T (corresponding author), Tartu State Univ, Inst Mol & Cell Biol, Dept Cell Biol, Riia 23, EE-2400 Tartu, Estonia.		Maimets, Toivo/E-9268-2017	Maimets, Toivo/0000-0001-6461-3365; Kristjuhan, Arnold/0000-0002-5842-4952; Joers, Arvi/0000-0003-2083-3977				BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; GOGA A, 1995, ONCOGENE, V11, P791; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Knippschild U, 1996, ONCOGENE, V13, P1387; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEGROS Y, 1994, ONCOGENE, V9, P2071; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1995, CELL, V80, P293; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; PELLEGATA NS, 1995, ONCOGENE, V11, P337; Sambrook J., 2002, MOL CLONING LAB MANU; SANG BC, 1994, ONCOGENE, V9, P853; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; SUBLER MA, 1994, ONCOGENE, V9, P1351; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TARUNINA M, 1993, ONCOGENE, V8, P3165; Thomas M, 1996, ONCOGENE, V13, P265; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WOLKOWICZ R, 1995, ONCOGENE, V10, P1167; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	60	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2351	2358		10.1038/sj.onc.1202146	http://dx.doi.org/10.1038/sj.onc.1202146			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811466				2022-12-28	WOS:000076723300009
J	Blattner, C; Tobiasch, E; Litfen, M; Rahmsdorf, HJ; Herrlich, P				Blattner, C; Tobiasch, E; Litfen, M; Rahmsdorf, HJ; Herrlich, P			DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation	ONCOGENE			English	Article						ultraviolet irradiation; gamma irradiation; actinomycin D; p53 stabilization	CASEIN KINASE-II; TUMOR-SUPPRESSOR PROTEIN; ALTERNATIVELY SPLICED P53; FULL-LENGTH P53; IN-VIVO; BINDING FUNCTION; NUCLEAR ACCUMULATION; TERMINAL DOMAIN; CELL-CYCLE; RETROVIRAL VECTORS	Abundance and activity of p53 are predominantly regulated posttranslationally, Structural disturbance in transcribed genes induced by radiation, e.g. DNA damage, or by transcriptional inhibitors cause p53 protein stabilization by a yet unknown mechanism. Using stable and transient transfections for the analysis of p53 mutant proteins, we have ruled out a role in stabilization by UV, gamma irradiation or actinomycin C for the following putative phosphorylation sites in the p53 protein: serines 6, 9, 15, 33, 315 and 392, and threonine 18. By double mutation combinations of phosphorylations were also ruled out; 6,9; 15,18; 15,37, These mutations eliminate modifications by casein kinases I and II, DNA-PK, ATM, CDK and JNK, Also the 30 carboxyterminal amino acids are not required for induced p53 stabilization. Thus neither phosphorylations of individual amino acids nor interactions of the carboxyterminus of p53 with cellular macromolecules appear to play a role in the stabilization process. The only single prerequisite for induced stabilization of p53 is its prior destabilization by Mdm2, However, the level of active Mdm2 must be controlled carefully: overexpression of Mdm2 inhibits UV induced p53 stabilization.	Univ Karlsruhe, Forschungszentrum Karlsruhe, Genet Inst, D-76021 Karlsruhe, Germany	Helmholtz Association; Karlsruhe Institute of Technology	Herrlich, P (corresponding author), Univ Karlsruhe, Forschungszentrum Karlsruhe, Genet Inst, POB 3640, D-76021 Karlsruhe, Germany.		Blattner, Christine/ABI-2152-2020; Blattner, Christine/H-2105-2013	Blattner, Christine/0000-0002-7250-5273; Blattner, Christine/0000-0002-7250-5273				BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BLATTNER C, 1994, ENVIRON MOL MUTAGEN, V24, P3, DOI 10.1002/em.2850240103; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Candeias SM, 1997, BIOCHIMIE, V79, P607, DOI 10.1016/S0300-9084(97)82010-X; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; COHEN PA, 1998, IN PRESS ONCOGENE; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gurley KE, 1996, CARCINOGENESIS, V17, P2537, DOI 10.1093/carcin/17.12.2537; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERRMANN CPE, 1991, ONCOGENE, V6, P877; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Huang LC, 1996, CANCER RES, V56, P2940; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1995, ONCOGENE, V10, P1485; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1991, CANCER RES, V51, P6304; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Milne DM, 1996, ONCOGENE, V13, P205; Molinari M, 1996, ONCOGENE, V13, P2077; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RENZING J, 1995, ONCOGENE, V10, P1865; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Wagner P, 1998, ONCOGENE, V16, P105, DOI 10.1038/sj.onc.1201510; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; Youmell M, 1998, BIOCHEM BIOPH RES CO, V245, P514, DOI 10.1006/bbrc.1998.8471; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	77	131	135	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	1999	18	9					1723	1732		10.1038/sj.onc.1202480	http://dx.doi.org/10.1038/sj.onc.1202480			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208433				2022-12-28	WOS:000079025000007
J	Habelhah, H; Okada, F; Kobayashi, M; Nakai, K; Choi, SK; Hamada, J; Moriuchi, T; Kaya, M; Yoshida, K; Fujinaga, K; Hosokawa, M				Habelhah, H; Okada, F; Kobayashi, M; Nakai, K; Choi, SK; Hamada, J; Moriuchi, T; Kaya, M; Yoshida, K; Fujinaga, K; Hosokawa, M			Increased E1AF expression in mouse fibrosarcoma promotes metastasis through induction of MT1-MMP expression	ONCOGENE			English	Article						mouse-fibrosarcoma; metastasis; MMP-2; MT1-MMP; E1AF	METALLOPROTEINASE GENE-EXPRESSION; TRANSFORMING GROWTH FACTOR-BETA-1; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR; TRANSCRIPTION FACTORS; IV COLLAGENASE; GELATINASE-A; TUMOR-CELLS; 72-KDA GELATINASE; HUMAN FIBROBLASTS	In this study, we investigated the role of E1AF, a member of ets family transcription factor, in the acquisition of metastatic capacity by non-metastatic mouse fibrosarcoma cell clone, QR-32, The QR-32 cell clone grows progressively after co-implantation with gelatin sponge in syngeneic C57BL/6 mice. The cell lines (QRsP) established from arising tumors after the co-implantation exhibited enhanced tumorigenicity and pulmonary metastasis in vivo as compared with parent QR-32 cells. The enhanced pulmonary metastasis of QRsP cells was correlated well with augmented production of matrix metalloproteinase-2 (MMP-2) and increased expression of membrane-type 1-IMMP (MT1-MMP). The QRsP cells also acquired higher chemokinetic activities to fibronectin and higher invasive activities through a reconstituted basement membrane. Furthermore we observed the elevated mRNA expression of E1AF in QRsP cells compared to parent QR-32 cells. Therefore, we transfected QR-32 cells with E1AF cDNA. Overexpression of E1AF in the QR-32 cells resulted in the induction of MT1-MMP expression and converting an exogenously added precursor MMP-2 into active form. E1AF transfectants exhibited more motile and invasive activities, and moderately increased pulmonary metastatic activities than parental QR-32 cells in vivo, although their metastatic activities were lower than those of QRsP cells. These findings suggest that the increased expression of E1AF in fibrosarcoma contributes to invasive phenotypes including MT1-MIMP expression and enhanced cell migration, but not sufficient for exhibiting highly metastatic activity in vivo.	Hokkaido Univ, Sch Med, Inst Canc, Pathol Lab,Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Sch Med, Inst Canc, Div Cell Biol,Kita Ku, Sapporo, Hokkaido 0608638, Japan; Sapporo Med Univ, Canc Res Inst, Dept Mol Biol, Sch Med,Chuo Ku, Sapporo, Hokkaido 0600061, Japan	Hokkaido University; Hokkaido University; Sapporo Medical University	Hosokawa, M (corresponding author), Hokkaido Univ, Sch Med, Inst Canc, Pathol Lab,Kita Ku, Sapporo, Hokkaido 0608638, Japan.		Hamada, Jun-ichi/D-7452-2012	Okada, Futoshi/0000-0003-4733-1037; Habelhah, Hasem/0000-0003-4097-1007				ALBINI A, 1987, CANCER RES, V47, P3239; ASCHER NL, 1979, TRANSPLANTATION, V27, P254, DOI 10.1097/00007890-197904000-00010; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chen JH, 1996, ONCOGENE, V13, P1667; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Imai K, 1997, AM J PATHOL, V151, P245; Imai K, 1996, CANCER RES, V56, P2707; Kadono Y, 1998, CANCER RES, V58, P2240; Kaya M, 1996, ONCOGENE, V12, P221; KOHN EC, 1994, J BIOL CHEM, V269, P21505; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Lohi J, 1996, EUR J BIOCHEM, V239, P239, DOI 10.1111/j.1432-1033.1996.0239u.x; MATRISIAN LM, 1994, ANN NY ACAD SCI, V732, P42, DOI 10.1111/j.1749-6632.1994.tb24723.x; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MONSKY WL, 1993, CANCER RES, V53, P3159; OHagan RC, 1996, ONCOGENE, V13, P1323; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; OKADA F, 1992, BRIT J CANCER, V66, P635, DOI 10.1038/bjc.1992.329; OVERALL CM, 1994, ANN NY ACAD SCI, V732, P51, DOI 10.1111/j.1749-6632.1994.tb24724.x; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; ROSEN GM, 1995, FASEB J, V9, P200, DOI 10.1096/fasebj.9.2.7540156; SALO T, 1991, J BIOL CHEM, V266, P11436; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; Shindoh M, 1996, AM J PATHOL, V148, P693; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; Taguchi K, 1997, JPN J CANCER RES, V88, P394, DOI 10.1111/j.1349-7006.1997.tb00395.x; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Turck J, 1996, J BIOL CHEM, V271, P15074, DOI 10.1074/jbc.271.25.15074; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEITZMAN SA, 1990, BLOOD, V76, P655	40	53	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	1999	18	9					1771	1776		10.1038/sj.onc.1202465	http://dx.doi.org/10.1038/sj.onc.1202465			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208438				2022-12-28	WOS:000079025000012
J	Rutberg, SE; Adams, TL; Olive, M; Alexander, N; Vinson, C; Yuspa, SH				Rutberg, SE; Adams, TL; Olive, M; Alexander, N; Vinson, C; Yuspa, SH			CRE DNA binding proteins bind to the AP-1 target sequence and suppress AP-1 transcriptional activity in mouse keratinocytes	ONCOGENE			English	Article						keratinocyte; differentiation; AP-1; transcription	DIFFERENTIATION-SPECIFIC EXPRESSION; HUMAN INVOLUCRIN GENE; C-JUN; EPIDERMAL DIFFERENTIATION; REPRESSES TRANSCRIPTION; SKIN CARCINOGENESIS; PROXIMAL PROMOTER; PROFILAGGRIN GENE; RESPONSE ELEMENT; CARCINOMA-CELLS	Previously, we have shown that nuclear extracts from cultured mouse keratinocytes induced to differentiate by increasing the levels of extra-cellular calcium contain Fra-1, Fra-2, Jun B, Jun D and c-Jun proteins that bind to the AP-1 DNA binding sequence. Despite this DNA binding activity, AP-1 reporter activity was suppressed in these cells. Here, we have detected the CREB family proteins CREB and CREM alpha as additional participants in the AP-1 DNA binding complex in differentiating keratinocytes, AP-1 and CRE DNA binding activity correlated with the induction of CREB, CREM alpha and ATF-1 and CREB phosphorylation at ser(133) (ser(133) phospho-CREB) in the transition from basal to differentiating keratinocytes, but the activity of a CRE reporter remained unchanged. In contrast, the CRE reporter was activated in the presence of the dominant-negative (DN) CREB mutants, KCREB and A-CREB, proteins that dimerize with CREB family members and block their ability to bind to DNA. The increase in CRE reporter activity in the presence of these mutants suggests that CRE-mediated transcriptional activity is suppressed in keratinocytes through protein-protein interactions involving a factor that dimerizes with the CREB leucine zipper. In experiments where the A-CREB mutant was co-transfected with an AP-1 reporter construct, transcriptional activity was also increased indicating that a CREB family member binds AP-1 sites and represses AP-1 transcriptional activity as well. Exogenous expression of the transcriptional repressor CREM alpha down-regulated both CRE and AP-1 reporters in keratinocytes suggesting that this factor may contribute to the suppression of AP-1 transcriptional activity observed in differentiating keratinocytes.	NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; NCI, Biochem Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yuspa, SH (corresponding author), Bldg 37,Room 3B25,37 Convent Dr MSC 4255, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [Z01BC005445, ZIABC005445] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Andersen B, 1997, GENE DEV, V11, P1873, DOI 10.1101/gad.11.14.1873; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; Bernerd Francoise, 1993, Gene Expression, V3, P187; BROWN AD, 1995, ONCOGENE, V10, P1749; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHATTON B, 1994, ONCOGENE, V9, P375; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; FISHER C, 1991, DEVELOPMENT, V111, P253; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Foulkes NS, 1996, NATURE, V381, P83, DOI 10.1038/381083a0; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; HADMAN M, 1993, ONCOGENE, V8, P1895; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUFF CA, 1993, J BIOL CHEM, V268, P377; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KELLY D, 1995, MOL REPROD DEV, V40, P135, DOI 10.1002/mrd.1080400202; KRYLOV D, 1995, EMBO J, V14, P5329, DOI 10.1002/j.1460-2075.1995.tb00217.x; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; LU B, 1994, J BIOL CHEM, V269, P7443; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; NAVARRO JM, 1995, J BIOL CHEM, V270, P21362, DOI 10.1074/jbc.270.36.21362; OFIR R, 1991, GENE EXPRESSION, V1, P55; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; PRESLAND RB, 1992, J BIOL CHEM, V267, P23772; REDDY SPM, 1995, J BIOL CHEM, V270, P26451, DOI 10.1074/jbc.270.44.26451; Rutberg SE, 1997, ONCOGENE, V15, P1337, DOI 10.1038/sj.onc.1201293; Rutberg SE, 1996, ONCOGENE, V13, P167; RYSECK RP, 1991, ONCOGENE, V6, P533; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; TENNENBAUM T, 1993, CANCER RES, V53, P4803; Walker WH, 1996, J BIOL CHEM, V271, P20145, DOI 10.1074/jbc.271.33.19668; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WATT FM, 1993, DEVELOPMENT, P185; YAMADA K, 1994, BIOCHEM MOL BIOL INT, V34, P827; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858; YUSPA SH, 1994, CANCER RES, V54, P1178; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; ZHANG XK, 1994, CANCER RES, V54, P5663	56	42	42	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1569	1579		10.1038/sj.onc.1202463	http://dx.doi.org/10.1038/sj.onc.1202463			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102627				2022-12-28	WOS:000078770700007
J	Hagemann, D; Troppmair, J; Rapp, UR				Hagemann, D; Troppmair, J; Rapp, UR			Cot protooncoprotein activates the dual specificity kinases MEK-1 and SEK-1 and induces differentiation of PC12 cells	ONCOGENE			English	Article						cot; classic cytoplasmic cascade; stress kinase pathway; transformation; differentiation	PROTEIN-KINASE; SIGNAL-TRANSDUCTION; C-JUN; MAMMALIAN-CELLS; GENE-PRODUCT; MAP KINASES; RAF; GROWTH; TPL-2; TRANSFORMATION	Mitogenic signals initiated at the plasma membrane are transmitted to the nucleus through an intricate signalling network. We identified the protooncoprotein Cot as a new component of mitogenic signalling cascades, which activates both the classic cytoplasmic cascade and the SAFE stress pathway. Wildtype and activated Cot phosphorylate and activate MEK-1 and SEK-1 in vitro. These findings are consistent with the sequence homology between Cot and the rat gene Tpl-2. Expression of oncogenic Cot in 293, NIH3T3 and PC12 cells leads to in vivo phosphorylation of endogenous c-Jun and Erk-1/2 suggesting that the serine/threonine kinase Cot functions beside c-Raf-l and Mos asa direct activator of MEK-1. Furthermore, we have examined the biological effects of Cot on the phenotype of fibroblastic and neuronal cells. In order to test a potential c-Raf-l dependency of Cot transformation, the effect of oncogenic Cot on Raf revertant CHP25 cells was determined. Cot could restore the transformed phenotype indicating that Cot transformation is not dependent on active c-Raf-l and that Cot is not a target for the putative Raf inhibitor, which is presumably active in the revertant cell line. Expression of oncogenic versions of Raf as well as v-Mos leads to differentiation of PC12 cells. Cot also induces neurite outgrowth of PC12 cells. These data are consistent with the role of Cot in the classic mitogenic cascade and suggest that the simultaneously activated JNK/SAPK stress pathway has no antagonistic effects in this context.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany	University of Wurzburg	Rapp, UR (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, Versbacher Str 5, D-97078 Wurzburg, Germany.			Troppmair, Jakob/0000-0002-0611-3837				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; AOKI M, 1993, J BIOL CHEM, V268, P22723; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HEIDECKER G, 1989, GENES SIGNAL TRANSDU, P339; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; KOLCH W, 1993, ONCOGENE, V8, P361; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1983, J VIROL, V45, P914, DOI 10.1128/JVI.45.3.914-924.1983; RAPP UR, 1978, P NATL ACAD SCI USA, V75, P2468, DOI 10.1073/pnas.75.5.2468; RAPP UR, 1988, HDB ONCOGENES, P213; RAPP UR, 1994, FOS JUN FAMILIES TRA, P221; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUPSKY JR, 1998, CELL GROWTH ONCOGENE, P75; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Wixler V, 1996, FEBS LETT, V385, P131, DOI 10.1016/0014-5793(96)00363-8; Woodgett JR, 1996, CANCER SURV, V27, P127; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798	45	37	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1391	1400		10.1038/sj.onc.1202431	http://dx.doi.org/10.1038/sj.onc.1202431			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050876				2022-12-28	WOS:000078651600001
J	Czerniak, B; Chaturvedi, V; Li, L; Hodges, S; Johnston, D; Ro, JY; Luthra, R; Logothetis, C; Von Eschenbach, AC; Grossman, HB; Benedict, WF; Batsakis, JG				Czerniak, B; Chaturvedi, V; Li, L; Hodges, S; Johnston, D; Ro, JY; Luthra, R; Logothetis, C; Von Eschenbach, AC; Grossman, HB; Benedict, WF; Batsakis, JG			Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer	ONCOGENE			English	Article						bladder cancer; chromosome 9; MTS; microsatellites; multistep carcinogenesis; superimposed histologic and genetic mapping	TRANSITIONAL-CELL-CARCINOMA; TUMOR-SUPPRESSOR GENE; CRITICAL REGION; HIGH-FREQUENCY; LUNG CANCERS; DELETION; P16; MUTATIONS; LOCI; DEFINES	The evolution of alterations on chromosome 9, including the putative tumor suppressor genes mapped to the 9p21-22 region (the MTS genes), was studied in relation to the progression of human urinary bladder neoplasia by using whole organ superimposed histologic and genetic mapping in cystectomy specimens and was verified in urinary bladder tumors of various pathogenetic subsets with longterm follow-up, The applicability of chromosome 9 allelic losses as non-invasive markers of urothelial neoplasia was tested on voided urine and/or bladder washings of patients with urinary bladder cancer, Although sequential multiple hits in the MTS locus were documented in the development of intraurothelial precursor lesions, the MTS genes do not seem to represent a major target for p21-23 deletions in bladder cancer, Two additional tumor suppressor genes involved in bladder neoplasia located distally and proximally to the MTS locus within p22-23 and p11-13 regions respectively were identified. Several distinct putative tumor suppressor gene loci within the q12-13, q21-22, and q34 regions were identified on the q arm. In particular, the pericentromeric q12-13 area may contain the critical tumor suppressor gene or genes for the development of early urothelial neoplasia, Allelic losses of chromosome 9 were associated with expansion of the abnormal urothelial clone which frequently involved large areas of urinary bladder mucosa, These losses could be found in a high proportion of urothelial tumors and in voided urine or bladder washing samples of nearly all patients with urinary bladder carcinoma.	Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Biomath, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Urol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Czerniak, B (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA.				NCI NIH HHS [CA66723-04, CA54672] Funding Source: Medline; NEI NIH HHS [EYO6195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA066723, R01CA054672, R01CA066723] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1997, AJCC CANC STAGING MA; ATKIN NB, 1985, CANCER GENET CYTOGEN, V15, P253, DOI 10.1016/0165-4608(85)90169-4; BABU VR, 1987, CANCER RES, V47, P6800; Benedict WF, 1999, ONCOGENE, V18, P1197, DOI 10.1038/sj.onc.1202452; BERGER CS, 1986, CANCER GENET CYTOGEN, V23, P1, DOI 10.1016/0165-4608(86)90145-7; Brownlee K. A, 1965, STAT THEORY METHODOL; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1993, ONCOGENE, V8, P1083; CAIRNS P, 1993, CANCER RES, V53, P1230; Chaturvedi V, 1997, ONCOGENE, V14, P2059, DOI 10.1038/sj.onc.1201044; COLEMAN A, 1994, CANCER RES, V54, P344; DEVLIN J, 1994, ONCOGENE, V9, P2757; GIBAS Z, 1984, CANCER RES, V44, P1257; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HABUCHI T, 1995, ONCOGENE, V11, P1671; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; Hartigan J., 1975, CLUSTERING ALGORITHM; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KISHIMOTO Y, 1995, JNCI-J NATL CANCER I, V87, P1224, DOI 10.1093/jnci/87.16.1224; KOSS LG, 1995, DIAGNOSTIC CYTOLOGY; Larsen C J, 1997, Prog Cell Cycle Res, V3, P109; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; LIU Q, 1995, ONCOGENE, V10, P1061; Maniatis T., 1989, MOL CLONING LAB MANU; MERLO A, 1995, NATURE, V1, P7; MIYAO N, 1993, CANCER RES, V53, P4066; OLOPADE OI, 1993, CANCER RES, V53, P2410; OLUMI AF, 1990, CANCER RES, V50, P7081; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; Ott J., 1991, ANAL HUMAN GENETIC L; PACKENHAM JP, 1995, MOL CARCINOGEN, V14, P147, DOI 10.1002/mc.2940140303; Reed AL, 1996, CANCER RES, V56, P3630; Simoneau AR, 1996, CANCER RES, V56, P5039; SIMONEAU AR, 1994, WORLD J UROL, V12, P89; SMEETS W, 1987, CANCER GENET CYTOGEN, V29, P29, DOI 10.1016/0165-4608(87)90028-8; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SPRUCK CH, 1994, CANCER RES, V54, P784; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TSAI YC, 1990, CANCER RES, V50, P44; VANNI R, 1988, CANCER GENET CYTOGEN, V30, P35, DOI 10.1016/0165-4608(88)90090-8; WILLIAMSON MP, 1995, HUM MOL GENET, V4, P1569, DOI 10.1093/hmg/4.9.1569; Wong DJ, 1997, CANCER RES, V57, P2619	42	104	108	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1185	1196		10.1038/sj.onc.1202385	http://dx.doi.org/10.1038/sj.onc.1202385			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022124				2022-12-28	WOS:000078510700007
J	Egan, C; Pang, A; Durda, D; Cheng, HC; Wang, JH; Fujita, DJ				Egan, C; Pang, A; Durda, D; Cheng, HC; Wang, JH; Fujita, DJ			Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530	ONCOGENE			English	Article						Src kinase; phosphotyrosyl phosphatase; breast cancer	EPIDERMAL-GROWTH-FACTOR; PP60C-SRC PROTEIN-KINASE; C-SRC; FACTOR RECEPTOR; MAMMARY-TUMORS; MITOGENIC RESPONSIVENESS; NEU PROTOONCOGENE; SH2 DOMAIN; EXPRESSION; PP60(C-SRC)	Elevated levels of Src kinase activity have been reported in a number of human cancers, including colon and breast cancer, We have analysed four human breast tumor cell lines that exhibit high levels of Src kinase activity, and have determined that these cell lines also exhibit a high level of a phosphotyrosine phosphatase activity that recognizes the Src carboxy-terminal P-Tyr530 negative regulatory site. Total Src kinase activity in these cell lines is elevated as much as 30-fold over activity in normal control cells and specific activity is elevated as much as 5.6-fold. When the breast tumor cells were grown in the presence of the tyrosine phosphatase inhibitor vanadate, Src kinase activity was reduced in all four breast tumor cell lines, suggesting that Src was being activated by a phosphatase which could recognize the Tyr530 negative regulatory site, In fractionated cell extracts from the breast tumor cells, we found elevated levels of a membrane associated tyrosine phosphatase activity that preferentially dephosphorylated a Src family carboxy-terminal phosphopeptide containing the regulatory tyrosine 530 site, Src was hypophosphorylated in vivo at tyrosine 530 in at least two of the tumor cell lines, further suggesting that Src was being activated by a phosphatase in these cells, In preliminary immunoprecipitation and antibody depletion experiments, we were unable to correlate the major portion of this phosphatase activity with several known phosphatases.	Univ Calgary, Med Ctr, Cell Regulat Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Med Ctr, Cell Regulat Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Med Ctr, Canc Biol Res Grp, Dept Biochem Med, Calgary, AB T2N 4N1, Canada; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Peoples R China	University of Calgary; University of Calgary; University of Calgary; Hong Kong University of Science & Technology	Fujita, DJ (corresponding author), Univ Calgary, Med Ctr, Cell Regulat Grp, Calgary, AB T2N 4N1, Canada.			Cheng, Heung-Chin/0000-0002-4965-7148				BERGER MS, 1988, CANCER RES, V48, P1238; BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; JACOBS C, 1983, CANCER RES, V43, P1696; JANES PW, 1994, ONCOGENE, V9, P3601; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LITWIN CME, 1991, J BIOL CHEM, V266, P2557; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; OCONNOR TJ, 1995, CELL GROWTH DIFFER, V6, P123; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Pallen C J, 1993, Semin Cell Biol, V4, P403, DOI 10.1006/scel.1993.1048; PENG ZY, 1995, ONCOGENE, V11, P1955; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TANAKA A, 1990, ONCOGENE RES, V5, P305; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Uckun FM, 1996, J BIOL CHEM, V271, P6389, DOI 10.1074/jbc.271.11.6389; VARLEY JM, 1987, ONCOGENE, V1, P423; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; WEERNINK PAO, 1994, FEBS LETT, V352, P296, DOI 10.1016/0014-5793(94)00977-5; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; YUAN ZM, 1995, BIOCHEMISTRY-US, V34, P1058, DOI 10.1021/bi00003a041; ZHAI YF, 1993, CANCER RES, V53, P2272; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	46	98	103	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	1999	18	5					1227	1237		10.1038/sj.onc.1202233	http://dx.doi.org/10.1038/sj.onc.1202233			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022129				2022-12-28	WOS:000078510700012
J	Zhang, YK; Fujita, N; Tsuruo, T				Zhang, YK; Fujita, N; Tsuruo, T			Caspase-mediated cleavage of p21(Wafl)/(Cip1) converts cancer cells from growth arrest to undergoing apoptosis	ONCOGENE			English	Article						p21; apoptosis; caspases; DNA damage; p53	CYCLIN-DEPENDENT KINASES; P53-MEDIATED G(1) ARREST; DNA-REPLICATION; P53-INDUCED APOPTOSIS; PROTEASE ACTIVATION; NUCLEAR ANTIGEN; CYTOCHROME-C; IN-VIVO; INHIBITION; P21	The cyclin-dependent kinase inhibitor p21(Waf1/Cip1) is a downstream effector of the p53-dependent cell growth arrest. We report herein that p21 was cleaved by caspase-3/CPP32 at the site of (DHVDL)-L-112 down arrow during the DNA damage-induced apoptosis of cancer cells. The cleaved p21 fragment could no more arrest the cells in G(1) phase nor suppress the cells undergoing apoptosis because it failed to bind to the proliferating cell nuclear antigen (PCNA) and lost its capability to localize in the nucleus. Thus, caspase-3-mediated cleavage and inactivation of p21 protein may convert cancer cells from growth arrest to undergoing apoptosis, leading to the acceleration of chemotherapy-induced apoptotic process in cancer cells.	Univ Tokyo, Lab Biomed Sci, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1700012, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Lab Biomed Sci, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.		Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264				Adams PD, 1996, MOL CELL BIOL, V16, P6623; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen IT, 1996, ONCOGENE, V12, P595; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; Gorospe M, 1996, CANCER RES, V56, P475; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; KING KL, 1995, J CELL BIOCHEM, V58, P175, DOI 10.1002/jcb.240580206; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Lee SH, 1996, ONCOGENE, V13, P2131; LEHMAN TA, 1991, CANCER RES, V51, P4090; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MIYASHITA T, 1995, CELL, V80, P293; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIMIZU T, 1995, CANCER RES, V55, P228; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TOMIDA A, 1996, ONCOGENE, V13, P299; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	51	213	222	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1131	1138		10.1038/sj.onc.1202426	http://dx.doi.org/10.1038/sj.onc.1202426			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022118				2022-12-28	WOS:000078510700001
J	Magae, J; Illenye, S; Chang, YC; Mitsui, Y; Heintz, NH				Magae, J; Illenye, S; Chang, YC; Mitsui, Y; Heintz, NH			Association with E2F-1 governs intracellular trafficking and polyubiquitination of DP-1	ONCOGENE			English	Article						E2F; ubiquitination; c-jun; CKI	UBIQUITIN-PROTEASOME PATHWAY; S-PHASE ENTRY; RETINOBLASTOMA FAMILY PROTEINS; TRANSCRIPTION FACTOR E2F; CELL-CYCLE; DIHYDROFOLATE-REDUCTASE; IN-VIVO; SUBCELLULAR-LOCALIZATION; NUCLEAR-LOCALIZATION; GENE-EXPRESSION	The cell cycle-regulated transcription factor E2F is a family of heterodimers composed of E2F and DP protein subunits, While DP proteins stabilize DNA binding of E2F proteins, and influence the entry of E2F-4 and E2F-5 into the nucleus, the role of DP proteins in E2F-dependent gene expression is not well understood. Using immunolocalization, immunoprecipitation, and cell fractionation experiments, here we show association with E2F subunits governs intracellular trafficking and ubiquitination of DP-1, In transient transfection experiments, DP-1 polypeptides that stably bound E2F-1 entered the nucleus. DP-1 proteins that failed to associate with E2F subunits accumulated in the cell cytoplasm as polyubiquitinated DP-1, A Chinese hamster cell line that conditionally expresses HA-DP-1 was used to examine the effect of DP-1 on cell cycle progression, In serum response experiments, moderate increases in HA-DP-1 led to a threefold increase in E2F DNA binding activity in vitro, a corresponding increase in dhfr gene expression during transition of G1, and higher rates of S phase entry. However, flow cytometry showed cells expressing very high levels of HA-DP-1 failed to enter the S phase. Inhibition of cell cycle progression by high levels of HA-DP-1 was associated with the accumulation of other ubiquitinated cellular proteins, including c-jun and the cyclin-dependent kinase inhibitor p21, indicating that degradation of ubiquitinated proteins is required for progression from G(0) to S phase even in the presence of activated E2F, Under similar conditions, expression of E2F-1 reduced the levels of ubiquitinated cellular proteins and accelerated cell cycle progression. Our studies indicate association with E2F subunits prevents ubiquitin-dependent degradation of DP-1 in the cytoplasm by promoting nuclear entry of E2F/DP heterodimers.	Univ Vermont, Dept Pathol, Coll Med, Burlington, VT 05405 USA; Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 305, Japan	University of Vermont; National Institute of Advanced Industrial Science & Technology (AIST)	Heintz, NH (corresponding author), Univ Vermont, Dept Pathol, Coll Med, Soule Med Alumni Bldg, Burlington, VT 05405 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054726] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54726] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; Gopalkrishnan RV, 1996, ONCOGENE, V13, P2671; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HARPER JW, 1993, CELL, V75, P805; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; JOOSS K, 1995, ONCOGENE, V10, P1529; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Magae J, 1996, J CELL SCI, V109, P1717; Maki CG, 1996, CANCER RES, V56, P2649; MILBRANDT JD, 1981, P NATL ACAD SCI USA, V78, P6042; Muller H, 1997, MOL CELL BIOL, V17, P5508; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Sanchez I, 1996, CURR OPIN CELL BIOL, V8, P318, DOI 10.1016/S0955-0674(96)80004-4; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Schilling Lynda J., 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P19; SCHOWB E, 1994, CELL, V79, P233; Shan B, 1996, CELL GROWTH DIFFER, V7, P689; SHULL S, 1991, J BIOL CHEM, V266, P24398; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; TELFORD WG, 1994, J IMMUNOL METHODS, V172, P1, DOI 10.1016/0022-1759(94)90373-5; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Warburg O., 1942, BIOCHEM Z, V310, P384; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wells J, 1996, MOL CELL BIOL, V16, P634; Wells JM, 1997, J BIOL CHEM, V272, P4483, DOI 10.1074/jbc.272.7.4483; Wu CL, 1996, MOL CELL BIOL, V16, P3698; WU CL, 1995, MOL CELL BIOL, V15, P2536; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	50	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					593	605		10.1038/sj.onc.1202345	http://dx.doi.org/10.1038/sj.onc.1202345			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989809				2022-12-28	WOS:000078394400004
J	Sanz, C; Leon, Y; Troppmair, J; Rapp, UR; Varela-Nieto, I				Sanz, C; Leon, Y; Troppmair, J; Rapp, UR; Varela-Nieto, I			Strict regulation of c-Raf kinase levels is required for early organogenesis of the vertebrate inner ear	ONCOGENE			English	Article						insulin-like growth factor-I; mitogen-activated protein kinase; NGF; organotypic otic vesicle cultures; RCAS vectors; retinoic acid	PROGRAMMED CELL-DEATH; GROWTH-FACTOR-I; ACTIVATED PROTEIN-KINASE; MAP KINASE; RETROVIRAL VECTORS; RETINOIC ACID; SIGNAL-TRANSDUCTION; FOS EXPRESSION; CHICK-EMBRYO; GENE	Regulation of organogenesis involves a dynamic balance of the mechanisms regulating cell division, differentiation and death. Here we have investigated the pattern of expression of c-Raf kinase in the inner ear during early developmental stages and the consequences of manipulating c-Raf levels by misexpression of c-raf viral vectors in organotypic cultures of otic vesicle explants. We found that otic vesicles expressed c-Raf and its level remained constant during embryonic days 2 and 3 (E2-E3). c-Raf activity was increased in response to insulin like growth factor-I (IGF-I) and the activation by IGF-I of the c-Raf kinase pathway was a requirement to turn on cell proliferation in the otic vesicle. Overexpression of c-raf in E2.5 explants increased the proliferative response to low serum and ICF-I and blocked differentiation induced by retinoic acid. The increase in c-Raf levels also prevented nerve growth factor (NGF)-dependent induction of programmed cell death. Consistent with these results, the expression of a dominant negative c-Raf mutant potentiated retinoic acid action and decreased the rate of cell proliferation. We conclude that a strict control of c-Raf levels is essential for the co-ordination of the biological processes that operate simultaneously during early inner ear development.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, MSZ, D-97078 Wurzburg, Germany	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Wurzburg	Varela-Nieto, I (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		Varela-Nieto, Isabel/G-5289-2015; Leon, Yolanda/ABG-6797-2020; SANZ, CARMEN/L-7266-2014	Varela-Nieto, Isabel/0000-0003-3077-0500; SANZ, CARMEN/0000-0001-7025-6667; Leon Alvarez, Yolanda/0000-0002-4536-8373; Troppmair, Jakob/0000-0002-0611-3837				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Bergeron L, 1998, CURR OPIN NEUROBIOL, V8, P55, DOI 10.1016/S0959-4388(98)80008-1; BISSONNETTE JP, 1996, J COMP NEUROL, V174, P1; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Cacace AM, 1996, ONCOGENE, V13, P2517; CEPKO CL, 1992, CURRENT PROTOCOLS MO; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Federspiel MJ, 1997, METHOD CELL BIOL, V52, P179, DOI 10.1016/S0091-679X(08)60379-9; FEKETE DM, 1993, MOL CELL BIOL, V13, P2604, DOI 10.1128/MCB.13.4.2604; Fekete DM, 1997, DEVELOPMENT, V124, P2451; Fekete DM, 1996, CURR OPIN NEUROBIOL, V6, P533, DOI 10.1016/S0959-4388(96)80061-4; Frago LM, 1998, J CELL SCI, V111, P549; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HEMOND SG, 1991, ANAT EMBRYOL, V184, P1, DOI 10.1007/BF01744256; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HUNTER E, 1979, METHOD ENZYMOL, P379; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; Kiernan AE, 1997, AUDIOL NEURO-OTOL, V2, P12, DOI 10.1159/000259226; KOENEN M, 1988, ONCOGENE, V2, P179; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lee KH, 1996, HEARING RES, V94, P1, DOI 10.1016/0378-5955(95)00220-0; Lein Y, 1998, J COMP NEUROL, V398, P323, DOI 10.1002/(SICI)1096-9861(19980831)398:3<323::AID-CNE2>3.0.CO;2-1; LEON Y, 1995, DEV BIOL, V167, P75, DOI 10.1006/dbio.1995.1008; LEON Y, 1995, ENDOCRINOLOGY, V136, P3494, DOI 10.1210/en.136.8.3494; MACNICOL AM, 1995, MOL CELL BIOL, V15, P6686; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; MARK GE, 1984, SCIENCE, V224, P285, DOI 10.1126/science.6324342; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MINER C, 1988, ROUX ARCH DEV BIOL, V197, P294, DOI 10.1007/BF00380023; MORRISON DK, 1995, MOL REPROD DEV, V42, P507, DOI 10.1002/mrd.1080420420; Naumann U, 1997, Recent Results Cancer Res, V143, P237; Oesterle EC, 1997, J COMP NEUROL, V380, P262, DOI 10.1002/(SICI)1096-9861(19970407)380:2<262::AID-CNE8>3.0.CO;2-1; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PERRIMON N, 1994, TRENDS BIOCHEM SCI, V19, P509, DOI 10.1016/0968-0004(94)90140-6; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; PETROPOULOS CJ, 1989, MOL CELL BIOL, V9, P3785, DOI 10.1128/MCB.9.9.3785; Pritchard C, 1997, NAT GENET, V16, P214, DOI 10.1038/ng0797-214; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REPRESA J, 1990, DEVELOPMENT, V110, P1081; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; SPAGNOLI A, 1997, CURR OPIN ENDOCRINOL, V4, P1; STEWART L, 1990, J VIROL, V64, P5076, DOI 10.1128/JVI.64.10.5076-5092.1990; STORM SM, 1990, ONCOGENE, V5, P345; Torres M, 1998, MECH DEVELOP, V71, P5, DOI 10.1016/S0925-4773(97)00155-X; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VONBARTHELD CS, 1991, DEVELOPMENT, V113, P455; Wassarman DA, 1996, GENE DEV, V10, P272, DOI 10.1101/gad.10.3.272; Weil M, 1997, CURR BIOL, V7, P281, DOI 10.1016/S0960-9822(06)00125-4; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Woods KA, 1996, NEW ENGL J MED, V335, P1363, DOI 10.1056/NEJM199610313351805; Xu RH, 1996, P NATL ACAD SCI USA, V93, P834, DOI 10.1073/pnas.93.2.834; Zheng JL, 1997, J NEUROSCI, V17, P216, DOI 10.1523/JNEUROSCI.17-01-00216.1997	59	26	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					429	437		10.1038/sj.onc.1202312	http://dx.doi.org/10.1038/sj.onc.1202312			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927199				2022-12-28	WOS:000078166500015
J	Shtil, AA; Mandlekar, S; Yu, R; Walter, RJ; Hagen, K; Tan, TH; Roninson, IB; Kong, ANT				Shtil, AA; Mandlekar, S; Yu, R; Walter, RJ; Hagen, K; Tan, TH; Roninson, IB; Kong, ANT			Differential regulation of mitogen-activated protein kinases by microtubule-binding agents in human breast cancer cells	ONCOGENE			English	Article						taxol; colchicine; MAP kinases; microtubules; breast cancer	N-TERMINAL KINASE-1; EPIDERMAL GROWTH-FACTOR; C-JUN; KAPPA-B; INDUCED APOPTOSIS; GENE-EXPRESSION; UV IRRADIATION; JNK ACTIVATION; LEUKEMIA-CELLS; STRESS	Drug design targeted at microtubules has led to the advent of some potent anti-cancer drugs. In the present study, we demonstrated that microtubule-binding agents (MBAs) taxol and colchicine induced immediate early gene (c-jun and A TF3) expression, cell cycle arrest, and apoptosis in the human breast cancer cell line MCF-7. To elucidate the signal transduction pathways that mediate such biological activities of MBAs, we studied the involvement of mitogen-activated protein (MAP) kinases, Treatment,vith tah;ol, colchicine, or other MBAs (vincristine, podophyllotoxin, nocodazole) stimulated the activity of c-jun N-terminal kinase 1 (JNK1) in MCF-7 cells. In contrast, p38 was activated only by taxol and none of the MBAs changed the activity of extracellular signal-regulated protein kinase 2 (ERK2), Activation of JNK1 or p38 by MBAs occurred subsequent to the morphological changes in the microtubule cytoskeleton induced by these compounds. furthermore, baccatine III and beta-lumicolchicine, inactive analogs of taxol and colchicine, respectively, did not activate JNK1 or p38, These results suggest that interactions between microtubules and MBAs are essential for the activation of these kinases, Pretreatment with the antioxidants N-acetyl-L-cysteine (NAC), ascorbic acid or vitamin E, blocked H2O2- or doxorubicin-induced JNK1 activity, but had no effect on JNK1 activation by MBAs, excluding a role for oxidative stress. However, BAPTA/AM, a specific intracellular Ca2+ chelator, attenuated JNK1 activation by taxol but not by colchicine, and had no effect on microtubule changes induced by taxol. Thus, stabilization or depolymerization of microtubules may regulate JNK1 activity via distinct downstream signaling pathways. The differential activation of MAP kinases opens up a new avenue for addressing the mechanism of action of anti-microtubule drugs.	Univ Illinois, Ctr Pharmaceut Biotechnol, Dept Pharmaceut & Pharmacodynam, Coll Pharm, Chicago, IL 60607 USA; Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Cook Cty Hosp, Dept Surg, Chicago, IL 60612 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; John H Stroger Junior Hospital Cook County; Baylor College of Medicine	Kong, ANT (corresponding author), Univ Illinois, Ctr Pharmaceut Biotechnol, Dept Pharmaceut & Pharmacodynam, Coll Pharm, Chicago, IL 60607 USA.		Roninson, Igor/K-1310-2017; Tan, Tse-Hua/ABD-7080-2021; Kong, Ah-Ng Tony/AAX-2828-2020; Shtil, Alexander A./K-1568-2017; Tan, Tse-Hua/E-3983-2010	Roninson, Igor/0000-0002-9211-1327; Tan, Tse-Hua/0000-0003-4969-3170; Shtil, Alexander A./0000-0001-6469-0221; Tan, Tse-Hua/0000-0003-4969-3170	NCI NIH HHS [R37CA40333] Funding Source: Medline; NIAID NIH HHS [R01-AI38649] Funding Source: Medline; NIEHS NIH HHS [R01-ES06887] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040333] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006887] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Assefa Z, 1997, J INVEST DERMATOL, V108, P886, DOI 10.1111/1523-1747.ep12292595; BACHUR NR, 1979, P NATL ACAD SCI USA, V76, P954, DOI 10.1073/pnas.76.2.954; BHALLA K, 1993, LEUKEMIA, V7, P563; BUCKLER AJ, 1988, MOL CELL BIOL, V8, P1371, DOI 10.1128/MCB.8.3.1371; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Cadwallader K, 1997, BIOCHEM J, V321, P795, DOI 10.1042/bj3210795; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dustin P., 1984, MICROTUBULES; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JORDAN MA, 1991, CANCER RES, V51, P2212; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Komarov PG, 1996, INT J CANCER, V68, P245, DOI 10.1002/(SICI)1097-0215(19961009)68:2<245::AID-IJC18>3.0.CO;2-9; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MANIE S, 1993, J BIOL CHEM, V268, P13675; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; SYMPSON CJ, 1990, EXP CELL RES, V189, P28, DOI 10.1016/0014-4827(90)90252-6; UNEMORI EN, 1986, J CELL BIOL, V103, P1021, DOI 10.1083/jcb.103.3.1021; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yu R, 1996, CANCER RES, V56, P2954; Yu R, 1996, CANCER LETT, V107, P73, DOI 10.1016/0304-3835(96)04345-5; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	42	147	156	1	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					377	384		10.1038/sj.onc.1202305	http://dx.doi.org/10.1038/sj.onc.1202305			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927194				2022-12-28	WOS:000078166500010
J	Velasco-Miguel, S; Buckbinder, L; Jean, P; Gelbert, L; Talbott, R; Laidlaw, J; Seizinger, B; Kley, N				Velasco-Miguel, S; Buckbinder, L; Jean, P; Gelbert, L; Talbott, R; Laidlaw, J; Seizinger, B; Kley, N			PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes	ONCOGENE			English	Article						p53; GADD genes; 6q21; genotoxic stress; serum regulation	NON-HODGKINS-LYMPHOMA; BREAST-CANCER-CELLS; WILD-TYPE P53; MDM-2 ONCOGENE; CHROMOSOME 6Q; PROTEIN; APOPTOSIS; INDUCTION; REGIONS; HETEROZYGOSITY	Exposure of mammalian cells to hypoxia, radiation and certain chemotherapeutic agents promotes cell cycle arrest and/or apoptosis. Activation of p53 responsive genes is believed to play an important role in mediating such responses. In this study we identified a novel gene, PA26, which maps to chromosome 6q21 and encodes at least three transcript isoforms, of which two are differentially induced by genotoxic stress (UV, gamma-irradiation and cytotoxic drugs) in a p53-dependent manner. A functional p53-responsive element was identified in the second intron of the PA26 gene, in consistence with a mechanism of transcriptional induction of the PA26 gene by p53. No clues to its functions were revealed by sequence analysis, although pronounced negative regulation by serum factors argues fbr a potential role of PA26 in growth regulation. Immunological analysis suggests that PA26 protein(s) is localized to the cell nucleus. Our results suggest that the PA26 gene is a novel p53 target gene with properties common to the GADD family of growth arrest and DNA damage-inducible stress-response genes, and, thus, a potential novel regulator of cellular growth.	Bristol Myers Squibb Pharmaceut Res Inst, Dept Oncol, Princeton, NJ 08543 USA; Pfizer Inc, Cent Res, Groton, CT 06340 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08543 USA; Genome Therapeut Corp, Waltham, MA 02154 USA	Bristol-Myers Squibb; Pfizer; Princeton University	Kley, N (corresponding author), Univ Texas, SW Med Ctr, Dept Dev Biol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BROWN JL, 1994, CANCER GENET CYTOGEN, V72, P116, DOI 10.1016/0165-4608(94)90126-0; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chen JD, 1996, MOL CELL BIOL, V16, P2445; COWAN KH, 1986, P NATL ACAD SCI USA, V83, P9328, DOI 10.1073/pnas.83.24.9328; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1474; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Gerard B, 1997, LEUKEMIA, V11, P228, DOI 10.1038/sj.leu.2400566; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; JACKMAN J, 1994, CANCER RES, V54, P5656; JOHANSSON B, 1995, BLOOD, V86, P3905, DOI 10.1182/blood.V86.10.3905.bloodjournal86103905; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Madden SL, 1996, CANCER RES, V56, P5384; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Morelli C, 1997, CANCER RES, V57, P4153; NEGRINI M, 1994, CANCER RES, V54, P1331; Noviello C, 1996, CLIN CANCER RES, V2, P1601; OFFIT K, 1993, BLOOD, V82, P2157; OKAMOTO K, 1994, EMBO J, V13, P4813; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; PEJOVIC T, 1995, ANN MED, V27, P73, DOI 10.3109/07853899509031940; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; RAO PH, 1994, CANCER GENET CYTOGEN, V77, P60, DOI 10.1016/0165-4608(94)90150-3; ROAULT JP, 1996, NAT GENT, V14, P482; Sambrook J., 2002, MOL CLONING LAB MANU; Sandhu AK, 1996, ONCOGENE, V12, P247; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Winkles JA, 1998, PROG NUCLEIC ACID RE, V58, P41; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141	51	177	186	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					127	137		10.1038/sj.onc.1202274	http://dx.doi.org/10.1038/sj.onc.1202274			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926927				2022-12-28	WOS:000078166000014
J	Amundson, SA; Myers, TG; Fornace, AJ				Amundson, SA; Myers, TG; Fornace, AJ			Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress	ONCOGENE			English	Review						cell cycle; stress-response; p53; functional genomics	WILD-TYPE P53; CELL-CYCLE CHECKPOINT; NATIONAL-CANCER-INSTITUTE; GENE-EXPRESSION PATTERNS; ANTICANCER DRUG SCREEN; TUMOR-SUPPRESSOR GENE; ABL TYROSINE KINASE; DIFFERENTIAL CYTOTOXICITY DATA; NUCLEOTIDE EXCISION-REPAIR; P53-DEPENDENT G(1) ARREST	The tumor suppressor gene p53 plays a major role in regulation of the mammalian cellular stress response, in part through the transcriptional activation of genes involved in cell cycle control, DNA repair, and apoptosis. Many factors contribute to control of the activation of p53, and the downstream response to its activation may also vary depending on the cellular environment or other modifying factors in the cell. The complexity of the p53 response makes this an ideal system for application of newly emerging rapid throughput analysis techniques and informatics analysis.	NCI, Div Basic Sci, NIH, Bethesda, MD 20892 USA; NCI, Dev Therapeut Program, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Amundson, SA (corresponding author), NCI, Div Basic Sci, NIH, Bethesda, MD 20892 USA.		; Fornace, Albert/A-7407-2008	Myers, Timothy Gene/0000-0002-7059-5906; Fornace, Albert/0000-0001-9695-085X				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; AMUNDSON SA, 1998, IN PRESS ONCOGENE; Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; ASKEW DS, 1991, ONCOGENE, V6, P1915; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Bae I, 1996, CANCER RES, V56, P840; BAI R, 1991, J BIOL CHEM, V266, P15882; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bian JH, 1997, P NATL ACAD SCI USA, V94, P14753, DOI 10.1073/pnas.94.26.14753; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1994, CANCER RES, V54, P5054; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARRIER F, 1998, UNPUB; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DeRisi J, 1996, NAT GENET, V14, P457; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Ermolaeva O, 1998, NAT GENET, V20, P19, DOI 10.1038/1670; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FAN SJ, 1995, CANCER RES, V55, P1649; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Freije JMP, 1997, NAT MED, V3, P395, DOI 10.1038/nm0497-395; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gadbois DM, 1997, CANCER RES, V57, P1151; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOGA A, 1995, ONCOGENE, V11, P791; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Gottlieb E, 1996, CELL GROWTH DIFFER, V7, P301; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; GREVER MR, 1992, SEMIN ONCOL, V19, P622; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; GUILLOUF C, 1995, ONCOGENE, V10, P2263; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Haupt Y, 1996, Behring Inst Mitt, P32; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hecker D, 1996, ONCOGENE, V12, P953; HERMEKING H, 1995, ONCOGENE, V11, P1409; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Hollander MC, 1997, J BIOL CHEM, V272, P13731, DOI 10.1074/jbc.272.21.13731; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Iliakis G, 1997, SEMIN ONCOL, V24, P602; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; ITOH N, 1993, J IMMUNOL, V151, P621; Iwamoto KS, 1996, CANCER RES, V56, P3862; JAYARAMAN L, 1995, CELL, V81, P10231; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kao GD, 1997, CANCER RES, V57, P753; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Koo HM, 1996, CANCER RES, V56, P5211; KOUTSOUKOS AD, 1994, STAT MED, V13, P719, DOI 10.1002/sim.4780130532; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEE JS, 1994, MOL PHARMACOL, V46, P627; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li G, 1996, AM J PATHOL, V148, P1113; Linke SP, 1997, CANCER RES, V57, P1171; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUNA RMD, 1995, NATURE, V378, P203; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; Mai M, 1998, CANCER RES, V58, P2347; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; Myers TG, 1997, ELECTROPHORESIS, V18, P647, DOI 10.1002/elps.1150180351; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NEVINS JR, 1992, SCIENCE, V258, P424; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; OConnor PM, 1997, CANCER RES, V57, P4285; OConnor PM, 1997, CANCER SURV, V29, P151; OCONNOR PM, 1993, CANCER RES, V53, P4776; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PAULL KD, 1992, CANCER RES, V52, P3892; PAULL KD, 1995, FOYE WO, P9; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; POHL J, 1988, MOL CELL BIOL, V8, P2078, DOI 10.1128/MCB.8.5.2078; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; POWELL SN, 1995, CANCER RES, V55, P1643; Prabhu NS, 1998, INT J ONCOL, V13, P5; PRICE BD, 1994, CANCER RES, V54, P896; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P217, DOI 10.1080/09553009414550251; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; RUBINSTEIN LV, 1990, J NATL CANCER I, V82, P1113, DOI 10.1093/jnci/82.13.1113; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SCHOTT AF, 1995, ONCOGENE, V11, P1389; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHEIKH MS, 1998, IN PRESS CANC RES; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 1996, AM J PATHOL, V148, P1019; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; STEWART N, 1995, ONCOGENE, V10, P109; STINSON SF, 1992, ANTICANCER RES, V12, P1035; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Theis S, 1998, ONCOGENE, V17, P557, DOI 10.1038/sj.onc.1201973; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; VANOSDOL WW, 1994, J NATL CANCER I, V86, P1853, DOI 10.1093/jnci/86.24.1853; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wahl GM, 1997, CANCER SURV, V29, P183; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Wang X. W., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P201; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; WEINSTEIN JN, 1992, SCIENCE, V258, P447, DOI 10.1126/science.1411538; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wosikowski K, 1997, JNCI-J NATL CANCER I, V89, P1505, DOI 10.1093/jnci/89.20.1505; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zeng XY, 1998, P NATL ACAD SCI USA, V95, P6681, DOI 10.1073/pnas.95.12.6681; ZHAN Q, 1998, IN PRESS ONCOGENE; Zhan QM, 1997, ONCOGENE, V14, P1031, DOI 10.1038/sj.onc.1200927; Zhan QM, 1996, ONCOGENE, V13, P2287; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250	212	377	385	0	13	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 24	1998	17	25					3287	3299		10.1038/sj.onc.1202576	http://dx.doi.org/10.1038/sj.onc.1202576			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916991				2022-12-28	WOS:000078048200010
J	Munnes, M; Patrone, G; Schmitz, B; Romeo, G; Doerfler, W				Munnes, M; Patrone, G; Schmitz, B; Romeo, G; Doerfler, W			A 5 '-CG-3 '-rich region in the promoter of the transcriptionally frequently silenced RET protooncogene lacks methylated cytidine residues	ONCOGENE			English	Article						HSCR patients; RET protooncogene promoter; 5 '-CG-3 '-rich region in the RET promoter	NEUROBLASTOMA CELL-LINES; DNA METHYLATION; HIRSCHSPRUNGS-DISEASE; CHLORAMPHENICOL ACETYLTRANSFERASE; NEURONAL DIFFERENTIATION; ADENOVIRUS TYPE-2; MAMMALIAN-CELLS; GENE-EXPRESSION; MESSENGER-RNA; MUTATIONS	In a large proportion of familial and sporadic cases of Hirschsprung disease (HSCR) mutations in the RET (rearranged during transfection) protooncogene have been described. We have investigated the structure of the RET gene promoter and have analysed a region of approximately 1000 nucleotides in its promoter and 5'-upstream segments for the occurrence of 5-methyldeoxycytidine (5-mC) residues by using the bisulfite protocol of the genomic sequencing method. With an estimated sensitivity of about 93% of this technique, not a single 5-mC residue could be detected in the control region of a gene that seems to be silenced or exhibit low activity in many adult tissues. In these experiments, the DNAs of peripheral white blood cells (PWBC) from four healthy individuals, from seven patients with familial HSCR, as well as DNAs from different human tissues and from a human embryonic kidney (HEK) cell line have been included. Tn a DNA segment starting 790 nucleotides upstream of the transcriptional start site of the RET gene, a few 5-mC residues have been identified. This region possibly constitutes the transition site from an unmethylated promoter to a more extensively methylated region in the human genome. The data presented are remarkable in that a highly 5'-CG-3'-enriched segment of the human genome with 49 5'-CG-3' dinucleotide pairs in 400 bp within the putative promoter region is completely devoid of 5-mC residues, although this control region is not actively transcribed in most adult human tissues. By hybridization of a PCR-amplified RET protooncogene cDNA probe harboring exons 9-15 to a membrane (Clontech) containing poly-A selected RNAs from 50 different human tissues, weak RET protooncogene expression in many of the neural cell derived tissues has been detected. RNAs extracted from many other human tissues do not share sequence homologies to this P-32-labeled probe. Mechanisms other than DNA methylation obviously play the crucial role in the inactivation of the RET gene promoter in these tissues. We have also demonstrated by the in vitro premethylation of a RET promoter-chloramphenicol acetyltransferase (CAT) gene construct and transient transfection experiments into neuroblastoma cells that the transcriptional activity of the RET promoter is decreased by HpaII (5'-CCGG-3') methylation and abolished by SssI (5'-CG-3') methylation, Hence, the RET promoter region is sensitive to this regulatory signal. However in vivo, DNA methylation of the promoter region seems not to be the predominant regulatory mechanism for the RET protooncogene, Possibly, in adults the RET gene can be occasionally activated.	Univ Cologne, Inst Genet, D-5000 Cologne 41, Germany; Univ Genoa, Fac Med, I-16148 Genoa, Italy; Ist Giannina Gaslini, Genet Mol Lab, I-16148 Genoa, Italy	University of Cologne; University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini	Doerfler, W (corresponding author), Univ Cologne, Inst Genet, D-5000 Cologne 41, Germany.							ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BADNER JA, 1990, AM J HUM GENET, V46, P568; BEHNKRAPPA A, 1993, HUM MOL GENET, V2, P993, DOI 10.1093/hmg/2.7.993; BODIAN M, 1963, ANN HUM GENET, V26, P261, DOI 10.1111/j.1469-1809.1963.tb01983.x; BONGARZONE I, 1994, CANCER RES, V54, P2979; BUNONE G, 1995, EXP CELL RES, V217, P92, DOI 10.1006/excr.1995.1067; CECCHERINI I, 1994, ONCOGENE, V9, P3025; CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/bbrc.1993.2392; CEDAR H, 1990, BIOCHIM BIOPHYS ACTA, V1049, P1, DOI 10.1016/0167-4781(90)90076-E; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CONSTANTINIDES PG, 1977, NATURE, V267, P364, DOI 10.1038/267364a0; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; DURBEC P, 1996, NATURE, V381, P785; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GOLDBERG EL, 1984, INT J EPIDEMIOL, V13, P479, DOI 10.1093/ije/13.4.479; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hofstra RMW, 1996, NAT GENET, V12, P445, DOI 10.1038/ng0496-445; IKEDA I, 1990, ONCOGENE, V5, P1291; ITOH F, 1992, ONCOGENE, V7, P1210; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; Kambouris M, 1996, HUM MUTAT, V8, P64, DOI 10.1002/(SICI)1098-1004(1996)8:1<64::AID-HUMU9>3.0.CO;2-P; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; KOCHANEK S, 1993, EMBO J, V12, P1141, DOI 10.1002/j.1460-2075.1993.tb05755.x; KOCHANEK S, 1990, P NATL ACAD SCI USA, V87, P8830, DOI 10.1073/pnas.87.22.8830; KRUCZEK I, 1983, P NATL ACAD SCI-BIOL, V80, P7586, DOI 10.1073/pnas.80.24.7586; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LANGNER KD, 1984, P NATL ACAD SCI-BIOL, V81, P2950, DOI 10.1073/pnas.81.10.2950; LARIMORE TC, 1993, P NATL ACAD SCI USA, V90, P492; LYONNET S, 1994, CR ACAD SCI III-VIE, V317, P358; MARTUCCIELLO G, 1992, PEDIATR SURG INT, V7, P308; MUNNES M, 1995, J VIROL, V69, P2240, DOI 10.1128/JVI.69.4.2240-2247.1995; NAGAO M, 1990, JPN J CANCER RES, V81, P309, DOI 10.1111/j.1349-7006.1990.tb02566.x; Okamoto E, 1967, J PEDIATR SURG, V2, P437; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PASINI B, 1995, ONCOGENE, V11, P1737; PASSARGE E, 1997, PRINCIPLES PRACTICE, P1527; Patrone G, 1997, FEBS LETT, V419, P76, DOI 10.1016/S0014-5793(97)01435-X; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; PULITI A, 1993, CYTOGENET CELL GENET, V63, P102, DOI 10.1159/000133510; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCHUCHARDT A, 1995, ONCOGENE, V10, P641; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SZENTIRMAY Z, 1990, ONCOGENE, V5, P701; TAHIRA T, 1991, ONCOGENE, V6, P2333; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; Takaya K, 1996, J MOL MED-JMM, V74, P617, DOI 10.1007/s001090050065; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; WEISSHAAR B, 1988, J MOL BIOL, V202, P255, DOI 10.1016/0022-2836(88)90456-1; Zeschnigk M, 1997, HUM MOL GENET, V6, P387, DOI 10.1093/hmg/6.3.387	55	34	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2573	2583		10.1038/sj.onc.1202165	http://dx.doi.org/10.1038/sj.onc.1202165			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840920				2022-12-28	WOS:000077058900004
J	Yasuda, M; D'Sa-Eipper, C; Gong, XL; Chinnadurai, G				Yasuda, M; D'Sa-Eipper, C; Gong, XL; Chinnadurai, G			Regulation of apoptosis by a Caenorhabditis elegans BNIP3 homolog	ONCOGENE			English	Article						apoptosis; ceBNIP3; mitochondria; CED-9; CED-3	CELL-DEATH; BCL-2 FAMILY; CYTOCHROME-C; CED-4; PROTEINS; ENCODES; ACTIVATION; DISTINCT; PROTEASE	We have identified a C. elegans protein, ceBNIP3, homologous to the human BCL-2/EIB-19K interacting BCL-2 family pro-apoptotic protein BNIP3. In transiently transfected mammalian cells, ceBNIP3 complexes with CED-9, the worm homolog of BCL-2, CeBNIP3 also efficiently heterodimerizes with the cell death protease proCED-3 by direct binding via the prodomain, Transfection of ceBNIP3 and CED-3 results in enhanced proteolytic processing of the CED-3 zymogen and in cooperative induction of apoptosis. Coexpression of CED-9 suppresses the cooperative cell death induced by ceBNIP3 and CED-3, In cells coexpressing CED-9, ceBNIP3 and CED-3, all three proteins exist as a ternary complex suggesting that CED-9 may suppress cooperative apoptosis induced by CED-3 and ceBNIP3 by simultaneous complex formation with CED-3 and ceBNIP3, Our results suggest that ceBNIP3 may be a novel component of the C, elegans apoptosis paradigm and may initiate apoptosis by recruiting CED-3 to mitochondria and other cytoplasmic membranes.	St Louis Univ, Med Ctr, Inst Mol Virol, St Louis, MO 63110 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Med Ctr, Inst Mol Virol, 3681 Pk Ave, St Louis, MO 63110 USA.				NCI NIH HHS [CA-73803, CA-33616, R01 CA033616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073803, R01CA033616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hengartner MO, 1997, NATURE, V388, P714, DOI 10.1038/41873; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Theodorakis P, 1996, ONCOGENE, V12, P1707; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	25	29	37	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2525	2530		10.1038/sj.onc.1202467	http://dx.doi.org/10.1038/sj.onc.1202467			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824163	Bronze			2022-12-28	WOS:000076927300012
J	Rieger, J; Stander, M; Loschmann, PA; Heneka, M; Dichgans, J; Klockgether, T; Weller, M				Rieger, J; Stander, M; Loschmann, PA; Heneka, M; Dichgans, J; Klockgether, T; Weller, M			Synthesis and biological effects of NO in malignant glioma cells: modulation by cytokines including CD95L and TGF-beta, dexamethasone, and p53 gene transfer	ONCOGENE			English	Article						nitric oxide; glioma; CD 95 ligand; p53	NITRIC-OXIDE SYNTHASE; WILD-TYPE P53; ANTIBODY-MEDIATED APOPTOSIS; TUMOR-NECROSIS-FACTOR; TATA-BINDING PROTEIN; GROWTH-FACTOR-BETA; GLIAL-CELLS; ENDOTHELIAL-CELLS; BCL-2 EXPRESSION; L-ARGININE	Nitric oxide (NO) is thought to play an important role in neurotransmission, inflammation, and regulation of cell death in the mammalian brain. Here, we examined the synthesis and biological effects of NO in human malignant glioma cells. Exposure to cytokines such as interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha or interleukin (IL)-1 beta and lipopolysaccharide (LPS) induced NO synthesis in rat C6 and A172 human glioma cells, but not in LN-229, T98G or LN-18 human malignant glioma cells. Induced release of NO involved enhanced expression of inducible NO synthase (iNOS). Failure to detect NO release in the latter cell lines was not overcome by neutralization of endogenous TGF-beta or by coexposure to cytokines, LPS, and antioxidants. Apoptosis induced by CD95 ligand (CD95L) did not involve NO formation. Neither NOS inhibitors nor NO donators modulated CD95L-induced apoptosis. Dexamethasone (DEX)-mediated protection of glioma cells from CD95L-induced apoptosis was also independent of DEX effects on NO metabolism. DEX inhibited not only cytokine/ LPS-evoked NO release but also attenuated the toxicity of NO in three of five cell lines. Forced expression of temperature-sensitive p53 val(135) in C6 cells in either mutant or wild-type conformation inhibited cytokine/LPS-induced NO synthesis. Further, accumulation of p53 in both mutant or wild-type conformation protected glioma cells from the toxicity of exogenous NO, consistent with a gain of p53 function associated with p53 accumulation. We conclude that resistance to NO-dependent immune defense mechanisms may contribute to the malignant progression of human cancers with p53 alterations, notably those associated with the accumulation of mutant p53 protein.	Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72074 Tubingen, Germany; Univ Tubingen, Sch Med, Dept Neurol, Neuropharmacol Lab, D-72074 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72074 Tubingen, Germany.		Heneka, Michael/E-8072-2015	Heneka, Michael/0000-0003-4996-1630; Weller, Michael/0000-0002-1748-174X				ALBINA JE, 1993, J IMMUNOL, V150, P5080; ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; BERNATOWICZ A, 1995, J NEUROIMMUNOL, V60, P53, DOI 10.1016/0165-5728(95)00053-5; BIANCO FJ, 1995, AM J PATHOL, V146, P75; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Calmels S, 1997, CANCER RES, V57, P3365; COBBS CS, 1995, CANCER RES, V55, P727; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Ellie E, 1995, NEUROREPORT, V7, P294, DOI 10.1097/00001756-199512290-00070; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; FEHSEL K, 1995, J IMMUNOL, V155, P2858; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; FUJISAWA H, 1995, J NEUROCHEM, V64, P85; Fukuo K, 1996, HYPERTENSION, V27, P823, DOI 10.1161/01.HYP.27.3.823; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Kawase M, 1996, BRAIN RES, V738, P319, DOI 10.1016/S0006-8993(96)00924-9; KILBOURN RG, 1990, J NATL CANCER I, V82, P772, DOI 10.1093/jnci/82.9.772; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MESSMER UK, 1994, FEBS LETT, V355, P23; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MURATA J, 1995, INT J CANCER, V62, P743, DOI 10.1002/ijc.2910620616; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; RENSINGEHL A, 1995, EUR J IMMUNOL, V25, P2253, DOI 10.1002/eji.1830250821; Roth W, 1997, CANCER IMMUNOL IMMUN, V44, P55, DOI 10.1007/s002620050355; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SIMMONS ML, 1993, EUR J NEUROSCI, V5, P825, DOI 10.1111/j.1460-9568.1993.tb00934.x; SIMMONS ML, 1992, J NEUROCHEM, V59, P597; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TREPEL M, 1997, J NEUROONCOL; TREPEL M, 1997, IN PRESS LEUKEMIA; TREPEL M, 1996, J NEUROONCOL, V30, P95; VAN MEIR EG, 1994, CANCER RES, V54, P649; VIGNE P, 1993, BRAIN RES, V606, P332, DOI 10.1016/0006-8993(93)91003-B; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; Wagenknecht B, 1997, FEBS LETT, V409, P17, DOI 10.1016/S0014-5793(97)00468-7; WAGENKNECHT B, 1997, CELL PHYSIOL BIOCHEM, V19, P459; Weller M, 1997, NEUROL RES, V19, P459; Weller M, 1995, BRAIN RES REV, V21, P128, DOI 10.1016/0165-0173(95)00010-0; Weller M, 1997, INT J CANCER, V73, P707, DOI 10.1002/(SICI)1097-0215(19971127)73:5<707::AID-IJC16>3.3.CO;2-5; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; Weller M, 1997, NEUROLOGY, V48, P1704, DOI 10.1212/WNL.48.6.1704; WELLER M, 1995, CANCER RES, V55, P2936; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; WU CC, 1995, P NATL ACAD SCI USA, V92, P3473, DOI 10.1073/pnas.92.8.3473; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	53	31	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2323	2332		10.1038/sj.onc.1202154	http://dx.doi.org/10.1038/sj.onc.1202154			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811463				2022-12-28	WOS:000076723300006
J	Crook, T; Brooks, LA; Crossland, S; Osin, P; Barker, KT; Waller, J; Philp, E; Smith, PD; Yulug, I; Peto, J; Parker, G; Allday, MJ; Crompton, MR; Gusterson, BA				Crook, T; Brooks, LA; Crossland, S; Osin, P; Barker, KT; Waller, J; Philp, E; Smith, PD; Yulug, I; Peto, J; Parker, G; Allday, MJ; Crompton, MR; Gusterson, BA			p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours	ONCOGENE			English	Article						BRCA1; BRCA2; p53; mutation(s); breast; tumour; familial	WILD-TYPE CHROMOSOME; OVARIAN-CANCER; FAMILIAL BREAST; MICROSATELLITE INSTABILITY; GERMLINE MUTATIONS; POINT MUTATION; CELL-LINES; GENE; CARCINOMA; TUMORS	The status of p53 was investigated in breast tumours arising in germ-line carriers of mutant alleles of BRCA1 and BRCA2 and in a control series of sporadic breast tumours, p53 expression was detected in 20/26 (77%) BRCA1-, 10/22 (45%) BRCA2-associated and 25/72 (35%) grade-matched sporadic tumours, Analysis of p53 sequence revealed that the gene was mutant in 33/50 (66%) BRCA-associated tumours, whereas 7/20 (35%) sporadic grade-matched tumours contained p53 mutation (P<0.05), A number of the mutations detected in the BRCA-associated tumours have not been previously described in human cancer databases, whilst others occur extremely rarely. Analysis of additional genes, p16(INK4), Ki-ras and beta-globin revealed absence or very low incidence of mutations, suggesting that the higher frequency of p53 mutation in the BRCA-associated tumours does not reflect a generalized increase in susceptibility to the acquisition of somatic mutation. Furthermore, absence of frameshift mutations in the polypurine tracts present in the coding sequence of the TGF beta type II receptor (TGF beta IIR) and Bax implies that loss of function of BRCA1 or BRCA2 does not confer a mutator phenotype such as that found in tumours with microsatellite instability (MST), p21(Waf1) was expressed in BRCA-associated tumours regardless of p53 status and, furthermore, some tumours expressing wild-type p53 did not express detectable p21(Waf1). These data do not support, therefore, the simple model based on studies of BRCA-/- embryos, in which mutation of p53 in BRCA-associated tumours results in loss of p21(Waf1) expression and deregulated proliferation, Rather, they imply that proliferation of such tumours will be subject to multiple mechanisms of growth regulation.	Inst Canc Res, Haddow Labs, Sutton SM2 5NG, Surrey, England; London Sch Hyg & Trop Med, Div Clin Sci, London W1, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Sect Virol & Cell Biol, London W2 1PG, England	University of London; Institute of Cancer Research - UK; University of London; London School of Hygiene & Tropical Medicine; Imperial College London; Ludwig Institute for Cancer Research; Imperial College London	Crook, T (corresponding author), Inst Canc Res, Haddow Labs, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.		gusterson, barry a/D-3752-2009	Yulug, Isik/0000-0002-7577-2502	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; BOS JL, 1989, CANCER RES, V49, P4682; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Chung YJ, 1997, ONCOGENE, V15, P1719, DOI 10.1038/sj.onc.1201343; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; COLLINS N, 1995, ONCOGENE, V10, P1673; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Eisinger F, 1996, CANCER RES, V56, P471; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Gayther SA, 1997, NAT GENET, V15, P103, DOI 10.1038/ng0197-103; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; GLEBOV OK, 1994, CANCER RES, V54, P3703; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HUTCHINSON F, 1994, MUTAT RES-FUND MOL M, V309, P11, DOI 10.1016/0027-5107(94)90037-X; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Kelsell DP, 1996, LANCET, V347, P1554, DOI 10.1016/S0140-6736(96)90707-2; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Lakhani SR, 1997, LANCET, V349, P1505; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; PROSPERI MT, 1990, CANCER LETT, V51, P169, DOI 10.1016/0304-3835(90)90053-Z; QUESNEL B, 1995, BRIT J CANCER, V72, P351, DOI 10.1038/bjc.1995.337; REID TM, 1993, P NATL ACAD SCI USA, V90, P3904, DOI 10.1073/pnas.90.9.3904; ROCHLITZ CF, 1989, CANCER RES, V49, P357; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Visscher DW, 1996, DIAGN MOL PATHOL, V5, P187, DOI 10.1097/00019606-199609000-00007; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; XU L, 1994, CANCER RES, V54, P5262; Zhang HB, 1998, CELL, V92, P433, DOI 10.1016/S0092-8674(00)80936-8; ZHANG SY, 1994, CANCER RES, V54, P5050	44	147	150	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	1998	17	13					1681	1689		10.1038/sj.onc.1202106	http://dx.doi.org/10.1038/sj.onc.1202106			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796697	Green Published			2022-12-28	WOS:000076200100006
J	Wurfel, J; Rosel, M; Seiter, S; Claas, C; Herlevsen, M; Weth, R; Zoller, M				Wurfel, J; Rosel, M; Seiter, S; Claas, C; Herlevsen, M; Weth, R; Zoller, M			Metastasis-association of the rat ortholog of the human epithelial glycoprotein antigen EGP314	ONCOGENE			English	Article						rat; metastasis; epithelial glycoprotein; adhesion	CARCINOMA-ASSOCIATED ANTIGEN; CELL ADHESION MOLECULE; HUMAN-BREAST-CANCER; MONOCLONAL-ANTIBODY; EP-CAM; SURFACE GLYCOPROTEIN; COLORECTAL-CARCINOMA; MURINE HOMOLOG; COMPLEMENTARY-DNA; TUMOR INVASION	Screening for surface molecules expressed by metastasizing rat tumors had revealed evidence for metastasis-association of a molecule also expressed on epithelial cells. The similarity to the expression profile of the panepithelial glycoprotein EGP314 prompted us to isolate and sequence the gene and to explore functional features of the molecule in transfected tumor lines. The molecule D5.7A, named according to the antibody, D5.7, used for selection, indeed, is the ortholog of EGP314 with 92% and 80% identity to the murine and the human molecules. Like EGP314, D5.7A has a particular cleavage site, a small cleavage product being resolved under reducing conditions from the membrane anchored part of the molecule. Transfection of a low metastasizing fibrosarcoma, pheochromoblastoma and adenocarcinoma revealed that expression of D5.7A facilitates tumor progression. Depending on the origin of the tumor, D5.7A transfectants either metastasized via the lymphatic system (pheochromoblastoma, adenocarcinoma) or hematogeneously (fibrosarcoma). Particularly after proteolytic cleavage, D5.7A facilitated cell - cell adhesion and provided a proliferative signal upon crosslinking. Thus, the rat ortholog of EGP314 is involved in metastasis formation. Importantly, its functional activities apparently rely on proteolytic cleavage. These findings provide a first evidence on how a panepithelial marker can be involved in tumor progression.	German Canc Res Ctr, Dept Tumor Progress & Immune Def, D-69120 Heidelberg, Germany; Univ Hosp Homburg, Dept Dermatol, Homburg, Germany; Univ Karlsruhe, Dept Appl Genet, Karlsruhe, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Universitatsklinikum des Saarlandes; Helmholtz Association; Karlsruhe Institute of Technology	Zoller, M (corresponding author), German Canc Res Ctr, Dept Tumor Progress & Immune Def, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.			Wuerfel, Jens/0000-0002-0034-8053				Basak S, 1998, JNCI-J NATL CANCER I, V90, P691, DOI 10.1093/jnci/90.9.691; BEHRENS J, 1993, BREAST CANCER RES TR, V24, P175, DOI 10.1007/BF01833258; BERGSAGEL PL, 1992, J IMMUNOL, V148, P590; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BJORK P, 1993, J BIOL CHEM, V268, P24232; Borkowski TA, 1996, EUR J IMMUNOL, V26, P110, DOI 10.1002/eji.1830260117; BUMOL TF, 1988, HYBRIDOMA, V7, P407, DOI 10.1089/hyb.1988.7.407; Claas C, 1996, CELL GROWTH DIFFER, V7, P663; Claas C, 1998, J CELL BIOL, V141, P267, DOI 10.1083/jcb.141.1.267; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DELEIJ L, 1994, INT J CANCER, P60; EDWARDS DP, 1986, CANCER RES, V46, P1306; EVANS CW, 1992, CELL BIOL INT REP, V16, P1, DOI 10.1016/S0309-1651(06)80150-5; FAGERBERG J, 1995, P NATL ACAD SCI USA, V92, P4773, DOI 10.1073/pnas.92.11.4773; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FERNSTEN PD, 1990, CANCER RES, V50, P4656; FIDLER IJ, 1990, J NATL CANCER I, V82, P166, DOI 10.1093/jnci/82.3.166; FORNARO M, 1995, INT J CANCER, V62, P610, DOI 10.1002/ijc.2910620520; GLINSKY GV, 1993, CRIT REV ONCOL HEMAT, V14, P229, DOI 10.1016/1040-8428(93)90011-R; GOTTLINGER H, 1986, HYBRIDOMA, V5, pS29; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HELFRICH W, 1994, INT J CANCER, P70; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDO PA, 1993, CANCER IMMUNOL IMMUN, V36, P223, DOI 10.1007/BF01740903; LARSON LN, 1988, INT J CANCER, V42, P877, DOI 10.1002/ijc.2910420615; Li WP, 1997, J IMMUNOL, V159, P763; LINNENBACH AJ, 1993, MOL CELL BIOL, V13, P1507, DOI 10.1128/MCB.13.3.1507; LIOTTA LA, 1983, LAB INVEST, V49, P636; Litvinov SV, 1997, J CELL BIOL, V139, P1337, DOI 10.1083/jcb.139.5.1337; LITVINOV SV, 1994, J CELL BIOL, V125, P437, DOI 10.1083/jcb.125.2.437; Litvinov SV, 1996, AM J PATHOL, V148, P865; MALTHIERY Y, 1987, EUR J BIOCHEM, V165, P491, DOI 10.1111/j.1432-1033.1987.tb11466.x; Mareel M. M., 1991, MECH INVASION METAST; MAREEL MM, 1993, CRIT REV ONCOGENESIS, V4, P559; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MATZKU S, 1983, INVAS METAST, V3, P109; MATZKU S, 1989, CANCER RES, V49, P1294; MATZKU S, 1985, INVAS METAST, V5, P356; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MOMBURG F, 1987, CANCER RES, V47, P2883; Nelson AJ, 1996, EUR J IMMUNOL, V26, P401, DOI 10.1002/eji.1830260220; OSSOWSKI L, 1992, CANCER RES, V52, P6754; PEREZ MS, 1989, J IMMUNOL, V142, P3662; REISSER D, 1993, INT J CANCER, V53, P651, DOI 10.1002/ijc.2910530421; RemacleBonnet MM, 1997, INT J CANCER, V72, P835, DOI 10.1002/(SICI)1097-0215(19970904)72:5<835::AID-IJC21>3.0.CO;2-6; ROSEL M, 1998, IN PRESS ONCOGENE; ROSS AH, 1984, BIOCHEM BIOPH RES CO, V135, P297; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHON MP, 1993, INT J CANCER, V55, P988, DOI 10.1002/ijc.2910550619; SCHON MP, 1995, BRIT J DERMATOL, V133, P176, DOI 10.1111/j.1365-2133.1995.tb02613.x; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHETYE J, 1988, CANCER IMMUNOL IMMUN, V27, P154; SIMON B, 1990, P NATL ACAD SCI USA, V87, P2755, DOI 10.1073/pnas.87.7.2755; SPURR NK, 1986, INT J CANCER, V38, P631, DOI 10.1002/ijc.2910380503; STEIN R, 1994, INT J CANCER, P98; STRNAD J, 1989, CANCER RES, V49, P314; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; SZALA S, 1990, P NATL ACAD SCI USA, V87, P3542, DOI 10.1073/pnas.87.9.3542; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takes RP, 1997, ARCH OTOLARYNGOL, V123, P412; TANDON AK, 1990, CANCER RES, V50, P3317; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUBURA A, 1992, J CUTAN PATHOL, V19, P73, DOI 10.1111/j.1600-0560.1992.tb01562.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Zaloudik J, 1997, BRIT J CANCER, V76, P909, DOI 10.1038/bjc.1997.483; ZETTER BR, 1993, SEMIN CANCER BIOL, V4, P219; ZOLLER M, 1978, BRIT J CANCER, V37, P61, DOI 10.1038/bjc.1978.9; ZOLLER M, 1992, J NUCL MED, V33, P1366; ZORAS J, 1995, EUR UROL, V28, P251	74	23	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	1999	18	14					2323	2334		10.1038/sj.onc.1202542	http://dx.doi.org/10.1038/sj.onc.1202542			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327052				2022-12-28	WOS:000079595500004
J	Oki, E; Oda, S; Maehara, Y; Sugimachi, K				Oki, E; Oda, S; Maehara, Y; Sugimachi, K			Mutated gene-specific phenotypes of dinucleotide repeat instability in human colorectal carcinoma cell lines deficient in DNA mismatch repair	ONCOGENE			English	Article						hMSH2; hMSH6 (GTBP); hMLH1; microsatellite instability; RER	NONPOLYPOSIS COLON-CANCER; MICROSATELLITE INSTABILITY; REPEATED SEQUENCES; HMSH2 MUTATIONS; TUMOR-CELLS; HOMOLOG; MSH2; DEFECTS; HMLH1; ASSOCIATION	Mutations in DNA mismatch repair (MMR) genes in hereditary non-polyposis colon cancer (HNPCC) patients revealed the importance of MMR deficiency as a risk for carcinogenesis. Since diverse mutations occur in several MMR genes, the instability of repeat sequences dispersed in the genome, which are also governed by the MMR system, is a well used marker. However, the relationship between repeat sequence instability and MMR gene mutation in human cells has not been well defined mainly because precise systems to analyse repeat sequences have not been available. Using our newly developed system, we analysed alteration of dinucleotide repeats in human cell lines which harbour mutations in MMR genes. Among 24 subclones of DLD-1 cells (hMSH6(-)) only one had a dinucleotide repeat alteration in only one microsatellite locus, while LoVo cells (hMSH2(-)/hMSH6(-)) exhibited marked dinucleotide repeat instability (DRI). HCT116 cells, a hMLH1-mutant, showed an ultimate DRI phenotype. Interestingly, SW48 cells lacking hMLH1 expression also demonstrated DRI, albeit the extent of diversity being significantly lower than HCT116. These data suggest that the DRI phenotype in human cells is highly dependent on mutated MMR genes and on forms of mutation. The results of DRI analyses used to detect MMR-deficiency should be interpreted with caution.	Kyushu Univ Hosp, Ctr Canc, Fukuoka 8128582, Japan; Kyushu Univ, Fac Med, Dept Surg 2, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Oda, S (corresponding author), Kyushu Univ Hosp, Ctr Canc, Fukuoka 8128582, Japan.		Maehara, Yoshihiko/A-4867-2010					Ahuja N, 1997, CANCER RES, V57, P3370; Akiyama Y, 1997, CANCER RES, V57, P3920; Beck NE, 1997, HUM GENET, V99, P219, DOI 10.1007/s004390050343; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BOYER JC, 1995, CANCER RES, V55, P6063; BRANCH P, 1995, CANCER RES, V55, P2304; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Herfarth KKF, 1997, GENE CHROMOSOME CANC, V18, P42, DOI 10.1002/(SICI)1098-2264(199701)18:1<42::AID-GCC5>3.0.CO;2-1; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kowalski LD, 1997, GENE CHROMOSOME CANC, V18, P219, DOI 10.1002/(SICI)1098-2264(199703)18:3<219::AID-GCC8>3.0.CO;2-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1994, CANCER RES, V54, P4590; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; Oda S, 1997, NUCLEIC ACIDS RES, V25, P3415, DOI 10.1093/nar/25.17.3415; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Schug MD, 1997, NAT GENET, V15, P99, DOI 10.1038/ng0197-99; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thibodeau SN, 1996, CANCER RES, V56, P4836; Weber TK, 1997, CANCER RES, V57, P3798; Wu MS, 1997, CANCER LETT, V112, P161, DOI 10.1016/S0304-3835(96)04565-X; Wu Y, 1997, GENE CHROMOSOME CANC, V18, P269, DOI 10.1002/(SICI)1098-2264(199704)18:4<269::AID-GCC4>3.0.CO;2-Z	32	59	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2143	2147		10.1038/sj.onc.1202583	http://dx.doi.org/10.1038/sj.onc.1202583			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321739				2022-12-28	WOS:000079346200012
J	Zeng, WR; Watson, P; Lin, J; Jothy, S; Lidereau, R; Park, M; Nepveu, A				Zeng, WR; Watson, P; Lin, J; Jothy, S; Lidereau, R; Park, M; Nepveu, A			Refined mapping of the region of loss of heterozygosity on the long arm of chromosome 7 in human breast cancer defines the location of a second tumor suppressor gene at 7q22 in the region of the CUTL1 gene	ONCOGENE			English	Article						breast cancer; tumor suppressor gene; chromosome 7q22; CUTL1; human Cut homeobox gene; loss of heterozygosity	CCAAT DISPLACEMENT PROTEIN; HOMEODOMAIN PROTEIN; UTERINE LEIOMYOMATA; DROSOPHILA CUT; SUSCEPTIBILITY; EXPRESSION; PROMOTER; DELETION; 7Q31; LOCALIZATION	In breast cancer, loss of heterozygosity (LOH) has been described on the long arm of chromosome 7, at band q31, suggesting the presence of a tumor suppressor gene in this region, In this study, we have identified a second region of LOH on 7q, at band 7q22. Deletion of genetic material at 7q22 was found in all tumor types and grades and was associated with increased tumor size. The region of LOH at 7q22 in every case included one or more of three polymorphic markers that are located within the CUTL1 gene. LOH of 7q22 has also been documented in the case of human uterine leiomyomas (Zeng et al., 1997; Ishmad et al., 1997), Interestingly, in both leiomyomas and mammary tumors induced in transgenic mice expressing the Polyomavirus (PyV) large T (LT) antigen, immunocomplexes of CUTL1 and PyV LT antigen were detected (Webster et al., 1998), Altogether, genetic data in human breast cancer and biochemical analyses in breast tumors from transgenic mice suggest that CUTL1 is a candidate tumor suppressor gene.	McGill Univ, Mol Oncol Grp, Dept Med, Montreal, PQ, Canada; McGill Univ, Mol Oncol Grp, Dept Oncol, Montreal, PQ, Canada; Univ Manitoba, Fac Med, Dept Pathol & Physiol, Winnipeg, MB R3T 2N2, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Ctr Rene Huguenin, Lab Oncogenet, F-92211 St Cloud, France	McGill University; McGill University; University of Manitoba; University of Toronto; Rene Huguenin Hospital	Nepveu, A (corresponding author), McGill Univ, Mol Oncol Grp, Dept Med, Montreal, PQ, Canada.		/AAB-8315-2020	Watson, Peter/0000-0002-1642-0638				ANDRES V, 1992, DEVELOPMENT, V116, P321; Berker-Karauzum S, 1998, CANCER GENET CYTOGEN, V100, P114, DOI 10.1016/S0165-4608(96)00422-0; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; Bieche I, 1997, CLIN CANCER RES, V3, P1009; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; CALLAHAN R, 1993, CLIN CHIM ACTA, V217, P63, DOI 10.1016/0009-8981(93)90238-Y; CHAMPEME MH, 1995, GENE CHROMOSOME CANC, V12, P304, DOI 10.1002/gcc.2870120411; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; DAVE BJ, 1995, CANCER EPIDEM BIOMAR, V4, P743; DENG G, 1994, CANCER RES, V54, P499; Devilee P, 1997, GENE CHROMOSOME CANC, V18, P193; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; Fischer K, 1998, RECENT RESULTS CANC, V144, P46; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; HARADA R, 1994, J BIOL CHEM, V269, P2062; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; Ishwad CS, 1997, GENE CHROMOSOME CANC, V19, P156, DOI 10.1002/(SICI)1098-2264(199707)19:3<156::AID-GCC4>3.0.CO;2-X; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; Kerangueven F, 1997, CANCER RES, V57, P5469; Kristjansson AK, 1997, ANTICANCER RES, V17, P93; LARSSON C, 1990, GENE CHROMOSOME CANC, V2, P191, DOI 10.1002/gcc.2870020305; Lin JC, 1996, ONCOGENE, V13, P2001; LUNDGREN R, 1992, GENE CHROMOSOME CANC, V4, P16, DOI 10.1002/gcc.2870040103; LUNDGREN R, 1991, SCAND J UROL NEPHROL, P1; Mailly F, 1996, MOL CELL BIOL, V16, P5346; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; Mertens F, 1997, CANCER RES, V57, P2765; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILLER C, 1986, NATURE, V319, P783, DOI 10.1038/319783a0; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; OZISIK YY, 1993, CANCER GENET CYTOGEN, V71, P1, DOI 10.1016/0165-4608(93)90195-R; Quaggin SE, 1996, J BIOL CHEM, V271, P22624, DOI 10.1074/jbc.271.37.22624; SARGENT MS, 1994, CANCER GENET CYTOGEN, V77, P65, DOI 10.1016/0165-4608(94)90151-1; SATO T, 1990, CANCER RES, V50, P7184; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SolinasToldo S, 1996, CANCER RES, V56, P3803; STORTO PD, 1990, GENE CHROMOSOME CANC, V2, P300, DOI 10.1002/gcc.2870020408; Tougas L, 1996, CLIN INVEST MED, V19, P222; VALARCHE I, 1993, DEVELOPMENT, V119, P881; Watson PH, 1996, CAN MED ASSOC J, V155, P281; WATSON PH, 1993, J NATL CANCER I, V85, P902, DOI 10.1093/jnci/85.11.902; Webster MA, 1998, ONCOGENE, V16, P1963, DOI 10.1038/sj.onc.1201707; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xing YP, 1997, CANCER GENET CYTOGEN, V98, P69; YOON SO, 1994, J BIOL CHEM, V269, P18453; Zeng WR, 1997, ONCOGENE, V14, P2355, DOI 10.1038/sj.onc.1201076; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155	48	41	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	1999	18	11					2015	2021		10.1038/sj.onc.1202519	http://dx.doi.org/10.1038/sj.onc.1202519			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208423				2022-12-28	WOS:000079191300011
J	Laudet, V; Hanni, C; Stehelin, D; Duterque-Coquillaud, M				Laudet, V; Hanni, C; Stehelin, D; Duterque-Coquillaud, M			Molecular phylogeny of the ETS gene family	ONCOGENE			English	Article						phylogeny; ETS family; transcription factors; DNA binding domains	EWINGS-SARCOMA TRANSLOCATION; DNA-BINDING SPECIFICITIES; TRANSCRIPTION FACTOR PU.1; C-FOS; CHROMOSOMAL TRANSLOCATION; DOMAIN PROTEIN; FACTORS ELK-1; MURINE ETS-1; HOX GENES; EWS GENE	We have constructed a molecular phylogeny of the ETS gene family, By distance and parsimony analysis of the ETS conserved domains we show that the family containing so far 29 different genes in vertebrates can be divided into 13 groups of genes namely ETS, ER71, GABP, PEA3, ERG, ERF, ELK, DETS4, ELF, ESE, TEL, YAN, SPI, Since the three dimensional structure of the ETS domain has revealed a similarity with the winged-helix - turn- helix proteins, we used two of them (CAP and HSF) to root the tree. This allowed us to show that the family can be divided into five subfamilies: ETS, DETS4, ELF, TEL and SPI, The ETS subfamily comprises the ETS, ER71, GABP, PEA3, ERG, ERF and the ELK groups which appear more related to each other than to any other ETS family members. The fact that some members of these subfamilies were identified in early metazoans such as diploblasts and sponges suggests that the diversification of ETS family genes predates the diversification of metazoans. By the combined analysis of both the ETS and the PNT domains, which are conserved in some members of the family, we showed that the GABP group, and not the ERG group, is the one most closely related to the ETS group. We also observed that the speed of accumulation of mutations in the various genes of the family is highly variable, Noticeably, paralogous members of the ELK group exhibit strikingly different evolutionary speed suggesting that the evolutionary pressure they support is very different.	Ecole Normale Super Lyon, UMR 49 CNRS, F-69364 Lyon 07, France; Inst Biol Lille, CNRS UMR 319, F-59021 Lille, France; Univ Lyon 1, CGMC, UMR CNRS 5534, F-69962 Villeurbanne, France	Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Laudet, V (corresponding author), Ecole Normale Super Lyon, UMR 49 CNRS, 46 Allee Italie, F-69364 Lyon 07, France.			Duterque-Coquillaud, Martine/0000-0003-3943-5629				Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Averof M, 1997, CURR BIOL, V7, pR634, DOI 10.1016/S0960-9822(06)00321-6; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Bornemann D, 1996, DEVELOPMENT, V122, P1621; Buttice G, 1996, ONCOGENE, V13, P2297; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; Escriva H, 1997, P NATL ACAD SCI USA, V94, P6803, DOI 10.1073/pnas.94.13.6803; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; JEON IS, 1995, ONCOGENE, V10, P1229; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kasahara M, 1996, P NATL ACAD SCI USA, V93, P9096, DOI 10.1073/pnas.93.17.9096; Katsanis N, 1996, GENOMICS, V35, P101, DOI 10.1006/geno.1996.0328; Kherrouche Z, 1998, ONCOGENE, V16, P1357, DOI 10.1038/sj.onc.1201650; KLAMBT C, 1993, DEVELOPMENT, V117, P163; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LANDSMAN D, 1995, TRENDS BIOCHEM SCI, V20, P225, DOI 10.1016/S0968-0004(00)89021-0; Laudet V, 1997, J MOL ENDOCRINOL, V19, P207, DOI 10.1677/jme.0.0190207; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; Ohno S., 1970, EVOLUTION GENE DUPLI; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; PHILIPPE H, 1994, DEVELOPMENT, P15; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SETH A, 1990, ONCOGENE, V5, P1761; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; VERNIER P, 1995, TRENDS PHARMACOL SCI, V16, P375, DOI 10.1016/S0165-6147(00)89078-1; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	69	115	118	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1351	1359		10.1038/sj.onc.1202444	http://dx.doi.org/10.1038/sj.onc.1202444			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022817				2022-12-28	WOS:000078510900011
J	Perletti, GP; Marras, E; Concari, P; Piccinini, F; Tashjian, AH				Perletti, GP; Marras, E; Concari, P; Piccinini, F; Tashjian, AH			PKC delta acts as a growth and tumor suppressor in rat colonic epithelial cells	ONCOGENE			English	Article						PKC isoforms; colon cancer; src oncogene	PROTEIN-KINASE-C; PHORBOL ESTER; EPSILON; OVEREXPRESSION; FIBROBLASTS; ACTIVATION; ONCOGENE	We have analysed the expression of three calcium-independent isoforms of protein kinase C (PKC), PKC delta, PKC epsilon and PKC zeta, in an in vitro model of colon carcinogenesis consisting of the nontumorigenic rat colonic epithelial cell line D/WT, and a derivative src-transformed line D/src. While PKC zeta and PKC epsilon showed similar protein levels, PKC delta was markedly decreased in D/src cells when compared to the D/WT line. To assess whether down-regulation of PKC delta was causally involved in the neoplastic phenotype in D/src cells, we prepared a kinase-defective mutant of PKC delta, Stable transfection of this sequence caused morphological and growth changes characteristic of partial transformation in D/WT cells. Moreover, to test whether PKC delta was involved in growth control and transformation in this model, we over-expressed PKC delta in D/src cells. Transfected cells underwent marked growth and morphological modifications toward the D/WT phenotype, In a late stage in culture, transfected cells ceased to proliferate, rounded up and degenerated into multinucleated, giant-like cells, We conclude that PKC delta can reverse the transformed phenotype and act as a suppressor of cell growth in D/src cells, Moreover, our data show that downregulation of this isoenzyme of PKC may cooperate in the neoplastic transformation induced by the src oncogene in D/WT cells.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Univ Milan, Ist Farmacol, I-20129 Milan, Italy; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; University of Milan; Harvard University; Harvard Medical School	Tashjian, AH (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00002] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Blobe GC, 1996, CANCER SURV, V27, P213; CACACE AM, 1993, ONCOGENE, V8, P2095; Cacace AM, 1996, ONCOGENE, V13, P2517; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; JIANG YH, 1997, CARCINOGENESIS, V18, P31; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Perletti GP, 1996, INT J ONCOL, V9, P171; Perletti GP, 1998, ONCOGENE, V16, P3345, DOI 10.1038/sj.onc.1201871; Perletti GP, 1996, ONCOGENE, V12, P847; PORIES SE, 1993, GASTROENTEROLOGY, V104, P1346, DOI 10.1016/0016-5085(93)90343-B; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAEFFER WI, 1976, CANCER LETT, V1, P259; Ueffing M, 1997, ONCOGENE, V15, P2921, DOI 10.1038/sj.onc.1201477; Wang QJ, 1998, ONCOGENE, V16, P53, DOI 10.1038/sj.onc.1201507; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	20	75	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1251	1256		10.1038/sj.onc.1202408	http://dx.doi.org/10.1038/sj.onc.1202408			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022132				2022-12-28	WOS:000078510700015
J	Dunn, J; Garde, J; Dolan, K; Gosney, JR; Sutton, R; Meltzer, SJ; Field, JK				Dunn, J; Garde, J; Dolan, K; Gosney, JR; Sutton, R; Meltzer, SJ; Field, JK			Multiple target sites of allelic imbalance on chromosome 17 in Barrett's oesophageal cancer	ONCOGENE			English	Article						Barrett's adenocarcinoma; deletion mapping; chromosome 17; target regions	TUMOR-SUPPRESSOR GENE; EPITHELIAL OVARIAN-TUMORS; HUMAN BREAST CARCINOMAS; ESOPHAGEAL ADENOCARCINOMA; PROGNOSTIC VALUE; PROSTATE-CANCER; P53 MUTATIONS; FREQUENT LOSS; HETEROZYGOSITY; REGIONS	Twelve Barrett's adenocarcinomas have been analysed for the occurrence of allelic imbalance (LOH) on chromosome 17 using 41 microsatellite markers. This study provides evidence for 13 minimal regions of LOH, six on 17p and seven on 17q. Four of these centre in the vicinity of the known tumour suppressor genes (TSGs) TP53 (17p13.1), NF1 (17q11.2), BRCA1 (17q21.1), and a putative TSG (17p13.3), The tumours all displayed relatively small regions of LOH (1-10 cM), and in several tumours extensive regions of LOH were detected. One tumour displayed only two very small regions of LOH; 17p11.2 and 17p13.1. The frequency of allelic imbalance has been calculated based on the LOH encompassing only one minimal region, and based on all the LOH observations. By both evaluations the highest LOH frequencies were found for regions II (p53), III (17p13.1 centromeric to p53), IV (17p12), V (17p11.2) and VII (NF1, 17q11.2). Our data supports the existence of multiple TSGs on chromosome 17 and challenges the view that p53 is the sole target of LOH on 17p in Barrett's adenocarcinoma.	Univ Liverpool, Mol Genet & Oncol Grp, Liverpool L69 3BX, Merseyside, England; Thameside Gen Hosp, Dept Surg, Ashton Under Lyne OL6 9RW, Greater Manches, England; Univ Liverpool, Dept Pathol, Liverpool L69 3BX, Merseyside, England; Univ Liverpool, Dept Surg, Liverpool L69 3BX, Merseyside, England; Univ Maryland, Baltimore, MD 21201 USA; Vet Affairs Hosp, Baltimore, MD 21201 USA	University of Liverpool; University of Liverpool; University of Liverpool; University System of Maryland; University of Maryland Baltimore	Field, JK (corresponding author), Univ Liverpool, Mol Genet & Oncol Grp, Liverpool L69 3BX, Merseyside, England.		Sutton, Robert/I-3587-2016; Field, John K./AAD-5674-2020	Sutton, Robert/0000-0001-6600-562X; Field, John K./0000-0003-3951-6365				ABERLE H, 1995, P NATL ACAD SCI USA, V92, P6384, DOI 10.1073/pnas.92.14.6384; ALESSANDRA V, 1995, CANCER RES, V55, P2645; ALKASSPOOLES M, 1993, INT J CANCER, V54, P213, DOI 10.1002/ijc.2910540209; ATKIN NB, 1989, CANCER GENET CYTOGEN, V37, P229, DOI 10.1016/0165-4608(89)90053-8; Audrezet MP, 1996, HUM MUTAT, V7, P109, DOI 10.1002/(SICI)1098-1004(1996)7:2<109::AID-HUMU4>3.0.CO;2-7; Barrett MT, 1996, ONCOGENE, V12, P1873; Barrett MT, 1996, ONCOGENE, V13, P1867; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; BLOUNT PL, 1994, CANCER RES, V54, P2292; CAMERON AJ, 1995, GASTROENTEROLOGY, V109, P1541, DOI 10.1016/0016-5085(95)90642-8; CAMERON AJ, 1993, ENDOSCOPY, V25, P635, DOI 10.1055/s-2007-1010420; CAMERON AJ, 1992, GASTROENTEROLOGY, V103, P1241, DOI 10.1016/0016-5085(92)91510-B; Campomenosi P, 1996, CANCER EPIDEM BIOMAR, V5, P559; CASSON AG, 1994, AM J SURG, V167, P52, DOI 10.1016/0002-9610(94)90053-1; Chekmareva MA, 1997, PROSTATE, V33, P271; COGEN PH, 1992, AM J HUM GENET, V50, P584; CORNELIS RS, 1993, ONCOGENE, V8, P781; CORNELIS RS, 1994, CANCER RES, V54, P4200; CROPP CS, 1993, CANCER RES, V53, P5617; FENNERTY MB, 1993, ALIMENT PHARM THER, V7, P339; FILIPE MI, 1993, ENDOSCOPY, V25, P637, DOI 10.1055/s-2007-1010421; FLEJOU JF, 1994, PATHOL RES PRACT, V190, P1141, DOI 10.1016/S0344-0338(11)80440-1; FONG KM, 1995, CANCER RES, V55, P4268; FUTREAL PA, 1992, CANCER RES, V52, P2624; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; GAO X, 1995, ONCOGENE, V11, P1241; GLEESON CM, 1995, CANCER RES, V55, P3406; Gonzalez MV, 1997, J CLIN PATHOL, V50, P212, DOI 10.1136/jcp.50.3.212; GREENWALD BD, 1992, INT J ONCOL, V1, P271; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HUANG Y, 1993, CANCER RES, V53, P1889; HUANG Y, 1992, CANCER RES, V52, P6525; Kelsell DP, 1996, HUM MOL GENET, V5, P857, DOI 10.1093/hmg/5.6.857; Kerangueven F, 1997, ONCOGENE, V14, P339, DOI 10.1038/sj.onc.1200818; KIRCHWEGER R, 1994, INT J CANCER, V56, P193, DOI 10.1002/ijc.2910560208; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KRISHNADATH KK, 1995, EUR J GASTROEN HEPAT, V7, P81; MORI T, 1994, CANCER RES, V54, P1638; NAGAI MA, 1995, CANCER RES, V55, P112; NAKAMURA T, 1994, CANCER-AM CANCER SOC, V73, P1785, DOI 10.1002/1097-0142(19940401)73:7<1785::AID-CNCR2820730703>3.0.CO;2-0; NEIDERACHER D, 1997, GENES CHROM CANC, V18, P181; NESHAT K, 1994, GASTROENTEROLOGY, V106, P1589, DOI 10.1016/0016-5085(94)90415-4; Phelan CM, 1998, CANCER RES, V58, P1004; PHILLIPS N, 1993, INT J CANCER, V54, P85, DOI 10.1002/ijc.2910540115; PIERETTI M, 1995, HUM PATHOL, V26, P393, DOI 10.1016/0046-8177(95)90139-6; Plummer SJ, 1997, ONCOGENE, V14, P2339, DOI 10.1038/sj.onc.1201073; RISK JM, 1994, NAT GENET, V8, P319, DOI 10.1038/ng1294-319; SAITO H, 1993, CANCER RES, V53, P3382; SATO T, 1992, CANCER RES, V52, P1643; SAUNTER ER, 1995, J SURG ONCOL, V58, P269; SAXENA A, 1992, CANCER RES, V52, P6716; SCHULTZ DC, 1996, CANCER RES, V56, P2002; SEIZINGER BR, 1993, NAT GENET, V3, P97, DOI 10.1038/ng0293-97; Stein Hubert J., 1993, Dysphagia, V8, P276, DOI 10.1007/BF01354551; SWIFT A, 1995, BRIT J CANCER, V71, P995, DOI 10.1038/bjc.1995.191; VONBREVERN M, 1998, IN PRESS ONCOGENE; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wang TH, 1996, J FORMOS MED ASSOC, V95, P509; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Wertheim I, 1996, ONCOGENE, V12, P2147; White GRM, 1996, BRIT J CANCER, V74, P863, DOI 10.1038/bjc.1996.449; WRIGHT TA, 1994, EUR J GASTROEN HEPAT, V6, P656, DOI 10.1097/00042737-199408000-00003	63	31	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					987	993		10.1038/sj.onc.1202371	http://dx.doi.org/10.1038/sj.onc.1202371			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023674				2022-12-28	WOS:000078510600015
J	Joh, T; Hosokawa, Y; Suzuki, R; Takahashi, T; Seto, M				Joh, T; Hosokawa, Y; Suzuki, R; Takahashi, T; Seto, M			Establishment of an inducible expression system of chimeric MLL-LTG9 protein and inhibition of Hox a7, Hox b7 and Hox c9 expression by MLL-LTG9 in 32Dc13 cells	ONCOGENE			English	Article						translocation; 11q23; MLL; LTGB; Hox; leukemogenesis	ACUTE-LEUKEMIA; DROSOPHILA-TRITHORAX; 11Q23 TRANSLOCATIONS; ALL-1 GENE; POLYCOMB; PRODUCTS; MICE; MLL; ABNORMALITIES; HOMOLOG	The MLL (HRX/ALL-1 gene is frequently disrupted in infantile leukemias and therapy-related leukemias and fused to various translocation partner genes, We previously showed that chimeric MLL proteins localize in the nuclei in a fashion similar to that of MLL protein even if the partner gene encodes a cytoplasmic protein and indicated the importance of the IV-terminal portion of MLL common to various MLL translocations, This time we established an inducible expression system for chimeric MLL-LTG9 and truncated N-terminal MLL proteins (MLL-Zf(-)) in 32Dc13 cells. By utilizing this system, we were able to show inhibition of Hox a7, Hox b7 and Hox c9 genes' expression by induced MLL-LTG9 and MLL-Zf(-). Up-regulation of Hox a7, Hox b7 and Hox c9 was observed when 32Dc13 cells were cultured with granulocyte colony stimulating factor (G-CSF) in place of interleukin 3 and induction of MLL-LTG9 and MLL-Zf(-) was shown to suppress this upregulation. At the same time, expression of two mammalian Polycomb group genes, M33 and mel-18, which both reportedly affect Hox genes' expression, was not inhibited by MLL-LTG9 and MLL-Zf(-) induction. These results indicate that MLL has an important effect on the expression of at least some Hox genes in hematopoietic cells and suggest that inhibition of the proper expression of Hox genes by chimeric MLL proteins may dysregulate hematopoietic cell differentiation and proliferation, which then can lead to leukemogenesis.	Aichi Canc Ctr, Res Inst, Lab Chemotherapy, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Immunol Lab, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center; Aichi Cancer Center	Seto, M (corresponding author), Aichi Canc Ctr, Res Inst, Lab Chemotherapy, Nagoya, Aichi 4648681, Japan.			Suzuki, Ritsuro/0000-0002-5974-7614				ABE R, 1984, CANCER GENET CYTOGEN, V13, P121, DOI 10.1016/0165-4608(84)90053-0; Akasaka T, 1996, DEVELOPMENT, V122, P1513; Arakawa H, 1998, P NATL ACAD SCI USA, V95, P4573, DOI 10.1073/pnas.95.8.4573; Core N, 1997, DEVELOPMENT, V124, P721; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; IIDA S, 1993, ONCOGENE, V8, P3085; Joh T, 1997, ONCOGENE, V15, P1681, DOI 10.1038/sj.onc.1201332; Joh T, 1996, ONCOGENE, V13, P1945; KANEKO Y, 1986, BLOOD, V67, P484; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; LAWRENCE HJ, 1992, BLOOD, V80, P2445; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MAVILIO F, 1989, ONCOGENE, V4, P301; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, BLOOD, V77, P440; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SCHICHMAN SA, 1994, P NATL ACAD SCI USA, V91, P6236, DOI 10.1073/pnas.91.13.6236; SIMON J, 1992, DEVELOPMENT, V114, P493; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; Waring PM, 1997, CURR TOP MICROBIOL, V220, P1; YAMAMOTO K, 1993, ONCOGENE, V8, P479; YAMAMOTO K, 1993, ONCOGENE, V8, P2617; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	27	24	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1125	1130		10.1038/sj.onc.1202400	http://dx.doi.org/10.1038/sj.onc.1202400			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023690				2022-12-28	WOS:000078510600031
J	Feng, ZW; Joos, HJ; Vallan, C; Muhlbauer, R; Altermatt, HJ; Jaggi, R				Feng, ZW; Joos, HJ; Vallan, C; Muhlbauer, R; Altermatt, HJ; Jaggi, R			Apoptosis during castration-induced regression of the prostate is Fos dependent	ONCOGENE			English	Article						apoptosis; castration; c-Fos; prostate; transcription factor AP-1	PROGRAMMED CELL-DEATH; TRANSCRIPTION FACTOR AP-1; MAMMARY-GLAND INVOLUTION; RAT VENTRAL PROSTATE; C-FOS; GENE-EXPRESSION; GLUCOCORTICOID RECEPTOR; ANDROGEN ABLATION; TRANSGENIC MICE; IN-VIVO	Apoptotic cell death was shown to be accompanied or preceded by an elevated expression of the c-fos protooncogene and DNA binding activity of transcription factor AP-1. We used Fos-deficient mice to study the role of c-Fos during programmed cell death in the prostate. In normal mice apoptosis is induced in the prostate within 2-4 days after castration. Histological features of reduced secretory activity and morphological signs of programmed cell death become obvious. No apparent decrease in secretory activity and no epithelial cell death were observed in Fos-deficient animals after castration. Fragmentation of nuclear DNA was measured by in situ terminal transferase reaction. DNA fragmentation was observed in the prostate epithelium of control mice after castration whereas no similar fragmentation was found in Fos-deficient animals. After castration an AP-1 complex accumulated in the prostate of Fos deficient mice which mainly consists of FosB, Fra-2 and JunD whereas in control animals the AP-1 complex in addition contained c-Fos. Our data strongly suggest that c-Fos is required for programmed cell death of prostate epithelial cells.	Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore; Pathol Langgasse, CH-3012 Bern, Switzerland	University of Bern; Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Jaggi, R (corresponding author), Univ Bern, Dept Clin Res, Murtenstr 35, CH-3010 Bern, Switzerland.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; Bielke W, 1997, CELL DEATH DIFFER, V4, P114, DOI 10.1038/sj.cdd.4400220; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; COLOMBEL M, 1992, CANCER RES, V52, P4313; COLOMBEL M, 1995, ONCOGENE, V10, P1269; COLOMBEL M, 1993, AM J PATHOL, V143, P390; COLOMBEL MC, 1995, METHOD CELL BIOL, V46, P369; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; Foletta VC, 1996, IMMUNOL CELL BIOL, V74, P121, DOI 10.1038/icb.1996.17; FOLETTA VC, 1994, ONCOGENE, V9, P3305; FREEMAN SN, 1990, BIOCHEM J, V269, P189, DOI 10.1042/bj2690189; FURUYA Y, 1995, ENDOCRINOLOGY, V136, P1898, DOI 10.1210/en.136.5.1898; Gajate C, 1996, BIOCHEM BIOPH RES CO, V218, P267, DOI 10.1006/bbrc.1996.0047; GIANNAKIS C, 1991, BIOCHEM BIOPH RES CO, V181, P915, DOI 10.1016/0006-291X(91)91278-K; GONZALEZMARTIN C, 1992, DEV BRAIN RES, V68, P83, DOI 10.1016/0165-3806(92)90250-Z; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; Jehn BM, 1997, CRIT REV EUKAR GENE, V7, P179, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.100; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kueng P, 1997, J CELL BIOL, V139, P1851, DOI 10.1083/jcb.139.7.1851; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; Lund LR, 1996, DEVELOPMENT, V122, P181; MARTI A, 1994, ONCOGENE, V9, P1213; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; OSSOWSKI L, 1979, CELL, V16, P929, DOI 10.1016/0092-8674(79)90108-9; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; Preston GA, 1996, MOL CELL BIOL, V16, P211; RAFFO AJ, 1995, CANCER RES, V55, P4438; RENNIE PS, 1989, MOL ENDOCRINOL, V3, P703, DOI 10.1210/mend-3-4-703; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STRANGE R, 1992, DEVELOPMENT, V115, P49; Sukharev SA, 1997, CELL DEATH DIFFER, V4, P457, DOI 10.1038/sj.cdd.4400263; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; Zhang XJ, 1997, PROSTATE, V32, P16, DOI 10.1002/(SICI)1097-0045(19970615)32:1<16::AID-PROS3>3.0.CO;2-A	61	30	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2593	2600		10.1038/sj.onc.1202195	http://dx.doi.org/10.1038/sj.onc.1202195			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840922				2022-12-28	WOS:000077058900006
J	Cohen, SB; Nicol, R; Stavnezer, E				Cohen, SB; Nicol, R; Stavnezer, E			A domain necessary for the transforming activity of SnoN is required for specific DNA binding, transcriptional repression and interaction with TAF(II)110	ONCOGENE			English	Article						oncogene; repression; SnoN; transcription; transformation	THYROID-HORMONE RECEPTOR; ADENOVIRUS E1A PROTEIN; FUNCTIONAL-ANALYSIS; CDNA CLONES; GENE; ACTIVATION; SKI; GAL4; OVEREXPRESSION; IDENTIFICATION	sno is a member of the ski oncogene family and shares ski's ability to transform avian fibroblasts and induce muscle differentiation. Ski and Sno are nuclear proteins that form homodimers and heterodimers, Ski activates transcription of cellular and viral enhancers and we have identified a DNA binding site (GTCTAGAC) through which it represses transcription. In this work, we show that SnoN binds this site and represses transcription of reporters a with this binding site as an upstream element. Using fusions with the Gal4-DNA binding domain in a heterologous reporter assay, we identify a tripartite repression domain in SnoN, A 107 amino acid stretch of the SnoN repression domain, that contains two of the subdomains, is closely related to the minimal region of Ski required for transformation. The third subdomain is unique to SnoN, By analysing deletions involving each of the subdomains, we show that subdomains II and III are also required for DNA binding and cellular transformation. We provide evidence for a quenching mechanism of transcriptional repression by which subdomain II binds to TAF(II)11O.	Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	Case Western Reserve University; University System of Ohio; University of Cincinnati	Stavnezer, E (corresponding author), Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA.				NCI NIH HHS [CA43600] Funding Source: Medline; NIGMS NIH HHS [T32-GM08056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BOYER PL, 1993, ONCOGENE, V8, P457; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; Chen CMA, 1996, CELL, V86, P731, DOI 10.1016/S0092-8674(00)80148-8; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Fondell JD, 1996, MOL CELL BIOL, V16, P281; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GIVOL I, 1995, GENE, V156, P271, DOI 10.1016/0378-1119(95)00066-F; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HEYMAN HC, 1994, J BIOL CHEM, V269, P26996; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Liang SD, 1996, MOL CELL BIOL, V16, P3773; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LYONS GE, 1994, TRENDS CARDIOVAS MED, V4, P70, DOI 10.1016/1050-1738(94)90012-4; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; Mimura N, 1996, FEBS LETT, V397, P253, DOI 10.1016/S0014-5793(96)01165-9; Nicol R, 1998, J BIOL CHEM, V273, P3588, DOI 10.1074/jbc.273.6.3588; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; PearsonWhite S, 1997, NUCLEIC ACIDS RES, V25, P2930, DOI 10.1093/nar/25.14.2930; Pelzer T, 1996, DEV DYNAM, V205, P114; QIAN Z, 1995, J VIROL, V69, P4037, DOI 10.1128/JVI.69.7.4037-4044.1995; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; UM M, 1995, MOL CELL BIOL, V15, P5007; Zheng GX, 1997, ONCOGENE, V15, P459, DOI 10.1038/sj.onc.1201205	35	21	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2505	2513		10.1038/sj.onc.1202177	http://dx.doi.org/10.1038/sj.onc.1202177			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824161				2022-12-28	WOS:000076927300010
J	Magnusson, KP; Satalino, R; Qian, W; Klein, G; Wiman, KG				Magnusson, KP; Satalino, R; Qian, W; Klein, G; Wiman, KG			Is conversion of solid into more anoxic ascites tumors associated with p53 inactivation?	ONCOGENE			English	Article						hypoxia; tumor progression; alternative spliced p53; p53 mutation	ALTERNATIVELY SPLICED P53; DNA-BINDING; MESSENGER-RNA; PROTEIN; CELLS; MICE	Most solid tumors are unable to grow in the ascites form, unless selected by prolonged serial transfer of peritoneal fluid (Klein, 1955), Established ascites tumor cells grow under highly crowded, virtually anoxic conditions (Warburg and Hiepler, 1953), Hypoxia was recently identified as a powerful inducer of p53 dependent apoptosis (Graeber et nl,, 1996), We wished to examine whether the conversion of relatively well-vascularized solid mouse tumors into freely growing ascitic cell variants favors cell with mutated or deleted p53, We have sequenced exons 4-9 of p53 cDNA from two serially transplanted methylcholanthrene induced sarcomas (MCIM and MSWBS) that were available in the original solid and the gradually converted ascites form, We have also examined five additional solid tumors, four carcinomas and one sarcoma and six additional ascites tumors, five carcinomas and one sarcoma, Sequence analysis showed that all solid tumors carried exclusively wild type p53, Among the eight ascites tumors, five carried mutant p53 and three had only the wild type gene. In one of the two isogenic pairs, the original solid tumor line had only wild type, whereas the derived ascites line had only mutant p53, In the second pair, the solid tumor was mild type whereas the ascitic variant was heterozygous, The naturally occurring alternatively spliced p53 (p53as) mRNA was detected in all solid tumors, but not in five of the eight ascites tumors. Our findings indicate that conversion of solid into ascites tumors favors the selection of cell variants with mutated p53 and of cells that lack the alternatively spliced form of p53.	Karolinska Inst, Microbiol & Tumor Biol Ctr, S-17177 Stockholm, Sweden; CODE Genet, IS-110 Reykjavik, Iceland; Univ Bari, Dept Anat, I-70124 Bari, Italy	Karolinska Institutet; Universita degli Studi di Bari Aldo Moro	Magnusson, KP (corresponding author), Karolinska Inst, Microbiol & Tumor Biol Ctr, Box 280, S-17177 Stockholm, Sweden.		Magnusson, Kristinn/A-6479-2011; Magnusson, Kristinn P Pétur/X-4907-2019; Wiman, Klas/AAB-8399-2021	Magnusson, Kristinn/0000-0003-4528-6826; Magnusson, Kristinn P Pétur/0000-0003-4528-6826; Wiman, Klas/0000-0002-7113-524X				BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HELLSTROM U, 1978, EUR J CANCER, V14, P1265, DOI 10.1016/0014-2964(78)90234-7; KLEIN E, 1955, EXP CELL RES, V8, P188, DOI 10.1016/0014-4827(55)90056-2; KLEIN E, 1955, EXP CELL RES, V8, P213, DOI 10.1016/0014-4827(55)90057-4; KLEIN G, 1951, CANCER RES, V11, P466; KLEIN G, 1960, CANCER RES, V20, P1561; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; KUZUMAKI N, 1980, EUR J CANCER, V16, P1181, DOI 10.1016/0014-2964(80)90177-2; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LETTRE H, 1950, Z KREBSFORSCH, V57, P1; Provencher DM, 1997, TUMOR BIOL, V18, P167, DOI 10.1159/000218027; PURDOM L, 1958, NATURE, V181, P1586, DOI 10.1038/1811586a0; RINGERTZ N, 1957, J NATL CANCER I, V18, P173; Schumacher U, 1997, EXP MOL PATHOL, V64, P103, DOI 10.1006/exmp.1997.2213; THOMLINSON RH, 1955, BRIT J CANCER, V9, P539, DOI 10.1038/bjc.1955.55; Wang Q, 1997, J GEN VIROL, V78, P893, DOI 10.1099/0022-1317-78-4-893; WARBURG O, 1952, Z NATURFORSCH B, V7, P193; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WOLKOWICZ R, 1995, P NATL ACAD SCI USA, V92, P6842, DOI 10.1073/pnas.92.15.6842; Wu Y, 1997, P NATL ACAD SCI USA, V94, P8982, DOI 10.1073/pnas.94.17.8982; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x	25	21	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	1998	17	18					2333	2337		10.1038/sj.onc.1202149	http://dx.doi.org/10.1038/sj.onc.1202149			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811464				2022-12-28	WOS:000076723300007
J	Bolognese, F; Wasner, M; Lange-zu Dohna, C; Gurtner, A; Ronchi, A; Muller, H; Manni, I; Mossner, J; Piaggio, G; Mantovani, R; Engeland, K				Bolognese, F; Wasner, M; Lange-zu Dohna, C; Gurtner, A; Ronchi, A; Muller, H; Manni, I; Mossner, J; Piaggio, G; Mantovani, R; Engeland, K			The cyclin B2 promoter depends on NF-Y, a trimer whose CCAAT-binding activity is cell-cycle regulated	ONCOGENE			English	Article						NF-Y; cell cycle; cyclin B2	II GENE-TRANSCRIPTION; S-PHASE; GROWTH-REGULATION; BREAST-CANCER; A GENE; EXPRESSION; REPRESSION; PROTEIN; DIFFERENTIATION; ACTIVATION	Cyclin B2 is a regulator of p34cdc2 kinase, involved in G2/M progression of the cell cycle, whose gene is strictly regulated at the transcriptional level in cycling cells, The mouse promoter was cloned and three conserved CCAAT boxes were found. In this study, we analysed the mechanisms leading to activation of the cyclin B2 CCAAT boxes: a combination of (i) genomic footprinting, (ii) transfections with single, double and triple mutants, (iii) EMSAs with nuclear extracts, antibodies and NF-Y recombinant proteins and (iv) transfections with an NF-YA dominant negative mutant established the positive role of the three CCAAT sequences and proved that NF-Y plays a crucial role in their activation. NF-Y, an ubiquitous trimer containing histone fold subunits, activates several other promoters regulated during the cell cycle. To analyse the levels of NF-Y subunits in the different phases of the cycle, we separated MEL cells by elutriation, obtaining fractions >80% pure. The mRNA and protein levels of the histone-fold containing IVF-YB and NF-YC were invariant, whereas the NF-YA protein, but not its mRNA, was maximal in mid-S and decreased in G2/M. EMSA confirmed that the CCAAT-binding activity followed the amount of NF-YA, indicating that this subunit is limiting within the NF-Y complex, and suggesting that post-transcriptional mechanisms regulate NF-YA levels. Our results support a model whereby fine tuning of this activator is important for phase-specific transcription of CCAAT-containing promoters.	Univ Milan, Dipartimento Genet & Biol Microrganismi, I-20133 Milan, Italy; Univ Leipzig, Zentrum Innere Med, D-04103 Leipzig, Germany; Ctr Ricerca Sperimentale, Ist Regina Elena, I-00158 Rome, Italy; Ist Europeo Oncol, I-20141 Milan, Italy	University of Milan; Leipzig University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS European Institute of Oncology (IEO)	Mantovani, R (corresponding author), Univ Milan, Dipartimento Genet & Biol Microrganismi, Via Celoria 26, I-20133 Milan, Italy.		Engeland, Kurt/AAW-9965-2020; Piaggio, Giulia/AAD-7336-2022; gurtner, aymone/AAB-8843-2020; Piaggio, Giulia/J-7214-2018; Gurtner, Aymone/J-7217-2018; Manni, Isabella/ABH-6460-2020	Engeland, Kurt/0000-0003-3525-0440; gurtner, aymone/0000-0002-7661-9059; Piaggio, Giulia/0000-0003-2114-1892; Gurtner, Aymone/0000-0002-7661-9059; Manni, Isabella/0000-0003-4823-0596; Muller, Heiko/0000-0001-9873-3146	Telethon [1035] Funding Source: Medline	Telethon(Fondazione Telethon)		Baxevanis AD, 1998, NUCLEIC ACIDS RES, V26, P372, DOI 10.1093/nar/26.1.372; Bellorini M, 1997, GENE, V193, P119, DOI 10.1016/S0378-1119(97)00109-1; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DEY A, 1992, MOL CELL BIOL, V12, P3590, DOI 10.1128/MCB.12.8.3590; Eggers A, 1998, J BIOL CHEM, V273, P18499, DOI 10.1074/jbc.273.29.18499; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; FARINA A, INP RESS ONCOGENE; FILATOV D, 1995, J BIOL CHEM, V270, P25239, DOI 10.1074/jbc.270.42.25239; GONG JP, 1994, CANCER RES, V54, P4285; Good LF, 1996, BIOL SIGNAL, V5, P163; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Huet X, 1996, MOL CELL BIOL, V16, P3789; INOSTROZA JA, 1992, CELL, V70, P477; Isaacs RJ, 1996, J BIOL CHEM, V271, P16741, DOI 10.1074/jbc.271.28.16741; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Kim EC, 1997, CELL GROWTH DIFFER, V8, P1329; Kishimoto T, 1997, Prog Cell Cycle Res, V3, P241; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LI XY, 1992, J BIOL CHEM, V267, P8984; Liberati C, 1998, J BIOL CHEM, V273, P16880, DOI 10.1074/jbc.273.27.16880; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Liu QQ, 1998, CIRC RES, V82, P251; Lu CC, 1996, VIROLOGY, V225, P387, DOI 10.1006/viro.1996.0613; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; MARZIALI G, IN PRESS; Mermelstein F, 1996, GENE DEV, V10, P1033, DOI 10.1101/gad.10.8.1033; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PIAGGIO G, 1995, EXP CELL RES, V216, P396, DOI 10.1006/excr.1995.1050; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; vanGinkel PR, 1997, J BIOL CHEM, V272, P18367, DOI 10.1074/jbc.272.29.18367; VIVILLE S, 1991, J IMMUNOL, V146, P3211; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Zwicker J, 1997, NUCLEIC ACIDS RES, V25, P4926, DOI 10.1093/nar/25.24.4926; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	52	106	109	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1845	1853		10.1038/sj.onc.1202494	http://dx.doi.org/10.1038/sj.onc.1202494			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086339				2022-12-28	WOS:000079090000008
J	Guo, XYD; Balague, C; Wang, T; Randhawa, G; Yuan, ZM; Bachier, C; Greenberger, J; Arlinghaus, R; Kufe, D; Deisseroth, AB				Guo, XYD; Balague, C; Wang, T; Randhawa, G; Yuan, ZM; Bachier, C; Greenberger, J; Arlinghaus, R; Kufe, D; Deisseroth, AB			The presence of the Rb c-box peptide in the cytoplasm inhibits p210(bcr-abl) transforming function	ONCOGENE			English	Article						CML; kinases; oncogenes; leukemia; suppressor genes	ABL TYROSINE KINASE; CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL; HEMATOPOIETIC-CELLS; GENE-PRODUCT; ACTIVATION; ONCOGENE; BCR/ABL; DNA; BINDING	In order to test if the carboxyl terminal polypeptide of the Retinoblastoma (Rb) tumor suppressor protein, could be used to suppress the growth factor-independent growth phenotype of p210(bcr-abl) positive myeloid cells, we introduced a truncated form of the 3' end of the Rb cDNA encoding its last 173 amino acid residues (Rb C-box) which localize into the cytoplasm where the p210(bcr-abl) transforming protein is found, into myeloid cells (32D) which depends on the p210(bcr-abl) protein for IL3 growth factor-independent growth (32D-p210). The expression of the plasmid vectors carrying the Rb C-box cDNAs was shown to inhibit the abl tyrosine specific protein kinase activity of the p210(bcr-abl) oncoprotein and to suppress the IL3-independent growth phenotype of the 32D-p210 cells, The Rb C-box polypeptides did not suppress the growth of the untransfected 32D parental cell line in methylcellulose in the presence of IL3-conditioned medium, These results suggest that the cytoplasmic localization of the p210(bcr-abl) allows it to escape the effect of intranuclear proteins such as Rb which negatively regulate the p145(c-abl) kinase.	Yale Univ, Sch Med, Yale Canc Ctr, Dept Internal Med,Med Oncol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Yale Canc Ctr, Gene Therapy Program, New Haven, CT 06520 USA; Baxter Hlth Care Corp, Round Lake, IL USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Yale University; Yale University; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Dana-Farber Cancer Institute	Deisseroth, AB (corresponding author), Yale Univ, Sch Med, Yale Canc Ctr, Dept Internal Med,Med Oncol Sect, WWW221,333 Cedar St, New Haven, CT 06520 USA.				NCI NIH HHS [P01 CA55164, P01 CA49639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055164, P01CA049639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; GALE RP, 1984, P NATL ACAD SCI-BIOL, V81, P5648, DOI 10.1073/pnas.81.18.5648; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Henderson YC, 1997, CLIN CANCER RES, V3, P145; Jain SK, 1997, ONCOGENE, V14, P2217, DOI 10.1038/sj.onc.1201049; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1988, ONCOGENE RES, V3, P293; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588; ZHANG W, 1994, ONCOGENE, V9, P2513	24	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	1999	18	8					1589	1595		10.1038/sj.onc.1202479	http://dx.doi.org/10.1038/sj.onc.1202479			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102629				2022-12-28	WOS:000078770700009
J	Okamoto, I; Kawano, Y; Tsuiki, H; Sasaki, J; Nakao, M; Matsumoto, M; Suga, M; Ando, M; Nakajima, M; Saya, H				Okamoto, I; Kawano, Y; Tsuiki, H; Sasaki, J; Nakao, M; Matsumoto, M; Suga, M; Ando, M; Nakajima, M; Saya, H			CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration	ONCOGENE			English	Article						CD44; cleavage; metalloprotease; hyaluronic acid; tumor cell migration	LYMPHOCYTE HOMING RECEPTOR; MATRIX METALLOPROTEINASE; HYALURONATE BINDING; CARCINOMA-CELLS; MELANOMA-CELLS; CYTOPLASMIC DOMAIN; GLYCOPROTEIN CD44; BREAST-CARCINOMA; COLON CARCINOMAS; SPLICED EXONS	CD44 is a cell surface receptor for hyaluronate, a component of the extracellular matrix (ECM), Although CD44 has been implicated in tumor invasion and metastasis, the molecular mechanisms remain to be elucidated. Here we find that CD44 expressed in cancer cells is cleaved at the membrane-proximal region of the ectodomain and the membrane-bound cleavage product can be detected using an antibody against the cytoplasmic domain of CD44, Furthermore, we report that CD44 cleavage is mediated by a membrane-associated metalloprotease expressed in cancer cells, A tissue inhibitor of metalloproteases-l (TIMP-1), as well as metalloprotease inhibitor's, inhibit CD44 cleavage in the cell-free assay. Contrary, serine protease inhibitors enhance CD44 cleavage, and the enhancement can be prevented by pretreatment with a metalloprotease inhibitor. Thus, CD44 cleavage is regulated by an intricate balance between some proteases and their inhibitors. Interestingly, treatment with the metalloprotease blocker l,10-phenanthroline, which strongly prevent the CD44 cleavage, suppressed RERF-LC-OK lung cancer cell migration on a hyaluronate substrate, but not on several other substrates. These results suggest that CD44 cleavage plays a critical role in an efficient cell-detachment from a hyaluronate substrate during the cell migration and consequently promotes CD44-mediated cancer cell migration. Our present data indicate that CD44, not only ECM per se, is one of the targets of pericellular proteolysis involved in tumor invasion and metastasis.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Novartis Pharma KK, Oncol Res, Takarazuka, Hyogo 6650042, Japan	Kumamoto University; Novartis	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.		Saya, Hideyuki/J-4325-2013					ALBELDA SM, 1993, LAB INVEST, V68, P4; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTOLAZZI A, 1995, J CELL SCI, V108, P1723; Bartolazzi A, 1996, J CELL BIOL, V132, P1199, DOI 10.1083/jcb.132.6.1199; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BAZIL V, 1994, J IMMUNOL, V152, P1314; BENNETT KL, 1995, J CELL BIOL, V131, P1623, DOI 10.1083/jcb.131.6.1623; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Friedl P, 1997, CANCER RES, V57, P2061; Goebeler M, 1996, J CELL SCI, V109, P1957; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; Gunthert AR, 1996, J CELL BIOL, V134, P1089, DOI 10.1083/jcb.134.4.1089; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; ISACKE CM, 1994, J CELL SCI, V107, P2353; Iwamura T, 1997, CANCER RES, V57, P1206; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LESLEY J, 1995, J EXP MED, V182, P431, DOI 10.1084/jem.182.2.431; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; Okamoto I, 1998, J NATL CANCER I, V90, P307, DOI 10.1093/jnci/90.4.307; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Puente XS, 1996, CANCER RES, V56, P944; PURE E, 1995, J EXP MED, V181, P55, DOI 10.1084/jem.181.1.55; Sasaki J, 1998, INT J ONCOL, V12, P525; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Sheng Y, 1997, INT J CANCER, V73, P850, DOI 10.1002/(SICI)1097-0215(19971210)73:6<850::AID-IJC15>3.0.CO;2-8; Sleeman J, 1996, J CELL BIOL, V135, P1139, DOI 10.1083/jcb.135.4.1139; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; Takahashi K, 1995, ONCOGENE, V11, P2223; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Talbot DC, 1996, EUR J CANCER, V32A, P2528; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; TANABE KK, 1993, MOL CARCINOGEN, V7, P212, DOI 10.1002/mc.2940070403; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; ToyamaSorimachi N, 1997, J BIOL CHEM, V272, P26714, DOI 10.1074/jbc.272.42.26714; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x	49	199	203	1	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1435	1446		10.1038/sj.onc.1202447	http://dx.doi.org/10.1038/sj.onc.1202447			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050880				2022-12-28	WOS:000078651600005
J	Balasubramanian, S; Kim, KH; Ahmad, N; Mukhtar, H				Balasubramanian, S; Kim, KH; Ahmad, N; Mukhtar, H			Activation of telomerase and its association with G1-phase of the cell cycle during UVB-induced skin tumorigenesis in SKH-1 hairless mouse	ONCOGENE			English	Article						telomerase; cell cycle; cyclin; cyclin dependent kinase; cyclin dependent kinase inhibitor; skin carcinogenesis	HUMAN BREAST-CANCER; HEMATOPOIETIC-CELLS; IMMORTAL CELLS; CDK INHIBITOR; OVEREXPRESSION; DIFFERENTIATION; CARCINOGENESIS; AMPLIFICATION; PROGRESSION; P15(INK4B)	Telomerase is a ribonucleoprotein enzyme that adds hexanucleotide repeats TTAGGG to the ends of chromosomes, Telomerase activation is known to play a crucial role in cell-immortalization and carcinogenesis. Telomerase is shown to have a correlation with cell cycle progression, which is controlled by the regulation of cyclins, cyclin dependent kinases (cdks) and cyclin dependent kinase inhibitors (cdkis), Abnormal expression of these regulatory molecules may cause alterations in cell cycle with uncontrolled cell growth, a universal feature of neoplasia, Skin cancer is the most prevalent form of cancer in humans and the solar UV radiation is its major cause. Here, we investigated modulation in telomerase activity and protein expression of cell cycle regulatory molecules during the development of UVB-induced tumors in SKH-1 hairless mice, The mice were exposed to 180 mjoules/cm(2) UVB radiation, thrice weekly for 24 weeks. The animals were sacrificed at 4 week intervals and the studies were performed in epidermis, Telomerase activity was barely detectable in the epidermis of non-irradiated mouse. UVB exposure resulted in a progressive increase in telomerase activity starting from the 4th week of exposure. The increased telomerase activity either persisted or further increased with the increased exposure, In papillomas and carcinomas the enzyme activity was comparable and was 45-fold higher than in the epidermis of control mice. Western blot analysis showed an upregulation in the protein expression of cyclin D1 and cyclin E and their regulatory subunits cdk4 and cdk2 during the course of UVB exposure and in papillomas and carcinomas. The protein expression of cdk6 and ckis viz, p16/Ink4A, p21/Waf1 and p27/Kip1 did not show any significant change in WE exposed skin, but significant upregulation was observed both in papillomas and carcinomas. The results suggest that telomerase activation may be involved in UVB-induced tumorigenesis in mouse skin and that increased telomerase activity may be associated with G1 phase of the cell cycle.	Case Western Reserve Univ, Dept Dermatol, Cleveland, OH 44106 USA	Case Western Reserve University	Mukhtar, H (corresponding author), Case Western Reserve Univ, Dept Dermatol, 11100 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [P30CA043703, R01CA051802, P01CA048735] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 43703, R01 CA 51802, P01 CA 48735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balasubramanian S, 1998, BIOCHEM BIOPH RES CO, V243, P744, DOI 10.1006/bbrc.1998.8172; BEDNAREK A, 1995, CANCER RES, V55, P4566; Bednarek AK, 1997, MOL CARCINOGEN, V20, P329, DOI 10.1002/(SICI)1098-2744(199712)20:4<329::AID-MC1>3.0.CO;2-E; BIANCHI AB, 1993, ONCOGENE, V8, P1127; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CHADENEAU C, 1995, ONCOGENE, V11, P893; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DAS M, 1987, CANCER RES, V47, P760; Engelhardt M, 1997, BLOOD, V90, P182; GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Katiyar SK, 1997, JNCI-J NATL CANCER I, V89, P556, DOI 10.1093/jnci/89.8.556; KAWAMATA N, 1995, CANCER RES, V55, P2266; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Landberg G, 1997, CANCER RES, V57, P549; LEACH FS, 1993, CANCER RES, V53, P1986; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; Pandita TK, 1996, ONCOGENE, V13, P1423; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SGAMBATO A, 1995, CARCINOGENESIS, V16, P2193, DOI 10.1093/carcin/16.9.2193; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; Taylor RS, 1996, J INVEST DERMATOL, V106, P759, DOI 10.1111/1523-1747.ep12345811; Tron VA, 1996, AM J PATHOL, V149, P1139; Ueda M, 1997, CANCER RES, V57, P370; WHITAKER NJ, 1995, ONCOGENE, V11, P971; Yashima K, 1998, CLIN CANCER RES, V4, P229; Yasumoto S, 1996, ONCOGENE, V13, P433; Yoshimi N, 1996, MOL CARCINOGEN, V16, P1, DOI 10.1002/(SICI)1098-2744(199605)16:1<1::AID-MC1>3.0.CO;2-N; Zhang T, 1997, CANCER RES, V57, P169; ZHOU P, 1995, ONCOGENE, V11, P571	39	25	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1297	1302		10.1038/sj.onc.1202417	http://dx.doi.org/10.1038/sj.onc.1202417			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022811				2022-12-28	WOS:000078510900005
J	Bardelli, A; Basile, ML; Audero, E; Giordano, S; Wennstrom, S; Menard, S; Comoglio, PM; Ponzetto, C				Bardelli, A; Basile, ML; Audero, E; Giordano, S; Wennstrom, S; Menard, S; Comoglio, PM; Ponzetto, C			Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis	ONCOGENE			English	Article						Met-mediated metastasis; met signaling; PI 3-kinase; Grb2; Ras	HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; SCATTER FACTOR-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; BINDING-SITE; DOCKING PROTEIN; TPR-MET; TRANSFORMATION; ONCOGENE; MOTILITY	The Met tyrosine kinase - the HGF receptor - induces cell transformation and metastasis when constitutively activated. Met signaling is mediated by phosphorylation of two carboxy-terminal tyrosines which act as docking sites for a number of SH2-containing molecules. These include Grb2 and p85 which couple the receptor, respectively, with Ras and PI 3-kinase, We previously showed that a Met mutant designed to obtain preferential coupling with Grb2 (Met(2xGrb2)) is permissive for motility, increases transformation, but - surprisingly - is impaired in causing invasion and metastasis. In this work, we used Met mutants optimized for binding either p85 alone (Met(2xPI3K)) Or p85 and Grb2 (Met(P13/Grb2)) to evaluate the relative importance of Pas and PI 3-kinase as downstream effecters of Met. Met(2xPI3K) was competent in eliciting motility, but not transformation, invasion, or metastasis. Conversely, Met(PI3K/Grb2) induced motility, transformation, invasion and metastasis as efficiently as wild type Met. Furthermore, the expression of constitutively active PI 3-kinase in cells transformed by the Met(2xGrb2) mutant, fully rescued their ability to invade and metastasize. These data point to a central role for PI 3-kinase in Met-mediated invasiveness, and indicate that simultaneous activation of Ras and PI 3-kinase is required to unleash the Met metastatic potential.	Univ Turin, Sch Med, Dept Biomed Sci & Oncol, I-10126 Turin, Italy; Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, I-10126 Turin, Italy; Imperial Canc Res Fund, London WC2A 3PX, England; Ist Nazl Tumori, I-20133 Milan, Italy	University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Cancer Research UK; Fondazione IRCCS Istituto Nazionale Tumori Milan	Ponzetto, C (corresponding author), Univ Turin, Sch Med, Dept Biomed Sci & Oncol, Cso Massimo dAzeglio 52, I-10126 Turin, Italy.		Giordano, Silvia/J-9858-2018; menard, sylvie mm/C-7940-2011; BARDELLI, Alberto/J-9721-2018	Giordano, Silvia/0000-0003-1854-1086; BARDELLI, Alberto/0000-0003-1647-5070; Comoglio, Paolo/0000-0002-7056-5328; Audero, Enrica/0000-0002-6138-244X				Bardelli A, 1997, BBA-REV CANCER, V1333, pM41, DOI 10.1016/S0304-419X(97)00026-7; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Besser D, 1997, ONCOGENE, V14, P705, DOI 10.1038/sj.onc.1200879; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DERMAN MP, 1996, AM J PHYSIOL, V268, pF1211; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; Fischer J, 1998, ONCOGENE, V17, P733, DOI 10.1038/sj.onc.1201983; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; LAROSE L, 1995, J BIOL CHEM, V270, P3858, DOI 10.1074/jbc.270.8.3858; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SHAW LM, 1972, CELL, V9194, P97; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; Sporken R, 1997, MRS INTERNET J N S R, V2, part. no.; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	44	59	66	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	1999	18	5					1139	1146		10.1038/sj.onc.1202607	http://dx.doi.org/10.1038/sj.onc.1202607			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022119				2022-12-28	WOS:000078510700002
J	Biden, KG; Simms, LA; Cummings, M; Buttenshaw, R; Schoch, E; Searle, J; Gobe, G; Jass, JR; Meltzer, SJ; Leggett, BA; Young, J				Biden, KG; Simms, LA; Cummings, M; Buttenshaw, R; Schoch, E; Searle, J; Gobe, G; Jass, JR; Meltzer, SJ; Leggett, BA; Young, J			Expression of bcl-2 protein is decreased in colorectal adenocarcinomas with microsatellite instability	ONCOGENE			English	Article						bcl-2; apoptosis; microsatellite instability; colorectal adenocarcinoma	PROGRAMMED CELL-DEATH; C-MYB; CANCER; P53; APOPTOSIS; GENE; SURVIVAL; COLON; POLYMORPHISM; INHIBITION	Bcl-2 is known to inhibit apoptosis and is thought to play a role in colorectal tumour development. Studies of the promoter region of bcl-2 have indicated the presence of a p53 responsive element which downregulates bcl-2 expression, Since p53 is commonly mutated in colorectal cancers, but rarely in those tumours showing microsatellite instability (MSI), the aim of this study was to examine the relationship of bcl-2 protein expression to MSI, as well as to other clinicopathological and molecular variables, in colorectal adenocarcinomas. Expression of bcl-2 was analysed by immunohistochemistry in 71 colorectal cancers which had been previously assigned to three classes depending upon their levels of MSI. MSI-high tumours demonstrated instability in three or more of six microsatellite markers tested, MSI-low tumours in one or two of six, and MSI-null in none of six, Bcl-2 expression in tumours was quantified independently by two pathologists and assigned to one of five categories, with respect to the number of cells which showed positive staining: 0, up to 5%; 1, 6-25%; 2, 26-50%; 3, 51-75%; and 4, greater than or equal to 76%, Bcl-2 negative tumours were defined as those with a score of 0. Bcl-2 protein expression was tested for association with clinicopathological stage, differentiation level, tumour site, age, sex, survival, evidence of p53 inactivation and MSI level, A significant association was found between bcl-2 expression and patient survival (P = 0.012, Gehan Wilcoxon test). Further, a significant reciprocal relationship was found between bcl-2 expression and the presence of MSI (P = 0.012, Wilcoxon rank sum test). We conclude that bcl-2 expressing colorectal cancers are more likely to be MSI-null, and to be associated with improved patient survival.	Royal Brisbane Hosp Fdn Clin Res Ctr, Conjoint Gastroenterol Lab, Brisbane, Qld, Australia; Royal Brisbane Hosp, Dept Pathol, Brisbane, Qld 4029, Australia; Univ Queensland, Dept Pathol, Brisbane, Qld, Australia; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Greenbaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Grad Program Mol & Cell Biol, Baltimore, MD 21201 USA; Baltimore Vet Affairs Med Ctr, Baltimore, MD 21201 USA	Royal Brisbane & Women's Hospital; University of Queensland; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center	Biden, KG (corresponding author), RBHRF, Clin Res Ctr, Conjoint Gastroenterol Lab, Bancroft Ctr, 300 Herston Rd, Brisbane, Qld 4029, Australia.		Gobe, Glenda C/G-2315-2010; Cummings, Margaret/B-5747-2011; Young, Joanne P/H-7774-2014; Young, Joanne P/B-9981-2011; Leggett, Barbara A/D-3579-2011	Cummings, Margaret/0000-0002-7657-0240; Leggett, Barbara/0000-0003-2062-7380; Simms, Lisa/0000-0002-5387-7397	NATIONAL CANCER INSTITUTE [R01CA067497, R01CA077057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER; NCI NIH HHS [CA67497, CA77057] Funding Source: Medline; NIDDK NIH HHS [DK47717] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEDI A, 1995, CANCER RES, V55, P1811; BJERKESET T, 1987, DIS COLON RECTUM, V30, P934, DOI 10.1007/BF02554279; BRONNER MP, 1995, AM J PATHOL, V146, P20; Cottu PH, 1996, ONCOGENE, V13, P2727; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; HAGUE A, 1994, ONCOGENE, V9, P3367; HENRIKSEN R, 1995, BRIT J CANCER, V72, P1324, DOI 10.1038/bjc.1995.509; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Jass JR, 1998, GUT, V42, P673, DOI 10.1136/gut.42.5.673; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; Kaklamanis L, 1996, J PATHOL, V179, P10; KASTAN MB, 1991, CANCER RES, V51, P6304; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lukish JR, 1998, ANN SURG, V227, P51, DOI 10.1097/00000658-199801000-00008; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4976, DOI 10.1073/pnas.88.11.4976; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MIYASHITA T, 1994, CANCER RES, V54, P3131; OFNER D, 1995, BRIT J CANCER, V72, P981, DOI 10.1038/bjc.1995.446; OLSCHWANG S, 1991, HUM GENET, V86, P369; PIETENPOL JA, 1994, CANCER RES, V54, P3714; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; Simms LA, 1998, ONCOGENE, V17, P2003, DOI 10.1038/sj.onc.1202109; Simms LA, 1997, ONCOGENE, V14, P2613, DOI 10.1038/sj.onc.1201094; SINICROPE FA, 1995, CANCER RES, V55, P237; Sun XF, 1996, APMIS, V104, P35, DOI 10.1111/j.1699-0463.1996.tb00683.x; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thompson MA, 1997, ONCOGENE, V14, P1715, DOI 10.1038/sj.onc.1201007; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Vairo G, 1996, ONCOGENE, V13, P1511; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Watson AJM, 1996, BRIT J CANCER, V73, P889, DOI 10.1038/bjc.1996.178; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686	35	49	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1245	1249		10.1038/sj.onc.1202413	http://dx.doi.org/10.1038/sj.onc.1202413			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022131				2022-12-28	WOS:000078510700014
J	Jouanneau, J; Moens, G; Thiery, JP				Jouanneau, J; Moens, G; Thiery, JP			The community effect in FGF-1 mediated tumor progression of a rat bladder carcinoma does not involve a direct paracrine signaling	ONCOGENE			English	Article						dominant-negative FGFR mutant; community effect; tumor heterogeneity; tumor cell interactions	FIBROBLAST GROWTH-FACTOR; TISSUE-CULTURE; ATHYMIC MICE; CELL-LINE; IN-VIVO; EXPRESSION; RECEPTORS; TUMORIGENICITY; TRANSFORMATION; ORGANIZATION	A community effect was found to occur between heterogeneous tumor cell populations leading to an overall increased tumorigenicity without a clonal dominance of the more tumorigenic clone. In the rat bladder carcinoma cell line NET-II, this effect appears mediated by the Fibroblast Growth Factor-1 (FGF-1) through either a direct or an indirect signaling pathway. Neovascularization induced by FGF-1 was found not to be responsible for the community effect. The present study shows that the community effect does not involve a direct FGF-1 signaling since tumor cells expressing a dominant-negative FGF receptor mutant were still responding to the highly tumorigenic FGF-1 expressing cells. Tumors arising from inoculates of the FGF-1 producing NET-II cells mixed with non tumorigenic epithelial MDCK cells contain only the tumorigenic cells indicating that MDCK cells may exerce a helper effect for the growth of the tumor not dependant on their own growth. Therefore the helper function of MDCK cells must be distinguished from a community effect where the contribution of low tumorigenic cells not only provides an in vivo growth advantage to few highly tumorigenic cells but become themselves highly tumorigenic indicating that the community effect may require cell-cell specific cooperativity independent from an helper effect.	UMR 144 CNRS, F-75248 Paris 05, France; Inst Curie, F-75248 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Jouanneau, J (corresponding author), UMR 144 CNRS, 26 Rue Ulm, F-75248 Paris 05, France.		Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020				AABO K, 1995, EUR J CANCER, V31A, P222, DOI 10.1016/0959-8049(94)00434-7; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BOYER B, 1989, J CELL BIOL, V109, P1495, DOI 10.1083/jcb.109.4.1495; CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75; COLBEREGARAPIN F, 1981, J MOL BIOL, V105, P1; DeBoth NJ, 1997, INT J CANCER, V72, P1137, DOI 10.1002/(SICI)1097-0215(19970917)72:6<1137::AID-IJC32>3.0.CO;2-Z; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIDMAN R, 1992, INT J CANCER, V51, P740, DOI 10.1002/ijc.2910510513; GARTNER MFRM, 1992, INT J CANCER, V51, P788, DOI 10.1002/ijc.2910510520; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gregoire M, 1995, CANCER METAST REV, V14, P339, DOI 10.1007/BF00690602; GURDON JB, 1993, CELL, V75, P831, DOI 10.1016/0092-8674(93)90526-V; HENNIGAN TW, 1994, SURG ONCOL, V3, P275, DOI 10.1016/0960-7404(94)90029-9; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; Jouanneau J, 1997, ONCOGENE, V14, P671, DOI 10.1038/sj.onc.1200883; JOUANNEAU J, 1994, P NATL ACAD SCI USA, V91, P286, DOI 10.1073/pnas.91.1.286; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; Loizidou MC, 1996, BRIT J SURG, V83, P24, DOI 10.1002/bjs.1800830107; MEHTA RR, 1993, BREAST CANCER RES TR, V25, P65, DOI 10.1007/BF00662402; Nakajima M, 1993, Hum Cell, V6, P7; PAWELETZ N, 1994, CRIT REV ONCOGENESIS, V5, P69, DOI 10.1615/CritRevOncog.v5.i1.40; RAK JW, 1993, IN VITRO CELL DEV-AN, V29A, P742; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; Schor S L, 1995, EXS, V74, P273; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; TOYOSHIMA K, 1971, JNCI-J NATL CANCER I, V47, P979; ULRICH A, 1990, CELL, V61, P203; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4	33	12	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					327	333		10.1038/sj.onc.1202285	http://dx.doi.org/10.1038/sj.onc.1202285			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927189				2022-12-28	WOS:000078166500005
J	Ioannidis, P; Courtis, N; Havredaki, M; Michailakis, E; Tsiapalis, CM; Trangas, T				Ioannidis, P; Courtis, N; Havredaki, M; Michailakis, E; Tsiapalis, CM; Trangas, T			The polyadenylation inhibitor cordycepin (3 ' dA) causes a decline in c-MYC mRNA levels without affecting c-MYC protein levels	ONCOGENE			English	Article						c-myc mRNA; translation; poly(A) tail; cordycepin	MESSENGER-RNA DEGRADATION; AU-RICH ELEMENTS; TUMOR NECROSIS FACTOR; POLY(A) TAIL; 3'-UNTRANSLATED REGION; UNTRANSLATED REGION; CELL-CYCLE; TRANSLATIONAL EFFICIENCY; INITIATION; SEQUENCE	Study of the distribution of the poly(A) tail length of c-myc mRNA in several cell lines revealed a distinct, prevailing population with short poly(A) tails, derived through sequential deadenylation, To elucidate the possible in vivo function of this distinct short failed c-myc mRNA population, the polyadenylation inhibitor cordycepin was used, This resulted in a decline in steady state c-myc mRNA levels with the remaining messenger mostly oligoadenylated, However, c-MYC proteins did not follow the reduction of the c-myc mRNA, On the other hand, in cells exposed to physiological agents known to downregulate c-myc expression, the reduction of mRNA steady state levels, was reflected upon c-MYC protein levels, The dissociation between c-myc mRNA and protein levels caused by cordycepin was not dare to the stabilization of the c-MYC proteins and was not an indiscriminate effect since in the presence of cordycepin, c-fos mRNA and protein levels concomitantly declined, Our data indicate that under these conditions, a long poly(A) tail is not instrumental for c-myc mRNA translation and furthermore, the discrepancy in the steady state of c-myc mRNA level: c-MYC protein ratio between control cells and cells treated with cordycepin indicates that c-myc mRNA is subjected to translational control.	St Savvas Hosp, Papanikolaou Res Ctr Oncol, Athens 11522, Greece; NCSR Democritos, Athens, Greece; Athens Gen Hosp, Oncol Unit, Athens, Greece	National Centre of Scientific Research "Demokritos"	Trangas, T (corresponding author), St Savvas Hosp, Papanikolaou Res Ctr Oncol, 171 Alexandras Ave, Athens 11522, Greece.							BACHVAROVA RF, 1992, CELL, V69, P895, DOI 10.1016/0092-8674(92)90606-D; BALLANTINE JEM, 1985, FEBS LETT, V180, P224, DOI 10.1016/0014-5793(85)81075-9; BEACH LR, 1978, J BIOL CHEM, V253, P2628; BERNSTEIN J, 1995, J BIOL CHEM, V270, P10559, DOI 10.1074/jbc.270.18.10559; Black BL, 1997, MOL CELL BIOL, V17, P2756, DOI 10.1128/MCB.17.5.2756; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; BREWER G, 1990, METHOD ENZYMOL, V181, P202; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTENSEN AK, 1987, AM J ANAT, V178, P1, DOI 10.1002/aja.1001780102; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; Dehlin E, 1996, MOL CELL BIOL, V16, P468; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; GRAFI G, 1993, MOL CELL BIOL, V13, P3487, DOI 10.1128/MCB.13.6.3487; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Ioannidis P, 1996, NUCLEIC ACIDS RES, V24, P4969, DOI 10.1093/nar/24.24.4969; Jackson RJ, 1995, CURR TOP MICROBIOL, V203, P1; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KLEENE KC, 1989, DEVELOPMENT, V106, P367; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; KRUYS VI, 1988, GENE, V72, P191, DOI 10.1016/0378-1119(88)90144-8; LIN JX, 1987, J BIOL CHEM, V262, P11908; Lorenzini EC, 1997, BIOCHEM J, V326, P361, DOI 10.1042/bj3260361; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; MACIEJEWSKILENOIR D, 1993, P NATL ACAD SCI USA, V90, P1435, DOI 10.1073/pnas.90.4.1435; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; NABRU C, 1997, J BIOL CHEM, V272, P32061; Paulin FEM, 1996, ONCOGENE, V13, P505; Ranganathan G, 1997, J BIOL CHEM, V272, P2515; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SACHS A, 1993, J BIOL CHEM, V268, P22955; Sachs A, 1990, CURR OPIN CELL BIOL, V2, P1092, DOI 10.1016/0955-0674(90)90161-7; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SALLES FJ, 1994, SCIENCE, V266, P1996, DOI 10.1126/science.7801127; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEETS MD, 1994, GENE DEV, V8, P926, DOI 10.1101/gad.8.8.926; SHEETS MD, 1995, NATURE, V374, P511, DOI 10.1038/374511a0; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; STOECKLE MY, 1993, BIOTECHNIQUES, V15, P227; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; SWARTWOUT SG, 1989, MOL CELL BIOL, V9, P288, DOI 10.1128/MCB.9.1.288; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; Yang Q, 1997, J BIOL CHEM, V272, P15466, DOI 10.1074/jbc.272.24.15466; ZEEVI M, 1982, MOL CELL BIOL, V2, P517, DOI 10.1128/MCB.2.5.517; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	60	23	30	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					117	125		10.1038/sj.onc.1202255	http://dx.doi.org/10.1038/sj.onc.1202255			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926926				2022-12-28	WOS:000078166000013
J	Sugihara, K; Nakatsuji, N; Nakamura, K; Nakao, K; Hashimoto, R; Otani, H; Sakagami, H; Kondo, H; Nozawa, S; Aiba, A; Katsuki, M				Sugihara, K; Nakatsuji, N; Nakamura, K; Nakao, K; Hashimoto, R; Otani, H; Sakagami, H; Kondo, H; Nozawa, S; Aiba, A; Katsuki, M			Rac1 is required for the formation of three germ layers during gastrulation	ONCOGENE			English	Article						Rac1; gene targeting; cell adhesion; motility; early development	GTP-BINDING PROTEIN; ACTIN STRESS FIBERS; NADPH OXIDASE; RAS TRANSFORMATION; EXCHANGE PROTEINS; PRIMITIVE-STREAK; CDC42 GTPASES; CELL-DEATH; RHO-FAMILY; ACTIVATION	The Rad, a member of the Rho family proteins, regulates actin organization of cytoskeleton and cell adhesion. We used genetic analysis to elucidate the role of Rad in mouse embryonic development. The rac1 deficient embryos showed numerous cell deaths in the space between the embryonic ectoderm and endoderm at the primitive streak stage. Investigation of the primary epiblast culture isolated from rac1 deficient embryos indicated that Rad is involved in lamellipodia formation, cell adhesion and cell migration in vivo. These results suggest that Rad-mediated cell adhesion is essential for the formation of three germ layers during gastrulation.	Univ Tokyo, Inst Med Sci, Ctr Med Expt, Div DNA Biol & Embryo Engn,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, CREST, Minato Ku, Tokyo 1088639, Japan; Keio Univ, Sch Med, Dept Obstet & Gynecol, Shinjuku Ku, Tokyo 1608582, Japan; Natl Inst Genet, Mammalian Dev Lab, Mishima, Shizuoka 4118540, Japan; Shimane Med Univ, Dept Anat, Izumo, Shimane 6938501, Japan; Tohoku Univ, Grad Sch Med Sci, Dept Cell Biol, Div Histol,Aoba Ku, Sendai, Miyagi 9808575, Japan	University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo; Keio University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Shimane University; Tohoku University	Katsuki, M (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Med Expt, Div DNA Biol & Embryo Engn,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.			Aiba, Atsu/0000-0002-8192-0778; zhong wei, he gui/0000-0002-3066-3564				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ANDO S, 1992, J BIOL CHEM, V267, P25709; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HASHIMOTO K, 1987, DEVELOPMENT, V100, P587; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; MACKAY DJG, 1995, TRENDS NEUROSCI, V18, P496, DOI 10.1016/0166-2236(95)92773-J; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MOLL J, 1991, ONCOGENE, V6, P863; NAKATSUJI N, 1986, J EMBRYOL EXP MORPH, V96, P99; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sanders EJ, 1997, ANAT EMBRYOL, V195, P147, DOI 10.1007/s004290050033; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295	37	258	260	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3427	3433		10.1038/sj.onc.1202595	http://dx.doi.org/10.1038/sj.onc.1202595			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030666				2022-12-28	WOS:000078086200003
J	Garriga, J; Peng, JM; Parreno, M; Price, DH; Henderson, EE; Grana, X				Garriga, J; Peng, JM; Parreno, M; Price, DH; Henderson, EE; Grana, X			Upregulation of cyclin T1/CDK9 complexes during T cell activation	ONCOGENE			English	Article						PITALRE; CDK; RNA polymerase II; HIV; Tat; peripheral blood lymphocytes	HUMAN-IMMUNODEFICIENCY-VIRUS; RNA-POLYMERASE-II; CDC2-RELATED KINASE PITALRE; CARBOXYL-TERMINAL DOMAIN; TAT-ASSOCIATED KINASE; PROTEIN-KINASE; IN-VITRO; P-TEFB; LARGE SUBUNIT; PHOSPHORYLATION	Cyclin T1 has been identified recently as a regulatory subunit of CDK9 and as a component of the transcription elongation factor P-TEFb, Cyclin TL/CDK9 complexes phosphorylate the carboxy terminal domain (CTD) of RNA polymerase II (RNAP II) in vitro. Here we report that the levels of cyclin T1 are dramatically upregulated by two independent signaling pathways triggered respectively by PMA and PHA in primary human peripheral blood lymphocytes (PBLs), Activation of these two pathways in tandem is sufficient for PBLs to enter and progress through the cell cycle. However, the expression of cyclin T1 is not growth and/or cell cycle regulated in other cell types, indicating that regulation of cyclin T1 expression is dependent on tissue-specific signaling pathways, Upregulation of cyclin T1 in stimulated PBLs results in induction of the CTD kinase activity of the cyclin T1/CDK9 complex, which in turn correlates directly with phosphorylation of RNAP II in vivo, linking for the first time activation of the cyclin T1/CDK9 pair with phosphorylation of RNAP II in vivo. In addition, we report here that endogenous CDK9 and cyclin T1 complexes associate with HIV-1 generated Tat in relevant cells and under physiological conditions (HIV-1 infected T cells). This, together with our results showing that HIV-1 replication in stimulated PBLs correlates with the levels of cyclin T1 protein and associated CTD kinase activity, suggests that the cyclin T1/CDK9 pair is one of the HIV-1 required host cellular cofactors generated during T cell activation.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Iowa	Grana, X (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.		Peng, Junmin/N-2614-2018; Price, David H/F-6173-2010	Peng, Junmin/0000-0003-0472-7648; Price, David/0000-0002-5597-385X; Grana, Xavier/0000-0001-7134-0473	NATIONAL CANCER INSTITUTE [R55CA075909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500, R29GM054894] Funding Source: NIH RePORTER; NCI NIH HHS [CA/DO75909-01] Funding Source: Medline; NIGMS NIH HHS [GM35500, GM54894] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashihara T, 1979, Methods Enzymol, V58, P248; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; FINZI, 1998, CELL, V93, P665; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Garriga J, 1996, BIOCHEM J, V319, P293, DOI 10.1042/bj3190293; Garriga J, 1996, BIOCHEM J, V320, P983, DOI 10.1042/bj3200983; GRANA X, 1994, ONCOGENE, V9, P2097; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; GRANA X, 1995, ONCOGENE, V11, P211; Guan MX, 1996, J VIROL, V70, P7341, DOI 10.1128/JVI.70.10.7341-7346.1996; HERRMANN CH, 1993, VIROLOGY, V197, P601, DOI 10.1006/viro.1993.1634; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Liu ZJ, 1998, MOL CELL BIOL, V18, P3445, DOI 10.1128/MCB.18.6.3445; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Nekhai S, 1997, J VIROL, V71, P7436, DOI 10.1128/JVI.71.10.7436-7441.1997; Peng JM, 1998, J BIOL CHEM, V273, P13855, DOI 10.1074/jbc.273.22.13855; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Xiong Y, 1996, Biochim Biophys Acta, V1288, P01; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	38	107	107	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 17	1998	17	24					3093	3102		10.1038/sj.onc.1202548	http://dx.doi.org/10.1038/sj.onc.1202548			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872325				2022-12-28	WOS:000077517400003
J	Matsuguchi, T; Kraft, AS				Matsuguchi, T; Kraft, AS			Regulation of myeloid cell growth by distinct effectors of Ras	ONCOGENE			English	Article						ras; cell growth; myeloid cells; apoptosis; kip1	DEPENDENT KINASE INHIBITOR; NUCLEOTIDE DISSOCIATION STIMULATOR; PROTEIN-KINASE; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; INDEPENDENT PATHWAYS; HEMATOPOIETIC-CELLS; SIGNALING PATHWAY; TRANSFORMATION; AKT; P27(KIP1)	To examine the biochemical pathways by which activated Ha-Ras(G12V) (Ha-RasV12) induces factor-independent growth of myeloid cells, Ha-Ras effector loop mutations, including Y40C, T35S, and E37G, were analysed in a mouse factor-dependent myeloid cell line, WT19. Expression of a single effector loop mutant, Ha-Ras(G12V, Y40C) (Ha-RasV12C40), inhibited factor-withdrawal apoptosis, suggesting that activation of the phosphatidylinositol 3'-kinase (Pl3K) pathway is essential to prevent cell death. Neither Ha-Ras (G12V, T35S) (Ha-RasV12S35), which activates the Ran signaling pathway, nor Ha-Ras(G12V, E37G) (Ha-RasV12G37), which stimulates the RalGDS pathway, did not have significant effects on factor-withdrawal apoptosis of myeloid cells. Although Ha-RasV12C40 inhibited apoptosis, it did not stimulate entry into the cell cycle. Cell lines containing the combination of Ha-RasV12G37 and Ha-RasV12C40 were capable of factor-independent cell growth, while expression of the other combinations of the Ha-Ras effector mutants were not. The combined expression of Bcl-2 and Ha-RasV12G37 was not sufficient to stimulate factor independent growth, suggesting that Ha-RasV12C40 activates additional signals, besides blocking apoptosis, which are critical for factor-independent growth of myeloid cells. In factor-starved myeloid cells, inducible expression of Ha-RasV12G37 results in decreased level of p27(Kip1) protein, a cyclin-dependent kinase inhibitor (CKI). These data suggest that the factor-independent growth of myeloid cells requires the activation of at least two pathways, one inhibiting factor-withdrawal apoptosis, and another causing cell cycle progression.	Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kraft, AS (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Med Oncol, 4200 E 9th Ave, Denver, CO 80262 USA.				NIDDK NIH HHS [DK44741] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044741] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; BOSWELL HS, 1990, EXP HEMATOL, V18, P452; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Murai H, 1997, J BIOL CHEM, V272, P10483; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	50	13	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2701	2709		10.1038/sj.onc.1202201	http://dx.doi.org/10.1038/sj.onc.1202201			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840934				2022-12-28	WOS:000077146700003
J	Schneider, E; Montenarh, M; Wagner, P				Schneider, E; Montenarh, M; Wagner, P			Regulation of CAK kinase activity by p53	ONCOGENE			English	Article						cyclin H; tms1; CAK kinase; TFIIH; p53; CTD phosphorylation	CDK-ACTIVATING KINASE; RNA-POLYMERASE-II; DNA-BINDING ACTIVITY; RING FINGER PROTEIN; FISSION YEAST; INDUCED APOPTOSIS; GROWTH ARREST; CELL-CYCLE; TRANSCRIPTIONAL ACTIVATION; SUBSTRATE-SPECIFICITY	The growth suppressor p53 is an important key element which controls cell cycle progression in response to cellular stress like DNA damage. Its ability to act as transcriptional activator or repressor links transcription and cell cycle control. Several target genes selectively transactivated by p53 are implicated in growth control, apoptosis and DNA repair. Here we report the interaction of p53 with another important dual player of cell cycle control and transcription, the protein kinase complex CDK7/cyclin H/Mat1 (CDK activating kinase, CAK kinase). This is implicated in the activating phosphorylation of CDK2/cyclin A kinase required to allow cells to proceed through the G(1)/S transition, and on the other hand, as a component of the basal transcription factor TFIIH found to be necessary for CTD phosphorylation of RNA polymerase II in order to allow elongation of transcription. Based on previous binding studies of p53 with other C-terminal interaction partners of p53 we demonstrate a direct physical interaction of p53 with cyclin H in vitro and in vivo. As a consequence of this interaction we tested the influence of p53 on the kinase activity of CAK kinase for CTD and CDK2 phosphorylation. The addition of wild type p53 to the kinase reactions resulted in a significant downregulation of CDK2 phosphorylation and CTD phosphorylation by the CDK activating kinase. On the other hand addition of a mutant p53His175 failed to downregulate CDK2 and CTD phosphorylation by the CDK activating kinase. In an attempt to support our findings in vivo we measured CAK kinase activity in p21(-/-) and p53(-/-) mice embryonal fibroblasts under conditions when p53 gets activated by irradiation. In the case of p21(-/-) cells this led to a significant reduction of CTD phosphorylation activity of the CDK activating kinase by irradiation of the cells. On the other hand in p53(-/-) cells no downregulation of CTD phosphorylation activity of CAK kinase was observed indicating that this kind of negative regulation of CAK kinase activity is exclusively due to a functional p53. These findings imply a direct involvement of p53 in triggering growth arrest by its interaction with the CDK activating kinase complex without the need of cyclin-dependent kinase inhibitors (CKIs) and potentially suggest a new mechanism for p53-dependent apoptosis.	Univ Saarland, D-66421 Homburg, Germany	Saarland University	Wagner, P (corresponding author), Univ Saarland, Bldg 44, D-66421 Homburg, Germany.							Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; APPEL K, 1995, ONCOGENE, V11, P1971; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Bureik M, 1997, BIOL CHEM, V378, P1361, DOI 10.1515/bchm.1997.378.11.1361; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HARPER JW, 1993, CELL, V75, P805; Hecker D, 1996, ONCOGENE, V12, P953; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; KAN ZY, 1995, MOL CELL BIOL, V15, P5849; Knippschild U, 1996, ONCOGENE, V13, P1387; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; LEGROS Y, 1994, ONCOGENE, V9, P3689; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ljungman M, 1996, ONCOGENE, V13, P823; Lohrum M, 1996, ONCOGENE, V13, P2527; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MOLZ L, 1993, EMBO J, V12, P1723, DOI 10.1002/j.1460-2075.1993.tb05817.x; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; WAGNER P, 1993, EUR J BIOCHEM, V217, P731, DOI 10.1111/j.1432-1033.1993.tb18299.x; WAGNER P, 1991, ONCOGENE, V6, P1539; Wagner P, 1998, ONCOGENE, V16, P105, DOI 10.1038/sj.onc.1201510; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	43	58	61	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	1998	17	21					2733	2741		10.1038/sj.onc.1202504	http://dx.doi.org/10.1038/sj.onc.1202504			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840937				2022-12-28	WOS:000077146700006
J	Su, LK; Wang, SC; Qi, Y; Luo, WP; Hung, MC; Lin, SH				Su, LK; Wang, SC; Qi, Y; Luo, WP; Hung, MC; Lin, SH			Characterization of BRCA2: temperature sensitivity of detection and cell-cycle regulated expression	ONCOGENE			English	Article						BRCA2; tumor suppressor gene; breast cancer; cell cycle	BREAST-CANCER FAMILIES; MUTATIONS; GENE; PROTEIN; ASHKENAZI; MICE; PROLIFERATION; PROGRESSION; PHENOTYPES; 6174DELT	People carrying a mutant BRCA2 gene are susceptible to breast, ovarian, pancreatic and other tumors. Many facets of BRCA2 have been studied, including its mutation in human cancers, its role in mouse embryogenesis and its RNA expression in different tissues and different mouse embryogenesis stages. However, there has been very little characterization of BRCA2 protein. We investigated the biochemical and biological properties of BRCA2 by using a monoclonal antibody we generated against the N-terminal portion of BRCA2, We discovered that the detection of BRCA2 by immunoblot analysis was sensitive to the temperature used to denature the samples before gel electrophoresis. BRCA2 was easily detectable when samples were denatured at low temperature instead of boiling. Although the precise mechanism underlying this observation is not clear yet, this finding mill significantly improve our ability to study BRCA2, We examined the expression of BRCA2 using an immunoblot analysis protocol modified according to this observation. We showed that BRCA2 was presented in every human cell lines examined, including Capan-1, which expressed a truncated BRCA2 due to a BRCA2 frameshift mutation. We also showed that the expression of BRCA2 was cell-cycle regulated. Our results suggest that BRCA2 has an important role in cell growth regulation.	Univ Texas, MD Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Su, LK (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021; Wang, Shao-Chun/P-9904-2019	Hung, Mien-Chie/0000-0003-4317-4740; Wang, Shao-Chun/0000-0002-5477-1682	NATIONAL CANCER INSTITUTE [R01CA064856, R29CA070371, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672, CA 70371, CA 64856] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abeliovich D, 1997, AM J HUM GENET, V60, P505; Berman DB, 1996, CANCER RES, V56, P3409; Bertwistle D, 1997, CANCER RES, V57, P5485; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Connor F, 1997, HUM MOL GENET, V6, P291, DOI 10.1093/hmg/6.2.291; Friedman LS, 1998, CANCER RES, V58, P1338; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; Katagiri T, 1998, GENE CHROMOSOME CANC, V21, P217, DOI 10.1002/(SICI)1098-2264(199803)21:3<217::AID-GCC5>3.0.CO;2-2; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Liang TC, 1996, ARCH BIOCHEM BIOPHYS, V329, P208, DOI 10.1006/abbi.1996.0210; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Neuhausen S, 1996, NAT GENET, V13, P126, DOI 10.1038/ng0596-126; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; RON D, 1992, BIOTECHNIQUES, V13, P866; Sharan SK, 1997, GENOMICS, V40, P234, DOI 10.1006/geno.1996.4573; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; Tirkkonen M, 1997, CANCER RES, V57, P1222; Vaughn JP, 1996, CANCER RES, V56, P4590; Wang SC, 1997, BIOCHEM BIOPH RES CO, V234, P247, DOI 10.1006/bbrc.1997.6544; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	33	18	18	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2377	2381		10.1038/sj.onc.1202162	http://dx.doi.org/10.1038/sj.onc.1202162			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811469				2022-12-28	WOS:000076723300012
J	Wong, AKC; Ormonde, PA; Pero, R; Chen, Y; Lian, LB; Salada, G; Berry, S; Lawrence, Q; Dayananth, P; Ha, P; Tavtigian, SV; Teng, DHF; Bartel, PL				Wong, AKC; Ormonde, PA; Pero, R; Chen, Y; Lian, LB; Salada, G; Berry, S; Lawrence, Q; Dayananth, P; Ha, P; Tavtigian, SV; Teng, DHF; Bartel, PL			Characterization of a carboxy-terminal BRCA1 interacting protein	ONCOGENE			English	Article						BRCA1 interactor; tumor suppressor; mutation; transcription	CANCER SUSCEPTIBILITY GENE; TUMOR-SUPPRESSOR; BREAST-CANCER; TRANSCRIPTIONAL ACTIVATION; SUBCELLULAR-LOCALIZATION; CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION; E1A PROTEIN; DNA-REPAIR; RAD51	There are several lines of evidence indicating that the carboxy-terminal region of the tumor suppressor protein BRCA1 is a functionally significant domain. Using the yeast two-hybrid and in vitro biochemical assays, we show that a protein, CtIP, interacts specifically with the carboxy-terminal segment of human BRCA1 from residues 1602-1863. A germ line truncation mutation, Y1853ter, that removes the last 11 amino acids from the carboxy-terminus of BRCA1, abolishes not only its transcriptional activation function, but also binding to CtIP. The function of CtIP is unknown, but its reported association with a transcriptional repressor CtBP lends further support that it may have a role in transcription. A sequence based screen of a panel of 89 tumor cell line cDNAs for mutations in the CtIP coding region identified five missense variants. In the pancreatic carcinoma cell line, BxPC3, the non-conservative lysine to glutamic acid change at codon 337 is accompanied with apparent loss of heterozygosity or non-expression of the wild type allele. Thus it is plausible that CtIP may itself be a tumor suppressor acting in the same pathway as BRCA1.	Myriad Genet Inc, Salt Lake City, UT 84108 USA	Myriad Genetics, Inc	Wong, AKC (corresponding author), Myriad Genet Inc, 390 Wakara Way, Salt Lake City, UT 84108 USA.							Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; CannonAlbright LA, 1996, SEMIN ONCOL, V23, P1; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; McAllister KA, 1997, CANCER RES, V57, P3121; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; PIDDER JD, 1996, TRENDS GENET, V12, P272; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V15, P535; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sobol A, 1996, CANCER RES, V56, P3216; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Teng DHF, 1997, CANCER RES, V57, P4177; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	46	136	139	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	1998	17	18					2279	2285		10.1038/sj.onc.1202150	http://dx.doi.org/10.1038/sj.onc.1202150			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811458				2022-12-28	WOS:000076723300001
J	Terradillos, O; Pollicino, T; Lecoeur, H; Tripodi, M; Gougeon, ML; Tiollais, P; Buendia, MA				Terradillos, O; Pollicino, T; Lecoeur, H; Tripodi, M; Gougeon, ML; Tiollais, P; Buendia, MA			p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro	ONCOGENE			English	Article						hepatitis B virus; apoptosis; X protein; liver; p53	WILD-TYPE P53; MYC-MEDIATED APOPTOSIS; X-PROTEIN; HEPATOCELLULAR-CARCINOMA; TRANSGENIC MICE; LIVER-CANCER; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVITY; CELL-DEATH; HELA-CELLS	The hepatitis B virus protein HBx is a promiscuous transactivator implicated in both cell growth and death and in the development of hepatocellular carcinoma. We recently reported that HBx can potentiate c-myc-induced liver oncogenesis in a transgenic model where low level expression of HBx induces no pathology, To assess if HBx could affect the hepatocyte turnover, we investigated the HBx-elicited apoptotic responses in transgenic livers and in primary hepatocyte cultures. Here we show that transgenic expression of HBx is associated with a twofold increase of spontaneous cell death in the mouse liver, The finding that apoptosis was enhanced to similar extents in HBx mice carrying homozygous p53 null mutations implied that functionally intact p53 was not required to transduce the death signal, A direct, dose-dependent apoptotic function of HBx was demonstrated in transient transfections of liver-derived cell lines. We further show that stable expression of HBx at low, presumably physiological levels in primary hepatocytes, induced cellular susceptibility to diverse apoptotic insults, including growth factor deprivation, treatment with anti-Fas antibodies or doxorubicine and oxidative stress, HBx expression, but not p53 status profoundly affected the commitment of cells to die upon apoptotic stimuli, These data strengthen the notion that HEX may contribute to HBV pathogenesis by enhancing apoptotic death in the chronically infected liver.	Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75724 Paris, France; Inst Pasteur, Unite Oncol Virale, F-75724 Paris, France; Univ Roma La Sapienza, Sez Genet Mol, Dipartimento Biotechnol Cellulari, Fdn Inst Pasteur Cenci Bolognetti, Rome, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Sapienza University Rome	Buendia, MA (corresponding author), Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75724 Paris, France.		Pollicino, Teresa/K-5790-2016; Pollicino, Teresa/HDN-3708-2022; Tripodi, Marco/F-1143-2011; Tripodi, Marco/ABO-1160-2022	Pollicino, Teresa/0000-0001-6602-3035; Tripodi, Marco/0000-0001-6135-971X; Tripodi, Marco/0000-0001-6135-971X				Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; BALSANO C, 1993, ARCH VIROL, P63; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BEASLEY RP, 1981, LANCET, V2, P1129; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; BILLET O, 1995, J VIROL, V69, P5912, DOI 10.1128/JVI.69.9.5912-5916.1995; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FISCHER M, 1995, VIRUS GENES, V10, P99, DOI 10.1007/BF01724303; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; HOOPER ML, 1994, J CELL SCI, P13; HSU B, 1995, ONCOGENE, V11, P175; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Lecoeur H, 1997, J IMMUNOL METHODS, V209, P111, DOI 10.1016/S0022-1759(97)00138-5; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lin Y, 1997, CANCER RES, V57, P5137; NATOLI G, 1994, ONCOGENE, V9, P2837; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; Peterhans E, 1997, J NUTR, V127, pS962, DOI 10.1093/jn/127.5.962S; Petersen J, 1997, J VIROL, V71, P5455, DOI 10.1128/JVI.71.7.5455-5463.1997; PUISIEUX A, 1995, P NATL ACAD SCI USA, V92, P1342, DOI 10.1073/pnas.92.5.1342; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; Sakamuro D, 1995, ONCOGENE, V11, P2411; SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; SLADOWSKI D, 1993, J IMMUNOL METHODS, V157, P203, DOI 10.1016/0022-1759(93)90088-O; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; Takada S, 1997, ONCOGENE, V15, P1895, DOI 10.1038/sj.onc.1201369; TEODORO JG, 1995, ONCOGENE, V11, P467; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG WL, 1991, CANCER RES, V51, P4971; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	65	152	158	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	1998	17	16					2115	2123		10.1038/sj.onc.1202432	http://dx.doi.org/10.1038/sj.onc.1202432			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798683				2022-12-28	WOS:000076540900011
J	Wang, RX; Brunner, T; Zhang, LY; Shi, YF				Wang, RX; Brunner, T; Zhang, LY; Shi, YF			Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression	ONCOGENE			English	Article						fungal metabolite; c-myc; FasL; apoptosis; T cell hybridoma	T-CELL HYBRIDOMAS; ACTIVATION-INDUCED APOPTOSIS; CHROMOBACTERIUM-VIOLACEUM NO-968; CYCLOSPORINE-A; CYCLE BLOCK; DEATH; LYMPHOCYTES; ANTIGEN; CD95; SENSITIVITY	Activation of T lymphocytes often leads to cellular activation, production of cytokines, entry into cell cycle, and expression of Fas (CD95) and Fas ligand (FasL), Although it is well established that the interaction of Fas and Fast results in apoptosis, mechanisms for regulated expression of Fas and Fast are unclear. Our previous work with antisense oligodeoxynucleotides suggested that the protooncogene c-myc is obligatory for activation-induced apoptosis, To study the relationship between myc and the Fas/FasL expression, we employed the antisense method and a newly identified fungal metabolite, FR901228, which has been shown to specifically inhibit expression of c-myc in fibroblasts, We found that FR901228 could effectively block activation-induced apoptosis in T cell hybridomas and this was correlated with its specific inhibition of c-myc expression, Both FR901228 and antisense oligodeoxynucleotide to c-myc had similar effect in inhibiting Fast expression. These treatments did not affect activation-induced production of IL-2, nor the expression of Fas, In addition, FR901228 inhibited the expression of Fast in 3T3 fibroblasts, but not these transfected with c-myc, supporting a specific role of c-myc in this process. Thus, c-Myc plays a fundamental role in the regulation of the expression of Fast, but not Fas and IL-2, Our data further defined the requirement of c-Myc in activation-induced apoptosis in T cells.	Amer Red Cross, Jerome H Holland Lab, Dept Immunol, Rockville, MD 20855 USA; La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA	American Red Cross; La Jolla Institute for Immunology	Shi, YF (corresponding author), Amer Red Cross, Jerome H Holland Lab, Dept Immunol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.		Shi, Yufang/AAE-4431-2020	Shi, Yufang/0000-0001-8964-319X				Adachi M, 1996, P NATL ACAD SCI USA, V93, P2131, DOI 10.1073/pnas.93.5.2131; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Brunner T, 1996, INT IMMUNOL, V8, P1017, DOI 10.1093/intimm/8.7.1017; Castro JE, 1996, IMMUNITY, V5, P617, DOI 10.1016/S1074-7613(00)80275-7; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FOTEDAR A, 1985, J IMMUNOL, V135, P3028; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; GREEN DR, 1994, IMMUNOL REV, V142, P321, DOI 10.1111/j.1600-065X.1994.tb00895.x; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; MERCEP M, 1989, J IMMUNOL, V142, P4085; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Park CG, 1996, IMMUNITY, V4, P583, DOI 10.1016/S1074-7613(00)80484-7; RIDGWAY WM, 1994, CURR OPIN IMMUNOL, V6, P946, DOI 10.1016/0952-7915(94)90018-3; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; RUSSELL JH, 1991, P NATL ACAD SCI USA, V88, P2151, DOI 10.1073/pnas.88.6.2151; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SHI YF, 1990, J IMMUNOL, V144, P3326; SHI YF, 1995, CANCER RES, V55, P1982; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SUDA T, 1995, J IMMUNOL, V154, P3806; UEDA H, 1994, J ANTIBIOT, V47, P301; UEDA H, 1994, BIOSCI BIOTECH BIOCH, V58, P1579, DOI 10.1271/bbb.58.1579; Williams MS, 1996, J IMMUNOL, V157, P2395; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673	37	62	73	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1503	1508		10.1038/sj.onc.1202059	http://dx.doi.org/10.1038/sj.onc.1202059			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794227	Green Submitted			2022-12-28	WOS:000076089900002
J	Hubbs, AE; Majidi, M; Lichy, JH				Hubbs, AE; Majidi, M; Lichy, JH			Expression of an isoform of the novel signal transduction protein ST5 is linked to cell morphology	ONCOGENE			English	Article						ST5; signal transduction; cytoskeleton; contact-inhibition	KINASE-ACTIVITY; IDENTIFICATION; MICROTUBULES; INVOLVEMENT; DISRUPTION; HYBRIDS; LINES; GENE	The human ST5 gene is expressed as 4.6, 3.1 and 2.8 kb transcripts encoding putative 126, 82 and 70 kDa proteins that function in the MAP kinase signaling pathway in transient expression assays, Expression of the 2.8 kb transcript correlates with reduced tumorigenicity in HeLa-fibroblast hybrids, suggesting a role in tumor suppression. We now report the detection of ST5 proteins in cellular extracts, demonstrate specific expression of p70 in non-tumorigenic HeLa-fibroblast hybrids, extend the correlation between p70 expression and cellular morphology to a wide variety of cell lines, and provide direct evidence that p70 can effect changes in cell growth and morphology. ST5 proteins were identified in extracts of human, mouse and simian epithelial cells and fibroblasts, but were absent from lymphoid cells. Transfection of the 2.8 kb cDNA into a p70-negative mouse fibroblast line yielded stable transfectants with a Battened, less refractile morphology relative to controls. The p70 expressing clones had initial growth rates similar to those of control cells but their saturation density was reduced threefold, suggesting a restoration of contact-regulated growth. In conjunction with previous findings, these results suggest that ST5 proteins participate directly in events affecting cytoskeletal organization and tumorigenicity.	Armed Forces Inst Pathol, Dept Cellular Pathol, Washington, DC 20306 USA	United States Department of Defense	Lichy, JH (corresponding author), Armed Forces Inst Pathol, Dept Cellular Pathol, Washington, DC 20306 USA.				NATIONAL CANCER INSTITUTE [R01CA064114] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA64114] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V1, pCH9; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; KAJSTURA J, 1993, CELL BIOL INT, V17, P1023, DOI 10.1006/cbir.1993.1032; Lichy JH, 1996, NUCLEIC ACIDS RES, V24, P4700, DOI 10.1093/nar/24.23.4700; LICHY JH, 1992, CELL GROWTH DIFFER, V3, P541; Lu Q, 1998, MOL CELL BIOL, V18, P3257, DOI 10.1128/MCB.18.6.3257; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Majidi M, 1998, J BIOL CHEM, V273, P16608, DOI 10.1074/jbc.273.26.16608; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; STANBRIDGE EJ, 1980, INT J CANCER, V26, P1, DOI 10.1002/ijc.2910260102; Sudhof TC, 1997, NEURON, V18, P519, DOI 10.1016/S0896-6273(00)80292-5; Taubenberger JK, 1996, CELL IMMUNOL, V171, P41, DOI 10.1006/cimm.1996.0170; Zhu JY, 1996, MOL CELL BIOL, V16, P7054	19	10	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2519	2525		10.1038/sj.onc.1202554	http://dx.doi.org/10.1038/sj.onc.1202554			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229203				2022-12-28	WOS:000079703300012
J	Duyndam, MCA; van Dam, H; Smits, PHM; Verlaan, M; van der Eb, AJ; Zantema, A				Duyndam, MCA; van Dam, H; Smits, PHM; Verlaan, M; van der Eb, AJ; Zantema, A			The N-terminal transactivation domain of ATF2 is a target for the co-operative activation of the c-jun promoter by p300 and 12S E1A	ONCOGENE			English	Article						ATF; Jun; SAPK; CBP; transcription; coactivator	TRANSCRIPTION FACTOR FAMILY; CBP-INDUCED STIMULATION; NUCLEAR-PROTEIN CBP; ADENOVIRUS E1A; HETERODIMER FORMATION; GENE-TRANSCRIPTION; COACTIVATOR P300; RETINOIC ACID; UV RESPONSE; CYCLIC-AMP	The adenovirus EIA proteins activate the c-jun promoter through two Jun/ATF-binding sites, jun1 and jun2. P300, a transcriptional coactivator of several AP1 and ATF transcription factors has been postulated to play a role in this activation, Here,,ve present evidence that p300 can control c-jun transcription by acting as a cofactor for ATF2: (1) Over-expression of p300 mas found to stimulate c-jun transcription both in the presence and absence of EIA. (2) Like E1A, p300 activates the c-jun promoter through the jun1 and jun2 elements and preferentially activates the N-terminal domain of ATF2. (3) Co-immunoprecipitation assays of crude cell extracts indicate that endogenous p300/CBP(-like) proteins and ATF2 proteins are present in a multiprotein complex that can bind specifically to the jun2 element, We further demonstrate that the Stress-Activated-Protein-Kinase (SAPK) target sites of ATF2, Thr69 and Thr71 are not required for the formation of the p300/CBP-ATF2 multiprotein complex. These data indicate that E1A does not inhibit all transcription activation functions of p300, and, in fact, cooperates with p300 in the activation of the ATF2 N-terminus.	Leiden Univ, Med Ctr, Mol Carcinogenesis Lab, NL-2333 AL Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Zantema, A (corresponding author), Leiden Univ, Med Ctr, Mol Carcinogenesis Lab, Wassenaarseweg 72, NL-2333 AL Leiden, Netherlands.			van Dam, Hans/0000-0002-8307-4325				ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V351, P494; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; BENBROOK DM, 1990, ONCOGENE, V5, P295; Billon N, 1996, ONCOGENE, V13, P2047; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DORSMAN JC, 1995, J VIROL, V69, P2962, DOI 10.1128/JVI.69.5.2962-2967.1995; Duyndam MCA, 1996, J VIROL, V70, P5852, DOI 10.1128/JVI.70.9.5852-5859.1996; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FLINT KJ, 1991, ONCOGENE, V6, P2019; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hagmeyer BM, 1996, ONCOGENE, V12, P1025; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAGMEYER BM, 1995, BIOESSAYS, V17, P621, DOI 10.1002/bies.950170708; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hasegawa K, 1997, J BIOL CHEM, V272, P20049, DOI 10.1074/jbc.272.32.20049; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; Kawasaki H, 1996, EUR J BIOCHEM, V241, P315, DOI 10.1111/j.1432-1033.1996.00315.x; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; LOW KG, 1994, MOL CELL BIOL, V14, P4958, DOI 10.1128/MCB.14.7.4958; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Smits PHM, 1996, ONCOGENE, V12, P1529; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1989, ONCOGENE, V4, P1207; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VIEIRA J, 1991, GENE, V100, P189, DOI 10.1016/0378-1119(91)90365-I; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	71	27	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2311	2321		10.1038/sj.onc.1202584	http://dx.doi.org/10.1038/sj.onc.1202584			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327051				2022-12-28	WOS:000079595500003
J	Fuchs, SY; Chen, A; Xiong, Y; Pan, ZQ; Ronai, Z				Fuchs, SY; Chen, A; Xiong, Y; Pan, ZQ; Ronai, Z			HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of I kappa B and beta-catenin	ONCOGENE			English	Article						ubiquitination; SCF E2 ligase; I kappa B; beta-catenin; phosphorylation; degradation	UBIQUITIN-PROTEASOME PATHWAY; F-BOX; PROTEINS; ACTIVATION; FAMILY; KINASE; ALPHA; CDC4P; APC	SCF E3 ubiquitin ligases mediate ubiquitination and proteasome-dependent degradation of phosphorylated substrates. We identified a human F-box/WD40 repeats protein (HOS), which is homologous to Slimb/h beta TrCP. Being a part of SCF complex with Skp1 and Cullin1, HOS specifically interacted with the phosphorylated I kappa B and beta-catenin, targeting these proteins for proteasome-dependent degradation in vivo, This targeting required Cullin1 as expression of a mutant Cullin1 abrogated the degradation of I kappa B and of beta-catenin. Mutant HOS which lacks the F-box blocked TNF alpha-induced degradation of I kappa B as well as GSK3 beta-mediated degradation of beta-catenin. This mutant also inhibited NF-kappa B transactivation and increased the beta-catenine-dependent transcription activity of Tcf. These results demonstrate that SCFHOS E3 ubiquitin ligase regulate both NF-kappa B and beta-catenin signaling pathways.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Fuchs, SY (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, 1 Gustave L Levy Pl, New York, NY 10029 USA.			RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R01CA078419] Funding Source: NIH RePORTER; NCI NIH HHS [CA 78419] Funding Source: Medline; NIGMS NIH HHS [GM 55059] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Elledge SJ, 1998, BBA-REV CANCER, V1377, pM61, DOI 10.1016/S0304-419X(98)00005-5; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	37	158	164	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	1999	18	12					2039	2046		10.1038/sj.onc.1202760	http://dx.doi.org/10.1038/sj.onc.1202760			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321728				2022-12-28	WOS:000079346200001
J	Blankenship, C; Naglich, JG; Whaley, JM; Seizinger, B; Kley, N				Blankenship, C; Naglich, JG; Whaley, JM; Seizinger, B; Kley, N			Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity	ONCOGENE			English	Article						pVHL; VEGF; elongins; Hs-CUL2	ENDOTHELIAL GROWTH-FACTOR; RENAL-CARCINOMA; MESSENGER-RNA; SOMATIC MUTATIONS; HUMAN TISSUES; PROTEIN; TRANSLATION; EXPRESSION; BINDING; HEMANGIOBLASTOMAS	The VHL tumor suppressor gene has previously been reported to encode a protein of 213 amino acid residues. Here we report the identification of a second major VHL gene product with an apparent molecular weight of 18 kD, pVHL18, which appears to arise from alternate translation initiation at a second AUG codon (codon 54) within the VHL open reading frame. In vitro and in vivo studies indicate that the internal codon in the VHL mRNA is necessary and sufficient for production of pVHL18. pVHL18 can bind to elongin B, elongin C, and Hs-CUL2, When reintroduced into renal carcinoma cells that lack a wild-type VHL allele, pVHL18 suppresses basal levels of VEGF expression, restores hypoxia-inducibility of VEGF expression, and inhibits tumor formation in nude mice. These data strongly support the existence of two distinct VHL gene products in VHL tumor suppression.	Genome Therapeut Corp, Dept Funct Genom, Waltham, MA 02154 USA; Bristol Myers Squibb Pharmaceut Res Inst, Dept Oncol, Princeton, NJ 08540 USA; Bristol Myers Squibb Pharmaceut Res Inst, Dept Metab Dis, Princeton, NJ 08540 USA	Bristol-Myers Squibb; Bristol-Myers Squibb	Kley, N (corresponding author), Genome Therapeut Corp, Dept Funct Genom, 100 Beaver St, Waltham, MA 02154 USA.							ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Corless CL, 1997, HUM PATHOL, V28, P459, DOI 10.1016/S0046-8177(97)90035-6; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; GAO JZ, 1995, CANCER RES, V55, P743; GILLMAN EC, 1991, MOL CELL BIOL, V11, P2382, DOI 10.1128/MCB.11.5.2382; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Harlow E., 1988, ANTIBODIES LAB MANUA; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Iizuka N, 1995, CURR TOP MICROBIOL, V203, P155; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; KANNO H, 1994, CANCER RES, V54, P4845; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KISHIDA T, 1995, CANCER RES, V55, P4544; Knebelmann B, 1998, CANCER RES, V58, P226; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Los M, 1996, LAB INVEST, V75, P231; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; SHUIN T, 1994, CANCER RES, V54, P2852; Siemeister G, 1996, CANCER RES, V56, P2299; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WHALEY JM, 1994, AM J HUM GENET, V55, P1092; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; Zbar Berton, 1995, V25, P219	33	96	100	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	1999	18	8					1529	1535		10.1038/sj.onc.1202473	http://dx.doi.org/10.1038/sj.onc.1202473			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102622				2022-12-28	WOS:000078770700002
J	Tari, AM; Hung, MC; Li, KY; Lopez-Berestein, G				Tari, AM; Hung, MC; Li, KY; Lopez-Berestein, G			Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells	ONCOGENE			English	Article						Grb2; EGFR; ErbB2; MAP kinase; breast cancer	RECEPTOR TYROSINE KINASES; NUCLEOTIDE EXCHANGE FACTOR; SIGNALING GENE SEM-5; AUTOPHOSPHORYLATION SITES; ADAPTER PROTEIN; C-ERBB-2 GENE; PHOSPHATIDYLINOSITOL-3 KINASE; SEVENLESS GENE; NEU ONCOGENE; SH3 DOMAINS	Increased breast cancer growth has been associated with increased expression of epidermal growth factor receptor (EGFR) and ErbB2 receptor tyrosine kinases (RTKs), Upon activation, RTKs may transmit their oncogenic signals by binding to the growth factor receptor bound protein-2 (Grb2), which in turn binds to SOS and activates the Ras/Raf/MEK/mitogen-activated protein (MAP) kinase pathway. Grb2 is important for the transformation of fibroblasts by EGFR and ErbB2; however, whether Grb2 is also important for the proliferation of breast cancer cells expressing these RTKs is unclear. We have used liposomes to deliver nuclease-resistant antisense oligodeoxynucleotides (oligos) specific for the GRB2 mRNA to breast cancer cells. Grb2 protein downregulation could inhibit breast cancer cell growth; the degree of growth inhibition was dependent upon the activation and/or endogenous levels of the RTKs. Grb2 inhibition led to MAP kinase inactivation in EGFR, but not in ErbB2, breast cancer cells, suggesting that different pathways might be used by EGFR and ErbB2 to regulate breast cancer growth.	Univ Texas, MD Anderson Cancer Ctr, Dept Bioimmunotherapy, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Tari, AM (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Bioimmunotherapy, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; ALIMANDI M, 1995, ONCOGENE, V10, P1813; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANCE WG, 1995, BREAST CANCER RES TR, V35, P105, DOI 10.1007/BF00694751; CHRYSOGELOS SA, 1994, BREAST CANCER RES TR, V29, P29, DOI 10.1007/BF00666179; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DALY RJ, 1994, ONCOGENE, V9, P2723; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; FITZPATRICK SL, 1984, CANCER RES, V44, P3442; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; Heldin CH, 1996, CANCER SURV, V27, P7; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; JANES PW, 1994, ONCOGENE, V9, P3601; JARDINES L, 1993, PATHOBIOLOGY, V61, P268, DOI 10.1159/000163805; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; Koenders P., 1992, Breast Cancer Research and Treatment, V23, P134; LI K, 1998, P AM ASSOC CANC RES, V39, P1404; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Marais R, 1996, CANCER SURV, V27, P101; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; NICHOLSON S, 1988, BRIT J CANCER, V58, P810, DOI 10.1038/bjc.1988.315; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELES E, 1992, J BIOL CHEM, V267, P12266; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PIETRAS R, 1995, ONCOGENE, V10, P2345; Ram TG, 1996, CELL GROWTH DIFFER, V7, P551; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEGATTO O, 1993, ONCOGENE, V8, P2105; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; Tan M, 1997, CANCER RES, V57, P1199; Tari AM, 1997, BIOCHEM BIOPH RES CO, V235, P383, DOI 10.1006/bbrc.1997.6791; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vanhaesebroeck B, 1996, CANCER SURV, V27, P249; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yu DH, 1996, ONCOGENE, V13, P1359; ZHANG LS, 1995, CANCER RES, V55, P3890	65	55	68	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1325	1332		10.1038/sj.onc.1202422	http://dx.doi.org/10.1038/sj.onc.1202422			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022814				2022-12-28	WOS:000078510900008
J	Latres, E; Chiaur, DS; Pagano, M				Latres, E; Chiaur, DS; Pagano, M			The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin	ONCOGENE			English	Article						ubiquitin; F-box; SCF; beta-catenin; cancer	CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; HUMAN FIBROBLASTS; PATHWAY; KINASE	Ubiquitin-conjugation targets numerous cellular regulators for proteasome-mediated degradation. Thus, the identification of ubiquitin ligases and their physiological substrates is crucially important, especially for those cases in which aberrant levels of regulatory proteins (e.g., beta-catenin, p27) result from a deregulated ubiquitination pathway. In yeast, the proteolysis of several G1 regulators is controlled by ubiquitin ligases (or SCFs) formed by three subunits: (S) under bar kp1, (C) under bar ul A (Cdc53), and one of many (F) under bar-box proteins. Specific F-box proteins (Fbps) recruit different substrates to the SCF, Although many Fbps have been identified in mammals, their specific substrates and the existence of multiple SCFs have not yet been reported. We have found that one human Fbp, beta-Trcp (beta-Transducin repeat containing protein), does indeed form a novel SCF with human Skp1 and Cul1. Consistent with recent reports indicating that Xenopus and Drosophila beta-Trcp homologs act as negative regulators of the wnt/beta-catenin signaling pathway, we report here that human beta-Trcp interacts with beta-catenin in vivo, Furthermore, beta-catenin is specifically stabilized in vivo by the expression of a dominant negative beta-Trcp, These results indicate that the Cul1/Skp1/beta-Trcp complex forms a ubiquitin ligase that mediates the degradation of beta-catenin.	NYU Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University	Pagano, M (corresponding author), NYU Med Ctr, Dept Pathol, MSB 548,550 1st Ave, New York, NY 10016 USA.		高, 雨莉/HGU-8187-2022	pagano, michele/0000-0003-3210-2442	NATIONAL CANCER INSTITUTE [R01CA076584, T32CA009161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER; NCI NIH HHS [5T32-CA09161, R01-CA76584] Funding Source: Medline; NIGMS NIH HHS [R01-GM57587] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; GONEN H, 1999, UNPUB; HANNON GJ, 1995, CELL CYCLE MAT METHO, P231; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; KIPREOS ET, 1999, UNPUB; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MOUNTAIN HA, 1993, MOL MICROBIOL, V7, P215, DOI 10.1111/j.1365-2958.1993.tb01113.x; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Pennisi E, 1998, SCIENCE, V281, P1438, DOI 10.1126/science.281.5382.1438; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SPEVAK W, 1993, MOL CELL BIOL, V13, P4953, DOI 10.1128/MCB.13.8.4953; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324	26	354	367	3	15	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					849	854		10.1038/sj.onc.1202653	http://dx.doi.org/10.1038/sj.onc.1202653			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023660				2022-12-28	WOS:000078510600001
J	Dkhissi, F; Raynal, SP; Jullien, P; Lawrence, DA				Dkhissi, F; Raynal, SP; Jullien, P; Lawrence, DA			Growth stimulation of murine fibroblasts by TGF-beta 1 depends on the expression of a functional p53 protein	ONCOGENE			English	Article						TGF-beta 1; P53; pRB; SV40; p21Waf; growth stimulation; growth inhibition	LARGE TUMOR-ANTIGEN; RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE PROGRESSION; FACTOR-BETA; TGF-BETA; MOUSE FIBROBLASTS; TRANSFORMING GROWTH-FACTOR-BETA-1; DOWN-REGULATION; INDUCTION; INHIBITION	Transforming Growth Factor-beta 1 (TGF-beta 1) inhibits the proliferation of most cells, but stimulates some mesenchymal cell types, including murine NIH3T3 fibroblasts, We show here that TGF-beta 1 growth stimulation of NIH3T3 fibroblasts is reversed when these cells are transformed by SV40 or are transfected with a plasmid encoding the SV40 Large T antigen. Inversion of the TGF-beta 1 growth stimulation of NIH3T3 cells is not observed when these cells are transfected with plasmids expressing either a mutant Large T, unable to bind P53, or the E1A adenovirus oncoprotein which binds the retinoblastoma protein pRB but not P53, But when the TGF-beta 1-growth stimulated cells are transfected with a plasmid expressing a mutant form of Large T capable of binding to P53, but not to pRB, or with one expressing the E1B-55 kD adenovirus oncoprotein, which also binds to P53 but not to pRB, the cells are growth-inhibited by TGF-beta 1. The cdk inhibitor p21Waf is decreased in TGF-beta 1-stimulated NIH3T3 fibroblasts and increased in TGF-beta 1-inhibited SV40-transformed cells. Finally, we show that T12 fibroblasts, from a P53 knockout mouse, are growth inhibited by TGF-beta 1 and that they remain so upon transfection with a P53 which is mutant at restrictive temperature, but become growth-stimulated by this factor at permissive temperature when P53 is functional. These data strongly suggest that growth-stimulation of fibroblasts by TGF-beta 1 depends on the presence of a functional P53 protein and that inversion of this response occurs if P53 is absent or inactivated.	CNRS, UPR 9079, F-94801 Villejuif, France; CNRS, Inst Curie, UMR 146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Lawrence, DA (corresponding author), CNRS, UPR 9079, BP 8, F-94801 Villejuif, France.							ALEXANDROW MG, 1995, CANCER RES, V55, P1452; BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; Benzakour O, 1992, GROWTH FACTORS, V6, P265, DOI [10.3109/08977199209021539, 10.3109/08977199209026933]; BLAYDES JP, 1995, ONCOGENE, V10, P307; DANIEL TO, 1987, J BIOL CHEM, V262, P11893; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evangelisti R, 1997, CELL BIOCHEM FUNCT, V15, P47; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GREGOIRE M, 1984, EXP CELL RES, V152, P38, DOI 10.1016/0014-4827(84)90228-3; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HILL DJ, 1986, J CELL PHYSIOL, V128, P322, DOI 10.1002/jcp.1041280226; HUANG F, 1994, ONCOGENE, V9, P3701; JOCHEMSEN AG, 1987, EMBO J, V6, P3399, DOI 10.1002/j.1460-2075.1987.tb02663.x; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KIM TA, 1993, CANCER LETT, V71, P125, DOI 10.1016/0304-3835(93)90107-K; KIM TA, 1994, J CELL PHYSIOL, V160, P1, DOI 10.1002/jcp.1041600102; KOIKE M, 1994, BIOCHEM BIOPH RES CO, V201, P673, DOI 10.1006/bbrc.1994.1753; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAWRENCE DA, 1995, KIDNEY INT, V47, P19; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; MACHWATE M, 1995, MOL ENDOCRINOL, V9, P187, DOI 10.1210/me.9.2.187; Malliri A, 1996, CELL GROWTH DIFFER, V7, P1291; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MICHIELI P, 1994, CANCER RES, V54, P3391; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MULLER W, 1975, EUR J BIOCHEM, V54, P385, DOI 10.1111/j.1432-1033.1975.tb04149.x; NAGY J A, 1988, Biochimica et Biophysica Acta, V948, P305; OKADOME T, 1994, J BIOL CHEM, V269, P30753; ONG G, 1991, ONCOGENE, V6, P761; ORMEROD MG, 1992, J IMMUNOL METHODS, V153, P57, DOI 10.1016/0022-1759(92)90305-D; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; RAVITZ MJ, 1995, CANCER RES, V55, P1413; RAYNAL S, 1994, GROWTH FACTORS, V11, P197, DOI 10.3109/08977199409046917; RAYNAL S, 1995, INT J ONCOL, V7, P337; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBERTS AB, 1990, HDB EXPT PHARM, V95; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Sgambato A, 1997, CELL GROWTH DIFFER, V8, P393; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; WATABE K, 1994, J NEUROSCI RES, V39, P525, DOI 10.1002/jnr.490390504; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0	49	20	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					703	711		10.1038/sj.onc.1202341	http://dx.doi.org/10.1038/sj.onc.1202341			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989820				2022-12-28	WOS:000078394400015
J	Giamarchi, C; Solanas, M; Chailleux, C; Augereau, P; Vignon, F; Rochefort, H; Richard-Foy, H				Giamarchi, C; Solanas, M; Chailleux, C; Augereau, P; Vignon, F; Rochefort, H; Richard-Foy, H			Chromatin structure of the regulatory regions of pS2 and cathepsin D genes in hormone-dependent and -independent breast cancer cell lines	ONCOGENE			English	Article						breast cancer; chromatin; pS2; cathepsin D; estrogens; IGFI	ESTROGEN-RESPONSIVE ELEMENT; GROWTH-FACTORS; RECEPTOR; PROMOTER; BINDING; ANTIESTROGENS; EXPRESSION; PROTEIN; CBP; TRANSFECTION	We have compared the DNase I hypersensitivity of the regulatory region of two estrogen-regulated genes, pS2 and cathepsin D in hormone-dependent and -independent breast carcinoma cell lines. This strategy allowed the identification of two important control regions, one in pS2 and the other in cathepsin D genes, In the hormone-dependent MCF7 cell line within the pS2 gene 5'-flanking region, we detected two major DNase I hypersensitive sites, induced by estrogens and/or IGFI: pS2-HS1, located in the proximal promoter and pS2-HS4, located -10.5 Kb from the CAP site, within a region that has not been cloned. The presence of these two DNase I hypersensitive sites correlates with pS2 expression. Interestingly in MCF7 cells, estrogens and IGFI induced indistinguishable chromatin structural changes over the pS2 regulatory region, suggesting that the two transduction-pathways converge to a unique chromatin target, In two cell lines that do not express pS2, MDA MB 231, a hormone-independent cell line that lacks the estrogen receptor alpha, and HE5, a cell line derived from MDA MB 231 by transfection that expresses estrogen receptor alpha, there was only one hormone-independent DNase I hypersensitive site. This site, pS2-HS2, was located immediately upstream of pS2-HS1, In MCF7 cells, two major DNase I hypersensitive sites were present in the 5'-flanking sequences of the cathepsin D gene, which is regulated by estrogens in these cells. These sites, catD-HS2 and catD-HS3, located at positions -2.3 Kb and -3.45 Kb, respectively, were both hormone-independent. A much weaker site, catD-HS1, covered the proximal promoter. In MDA MB 231 cells, that express cathepsin D constitutively we detected an additional strong hormone-independent DNase I hypersensitive site, catD-HS4, located at position -4.3 Kb, This region might control the constitutive over-expression of cathepsin D in hormone-independent breast cancer cells, All together, these data demonstrate that a local reorganization of the chromatin structure over pS2 and cathepsin D promoters accompanies the establishment of the hormone-independent phenotype of the cells.	CNRS, Lab Biol Mol Eucaryote, F-31062 Toulouse, France; Univ Autonoma Barcelona, Fac Med, Dept Biol Cellular & Fisiol, E-08193 Barcelona, Spain; INSERM, U148, Unite Hormones & Canc, F-34090 Montpellier, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Autonomous University of Barcelona; University of Barcelona; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Richard-Foy, H (corresponding author), CNRS, Lab Biol Mol Eucaryote, 118 Route Narbonne, F-31062 Toulouse, France.		Solanas Garcia, Montserrat/O-4684-2016; Medale Giamarchi, Claire/M-3263-2014	Solanas Garcia, Montserrat/0000-0003-2949-1344; 				AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; CARR KD, 1990, P NATL ACAD SCI USA, V87, P9300, DOI 10.1073/pnas.87.23.9300; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552; CAVAILLES V, 1993, P NATL ACAD SCI USA, V90, P203, DOI 10.1073/pnas.90.1.203; CHALBOS D, 1993, ENDOCRINOLOGY, V133, P571, DOI 10.1210/en.133.2.571; CHALBOS D, 1992, J STEROID BIOCHEM, V43, P223, DOI 10.1016/0960-0760(92)90211-Z; Dumont JA, 1996, CELL GROWTH DIFFER, V7, P351; FOEKENS JA, 1993, J CLIN ONCOL, V11, P899, DOI 10.1200/JCO.1993.11.5.899; GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538; Gillesby BE, 1997, BIOCHEMISTRY-US, V36, P6080, DOI 10.1021/bi962131b; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; LEVENSON AS, 1994, J STEROID BIOCHEM, V51, P229, DOI 10.1016/0960-0760(94)90035-3; Martin V, 1997, J CELL BIOCHEM, V65, P95, DOI 10.1002/(SICI)1097-4644(199704)65:1<95::AID-JCB10>3.0.CO;2-G; Montminy M, 1997, NATURE, V387, P654, DOI 10.1038/42594; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; RICHARDFOY H, 1987, MOL ENDOCRINOL, V1, P659, DOI 10.1210/mend-1-9-659; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROCHEFORT H, 1990, BREAST CANCER RES TR, V16, P3, DOI 10.1007/BF01806570; Sewack GF, 1997, J BIOL CHEM, V272, P31118, DOI 10.1074/jbc.272.49.31118; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TOUITOU I, 1991, J STEROID BIOCHEM, V40, P231, DOI 10.1016/0960-0760(91)90187-A; VIGNON F, 1987, BIOCHEM BIOPH RES CO, V146, P1502, DOI 10.1016/0006-291X(87)90819-9; Vladusic EA, 1998, CANCER RES, V58, P210	32	43	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					533	541		10.1038/sj.onc.1202317	http://dx.doi.org/10.1038/sj.onc.1202317			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927210				2022-12-28	WOS:000078166500026
J	Spencer, W; Kwon, H; Crepieux, P; Leclerc, N; Lin, RT; Hiscott, J				Spencer, W; Kwon, H; Crepieux, P; Leclerc, N; Lin, RT; Hiscott, J			Taxol selectively blocks microtubule dependent NF-kappa B activation by phorbol ester via inhibition of I kappa-B alpha phosphorylation and degradation	ONCOGENE			English	Article						NF-kappa B; taxol; I kappa B; microtubules; gene regulation	PROTEIN-KINASE-C; SIGNAL-INDUCED PHOSPHORYLATION; TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; GENE-EXPRESSION; TRANSDUCTION PATHWAY; ARACHIDONIC-ACID; CANCER CELLS; MAP KINASE; TNF-ALPHA	Activation of the NF-kappa B transcription factors has been shown to be directly influenced by changes in the microtubule cytoskeleton network, To better understand cytoskeletal regulation of NF-kappa B, experiments were performed to determine whether the microtubule (MT) stabilizing agent taxol could modulate NF-kappa B activation in the presence of different NF-kappa B inducers. Pretreatment of murine NIH3T3 and human 293 cells with 5 mu M taxol resulted in complete inhibition of phorbol, 12-myristate, 13-acetate (PMA) mediated NF-kappa B activation, detected as the loss of DNA binding and reduced NF-kappa B dependent reporter gene activity. Furthermore, in COS-7 and NIH3T3 cells, PMA-induced I kappa B alpha turnover was dramatically reduced in taxol treated cells, mediated via the inhibition of I kappa-B alpha phosphorylation, However, taxol did not prevent TNF-alpha induced I kappa B alpha phosphorylation, degradation, or NF-kappa B activation, indicating that TNF-alpha acts through a microtubule-independent pathway. In vitro kinase assays with PMA stimulated cell extracts demonstrated that taxol reduced protein kinase C activity by 30%, thus implicating the loss of PKC activity as a possible regulatory target of taxol-mediated suppression of NF-kappa B, Since PMA causes modulation of cytoarchitecture through PKC activation, microtubule integrity and cell morphology was analysed by indirect immunofluorescence. Both PMA and nocodazole, a MT depolymerizing agent, caused microtubule depolymerization, whereas TNF-alpha did not alter MT integrity; concomitant taxol treatment blocked both nocodazole and PMA induced depolymerization of MTs, as well as NF-kappa B induction, thus demonstrating a link between microtubule depolymerization and NF-kappa B activation, These observations illustrate a novel biological activity of taxol as a selective inhibitor of NF-kappa B activity, suggesting a link between the state of microtubule integrity and gene regulation.	McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; Univ Montreal, Dept Pathol, Montreal, PQ H3C 3J7, Canada	Lady Davis Institute; McGill University; McGill University; McGill University; Universite de Montreal	Hiscott, J (corresponding author), McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada.		Crepieux, Pascale/X-3217-2019; Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503; Spencer, Will/0000-0003-0633-1575				ALEXANDROVA AY, 1993, CELL MOTIL CYTOSKEL, V25, P254, DOI 10.1002/cm.970250306; ARNAL I, 1995, CURR BIOL, V5, P900, DOI 10.1016/S0960-9822(95)00180-1; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Basu A, 1996, CELL GROWTH DIFFER, V7, P1507; BASU A, 1990, J BIOL CHEM, V265, P8451; Beauparlant Pierre, 1996, Cytokine and Growth Factor Reviews, V7, P175, DOI 10.1016/1359-6101(96)00020-2; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BITAR R, 1995, CELL GROWTH DIFFER, V6, P965; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Bouron A, 1997, FEBS LETT, V404, P221, DOI 10.1016/S0014-5793(97)00135-X; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; Crepieux P, 1997, MOL CELL BIOL, V17, P7375, DOI 10.1128/MCB.17.12.7375; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Debal V, 1997, ANTICANCER RES, V17, P1147; DEBRABANDER MJ, 1976, CANCER RES, V36, P905; DEVENTE J, 1995, CELL GROWTH DIFFER, V6, P371; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DwyerNield LD, 1996, AM J PHYSIOL-LUNG C, V270, pL526, DOI 10.1152/ajplung.1996.270.4.L526; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FOGUEIRA L, 1996, J VIROL, V70, P223; Forgacs G, 1995, BIOCHEM CELL BIOL, V73, P317, DOI 10.1139/o95-040; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; Haldar S, 1996, CANCER RES, V56, P1253; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HUGHES DA, 1995, SEMIN CELL BIOL, V6, P89, DOI 10.1016/1043-4682(95)90005-5; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; JUN CD, 1995, J IMMUNOL, V154, P6541; KAWASUGI K, 1995, CELL MOTIL CYTOSKEL, V31, P215, DOI 10.1002/cm.970310305; Kiley SC, 1997, CELL GROWTH DIFFER, V8, P231; Lee LF, 1997, MOL CELL BIOL, V17, P5097, DOI 10.1128/MCB.17.9.5097; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Liu DC, 1996, CELL IMMUNOL, V174, P73, DOI 10.1006/cimm.1996.0295; Lyss G, 1997, BIOL CHEM, V378, P951, DOI 10.1515/bchm.1997.378.9.951; MANGOURA D, 1995, DEV BRAIN RES, V87, P1, DOI 10.1016/0165-3806(95)00046-G; MANIE S, 1993, J BIOL CHEM, V268, P13675; McGowan K, 1996, J CELL PHYSIOL, V167, P113, DOI 10.1002/(SICI)1097-4652(199604)167:1<113::AID-JCP13>3.0.CO;2-C; MELAMED I, 1995, BIOCHEM BIOPH RES CO, V209, P1102, DOI 10.1006/bbrc.1995.1611; MOORE GD, 1995, DEV BIOL, V170, P519, DOI 10.1006/dbio.1995.1233; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NIU MY, 1994, CELL MOTIL CYTOSKEL, V27, P327, DOI 10.1002/cm.970270405; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Reszka AA, 1997, MOL BIOL CELL, V8, P1219, DOI 10.1091/mbc.8.7.1219; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; ROULSTON A, 1993, J VIROL, V67, P5235, DOI 10.1128/JVI.67.9.5235-5246.1993; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Seufferlein T, 1996, CANCER RES, V56, P5758; Shibata Y, 1996, J IMMUNOL, V156, P772; Simms H, 1996, J LAB CLIN MED, V127, P364, DOI 10.1016/S0022-2143(96)90185-7; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Sun SC, 1996, MOL CELL BIOL, V16, P1058; SWEET MJ, 1995, J INFLAMM, V45, P126; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Vani K, 1997, BBA-MOL CELL RES, V1358, P67, DOI 10.1016/S0167-4889(97)00079-7; Veis N, 1996, J INFLAMM, V46, P106; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Young SW, 1996, FEBS LETT, V384, P181, DOI 10.1016/0014-5793(96)00287-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	78	42	42	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					495	505		10.1038/sj.onc.1202335	http://dx.doi.org/10.1038/sj.onc.1202335			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927206				2022-12-28	WOS:000078166500022
J	Moorman, JP; Luu, D; Wickham, J; Bobak, DA; Hahn, CS				Moorman, JP; Luu, D; Wickham, J; Bobak, DA; Hahn, CS			A balance of signaling by Rho family small GTPases RhoA, Rac1 and Cdc42 coordinates cytoskeletal morphology but not cell survival	ONCOGENE			English	Article						Rho family; apoptosis; cytoskeleton; C3 exoenzyme	BINDING PROTEIN-RHO; ACTIN STRESS FIBERS; FOCAL COMPLEXES; T-LYMPHOCYTES; TOXIN-A; RAS; TRANSDUCTION; APOPTOSIS; EXPRESSION; ACTIVATION	Rho family GTPases are known to be involved in cytoskeletal reorganization. We examined the possibility that these functions may be dictated by a balance of Rho family GTPase signaling. Using transient viral expression of RhoA, Rac1, Cdc42 and their mutants, as well as C3 exoenzyme, we altered cytoskeletal organization under normal growth conditions. Overexpression of wild-type or constitutively active forms of the Rho family GTPases led to their respective activation phenotypes, Overexpression of dominant negative forms of given Rho family GTPases led to a phenotype consistent with activation of the other Rho family GTPase, Treatment with C, difficile toxin A, that inactivates all Rho family GTPases, led to the transient appearance of a variety of activation phenotypes, Previously, we reported that inactivation of Rho led to induction of apoptosis, implying that Rho may play an important role in cell survival signaling. This signaling, however, is not affected by expression of tiny forms of Rad or Cdc42, and only inactivation of Rho led to induction of apoptosis, Rho family GTPases appear to coordinate cytoskeletal organization by a balance of signaling, while cell survival is regulated by :I distinct Rho-mediated signaling pathway.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Hahn, CS (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001478, R01AI033434] Funding Source: NIH RePORTER; NIAID NIH HHS [AI01478, AI33434] Funding Source: Medline; NIGMS NIH HHS [GM54572] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; ChavesOlarte E, 1997, J CLIN INVEST, V100, P1734, DOI 10.1172/JCI119698; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; FIORENTINI C, 1991, TOXICON, V29, P543, DOI 10.1016/0041-0101(91)90050-2; Galandrini R, 1997, IMMUNITY, V7, P163, DOI 10.1016/S1074-7613(00)80519-1; Gomez J, 1997, EUR J IMMUNOL, V27, P2793, DOI 10.1002/eji.1830271108; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; HAHN CS, 1992, P NATL ACAD SCI USA, V89, P2679, DOI 10.1073/pnas.89.7.2679; Hall A, 1995, GUIDEBOOK SMALL GTPA, P3; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Li GP, 1997, J BIOL CHEM, V272, P10337; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Lores P, 1997, ONCOGENE, V15, P601, DOI 10.1038/sj.onc.1201378; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Moorman JP, 1996, J IMMUNOL, V156, P4146; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SZAMEL M, 1995, EUR J BIOCHEM, V228, P1; THELESTAM M, 1984, J TOXICOL-TOXIN REV, V3, P139, DOI 10.3109/15569548409097924; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	33	81	81	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					47	57		10.1038/sj.onc.1202262	http://dx.doi.org/10.1038/sj.onc.1202262			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926919				2022-12-28	WOS:000078166000006
J	Simoneau, M; Aboulkassim, TO; LaRue, H; Rousseau, F; Fradet, Y				Simoneau, M; Aboulkassim, TO; LaRue, H; Rousseau, F; Fradet, Y			Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31	ONCOGENE			English	Article						chromosome 9; microsatellites; bladder cancer; tumor suppressor gene	TRANSITIONAL-CELL CARCINOMA; INTERNATIONAL WORKSHOP; HOMOZYGOUS DELETIONS; GENE; YAC; UK; HETEROZYGOSITY; LOCALIZATION; CAMBRIDGE; COLLEGE	The most common genetic alteration identified in transitional cell carcinoma (TCC) of the bladder is loss of heterozygosity (LOH) on chromosome 9, However, localization of tumor suppressor genes on 9q has been hampered by the low frequency of subchromosomal deletions. We have analysed 139 primary, initial low stage TCC of the bladder using a panel of 28 microsatellite markers spanning chromosome 9 at an average distance of 5 Mb, following a primer-extension preamplification (PEP) technique. Sixty-seven (48%) tumors showed LOH at one or more loci and partial deletions were detected in 62 (45%) tumors; apparent monosomy 9 was detected in only five (4%) tumors. Deletions were more frequent on 9q (44%) than on 9p (23%), the latter being mostly associated with 9q deletion, suggesting that alteration of genes on 9q may be an early event associated with superficial papillary tumors. Combined data from the cases with partial 9q deletions displayed four candidate regions for tumor suppressor loci, based on the frequency of deletion observed and tumors with unique deletions at these sites. In two tumors, the unique partial deletion comprised D9S12 at 9q22.3, a region encompassing loci for the Gorlin syndrome and multiple self-healing squamous epithelioma gene. In two other tumors, the single LOH was identified at the D9S172 locus at 9q31-32 where the dysautonia and Fukuyama-type congenital muscular dystrophy genes have been Located. One tumor showed unique LOH at the GSN locus at 9q33, a region frequently deleted in other sporadic tumors while the fourth region of deletion was observed at 9q34 between ASS and ABL-I, in two tumors. This region is frequently deleted in tumors and encompasses the locus for the hereditary hemorrhagic telangiectasia gene. These findings suggest four target regions on 9q within which suppressor genes for TCC may reside.	Pavillon Hotel Dieu Quebec, Ctr Rech Cancerol, Lab Urooncol Expt, Quebec City, PQ, Canada; CHU Quebec, Unite Rech Genet Humaine & Mol, Quebec City, PQ, Canada	Laval University; Laval University	Fradet, Y (corresponding author), Pavillon Hotel Dieu Quebec, Ctr Rech Cancerol, Lab Urooncol Expt, Quebec City, PQ, Canada.			Fradet, Yves/0000-0002-7581-2500	NCI NIH HHS [CA47526] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA047526, R01CA047526] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allard P, 1995, CLIN CANCER RES, V1, P1195; CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1993, CANCER RES, V53, P1230; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; DEVLIN J, 1994, ONCOGENE, V9, P2757; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; HABUCHI T, 1995, ONCOGENE, V11, P1671; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; Hornigold N, 1997, GENOMICS, V41, P385, DOI 10.1006/geno.1997.4681; KAMB A, 1994, SCIENCE, V264, P440; KEEN AJ, 1994, ONCOGENE, V9, P2083; KNOWLES MA, 1994, CANCER RES, V54, P531; LARUE H, 1995, CLIN CANCER RES, V1, P435; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; MARCHUK DA, 1994, ANN HUM GENET, V58, P224; MCDONALD MT, 1994, NAT GENET, V6, P197, DOI 10.1038/ng0294-197; MELDGAARD P, 1995, INT J CANCER, V63, P341, DOI 10.1002/ijc.2910630306; MERLO A, 1994, CANCER RES, V54, P2322; Miyake M, 1997, GENOMICS, V40, P284, DOI 10.1006/geno.1996.4584; MIYAO N, 1993, CANCER RES, V53, P4066; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NORTHRUP H, 1994, ANN HUM GENET, V58, P229; OLOPADE OI, 1992, CANCER RES, V52, P2523; ORLOW I, 1994, CANCER RES, V54, P2848; Ozelius LJ, 1997, GENOME RES, V7, P483, DOI 10.1101/gr.7.5.483; PERICAKVANCE MA, 1995, ANN HUM GENET, V59, P347, DOI 10.1111/j.1469-1809.1995.tb00756.x; Povey S, 1997, ANN HUM GENET, V61, P183, DOI 10.1017/S0003480097006106; POVEY S, 1994, ANN HUM GENET, V58, P177, DOI 10.1111/j.1469-1809.1994.tb01887.x; POVEY S, 1992, ANN HUM GENET, V56, P167, DOI 10.1111/j.1469-1809.1992.tb01145.x; ROUSSEAU F, 1994, HUM MUTAT, V4, P51, DOI 10.1002/humu.1380040107; RUPPERT JM, 1993, CANCER RES, V53, P5093; Shapiro GI, 1996, BBA-REV CANCER, V1242, P165, DOI 10.1016/0304-419X(95)00011-4; Simoneau AR, 1996, CANCER RES, V56, P5039; STADLER WM, 1994, CANCER RES, V54, P2060; TANAKA M, 1995, CANCER RES, V55, P3228; Van Tilborg AAG, 1998, INT J CANCER, V75, P9, DOI 10.1002/(SICI)1097-0215(19980105)75:1<9::AID-IJC2>3.3.CO;2-I; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847	39	90	95	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					157	163		10.1038/sj.onc.1202277	http://dx.doi.org/10.1038/sj.onc.1202277			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926930	Bronze			2022-12-28	WOS:000078166000017
J	Stahler, F; Roemer, K				Stahler, F; Roemer, K			Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wild-type p53	ONCOGENE			English	Article						cell death; p53; c-Myc; serine protease	KAPPA-B ACTIVATION; DNA-DAMAGE; INDUCE APOPTOSIS; HEPATOMA-CELLS; GROWTH ARREST; DOMAIN; CHECKPOINT; PROMOTERS; PROTEIN; DEATH	Wild-type (wt) p53 frequently induces apoptosis when expressed in tumor cells whereas mutant p53 acts as an oncoprotein and consequently, stimulates cell proliferation. We report here exceptions to that rule, p53 conformational mutant 175H and DNA contact mutant 273H provoke apoptosis in human p53-deficient Hep3B hepatoma cells with delayed kinetics relative to wt p53. Similarly, c-Myc strongly stimulates apoptosis in these cells. In contrast,, viral oncoproteins EIA and E7, and the cellular oncoprotein MDM-2, fail to elicit cytocidal responses. Efficient apoptotic cell death by mutant p53 requires oligomerization as 175H and 273H with deletions between amino acid residues 326 and 347 of the oligomerization domain are nontoxic. Apoptosis by mutant or wt p53 was significantly inhibited by the serine protease inhibitor AEBSF but not by the inactive analog AEBSA, Together, these results suggest that a nit p53-independent control mechanism is operational in Hep3B cells that eliminates cells upon sensing illegitimate proliferation signals originating from certain oncoproteins, including mutant p53 and Myc. We suggest that some tumor cell types lack p53 altogether because they tolerate neither wild-type nor mutant forms of the protein.	Univ Saarlandes, Sch Med, Dept Virol, D-66421 Homburg, Germany	Saarland University	Roemer, K (corresponding author), Univ Saarlandes, Sch Med, Dept Virol, D-66421 Homburg, Germany.							ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chandler JM, 1997, BIOCHEM J, V322, P19, DOI 10.1042/bj3220019; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Friedman SL, 1997, ONCOGENE, V15, P63, DOI 10.1038/sj.onc.1201149; Fuchs EJ, 1997, CANCER RES, V57, P2550; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Roemer K, 1996, ONCOGENE, V12, P2069; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Theis S, 1997, INT J CANCER, V71, P858; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; YEE JK, 1994, METHOD CELL BIOL, V43, P99; YonishRouach E, 1995, ONCOGENE, V11, P2197	29	29	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3507	3512		10.1038/sj.onc.1202245	http://dx.doi.org/10.1038/sj.onc.1202245			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030675				2022-12-28	WOS:000078086200012
J	Baker, SJ; Reddy, EP				Baker, SJ; Reddy, EP			Modulation of life and death by the TNF receptor superfamily	ONCOGENE			English	Article						TNFR; death domain; apoptosis; TRAF; TRADD; FADD; DAXX; ASK; JNK; NF-kappa B	NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; INDUCED CELL-DEATH; SIGNALING COMPLEX; INDUCED APOPTOSIS; PROTEIN; ACTIVATION; DOMAIN; FAS; INVOLVEMENT	The tumor necrosis factor receptor (TNFR) superfamily represents a growing family, with over 20 members having been identified thus far in mammalian cells. These proteins share significant homologies in their extracellular ligand binding domains and intracellular effector (death) domains. These receptors appear to transmit their signals via protein-protein interactions, which convey either a death or survival signal. Isolation and characterization of death domain containing proteins (TRADD, FADD/MORT-1, RIP), TRAF domain containing proteins (TRAF1-6) as well as new members and adaptor proteins such as DAXX have provided new insights to our understanding of signaling mechanisms associated with this family of receptors, While the death signals seem to be associated,vith the activation of both the caspase and JUN kinase pathways, the survival signals are mediated via the activation of the NF-kappa B pathway.	Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Baker, SJ (corresponding author), Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, 3307 N Broad St, Philadelphia, PA 19140 USA.		Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [CA 65779] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065779] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Boise LH, 1996, SCIENCE, V274, P67, DOI 10.1126/science.274.5284.67; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CONLEY ME, 1994, CURR OPIN GENET DEV, V4, P401, DOI 10.1016/0959-437X(94)90028-0; DADOGSTAR H, 1998, J BIOL CHEM, V273, P24775; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Force WR, 1997, J BIOL CHEM, V272, P30835, DOI 10.1074/jbc.272.49.30835; Gilmore TD, 1996, ONCOGENE, V13, P1367; Grammer AC, 1998, J IMMUNOL, V161, P1183; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HOFFMAN B, 1994, ONCOGENE, V9, P1807; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; HU HM, 1994, J BIOL CHEM, V269, P30069; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; ITOH N, 1993, J BIOL CHEM, V268, P10932; Kawamata S, 1998, J BIOL CHEM, V273, P5808, DOI 10.1074/jbc.273.10.5808; KELLIHER MA, 1998, CELL, V8, P297; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; Miller WE, 1997, J VIROL, V71, P586, DOI 10.1128/JVI.71.1.586-594.1997; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHITE JL, 1995, INT POLYM PROC, V10, P15, DOI 10.3139/217.950015; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WILLIAMS G T, 1992, Trends in Cell Biology, V2, P263, DOI 10.1016/0962-8924(92)90198-V; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Winoto A, 1997, CURR OPIN IMMUNOL, V9, P365, DOI 10.1016/S0952-7915(97)80083-0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Yuan JY, 1996, J CELL BIOCHEM, V60, P4, DOI 10.1002/(SICI)1097-4644(19960101)60:1<4::AID-JCB2>3.0.CO;2-1; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	75	463	481	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 24	1998	17	25					3261	3270		10.1038/sj.onc.1202568	http://dx.doi.org/10.1038/sj.onc.1202568			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916988				2022-12-28	WOS:000078048200007
J	Angrist, M; Bolk, S; Bentley, K; Nallasamy, S; Halushka, MK; Chakravarti, A				Angrist, M; Bolk, S; Bentley, K; Nallasamy, S; Halushka, MK; Chakravarti, A			Genomic structure of the gene for the SH2 and pleckstrin homology domain-containing protein GRB10 and evaluation of its role in Hirschsprung disease	ONCOGENE			English	Article						Hirschsprung disease; GRB10; GRB-IR; RET receptor tyrosine kinase; mutation detection; genomic structure; mapping	ENDOTHELIN-B RECEPTOR; MICE LACKING GDNF; TYROSINE KINASE; RET PROTOONCOGENE; MUTATION ANALYSIS; INSULIN-RECEPTOR; BINDING-PROTEIN; GROWTH; FAMILY; CLONING	Hirschsprung disease (HSCR), or congenital aganglionic megacolon, is the most frequent cause of congenital bowel obstruction. Germline mutations in the RET receptor tyrosine kinase have been shown to cause HSCR. Mice that carry null alleles for RET or for its ligand, glial cell line-derived neurotrophic factor (GDNF), both exhibit complete intestinal aganglionosis and renal defects. Recently, the Src homology 2 (SH2) domain-containing protein Grb10 has been shown to interact with RET in vitro and in vivo, early in development. We have confirmed the map location of GRB10 on human chromosome 7, isolated human BACs containing the gene, elucidated its genomic structure, isolated a highly polymorphic microsatellite marker adjacent to exon 14 and scanned the gene for mutations in a large panel of HSCR patients. No evidence of linkage was detected in HSCR kindreds and no mutations were found in patients. These data suggest that while GRB10 may be important for signal transduction in developing embryos, it does not play an obvious role in HSCR.	Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Human Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Chakravarti, A (corresponding author), Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.			Halushka, Marc/0000-0002-7112-7389	NICHD NIH HHS [HD-28088] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028088] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Angrist M, 1995, GENOMICS, V30, P623, DOI 10.1006/geno.1995.1289; ANGRIST M, 1995, HUM MOL GENET, V4, P821, DOI 10.1093/hmg/4.5.821; Angrist M, 1998, GENOMICS, V48, P354, DOI 10.1006/geno.1997.5191; ANGRIST M, 1993, NAT GENET, V4, P351, DOI 10.1038/ng0893-351; Angrist M, 1996, NAT GENET, V14, P341, DOI 10.1038/ng1196-341; ANGRIST M, 1996, THESIS CASE W RESERV; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; BADNER JA, 1990, AM J HUM GENET, V46, P568; BODIAN M, 1963, ANN HUM GENET, V26, P261, DOI 10.1111/j.1469-1809.1963.tb01983.x; Bolande RP, 1997, PEDIATR PATHOL LAB M, V17, P1, DOI 10.1080/107710497174994; Bouffard GG, 1997, GENOME RES, V7, P673, DOI 10.1101/gr.7.7.673; Chakravarti A, 1996, HUM MOL GENET, V5, P303; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Hofstra RMW, 1996, NAT GENET, V12, P445, DOI 10.1038/ng0496-445; HOLSCHNEIDER AM, 1982, HIRSCHSPRUNGS DIS; Jerome CA, 1997, GENOMICS, V40, P215, DOI 10.1006/geno.1996.4535; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Kusafuka T, 1997, J PEDIATR SURG, V32, P501, DOI 10.1016/S0022-3468(97)90616-3; Kusafuka T, 1996, HUM MOL GENET, V5, P347, DOI 10.1093/hmg/5.3.347; Liu F, 1998, MOL CELL BIOCHEM, V182, P73, DOI 10.1023/A:1006899832614; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; LYONNET S, 1993, NAT GENET, V4, P346, DOI 10.1038/ng0893-346; Manser J, 1997, DEV BIOL, V184, P150, DOI 10.1006/dbio.1997.8516; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; MARGOLIS B, 1994, PROG BIOPHYS MOL BIO, V62, P223, DOI 10.1016/0079-6107(94)90013-2; Martin RE, 1997, DYSPHAGIA, V12, P2, DOI 10.1007/PL00009513; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; Okamoto E, 1967, J PEDIATR SURG, V2, P437; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1621; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; PUFFENBERGER EG, 1994, HUM MOL GENET, V3, P1217; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Seri M, 1997, HUM MUTAT, V9, P243; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; SPOUGE D, 1985, TERATOLOGY, V32, P171, DOI 10.1002/tera.1420320204; WEBSTER W, 1973, J EMBRYOL EXP MORPH, V30, P573	50	18	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	1998	17	23					3065	3070		10.1038/sj.onc.1202226	http://dx.doi.org/10.1038/sj.onc.1202226			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881709				2022-12-28	WOS:000077427800014
J	Herrmann, JL; Briones, F; Brisbay, S; Logothetis, CJ; McDonnell, TJ				Herrmann, JL; Briones, F; Brisbay, S; Logothetis, CJ; McDonnell, TJ			Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53	ONCOGENE			English	Article						proteasome; cell death; bcl-2; p53; prostate cancer	MULTICATALYTIC PROTEINASE COMPLEX; KAPPA-B-ALPHA; INDUCED APOPTOSIS; UBIQUITIN LIGASE; CANCER CELLS; IN-VIVO; C-JUN; DEGRADATION; PATHWAY; PHOSPHORYLATION	The ATP/ubiquitin-dependent 26S proteasome is a central regulator of cell cycle progression and stress responses. While investigating the application of peptide aldehyde proteasome inhibitors to block signal-induced I kappa B alpha degradation in human LNCaP prostate carcinoma cells, we observed that persistent inhibition of proteasomal activity signals a potent cell death program. Biochemically, this program included substantial upregulation of PAR-4 (prostate apoptosis response-4), a putative pro-apoptotic effector protein and stabilization of c-jun protein, a potent pro-death effector in certain cells. We also observed modest downregulation of bcl-X-L, a pro-survival effector protein. However, in contrast to some recent reports stable, high level, expression of functional bcl-2 protein in prostate carcinoma cells failed to signal protection against cell death induction by proteasome inhibitors. Also in disagreement to a recent report, no evidence was found for activation of the JNK stress kinase pathway, A role for p53, a protein regulated by the proteasome pathway, was ruled out, since comparable cell death induction by proteasome inhibitors occurred in PC-3 cells that db not express functional p53 protein. These data signify that the ubiquitin/proteasome pathway represents a potential therapeutic target for prostate cancers irrespective of bcl-2 expression or p53 mutations.	Univ Texas, MD Anderson Cancer Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Herrmann, JL (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Genitourinary Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.							BARTOLI F, 1994, J BIOL CHEM, V269, P15625; Beham A, 1997, ONCOGENE, V15, P2767, DOI 10.1038/sj.onc.1201464; Blagosklonny MV, 1996, CANCER RES, V56, P1851; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; Haldar S, 1996, CANCER RES, V56, P1253; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; Herrmann JL, 1997, EXP CELL RES, V234, P442, DOI 10.1006/excr.1997.3653; ISAACS WB, 1991, CANCER RES, V51, P4716; ISHIDA N, 1993, FEBS LETT, V324, P345, DOI 10.1016/0014-5793(93)80148-N; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Maki CG, 1996, CANCER RES, V56, P2649; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MCDONNELL TJ, 1993, MOL CARCINOGEN, V8, P209, DOI 10.1002/mc.2940080402; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Milligan SA, 1996, ARCH BIOCHEM BIOPHYS, V335, P388, DOI 10.1006/abbi.1996.9998; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rolfe M, 1997, J MOL MED-JMM, V75, P5, DOI 10.1007/s001090050081; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; Soldatenkov VA, 1997, CANCER RES, V57, P3881; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Tanimoto Y, 1997, J BIOCHEM-TOKYO, V121, P542; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TU SM, 1995, CANCER LETT, V93, P147, DOI 10.1016/0304-3835(95)03795-X; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; Westin P, 1997, INT J ONCOL, V10, P113; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x	52	110	115	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 3	1998	17	22					2889	2899		10.1038/sj.onc.1202221	http://dx.doi.org/10.1038/sj.onc.1202221			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879995				2022-12-28	WOS:000077286400009
J	Strobel, T; Tai, YT; Korsmeyer, S; Cannistra, SA				Strobel, T; Tai, YT; Korsmeyer, S; Cannistra, SA			BAD partly reverses paclitaxel resistance in human ovarian cancer cells	ONCOGENE			English	Article						apoptosis; BAD; drug resistance; paclitaxel; ovarian cancer	INDUCED APOPTOSIS; IN-VIVO; BCL-2 PHOSPHORYLATION; NEUROBLASTOMA-CELLS; MYELOID-LEUKEMIA; BCL-X(L); DEATH; TAXOL; EXPRESSION; OVEREXPRESSION	Although paclitaxel is an important chemotherapy agent for the treatment of patients with epithelial ovarian cancer, its utility is significantly limited by the frequent development of drug resistance, Recent evidence suggests that resistance to chemotherapy may be partly related to defects in the apoptotic pathway. In this study me have investigated whether enhancement of apoptotic pathway function through stable expression of the BAD protein is capable of sensitizing human epithelial ovarian cancer cells to the effects of chemotherapy. Expression of HA-BAD in sis separate clonal transfectants from two different ovarian cancer cell lines was found to significantly enhance the cytotoxic effects of paclitaxel, vincristine, and, to a lesser extent, etoposide, Enhancement of paclitaxel-induced apoptosis in HA-BAD-expressing clones was demonstrated by trypan blue exclusion, clonogenic cell assay, and flow cytometric evaluation. Importantly, this effect was associated with binding of HA-BAD to BCL-x(L) and concomitant disruption of BAX:BCL-x(L) interaction. Taken together, these data suggest that the development of small molecules which mimic the effects of BAD may represent a new class of drugs capable of preventing or reversing resistance to chemotherapy agents such as paclitaxel.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Div Mol Oncol, St Louis, MO 63110 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Washington University (WUSTL)	Cannistra, SA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA60670] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060670] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCECI RJ, 1993, BLOOD, V81, P2215; Blagosklonny MV, 1996, CANCER RES, V56, P1851; CABRAL FR, 1983, J CELL BIOL, V97, P22, DOI 10.1083/jcb.97.1.22; CANNISTRA SA, 1985, BLOOD, V65, P414; CANNISTRA SA, 1993, NEW ENGL J MED, V329, P1550, DOI 10.1056/NEJM199311183292108; CANNISTRA SA, 1993, CANCER RES, V53, P3830; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; DOLE MG, 1995, CANCER RES, V55, P2576; Dole MG, 1996, CANCER RES, V56, P5734; Dumontet C, 1996, CANCER RES, V56, P1091; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Haber M, 1995, J BIOL CHEM, V270, P31269, DOI 10.1074/jbc.270.52.31269; Haldar S, 1996, CANCER RES, V56, P1253; Horwitz S B, 1994, Ann Oncol, V5 Suppl 6, pS3; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Ibrado AM, 1997, CANCER RES, V57, P1109; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; IZQUIERDO MA, 1995, JNCI-J NATL CANCER I, V87, P1230; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Strobel T, 1997, CANCER RES, V57, P1228; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; Strobel T, 1997, ONCOGENE, V14, P2753, DOI 10.1038/sj.onc.1201132; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	37	32	34	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2419	2427		10.1038/sj.onc.1202180	http://dx.doi.org/10.1038/sj.onc.1202180			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824152				2022-12-28	WOS:000076927300001
J	Pietras, RJ; Pegram, MD; Finn, RS; Maneval, DA; Slamon, DJ				Pietras, RJ; Pegram, MD; Finn, RS; Maneval, DA; Slamon, DJ			Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs	ONCOGENE			English	Article						breast cancer; ovarian cancer; monoclonal antibody; HER-2/neu; cisplatin; doxorubicin	GROWTH-FACTOR RECEPTOR; NEU DIFFERENTIATION FACTOR; MAMMARY EPITHELIAL-CELLS; OVARIAN-CARCINOMA CELLS; INTERSTRAND CROSS-LINKS; PROTEIN-KINASE-C; TYROSINE KINASE; TUMOR-CELLS; C-ERBB-2 EXPRESSION; SIGNAL-TRANSDUCTION	HER-2 oncogene encodes a transmembrane growth factor receptor that is overexpressed in 25-30% of patients with primary breast and ovarian cancer, A murine monoclonal antibody, 4D5, to the extracellular domain of HER-2 receptor elicits cytostatic growth inhibition of tumor cells overexpressing HER-2 protein, but clinical use of this antibody is limited by genesis of human anti-mouse antibodies, To avoid this problem, a recombinant humanized 4D5 monoclonal antibody (rhuMAb HER-2) was developed and tested using a human tumor xenograft model, Human breast and ovarian cancer cells which overexpress HER-2 were inhibited in vivo by the rhuMAb HER-2 antibody, Tumor growth relative to control was reduced at all doses of antibody tested, and the magnitude of growth inhibition was directly related to dose of rhuMAb HER-2, Tumor growth resumed on termination of antibody therapy, indicating a cytostatic effect, To elicit a cytotoxic response, human breast tumor xenografts were treated with a combination of antibody and antitumor drugs, cisplatin or doxorubicin, The combination of antibody with either cisplatin or doxorubicin resulted in significantly greater growth inhibition, with the cisplatin combination demonstrating a greater response, In addition, therapy with cisplatin and antireceptor antibody elicited complete tumor remissions after 2-3 cycles of therapy, The schedule of administration of antireceptor antibody and cisplatin was critical for occurrence of antibody-induced potentiation in cisplatin cytotoxicity. Enhanced killing of tumor cells was found only if antibody and drug were given in close temporal proximity, Since interference with DNA repair pathways may contribute to this receptor-enhanced chemosensitivity, repair of cisplatin-damaged reporter DNA (pCMV-beta) was determined in human breast cells, As in studies of antibody-enhanced cisplatin cytotoxicity in vivo, treatment with rhuMAb HER-2 blocked the repair of cisplatin-damaged DNA. only if the antibody was administered in close temporal proximity to transfection of the drug-exposed reporter DNA, An alternative measure of DNA repair, unscheduled DNA synthesis, was also assessed, Treatment with either cisplatin or doxorubicin led to an increase in unscheduled DNA synthesis that was reduced by combined therapy with antireceptor antibody specific to HER-2-overexpressing breast cancer cells, Using a direct measure of DNA repair, therapy of HER-2-overexpressing cells with rhuMAb HER-2 also blocked the removal of cisplatin-induced DNA adducts. Expression of p21/WAF1, an important mediator of DNA repair, was disrupted in breast cancer cells with HER-2 overexpression, but not in control cells, after treatment with HER-2 antibody, thus suggesting cross-communication between the HER-2 signaling and DNA repair pathways, These data demonstrate an in vivo antiproliferative effect of rhuMAb HER-2 on tumors that overexpress HER-2 receptor and a therapeutic advantage in the administration of the antireceptor antibody in combination with chemotherapeutic agents.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA; Genentech Inc, San Francisco, CA 90078 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Roche Holding; Genentech	Slamon, DJ (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA.			Pietras, Richard/0000-0002-2846-3192	NCI NIH HHS [P01-CA32737, R01-CA60835, R01-CA36827] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA032737, R01CA036827] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ABOUDPIRAK E, 1989, P NATL ACAD SCI USA, V86, P3778, DOI 10.1073/pnas.86.10.3778; ABOUDPIRAK E, 1988, J NATL CANCER I, V80, P1605, DOI 10.1093/jnci/80.20.1605; ALLRED DC, 1992, J CLIN ONCOL, V10, P599, DOI 10.1200/JCO.1992.10.4.599; ANDREWS PA, 1988, CANCER RES, V48, P68; ARTEAGA CL, 1994, CANCER RES, V54, P3758; Bacus SS, 1996, ONCOGENE, V12, P2535; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BENZ CC, 1993, BREAST CANCER RES TR, V24, P85; BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; Boven E, 1996, EUR J CANCER, V32A, P1382, DOI 10.1016/0959-8049(96)00110-4; CAMPBELL RC, 1976, STAT BIOL; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; CHRISTEN RD, 1990, J CLIN INVEST, V86, P1632, DOI 10.1172/JCI114885; CHU G, 1994, J BIOL CHEM, V269, P787; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Cutts SM, 1996, J BIOL CHEM, V271, P5422, DOI 10.1074/jbc.271.10.5422; DESANTES K, 1992, CANCER RES, V52, P1916; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Dixit M, 1997, J NATL CANCER I, V89, P365, DOI 10.1093/jnci/89.5.365; DREBIN JA, 1988, ONCOGENE, V2, P387; ELDIERY WS, 1993, CELL, V75, P817; FENDLY BM, 1990, CANCER RES, V50, P1550; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HANCOCK MC, 1991, CANCER RES, V51, P4575; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HOFMANN J, 1988, INT J CANCER, V42, P382, DOI 10.1002/ijc.2910420313; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; ISONISHI S, 1991, CANCER RES, V51, P5903; ISONISHI S, 1990, J BIOL CHEM, V265, P3623; JENSEN L, 1988, MOL CELL BIOL, V8, P3964, DOI 10.1128/MCB.8.9.3964; JONES JC, 1991, J BIOL CHEM, V266, P7101; KASTAN MB, 1991, CANCER RES, V51, P6304; KINZEL V, 1990, CANCER RES, V50, P7932; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Kurbacher CM, 1996, CANCER LETT, V103, P183, DOI 10.1016/0304-3835(96)04212-7; LEMOINE NR, 1990, ONCOGENE, V5, P237; Lewis GD, 1996, CANCER RES, V56, P1457; Liu Y, 1996, CANCER RES, V56, P31; Lofts F J, 1992, Cancer Treat Res, V61, P161; MANEVAL DC, 1991, J NUCL MED, V32, P1837; MARTE BM, 1995, ONCOGENE, V10, P167; McDonald E, 1996, CANCER RES, V56, P2250; Mendelsohn J, 1997, J NATL CANCER I, V89, P341, DOI 10.1093/jnci/89.5.341; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; Nielsen D, 1996, GEN PHARMACOL-VASC S, V27, P251, DOI 10.1016/0306-3623(95)02013-6; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; Pauletti G, 1996, ONCOGENE, V13, P63; PEGRAM M, 1995, P AN M AM SOC CLIN, V14, P106; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; PIERCE JH, 1991, ONCOGENE, V6, P1189; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PRESS MF, 1993, CANCER RES, V53, P4960; PRESS MF, 1990, ONCOGENE, V5, P953; PUREWAL M, 1993, CANCER CHEMOTH PHARM, V33, P239, DOI 10.1007/BF00686222; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; RO J, 1989, CANCER RES, V49, P6941; SARUP JC, 1991, GROWTH REGULAT, V1, P72; SAWYER TW, 1988, CARCINOGENESIS, V9, P1197, DOI 10.1093/carcin/9.7.1197; SCANLON KJ, 1989, ANTICANCER RES, V9, P1301; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6479; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; SHEPARD HM, 1991, J CLIN IMMUNOL, V11, P117, DOI 10.1007/BF00918679; SLAMON DJ, 1989, CANCER CEL, V7, P371; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; SOULE HD, 1980, CANCER LETT, V10, P177, DOI 10.1016/0304-3835(80)90042-7; Tsai CM, 1996, CANCER RES, V56, P1068; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; VANDIEST PJ, 1992, PATHOL RES PRACT, V188, P344, DOI 10.1016/S0344-0338(11)81215-X; WAMPLER GL, 1992, CANCER CHEMOTH PHARM, V31, P111, DOI 10.1007/BF00685096; Wu GS, 1996, CLIN CANCER RES, V2, P623; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Yen L, 1997, ONCOGENE, V14, P1827, DOI 10.1038/sj.onc.1201019; Zhang LS, 1996, ONCOGENE, V12, P571; ZHEN WP, 1992, MOL CELL BIOL, V12, P3689, DOI 10.1128/MCB.12.9.3689	85	314	349	1	20	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2235	2249		10.1038/sj.onc.1202132	http://dx.doi.org/10.1038/sj.onc.1202132			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811454				2022-12-28	WOS:000076698200009
J	Sheppard, RD; Samant, SA; Rosenberg, M; Silver, LM; Cole, MD				Sheppard, RD; Samant, SA; Rosenberg, M; Silver, LM; Cole, MD			Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors	ONCOGENE			English	Article						N-myc; indolent B cell lymphoma; retroviral insertion; tumor progression	E-MU-MYC; PUTATIVE ONCOGENE PIM-1; FOLLICULAR LYMPHOMA; C-MYC; BCL-2 GENE; DIFFERENTIAL EXPRESSION; HUMAN NEUROBLASTOMAS; PROVIRAL INSERTION; LYMPHOCYTES-B; MICE BEARING	Little is known about stepwise deregulation of specific genes leading to lymphoid malignancy. Aberrant myc gene expression in transgenic mice is correlated with B cell lymphomagenesis. We generated a unique transgenic mouse model in which deregulated murine E mu-N-myc transgene expression leads to development of indolent B cell lymphoma. Tumor cells were monoclonal, morphologically mature and surface immunoglobulin expressing B cells. Tumors arose in a disease course and exhibited a cytoarchitectural appearance reminiscent of human follicular lymphoma. Yet tumor cells were staged as preB since they failed to rearrange the immunoglobulin light chain genes. Retroviral insertion mutagenesis analyses of adult transgenic mice infected as newborns with murine leukemia virus revealed decreased disease latency, increased lymphoma incidence and a histologically more mature tumor type. Proviral insertion sites were not equivalent when accelerated E mu-N-myc indolent lymphomas were compared to accelerated c-myc preB cell lymphomas. The bcl-2 gene was not disrupted in either spontaneous or provirally accelerated E mu-N-myc lymphomas. These findings suggest that tumor progression in N-myc-associated indolent B cell lymphoma can proceed along diverse pathways involving distinctly different combinations of deregulated and/or intact genes than those pathways described in highly aggressive forms of myc-related murine preB cell disease.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19140 USA	Princeton University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Sheppard, RD (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Lindhurst, Marjorie/AHD-3412-2022		NATIONAL CANCER INSTITUTE [R01CA039192] Funding Source: NIH RePORTER; NCI NIH HHS [CA39192] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ALEXANDER WS, 1989, ONCOGENE, V4, P575; BERNS A, 1991, J CELL BIOCHEM, V47, P130, DOI 10.1002/jcb.240470206; BERNS A, 1989, INT J CANCER, P22; BREUER M, 1991, CANCER RES, V51, P958; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND JL, 1986, J CELL BIOCHEM, V30, P195, DOI 10.1002/jcb.240300303; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COLLUM RG, 1990, CANCER CELL-MON REV, V2, P69; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; CUYPERS HT, 1984, CELL, V37, P141; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; DOLCETTI R, 1989, ONCOGENE, V4, P1009; FINKE J, 1993, J CLIN ONCOL, V11, P1668, DOI 10.1200/JCO.1993.11.9.1668; FRIZZERA G, 1991, AM J CLIN PATHOL, V95, P684, DOI 10.1093/ajcp/95.5.684; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GOATES JJ, 1994, AM J SURG PATHOL, V18, P37, DOI 10.1097/00000478-199401000-00004; GRAY DA, 1991, CANCER INVEST, V9, P295; HAMILTON MS, 1991, LEUKEMIA, V5, P768; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Harris NL, 1992, NEOPLASTIC HEMATOPAT, P645; HAUPT Y, 1993, ONCOGENE, V8, P3161; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HILKENS J, 1986, SOMAT CELL MOLEC GEN, V12, P81, DOI 10.1007/BF01560730; HILLION J, 1991, ONCOGENE, V6, P169; HIRVONEN H, 1991, BLOOD, V78, P3012; HIRVONEN HE, 1994, BRIT J CANCER, V69, P16, DOI 10.1038/bjc.1994.3; INGHIRAMI G, 1992, NEOPLASTIC HEMATOPAT, P27; JAFFE ES, 1985, SURF PATH LYMPH ORGA; KANTOR AB, 1993, ANNU REV IMMUNOL, V11, P501, DOI 10.1146/annurev.immunol.11.1.501; Kincade Paul W., 1993, P43; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; Kung H. T., 1991, Computation and Cognition. Proceedings of the First NEC Research Symposium, P1; KURIE JM, 1990, ONCOGENE, V5, P577; LADANYI M, 1992, BLOOD, V79, P2124; LANGDON WY, 1989, ONCOGENE RES, V4, P253; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Lee W M, 1989, Cancer Treat Res, V47, P37; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; LEVINE PH, 1992, CANCER RES, V52, pS5425; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MAGRATH I, 1992, CANCER RES, V52, pS5529; MARIN MC, 1994, ONCOGENE, V9, P3107; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MELCHERS F, 1994, ANNU REV IMMUNOL, V12, P209, DOI 10.1146/annurev.immunol.12.1.209; MITANI S, 1993, JPN J CANCER RES, V84, P37, DOI 10.1111/j.1349-7006.1993.tb02781.x; Mizukami Y, 1995, ANTICANCER RES, V15, P2899; MORGENBESSER SD, 1994, SEMIN CANCER BIOL, V5, P21; MOROY T, 1991, ONCOGENE, V6, P1941; MORROW MA, 1992, GENE DEV, V6, P61, DOI 10.1101/gad.6.1.61; NADEAU JH, 1987, GENETICS, V117, P533; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NISEN PD, 1986, CANCER RES, V46, P6217; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Osmond D G, 1990, Semin Immunol, V2, P173; POTTER M, 1990, CARCINOGENESIS, V11, P1, DOI 10.1093/carcin/11.1.1; PRICE CGA, 1991, J CLIN ONCOL, V9, P1527, DOI 10.1200/JCO.1991.9.9.1527; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RETH MG, 1985, NATURE, V317, P353, DOI 10.1038/317353a0; RIMOKH R, 1993, BLOOD, V81, P136; ROLINK A, 1993, ADV IMMUNOL, V53, P123, DOI 10.1016/S0065-2776(08)60499-X; RONCALLI M, 1994, CANCER-AM CANCER SOC, V74, P134, DOI 10.1002/1097-0142(19940701)74:1<134::AID-CNCR2820740122>3.0.CO;2-M; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; Schmidt T, 1996, NUCLEIC ACIDS RES, V24, P2528, DOI 10.1093/nar/24.13.2528; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SHEPPARD RD, 1991, MAMM GENOME, V1, P104, DOI 10.1007/BF02443786; SHUIN T, 1994, CANCER, V73, P1721, DOI 10.1002/1097-0142(19940315)73:6<1721::AID-CNCR2820730628>3.0.CO;2-W; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMITH RK, 1992, MOL CELL BIOL, V12, P1578, DOI 10.1128/MCB.12.4.1578; SOLE F, 1994, CANCER GENET CYTOGEN, V75, P72, DOI 10.1016/0165-4608(94)90219-4; STRAKA C, 1993, LEUKEMIA, V7, P268; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TAKAO S, 1991, Kobe Journal of Medical Sciences, V37, P227; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WANG J, 1993, LEUKEMIA, V7, P1834; WEISS R, 1985, RNA TUMOR VIRUSES, V2; WEISS RA, 1985, RNA TUMOR VIRUSES, V1; WETHERALL NT, 1992, PATHOBIOLOGY, V60, P87, DOI 10.1159/000163704; WLODARSKA I, 1994, GENE CHROMOSOME CANC, V10, P171, DOI 10.1002/gcc.2870100304; YANO T, 1992, BLOOD, V80, P758; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204; ZELENETZ AD, 1991, J EXP MED, V173, P197, DOI 10.1084/jem.173.1.197; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0; ZUTTER M, 1991, BLOOD, V78, P1062	97	19	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	1998	17	16					2073	2085		10.1038/sj.onc.1202125	http://dx.doi.org/10.1038/sj.onc.1202125			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798678				2022-12-28	WOS:000076540900006
J	Weinstein, EJ; Grimm, S; Leder, P				Weinstein, EJ; Grimm, S; Leder, P			The oncogene heregulin induces apoptosis in breast epithelial cells and tumors	ONCOGENE			English	Article						heregulin; apoptosis; Bcl-2; caspase; breast cancer	NEU DIFFERENTIATION FACTOR; GROWTH-FACTOR RECEPTOR; TRANSGENIC MICE; CANCER CELLS; C-MYC; PROTEIN; EXPRESSION; DEATH; INHIBITION; LIGAND	The products of a growing number of genes have been shown to display seemingly contradictory functions; namely, the induction of tumorigenesis and the induction of apoptosis, Heregulin's involvement in oncogenesis occurs through its interactions with members of the EGF receptor tyrosine kinase family, Recently one isoform of heregulin, beta 2b, was isolated in an in vitro screen for dominant, apoptosis-inducing genes in kidney epithelial cells. Here we show that heregulin is also capable of mediating apoptosis in human and murine mammary tumor cell lines and murine tumors. Furthermore, through transfection of the human breast cancer cell line MCF-7 with the truncated transmembrane/cytoplasmic segment of the heregulin gene, we show that the intracellular region of the heregulin precursor is sufficient for induction of apoptosis, Through the use of DNA fragmentation assays me also show that apoptosis occurs in cell lines established from heregulin-induced mammary gland tumors. TdT addition of digoxigenin labeled nucleotides to 3' OH ends of DNA breaks recapitulated these results in the actual tumors. Finally, over-expression of heregulin is shown to lead to the down-regulation of Bcl-2, an inhibitor of apoptosis. Conversely, the transfection of Bcl-2 into MCF-7 cells inhibits heregulin-mediated programmed cell death.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Leder, P (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.							ADAM L, 1995, CANCER RES, V55, P5156; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Amundadottir LT, 1996, ONCOGENE, V13, P757; Baulida J, 1996, J BIOL CHEM, V271, P5251; Benjamin CW, 1998, MOL PHARMACOL, V53, P446, DOI 10.1124/mol.53.3.446; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FOECKING MK, 1986, GENE, V45, P101, DOI 10.1016/0378-1119(86)90137-X; GOLD R, 1994, LAB INVEST, V71, P219; Grimm S, 1997, J EXP MED, V185, P1137, DOI 10.1084/jem.185.6.1137; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; GRIMM S, 1998, IN PRESS J EXP MED; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JAATTELA M, 1995, ONCOGENE, V10, P2297; Krane IM, 1996, ONCOGENE, V12, P1781; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; MAKAR AP, 1990, ACTA ONCOL, V29, P931, DOI 10.3109/02841869009096392; Mandal M, 1996, CELL GROWTH DIFFER, V7, P311; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Nickerson T, 1997, BIOCHEM BIOPH RES CO, V237, P690, DOI 10.1006/bbrc.1997.7089; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; Shimizu S, 1996, ONCOGENE, V12, P2251; SHUM L, 1994, J CELL BIOL, V125, P906; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; THIRY M, 1992, J HISTOCHEM CYTOCHEM, V40, P411, DOI 10.1177/40.3.1552179; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; ZEILLINGER R, 1989, ONCOGENE, V4, P109; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	45	33	34	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2107	2113		10.1038/sj.onc.1202428	http://dx.doi.org/10.1038/sj.onc.1202428			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798682				2022-12-28	WOS:000076540900010
J	Kim, JH; Hui, P; Yue, DX; Aycock, J; Leclerc, C; Bjoring, AR; Perkins, AS				Kim, JH; Hui, P; Yue, DX; Aycock, J; Leclerc, C; Bjoring, AR; Perkins, AS			Identification of candidate target genes for EVI-1, a zinc finger oncoprotein, using a novel selection strategy	ONCOGENE			English	Article						myeloid leukemia; transcription factor; target gene	MYELOID-TRANSFORMING GENE; ACUTE MYELOGENOUS LEUKEMIAS; DNA-BINDING PROTEINS; TRANSCRIPTIONAL REGULATION; CONSENSUS SEQUENCE; CELL-LINES; EXPRESSION; PROTOONCOGENE; ACTIVATION; RECEPTOR	We have sought to identify and isolate target genes for the zinc finger protein, EVI-1, which has been implicated in the genesis of myelogenous leukemia both in mouse and human. We have approached this with a two-step selection: we first selected for genomic fragments of mouse DNA that bind to the protein with high affinity; second, we employed cDNA hybrid selection to identify gene sequences contained within these fragments. We show that we have constructed a sublibrary of genomic fragments that contains a significant fraction of the EVI-1-binding sites in the mouse genome, Our data has allowed us to estimate that there are approximately 4300 binding sites per haploid genome in the mouse. We further demonstrate that by using cDNA hybrid selection, it is relatively straightforward to isolate cDNAs that correspond to genes embedded in the EVI-1-binding sublibrary. Several of these are novel, but are represented in databases of anonymous human or mouse cDNAs (expressed sequence tags), One selected gene is Itpr2, encoding the inositol trisphosphate type two receptor, which is transcriptionally regulated during myelopoiesis. Finally, using a chimeric EVI-1-VP16-fusion protein under the control of a tetracycline-regulated system, we have shown that this chimeric activator can directly regulate Itpr2.	Yale Univ, Dept Pathol, New Haven, CT 06520 USA	Yale University	Perkins, AS (corresponding author), Yale Univ, Dept Pathol, POB 208023, New Haven, CT 06520 USA.							Bartholomew C, 1997, ONCOGENE, V14, P569, DOI 10.1038/sj.onc.1200864; BRADFORD PG, 1992, J BIOL CHEM, V267, P20959; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FICHELSON S, 1992, LEUKEMIA, V6, P93; FUNABIKI T, 1994, ONCOGENE, V9, P1575; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hoyt PR, 1997, MECH DEVELOP, V65, P55, DOI 10.1016/S0925-4773(97)00057-9; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAFATOS FC, 1979, NUCLEIC ACIDS RES, V7, P1541, DOI 10.1093/nar/7.6.1541; KINZLER KW, 1989, NUCLEIC ACIDS RES, V17, P3645, DOI 10.1093/nar/17.10.3645; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; LEVY ER, 1994, BLOOD, V83, P1348; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MATSUGI T, 1995, ONCOGENE, V11, P191; MCENTEE K, 1980, P NATL ACAD SCI-BIOL, V77, P857, DOI 10.1073/pnas.77.2.857; MIKSICEK R, 1986, CELL, V46, P283, DOI 10.1016/0092-8674(86)90745-2; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MOHLER JD, 1977, GENETICS, V85, P259; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1995, ONCOGENE, V10, P1961; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; PARIMOO S, 1993, METHODS MOL GENETICS, V1, P23; Peeters P, 1997, CANCER RES, V57, P564; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PERKINS AS, 1991, DEVELOPMENT, V111, P479; Perkins AS, 1996, J BIOL CHEM, V271, P1104, DOI 10.1074/jbc.271.2.1104; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; SOMPAYRAC L, 1990, P NATL ACAD SCI USA, V87, P3274, DOI 10.1073/pnas.87.9.3274; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUGIYAMA T, 1994, FEBS LETT, V349, P191, DOI 10.1016/0014-5793(94)00662-8; Summers MD, 1987, TEXAS AGR EXPT STATI; SUZUKAWA K, 1994, BLOOD, V84, P2681; TANAKA T, 1994, J BIOL CHEM, V269, P24020; TSANG SY, 1990, MOL CELL BIOL, V10, P711, DOI 10.1128/MCB.10.2.711; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505	49	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1527	1538		10.1038/sj.onc.1202331	http://dx.doi.org/10.1038/sj.onc.1202331			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794230				2022-12-28	WOS:000076089900005
J	Kim, YB; Lee, KH; Sugita, K; Yoshida, M; Horinouchi, S				Kim, YB; Lee, KH; Sugita, K; Yoshida, M; Horinouchi, S			Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase	ONCOGENE			English	Article						histone acetylation; cell cycle; p21(WAF1/cip1); antitumor	CHROMOBACTERIUM-VIOLACEUM NO-968; TRICHOSTATIN-A; TRANSCRIPTIONAL REPRESSION; MORPHOLOGICAL TRANSFORMATION; GELSOLIN EXPRESSION; CHROMATIN STRUCTURE; SODIUM-BUTYRATE; CARCINOMA CELL; NIH3T3 CELLS; ACETYLTRANSFERASE	Oxamflatin [(2E)-5-[3-](phenylsufonyl)amino]phenyl]pent-2-en-4-ynohydroxamic acid] induces transcriptional activation of junD and morphological reversion in various NIH3T3-dtrived transformed cell lines. We found that oxamflatin showed in vitro antiproliferative activity against various mouse and human tumor cell lines with drastic changes in the cell morphology and in vivo antitumor activity against B16 melanoma, Oxamflatin caused an elongated cell shape with filamentous protrusions as well as arrest of the cell cycle at the G1 phase in HeLa cells, These phenotypic changes of HeLa cells were apparently similar to those by trichostatin A (TSA), a specific inhibitor of histone deacetylase (HDAC), The effect of oxamflatin on the transcriptional activity of the cytomegalovirus (CMV) promoter was examined and compared with known HDAC inhibitors, TSA, sodium n-butyrate, and FR901228, Oxamflatin as well as all these inhibitors greatly enhanced the transcriptional activity of the CMV promoter in a dose-dependent manner. Oxamflatin, like TSA, inhibited intracellular HDAC activity, as a result of which marked amounts of acetylated histone species accumulated. Finally, effects on expression of several endogenous genes in,oh td in cell morphology and cell cycle control in HeLa cells were analysed. Expression of gelsolin, cyclin E and Cdk inhibitors including p21(WAF1/Cip1) was highly augmented, while that of cyclin A and cyclin D1 was decreased by oxamflatin. These results suggest that changes in the expression pattern of the genes regulating cell morphology and the cell cycle due to histone hyperacetylation are responsible for the antitumor activity, the morphological change and the cell cycle arrest induced by oxamflatin.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 113, Japan; Shionogi & Co Ltd, Shionogi Res Labs, Hukushima Ku, Osaka 533, Japan	University of Tokyo; Shionogi & Company Limited	Yoshida, M (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Yayoi 1-1-1, Tokyo 113, Japan.		Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674				AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; CHAPONNIER C, 1989, AM J PATHOL, V134, P597; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; Chen WY, 1997, P NATL ACAD SCI USA, V94, P5798, DOI 10.1073/pnas.94.11.5798; COUSENS LS, 1979, J BIOL CHEM, V254, P1716; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; Dion LD, 1997, VIROLOGY, V231, P201, DOI 10.1006/viro.1997.8538; FALLON RJ, 1979, J CELL PHYSIOL, V100, P251, DOI 10.1002/jcp.1041000206; FUTAMURA M, 1995, ONCOGENE, V10, P1119; GOLBERG YP, 1992, J CELL BIOCHEM, V49, P74; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; INAGAKI M, 1985, J BIOL CHEM, V260, P2922; INOUE A, 1970, BIOCHIM BIOPHYS ACTA, V220, P307, DOI 10.1016/0005-2744(70)90015-X; ITAZAKI H, 1990, J ANTIBIOT, V43, P1524, DOI 10.7164/antibiotics.43.1524; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Khochbin S, 1997, FEBS LETT, V419, P157, DOI 10.1016/S0014-5793(97)01423-3; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Kwon HJ, 1997, ONCOGENE, V15, P2625, DOI 10.1038/sj.onc.1201443; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MORIYA S, 1994, INT J ONCOL, V5, P1347; MORIYA S, 1996, CELL, V87, P1261; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLAUER L, 1993, ONCOGENE, V8, P2531; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NOGUCHI PD, 1978, J HISTOCHEM CYTOCHEM, V26, P761, DOI 10.1177/26.9.361885; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; PORTER RM, 1993, J PATHOL, V170, P435, DOI 10.1002/path.1711700406; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Siddique H, 1998, ONCOGENE, V16, P2283, DOI 10.1038/sj.onc.1202003; Sonoda H, 1996, ONCOGENE, V13, P143; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; SUGITA K, 1992, CANCER RES, V52, P168; Supuran CT, 1997, J ENZYM INHIB, V12, P175, DOI 10.3109/14756369709029313; Tamura Y, 1998, J MED CHEM, V41, P640, DOI 10.1021/jm9707582; TANAKA J, 1991, VIROLOGY, V185, P271, DOI 10.1016/0042-6822(91)90774-6; TANAKA M, 1995, CANCER RES, V55, P3228; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; UEDA H, 1994, J ANTIBIOT, V47, P301; VANDEKERCKHOVE J, 1990, J CELL BIOL, V111, P95, DOI 10.1083/jcb.111.1.95; VanLint C, 1996, GENE EXPRESSION, V5, P245; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	64	229	261	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	1999	18	15					2461	2470		10.1038/sj.onc.1202564	http://dx.doi.org/10.1038/sj.onc.1202564			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229197				2022-12-28	WOS:000079703300006
J	Marsh, SK; Bansal, GS; Zammit, C; Barnard, R; Coope, R; Roberts-Clarke, D; Gomm, JJ; Coombes, RC; Johnston, CL				Marsh, SK; Bansal, GS; Zammit, C; Barnard, R; Coope, R; Roberts-Clarke, D; Gomm, JJ; Coombes, RC; Johnston, CL			Increased expression of fibroblast growth factor 8 in human breast cancer	ONCOGENE			English	Article						fibroblast growth factor 8; human breast cancer; fibroblast growth factor receptor 4	HIGH-AFFINITY RECEPTOR; FACTOR FGF RECEPTORS; HUMAN MAMMARY-GLAND; CARCINOMA-CELLS; MOLECULAR-CLONING; FACTOR FAMILY; FACTOR-VIII; SIGNAL-TRANSDUCTION; GENE; ANDROGEN	Fibroblast growth factor 8 (FGF8) is an important developmental protein which is oncogenic and able to cooperate with wnt-1 to produce mouse mammary carcinoma. The level of expression of FGF8 mRNA was measured in 68 breast cancers and 24 non-malignant breast tissues. Elevated levels of FGF8 mRNA were found in malignant compared to non-malignant breast tissues with significantly more malignant tissues expressing FGF8 (P = 0.019) at significantly higher levels (P = 0.031), In situ hybridization of breast cancer tissues and analysis of purified populations of normal epithelial cells and breast cancer cell lines showed that malignant epithelial cells expressed FGF8 mRNA at high levels compared to non-malignant epithelial and myoepithelial cells and fibroblasts. Although two of the receptors which FGF8 binds to (FGFR2-IIIc, FGFR3-IIIc) are not expressed in breast cancer cells, an autocrine activation loop is possible since expression of fibroblast growth factor receptor (FGFR) 4 and FGFR1 are retained in malignant epithelial cells. This is the first member of the FGF family to have increased expression in breast cancer and a potential autocrine role in its progression.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Med Oncol, London W6 8RP, England	Imperial College London	Johnston, CL (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Med Oncol, Charing Cross Campus,St Dunstans Rd, London W6 8RP, England.			Coombes, Raoul Charles/0000-0002-4811-1100				ANANDAPPA SY, 1994, BRIT J CANCER, V69, P772, DOI 10.1038/bjc.1994.146; Bansal GS, 1997, BRIT J CANCER, V75, P1567, DOI 10.1038/bjc.1997.269; BANSAL GS, 1995, BRIT J CANCER, V72, P1420, DOI 10.1038/bjc.1995.524; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Blunt AG, 1997, J BIOL CHEM, V272, P3733, DOI 10.1074/jbc.272.6.3733; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coope RC, 1997, BRIT J CANCER, V75, P1621, DOI 10.1038/bjc.1997.277; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Gemel J, 1996, GENOMICS, V35, P253, DOI 10.1006/geno.1996.0349; Ghosh AK, 1996, CELL GROWTH DIFFER, V7, P1425; Gomm JJ, 1997, EXP CELL RES, V234, P165, DOI 10.1006/excr.1997.3593; GOMM JJ, 1991, CANCER RES, V51, P4685; GOMM JJ, 1995, ANAL BIOCHEM, V226, P91, DOI 10.1006/abio.1995.1196; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643; JOHNSTON CL, 1995, BIOCHEM J, V306, P609, DOI 10.1042/bj3060609; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOUHARA H, 1994, ONCOGENE, V9, P455; Leung HY, 1996, ONCOGENE, V12, P1833; LORENZI MV, 1995, ONCOGENE, V10, P2051; LUQMANI YA, 1992, BRIT J CANCER, V66, P273, DOI 10.1038/bjc.1992.256; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MCLESKEY SW, 1994, CANCER RES, V54, P523; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Payson RA, 1996, ONCOGENE, V13, P47; PEKONEN F, 1993, MOL CELL ENDOCRINOL, V95, P43, DOI 10.1016/0303-7207(93)90027-H; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RON D, 1993, J BIOL CHEM, V268, P5388; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; Schmitt JF, 1996, J STEROID BIOCHEM, V57, P173, DOI 10.1016/0960-0760(95)00259-6; SMITH J, 1994, EUR J CANCER, V30A, P496, DOI 10.1016/0959-8049(94)90426-X; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; Vainikka S, 1996, J BIOL CHEM, V271, P1270, DOI 10.1074/jbc.271.3.1270; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yiangou C, 1997, BRIT J CANCER, V75, P28, DOI 10.1038/bjc.1997.5; Yiangou C, 1997, BRIT J CANCER, V76, P1419, DOI 10.1038/bjc.1997.573	53	71	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1053	1060		10.1038/sj.onc.1202392	http://dx.doi.org/10.1038/sj.onc.1202392			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023681				2022-12-28	WOS:000078510600022
J	Vermeulen, SJ; Nollet, F; Teugels, E; Vennekens, KM; Malfait, F; Philippe, J; Speleman, F; Bracke, ME; van Roy, FM; Mareel, MM				Vermeulen, SJ; Nollet, F; Teugels, E; Vennekens, KM; Malfait, F; Philippe, J; Speleman, F; Bracke, ME; van Roy, FM; Mareel, MM			The alpha E-catenin gene (CTNNA1) acts as an invasion-suppressor gene in human colon cancer cells	ONCOGENE			English	Article						colon cancer; invasion; alpha E-catenin; genetic instability	NONPOLYPOSIS COLORECTAL-CARCINOMA; II RECEPTOR GENE; E-CADHERIN; MICROSATELLITE INSTABILITY; GROWTH-FACTOR; LYNCH SYNDROME; RETINOIC ACID; BETA-CATENIN; TUMOR-CELLS; MUTATIONS	The acquisition of invasiveness is a crucial step in the malignant progression of cancer. In cancers of the colon and of other organs the E-cadherin/catenin complex, which is implicated in homotypic cell-cell adhesion as well as in signal transduction, serves as a powerful inhibitor of invasion. We show here that one allele of the alpha E-catenin (CTNNA1) gene is mutated in the human colon cancer cell family HCT-8, which is identical to HCT-15, DLD-1 and HRT-18. Genetic instability, due to mutations in the HMSH6 (also called GTBP) mismatch repair gene, results in the spontaneous occurrence of invasive variants, all carrying either a mutation or exon skipping in the second alpha E-catenin allele, The alpha E-catenin gene is therefore, an invasion-suppressor gene in accordance with the two-hit model of Knudsen for tumour-suppressor genes.	State Univ Ghent Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, B-9000 Ghent, Belgium; State Univ Ghent, Dept Mol Biol, Mol Cell Biol Lab, B-9000 Ghent, Belgium; VIB, B-9000 Ghent, Belgium; Univ Hosp Brussels, Lab Med Oncol, B-1010 Jette, Belgium; State Univ Ghent Hosp, Dept Clin Chem Microbiol & Immunol, B-9000 Ghent, Belgium; State Univ Ghent Hosp, Dept Med Genet, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital; Ghent University; Flanders Institute for Biotechnology (VIB); University Hospital Brussels; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital	Mareel, MM (corresponding author), State Univ Ghent Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, Pintelaan 185, B-9000 Ghent, Belgium.		van Roy, Frans M/C-6123-2009; philippé, jan/AAG-8964-2019; speleman, frank/AAR-5184-2020; Malfait, Fransiska/K-7897-2014; Philippé, Jan/A-1027-2008	van Roy, Frans M/0000-0003-4358-1039; philippé, jan/0000-0003-4857-5746; speleman, frank/0000-0002-6628-8559; Philippé, Jan/0000-0003-4857-5746; Malfait, Fransiska/0000-0002-5010-0304; Vermeulen, Stefan/0000-0003-3710-800X				BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BHATTACHARYYA NP, 1995, HUM MOL GENET, V4, P2057, DOI 10.1093/hmg/4.11.2057; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123; BRACKE ME, 1993, BRIT J CANCER, V68, P282, DOI 10.1038/bjc.1993.329; BRACKE ME, 1991, BRIT J CANCER, V63, P867, DOI 10.1038/bjc.1991.191; BREEN E, 1993, CELL ADHES COMMUN, V1, P239, DOI 10.3109/15419069309097257; BRUSSEMAKERS MJG, 1996, CLIN EXP METASTAS S1, V14, P15; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; Casares S, 1995, ONCOGENE, V11, P2303; CHEN TR, 1995, CANCER GENET CYTOGEN, V81, P103, DOI 10.1016/0165-4608(94)00225-Z; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; Eshleman JR, 1996, ONCOGENE, V12, P1425; EWING CM, 1995, CANCER RES, V55, P4813; FREI JV, 1992, CANCER, V69, P1108; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KNUDSON AG, 1985, CANCER RES, V45, P1437; KOI M, 1994, CANCER RES, V54, P4308; KOURI M, 1990, CANCER, V65, P1825, DOI 10.1002/1097-0142(19900415)65:8<1825::AID-CNCR2820650827>3.0.CO;2-H; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; Luria SE, 1943, GENETICS, V28, P491; Lynch HT, 1996, CANCER, V78, P1149, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1149::AID-CNCR1>3.3.CO;2-Q; Mareel M, 1996, J CELL BIOCHEM, V61, P524; MAREEL M, 1997, HDB CLIN NEUROLOGY 3, V25, P105; Mareel M. M., 1991, MECH INVASION METAST; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MORTON RA, 1993, CANCER RES, V53, P3585; NOLLET F, 1995, GENOMICS, V26, P410, DOI 10.1016/0888-7543(95)80231-A; ODA T, 1993, BIOCHEM BIOPH RES CO, V193, P897, DOI 10.1006/bbrc.1993.1710; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, CANCER RES, V55, P5548; Rhyu MS, 1996, J NATL CANCER I, V88, P240, DOI 10.1093/jnci/88.5.240; ROEST PAM, 1993, HUM MOL GENET, V2, P1719, DOI 10.1093/hmg/2.10.1719; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SHIOZAKI H, 1994, AM J PATHOL, V144, P667; SHIOZAKI H, 1995, BRIT J CANCER, V71, P250, DOI 10.1038/bjc.1995.52; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; SPELEMAN F, 1992, CANCER GENET CYTOGEN, V58, P176; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TOMPKINS WA, 1974, J NATL CANCER I, V52, P1101, DOI 10.1093/jnci/52.4.1101; Vermeulen S, 1996, PATHOL RES PRACT, V192, P694, DOI 10.1016/S0344-0338(96)80091-4; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; VERMEULEN SJ, 1995, BRIT J CANCER, V72, P1447, DOI 10.1038/bjc.1995.528; VERMEULEN SJ, 1998, IN PRESS CANC GENET; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M	51	65	67	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					905	915		10.1038/sj.onc.1202348	http://dx.doi.org/10.1038/sj.onc.1202348			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023666				2022-12-28	WOS:000078510600007
J	Kanoe, H; Nakayama, T; Hosaka, T; Murakami, H; Yamamoto, H; Nakashima, Y; Tsuboyama, T; Nakamura, T; Ron, D; Sasaki, MS; Toguchida, J				Kanoe, H; Nakayama, T; Hosaka, T; Murakami, H; Yamamoto, H; Nakashima, Y; Tsuboyama, T; Nakamura, T; Ron, D; Sasaki, MS; Toguchida, J			Characteristics of genomic breakpoints in TLS-CHOP translocations in liposarcomas suggest the involvement of Translin and topoisomerase II in the process of translocation	ONCOGENE			English	Article						TLS; CHOP; liposarcoma; topoisomerase II; Translin	ROUND-CELL LIPOSARCOMA; ACUTE MYELOID-LEUKEMIA; RNA-BINDING PROTEIN; MYXOID LIPOSARCOMA; CHROMOSOMAL TRANSLOCATIONS; DNA-SEQUENCE; BCR GENE; ONCOGENIC TRANSFORMATION; CLUSTER REGION; RECOMBINATION	Fusion of TLS/FUS and CHOP gene by reciprocal translocation t(12;16)(q32;q16) is a common genetic event found in myxoid and round-cell liposarcomas, Characterization of this genetic event was performed by three methods, Southern blot, RT-PCR, and genomic long-distance PCR in nine myxoid and three round-cell liposarcomas. All but one tumors showed genetic alternations indicating the fusion of TLS/FUS and CHOP gene, Two novel types of fusion transcripts were found, of which one lacked exon 2 sequence of CHOP gene, and the other lacked 3' half of exon 5 of TLS gene, The latter case was caused by a cryptic splicing site which,vas created by the genomic fusion, Detailed analyses genomic fusion points revealed several sequence characteristics surrounding the fusion points, Homology analyses of breakpoint sequences with known sequence motifs possibly involve in the process of translocation uncovered Translin binding sequences at both of TLS/ FUS and CHOP breakpoints in two cases. Translocations were always associated with other genetic alterations, such as deletions, duplications, or insertions. Short direct repeats were almost always found at both ends of deleted or duplicated fragments some of which had apparently been created by joining of sequences that flank the rearrangement. Finally, consensus topoisomerase II cleavage sites were found at breakpoints in all cases analysed, suggesting a role of this enzyme in creating staggered ends at the breakpoint, These data suggested that sequence characteristics may play an important role to recruit several factors such as Translin and topoisomerase II in the process of chromosomal translation in liposarcomas.	Kyoto Univ, Dept Orthopaed Surg, Kyoto 606, Japan; Kyoto Univ, Dept Pathol, Kyoto 606, Japan; Kyoto Univ, Ctr Radiat Biol, Kyoto 606, Japan; Kyoto Univ, Inst Frontier Med Sci, Kyoto 606, Japan; NYU Med Ctr, Skirball Inst Biomol Med, New York, NY 10016 USA	Kyoto University; Kyoto University; Kyoto University; Kyoto University; New York University	Toguchida, J (corresponding author), Kyoto Univ, Dept Orthopaed Surg, Kyoto 606, Japan.			Ron, David/0000-0002-3014-5636	NATIONAL CANCER INSTITUTE [R01CA060945] Funding Source: NIH RePORTER; NCI NIH HHS [CA60945] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI K, 1994, ONCOGENE, V9, P1109; AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; Chalk JG, 1997, ONCOGENE, V15, P1199, DOI 10.1038/sj.onc.1201285; CHEN SJ, 1989, ONCOGENE, V4, P195; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; CROWTHER PJ, 1991, NUCLEIC ACIDS RES, V19, P2395, DOI 10.1093/nar/19.9.2395; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; KARIYA Y, 1987, GENE, V53, P1, DOI 10.1016/0378-1119(87)90087-4; KAS E, 1992, EMBO J, V11, P705, DOI 10.1002/j.1460-2075.1992.tb05103.x; KASAI M, 1994, INT IMMUNOL, V6, P1017, DOI 10.1093/intimm/6.7.1017; KNIGHT JC, 1995, CANCER RES, V55, P24; Kovalchuk AL, 1997, ONCOGENE, V15, P2369, DOI 10.1038/sj.onc.1201409; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; KURODA M, 1995, AM J PATHOL, V147, P1221; Kuroda M, 1997, AM J PATHOL, V151, P735; NILBERT M, 1994, CANCER GENET CYTOGEN, V72, P155, DOI 10.1016/0165-4608(94)90133-3; Panagopoulos I, 1996, GENE CHROMOSOME CANC, V17, P102, DOI 10.1002/(SICI)1098-2264(199610)17:2<102::AID-GCC5>3.0.CO;2-9; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; Panagopoulos I, 1997, ONCOGENE, V15, P1357, DOI 10.1038/sj.onc.1201281; Panagopoulos I, 1996, ONCOGENE, V12, P489; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SOWERBY SJ, 1993, ONCOGENE, V8, P1679; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; SPTIZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; ZHANG JG, 1995, BRIT J HAEMATOL, V90, P138, DOI 10.1111/j.1365-2141.1995.tb03392.x; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	40	53	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					721	729		10.1038/sj.onc.1202364	http://dx.doi.org/10.1038/sj.onc.1202364			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989822	Green Submitted			2022-12-28	WOS:000078394400017
J	Soulie, P; Poupon, MF; Remvikos, Y; Dutrillaux, B; Muleris, M				Soulie, P; Poupon, MF; Remvikos, Y; Dutrillaux, B; Muleris, M			Distinct chromosomal alterations associated with TP53 status of LoVo cells under PALA selective pressure: a parallel with cytogenetic pathways of colorectal cancers	ONCOGENE			English	Article						gene amplification; human colon cancer; p53; drug resistance; chromosome; PALA	WILD-TYPE P53; DIHYDROFOLATE-REDUCTASE GENE; CHINESE-HAMSTER CELLS; MUTANT P53; MULTIPLE MECHANISMS; HUMAN FIBROBLASTS; CYCLE REGULATION; AMPLIFICATION; DNA; LINES	This study investigates the chromosomal alterations involved in the acquisition of PALA resistance of LoVo colorectal cancer cells homozygous for wild-type TP53 before and after transfection with a 143Ala-mutated TP53 gene. PALA resistance was always associated with an increased number of CAD gene copies, but gene amplification sensu stricto was rarely observed, Interestingly, distinct chromosome patterns were found in relation to the TP53 status of the cells. In parental LoVo cells, the CAD copy number was increased through gains of normal chromosome 2 whereas in transfectant clones, resistance mostly occurred through chromosome rearrangements. The relationship with the two different cytogenetic patterns described in colorectal tumors is discussed.	Inst Curie, CNRS, UMR 147, Lab Cytogenet Mol & Oncol, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Muleris, M (corresponding author), Inst Curie, CNRS, UMR 147, Lab Cytogenet Mol & Oncol, 26 Rue dUlm, F-75248 Paris 05, France.							Agapova LS, 1996, MUTAT RES-FUND MOL M, V354, P129, DOI 10.1016/0027-5107(96)00062-0; Caron De Fromentel Claude, 1992, Genes Chromosomes and Cancer, V4, P1; Chen CYM, 1996, CANCER RES, V56, P3659; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; Cottu PH, 1996, ONCOGENE, V13, P2727; DI LEONARDO A, 1993, COLD SPRING HARB SYM, V58, P655, DOI 10.1101/SQB.1993.058.01.073; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FREBOURG T, 1994, CANCER RES, V54, P878; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; Lesec G, 1997, INT J ONCOL, V10, P747; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; McClintock B, 1939, P NATL ACAD SCI USA, V25, P405, DOI 10.1073/pnas.25.8.405; MULERIS M, 1987, CANCER GENET CYTOGEN, V29, P289, DOI 10.1016/0165-4608(87)90239-1; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; Muleris M, 1996, CANCER GENET CYTOGEN, V92, P11, DOI 10.1016/S0165-4608(96)00116-1; MULERIS M, 1994, CYTOGENET CELL GENET, V65, P82, DOI 10.1159/000133605; PARK DJ, 1994, ONCOGENE, V9, P1899; Pocard M, 1996, ONCOGENE, V12, P875; Poupon MF, 1996, MOL BIOL CELL, V7, P345, DOI 10.1091/mbc.7.3.345; Remvikos Y, 1997, CANCER GENET CYTOGEN, V93, P63, DOI 10.1016/S0165-4608(96)00305-6; SCHAEFER DI, 1993, CANCER RES, V53, P4946; SHARMA RC, 1994, MUTAT RES, V304, P243, DOI 10.1016/0027-5107(94)90217-8; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; Smith KA, 1997, P NATL ACAD SCI USA, V94, P1816, DOI 10.1073/pnas.94.5.1816; SMITH KA, 1995, PHILOS T ROY SOC B, V347, P49, DOI 10.1098/rstb.1995.0008; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; STARK GR, 1986, CANCER SURV, V5, P1; STARK GR, 1993, ADV CANCER RES, V61, P87, DOI 10.1016/S0065-230X(08)60956-2; TLSTY TD, 1992, SCIENCE, V255, P1425, DOI 10.1126/science.1542791; TOLEDO F, 1993, CURR BIOL, V3, P255, DOI 10.1016/0960-9822(93)90175-N; TOLEDO F, 1992, EMBO J, V11, P2665, DOI 10.1002/j.1460-2075.1992.tb05332.x; TRASK BJ, 1989, GENE DEV, V3, P1913, DOI 10.1101/gad.3.12a.1913; UMAR A, 1994, J BIOL CHEM, V269, P14367; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WILLIAMS AC, 1995, ONCOGENE, V11, P141; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	44	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					775	781		10.1038/sj.onc.1202336	http://dx.doi.org/10.1038/sj.onc.1202336			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989828				2022-12-28	WOS:000078394400023
J	Martinez, LA; Chen, Y; Fischer, SM; Conti, CJ				Martinez, LA; Chen, Y; Fischer, SM; Conti, CJ			Coordinated changes in cell cycle machinery occur during keratinocyte terminal differentiation	ONCOGENE			English	Article						cell cycle; cyclins; CDK; epidermis; terminal differentiation; keratinocytes	RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; IN-VITRO; G1 PHASE; EXPRESSION; GENE; P21; INHIBITOR; GROWTH; PROGRESSION	Differentiation of cells is typically marked by a cessation of proliferation with a concurrent entrance into a distinct metabolic state marked by tissue specific gene expression, The mechanism by which the cell exits the cell cycle in this process is poorly understood. To determine the potential roles of the cell cycle machinery in the regulation of the terminal differentiation process of epidermal cells, we selected a well characterized in vitro model in which primary mouse keratinocytes are induced to differentiate in response to a raised calcium ion concentration in the medium. The withdrawal from the cell cycle correlates very well with a number of changes in the cell cycle machinery. Changes in the phosphorylation status of the Rb family of proteins occurs coordinately with an increased association of p21, p27 and p57 with cdk2, Furthermore, we find that inhibition of cdk2 activity is not sufficient to elicit changes that occur during keratinocyte differentiation. Finally, the previously described v-Ha-ras block of keratinocyte differentiation correlates with altered regulation of both cyclin D1 and cdk2 suggesting that these genes may play a role in the Ha-ras transformation of a keratinocyte.	Univ Texas, MD Anderson Cancer Ctr, Sci Pk Res Div, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Conti, CJ (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Sci Pk Res Div, Smithville, TX 78957 USA.				NCI NIH HHS [CA 57596, CA 42157] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA057596, R01CA042157] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BIANCHI AB, 1993, ONCOGENE, V8, P1127; Botz J, 1996, MOL CELL BIOL, V16, P3401; CHIN L, 1995, P NATL ACAD SCI USA, V92, P8488, DOI 10.1073/pnas.92.18.8488; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FILMUS J, 1994, ONCOGENE, V9, P3627; Gotz C, 1996, ONCOGENE, V13, P391; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALL M, 1995, ONCOGENE, V11, P1581; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Hurlin PJ, 1995, ONCOGENE, V11, P2487; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG HP, 1994, ONCOGENE, V9, P3397; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KIESS M, 1995, ONCOGENE, V10, P159; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KRANENBURG O, 1995, FEBS LETT, V367, P103, DOI 10.1016/0014-5793(95)00587-Y; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Lin JY, 1996, MOL CELL BIOL, V16, P1786; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; STEINMAN RA, 1994, ONCOGENE, V9, P3389; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINBERG WC, 1995, ONCOGENE, V10, P2271; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; YUSPA SH, 1985, NATURE, V314, P459, DOI 10.1038/314459a0	48	59	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					397	406		10.1038/sj.onc.1202300	http://dx.doi.org/10.1038/sj.onc.1202300			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927196				2022-12-28	WOS:000078166500012
J	Russo, I; Silver, ARJ; Cuthbert, AP; Griffin, DK; Trott, DA; Newbold, RF				Russo, I; Silver, ARJ; Cuthbert, AP; Griffin, DK; Trott, DA; Newbold, RF			A telomere-independent senescence mechanism is the sole barrier to Syrian hamster cell immortalization	ONCOGENE			English	Article						telomere; telomerase; senescence; immortalization; hamster; carcinogenesis	MALIGNANT TRANSFORMATION; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; HUMAN CANCER; MOUSE CELLS; IN-VITRO; LENGTH; DNA; CARCINOMA; EXPRESSION	Reactivation of telomerase and stabilization of telomeres occur simultaneously during human cell immortalization in, vitro and the vast majority of human cancers possess high le, els of telomerase activity, Telomerase repression in human somatic cells may therefore have evolved as a powerful resistance mechanism against immortalization, clonal evolution and malignant progression. The comparative ease with, which rodent cells immortalize in vitro suggests that they have less stringent controls over replicative senescence than human cells. Here, we report that Syrian hamster dermal fibroblasts possess substantial levels of telomerase activity throughout their culture life-span, even after growth arrest in senescence. In our studies, telomerase,vas also detected in uncultured new-horn hamster skin, in several adult tissues, and in cultured fibroblasts induced to enter the post-mitotic state irreversibly by serum withdrawal. Transfection of near-senescent dermal fibroblasts with a selectable plasmid vector expressing the SV40 T-antigen gene resulted in high-frequency single-step immortalization without the crisis typically observed during the immortalization of human cells, Collectively, these data provide an explanation for the increased susceptibility of rodent cells to immortalization (and malignant transformation) compared with their human equivalents, and provide evidence for a novel, growth factor-sensitive, mammalian senescence mechanism unrelated to telomere maintenance.	Brunel Univ, Dept Biol & Biochem, Human Canc Genet Unit, Uxbridge UB8 3PH, Middx, England; Natl Radiol Protect Board, Biomed Effects Dept, Chilton OX11 0RQ, Oxon, England	Brunel University	Newbold, RF (corresponding author), Brunel Univ, Dept Biol & Biochem, Human Canc Genet Unit, Uxbridge UB8 3PH, Middx, England.							ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ANNAND R, 1986, TRENDS GENET, V2, P278; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; Bryan TM, 1997, EUR J CANCER, V33, P767, DOI 10.1016/S0959-8049(97)00065-8; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; CHADENEAU C, 1995, ONCOGENE, V11, P893; COSTA M, 1995, AM J CLIN NUTR, V61, p666S, DOI 10.1093/ajcn/61.3.666S; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; GONOS ES, 1992, INT J ONCOL, V1, P209; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hara E, 1996, MOL CELL BIOL, V16, P859; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Holliday R, 1996, BIOESSAYS, V18, P3, DOI 10.1002/bies.950180103; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Holt SE, 1997, EUR J CANCER, V33, P761, DOI 10.1016/S0959-8049(97)00066-X; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; Kipling D., 1995, TELOMERE; KRAEMER PM, 1986, J NATL CANCER I, V76, P703, DOI 10.1093/jnci/76.4.703; Mazars GR, 1997, P NATL ACAD SCI USA, V94, P151, DOI 10.1073/pnas.94.1.151; Meijne EIM, 1996, GENE CHROMOSOME CANC, V16, P230, DOI 10.1002/(SICI)1098-2264(199608)16:4<230::AID-GCC2>3.0.CO;2-Z; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Newbold R F, 1985, Carcinog Compr Surv, V9, P17; NEWBOLD RF, 1982, NATURE, V299, P633, DOI 10.1038/299633a0; NEWBOLD RF, 1993, TOXICOL LETT, V67, P211, DOI 10.1016/0378-4274(93)90057-5; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Ramirez RD, 1997, J INVEST DERMATOL, V108, P113, DOI 10.1111/1523-1747.ep12285654; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SILVER A, 1991, GENE CHROMOSOME CANC, V3, P376, DOI 10.1002/gcc.2870030508; SLIJEPCEVIC P, 1995, CYTOGENET CELL GENET, V69, P87, DOI 10.1159/000133944; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STARLING JA, 1990, NUCLEIC ACIDS RES, V18, P6881, DOI 10.1093/nar/18.23.6881; TROTT DA, 1995, CARCINOGENESIS, V16, P193, DOI 10.1093/carcin/16.2.193; VAZIRI H, 1993, AM J HUM GENET, V52, P661; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WynfordThomas D, 1997, EUR J CANCER, V33, P716, DOI 10.1016/S0959-8049(97)00064-6; Yamasaki H, 1996, MUTAT RES-FUND MOL M, V356, P1, DOI 10.1016/0027-5107(96)90031-7; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	62	46	47	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3417	3426		10.1038/sj.onc.1202261	http://dx.doi.org/10.1038/sj.onc.1202261			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030665				2022-12-28	WOS:000078086200002
J	Serfas, MS; Tyner, AL				Serfas, MS; Tyner, AL			Ryk is expressed in a differentiation-specific manner in epithelial tissues and is strongly induced in decidualizing uterine stroma	ONCOGENE			English	Article						Ryk; tyrosine kinase; differentiation; epithelia	PROTEIN-TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; MOUSE SMALL-INTESTINE; VULVAL CELL LINEAGES; MOLECULAR-CLONING; CAENORHABDITIS-ELEGANS; STEM-CELLS; GENE; FAMILY; IDENTIFICATION	Ryk is a ubiquitously expressed tyrosine kinase-like receptor of unknown activity and associations, We examined ryk expression in adult mouse epithelial tissues and during embryonic development at the histological level. Ryk RNA is present at greatly increased le, els in cells at particular stages of epithelial differentiation: the basal layer of skin and tongue epithelia, the intervillous layer and some crypt bases of the intestine and the lower matrix region of the hair follicle, Although ryk RNA is expressed at similar levels in a variety of tissues from embryonic day 10.5 to 18.5, specific induction of ryk RNA can be seen by ill situ hybridization in the basal layer of skin and hair follicle at day 15.5-16.5, and protein staining localizes to the hair follicle by immunohistochemistry. At day 4.5 and 6.5, little if any ryk is present in the blastocyst, but it is transiently induced at a high le, el in mature decidual cells of the uterine stroma, We review a number of independent isolations of ryk, including fruit fly and nematode members of the ryk family, Because ryk is induced in epithelial cells seeking a final place in a differentiated tissue, or during remodeling of the endometrium, and a homologous gene, derailed, is known to regulate muscle and nerve target seeking in Drosophila, ryk mag also be involved in cellular recognition of appropriate contest.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Tyner, AL (corresponding author), Univ Illinois, Dept Mol Genet, M-C 669,Mol Biol Res Bldg, Chicago, IL 60607 USA.			Tyner, Angela/0000-0001-7448-8625	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK044525, R01DK044525] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44525, R01 DK044525-06, R01 DK044525] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMSOHN PA, 1993, J EXP ZOOL, V266, P603, DOI 10.1002/jez.1402660610; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; Callahan CA, 1996, DEVELOPMENT, V122, P2761; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; Dey SK, 1996, REPROD ENDOCRINOLOGY, V1, P421; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; GOUGH NM, 1995, MAMM GENOME, V6, P255, DOI 10.1007/BF00352411; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; HUME WJ, 1976, J CELL SCI, V22, P149; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; Kee NJ, 1997, KIDNEY INT, V52, P309, DOI 10.1038/ki.1997.336; KELMAN Z, 1993, ONCOGENE, V8, P37; LARSSONBLOMBERG L, 1994, FEBS LETT, V348, P119, DOI 10.1016/0014-5793(94)00577-X; LEE JJ, 1992, DEVELOPMENT, V115, P277; Lim H, 1997, ENDOCRINOLOGY, V138, P1328, DOI 10.1210/en.138.3.1328; MAMINTA MLD, 1992, BIOCHEM BIOPH RES CO, V189, P1077; MOSSIE K, 1995, ONCOGENE, V11, P2179; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PAUL SR, 1992, INT J CELL CLONING, V10, P309, DOI 10.1002/stem.5530100509; Potworowski EF, 1996, IMMUNOL LETT, V50, P65, DOI 10.1016/0165-2478(96)02520-5; ROCHAT A, 1994, CELL, V76, P1063, DOI 10.1016/0092-8674(94)90383-2; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIMONEAUX DK, 1995, J IMMUNOL, V154, P1157; SIYANOVA EY, 1994, ONCOGENE, V9, P2053; STACKER SA, 1993, ONCOGENE, V8, P1347; STARK KL, 1991, DEVELOPMENT, V113, P641; TAMAGNONE L, 1993, ONCOGENE, V8, P2009; Wang XC, 1996, MOL MED, V2, P189, DOI 10.1007/BF03401616; Weiner HL, 1996, PEDIATR NEUROSURG, V25, P64, DOI 10.1159/000121099; WELSH AO, 1985, AM J ANAT, V172, P1, DOI 10.1002/aja.1001720102; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YEE K, 1993, BLOOD, V82, P1335	37	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3435	3444		10.1038/sj.onc.1202266	http://dx.doi.org/10.1038/sj.onc.1202266			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030667				2022-12-28	WOS:000078086200004
J	Izawa, I; Amano, M; Chihara, K; Yamamoto, T; Kaibuchi, K				Izawa, I; Amano, M; Chihara, K; Yamamoto, T; Kaibuchi, K			Possible involvement of the inactivation of the Rho-Rho-kinase pathway in oncogenic Ras-induced transformation	ONCOGENE			English	Article						Ras; Rho; Rho-kinase; cell adhesion	ACTIN STRESS FIBERS; BINDING PROTEIN-RHO; SERINE-THREONINE KINASE; CELL-CELL ADHESION; PUTATIVE TARGET; FOCAL ADHESIONS; CDC42 GTPASES; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; TIGHT JUNCTIONS	Recent evidence has strongly suggested the involvement of Rho family small guanosine triphosphatases (GTPases) in Ras-induced transformation. To further clarify the role of Rho family GTPases in Ras-induced transformation, we examined the effects of dominant active or dominant negative forms of Rho family GTPases on the morphological changes induced by oncogenic Ras (Ras(V12)) in Rat1 fibroblasts. The cells expressing Ras(V12) showed the severe disruption of actin stress fibers and cell adhesions. The coexpression of dominant active form of Rho (Rho(V14)) reverted not only the formation of stress fibers and focal adhesions but also cell-cell adhesions in Ras-transformed Rat1 cells. In addition, the coexpression of constitutively activated Rho-kinase, a downstream effector of Rho, restored the assembly of stress fibers and focal adhesions. Treatment of Rat cells with lysophosphatidic acid, which is known to activate the Rho-Rho-kinase pathway, enhanced the stress fiber formation, whereas it failed to induce the stress fiber formation in the cells expressing Ras(V12). These results suggest that the Rho-Rho-kinase pathway may be inactivated in the cells expressing Ras(V12), and this may contribute to oncogenic Ras-induced transformation.	Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Yokohama, Kanagawa 2360004, Japan	Nara Institute of Science & Technology; Kirin Brewery Company Limited	Kaibuchi, K (corresponding author), Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan.		Amano, Mutsuki/M-4820-2014	Amano, Mutsuki/0000-0002-0662-1524				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HAN L, 1995, MOL CELL BIOL, V15, P1319; Harlow E., 1988, ANTIBODIES LAB MANUA; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329	54	47	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 3	1998	17	22					2863	2871		10.1038/sj.onc.1202213	http://dx.doi.org/10.1038/sj.onc.1202213			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879992	Bronze			2022-12-28	WOS:000077286400006
J	Huynh, KD; Bardwell, VJ				Huynh, KD; Bardwell, VJ			The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT	ONCOGENE			English	Article						POZ domain; BCL-6; transcriptional repression; N-CoR; SMRT	NUCLEAR HORMONE RECEPTORS; GERMINAL-CENTER FORMATION; ZINC-FINGER PROTEINS; CENTER B-CELLS; ACUTE PROMYELOCYTIC LEUKEMIA; POSITION-EFFECT VARIEGATION; GAGA TRANSCRIPTION FACTOR; NON-HODGKINS-LYMPHOMAS; BTB/POZ DOMAIN; DNA-BINDING	Virtually all diffuse large cell lymphomas and a significant fraction of follicular lymphomas contain translocations and/or point mutations in the 5' noncoding region of the putative oncogene BCL-6, that are presumed to deregulate its expression. BCL-6 encodes a Cys(2)-His(2) zinc finger transcriptional repressor with a POZ domain at its amino-terminus, The POZ (or BTB) domain, a 120-amino-acid motif, mediates homomeric and, in some proteins, heteromeric POZ-POZ interactions. In addition, the POZ domain is required for transcriptional repression of several proteins, including BCL-6, Using a yeast two-hybrid screen, we identified N-CoR and SMRT as BCL-6 interacting proteins. Both N-CoR and SMRT, which were originally identified as co-repressors for the unliganded nuclear thyroid hormone and retinoic acid receptors, are components of large complexes containing histone deacetylases, We show that the interaction between BCL-6 and these co-repressors is also detected in the more physiologically relevant mammalian two-hybrid assay. The POZ domain is necessary and sufficient for interaction with these corepressors. BCL-6 and N-CoR co-localize to punctate regions of the nucleus. Furthermore, when BCL-6 is bound to its consensus recognition sequence in vivo, it can interact with N-CoR and SMRT, We find, in vitro, that POZ domains from a variety of other POZ domain-containing proteins, including the transcriptional repressor PLZF, as well as ZID, GAGA and a vaccinia virus protein, SalF17R, also interact with varying affinities with N-CoR and SMRT, We find that BCL-6 POZ domain mutations that disrupt the interaction with N-CoR and SMRT no longer repress transcription. In addition, these mutations no longer self associate suggesting that self interaction is required for interaction with the co-repressors and for repression. More recently N-CoR has also been implicated in transcriptional repression by the Mad/Mxi proteins. Our demonstration that N-CoR and SMRT interact with the POZ domain containing proteins indicates that these co-repressors are likely involved in the mediation of repression by multiple classes of repressors and may explain, in part, how POZ domain containing repressors mediate transcriptional repression.	Univ Minnesota, Dept Biochem, Minneapolis, MN 55455 USA; Univ Minnesota, Biochem Mol Biol & Biophys Program, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Bardwell, VJ (corresponding author), Univ Minnesota, Dept Biochem, 4-225 Millard Hall,435 Delaware St SE, Minneapolis, MN 55455 USA.				NATIONAL CANCER INSTITUTE [R29CA071540] Funding Source: NIH RePORTER; NCI NIH HHS [5R29CA71540, R29 CA071540] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BARON BW, 1995, GENE CHROMOSOME CANC, V13, P221, DOI 10.1002/gcc.2870130314; Baron BW, 1997, GENE CHROMOSOME CANC, V19, P14, DOI 10.1002/(SICI)1098-2264(199705)19:1<14::AID-GCC3>3.0.CO;2-3; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DEWEINDT C, 1993, GENE CHROMOSOME CANC, V8, P149, DOI 10.1002/gcc.2870080303; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1995, ONCOGENE, V11, P2689; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FLENGHI L, 1995, AM J PATHOL, V147, P405; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; GERASIMOVA TI, 1995, CELL, V82, P587, DOI 10.1016/0092-8674(95)90031-4; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HOWARD ST, 1991, VIROLOGY, V180, P633, DOI 10.1016/0042-6822(91)90077-O; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; Kaplan J, 1997, NUCLEIC ACIDS RES, V25, P1108, DOI 10.1093/nar/25.6.1108; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P213, DOI 10.1016/0968-0004(92)90379-N; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Li XM, 1997, J BIOL CHEM, V272, P27324, DOI 10.1074/jbc.272.43.27324; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LO CF, 1994, BLOOD, V83, P1757; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P217; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; OHNO H, 1994, JPN J CANCER RES, V85, P592, DOI 10.1111/j.1349-7006.1994.tb02401.x; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; Pittaluga S, 1996, J PATHOL, V179, P145; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Seyfert VL, 1996, ONCOGENE, V12, P2331; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; STEIN H, 1992, NEOPLASTIC HEMATOPAT, P675; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; Wilkinson JR, 1997, J BIOL CHEM, V272, P23824, DOI 10.1074/jbc.272.38.23824; XIONG WC, 1993, GENE DEV, V7, P1085, DOI 10.1101/gad.7.6.1085; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, BIOCHEM BIOPH RES CO, V53, P2732; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zamir I, 1996, MOL CELL BIOL, V16, P5458; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	73	249	255	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2473	2484		10.1038/sj.onc.1202197	http://dx.doi.org/10.1038/sj.onc.1202197			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824158	Bronze			2022-12-28	WOS:000076927300007
J	Dominguez, A; Ramos-Morales, F; Romero, F; Rios, RM; Dreyfus, F; Tortolero, M; Pintor-Toro, JA				Dominguez, A; Ramos-Morales, F; Romero, F; Rios, RM; Dreyfus, F; Tortolero, M; Pintor-Toro, JA			hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG	ONCOGENE			English	Article						PTTG; oncogene; transcription; tumorigenesis	SECONDARY-STRUCTURE; IMMUNE PRIVILEGE; PROTEINS; YEAST; GENE; DOMAINS; LIGAND; BRCA1	We have isolated a human cDNA clone encoding a novel protein of 22 kDa that is a human counterpart of the rat oncoprotein PTTG. We show that the corresponding gene (hpttg) is overexpressed in Jurkat cells (a human T lymphoma cell line) and in samples from patients with different kinds of hematopoietic malignancies. Analysis of the sequence showed that hPTTG has an aminoterminal basic domain and a carboxyl-terminal! acidic domain, and that it is a proline-rich protein with several putative SH3-binding sites, Subcellular fractionation studies show that, although hPTTG is mainly a cytosolic protein, it is partially localized in the nucleus. In addition we demonstrate that the acidic carboxyl-terminal region of hPTTG acts as a transactivation domain when fused to a heterologous DNA binding domain, both in yeast and in mammalian cells.	CSIC, Inst Recursos Nat & Agrobiol, E-41080 Seville, Spain; Univ Sevilla, Fac Biol, Dept Microbiol, E-41080 Seville, Spain; Hop Cochin, Hematol Serv, F-75015 Paris, France	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS); University of Sevilla; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Pintor-Toro, JA (corresponding author), CSIC, Inst Recursos Nat & Agrobiol, Apdo 1052, E-41080 Seville, Spain.		Romero, Francisco/K-2101-2014; Tortolero, Maria/K-5744-2014; Ramos-Morales, Francisco/C-5734-2008; rios, rosa m/G-5742-2015	Romero, Francisco/0000-0002-9588-6881; Tortolero, Maria/0000-0003-1797-9940; Ramos-Morales, Francisco/0000-0002-1151-4547; rios, rosa m/0000-0001-5778-6946				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HWANG LY, 1995, CURR OPIN IMMUNOL, V7, P659, DOI 10.1016/0952-7915(95)80074-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RamosMorales F, 1997, BIOCHEM BIOPH RES CO, V237, P735, DOI 10.1006/bbrc.1997.7221; Remacle JE, 1997, EMBO J, V16, P5722, DOI 10.1093/emboj/16.18.5722; RIOS RM, 1994, J CELL BIOL, V125, P997, DOI 10.1083/jcb.125.5.997; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SANZ L, 1995, MOL CELL BIOL, V15, P3164; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SETH A, 1992, J BIOL CHEM, V267, P24796; Sherman F., 1986, METHODS YEAST GENETI; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; STREILEIN JW, 1993, CURR OPIN IMMUNOL, V5, P428, DOI 10.1016/0952-7915(93)90064-Y; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z	39	163	185	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2187	2193		10.1038/sj.onc.1202140	http://dx.doi.org/10.1038/sj.onc.1202140			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811450				2022-12-28	WOS:000076698200005
J	Ayi, TC; Tsan, JT; Hwang, LY; Bowcock, AM; Baer, R				Ayi, TC; Tsan, JT; Hwang, LY; Bowcock, AM; Baer, R			Conservation of function and primary structure in the BRCA1-associated RING domain (BARD1) protein	ONCOGENE			English	Article						BRCA1; breast cancer; RING domain; BRCT domain; tumor suppressor	CANCER SUSCEPTIBILITY GENE; BREAST-CANCER; CELL-CYCLE; SUBCELLULAR-LOCALIZATION; EXPRESSION PATTERN; FAMILIAL BREAST; MESSENGER-RNA; MURINE BRCA1; DNA-DAMAGE; SEQUENCE	The BRCA1 gene encodes a tumor suppressor that has been implicated in hereditary forms of breast and ovarian cancer. During S phase of the cell cycle, BRCA1 polypeptides are found in discrete nuclear bodies ('BRCA1 nuclear dots') together with HsRad51, a human homolog of the E. coli recA protein, and BARD1, a protein that interacts with BRCA1 to form a stable heterodimer. BARD1 is structurally similar to BRCA1 in that both molecules harbor an amino-terminal RING domain and two carboxy-terminal BRCT domains. Here we describe the amino acid sequence and expression pattern of murine Bard1. A comparison of the mouse and human sequences reveals that the recognizable protein motifs of BARD1 are well conserved, including the RING domain, the three tandem ankyrin repeats, and, to a lesser extent, the two BRCT domains. However, the remaining sequences of BARD1 display a markedly lower degree of phylogenetic conservation, comparable to those reported for BRCA1 and BRCA2. Moreover, murine Bard1 retains the ability to associate in vivo with BRCA1, and its expression pattern in adult mice mirrors that of Brca1, with elevated levels of RNA transcripts found in the testes and spleen. These data suggest that BRCA1 and BARD1 have co-evolved to participate in a common pathway of tumor suppression.	Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Baer, R (corresponding author), Univ Texas, SW Med Ctr, Dept Microbiol, 6000 Harry Hines Blvd, Dallas, TX 75235 USA.			Bowcock, Anne/0000-0001-8691-9090	NATIONAL CANCER INSTITUTE [R01CA076334, R01CA060650] Funding Source: NIH RePORTER; NCI NIH HHS [CA76334, CA60650] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; Bertwistle D, 1997, CANCER RES, V57, P5485; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Chen YM, 1996, SCIENCE, V272, P125, DOI 10.1126/science.272.5258.125; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Connor F, 1997, HUM MOL GENET, V6, P291, DOI 10.1093/hmg/6.2.291; Cox MM, 1997, P NATL ACAD SCI USA, V94, P11764, DOI 10.1073/pnas.94.22.11764; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Karlin S, 1996, J BACTERIOL, V178, P1881, DOI 10.1128/jb.178.7.1881-1894.1996; Katagiri T, 1998, GENE CHROMOSOME CANC, V21, P217, DOI 10.1002/(SICI)1098-2264(199803)21:3<217::AID-GCC5>3.0.CO;2-2; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; McAllister KA, 1997, CANCER RES, V57, P3121; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; SHARAN SK, 1995, HUM MOL GENET, V4, P2275, DOI 10.1093/hmg/4.12.2275; Sharan SK, 1997, GENOMICS, V40, P234, DOI 10.1006/geno.1996.4573; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Spillman MA, 1996, ONCOGENE, V13, P1639; Szabo CI, 1996, HUM MOL GENET, V5, P1289, DOI 10.1093/hmg/5.9.1289; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; Thomas JE, 1996, J BIOL CHEM, V271, P28630, DOI 10.1074/jbc.271.45.28630; TSAN JT, 1997, YEAST 2 HYBRID SYSTE, P217; Vaughn JP, 1996, CANCER RES, V56, P4590; Wang SC, 1997, BIOCHEM BIOPH RES CO, V234, P247, DOI 10.1006/bbrc.1997.6544; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Zabludoff SD, 1996, ONCOGENE, V13, P649	48	33	38	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2143	2148		10.1038/sj.onc.1202123	http://dx.doi.org/10.1038/sj.onc.1202123			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798686				2022-12-28	WOS:000076540900014
J	Mengubas, K; Riordan, FA; Bravery, CA; Lewin, J; Owens, DL; Mehta, AB; Hoffbrand, AV; Wickremasinghe, RG				Mengubas, K; Riordan, FA; Bravery, CA; Lewin, J; Owens, DL; Mehta, AB; Hoffbrand, AV; Wickremasinghe, RG			Ceramide-induced killing of normal and malignant human lymphocytes is by a non-apoptotic mechanism	ONCOGENE			English	Article						ceramide; leukaemia; apoptosis; necrosis	RADIATION-INDUCED APOPTOSIS; DAUNORUBICIN-INDUCED APOPTOSIS; ACTIVATED PROTEIN-KINASES; CELL-DEATH; HL-60 CELLS; DNA-DAMAGE; IN-VITRO; B-CELL; LEUKEMIA; RESISTANCE	Synthetic ceramides induce apoptotic death of Jurkat and HL60 leukaemia cell lines. By contrast we show here that ceramide induces non-apoptotic killing of malignant cells from patients with B-chronic lymphocytic leukaemia (B-CLL) and of normal B lymphocytes, The protein phosphatase inhibitor okadaic acid readily induces apoptosis of B-CLL cells, indicating that this death pathway is fully functional in these cells. The ability of ceramide to activate the apoptotic protease caspase 3 in HL60 cells but not in B-CLL cells, as well as the lack of correlation of ceramide-mediated killing of different B-CLL isolates with expression of the apoptosis-regulating proteins bcl-2 and bax reinforce the conclusion that ceramide killing of B-CLL cells is by a non-apoptotic mechanism. Fludarabine treatment or gamma-irradiation of B-CLL cells resulted in ceramide elevation and in killing by both apoptotic and non-apoptotic mechanisms, suggesting that a ceramide-triggered non-apoptotic mechanism may play a role in the killing of these cells. Therefore, the results here show that ceramide can induce either apoptotic or non-apoptotic death, depending on the cellular conte it. The inability of synthetic dihydroceramide to kill B-CLL cells or normal B lymphocytes suggests that non-apoptotic killing by ceramide is via interaction with a specific, but unidentified, cellular target.	UCL Royal Free & Univ Coll Sch Med, Dept Hematol, London NW3 2PF, England; UCL Royal Free & Univ Coll Sch Med, Dept Histopathol, London NW3 2PF, England; UCL Royal Free & Univ Coll Sch Med, Hemophilia Ctr, London NW3 2PF, England	University of London; University College London; University of London; University College London; University of London; University College London	Wickremasinghe, RG (corresponding author), UCL Royal Free & Univ Coll Sch Med, Dept Hematol, Rowland Hill St, London NW3 2PF, England.		Mehta, Atul/GPC-7364-2022					Allouche M, 1997, ONCOGENE, V14, P1837, DOI 10.1038/sj.onc.1201023; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Chmura SJ, 1997, CANCER RES, V57, P1270; Consoli U, 1998, BLOOD, V91, P1742, DOI 10.1182/blood.V91.5.1742.1742_1742_1748; Cotter T.G., 1996, TECHNIQUES APOPTOSIS; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Eguchi Y, 1997, CANCER RES, V57, P1835; FernandezSanchez MT, 1996, FEBS LETT, V398, P106, DOI 10.1016/S0014-5793(96)01192-1; FOON KA, 1990, ANN INTERN MED, V113, P525, DOI 10.7326/0003-4819-113-7-525; Haimovitz-Friedman A, 1997, BRIT MED BULL, V53, P539; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Jarvis WD, 1997, MOL PHARMACOL, V52, P935, DOI 10.1124/mol.52.6.935; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Kojima H, 1996, ONCOL RES, V8, P497; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Michael JM, 1997, CANCER RES, V57, P3600; Naito M, 1997, BLOOD, V89, P2060, DOI 10.1182/blood.V89.6.2060; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Ohmori M, 1997, CANCER RES, V57, P4714; PANAYIOTIDIS P, 1993, BRIT J HAEMATOL, V85, P439; Panayiotidis P., 1995, Blood, V86, p607A; Pepper C, 1997, BRIT J CANCER, V76, P935, DOI 10.1038/bjc.1997.487; PUSHKAREVA M, 1995, BIOCHEMISTRY-US, V34, P1885, DOI 10.1021/bi00006a009; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Shimizu S, 1996, ONCOGENE, V12, P2045; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Tay DLM, 1996, EXP HEMATOL, V24, P277; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Thomas A, 1996, ONCOGENE, V12, P1055; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Wright SC, 1996, FASEB J, V10, P325, DOI 10.1096/fasebj.10.2.8641566; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	48	37	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2499	2506		10.1038/sj.onc.1202622	http://dx.doi.org/10.1038/sj.onc.1202622			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229201				2022-12-28	WOS:000079703300010
J	Sawamoto, K; Yamada, C; Kishida, S; Hirota, Y; Taguchi, A; Kikuchi, A; Okano, H				Sawamoto, K; Yamada, C; Kishida, S; Hirota, Y; Taguchi, A; Kikuchi, A; Okano, H			Ectopic expression of constitutively activated Ral GTPase inhibits cell shape changes during Drosophila eye development	ONCOGENE			English	Article						actin; cell shape; Drosophila; Ra1	NUCLEOTIDE DISSOCIATION STIMULATOR; PROTEIN TYROSINE KINASE; C-FOS PROMOTER; PUTATIVE EFFECTOR; FATE; MEMBRANE; GROWTH; IDENTIFICATION; TRANSFORMATION; MELANOGASTER	The small GTP-binding protein Ral is activated by RalGDS, one of the effector molecules for Ras. Active Ral binds to a GTPase activating protein for CDC42 and Rac. Although previous studies suggest a role for Ral in the regulation of CDC42 and Rac, which are involved in arranging the cytoskeleton, its in vivo function is largely unknown. To examine the effect of overexpressing Ral on development, transgenic Drosophila were generated that overexpress wild-type or mutated Ral during eye development. While wild-type Ral caused no developmental defects, expression of a constitutively activated protein resulted in a rough eye phenotype, Activated Ral did not affect cell fate determination in the larval eye discs but caused severe disruption of the ommatidial organization later in pupal development. Phalloidin staining showed that activated Ral perturbed the cytoskeletal structure and cell shape changes during pupal development. This phenotype is similar to that caused by RhoA overexpression. In addition, the phenotype was synergistically enhanced by the coexpression of RhoA, These results suggest that Ral functions to control the cytoskeletal structure required for cell shape changes during Drosophila development.	Osaka Univ, Sch Med, Biomed Res Ctr, Dept Neuroanat, Suita, Osaka 5650871, Japan; Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7340037, Japan; JST, CREST, Minato Ku, Tokyo 1050011, Japan	Osaka University; Hiroshima University; Japan Science & Technology Agency (JST)	Okano, H (corresponding author), Osaka Univ, Sch Med, Biomed Res Ctr, Dept Neuroanat, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Okano, Hideyuki/I-7584-2019; Hirota, Yuki/A-9736-2015	Hirota, Yuki/0000-0001-9629-0038; Sawamoto, Kazunobu/0000-0003-1984-5129; kishida, shosei/0000-0003-0405-851X				Aelst L, 1997, GENE DEV, V11, P2295; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BLOCHLINGER K, 1993, DEVELOPMENT, V117, P441; Bos JL, 1997, BBA-REV CANCER, V1333, pM19, DOI 10.1016/S0304-419X(97)00015-2; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; DENOOIJ JC, 1995, SCIENCE, V270, P983, DOI 10.1126/science.270.5238.983; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FRECH M, 1990, J BIOL CHEM, V265, P6353; HARDEN N, 1995, DEVELOPMENT, V121, P903; HARIHARAN IK, 1995, EMBO J, V14, P292, DOI 10.1002/j.1460-2075.1995.tb07003.x; HAY BA, 1994, DEVELOPMENT, V120, P2121; HIGASHIJIMA SI, 1992, GENE DEV, V6, P50, DOI 10.1101/gad.6.1.50; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Karim FD, 1998, DEVELOPMENT, V125, P1; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; Lee T, 1996, DEVELOPMENT, V122, P409; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; LONGLEY RL, 1995, DEV BIOL, V171, P415, DOI 10.1006/dbio.1995.1292; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Matsuo T, 1997, DEVELOPMENT, V124, P2671; Miller DT, 1998, DEVELOPMENT, V125, P2327; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; MIYAMOTO H, 1995, GENE DEV, V9, P612, DOI 10.1101/gad.9.5.612; Murai H, 1997, J BIOL CHEM, V272, P10483; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; Park SH, 1995, ONCOGENE, V11, P2349; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sawamoto K, 1998, CELL DEATH DIFFER, V5, P262, DOI 10.1038/sj.cdd.4400342; SAWAMOTO K, 1994, DEV BIOL, V164, P267, DOI 10.1006/dbio.1994.1197; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; WASSARMAN DA, 1997, ADV DEV BIO, V5, P1; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WOLFF T, 1991, DEVELOPMENT, V113, P825; Wolff T, 1993, DEV DROSOPHILA MELAN; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	58	17	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					1967	1974		10.1038/sj.onc.1202522	http://dx.doi.org/10.1038/sj.onc.1202522			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208418				2022-12-28	WOS:000079191300006
J	Plattner, R; Gupta, S; Khosravi-Far, R; Sato, KY; Perucho, M; Der, CJ; Stanbridge, EJ				Plattner, R; Gupta, S; Khosravi-Far, R; Sato, KY; Perucho, M; Der, CJ; Stanbridge, EJ			Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells	ONCOGENE			English	Article						Ras; ERK; JNK	NUCLEOTIDE DISSOCIATION STIMULATOR; EPITHELIAL-CELLS; PLASMA-MEMBRANE; IN-VITRO; C-JUN; GROWTH; IDENTIFICATION; SUFFICIENT; EXPRESSION; ONCOGENES	Although an important contribution of ERK and JNK mitogen-activated protein kinase (MAPK) activation in Ras transformation of rodent fibroblasts has been determined, their role in mediating oncogenic Ras transformation of human tumor cells remains to be established. We have utilized the human HT1080 fibrosarcoma and DLD-1 colon carcinoma cell lines, which contain endogenous mutated and oncogenic N- and K-ras alleles, respectively, to address this role. Study of these cells is advantageous over Ras-transformed rodent model cell systems for two key reasons. First, the ras mutations occurred naturally in the progression of the tumors from which the cell lines were derived, rather than due to overexpression of an exogenously introduced gene, Second, although these tumor cells possess defects in multiple genetic loci, it has been established that mutated Ras contributes significantly to the transformed phenotype of these cells. Clonal variant lines of HT1080 and DLD-1 have been isolated which have lost the oncogenic was allele and exhibit a corresponding impairment in growth transformation in vitro and in vivo. We found that upregulation of Raf/MEK/ERK and JNK correlated with expression of oncogenic Ras in HT1080, but not DLD-1 cells. Furthermore, inhibition of ERK activation in parental HT1080 cells caused the same changes in cell morphology and actin stress fiber organization seen with loss of expression of activated N-Ras(61K). Thus, we suggest that constitutive activation of the Raf/MEK/ERK and JNK pathways is necessary for Ras-induced transformation of HT1080 but not DLD-1 cells. These results emphasize that cell type differences exist in the signaling pathways by which oncogenic pas causes transformation.	Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Curriculum Genet & Mol Biol,Dept Pharmacol, Chapel Hill, NC 27599 USA; Burnham Inst, La Jolla, CA 92093 USA	University of California System; University of California Irvine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Sanford Burnham Prebys Medical Discovery Institute	Stanbridge, EJ (corresponding author), Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.		Khosravi-Far, Roya/C-3789-2008	Der, Channing/0000-0002-7751-2747; Perucho, Manuel/0000-0002-2169-2662	NCI NIH HHS [CA69515, CA42978, CA19401] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042978, R01CA019401, R01CA069515, R37CA019401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON MJ, 1994, GENE CHROMOSOME CANC, V9, P266, DOI 10.1002/gcc.2870090407; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; Graham SM, 1996, MOL CELL BIOL, V16, P6132; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Hua VY, 1997, P NATL ACAD SCI USA, V94, P9614, DOI 10.1073/pnas.94.18.9614; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; OLDHAM SM, 1998, IN PRESS ONCOGENE; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; Plattner R, 1996, P NATL ACAD SCI USA, V93, P6665, DOI 10.1073/pnas.93.13.6665; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VANAELST L, 1994, COLD SPRING HARB SYM, V59, P181, DOI 10.1101/SQB.1994.059.01.022; WESTWICK JK, 1995, METHOD ENZYMOL, V255, P342; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WINTER E, 1986, MOL CELL BIOL, V6, P2562, DOI 10.1128/MCB.6.7.2562; Wolthuis RMF, 1996, ONCOGENE, V13, P353	48	50	50	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1807	1817		10.1038/sj.onc.1202482	http://dx.doi.org/10.1038/sj.onc.1202482			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086335				2022-12-28	WOS:000079090000004
J	Schmandt, R; Liu, SK; McGlade, CJ				Schmandt, R; Liu, SK; McGlade, CJ			Cloning and characterization of mPAL, a novel Shc SH2 domain-binding protein expressed in proliferating cells	ONCOGENE			English	Article						SHC; SH2 domain; phosphotyrosine-independent; cell proliferation	NUCLEOTIDE EXCHANGE FACTOR; PHOSPHOTYROSINE-INDEPENDENT LIGAND; TYROSINE-PHOSPHORYLATED PROTEIN; GROWTH-FACTOR RECEPTORS; ADAPTER PROTEIN; SIGNAL-TRANSDUCTION; CONSTITUTIVE PHOSPHORYLATION; NEURONAL DIFFERENTIATION; KINASE ACTIVATION; DEPENDENT MANNER	Shc adaptor proteins play a role in linking activated cell surface receptors to the Ras signaling pathway in response to receptor mediated tyrosine kinase activation. While the function of Shc in the activation of the Ras pathway, ia binding to Grb2 has been well characterized, it is becoming increasingly apparent that Shc participates in additional signaling pathways through interactions with other cytoplasmic proteins. Using the yeast two-hybrid system, we have identified a unique She binding protein designated PAL (Protein expressed in Activated Lymphocytes) with no similarity to other known proteins. mPAL binds specifically to the Shc SH2 domain and unlike previously described Shc SH2 domain-protein interactions, the association of mPAL and She is phosphotyrosine-independent. RNA and protein expression are restricted to tissues containing actively dividing cells and proliferating cells in culture, mPAL expression is induced upon growth factor stimulation and is down-regulated upon growth inhibition. This pattern, and timing of mPAL expression and its association with the She adaptor molecule suggests a role for this protein in signaling pathways governing cell cycle progression.	Univ Toronto, Dept Med Biophys, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	McGlade, CJ (corresponding author), Univ Toronto, Dept Med Biophys, Ontario Canc Inst, 620 Univ Ave,Suite 706, Toronto, ON M5G 2C1, Canada.			Liu, Stanley/0000-0001-6851-0857				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Bai C, 1996, METHOD ENZYMOL, V273, P331; BALDARI CT, 1995, ONCOGENE, V10, P1141; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; CROWE AJ, 1994, ONCOGENE, V9, P537; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAMEN JE, 1993, BLOOD, V82, P2296; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Gotoh N, 1995, ONCOGENE, V11, P2525; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU SK, 1998, IN PRESS ONCOGENE; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; MALEK SN, 1994, J BIOL CHEM, V269, P33009; Marengere LEM, 1997, J IMMUNOL, V159, P70; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; O'Bryan JP, 1998, J BIOL CHEM, V273, P20431, DOI 10.1074/jbc.273.32.20431; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; Raffel GD, 1996, J BIOL CHEM, V271, P4640; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUDNICKI MA, 1990, J CELL PHYSIOL, V142, P89, DOI 10.1002/jcp.1041420112; SALCINI AE, 1994, ONCOGENE, V9, P2827; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAXTON TM, 1994, J IMMUNOL, V153, P623; SEGATTO O, 1993, ONCOGENE, V8, P2105; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; Vadlamudi RK, 1996, J BIOL CHEM, V271, P20235, DOI 10.1074/jbc.271.34.20235; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	79	46	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	1999	18	10					1867	1879		10.1038/sj.onc.1202507	http://dx.doi.org/10.1038/sj.onc.1202507			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086341				2022-12-28	WOS:000079090000010
J	Fulda, S; Lutz, W; Schwab, M; Debatin, KM				Fulda, S; Lutz, W; Schwab, M; Debatin, KM			MycN sensitizes neuroblastoma cells for drug-induced apoptosis	ONCOGENE			English	Article						MycN; apoptosis; CD95; drugs; neuroblastoma	APO-1/FAS RECEPTOR/LIGAND SYSTEM; CHEMOTHERAPY-INDUCED APOPTOSIS; SIGNALING COMPLEX DISC; C-MYC; TRANSGENIC MICE; CELLULAR-SUSCEPTIBILITY; CANCER-THERAPY; LEUKEMIA-CELLS; WILD-TYPE; DEATH	Amplification of the MYCN gene is found in a large proportion of neuroblastoma and considered as an adverse prognostic factor. To investigate the effect of ectopic MycN expression on the susceptibility of neuroblastoma cells to cytotoxic drugs we used a human neuroblastoma cell line harboring tetracycline-controlled expression of MycN, Neither conditional expression of MycN alone nor low drug concentrations triggered apoptosis. However, when acting in concert, MycN and cytotoxic drugs efficiently induced cell death. Apoptosis depended on mitochondrial permeability transition and activation of caspases, since the mitochondrion-specific inhibitor bongkrekic acid and the caspase inhibitor zVAD-fmk almost completely abrogated apoptosis, Loss of mitochondrial transmembrane potential and release of cytochrome c from mitochondria preceded activation of caspase-8 and caspase-3 and cleavage of PARP. CD95 expression was upregulated by treatment with cytotoxic drugs, while MycN cooperated with cytotoxic drugs to increase sensitivity to CD95-induced apoptosis and enhancing CD95-L expression. MycN overexpression and cytotoxic drugs also synergized to induce p53 and Bar protein expression, while Bcl-2 and Bcl-X-L protein levels remained unchanged. Since amplification of MYCN is usually associated with a poor prognosis, these findings suggest that dysfunctions in apoptosis pathways may be a mechanism by which MycN-induced apoptosis of neuroblastoma cells is inhibited.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany; German Canc Res Ctr, Dept Cytogenet, D-69120 Heidelberg, Germany	Ulm University; Helmholtz Association; German Cancer Research Center (DKFZ)	Debatin, KM (corresponding author), Univ Ulm, Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.		Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; BERTHOLD F, 1990, OVERVIEW BIOL NEUROB, P1; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Dong JA, 1997, ONCOGENE, V15, P639, DOI 10.1038/sj.onc.1201237; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Faris M, 1998, J IMMUNOL, V160, P134; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 1998, INT J CANCER, V76, P105; FULDA S, 1998, IN PRESS CELL DEATH; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; Lutz W, 1996, ONCOGENE, V13, P803; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NIIMI S, 1991, BRIT J CANCER, V63, P237, DOI 10.1038/bjc.1991.56; OEHM A, 1992, J BIOL CHEM, V267, P10709; Packham G, 1996, ONCOGENE, V13, P461; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Peter ME, 1996, CELL DEATH DIFFER, V3, P161; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schwab M, 1995, NEUROSCIENTIST, V1, P277; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Villunger A, 1997, CANCER RES, V57, P3331; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yu K, 1997, CELL GROWTH DIFFER, V8, P731; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZORNIG M, 1995, ONCOGENE, V11, P2165; ZORNIG M, 1995, ONCOGENE, V10, P2397	50	114	116	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	1999	18	7					1479	1486		10.1038/sj.onc.1202435	http://dx.doi.org/10.1038/sj.onc.1202435			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050884				2022-12-28	WOS:000078651600009
J	Bell, A; Chen, QY; DeFrances, MC; Michalopoulos, GK; Zarnegar, R				Bell, A; Chen, QY; DeFrances, MC; Michalopoulos, GK; Zarnegar, R			The five amino acid-deleted isoform of hepatocyte growth factor promotes carcinogenesis in transgenic mice	ONCOGENE			English	Article						dHGF; hepatocellular carcinoma; liver; Met	FACTOR SCATTER FACTOR; MET PROTOONCOGENE PRODUCT; IN-VIVO; C-MET; HEPATOCELLULAR-CARCINOMA; STRUCTURAL ORGANIZATION; NEOPLASTIC DEVELOPMENT; LIVER-REGENERATION; EPITHELIAL-CELLS; GENE-EXPRESSION	Hepatocyte growth factor (HGF) is a polypeptide with mitogenic, motogenic, and morphogenic effects on different cell types including hepatocytes. HGF is expressed as two biologically active isotypes resulting from alternative RNA splicing, The roles of each HGF isoform in development, liver regeneration and tumorigenesis have not yet been well characterized. We report the generation and analysis of transgenic mice overexpressing the five amino acid-deleted variant of HGF (dHGF) in the liver by virtue of an albumin expression vector. These ALB-dHGF transgenic mice develop normally, have an enhanced rate of liver regeneration after partial hepatectomy, and exhibit a threefold higher incidence of hepatocellular carcinoma (HCC) beyond 17 months of age. Moreover, overexpression of dHGF dramatically accelerates diethyl-nitrosamine induced HCC tumorigenesis, These tumors arise faster, are significantly larger, more numerous and more invasive than those appearing in non-transgenic littermates. Approximately 90% of female dHGF-transgenic mice had multiple macroscopic HCCs 40 weeks after injection of DEN; whereas the non-transgenic counterparts had only microscopic nodules, Liver tumors and cultured tumor cell lines from dHGF transgenics showed high levels of HGF and c-Met mRNA and protein, Together, these results reveal that in vivo dHGF plays an active role in liver regeneration and HCC tumorigenesis.	Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zarnegar, R (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, Pittsburgh, PA 15261 USA.				NIEHS NIH HHS [R01ES06109] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006109] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; BLADT F, 1995, NATURE, V373, P702; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Chan A, 1993, EXS, V65, P67; Chen QY, 1996, CELL GROWTH DIFFER, V7, P821; Chen QY, 1997, HEPATOLOGY, V26, P59; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HOGAN B, 1986, MANIPULATING MOUSE E, P174; JOHNSON M, 1995, CANCER LETT, V96, P37, DOI 10.1016/0304-3835(95)03915-J; Kawasaki E.S., 1990, PCR PROTOCOLS GUIDE, P146; LIU ML, 1995, CARCINOGENESIS, V16, P841, DOI 10.1093/carcin/16.4.841; LIU YH, 1994, GENE, V144, P179, DOI 10.1016/0378-1119(94)90376-X; LIU YH, 1994, MOL CELL ENDOCRINOL, V104, P173, DOI 10.1016/0303-7207(94)90120-1; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MIYAZAWA K, 1991, BIOCHEMISTRY-US, V30, P9170, DOI 10.1021/bi00102a007; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NAKANUMA Y, 1993, LIVER, V13, P1; NALDINI L, 1991, ONCOGENE, V6, P501; OKAJIMA A, 1990, EUR J BIOCHEM, V193, P375, DOI 10.1111/j.1432-1033.1990.tb19349.x; PUGH TD, 1983, CANCER RES, V43, P1261; RONG S, 1993, CANCER RES, V53, P5355; ROOS F, 1995, AM J PHYSIOL-GASTR L, V268, pG380, DOI 10.1152/ajpgi.1995.268.2.G380; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513; SantoniRugiu E, 1996, AM J PATHOL, V149, P407; SantoniRugiu E, 1996, P NATL ACAD SCI USA, V93, P9577, DOI 10.1073/pnas.93.18.9577; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SEKI T, 1990, BIOCHEM BIOPH RES CO, V172, P321, DOI 10.1016/S0006-291X(05)80212-8; SHIMA N, 1994, BIOCHEM BIOPH RES CO, V200, P808, DOI 10.1006/bbrc.1994.1523; SHIMA N, 1991, BIOCHEM BIOPH RES CO, V180, P1151, DOI 10.1016/S0006-291X(05)81187-8; SHIOTA G, 1994, HEPATOLOGY, V19, P962, DOI 10.1016/0270-9139(94)90297-6; Shiota G, 1996, RES COMMUN MOL PATH, V91, P33; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; TONJES RR, 1995, ONCOGENE, V10, P765; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WANLESS IR, 1990, HEPATOLOGY, V11, P787, DOI 10.1002/hep.1840110512; WEBBER EM, 1994, HEPATOLOGY, V19, P489; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WOLF H, 1991, AM J PATHOL, V138, P1305; YAONO M, 1995, JPN J CANCER RES, V86, P718, DOI 10.1111/j.1349-7006.1995.tb02459.x; YEE CJ, 1993, BIOCHEMISTRY-US, V32, P7922, DOI 10.1021/bi00082a013; ZARNEGAR R, 1989, CANCER RES, V49, P3314	50	61	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					887	895		10.1038/sj.onc.1202379	http://dx.doi.org/10.1038/sj.onc.1202379			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023664				2022-12-28	WOS:000078510600005
J	Plaza, S; Aumercier, M; Bailly, M; Dozier, C; Saule, S				Plaza, S; Aumercier, M; Bailly, M; Dozier, C; Saule, S			Involvement of poly(ADP-ribose)-polymerase in the Pax-6 gene regulation in neuroretina	ONCOGENE			English	Article						Pax-6; neuroretina; PARP; enhancer	HOMEOBOX-CONTAINING GENE; DNA-DAMAGE; ALVEOLAR RHABDOMYOSARCOMA; EYELESS GENE; P53 PROTEIN; IN-VITRO; POLYMERASE; QNR; TRANSCRIPTION; EXPRESSION	The quail Pax-6 gene is expressed from two promoters named P0 and P1. P0 promoter is under the control of a neuroretina-specific enhancer (EP), This enhancer activates the P0 promoter specifically in neuroretina cells and in a de developmental stage-dependent manner, The EP enhancer binds efficiently, as revealed by southwestern experiments, to a 110 kDa protein present in neuroretina cells but not in Quail Embryos Cells and Retinal Pigmented Epithelium which do not express the P0-initiated mRNAs, To study the role of p110 in Pax-6 regulation, we have purified the p110 from neuroretina cells extracts. Based on the peptide sequence of the purified protein, we have identified the p110 as the poly(ADP-ribose) polymerase (PARP). Using bandshift experiments and footprinting studies, we present evidence that PARP is a component of protein complexes bound to the EP enhancer that increases the on rate of the protein complex formation to DNA. Using PARP inhibitors (3AB and 6.5 Hphe), we show that these products are able to inhibit EP enhancer activity in neuroretina cells. Finally, we demonstrate that these inhibitors are able to decrease the expression of the P0-initiated mRNA in the MC29-infected RPE cells which, in contrast to the RPE cells, accumulated the PARP in response to v-myc expression, Our results suggest that PARP is involved in the Pax-6 regulation.	Inst Pasteur, Inst Biol, CNRS, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Saule, S (corresponding author), Inst Pasteur, Inst Biol, CNRS, EP 560,BP 447,1 Rue Calmette, F-59021 Lille, France.		plaza, serge/F-5290-2015; DOZIER, Christine/P-1539-2014	Aumercier, Marc/0000-0002-0370-3452				BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; Calligaro DO, 1997, BIOORG MED CHEM LETT, V7, P25, DOI 10.1016/S0960-894X(96)00567-7; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CHATTERJEE S, 1994, MOL CELL BIOCHEM, V138, P61, DOI 10.1007/BF00928444; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; DAVIS RJ, 1994, CANCER RES, V54, P2869; Dear TN, 1997, ONCOGENE, V14, P891, DOI 10.1038/sj.onc.1200912; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DING RC, 1994, CANCER RES, V54, P4627; DOZIER C, 1993, CELL GROWTH DIFFER, V4, P281; FUJIWARA M, 1994, DIFFERENTIATION, V57, P31, DOI 10.1046/j.1432-0436.1994.5710031.x; GAILLARD C, 1994, SCIENCE, V264, P433, DOI 10.1126/science.8153633; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Glardon S, 1997, DEVELOPMENT, V124, P817; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; ITTEL ME, 1991, GENE, V102, P157, DOI 10.1016/0378-1119(91)90073-K; LARSON CJ, 1992, NUCLEIC ACIDS RES, V20, P3525, DOI 10.1093/nar/20.13.3525; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; MANSOURI A, 1996, CURR OPIN CELL BIOL, V8, P951; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; MONCOLLIN V, 1990, NUCLEIC ACIDS RES, V18, P4817, DOI 10.1093/nar/18.16.4817; NESTERENKO MV, 1994, J BIOCHEM BIOPH METH, V28, P239, DOI 10.1016/0165-022X(94)90020-5; Nie J, 1998, FEBS LETT, V424, P27, DOI 10.1016/S0014-5793(98)00131-8; Oei S L, 1997, Rev Physiol Biochem Pharmacol, V131, P127; Oei SL, 1997, BIOCHEM BIOPH RES CO, V240, P108, DOI 10.1006/bbrc.1997.7621; PLAZA S, 1993, CELL GROWTH DIFFER, V4, P1041; PLAZA S, 1995, MOL CELL BIOL, V15, P3344; PLAZA S, 1995, MOL CELL BIOL, V15, P892; Prosser J, 1998, HUM MUTAT, V11, P93, DOI 10.1002/(SICI)1098-1004(1998)11:2<93::AID-HUMU1>3.0.CO;2-M; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; SASTRY SS, 1990, BIOCHEM BIOPH RES CO, V167, P842, DOI 10.1016/0006-291X(90)92102-6; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; SMULSON M, 1994, BIOCHEMISTRY-US, V33, P6186, DOI 10.1021/bi00186a018; STEVNSNER T, 1994, NUCLEIC ACIDS RES, V22, P4620, DOI 10.1093/nar/22.22.4620; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Tomarev SI, 1997, P NATL ACAD SCI USA, V94, P2421, DOI 10.1073/pnas.94.6.2421; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Weltin D, 1997, INT J RADIAT BIOL, V72, P685, DOI 10.1080/095530097142843; WesierskaGadek J, 1996, BIOCHEM BIOPH RES CO, V224, P96, DOI 10.1006/bbrc.1996.0990	49	35	35	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1041	1051		10.1038/sj.onc.1202406	http://dx.doi.org/10.1038/sj.onc.1202406			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023680				2022-12-28	WOS:000078510600021
J	Hoshino, R; Chatani, Y; Yamori, T; Tsuruo, T; Oka, H; Yoshida, O; Shimada, Y; Ari-i, S; Wada, H; Fujimoto, J; Kohno, M				Hoshino, R; Chatani, Y; Yamori, T; Tsuruo, T; Oka, H; Yoshida, O; Shimada, Y; Ari-i, S; Wada, H; Fujimoto, J; Kohno, M			Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors	ONCOGENE			English	Article						41-/43-kDa MAP kinases (ERKs); MEK; aberrant activation; human tumor; carcinogenesis	CANCER CELL-LINES; BONE MORPHOGENETIC PROTEIN-2; MAMMALIAN-CELLS; AGENTS INDUCE; MAP KINASES; TYROSINE; TRANSFORMATION; GROWTH; GENES; PHOSPHORYLATION	The 41-kDa and 43-kDa mitogen-activated protein (MAP) kinases play a pivotal role in the mitogenic signal transduction pathway and are essential components of the MAP kinase cascade, which includes MAP kinase kinase (MEK) and Raf-l, As aberrant activation of signal transducing molecules such as Pas and Raf-l has been linked with cancer, we examined whether constitutive activation of the 41-/43-kDa MAP kinases is associated with the neoplastic phenotype of 138 tumor cell lines and 102 primary tumors derived from various human organs. Constitutive activation of the MAP kinases was observed in 50 tumor cell lines (36.2%) in a rather tissue-specific manner: cell lines derived from pancreas, colon, lung, ovary and kidney showed especially high frequencies with a high degree of MAP kinase activation, while those derived from brain, esophagus, stomach, liver and of hematopoietic origin showed low frequencies with a limited degree of MAP kinase activation. We also detected constitutive activation of the 41-/43-kDa MAP kinases in a relatively large number of primary human tumors derived from kidney, colon and lung tissues but not from liver tissue. Many tumor cells, in which point mutations of vas genes mere detected, showed constitutive activation of MAP kinases, however, there were also many exceptions to this observation. In contrast, the activation of the 41-/43-kDa MAP kinases was accompanied by the activation of Raf-l in the majority of tumor cells and was completely associated with the activation of MEK and p90(rsk) in all the tumor cells examined, These results suggest that the constitutive activation of 41-/43-kDa MAP kinases in tumor cells is not due to the disorder of MAP kinases themselves, but is due to the disorder of Raf-l, Pas, or some other signaling molecules upstream of Ras.	Nagasaki Univ, Sch Pharmaceut Sci, Lab Cell Regulat, Nagasaki 8528131, Japan; Gifu Pharmaceut Univ, Gifu 5028585, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1138657, Japan; Kyoto Univ, Fac Med, Grad Sch Med, Dept Surg & Surg Basic Sci, Kyoto 6068507, Japan; Kyoto Univ, Dept Thorac Surg, Chest Dis Res Inst, Kyoto 6068507, Japan; Hyogo Coll Med, Dept Surg 1, Nishinomiya, Hyogo 6638501, Japan	Nagasaki University; Gifu Pharmaceutical University; Japanese Foundation for Cancer Research; University of Tokyo; Kyoto University; Kyoto University; Hyogo College of Medicine	Kohno, M (corresponding author), Nagasaki Univ, Sch Pharmaceut Sci, Lab Cell Regulat, 1-14 Bunkyo Machi, Nagasaki 8528131, Japan.		Kohno, Michiaki/R-6532-2019	Kohno, Michiaki/0000-0002-7644-0059				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P273; Bansal A, 1997, ONCOGENE, V14, P1231, DOI 10.1038/sj.onc.1200947; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUNET A, 1994, ONCOGENE, V9, P3379; CHATANI Y, 1992, J BIOL CHEM, V267, P9911; Chatani Y, 1995, J BIOL CHEM, V270, P30686, DOI 10.1074/jbc.270.51.30686; Chaubert P, 1997, HEPATOLOGY, V25, P1376, DOI 10.1002/hep.510250613; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P409; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Iwasaki S, 1996, J BIOL CHEM, V271, P17360, DOI 10.1074/jbc.271.29.17360; IWASAKI S, 1995, J BIOL CHEM, V270, P5476, DOI 10.1074/jbc.270.10.5476; Kawada M, 1998, JPN J CANCER RES, V89, P110, DOI 10.1111/j.1349-7006.1998.tb00537.x; Kawaguchi Y, 1997, CANCER LETT, V116, P53, DOI 10.1016/S0304-3835(97)04751-4; KOHNO M, 1985, J BIOL CHEM, V260, P1771; LI PM, 1993, ONCOGENE, V8, P1731; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; NAKATSU Y, 1985, COLD SPRING HARB SYM, V51, P1001; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OKA H, 1995, CANCER RES, V55, P4182; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1902; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; SMITH DB, 1990, CURRENT PROTOCOLS MO, V2; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; YAO M, 1988, CANCER RES, V48, P6753	41	594	658	1	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					813	822		10.1038/sj.onc.1202367	http://dx.doi.org/10.1038/sj.onc.1202367			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989833				2022-12-28	WOS:000078394400028
J	Kato, M; Liu, W; Akhand, AA; Dai, Y; Ohbayashi, M; Tuzuki, T; Suzuki, H; Isobe, K; Takahashi, M; Nakashima, I				Kato, M; Liu, W; Akhand, AA; Dai, Y; Ohbayashi, M; Tuzuki, T; Suzuki, H; Isobe, K; Takahashi, M; Nakashima, I			Linkage between melanocytic tumor development and early burst of Ret protein expression for tolerance induction in metallothionein-I ret transgenic mouse lines	ONCOGENE			English	Article						metallothionein-I ret transgenic mouse lines; melanocytic tumor; Ret protein expression; immune surveillance; oncogene product-specific-tolerance	SV40 T-ANTIGEN; PROTOONCOGENE PRODUCTS; SAIKOSAPONIN-D; LYMPHOCYTES-T; CELLS; MICE; MECHANISM; RESPONSES; ONCOGENE; PEPTIDE	We examined the basis of the all or none difference in inducing melanocytic tumor development among three transgenic mouse lines (304, 192 and 242) to which the same promoter-enhancer (metallothionein-I) and oncogene (ret) were introduced. We initially demonstrated that both skin melanosis and Ret protein expression in skin, thymus and brain first became detectable before or immediately after birth in the mice of the tumor developing lines (304 and 192), whereas they became detectable a few days after birth in the mice of the nontumor developing line (242) by Western blotting and immunohistochemical analysis. Interestingly, the Ret protein expression in skin developed rapidly after birth as a burst with peak levels on 0.5-1.5 day newborns of lines 304 and 192 and on 7.0-7.5 day-old mice of line 242, The levels of autophosphorylation of Ret kinase in skin were, however, invariable among these three transgenic mouse lines. The mice of line 242, but not those of lines 192 and 304, responded to Ret protein immunization by increased antigen-dependent lymphocyte proliferation and T-cell-mediated tumor growth suppression in vitro. Furthermore, ret-transgenic mice of line 242, but not line 304, rejected the subcutaneously transplanted tumors that had originally developed in a mouse of line 304, These results suggest that whether oncogene product-specific-tolerance is established or not to antitumor immunity may be decided by the dynamics of rer oncogene expression before and after delivery and this is the primary factor determining development or non-development of melanoma.	Nagoya Univ, Sch Med, Dept Immunol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Chubu Natl Hosp, Inst Longev Sci, Dept Basic Gerontol, Aichi 4748511, Japan	Nagoya University; Nagoya University	Nakashima, I (corresponding author), Nagoya Univ, Sch Med, Dept Immunol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		isobe, ken-ichi/A-6685-2011; KATO, Masashi/I-7250-2014; Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014	isobe, ken-ichi/0000-0002-8150-2496; Takahashi, Masahide/0000-0002-2803-2683; 				ASAI N, 1995, MOL CELL BIOL, V15, P1613; CAMPBELL AE, 1983, J IMMUNOL, V130, P490; CHEN LP, 1991, P NATL ACAD SCI USA, V88, P110, DOI 10.1073/pnas.88.1.110; CORRADIN G, 1977, J IMMUNOL, V119, P1048; DAI Y, 1994, INT J ONCOL, V5, P661; FAAS SJ, 1987, J EXP MED, V165, P417, DOI 10.1084/jem.165.2.417; ICHIHARA M, 1995, BRIT J CANCER, V71, P808, DOI 10.1038/bjc.1995.156; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; JUNG S, 1991, J EXP MED, V173, P273, DOI 10.1084/jem.173.1.273; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KATO M, 1994, CELL IMMUNOL, V159, P15, DOI 10.1006/cimm.1994.1291; KATO M, 1995, IMMUNOPHARMACOLOGY, V29, P207, DOI 10.1016/0162-3109(95)00059-3; MOSMANN TR, 1991, IMMUNOL REV, V123, P209, DOI 10.1111/j.1600-065X.1991.tb00612.x; NAKASHIMA I, 1982, EUR J IMMUNOL, V12, P713, DOI 10.1002/eji.1830120904; SCHRIMBECK R, 1992, EUR J IMMUNOL, V22, P759; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TANIGUCHI M, 1992, ONCOGENE, V7, P1491; TEVETHIA SS, 1980, VIROLOGY, V107, P13, DOI 10.1016/0042-6822(80)90268-8; TSUZUKI T, 1995, ONCOGENE, V10, P191; YANUCK M, 1993, CANCER RES, V53, P3257	21	33	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					837	842		10.1038/sj.onc.1202329	http://dx.doi.org/10.1038/sj.onc.1202329			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989837				2022-12-28	WOS:000078394400032
J	Rapp, L; Liu, Y; Hong, YH; Androphy, EJ; Chen, JJ				Rapp, L; Liu, Y; Hong, YH; Androphy, EJ; Chen, JJ			The bovine papillomavirus type 1 E6 oncoprotein sensitizes cells to tumor necrosis factor alpha-induced apoptosis	ONCOGENE			English	Article						BPV-1 E6; TNF; cytolysis; apoptosis; p53; arachidonic acid	CYTOSOLIC PHOSPHOLIPASE A(2); CALCIUM-BINDING PROTEIN; OPEN READING FRAME; P53 FUNCTION; TRANSCRIPTIONAL ACTIVATION; TRANSFORMING GENE; ARACHIDONIC-ACID; ENDOPLASMIC-RETICULUM; MUTATIONAL ANALYSIS; VIRUS DNA	Expression of viral proteins may result in susceptibility of cells to the cytotoxic effect of Tumor Necrosis Factor Alpha (TNF), While murine C127 cells containing the bovine papillomavirus type 1 (BPV-1) genome were reported to exhibit increased TNF sensitivity, the gene(s) responsible was not identified. The BPV-1 E6 oncoprotein induces tumorigenic transformation of murine C127 cells and stimulates transcription when targeted to a promoter. BPV-1 E6 was introduced into C127 cells (PBE6) by retroviral infection and stable clones were isolated. These cells showed increased apoptosis in response to TNF, as measured by several criteria. TNF-induced apoptosis in PBE6 cells was accompanied by increased release of arachidonic acid, indicating that phospholipase A, was activated. We also provide evidence that BPV-1 E6 mediated-sensitization of cells to TNF-induced apoptosis can ocur in the absence of p53.	New England Med Ctr, Dept Dermatol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Chen, JJ (corresponding author), New England Med Ctr, Dept Dermatol, 750 Washington St,Box 166, Boston, MA 02111 USA.			Androphy, Elliot/0000-0002-8104-0703	NATIONAL CANCER INSTITUTE [R01CA073558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007562] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA73558] Funding Source: Medline; NIAMS NIH HHS [T32 AR 07562] Funding Source: Medline; PHS HHS [F32] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDROPHY EJ, 1985, SCIENCE, V230, P442, DOI 10.1126/science.2996134; Bergqvist A, 1997, J VIROL, V71, P276, DOI 10.1128/JVI.71.1.276-283.1997; Brown J, 1997, J CELL BIOCHEM, V66, P245, DOI 10.1002/(SICI)1097-4644(19970801)66:2<245::AID-JCB11>3.0.CO;2-G; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Chen JJ, 1997, VIROLOGY, V236, P30, DOI 10.1006/viro.1997.8725; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEURKSENHUGHES P, 1989, J IMMUNOL, V143, P4193; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DODDS D, 1995, J NEUROCHEM, V64, P2339; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; DVORETZKY I, 1980, VIROLOGY, V103, P369, DOI 10.1016/0042-6822(80)90195-6; FAN SJ, 1995, CANCER RES, V55, P1649; GOODING LR, 1991, J VIROL, V65, P4114, DOI 10.1128/JVI.65.8.4114-4123.1991; Green DR, 1997, SCIENCE, V278, P1246, DOI 10.1126/science.278.5341.1246; GROFF DE, 1986, VIROLOGY, V150, P221, DOI 10.1016/0042-6822(86)90281-3; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hardwick J M, 1997, Adv Pharmacol, V41, P295, DOI 10.1016/S1054-3589(08)61063-7; Hawkins DS, 1996, CANCER RES, V56, P892; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HOWLEY PM, 1996, FIELDS VIROLOGY, P2045; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KERR JFR, 1992, APOPTOSIS MOL BASIS, P5; Krajcsi P, 1996, J VIROL, V70, P4904, DOI 10.1128/JVI.70.8.4904-4913.1996; KULL FC, 1981, CANCER RES, V41, P4885; LAMBERTI C, 1990, EMBO J, V9, P1907, DOI 10.1002/j.1460-2075.1990.tb08317.x; LASTER SM, 1988, J IMMUNOL, V141, P2629; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; LOWY DR, 1980, NATURE, V287, P72, DOI 10.1038/287072a0; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Ned R, 1997, J VIROL, V71, P4866, DOI 10.1128/JVI.71.6.4866-4870.1997; OSTROVE JM, 1979, P SOC EXP BIOL MED, V160, P354; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Puthenveettil JA, 1996, ONCOGENE, V13, P1123; QUI ZH, 1998, J BIOL CHEM, V273, P8203; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SCHILLER JT, 1986, J VIROL, V57, P1; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; Steller MA, 1996, CANCER RES, V56, P5087; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Thomas M, 1996, ONCOGENE, V13, P265; Thorne TE, 1996, J VIROL, V70, P8502, DOI 10.1128/JVI.70.12.8502-8507.1996; Tong X, 1998, J VIROL, V72, P476, DOI 10.1128/JVI.72.1.476-482.1998; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TSANG NM, 1995, ONCOGENE, V10, P2403; Vande Pol SB, 1998, ONCOGENE, V16, P43, DOI 10.1038/sj.onc.1201504; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VoelkelJohnson C, 1996, J IMMUNOL, V156, P201; VOUSDEN KH, 1989, J VIROL, V63, P2340, DOI 10.1128/JVI.63.5.2340-2342.1989; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; WEIS K, 1994, J BIOL CHEM, V269, P19142; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; XU C, 1995, P NATL ACAD SCI USA, V92, P7829, DOI 10.1073/pnas.92.17.7829; Yu YJ, 1997, ONCOGENE, V14, P1661, DOI 10.1038/sj.onc.1201026; ZURHAUSEN H, 1996, BIOCHIM BIOPHYS ACTA, V1288, pF55; [No title captured]	70	13	13	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					607	615		10.1038/sj.onc.1202373	http://dx.doi.org/10.1038/sj.onc.1202373			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989810				2022-12-28	WOS:000078394400005
J	Yamochi, T; Kaneita, Y; Akiyama, T; Mori, S; Moriyama, M				Yamochi, T; Kaneita, Y; Akiyama, T; Mori, S; Moriyama, M			Adenovirus-mediated high expression of BCL-6 in CV-1 cells induces apoptotic cell death accompanied by down-regulation of BCL-2 and BCL-X-L	ONCOGENE			English	Article						BCL-6; apoptosis; cell cycle; BCL-2; recombinant adenovirus	GERMINAL-CENTER FORMATION; CENTER B-CELLS; PROTEIN INTERACTION MOTIF; FINGER ENCODING GENE; IN-VIVO; BTB/POZ DOMAIN; TRANSCRIPTIONAL REPRESSION; RECOMBINANT ADENOVIRUS; DNA-BINDING; LYMPHOMA	The BCL-6 proto-oncogene encodes a 92- to 98-kDa transcriptional repressor containing the BTB/POZ domain at its N-terminal region and the zinc finger domain at its C-terminal region, respectively. In the present study, we examined the function of BCL-6 by using a recombinant adenovirus expressing BCL-6 (Ax1CA-BCL-6) and the lacZ reporter gene (Ax1CA-lacZ), Viability of CV-1 and HeLa cells infected, with Ax1CA-BCL-6 was markedly reduced due to apoptosis, suggesting that BCL-6-overexpression induces apoptosis in CV-1 and HeLa cells. FAGS analysis revealed that BCL-6-overexpressing cells are accumulated not only at the sub-G1 but also at G2/M phase. Induction of apoptosis by BCL-6 was preceded by down-regulation of apoptosis repressors BCL-2 and BCL-X-L. These results suggest that BCL-6 induces apoptosis by regulating the expression of these apoptosis-regulating genes.	Univ Tokyo, Inst Med Sci, Dept Pathol, Minato Ku, Tokyo 108, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Oncogene Res, Suita, Osaka 565, Japan	University of Tokyo; Osaka University	Moriyama, M (corresponding author), Univ Tokyo, Inst Med Sci, Dept Pathol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.							Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1995, GENE CHROMOSOME CANC, V13, P221, DOI 10.1002/gcc.2870130314; BASTARD C, 1994, BLOOD, V83, P2423; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 1995, ONCOGENE, V11, P2689; FAN SJ, 1995, CANCER RES, V55, P1649; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Ghia P, 1998, BLOOD, V91, P244, DOI 10.1182/blood.V91.1.244.244_244_251; ISHIDA T, 1995, J IMMUNOL, V155, P5527; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Liu YJ, 1997, IMMUNOL REV, V156, P111, DOI 10.1111/j.1600-065X.1997.tb00963.x; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; LO CF, 1994, BLOOD, V83, P1757; MartinezValdez H, 1996, J EXP MED, V183, P971, DOI 10.1084/jem.183.3.971; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moriyama M, 1997, ONCOGENE, V14, P2465, DOI 10.1038/sj.onc.1201084; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Seyfert VL, 1996, ONCOGENE, V12, P2331; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; Tuscano JM, 1996, BLOOD, V88, P1359, DOI 10.1182/blood.V88.4.1359.bloodjournal8841359; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596	41	56	66	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					487	494		10.1038/sj.onc.1202334	http://dx.doi.org/10.1038/sj.onc.1202334			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927205				2022-12-28	WOS:000078166500021
J	Callaghan, MJ; Russell, AJ; Woollatt, E; Sutherland, GR; Sutherland, RL; Watts, CKW				Callaghan, MJ; Russell, AJ; Woollatt, E; Sutherland, GR; Sutherland, RL; Watts, CKW			Identification of a human HECT family protein with homology to the Drosophila tumor suppressor gene hyperplastic discs	ONCOGENE			English	Article						ubiquitination; tumor suppressor; progestin; breast cancer	HUMAN-BREAST-CANCER; UBIQUITIN-DEPENDENT DEGRADATION; SQUAMOUS-CELL CARCINOMA; NF-KAPPA-B; PROTEASOME PATHWAY; CYCLE PROGRESSION; ANGELMAN SYNDROME; GROWTH-FACTOR; C-JUN; EXPRESSION	Use of the differential display technique to isolate progestin-regulated genes in T-47D human breast cancer cells led to identification of a novel gene, EDD, The cDNA sequence contains a 2799 amino acid open reading frame sharing 40% identity with the predicted 2894 amino acid product of the Drosophila melanogaster tumor suppressor gene hyperplastic discs, while the carboxy-terminal 889 amino acids show 96% identity to a rat 100 kDa HECT domain protein. EDD mRNA was progestin-induced in T-47D cells and was highly abundant in testes and expressed at moderately high le,els in other tissues, suggesting a broad role for EDD, Anti-EDD antibodies immunoprecipitated an approximately 300 kDa protein from T-47D cell lysates, HECT family proteins function as E3 ubiquitin-protein ligases, targeting specific proteins for ubiquitin-mediated proteolysis. EDD is likely to function as an E3 as irt vitro translated protein hound ubiquitin reversibly through a conserved HECT domain cysteine residue. EDD was localized by FISH to chromosome 8q22, a locus disrupted in a variety of cancers. Given the homology between EDD and the hyperplastic discs protein, which is required for control of imaginal disc growth in Drosophila, EDD potentially has a role in regulation of cell proliferation or differentiation.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; Womens & Childrens Hosp, Dept Cytogenet & Mol Genet, Ctr Genet Med, Adelaide, SA 5006, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Womens & Childrens Hospital Australia	Watts, CKW (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia.		Sutherland, Grant Robert/D-2606-2012; henderson, Michelle/G-6657-2012; Sutherland, Robert L/A-8378-2008					ALEXANDER IE, 1989, MOL ENDOCRINOL, V3, P1377, DOI 10.1210/mend-3-9-1377; Benito J, 1998, EMBO J, V17, P482, DOI 10.1093/emboj/17.2.482; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; CHAN YL, 1984, J BIOL CHEM, V259, P224; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; CLARKE RA, 1995, AM J HUM GENET, V57, P1364; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ElRifai W, 1996, CANCER RES, V56, P3230; ERICKSON P, 1992, BLOOD, V80, P1825; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; GU J, 1994, MOL BRAIN RES, V24, P77, DOI 10.1016/0169-328X(94)90120-1; HALL RE, 1990, INT J CANCER, V46, P1081, DOI 10.1002/ijc.2910460622; Hamilton JA, 1997, MOL ENDOCRINOL, V11, P490, DOI 10.1210/me.11.4.490; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P5249, DOI 10.1073/pnas.92.11.5249-a; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; LAIDLAW IJ, 1995, ENDOCRINOLOGY, V136, P164, DOI 10.1210/en.136.1.164; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MANSFIELD E, 1994, DEV BIOL, V165, P507, DOI 10.1006/dbio.1994.1271; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; MULLER D, 1992, NUCLEIC ACIDS RES, V20, P1471, DOI 10.1093/nar/20.7.1471; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Musgrove EA, 1998, MOL CELL BIOL, V18, P1812, DOI 10.1128/MCB.18.4.1812; MUSGROVE EA, 1991, MOL CELL BIOL, V11, P5032, DOI 10.1128/MCB.11.10.5032; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; NAWROZ H, 1994, CANCER RES, V54, P1152; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Piao Z, 1998, INT J CANCER, V75, P29, DOI 10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.3.CO;2-#; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; SATO S, 1994, CANCER RES, V54, P5652; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Sutherland RL, 1998, J MAMMARY GLAND BIOL, V3, P63, DOI 10.1023/A:1018774302092; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x	56	96	103	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3479	3491		10.1038/sj.onc.1202249	http://dx.doi.org/10.1038/sj.onc.1202249			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030672				2022-12-28	WOS:000078086200009
J	White, GRM; Varley, JM; Heighway, J				White, GRM; Varley, JM; Heighway, J			Isolation and characterization of a human homologue of the latrophilin gene from a region of 1p31.1 implicated in breast cancer	ONCOGENE			English	Article						latrophilin; breast cancer; chromosome 1; alternative splicing	ALPHA-LATROTOXIN; RECEPTOR; PROTEIN; HETEROZYGOSITY; CLONING	We have identified a region of chromosome 1p31.1 that shows high frequency loss of heterozygosity (LOH) in human breast cancer. This region forms part of a 7 Mb YAC/BAC contig, In order to identify candidate sequences, mutation of which might contribute to the development of disease, we have carried out mapping studies of ESTs localized to 1p31.1. This analysis, coupled with library screening and a modified 5' RACE-PCR strategy, resulted in the identification and characterization of a novel gene (LPHH1) which is located adjacent to the smallest region of overlapping loss (SRO) seen in tumours, The 4209 bp open reading frame of the 7 kb LPHH1 transcript encodes a peptide which shows approximately 65% identity to rat latrophilin, a G-coupled, seven span transmembrane protein, which binds alpha-latrotoxin. In the human sequence, whilst conservation of the transmembrane domain is high, the intra- and extracellular domains show two regions of variable structure, which are presumably generated by alternative splicing. Surprisingly, while expression of the rat gene is tightly restricted to neurological and perhaps some endocrine cells, the human sequence appears to be expressed very widely in all normal tissues tested. Northern and RT-PCR analysis of a panel of tumour cell lines showed that LPHH1 expression was variable, apparently elevated in some lines and absent or markedly reduced in others. Furthermore, characterization of the range of transcripts encoded in a breast tumour cell line, compared to normal breast, suggested that gene product variability was higher in the tumour.	Christie Hosp NHS Trust, Paterson Inst Canc Res, CRC, Mol Genet Sect, Manchester M20 4BX, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Varley, JM (corresponding author), Christie Hosp NHS Trust, Paterson Inst Canc Res, CRC, Mol Genet Sect, Wilmslow Rd, Manchester M20 4BX, Lancs, England.							Bittner MA, 1998, J NEUROSCI, V18, P2914; Davletov BA, 1996, J BIOL CHEM, V271, P23239, DOI 10.1074/jbc.271.38.23239; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; Geppert M, 1998, J BIOL CHEM, V273, P1705, DOI 10.1074/jbc.273.3.1705; HOGGARD N, 1995, GENOMICS, V30, P233, DOI 10.1006/geno.1995.9882; HOGGARD N, 1995, GENE CHROMOSOME CANC, V12, P24, DOI 10.1002/gcc.2870120105; Krasnoperov VG, 1996, BIOCHEM BIOPH RES CO, V227, P868, DOI 10.1006/bbrc.1996.1598; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lang JC, 1998, EMBO J, V17, P648, DOI 10.1093/emboj/17.3.648; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; NACHEVA E, 1990, BRIT J HAEMATOL, V74, P70, DOI 10.1111/j.1365-2141.1990.tb02540.x; NAGAI H, 1995, CANCER RES, V55, P1752; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Yamamichi K, 1998, INT J CANCER, V79, P256, DOI 10.1002/(SICI)1097-0215(19980619)79:3<256::AID-IJC8>3.0.CO;2-O	14	23	26	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3513	3519		10.1038/sj.onc.1202487	http://dx.doi.org/10.1038/sj.onc.1202487			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030676				2022-12-28	WOS:000078086200013
J	Canman, CE; Lim, DS				Canman, CE; Lim, DS			The role of ATM in DNA damage responses and cancer	ONCOGENE			English	Review						ataxia telangiectasia; cell cycle; DNA damage; apoptosis	DEPENDENT PROTEIN-KINASE; ATAXIA-TELANGIECTASIA CELLS; RADIATION-INDUCED PHOSPHORYLATION; CYCLE CHECKPOINT PATHWAY; P53-MEDIATED G(1) ARREST; DOUBLE-STRAND BREAKS; ABL TYROSINE KINASE; IONIZING-RADIATION; C-ABL; SACCHAROMYCES-CEREVISIAE	Ataxia-telangiectasia (AT) is a complex, autosomal recessive disorder characterized by cerebellar ataxia, believed to result from progressive neurodegeneration, and telangiectasia, dilation of blood vessels within the eyes and parts of the facial region. AT patients suffer from recurrent infections caused by both cellular and humoral immune deficiencies and as a population, are significantly predisposed to cancer, particularly lymphomas and leukemias. Early attempts at treating these malignancies with radiotherapy revealed another hallmark of AT, a profound hypersensitivity to the cytotoxic effects of ionizing radiation (IR) which is recapitulated at the cellular level in culture. Predisposition to cancer and radiosensitivity observed in AT has been linked to chromosomal instability, abnormalities in genetic recombination, and defective signaling to programmed cell death and several cell cycle checkpoints activated by DNA damage. These earlier observations predicted that the gene defective in AT may encode a protein which plays a crucial role in sensing DNA damage and transducing signals that promote cell survival. Through the combined efforts of linkage analysis and positional cloning, a single gene was identified on chromosome 11q22-33 by Shiloh and colleagues and was found to be mutated in all four complementation groups previously characterized in cell lines derived from AT patients (Savitsky et al,, 1995a,b), The predicted ATM gene product shows considerable homology to an emerging family of high molecular weight, phosphatidylinositol -3 kinase (PI-3 K)-related proteins involved in eukaryotic cell cycle control, DNA repair, and DNA recombination (Zakian, 1995), This landmark discovery has triggered a resurgence of biochemical and genetic studies focusing on ATM function which has brought forth insights regarding ATM activity and its role in DNA damage signaling.	St Jude Childrens Res Hosp, Dept Hematol & Oncol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Canman, CE (corresponding author), St Jude Childrens Res Hosp, Dept Hematol & Oncol, 332 N Lauderdale St D-1034, Memphis, TN 38105 USA.		Lim, Dae-Sik/C-1599-2011	Lim, Dae-Sik/0000-0003-2356-7555; , Christine/0000-0001-8892-7430				Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; Canman C E, 1997, Adv Pharmacol, V41, P429, DOI 10.1016/S1054-3589(08)61068-6; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CARDENAS ME, 1995, EMBO J, V5892, P5907; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; Cheng XB, 1996, RADIOTHER ONCOL, V39, P43, DOI 10.1016/0167-8140(96)01712-4; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Concannon P, 1997, HUM MUTAT, V10, P100, DOI 10.1002/(SICI)1098-1004(1997)10:2<100::AID-HUMU2>3.0.CO;2-O; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; Dar ME, 1997, MUTAT RES-DNA REPAIR, V384, P169, DOI 10.1016/S0921-8777(97)00021-9; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Duchaud E, 1996, CANCER RES, V56, P1400; DULLIC V, 1994, CELL, V76, P1013; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Enns L, 1998, RADIAT RES, V150, P11, DOI 10.2307/3579639; Enokido Y, 1996, EUR J NEUROSCI, V8, P1812, DOI 10.1111/j.1460-9568.1996.tb01325.x; Featherstone C, 1998, CURR BIOL, V8, pR622, DOI 10.1016/S0960-9822(98)70392-6; Gabra H, 1996, CANCER RES, V56, P950; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GOGA A, 1995, ONCOGENE, V11, P791; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; HAMPTON GM, 1994, CANCER RES, V54, P4586; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson SP, 1996, CANCER SURV, V28, P261; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Khanna KK, 1997, J BIOL CHEM, V272, P9489; KHANNA KK, 1993, ONCOGENE, V8, P3307; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOJIS TL, 1991, CANCER GENET CYTOGEN, V56, P143, DOI 10.1016/0165-4608(91)90164-P; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Laake K, 1997, GENE CHROMOSOME CANC, V18, P175, DOI 10.1002/(SICI)1098-2264(199703)18:3<175::AID-GCC4>3.0.CO;2-Z; Lakin ND, 1996, ONCOGENE, V13, P2707; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Lim DS, 1998, P NATL ACAD SCI USA, V95, P10146, DOI 10.1073/pnas.95.17.10146; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LOWE SW, 1993, NATURE, V362, P849; Luo CM, 1996, J BIOL CHEM, V271, P4497; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MCKINNON PJ, 1985, EUR J CELL BIOL, V39, P161; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MEYN MS, 1995, CANCER RES, V55, P5991; MEYN MS, 1994, INT J RADIAT BIOL, V66, P141; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Monaco C, 1997, GENOMICS, V46, P217, DOI 10.1006/geno.1997.5036; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; Morgan SE, 1997, CANCER RES, V57, P3386; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; NEGRINI M, 1995, CANCER RES, V55, P3003; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Niu HW, 1997, J BIOL CHEM, V272, P12634, DOI 10.1074/jbc.272.19.12634; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULES RS, 1995, CANCER RES, V55, P1763; Plug AW, 1997, NAT GENET, V17, P457, DOI 10.1038/ng1297-457; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; PURDIE CA, 1994, ONCOGENE, V9, P603; Rathmell WK, 1997, CANCER RES, V57, P68; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sarkaria JN, 1998, CANCER RES, V58, P4375; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHAFMAN TD, 1995, CANCER RES, V55, P3242; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; SHILOH Y, 1982, EXP CELL RES, V140, P191, DOI 10.1016/0014-4827(82)90169-0; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Telatar M, 1996, AM J HUM GENET, V59, P40; Uhrhammer Nancy, 1998, Cancer Research, V58, P3480; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; WALDMAN T, 1995, CANCER RES, V55, P5187; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; WESTPHAL CH, 1998, IN PRESS CANC RES; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WINQVIST R, 1995, CANCER RES, V55, P2660; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; WOOD KA, 1995, J NEUROSCI, V15, P5851; Wright J, 1996, AM J HUM GENET, V59, P839; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; YAUN ZM, 1996, NATURE, V382, P272; Yavuzer U, 1998, GENE DEV, V12, P2188, DOI 10.1101/gad.12.14.2188; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	143	131	152	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 24	1998	17	25					3301	3308		10.1038/sj.onc.1202577	http://dx.doi.org/10.1038/sj.onc.1202577			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916992				2022-12-28	WOS:000078048200011
J	Hoffman, B; Liebermann, DA				Hoffman, B; Liebermann, DA			The proto-oncogene c-myc and apoptosis	ONCOGENE			English	Article						c-myc; proliferation; apoptosis; tumorigenesis	ORNITHINE DECARBOXYLASE GENE; CELL-CYCLE PROGRESSION; MYELOID-LEUKEMIA CELLS; WILD-TYPE P53; GROWTH ARREST; TRANSCRIPTIONAL REPRESSION; TRANSGENIC MICE; DNA-BINDING; TERMINAL DIFFERENTIATION; HISTONE DEACETYLASE	Deregulated expression of c-Myc not only promotes proliferation, but also can either induce or sensitize cells to apoptosis, Inappropriate expression of c-Myc under conditions which inhibit growth and down-regulate endogenous c-Myc expression, including serum deprivation and exposure to cytotoxic agents including the anticancer agents vinblastine, etoposide, Ara-C, and nocodazole, usually results in programmed cell death in many different cell types. Also, inappropriate Myc expression is associated with an apoptotic response elicited by induction of differentiation. The proapoptotic property of c-Myc requires an intact N-terminal transactivation domain and bHLHZip domain, as well as interaction with Max, thereby implicating c-Myc target genes in this apoptotic process. Although some target genes, namely cdc25A and ODC, have been shown to participate in Myc-mediated apoptosis, no target gene has yet been identified which is essential for this apoptotic response. It is possible that the response of cells inappropriately expressing c-Myc is due not only to the growth arrest signals per se, but also to signals elicited by specific growth inhibitors in the context of a particular biological setting. Also regulating the response of the cells is expression of other oncogenes and tumor suppressor genes, as well as paracrine and autocrine survival factors. Apoptosis associated with inappropriate Myc expression limits the tumorigenic effect of the c-myc proto-oncogene, Mechanisms which inhibit apoptosis should enhance or promote tumorigenesis.	Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Dept Biochem, Sch Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Hoffman, B (corresponding author), Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, 3307 N Broad St, Philadelphia, PA 19140 USA.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ALNEMRI ES, 1992, CANCER RES, V52, P491; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; ASKEW DS, 1991, ONCOGENE, V6, P1915; ASKEW DS, 1993, BLOOD, V82, P2079; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Braun K, 1998, DNA CELL BIOL, V17, P789, DOI 10.1089/dna.1998.17.789; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Cultraro CM, 1997, MOL CELL BIOL, V17, P2353, DOI 10.1128/MCB.17.5.2353; DiazJullien C, 1996, BBA-PROTEIN STRUCT M, V1296, P219, DOI 10.1016/0167-4838(96)00072-6; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fanidi A, 1998, J VIROL, V72, P8392, DOI 10.1128/JVI.72.10.8392-8395.1998; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GIBSON AW, 1995, EXP CELL RES, V218, P351, DOI 10.1006/excr.1995.1166; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GREEN DR, 1994, IMMUNOL REV, V142, P321, DOI 10.1111/j.1600-065X.1994.tb00895.x; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; Harper SE, 1996, P NATL ACAD SCI USA, V93, P8536, DOI 10.1073/pnas.93.16.8536; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIBSHOOSH H, 1991, ONCOGENE, V6, P739; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; Hoffman B, 1996, CURR TOP MICROBIOL, V211, P17; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HSU B, 1995, ONCOGENE, V11, P175; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LINDEMAN GJ, 1995, ONCOGENE, V10, P1013; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MOSHIER JA, 1993, CANCER RES, V53, P2618; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Rao G, 1996, ONCOGENE, V12, P1165; REYNOLDS JE, 1994, CANCER RES, V54, P6348; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Rupnow BA, 1998, CANCER LETT, V127, P211, DOI 10.1016/S0304-3835(98)00045-7; Ryan KM, 1997, ONCOGENE, V14, P2835, DOI 10.1038/sj.onc.1201124; Sakamuro D, 1995, ONCOGENE, V11, P2411; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; Selvakumaran M, 1996, BLOOD, V88, P1248, DOI 10.1182/blood.V88.4.1248.bloodjournal8841248; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Shichiri M, 1998, MOL ENDOCRINOL, V12, P172, DOI 10.1210/me.12.2.172; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; Wu SJ, 1996, ONCOGENE, V12, P621; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhan Y, 1997, MOL CELL BIOL, V17, P6755, DOI 10.1128/MCB.17.11.6755; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	92	134	140	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 24	1998	17	25					3351	3357		10.1038/sj.onc.1202592	http://dx.doi.org/10.1038/sj.onc.1202592			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916997				2022-12-28	WOS:000078048200016
J	Kawahara, A; Kobayashi, T; Nagata, S				Kawahara, A; Kobayashi, T; Nagata, S			Inhibition of Fas-induced apoptosis by Bcl-2	ONCOGENE			English	Article						apoptosis; Bcl-2; caspase; Fas	SIGNALING COMPLEX DISC; MEDIATED CELL-DEATH; PROTEASE ACTIVATION; T-CELLS; FAMILY; LIGAND; FLICE; REGULATORS; RESISTANCE; EXPRESSION	Jurkat cells express Fas, and rapidly undergo apoptosis in response to Fas ligand or an agonistic anti-Fas antibody. This apoptotic pathway is mediated by a cascade of caspases, In this report, we show that Fas activation induced the processing of caspase 8 in Jurkat cells with a time frame similar to the activation of caspase 3 and the proteolysis of nuclear proteins. Jurkat cell transformants that overexpress Bcl-2 were partially but not completely resistant to the Fas-induced apoptosis. Little processing of caspase 8 was observed upon Fas activation in these transformants. Furthermore, although caspase 8 was recruited to Fas upon Fas activation in the parental Jurkat cells, the recruitment of caspase 8 to Fas was inhibited in the transformants overexpressing Bcl-2, These results suggest that Bcl-2 inhibits Fas-induced apoptosis by preventing the formation of the death-inducing signaling complex that is composed of Fas, FADD/MORT1, and caspase 8.	Osaka Biosci Inst, Osaka 5650874, Japan; Osaka Univ, Sch Med, Dept Genet, Osaka 5650871, Japan; MBL Co Ltd, Ina Labs, Nagano 3960002, Japan	Osaka University	Nagata, S (corresponding author), NICHHD, Mol Genet Lab, NIH, Bldg 6B,Room 420, Bethesda, MD 20892 USA.		Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; ITOH N, 1993, J IMMUNOL, V151, P621; JAATTELA M, 1995, ONCOGENE, V10, P2297; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEMON SA, 1995, J IMMUNOL, V155, P4644; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Suda T, 1996, J IMMUNOL, V157, P3918; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wyllie A H, 1980, Int Rev Cytol, V68, P251	38	59	67	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	1998	17	20					2549	2554		10.1038/sj.onc.1202192	http://dx.doi.org/10.1038/sj.onc.1202192			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840917				2022-12-28	WOS:000077058900001
J	Coxon, AB; Ward, JM; Geradts, J; Otterson, GA; Zajac-Kaye, M; Kaye, FJ				Coxon, AB; Ward, JM; Geradts, J; Otterson, GA; Zajac-Kaye, M; Kaye, FJ			RET cooperates with RB/p53 inactivation in a somatic multi-step model for murine thyroid cancer	ONCOGENE			English	Article						mouse model; p53; RB; Ret; thyroid cancer	GERMLINE MUTATIONS; MICE; RB; TUMORS; SYSTEM; P53	Mice bred to carry germline Rb and p53 null alleles are associated with a tumor spectrum that overlaps with the inherited multiple endocrine neoplasia-1 (MEN1) and MEN2 syndromes in humans, including medullary thyroid cancer (MTC). To study the genetic basis for these tumors, we microdissected MTC specimens or obtained fresh MTC tissue from nine independent Rb+/- p53(+/-) mice, amplified the region of the Ret gene known to be mutated in human MTC, and detected acquired missense Ret mutations in four different mice, These mutations were Localized to a group of tandem cysteines which are analogous to activating germline mutations observed in human MEN2A and familial MTC (FMTC), To determine whether the remaining wild type Rb allele was inactivated in these murine MTC samples, we subjected tumor tissue to immunohistochemical staining with an Rb antibody, and demonstrated the absence of RE staining in murine MTC, while normal tissue retained RE nuclear staining. These findings demonstrate the ability of the gene knockout model to recapitulate somatic multi-step tumorigenesis and suggest that the development of a murine neuroendocrine tumor requires mutational dysregulation within both receptor tyrosine kinase and nuclear tumor suppressor gene pathways.	NCI, Dept Genet, Bethesda, MD 20889 USA; Natl Naval Med Ctr, Bethesda, MD 20889 USA; Div Basic Sci, Anim Sci Branch, Vet & Tumor Pathol Sect, Frederick, MD 21702 USA; Univ N Carolina, Dept Lab Med & Pathol, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center; University of North Carolina; University of North Carolina Chapel Hill	Kaye, FJ (corresponding author), Naval Hosp, NCI, Bldg 8-Rm 5101, Bethesda, MD 20889 USA.		kaye, frederic/E-2437-2011					Edery P, 1997, BIOESSAYS, V19, P389, DOI 10.1002/bies.950190506; ERLANDSON RA, 1994, ULTRASTRUCT PATHOL, V18, P149, DOI 10.3109/01913129409016286; HARVEY M, 1995, CANCER RES, V55, P1146; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kloppel G, 1994, Ann N Y Acad Sci, V733, P19; LARSSON C, 1994, ANN NY ACAD SCI, V733, P453, DOI 10.1111/j.1749-6632.1994.tb17295.x; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SMITH DP, 1994, J CELL SCI, P43; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480	12	34	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1625	1628		10.1038/sj.onc.1202381	http://dx.doi.org/10.1038/sj.onc.1202381			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794240				2022-12-28	WOS:000076089900015
J	Naumann, U; Durka, S; Weller, M				Naumann, U; Durka, S; Weller, M			Dexamethasone-mediated protection from drug cytotoxicity: association with p21(WAF1/CIP1) protein accumulation?	ONCOGENE			English	Article						steroid; chemotherapy; cell cycle; apoptosis; glioma	HUMAN-MALIGNANT GLIOMA; CELL-CYCLE ARREST; HUMAN NEUTROPHILS; INDUCED APOPTOSIS; BCL-2 EXPRESSION; CARCINOMA CELLS; IMMUNE-SYSTEM; GENE-TRANSFER; P53; P21	Dexamethasone (DEX)-mediated inhibition of drug-induced, but not CD95 ligand-induced, apoptosis in malignant glioma cells correlates with wild-type p53 status. Here, we examined mechanisms underlying DEX-mediated protection from apoptosis, DEX did not induce p53 expression in two p53 wild-type cell lines (U87MG, LN-229) and did not alter drug-induced p53 accumulation. Forced expression of temperature-sensitive p53val(135) in mutant conformation failed to prevent accumulation of endogenous wild-type p53 but acted in a transdominant negative manner to inhibit p53-mediated, camptothecin-induced p21(WAF1/CIF1) expression, p53val(135)-transfected cells retained responsiveness to DEX at restrictive temperature, suggesting that p53 activity is not required for cytoprotection, Forced expression of wild-type p53val(135) abrogated the protective effect of DEX, suggesting redundant cytoprotective effects of DEX and p53, Indeed, DEX induced moderate accumulation of p21(WAF1/CIP1) in U87MG, LN-229 and p53 mutant LN-18 cells, but not in p53 mutant LN-308 or T98G cells. LN-18 is also the p53 mutant cell line with the best cytoprotective response to DEX, p21(WAF1/CIP1) accumulation occurred in the absence of changes in p21(WAF1\CIP1) mRNA expression, Wild-type p53 was not required for this DEX effect since DEX induced p21(WAF1/CIP1) accumulation in p53val(135)-transfected LN-229 cells, too. DEX failed to induce p21(WAF1/CIP1) expression or cytoprotection in untransformed rat astrocytes, The same lack of modulation of p21(WAF1/CIP1) expression and drug toxicity was observed in p21(+/+), p21(+/-) and p21(-/-) human colon carcinoma cells. Paradoxically, while only p21(+/+) and p21(+/-) mouse embryonic fibroblasts showed enhance p21(WAF1/CIP1) levels after exposure to DEX, only p21(-/-) fibroblasts were protected from drug toxicity by DEX, The present study links DEX-mediated protection from cancer chemotherapy to a p53-independent pathway of regulating p21(WAF1/CIP1) expression in glioma cells but this effect appears to cell type-specific.	Univ Tubingen, Sch Med, Dept Neurol, Lab Mol Neurooncol, Tubingen, Germany	Eberhard Karls University of Tubingen	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Lab Mol Neurooncol, Tubingen, Germany.			Weller, Michael/0000-0002-1748-174X				BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chang TC, 1997, FEBS LETT, V415, P11, DOI 10.1016/S0014-5793(97)01083-1; Chen J, 1996, ONCOGENE, V13, P1395; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COX G, 1995, J IMMUNOL, V154, P4719; Cox G, 1997, J LEUKOCYTE BIOL, V61, P224, DOI 10.1002/jlb.61.2.224; EASTHAM JA, 1995, CANCER RES, V55, P5151; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; GOLSTEIN P, 1991, IMMUNOL REV, V121, P29, DOI 10.1111/j.1600-065X.1991.tb00822.x; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; Kondo S, 1996, ONCOGENE, V13, P1279; Li XS, 1996, CANCER RES, V56, P5055; NAUMANN U, 1998, IN PRESS INT J CANC; Roth W, 1997, CANCER IMMUNOL IMMUN, V44, P55, DOI 10.1007/s002620050355; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; TREPEL M, 1998, IN PRESS J NEUROONCO; VAN MEIR EG, 1994, CANCER RES, V54, P649; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Weller M, 1997, NEUROL RES, V19, P459; Weller M, 1997, INT J CANCER, V73, P707, DOI 10.1002/(SICI)1097-0215(19971127)73:5<707::AID-IJC16>3.3.CO;2-5; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; Weller M, 1997, NEUROLOGY, V48, P1704, DOI 10.1212/WNL.48.6.1704; WELLER M, 1994, EUR J IMMUNOL, V24, P1293, DOI 10.1002/eji.1830240608; WELLER M, 1995, CANCER RES, V55, P2936; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Wolff JEA, 1996, ANTICANCER RES, V16, P805; Wullner U, 1996, NEUROREPORT, V7, P921; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	34	66	66	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1567	1575		10.1038/sj.onc.1202071	http://dx.doi.org/10.1038/sj.onc.1202071			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794234				2022-12-28	WOS:000076089900009
J	Fujimoto, A; Morita, R; Hatta, N; Takehara, K; Takata, M				Fujimoto, A; Morita, R; Hatta, N; Takehara, K; Takata, M			p16(INK4a) inactivation is not frequent in uncultured sporadic primary cutaneous melanoma	ONCOGENE			English	Article						loss of heterozygosity; microsatellites; gene mutation; tumour suppressor gene; immunohistochemistry	TUMOR-SUPPRESSOR GENE; CELL LUNG-CANCER; ACRAL LENTIGINOUS MELANOMA; CHROMOSOME 9P DELETIONS; KINASE-4 INHIBITOR GENE; HOMOZYGOUS DELETIONS; GERMLINE MUTATIONS; DELETED REGION; OVARIAN-TUMORS; METHYLATION	In an attempt to examine whether the inactivation of p16(INK4a) is an important early event in the development of sporadic melanoma in vivo, we have systematically analysed 46 uncultured primary cutaneous melanomas, Loss of heterozygosity (LOH) of chromosome region 9p21-22 (where the p16(INK4a) resides) was detected in II tumours (24%) by PCR-based LOH analyses. Direct sequencing of all three exons of the p16(INK4a) gene in these 11 tumours revealed no somatic mutation although germline mutations which have not been reported previously as common polymorphisms were detected in two patients. Further sequencing analyses of the p16(INK4a) gene exon 2 in 19 additional tumours with no evidence of LOH on 9p21-22 identified only one heterozygous C->T mutation at codon 81 altering a proline to a leucine. A sensitive methylation-specific PCR assay did not reveal ne novo methylation of the 5'CpG island in exon 1 of the p16(INK4a) gene in any of the tumours showing 9p21-22 allelic loss or a heterozygous p16(INK4a) mutation. Complete loss of p16(INK4a) protein, most likely due to homozygous deletion of the p16(INK4a) gene, was observed in 6 (15%) out of 39 evaluable cases by immunohistochemical analyses on frozen sections using two different anti-p16(INK4a) antibodies. The results show that inactivation of p16(INK4a) is not as frequent in primary melanoma as has been reported in cell lines, and warrant further search for another tumour suppressor on 9p21-22. This study also emphasizes the importance of examining uncultured primary tumours rather than cell lines to define early events in tumorigenesis.	Kanazawa Univ, Sch Med, Dept Dermatol, Kanazawa, Ishikawa 9208641, Japan	Kanazawa University	Takata, M (corresponding author), Kanazawa Univ, Sch Med, Dept Dermatol, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan.			HATTA, NAOHITO/0000-0003-1590-8348				Biden K, 1997, HEPATOLOGY, V25, P593, DOI 10.1002/hep.510250317; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Castellano M, 1997, CANCER RES, V57, P4868; ElNaggar AK, 1997, AM J PATHOL, V151, P1767; Farrell WE, 1997, CANCER RES, V57, P2703; Flores JF, 1996, CANCER RES, V56, P5023; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; Gazzeri S, 1998, ONCOGENE, V16, P497, DOI 10.1038/sj.onc.1201559; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; Gonzalgo ML, 1997, CANCER RES, V57, P5336; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Healy E, 1996, J INVEST DERMATOL, V107, P318, DOI 10.1111/1523-1747.ep12363118; HEALY E, 1995, GENE CHROMOSOME CANC, V12, P152, DOI 10.1002/gcc.2870120211; Healy E, 1996, CANCER RES, V56, P589; HERMAN JG, 1995, CANCER RES, V55, P4525; Hermann RC, 1996, HARVARD REV PSYCHIAT, V4, P98, DOI 10.3109/10673229609030529; HOLLAND EA, 1994, ONCOGENE, V9, P1361; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; ISSHIKI K, 1994, ONCOGENE, V9, P1649; KAGESHITA T, 1991, CANCER RES, V51, P1726; Kamb A, 1994, Nat Genet, V8, P23; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kim SK, 1997, CANCER RES, V57, P400; Kinoshita I, 1996, CANCER RES, V56, P5557; KREMENTZ ET, 1982, ANN SURG, V195, P632, DOI 10.1097/00000658-198205000-00013; LIU Q, 1995, ONCOGENE, V10, P1061; Marchini S, 1997, BRIT J CANCER, V76, P146, DOI 10.1038/bjc.1997.355; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Morita R, 1998, J INVEST DERMATOL, V111, P919, DOI 10.1046/j.1523-1747.1998.00458.x; Myohanen SK, 1998, CANCER RES, V58, P591; NAKAGAWA K, 1995, ONCOGENE, V11, P1843; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTA M, 1994, CANCER RES, V54, P5269; Ohta M, 1996, INT J CANCER, V65, P762, DOI 10.1002/(SICI)1097-0215(19960315)65:6<762::AID-IJC9>3.0.CO;2-X; POLLOCK PM, 1995, ONCOGENE, V11, P663; PUIG S, 1995, AM J HUM GENET, V57, P395; REED JA, 1995, CANCER RES, V55, P2713; Schmidt EE, 1997, BRIT J CANCER, V75, P2, DOI 10.1038/bjc.1997.2; SEIJI M, 1979, PIGMENT CELL, V5, P95; Shih YC, 1997, INT J CANCER, V70, P508, DOI 10.1002/(SICI)1097-0215(19970304)70:5<508::AID-IJC3>3.3.CO;2-6; SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9; WALKER GJ, 1994, INT J CANCER, V58, P203, DOI 10.1002/ijc.2910580210; Walker GJ, 1998, GENE CHROMOSOME CANC, V22, P157, DOI 10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563; Wiest JS, 1997, CANCER RES, V57, P1	47	55	55	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2527	2532		10.1038/sj.onc.1202803	http://dx.doi.org/10.1038/sj.onc.1202803			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229204				2022-12-28	WOS:000079703300013
J	Wasylyk, C; Salvi, R; Argentini, M; Dureuil, C; Delumeau, I; Abecassis, J; Debussche, L; Wasylyk, B				Wasylyk, C; Salvi, R; Argentini, M; Dureuil, C; Delumeau, I; Abecassis, J; Debussche, L; Wasylyk, B			p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53	ONCOGENE			English	Article						p21(WAF1/CIP1); E2F; E6; cell cycle; apoptosis; antisense	WILD-TYPE P53; HUMAN TUMOR-CELLS; S-PHASE ENTRY; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; DNA-DAMAGE; P53-MEDIATED APOPTOSIS; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ONCOPROTEIN MDM2	The p53 tumour suppressor is frequently inactivated in human tumours, One form of inactivation results from overexpression of MDM2, that normally forms a negative auto-regulatory loop with p53 and inhibits its activity through complex formation, We have investigated whether disrupting the MDM2-p53 complex in cells that overexpress MDM2 is sufficient to trigger p53 mediated cell death. We find that expression of a peptide homologue of p53 that binds to MDM2 leads to increased p53 levels and transcriptional activity. The consequences are increased expression of the downstream effecters MDM2 and p21(WAF1/CIP1), inhibition of colony formation, cell cycle arrest and cell death. There is also a decrease in E2F activity, that might have been due to the known physical and functional interactions of MDM2 with E2F1/DP1, However, this decrease is p53 dependent, as are also colony formation, cell cycle arrest and cell death, These results show that a peptide homologue of p53 is sufficient to induce p53 dependent cell death in cells overexpressing MDM2, and support the notion that disruption of the p53-MDM2 complex is a target for the development of therapeutic agents.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, Dept Oncol, F-94403 Vitry, France; Lab Biol Tumorale, F-67085 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Sanofi-Aventis	Wasylyk, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch Graffenstaden, France.		Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				ALKHALAF M, 1998, IN PRESS ONCOGENE; Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bernards R, 1997, BBA-REV CANCER, V1333, pM33, DOI 10.1016/S0304-419X(97)00027-9; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Bottger V, 1996, ONCOGENE, V13, P2141; BRUGIDOU J, 1995, BIOCHEM BIOPH RES CO, V214, P685, DOI 10.1006/bbrc.1995.2340; CASEY G, 1991, ONCOGENE, V6, P1791; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; Conseiller E, 1998, J CLIN INVEST, V101, P120, DOI 10.1172/JCI1140; CORDONCARDO C, 1994, CANCER RES, V54, P794; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Haines DS, 1997, LEUKEMIA LYMPHOMA, V26, P227, DOI 10.3109/10428199709051772; Hall PA, 1997, CURR BIOL, V7, pR144, DOI 10.1016/S0960-9822(97)70074-5; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Johnson David G., 1998, Frontiers in Bioscience, V3, pD447; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KASTAN MB, 1991, CANCER RES, V51, P6304; Kondo S, 1996, ONCOGENE, V13, P1773; KONDO S, 1995, ONCOGENE, V10, P2001; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Landers JE, 1997, CANCER RES, V57, P3562; LANDERS JE, 1994, ONCOGENE, V9, P2745; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; Leveillard T, 1998, MECH DEVELOP, V74, P189, DOI 10.1016/S0925-4773(98)00074-4; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Mayo LD, 1997, CANCER RES, V57, P5013; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1996, ONCOGENE, V12, P2279; Momand J, 1997, J CELL BIOCHEM, V64, P343; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Picksley SM, 1996, ACTA ONCOL, V35, P429, DOI 10.3109/02841869609109917; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SAKAI E, 1992, ONCOGENE, V7, P927; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Teoh G, 1997, BLOOD, V90, P1982, DOI 10.1182/blood.V90.5.1982; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Wubah JA, 1996, CURR BIOL, V6, P60, DOI 10.1016/S0960-9822(02)00422-0; Wurl P, 1998, ONCOGENE, V16, P1183, DOI 10.1038/sj.onc.1201646; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YAGINUMA Y, 1991, CANCER RES, V51, P6506; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	96	111	119	1	15	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					1921	1934		10.1038/sj.onc.1202528	http://dx.doi.org/10.1038/sj.onc.1202528			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208414				2022-12-28	WOS:000079191300002
J	Srivastava, RK; Srivastava, AR; Cho-Chung, YS; Longo, DL				Srivastava, RK; Srivastava, AR; Cho-Chung, YS; Longo, DL			Synergistic effects of retinoic acid and 8-Cl-cAMP on apoptosis require caspase-3 activation in human ovarian cancer cells	ONCOGENE			English	Article						retinoic acid; caspase protein kinase A; cytochrome c; apoptosis	DEPENDENT PROTEIN-KINASE; MITOCHONDRIAL PERMEABILITY TRANSITION; RECEPTOR-BETA; POLY(ADP-RIBOSE) POLYMERASE; CATALYTIC SUBUNIT; UP-REGULATION; CYTOCHROME-C; ELEMENT; SUPPRESSION; GROWTH	We investigated the intracellular mechanisms of retinoic acid (9-cis-RA, 13-cis-RA or all-trans-RA) and a cyclic AMP analog 8-Cl-cAMP on growth-inhibition and apoptosis in human ovarian cancer NIH: OVCAR-3 and OVCGR-8 cells, The cyclic AMP analog, 8-Cl-cAMP, acted synergistically with RA in inducing and activating retinoic acid receptor beta (RAR beta) which correlated with the growth inhibition, cell cycle arrest, and apoptosis in both cell types. In addition, combined treatment of cells with RA plus 8-Cl-cAMP resulted in the release of cytochrome c, loss in mitochondrial membrane potential and activation of caspase-3 followed by cleavage of anti-poly(ADP-ribose)polymerase and DNA-dependent protein kinase (catalytic subunit), Interestingly, inhibition of caspase-3 activation blocked RA plus 8-Cl-cAMP induced apoptosis, Furthermore, mutations in a CRE-related motif within the RAR beta promoter resulted in loss of both transcriptional activation of RAR beta and synergy between RA and 8-Cl-cAMP, Thus, RAR beta can mediate RA and/or cyclic AMP action in ovarian cancer cells by promoting apoptosis, Loss of RAR beta expression, therefore, may contribute to the tumorigenicity of human ovarian cancer cells, These findings suggest that RA and 8-Cl-cAMP act in a synergistic fashion in inducing apoptosis via caspase-3 activation, and may have potential for combination biotherapy for the treatment of malignant disease such as ovarian cancer.	NIA, Immunol Lab, NIH, Baltimore, MD 21224 USA; NCI, Med Branch, Bethesda, MD 20892 USA; NCI, Tumor Immunol & Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Srivastava, RK (corresponding author), NIA, Immunol Lab, NIH, Box 28,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Longo, Dan L./F-6022-2011					ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Heiden MGV, 1997, CELL, V91, P627; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; Hong Waun Ki, 1994, P597; Hong WK, 1995, CLIN CANCER RES, V1, P677; HOULE B, 1993, EXP CELL RES, V195, P163; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KOGA M, 1991, J STEROID BIOCHEM, V39, P455, DOI 10.1016/0960-0760(91)90238-Z; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KRUYT FAE, 1992, NUCLEIC ACIDS RES, V20, P6393, DOI 10.1093/nar/20.23.6393; LANOTTE M, 1991, J CELL PHYSIOL, V146, P73, DOI 10.1002/jcp.1041460110; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Sabichi AL, 1998, J NATL CANCER I, V90, P597, DOI 10.1093/jnci/90.8.597; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Sporn M.B., 1994, RETINOIDS BIOL CHEM; Srivastava RK, 1998, BREAST CANCER RES TR, V49, P97, DOI 10.1023/A:1005905723550; Srivastava RK, 1998, CLIN CANCER RES, V4, P755; SRIVASTAVA RK, 1998, IN PRESS MOL CELL BI; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; TORTORA G, 1995, CLIN CANCER RES, V1, P377; VAVSSIARE JL, 1994, P NATL ACAD SCI USA, V91, P11752; VINTERMYR OK, 1993, EXP CELL RES, V206, P157, DOI 10.1006/excr.1993.1132; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WIDSCHWENDTER M, 1995, CANCER RES, V55, P2135; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; Xu XC, 1997, CANCER RES, V57, P4992; ZHANG XK, 1994, CANCER RES, V54, P5663	45	30	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	1999	18	9					1755	1763		10.1038/sj.onc.1202464	http://dx.doi.org/10.1038/sj.onc.1202464			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208436				2022-12-28	WOS:000079025000010
J	Yamamoto, H; Kihara-Negishi, F; Yamada, T; Hashimoto, Y; Oikawa, T				Yamamoto, H; Kihara-Negishi, F; Yamada, T; Hashimoto, Y; Oikawa, T			Physical and functional interactions between the transcription factor PU.1 and the coactivator CBP	ONCOGENE			English	Article						PU.1; CBP; transcription factor	NUCLEAR-PROTEIN CBP; C-MYB; ACTIVATION; P300; DIFFERENTIATION; ERYTHROLEUKEMIA; FAMILY; CREB; ONCOPROTEIN; SIMILARITY	Yeast two-hybrid system was employed to isolate novel proteins that physically interact with PU.1, a member of Ets family transcription factors. Sequence analyses of several isolated clones positive for beta-galactosidase activity revealed that one of these clones was confirmed to encode a transcriptional coactivator, CREB binding protein (CBP), GST binding assay showed that the interacting sites were located at the transcriptional activation domain of PU,1 through 74-122 and the region spanning residues 1283-1915 of CBP. CBP potentiated PU.1-mediated transcription of the reporter gene driven by the multimerized PU.1-binding sites, suggesting that CBP functions as a coactivator for PU.1. Considering that CBP is a limited cellular component to function as a coactivator for several transcription factors, CBP may mediate synergistic and antagonistic interactions between PU.1 and other transcription factors during the process of hematopoietic cell differentiation.	Sasaki Inst, Dept Cell Genet, Chiyoda Ku, Tokyo 1010062, Japan		Oikawa, T (corresponding author), Sasaki Inst, Dept Cell Genet, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.							ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bellon T, 1997, BLOOD, V90, P1828, DOI 10.1182/blood.V90.5.1828; Beug H, 1996, BBA-REV CANCER, V1288, pM35, DOI 10.1016/S0304-419X(96)00032-7; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Gong QH, 1996, MOL CELL BIOL, V16, P6055; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kihara-Negishi F, 1998, INT J CANCER, V76, P523, DOI 10.1002/(SICI)1097-0215(19980518)76:4<523::AID-IJC14>3.0.CO;2-8; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; TENEN DG, 1997, BLOOD, V90, P498; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	47	100	100	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1495	1501		10.1038/sj.onc.1202427	http://dx.doi.org/10.1038/sj.onc.1202427			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050886				2022-12-28	WOS:000078651600011
J	Gimm, O; Neuberg, DS; Marsh, DJ; Dahia, PLM; Cuong, HV; Raue, F; Hinze, R; Dralle, H; Eng, C				Gimm, O; Neuberg, DS; Marsh, DJ; Dahia, PLM; Cuong, HV; Raue, F; Hinze, R; Dralle, H; Eng, C			Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation	ONCOGENE			English	Article						tyrosine kinase; polymorphism; germline mutation; somatic mutation; medullary thyroid cancer	MULTIPLE-ENDOCRINE-NEOPLASIA; TYROSINE KINASE DOMAIN; POINT MUTATION; MESSENGER-RNA; PROTOONCOGENE; POLYMORPHISM; FMTC; GENE; ACTIVATION; DISEASE	The aetiology of sporadic medullary thyroid carcinoma is unknown, About 50% harbour a somatic mutation at codon 918 of RET (M918T). To investigate whether other RET sequence variants may be associated with or predispose to the development of sporadic medullary thyroid carcinoma, we analysed genomic DNA from the germline and corresponding tumour from 50 patients to identify RET sequence variants. In one patient, tumour DNA showed a novel somatic 12 bp in-frame deletion in exon 15. More interestingly, we found that the rare polymorphism at codon 836 (c.2439C > T; S836S) occurred at a significantly higher frequency than that in control individuals without sporadic medullary thyroid carcinoma (Fisher's exact test, P = 0.03), Further, among the nine evaluable cases with germline c.2439C/T, eight also had the somatic M918T mutation in MTC DNA which was more frequent than in patients with the more common c.2439C/C (89% vs 40%, respectively; Fisher's exact test, P = 0.01), These findings suggest that the rare sequence variant at codon 836 may somehow play a role in the genesis of sporadic medullary thyroid carcinoma.	Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA; Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Halle Wittenberg, Klin Allgemeinchirurg, D-06097 Halle, Germany; Endokrinol Gemeinschaftspraxis, D-69120 Heidelberg, Germany; Univ Halle Wittenberg, Inst Pathol, D-06097 Halle, Germany; Univ Cambridge, Canc Res Campaign, Human Canc Genet Res Grp, Cambridge CB2 2QQ, England	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Harvard University; Dana-Farber Cancer Institute; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; CRUK Cambridge Institute; University of Cambridge	Eng, C (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, 420 W 12th Ave,690 MRF, Columbus, OH 43210 USA.		Marsh, Deborah J/I-1491-2014; Raue, Friedhelm/ABD-6150-2021; Dralle, Henning/ABD-4454-2020	Marsh, Deborah J/0000-0001-5899-4931; Raue, Friedhelm/0000-0002-7700-1648; Eng, Charis/0000-0002-3693-5145				BERGHOLM U, 1990, ACTA ONCOL, V29, P9, DOI 10.3109/02841869009089985; BOLINO A, 1995, ONCOGENE, V10, P2415; Borrello MG, 1995, ONCOGENE, V11, P2419; CARLSON KM, 1994, AM J HUM GENET, V55, P1076; CECCHERINI I, 1994, ONCOGENE, V9, P3025; Ceccherini I, 1997, ONCOGENE, V14, P2609, DOI 10.1038/sj.onc.1201079; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; Gimm O, 1997, J CLIN ENDOCR METAB, V82, P3902, DOI 10.1210/jc.82.11.3902; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Leviev I, 1997, ARTERIOSCL THROM VAS, V17, P2935, DOI 10.1161/01.ATV.17.11.2935; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LIGTENBERG MJL, 1991, NUCLEIC ACIDS RES, V19, P297, DOI 10.1093/nar/19.2.297; Marsh DJ, 1996, CLIN ENDOCRINOL, V44, P249, DOI 10.1046/j.1365-2265.1996.681503.x; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, HUM MOL GENET, V3, P2163, DOI 10.1093/hmg/3.12.2163; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Platten M, 1997, J NEUROPATH EXP NEUR, V56, P806; RAUE F, 1993, CLIN INVESTIGATOR, V71, P7, DOI 10.1007/BF00210956; Rodien P, 1997, HORM RES, V47, P263, DOI 10.1159/000185474; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; Smith DP, 1997, ONCOGENE, V15, P1213, DOI 10.1038/sj.onc.1201481; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; StallingsMann ML, 1996, P NATL ACAD SCI USA, V93, P12394, DOI 10.1073/pnas.93.22.12394	31	114	121	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1369	1373		10.1038/sj.onc.1202418	http://dx.doi.org/10.1038/sj.onc.1202418			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022819				2022-12-28	WOS:000078510900013
J	Malumbres, M; Perez de Castro, I; Santos, J; Piqueras, JF; Pellicer, A				Malumbres, M; Perez de Castro, I; Santos, J; Piqueras, JF; Pellicer, A			Hypermethylation of the cell cycle inhibitor p15(INK4b) 3 '-untranslated region interferes with its transcriptional regulation in primary lymphomas	ONCOGENE			English	Article						DNA methylation; p15(INK4b) CDK inhibitor; 3'-UTR; T-cell; lymphoma	DEPENDENT KINASE INHIBITOR; TUMOR-SUPPRESSOR; DNA METHYLATION; TGF-BETA; P16(INK4) GENE; HUMAN CANCERS; EXPRESSION; INACTIVATION; MOUSE; P15	The cyclin-dependent kinase inhibitor p15(INK4h) has been shown to he involved in human and rodent tumors and seems to act as a tumor suppressor gene in hematological malignancies, Alterations of this gene in tumors include mainly homozygous deletions and hypermethylation of the CpG island in the promoter region. In this work, we describe a new area sensitive to methylation in the 3' untranslated region (UTR) of the murine p15(INK4b) gene, This region shows different levels of methylation depending on the tissues, being relatively highly methylated in brain and gut, and weakly methylated in liver, spleen or thymus, DNA methylation and expression is similar in both maternal and paternal alleles indicating no imprinting effect. Although methylation of the p15(INK4h) 3'-UTR is low in normal thymus, increased levels (up to 100%) of specific methylation in this region are found in up to 30% of radiation- or carcinogen-induced thymic Lymphomas, correlating with decreased gene expression. Hypermethylation of the p15(INK4b) 3'-UTR frequently occurs in tumors with loss of heterozygosity (LOH) but without methylation of the promoter CpG island or intragenic mutations. Furthermore, in vitro CpG methylation of the 3'-UTR produces reduced levels of a luciferase reporter in cultured cells, Methylation of two CpG sites in a 120 bp region is sufficient to interfere with transcription of the reporter gene. These data suggest that although the levels of p15(INK4h) in normal tissues can be mainly determined by promoter regulatory elements, strong hypermethylation of the 3'-UTR can interfere with transcription, Thus, hypermethylation of the 3'-UTR may explain the lack of p15(INK4b) gene expression in a subset of tumors with no promoter methylation and could be a new alternative mechanism for tumor suppressor gene inactivation in tumorigenesis.	NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; Univ Autonoma Madrid, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain	New York University; New York University; Autonomous University of Madrid	Pellicer, A (corresponding author), NYU, Med Ctr, Dept Pathol, 550 1St Ave, New York, NY 10016 USA.		Holt, Janet E/B-2415-2013; Malumbres, Marcos/E-8834-2011; de Castro, Ignacio Pérez/A-6260-2012; MARTINEZ, ANTONIO PELLICER/C-4832-2015; Santos, Javier/ABF-5755-2021	Malumbres, Marcos/0000-0002-0829-6315; de Castro, Ignacio Pérez/0000-0002-8822-8274; Santos, Javier/0000-0002-4168-6251; Pellicer, Angel/0000-0002-5062-0692	NATIONAL CANCER INSTITUTE [R01CA050434, R01CA036327, R37CA036327] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50434, CA 36327] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschmied J, 1997, BIOTECHNIQUES, V23, P436, DOI 10.2144/97233bm19; Batova A, 1997, CANCER RES, V57, P832; BATTISTUZZI G, 1985, P NATL ACAD SCI USA, V82, P1465, DOI 10.1073/pnas.82.5.1465; Baylin SB, 1998, ADV CANCER RES, V72, P141; BORRELLO MG, 1992, ONCOGENE, V7, P269; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Cost GJ, 1997, CANCER RES, V57, P926; GLENDENING JM, 1995, CANCER RES, V55, P5531; GRANA X, 1995, ONCOGENE, V11, P211; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1997, CANCER RES, V57, P837; HIRAMA T, 1995, BLOOD, V86, P841; Iavarone A, 1997, NATURE, V387, P417; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kay PH, 1997, GENE, V184, P45, DOI 10.1016/S0378-1119(96)00572-0; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Li XS, 1996, CANCER RES, V56, P5055; LOIS AF, 1995, CANCER RES, V55, P4010; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; Malumbres M, 1998, MAMM GENOME, V9, P183, DOI 10.1007/s003359900722; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MULLINS LJ, 1987, MOL CELL BIOL, V7, P3916, DOI 10.1128/MCB.7.11.3916; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; QUELLE DE, 1995, ONCOGENE, V11, P635; RASOOL O, 1995, BLOOD, V85, P3431, DOI 10.1182/blood.V85.12.3431.bloodjournal85123431; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; RIGGS AD, 1983, ADV CANCER RES, V40, P1, DOI 10.1016/S0065-230X(08)60678-8; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; Rishi AK, 1997, CANCER RES, V57, P5129; Santos J, 1996, ONCOGENE, V12, P669; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SHANDU C, 1997, MOL CELL BIOL, V17, P2458; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Tsubari M, 1997, CANCER RES, V57, P2966; Umezawa A, 1997, MOL CELL BIOL, V17, P4885, DOI 10.1128/MCB.17.9.4885; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	52	43	45	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					385	396		10.1038/sj.onc.1202299	http://dx.doi.org/10.1038/sj.onc.1202299			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927195				2022-12-28	WOS:000078166500011
J	Shen, SX; Weaver, Z; Xu, XL; Li, CL; Weinstein, M; Chen, L; Guan, XY; Ried, T; Deng, CX				Shen, SX; Weaver, Z; Xu, XL; Li, CL; Weinstein, M; Chen, L; Guan, XY; Ried, T; Deng, CX			A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability	ONCOGENE			English	Article						BRCA1; p53; radiation sensitivity and chromosome abnormality	EARLY EMBRYONIC LETHALITY; CYCLIN-DEPENDENT KINASES; STRANDED-DNA ENDS; BREAST-CANCER; P53; MOUSE; RAD51; MICE; MUTATIONS; RECOMBINATION	Germline mutations of the Brca1 gene are responsible for most cases of familial breast and ovarian cancers, but somatic mutations are rarely detected in sporadic events. Moreover, mouse embryos deficient for Brca1 have been shown to die during early embryogenesis due to a proliferation defect, These findings seem incompatible with the tumor suppress function assigned to this gene and raise questions about the mechanism by which Brca1 mutations cause tumorigenesis. We now directly demonstrate that BRCA1 is responsible for the integrity of the genome, Murine embryos carrying a Brca1 null mutation are developmentally retarded and hypersensitive to gamma-irradiation, suggesting a failure in DNA damage repair. This notion is supported by spectral karyotyping (SKY) of metaphase chromosomes, which display numerical and structural aberrations. However, massive chromosomal abnormalities are only observed when a p53(-/-) background is introduced, Thus, a p53 dependent cell cycle checkpoint arrests the mutant embryos and prevents the accumulation of damaged DNA, Brca1(-/-) fibroblasts are not viable, nor are Brca1(-/-):p53(-/-) fibroblasts, However, proliferative foci arise from Brca1(-/-):p53(-/-) cells, probably due to additional mutations that are a consequence of the accumulating DNA damage, We believe that the increased incidence of such additional mutations accounts for the mechanism of tumorigenesis associated with Brca1 mutations in humans.	NIDDKD, Biochem & Metab Lab, NIH, Bethesda, MD 20892 USA; Natl Human Genome Res Inst, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; Natl Human Genome Res Inst, Canc Genet Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Deng, CX (corresponding author), NIDDKD, Biochem & Metab Lab, NIH, Bldg 10,9N105, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016; Guan, Xin-Yuan/A-3639-2009	Weaver Ohler, Zoe/0000-0002-6287-2504; Guan, Xin-Yuan/0000-0002-4485-6017				Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; Bienstock RJ, 1996, CANCER RES, V56, P2539; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Easton D, 1997, NAT GENET, V16, P210, DOI 10.1038/ng0797-210; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVANS E P, 1987, P93; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HARPER JW, 1993, CELL, V75, P805; Hill ADK, 1997, BRIT J SURG, V84, P1334; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIYASHITA T, 1995, CELL, V80, P293; MURIS DFR, 1993, NUCLEIC ACIDS RES, V21, P4586, DOI 10.1093/nar/21.19.4586; OGAWA T, 1993, COLD SPRING HARB SYM, V58, P567, DOI 10.1101/SQB.1993.058.01.063; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; RITTER MA, 1977, NATURE, V266, P653, DOI 10.1038/266653a0; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; TELENIUS H, 1992, GENE CHROMOSOME CANC, V4, P257, DOI 10.1002/gcc.2870040311; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xu CF, 1996, SEMIN CANCER BIOL, V7, P33, DOI 10.1006/scbi.1996.0005	50	284	288	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 17	1998	17	24					3115	3124		10.1038/sj.onc.1202243	http://dx.doi.org/10.1038/sj.onc.1202243			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872327				2022-12-28	WOS:000077517400005
J	Fridman, JS; Rehemtulla, A; Hofmann, A; Blau, HM; Maybaum, J				Fridman, JS; Rehemtulla, A; Hofmann, A; Blau, HM; Maybaum, J			Expression of Bcl-XS alters cytokinetics and decreases clonogenic survival in K12 rat colon carcinoma cells	ONCOGENE			English	Article						Bcl-X; programmed cell death; apoptosis; cell cycle; K12	TETRACYCLINE-REGULATED SYSTEM; INDUCIBLE GENE-EXPRESSION; LEUKEMIA HL-60 CELLS; INDUCED APOPTOSIS; CYCLE ENTRY; TRANSGENIC MICE; CANCER-CELLS; BCL-X(S); BAX; DEATH	bcl-XS, a member of the bcl-2 family, has been shown to induce and/or sensitize some cells to undergo programmed cell death, and to negate the anti-apoptotic activity of bcl-XL and bcl-2 by mechanisms which are still uncertain. To help understand these mechanisms we have established stable derivatives of the K12 rat colon carcinoma cell line that express bcl-XS in a tetracycline-regulated manner, using an autoregulatory retroviral cassette. When bcl-XS expression is induced, we observe two phenotypic responses. A small fraction of cells appear to undergo spontaneous apoptosis while the majority of cells undergo a form of cytostasis. In the latter case, the cells stop dividing (or divide a limited number of times at a retarded rate) and swell to many times their original size. These cells can take on a ghostlike appearance and subsequently detach from the culture plates and die or they may remain intact in a hindered state of proliferation. Doubling times were calculated to be 31.4 h in the presence of tetracycline and 50.4 h without tetracycline, bcl-XS expression also causes dramatic alterations in the cell cycle distribution of K12 cells manifesting as a substantial decrease (approximate to 50%) in the fraction of S phase cells with a concomitant increase in the G1 population. Continuous expression of bcl-XS, at levels approximately equal to that of bcl-XL, decreased the viability of K12 cells as demonstrated by a log decline in clonogenic survival. This decrease occurred without considerable apoptosis or a compensatory increase in the level of bcl-XL. None of these phenotyes were present in control cells expressing beta-galactosidase in a similar retroviral cassette. These observations demonstrate that bcl-XS can have substantial cytokinetic effects under circumstances that produce relatively little apoptosis.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Univ Cologne, Fak Med, Inst Biochem 1, D-5000 Cologne 41, Germany	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Stanford University; University of Cologne	Maybaum, J (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA.				NATIONAL CANCER INSTITUTE [R01CA059717, R01CA056663] Funding Source: NIH RePORTER; NCI NIH HHS [CA56663, CA59717] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEDI A, 1995, CANCER RES, V55, P1811; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOSARI S, 1995, HUM PATHOL, V26, P534, DOI 10.1016/0046-8177(95)90250-3; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; CAIGNARD A, 1985, INT J CANCER, V36, P273, DOI 10.1002/ijc.2910360221; CLARKE MF, 1995, P NATL ACAD SCI USA, V92, P11024, DOI 10.1073/pnas.92.24.11024; DHAWAN J, 1995, SOMAT CELL MOLEC GEN, V21, P233, DOI 10.1007/BF02255778; Dole MG, 1996, CANCER RES, V56, P5734; Ealovega MW, 1996, CANCER RES, V56, P1965; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Han ZY, 1996, CANCER RES, V56, P1621; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; HOY CA, 1989, CYTOMETRY, V10, P718, DOI 10.1002/cyto.990100608; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Ibrado AM, 1996, CANCER RES, V56, P4743; Iida A, 1996, J VIROL, V70, P6054, DOI 10.1128/JVI.70.9.6054-6059.1996; Kitanaka C, 1997, ONCOGENE, V15, P1763, DOI 10.1038/sj.onc.1201349; Krajewska M, 1996, CANCER RES, V56, P2422; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Merchant AK, 1996, ONCOGENE, V13, P2631; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; MIYASHITA T, 1994, CANCER RES, V54, P3131; NOEL RA, 1994, J PEDIATR GASTR NUTR, V19, P43, DOI 10.1097/00005176-199407000-00007; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Pritchard DM, 1996, PHARMACOL THERAPEUT, V72, P149, DOI 10.1016/S0163-7258(96)00102-7; Ray S, 1996, CELL GROWTH DIFFER, V7, P1617; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; SINICROPE FA, 1995, CANCER RES, V55, P237; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Wagener C, 1996, INT J CANCER, V67, P138, DOI 10.1002/(SICI)1097-0215(19960703)67:1<138::AID-IJC22>3.0.CO;2-9; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; ZHAN QM, 1994, ONCOGENE, V9, P3743	35	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	1998	17	23					2981	2991		10.1038/sj.onc.1202224	http://dx.doi.org/10.1038/sj.onc.1202224			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881700				2022-12-28	WOS:000077427800005
J	Hengstermann, A; Whitaker, NJ; Zimmer, D; Zentgraf, H; Scheffner, M				Hengstermann, A; Whitaker, NJ; Zimmer, D; Zentgraf, H; Scheffner, M			Characterization of sequence elements involved in p53 stability regulation reveals cell type dependence for p53 degradation	ONCOGENE			English	Article						degradation; E6-AP; p53; phosphorylation; UV	HUMAN PAPILLOMAVIRUS TYPE-16; DNA-DAMAGE; TUMOR-SUPPRESSOR; E6 ONCOPROTEIN; WILD-TYPE; IN-VIVO; RAPID DEGRADATION; TRANSFORMED-CELLS; PROTEIN; PHOSPHORYLATION	The growth suppressive properties of the tumor suppressor protein p53 are activated upon DNA damage. The activation of p53 is reflected in increased p53 levels which are, at least in part, the result of an extended half-life of the protein. Although this suggests that stabilization of p53 is an intrinsic feature of p53 activation, the mechanisms involved in p53 degradation and stabilization are poorly understood. Here we report on the identification of an internal deletion mutant of wild-type p53, termed Delta 62-96, which can be stably expressed in various cell lines. This deletion mutant has a turnover rate similar to wild-type p53 and its stability is upregulated by treatment with UV light. In cell lines that express endogenous mutant or no p53, however, Delta 62-96 appears to be stable, strongly indicating that these cell lines have lost the ability to degrade p53. Further characterization of Delta 62-96 by mutational analyses defines sequence and structural requirements for p53 degradation and indicates that none of the known p53 phosphorylation sites is essential with respect to p53 stability regulation upon UV-irradiation.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Scheffner, M (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.		Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128				BeerRomero P, 1997, ONCOGENE, V14, P595, DOI 10.1038/sj.onc.1200872; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; FISCELLA M, 1993, ONCOGENE, V8, P1519; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Maki CG, 1996, CANCER RES, V56, P2649; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Mayo LD, 1997, CANCER RES, V57, P5013; Meek DW, 1997, BIOCHEM SOC T, V25, P416, DOI 10.1042/bst0250416; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; Momand J, 1997, J CELL BIOCHEM, V64, P343; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REIHSAUS E, 1990, ONCOGENE, V5, P137; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	55	29	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 3	1998	17	22					2933	2941		10.1038/sj.onc.1202282	http://dx.doi.org/10.1038/sj.onc.1202282			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879999				2022-12-28	WOS:000077286400013
J	Rohn, JL; Hueber, AO; McCarthy, NJ; Lyon, D; Navarro, P; Burgering, BMT; Evan, GI				Rohn, JL; Hueber, AO; McCarthy, NJ; Lyon, D; Navarro, P; Burgering, BMT; Evan, GI			The opposing roles of the Akt and c-Myc signalling pathways in survival from CD95-mediated apoptosis	ONCOGENE			English	Article						proto-oncogene c-myc; Akt protein kinase B; apoptosis; CD95/APO-1/Fas	DOMAIN-CONTAINING PROTEIN; CELL-DEATH; MOLECULAR-CLONING; GENE-TRANSFER; FAS; KINASE; INTERACTS; BAD; PHOSPHORYLATION; ACTIVATION	Expression of the proto-oncogene c-myc stimulates cell proliferation in the presence of the appropriate survival factors and triggers apoptosis in their absence; this dual capacity ensures that cell growth is restricted to the correct paracrine environment and is thereby strictly controlled. Recently our laboratory demonstrated that c-Myc-induced apoptosis requires the CD95 death receptor pathway and that insulin-like growth factor (IGF-1) signalling suppresses this killing. To investigate further the links between c-Myc and IGF-1 pathways in CD95-induced apoptosis, we examined the effects of c-Myc and a downstream IGF-I survival kinase, Akt, on killing mediated by CD95 and its recruited effector proteins (FADD and caspase-8). Here, we show that c-Myc activation does not exacerbate killing induced by FADD or pro-caspase-8, which narrows the point at which c-Myc exerts its action downstream of the interaction of CD95 with its ligand and upstream of FADD. We show further that activated Akt suppresses CD95-induced apoptosis and that Akt exerts its activity at a point downstream of FADD but upstream of caspase-8. These results restrict the possible mechanisms by which CD95-induced apoptosis is modulated by death signals and survival factors.	Imperial Canc Res Fund, Biochem Cell Nucleus Lab, London WC2A 3PX, England; Univ Complutense, Fac Pharm, Dept Biochem & Mol Biol, E-28040 Madrid, Spain; Univ Utrecht, Physiol Chem Lab, NL-3521 GG Utrecht, Netherlands	Cancer Research UK; Complutense University of Madrid; Utrecht University	Evan, GI (corresponding author), Imperial Canc Res Fund, Biochem Cell Nucleus Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Anne-Odile, Hueber/P-9860-2019; Anne-Odile, Hueber/G-4352-2013	Anne-Odile, Hueber/0000-0003-3816-2446; Anne-Odile, Hueber/0000-0003-3816-2446; Rohn, Jennifer/0000-0001-8766-6056; McCarthy, Nicola/0000-0001-6990-3943				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FIELD JK, 1990, ANTICANCER RES, V10, P1; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; HUEBER AO, 1998, IN PRESS TRENDS GENE; ITOH N, 1993, J IMMUNOL, V151, P621; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; WANTANABEFUKUNA.R, 1992, NATURE, V356, P314; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zornig M, 1998, CURR BIOL, V8, P467, DOI 10.1016/S0960-9822(98)70182-4	52	65	67	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	1998	17	22					2811	2818		10.1038/sj.onc.1202393	http://dx.doi.org/10.1038/sj.onc.1202393			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879987				2022-12-28	WOS:000077286400001
J	Stewart, C; Parente, F; Piehl, F; Farnebo, F; Quincey, D; Silins, G; Bergman, L; Carle, GF; Lemmens, I; Grimmond, S; Xian, CZ; Khodei, S; Teh, BT; Lagercrantz, J; Siggers, P; Calender, A; Van de Vem, V; Kas, K; Weber, G; Hayward, N; Gaudray, P; Larsson, C				Stewart, C; Parente, F; Piehl, F; Farnebo, F; Quincey, D; Silins, G; Bergman, L; Carle, GF; Lemmens, I; Grimmond, S; Xian, CZ; Khodei, S; Teh, BT; Lagercrantz, J; Siggers, P; Calender, A; Van de Vem, V; Kas, K; Weber, G; Hayward, N; Gaudray, P; Larsson, C			Characterization of the mouse Men1 gene and its expression during development	ONCOGENE			English	Article						menin; multiple endocrine neoplasia type 1; mouse RNA in situ hybridization	ENDOCRINE NEOPLASIA TYPE-1; SPORADIC GASTRINOMAS; PARATHYROID TUMORS; MULTIPLE; MUTATIONS; IDENTIFICATION; CHROMOSOME-11; PROTEINS	The gene responsible for multiple endocrine neoplasia type 1 (MEN1), a heritable predisposition to endocrine tumours in man, has recently been identified. Here we have characterized the murine homologue with regard to cDNA sequence, genomic structure, expression pattern and chromosomal localisation, The murine Men1 gene spans approximately 6.7 kb of genomic DNA and is comprised of 10 exons with similar genomic structure to the human locus. It was mapped to the pericentromeric region of mouse chromosome 19, which is conserved with the human 11q13 band where MEN1 is located. The predicted protein is 611 amino acids in length and overall is 97% homologous to the human orthologue. The 45 reported MEN1 mutations which alter or delete a single amino acid in human all occur at conserved residues, thereby supporting their functional significance. Two transcripts of approximately 3.2 and 2.8 kb were detected in both embryonal and adult murine tissues, resulting from alternative splicing of intron 1, By RNA in situ hybridization and Northern analysis the spatiotemporal expression pattern of Men1 was determined during mouse development. Men1 gene activity was detected already at gestational day 7, At embryonic day 14 expression was generally high throughout the embryo, while at day 17 the thymus, skeletal muscle, and CNS showed the strongest signal. In selected tissues from postnatal mouse Men1 was detected in all tissues analysed and was expressed at high levels in cerebral cortex, hippocampus, testis, and thymus. In brain the menin protein was detected mainly in nerve cell nuclei, whereas in testis it appeared perinuclear in spermatogonia, These results show that Men1 expression is not confined to organs affected in MEN1, suggesting that Men1 has a significant function in many different cell types including the CNS and testis.	Karolinska Hosp, CMM, Dept Mol Med, S-17176 Stockholm, Sweden; PO Royal Brisbane Hosp, Queensland Inst Med Res, Queensland Canc Fund Res Labs, Herston, Qld 4029, Australia; UNSA, CNRS, UMR 6549, F-06107 Nice, France; Karolinska Hosp, CMM, Dept Neurosci, S-17176 Stockholm, Sweden; Karolinska Hosp, CMM, Dept Surg, S-17176 Stockholm, Sweden; Katholieke Univ Leuven, Mol Oncol Lab, B-3000 Louvain, Belgium; Katholieke Univ Leuven VIB, Ctr Human Genet, B-3000 Louvain, Belgium; MRC, Didcot OX11 0RD, Oxon, England; Med Univ Claude Bernard Lyon 1, UMR 5641, CNRS, Lab Genet & Canc, Lyon, France	Karolinska Institutet; Karolinska University Hospital; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; MRC Harwell; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Larsson, C (corresponding author), Karolinska Hosp, CMM, Dept Mol Med, S-17176 Stockholm, Sweden.		Carle, Georges/GWC-5240-2022; hayward, nick/AAV-8802-2020; Grimmond, Sean M/J-5304-2016; Grimmond, Sean/K-3246-2019; Piehl, Fredrik/E-3451-2013; hayward, nicholas k/C-1367-2015; Weber, Günther/F-3410-2016	Grimmond, Sean M/0000-0002-8102-7998; Grimmond, Sean/0000-0002-8102-7998; hayward, nicholas k/0000-0003-4760-1033; Zhang, Chang Xian/0000-0002-5443-8951; Weber, Gunther/0000-0002-3861-808X; Bergman, Lee/0000-0002-0111-411X; Carle, Georges/0000-0002-3901-1052; Teh, Bin Tean/0000-0003-1514-1124				Agarwal SK, 1997, HUM MOL GENET, V6, P1169, DOI 10.1093/hmg/6.7.1169; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARON B, 1984, EXP CELL RES, V152, P220, DOI 10.1016/0014-4827(84)90247-7; Bassett JHD, 1998, AM J HUM GENET, V62, P232, DOI 10.1086/301729; BRANDI ML, 1993, AM J HUM GENET, V53, P1167; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; CHISHOLM D, 1989, BIOTECHNIQUES, V7, P21; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Courseaux A, 1996, GENOMICS, V37, P354, DOI 10.1006/geno.1996.0570; DAGERLIND A, 1992, HISTOCHEMISTRY, V98, P39, DOI 10.1007/BF00716936; Debelenko LV, 1997, CANCER RES, V57, P2238; Debelenko LV, 1997, HUM MOL GENET, V6, P2285, DOI 10.1093/hmg/6.13.2285; Farnebo F, 1998, J CLIN ENDOCR METAB, V83, P2627, DOI 10.1210/jc.83.8.2627; FRIEDMAN E, 1989, NEW ENGL J MED, V321, P213, DOI 10.1056/NEJM198907273210402; FRIEDMAN E, 1994, PARATHYROIDS BASIC C, V38, P647; GU W, 1995, J BIOL CHEM, V270, P236, DOI 10.1074/jbc.270.1.236; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Heppner C, 1997, NAT GENET, V16, P375, DOI 10.1038/ng0897-375; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; Lemmens I, 1997, HUM MOL GENET, V6, P1177, DOI 10.1093/hmg/6.7.1177; LINK DC, 1992, ONCOGENE, V7, P877; SAWICKI MP, 1992, HUM GENET, V89, P445; Shows TB, 1996, CYTOGENET CELL GENET, V74, P2; Teh BT, 1998, J CLIN ENDOCR METAB, V83, P2621, DOI 10.1210/jc.83.8.2621; THAKKER RV, 1989, NEW ENGL J MED, V318, P658; Toliat MR, 1997, LANCET, V350, P1223, DOI 10.1016/S0140-6736(05)63453-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Zhuang ZP, 1997, CANCER RES, V57, P4682; Zhuang ZP, 1997, CANCER RES, V57, P5446	30	115	117	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	1998	17	19					2485	2493		10.1038/sj.onc.1202164	http://dx.doi.org/10.1038/sj.onc.1202164			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824159				2022-12-28	WOS:000076927300008
J	Jerry, DJ; Kuperwasser, C; Downing, SR; Pinkas, J; He, C; Dickinson, E; Marconi, S; Naber, SP				Jerry, DJ; Kuperwasser, C; Downing, SR; Pinkas, J; He, C; Dickinson, E; Marconi, S; Naber, SP			Delayed involution of the mammary epithelium in BALB/c-p53(null) mice	ONCOGENE			English	Article						p53; mice; mammary involution; p21(WAF1) apoptosis	PROGRAMMED CELL-DEATH; TRANSGENIC MICE; BASEMENT-MEMBRANE; GLAND INVOLUTION; P53; APOPTOSIS; TISSUE; DIFFERENTIATION; SUPPRESSION; STROMELYSIN-1	In mammals, weaning of neonates and subsequent milk stasis initiates removal of the secretory epithelium of the mammary gland by apoptosis, The p53 tumor suppressor gene is induced rapidly following weaning of neonates, but its role in the process of involution has not been defined. Therefore, experiments were performed to identify the cell types in which the p53 gene is expressed during involution and determine the consequences of its absence in BALB/c-p53(null) mice. Both p53 mRNA and protein were detected in the mammary epithelium within 48 h following meaning and resulted in an eightfold increase in levels of p21(WAF1) mRNA, Induction of p21(WAF1) mRNA was absent in BALB/c-p53(null) mice, and therefore, was shown to be p53-dependent, The BALB/c-p53(null) mice exhibited delayed involution of the mammary epithelium, as measured by 60% greater epithelial area compared to BALB/c-p53(wt) mice through 5 days postweaning, The delay was transient with no differences being apparent at 7 days post-weaning. Expression of the stromal protease stromelysin-1 was unaffected by the absence of p53 suggesting that stromal responses were intact. These data demonstrate that p53 participates in the first stage of involution initiated by the epithelium itself, but does not affect the second phase during which stromal proteases are induced.	Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; Baystate Med Ctr, Dept Pathol, Springfield, MA 01199 USA	University of Massachusetts System; University of Massachusetts Amherst; Baystate Medical Center	Jerry, DJ (corresponding author), Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA.				NATIONAL CANCER INSTITUTE [R29CA066670] Funding Source: NIH RePORTER; NCI NIH HHS [CA66670] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; ATWOOD CS, 1995, BIOCHEM BIOPH RES CO, V207, P860, DOI 10.1006/bbrc.1995.1265; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; COLOMBEL M, 1995, ONCOGENE, V10, P1269; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Godley LA, 1996, GENE DEV, V10, P836, DOI 10.1101/gad.10.7.836; HENSON DE, 1994, CANCER, V74, P424, DOI 10.1002/cncr.2820741330; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; LI BL, 1994, CELL GROWTH DIFFER, V5, P711; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; Lund LR, 1996, DEVELOPMENT, V122, P181; MacCallum DE, 1996, ONCOGENE, V13, P2575; MUNFORD RE, 1963, J ENDOCRINOL, V28, P17, DOI 10.1677/joe.0.0280017; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; Petersen SL, 1996, ENDOCRINOLOGY, V137, P234, DOI 10.1210/en.137.1.234; Pullan S, 1996, J CELL SCI, V109, P631; QUARRIE LH, 1995, CELL TISSUE RES, V281, P413, DOI 10.1007/BF00417859; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SCHMID P, 1991, DEVELOPMENT, V113, P857; STRANGE R, 1992, DEVELOPMENT, V115, P49; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; WITTY JP, 1995, CANCER RES, V55, P1401	32	71	72	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2305	2312		10.1038/sj.onc.1202157	http://dx.doi.org/10.1038/sj.onc.1202157			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811461				2022-12-28	WOS:000076723300004
J	Hilbert, DM; Theisen, PW; Rudikoff, EK; Bauer, SR				Hilbert, DM; Theisen, PW; Rudikoff, EK; Bauer, SR			Interaction of abl and raf with IL-7 signaling pathway and transformation of pre-B cells from resistant mice	ONCOGENE			English	Article						pre-B lymphomagenesis; JAK-STAT signaling; raf/myc retrovirus; abl/myc retrovirus; IL-7 signal transduction	T-CELLS; MURINE PLASMACYTOMAGENESIS; LEUKEMIA-VIRUS; MYC ONCOGENES; V-ABL; EXPRESSION; ABROGATION; MOUSE; DEPENDENCE; RETROVIRUS	After in vivo inoculation with abl/myc- and raf/myc-containing retroviruses, BALB/c mice predominantly develop late stage B cell tumors (plasmacytomas) and less frequently develop earlier B-lineage tumors while DBA/2 mice do not develop B-lineage tumors. We have investigated the in vitro tumorigenic potential of these viruses using cultured normal pre-B cell lymphocytes from both BALB/c and DBA/2 mice. Interestingly, both viruses infect cultured pre-B lymphocytes from both mouse strains. Following infection, IL-7 dependent pre-B cells become independent of normal in vitro growth requirements within 24 h and can rapidly form in vivo pre-B lymphomas in both mouse strains, Mechanisms mediating loss of IL-7 dependence are different depending on whether the I nf or abl gene is present in myc-containing viruses. IL-7 JAK-STAT signaling is constitutively active in abl/myc induced pre-B cell tumors, In contrast, IL-7 JAK-STAT signaling is not constitutive in raf/myc induced pre-B cell tumors, demonstrating that subversion of this component of IL-7 signal transduction is not obligatory for pre-B cell transformation or loss of IL-7 dependence.	US FDA, Mol Immunol Lab, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Rockville, MD 20852 USA; NCI, Genet Lab, NIH, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bauer, SR (corresponding author), US FDA, Mol Immunol Lab, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Bldg 29B,2E16 HFM-521,1401 Rockville Pike, Rockville, MD 20852 USA.		Bauer, Steven/G-5559-2012	Bauer, Steven/0000-0003-2831-846X				ANDERSON PN, 1969, NATURE, V222, P994, DOI 10.1038/222994a0; ANDERSON SM, 1990, ONCOGENE, V5, P317; BENDER TP, 1987, J IMMUNOL, V139, P3822; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Corcoran AE, 1996, EMBO J, V15, P1924, DOI 10.1002/j.1460-2075.1996.tb00543.x; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DEAN M, 1987, ONCOGENE RES, V1, P279; GHIA P, 1995, EUR J IMMUNOL, V25, P3108, DOI 10.1002/eji.1830251118; HILBERT DM, 1993, ONCOGENE, V8, P1993; HILBERT DM, 1995, P NATL ACAD SCI USA, V92, P649, DOI 10.1073/pnas.92.3.649; Hilbert DM, 1996, IMMUNITY, V5, P81, DOI 10.1016/S1074-7613(00)80312-X; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LANEUVILLE P, 1992, BLOOD, V80, P1788; LARGAESPADA DA, 1992, ONCOGENE, V7, P811; LIN AY, 1996, NEOPLASTIC DIS BLOOD; MCCUBREY JA, 1993, ONCOGENE, V8, P2905; MERWIN RM, 1959, P SOC EXP BIOL MED, V101, P437; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; OKABE T, 1992, EUR J IMMUNOL, V22, P31, DOI 10.1002/eji.1830220106; POPLACK DG, 1989, CANC PRINCIPLES PRAC, P1671; Potter M, 1995, Curr Top Microbiol Immunol, V194, P83; POTTER M, 1962, NATURE, V193, P1086, DOI 10.1038/1931086a0; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; ROLINK A, 1993, ADV IMMUNOL, V53, P123, DOI 10.1016/S0065-2776(08)60499-X; ROLINK A, 1993, BLOOD, V81, P2290; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROLINK A, 1991, BIOCHEM SOC T, V19, P275, DOI 10.1042/bst0190275; ROSE FV, 1992, VIROLOGY, V188, P650, DOI 10.1016/0042-6822(92)90519-U; ROSENBERG N, 1982, CURR TOP MICROBIOL, V101, P95; Sambrook J., 1989, MOL CLONING; SCHEUERMANN RH, 1993, METHOD ENZYMOL, V218, P446; SILVA S, 1991, INT J CANCER, V49, P224, DOI 10.1002/ijc.2910490214; Smith MR, 1996, CURR PROB CANCER, V20, P6, DOI 10.1016/S0147-0272(96)80303-5; TROPPMAIR J, 1989, P NATL ACAD SCI USA, V86, P9941, DOI 10.1073/pnas.86.24.9941; WEISSINGER EM, 1993, MOL CELL BIOL, V13, P2578, DOI 10.1128/MCB.13.4.2578; WHITLOCK CA, 1981, J VIROL, V40, P577, DOI 10.1128/JVI.40.2.577-584.1981; WIERNIK PH, 1996, NEOPLASTIC DIS BLOOD	38	5	5	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2125	2135		10.1038/sj.onc.1202134	http://dx.doi.org/10.1038/sj.onc.1202134			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798684				2022-12-28	WOS:000076540900012
J	Grossi, M; La Rocca, SA; Pierluigi, G; Vannucchi, S; Ruaro, EM; Schneider, C; Tato, F				Grossi, M; La Rocca, SA; Pierluigi, G; Vannucchi, S; Ruaro, EM; Schneider, C; Tato, F			Role of Gas1 down-regulation in mitogenic stimulation of quiescent NIH3T3 cells by v-Src	ONCOGENE			English	Article						v-Src; proliferation; gas1; PI 3-kinase	PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; MAP KINASE; SIGNAL-TRANSDUCTION; TYROSINE KINASES; TRANSFORMATION; PROTEINS; ACTIVATION; INHIBITOR; 3-KINASE; GENES	Quiescent mammalian fibroblasts can be induced to reenter the cell cycle by growth factors and oncoproteins, We studied the pathway(s) through which v-Src, the oncogenic tyrosine kinase encoded by the v-src oncogene of Rous sarcoma virus, forces serum-starved NIH3T3 cells to enter S-phase, To this purpose, we isolated and characterized a polyclonal population of NIH3T3 cells transformed by the MR31 retroviral vector, encoding G418 resistance and the v-src temperature-sensitive allele from the mutant ts LA31 PR-A, NIH(MR31! cells displayed a temperature-conditional transformed phenotype and could be made quiescent by serum deprivation at the restrictive temperature, Serum stimulation or thermolabile v-Src reactivation induced entry into S-phase to a comparable extent, although with different kinetics. The data suggest that v-Src mitogenic activity involves early activation of the Erk1/Erk2 MAP kinases with very little tyrosine phosphorylation of the Shc adaptor proteins at least during the early stages of v-Src reactivation and that v-Src-induced S-phase entry was strongly inhibited by drugs affecting MEK or PI 3-kinase, Our results also suggest that down-regulation of gas1 gene expression plays an important role in regulating the efficiency of entry into S-phase triggered by reactivated v-Src and that Gas1 down-regulation does not require PI 3-kinase dependent signals.	Univ Rome La Sapienza, Fdn Cenci Bolognetti, Inst Pasteur, Dipartimento Biol Cellulare & Sviluppo, I-00185 Rome, Italy; Lab Nazl Consorzio Interuni Biotecnol, I-34012 Trieste, Italy	Fondazione Cenci Bolognetti; Sapienza University Rome	Tato, F (corresponding author), Univ Rome La Sapienza, Fdn Cenci Bolognetti, Inst Pasteur, Dipartimento Biol Cellulare & Sviluppo, Vie Apuli, I-00185 Rome, Italy.		la rocca, severina anna/D-8028-2011; Grossi, Milena/D-2955-2009					ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; CATLING AD, 1993, ONCOGENE, V8, P1875; CHAN TO, 1990, MOL CELL BIOL, V10, P3280, DOI 10.1128/MCB.10.6.3280; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dahl J, 1996, MOL CELL BIOL, V16, P2728; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DELSAL G, 1995, MOL CELL BIOL, V15, P7152; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FINCHAM VJ, 1986, J VIROL, V58, P694, DOI 10.1128/JVI.58.2.694-699.1986; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; Haefner B, 1997, BIOCHEM J, V328, P649, DOI 10.1042/bj3280649; HAEFNER B, 1995, J BIOL CHEM, V270, P7937, DOI 10.1074/jbc.270.14.7937; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCCLADE J, 1992, P NATL ACAD SCI USA, V89, P8869; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VERDERAME MF, 1995, MOL BIOL CELL, V6, P953, DOI 10.1091/mbc.6.8.953; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WELHAM MJ, 1990, ONCOGENE, V5, P161; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011	33	17	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1629	1638		10.1038/sj.onc.1202090	http://dx.doi.org/10.1038/sj.onc.1202090			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796692				2022-12-28	WOS:000076200100001
J	Cereseto, A; Parks, RW; Rivadeneira, E; Franchini, G				Cereseto, A; Parks, RW; Rivadeneira, E; Franchini, G			Limiting amounts of p27(Kip1) correlates with constitutive activation of cyclin E-CDK2 complex in HTLV-I-transformed T-cells	ONCOGENE			English	Article						p27(Kip1); cyclin E; HTLV-I infection	DEPENDENT KINASE INHIBITOR; LEUKEMIA-LYMPHOMA VIRUS; P21(WAF1/CIP1) EXPRESSION; INTERLEUKIN-2 RECEPTOR; MOLECULAR MECHANISMS; POTENTIAL MEDIATOR; RESTRICTION POINT; BREAST-CANCER; MICE LACKING; PROTEIN	Human T-cells immortalized (interleukin-2 [IL-2] dependent) by the human T-cell lymphotropic/leukemia virus type I (HTLV-I), in time, become transformed (IL-2 independent). To understand the biochemical basis of this transition, we have used the sibling HTLV-I-infected T-cell lines, N1186 (IL-2 dependent) and N1186-94 (IL-2 independent), as models to assess the responses to antiproliferative signals. In N1186 cells arrested in G1 after serum/interleukin-2 (IL-2) deprivation, downregulation of the cyclin E-CDK2 kinase activity correlated with decreased phosphorylation of CDK2 and accumulation of p27(Kip1) bound to the cyclin E-CDK2 complex, as seen in normal activated PBMCs (peripheral blood mononuclear cells). In contrast, N1186-94 cells failed to arrest in G1 upon serum starvation, displayed constitutive cyclin E-associated kinase activity, and, although CDK2 was partially dephosphorylated, the amount of p27(Kip1) bound to the complex did not increase. This observation, extended to two other IL-2-dependent as well as to three IL-2-independent HTLV-I-infected T-cell lines, suggests that the lack of cyclin E-CDK2 kinase downregulation found in the late phase of HTLV-I transformation may correlate with insufficient amounts of p27(Kip1) associated with the cyclin E-CDK2 complex. Reconstitution experiments demonstrated that the addition of p27(Kip1) to lysates from N1186-94 starved cells resulted in the downregulation of cyclin E-associated kinase activity supporting the notion that the unresponsiveness of the cyclin E-CDK2 complex to growth inhibitory signals may be due to inadequate amounts of p27(Kip1) assembled with the complex in HTLV-I-transformed T-cells, In fact, the amount of p27(Kip1) protein was lower in most HTLV-I-transformed (IL-2-independent) than in the immortalized (IL-2-dependent) HTLV-I-infected T-cells, Furthermore, specific inhibitors of the phosphatidylinositol 3-kinase (PI3K) induced an increase of p27(Kip1) protein levels, which correlated,vith G1 arrest, in both IL-2-dependent and IL-2-independent HTLV-I-infected T-cells, Altogether, these results suggest that maintaining a low level of expression of p27(Kip1) is a key event in HTLV-I transformation.	NCI, Basic Res Lab, Div Basic Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cereseto, A (corresponding author), NCI, Basic Res Lab, Div Basic Sci, Bethesda, MD 20892 USA.			Cereseto, Anna/0000-0003-4453-2597	NATIONAL CANCER INSTITUTE [ZIABC005645, Z01BC005645] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1996, ONCOGENE, V12, P1645; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Cereseto A, 1997, LEUKEMIA, V11, P866, DOI 10.1038/sj.leu.2400665; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Dumont FJ, 1995, LIFE SCI, V58, P373, DOI 10.1016/0024-3205(95)02233-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; GONG JP, 1994, CANCER RES, V54, P4285; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARPER JW, 1993, CELL, V75, P805; Johnson D, 1998, ONCOGENE, V16, P2017, DOI 10.1038/sj.onc.1201727; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOFF A, 1992, SCIENCE, V257, P1959; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEACH FS, 1993, CANCER RES, V53, P1986; Liu Y, 1996, CANCER RES, V56, P31; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; MARKHAM PD, 1983, INT J CANCER, V31, P413, DOI 10.1002/ijc.2910310404; Migone TS, 1998, P NATL ACAD SCI USA, V95, P3845, DOI 10.1073/pnas.95.7.3845; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mulloy JC, 1998, J VIROL, V72, P4408, DOI 10.1128/JVI.72.5.4408-4412.1998; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POPOVIC M, 1983, P NATL ACAD SCI-BIOL, V80, P5402, DOI 10.1073/pnas.80.17.5402; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	42	33	33	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2441	2450		10.1038/sj.onc.1202567	http://dx.doi.org/10.1038/sj.onc.1202567			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229195				2022-12-28	WOS:000079703300004
J	Schmidt, L; Junker, K; Nakaigawa, N; Kinjerski, T; Weirich, G; Miller, M; Lubensky, I; Neumann, HPH; Brauch, H; Decker, J; Vocke, C; Brown, JA; Jenkins, R; Richard, S; Bergerheim, U; Gerrard, B; Dean, M; Linehan, WM; Zbar, B				Schmidt, L; Junker, K; Nakaigawa, N; Kinjerski, T; Weirich, G; Miller, M; Lubensky, I; Neumann, HPH; Brauch, H; Decker, J; Vocke, C; Brown, JA; Jenkins, R; Richard, S; Bergerheim, U; Gerrard, B; Dean, M; Linehan, WM; Zbar, B			Novel mutations of the MET proto-oncogene in papillary renal carcinomas	ONCOGENE			English	Article						papillary renal carcinoma; MET protooncogene mutations; receptor tyrosine kinase	TYROSINE KINASE DOMAIN; TUMOR-SUPPRESSOR GENE; GROWTH-FACTOR RECEPTORS; ACTIVATING MUTATIONS; CRYSTAL-STRUCTURE; INSULIN-RECEPTOR; POINT MUTATIONS; CELL CARCINOMA; PROTOONCOGENE; ERBB	Hereditary papillary renal carcinoma (HPRC) is characterized by multiple, bilateral papillary renal carcinomas. Previously, we demonstrated missense mutations in the tyrosine kinase domain of the MET proto-oncogene in HPRC and a subset of sporadic papillary renal carcinoma In this study, me screened a large panel of sporadic papillary renal carcinomas and various solid tumors for mutations in the MET protooncogene, Summarizing these and previous results, mutations of the MET proto-oncogene were detected in 17/129 sporadic papillary renal carcinomas but not in other solid tumors. We detected five novel: missense mutations; three of five mutations were located in the ATP-binding region of the tyrosine kinase domain of MET. One novel mutation in MET, V1110I, was located at a codon homologous to an activating mutation in the c-erbB proto-oncogene, These mutations caused constitutive phosphorylation of MET when transfected into NIH3T3 cells. Molecular modeling studies suggest that these activating mutations interfere with the intrasteric mechanism of tyrosine kinase autoinhibition and facilitate transition to the active form of the MET kinase, The low frequency of MET mutations in noninherited papillary renal carcinomas (PRC) suggests that noninherited PRC may develop by a different mechanism than hereditary papillary renal carcinoma.	NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, SAIC Frederick, Intramural Res Support Program, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Macromol Struct Lab, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Lab Genom Divers, Frederick, MD 21702 USA; NIH, Urol Oncol Branch, Bethesda, MD 20892 USA; NIH, Pathol Lab, Bethesda, MD 20892 USA; Univ Freiburg, D-79106 Freiburg, Germany; Univ Hamburg, Womens Clin, Hamburg Eppendorf UKE, D-20246 Hamburg, Germany; Johannes Gutenberg Univ Mainz, D-55131 Mainz, Germany; Mayo Clin & Mayo Fdn, Div Lab Genet, Rochester, MN 55905 USA; Karolinska Inst, Stockholm, Sweden; Hop Bicetre, Dept Urol, Paris, France; EPHE, Lab Neuoroncol, F-75006 Paris, France; Univ Jena, Dept Urol, D-07743 Jena, Germany; David Grant Med Ctr, Travis AFB, CA 94535 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; University of Freiburg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Johannes Gutenberg University of Mainz; Mayo Clinic; Karolinska Institutet; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Friedrich Schiller University of Jena	Schmidt, L (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Bldg 560 Rm 12-29, Frederick, MD 21702 USA.		Dean, Michael/R-7501-2019; Dean, Michael C/G-8172-2012; Miller, Maria/I-1636-2013; RICHARD, Stéphane/O-1005-2017	Dean, Michael C/0000-0003-2234-0631; Miller, Maria/0000-0003-0252-5348; RICHARD, Stéphane/0000-0002-9859-9773; Brauch, Hiltrud/0000-0001-7531-2736; Brown, James/0000-0002-6065-1716	NATIONAL CANCER INSTITUTE [Z01BC008579, Z01BC005652] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berndt I, 1998, J CLIN ENDOCR METAB, V83, P770, DOI 10.1210/jc.83.3.770; BORDEN EC, 1982, CANCER RES, V42, P4948; Brown JA, 1997, J UROLOGY, V158, P370, DOI 10.1016/S0022-5347(01)64482-3; DIRENZO MF, 1995, J ENDOCRINOL INVEST, V18, P134, DOI 10.1007/BF03349722; Duh FM, 1997, ONCOGENE, V15, P1583, DOI 10.1038/sj.onc.1201338; ERMIS A, 1995, HUM GENET, V96, P651, DOI 10.1007/BF00210293; Fattoruso O, 1998, HUM MUTAT, pS167; Fischer Joachim, 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P130; Grignon DJ, 1998, SEMIN DIAGN PATHOL, V15, P41; Hanafusa H., 1986, ONCOGENES GROWTH CON, P100; Huang HJ, 1998, GENE CHROMOSOME CANC, V21, P152, DOI 10.1002/(SICI)1098-2264(199802)21:2<152::AID-GCC11>3.0.CO;2-T; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; KOVACS G, 1993, ADV CANCER RES, V62, P89, DOI 10.1016/S0065-230X(08)60316-4; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; Lin JC, 1996, ONCOGENE, V13, P2001; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Pignon JM, 1997, HEMATOL CELL THER, V39, P114, DOI 10.1007/s00282-997-0114-4; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Schmidt L, 1995, Cancer J Sci Am, V1, P191; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; SCHMIDT L, 1993, HUM MOL GENET, V2, P817, DOI 10.1093/hmg/2.6.817; SHU HKG, 1991, J VIROL, V65, P6173, DOI 10.1128/JVI.65.11.6173-6180.1991; SHU HKG, 1994, MOL CELL BIOL, V14, P6868, DOI 10.1128/MCB.14.10.6868; SHU HKG, 1990, P NATL ACAD SCI USA, V87, P9103, DOI 10.1073/pnas.87.23.9103; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Underhill PA, 1996, P NATL ACAD SCI USA, V93, P196, DOI 10.1073/pnas.93.1.196; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; ZBAR B, 1994, J UROLOGY, V151, P561, DOI 10.1016/S0022-5347(17)35015-2; Zbar B, 1998, ADV CANCER RES, V75, P163, DOI 10.1016/S0065-230X(08)60742-3; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	37	386	423	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	1999	18	14					2343	2350		10.1038/sj.onc.1202547	http://dx.doi.org/10.1038/sj.onc.1202547			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327054				2022-12-28	WOS:000079595500006
J	Dobbelstein, M; Wienzek, S; Konig, C; Roth, J				Dobbelstein, M; Wienzek, S; Konig, C; Roth, J			Inactivation of the p53-homologue p73 by the mdm2-oncoprotein	ONCOGENE			English	Article						p53; p73; mdm2; transcription; protein stability	TUMOR-SUPPRESSOR; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; P53 BINDING; MDM2; PROTEIN; DOMAIN; TRANSACTIVATION; GROWTH; ACTIVATION	The p73 beta protein shares structural and functional similarities with the tumor suppressor gene product p53, Both proteins activate transcription from p53-responsive promoters. p53's activity is antagonized by the mdm2 protein (also termed hdma in human cells). Complex formation between p53 and mdm2 results in p53's transcriptional inactivation and destabilization, Here we show that overexpression of mdm2 reduces p73 beta's ability to activate transcription, too. The mdm2 protein forms a specific complex with p73 beta in vitro with an efficiency comparable to p53-binding. Further, both p73 beta and p53 relocalize a transport-defective mutant of mdm2 from the cytoplasm to the nucleus, arguing that complex formation occurs in vivo as well. Mutational analysis suggests that the interaction between p73 beta and mdm2 follows structural principles analogous to the p53-mdm2-complex, Whereas p53 is destabilized in the presence of mdm2, the amount of intracellular p73 beta was not detectably reduced by mdm2, The carboxyterminal RING finger domain of mdm2 was found to be required to reduce the intracellular abundance of p53, but it was dispensable for transcriptionally inactivating either p53 or p73 beta, Our results suggest that the autoregulatory feedback loop between p53 and mdm2 also controls p73's activity, but that mdm2-mediated protein degradation is unique to p53.	Univ Marburg, Fachbereich Med, Abt Gastroenterol & Stoffwechsel, Zentrum Innere Med, D-35045 Marburg, Germany; Univ Marburg, Zentrum Mikrobiol & Hyg, Inst Virol, D-35037 Marburg, Germany	Philipps University Marburg; Philipps University Marburg	Roth, J (corresponding author), Univ Marburg, Fachbereich Med, Abt Gastroenterol & Stoffwechsel, Zentrum Innere Med, Baldingerstr, D-35045 Marburg, Germany.			Dobbelstein, Matthias/0000-0001-5052-3967				Bian JH, 1997, P NATL ACAD SCI USA, V94, P14753, DOI 10.1073/pnas.94.26.14753; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Dickman S, 1997, SCIENCE, V277, P1605, DOI 10.1126/science.277.5332.1605; DOBBELSTEIN M, 1992, ONCOGENE, V7, P837; DOBBLESTEIN M, 1997, IN PRESS J GEN VIROL; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; Freedman DA, 1997, MOL MED, V3, P248, DOI 10.1007/BF03401678; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nomoto S, 1998, CANCER RES, V58, P1380; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prabhu NS, 1998, INT J ONCOL, V13, P5; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Sunahara M, 1998, INT J ONCOL, V13, P319; Takahashi H, 1998, CANCER RES, V58, P2076; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Zeng XY, 1998, P NATL ACAD SCI USA, V95, P6681, DOI 10.1073/pnas.95.12.6681; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	43	142	145	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2101	2106		10.1038/sj.onc.1202512	http://dx.doi.org/10.1038/sj.onc.1202512			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321734				2022-12-28	WOS:000079346200007
J	Lai, A; Marcellus, RC; Corbeil, HB; Branton, PE				Lai, A; Marcellus, RC; Corbeil, HB; Branton, PE			RBP1 induces growth arrest by repression of E2F-dependent transcription	ONCOGENE			English	Article						growth arrest; transcriptional repression; E2F; retinoblastoma protein; pocket binding protein; cell cycle	RETINOBLASTOMA GENE-PRODUCT; HUMAN ADENOVIRUS TYPE-5; CELL-CYCLE; BINDING PROTEIN; FACTOR E2F; E1B PROTEIN; DNA; PHOSPHORYLATION; COMPLEX; FAMILY	Growth arrest and cell cycle progression are regulated by the retinoblastoma tumour suppressor pRB and related proteins p130 and p107 that bind to and inhibit the E2F family of transcription factors. Although the precise mechanism of this inhibition remains to be established, previous studies indicated the presence of transcriptional repression activity in the 'pocket' of RE family members. We show here that RBP1, a known pRB pocket-binding protein, possesses transcriptional repression activity and associates with p130-E2F and pRB-E2F complexes specifically during growth arrest. Overexpression of RBP1 both inhibited E2F-dependent gene expression and suppressed cell growth. Thus repression of E2F-dependent transcription by RBP1 via RE family members may play a central role in inducing growth arrest.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	Branton, PE (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Bldg,3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.							Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CORBEIL HB, 1995, ONCOGENE, V11, P909; Corbeil HB, 1997, ONCOGENE, V15, P657, DOI 10.1038/sj.onc.1201224; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; FATTAEY AR, 1993, ONCOGENE, V8, P3149; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Gregory SL, 1996, MOL CELL BIOL, V16, P792; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Huang TH, 1996, NUCLEIC ACIDS RES, V24, P1695, DOI 10.1093/nar/24.9.1695; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIM YW, 1994, MOL CELL BIOL, V14, P7256, DOI 10.1128/MCB.14.11.7256; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITSUDOMI T, 1992, ONCOGENE, V7, P171; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; OTTERSON GA, 1993, ONCOGENE, V8, P949; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Starostik P, 1996, MOL CELL BIOL, V16, P3606; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; TEODORO JG, 1994, J VIROL, V68, P776, DOI 10.1128/JVI.68.2.776-786.1994; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190	49	58	66	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2091	2100		10.1038/sj.onc.1202520	http://dx.doi.org/10.1038/sj.onc.1202520			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321733				2022-12-28	WOS:000079346200006
J	Jang, JS; Lee, SJ; Choi, YH; Nguyen, P; Lee, J; Hwang, SG; Wu, ML; Takano, E; Maki, M; Henkart, PA; Trepel, JB				Jang, JS; Lee, SJ; Choi, YH; Nguyen, P; Lee, J; Hwang, SG; Wu, ML; Takano, E; Maki, M; Henkart, PA; Trepel, JB			Posttranslational regulation of the retinoblastoma gene family member p107 by calpain protease	ONCOGENE			English	Article						proteolysis; p107; calpain; proteasome	LARGE T-ANTIGEN; ACTIVATED NEUTRAL PROTEASE; CELL-CYCLE; PROTEINS P130; KAPPA-B; IN-VIVO; C-JUN; UBIQUITIN; DEGRADATION; PATHWAY	The retinoblastoma protein plays a critical role in regulating the G1/S transition. Less is known about the function and regulation of the homologous pocket protein p107. Here we present evidence for the posttranslational regulation of p107 by the Ca2+-activated protease calpain. Three negative growth regulators, the HMG-CoA reductase inhibitor lovastatin, the antimetabolite 5-fluorouracil, and the cyclic nucleotide dibutyryl cAMP were found to induce cell type-specific loss of p107 protein which was reversible by the calpain inhibitor leucyl-leucyl-norleucinal but not by the serine protease inhibitor phenylmethylsulfonylfluoride, caspase inhibitors, or lactacystin, a specific inhibitor of the 26S proteasome, Purified calpain induced Ca2+-dependent p107 degradation in cell lysates. Transient expression of the specific calpain inhibitor calpastatin blocked the loss of p107 protein in lovastatin-treated cells, and the half-life of p107 was markedly lengthened in lovastatian-treated cells stably transfected with a calpastatin expression vector versus cells transfected with vector alone. The data presented here demonstrate downregulation of p107 protein in response to various antiproliferative signals, and implicate calpain in p107 posttranslational regulation.	NCI, Med Branch, Div Clin Sci, NIH, Bethesda, MD 20892 USA; NCI, Expt Immunol Branch, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Natl Kyoto Hosp, Kyoto 612, Japan; Nagoya Univ, Nagoya, Aichi 46401, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Nagoya University	Trepel, JB (corresponding author), NCI, Med Branch, Div Clin Sci, NIH, Bldg 10,Room 12N226, Bethesda, MD 20892 USA.		Maki, Masatoshi/AAM-6839-2021	Maki, Masatoshi/0000-0001-9144-5491	DIVISION OF BASIC SCIENCES - NCI [Z01BC009263] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; Bonvini P, 1998, ONCOGENE, V16, P1131, DOI 10.1038/sj.onc.1201625; Boyer SN, 1996, CANCER RES, V56, P4620; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; ETO A, 1995, J BIOL CHEM, V270, P25115, DOI 10.1074/jbc.270.42.25115; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gonen H, 1997, FEBS LETT, V406, P17, DOI 10.1016/S0014-5793(97)00225-1; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; KATO J, 1993, GENE DEV, V7, P331; KAVITA U, 1995, J BIOL CHEM, V270, P27758, DOI 10.1074/jbc.270.46.27758; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Knudsen ES, 1998, ONCOGENE, V16, P1655, DOI 10.1038/sj.onc.1201682; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; Lee MJ, 1996, FASEB J, V10, P16; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; Liu ZQ, 1996, FEBS LETT, V385, P109, DOI 10.1016/0014-5793(96)00360-2; Maki CG, 1996, CANCER RES, V56, P2649; MAYOL X, 1993, ONCOGENE, V8, P2561; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MOHAN PS, 1995, J NEUROCHEM, V64, P859; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; Stubdal H, 1996, J VIROL, V70, P2781, DOI 10.1128/JVI.70.5.2781-2788.1996; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; SZEKELY L, 1991, CELL GROWTH DIFFER, V2, P287; TORTORA G, 1994, ONCOGENE, V9, P3233; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Walowitz JL, 1998, J BIOL CHEM, V273, P6656, DOI 10.1074/jbc.273.12.6656; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	68	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1789	1796		10.1038/sj.onc.1202497	http://dx.doi.org/10.1038/sj.onc.1202497			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086333				2022-12-28	WOS:000079090000002
J	Fujii, GH; Morimoto, AM; Berson, AE; Bolen, JB				Fujii, GH; Morimoto, AM; Berson, AE; Bolen, JB			Transcriptional analysis of the PTEN/MMAC1 pseudogene, Psi PTEN	ONCOGENE			English	Article						MMAC; PTEN; tumor suppressor; pseudogene	TUMOR-SUPPRESSOR GENE; CELL LUNG-CANCER; HOMOZYGOUS DELETION; PHOSPHATASE; PROTEIN; BREAST; BETA; CHROMOSOME-9; MUTATIONS; LOCUS	PTEN/MMAC1 is a recently characterized tumor suppressor. A pseudogene derived from the human PTEN/MMAC1 phosphatase, Psi PTEN, has been reported. Recent analysis of the pseudogene revealed conflicting results about the expression of Psi PTEN. In this study, we show that the PTEN/MMAC1 pseudogene is actively transcribed in all cells and tissues examined. In some cases, pseudogene transcripts were found to represent as much as 70% of the total PTEN/MMAC1 RNA. As Psi PTEN is transcribed, there is a potential for misinterpretation of PTEN/MMAC1 mutations when RT - PCR techniques are used, as well as potential for a Psi PTEN-encoded translation product, Although we were unable to detect a pseudogene protein product in the cell lines examined, a baculovirus produced GST pseudogene fusion protein exhibited phosphatase activity comparable to wild type. The results of this study, taken together, indicate the potential complication of PTEN/MMAC1 molecular analysis caused by the expression of Psi PTEN.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Cellular Signaling, Palo Alto, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Fujii, GH (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Cellular Signaling, 901 Calif Ave, Palo Alto, CA 94304 USA.							CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Cheney IW, 1998, CANCER RES, V58, P2331; CHENG JQ, 1994, CANCER RES, V54, P5547; Dahia PLM, 1998, ONCOGENE, V16, P2403, DOI 10.1038/sj.onc.1201762; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kim SK, 1998, ONCOGENE, V16, P89, DOI 10.1038/sj.onc.1201512; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MERLO A, 1994, CANCER RES, V54, P2322; MERLO A, 1994, CANCER RES, V54, P640; MORIMOTO AM, 1998, UNPUB; MORIMOTO AM, 1999, IN PRESS ONCOGENE; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Rhei E, 1997, CANCER RES, V57, P3657; ROBINSON MA, 1993, P NATL ACAD SCI USA, V90, P2433, DOI 10.1073/pnas.90.6.2433; Rowen L, 1996, SCIENCE, V272, P1755, DOI 10.1126/science.272.5269.1755; SOLOVYEV V, 1997, ISMB, V5, P294; SPANA C, 1993, PROTEIN EXPRES PURIF, V4, P390, DOI 10.1006/prep.1993.1051; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Teng DHF, 1997, CANCER RES, V57, P5221; VANIN EF, 1985, ANNU REV GENET, V19, P253, DOI 10.1146/annurev.genet.19.1.253; Whang YE, 1998, J NATL CANCER I, V90, P859, DOI 10.1093/jnci/90.11.859; WILDE CD, 1986, CRIT REV BIOCHEM MOL, V19, P323	27	74	78	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	1999	18	9					1765	1769		10.1038/sj.onc.1202492	http://dx.doi.org/10.1038/sj.onc.1202492			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208437				2022-12-28	WOS:000079025000011
J	Rojas, JM; Subleski, M; Coque, JJR; Guerrero, C; Saez, R; Li, BQ; Lopez, E; Zarich, N; Aroca, P; Kamata, T; Santos, E				Rojas, JM; Subleski, M; Coque, JJR; Guerrero, C; Saez, R; Li, BQ; Lopez, E; Zarich, N; Aroca, P; Kamata, T; Santos, E			Isoform-specific insertion near the Grb2-binding domain modulates the intrinsic guanine nucleotide exchange activity of hSos1	ONCOGENE			English	Article						hSos1; isoforms; Ras activation; GEF activity; oocyte maturation	EPIDERMAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; ACTIVATED PROTEIN-KINASE; NIH 3T3 CELLS; SIGNAL-TRANSDUCTION; OOCYTE MATURATION; FACTOR SON; PHOSPHATIDYLINOSITOL 3-KINASE; MONOCLONAL-ANTIBODIES; XENOPUS OOCYTES	Two human hSos1 isoforms (Isf I and Isf II; Rojas et al,, Oncogene 12, 2291-2300, 1996) defined by the presence of a distinct 15 amino acid stretch in one of them, were compared biologically and biochemically using representative NIH3T3 transfectants overexpressing either one. We showed that hSos1-Isf II is significantly more effective than hSos1-Isf I to induce proliferation or malignant transformation of rodent fibroblasts when transfected alone or in conjunction with normal H-Ras (Gly12), The hSos1-Isf II-Ras cotransfectants consistently exhibited higher saturation density, lower cell-doubling times, increased focus-forming activity and higher ability to grow on semisolid medium and at low serum concentration than their hSos1-Isf I-Ras counterparts. Furthermore, the ratio of GTP/GDP bound to cellular p21(ras) was consistently higher in the hSos1-Isf II-transfected clones, both under basal and stimulated conditions. However, no significant differences were detected in vivo between Isf I- and Isf II-transfected clones regarding the amount, stability and subcellular localization of Sos1-Grb2 complex, or the level of hSos1 phosphorylation upon cellular stimulation, Interestingly, direct Ras guanine nucleotide exchange activity assays in cellular lysates showed that Isf II transfectants consistently exhibited about threefold higher activity than Isf I transfectants under basal, unstimulated conditions. Microinjection into Xenopus oocytes of purified peptides corresponding to the C-terminal region of both isoforms (encompassing the 15 amino acid insertion area and the first Grb2-binding motif) showed that only the Isf II peptide, but not its corresponding Isf I peptide, was able to induce measurable rates of meiotic maturation, and synergyzed with insulin, but not progesterone, in induction of GVBD. Our results suggest that the increased biological potency displayed by hSos1-Isf II is due to higher intrinsic guanine nucleotide exchange activity conferred upon this isoform by the 15 a.a. insertion located in proximity to its Grb2 binding region.	NCI, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, Lab Biochem Physiol, Frederick, MD 21071 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Santos, E (corresponding author), NCI, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA.		Guerrero, Carmen/F-1776-2010; Rojas, José M./AAA-3354-2021; Aroca, Pilar/P-2141-2017; Rojas, José M/D-3718-2018; Coque, Juan Jose Rubio/AAV-2049-2021	Guerrero, Carmen/0000-0002-8747-6831; Rojas, José M./0000-0002-7547-2825; Aroca, Pilar/0000-0002-7557-6931; Rojas, José M/0000-0002-5383-3482; Coque, Juan Jose Rubio/0000-0001-8221-7817; Zarich, Natasha/0000-0003-1058-6191				Aroca P, 1996, ONCOGENE, V13, P1839; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Byrne JL, 1996, ONCOGENE, V13, P2055; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; deMora JF, 1996, J BIOL CHEM, V271, P18272, DOI 10.1074/jbc.271.30.18272; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Douville E, 1997, ONCOGENE, V15, P373, DOI 10.1038/sj.onc.1201214; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; HEIDARAN MA, 1992, ONCOGENE, V7, P147; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KATZAV S, 1995, ONCOGENE, V11, P1079; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; LI BQ, 1993, P NATL ACAD SCI USA, V90, P8504, DOI 10.1073/pnas.90.18.8504; Li BQ, 1996, P NATL ACAD SCI USA, V93, P1001, DOI 10.1073/pnas.93.3.1001; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Mendelsohn Andrew R., 1994, Current Opinion in Biotechnology, V5, P482, DOI 10.1016/0958-1669(94)90061-2; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P6661, DOI 10.1128/MCB.13.11.6661; PAWSON T, 1993, CURR BIOL, V3, P4345; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Rojas JM, 1996, ONCOGENE, V12, P2291; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SORRENTINO V, 1989, ONCOGENE, V4, P215; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	56	10	11	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	1999	18	9					1651	1661		10.1038/sj.onc.1202483	http://dx.doi.org/10.1038/sj.onc.1202483			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208427				2022-12-28	WOS:000079025000001
J	Alkhalaf, M; Ganguli, G; Messaddeq, N; Le Meur, M; Wasylyk, B				Alkhalaf, M; Ganguli, G; Messaddeq, N; Le Meur, M; Wasylyk, B			MDM2 overexpression generates a skin phenotype in both wild type and p53 null mice	ONCOGENE			English	Article						cytokeratins; desquamation; differentiation; epidermis; proliferation ichthyosis vulgaris	HUMAN PAPILLOMAVIRUS TYPE-16; TRANSGENIC MICE; TARGETED EXPRESSION; TRANSCRIPTIONAL ACTIVITY; MALIGNANT PROGRESSION; CELL-DIFFERENTIATION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ENHANCER PROMOTER; TUMOR-DEVELOPMENT	The MDM2 proto-oncogene is overexpressed in human tumours and regulates the activities of the tumour suppressors p53 and pRB We created mice that overexpress MDM2 under the control of the CMV promoter. These mice did not display an increased tumour incidence, but rather a specific skin phenotype, characterized by desquamation and hyperkeratosis. Transgenic MDM2 was found to be overexpressed in the epidermis, a tissue that normally expresses high levels of MDM2. The phenotype appeared during the first week after birth and then lessened with age, closely following the level of expression of the transgene. MDM2 overexpression was associated with an increase in proliferation in the basal layer, thickening of the epidermis, altered expression of the differentiation markers cytokeratin CK14, CK10 and CK1, and a decrease in the size and the number of granules that contain products of differentiation. Transgenic mice on a p53 null background displayed similar although not identical changes, showing that the effects of MDM2 are to a certain degree p53 independent. The skin is a major site of MDM2 expression in mice, raising the possibility that MDM2 overexpression perturbs the normal pattern of MDM2 expression and inhibits differentiation of the epidermis.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wasylyk, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch Graffenstaden, France.		Indra, Gitali/G-2963-2016; Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; Arbeit JM, 1996, CANCER SURV, V26, P7; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; AUEWARAKUL P, 1994, MOL CELL BIOL, V14, P8250, DOI 10.1128/MCB.14.12.8250; BALE SJ, 1994, J INVEST DERMATOL, V102, pS49, DOI 10.1111/1523-1747.ep12388591; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bol D, 1998, MOL CARCINOGEN, V21, P2, DOI 10.1002/(SICI)1098-2744(199801)21:1<2::AID-MC2>3.3.CO;2-7; Bol DK, 1997, ONCOGENE, V14, P1725, DOI 10.1038/sj.onc.1201011; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Brown K, 1998, CURR BIOL, V8, P516, DOI 10.1016/S0960-9822(98)70203-9; BROWN K, 1995, CANCER METAST REV, V14, P113, DOI 10.1007/BF00665795; BuesoRamos CE, 1996, BREAST CANCER RES TR, V37, P179, DOI 10.1007/BF01806499; BUESORAMOS CE, 1995, LEUKEMIA LYMPHOMA, V17, P13, DOI 10.3109/10428199509051698; Byrne C, 1997, BIOESSAYS, V19, P691, DOI 10.1002/bies.950190809; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; Carroll JM, 1997, J INVEST DERMATOL, V108, P412, DOI 10.1111/1523-1747.ep12289702; CARROLL JM, 1995, CELL, V83, P957, DOI 10.1016/0092-8674(95)90211-2; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CORDONCARDO C, 1994, CANCER RES, V54, P794; Coussens LM, 1996, AM J PATHOL, V149, P1899; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Dazard JE, 1997, ONCOGENE, V14, P1123, DOI 10.1038/sj.onc.1200922; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Epstein EH, 1996, CURR OPIN GENET DEV, V6, P295, DOI 10.1016/S0959-437X(96)80005-0; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Francis Julie S., 1994, Current Opinion in Pediatrics, V6, P447, DOI 10.1097/00008480-199408000-00016; FUCHS E, 1992, P NATL ACAD SCI USA, V89, P6906, DOI 10.1073/pnas.89.15.6906; FURTH PA, 1991, NUCLEIC ACIDS RES, V19, P6205, DOI 10.1093/nar/19.22.6205; GREENHALGH DA, 1994, CELL GROWTH DIFFER, V5, P667; Haines DS, 1997, LEUKEMIA LYMPHOMA, V26, P227, DOI 10.3109/10428199709051772; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; Hall PA, 1997, CURR BIOL, V7, pR144, DOI 10.1016/S0960-9822(97)70074-5; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; HOLBROOK KA, 1989, J INVEST DERMATOL, V92, pS84, DOI 10.1111/1523-1747.ep13075079; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jones SJ, 1997, J INVEST DERMATOL, V109, P187, DOI 10.1111/1523-1747.ep12319308; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KOEDOOD M, 1995, J VIROL, V69, P2194, DOI 10.1128/JVI.69.4.2194-2207.1995; Kondo S, 1996, ONCOGENE, V13, P1773; KONDO S, 1995, ONCOGENE, V10, P2001; KOTHARY R, 1991, MECH DEVELOP, V35, P25, DOI 10.1016/0925-4773(91)90038-8; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LUNA RMD, 1995, NATURE, V378, P203; Luna RMDO, 1996, GENOMICS, V33, P352, DOI 10.1006/geno.1996.0210; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Marks DI, 1996, BRIT J HAEMATOL, V92, P890, DOI 10.1046/j.1365-2141.1996.439978.x; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MAXWELL SA, 1994, ANTICANCER RES, V14, P2541; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Momand J, 1997, J CELL BIOCHEM, V64, P343; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Neil JC, 1997, TRENDS MICROBIOL, V5, P115, DOI 10.1016/S0966-842X(96)10083-4; OLSON DC, 1993, ONCOGENE, V8, P2353; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Raskin CA, 1997, J AM ACAD DERMATOL, V36, P885, DOI 10.1016/S0190-9622(97)80266-6; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Santos M, 1997, MOL CARCINOGEN, V20, P3, DOI 10.1002/(SICI)1098-2744(199709)20:1<3::AID-MC2>3.0.CO;2-R; Schlott T, 1997, J PATHOL, V182, P54; SCHMIDT EV, 1990, MOL CELL BIOL, V10, P4406, DOI 10.1128/MCB.10.8.4406; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Wang XJ, 1998, ONCOGENE, V17, P35, DOI 10.1038/sj.onc.1201890; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WILLIAMS ML, 1992, PEDIATR DERMATOL, V9, P365, DOI 10.1111/j.1525-1470.1992.tb00632.x; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Xie W, 1998, CELL GROWTH DIFFER, V9, P313; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	88	34	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1419	1434		10.1038/sj.onc.1202448	http://dx.doi.org/10.1038/sj.onc.1202448			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050879	Bronze			2022-12-28	WOS:000078651600004
J	Arriola, EL; Rodriguez-Lopez, AM; Hickman, JA; Chresta, CM				Arriola, EL; Rodriguez-Lopez, AM; Hickman, JA; Chresta, CM			Bcl-2 overexpression results in reciprocal downregulation of Bcl-X-L and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis	ONCOGENE			English	Article						testicular tumours; apoptosis; Bcl-2; Bcl-X-L	CISPLATIN-INDUCED APOPTOSIS; ETOPOSIDE-INDUCED APOPTOSIS; CYTOCHROME-C; IN-VIVO; IMMUNOHISTOCHEMICAL ANALYSIS; CLONOGENIC SURVIVAL; UP-REGULATION; DEATH; EXPRESSION; PROTEIN	Testicular germ cell tumours are hypersentive to chemotherapy and cell lines derived from these tumours are chemosensitive in vitro. We have previously shown that these cell lines express undetectable levels of the suppressor of apoptosis Bcl-2 and relatively high levels of the apoptosis inducer Bar (Chresta et al., 1996). To determine whether the absence of Bcl-2 in these cell lines makes them highly susceptible to drug-induced apoptosis, Bcl-2 was expressed ectopically in the 833K testicular germ cell tumour cell line. Stable overexpressing clones were isolated and three clones were studied further. Surprisingly, Eel-2 overexpressing cells were sensitized to chemotherapy-induced apoptosis compared to the parental and vector control cells. Analysis of potential mechanisms of sensitization revealed there was reciprocal downregulation of the endogenously expressed Bcl-X-L in the Eel-2 overexpressing clones. Downregulation of Bcl-X-L to the same extent using antisense oligonucleotides enhanced etoposide-induced apoptosis by twofold. Our results indicate that Eel-2 and Bcl-X-L have different abilities to protect against chemotherapy-induced apoptosis in testicular germ cell tumours. In contrast to findings in some tumour cell types, Eel-2 did not act as a gatekeeper to prevent entry of p53 to the nucleus.	Univ Manchester, Sch Biol Sci, CRC, Mol & Cellular Pharmacol Res Grp, Manchester M13 9PT, Lancs, England	University of Manchester	Chresta, CM (corresponding author), Univ Manchester, Sch Biol Sci, CRC, Mol & Cellular Pharmacol Res Grp, G38 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.							Beham A, 1997, ONCOGENE, V15, P2767, DOI 10.1038/sj.onc.1201464; BERTRAND R, 1991, CANCER RES, V51, P6280; Boersma AWM, 1997, CYTOMETRY, V27, P275, DOI 10.1002/(SICI)1097-0320(19970301)27:3<275::AID-CYTO10>3.0.CO;2-Q; Burger H, 1997, INT J CANCER, V73, P592, DOI 10.1002/(SICI)1097-0215(19971114)73:4<592::AID-IJC22>3.0.CO;2-A; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chresta CM, 1996, CANCER RES, V56, P1834; Cosulich SC, 1996, CURR BIOL, V6, P997, DOI 10.1016/S0960-9822(02)00644-9; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; EINHORN LH, 1990, J CLIN ONCOL, V8, P1777, DOI 10.1200/JCO.1990.8.11.1777; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; FISHER TC, 1993, CANCER RES, V53, P3321; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Han ZY, 1996, CANCER RES, V56, P1621; HASHIMOTO H, 1995, CANCER RES, V55, P4029; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; KAMESAKI S, 1993, CANCER RES, V53, P4251; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lock RB, 1996, CANCER RES, V56, P4006; LU QL, 1993, J PATHOL, V169, P431, DOI 10.1002/path.1711690408; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SCHWARZE MMK, 1995, CANCER RES, V55, P2262; Simonian PL, 1997, BLOOD, V90, P1208, DOI 10.1182/blood.V90.3.1208.1208_1208_1216; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; Uhlmann EJ, 1998, J BIOL CHEM, V273, P17926, DOI 10.1074/jbc.273.28.17926; Walker A, 1997, CANCER RES, V57, P1939; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN DX, 1995, CANCER RES, V55, P4922; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	50	63	65	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	1999	18	7					1457	1464		10.1038/sj.onc.1202420	http://dx.doi.org/10.1038/sj.onc.1202420			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050882				2022-12-28	WOS:000078651600007
J	Galloway, AM; Spencer, CA; Anderson, CW; Allalunis-Turner, MJ				Galloway, AM; Spencer, CA; Anderson, CW; Allalunis-Turner, MJ			Differential stability of the DNA-activated protein kinase catalytic subunit mRNA in human glioma cells	ONCOGENE			English	Article						DNA-PKcs; radiation sensitivity; M059J cell line; mRNA stability; transcription rates	STRAND BREAK REPAIR; MESSENGER-RNA DECAY; NONSENSE CODONS; TRANSLATION; RADIATION; REGION; GENE; TRANSCRIPTION; SITE; KU	DNA-dependent protein kinase (DNA-PK) functions in double-strand break repair and immunoglobulin [V(D)J] recombination. We previously established a radiation-sensitive human cell line, M059J, derived from malignant glioma, which lacks the catalytic subunit (DNA-PKcs) of the DNA-PK multiprotein complex, Although previous Northern blot analysis failed to detect the DNA-PKcs transcript in these cells, we show here through quantitative studies that the transcript is present, albeit at greatly reduced ( similar to 20x) levels. Sequencing revealed no genetic alteration in either the promoter region, the kinase domain, or the 3' untranslated region of the DNA-PKcs gene to account for the reduced transcript levels. Nuclear run-on transcription assays indicated that the rate of DNA-PKcs transcription in M059J and DNA-PKcs proficient cell lines was similar, but the stability of the DNA-PKcs message in the M059J cell line was drastically ( similar to 20x) reduced. Furthermore, M059J cells lack an alternately spliced DNA-PKcs transcript that accounts for a minor (5 - 20%) proportion of the DNA-PKcs message in all other cell lines tested. Thus, alterations in DNA-PKcs mRNA stability and/or the lack of the alternate mRNA may result in the loss of DNA-PKcs activity, This finding has important implications as DNA-PKcs activity is essential to cells repairing damage induced by radiation or radiomimetric agents.	Univ Alberta, Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	University of Alberta; University of Alberta; United States Department of Energy (DOE); Brookhaven National Laboratory	Allalunis-Turner, MJ (corresponding author), Univ Alberta, Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLALUNISTURNER MJ, 1995, RADIAT RES, V144, P288, DOI 10.2307/3578948; ALLALUNISTURNER MJ, 1993, RADIAT RES, V134, P349, DOI 10.2307/3578196; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Anderson Carl W., 1994, Seminars in Cell Biology, V5, P427, DOI 10.1006/scel.1994.1050; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Anderson CW, 1996, CURR TOP MICROBIOL, V217, P91; Belasco J.G., 2012, CONTROL MESSENGER RN; BELGRADER P, 1993, P NATL ACAD SCI USA, V90, P482, DOI 10.1073/pnas.90.2.482; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; Chen P, 1996, INT J RADIAT BIOL, V69, P385, DOI 10.1080/095530096145940; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Connelly MA, 1998, GENOMICS, V47, P71, DOI 10.1006/geno.1997.5076; Connelly MA, 1996, GENE, V175, P271, DOI 10.1016/0378-1119(96)00135-7; CURATOLA AM, 1995, MOL CELL BIOL, V15, P6331; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; FALZON M, 1993, J BIOL CHEM, V268, P10546; HAGAN KW, 1995, MOL CELL BIOL, V15, P809; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HORIKOSHI T, 1992, CANCER RES, V52, P108; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Jin SF, 1997, CANCER SURV, V29, P221; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LIM SK, 1992, MOL CELL BIOL, V12, P1149, DOI 10.1128/MCB.12.3.1149; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; SIPLEY JD, 1995, P NATL ACAD SCI USA, V92, P7515, DOI 10.1073/pnas.92.16.7515; Spencer CA, 1997, J VIROL, V71, P2031, DOI 10.1128/JVI.71.3.2031-2040.1997; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; THOMPSON LH, 1995, MUTAT RES-DNA REPAIR, V337, P131, DOI 10.1016/0921-8777(95)00018-F; YUN DF, 1995, MOL CELL BIOL, V15, P1021; ZHANG SA, 1995, MOL CELL BIOL, V15, P2231	35	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1361	1368		10.1038/sj.onc.1202433	http://dx.doi.org/10.1038/sj.onc.1202433			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022818				2022-12-28	WOS:000078510900012
J	Millar, DS; Ow, KK; Paul, CL; Russell, PJ; Molloy, PL; Clark, SJ				Millar, DS; Ow, KK; Paul, CL; Russell, PJ; Molloy, PL; Clark, SJ			Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer	ONCOGENE			English	Article						DNA methylation; bisulphite genomic sequencing; GSTP1; prostate cancer	DNA METHYLATION; EXPRESSION; CELLS; PATTERNS; PROMOTER; TUMORS; OVEREXPRESSION; CARCINOGENESIS; CARCINOMAS; SEQUENCES	Glutathione-S-Transferases (GSTs) comprise a family of isoenzymes that provide protection to mammalian cells against electrophilic metabolites of carcinogens and reactive oxygen species. Previous studies have shown that the CpG-rich promoter region of the pi-class gene GSTP1 is methylated at single restriction sites in the majority of prostate cancers, In order to understand the nature of abnormal methylation of the GSTP1 gene in prostate cancer we undertook a detailed analysis of methylation at 131 CpG sites spanning the promoter and body of the gene. Our results show that DNA methylation is not confined to specific CpG sites in the promoter region of the GSTP1 gene but is extensive throughout the CpG island in prostate cancer cells. Furthermore we found that both alleles are abnormally methylated in this region. In normal prostate tissue, the entire CpG island was unmethylated, but extensive methylation was found outside the island in the body of the gene. Loss of GSTP1 expression correlated with DNA methylation of the CpG island in both prostate cancer cell lines and cancer tissues whereas methylation outside the CpG island in normal prostate tissue appeared to have no effect on gene expression.	CSIRO, Div Mol Sci, Sydney Lab, N Ryde, NSW 1670, Australia; Royal Prince Alfred Hosp, Kanematsu Labs, Camperdown, NSW 2050, Australia; Prince Wales Hosp, Oncol Res Ctr, Randwick, NSW 2031, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Sydney	Clark, SJ (corresponding author), CSIRO, Div Mol Sci, Sydney Lab, POB 184, N Ryde, NSW 1670, Australia.		Clark, Susan J/B-2272-2008; Molloy, Peter L/H-7931-2013; Russell, Pamela J/G-1685-2010; Russell, Pamela/O-8504-2019; Clark, Susan J/U-7365-2019	Clark, Susan J/0000-0001-5925-5030; Molloy, Peter L/0000-0002-7788-3417; Russell, Pamela J/0000-0002-3995-1239; Clark, Susan J/0000-0001-5925-5030				BATIST G, 1986, J BIOL CHEM, V261, P5544; Baylin SB, 1998, ADV CANCER RES, V72, P141; Clark S. J., 1997, P151; Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CLARK SJ, 1995, DNA NUCLEOPROTEIN ST, P103; Cookson MS, 1997, J UROLOGY, V157, P673, DOI 10.1016/S0022-5347(01)65248-0; COWELL IG, 1988, BIOCHEM J, V255, P79, DOI 10.1042/bj2550079; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; ISAACS WB, 1995, CANCER SURV, V23, P19; ISHIOKA C, 1991, CANCER, V67, P2560, DOI 10.1002/1097-0142(19910515)67:10<2560::AID-CNCR2820671028>3.0.CO;2-M; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Melki JR, 1998, LEUKEMIA, V12, P311, DOI 10.1038/sj.leu.2400932; Moffat GJ, 1996, J BIOL CHEM, V271, P1054, DOI 10.1074/jbc.271.2.1054; MORROW CS, 1989, GENE, V75, P3, DOI 10.1016/0378-1119(89)90377-6; Moskaluk CA, 1997, CANCER-AM CANCER SOC, V79, P1595, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1595::AID-CNCR23>3.0.CO;2-S; MULDER TPJ, 1995, CANCER RES, V55, P2696; Paul CL, 1996, BIOTECHNIQUES, V21, P126; PETERS WHM, 1990, CARCINOGENESIS, V11, P1593, DOI 10.1093/carcin/11.9.1593; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; Schmutte C, 1996, CANCER RES, V56, P2375; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; Stirzaker C, 1997, CANCER RES, V57, P2229; Stoger R, 1997, HUM MOL GENET, V6, P1791, DOI 10.1093/hmg/6.11.1791; TOMMASI S, 1993, SOMAT CELL MOLEC GEN, V19, P529, DOI 10.1007/BF01233380; TOTH M, 1990, J MOL BIOL, V214, P673, DOI 10.1016/0022-2836(90)90285-T; Wang X, 1997, CLIN CANCER RES, V3, P111; Warnecke PM, 1998, GENOMICS, V51, P182, DOI 10.1006/geno.1998.5371; Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422; Warnecke PM, 1998, DEV GENET, V22, P111, DOI 10.1002/(SICI)1520-6408(1998)22:2&lt;111::AID-DVG1&gt;3.0.CO;2-9	38	177	196	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1313	1324		10.1038/sj.onc.1202415	http://dx.doi.org/10.1038/sj.onc.1202415			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022813				2022-12-28	WOS:000078510900007
J	Kuhn, C; Muller, F; Melle, C; Nasheuer, HP; Janus, F; Deppert, W; Grosse, F				Kuhn, C; Muller, F; Melle, C; Nasheuer, HP; Janus, F; Deppert, W; Grosse, F			Surface plasmon resonance measurements reveal stable complex formation between p53 and DNA polymerase alpha	ONCOGENE			English	Article						DNA replication; DNA repair; protein-protein interactions; biomolecular interaction analysis (BIA); BIAcore	REPLICATION PROTEIN-A; SV40 T-ANTIGEN; SV40-TRANSFORMED CELLS; IN-VITRO; BINDING; DOMAINS; SUBUNIT; PRIMASE; EXPRESSION; ACTIVATION	Surface plasmon resonance measurements were used for detecting and quantifying protein-protein interactions detecting and quantifying protein-protein interactions between the tumorsuppressor protein p53, the SV40 large T antigen (T-ag), the cellular DNA polymerase alpha-primase complex (pol-prim), and the cellular single-strand DNA binding protein RPA, Highly purified p53 protein bound to immobilized T-ag with an apparent binding constant of 2 x 10(8) M-1. Binding of p53 to RPA was in the same order of magnitude with a binding constant of 4 x 10(8) M-1, when RPA was coupled to the sensor chip via its smallest subunit, and 1 x 10(8) M-1, when RPA,vas coupled via its p70 subunit, Furthermore, p53 bound human DNA polymerase a-primase complex (pol-prim) with a K-A value of 1 x 10(10) M-1. Both the p68 subunit and the p180 subunit of pol-prim could interact with p53 displaying binding constants of 2 x 10(10) M-1 and 5 x 10(9) M-1, respectively, Complex formation was also observed with a p180/p68 heterodimer, and again with a binding constant similar. Hence, there was no synergistic effect when p53 bound to higher order complexes of pol-prim. A truncated form of p53, consisting of amino acids 1-320, bound pol-prim by four orders of magnitude less efficiently, Therefore, an intact C-terminus of p53 seems to be important for efficient binding to pol-prim. It was also tried to measure complex formation between p53, pol-prim, and T-ag. However there was no evidence for the existence of a ternary complex consisting of T-ag, pol-prim, and p53.	Inst Mol Biotechnol, Abt Biochem, D-07745 Jena, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Abt Tumorvirol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Grosse, F (corresponding author), Inst Mol Biotechnol, Abt Biochem, Beutenbergstr 11, D-07745 Jena, Germany.			Melle, Christian/0000-0002-1870-9419; Nasheuer, Heinz Peter/0000-0002-9218-9079				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; Boulikas T, 1996, ANTICANCER RES, V16, P693; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; COLLINS KL, 1993, EMBO J, V12, P4555, DOI 10.1002/j.1460-2075.1993.tb06144.x; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Fortunato EA, 1998, J VIROL, V72, P2033, DOI 10.1128/JVI.72.3.2033-2039.1998; GANNON J V, 1990, New Biologist, V2, P84; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HOCHULI E, 1987, J CHROMATOGR, V411, P371, DOI 10.1016/S0021-9673(00)93988-8; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Kernohan NM, 1996, J BIOL CHEM, V271, P4954; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; Li R, 1998, MOL CELL BIOL, V18, P1296, DOI 10.1128/MCB.18.3.1296; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MOAREFI IF, 1993, J VIROL, V67, P4992, DOI 10.1128/JVI.67.8.4992-5002.1993; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; STADLBAUER F, 1994, EUR J BIOCHEM, V222, P781, DOI 10.1111/j.1432-1033.1994.tb18925.x; Stadlbauer F, 1996, MOL CELL BIOL, V16, P94; TANAKA S, 1982, J BIOL CHEM, V257, P8386; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Warbrick E, 1996, CURR BIOL, V6, P1057, DOI 10.1016/S0960-9822(02)70663-5; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0	37	31	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					769	774		10.1038/sj.onc.1202327	http://dx.doi.org/10.1038/sj.onc.1202327			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989827				2022-12-28	WOS:000078394400022
J	Blandino, G; Levine, AJ; Oren, M				Blandino, G; Levine, AJ; Oren, M			Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy	ONCOGENE			English	Article						apoptosis; mutant p53; etoposide; chemoresistance	CISPLATIN-BASED CHEMOTHERAPY; BREAST-CANCER PATIENTS; DNA-DAMAGING AGENTS; FUNCTION MUTATIONS; DRUG-RESISTANCE; GROWTH ARREST; APOPTOSIS; GENE; EXPRESSION; PROTEIN	Many tumors overexpress mutant forms of p53, A growing number of studies suggest that the nature of a p53 mutation in a cell can impact upon cellular properties, clinical responses to therapy and prognosis of a tumor. To explore the cellular basis of these observations, experiments were designed to compare the properties of cells with and without p53 mutations within the same cell population. To that end, various tumor-derived human p53 mutants,were introduced into p53-null H1299 lung adenocarcinoma cells. Clonogenic survival assays revealed that cells overexpressing the p53His175 mutant, but not the p53His273 mutant, recover preferentially from etoposide treatment, Moreover, p53His175 as well as p53His179 reduced substantially the rate of etoposide-induced apoptosis, whereas p53His273 and p53Trp248 had a much milder protective effect. In contrast, p53His175 and p53His273 exerted, very similar effects on the cellular response to cisplatin; both conferred increased resistance to low concentrations of the drug (2.5 mu g/ml), but did not protect at all against high concentrations (10 mu g/ml). Hence particular p53 mutants may confer upon tumor cells a selective survival advantage during chemotherapy, These findings define a new type of mutant p53 selective gain of function which may compromise the efficacy of cancer chemotherapy.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Weizmann Institute of Science; Princeton University	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Blandino, Giovanni/B-1137-2013	Blandino, Giovanni/0000-0002-6970-2241; Oren, Moshe/0000-0003-4311-7172	NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; BORRESEN AL, 1995, GENE CHROMOSOME CANC, V14, P71, DOI 10.1002/gcc.2870140113; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cote RJ, 1997, NATURE, V385, P123, DOI 10.1038/385123b0; DARZYNKIEWICZ Z, 1995, J CELL BIOCHEM, V58, P151, DOI 10.1002/jcb.240580204; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELROUBY S, 1993, BLOOD, V82, P3452; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; FRITSCHE M, 1993, ONCOGENE, V8, P307; GOH HS, 1995, CANCER RES, V55, P5217; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Hamada M, 1996, J CANCER RES CLIN, V122, P360, DOI 10.1007/BF01220804; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; HSIAO M, 1994, AM J PATHOL, V145, P702; KASTAN MB, 1991, CANCER RES, V51, P6304; Kremenetskaya OS, 1997, ONCOL RES, V9, P155; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MAKRIS A, 1995, LANCET, V345, P1181, DOI 10.1016/S0140-6736(95)91014-X; MATHIEU MC, 1995, LANCET, V345, P1182; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Peled A, 1996, CANCER RES, V56, P2148; Reeve JG, 1996, BRIT J CANCER, V73, P1193, DOI 10.1038/bjc.1996.230; Ribeiro JCC, 1997, INT J RADIAT BIOL, V72, P11, DOI 10.1080/095530097143491; Righetti SC, 1996, CANCER RES, V56, P689; RUSCH V, 1995, CANCER RES, V55, P5038; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; TRAUBERT H, 1996, CANCER RES, V56, P4134; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	48	363	371	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					477	485		10.1038/sj.onc.1202314	http://dx.doi.org/10.1038/sj.onc.1202314			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927204				2022-12-28	WOS:000078166500020
J	Jenkins, TD; Mueller, A; Odze, R; Shahsafaei, A; Zukerberg, LR; Kent, R; Stoner, GD; Rustgi, AK				Jenkins, TD; Mueller, A; Odze, R; Shahsafaei, A; Zukerberg, LR; Kent, R; Stoner, GD; Rustgi, AK			Cyclin D1 overexpression combined with N-nitrosomethylbenzylamine increases dysplasia and cellular proliferation in murine esophageal squamous epithelium	ONCOGENE			English	Article						cyclin D1; N-nitrosomethylbenzylamine; esophageal squamous dysplasia; transgenic mice	MOUSE SKIN CARCINOGENESIS; RAT ESOPHAGUS; HA-RAS; GENE; EXPRESSION; ONCOGENE; CANCER; MICE; P53; METHYLBENZYLNITROSAMINE	We previously described the oral-esophageal tissue-specific expression of cyclin D1 with the Epstein-Barr virus ED-L2 promoter in transgenic mice, and resulting dysplasia, Given the evidence for an interplay between environmental and genetic factors in esophageal squamous carcinogenesis, the aim of this study was tot determine the potential cooperation of the nitrosamine compound N-nitrosomethylbenzylamine (NMBA), an esophageal specific carcinogen, in the cyclin D1 transgenic mice, NMBA was first demonstrated to induce dysplasia in two strains of inbred mice, C57BL/6 and FVB/N, Subcutaneous NMBA was then administrated to wild type and transgenic mice beginning at 4 weeks of age. Mice were monitered for the duration of the study for general appearance, activity and weight, and were euthanized at 12 and 15 months. Histopathologic analysis revealed increased severity of dysplasia in cyclin D1 mice treated with NMBA compared with treated age-matched wild-type mice and untreated mice. There was also increased proliferating cell nuclear antigen (PCNA) expression in the esophagi of NMBA treated cyclin D1 mice. Taken together, these findings suggest that a genetic alteration, specifically cyclin D1 overexpression and a chemical carinogen, NMBA, may cooperate to increase the severity of esophageal squamous dysplasia, a prominent precursor to carcinoma.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Hematol Oncol Unit, Boston, MA USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA; Forsyth Dent Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Dent Med, Boston, MA 02115 USA; Ohio State Univ, Dept Prevent Med, Canc Etiol & Chemoprevent Lab, Columbus, OH 43210 USA; Ohio State Univ, Arthur James Canc Hosp & Res Inst, Columbus, OH 43210 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Forsyth Institute; Harvard University; Harvard School of Dental Medicine; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Rustgi, AK (corresponding author), Univ Penn, Div Gastroenterol, 6CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053377] Funding Source: NIH RePORTER; NIDCR NIH HHS [P01 DE12467-01A1] Funding Source: Medline; NIDDK NIH HHS [NIDDK K08, DK53377] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERT JM, 1994, J VIROL, V68, P4358; ANTRUP H, 1982, CANCER RES, V42, P1307; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARCH DH, 1986, J NATL CANCER I, V77, P1145; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; CRADDOCK VM, 1987, CARCINOGENESIS, V8, P1129, DOI 10.1093/carcin/8.8.1129; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONIGER J, 1985, P NATL ACAD SCI USA, V82, P421, DOI 10.1073/pnas.82.2.421; DRUCKREY H, 1963, NATURWISSENSCHAFTEN, V50, P100, DOI 10.1007/BF00590822; FONG LYY, 1979, INT J CANCER, V23, P679, DOI 10.1002/ijc.2910230514; Garber SA, 1997, CARCINOGENESIS, V18, P1149, DOI 10.1093/carcin/18.6.1149; HARRIS CC, 1979, CANCER RES, V39, P4401; HODGSON RM, 1982, CANCER RES, V42, P2836; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1992, CANCER RES, V52, P2980; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; LABUC GE, 1982, CANCER RES, V42, P3181; Li M H, 1986, Nutr Cancer, V8, P63, DOI 10.1080/01635588609513877; LIJINSKY W, 1982, J NATL CANCER I, V68, P681; MITSUNAGA SI, 1995, CARCINOGENESIS, V16, P1629, DOI 10.1093/carcin/16.7.1629; MORSE MA, 1993, CARCINOGENESIS, V14, P1737, DOI 10.1093/carcin/14.9.1737; Mueller A, 1997, CANCER RES, V57, P5542; Nakagawa H, 1997, ONCOGENE, V14, P1185, DOI 10.1038/sj.onc.1200937; NAKAGAWA H, 1995, CANCER-AM CANCER SOC, V76, P541, DOI 10.1002/1097-0142(19950815)76:4<541::AID-CNCR2820760402>3.0.CO;2-I; ODELEYE OE, 1992, CARCINOGENESIS, V13, P1811, DOI 10.1093/carcin/13.10.1811; ODELEYE OE, 1992, ANN NY ACAD SCI, V669, P368; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Sheyn I, 1997, HUM PATHOL, V28, P270, DOI 10.1016/S0046-8177(97)90123-4; Siglin JC, 1996, CARCINOGENESIS, V17, P1135, DOI 10.1093/carcin/17.5.1135; STERN MC, 1995, CARCINOGENESIS, V16, P1947, DOI 10.1093/carcin/16.8.1947; STINSON SF, 1978, JNCI-J NATL CANCER I, V61, P1471; VANBENTHEM J, 1992, CARCINOGENESIS, V13, P2101; WALKER EA, 1979, J NATL CANCER I, V63, P947; Wang D, 1996, CARCINOGENESIS, V17, P625, DOI 10.1093/carcin/17.4.625; Wang QS, 1996, MOL CARCINOGEN, V15, P144, DOI 10.1002/(SICI)1098-2744(199602)15:2<144::AID-MC7>3.0.CO;2-J; Wang QS, 1996, CARCINOGENESIS, V17, P1583, DOI 10.1093/carcin/17.8.1583; WANG Y, 1990, CANCER RES, V50, P1591; Yan YX, 1997, J BIOL CHEM, V272, P33181, DOI 10.1074/jbc.272.52.33181; Youssef EM, 1997, JPN J CANCER RES, V88, P18, DOI 10.1111/j.1349-7006.1997.tb00296.x	41	24	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					59	66		10.1038/sj.onc.1202296	http://dx.doi.org/10.1038/sj.onc.1202296			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926920				2022-12-28	WOS:000078166000007
J	Venugopal, R; Jaiswal, AK				Venugopal, R; Jaiswal, AK			Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes	ONCOGENE			English	Article						NF-E2 related factors; Jun; antioxidant response element; regulation of expression; detoxifying enzyme genes	GLUTATHIONE-S-TRANSFERASE; NF-KAPPA-B; NAD(P)H-QUINONE OXIDOREDUCTASE GENE; YA SUBUNIT GENE; TRANSCRIPTION FACTOR; QUINONE REDUCTASE; ACTIVATION; AP-1; FOS; OXYGEN	Antioxidant response element (ARE)-mediated expression and coordinated induction of genes encoding detoxifying enzymes is one mechanism of critical importance to cellular protection against oxidative stress. In the present report, we demonstrate that nuclear transcription factors Nrf2 and Nrf1 associate with Jun (c-Jun, Jun-B and Jun-D) proteins to upregulate ARE-mediated expression and coordinated induction of detoxifying enzymes in response to antioxidants and xenobiotics. Nrf-Jun association/heterodimerization and binding to the ARE required unknown cytosolic factor(s), Nrf2 containing one mutated leucine in its leucine zipper region was more efficient in upregulation of ARE-mediated gene expression, as compared to Nrf1 with two mutated leucines.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047466, R29GM047466] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BERGELSON S, 1994, ONCOGENE, V9, P565; CESARE DD, 1995, ONCOGENE, V11, P365; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; DELONG MJ, 1987, CARCINOGENESIS, V8, P1549, DOI 10.1093/carcin/8.10.1549; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAVREAU LV, 1993, J BIOL CHEM, V268, P19875; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; KADONAGA JT, 1991, METHOD ENZYMOL, V208, P11; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI Y, 1992, J BIOL CHEM, V267, P15097; LI Y, 1994, EUR J BIOCHEM, V226, P31, DOI 10.1111/j.1432-1033.1994.tb20023.x; Liu SX, 1996, BIOCHEMISTRY-US, V35, P11517, DOI 10.1021/bi960572p; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; MULKAHY RT, 1997, J BIOL CHEM, V272, P7445; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEBERT DW, 1994, BIOCHEM PHARMACOL, V47, P25, DOI 10.1016/0006-2952(94)90434-0; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; PRESTERA T, 1995, MOL MED, V1, P827, DOI 10.1007/BF03401897; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; SCHRECK R, 1994, METHOD ENZYMOL, V234, P151; Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2; VASLIOU V, 1995, BIOCHEM PHARMACOL, V12, P2057; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Venugopal R., 1997, OXIDATIVE STRESS SIG, P441; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; XIE T, 1995, J BIOL CHEM, V270, P6894, DOI 10.1074/jbc.270.12.6894; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	38	454	467	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	1998	17	24					3145	3156		10.1038/sj.onc.1202237	http://dx.doi.org/10.1038/sj.onc.1202237			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872330				2022-12-28	WOS:000077517400008
J	Han, JH; Modha, D; White, E				Han, JH; Modha, D; White, E			Interaction of E1B 19K with Bax is required to block Bax-induced loss of mitochondrial membrane potential and apoptosis	ONCOGENE			English	Article						Bax; E1B 19K; mitochondrial membrane potential; apoptosis	PROGRAMMED CELL-DEATH; CYTOCHROME-C; INTERMEDIATE FILAMENTS; 19-KILODALTON PROTEIN; BCL-2 FAMILY; DNA-DAMAGE; IN-VIVO; BCL-X(L); INHIBITION; INDUCTION	The Bcl-2 homologous region 3 (BH3) is sufficient fbr interaction of pro-apoptotic with anti-apoptotic Bcl-2 family members, and functional antagonism may determine whether cell survival or death is the outcome of this protein-protein interaction. To address the biological role of BH3, two Bax-Bcl2 chimeras were generated in which 13 amino acids encompassing BH3 was swapped between anti-apoptotic Bcl-2 and pro-apoptotic Bax, thereby generating Bax with BH3 of Bcl-2 (Bax-BH3Bcl2), and Bcl-2 with BH3 of Bax (Bcl2-BH3Bax). Function and binding of the chimeras was then assessed utilizing the adenoviral Bcl-2 homologue, E1B 19K, which blocks apoptosis, and interacts with Bax, but not with Bcl-2. E1B 19K did not interact with Bax-BH3Bcl2 but did interact with Bcl2-BH3Bax. Bax-BH3Bcl2 retained pro-apoptotic function, while Bcl2-BH3Bax did not exhibit either pro- or anti-apoptotic activity. Thus, BH3 of Bcl-2 encodes binding specificity but not the apoptotic propensity. E1B 19K could not block Bax-P3H3Bc12-induced apoptosis, suggesting that E1B 19K may act to antagonize pro-apoptotic proteins rather than as an effector of survival. Furthermore, Bax expression disrupted the mitochondrial membrane potential, which could be rescued by E1B 19K expression. Thus, BH3 controls the binding specificity among Bcl-2 family members, and direct interaction between pro-apoptotic and anti-apoptotic proteins is a mechanism to regulate mitochondrial membrane potential and apoptosis.	Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Rutgers State Univ, Canc Inst New Jersey, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	White, E (corresponding author), Rutgers State Univ, Ctr Adv Biotechnol & Med, 679 Hoes Lane, Piscataway, NJ 08854 USA.		White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065	NATIONAL CANCER INSTITUTE [R01CA053370, R37CA053370] Funding Source: NIH RePORTER; NCI NIH HHS [CA53370] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BOYD JM, 1995, ONCOGENE, V11, P1921; Chen G, 1996, J BIOL CHEM, V271, P24221, DOI 10.1074/jbc.271.39.24221; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Han J, 1996, MOL CELL BIOL, V16, P5857; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Kaushal GP, 1997, KIDNEY INT, V52, P438, DOI 10.1038/ki.1997.350; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Shimizu S, 1996, ONCOGENE, V13, P21; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; WHITE E, 1984, MOL CELL BIOL, V4, P2865, DOI 10.1128/MCB.4.12.2865; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	43	42	42	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	1998	17	23					2993	3005		10.1038/sj.onc.1202215	http://dx.doi.org/10.1038/sj.onc.1202215			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881701				2022-12-28	WOS:000077427800006
J	Higuchi, M; Honda, T; Proske, RJ; Yeh, ETH				Higuchi, M; Honda, T; Proske, RJ; Yeh, ETH			Regulation of reactive oxygen species-induced apoptosis and necrosis by caspase 3-like proteases	ONCOGENE			English	Article						reactive oxygen species; caspases; apoptosis; necrosis; cytochrome c	PROGRAMMED CELL-DEATH; MANGANOUS SUPEROXIDE-DISMUTASE; FAS-MEDIATED APOPTOSIS; NF-KAPPA-B; CYTOCHROME-C; U937 CELLS; THYMOCYTE APOPTOSIS; CYTO-TOXICITY; FACTOR-ALPHA; ACTIVATION	Reactive oxygen species (ROS) and caspases have been implicated as potential mediators of cell death. However, their mechanistic relationship remains to be elucidated, Here we investigated the roles of caspases in apoptosis and necrosis induced by ROS, generated by the mixture of xanthine and xanthine oxidase (X/XO), A low concentration of XO (0.025 U/ml) induced DNA fragmentation with little cellular membrane damage 3 h after treatment, suggesting the induction of apoptosis, The same treatment induced membrane blebbing, a morphological change typical of apoptosis, 15 min after treatment, A high concentration of XO (0.1 U/ml) damaged cell membranes with little concomitance of DNA fragmention, suggesting the induction of necrosis, ROS also activated caspase 3-like proteases and caspase 3 itself together with the release of cytochrome c which might be the cause of caspase activation. Apoptosis induced by low concentrations of XO and necrosis induced by high concentrations of XO was inhibited by z-DEVD-CH2F, an irreversible inhibitor of caspase 3. However, rapid induction of membrane blebbing was not inhibited by z-DEVD-CH2F. These results suggest that both apoptosis and necrosis could be induced by ROS through the activation of caspase 3-like protease; however, caspase 3 activation is not needed for ROS-induced membrane blebbing.	Univ Texas, Hlth Sci Ctr, Res Ctr Cardiovasc Dis, Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Div Mol Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Higuchi, M (corresponding author), Univ Texas, Hlth Sci Ctr, Res Ctr Cardiovasc Dis, Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA.							Barinaga M, 1996, SCIENCE, V273, P735, DOI 10.1126/science.273.5276.735; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; CHANG DJ, 1992, BIOCHEM BIOPH RES CO, V188, P538, DOI 10.1016/0006-291X(92)91089-9; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; COHEN JJ, 1984, J IMMUNOL, V132, P38; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; Eguchi Y, 1997, CANCER RES, V57, P1835; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; HIGUCHI M, 1995, J IMMUNOL METHODS, V178, P173, DOI 10.1016/0022-1759(94)00254-T; HIGUCHI M, 1992, J IMMUNOTHER, V12, P41, DOI 10.1097/00002371-199207000-00005; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; IKEBUCHI Y, 1991, J BIOL CHEM, V266, P13233; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KULL FC, 1981, CANCER RES, V41, P4885; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LYNCH RE, 1978, J BIOL CHEM, V253, P4697; MALORNI W, 1993, FEBS LETT, V327, P75, DOI 10.1016/0014-5793(93)81043-Y; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MATSUDA M, 1991, J IMMUNOL, V147, P3837; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; MAYER M, 1994, P NATL ACAD SCI USA, V91, P7496, DOI 10.1073/pnas.91.16.7496; MCCONKEY DJ, 1994, IMMUNOL REV, V142, P343, DOI 10.1111/j.1600-065X.1994.tb00896.x; McGowan AJ, 1996, FEBS LETT, V392, P299, DOI 10.1016/0014-5793(96)00838-1; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Palomba L, 1996, FEBS LETT, V390, P91, DOI 10.1016/0014-5793(96)00634-5; RUBIN R, 1984, ARCH BIOCHEM BIOPHYS, V228, P450, DOI 10.1016/0003-9861(84)90010-9; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Shimizu S, 1996, ONCOGENE, V12, P2045; Tsang SY, 1996, BIOCHEM J, V317, P13, DOI 10.1042/bj3170013; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; WONG GHW, 1995, BBA-MOL BASIS DIS, V1271, P205, DOI 10.1016/0925-4439(95)00029-4; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	42	173	174	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2753	2760		10.1038/sj.onc.1202211	http://dx.doi.org/10.1038/sj.onc.1202211			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840939				2022-12-28	WOS:000077146700008
J	Cayrol, C; Ducommun, B				Cayrol, C; Ducommun, B			Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21	ONCOGENE			English	Article						cyclin-dependent kinases; p21Cip1; PCNA; degradation	S-PHASE; INHIBITOR; P27(KIP1); PROTEIN; PATHWAY; G(1); PHOSPHORYLATION; CELLS; PROGRESSION; RADIATION	The cyclin-dependent kinase (CDK) inhibitor p21(Cip1/Waf1) plays an essential role in the control of cell proliferation by modulating the activity of cyclin/CDK complexes in response to various intracellular or extracellular signals. Small variations in p21 expression levels may determine whether it acts as an inhibitor or an assembly factor for cyclin/CDK complexes. It is therefore critical to better characterize the mechanisms regulating p21 abundance. Here, we show, using a tetracycline-regulated system in p53-deficient DLD-1 human colon cancer cells, that p21 protein levels and stability are regulated by the proteasome-dependent degradation pathway and by association with its partners, CDKs and PCNA, A p21 mutant deficient for interaction with CDKs, p21(CDK-), displayed an enhanced stability and greatly reduced sensitivity to proteasome-mediated proteolysis, indicating that association with cyclin/CDK complexes may trigger p21 degradation. In contrast, a p21 mutant impaired in the interaction with PCNA, p21(PCNA-), exhibited a decreased stability, suggesting that association with PCNA protects p21 from proteasome-dependent degradation. Furthermore, the abundance of p21 itself, in addition to protein-protein interactions, may also modulate p21 stability since we found that high levels of p21 expression overcome proteasome-dependent regulation of p21 accumulation.	Univ Toulouse 3, CNRS, IPBS, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Ducommun, B (corresponding author), Univ Toulouse 3, CNRS, IPBS, 205 Route Narbonne, F-31077 Toulouse, France.		DUCOMMUN, Bernard/B-3208-2008; CAYROL, Corinne/C-2106-2011	CAYROL, Corinne/0000-0002-7813-4397; DUCOMMUN, Bernard/0000-0002-7126-8368				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fernandes ER, 1998, MOL CELL BIOL, V18, P459, DOI 10.1128/MCB.18.1.459; GOUBIN F, 1995, ONCOGENE, V10, P2281; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Henchoz S, 1997, GENE DEV, V11, P3046, DOI 10.1101/gad.11.22.3046; Hirai A, 1997, J BIOL CHEM, V272, P13; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	34	124	126	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2437	2444		10.1038/sj.onc.1202189	http://dx.doi.org/10.1038/sj.onc.1202189			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824154				2022-12-28	WOS:000076927300003
J	Liu, ML; Von Lintig, FC; Liyanage, M; Shibata, MA; Jorcyk, CL; Ried, T; Boss, GR; Green, JE				Liu, ML; Von Lintig, FC; Liyanage, M; Shibata, MA; Jorcyk, CL; Ried, T; Boss, GR; Green, JE			Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice	ONCOGENE			English	Article						CGH; Ki-ras; gene amplification; MAP kinase; mammary gland tumor; transgenic mice; Ras-bound GTP and GDP	LARGE T-ANTIGEN; HUMAN-BREAST CARCINOMAS; C-MYC; ONCOGENE AMPLIFICATION; PROTO-ONCOGENE; GENE; CELLS; EXPRESSION; CANCER; TUMORIGENESIS	We have previously documented that transgenic mice expressing SV40 Tag regulated by the rat prostatic steroid-binding protein C3(1) 5'-flanking region display multistage mammary tumorigenesis. To delineate genetic changes associated with mammary tumor progression, comparative genomic hybridization (CGH) was performed. CGH revealed a consistent gain of the telomeric region of chromosome 6, This region contains the Ki-ras proto-oncogene, Analyses of genomic DNA by Southern blot demonstrated up to 40-fold amplification of the Ki-ras gene. Ki-ras amplification was detected in 12, 46 and 68% of tumors from 4, 5 and 6 month old mice, respectively, whereas no amplifications were found in any preneoplastic mammary tissues. Tumors bearing Ki-ras gene amplification exhibited high levels of Ki-ras RNA and protein, The over-expressed Ki-Ras protein in these tumors appeared functionally active as indicated by the elevated MAP kinase activity, These data demonstrate that while Ki-ras amplification might not be an early event, there is a strong association between Ki-ras amplification and over-expression and mammary tumor progression in this model. This study also shows that CGH is a powerful and useful technique for identifying chromosomal copy number changes during tumor progression, and that this model may provide a predictable in vivo system for studying gene amplification.	NCI, Div Basic Sci, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; NIH, Natl Human Genome Res Inst, Bethesda, MD USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of California System; University of California San Diego	Green, JE (corresponding author), NCI, Div Basic Sci, Lab Cell Regulat & Carcinogenesis, Bldg 41 Room C619, Bethesda, MD 20892 USA.		Shibata, Masa-Aki/L-1624-2019	Shibata, Masa-Aki/0000-0002-3350-7305; Boss, Gerry/0000-0002-9758-8714				ALDAZ CM, 1993, CANCER RES, V53, P5339; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CHRISTOFORI G, 1994, SEMIN CANCER BIOL, V5, P3; CZERNIAK B, 1989, CANCER, V63, P2008, DOI 10.1002/1097-0142(19890515)63:10<2008::AID-CNCR2820631024>3.0.CO;2-D; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GARCIA I, 1989, CANCER RES, V49, P6675; Guha A, 1996, ONCOGENE, V12, P507; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; Jenkins RB, 1997, CANCER RES, V57, P524; Jones KA, 1995, CANCER SURV, V25, P315; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MATIN A, 1993, CELL GROWTH DIFFER, V4, P1051; PROSPERI MT, 1990, CANCER LETT, V51, P169, DOI 10.1016/0304-3835(90)90053-Z; RIED T, 1995, CANCER RES, V55, P5415; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; SHEKHAR PVM, 1994, INVAS METAST, V14, P27; Shibata MA, 1996, CANCER RES, V56, P2998; Shibata MA, 1996, CANCER RES, V56, P4894; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; THEILLET C, 1986, CANCER RES, V46, P4776; VARLEY JM, 1987, ONCOGENE, V1, P423; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	33	38	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2403	2411		10.1038/sj.onc.1202456	http://dx.doi.org/10.1038/sj.onc.1202456			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811472				2022-12-28	WOS:000076723300015
J	Webb, CP; Taylor, GA; Jeffers, M; Fiscella, M; Oskarsson, M; Resau, JH; Woude, GFV				Webb, CP; Taylor, GA; Jeffers, M; Fiscella, M; Oskarsson, M; Resau, JH; Woude, GFV			Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis	ONCOGENE			English	Article						Ras; Met; HGF/SF; tumorigenesis; metastasis	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; PROTOONCOGENE PRODUCT; ONCOGENE ACTIVATION; FACTOR RECEPTOR; NIH/3T3 CELLS; HUMAN CANCER; EXPRESSION; TRANSFORMATION; TUMORIGENICITY	Aberrations in Met-hepatocyte growth factor/scatter factor (HGF/SF) signaling have been implicated in the acquisition of tumorigenic and metastatic phenotypes, Here we show that murine NIH3T3 and C127 cells transformed by the Ras oncogene overexpress the Met receptor, resulting in enhanced HGF/SF-mediated responses in vitro including invasion through basement membrane. Accompanying the increase in Met in ras-transformed NIH3T3 cells, there is a decrease in endogenous HGF/SF expression as previously observed in cells exogenously overexpressing Met. However, subcutaneously grown tumors and experimental lung metastases derived from these cells express significantly higher levels of endogenous HGF/SF together with high levels of Met, These results suggest Met-HGF/SF signaling enhances tumor growth and metastasis of Ras-transformed NIH3T3 cells.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Woude, GFV (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, POB B, Frederick, MD 21702 USA.		Webb, Craig/I-8123-2012		OFFICE OF THE DIRECTOR, NCI [N01CO046000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-46000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAIR DG, 1980, P NATL ACAD SCI-BIOL, V77, P3504, DOI 10.1073/pnas.77.6.3504; BONDY GP, 1985, CANCER RES, V45, P6005; BOS JL, 1989, CANCER RES, V49, P4682; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; GALANG CK, 1994, ONCOGENE, V9, P2913; Gambarotta G, 1996, ONCOGENE, V13, P1911; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GREIG RG, 1985, P NATL ACAD SCI USA, V82, P3698, DOI 10.1073/pnas.82.11.3698; GUNNING P, 1983, MOL CELL BIOL, V3, P1985, DOI 10.1128/MCB.3.11.1985; Ivan M, 1997, ONCOGENE, V14, P2417, DOI 10.1038/sj.onc.1201083; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jeffers M, 1996, ONCOGENE, V13, P853; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NAKAMURA T, 1991, Progress in Growth Factor Research, V3, P67, DOI 10.1016/0955-2235(91)90014-U; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1995, CANCER RES, V55, P1963; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	31	66	70	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2019	2025		10.1038/sj.onc.1202135	http://dx.doi.org/10.1038/sj.onc.1202135			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798673				2022-12-28	WOS:000076540900001
J	Sidoti-de Fraisse, C; Rincheval, V; Risler, Y; Mignotte, B; Vayssiere, JL				Sidoti-de Fraisse, C; Rincheval, V; Risler, Y; Mignotte, B; Vayssiere, JL			TNF-alpha activates at least two apoptotic signaling cascades	ONCOGENE			English	Article						apoptosis; caspase; mitochondria; ROS	TUMOR-NECROSIS-FACTOR; PROGRAMMED CELL-DEATH; NF-KAPPA-B; MITOCHONDRIAL RESPIRATORY-CHAIN; CYTOCHROME-C; SUPEROXIDE-DISMUTASE; MEDIATED APOPTOSIS; REDOX REGULATION; NEURONAL DEATH; BCL-2	Apoptosis, the process whereby cells activate an intrinsic death program, can be induced in HeLa cells by TNF-alpha treatment. The aims of the present study were (i) to examine the precise role and the origin of Reactive Oxygen Species (ROS) in the TNF-alpha-induced programmed cell death, (ii) to characterize and order the morphological and mitochondrial changes associated with this process and (iii) to link these events with the activation of caspases, Analyses were performed on TNF-alpha-treated cells in the presence of an anti-oxidant, or of a general caspase inhibitor, To assess the role of mitochondria in the cell death signal transduction, these studies were also realized on HeLa-variant cell lines lacking functional mitochondrial respiratory chain. We show that at least two separate signaling cascades, both mediated by Z-VAD-sensitive caspase(s), contribute to the TNF-alpha-induced apoptosis of HeLa cells, One signaling pathway involves an early mitochondria-dependent ROS production, the other being ROS-independent.	CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France; Univ Versailles St Quentin Yvelines, F-78035 Versailles, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	Vayssiere, JL (corresponding author), CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France.		Mignotte, Bernard/A-3499-2009	Mignotte, Bernard/0000-0002-8512-8518				Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; Bojes HK, 1997, BIOCHEM J, V325, P315, DOI 10.1042/bj3250315; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FranceLanord V, 1997, J NEUROCHEM, V69, P1612; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GAMEN S, 1995, FEBS LETT, V376, P15, DOI 10.1016/0014-5793(95)01236-1; Golstein P, 1997, SCIENCE, V275, P1081, DOI 10.1126/science.275.5303.1081; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HSU H, 1995, CELL, V8145, P495; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; Marchetti P, 1996, CANCER RES, V56, P2033; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; MAYER M, 1994, P NATL ACAD SCI USA, V91, P7496, DOI 10.1073/pnas.91.16.7496; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Mirkovic N, 1997, ONCOGENE, V15, P1461, DOI 10.1038/sj.onc.1201310; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; ODONNELL VB, 1995, BIOCHEM J, V310, P133, DOI 10.1042/bj3100133; PACKER MA, 1994, FEBS LETT, V345, P237, DOI 10.1016/0014-5793(94)00461-7; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; SATO N, 1995, J IMMUNOL, V154, P3194; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SUSIN SA, 1996, J EXP MED, V184, P1; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	73	126	128	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1639	1651		10.1038/sj.onc.1202094	http://dx.doi.org/10.1038/sj.onc.1202094			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796693	Green Published			2022-12-28	WOS:000076200100002
J	Niederreither, K; Harbers, M; Chambon, P; Dolle, P				Niederreither, K; Harbers, M; Chambon, P; Dolle, P			Expression of T: G mismatch-specific thymidine-DNA glycosylase and DNA methyl transferase genes during development and tumorigenesis	ONCOGENE			English	Article						in situ hybridization; DNA repair; mouse mammary tumor virus; p53; transgenic mice	SIGNALING PATHWAY; P53 GENE; METHYLTRANSFERASE; CANCER; CELLS; MICE; TUMORS; HYPERMETHYLATION; HYPOMETHYLATION; PROGRESSION	In situ hybridization was used to characterize the expression pattern of the T:G mismatch-specific thymidine-DNA glycosylase (TDG) gene, encoding a DNA repair enzyme which corrects G:T mismatches that result from the hydrolytic deamination of 5-methyl cytosines, TDG transcripts were uniformly and ubiquitously expressed from 7.5-13.5 days post-coitum, but were then markedly enriched in specific tissues of the developing fetus. At 14.5 gestational days, TDG was strongly expressed in the developing nervous system, thymus, lung, liver, kidney and intestine, At later stages, high levels of expression were detected in the thymus, brain, nasal epithelium and within proliferating regions of the intestine, skin, kidney, teeth and bone, This pattern of expression strongly correlated with those of the methyl transferase (MTase) gene, coding for the enzyme which specifically methylates CpG dinucleotides, and the p53 tumour suppressor gene. However, TDG and MTase were differentially expressed during maturation of the male and female germline, We also report that tumors occuring in mice which overexpress MMTV-v-Ha-ras or MMTV-c-myc transgenes or mice heterozygous for p53 gene disruption, all show elevated TDG and MTase expression specific to the transformed tissue.	ULP, Coll France, INSERM, CNRS,Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Dolle, P (corresponding author), ULP, Coll France, INSERM, CNRS,Inst Genet & Biol Mol & Cellulaire, BP 163,CU Strasbourg, F-67404 Illkirch Graffenstaden, France.		Dolle, Pascal/A-8037-2010	Dolle, Pascal/0000-0002-9294-9090; Harbers, Matthias/0000-0002-5613-7220				Ahmad I, 1996, CRIT REV BIOCHEM MOL, V31, P361, DOI 10.3109/10409239609108722; ALCIVAR AA, 1992, BIOL REPROD, V46, P201, DOI 10.1095/biolreprod46.2.201; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BENOIT G, 1994, BIOL REPROD, V50, P1312, DOI 10.1095/biolreprod50.6.1312; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CARLSON LL, 1992, GENE DEV, V6, P2536, DOI 10.1101/gad.6.12b.2536; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Heby O, 1995, INT J DEV BIOL, V39, P737; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JacksonGrusby L, 1996, SEMIN CANCER BIOL, V7, P261, DOI 10.1006/scbi.1996.0034; Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103; Jones PA, 1996, CANCER RES, V56, P2463; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; Koken MHM, 1996, DEV BIOL, V173, P119, DOI 10.1006/dbio.1996.0011; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MAKOS M, 1993, CANCER RES, V53, P2715; MAKOS M, 1993, CANCER RES, V53, P2719; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Niederreither K, 1998, METH MOL B, V89, P247; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Pfeifer GP, 1997, BBA-REV CANCER, V1333, pM1, DOI 10.1016/S0304-419X(97)00004-8; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; Robertson KD, 1997, AM J HUM GENET, V61, P1220, DOI 10.1086/301658; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; SCHMID P, 1991, DEVELOPMENT, V113, P857; SHEN JC, 1992, CELL, V71, P1073, DOI 10.1016/S0092-8674(05)80057-1; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SZYF M, 1991, J BIOL CHEM, V266, P10027; TORNALETTI S, 1995, ONCOGENE, V10, P1493; WALTER CA, 1994, SOMAT CELL MOLEC GEN, V20, P451, DOI 10.1007/BF02255837; WIND N, 1995, CELL, V82, P321; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; YEBRA MJ, 1995, BIOCHEMISTRY-US, V34, P14752, DOI 10.1021/bi00045a016	43	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 24	1998	17	12					1577	1585		10.1038/sj.onc.1202072	http://dx.doi.org/10.1038/sj.onc.1202072			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794235				2022-12-28	WOS:000076089900010
J	Kon, A; Vindevoghel, L; Kouba, DJ; Fujimura, Y; Uitto, J; Mauviel, A				Kon, A; Vindevoghel, L; Kouba, DJ; Fujimura, Y; Uitto, J; Mauviel, A			Cooperation between SMAD and NF-kappa B in growth factor regulated type VII collagen gene expression	ONCOGENE			English	Article						SMAD; NF-kappa B; TGF-beta; TNF-alpha; transcription; promoter	HUMAN DERMAL FIBROBLASTS; NECROSIS-FACTOR-ALPHA; FACTOR-BETA; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; DNA-BINDING; C-REL; PROTEINS; KERATINOCYTES; ACTIVATION	We have previously demonstrated that transforming growth factor-beta (TGF-beta) and pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) or interteukin-1 beta, synergistically enhance the expression of type VII collagen gene (COL7A1) in human dermal fibroblasts in culture (Mauviel rt nl., 1994), Recently, we identified a SMAD-containing complex, rapidly induced by TGF-beta and binding the region [-496/-444] of the COL7A1 promoter, responsible for COL7A1 gene transactivation (Vindevoghel rt al., 1998a), In this report, we demonstrate that TGF-beta and TNF-alpha response elements are distinct entities within the COL7A1 promoter. In particular, we demonstrate that the TNF-alpha effect is mediated by NF-kappa B1/RelA (p50/p65) and RelA/RelA (p65/p65) NF-kappa B complexes binding the TNF-alpha response element (TaRE) located in the region [-252/-230], with RelA acting as the transcriptional activator, Finally, we provide definitive evidence for the role of both TGF-beta and TNF-alpha response elements as enhancer sequences, functioning in the contest of a heterologous promoter in an additive manner in response to TGF-beta and TNF-alpha, This study provides the first identification of a functional interaction between the two immediate-early transcription factors, SMAD and NF-kappa B, to activate the expression of an extracellular matrix-related gene, COL7Al.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Jefferson Inst Mol Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Allegheny Univ Hlth Sci, Dept Human Genet, Philadelphia, PA 19102 USA	Jefferson University; Jefferson University; Jefferson University; Jefferson University; Drexel University	Mauviel, A (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA.		MAUVIEL, Alain/F-6251-2013	Mauviel, Alain/0000-0002-0438-2793	NIAMS NIH HHS [R29-AR43751, R01-AR41439, T32-AR07651] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041439, R29AR043751] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alevizopoulos A, 1996, J BIOL CHEM, V271, P29672, DOI 10.1074/jbc.271.47.29672; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; Chen Y.Q., 1994, J GERIATR DERMATOL, V2, P163; CHEN YQ, 1994, J INVEST DERMATOL, V102, P205, DOI 10.1111/1523-1747.ep12371763; CHRISTIANO AM, 1996, CURR OPIN DERMATOL, V3, P225; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Helenius M, 1996, BIOCHEM J, V318, P603, DOI 10.1042/bj3180603; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; IWASAKI T, 1993, BIOCHEM BIOPH RES CO, V193, P604, DOI 10.1006/bbrc.1993.1667; Kouba DJ, 1997, J INVEST DERMATOL, V108, P292; LANOIX J, 1994, ONCOGENE, V9, P841; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; MAUVIEL A, 1993, WOUNDS, V5, P137; MAUVIEL A, 1994, J BIOL CHEM, V269, P25; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Sambrook J., 2002, MOL CLONING LAB MANU; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; Trebilcock GU, 1996, GERONTOLOGY, V42, P137, DOI 10.1159/000213785; UITTO J, 1998, PRINCIPLES MOL MED, P729; VARGA J, 1987, BIOCHEM J, V247, P597, DOI 10.1042/bj2470597; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Vindevoghel L, 1997, J BIOL CHEM, V272, P10196; VINDEVOGHEL L, 1998, IN PRESS P NATL ACAD; WOODLEY DT, 1990, JAMA-J AM MED ASSOC, V263, P3057, DOI 10.1001/jama.263.22.3057	33	54	55	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1837	1844		10.1038/sj.onc.1202495	http://dx.doi.org/10.1038/sj.onc.1202495			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086338				2022-12-28	WOS:000079090000007
J	Kessler, R; Zacharova-Albinger, A; Laursen, NB; Kalousek, M; Klemenz, R				Kessler, R; Zacharova-Albinger, A; Laursen, NB; Kalousek, M; Klemenz, R			Attenuated expression of the serum responsive T1 gene in ras transformed fibroblasts due to the inhibition of c-fos gene activity	ONCOGENE			English	Article						AP-1; fos; fra; T1; ras; transformation; serum induction	GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; H-RAS; INTERLEUKIN-1 RECEPTOR; CELL-TRANSFORMATION; SIGNAL-TRANSDUCTION; MEDIATED INDUCTION; BINDING-PROTEINS; MAMMALIAN-CELLS; AP-1 ACTIVITY	The T1 gene encodes a protein, which shares homology with the IL-1 receptors, In fibroblasts, T1 is induced by growth factors and in response to the onset of oncogene expression. The c-fos gene is transiently activated in these situations and was shown to be the major mediator of T1 gene induction, In contrast, the sustained expression of a ras oncogene in NIH3T3 cells resulted in the downregulation of basal T1 gene activity and the attenuation of T1 gene induction in response to mitogenic signals, Likewise, the immediate early genes encoding c-Fos, FosB, and Fra-2 are repressed in these cells. T1 gene repression could be overcome by the forced expression of c-fos in ras transformed fibroblasts, Thus, the lack of c-fos gene expression is the likely cause for ns mediated T1 gene repression. Fra-1, in contrast to the other three members of the Fos family, is permanently synthesized in high amounts in ms transformed NIH3T3 fibroblasts, We show that AP-1, which is abundant in these cells throughout the whole cell cycle, consists predominantly of Fra-1/c-Jun and Fra1/JunD heterodimers, We provide evidence that Fra1/c-Jun heterodimers are responsible for the repression of c-fos gene induction following serum stimulation, The introduction of a dominant negative version of c-Jun into rns transformed fibroblasts was able to rescue c-fos gene induction in response to serum stimulation, further demonstrating that AP-1 is indeed involved in c-fos gene repression, We conclude that oncogenic ms mediates the activation of the fra-1 gene which results in elevated AP-1 activity throughout the cell cycle. Fra-1 containing AP-1 complexes repress the c-fos and possibly other immediate early genes thereby preventing the induction of certain delayed early genes such as the T1 gene in response to mitogenic stimulation.	Univ Zurich Hosp, Dept Pathol, Div Canc Res, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Klemenz, R (corresponding author), Univ Zurich Hosp, Dept Pathol, Div Canc Res, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Angel P. E., 1994, FOS JUN FAMILIES TRA; BAR SD, 1986, SCIENCE, V233, P1061; Battista S, 1998, ONCOGENE, V17, P377, DOI 10.1038/sj.onc.1201953; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; BRASELMANN S, 1992, J CELL SCI, P97; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; Chen CY, 1996, MOL CELL BIOL, V16, P6582; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERAMISCO JR, 1985, NATURE, V314, P639, DOI 10.1038/314639a0; Foulkes, 1991, HORMONAL CONTROL REG, P257; Gachter T, 1996, J BIOL CHEM, V271, P124; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GROSKOPF JC, 1994, MOL CELL BIOL, V14, P6013, DOI 10.1128/MCB.14.9.6013; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HAGENBUCHLE O, 1992, NUCLEIC ACIDS RES, V20, P3555, DOI 10.1093/nar/20.14.3555; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HINO O, 1995, J CANCER RES CLIN, V121, P602, DOI 10.1007/BF01197777; ITO E, 1990, ONCOGENE, V5, P1755; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; KALOUSEK MB, 1994, J BIOL CHEM, V269, P6866; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; Kessler R, 1997, BIOL CHEM, V378, P657; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Laursen NB, 1998, ONCOGENE, V16, P575, DOI 10.1038/sj.onc.1201522; LEVIN WJ, 1995, ONCOGENE, V11, P1261; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MORITZ D, 1998, IN PRESS J IMMUNOL; Moritz DR, 1998, HYBRIDOMA, V17, P107, DOI 10.1089/hyb.1998.17.107; NOSE K, 1989, MOL CARCINOGEN, V2, P208, DOI 10.1002/mc.2940020407; Okimoto T, 1996, ONCOGENE, V12, P1625; OSEIFRIMPONG J, 1994, MOL CARCINOGEN, V10, P72, DOI 10.1002/mc.2940100204; Rosl F, 1997, J VIROL, V71, P362; ROSSLER U, 1993, ONCOGENE, V8, P609; SANTOS E, 1984, FED PROC, V43, P2280; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUERMANN M, 1993, ONCOGENE, V8, P2781; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; SUZUKI H, 1989, EXP CELL RES, V184, P524, DOI 10.1016/0014-4827(89)90350-9; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; TOMINAGA S, 1989, FEBS LETT, V258, P301, DOI 10.1016/0014-5793(89)81679-5; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TRUB T, 1994, P NATL ACAD SCI USA, V91, P3896, DOI 10.1073/pnas.91.9.3896; Urakami S, 1997, BIOCHEM BIOPH RES CO, V241, P24, DOI 10.1006/bbrc.1997.7731; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; WERENSKIOLD AK, 1989, MOL CELL BIOL, V9, P5207, DOI 10.1128/MCB.9.11.5207; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YAMITHEZI A, 1994, ONCOGENE, V9, P1065; YANAGISAWA K, 1992, FEBS LETT, V302, P51, DOI 10.1016/0014-5793(92)80282-L; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	77	14	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	1999	18	9					1733	1744		10.1038/sj.onc.1202484	http://dx.doi.org/10.1038/sj.onc.1202484			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208434				2022-12-28	WOS:000079025000008
J	Sakisaka, T; Nakanishi, H; Takahashi, K; Mandai, K; Miyahara, M; Satoh, A; Takaishi, K; Takai, Y				Sakisaka, T; Nakanishi, H; Takahashi, K; Mandai, K; Miyahara, M; Satoh, A; Takaishi, K; Takai, Y			Different behavior of l-afadin and Neurabin-II during the formation and destruction of cell-cell adherens junction	ONCOGENE			English	Article						1-afadin; Neurabin-II; ZO-1; E-cadherin; cell-cell adherens junction	FILAMENT-BINDING PROTEIN; EPITHELIAL-CELLS; TIGHT JUNCTIONS; CYTOPLASMIC DOMAIN; ADHESION COMPLEX; CDNA CLONING; E-CADHERIN; ACTIN; CATENIN; ZO-1	We have recently isolated two novel actin filament-binding proteins, l-afadin and neurabin-II and shown that they are localized at cell-cell adherens junction (AJ) in epithelial cells. We found here that l-afadin, neurabin-II, ZO-1, and E-cadherin showed similar and different behavior during the formation and destruction of cell-cell AJ in MDCK cells. In MDCK cells, the accumulation of both l-afadin and E-cadherin, but not that of ZO-1, changed in parallel depending on Rac small G protein activity. Dissociation of MDCK cells by culturing the cells at 2 mu M Ca2+ caused rapid endocytosis of E-cadherin, but not that of l-afadin or ZO-1, Addition of phorbol 12-myristate 13-acetate to these dissociated cells formed a tight junction-like structure where ZO-1 and l-afadin, but not neurabin-II or E-cadherin, accumulated. We furthermore found that, in nonepithelial EL cells, which expressed E-cadherin and attached to each other, l-afadin, neurabin-II, ZO-1 and E-cadherin were all localized at AJ. In cadherin-deficient L cells, l-afadin was mainly localized at cell-cell contact sites, but ZO-1 was mainly localized at the tip area of cell processes. Neurabin-II did not accumulate at the plasma membrane area. Neither l-afadin nor neurabin-II significantly interacted with alpha-, beta-catenin, E-cadherin, ZO-1 or occludin.	Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan	Osaka University; Japan Science & Technology Agency (JST)	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan.			Mandai, Kenji/0000-0002-0115-6635; Nakanishi, Hiroyuki/0000-0002-9765-0266				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bretscher A, 1993, CURR OPIN CELL BIOL, V5, P653, DOI 10.1016/0955-0674(93)90136-E; CIMINO G, 1991, CANCER RES, V51, P6712; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; ITOH M, 1991, J CELL BIOL, V115, P1449, DOI 10.1083/jcb.115.5.1449; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Papkoff J, 1997, J BIOL CHEM, V272, P4536; PRASAD R, 1993, CANCER RES, V53, P5624; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785	36	77	77	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1609	1617		10.1038/sj.onc.1202451	http://dx.doi.org/10.1038/sj.onc.1202451			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102631				2022-12-28	WOS:000078770700011
J	Koreth, J; Bakkenist, CJ; Larin, Z; Hunt, NCA; James, MR; McGee, JO				Koreth, J; Bakkenist, CJ; Larin, Z; Hunt, NCA; James, MR; McGee, JO			11q23.1 and 11q25-qter YACs suppress tumour growth in vivo	ONCOGENE			English	Article						tumour suppressor gene; YAC functional complementation; chromosome 11q; cancer; A9 cells	BREAST-CANCER; OVARIAN-CANCER; ATAXIA-TELANGIECTASIA; CERVICAL-CARCINOMA; MALIGNANT-MELANOMA; CHROMOSOME 11Q23; HUMAN GENE; HETEROZYGOSITY; REGION; CELLS	Frequent allelic deletion at chromosome 11q22-q23.1 has been described in breast cancer and a number of other malignancies, suggesting putative tumour suppressor gene(s) within the similar to 8 Mb deleted region. In addition, we recently described another locus, at the 11q25-qter region, frequently deleted in breast cancer, suggesting additional tumour suppressor gene(s) in this similar to 2 Mb deleted region. An 11q YAC contig was accessed and three YACs, one containing the candidate gene A TM at 11q23.1, and two contiguous YACs (overlapping for similar to 400-600kb) overlying most of the 11q25 deleted region, were retrofitted with a G418 resistance marker and transfected into murine A9 fibrosarcoma cells, Selected A9 transfectant clones (and control untransfected and 'irrelevant' alphoid YAC transfectant A9 clones) were assayed for in vivo tumorigenicity in athymic female Balb c-nu/nu mice. All the 11q YAC transfectant clones demonstrated significant tumour suppression compared to the control untransfected and 'irrelevant' YAC transfected A9 cells. These results define two discrete tumour suppressor loci on chromosome 11q by functional complementation, one to a similar to 1.2 Mb region on 11q23.1 (containing the ATM locus) and another to a similar to 400-600 kb subterminal region on 11q25-qter.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Pathol & Bacteriol, Oxford OX3 9DU, England; Univ Oxford, John Radcliffe Hosp, Wellcome Trust Ctr Human Genet, Oxford OX3 9DU, England; Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England	University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford	McGee, JO (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Pathol & Bacteriol, Oxford OX3 9DU, England.		Monaco, Zoia L/C-5762-2011					Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Baffa R, 1996, CANCER RES, V56, P268; BETHWAITE PB, 1995, BRIT J CANCER, V71, P814, DOI 10.1038/bjc.1995.157; CARTER SL, 1994, CANCER RES, V54, P6270; Davis M, 1996, CANCER RES, V56, P741; Dohner H, 1997, BLOOD, V89, P2516, DOI 10.1182/blood.V89.7.2516; EASTON DF, 1994, INT J RADIAT BIOL, V66, P6270; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; FOULKES WD, 1993, BRIT J CANCER, V67, P268, DOI 10.1038/bjc.1993.51; Gabra H, 1996, CANCER RES, V56, P950; GABRA H, 1995, BRIT J CANCER, V72, P367, DOI 10.1038/bjc.1995.340; Gioeli D, 1997, CANCER RES, V57, P1157; HAMPTON GM, 1994, CANCER RES, V54, P4586; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HERBST RA, 1995, CANCER RES, V55, P2494; HIRST MC, 1991, NUCLEIC ACIDS RES, V19, P3283, DOI 10.1093/nar/19.12.3283; Horikawa I, 1995, CANCER GENET CYTOGEN, V85, P97, DOI 10.1016/0165-4608(95)00147-6; HUXLEY C, 1991, GENOMICS, V9, P742, DOI 10.1016/0888-7543(91)90369-P; IIZUKA M, GENES CHROMOSOMES CA, V13, P40; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; KELDYSH PL, 1993, GENE CHROMOSOME CANC, V6, P45, DOI 10.1002/gcc.2870060109; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; Koreth J, 1997, ONCOGENE, V14, P431, DOI 10.1038/sj.onc.1200847; KORETH J, 1995, J PATHOL, V176, P11, DOI 10.1002/path.1711760104; KORETH J, 1998, IN PRESS J PATHOL; Laake K, 1997, GENE CHROMOSOME CANC, V18, P175, DOI 10.1002/(SICI)1098-2264(199703)18:3<175::AID-GCC4>3.0.CO;2-Z; LARIN Z, 1995, PULSED FIELD GEL ELE, P139; MARKIE D, 1993, SOMAT CELL MOLEC GEN, V19, P161, DOI 10.1007/BF01233531; NEGRINI M, 1994, CANCER RES, V54, P1331; NEGRINI M, 1995, CANCER RES, V55, P3003; Phillips KK, 1996, CANCER RES, V56, P1222; RASIO D, 1995, CANCER RES, V55, P3988; Robertson G, 1996, CANCER RES, V56, P4487; Savitsky K, 1996, GENOMICS, V33, P199, DOI 10.1006/geno.1996.0184; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SHAW ME, 1995, GENE CHROMOSOME CANC, V13, P1, DOI 10.1002/gcc.2870130102; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; SRIVATSAN ES, 1986, CANCER RES, V46, P6174; Stilgenbauer S, 1996, P NATL ACAD SCI USA, V93, P11837, DOI 10.1073/pnas.93.21.11837; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Todd MC, 1996, ONCOGENE, V13, P2387; Tomlinson IPM, 1996, J CLIN PATHOL, V49, P386, DOI 10.1136/jcp.49.5.386; VANHEYNINGEN V, 1995, CYTOGENET CELL GENET, V69, P128, DOI 10.1159/000133953; Vorechovsky I, 1996, CANCER RES, V56, P2726; WINQVIST R, 1995, CANCER RES, V55, P2660; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	46	13	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	1999	18	5					1157	1164		10.1038/sj.onc.1202372	http://dx.doi.org/10.1038/sj.onc.1202372			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022121				2022-12-28	WOS:000078510700004
J	Kumagai, T; Miki, T; Kikuchi, M; Fukuda, T; Miyasaka, N; Kamiyama, R; Hirosawa, S				Kumagai, T; Miki, T; Kikuchi, M; Fukuda, T; Miyasaka, N; Kamiyama, R; Hirosawa, S			The proto-oncogene Bc16 inhibits apoptotic cell death in differentiation-induced mouse myogenic cells	ONCOGENE			English	Article						Bc16; apoptosis; muscle cell	GERMINAL-CENTER FORMATION; NON-HODGKINS-LYMPHOMA; FINGER ENCODING GENE; CENTER B-CELLS; GROWTH-FACTOR; DNA-BINDING; MYOCYTE DIFFERENTIATION; 3Q27 TRANSLOCATION; BCL-6 GENE; EXPRESSION	The Bc16 gent is located at chromosomal band 3q27, a breakpoint for translocation that frequently occurs in B cell lymphomas. Bc16 has been found to be preferentially expressed in germinal center B cells, and expression of this gene has been shown to be essential for germinal center formation in vivo. The physiological function of Bc16 and its role in lymphomagenesis, however, are not yet known, Since significant expression of Bc16 has been demonstrated in skeletal muscle, we have utilized a differentiation-inducible mouse myogenic cell line, C2C12, to elucidate the function of the Bc16 gene product. Expression of Bc16 mRNA was very low in growing myocytes, but was increased in differentiating myocytes cultured in serum-started medium, Incubation of these cells with cytokines or chemicals that are known to block differentiation suppressed this increased Bc16 message abundance, indicating that Bc16 induction is related to the process of terminal differentiation in muscle cells. While a fraction of myocytes is known to undergo apoptosis after serum-starvation to induce differentiation, adenovirus-mediated overexpression of Bc16 enhanced the viability of the differentiating cells by preventing the apoptosis, High levels of Bc16 antisense mRNA expression induced substantial apoptosis during the differentiation of C2C12 cells, but this,vas effectively prevented by infection with adenovirus that expressed Bc16 sense mRNA, These results indicate that Bc16 acts to prevent apoptotic cell death in differentiating myocytes. The deregulation of expression of this anti-apoptotic gene may also contribute to the development of B cell lymphomas.	Tokyo Med & Dent Univ, Fac Med, Dept Internal Med 1, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Fac Med, Sch Allied Hlth Sci, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Hirosawa, S (corresponding author), Tokyo Med & Dent Univ, Fac Med, Dept Internal Med 1, Tokyo 1138519, Japan.							Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BASTARD C, 1992, BLOOD, V79, P2527; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BUSKIN JN, 1985, J MOL EVOL, V22, P334, DOI 10.1007/BF02115689; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DIBELLO PR, 1991, GENETICS, V129, P385; FUJISAWASEHARA A, 1990, J BIOL CHEM, V265, P15219; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; FUKUDA T, 1995, ONCOGENE, V11, P1657; GUO K, 1995, MOL CELL BIOL, V15, P3823; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KIM SJ, 1992, J BIOL CHEM, V267, P15140; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Mathews CC, 1996, J CELL PHYSIOL, V166, P323; MIKI T, 1994, BLOOD, V83, P217; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OFFIT K, 1989, BLOOD, V74, P1876; OHASHI K, 1995, BIOCHEM BIOPH RES CO, V214, P461, DOI 10.1006/bbrc.1995.2309; Okada S, 1998, J IMMUNOL, V160, P2590; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Stewart CEH, 1996, J BIOL CHEM, V271, P11330, DOI 10.1074/jbc.271.19.11330; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang J, 1997, CANCER RES, V57, P351; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596	45	54	56	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					467	475		10.1038/sj.onc.1202306	http://dx.doi.org/10.1038/sj.onc.1202306			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927203				2022-12-28	WOS:000078166500019
J	Daphna-Iken, D; Shankar, DB; Lawshe, A; Ornitz, DM; Shackleford, GM; MacArthur, CA				Daphna-Iken, D; Shankar, DB; Lawshe, A; Ornitz, DM; Shackleford, GM; MacArthur, CA			MMTV-Fgf8 transgenic mice develop mammary and salivary gland neoplasia and ovarian stromal hyperplasia	ONCOGENE			English	Article						fibroblast growth factor; FGF8; fgf8; mammary tumorigenesis; oncogenesis; breast cancer	KERATINOCYTE GROWTH-FACTOR; BREAST-CANCER CELLS; GENE-EXPRESSION; TUMOR VIRUS; PROVIRAL INSERTION; CARCINOMA-CELLS; FACTOR FAMILY; RECEPTOR; FGF-8; ACTIVATION	Prior studies have identified Fibroblast Growth Factor-8 (Fgf8) as a possible proto-oncogene in mouse mammary tumorigenesis. We now report on the generation of two types of Fgf8 transgenic mice that each utilize the mouse mammary tumor virus (MMTV) promoter. The first transgene (MMTV-Fgf8b) results in the overexpression of the FGF8b isoform exclusively. Male and female MMTV-Fgf8b transgenic mice are viable and fertile. RNA for FGF8b is detected in mammary gland and salivary gland tissues of transgenic mice by Northern blot analysis. Nearly 85% of breeding transgenic female mice developed mammary lobular adenocarcinomas by 12 months of age, while no tumors developed in nontransgenic littermates. Salivary gland tumors occurred in some animals, always in association with mammary tumors. Several MMTV-Fgf8b transgenic mice had lung metastases at necropsy. The second transgene (MMTV-Fgf8) uses the entire Fgf8 gene and potentially encodes all FGF8 isoforms. Fgf8 is expressed by this transgene in several tissues in addition to those described above, notably the ovaries. The two MMTV-Fgf8 founders developed mammary ductal adenocarcinomas at five and eight months of age, and both displayed ovarian stromal hyperplasia. The founders expressing either transgene did not successfully nurse their pups. These results demonstrate that production of FGF8b, and possibly other FGF8 isoforms, in the mammary and salivary glands contributes to oncogenesis, and that ovarian expression results in stromal hyperplasia.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Childrens Hosp Los Angeles, Div Hematol Oncol, Los Angeles, CA USA; Univ So Calif, Sch Med, Dept Pediat, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Dept Microbiol, Los Angeles, CA 90027 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Children's Hospital Los Angeles; University of Southern California; University of Southern California; Washington University (WUSTL)	MacArthur, CA (corresponding author), Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.			Ornitz, David/0000-0003-1592-7629	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD053229] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA060673, R01CA070106] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 70106, R01 CA 60673] Funding Source: Medline; NICHD NIH HHS [N01-HD-53229] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bansal GS, 1997, BRIT J CANCER, V75, P1567, DOI 10.1038/bjc.1997.269; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Blunt AG, 1997, J BIOL CHEM, V272, P3733, DOI 10.1074/jbc.272.6.3733; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMANKRNACIK S, 1994, MOL ENDOCRINOL, V8, P218, DOI 10.1210/me.8.2.218; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; Haraguchi S, 1997, MOL CELL ENDOCRINOL, V129, P145, DOI 10.1016/S0303-7207(97)04053-7; HARAGUCHI S, 1992, INT J CANCER, V52, P928, DOI 10.1002/ijc.2910520617; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; IMAGAWA W, 1994, BIOCHEM BIOPH RES CO, V204, P1165, DOI 10.1006/bbrc.1994.2585; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; JACQUEMIER J, 1994, INT J CANCER, V59, P373, DOI 10.1002/ijc.2910590314; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kapoun AM, 1997, ONCOGENE, V14, P2985, DOI 10.1038/sj.onc.1201146; Kitsberg DI, 1996, ONCOGENE, V13, P2507; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; LeRicousse S, 1996, P NATL ACAD SCI USA, V93, P5072, DOI 10.1073/pnas.93.10.5072; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MATHIEU M, 1995, J BIOL CHEM, V270, P24197, DOI 10.1074/jbc.270.41.24197; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCKEEHAN WL, 1994, MOL REPROD DEV, V39, P69, DOI 10.1002/mrd.1080390112; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; Payson RA, 1996, ONCOGENE, V13, P47; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; ULICH TR, 1994, AM J PATHOL, V144, P862; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; Wu J, 1997, J STEROID BIOCHEM, V62, P1, DOI 10.1016/S0960-0760(97)00022-8; Yiangou C, 1997, BRIT J CANCER, V75, P28, DOI 10.1038/bjc.1997.5	46	60	64	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2711	2717		10.1038/sj.onc.1202212	http://dx.doi.org/10.1038/sj.onc.1202212			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840935				2022-12-28	WOS:000077146700004
J	Penna, D; Schmidt, A; Beermann, F				Penna, D; Schmidt, A; Beermann, F			Tumors of the retinal pigment epithelium metastasize to inguinal lymph nodes and spleen in tyrosinase-related protein 1 SV40 T antigen transgenic mice	ONCOGENE			English	Article						metastasis; pigmentation; retinal pigment epithelium; transgenic mice; TRP-1; tyrosinase	MALIGNANT SKIN MELANOMA; FUSION GENE; MOUSE; PROMOTER; EXPRESSION; ADENOCARCINOMA; MELANOCYTES; HYPERPLASIA; ACTIVATION; SURVIVAL	The pigment epithelium of the retina (RPE) is derived from the optic cup and is essential for function and development of the eye. We produced a transgenic mouse line that expresses simian virus (SV40) transforming sequences under control of the 1.4 kb tyrosinase-related protein 1 (TRP-1) promoter, targeting expression of T antigen (Tag) to the RPE. In transgenic embryos, RPE cells proliferated in the anterior part of the eye and near the optic nerve. This resulted in formation of tumors, which were pigmented and of epithelial origin. In 3 months-old mice, pigmented cells were detected in spleen and inguinal lymph nodes. In spleen, tyrosinase, TRP-1 and SV40 Tag were expressed and tyrosinase was enzymatically active, Pigmented regions were positive for an epithelial marker, cytokeratin. Cell lines were established from tumor and metastases and kept in culture for more than 2 months. These were pigmented, and maintained expression of tyrosinase, TRP-1, cytokeratin and SV40 Tag. This demonstrates that RPE tumor cells metastasize to lymph node and spleen. In conclusion, the metastasis from TRP-1/Tag RPE tumors towards spleen and lymph nodes serves as potential tool to investigate biology and metastasis of tumors derived from the pigment epithelium.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research	Beermann, F (corresponding author), Swiss Inst Expt Canc Res, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.							ALBERT DM, 1972, ARCH OPHTHALMOL-CHIC, V88, P70; ANAND R, 1994, INVEST OPHTH VIS SCI, V35, P3533; BEERMANN F, 1993, MECH DEVELOP, V42, P59, DOI 10.1016/0925-4773(93)90098-I; BEERMANN F, 1992, P NATL ACAD SCI USA, V89, P2809, DOI 10.1073/pnas.89.7.2809; BRADL M, 1991, P NATL ACAD SCI USA, V88, P164, DOI 10.1073/pnas.88.1.164; CABLE J, 1995, MECH DEVELOP, V50, P139, DOI 10.1016/0925-4773(94)00331-G; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; CHAR D, 1994, MALIGNANT MELANOMA, P343; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; delMarmol V, 1996, FEBS LETT, V381, P165, DOI 10.1016/0014-5793(96)00109-3; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; FAN JT, 1995, AM J OPHTHALMOL, V119, P243, DOI 10.1016/S0002-9394(14)73887-5; FIDLER IJ, 1990, CANCER RES, V50, P6130; FIERS W, 1978, NATURE, V273, P113, DOI 10.1038/273113a0; Frayer W C, 1966, Trans Am Ophthalmol Soc, V64, P586; GARNER A, 1970, BRIT J OPHTHALMOL, V54, P715, DOI 10.1136/bjo.54.11.715; Greer CH, 1952, T OPHTHAL SOC UK, V72, P265; HUDSPETH AJ, 1973, INVEST OPHTH VISUAL, V12, P354; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3799, DOI 10.1093/nar/19.14.3799; KLEINSZANTO A, 1991, P NATL ACAD SCI USA, V88, P169, DOI 10.1073/pnas.88.1.169; LOEFFLER KU, 1996, GRAEFES ARCH CLIN EX, V234, P70; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MCKAY BS, 1994, EXP CELL RES, V213, P85, DOI 10.1006/excr.1994.1176; MINTZ B, 1992, P NATL ACAD SCI USA, V89, P11421, DOI 10.1073/pnas.89.23.11421; MINTZ B, 1993, P NATL ACAD SCI USA, V90, P8822, DOI 10.1073/pnas.90.19.8822; MINTZ B, 1993, P NATL ACAD SCI USA, V90, P8817, DOI 10.1073/pnas.90.19.8817; POWELL MB, 1995, MOL CARCINOGEN, V12, P82, DOI 10.1002/mc.2940120205; RAYMOND SM, 1995, CURR BIOL, V5, P1286, DOI 10.1016/S0960-9822(95)00255-7; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; ROBINSON W, 1987, BASIC CLIN ASPECTS M, P155; SCHMIDT A, 1994, P NATL ACAD SCI USA, V91, P4756, DOI 10.1073/pnas.91.11.4756; SHIELDS JA, 1994, ARCH OPHTHALMOL-CHIC, V112, P650, DOI 10.1001/archopht.1994.01090170094029; SINGH S, 1994, EPITHELIAL CELL BIOL, V3, P79; STEEL KP, 1992, DEVELOPMENT, V115, P1111; STEINBERG RH, 1979, RETINA PIGMENTED EPI, V1, P32; Tief K, 1997, PIGM CELL RES, V10, P153; Tief K, 1996, EUR J BIOCHEM, V241, P12, DOI 10.1111/j.1432-1033.1996.0012t.x; Tief K, 1996, DEV DYNAM, V205, P445, DOI 10.1002/(SICI)1097-0177(199604)205:4<445::AID-AJA8>3.0.CO;2-I; Zhao SL, 1997, INT REV CYTOL, V171, P225; Zhu H, 1998, J INVEST DERMATOL, V110, P247, DOI 10.1046/j.1523-1747.1998.00133.x	42	31	31	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2601	2607		10.1038/sj.onc.1202196	http://dx.doi.org/10.1038/sj.onc.1202196			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840923				2022-12-28	WOS:000077058900007
J	Fuks, F; Milner, J; Kouzarides, T				Fuks, F; Milner, J; Kouzarides, T			BRCA2 associates with acetyltransferase activity when bound to P/CAF	ONCOGENE			English	Article						BRCA2; P/CAF; histone acetyltransferase	HISTONE ACETYLTRANSFERASE; ACTIVATION; GENE; CBP	Predisposition to hereditary breast cancer has been attributed in part to inherited mutations in the BRCA2 gene. The large protein it encodes is still poorly characterized with respect to functions. We have previously shown that BRCA2 has transcriptional activation potential conferred by its amino-terminal third exon, Here, me show that BRCA2 interacts with a transcriptional co-activator protein, P/CAF, which possesses histone acetyltransferase activity, The interaction with P/CAF is demonstrated in vitro as well as in vivo and is shown to be mediated by residues 290-453 of BRCA2, Consistent with the binding to an acetyltransferase, BRCA2 is shown to associate with acetyltransferase activity in nuclear extracts. Contrary to a recent report, we find no evidence in support of an intrinsic HAT activity in BRCA2 amino-terminus. Our results further substantiate the notion that BRCA2 has transcriptional activation function and suggest that one mechanism by which BRCA2 regulates transcription may be through the recruitment of histone-modifying activity of the P/CAF co-activator.	Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QR, England	University of Cambridge; University of Cambridge	Kouzarides, T (corresponding author), Univ Cambridge, Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.			Kouzarides, Tony/0000-0002-8918-4162	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Davie JR, 1998, CURR OPIN GENET DEV, V8, P173, DOI 10.1016/S0959-437X(98)80138-X; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nordling M, 1998, CANCER RES, V58, P1372; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Siddique H, 1998, ONCOGENE, V16, P2283, DOI 10.1038/sj.onc.1202003; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	19	82	84	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2531	2534		10.1038/sj.onc.1202475	http://dx.doi.org/10.1038/sj.onc.1202475			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824164				2022-12-28	WOS:000076927300013
J	Lim, FL; Soulez, M; Koczan, D; Thiesen, HJ; Knight, JC				Lim, FL; Soulez, M; Koczan, D; Thiesen, HJ; Knight, JC			A KRAB-related domain and a novel transcription repression domain in proteins encoded by SSX genes that are disrupted in human sarcomas	ONCOGENE			English	Article						sarcoma; SSX; KRAB; transcription	ZINC-FINGER PROTEINS; KRUPPEL-ASSOCIATED BOX; HUMAN SYNOVIAL SARCOMA; SYT; TRANSLOCATION; FUSION; FAMILY; CHROMOSOME; ACTIVATOR; MEMBERS	SSX genes show extensive nucleotide sequence conservation but little is known of their function. Disruption of SSX1 or SSX2, by chromosome translocation and 'in-frame' fusion to SYT, is a consistent feature of synovial sarcomas, The resulting SYT-SSX1/SSX2 proteins are activators of transcription; transactivation function is located in SYT, Unrearranged SSX1 can repress transcription, and this has been attributed to a putative Kruppel associated box (KRAB) repression domain at the N-terminus. Here we isolated SSX-KRAB domains to specifically measure repression activity, using a previously characterized KOX1-KRAB domain as a control. In our repressor assay SSX1- and SSX2-KRAB domains down-modulated the transactivation of reporter gene by threefold, compared with 83-fold repression achieved by KOX1-KRAB in the assay. Yeast two-hybrid analysis showed that SSX1-KRAB, unlike KOX1-KRAB, fails to interact with the KRAB co-repressor TIF1 beta. These results raise questions about the evolutionary and functional relationship of SSX-KRAB and typical KRAB domains of Kruppel zinc finger genes. We found that full-length SSX1 showed potent (74-fold) repression in our repressor assay, indicating the existence of a repression domain distinct from SSX-KRAB. By assaying deletion constructs of SSX1 we localized repression activity to 33 amino acids at the C-terminus. This novel domain is conserved between SSX family members, and, unlike the KRAB-related domain, is retained on fusion with SYT, This has important implications in understanding the mechanism by which the SYT-SSX fusion protein could contribute to neoplasia.	Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, London W12 0HS, England; Univ London Imperial Coll Sci Technol & Med, Imperial Canc Res Fund, Mol Oncol Unit, London W12 0HS, England; Univ Rostock, Inst Immunol, D-18055 Rostock, Germany	Imperial College London; Cancer Research UK; Imperial College London; University of Rostock	Knight, JC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, Hammersmith Campus, London W12 0HS, England.			Lim, Fei Ling/0000-0002-7744-4836				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Bridge JA, 1994, CYTOGENETICS BONE SO; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; deBruijn DRH, 1996, ONCOGENE, V13, P643; deLeeuw B, 1996, CYTOGENET CELL GENET, V73, P179, DOI 10.1159/000134334; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; RENWICK PJ, 1995, CYTOGENET CELL GENET, V70, P58, DOI 10.1159/000133992; ROSATI M, 1991, NUCLEIC ACIDS RES, V19, P5661, DOI 10.1093/nar/19.20.5661; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; THIESEN H-J, 1990, New Biologist, V2, P363; Thiesen Hans-Juergen, 1997, P315; Tureci O, 1996, CANCER RES, V56, P4766; VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514	26	112	122	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					2013	2018		10.1038/sj.onc.1202122	http://dx.doi.org/10.1038/sj.onc.1202122			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788446				2022-12-28	WOS:000076423500016
J	Burstein, ES; Hesterberg, DJ; Gutkind, JS; Brann, MR; Currier, EA; Messier, TL				Burstein, ES; Hesterberg, DJ; Gutkind, JS; Brann, MR; Currier, EA; Messier, TL			The ras-related GTPase rac1 regulates a proliferative pathway selectively utilized by G-protein coupled receptors	ONCOGENE			English	Article						rac; ras; G-protein coupled receptor; tyrosine kinase linked receptor; JAK/STAT linked receptor	NIH 3T3 CELLS; HETEROTRIMERIC G-PROTEINS; KINASE KINASE KINASE; C-JUN; MUSCARINIC RECEPTORS; SIGNALING PATHWAY; BINDING PROTEINS; TYROSINE PHOSPHORYLATION; ALPHA-SUBUNIT; HA-RAS	Ras and rac are each members of the superfamily of monomeric GTPases and both function as molecular switches to link cell-surface signals to intracellular responses. Using a novel assay of cellular proliferation called R-SAT(TM) (Receptor Selection and Amplification Technology), we examined the roles of ras and rac in mediating the proliferative responses to a variety of cell-surface receptors, Activated, wild-type and dominant-negative mutants of rac and ras were tested for their effects on cellular proliferation either alone or in combination with receptors, Activated rac (rac Q61L, henceforth rac*) and ras (ras G12V, henceforth ras*) each induced strong proliferative responses. Dominant-negative rac (rac T17N, henceforth rac(-)) dramatically suppressed proliferative responses to G-protein coupled receptors (GPCR's) including the m5 muscarinic receptor and the alpha 1B adrenergic receptor. In contrast, rac(-) had little or no effect upon responses to the tyrosine kinase receptor TrkC, and only partially suppressed responses to the Janus kinase (JAK/STAT) linked granulocyte macrophage colony stimulating factor (GM-CSF) receptor. Dominant-negative ras (ras T17N, henceforth ras(-)) blocked the proliferative responses to all of the tested receptors, Compared to rac(-) and ras(-), wild-type rac and ras had only modest effects on the tested receptors, Overall these results demonstrate that rac mediates the proliferative effects of G-protein coupled receptors through a pathway that is distinct from the proliferative signaling pathway utilized by tyrosine kinase linked and JAK-linked receptors.	ACADIA Pharmaceut Inc, San Diego, CA 92121 USA; NIDR, Mol Signaling Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Burstein, ES (corresponding author), ACADIA Pharmaceut Inc, 3911 Sorrento Valley Blvd, San Diego, CA 92121 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482				ARECES LB, 1993, P NATL ACAD SCI USA, V90, P3963, DOI 10.1073/pnas.90.9.3963; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; BURSTEIN ES, 1995, FEBS LETT, V363, P261, DOI 10.1016/0014-5793(95)00323-2; Burstein ES, 1997, J NEUROCHEM, V68, P525; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1994, J BIOL CHEM, V269, P62; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Teramoto H, 1997, J BIOL CHEM, V272, P10751; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; YAN MH, 1994, NATURE, V372, P798	58	23	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 24	1998	17	12					1617	1623		10.1038/sj.onc.1202067	http://dx.doi.org/10.1038/sj.onc.1202067			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794239				2022-12-28	WOS:000076089900014
J	Forgacs, E; Biesterveld, EJ; Sekido, Y; Fong, K; Muneer, S; Wistuba, II; Milchgrub, S; Brezinschek, R; Virmani, A; Gazdar, AF; Minna, JD				Forgacs, E; Biesterveld, EJ; Sekido, Y; Fong, K; Muneer, S; Wistuba, II; Milchgrub, S; Brezinschek, R; Virmani, A; Gazdar, AF; Minna, JD			Mutation analysis of the PTEN/MMAC1 gene in lung cancer	ONCOGENE			English	Article						homozygous deletion; loss of heterozygosity; chromosome 10q23	TUMOR-SUPPRESSOR GENE; COWDEN-DISEASE; PROSTATE-CANCER; PTEN; CARCINOMAS; PHOSPHATASE; DELETIONS; FREQUENT; BREAST; IDENTIFICATION	We studied PTEN/MMAC1, a newly discovered candidate tumor suppressor gene at 10q23.3, for mutations in lung cancer. One hundred and thirty-six lung cancer cell line DNAs (66 small cell lung cancers, SCLC, 61 non-small cell lung cancers, NSCLC, four mesotheliomas, five extrapulmonary small cell cancers) were analysed for PTEN/MMAC1 homozygous deletions and five (8%) SCLC lines showed homozygous deletions interrupting the PTEN/MMAC1 gene. Using single stranded conformation polymorphism (SSCP) analysis, we screened the PTEN/MMAC1 open reading frame of 53 lung cancer cell line cDNAs for point mutations and found that 3/35 SCLCs and 3/18 NSCLCs contained homozygous amino acid sequence altering mutations. Northern blot analysis revealed that expression of the PTEN/MMAC1 gene was considerably lower in all the tumor cell lines with point mutations while no expression was detected for cell lines with PTEN/MMAC1 homozygous deletions. Mutation analysis of 22 uncultured, microdissected, primary SCLC tumors and metastases showed two silent mutations, and two apparent homozygous deletions. We also discovered a processed pseudogene (PTEN2) which has 98.5% nt identity to PTEN/MMAC1, that needs to be accounted for in cDNA mutation analysis, Our findings suggest that genetic abnormalities of the PTEN/MMAC1 gene are only involved in a relatively small subset of lung cancers.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Minna, JD (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Fong, Kwun M/G-6369-2010; Sekido, Yoshitaka/P-9756-2015; Muneer, Sowbiya/S-5382-2019	Fong, Kwun/0000-0002-6507-1403; Sekido, Yoshitaka/0000-0002-2428-3848	NCI NIH HHS [P50 CA70907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arch EM, 1997, AM J MED GENET, V71, P489, DOI 10.1002/(SICI)1096-8628(19970905)71:4<489::AID-AJMG24>3.0.CO;2-B; Bostrom J, 1998, CANCER RES, V58, P29; Dahia PLM, 1997, CANCER RES, V57, P4710; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; Frayling IM, 1997, CANCER GENET CYTOGEN, V97, P64, DOI 10.1016/S0165-4608(97)00011-3; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Guldberg P, 1997, CANCER RES, V57, P3660; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; Kawamata N, 1996, PROSTATE, V29, P191, DOI 10.1002/1097-0045(199609)29:3<191::AID-PROS2990290305>3.0.CO;2-1; LEVIN NA, 1994, CANCER RES, V54, P5086; Li DM, 1997, ENG FRACT MECH, V57, P1, DOI 10.1016/S0013-7944(97)00023-4; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Maniatis T., 1982, MOL CLONING; Marsh DJ, 1997, CANCER RES, V57, P500; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; Rhei E, 1997, CANCER RES, V57, P3657; RIED T, 1994, CANCER RES, V54, P1801; RIED T, 1997, BRIT J CANCER, V75, P79; Schwendel A, 1997, INT J CANCER, V74, P86, DOI 10.1002/(SICI)1097-0215(19970220)74:1<86::AID-IJC15>3.0.CO;2-G; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tashiro H, 1997, CANCER RES, V57, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; VIRMANI A, 1998, IN PRESS GENES CHROM; Wechsler DS, 1996, GENOMICS, V32, P466, DOI 10.1006/geno.1996.0144	29	166	175	7	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1557	1565		10.1038/sj.onc.1202070	http://dx.doi.org/10.1038/sj.onc.1202070			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794233				2022-12-28	WOS:000076089900008
J	Ekman, S; Thuresson, ER; Heldin, CH; Ronnstrand, L				Ekman, S; Thuresson, ER; Heldin, CH; Ronnstrand, L			Increased mitogenicity of an alpha beta heterodimeric PDGF receptor complex correlates with lack of RasGAP binding	ONCOGENE			English	Article						heterodimer; mitogenicity; PDGF receptor; phosphorylation; RasGAP	GROWTH-FACTOR RECEPTORS; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; AUTOPHOSPHORYLATION SITES; TYROSINE KINASES; PHOSPHOLIPASE-C; ACTIVATION; IDENTIFICATION; PHOSPHORYLATION; PROTEINS	The different platelet-derived growth factor (PDGF) isoforms cause activation of their alpha and beta protein tyrosine kinase receptors through dimerization, Homodimerization as well as heterodimerization of receptors occur. It has been shown previously that the heterodimeric receptor complex mediates a stronger mitogenic response than either of the homodimeric complexes. In this report, me show that in cells expressing both PDGF alpha- and beta-receptors, stimulation with PDGF-AB, which leads to preferential heterodimer formation, leads to a very low degree of phosphorylation of Tyr771 in the beta-receptor. In contrast, Tyr771 is phosphorylated in a homodimeric complex of beta-receptors. Phosphorylated Tyr771 is a binding site for RasGAP; an analogous site is not present in the alpha-receptor, which lacks the ability to associate with RasGAP, The lowered phosphorylation of Tyr771 in the heterodimeric receptor complex correlates with lowered association with RasGAP, as well as with a more efficient activation of Ras and MAP kinase, which is consistent with the increased mitogenicity elicited by PDGF-AB, compared to PDGF-AA or PDGF-BB.	Ludwig Inst Canc Res, Ctr Biomed, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Ronnstrand, L (corresponding author), Ludwig Inst Canc Res, Ctr Biomed, Box 595, S-75124 Uppsala, Sweden.		Ekman, Simon/AAB-9387-2021; Ronnstrand, Lars/A-2429-2011	Ronnstrand, Lars/0000-0003-1275-5809				ARVIDSSON AK, 1992, CELL GROWTH DIFFER, V3, P881; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BAZENET CE, 1994, ONCOGENE, V9, P517; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORI S, 1991, J BIOL CHEM, V266, P21158; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; RUPP E, 1994, EUR J BIOCHEM, V225, P29, DOI 10.1111/j.1432-1033.1994.00029.x; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; Yokote K, 1998, ONCOGENE, V16, P1229, DOI 10.1038/sj.onc.1201641; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	37	50	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2481	2488		10.1038/sj.onc.1202606	http://dx.doi.org/10.1038/sj.onc.1202606			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229199				2022-12-28	WOS:000079703300008
J	Rosenwald, IB; Chen, JJ; Wang, ST; Savas, L; London, IM; Pullman, J				Rosenwald, IB; Chen, JJ; Wang, ST; Savas, L; London, IM; Pullman, J			Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis	ONCOGENE			English	Article						eIF-4E; translation factors; cyclins; protein synthesis; transformation; colon cancer	CAP-BINDING PROTEIN; RNA 5' CAP; TRANSLATION INITIATION; FACTOR 4E; MESSENGER-RNA; CYCLIN D1; CELL-CYCLE; C-MYC; ORNITHINE DECARBOXYLASE; RETINOBLASTOMA PROTEIN	A general increase in protein synthesis and a specific increase in the synthesis of growth-promoting proteins are necessary for mitogenesis, Regulation of protein synthesis, as well as preferential translation of some mRNAs coding for growth promoting proteins (e.g. cyclin D1), involves the essential protein synthesis initiation factor eIF-4E. This factor is induced by various oncoproteins, and, when overexpressed, it can transform cultured cells. In this report we explore the roles of eIF-4E in human neoplastic disorders of the colon and in the regulation of general and specific protein synthesis, We find that eIF-4E is increased in colon adenomas and carcinomas, and this increase is accompanied in most but not all cases by elevation of cyclin D1 levels. While general protein synthesis is increased by eIF-4E overexpression in cultured cells, only a small proportion of proteins is preferentially upregulated by eIF-4E, as revealed by two-dimensional gel electrophoresis. These results are consistent with the view that eIF-4E plays a role in carcinogenesis by increasing general protein synthesis and by preferentially upregulating a subset of putative growth promoting proteins. Our results, taken together with the recent findings that c-myc transcription is negatively regulated by APC and our earlier data on transcriptional activation of eIF-4E expression by c-Myc suggest that eIF-4E is a downstream target of the APC/beta-catenin/Tcf-4 pathway, and is strongly involved in colon tumorigenesis.	Univ Massachusetts, Med Ctr, Dept Pathol, Worcester, MA 01655 USA; MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA	University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Massachusetts Institute of Technology (MIT)	Rosenwald, IB (corresponding author), Univ Massachusetts, Med Ctr, Dept Pathol, 55 Lake Ave N, Worcester, MA 01655 USA.				NIDDK NIH HHS [DK 16272, R01 DK016272] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016272] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; Epifanova O I, 1977, Int Rev Cytol Suppl, P303; GRAFF JR, 1995, INT J CANCER, V60, P255; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HERSHKO A, 1971, NATURE-NEW BIOL, V232, P206, DOI 10.1038/newbio232206a0; Jones RM, 1996, MOL CELL BIOL, V16, P4754; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOZAK M, 1994, BIOCHIMIE, V76, P815, DOI 10.1016/0300-9084(94)90182-1; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li BDL, 1997, CANCER-AM CANCER SOC, V79, P2385; Maeda K, 1997, INT J CANCER, V74, P310, DOI 10.1002/(SICI)1097-0215(19970620)74:3<310::AID-IJC13>3.0.CO;2-F; MAKIN CA, 1984, J CLIN PATHOL, V37, P975, DOI 10.1136/jcp.37.9.975; MELHEM MF, 1992, CANCER RES, V52, P5853; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MORRIS DR, 1995, PROG NUCLEIC ACID RE, V51, P339, DOI 10.1016/S0079-6603(08)60883-1; Nathan CAO, 1997, ONCOGENE, V15, P579, DOI 10.1038/sj.onc.1201216; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Rhoads RE, 1995, CURR TOP MICROBIOL, V203, P131; RHOADS RE, 1994, BIOCHIMIE, V76, P831, DOI 10.1016/0300-9084(94)90184-8; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; Rosenwald IB, 1996, BIOESSAYS, V18, P243, DOI 10.1002/bies.950180312; Rosenwald IB, 1995, CANCER LETT, V98, P77, DOI 10.1016/0304-3835(95)90206-6; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Shantz LM, 1996, CANCER RES, V56, P3265; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; ZETTERBERG A, 1991, COLD SH Q B, V56, P137; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0	44	154	173	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	1999	18	15					2507	2517		10.1038/sj.onc.1202563	http://dx.doi.org/10.1038/sj.onc.1202563			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229202				2022-12-28	WOS:000079703300011
J	Elly, C; Witte, S; Zhang, ZH; Rosnet, O; Lipkowitz, S; Altman, A; Liu, YC				Elly, C; Witte, S; Zhang, ZH; Rosnet, O; Lipkowitz, S; Altman, A; Liu, YC			Tyrosine phosphorylation and complex formation of Cbl-b upon T cell receptor stimulation	ONCOGENE			English	Article						protein tyrosine kinase; Cbl; proto-oncogene; Crk-L	EXCHANGE PROTEIN C3G; C-CBL; ANTIGEN RECEPTOR; V-CBL; ASSOCIATION; ACTIVATION; ZAP-70; PROTOONCOGENE; KINASE; 14-3-3-PROTEINS	Cbl-b, a mammalian homolog of Cbl, consists of an N-terminal region (Cbl-b-N) highly homologous to oncogenic v-Cbl, a Ring finger, and a C-terminal region containing multiple proline-rich stretches and potential tyrosine phosphorylation sites. In the present study, we demonstrate that upon engagement of the T cell receptor (TCR), endogenous Cbl-b becomes rapidly tyrosine-phosphorylated, In heterogeneous COS-1 cells, Cbl-b was phosphorylated on tyrosine residues by both Syk(Syk/Zap-70) and Src- (Fyn/Lck) family kinases, with Syk kinase inducing the most prominent effect. Syk associates and phosphorylates Cbl-b in Jurkat T cells, A Tyr-316 Chi-binding site in Syk was required for the association with and for the maximal tyrosine phosphorylation of Cbl-b, Mutation at a loss-of-function site (Gly-298) in Cbl-b-N disrupts its interaction with Syk, Cbl-b constitutively binds Grb2 and becomes associated with Crk-L upon TCR stimulation. The Grb2- and the Crk-L-binding regions were mapped to the C-terminus of Cbl-b, The Crk-L-binding sites were further determined to be (YDVP)-D-655 and (YKIP)-K-709, With th, latter being the primary binding site. Taken together, these results implicate that Cbl-b is involved in TCR-mediated intracellular signaling pathways.	La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA; INSERM U119, Mol Oncol Lab, F-13009 Marseille, France; NCI, Navy Med Oncol Branch, Gaithersburg, MD 20899 USA	La Jolla Institute for Immunology; Institut National de la Sante et de la Recherche Medicale (Inserm); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Liu, YC (corresponding author), La Jolla Inst Allergy & Immunol, Div Cell Biol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Rosnet, Olivier/G-3536-2013	LIU, YUN-CAI/0000-0002-0996-7109; Rosnet, Olivier/0000-0002-3020-910X	NATIONAL CANCER INSTITUTE [Z01SC007263, ZIASC007263] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andoniou CE, 1996, ONCOGENE, V12, P1981; BLAKE TJ, 1991, ONCOGENE, V6, P653; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; Donovan JA, 1996, J BIOL CHEM, V271, P26369, DOI 10.1074/jbc.271.42.26369; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; KEANE MM, 1995, ONCOGENE, V10, P2367; Kong GH, 1996, MOL CELL BIOL, V16, P5026; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Lavagna-Sevenier C, 1998, J BIOL CHEM, V273, P14962, DOI 10.1074/jbc.273.24.14962; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Liu YC, 1997, J BIOL CHEM, V272, P168; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Marengere LEM, 1997, J IMMUNOL, V159, P70; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; ZHANG Z, 1998, UNPUB; Zhao QH, 1996, MOL CELL BIOL, V16, P6765	33	56	61	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1147	1156		10.1038/sj.onc.1202411	http://dx.doi.org/10.1038/sj.onc.1202411			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022120				2022-12-28	WOS:000078510700003
J	Venturini, L; You, J; Stadler, M; Galien, R; Lallemand, VR; Koken, MHM; Mattei, MG; Ganser, A; Chambon, P; Losson, R; de The, H				Venturini, L; You, J; Stadler, M; Galien, R; Lallemand, VR; Koken, MHM; Mattei, MG; Ganser, A; Chambon, P; Losson, R; de The, H			TIF1 gamma, a novel member of the transcriptional intermediary factor 1 family	ONCOGENE			English	Article						TIF1; transcriptional control; RBCC; PHD; bromodomain	ACUTE PROMYELOCYTIC LEUKEMIA; NUCLEAR RECEPTOR COACTIVATORS; ACTIVATION FUNCTION AF-2; HUMAN ESTROGEN-RECEPTOR; ZINC-FINGER PROTEINS; RING FINGER; REPRESSOR DOMAIN; GENE; EXPRESSION; CELLS	We report the cloning and characterization of a novel member of the Transcriptional Intermediary Factor 1 (TIF1) gene family, human TIF1 gamma, Similar to TIF1 alpha and TIF1 beta, the structure of TIF1 beta is characterized by multiple domains: RING finger, B boxes, Coiled coil, PHD/TTC, and bromodomain, Although structurally related to TIF1 alpha and TIF1 beta, TIF1 gamma presents several functional differences. In contrast to TIF1 alpha, but like TIF1 beta, TIF1 gamma does not interact with nuclear receptors in yeast two-hybrid or GST pull-down assays and does not interfere with retinoic acid response in transfected mammalian cells. Whereas TIF1 alpha and TIF1 beta were previously found to interact with the KRAB silencing domain of KOX1 and with the HP1 alpha, MOD1 (HP1 beta) and MOD2 (HP1 gamma) heterochromatinic proteins, suggesting that they may participate in a complex involved in heterochromatin-induced gene repression, TIF1 gamma does not interact with either the KRAB domain of KOX1 or the HP1 proteins. Nevertheless, TIF1 gamma, like TIF1 alpha and TIF1 beta, exhibits a strong silencing activity when tethered to a promoter. Since deletion of a novel motif unique to the three TIF1 proteins, called TIF1 signature sequence (TSS), abrogates transcriptional repression by TIF1 gamma, this motif likely participates in TIF1 dependent repression.	Hop St Louis, CNRS, UPR 9051, Lab Associe Comite Paris de la Ligue Canc, F-75010 Paris, France; Hannover Med Sch, Abt Hamatol & Onkol, D-30625 Hannover, Germany; Univ Strasbourg 1, Inst Genet Biol Mol, CNRS, INSERM, F-67404 Illkirch Graffenstaden, France; CU Strasbourg, Strasbourg, France; INSERM U406, Marseille, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Hannover Medical School; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm)	de The, H (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, 20 N Pine St, Baltimore, MD 21201 USA.		koken, marcel/J-8154-2012; koken, marcel/N-1349-2019	koken, marcel/0000-0002-0839-0125; 				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BELLINI M, 1995, J CELL BIOL, V131, P563, DOI 10.1083/jcb.131.3.563; Boddy MN, 1997, J CELL SCI, V110, P2197; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; DANIEL MT, 1993, BLOOD, V82, P1858; Dent AL, 1996, BLOOD, V88, P1423, DOI 10.1182/blood.V88.4.1423.bloodjournal8841423; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRIGNANI F, 1994, BLOOD, V83, P10; Grimwade D, 1997, CURR TOP MICROBIOL, V220, P81; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; KOKEN MHM, 1995, CR ACAD SCI III-VIE, V318, P733; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; LeDouarin B, 1997, BIOCHEM SOC T, V25, P605, DOI 10.1042/bst0250605; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LI XX, 1994, EXP CELL RES, V213, P473, DOI 10.1006/excr.1994.1225; Losson R, 1997, BIOL CHEM, V378, P579; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; Mitelman F, 1993, HUMAN GENE MAPPING, P773; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Moosmann P, 1997, BIOL CHEM, V378, P669, DOI 10.1515/bchm.1997.378.7.669; PIERRAT B, 1992, GENE, V119, P237, DOI 10.1016/0378-1119(92)90277-V; QUIGNON F, 1997, BIOCHIM BIOPHYS ACTA, V1333, P753; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Sambrook J, 1989, MOL CLONING; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7	48	131	137	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	1999	18	5					1209	1217		10.1038/sj.onc.1202655	http://dx.doi.org/10.1038/sj.onc.1202655			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022127				2022-12-28	WOS:000078510700010
J	Sheng, HM; Shao, JY; O'Mahony, CA; Lamps, L; Albo, D; Isakson, PC; Berger, DH; DuBois, RN; Beauchamp, RD				Sheng, HM; Shao, JY; O'Mahony, CA; Lamps, L; Albo, D; Isakson, PC; Berger, DH; DuBois, RN; Beauchamp, RD			Transformation of intestinal epithelial cells by chronic TGF-beta 1 treatment results in downregulation of the type II TGF-beta receptor and induction of cyclooxygenase-2	ONCOGENE			English	Article						intestinal epithelial cells; transforming growth factor beta; cyclooxygenase-2; carcinogenesis	GROWTH-FACTOR-BETA; APC(DELTA-716) KNOCKOUT MICE; BREAST-CANCER-CELLS; BENIGN SKIN TUMORS; CYCLIN D1; DIFFERENTIAL SENSITIVITY; SELECTIVE-INHIBITION; MALIGNANT CONVERSION; CARCINOMA-CELLS; FAMILY SIGNALS	The precise role of TGF-P in colorectal carcinogenesis is not clear, The purpose of this study was to determine the phenotypic alterations caused by chronic exposure to TGF-beta in non-transformed intestinal epithelial (RIE-1) cells. Growth of RIE-1 cells was inhibited by >75% following TGF-beta 1 treatment for 7 days, after which the cells resumed a normal growth despite the presence of TGF-beta 1, These 'TGF-beta-resistant' cells (RIE-Tr) were continuously exposed to TGF-beta for >50 days, Unlike the parental RIE cells, RIE-Tr cells lost contact inhibition, formed foci in culture, grew in soft agarose, RIE-Tr cells demonstrated TGF-beta-dependent invasive potential in an in vitro assay and were resistant to Matrigel and Na-butyrate-induced apoptosis, The RIE-Tr cells were also tumorigenic in nude mice. The transformed phenotype of RIE-Tr cells was associated with a 95% decrease in the level of the type II TGF-P receptor (T beta RII) protein, a 40-fold increase in cyclooxygenase-2 (COX-2) protein, and 5.9-fold increase in the production of prostacyclin, Most RIE-Tr subclones that expressed low levels of T beta RII and high levels of COX-2 were tumorigenic. Those subclones that express abundant T beta RII and low levels of COX-2 were not tumorigenic in nude mice. A selective COX-2 inhibitor inhibited RIE-Tr cell growth in culture and tumor growth in nude mice. The reduced expression of T beta RII, increased expression of COX-2, and the ability to form colonies in Matrigel mere all reversible upon withdrawal of exogenous TGF-beta 1 for the RIE-Tr cells.	Vanderbilt Univ, Med Ctr N, Vanderbilt Canc Ctr, Dept Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Canc Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Canc Ctr, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Canc Ctr, Dept Pathol, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37232 USA; Searle Res & Dev, Dept Inflammatory Dis Res, St Louis, MO 63198 USA; Allegheny Univ Hlth Sci, Dept Surg, Philadelphia, PA 19102 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Pfizer; Drexel University	Beauchamp, RD (corresponding author), Vanderbilt Univ, Med Ctr N, Vanderbilt Canc Ctr, Dept Surg, CC2306, Nashville, TN 37232 USA.		DuBois, Raymond N./AAX-8869-2020	Beauchamp, Robert Daniel/0000-0002-8446-4114	NCI NIH HHS [CA68485, CA-69457] Funding Source: Medline; NIDDK NIH HHS [DK-52334] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, R01CA069457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052334] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson GD, 1996, J CLIN INVEST, V97, P2672, DOI 10.1172/JCI118717; ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193; ARTEAGA CL, 1988, CANCER RES, V48, P3898; BARNARD JA, 1993, GASTROENTEROLOGY, V105, P67, DOI 10.1016/0016-5085(93)90011-Z; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BEAUCHAMP RD, 1990, PANCREAS, V5, P369, DOI 10.1097/00006676-199007000-00001; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BLAY J, 1985, J CELL PHYSIOL, V124, P107, DOI 10.1002/jcp.1041240117; BLAY J, 1984, CELL BIOL INT REP, V8, P551, DOI 10.1016/0309-1651(84)90054-7; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHEN X, 1996, NATURE, V383, P791; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUI W, 1994, CANCER RES, V54, P5831; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DERYNCK R, 1987, CANCER RES, V47, P707; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FILMUS J, 1992, ONCOGENE, V7, P521; FILMUS J, 1994, ONCOGENE, V9, P3627; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GILBERT RS, 1994, J CELL PHYSIOL, V159, P67, DOI 10.1002/jcp.1041590110; GILBERT RS, 1994, CELL MOL BIOL RES, V40, P653; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; HAFEZ MM, 1992, CELL GROWTH DIFFER, V3, P753; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; KO TC, 1995, ONCOGENE, V10, P177; KUROKOWA M, 1987, BIOCHEM BIOPH RES CO, V142, P775, DOI 10.1016/0006-291X(87)91481-1; LAGNA G, 1996, NATURE, V383, P382; MANNING AM, 1991, ONCOGENE, V6, P1471; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Masferrer JL, 1996, GASTROENTEROL CLIN N, V25, P363, DOI 10.1016/S0889-8553(05)70252-1; Massague J, 1996, CANCER SURV, V27, P41; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oshima H, 1997, CANCER RES, V57, P1644; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; SCHROY P, 1990, CANCER RES, V50, P261; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 1997, CELL GROWTH DIFFER, V8, P463; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; SIEWEKE MH, 1990, SCIENCE, V248, P1656, DOI 10.1126/science.2163544; SIEWEKE MH, 1994, CRIT REV ONCOGENESIS, V5, P297, DOI 10.1615/CritRevOncog.v5.i2-3.90; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; WANG DH, 1995, J BIOL CHEM, V270, P14154, DOI 10.1074/jbc.270.23.14154; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, pG393; Winesett MP, 1996, CARCINOGENESIS, V17, P989, DOI 10.1093/carcin/17.5.989; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853; Zhang T, 1997, CANCER RES, V57, P169; Zhang T, 1997, CANCER RES, V57, P1638; ZHANG XY, 1994, CANCER RES, V54, P6122; ZHAO J, 1995, CANCER RES, V55, P6181	73	57	59	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					855	867		10.1038/sj.onc.1202397	http://dx.doi.org/10.1038/sj.onc.1202397			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023661				2022-12-28	WOS:000078510600002
J	Cambier, N; Zhang, Y; Vairo, G; Kosmopoulos, K; Metcalf, D; Nicola, NA; Elefanty, AG				Cambier, N; Zhang, Y; Vairo, G; Kosmopoulos, K; Metcalf, D; Nicola, NA; Elefanty, AG			Expression of BCR-ABL in M1 myeloid leukemia cells induces differentiation without arresting proliferation	ONCOGENE			English	Article						BCR-ABL oncogene; M1 cell differentiation	CHRONIC MYELOGENOUS LEUKEMIA; CONSTITUTIVE C-MYC; INHIBITORY FACTOR; TYROSINE KINASE; MONOCLONAL-ANTIBODY; SCAVENGER RECEPTOR; CYCLIN D1; V-ABL; ERYTHROLEUKEMIA-CELLS; ONCOGENE EXPRESSION	The mechanism leading to the expanding population of maturing myeloid cells which characterises chronic myeloid leukemia (CML) remains obscure. Because of its ability to mimic the proliferative and cell survival functions of hematopoietic growth factors, me hypothesized that the oncogene activated in CML, BCR-ABL, might also influence differentiation. To test this hypothesis, nle examined the effects of expressing BCR-ABL on the myeloid differentiation of murine M1 leukemic cells, which cease dividing and differentiate into macrophages in the presence of the cytokines leukemia inhibitory factor (LIF) or interleukin (IL)-6, We found that BCR-ABL induced macrophage differentiation in M1 cells, accompanied by increased expression of macrophage cell surface markers and the acquisition of phagocytic ability. Interestingly, clones of M1 cells which expressed BCR-ABL remained in cell cycle and were refractory to the growth inhibition and apoptosis induced by IL-6 or LIF in parental M1 cells. These cells also expressed inappropriately high levels of c-MYC mRNA for their degree of differentiation, which may have been important in maintaining cellular proliferation. These data suggest that BCR-ABL can stimulate both differentiation and proliferation and that these characterisitics may contribute to the phenotype observed in CML.	PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; PO Royal Melbourne Hosp, Cooperat Res Ctr Cellular Growth Factors, Melbourne, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital	Elefanty, AG (corresponding author), PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.		Elefanty, Andrew G/A-6066-2008; Nicola, Nicos/D-2989-2011	Nicola, Nicos/0000-0003-1054-7889; Elefanty, Andrew/0000-0001-6448-8314	NATIONAL CANCER INSTITUTE [R37CA022556, R01CA022556] Funding Source: NIH RePORTER; NCI NIH HHS [CA22556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1995, P NATL ACAD SCI USA, V92, P9540, DOI 10.1073/pnas.92.21.9540; AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BRUCE AG, 1992, J IMMUNOL, V149, P1271; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; Clarkson BD, 1997, LEUKEMIA, V11, P1404, DOI 10.1038/sj.leu.2400751; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; Cortez D, 1996, ONCOGENE, V13, P2589; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ELEFANTY AG, 1992, BLOOD, V79, P1271; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ELEFANTY AG, 1997, MOL HAEMOPOIESIS, P589; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GROFFEN J, 1987, CHRONIC MYELOID LEUK, P983; Hariharan I K, 1988, Oncogene Res, V3, P387; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; LANEUVILLE P, 1991, ONCOGENE, V6, P275; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; METCALF D, 1988, LEUKEMIA, V2, P216; Metcalf D, 1984, CLONAL CULTURE HEMOP; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P239; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHABO Y, 1988, BLOOD, V72, P2070; SIRARD C, 1994, BLOOD, V83, P1575; Skorski T, 1996, P NATL ACAD SCI USA, V93, P13137, DOI 10.1073/pnas.93.23.13137; Smith D, 1997, BRIT TELECOMMUN ENG, V16, P1; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; TANIGAWA T, 1995, BLOOD, V85, P379; TAUCHI T, 1995, INT J HEMATOL, V61, P105; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; Vairo G, 1996, ONCOGENE, V13, P1511; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAFRIRI D, 1993, P NATL ACAD SCI USA, V90, P477, DOI 10.1073/pnas.90.2.477	58	16	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					343	352		10.1038/sj.onc.1202302	http://dx.doi.org/10.1038/sj.onc.1202302			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927191				2022-12-28	WOS:000078166500007
J	Davies, JM; Hawe, N; Kabarowski, J; Huang, QH; Zhu, J; Brand, NJ; Leprince, D; Dhordain, P; Cook, M; Morriss-Kay, G; Zelent, A				Davies, JM; Hawe, N; Kabarowski, J; Huang, QH; Zhu, J; Brand, NJ; Leprince, D; Dhordain, P; Cook, M; Morriss-Kay, G; Zelent, A			Novel BTB/POZ domain zinc-finger protein, LRF, is a potential target of the LAZ-3/BCL-6 oncogene	ONCOGENE			English	Article						transcription factor; development; limb; lymphoma; dimerization	ACUTE PROMYELOCYTIC LEUKEMIA; ACID RECEPTOR-ALPHA; B-CELL LYMPHOMA; GERMINAL-CENTER FORMATION; TRANSCRIPTIONAL REPRESSION; LAZ3/BCL6 ONCOPROTEIN; MYELOGENOUS LEUKEMIA; 3Q27 TRANSLOCATION; INTERACTION MOTIF; GENE-EXPRESSION	BTB/POZ-domain C2H2 zinc(Zn)-finger proteins are encoded by a subfamily of genes related to the Drosophila gap gene kruppel. To date, two such proteins, PLZF and LAZ-3/BCL-6, have been implicated in oncogenesis. We have now identified a new member of this gent subfamily which encodes a 62 kDa Zn-finger protein, termed LRF, with a BTB/POZ domain highly similar to that of PLZF, Both human and mouse LRF genes, which localized to syntenic chromosomal regions (19p13.3 and 10B5.3, respectively), were widely expressed in adult tissues and cell lines. At approximately 9.5-10.0 days of embryonic development, the mouse LRF gene was expressed in the limb buds, pharyngeal arches, tail bud, placenta and neural tube. The LRF protein associated in vivo with LAZ-3/BCL-6, but not with PLZF to which it was more related. Although the LRF, or LAZ-3/BCL-6, BTB/POZ domain could readily homodimerize, no heterodimerization was detected in vivo between the LRF and LAZ-3/BCL-6 BTB/POZ domains and interaction between full length LRF and LAZ-3/BCL-6 required the presence of both the BTB/POZ domain and Zn-fingers in each partner protein. As expected from the above results, LRF and LAZ-3/BCL-6 also colocalized with each other in the nucleus. Taken together, our findings suggest that BTB/POZ-domain Zn-finger proteins may function as homo and heterodimeric complexes whose formation, and hence the resultant effect on transcription of their downstream target genes, is determined by the levels and expression domains of a given partner protein.	Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England; Natl Heart & Lung Inst, Imperial Coll, Sch Med, London SW3 6LY, England; Inst Rech Canc Lille, U124 INSERM, F-59045 Lille, France; Univ Oxford, Dept Human Anat, Oxford OX1 3QX, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Imperial College London; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Oxford	Zelent, A (corresponding author), Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, 237 Fulham Rd, London SW3 6JB, England.		Zelent, Arthur/B-3532-2009	Leprince, Dominique/0000-0002-1999-0775; O'Connor, Nicola/0000-0003-1981-3055; Zelent, Arthur/0000-0002-7968-9888	NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NCI NIH HHS [CA59936-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHEN SJ, 1992, ONCOGENE, V7, P1223; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN W, 1995, MOL CELL BIOL, V15, P3424; Chen XY, 1996, EMBO J, V15, P5888, DOI 10.1002/j.1460-2075.1996.tb00975.x; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5299; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; CONSTANTINOUDELTAS CD, 1992, GENOMICS, V12, P581, DOI 10.1016/0888-7543(92)90451-W; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1995, ONCOGENE, V11, P2689; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELBARADI T, 1991, MECH DEVELOP, V35, P155, DOI 10.1016/0925-4773(91)90015-X; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; FRIEND C, 1965, NATL CANC I MONO, V22, P505; FUKUDA T, 1995, ONCOGENE, V11, P1657; GALERA P, 1994, P NATL ACAD SCI USA, V91, P9372, DOI 10.1073/pnas.91.20.9372; Gietz R.D., 1994, MOL GENETICS YEAST P, P121; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GODT D, 1993, DEVELOPMENT, V119, P799; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GREENBERGER JS, 1983, CELL BIOL, V60, P2931; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; HARPER JW, 1993, CELL, V75, P805; Hawe N, 1996, BLOOD, V88, P1151; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; HEIM S, 1987, CANC CYTOGNETICS; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HU S, 1995, GENE DEV, V9, P2936, DOI 10.1101/gad.9.23.2936; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Johnston J.R., 1994, MOL GENETICS YEAST P; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Karin M, 1990, CURR OPIN CELL BIOL, V2, P996, DOI 10.1016/0955-0674(90)90148-8; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KEYDAR I, 1979, EUR J CANCER, V15, P659, DOI 10.1016/0014-2964(79)90139-7; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; KLEIN E, 1968, CANCER RES, V28, P1300; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P213, DOI 10.1016/0968-0004(92)90379-N; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MINOWADA J, 1978, J NATL CANCER I, V60, P1269, DOI 10.1093/jnci/60.6.1269; MITELMAN F, 1991, CATALOG CHROMOSOME A; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; ONIZUKA T, 1995, BLOOD, V86, P25; Oyake T, 1996, MOL CELL BIOL, V16, P6083; PALACIOS R, 1987, EMBO J, V6, P3687, DOI 10.1002/j.1460-2075.1987.tb02702.x; PUCK TT, 1958, J EXP MED, V108, P945, DOI 10.1084/jem.108.6.945; RALPH P, 1977, CANCER RES, V37, P546; RALPH P, 1973, J NATL CANCER I, V31, P883; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Sambrook J., 2002, MOL CLONING LAB MANU; Seyfert VL, 1996, ONCOGENE, V12, P2331; SHAKNOVICH R, 1998, IN PRESS MOL CELL BI; Shi YP, 1997, GENOMICS, V45, P42, DOI 10.1006/geno.1997.4904; SHIRASUNA K, 1981, CANCER, V48, P745, DOI 10.1002/1097-0142(19810801)48:3<745::AID-CNCR2820480314>3.0.CO;2-7; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WARNER NL, 1969, J NATL CANCER I, V43, P963; WEIMA SM, 1988, DIFFERENTIATION, V38, P203, DOI 10.1111/j.1432-0436.1988.tb00214.x; WEISS A, 1984, J IMMUNOL, V133, P1; Widom RL, 1997, GENE, V198, P407, DOI 10.1016/S0378-1119(97)00360-0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; YANCOPOULOS GD, 1984, NATURE, V311, P727, DOI 10.1038/311727a0; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZELENT A, 1997, METHOD MOL BIOL, V89, P307; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	92	116	132	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					365	375		10.1038/sj.onc.1202332	http://dx.doi.org/10.1038/sj.onc.1202332			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927193				2022-12-28	WOS:000078166500009
J	Mishra, L; Cai, T; Yu, P; Monga, SPS; Mishra, B				Mishra, L; Cai, T; Yu, P; Monga, SPS; Mishra, B			Elf3 encodes a novel 200-kD beta-spectrin: role in liver development	ONCOGENE			English	Article						spectrin; cloning; chromosome 11; mouse; liver; embryonic development; immunohistochemistry	PLASMA-MEMBRANE DOMAINS; POLARIZED EPITHELIAL-CELLS; BRAIN SPECTRIN; HEPATOCYTE DIFFERENTIATION; ERYTHROCYTE SPECTRIN; SELF-ASSOCIATION; CDNA LIBRARIES; MESSENGER-RNAS; MECHANISM; SEQUENCES	beta-spectrins are crucial for the maintenance of cell shape, the establishment of cell polarity, and the formation of distinct membrane domains. Our strategy for identifying genes important for hepatocyte polarity has been to utilize subtractive hybridization of early embryonic mouse cDNA liver libraries. As a result,,ve have cloned three isoforms of a novel beta-spectrin elf (embryonic liver beta-fodrin), and here we report the analysis of elf3, the longest isoform (8172 nt), ELF3 comprises 2154 residues with an overall similarity of 89.0% and 95.3% to mouse beta-spectrin (beta SpII Sigma 1) at the nucleotide and amino acid level, respectively. ELF3 is characterized by an actin-binding domain, a long repeat domain, and a short regulatory domain remarkable for the absence of a PH domain, Linkage analysis reveals that elf3 maps to mouse chromosome 11 between D11Bir6 and D11Xrf477, a different chromosomal locus from that of the other four spectrin genes, Northern blot analysis utilizing an elf3 3'-UTR probe demonstrates an abundant 9.0-kb transcript in brain, liver, and heart tissues. Western blot with a polyclonal antibody against ELF identifies a 200 kD protein in mouse liver, brain, kidney, and heart tissues. Immunohistochemical studies demonstrate ELF labeling of the basolateral or sinusoidal membranes surface as well as a granular cytoplasmic pattern in hepatocytes, Antisense studies utilizing cultured liver explants show a vital role of elf3 in hepatocyte differentiation and intrahepatic bile duct formation, The differential expression, tissue localization, and functional studies demonstrate the importance of elf3 in modulating interactions between various components of the cytoskeleton proteins controlling liver and bile duct development.	Dept Vet Affairs, Lab Dev Mol Biol, Washington, DC 20422 USA; Temple Univ, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Natl Human Genome Res Inst, Clin Gene Therapy Branch, NIH, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Mishra, L (corresponding author), Dept Vet Affairs, Lab Dev Mol Biol, Washington, DC 20422 USA.			Mishra, Lopa/0000-0002-6850-0808; Monga, Satdarshan/0000-0002-8437-3378; Cai, Tao/0000-0002-2877-8637	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK050458] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29-DK50458-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1996, METHOD ENZYMOL, V266, P460; Beck KA, 1996, AM J PHYSIOL-CELL PH, V270, pC1263, DOI 10.1152/ajpcell.1996.270.5.C1263; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BENNETT V, 1982, NATURE, V299, P126, DOI 10.1038/299126a0; BLAKESLEE D, 1977, J IMMUNOL METHODS, V17, P361, DOI 10.1016/0022-1759(77)90118-1; BOUWENS L, 1992, ENZYME, V46, P155, DOI 10.1159/000468782; CAI T, 1998, IN PRESS BIOCH BIOPH, V1390; Caplan MJ, 1997, AM J PHYSIOL-RENAL, V272, pF425, DOI 10.1152/ajprenal.1997.272.4.F425; CASCIO S, 1991, DEVELOPMENT, V113, P217; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN TR, 1989, CELL MOTIL CYTOSKEL, V12, P225, DOI 10.1002/cm.970120405; COOK J, 1983, J CELL BIOL, V97, P1823, DOI 10.1083/jcb.97.6.1823; Engvall E, 1980, Methods Enzymol, V70, P419; GALLAGHER PG, 1993, SEMIN HEMATOL, V30, P4; GOODMAN SR, 1981, P NATL ACAD SCI-BIOL, V78, P7570, DOI 10.1073/pnas.78.12.7570; GOODMAN SR, 1984, BRAIN RES BULL, V13, P813, DOI 10.1016/0361-9230(84)90239-9; GOODMAN SR, 1984, AM J PHYSIOL, V247, pC61, DOI 10.1152/ajpcell.1984.247.1.C61; GOODMAN SR, 1988, CRIT REV BIOCHEM MOL, V23, P171, DOI 10.3109/10409238809088319; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HARRIS HW, 1980, J BIOL CHEM, V255, P1512; HARRISON P, 1995, J NEUROSURG ANESTH, V7, P121, DOI 10.1097/00008506-199504000-00008; HOUSSAINT E, 1980, CELL DIFFER DEV, V9, P269, DOI 10.1016/0045-6039(80)90026-3; HU RJ, 1992, J BIOL CHEM, V267, P18715; KENNEDY SP, 1994, J BIOL CHEM, V269, P11400; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kwon Y, 1997, PHARMACEUT RES, V14, P780, DOI 10.1023/A:1012158607766; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDOUARIN NM, 1975, MED BIOL, V53, P427; LOMBARDO CR, 1994, J BIOL CHEM, V269, P29212; MA YP, 1993, MOL BRAIN RES, V18, P87, DOI 10.1016/0169-328X(93)90176-P; MAURICE M, 1988, J CELL SCI, V90, P79; Mishra L, 1997, ONCOGENE, V15, P2361, DOI 10.1038/sj.onc.1201405; MISHRA L, 1998, INT J DEV BIOL, V41, P747; Muller M, 1997, AM J PHYSIOL-GASTR L, V272, pG1285, DOI 10.1152/ajpgi.1997.272.6.G1285; NELSON WJ, 1991, BIOCHEM SOC T, V19, P1055, DOI 10.1042/bst0191055; PORTER GA, 1992, J CELL BIOL, V117, P997, DOI 10.1083/jcb.117.5.997; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEINFEST CW, 1990, GENET ANAL-BIOMOL E, V7, P64, DOI 10.1016/0735-0651(90)90042-E; THOMAS GH, 1994, DEVELOPMENT, V120, P2039; TSE WT, 1990, J CLIN INVEST, V86, P909, DOI 10.1172/JCI114792; Viel A, 1996, CURR OPIN CELL BIOL, V8, P49, DOI 10.1016/S0955-0674(96)80048-2; WINKELMANN JC, 1993, BLOOD, V81, P3173; ZIMMER WE, 1992, BRAIN RES, V594, P75, DOI 10.1016/0006-8993(92)91030-I	48	57	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					353	364		10.1038/sj.onc.1202313	http://dx.doi.org/10.1038/sj.onc.1202313			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927192				2022-12-28	WOS:000078166500008
J	Kharbanda, S; Yuan, ZM; Weichselbaum, R; Kufe, D				Kharbanda, S; Yuan, ZM; Weichselbaum, R; Kufe, D			Determination of cell fate by c-Abl activation in the response to DNA damage	ONCOGENE			English	Review						c-Abl; DNA damage; growth arrest; recombination; apoptosis	PROTEIN-KINASE-C; RADIATION-INDUCED APOPTOSIS; ATAXIA-TELANGIECTASIA GENE; NUCLEAR TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; DROSOPHILA-ABL; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; IONIZING-RADIATION; CATALYTIC SUBUNIT	The cellular response to DNA damage includes growth arrest and activation of DNA repair, Certain insights into how DNA damage is converted into intracellular signals that control the genotoxic stress response have been derived from the finding that the c-Abl protein tyrosine kinase is activated by ionizing radiation and other DNA-damaging agents. c-Abl associates with the DNA-dependent protein kinase (DNA-PK) and is activated by DNA-PK-dependent phosphorylation, The ataxia telangiectasia mutated (ATM) gene product also contributes to c-Abl activation, The demonstration that c-Abl binds to p53, induces the transactivation function of p53 and activates p21 expression has supported involvement of c-Abl in regulation of the p53-dependent G1 arrest response, Interaction between c-Abl and the Rad51 protein has also provided support for involvement of c-Abl in recombinational repair of DNA strand breaks, Defects in G1 arrest and repair predispose to replication of damaged templates and, in the event of irreparable DNA lesions, induction of apoptosis, The available evidence indicates that c-Abl effects proapoptotic function by a mechanism largely independent of p53, c-Abl also functions as an upstream effector of the proapoptotic JNK/SAPK and p38 MAPK pathways. In addition, c-Abl-dependent inhibition of PI 3-kinase contributes to the induction of apoptosis, The findings thus suggest that, in response to genotoxic stress, c-Abl functions in determining cell fate, that is growth arrest and repair or induction of apoptosis, The physiologic function of c-Abl may reside in control of the cellular response to DNA strand breaks that occur during DNA replication, genetic recombination and gene rearrangements.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Chicago	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA029431] Funding Source: NIH RePORTER; NCI NIH HHS [CA29431, CA 55241] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELSON HT, 1970, CANCER RES, V30, P2213; Agami R, 1998, ONCOGENE, V16, P1779, DOI 10.1038/sj.onc.1201708; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow AL, 1997, EMBO J, V16, P5207, DOI 10.1093/emboj/16.17.5207; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; CHEN PC, 1975, NATURE, V258, P427; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; Dikstein R, 1996, P NATL ACAD SCI USA, V93, P2387, DOI 10.1073/pnas.93.6.2387; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dorsch M, 1996, P NATL ACAD SCI USA, V93, P13131, DOI 10.1073/pnas.93.23.13131; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Game J., 1983, YEAST GENETICS FUNDA, P109; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Giniger E, 1998, NEURON, V20, P667, DOI 10.1016/S0896-6273(00)81007-7; GODDARD JM, 1986, P NATL ACAD SCI USA, V83, P2172, DOI 10.1073/pnas.83.7.2172; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GOGA A, 1995, ONCOGENE, V11, P791; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hardin JD, 1996, ONCOGENE, V12, P2669; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; Haynes R.H., 1981, MOL BIOL YEAST SACCH, P371; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HENKEMEYER MJ, 1988, MOL CELL BIOL, V8, P843, DOI 10.1128/MCB.8.2.843; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; HIRANO Y, 1995, ONCOGENE, V10, P1879; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; ISHII T, 1995, BIOCHEM BIOPH RES CO, V216, P970, DOI 10.1006/bbrc.1995.2715; ISHII T, 1993, J BIOL CHEM, V268, P18633; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jin SF, 1997, J BIOL CHEM, V272, P24763, DOI 10.1074/jbc.272.40.24763; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kharbanda S, 1998, ONCOGENE, V16, P1773, DOI 10.1038/sj.onc.1201934; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAVIN MF, 1995, TRENDS BIOCHEM SCI, V20, P382, DOI 10.1016/S0968-0004(00)89083-0; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Li MJ, 1996, P NATL ACAD SCI USA, V93, P10222, DOI 10.1073/pnas.93.19.10222; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MAESHIMA K, 1995, GENE, V160, P195, DOI 10.1016/0378-1119(95)00148-Y; MATTIONI T, 1995, ONCOGENE, V10, P1325; Milne GT, 1996, MOL CELL BIOL, V16, P4189; Milner LA, 1996, P NATL ACAD SCI USA, V93, P13014, DOI 10.1073/pnas.93.23.13014; MOORE KL, 1994, DEV BIOL, V164, P444, DOI 10.1006/dbio.1994.1214; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; PATERSON MC, 1979, CANCER RES, V39, P3725; PENDERGAST AM, 1987, MOL CELL BIOL, V7, P4280, DOI 10.1128/MCB.7.12.4280; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; RESNICK M A, 1987, P157; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SALEEM A, 1995, CELL GROWTH DIFFER, V6, P1651; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Ulrich E, 1998, ONCOGENE, V16, P825, DOI 10.1038/sj.onc.1201842; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VANETTEN RA, 1995, ONCOGENE, V10, P1977; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Walkenhorst J, 1996, ONCOGENE, V12, P1513; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1997, J BIOL CHEM, V272, P23485, DOI 10.1074/jbc.272.38.23485; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799; YUAN ZM, 1999, IN PRESS J BIOL CHEM; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	176	147	154	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 24	1998	17	25					3309	3318		10.1038/sj.onc.1202571	http://dx.doi.org/10.1038/sj.onc.1202571			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916993	Bronze			2022-12-28	WOS:000078048200012
J	Saikumar, P; Dong, Z; Weinberg, JM; Venkatachalam, MA				Saikumar, P; Dong, Z; Weinberg, JM; Venkatachalam, MA			Mechanisms of cell death in hypoxia/reoxygenation injury	ONCOGENE			English	Article						apoptosis; necrosis; Bax; Bcl-2; hypoxia; reoxygenation	FOCAL CEREBRAL-ISCHEMIA; CYTOCHROME-C; REPERFUSION INJURY; PROTEASE CASCADE; IN-VITRO; APOPTOSIS; BCL-2; RELEASE; NECROSIS; OXYGEN	Investigation of death pathways during cell injury in vivo caused by ischemia and reperfusion is of clinical importance, but technically difficult. Heterogeneity of cell types, differences between organ systems, diversity of death paradigms and exacerbation of tissue damage caused by inflammation are only some of the variables that need to be taken into account. With respect to the identification of necrosis and apoptosis in affected organs, technical issues related to preparation artifacts, occurrence of internucleosomal DNA cleavage in necrotic as well as apoptotic cells and other overlaps in death pathways bear consideration. In that caspase independent as well as caspase dependent processes cause cell death and that caspase inhibitors can act as anti-inflammatory agents, evaluation of ischemic death mechanisms in parenchymal cells needs to be performed with caution. When the effects of inflammation are removed by appropriate in vitro studies using purified or cultured cells, several mitochondrial factors that lead to cell death can be studied. Substantial evidence exists for the participation of electron transport defects, mitochondrial permeability transitions (MPT) and release of cytochrome c from mitochondria, effected by pro-apoptotic proteins such as Bax. The anti-apoptotic protein Bcl-2 exerts an overriding protective role in this type of injury by preserving mitochondrial structure and function. In contrast, caspase inhibitors cannot offer long-term protection to ischemically injured parenchymal cells regardless of how effectively they can inhibit apoptotic events, if the cells have suffered permanent mitochondrial damage impairing respiration.	Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA; Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA	University of Texas System; University of Texas Health San Antonio; University of Michigan System; University of Michigan	Saikumar, P (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.							Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Borutaite V, 1996, J MOL CELL CARDIOL, V28, P2195, DOI 10.1006/jmcc.1996.0211; CHAN PH, 1994, BRAIN PATHOL, V4, P59; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Chopp M, 1996, ACT NEUR S, V66, P21; Cotran R.S., 1998, ROBBINS PATHOLOGIC B; Dong Z, 1997, AM J PATHOL, V151, P1205; Dong Z, 1998, AM J PATHOL, V152, P231; Eguchi Y, 1997, CANCER RES, V57, P1835; ENGLER RL, 1989, AM J CARDIOL, V63, P19; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; FLITTER WD, 1993, BRIT MED BULL, V49, P545, DOI 10.1093/oxfordjournals.bmb.a072629; Frade JM, 1997, BIOESSAYS, V19, P827, DOI 10.1002/bies.950190913; GONZALEZFLECHA B, 1995, BBA-GEN SUBJECTS, V1243, P361, DOI 10.1016/0304-4165(94)00160-Y; GRANGER DN, 1988, AM J PHYSIOL, V255, pH1269, DOI 10.1152/ajpheart.1988.255.6.H1269; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Johnson K J, 1993, Curr Opin Nephrol Hypertens, V2, P625, DOI 10.1097/00041552-199307000-00014; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kajstura J, 1998, AM J CARDIOL, V82, p30K, DOI 10.1016/S0002-9149(98)00535-9; Kato H, 1997, EXP NEUROL, V148, P464, DOI 10.1006/exnr.1997.6707; Kaushal GP, 1998, AM J PHYSIOL-RENAL, V274, pF587, DOI 10.1152/ajprenal.1998.274.3.F587; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Leist M, 1997, BIOCHEM BIOPH RES CO, V236, P1, DOI 10.1006/bbrc.1997.6890; Lemaire C, 1998, FEBS LETT, V425, P266, DOI 10.1016/S0014-5793(98)00252-X; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li Y, 1998, J NEUROL SCI, V156, P119, DOI 10.1016/S0022-510X(98)00036-7; Lieberthal W, 1996, AM J PHYSIOL-RENAL, V271, pF477, DOI 10.1152/ajprenal.1996.271.3.F477; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacLellan WR, 1997, CIRC RES, V81, P137, DOI 10.1161/01.RES.81.2.137; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; MATSUYAMA T, 1995, MOL BRAIN RES, V34, P166, DOI 10.1016/0169-328X(95)00162-L; McCarthy NJ, 1998, CURR TOP DEV BIOL, V36, P259; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; MURFITT RR, 1978, J MOL CELL CARDIOL, V10, P109, DOI 10.1016/0022-2828(78)90036-6; NARO F, 1993, CARDIOSCIENCE, V4, P177; Noda T, 1998, AM J PHYSIOL-GASTR L, V274, pG270, DOI 10.1152/ajpgi.1998.274.2.G270; Nogae S, 1998, J AM SOC NEPHROL, V9, P620; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; PIPER HM, 1994, CARDIOVASC RES, V28, P1, DOI 10.1093/cvr/28.1.1; Piper HM, 1998, CARDIOVASC RES, V38, P291, DOI 10.1016/S0008-6363(98)00033-9; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; SAIKUMAR P, 1998, IN PRESS ONCOGENE; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; Shimizu S, 1996, ONCOGENE, V12, P2251; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Thiagarajan RR, 1997, THROMB HAEMOSTASIS, V78, P310; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Toleikis A, 1980, Adv Myocardiol, V2, P327; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Vogt M, 1998, FEBS LETT, V429, P67, DOI 10.1016/S0014-5793(98)00562-6; Wiegele G, 1998, NEPHROL DIAL TRANSPL, V13, P1158, DOI 10.1093/ndt/13.5.1158; WYLLIE AH, 1994, PHILOS T R SOC B, V345, P237, DOI 10.1098/rstb.1994.0099; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; ZAGER RA, 1993, CIRC RES, V73, P926, DOI 10.1161/01.RES.73.5.926; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	70	205	225	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 24	1998	17	25					3341	3349		10.1038/sj.onc.1202579	http://dx.doi.org/10.1038/sj.onc.1202579			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916996				2022-12-28	WOS:000078048200015
J	de Jong, R; van Wijk, A; Heisterkamp, N; Groffen, J				de Jong, R; van Wijk, A; Heisterkamp, N; Groffen, J			C3G is tyrosine-phosphorylated after integrin-mediated cell adhesion in normal but not in Bcr/Abl expressing cells	ONCOGENE			English	Article						C3G; Crkl; integrin; Bcr/Abl p210	CHRONIC MYELOGENOUS LEUKEMIA; SRC HOMOLOGY-3 DOMAIN; PROTOONCOGENE PRODUCT; ADAPTER PROTEIN; SIGNALING PATHWAYS; KINASE PATHWAY; CRK PROTEINS; R-RAS; C-ABL; P130(CAS)	The SH2-SH3 adaptor protein Crkl has been implicated in the signal transduction pathways of several membrane-bound receptors. Tyrosine phosphorylation of proteins associated with such signalling complexes can generate binding sites for the Crkl SH2-domain and can recruit proteins constitutively bound to Crkl via the Crkl SH3 domain into such complexes. In the current study we show that Crkl, but only a minor amount of the related Crk, form constitutive complexes in vivo with guanine nucleotide exchange factor C3G in 3T3 fibroblasts. Adhesion of both normal and transformed cells to fibronectin or other extracellular matrix proteins consistently induces the tyrosine-phosphorylation of C3G. Adhesion-induced tyrosine phosphorylation of C3G is dependent on an intact cytoskeleton and peaks at 5-10 min after attachment. In contrast, 3T3 cells stably transfected with Bcr/Abl P210 show a prominent reduction in the amount of C3G complexed to Crkl and do not exhibit tyrosine-phosphorylation of C3G upon spreading and attachment. These data establish that integrin-mediated cell adhesion results in Crkl-mediated tyrosine phosphorylation of C3G, a pathway which can be disrupted by Bcr/Abl.	Childrens Hosp Los Angeles, Inst Res, Dept Pathol, Sect Mol Carcinogenesis, Los Angeles, CA 90027 USA; USC, Sch Med, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California	Groffen, J (corresponding author), Childrens Hosp Los Angeles, Inst Res, Dept Pathol, Sect Mol Carcinogenesis, MS 103,4650 Sunset Blvd, Los Angeles, CA 90027 USA.		Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273	NATIONAL CANCER INSTITUTE [R01CA047456, R55CA047456, R01CA050248] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47456, CA 50248] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; de Jong R, 1997, J BIOL CHEM, V272, P32649, DOI 10.1074/jbc.272.51.32649; DEJONG R, 1995, ONCOGENE, V11, P1469; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; FELLER SM, 1995, ONCOGENE, V10, P1465; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6476; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; NICHOLS GL, 1994, BLOOD, V84, P2912; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; ODA T, 1994, J BIOL CHEM, V269, P22925; Petruzzelli L, 1996, J BIOL CHEM, V271, P7796, DOI 10.1074/jbc.271.13.7796; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Sattler M, 1996, ONCOGENE, V12, P839; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; TANAKA T, 1994, P NATL ACAD SCI USA, V91, P3433; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	39	30	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2805	2810		10.1038/sj.onc.1202207	http://dx.doi.org/10.1038/sj.onc.1202207			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840945				2022-12-28	WOS:000077146700014
J	Saville, MK; Watson, RJ				Saville, MK; Watson, RJ			The cell-cycle regulated transcription factor B-Myb is phosphorylated by cyclin A/Cdk2 at sites that enhance its transactivation properties	ONCOGENE			English	Article						B-Myb; cyclin A; Cdk2; phosphorylation; transcriptional regulation	GENE V-MYB; C-MYB; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; S-PHASE; HEMATOPOIETIC-CELLS; EXPRESSION; PRODUCT; ACTIVATION; PROLIFERATION	Expression of the B-Myb transcription factor is upregulated during late G(1) phase of the cell cycle by an E2F-dependent transcriptional mechanism. B-Myb is specifically phosphorylated during S phase, suggesting that a cyclin-dependent kinase (Cdk) regulates its activity. Consistent with this notion, the S phase-specific cyclin A/Cdk2 was found previously to enhance B-Myb transactivation activity in cotransfected cells. In this study we provide evidence that B-Myb is a direct physiological target for cyclin A/Cdk2. We demonstrate that B-Myb is an in vitro substrate for cyclin A/Cdk2, but not for cyclin D1/Cdk4 or cyclin E/Cdk2. By mutating candidate Cdk2 phosphorylation sites, we show that B-Myb is phosphorylated at Thr447, Thr490, Thr497 and Ser581 by cyclin A/Cdk2 in vitro and that these sites are also phosphorylated in cycling U-2 OS cells. Inhibition of endogenous Cdk2 by dominant negative Cdk2 attenuated phosphorylation of Thr447, Thr490 and Thr497, but had no effect upon Ser581 modification. B-Myb transactivation activity was significantly reduced in a mutant containing amino acid substitutions at all four identified cyclin A/Cdk2 sites and was constitutively low in Saos-2 cells where endogenous cyclin A/Cdk2 activity was unable to phosphorylate ectopically expressed B-Myb. These data indicate that phosphorylation by cyclin A/Cdk2 is directly involved in enhancing B-Myb transactivation activity and that levels of endogenous cyclin A/Cdk2 activity may contribute to cell line-specific B-Myb function.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Sect Virol & Cell Biol, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, London SW7 2AZ, England	Imperial College London; Imperial College London; Ludwig Institute for Cancer Research	Watson, RJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Sect Virol & Cell Biol, St Marys Campus, London SW7 2AZ, England.							Ansieau S, 1997, J MOL MED-JMM, V75, P815, DOI 10.1007/s001090050170; ARSURA M, 1992, BLOOD, V79, P2708; Bennett JD, 1996, ONCOGENE, V13, P1073; Bies J, 1996, ONCOGENE, V12, P355; BOUWMEESTER T, 1994, ONCOGENE, V9, P1029; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brandt TL, 1997, J BIOL CHEM, V272, P6278, DOI 10.1074/jbc.272.10.6278; Chang ZF, 1998, J BIOL CHEM, V273, P12095, DOI 10.1074/jbc.273.20.12095; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FOOS G, 1993, ONCOGENE, V8, P1775; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOLAY J, 1991, BLOOD, V77, P149; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Horton LE, 1997, ONCOGENE, V14, P491, DOI 10.1038/sj.onc.1200851; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kamano H, 1995, ONCOGENE, V11, P2575; KATO J, 1983, GENE DEV, V7, P331; KITAGAWA M, 1995, ONCOGENE, V10, P229; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; Marhamati DJ, 1996, J BIOL CHEM, V271, P3359; Mulligan GJ, 1998, MOL CELL BIOL, V18, P206, DOI 10.1128/MCB.18.1.206; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; NOMURA N, 1998, NUCLEIC ACIDS RES, V16, P11075; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PEEPER DS, 1995, ONCOGENE, V10, P39; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; Robinson C, 1996, ONCOGENE, V12, P1855; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; Saville MK, 1998, ADV CANCER RES, V72, P109; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sitzmann J, 1996, ONCOGENE, V12, P1889; TAKEMOTO Y, 1994, FEBS LETT, V350, P55, DOI 10.1016/0014-5793(94)00733-0; TASHIRO S, 1995, ONCOGENE, V10, P1699; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; Zarkowska T, 1997, ONCOGENE, V14, P249, DOI 10.1038/sj.onc.1200824; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	66	71	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	1998	17	21					2679	2689		10.1038/sj.onc.1202503	http://dx.doi.org/10.1038/sj.onc.1202503			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840932				2022-12-28	WOS:000077146700001
J	Floettmann, JL; Eliopoulos, AG; Jones, M; Young, LS; Rowe, M				Floettmann, JL; Eliopoulos, AG; Jones, M; Young, LS; Rowe, M			Epstein-Barr virus latent membrane protein-1 (LMP1) signalling is distinct from CD40 and involves physical cooperation of its two C-terminus functional regions	ONCOGENE			English	Article						Epstein-Barr virus; LMP-1; NF-kappa B; CD54; CD40; TNF-R	NF-KAPPA-B; LYMPHOCYTE GROWTH TRANSFORMATION; TRANSIENT EXPRESSION; EPITHELIAL-CELLS; BINDING-SITES; ACTIVATION; GENE; INDUCTION; TRAF2; MEMBRANE-PROTEIN-1	The Epstein-Barr virus (EBV) encoded Latent Membrane Protein-1 (LMP1) mimics a constitutively active receptor molecule, and has been shown to activate NF-kappa B and the MAPK and JNK pathways, Two regions within the cytosolic domain of LMP1 have been found to effect cell signalling. One of these, the carboxy-terminal activation region-1 (CTAR1), binds members of the TRAF family of proteins, and the other (CTAR2) binds TRADD, suggesting that LMP1 transduces signals similarly to the Tumour Necrosis Factor Receptor family of receptors, The ability to bind TRAFs, to activate NF-kappa B and the JNK pathway, to upregulate cellular genes such as CD54 (ICAM-1 adhesion molecule), and to affect cell growth and apoptosis has led to the suggestion that LMP1 signalling is similar to, or even identical to CD40, However, we now show that while ligand-induced CD40 signalling is impaired in the Jurkat T cell line, LMP1 was fully functional; therefore demonstrating that LMP1 and CD40 signalling differ, Mutated LMP1 genes, in which one or other of the CTAR1 and CTAR2 domains was non-functional, behaved more like CD40 in being unable to upregulate the CD54 cell surface marker in Jurkat cells, However, the CTAR1 domain of LMP1, which shared a TRAF-binding sequence motif with CD40, differed from CD40 in being unable to activate NF-kappa B in Jurkat, Cotransfection experiments with LMP1 mutants demonstrated that CTAR1 can cooperative with CTAR2 on separate LMP1 molecules, provided that they exist within the same oligomeric complex.	Cardiff Univ, Dept Med, Cardiff CF4 4XX, S Glam, Wales; Univ Birmingham, Sch Med, Inst Canc Studies, Birmingham B15 2TJ, W Midlands, England	Cardiff University; University of Birmingham	Rowe, M (corresponding author), Cardiff Univ, Dept Med, Heath Pk, Cardiff CF4 4XX, S Glam, Wales.		ELIOPOULOS, ARISTIDES/ABI-6632-2020; Rowe, Martin/B-2880-2009; Young, Lawrence S/B-7213-2009; ELIOPOULOS, ARISTIDES/R-9449-2018	ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Rowe, Martin/0000-0003-4139-7326; Young, Lawrence S/0000-0003-3919-4298; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761				ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; BAICHWAL VR, 1988, ONCOGENE, V2, P461; Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509; BRATTSAND G, 1990, J IMMUNOL, V144, P3651; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Eliopoulos AG, 1997, ONCOGENE, V14, P2899, DOI 10.1038/sj.onc.1201258; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Franken M, 1996, J VIROL, V70, P7819, DOI 10.1128/JVI.70.11.7819-7826.1996; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENRIQUEZ N, 1998, UNPUB; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HUEN DS, 1995, ONCOGENE, V10, P549; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; JEFFERIES WA, 1985, J EXP MED, V162, P117, DOI 10.1084/jem.162.1.117; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; PENG M, 1992, ONCOGENE, V7, P1775; PILON M, 1991, J IMMUNOL, V146, P1047; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Roberts ML, 1998, VIROLOGY, V240, P93, DOI 10.1006/viro.1997.8901; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; ZimberStrobl U, 1996, EMBO J, V15, P7070, DOI 10.1002/j.1460-2075.1996.tb01098.x	46	52	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	1998	17	18					2383	2392		10.1038/sj.onc.1202144	http://dx.doi.org/10.1038/sj.onc.1202144			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811470				2022-12-28	WOS:000076723300013
J	Konishi, H; Takahashi, T; Kozaki, K; Yatabe, Y; Mitsudomi, T; Fujii, Y; Sugiura, T; Matsuda, H; Takahashi, T; Takahashi, T				Konishi, H; Takahashi, T; Kozaki, K; Yatabe, Y; Mitsudomi, T; Fujii, Y; Sugiura, T; Matsuda, H; Takahashi, T; Takahashi, T			Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers	ONCOGENE			English	Article						17p13.3; LOH; p53; tumor suppressor gene; lung cancer	DINUCLEOTIDE REPEAT POLYMORPHISM; SQUAMOUS-CELL CARCINOMA; SHORT ARM; CHROMOSOME 17P13.3; BREAST-CANCER; HUMAN GENOME; ALLELE LOSS; MUTATIONS; DISTINCT; 17P	The short arm of chromosome 17 is one of the most frequently affected chromosomal regions in lung cancers, while there is solid evidence that the p53 gene at 17p13.1 is a target for frequent 17p deletions. In the present study, we re-evaluated 17p deletions in lung cancers by conducting a detailed analysis of the minimum deleted region(s) on 17p with reference to the p53 gene status in each 100 primary lung cancer cases. In addition to the p53 locus at 17p13.1, the presence of an independent, commonly deleted region(s) at 17p13.3 was identified, Furthermore, loss of heterozygosity (LOH) at 17p13.3 was shown to be even more frequent than that at 17p13.1 and it appeared to occur in the absence of p53 mutation and/or 17p13.1 deletion. These results suggest that in addition to the p53 gene at 17p13.1, an as yet unidentified tumor suppressor gene(s) residing at 17p13.3 might play a role in lung carcinogenesis possibly in an earlier phase than the p53 gene. This would warrant future studies to identify the putative tumor suppressor gene at 17p13.3 in order to gain a better understanding of the molecular pathogenesis of this fatal disease.	Aichi Canc Ctr, Res Inst, Ultrastruct Res Lab, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr, Res Inst, Pathophysiol Unit, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr, Res Inst, Immunol Lab, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr Hosp, Dept Pathol & Clin Labs, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr Hosp, Dept Thorac Surg, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr Hosp, Dept Internal Med, Chikusa Ku, Nagoya, Aichi 464, Japan; Osaka Univ, Sch Med, Dept Surg 1, Suita, Osaka 565, Japan; Gifu Univ, Sch Med, Dept Surg 2, Gifu 500, Japan; Nagoya City Univ, Sch Med, Dept Surg 2, Mizuho Ku, Nagoya, Aichi 467, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Osaka University; Gifu University; Nagoya City University	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Ultrastruct Res Lab, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 464, Japan.		Kozaki, Ken-ichi/M-6281-2014; Takahashi, Takashi/I-7262-2014; YATABE, Yasushi/J-6461-2014	Kozaki, Ken-ichi/0000-0003-3286-819X; Takahashi, Takashi/0000-0003-0615-7001; YATABE, Yasushi/0000-0003-1788-559X; Konishi, Hiroyuki/0000-0003-1131-4905; Mitsudomi, Tetsuya/0000-0001-9860-8505				BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; BIEGEL JA, 1992, CANCER RES, V52, P3391; CARROZZO R, 1993, HUM MOL GENET, V2, P615, DOI 10.1093/hmg/2.5.615; CHIBA I, 1990, ONCOGENE, V5, P1603; Chung GTY, 1995, ONCOGENE, V11, P2591; COGEN PH, 1992, AM J HUM GENET, V50, P584; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CORNELIS RS, 1994, CANCER RES, V54, P4200; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FUJIMORI M, 1991, CANCER RES, V51, P89; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; GERKEN SC, 1995, AM J HUM GENET, V56, P484; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Haataja L, 1997, CANCER RES, V57, P32; HIBI K, 1992, ONCOGENE, V7, P445; HORIO Y, 1994, ONCOGENE, V9, P1231; HORIO Y, 1993, CANCER RES, V53, P1; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kondo M, 1996, ONCOGENE, V12, P1365; LEDBETTER SA, 1990, GENOMICS, V7, P264, DOI 10.1016/0888-7543(90)90549-A; LUDWIG CU, 1991, INT J CANCER, V49, P661, DOI 10.1002/ijc.2910490506; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; MERLO GR, 1994, CANCER GENET CYTOGEN, V76, P106, DOI 10.1016/0165-4608(94)90458-8; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; MINNA JD, 1997, CANC PRINCIPLES PRAC, V1, P849; OLIPHANT AR, 1991, NUCLEIC ACIDS RES, V19, P4794; PARK SY, 1995, CANCER GENET CYTOGEN, V79, P74, DOI 10.1016/0165-4608(94)00103-I; Phillips NJ, 1996, CANCER RES, V56, P606; RADFORD DM, 1995, CANCER RES, V55, P3399; SATO T, 1990, CANCER RES, V50, P7184; SAXENA A, 1992, CANCER RES, V52, P6716; Schultz DC, 1996, CANCER RES, V56, P1997; STACK M, 1995, HUM MOL GENET, V4, P2047, DOI 10.1093/hmg/4.11.2047; SUZUKI H, 1992, CANCER RES, V52, P734; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; Todd S, 1997, CANCER RES, V57, P1344; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WILLIAMSON MP, 1994, GENE CHROMOSOME CANC, V9, P108, DOI 10.1002/gcc.2870090206; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOYAMA S, 1992, CANCER RES, V52, P873	49	53	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2095	2100		10.1038/sj.onc.1202128	http://dx.doi.org/10.1038/sj.onc.1202128			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798680				2022-12-28	WOS:000076540900008
J	Chen, WY; Butler, M; Rao, PH; Chaganti, SR; Louie, DC; Dalla-Favera, R; Chaganti, RSK				Chen, WY; Butler, M; Rao, PH; Chaganti, SR; Louie, DC; Dalla-Favera, R; Chaganti, RSK			The t(2;3)(q21;q27) translocation in non-Hodgkin's lymphoma displays BCL6 mutations in the 5 ' regulatory region and chromosomal breakpoints distant from the gene	ONCOGENE			English	Article						BCL6 mutation; 3q27 translocation; NHL	B-CELL LYMPHOMA; GERMINAL-CENTER FORMATION; FINGER ENCODING GENE; C-MYC; 3Q27 TRANSLOCATION; MALIGNANT-LYMPHOMA; BURKITT-LYMPHOMA; ABNORMALITIES; LAZ3/BCL6; PROTEIN	The BCL6 gene, mapped at the chromosomal band 3q27, encodes a POZ/Zinc finger transcription repressor protein, It is frequently activated in Non-Hodgkin's lymphomas (NHL) by translocations with breakpoints clustering in the 5' major breakpoint region (MBR) as well as by mutations in the same region, The translocations lead to BCL6 activation by substitution of promoters of rearranging genes derived from the reciprocal chromosomal partners such as IG. We report the molecular genetic analysis of a novel t(2;3)(q21;q27) translocation subset in NHL comprising three cases without apparent BCL6 involvement in the translocation, Southern blot analysis of tumor DNAs utilizing BCL6 MBR probes revealed no rearrangement in two cases, Two rearranged bands in the third case resulted from a deletion in one allele and a mutation in the other allele, Southern blot analysis of DNA from one of the two tumors without BCL6 rearrangement, using a probe derived from the recently identified alternative breakpoint region (ABR), showed a rearrangement,The ABR is located 200-270 kb telomeric to MBR, Mutations were identified in the previously reported hypermutable region of BCL6 in all three tumors, In one, the mutant allele alone was found to be expressed by RT-PCR analysis of RNA, These results demonstrate the presence of 3q27 translocation breakpoints at a distance from BCL6 suggesting distant breaks that deregulate the gene or involvement of other genes that may be subject to rearrangement.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, Div Oncol, New York, NY 10032 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Columbia University	Chaganti, RSK (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA044029, R01CA066999] Funding Source: NIH RePORTER; NCI NIH HHS [CA44029, CA66999] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akasaka T, 1997, CANCER RES, V57, P7; AXELSON H, 1994, INT J CANCER, V56, P418, DOI 10.1002/ijc.2910560322; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; Baron BW, 1997, GENE CHROMOSOME CANC, V19, P14, DOI 10.1002/(SICI)1098-2264(199705)19:1<14::AID-GCC3>3.0.CO;2-3; BASTARD C, 1992, BLOOD, V79, P2527; BENITEZ J, 1992, CANCER GENET CYTOGEN, V59, P68, DOI 10.1016/0165-4608(92)90161-Z; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; BLOOMFIELD CD, 1983, CANCER RES, V43, P2975; Butler M., 1997, Blood, V90, p316A; CHAGANTI SR, 1998, IN PRESS GENES CHROM; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DALLERY E, 1995, ONCOGENE, V10, P2171; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; GaliegueZouitina S, 1995, CR ACAD SCI III-VIE, V318, P1125; JOOS S, 1992, CANCER RES, V52, P6547; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KONISHI H, 1990, CANCER RES, V50, P2698; KORNBLAU SM, 1991, HEMATOL ONCOL, V9, P63; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; Nakamura Y, 1996, LEUKEMIA, V10, P658; OFFIT K, 1989, BLOOD, V74, P1876; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; Seyfert VL, 1996, ONCOGENE, V12, P2331; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TWEEDDALE ME, 1987, BLOOD, V69, P1307; WLODARSKA I, 1995, GENE CHROMOSOME CANC, V14, P1, DOI 10.1002/gcc.2870140102; XU L, 1994, INT J CANCER, V59, P383, DOI 10.1002/ijc.2910590316; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YE BHH, 1993, CANCER RES, V53, P2732	36	22	22	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1717	1722		10.1038/sj.onc.1202098	http://dx.doi.org/10.1038/sj.onc.1202098			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796700	Green Accepted			2022-12-28	WOS:000076200100009
J	Sundaresan, V; Chung, G; Heppell-Parton, A; Xiong, J; Grundy, C; Roberts, I; James, L; Cahn, A; Bench, A; Douglas, J; Minna, J; Sekido, Y; Lerman, M; Latif, F; Bergh, J; Li, H; Lowe, N; Ogilvie, D; Rabbitts, P				Sundaresan, V; Chung, G; Heppell-Parton, A; Xiong, J; Grundy, C; Roberts, I; James, L; Cahn, A; Bench, A; Douglas, J; Minna, J; Sekido, Y; Lerman, M; Latif, F; Bergh, J; Li, H; Lowe, N; Ogilvie, D; Rabbitts, P			Homozygous deletions at 3p12 in breast and lung cancer	ONCOGENE			English	Article						DUTT1/Hrobo-1; lung cancer; U2020 deletion; tumour suppressor gene; familial non-specific dementia	YEAST ARTIFICIAL CHROMOSOMES; MOLECULAR-GENETIC CHANGES; CELL-LINE U2020; SHORT ARM; CLONING; CARCINOMA; SEQUENCES; TUMORS; PCR; DNA	We have constructed a physical map of the region homozygously deleted in the U2020 cell line at 3p12, including the location of putative CpG islands. Adjacent to one of these islands, we have identified and cloned a new gene (DUTT1) and used probes from this gene to detect two other homozygous deletions occurring in lung and breast carcinomas: the smallest deletion is within the gene itself and would result in a truncated protein. The DUTT1 gene is a member of the neural cell adhesion molecule family, although its widespread expression suggests it plays a less specialized role compared to other members of the family.	Med Res Council Ctr, Macclesfield SK10 4TG, Cheshire, England; Zeneca Pharmaceut, Macclesfield SK10 4TG, Cheshire, England; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; NCI, Frederick Canc Res Facil, Immunobiol Lab, Frederick, MD 21701 USA; Univ Uppsala, Akad Sjukhuset, Dept Oncol, S-75185 Uppsala, Sweden	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uppsala University; Uppsala University Hospital	Rabbitts, P (corresponding author), Med Res Council Ctr, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.		Sekido, Yoshitaka/P-9756-2015	Bergh, Jonas/0000-0001-5526-1847; Sekido, Yoshitaka/0000-0002-2428-3848	NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABURENT H, 1994, AM J HUM GENET S, V55, P269; ANAND R, 1990, NUCLEIC ACIDS RES, V18, P1951, DOI 10.1093/nar/18.8.1951; BROWN J, 1995, HUM MOL GENET, V4, P1625, DOI 10.1093/hmg/4.9.1625; BUTLER R, 1992, GENOMICS, V12, P42, DOI 10.1016/0888-7543(92)90404-G; Chung GTY, 1995, ONCOGENE, V11, P2591; Chung GTY, 1996, CANCER RES, V56, P1609; DALY MC, 1991, GENOMICS, V9, P113, DOI 10.1016/0888-7543(91)90227-6; Fasman KH, 1996, NUCLEIC ACIDS RES, V24, P57, DOI 10.1093/nar/24.1.57; Franklin WA, 1997, J CLIN INVEST, V100, P2133, DOI 10.1172/JCI119748; GANLY PS, 1992, GENOMICS, V12, P221, DOI 10.1016/0888-7543(92)90369-4; GAZDAR AF, 1994, COLD SPRING HARB SYM, V59, P565, DOI 10.1101/SQB.1994.059.01.063; GEMMILL RM, 1995, NATURE, V377, P299; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HEPPELLPARTON AC, 1994, CYTOGENET CELL GENET, V66, P42, DOI 10.1159/000133661; HIBI K, 1992, ONCOGENE, V7, P445; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; LATIF F, 1992, GENE CHROMOSOME CANC, V5, P119, DOI 10.1002/gcc.2870050205; LERMAN MI, 1991, HUM GENET, V86, P567; OGILVIE D, 1993, METHOD MOL BIOL, V54, P131; PANDIS N, 1993, GENE CHROMOSOME CANC, V6, P151, DOI 10.1002/gcc.2870060304; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; RABBITTS PH, 1994, BRIT MED BULL, V50, P688, DOI 10.1093/oxfordjournals.bmb.a072917; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; Sundaresan V, 1998, MOL CELL NEUROSCI, V11, P29, DOI 10.1006/mcne.1998.0672; SUNDARESAN V, 1995, ANN ONCOL, V6, pS27; TASSONE F, 1995, HUM MOL GENET, V4, P1509, DOI 10.1093/hmg/4.9.1509; THON VJ, 1993, J BIOL CHEM, V268, P7509; TODD S, 1995, GENOMICS, V25, P19, DOI 10.1016/0888-7543(95)80105-U; VALDES JM, 1994, P NATL ACAD SCI USA, V91, P5377, DOI 10.1073/pnas.91.12.5377	31	89	92	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1723	1729		10.1038/sj.onc.1202103	http://dx.doi.org/10.1038/sj.onc.1202103			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796701				2022-12-28	WOS:000076200100010
J	Ohtani, K; Iwanaga, R; Nakamura, M; Ikeda, M; Yabuta, N; Tsuruga, H; Nojima, H				Ohtani, K; Iwanaga, R; Nakamura, M; Ikeda, M; Yabuta, N; Tsuruga, H; Nojima, H			Cell growth-regulated expression of mammalian MCM5 and MCM6 genes mediated by the transcription factor E2F	ONCOGENE			English	Article						mammalian MCM; E2F; promoter; cell cycle; DNA replication	S-PHASE ENTRY; REPLICATION LICENSING SYSTEM; DNA-REPLICATION; MCM/P1 PROTEINS; BUDDING YEAST; HUMAN HOMOLOG; CYCLE; COMPONENT; APOPTOSIS; FAMILY	Initiation of DNA replication requires the function of MCM gene products, which participate in ensuring that DNA replication occurs only once in the cell cycle, Expression of all mammalian genes of the MCM family is induced by growth stimulation, unlike yeast, and the mRNA levels peak at G1/S boundary, In this study, we examined the transcriptional activities of isolated human MCM gene promoters. Human MCMS and MCM6 promoters with mutation in the E2F sites failed in promoter regulation following serum stimulation and exogenous E2F expression. In addition, me identified a novel E2F-Like sequence in human MCM6 promoter which cooperates with the authentic E2F sites in E2F-dependent regulation. Forced expression of E2F1 could induce expression of all members of the endogenous MCM genes in rat embryonal fibroblast REF52 cells. Our results demonstrated that the growth-regulated expression of mammalian MCM5 and MCM6 genes, and presumably other MCM members, is primarily regulated by E2F through binding to multiple E2F sites in the promoters.	Tokyo Med & Dent Univ, Human Gene Sci Ctr, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Grad Sch Dent, Dept Dev Biol, Tokyo 1138549, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Mol Genet, Suita, Osaka 5650871, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Osaka University	Nakamura, M (corresponding author), Tokyo Med & Dent Univ, Human Gene Sci Ctr, Tokyo 1138510, Japan.							BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Fujita M, 1996, BIOCHEM BIOPH RES CO, V219, P604, DOI 10.1006/bbrc.1996.0280; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; Kiyono T, 1996, BBA-GENE STRUCT EXPR, V1307, P31, DOI 10.1016/0167-4781(96)00057-7; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Kubota Y, 1997, EMBO J, V16, P3320, DOI 10.1093/emboj/16.11.3320; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; NEVINS JR, 1992, SCIENCE, V258, P424; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; Tsuruga H, 1997, GENES CELLS, V2, P381, DOI 10.1046/j.1365-2443.1997.1290327.x; Tsuruga H, 1997, BIOCHEM BIOPH RES CO, V236, P118, DOI 10.1006/bbrc.1997.6865; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	31	110	114	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2299	2309		10.1038/sj.onc.1202544	http://dx.doi.org/10.1038/sj.onc.1202544			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327050				2022-12-28	WOS:000079595500002
J	Zhu, JH; Jiang, JY; Zhou, WJ; Zhu, KC; Chen, XB				Zhu, JH; Jiang, JY; Zhou, WJ; Zhu, KC; Chen, XB			Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity	ONCOGENE			English	Article						p53; p21(wafl/cipl); apoptosis; cell cycle arrest	WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION; GROWTH ARREST; TUMOR-CELLS; IN-VIVO; PATHWAY; P21(WAF1/CIP1); IDENTIFICATION; SUPPRESSION; INHIBITOR	Activation of the p53 tumor suppressor protein can lead to either cell cycle arrest or apoptosis. Several functional domains necessary for mediating cell cycle arrest and apoptosis in p53 have been mapped, e.g., the proline-rich domain. The proline-rich domain is located within residues 60-90, which comprise five PXXP motifs (where P represents proline and X any amino acid). To further delineate the function of the proline-rich domain and its potential role in transactivation, we generated several groups of cell lines that inducibly express various p53 mutants using a tetracycline-regulated expression system. We found that p53(Delta 62-91), which lacks all five PXXP motifs in human p53, is capable of inducing cell cycle arrest but not apoptosis, while p53(gln22-ser23/Delta 62-91), which contains a double point mutation in the activation domain as well as deletion of the proline-rich domain, completely loses its activity. However, p53(Delta 74-91), which contains only one PXXP motif at its N-terminus, is not only capable of inducing cell cycle arrest but also retains a partial apoptotic activity. Furthermore, we found that deletion of the proline-rich region has no or very mild effects on activation of several transiently transfected p53 target gene promoters, i.e., the p21, MDM2, BAX, and GADD45 promoters. However, such deletion differentially affects p53 induction of endogenous target genes, i.e., induction of p21, MDM2, BTG2, p85, PIG3, PIG6 and PIG11 was reduced or abrogated but induction of BAX, KILLER/DR5, PIG2, PIG7 and PIGS was not substantially affected. Interestingly, induction of GADD45 was enhanced. These results suggest that the proline-rich region may play a role in chromatin remodeling, which counteracts chromatin-mediated repression for some of the endogenous p53 target genes.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, CB-2803, Augusta, GA 30912 USA.			Zhu, Kuichun/0000-0002-3594-5616	NCI NIH HHS [CA76069] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076069, R29CA076069] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; GOTTLIEB TM, 1996, IOCH BIOPHYS ACTA, V1287, P77; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	30	100	102	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2149	2155		10.1038/sj.onc.1202533	http://dx.doi.org/10.1038/sj.onc.1202533			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321740				2022-12-28	WOS:000079346200013
J	Hurlstone, AFL; Reid, G; Reeves, JR; Fraser, J; Strathdee, G; Rahilly, M; Parkinson, EK; Black, DM				Hurlstone, AFL; Reid, G; Reeves, JR; Fraser, J; Strathdee, G; Rahilly, M; Parkinson, EK; Black, DM			Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines	ONCOGENE			English	Article						CAVEOLIN-1; CpG island; methylation; tumour suppressor gene	ONCOGENICALLY TRANSFORMED-CELLS; PRIMARY BREAST-CANCER; ROUS-SARCOMA VIRUS; SUPPRESSOR GENE; FREQUENT LOSS; LONG ARM; TYROSINE PHOSPHORYLATION; INDEFINITE DIVISION; PROTEIN-COMPONENT; MEMBRANE-PROTEIN	We identified CAVEOLIN-1 as a candidate for a tumour suppresser gent mapping to human chromosome 7q31.1. A number of studies suggest that caveolin could function as a tumour suppressor. Expression of caveolin, and in turn the number of caveolae within a cell, are inversely correlated with the transforming ability of numerous oncoproteins, including H-ras, v-abl, and bcr-abl, and caveolin is a major transformation-dependent substrate of v-src. Heterologous expression of caveolin has been shown to abrogate anchorage-independent growth and induce apoptosis in transformed fibroblasts and also to suppress anchorage-independent growth in human mammary carcinoma cells. We have analysed the status and expression of the human CA VEOLIN-1 gene in primary tumours and tumour-derived cell lines. We found no evidence for mutation of CAVEOLIN-1 in human cancers, Additionally, we found that while the first two exons of CAVEOLIN-1 are associated with a CpG island, this is not methylated in either primary tumours or in tumour-derived cell lines in which Caveolin-1 expression is low or undetectable. The level of expression of Caveolin-1 does not correlate,vith loss of heterozygosity at the CAVEOLIN-1 locus in these same cell lines. Contrary to other published studies, we have shown that CAVEOLIN-1 is not expressed in normal breast ductal epithelial cells in vivo. CAVEOLIN-1 is however highly expressed in breast myoepithelial cells and its expression is retained in tumours derived from breast myoepithelium. Together our data refute a role for CAVEOLIN-1 as a breast tumour suppressor gene in vivo.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Univ Glasgow, Dept Med Oncol, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Stobhill Gen Hosp, Dept Pathol, Glasgow G21 3UW, Lanark, Scotland; Univ Glasgow, Royal Infirm, Dept Surg, Glasgow G31 2ER, Lanark, Scotland	Beatson Institute; Beatson Institute; University of Glasgow; Royal Infirmary of Edinburgh; University of Glasgow	Black, DM (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland.			Strathdee, Gordon/0000-0001-9681-8429; Reid, George/0000-0002-0298-693X; Hurlstone, Adam/0000-0001-5260-9457				Achille A, 1996, CANCER RES, V56, P3808; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CUTHBERT AP, 1995, CYTOGENET CELL GENET, V71, P68, DOI 10.1159/000134066; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FAN JY, 1983, J CELL SCI, V61, P219; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; HERMAN JG, 1995, CANCER RES, V55, P4525; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Kerr J, 1996, ONCOGENE, V13, P1815; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Loughran O, 1996, ONCOGENE, V13, P561; Loughran O, 1997, ONCOGENE, V14, P1955, DOI 10.1038/sj.onc.1201028; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; REESE MG, 1996, LARGE SCALE SEQUENCI; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHULER GD, 1996, SCIENCE, V274, P50; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; TAKAHASHI S, 1995, CANCER RES, V55, P4114; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Zenklusen JC, 1996, MOL CARCINOGEN, V15, P167; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; Zenklusen JC, 1997, ONCOGENE, V14, P109, DOI 10.1038/sj.onc.1200806; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zenklusen JC, 1996, GENOME RES, V6, P1070, DOI 10.1101/gr.6.11.1070	50	118	120	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	1999	18	10					1881	1890		10.1038/sj.onc.1202491	http://dx.doi.org/10.1038/sj.onc.1202491			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086342				2022-12-28	WOS:000079090000011
J	Abraham, J; Spaner, D; Benchimol, S				Abraham, J; Spaner, D; Benchimol, S			Phosphorylation of p53 protein in response to ionizing radiation occurs at multiple sites in both normal and DNA-PK deficient cells	ONCOGENE			English	Article						p53; phosphorylation; DNA-PK; scid; ionizing radiation	PHOSPHATIDYLINOSITOL 3-KINASE; MOUSE CELLS; KINASE; DAMAGE; MICE; APOPTOSIS; INDUCTION; MUTATION; TRANSACTIVATION; ACTIVATION	The tumour suppressor gene product, p53, is involved in mediating cellular responses to DNA damage including growth arrest and/or apoptosis, The mechanism by which p53 protein senses the presence of damaged DNA is not understood. The possibility that p53 may be posttranslationally modified by enzymes that are activated in response to DNA damage including DNA-dependent protein kinase (DNA-PK), poly(ADP-ribose) polymerase and stress activated protein kinase has received considerable attention. Recent studies have indicated that DNA-PK is not required for the transactivation or apoptosis-promoting activities of p53 protein. However, the possibility that other functions of p53 may be dependent on phosphorylation by DNA-PK has not been explored. Here we describe a series of experiments that compares the expression, function and phosphorylation status of p53 protein in normal and DNA-PK-deficient scid cells. While several novel p53 phosphoforms are generated in response to DNA damage in normal cells, the same phosphoforms are observed in scid cells.	Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Benchimol, S (corresponding author), Univ Toronto, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Benchimol, Samuel/0000-0003-3433-890X				ADAMS LD, 1995, CURRENT PROTOCOLS MO, V2; Anderson Carl W., 1994, Seminars in Cell Biology, V5, P427, DOI 10.1006/scel.1994.1050; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Bogue MA, 1996, GENE DEV, V10, P553, DOI 10.1101/gad.10.5.553; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; Chernov MV, 1997, ONCOGENE, V14, P2503, DOI 10.1038/sj.onc.1201104; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; Di JA, 1996, J EXP MED, V183, P1923, DOI 10.1084/jem.183.4.1923; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOVER R, 1994, J CELL SCI, V107, P1181; FISCELLA M, 1994, ONCOGENE, V9, P3249; FISCELLA M, 1993, ONCOGENE, V8, P1519; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; FUCHS B, 1995, ONCOGENE, V10, P789; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Huang LC, 1996, CANCER RES, V56, P2940; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KHANNA KK, 1993, ONCOGENE, V8, P3307; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Mayo LD, 1997, CANCER RES, V57, P5013; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; Price BD, 1996, CANCER RES, V56, P246; Rathmell WK, 1997, CANCER RES, V57, P68; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHIMONKEVITZ R, 1984, J IMMUNOL, V133, P2067; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SPANER D, 1994, RES IMMUNOL, V145, P337, DOI 10.1016/S0923-2494(94)80196-7; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WU JM, 1993, BIOCHEM BIOPH RES CO, V193, P13, DOI 10.1006/bbrc.1993.1583; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2	48	17	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	1999	18	8					1521	1527		10.1038/sj.onc.1202454	http://dx.doi.org/10.1038/sj.onc.1202454			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102621				2022-12-28	WOS:000078770700001
J	Corbet, SW; Clarke, AR; Gledhill, S; Wyllie, AH				Corbet, SW; Clarke, AR; Gledhill, S; Wyllie, AH			P53-dependent and -independent links between DNA-damage, apoptosis and mutation frequency in ES cells	ONCOGENE			English	Article						p53; apoptosis; mutation; DNA-damage; tissue specificity	WILD-TYPE P53; RADIATION-INDUCED APOPTOSIS; P53-DEFICIENT MICE; IONIZING-RADIATION; GAMMA-IRRADIATION; TUMOR-SUPPRESSOR; NUCLEAR ACCUMULATION; GENE AMPLIFICATION; TRANSGENIC MICE; GROWTH ARREST	The hypothesis that p53 deficiency enhances the survival of DNA-damage bearing cells was investigated in wildtype and p53 mutant embryonic stem (ES) cells. Following UV-C irradiation, p53 is rapidly induced in wild-type cells and p53-dependent apoptosis follows within 8 h, resulting in the death of the majority of cells within 36 h. Increasing doses of UV-irradiation resulted in enhanced clonogenic survival of null cells as compared to wild-type. Amongst surviving clones, the Hprt mutation frequency was found to be dependent upon UV dose and influenced by p53 status. Treatment with ionizing radiation led to enhanced expression of p53 but resulted in little induction of apoptosis irrespective of p53 status. However, clonogenic potential was considerably reduced, particularly in wild-type cells which showed a tenfold lower survival than null cells. In contrast to the effects of UV-irradiation, the incidence of Hprt mutation did not differ significantly between wild-type and p53 null survivors. The data confirm that p53 restricts the numbers of cells bearing mutations that survive DNA damage induced by either agent, albeit by different mechanisms.	Univ Edinburgh, Sch Med, Dept Pathol, CRC Labs, Edinburgh, Midlothian, Scotland	University of Edinburgh	Corbet, SW (corresponding author), Univ Edinburgh, Sch Med, Dept Pathol, CRC Labs, Teviot Pl, Edinburgh, Midlothian, Scotland.		clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Clarke, Alan/0000-0002-4281-426X				Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BRAIN R, 1994, ONCOGENE, V9, P1775; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARDER P, 1993, ONCOGENE, V8, P1397; CLARKE AR, 1995, ONCOGENE, V11, P1913; CLARKE AR, 1994, ONCOGENE, V9, P1767; Clarke AR, 1997, ONCOGENE, V14, P2015, DOI 10.1038/sj.onc.1201040; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Clutton SM, 1996, CELL DEATH DIFFER, V3, P141; CROLLA JA, 1990, GENET RES, V55, P107, DOI 10.1017/S0016672300025349; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; FANTES JA, 1992, AM J HUM GENET, V51, P1286; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HARVEY M, 1993, ONCOGENE, V8, P2457; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANGLEY RE, 1994, INT J RADIAT BIOL, V65, P605, DOI 10.1080/09553009414550691; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Li G, 1996, AM J PATHOL, V148, P1113; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Linke SP, 1997, CANCER RES, V57, P1171; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MAHMUD KKS, 1992, CELL, V69, P367; MALCOMSON RDG, 1995, BRIT J CANCER, V72, P952, DOI 10.1038/bjc.1995.440; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1976, J CELL PHYSIOL, V89, P441, DOI 10.1002/jcp.1040890310; MELING GI, 1993, BRIT J CANCER, V67, P93, DOI 10.1038/bjc.1993.15; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NISHINO H, 1995, ONCOGENE, V11, P263; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PURDIE CA, 1994, ONCOGENE, V9, P603; Rafferty JA, 1996, ONCOGENE, V12, P693; RENZING J, 1995, ONCOGENE, V10, P1865; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROBERTSON EJ, 1986, EXPT APPROACHES MAMM, P475; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; Scherer SJ, 1996, BIOCHEM BIOPH RES CO, V221, P722, DOI 10.1006/bbrc.1996.0663; SEYMOUR C, 1992, MUTAT RES, V267, P19, DOI 10.1016/0027-5107(92)90107-D; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUGANO T, 1995, JPN J CANCER RES, V86, P415, DOI 10.1111/j.1349-7006.1995.tb03072.x; TSUKADA T, 1993, ONCOGENE, V8, P3313; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	71	65	66	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1537	1544		10.1038/sj.onc.1202436	http://dx.doi.org/10.1038/sj.onc.1202436			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102623				2022-12-28	WOS:000078770700003
J	Dennler, S; Huet, S; Gauthier, JM				Dennler, S; Huet, S; Gauthier, JM			A short amino-acid sequence in MH1 domain is responsible for functional differences between Smad2 and Smad3	ONCOGENE			English	Article						Smad; TGF beta; transcription; DNA-binding	TGF-BETA RECEPTOR; TUMOR-SUPPRESSOR SMAD4; MAD-RELATED PROTEIN; MICROSATELLITE INSTABILITY; INACTIVATION; SUPERFAMILY; ANTAGONIST; MUTATIONS; CANCER; GENE	Smad proteins are essential components of the signalling cascade initiated by members of the Transforming Growth Factor-beta family. TGF beta binding to heteromeric complexes of transmembrane Ser/Thr kinases induces Smad2 and Smad3 phosphorylation on their C terminus residues. This phosphorylation leads to oligomerization with Smad4, a common mediator of TGF-beta, activin and BMP signalling. The Smad complexes then translocate to the nucleus where they play transcription regulator roles. Even if they share 92% identity, the two TGF beta restricted Smad2 and Smad3 are not functionally equivalent. As we have previously shown, Smad3 acts as a transcription factor by binding to a TGF beta-responsive sequence termed CAGA box whereas Smad2 does not. Smad2 differs from Smad3 mainly in the N-terminal MH1 domain where it contains two additional stretches of amino acids that are lacking in Smad3. Here, we show that one of these domains corresponding to exon 3 is responsible for the absence of Smad2 transcriptional activity in CAGA box-containing promoters. Furthermore, in vitro studies indicate that this domain prevents Smad2 from binding to this DNA sequence. This suggests that Smad2 and Smad3 may have different subsets of target genes participating thus in distinct responses among TGF beta pleiotropic effects.	Lab Glaxo Wellcome, F-91951 Les Ulis, France	GlaxoSmithKline	Gauthier, JM (corresponding author), Lab Glaxo Wellcome, 25 Ave Quebec, F-91951 Les Ulis, France.							ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; Chen Y, 1996, P NATL ACAD SCI USA, V93, P12992, DOI 10.1073/pnas.93.23.12992; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hata A, 1998, MOL MED TODAY, V4, P257, DOI 10.1016/S1357-4310(98)01247-7; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1998, MINER ELECTROL METAB, V24, P131, DOI 10.1159/000057360; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Miyazono K, 1997, INT J HEMATOL, V65, P97; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; PARSONS R, 1995, CANCER RES, V55, P5548; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Takenoshita S, 1998, GENOMICS, V48, P1, DOI 10.1006/geno.1997.5149; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; White RL, 1998, CELL, V92, P591, DOI 10.1016/S0092-8674(00)81124-1; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	34	153	159	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1643	1648		10.1038/sj.onc.1202729	http://dx.doi.org/10.1038/sj.onc.1202729			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102636				2022-12-28	WOS:000078770700016
J	Pereira, R; Quang, CT; Lesault, I; Dolznig, H; Beug, H; Ghysdael, J				Pereira, R; Quang, CT; Lesault, I; Dolznig, H; Beug, H; Ghysdael, J			FLI-1 inhibits differentiation and induces proliferation of primary erythroblasts	ONCOGENE			English	Article						friend erythroleukemia; FLI-1; erythroid differentiation; erythropoietin; cell proliferation; apoptosis	ERYTHROPOIETIN RECEPTOR; ERYTHROID-DIFFERENTIATION; TERMINAL DIFFERENTIATION; ECTOPIC EXPRESSION; DNA-BINDING; F-MULV; GENE; ACTIVATION; ERYTHROLEUKEMIA; VIRUS	Friend virus-induced erythroleukemia involves two members of the ETS family of transcriptional regulators, both activated via proviral insertion in the corresponding loci. Spi-1/PU.1 is expressed in the disease induced by the original Friend virus SFFV(F-MuLV) complex in adult mice. In contrast, FLI-1 is overexpressed in about 75% of the erythroleukemias induced by the F-MuLV helper virus in newborn mice, To analyse the consequences of the enforced expression of FLI-1 on erythroblast differentiation and proliferation and to compare its activity to that of PU.1/Spi-1, we used a heterologous system of avian primary erythroblasts previously described to study the cooperation between Spi-1/PU.1 and the other molecular alterations observed in SFFV-induced disease, FLI-1 was found: (i) to inhibit the apoptotic cell death program normally activated in erythroblasts following Epo deprivation; (ii) to inhibit the terminal differentiation program induced in these cells in response to Epo and; (iii) to induce their proliferation, However, in contrast to Spi-1/PU.1, the effects of FLI-1 on erythroblast, differentiation and proliferation did not require its cooperation with an abnormally activated form of the EpoR, Enhanced survival of FLI-1 expressing erythroblasts correlated with the upregulation of bcl2 expression, FLI-1 also prevented the rapid downregulation of cyclin D2 and D3 expression normally observed during Epo-induced differentiation and delayed the downregulation of several other genes involved in cell cycle or cell proliferation control, Our results show that overexpression of FLI-1 profoundly deregulates the normal balance between differentiation and proliferation in primary erythroblasts, Thus, the activation of FLI-1 expression observed at the onset of F-MuLV-induced erythroleukemia may provide a proliferative advantage to virus infected cells that would otherwise undergo terminal differentiation or cell death.	Ctr Univ Orsay, Inst Curie, Sect Rech, CNRS,UMR 146, F-91405 Orsay, France; Univ Vienna, Vienna Bioctr, Inst Mol Biol, A-1030 Vienna, Austria; Univ Vienna, Vienna Bioctr, Inst Mol Pathol, A-1030 Vienna, Austria	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Pereira, R (corresponding author), Ctr Univ Orsay, Inst Curie, Sect Rech, CNRS,UMR 146, Bat 110, F-91405 Orsay, France.		Dolznig, Helmut/L-7005-2015; QUANG, christine TRAN/G-7508-2016; GHYSDAEL, Jacques/F-3377-2013	Dolznig, Helmut/0000-0002-6063-3585; 				AIZAWA S, 1990, EMBO J, V9, P2107, DOI 10.1002/j.1460-2075.1990.tb07379.x; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1977, EXP CELL RES, V107, P417, DOI 10.1016/0014-4827(77)90363-9; BOEHMELT G, 1994, CELL GROWTH DIFFER, V5, P221; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELGADO MD, 1994, ONCOGENE, V9, P1723; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; FUERSTENBERG S, 1990, J VIROL, V64, P5891, DOI 10.1128/JVI.64.12.5891-5902.1990; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; HOWARD JC, 1993, ONCOGENE, V8, P2721; Howard JC, 1996, ONCOGENE, V12, P1405; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; Quang CT, 1997, EMBO J, V16, P5639, DOI 10.1093/emboj/16.18.5639; QUANG CT, 1995, ONCOGENE, V11, P1229; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SETH A, 1993, ONCOGENE, V8, P1783; STEINLEIN P, 1994, GROWTH FACTORS, V10, P1, DOI 10.3109/08977199409019599; Tarr K, 1997, J BIOL CHEM, V272, P9099; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	36	86	86	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1597	1608		10.1038/sj.onc.1202534	http://dx.doi.org/10.1038/sj.onc.1202534			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102630				2022-12-28	WOS:000078770700010
J	Grand, RJA; Parkhill, J; Szestak, T; Rookes, SM; Roberts, S; Gallimore, PH				Grand, RJA; Parkhill, J; Szestak, T; Rookes, SM; Roberts, S; Gallimore, PH			Definition of a major p53 binding site on Ad2E1B58K protein and a possible nuclear localization signal on the Ad12E1B54K protein	ONCOGENE			English	Article						p53; nuclear localization signal; Ad2E1B; Ad12E1B; p53-binding proteins	REGION-4 34-KILODALTON PROTEIN; ADENOVIRUS E1A PROTEINS; WILD-TYPE P53; TRANSFORMED-CELLS; 55-KILODALTON PROTEIN; MESSENGER-RNA; GENE-PRODUCTS; TUMOR-ANTIGEN; CELLULAR P53; RAT-CELLS	Previous studies have established that adenovirus 2/5 early region 1B (Ad E1B) 58K protein binds p53 strongly and co-localizes with it to cytoplasmic dense bodies whilst the homologous Ad12E1B54K protein binds only weakly and co-localizes primarily to the nucleus in Ad12E1 transformed cells. We have used these properties of the E1B proteins from different viral serotypes to map the p53 binding site on the Ad2/5 protein. A set of chimaeric genes was constructed containing different proportions of the Ad12 and Ad2E1B DNA, These, together with Ad12E1A and E1B19K DNA, were transfected into baby rat kidney cells and transformed lines isolated, From an examination of the properties of these Ad12/Ad2E1B fusion proteins in co-immunoprecipitation and subcellular localization experiments it has been concluded that the p53 binding site on Ad2E1B58K protein lies between amino acids 216 and 235 and that the homologous region on Ad12E1B54K protein also binds p53. In addition, a unique nuclear localization signal is located on Ad12E1B54K between residues 228 and 239, We suggest that primary structure differences in these regions of the Ad2 and Ad12E1B proteins are responsible for the different subcellular localizations in AdE1 transformants.	Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England	University of Birmingham	Grand, RJA (corresponding author), Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England.		Parkhill, Julian/G-4703-2011; Roberts, Sally/N-6143-2014	Parkhill, Julian/0000-0002-7069-5958; Roberts, Sally/0000-0003-4653-9442				BABISS LE, 1984, J VIROL, V50, P202, DOI 10.1128/JVI.50.1.202-212.1984; BABISS LE, 1985, MOL CELL BIOL, V5, P2552, DOI 10.1128/MCB.5.10.2552; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BERNARDS R, 1984, BIOCHIM BIOPHYS ACTA, V783, P187, DOI 10.1016/0167-4781(84)90029-0; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BOYD JM, 1995, ONCOGENE, V11, P1921; BREIDING DE, 1988, VIROLOGY, V164, P390, DOI 10.1016/0042-6822(88)90552-1; BYRD PJ, 1988, VIROLOGY, V163, P156; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Gallimore PH, 1997, J VIROL, V71, P6629, DOI 10.1128/JVI.71.9.6629-6640.1997; GALLIMORE PH, 1985, CANCER RES, V45, P2670; GALLIMORE PH, 1985, VIRUSES CANCER, P125; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Grand RJA, 1996, VIROLOGY, V218, P23, DOI 10.1006/viro.1996.0162; GRAND RJA, 1993, VIROLOGY, V193, P579, DOI 10.1006/viro.1993.1166; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; LEPPARD KN, 1989, EMBO J, V8, P2329, DOI 10.1002/j.1460-2075.1989.tb08360.x; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MAK I, 1988, VIROLOGY, V163, P201, DOI 10.1016/0042-6822(88)90248-6; MERRICK RM, 1991, J GEN VIROL, V72, P955, DOI 10.1099/0022-1317-72-4-955; MONTELL C, 1984, CELL, V36, P951, DOI 10.1016/0092-8674(84)90045-X; MORAN E, 1994, SEMIN VIROL, V5, P327, DOI 10.1006/smvy.1994.1037; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; PARASKEVA C, 1982, J GEN VIROL, V58, P73, DOI 10.1099/0022-1317-58-1-73; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SARNOW P, 1984, J VIROL, V49, P592; SPRENGEL J, 1995, CURR TOP MICROBIOL, V199, P11; VANDENELSEN P, 1983, VIROLOGY, V131, P242, DOI 10.1016/0042-6822(83)90549-4; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAJDEL MEB, 1988, ONCOGENE, V2, P579; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	43	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					955	965		10.1038/sj.onc.1202358	http://dx.doi.org/10.1038/sj.onc.1202358			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023671				2022-12-28	WOS:000078510600012
J	Ichimiya, S; Nimura, Y; Kageyama, H; Takada, N; Sunahara, M; Shishikura, T; Nakamura, Y; Sakiyama, S; Seki, N; Ohira, M; Kaneko, Y; McKeon, F; Caput, D; Nakagawara, A				Ichimiya, S; Nimura, Y; Kageyama, H; Takada, N; Sunahara, M; Shishikura, T; Nakamura, Y; Sakiyama, S; Seki, N; Ohira, M; Kaneko, Y; McKeon, F; Caput, D; Nakagawara, A			p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent	ONCOGENE			English	Article						p73; neuroblastoma; loss of heterozygosity; 1p36; mutation; p53	N-MYC AMPLIFICATION; P53 GENE-MUTATIONS; SHORT ARM; EXPRESSION; DELETION; PROTEIN; REGION; INSTABILITY; TUMORS; LOCI	p73, a novel p53 family member, is a recently identified candidate neuroblastoma (NBL) suppressor gene mapped at chromosome 1p36.33 and was found to inhibit growth and induce apoptosis in cell lines. To test the hypothesis that p73 is a NBL suppressor gene, we analysed the p73 gene in primary human NBLs, Loss of heterozygosity (LOH) for p73 was observed in 19% (28/151) of informative cases which included 92 mass-screening (MS) tumors. The high frequency of p73 LOH was significantly associated with sporadic NBLs (9% vs 34%, P < 0.001), N-myc amplification (10% vs 71%, P < 0.001), and advanced stage (14% vs 28%, P < 0.05), Both p73 alpha and p73 beta transcripts were detectable in only 46 of 134 (34%) NBLs at low levels by RT-PCR methods, while they were easily detectable in most breast cancers and colorectal cancers under the same conditions. They found no correlation between p73 LOH and its expression levels (P > 0.1), We found two mutations out of 140 NBLs, one somatic and one germline, which result in amino acid substitutions in the C-terminal region of p73 which may affect transactivation functions, though, in the same tumor samples, no mutation of the p53 gene was observed as reported previously. These results suggest that allelic loss of the p73 gene may be a later event in NBL tumorigenesis. However, p73 is infrequently mutated in primary NBLs and may hardly function as a tumor suppressor in a classic Knudson's manner.	Chiba Canc Ctr, Res Inst, Div Biochem, Chiba 2608717, Japan; Kazusa DNA Res Inst, Lab Gene Struct 1, Chiba 2920812, Japan; Saitama Canc Ctr Hosp, Dept Canc Chemotherapy, Ina, Saitama 362, Japan; Sanofi Rech, F-31676 Labege, France; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Chiba Cancer Center; Kazusa DNA Research Institute; Sanofi-Aventis; Sanofi France; Harvard University; Harvard Medical School	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, 666-2 Nitona, Chiba 2608717, Japan.							AMLER LC, 1995, ONCOGENE, V10, P1095; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; CHENG JM, 1993, NAT GENET, V4, P191, DOI 10.1038/ng0693-191; CHRISTIANSEN H, 1992, GENE CHROMOSOME CANC, V5, P141, DOI 10.1002/gcc.2870050208; FONG CT, 1992, CANCER RES, V52, P1780; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kobayashi H, 1996, BRIT J HAEMATOL, V94, P105, DOI 10.1046/j.1365-2141.1996.d01-1762.x; KOMURO H, 1993, CANCER RES, V53, P5284; Mai M, 1998, CANCER RES, V58, P2347; MARTINSSON T, 1995, CANCER RES, V55, P5681; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MIHARA M, 1998, IN PRESS BR J CANC; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; NIMURA Y, 1998, IN PRESS INT J CANC; Nomoto S, 1998, CANCER RES, V58, P1380; Ohira M, 1996, GENOMICS, V33, P65, DOI 10.1006/geno.1996.0160; Ohtsu K, 1997, CLIN CANCER RES, V3, P1221; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; Sunahara M, 1998, INT J ONCOL, V13, P319; Takahashi H, 1998, CANCER RES, V58, P2076; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; VOGAN K, 1993, CANCER RES, V53, P5269; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520	31	120	127	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1061	1066		10.1038/sj.onc.1202390	http://dx.doi.org/10.1038/sj.onc.1202390			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023682				2022-12-28	WOS:000078510600023
J	Wang, XL; Uzawa, K; Imai, FL; Tanzawa, H				Wang, XL; Uzawa, K; Imai, FL; Tanzawa, H			Localization of a novel tumor suppressor gene associated with human oral cancer on chromosome 4q25	ONCOGENE			English	Article						chromosome 4; loss of heterozygosity (LOH); oral carcinoma; tumor suppressor gene (TSG)	SQUAMOUS-CELL CARCINOMA; LONG ARM; ALLELOTYPE ANALYSIS; CERVICAL-CARCINOMA; BLADDER-CARCINOMA; HEAD; HETEROZYGOSITY; DELETION; REGIONS	Recent cytogenetic and molecular studies with highly polymorphic microsatellite markers have implicated allele loss involving chromosome 4 in several human cancers, which suggests the presence of multiple tumor suppressor gene (TSG) loci, However, there has been no detailed analysis of loss of heterozygosity (LOH) on chromosome 4 in oral squamous cell carcinoma (OSCC). To determine the location of a putative TSG associated with OSCC on chromosome 4, polymerase chain reaction (PCR) analysis of microsatellite polymorphisms corresponding to 17 loci was performed to screen 32 patients with OSCC. LOH was observed in the majority of the tumors (75%) in at least one of the loci. The loci on the long arm exhibited a significantly higher frequency of deletions (66%) than those of the short arm (25%). Among the loci tested, frequent LOH was centered at D4S1573 on 4q25, which represents a region of about 4 centimorgans (cM), However, no commonly deleted regions were found on the short arm of the chromosome, We detected microsatellite instability (MI) in 31% of the cases. MI was also observed more frequently on the long arm (28%) than the short arm (6%), Thus, our data indicate that alterations of chromosome 4 regions, especially the long arm, are associated with OSCC tumorigenesis and that the 4q25 region may harbor at least one putative TSG.	Chiba Univ, Sch Med, Dept Oral Surg, Chuo Ku, Chiba 2608670, Japan	Chiba University	Tanzawa, H (corresponding author), Chiba Univ, Sch Med, Dept Oral Surg, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.			Uzawa, Katsuhiro/0000-0002-7036-0859				AHSEE KW, 1994, CANCER RES, V54, P1617; Chou YHW, 1998, CANCER LETT, V123, P1, DOI 10.1016/S0304-3835(97)00276-0; ELDER PA, 1994, ONCOGENE, V9, P3433; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Hammoud ZT, 1996, CANCER RES, V56, P4499; Hampton GM, 1996, P NATL ACAD SCI USA, V93, P6704, DOI 10.1073/pnas.93.13.6704; Larson AA, 1996, CANCER RES, V56, P1426; Leon M, 1996, ANTICANCER RES, V16, P349; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MITRA AB, 1994, CANCER RES, V54, P4481; NAWROZ H, 1994, CANCER RES, V54, P1152; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; Pershouse MA, 1997, ONCOGENE, V14, P369, DOI 10.1038/sj.onc.1200836; POLASCIK TJ, 1995, CANCER RES, V55, P5396; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Uzawa K, 1996, INT J CANCER, V67, P510, DOI 10.1002/(SICI)1097-0215(19960807)67:4<510::AID-IJC8>3.3.CO;2-R; VANDYKE DL, 1994, GENE CHROMOSOME CANC, V9, P192, DOI 10.1002/gcc.2870090308; Wang XL, 1998, INT J CANCER, V75, P671, DOI 10.1002/(SICI)1097-0215(19980302)75:5<671::AID-IJC2>3.3.CO;2-6; Wang XL, 1997, INT J ONCOL, V10, P535; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	22	31	33	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					823	825		10.1038/sj.onc.1202318	http://dx.doi.org/10.1038/sj.onc.1202318			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989834				2022-12-28	WOS:000078394400029
J	Fournier, E; Blaikie, P; Rosnet, O; Margolis, B; Birnbaum, D; Borg, JP				Fournier, E; Blaikie, P; Rosnet, O; Margolis, B; Birnbaum, D; Borg, JP			Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF Receptor 3 signaling	ONCOGENE			English	Article						angiogenesis; FLT4; SHC; signal transduction; tyrosine kinase; VEGF receptor	PHOSPHOTYROSINE BINDING-DOMAIN; ENDOTHELIAL GROWTH-FACTOR; MIDDLE T-ANTIGEN; FLT4 RECEPTOR; PHOSPHORYLATION SITES; TRANSFORMING ACTIVITY; MULTIPLE CYTOKINES; KINASE ACTIVATION; V-SRC; LIGAND	The VEGFR3/FLT4 receptor, which is involved in vasculogenesis and angiogenesis, binds and phosphorylates SHC proteins on tyrosine residues. SHC contains two phosphotyrosine interaction domains: a PTB (Phosphotyrosine Binding) and a SH2 (Src Homology 2) domain. Previous studies have shown that SHC proteins are phosphorylated on Y239/Y240 and Y313 (Y317 in humans) by tyrosine kinases such as the EGF and IL3 receptors, We have investigated which of the SHC tyrosine residues are targeted by the VEGFR3/FLT4 kinase and the role of the SHC PTB and SH2 domains in this process. Our results show that Y239/Y240 and Y313 are simultaneously phosphorylated by the kinase, creating GRB2 binding sites. Mutation of SHC PTB, but not SH2, domain interferes with the SHC phosphorylation by VEGFR3/FLT4, Soft agar assay experiments revealed that the VEGFR3/FLT4 transforming capacity is increased by the mutation of Y239/Y240 to phenylalanines in SHC, suggesting that these two residues mediate an inhibitory signal for cell growth. Mutation of the two phosphorylation sites increases this effect, suggesting that they have a synergistic role.	INSERM, U119, Mol Oncol Lab, F-13258 Marseille, France; Dept Internal Med & Biol Chem, Ann Arbor, MI USA; Howard Hughes Med Inst, Ann Arbor, MI USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Howard Hughes Medical Institute	Birnbaum, D (corresponding author), INSERM, U119, Mol Oncol Lab, F-13258 Marseille, France.		Rosnet, Olivier/G-3536-2013; Borg, Jean-Paul/AAX-8096-2020	Borg, Jean-Paul/0000-0001-8418-3382; Rosnet, Olivier/0000-0002-3020-910X				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Blaikie PA, 1997, J BIOL CHEM, V272, P20671, DOI 10.1074/jbc.272.33.20671; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BORG JP, 1995, ONCOGENE, V10, P973; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DeuterReinhard M, 1997, MOL CELL BIOL, V17, P2559, DOI 10.1128/MCB.17.5.2559; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Fournier E, 1996, J BIOL CHEM, V271, P12956, DOI 10.1074/jbc.271.22.12956; FOURNIER E, 1995, ONCOGENE, V11, P921; GALLAND F, 1992, GENOMICS, V13, P475, DOI 10.1016/0888-7543(92)90277-Y; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; Joukov V, 1996, EMBO J, V15, P290; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOEPELAINEN E, 1998, CURR OPIN CELL BIOL, V10, P159; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Wang JF, 1997, BLOOD, V90, P3507, DOI 10.1182/blood.V90.9.3507; Yajnik V, 1996, J BIOL CHEM, V271, P1813, DOI 10.1074/jbc.271.4.1813; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHOU S, 1995, J BIOL CHEM, V270, P14863	45	26	29	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					507	514		10.1038/sj.onc.1202315	http://dx.doi.org/10.1038/sj.onc.1202315			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927207				2022-12-28	WOS:000078166500023
J	Fogerty, FJ; Juang, JL; Petersen, J; Clark, MJ; Hoffmann, FM; Mosher, DF				Fogerty, FJ; Juang, JL; Petersen, J; Clark, MJ; Hoffmann, FM; Mosher, DF			Dominant effects of the bcr-abl oncogene on Drosophila morphogenesis	ONCOGENE			English	Article						Bcr-Abl; oncogene; Drosophila; tyrosine kinase	TYROSINE KINASE-ACTIVITY; CHRONIC MYELOGENOUS LEUKEMIA; C-ABL; ADAPTER PROTEIN; SUBCELLULAR-LOCALIZATION; SIGNAL-TRANSDUCTION; ECTOPIC EXPRESSION; TRANSGENIC MICE; CELL FATES; SH2 DOMAIN	We targeted expression of human/fly chimeric Bcr-Abl proteins to the developing central nervous system (CNS) and eye imaginal disc of Drosophila melanogaster, Neural expression of human/fly chimeric P210 Bcr-Abl or P185 Bcr-Abl rescued abl mutant flies from pupal lethality, indicating that P210 and P185 Bcr-Abl can substitute functionally for Drosophila Abl during axonogenesis, However, increased levels of neurally expressed P210 or P185 Bcr-Abl but not Drosophila Abl produced CNS defects and lethality. Expression of P210 or P185 in the eye imaginal disc produced a dominant rough eye phenotype that was dependent on dosage of the transgene. Drosophila Enabled, previously identified as a suppressor of the abl mutant phenotype and substrate for Drosophila Abl kinase, had markedly increased phosphotyrosine levels in Bcr-Abl expressing Drosophila, indicating that it is a substrate for Bcr-Abl as well, Drosophila, therefore, is a suitable model system to identify Bcr-Abl interactions important for signal transduction and oncogenesis.	Univ Wisconsin, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Ctr Comprehens Canc, Madison, WI 53706 USA; Univ Wisconsin, Mcardle Lab Canc Res, Madison, WI 53706 USA; Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Fogerty, FJ (corresponding author), Univ Wisconsin, Dept Med, 1300 Univ Ave, Madison, WI 53706 USA.		Juang, Jyh-Lyh/E-3944-2010	Hoffmann, F. Michael/0000-0002-2770-9656	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD073263] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021644, P50HL056396] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56396-01, HL21644] Funding Source: Medline; NICHD NIH HHS [N01-HD-7-3263] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHERNDJAMALI SM, 1998, IN PRESS MOL BIOL CE; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BASLER K, 1990, GENE DEV, V4, P728, DOI 10.1101/gad.4.5.728; BENNETT RL, 1992, DEVELOPMENT, V116, P953; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWN NL, 1991, DEVELOPMENT, V113, P1245; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Comer AR, 1998, MOL CELL BIOL, V18, P152, DOI 10.1128/MCB.18.1.152; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAINSTEIN E, 1989, ONCOGENE, V4, P1477; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1990, SCIENCE, V248, P857, DOI 10.1126/science.2188361; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HENKEMEYER MJ, 1988, MOL CELL BIOL, V8, P843, DOI 10.1128/MCB.8.2.843; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HILL KK, 1995, GENETICS, V141, P595; HOLLAND GD, 1990, J VIROL, V64, P2226, DOI 10.1128/JVI.64.5.2226-2235.1990; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; JUANG JL, 1994, CELL TISSUE RES, V277, P87, DOI 10.1007/BF00303084; KANTARJIAN HM, 1993, BLOOD, V82, P691; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; Laneuville P, 1995, Semin Immunol, V7, P255, DOI 10.1006/smim.1995.0030; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; McWhirter JR, 1997, ONCOGENE, V15, P1625, DOI 10.1038/sj.onc.1201342; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; ODA T, 1995, LEUKEMIA, V9, P295; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Paulson R, 1997, ONCOGENE, V14, P641, DOI 10.1038/sj.onc.1200875; Pendergast AM, 1996, CURR OPIN CELL BIOL, V8, P174, DOI 10.1016/S0955-0674(96)80063-9; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAMAKRISHNA NR, 1993, DEVELOPMENT, P95; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; ROBERTSON HM, 1988, GENETICS, V118, P461; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; SALGIA R, 1995, ONCOGENE, V11, P1149; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Santamaria P., 1986, DROSOPHILA PRACTICAL, P159; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHEJTER ED, 1985, EMBO J, V4, P407, DOI 10.1002/j.1460-2075.1985.tb03643.x; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Tauchi T, 1997, J BIOL CHEM, V272, P1389, DOI 10.1074/jbc.272.2.1389; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WONG KK, 1995, ONCOGENE, V10, P705; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	68	24	26	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					219	232		10.1038/sj.onc.1202239	http://dx.doi.org/10.1038/sj.onc.1202239			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926937				2022-12-28	WOS:000078166000024
J	Wieser, RJ; Faust, D; Dietrich, C; Oesch, F				Wieser, RJ; Faust, D; Dietrich, C; Oesch, F			p16(INK4) mediates contact-inhibition of growth	ONCOGENE			English	Article						contact-inhibition; cdk4; p16(INK4)	PLASMA-MEMBRANE GLYCOPROTEINS; DENSITY-DEPENDENT REGULATION; CELL-CYCLE REGULATION; RETINOBLASTOMA PROTEIN; HUMAN-FIBROBLASTS; KINASE; PHOSPHORYLATION; P27(KIP1); PROGRESSION; CANCER	Growth of non-transformed cells in vitro is regulated by density-dependent mechanisms via cell-cell contacts, leading to arrest in late G1-phase at confluency (contact-inhibition of growth). In the present study it is shown that this results from p16(INK4)-mediated dissociation of the complex cdk4-cyclin D1, which is responsible for the inactivation of the gate keeper of G1-S transition, the retinoblastoma protein pRb, As consequence of the inactivation of cdk4, downstream the activation of cdk2 and hyperphosphorylation and thus inactivation of pRb was impaired, Direct evidence for the central role of p16(INK4) in growth control comes from the observation that a competitive inhibitor of p16(INK4) repressed contact inhibition of growth, These findings provide an explanation for the high incidence of mutation or loss of INK4 in human tumours.	Inst Toxikol, D-55131 Mainz, Germany		Wieser, RJ (corresponding author), Inst Toxikol, Obere Zahlbacherstr 67, D-55131 Mainz, Germany.		Oesch, Franz/AAA-8746-2020					Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Botz J, 1996, MOL CELL BIOL, V16, P3401; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Dietrich C, 1997, ONCOGENE, V15, P2743, DOI 10.1038/sj.onc.1201439; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; GRADL G, 1995, CURR BIOL, V5, P526, DOI 10.1016/S0960-9822(95)00105-9; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Higashi H, 1997, BIOCHEM BIOPH RES CO, V231, P743, DOI 10.1006/bbrc.1997.6181; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; OESCH F, 1987, EUR J CELL BIOL, V43, P403; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RINDERKNECHT SB, 1983, J IMMUNOL METHODS, V65, P293, DOI 10.1016/0022-1759(83)90124-2; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WIESER RJ, 1990, J CELL BIOL, V111, P2681, DOI 10.1083/jcb.111.6.2681; WIESER RJ, 1986, J CELL BIOL, V103, P361, DOI 10.1083/jcb.103.2.361; WIESER RJ, 1985, EXP CELL RES, V158, P493, DOI 10.1016/0014-4827(85)90472-0; Yang R, 1996, BIOCHEM BIOPH RES CO, V218, P254, DOI 10.1006/bbrc.1996.0045; Yasaka T, 1996, CELL STRUCT FUNCT, V21, P483, DOI 10.1247/csf.21.483	33	61	62	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					277	281		10.1038/sj.onc.1202270	http://dx.doi.org/10.1038/sj.onc.1202270			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926944				2022-12-28	WOS:000078166000031
J	You, XL; Yen, LY; Zeng-Rong, N; Al Moustafa, AE; Alaoui-Jamali, MA				You, XL; Yen, LY; Zeng-Rong, N; Al Moustafa, AE; Alaoui-Jamali, MA			Dual effect of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cells	ONCOGENE			English	Article						erbB-2 receptor; DNA repair; cell cycle; apoptosis	NEU DIFFERENTIATION FACTOR; EPIDERMAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; BREAST-CARCINOMA CELLS; TUMOR-CELLS; INHIBITOR P27(KIP1); SIGNAL-TRANSDUCTION; C-ERBB-2 GENE; G(1) ARREST; PROTEIN	Overexpression of the erbB-2 tyrosine kinase receptor, p185(crbB-2), is a common alteration in non-small cell lung cancer (NSCLC) and has been associated with poor prognosis and a tumor drug resistance phenotype, In this study, we have examined the consequences of crbB-2 depletion on DNA repair, cell cycle, and apoptosis using a panel of NSCLC cell lines constitutively overexpressing er erbB-2 receptor. Depletion of the erbB-2 was achieved using the tyrosine kinase inhibitor CP127,374 which promotes erbB-2 degradation. Treatment with CP127,374 concentrations which deplete erbB-2 and inhibit tyrosine phosphorylation resulted in downregulation of DNA repair mechanisms and cell accumulation at G1 phase of the cell cycle. G1 arrest was observed in cells with mutated p53 as well as cells lacking p53 protein, suggesting a p53-independent mechanisms, NSCLC cells which overexpress erbB-2 were more resistant to cisplatin-induced cytotoxicity in comparison to cells expressing low levels of erbB-2. Treatment with CP127,374 alone did not result in any induction of apoptosis, A combination of CP127,374 and cisplatin, however, was more potent in cell growth inhibition and induction of apoptosis compared to treatment with cisplatin alone. Together, our results further support a pivotal role of erbB-2 signaling in the regulatory balance between DNA repair, cell cycle checkpoints and apoptosis; all these mechanisms are essential determinants for tumor cell destiny following chemotherapy stress.	McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, McGill Ctr Translat Res Canc, Montreal, PQ H3T 1E2, Canada; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	Lady Davis Institute; McGill University; McGill University; National Research Council Canada	Alaoui-Jamali, MA (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, 3755 Cote St Catherine, Montreal, PQ H3T 1E2, Canada.							Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALAOUIJAMALI MA, 1997, J BIOCH CELL BIOL, V75, P315; ALIMANDI M, 1995, ONCOGENE, V10, P1813; ARTEAGA CL, 1994, CANCER RES, V54, P3758; Bacus SS, 1996, ONCOGENE, V12, P2535; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Chaney SG, 1996, JNCI-J NATL CANCER I, V88, P1346, DOI 10.1093/jnci/88.19.1346; Chavany C, 1996, J BIOL CHEM, V271, P4974; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DENG D, 1996, CANCER RES, V56, P3666; Deshane J, 1996, CANCER GENE THER, V3, P89; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOUGALL WC, 1994, ONCOGENE, V9, P2109; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Ford JM, 1998, CANCER RES, V58, P599; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HYNES EN, 1994, BIOCHIM BIOPHYS ACTA, V1198, P165; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; KERN JA, 1990, CANCER RES, V50, P5184; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Lewis GD, 1996, CANCER RES, V56, P1457; LIU C, 1993, AM J PATHOL, V142, P413; McDonald E, 1996, CANCER RES, V56, P2250; MILLER P, 1994, CANCER RES, V54, P2724; NIE ZR, 1995, CANCER RES, V55, P4760; NOGUCHI M, 1993, CANCER RES, V53, P2035; Paterson J., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P363; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; Smit EF, 1996, THORAX, V51, P638, DOI 10.1136/thx.51.6.638; StCroix B, 1996, NAT MED, V2, P1204; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; SUDA Y, 1990, EMBO J, V9, P181, DOI 10.1002/j.1460-2075.1990.tb08094.x; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; VAUGHN JP, 1995, P NATL ACAD SCI USA, V92, P8338, DOI 10.1073/pnas.92.18.8338; Vreeswijk MPG, 1998, CANCER RES, V58, P1978; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; Wood Richard D., 1995, Methods (Orlando), V7, P163, DOI 10.1006/meth.1995.1022; Wu XP, 1996, ONCOGENE, V12, P1397; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yen L, 1997, ONCOGENE, V14, P1827, DOI 10.1038/sj.onc.1201019; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhang LS, 1996, ONCOGENE, V12, P571	61	23	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	1998	17	24					3177	3186		10.1038/sj.onc.1202246	http://dx.doi.org/10.1038/sj.onc.1202246			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872333				2022-12-28	WOS:000077517400011
J	Yamazaki, H; Kunisada, T; Ishizu, A; Ikeda, H; Miyoshi, I; Sudo, T; Hayashi, SI; Yoshiki, T				Yamazaki, H; Kunisada, T; Ishizu, A; Ikeda, H; Miyoshi, I; Sudo, T; Hayashi, SI; Yoshiki, T			Promotion of early osteoclastogenesis and B lymphopoiesis in the bone marrow of transgenic rats with the env-pX gene of human T-cell lymphotropic virus type I	ONCOGENE			English	Article						HTLV-I; env-pX transgenic rat; hematopoiesis; osteoclastogenesis; B lymphopoiesis	COLLAGEN-INDUCED ARTHRITIS; HORMONE-RELATED PROTEIN; HTLV-I; RHEUMATOID-ARTHRITIS; LEUKEMIA-VIRUS; TAX GENE; MICE; LYMPHOMA; DIFFERENTIATION; PATHOGENESIS	Human T-cell lymphotropic virus type I(HTLV-I) is associated with various clinical disorders including adult T cell leukemia, myelopathy, arthropathy. Hypercalcemia resulting from osteoclast activation and a variety of hematopoietic abnormalities have been also observed in HTLV-I infected patients, however, precise mechanism about initial trigger(s) prior to presenting symptoms is still unknown. In this study, to assess effects of HTLV-I on hematopoiesis, we analysed characteristics of early hematopoietic precursors in HTLV-I env-pX transgenic rats. Progenitor cells for osteoclasts were significantly increased even in the marrow of asymptomatic env-pX rats. Progenitors for B cells were also highly enriched, while colony forming cells (CFC) elicited by GM-CSF(CFU-GM) and M-CSF(CFU-M) were comparable to normal littermates. Following arthritis in env-pX transgenic rats, osteoclastogenesis was further augmented and the CFCs were increased. Bone marrow cells carrying adjuvant-induced arthritis retained a constant number of progenitors for osteoclast and B lymphocytes, whereas the number of CFU-CM and CFU-M increased. These results indicate that the env-pX transgene affect early stages of osteoclast and B-cell lineages prior to developing diseases, in contrast, an increase of the CFCs was caused indirectly by arthritis. This study provides a novel standpoint for the mechanisms of pathogenesis by HTLV-I.	Tottori Univ, Fac Med, Sch Life Sci, Dept Immunol, Yonago, Tottori 6830826, Japan; Hokkaido Univ, Sch Med, Dept Pathol, Sapporo, Hokkaido 0600815, Japan; Tohoku Univ, Sch Med, Inst Anim Expt, Sendai, Miyagi 9800872, Japan; Toray Industries Ltd, Basic Res Labs, Kamakura, Kanagawa 2480036, Japan	Tottori University; Hokkaido University; Tohoku University; Toray Industries, Inc.	Yamazaki, H (corresponding author), Tottori Univ, Fac Med, Sch Life Sci, Dept Immunol, Yonago, Tottori 6830826, Japan.		Ishizu, Akihiro/D-9607-2012					Cardoso EA, 1996, J CLIN PATHOL, V49, P938, DOI 10.1136/jcp.49.11.938; Conrad B, 1997, CELL, V90, P303, DOI 10.1016/S0092-8674(00)80338-4; DEAN LM, 1987, SCIENCE, V236, P1103; DUGGAN DB, 1988, BLOOD, V71, P1027; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; GOWEN M, 1983, NATURE, V306, P378, DOI 10.1038/306378a0; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; HAMILTON JA, 1993, LANCET, V342, P536, DOI 10.1016/0140-6736(93)91653-4; Hayashi S, 1997, J CELL PHYSIOL, V170, P241, DOI 10.1002/(SICI)1097-4652(199703)170:3<241::AID-JCP4>3.0.CO;2-O; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; HAYASHI SI, 1988, J IMMUNOL, V140, P2139; HAYASHIDA K, 1992, ARTHRITIS RHEUM, V35, P241, DOI 10.1002/art.1780350219; HOLLSBERG P, 1993, NEW ENGL J MED, V328, P1173, DOI 10.1056/NEJM199304223281608; HONDA S, 1988, JPN J CANCER RES, V79, P1264, DOI 10.1111/j.1349-7006.1988.tb01554.x; ISHIGURO N, 1992, J EXP MED, V176, P981, DOI 10.1084/jem.176.4.981; IWAKURA Y, 1991, SCIENCE, V253, P1026, DOI 10.1126/science.1887217; KIYOKAWA T, 1987, CANCER, V59, P1187, DOI 10.1002/1097-0142(19870315)59:6<1187::AID-CNCR2820590626>3.0.CO;2-8; METCALF D, 1995, HEMATOPOIETIC COLONY; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NIMER SD, 1989, ONCOGENE, V4, P671; NISHIKAWA SI, 1988, EUR J IMMUNOL, V18, P1767, DOI 10.1002/eji.1830181117; PEEBLES RS, 1995, ONCOGENE, V10, P1045; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RUDDLE NH, 1993, VIROLOGY, V197, P196, DOI 10.1006/viro.1993.1580; SHEVDE N, 1994, P SOC EXP BIOL MED, V205, P306; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SUDA T, 1995, ENDOCR REV, V131, P251; TANAKA H, 1992, J BONE MINER RES, V7, pS307; TAO D, 1993, INT J HEMATOL, V57, P139; TAUROG JD, 1985, J EXP MED, V162, P962, DOI 10.1084/jem.162.3.962; TENDLER CL, 1991, J CELL BIOCHEM, V46, P302, DOI 10.1002/jcb.240460405; THOMSON BM, 1987, J IMMUNOL, V138, P775; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; TOBINAI K, 1991, LEUKEMIA RES, V15, P837, DOI 10.1016/0145-2126(91)90468-9; TOKIOKA T, 1994, HAEMATOLOGIA, V26, P1; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; YAMADA S, 1995, CANCER RES, V55, P2524; Yamazaki H, 1997, INT IMMUNOL, V9, P339, DOI 10.1093/intimm/9.2.339; YOSHIKI T, 1974, J EXP MED, V140, P1011, DOI 10.1084/jem.140.4.1011	40	14	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	1998	17	23					2955	2960		10.1038/sj.onc.1202222	http://dx.doi.org/10.1038/sj.onc.1202222			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881697				2022-12-28	WOS:000077427800002
J	Lee, JM				Lee, JM			Inhibition of p53-dependent apoptosis by the KIT tyrosine kinase: regulation of mitochondrial permeability transition and reactive oxygen species generation	ONCOGENE			English	Article						p53; KIT; Steel; mitochondria; apoptosis; oxygen	PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR GENE; CYTOCHROME-C; STEEL FACTOR; P53-MEDIATED APOPTOSIS; LYMPHOCYTE APOPTOSIS; MAST-CELLS; W/C-KIT; BCL-2; P53	The KIT protein is a receptor tyrosine kinase of the platelet derived growth factor (PDGF) receptor family which regulates haematopoiesis, melanogenesis and gut and germ cell development. KIT regulates these diverse processes, at least in part, by inhibiting apoptosis. We have previously found that KIT can suppress p53-mediated apoptosis. The mechanism by which KIT suppresses apoptosis is, however, uncharacterized. Neither is it clear how p53 induces apoptosis. In this report me find that p53-dependent apoptosis proceeds through a pathway involving depolarization of the mitochondrial electropotential gradient (Delta Psi(m)) and the generation of reactive oxygen species (ROS). KIT activation suppresses p53-induced apoptosis in the mouse DP16 Friend erythroleukemia cell line by preventing Delta Psi(m) depolarization and ROS generation, Thus, the KIT kinase prevents apoptosis by regulating mitochondrial function and cellular redox state.	Hamilton Reg Canc Ctr, Hamilton, ON L8V 5C2, Canada; McMaster Univ, Dept Pathol, Hamilton, ON L8S 4K1, Canada	McMaster University; McMaster University	Lee, JM (corresponding author), Hamilton Reg Canc Ctr, 699 Concess St, Hamilton, ON L8V 5C2, Canada.							ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNSTEIN A, 1990, CIBA F SYMP, V148, P158; BERNSTEIN A, 1991, SEMIN HEMATOL, V28, P138; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CACERESCORTES J, 1994, J BIOL CHEM, V269, P12084; CARSON WE, 1994, P NATL ACAD SCI USA, V91, P7553, DOI 10.1073/pnas.91.16.7553; Castedo M, 1996, J IMMUNOL, V157, P512; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; delPeso L, 1997, SCIENCE, V278, P687; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Henkart PA, 1996, J EXP MED, V183, P1293, DOI 10.1084/jem.183.4.1293; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; HUNTER TV, 1994, ANN REV CELL BIOL, V10, P251; IEMURA A, 1994, AM J PATHOL, V144, P321; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LEE JM, 1995, CANCER METAST REV, V14, P149, DOI 10.1007/BF00665797; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEV S, 1992, J BIOL CHEM, V267, P15970; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LOWE SW, 1993, NATURE, V362, P849; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MEKORI YA, 1993, J IMMUNOL, V151, P3775; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; NETA R, 1993, BLOOD, V81, P324; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Shimizu S, 1996, ONCOGENE, V13, P21; SHUI CX, 1995, CANCER RES, V55, P3431; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Um HD, 1996, J IMMUNOL, V156, P3469; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YEE NS, 1994, J EXP MED, V179, P1777, DOI 10.1084/jem.179.6.1777; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	73	34	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1653	1662		10.1038/sj.onc.1202102	http://dx.doi.org/10.1038/sj.onc.1202102			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796694				2022-12-28	WOS:000076200100003
J	Mangues, R; Corral, T; Lu, SY; Symmans, WF; Liu, L; Pellicer, A				Mangues, R; Corral, T; Lu, SY; Symmans, WF; Liu, L; Pellicer, A			NF1 inactivation cooperates with N-Ras in in vivo lymphogenesis activating Erk by a mechanism independent of its Ras-GTPase accelerating activity	ONCOGENE			English	Article						NF1; N-ras proto-oncogene; lymphoma; Erk; Ras-GTPase	NEUROFIBROMATOSIS TYPE-1 GENE; INDUCED MALIGNANT PHENOTYPE; TRANSGENIC MICE; CELL-LINES; MUTATIONS; GROWTH; PROTOONCOGENE; PATHWAY; NEUROBLASTOMA; TUMORIGENESIS	We crossed transgenic mice overexpressing the N-ras proto-oncogene (RasTg) with mice carrying one inactivated copy of the NF1 tumor suppressor gene (NF1+/-)to assess their possible cooperation in tumorigenesis. We have found a significant increase in the incidence of lymphomas in animals with both lesions (RasTg NF1+/-), as compared with animals with single lesions, The mechanism of this cooperation appears to be independent of the NF1 GTPase activating activity since the level of Ras-GTP in primary cultures of tumor tissue do not differ among animals with double and with single lesions. Nevertheless, the finding of significantly higher levels of Erk-1 and Erk-2 activation in lymphomas in the RasTg NF1+/- than in the RasTg group suggests that this cooperative effect may be in part explained by increased signaling through the Erk pathways. Consistent with a role for Erk activation in transformation is the additional observation that Erk-1 and Erk-2 activation is significantly increased in lymphomas as compared with normal spleen. This activation is likely to occur by phosphorylation of previously synthesized and inactive Erk proteins since, despite differences in activation, Erk-1 and:Erk-2 expression is similar in normal and lymphoid tissue in all groups. The observed cooperation in in vivo lymphomagenesis between N-ras overexpression and NF1 inactivation emphasizes the importance of searching for additional functions for the NF1 protein and of intensifying the screening for NF1 mutations in human lymphomas.	NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Canc Ctr, New York, NY 10016 USA	New York University; New York University	Pellicer, A (corresponding author), NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA.		MARTINEZ, ANTONIO PELLICER/C-4832-2015; Mangues, Ramon/J-6396-2014	Mangues, Ramon/0000-0003-2661-9525; Pellicer, Angel/0000-0002-5062-0692; Corral, Teresa/0000-0003-2959-9910	NATIONAL CANCER INSTITUTE [R37CA036327, T32CA009161, R01CA036327, R01CA050434] Funding Source: NIH RePORTER; NCI NIH HHS [CA50434, CA36327, 5T32 CA09161] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN LB, 1993, NAT GENET, V3, P118, DOI 10.1038/ng0293-118; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Blakesley VA, 1997, J BIOL CHEM, V272, P16211, DOI 10.1074/jbc.272.26.16211; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOS JL, 1989, CANCER RES, V49, P4682; Carel K, 1996, J BIOL CHEM, V271, P30625, DOI 10.1074/jbc.271.48.30625; Clark GJ, 1996, P NATL ACAD SCI USA, V93, P1577, DOI 10.1073/pnas.93.4.1577; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; FRIDMAN M, 1994, J BIOL CHEM, V269, P30105; HEIM RA, 1995, HUM MOL GENET, V4, P975, DOI 10.1093/hmg/4.6.975; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; KALRA R, 1994, BLOOD, V84, P3435; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; Li Y, 1996, CANCER RES, V56, P2872; Malumbres M, 1997, BIOTECHNIQUES, V22, P1114, DOI 10.2144/97226st03; MANGUES R, 1994, CANCER RES, V54, P6395; MANGUES R, 1995, MOL CARCINOGEN, V14, P94, DOI 10.1002/mc.2940140205; Mangues R, 1996, ONCOGENE, V13, P1053; MANGUES R, 1992, ONCOGENE, V7, P2073; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MIYAUCHI J, 1994, BLOOD, V83, P2248; NEUBAUER A, 1991, BLOOD, V77, P594; NUREKAMAL MSA, 1993, J BIOL CHEM, V268, P22331; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; Shen MH, 1996, J MED GENET, V33, P2, DOI 10.1136/jmg.33.1.2; STILLER CA, 1994, BRIT J CANCER, V70, P969, DOI 10.1038/bjc.1994.431; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; UPADHYAYA M, 1994, HUM MUTAT, V4, P83, DOI 10.1002/humu.1380040202; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	39	15	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1705	1716		10.1038/sj.onc.1202097	http://dx.doi.org/10.1038/sj.onc.1202097			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796699				2022-12-28	WOS:000076200100008
J	Gerbitz, A; Mautner, J; Geltinger, C; Hortnagel, K; Christoph, B; Asenbauer, H; Klobeck, G; Polack, A; Bornkamm, GW				Gerbitz, A; Mautner, J; Geltinger, C; Hortnagel, K; Christoph, B; Asenbauer, H; Klobeck, G; Polack, A; Bornkamm, GW			Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma	ONCOGENE			English	Article						c-myc; lambda enhancer; gene regulation; Burkitt's lymphoma; Na-Butyrate	LOCUS-CONTROL REGION; EPSTEIN-BARR-VIRUS; IMMUNOGLOBULIN-KAPPA-ENHANCERS; HEAVY-CHAIN LOCUS; PROMOTER SHIFT; CHROMOSOMAL TRANSLOCATIONS; HYPERSENSITIVE SITES; GENE-EXPRESSION; SODIUM-BUTYRATE; DOWN-REGULATION	In Burkitt's lymphoma (BL) cells the proto-oncogene c-myc is juxtaposed to one of the immunoglobulin (Ig) loci on chromosomes 2, 14, or 22, The c-myc gene becomes transcriptionally activated as a consequence of the chromosomal translocation and shows preferential usage of promoter P1 over P2, a phenomenon referred to as promoter shift. In order to define the responsible regulatory elements within the Ig lambda locus, we studied the effect of the human Ig lambda enhancer (HuE lambda) on c-myc expression after stable transfection into BL cells. A 12 kb genomic fragment encompassing HuE lambda, but not HuE lambda alone, strongly activated c-myc expression and induced the promoter shift. To identify additional elements involved in c-myc deregulation, we mapped DNaseI hypersensitive sites within the 12 kb lambda fragment on the construct. Besides one hypersensitive site corresponding to HuE lambda, three additional sites were detected, Two of these elements displayed enhancer activity after transient transfection. The third element did not activate c-myc transcription, but was required for full c-myc activation and promoter shift. Deletion analyses of the c-myc promoter identified the immediate promoter region as sufficient for activation by the Ig lambda locus, but also revealed that induction of the promoter shift requires additional upstream elements.	Dana Farber Canc Inst, Boston, MA 02115 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; GSF Forschungszentrum Umwelt & Gesundheit, Inst Klin Mol Biol & Tumor Genet, D-81377 Munich, Germany; Univ Munich, Genet Inst, D-80336 Munich, Germany; Adolf Butenandt Inst Physiol Chem, D-80336 Munich, Germany	Harvard University; Dana-Farber Cancer Institute; Johns Hopkins University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Munich	Gerbitz, A (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.							ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ANISIMOVA E, 1982, J GEN VIROL, V58, P163, DOI 10.1099/0022-1317-58-1-163; ARONOW BJ, 1995, MOL CELL BIOL, V15, P1123; Asenbauer H, 1996, EUR J IMMUNOL, V26, P142, DOI 10.1002/eji.1830260122; BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; BLASQUEZ VC, 1989, J BIOL CHEM, V264, P21183; BLOMBERG BB, 1991, J IMMUNOL, V147, P2354; BORNKAMM GW, 1988, G KLEIN, P223; BREZNICK EH, 1997, P NATL ACAD SCI USA, V94, P4566; BURKITT D, 1958, BRIT J SURG, V46, P218, DOI 10.1002/bjs.18004619704; COMBRIATO G, 1991, EUR J IMMUNOL, V21, P1513, DOI 10.1002/eji.1830210627; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; Geltinger C, 1996, GENE EXPRESSION, V6, P113; Glozak MA, 1996, MOL IMMUNOL, V33, P427, DOI 10.1016/0161-5890(95)00146-8; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; HOLLIS GF, 1984, NATURE, V307, P752, DOI 10.1038/307752a0; HORTNAGEL K, 1995, ONCOGENE, V10, P1393; HUG BA, 1992, NUCLEIC ACIDS RES, V20, P5771, DOI 10.1093/nar/20.21.5771; JOOS S, 1992, CANCER RES, V52, P6547; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; MAGRATH I, 1990, ADV CANCER RES, V55, P134; Mautner J, 1996, ONCOGENE, V12, P1299; MAUTNER J, 1995, NUCLEIC ACIDS RES, V23, P72, DOI 10.1093/nar/23.1.72; NOWELL PC, 1960, SCIENCE, V132, P1497; NOWELL PC, 1990, AM J CLIN PATHOL, V94, P229, DOI 10.1093/ajcp/94.2.229; POLACK A, 1991, ONCOGENE, V6, P2033; POLACK A, 1993, EMBO J, V12, P3913, DOI 10.1002/j.1460-2075.1993.tb06069.x; POLACK A, 1987, EMBO J, V6, P2959, DOI 10.1002/j.1460-2075.1987.tb02601.x; PULVERTAFT RJV, 1964, LANCET, V1, P238; QUEEN C, 1984, MOL CELL BIOL, V4, P1042, DOI 10.1128/MCB.4.6.1042; RABBITTS TH, 1983, NATURE, V306, P806, DOI 10.1038/306806a0; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROTTLEB C, 1995, INT J CANCER, V62, P697, DOI 10.1002/ijc.2910620609; ROTTLEB C, 1996, INT J CANCER, V67, P1; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; STIEF A, 1989, NATURE, V341, P341; STROBL LJ, 1993, ONCOGENE, V8, P1437; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; ZEIDLER R, 1994, GENE CHROMOSOME CANC, V9, P282, DOI 10.1002/gcc.2870090408; ZIMBERSTROBL U, 1993, EMBO J, V12, P167, DOI 10.1002/j.1460-2075.1993.tb05642.x	55	45	50	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	1999	18	9					1745	1753		10.1038/sj.onc.1202468	http://dx.doi.org/10.1038/sj.onc.1202468			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208435				2022-12-28	WOS:000079025000009
J	Prasad, MVVSV; Dhanasekaran, N				Prasad, MVVSV; Dhanasekaran, N			GTPase deficient mutant of G alpha(13) regulates the expression of Egr-1 through the small GTPase Rho	ONCOGENE			English	Article						G protein; G alpha(13); Rho; Egr-1; transcription factors; SRE; signal transduction; oncogene	TRANSCRIPTION FACTOR EGR-1; C-FOS; CELLS; DIFFERENTIATION; ACTIVATION; GROWTH; TRANSFORMATION; ELEMENTS; IDENTIFICATION; REPRESSION	The alpha-subunit of the heterotrimeric G protein G13 regulate cell growth, differentiation and apoptosis in different cell types. Expression of the constitutively activated mutant of G alpha(13) (G alpha(13)QL) increases the expression of Egr-1, an immediate-early response gene that is identified to be involved in cell growth, differentiation, and apoptosis. Here we report that G alpha(13)QL activates the promoter of Egr-1 through specific sequence which includes the characteristic CArG boxes. We also demonstrate that the G alpha(13)QL activation of Egr-1 promoter is mediated by the Ras-like small GTPase Rho.	Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, N (corresponding author), Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, Philadelphia, PA 19140 USA.				NIGMS NIH HHS [GM 49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; JIANG H, 1993, FEBS LETT, V3, P319; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; MICEL JB, 1994, J CLIN INVEST, V94, P277; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RIM M, 1992, ONCOGENE, V7, P2065; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Wadsworth SJ, 1997, J BIOL CHEM, V272, P28829, DOI 10.1074/jbc.272.46.28829; Watanabe S, 1997, BLOOD, V89, P1197, DOI 10.1182/blood.V89.4.1197; Wolf G, 1996, HYPERTENSION, V27, P897, DOI 10.1161/01.HYP.27.4.897; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744	28	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	1999	18	8					1639	1642		10.1038/sj.onc.1202461	http://dx.doi.org/10.1038/sj.onc.1202461			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102635				2022-12-28	WOS:000078770700015
J	Bei, R; Masuelli, L; Moriconi, E; Visco, V; Moretti, A; Kraus, MH; Muraro, R				Bei, R; Masuelli, L; Moriconi, E; Visco, V; Moretti, A; Kraus, MH; Muraro, R			Immune responses to all ErbB family receptors detectable in serum of cancer patients	ONCOGENE			English	Article						ErbB receptors; cancer; serum antibody	EPIDERMAL GROWTH-FACTOR; NIH 3T3 CELLS; CARCINOMA PATIENTS; PROTO-ONCOGENE; OVARIAN-CANCER; BREAST-CANCER; SELF-PROTEIN; HER-2/NEU; ANTIBODY; TRANSFORMATION	Employing NIH3T3 transfectants with individual human ErbB receptor coding sequences as recombinant antigen sources, we detected by immunoblot analysis specific immunoreactivity against all four ErbB receptors among 13 of 41 sera obtained from patients with different types of epithelial malignancies. Overall, serum positivity was most frequently directed against ErbB2 followed by EGFR, ErbB3 and ErbB4, Specificity patterns comprised tumor patients with unique serum reactivity against ErbB2 or ErbB4, Moreover, approximately half of the positive sera exhibited concomitant reactivity with multiple ErbB receptors including EGFR and ErbB2, EGFR and ErbB4, ErbB2 and ErbB3 or EGFR, ErbB2 and ErbB3, Serum reactivity was confirmed for the respective ErbB receptors expressed by human tumor cells and corroborated on receptor-specific immunoprecipitates, Positive sera contained ErbB-specific antibodies of the IgG isotype. Representative immunohistochemical analysis of tumor tissues suggested overexpression of ErbB receptors for which serum antibodies were detectable in five of six patients. These findings implicate multiple ErbB receptors including ErbB3 and ErbB4 in addition to EGFR and ErbB2 in primary human cancer. Heterogeneity of natural ErbB-specific responses in cancer patients warrants their evaluation in Light of immunotherapeutic approaches targeting these receptors.	Univ G DAnnunzio, Dept Oncol & Neurosci, Chieti, Italy; European Inst Oncol, Dept Expt Oncol, Milan, Italy; Univ La Sapienza, Dept Expt Med & Pathol, Rome, Italy	G d'Annunzio University of Chieti-Pescara; IRCCS European Institute of Oncology (IEO); Sapienza University Rome	Muraro, R (corresponding author), Univ G DAnnunzio, Dept Oncol & Neurosci, Chieti, Italy.		Masuelli, Laura/AGW-4259-2022; Bei, Roberto/W-8023-2019	MASUELLI, Laura/0000-0001-8174-8034				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Baulida J, 1996, J BIOL CHEM, V271, P5251; BRICE EC, 1993, DEV GENET, V14, P174, DOI 10.1002/dvg.1020140304; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CEBRA JJ, 1984, ANNU REV IMMUNOL, V2, P493, DOI 10.1146/annurev.immunol.2.1.493; CIBOTTI R, 1992, P NATL ACAD SCI USA, V89, P416, DOI 10.1073/pnas.89.1.416; Clark MA, 1997, CLIN EXP IMMUNOL, V109, P166, DOI 10.1046/j.1365-2249.1997.4161316.x; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIFIORE PP, 1991, ADV CELLULAR MOL BIO, P139; Disis ML, 1996, J IMMUNOL, V156, P3151; Disis ML, 1997, J CLIN ONCOL, V15, P3363, DOI 10.1200/JCO.1997.15.11.3363; DISIS ML, 1994, CANCER RES, V54, P16; DISIS ML, 1994, CANCER RES, V54, P1071; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FISK B, 1995, J EXP MED, V181, P2109, DOI 10.1084/jem.181.6.2109; Glushkov AN, 1996, EXP ONCOL, V18, P81; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LUBIN R, 1995, NAT MED, V1, P701, DOI 10.1038/nm0795-701; MARIANICOSTANTINI R, 1991, CANCER-AM CANCER SOC, V67, P2880, DOI 10.1002/1097-0142(19910601)67:11<2880::AID-CNCR2820671129>3.0.CO;2-A; Nagata Y, 1997, J IMMUNOL, V159, P1336; NANDA NK, 1995, CELL, V82, P13, DOI 10.1016/0092-8674(95)90047-0; PEOPLES GE, 1995, P NATL ACAD SCI USA, V92, P432, DOI 10.1073/pnas.92.2.432; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PUPA SM, 1993, CANCER RES, V53, P5864; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tuttle TM, 1996, CANCER IMMUNOL IMMUN, V43, P135, DOI 10.1007/s002620050314; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Zafiropoulos A, 1997, J IMMUNOL METHODS, V200, P181, DOI 10.1016/S0022-1759(96)00207-4; Zhang K, 1996, J BIOL CHEM, V271, P3884	41	61	66	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1267	1275		10.1038/sj.onc.1202442	http://dx.doi.org/10.1038/sj.onc.1202442			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022808				2022-12-28	WOS:000078510900002
J	Chelbi-Alix, MK; de The, H				Chelbi-Alix, MK; de The, H			Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins	ONCOGENE			English	Article						nuclear bodies; PML; Sp100; ubiquitin; SUMO-1; HSV-1	ACUTE PROMYELOCYTIC LEUKEMIA; PRIMARY BILIARY-CIRRHOSIS; RETINOIC ACID; GROWTH-SUPPRESSOR; DOMAIN-10 ND10; PORE COMPLEX; RAR-ALPHA; CELLS; GENE; INTERFERON	The PML protein is associated to nuclear bodies (NBs) whose functions are as yet unknown. PML and two other NBs-associated proteins, Sp100 And ISG20 are directly induced by interferons (IFN). PML and Sp100 proteins are covalently linked to SUMO-1, and ubiquitin-like peptide. PML NBs are disorganized in acute promyelocytic leukemia and during several DNA virus infections. In particular, the HSV-1 ICP0 protein is known to delocalize PML from NBs. Thus, NBs could play an important role in oncogenesis, IFN response and viral infections. Here, we show that HSV-1 induced PML protein degradation without altering its mRNA level. This degradation was time- and multiplicity of infection-dependent. Sp100 protein was also degraded, while another SUMO-1 conjugated protein, RanGAP1 and the IFN-induced protein kinase PKR were not. The proteasome inhibitor MG132 abrogated the HSV-1-induced PML and Sp100 degradation and partially restored their NB-localization. HSV-1 induced PML and Sp100 degradation constitutes a new example of viral inactivation of IFN target gene products.	Univ Paris 07, Inst Univ Hematol, Com Paris Ligue Contre Canc, Lab Associe,CNRS,Unite Propre Rech 9051, Paris, France; Hop St Louis, Serv Biochim B, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Chelbi-Alix, MK (corresponding author), Hop St Louis, CNRS, UPR 9051, 1 Ave Vellefaux, F-75475 Paris 10, France.							Boddy MN, 1996, ONCOGENE, V13, P971; Borden KLB, 1998, J VIROL, V72, P758, DOI 10.1128/JVI.72.1.758-766.1998; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; CAYLEY PJ, 1984, EUR J BIOCHEM, V143, P165, DOI 10.1111/j.1432-1033.1984.tb08355.x; CHEBIALIX MK, 1996, PML PRIMARY TARGET G; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; CHOU J, 1995, P NATL ACAD SCI USA, V92, P10516, DOI 10.1073/pnas.92.23.10516; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DANIEL MT, 1993, BLOOD, V82, P1858; DEBOIS C, 1996, SCIENCE, V273, P951; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; Everett RD, 1997, EMBO J, V16, P566, DOI 10.1093/emboj/16.3.566; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Grotzinger T, 1996, J BIOL CHEM, V271, P25253, DOI 10.1074/jbc.271.41.25253; Grotzinger T, 1996, EUR J BIOCHEM, V238, P554, DOI 10.1111/j.1432-1033.1996.0554z.x; GULDNER HH, 1992, J IMMUNOL, V149, P4067; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Korioth F, 1996, EXP CELL RES, V229, P155, DOI 10.1006/excr.1996.0353; LAVAU C, 1995, ONCOGENE, V11, P871; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; Maul GG, 1996, VIROLOGY, V217, P67, DOI 10.1006/viro.1996.0094; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; MEREDITH M, 1995, VIROLOGY, V209, P174, DOI 10.1006/viro.1995.1241; Mu ZM, 1996, LEUKEMIA LYMPHOMA, V23, P277, DOI 10.3109/10428199609054830; Mu ZM, 1997, CARCINOGENESIS, V18, P2063, DOI 10.1093/carcin/18.11.2063; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V221, P448, DOI 10.1006/excr.1995.1396; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Rees S, 1996, BIOTECHNIQUES, V20, P102; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; Stadler M, 1995, ONCOGENE, V11, P2565; Sternsdorf T, 1997, IMMUNOBIOLOGY, V198, P307, DOI 10.1016/S0171-2985(97)80051-4; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Szekely L, 1996, J VIROL, V70, P2562, DOI 10.1128/JVI.70.4.2562-2568.1996; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yoshida H, 1996, CANCER RES, V56, P2945; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	57	271	276	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					935	941		10.1038/sj.onc.1202366	http://dx.doi.org/10.1038/sj.onc.1202366			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023669				2022-12-28	WOS:000078510600010
J	Fritz, G; Kaina, B				Fritz, G; Kaina, B			Phosphorylation of the DNA repair protein APE/REF-1 by CKII affects redox regulation of AP-1	ONCOGENE			English	Article						apurinic endonuclease; phosphorylation; casein kinase; DNA repair; AP-1; stress response	CASEIN KINASE-II; C-FOS; TOPOISOMERASE-II; ENZYME HAP1; TRANSCRIPTIONAL ACTIVITY; ATAXIA-TELANGIECTASIA; XERODERMA-PIGMENTOSUM; CELLULAR-PROTECTION; BINDING ACTIVITY; ACTIVITY INVITRO	The DNA repair protein apurinic endonuclease (APE/Ref-1) exerts several physiological functions such as cleavage of apurinic/apyrimidinic sites and redox regulation of the transcription factor AP-1, whose activation is part of the cellular response to DNA damaging treatments. Here we demonstrate that APE/Ref-1 is phosphorylated by casein kinase II (CKII), This was shown for both the recombinant APE/Ref-1 protein (Km = 0.55 mM) and for APE/Ref-1 expressed in COS cells. Phosphorylation of APE/Ref-1 did not alter the repair activity of the enzyme, whereas it stimulated its redox capability towards AP-1, thus promoting DNA binding activity of AP-1, Inhibition of CKII mediated phosphorylation of APE/Ref-1 blocked mutagen-stimulated increase in AP-1 binding. It also abrogated the induction of c-Jun protein and rendered cells more sensitive to induced DNA damage. Thus, phosphorylation of APE/Ref-1 appears to be involved in regulating the different physiological activities of the enzyme, CKII mediated phosphorylation of APE/Ref-1 and concomitant increase in AP-1 binding activity appears to be a novel mechanism of cellular stress response, forcing transcription of AP-1 target gene(s) the product(s) of which may exert protective function.	Univ Mainz, Inst Toxicol, Div Appl Toxicol, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Fritz, G (corresponding author), Univ Mainz, Inst Toxicol, Div Appl Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.							ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; BARZILAY G, 1995, NUCLEIC ACIDS RES, V23, P1544, DOI 10.1093/nar/23.9.1544; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COCHET C, 1982, BIOCHEM PHARMACOL, V31, P1357, DOI 10.1016/0006-2952(82)90028-4; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dosch J, 1996, ONCOGENE, V13, P1927; DUCEMAN BW, 1981, J BIOL CHEM, V256, P755; DURBAN E, 1985, EMBO J, V4, P2921, DOI 10.1002/j.1460-2075.1985.tb04024.x; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FRIEDBERG EC, 1995, DNA REPAIR MUTAGNESI; GRUNICKE H, 1994, ANN HEMATOL, V69, P1; GZUDER SN, 1994, NATURE, V369, P578; HAAS S, 1995, CARCINOGENESIS, V16, P985, DOI 10.1093/carcin/16.5.985; HAGIWARA M, 1988, BIOCHEM PHARMACOL, V37, P2987; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; ISSINGER OG, 1988, EMBO J, V7, P1621, DOI 10.1002/j.1460-2075.1988.tb02988.x; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JONES NJ, 1993, CARCINOGENESIS, V14, P2487, DOI 10.1093/carcin/14.12.2487; Kaina B, 1997, CANCER RES, V57, P2721; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE SK, 1984, J BIOL CHEM, V259, P4695; LEVIN JD, 1990, NUCLEIC ACIDS RES, V18, P5069, DOI 10.1093/nar/18.17.5069; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MATTER WF, 1992, BIOCHEM BIOPH RES CO, V186, P624, DOI 10.1016/0006-291X(92)90792-J; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; OKAZAKI T, 1994, J BIOL CHEM, V269, P27855; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; RITKE MK, 1995, MOL PHARMACOL, V48, P798; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHNEIDER HR, 1986, EUR J BIOCHEM, V161, P733, DOI 10.1111/j.1432-1033.1986.tb10501.x; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SMITH PJ, 1989, CANCER RES, V49, P1118; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; SRIVASTAVA AK, 1985, BIOCHEM BIOPH RES CO, V131, P1, DOI 10.1016/0006-291X(85)91761-9; STRYER L, 1998, BIOCHEMISTRY; TEITZ T, 1990, MUTAT RES, V236, P85, DOI 10.1016/0921-8777(90)90036-5; TUTEJA N, 1995, GENE, V160, P143, DOI 10.1016/0378-1119(95)00207-M; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Vassetzky YS, 1996, BRIT J CANCER, V73, P1201, DOI 10.1038/bjc.1996.231; Wada T, 1996, NUCLEIC ACIDS RES, V24, P876, DOI 10.1093/nar/24.5.876; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; WALKER LJ, 1994, NUCLEIC ACIDS RES, V22, P4884, DOI 10.1093/nar/22.23.4884; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997	60	97	101	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1033	1040		10.1038/sj.onc.1202394	http://dx.doi.org/10.1038/sj.onc.1202394			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023679				2022-12-28	WOS:000078510600020
J	Hengstschlager, M; Holzl, G; Hengstschlager-Ottnad, E				Hengstschlager, M; Holzl, G; Hengstschlager-Ottnad, E			Different regulation of c-Myc- and E2F-1-induced apoptosis during the ongoing cell cycle	ONCOGENE			English	Article						apoptosis; cell cycle; c-Myc; E2F-1; centrifugal elutriation	UBIQUITIN-PROTEASOME PATHWAY; S-PHASE ENTRY; DEREGULATED EXPRESSION; DNA-SYNTHESIS; E2F-1; INDUCTION; FIBROBLASTS; LEADS; PROLIFERATION; DEGRADATION	The transcription factors c-Myc and E2F-1 have been shown to harbour both mitogenic and apoptotic properties. Both factors have been implicated in the regulation of the transition from the G1 phase to the S phase in the mammalian cell cycle, However, whether cell death triggered by these molecules is dependent on the cell's position in the ongoing cell cycle remained elusive. Using centrifugal elutriation we here show for the first time that c-Myc induces apoptosis in G1 and in G2 phase, whereas E2F-l-induced apoptosis specifically occurs in G1, S phase cells are resistant to cell death triggered by these factors. We demonstrate that this is not a general phenomenon, since S phase cells are susceptible to apoptosis induced by treatment with actinomycin D and to the anti-apoptotic activity of Bcl-2, Our data indicate that S phase cells harbour specific protective activities against c-Myc- and E2F-l-induced apoptosis, Our results demonstrate that these transcription factors, although probably sharing specific apoptotic pathways, also take distinct routes to induce cell death and that apoptosis can occur at different phases of the cell cycle depending on the apoptotic stimulus. In this report we present the usefulness of a new approach to determine the regulation of apoptosis in the ongoing unperturbated cell cycle. This approach has clear implications for the identification of target genes involved in the regulation of cell death.	Univ Vienna, Dept Prenatal Diagnosis & Therapy, A-1090 Vienna, Austria; Univ Vienna, Inst Genet Mol, A-1030 Vienna, Austria	University of Vienna; University of Vienna	Hengstschlager, M (corresponding author), Univ Vienna, Dept Prenatal Diagnosis & Therapy, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.							ASKEW DS, 1991, ONCOGENE, V6, P1915; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Dao T, 1997, J IMMUNOL, V159, P4261; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hengstschlager M, 1997, BIOTECHNIQUES, V23, P232, DOI 10.2144/97232bm12; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Packham G, 1996, ONCOGENE, V13, P461; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pusch O, 1997, ONCOGENE, V15, P649, DOI 10.1038/sj.onc.1201236; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Reed J C, 1996, Behring Inst Mitt, P72; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Soucek T, 1997, ONCOGENE, V14, P2251, DOI 10.1038/sj.onc.1201061; STRASSER A, 1996, BEHRING I MITT, V97, P101; Vairo G, 1996, ONCOGENE, V13, P1511; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	30	19	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					843	848		10.1038/sj.onc.1202342	http://dx.doi.org/10.1038/sj.onc.1202342			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989838				2022-12-28	WOS:000078394400033
J	Yokouchi, M; Wakioka, T; Sakamoto, H; Yasukawa, H; Ohtsuka, S; Sasaki, A; Ohtsubo, M; Valius, M; Inoue, A; Komiya, S; Yoshimura, A				Yokouchi, M; Wakioka, T; Sakamoto, H; Yasukawa, H; Ohtsuka, S; Sasaki, A; Ohtsubo, M; Valius, M; Inoue, A; Komiya, S; Yoshimura, A			APS, an adaptor protein containing PH and SH2 domains, is associated with the PDGF receptor and c-Cbl and inhibits PDGF-indnced mitogenesis	ONCOGENE			English	Article						adaptor molecules containing PH and SH2 domains (APS); platelet derived growth factor receptor (PDGFR); signal transduction; molecular biology	FACTOR-BETA-RECEPTOR; EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASE; NEGATIVE REGULATOR; ACTIVATION; PROTOONCOGENE; RAS; CLONING; STIMULATION	Previously we cloned a novel adaptor protein, APS (adaptor molecules containing PH and SH2 domains) which was tyrosine phosphorylated in response to c-kit or B cell receptor stimulation. Here we report that APS was expressed in some human osteosarcoma cell lines, markedly so in SaOS-2 cells, and was tyrosine-phosphorylated in response to several growth factors, including platelet derived growth factor (PDGF), insulinlike growth factor (IGF), and granulocyte-macrophage colony stimulating factor (GM-CSF), Ectopic expression of the wild type APS, but not C-terminal truncated APS, in NIH3T3 fibroblasts suppressed PDGF-induced MAP kinase (Erk2) activation, c-fos and c-myc induction as well as cell proliferation. In vitro binding experiments suggest that APS bound to the beta type PDGF receptor, mainly via phosphotyrosine 1021 (pY1021), Indeed, tyrosine phosphorylation of PLC-gamma, which has been demonstrated to bind to pY1021, but not that of PI3 kinase and associated proteins, was reduced in APS transformants, PDGF induced phosphorylation of the tyrosine residue of APS close to the C-terminal end. in vitro and in vivo binding experiments indicate that the tyrosine phosphorylated C-terminal region of APS bound to c-Cbl, which has been shown to be a negative regulator of tyrosine kinases, Since coexpression of c-Cbl with wild type APS, but not C-terminal truncated APS, synergistically inhibited PDGF-induced c-fos promoter activation, c-Cbl could be a mechanism of inhibitory action of APS on PDGF receptor signaling.	Inst Life Sci, Kurume, Fukuoka 8390861, Japan; Kurume Univ, Fac Med, Dept Orthopaed Surg, Kurume, Fukuoka 8300011, Japan; Lithuania Acad Sci, Inst Biochem, LT-2600 Vilnius, Lithuania	Kurume University; Vilnius University	Yoshimura, A (corresponding author), Inst Life Sci, Aikawamachi 2432-3, Kurume, Fukuoka 8390861, Japan.		Valius, Mindaugas/N-1220-2019; Yoshimura, Akihiko/K-5515-2013; Valius, Mindaugas/F-2734-2012	Valius, Mindaugas/0000-0001-8478-8517; Sasaki, Atsuo/0000-0003-2963-4501; ohtsubo, motoaki/0000-0002-2479-3178				Alimandi M, 1997, ONCOGENE, V15, P585, DOI 10.1038/sj.onc.1201221; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KEANE MM, 1995, ONCOGENE, V10, P2367; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PAWSON T, 1992, CELL, V56, P5; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; RODAN SB, 1987, CANCER RES, V47, P4961; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; Takaki S, 1997, J BIOL CHEM, V272, P14562, DOI 10.1074/jbc.272.23.14562; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Wang J, 1998, J BIOL CHEM, V273, P3136, DOI 10.1074/jbc.273.6.3136; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	38	68	71	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					759	767		10.1038/sj.onc.1202326	http://dx.doi.org/10.1038/sj.onc.1202326			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989826				2022-12-28	WOS:000078394400021
J	Grutz, G; Forster, A; Rabbitts, TH				Grutz, G; Forster, A; Rabbitts, TH			Identification of the LMO4 gene encoding an interaction partner of the LIM-binding protein LDB1/NLI1: a candidate for displacement by LMO proteins in T cell acute leukaemia	ONCOGENE			English	Article						LIM domains; T cell; leukaemia; chromosomal translocations; protein interactions	TRANSGENIC MICE; DOMAIN PROTEINS; HOMEODOMAIN PROTEINS; RBTN2; RHOMBOTIN; LEUKEMIA; FAMILY; EXPRESSION; MOTIF; TAL1	The T cell oncogenes LMO2 and LMO2 are activated by distinct chromosomal translocations in childhood T cell acute leukaemias. Transgenic mouse models of this disease demonstrate that enforced expression of Lmo1 and Lmo2 cause T cell leukaemias with long latency and that Lmo2 expression leads to an inhibition of the T cell differentiation programme, prior to overt disease. These functions appear to be partly mediated by interaction of LMO1 or LMO2 with the LIM-binding protein LDB1/NLI1. We have now identified a new member of the Lmo family, designated Lmo4, via its interaction with Ldb1. Lmo4 is widely expressed in mouse tissues, including adult thymus (mainly CD4, CDS-double positive T cells) and embryonic thymus (mainly CD4, CD8-double negative T cells). These characteristics imply that Ldb1-Lmo4 interaction may function in the T cell developmental programme and that enforced expression of LMO1 or LMO2 by chromosomal translocations or transgenesis may displace Lmo4 from this complex and thereby influence T cell differentiation prior to T cell tumour occurrence.	MRC, Mol Biol Lab, Div Protein & Nucle Acid Chem, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Rabbitts, TH (corresponding author), MRC, Mol Biol Lab, Div Protein & Nucle Acid Chem, Hills Rd, Cambridge CB2 2QH, England.		Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1991, ONCOGENE, V6, P695; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISCH P, 1992, ONCOGENE, V7, P2389; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; Grutz GG, 1998, EMBO J, V17, P4594, DOI 10.1093/emboj/17.16.4594; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; Kenny DA, 1998, P NATL ACAD SCI USA, V95, P11257, DOI 10.1073/pnas.95.19.11257; LARSON RC, 1995, ONCOGENE, V11, P853; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LARSON RC, 1994, ONCOGENE, V9, P3675; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1991, BLOOD, V77, P599; NEALE GAM, 1995, BLOOD, V86, P3060; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; RABBITTS TH, 1998, IN PRESS CANC RES; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SANCHEZGARCIA I, 1995, ONCOGENE, V10, P1301; SANCHEZGARCIA I, 1993, SEMIN CANCER BIOL, V4, P349; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VALGEARCHER V, 1998, IN PRESS ONCOGENE; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; ZHU TH, 1995, ONCOGENE, V11, P1283	39	65	69	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2799	2803		10.1038/sj.onc.1202502	http://dx.doi.org/10.1038/sj.onc.1202502			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840944				2022-12-28	WOS:000077146700013
J	Esteller, M; Levine, R; Baylin, SB; Ellenson, LH; Herman, JG				Esteller, M; Levine, R; Baylin, SB; Ellenson, LH; Herman, JG			MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas	ONCOGENE			English	Article						MLH1; hypermethylation; endometrial carcinoma; microsatellite instability	MISMATCH REPAIR GENES; NONPOLYPOSIS COLORECTAL-CANCER; CPG ISLAND METHYLATION; COLON-CANCER; MUTATIONAL ANALYSIS; DNA METHYLATION; HOMOLOG; TUMORS; HMLH1; HMSH2	Microsatellite instability (MSI) has been detected in endometrial carcinomas occurring in women affected by hereditary nonpolyposis colorectal carcinoma (HNPCC) as well as in 20% of presumably sporadic endometrial tumors. While the MSI+ phenotype observed in endometrial tumors from HNPCC patients is attributed to germ line mutations in mismatch repair (MMR) genes, somatic mutations of known MMR genes are infrequent in MSI+ sporadic endometrial carcinomas, Recently, cytosine methylation of the MLH1 promoter region has been identified in a subset of MSI+ colon primary carcinomas and cell lines. We studied the MLH1 and MSH2 promoter methylation status in 29 presumably sporadic uterine endometrioid carcinomas (UECs), which had previously been characterized for the MSI phenotype and a subset for DNA MMR gene mutational status. We found that 13 (45%) of 29 cases of EC were hypermethylated in the 5' CpG island of MLH1. Hypermethylation of MSH2 was not observed, MLH1 was hypermethylated in 12 (92%) of 13 MSI+ tumors, while only 1 (6%) of 16 MSI- tumors (Fischer's exact test P < 0.0001). Other tumor types we tested did not demonstrate MLH1 promoter hypermethylation, Our data suggest that hypermethylation of MLH1, but not of MSH2, is associated with the MSI phenotype in sporadic endometrial carcinomas.	Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Herman, JG (corresponding author), Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA.		Esteller, Manel/L-5956-2014	Esteller, Manel/0000-0003-4490-6093	NATIONAL CANCER INSTITUTE [R01CA043318] Funding Source: NIH RePORTER; NCI NIH HHS [CA43318] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Ahuja N, 1997, CANCER RES, V57, P3370; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BURKS RT, 1994, ONCOGENE, V9, P1163; Caduff RF, 1996, AM J PATHOL, V148, P1671; DUGGAN BD, 1994, J NATL CANCER I, V86, P1216, DOI 10.1093/jnci/86.16.1216; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kane MF, 1997, CANCER RES, V57, P808; KATABUCHI H, 1995, CANCER RES, V55, P5556; Kobayashi K, 1996, JPN J CANCER RES, V87, P141, DOI 10.1111/j.1349-7006.1996.tb03151.x; KOBAYASHI K, 1995, GENE CHROMOSOME CANC, V14, P128, DOI 10.1002/gcc.2870140207; KOLODNER RD, 1995, CANCER RES, V55, P242; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Kowalski LD, 1997, GENE CHROMOSOME CANC, V18, P219, DOI 10.1002/(SICI)1098-2264(199703)18:3<219::AID-GCC8>3.0.CO;2-4; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lim PC, 1996, CLIN CANCER RES, V2, P1907; LIU B, 1994, CANCER RES, V54, P4590; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Risinger JI, 1997, CANCER RES, V57, P4736; RISINGER JI, 1993, CANCER RES, V53, P1; Tashiro H, 1997, CANCER RES, V57, P3935; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thibodeau SN, 1996, CANCER RES, V56, P4836; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#	32	392	401	0	14	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2413	2417		10.1038/sj.onc.1202178	http://dx.doi.org/10.1038/sj.onc.1202178			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811473				2022-12-28	WOS:000076723300016
J	Lounis, H; Mes-Masson, AM; Dion, F; Bradley, WEC; Seymour, RJ; Provencher, D; Tonin, PN				Lounis, H; Mes-Masson, AM; Dion, F; Bradley, WEC; Seymour, RJ; Provencher, D; Tonin, PN			Mapping of chromosome 3p deletions in human epithelial ovarian tumors	ONCOGENE			English	Article						ovarian; chromosome 3p; loss of heterozygosity; tumor suppressor	SUPPRESSOR GENE; RECEPTOR GENE; HUMAN GENOME; CELL-LINES; FHIT GENE; LOW-GRADE; CANCER; CARCINOMAS; MAP; IDENTIFICATION	Epithelial ovarian tumors frequently display deletions on the short arm of chromosome 3 suggesting the existence of tumor suppressor genes within the deleted regions. We have recently established a primary tissue culture system as a model to investigate the genetic events associated with ovarian cancer. The frequencies of loss of heterozygosity (LOH) at 16 loci representative of chromosome 3p in 33 tumor biopsies and 47 ovarian primary cultures derived from unselected ovarian cancers were examined, This repertoire also included benign and borderline tumors as well as malignant ovarian ascites, LOH was observed in 25 (31%) samples for at least one marker: 21 of 58 malignant, two of 12 borderline and two of 10 benign specimens, Chromosome 3p loss was not restricted to ovarian tumors of high grade and stage. LOH was observed in both cultured and non cultured tumors and ascites, A spontaneously immortalized cell line derived from a malignant ovarian ascites, OV-90, displayed LOH of the majority of markers suggesting loss of one homolog of chromosome 3p, The pattern of deletion displayed by these 25 samples enabled the determination of at least two distinct regions of overlapping deletions on chromosome 3p extending from D3S1270 to D3S1597 and from D3S1293 to D3S1283, In addition, a region proximal to D3S1300 was deleted in a subset of samples. Although loss of loci overlapping these three regions (Regions I, II and III) were observed in malignant and benign tumors, in borderline tumors loss was observed of markers representative of Region III only. While RAR beta is presently included in Region II, the minimal regions of deletion exclude VHL, TGFBR2, PTPasey and FHIT as candidate tumor suppressors in ovarian tumorigenesis.	CHUM Campus Notre Dame, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Obstet Gynecol, Montreal, PQ H3C 3J2, Canada; McGill Univ, Montreal Gen Hosp, Res Inst, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Obstet & Gynecol, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3G 1A4, Canada	Universite de Montreal; Universite de Montreal; McGill University; McGill University; McGill University; McGill University	Mes-Masson, AM (corresponding author), CHUM Campus Notre Dame, Inst Canc Montreal, 1560 Rue Sherbrooke Est, Montreal, PQ H2L 4M1, Canada.			Mes-Masson, Anne-Marie/0000-0002-6498-266X				Aebi S, 1996, CANCER RES, V56, P3087; BUICK RN, 1985, CANCER RES, V45, P3668; Cheng PC, 1996, J NATL CANCER I, V88, P510, DOI 10.1093/jnci/88.8.510; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DODSON MK, 1993, CANCER RES, V53, P4456; EHLEN T, 1990, ONCOGENE, V5, P219; Foster K, 1995, EUR J CANCER, V31A, P2392, DOI 10.1016/0959-8049(95)00437-8; Hendricks DT, 1997, CANCER RES, V57, P2112; HOULE B, 1994, CANCER RES, V54, P365; JONES MH, 1992, ONCOGENE, V7, P1631; KRUK PA, 1990, LAB INVEST, V63, P132; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LAFORGIA S, 1993, CANCER RES, V53, P3118; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LATIF F, 1993, CANCER RES, V53, P861; LOUNIS H, 1994, EXP CELL RES, V215, P303, DOI 10.1006/excr.1994.1346; MANNING A, 1998, UNPUB MOL CARCINOGEN; MATHEW S, 1994, GENOMICS, V20, P114, DOI 10.1006/geno.1994.1134; MATTEI MG, 1991, GENOMICS, V10, P1061, DOI 10.1016/0888-7543(91)90199-O; Nakashima R, 1996, ONCOL REP, V3, P887; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PARSONS R, 1995, CANCER RES, V55, P5548; PEJOVIC T, 1992, GENE CHROMOSOME CANC, V4, P58, DOI 10.1002/gcc.2870040108; Phillips NJ, 1996, CANCER RES, V56, P606; RIMESSI P, 1994, ONCOGENE, V9, P3467; Schuler GD, 1996, SCIENCE, V274, P547; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Sun HS, 1996, MAMM GENOME, V7, P128, DOI 10.1007/s003359900032; SUN LZ, 1994, J BIOL CHEM, V269, P26449; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WANG JC, 1998, UNPUB CANC GENET CYT; WARY KK, 1993, CANCER RES, V53, P1498; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V11, P91, DOI 10.1016/0165-4608(84)90102-X; WHITMAN G, 1993, NORMAL OVARIAN DEV F; Yonescu R, 1996, CANCER GENET CYTOGEN, V87, P167, DOI 10.1016/0165-4608(95)00241-3; ZHENG JP, 1991, CANCER RES, V51, P4045	37	38	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2359	2365		10.1038/sj.onc.1202152	http://dx.doi.org/10.1038/sj.onc.1202152			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811467				2022-12-28	WOS:000076723300010
J	Gupta, RW; Mayer, BJ				Gupta, RW; Mayer, BJ			Dominant-negative mutants of the SH2/SH3 adapters Nck and Grb2 inhibit MAP kinase activation and mesoderm-specific gene induction by eFGF in Xenopus	ONCOGENE			English	Article						SH2/SH3 adapters; MAPK; FGF; mesoderm induction	FIBROBLAST GROWTH-FACTOR; PC12 CELL-DIFFERENTIATION; SRC HOMOLOGY-3 DOMAINS; PROTEIN-KINASE; FGF-RECEPTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASES; POINT MUTATION; SH3 DOMAINS; PATHWAY	The SH2/SH3 adapters Nck, Grb2 and Crk promote the assembly of signaling complexes by binding to tyrosine phosphorylated proteins using their SH2 domains and to proline-rich sequences on effector molecules using their SH3 domains. FGF, which activates a receptor tyrosine kinase, induces mesoderm formation in Xenopus embryos through activation of the Ras/Raf/MAPK signaling pathway. We present evidence that dominant-negative mutants of Nck and Grb2, but not Crk1, can inhibit mesoderm-specific gene induction by eFGF in Xenopus animal cap explants. We also show that dominant-negative mutants of Grb2 and Nck can inhibit eFGF-induced Erk1 activation in Xenopus animal caps, and that targeting the first two SH3 domains of Nck to the membrane can activate Erk1 in the absence of eFGF.. Furthermore, combinations of the dominant-negative Grb2 mutants with the inhibitory Nck mutant synergistically inhibited Erk1 activation by eFGF in Xenopus animal caps, suggesting that the dominant-negative Nck and Grb2 mutants inhibit Erk1 activation by binding to different proteins. By contrast only Grb2 mutants could inhibit eFGF-induced Erk1 activation in human 293 cells, demonstrating diversity in the specific mechanisms of signaling from FGF to MAP kinases in different cells.	Harvard Med Sch, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Mayer, BJ (corresponding author), Harvard Med Sch, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.							CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FELLER SM, 1995, ONCOGENE, V10, P1465; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; Harlow E., 1988, ANTIBODIES LAB MANUA; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HU G, 1995, MOL CELL BIOL, V15, P1169; HUGHES DA, 1993, NATURE, V364, P349, DOI 10.1038/364349a0; ISAACS HV, 1992, DEVELOPMENT, V114, P711; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; Kitamura T, 1996, BIOCHEM BIOPH RES CO, V219, P509, DOI 10.1006/bbrc.1996.0264; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LABONNE C, 1995, DEVELOPMENT, V121, P1475; LALLEMAIN G, 1992, MOL CELL BIOL, V12, P2222, DOI 10.1128/MCB.12.5.2222; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MUSLIN AJ, 1994, MOL CELL BIOL, V14, P3006, DOI 10.1128/MCB.14.5.3006; NAKEILNY S, 1992, EMBO J, V11, P2123; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Okada S, 1996, J BIOL CHEM, V271, P25533, DOI 10.1074/jbc.271.41.25533; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Rockow S, 1996, ONCOGENE, V12, P2351; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; RYAN PJ, 1994, DEV BIOL, V166, P101, DOI 10.1006/dbio.1994.1299; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SPENCER DM, 1995, P NATL ACAD SCI USA, V92, P9805, DOI 10.1073/pnas.92.21.9805; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; Tanaka M, 1997, P NATL ACAD SCI USA, V94, P4493, DOI 10.1073/pnas.94.9.4493; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VIZE PD, 1991, METHOD CELL BIOL, V36, P367; Ward CW, 1996, J BIOL CHEM, V271, P5603, DOI 10.1074/jbc.271.10.5603; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0	61	38	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2155	2165		10.1038/sj.onc.1202158	http://dx.doi.org/10.1038/sj.onc.1202158			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811447				2022-12-28	WOS:000076698200002
J	Cipriano, SC; Chen, YQ				Cipriano, SC; Chen, YQ			Insensitivity to growth inhibition by TGF-beta 1 correlates with a lack of inhibition of the CDK2 activity in prostate carcinoma cells	ONCOGENE			English	Article						TGF-beta; G(1) arrest; cell cycle; p15(INK4B); p21(WAF1/Cip1/Sdi1); p27(KIP1); prostate cancer	DEPENDENT KINASE INHIBITOR; TGF-BETA; CANCER-CELLS; CYCLE ARREST; POTENTIAL MEDIATOR; SMAD PROTEINS; GENE; PROLIFERATION; DPC4; SUPPRESSION	TGF-beta is a potent growth inhibitor of epithelial cells. However, many transformed cells have lost their sensitivity to this growth inhibitory effect. The molecular mechanism of such insensitivity is not get understood, Here, we have studied the TGF-beta 1 effect on normal human prostate and carcinoma cells. Our results showed that normal cells were sensitive to growth inhibition, whereas tumor cells were not or only minimally inhibited regardless of the concentration of TGF-beta 1 (20 to 80 pM) or time of exposure (1-5 days). p21(WAF/Cip1/Sdi1) and p15(INK4B) but not p27(KIP1) were detectable by Western blotting in normal and tumor cells, TGF-beta 1 treatment increased the association of p21(WAF1/Cip1/Sdi1) with the Cdk2/cyclin E complex in both normal and prostate tumor cells. However, there was no increase in the association of p15(INK4B) nor p27(Kip1) with the Cdk/cyclin complexes, In normal cells, the increase in the association of p21(WAF1/Cip1/Sdi1). With th, Cdk2/cyclin E complex resulted in inhibition of the Cdk2 activity. In contrast, although there was an increase in the association of p21(WAF1/Cip1/Sdi1) With th, Cdk2/cyclin E complex in tumor cells, there was no inhibition of the Cdk2 activity, These results indicate that a lack of inhibition of the Cdk2 activity correlates with insensitivity to TGF-beta 1 in prostate tumor cells.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Wayne State University	Chen, YQ (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.		Chen, Yong Q/AAI-9864-2021	Chen, Yong Q/0000-0003-4747-4708				BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHEN YQ, 1992, J BIOL CHEM, V267, P17314; CHEN YQ, 1994, CANCER MOL BIOL, V1, P357; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FRANZEN P, 1993, EXP CELL RES, V207, P1, DOI 10.1006/excr.1993.1156; GAO X, 1995, ONCOGENE, V11, P1395; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GRUBECKLOBENSTE.B, 1989, J CLIN INVEST, V8, P764; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Herman JG, 1996, CANCER RES, V56, P722; HUGGETT AC, 1990, CANCER RES, V50, P7468; ICHIJO H, 1990, EXP CELL RES, V187, P263, DOI 10.1016/0014-4827(90)90090-W; IVARONE A, 1997, NATURE, V387, P417; Kim IY, 1996, CANCER RES, V56, P44; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; PIACIBELLO W, 1991, HAEMATOLOGICA, V76, P460; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Schutte M, 1996, CANCER RES, V56, P2527; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILDING G, 1989, MOL CELL ENDOCRINOL, V62, P79, DOI 10.1016/0303-7207(89)90115-9; Wrana J, 1997, NATURE, V388, P28, DOI 10.1038/40290; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	42	22	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 24	1998	17	12					1549	1556		10.1038/sj.onc.1202069	http://dx.doi.org/10.1038/sj.onc.1202069			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794232				2022-12-28	WOS:000076089900007
J	Care, A; Valtieri, M; Mattia, G; Meccia, E; Masella, B; Luchetti, L; Felicetti, F; Colombo, MP; Peschle, C				Care, A; Valtieri, M; Mattia, G; Meccia, E; Masella, B; Luchetti, L; Felicetti, F; Colombo, MP; Peschle, C			Enforced expression of HOXB7 promotes hematopoietic stem cell proliferation and myeloid-restricted progenitor differentiation	ONCOGENE			English	Article						homeobox genes; hematopoietic progenitors; retroviral vector expression	NATURAL-KILLER LYMPHOCYTES; FIBROBLAST GROWTH-FACTOR; HUMAN PERIPHERAL-BLOOD; HOMEOBOX GENES; FUNCTIONAL-ROLE; LEUKEMIA; OVEREXPRESSION; EXPANSION	Hematopoietic progenitor/stem cells (HPCs/HSCs) purified from human adult peripheral blood (PB) were triggered into cycling, retrovirally transduced with HOXB7 and then functionally assayed in vitro. HPCs were assayed in multi- and unilineage differentiation cultures in either liquid phase or semisolid medium, primitive HPCs in the high proliferative potential colony-forming cell (HPP-CFC) evaluation system and putative HSCs in Dexter type long-term culture (LTC) as LTC initiating cells (LTC-ICs), Control experiments ensured that the exogenous HOXB7 gene was constantly expressed, while the endogenous one was barely or not transcribed. Enforced expression of the gene markedly modulated the proliferation/differentiation program of the entire HSC/HPC population, Enforced HOXB7 expression exerted a potent stimulatory effect on the proliferation of the primitive HPC and putative HSC subsets, assayed as HPP-CFCs and LTC-ICs respectively. While not modifying the total number of HPCs, exogenous HOXB7 induced an increase of the number of granulo-monocytic (GM) HPCs [colony-forming unit GM (CFU-GM) CFU-GM, CFU-C and CFU-M, as evaluated by clonogenic assays] and markedly amplified the progeny of both CFU-G and CFU-M, which showed a sustained proliferation through at least 1-2 months (as evaluated in liquid suspension culture). The prolonged proliferative stimulus induced by HOXB7 transfer into LTC, primitive and GM oriented HPC culture was characterized by persistent proliferation of a discrete population of blast cells and a large pool of differentiated myeloid precursors. Altogether, these results suggest the hypothesis that the proliferative stimulus exerted by exogenous HOXB7 in primitive and GM-oriented HPCs may represent a preleukemic immortalization step. Consistent with the functional role of HOXB7 in the initial ontogenetic phase, these studies indicate that ectopic HOXB7 expression in early HPCs and HSCs from adult PB stimulates their self renewal, sustained proliferation and myeloid differentiation.	Ist Super Sanita, Dept Hematol & Oncol, I-00161 Rome, Italy; Ist Nazl Tumori, I-20133 Milan, Italy; T Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA USA	Istituto Superiore di Sanita (ISS); Fondazione IRCCS Istituto Nazionale Tumori Milan; Jefferson University	Care, A (corresponding author), Ist Super Sanita, Dept Hematol & Oncol, I-00161 Rome, Italy.		valtieri, mauro/H-1044-2016; felli, nadia/G-2088-2012; Colombo, Mario P./V-7166-2017; CARE', Alessandra/H-5090-2016; Felicetti, Federica/N-7077-2017; Mattia, Gianfranco/K-5194-2016	valtieri, mauro/0000-0002-9139-6754; felli, nadia/0000-0001-6763-3361; Colombo, Mario P./0000-0003-0042-7955; CARE', Alessandra/0000-0003-4106-3342; Felicetti, Federica/0000-0003-4628-0696; Mattia, Gianfranco/0000-0001-7047-6360; meccia, ettore/0000-0003-2076-5951				BLATT C, 1992, CELL GROWTH DIFFER, V3, P671; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Care A, 1998, ONCOGENE, V16, P3285, DOI 10.1038/sj.onc.1201875; CARE A, 1994, MOL CELL BIOL, V14, P4872, DOI 10.1128/MCB.14.7.4872; Care A, 1996, MOL CELL BIOL, V16, P4842; DEGUCHI Y, 1991, BLOOD, V78, P445; DESCHAMPS J, 1992, Critical Reviews in Oncogenesis, V3, P117; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GABBIANELLI M, 1995, BLOOD, V86, P1661, DOI 10.1182/blood.V86.5.1661.bloodjournal8651661; GIAMPAOLO A, 1994, BLOOD, V84, P3637, DOI 10.1182/blood.V84.11.3637.bloodjournal84113637; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LABBAYE C, 1995, J CLIN INVEST, V95, P2346, DOI 10.1172/JCI117927; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LICHTY BD, 1995, LEUKEMIA LYMPHOMA, V16, P209, DOI 10.3109/10428199509049759; Magli MC, 1997, J CELL PHYSIOL, V173, P168, DOI 10.1002/(SICI)1097-4652(199711)173:2<168::AID-JCP16>3.0.CO;2-C; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MAVILIO F, 1993, EUR J BIOCHEM, V212, P273, DOI 10.1111/j.1432-1033.1993.tb17660.x; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PETRINI M, 1992, BLOOD, V80, P185; Quaranta MT, 1996, J IMMUNOL, V157, P2462; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; Shimamoto T, 1998, INT J HEMATOL, V67, P339; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; Tocci A, 1996, BLOOD, V88, P2878, DOI 10.1182/blood.V88.8.2878.bloodjournal8882878; UDOMSAKDI C, 1992, BLOOD, V80, P2513; VALTIERI M, 1994, CANCER RES, V54, P4398; Valtieri M, 1998, CANCER RES, V58, P562; Ziegler B, 1998, Stem Cells, V16 Suppl 1, P51	32	53	56	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					1993	2001		10.1038/sj.onc.1202498	http://dx.doi.org/10.1038/sj.onc.1202498			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208421				2022-12-28	WOS:000079191300009
J	Guldberg, P; Straten, PT; Ahrenkiel, V; Seremet, T; Kirkin, AF; Zeuthen, J				Guldberg, P; Straten, PT; Ahrenkiel, V; Seremet, T; Kirkin, AF; Zeuthen, J			Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma	ONCOGENE			English	Article						STK11; LKB1; tumour suppressor; malignant melanoma; Peutz-Jeghers syndrome; serine/threonine kinase	CUTANEOUS MELANOMA; CELL-LINES; CANCER; IDENTIFICATION; BREAST; PTEN	Mutations in LKB1/STK11, a gene mapping to chromosome 19p13.3 and encoding a widely expressed serine/threonine kinase, were recently identified as the cause of Peutz-Jeghers syndrome. Despite the hamartomatous polyps and increased cancer risk associated with this syndrome, somatic alterations in LKB1/STK11 have not been identified in human tumours. Prompted by another feature of the syndrome, lentigines of the lips and oral mucosa, we evaluated the status of LKB1/STK11 expression, deletion, and mutation in cell lines and tumour samples from 35 patients with sporadic malignant melanoma, Two somatic mutations were identified, a nonsense mutation (Glu170Stop) causing exon skipping and intron retention, and a missense mutation (Asp194Tyr) affecting an invariant residue in the catalytic subunit of LKB1/STK11. Our data suggest that LKB1/STK11 may contribute to tumorigenesis in a small fraction of malignant melanomas.	Danish Canc Soc, Inst Canc Biol, Dept Tumor Cell Biol, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Guldberg, P (corresponding author), Danish Canc Soc, Inst Canc Biol, Dept Tumor Cell Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.							ABRAMS ES, 1992, METHOD ENZYMOL, V212, P71; Albino Anthony P., 1995, Current Opinion in Oncology, V7, P162, DOI 10.1097/00001622-199503000-00012; Avizienyte E, 1998, CANCER RES, V58, P2087; Bartkova J, 1996, CANCER RES, V56, P5475; Bignell GR, 1998, CANCER RES, V58, P1384; BRAITMAN M, 1979, CUTIS, V23, P617; Castellano M, 1997, CANCER RES, V57, P4868; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; Guldberg P, 1997, CANCER RES, V57, P3660; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Healy E, 1996, CANCER RES, V56, P589; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hoffmeyer S, 1998, AM J HUM GENET, V62, P269, DOI 10.1086/301715; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; KAMP A, 1994, SCIENCE, V264, P436; KOH HK, 1991, NEW ENGL J MED, V325, P171, DOI 10.1056/NEJM199107183250306; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; PARMITER AH, 1986, CANCER RES, V46, P1526; Ray ME, 1997, P NATL ACAD SCI USA, V94, P3229, DOI 10.1073/pnas.94.7.3229; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Teng DHF, 1997, CANCER RES, V57, P5221; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Walker GJ, 1998, GENE CHROMOSOME CANC, V22, P157, DOI 10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N; Welch DR, 1997, PATHOBIOLOGY, V65, P311, DOI 10.1159/000164143; Wong SS, 1996, BRIT J DERMATOL, V135, P439, DOI 10.1046/j.1365-2133.1996.d01-1017.x	28	96	97	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	1999	18	9					1777	1780		10.1038/sj.onc.1202486	http://dx.doi.org/10.1038/sj.onc.1202486			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208439				2022-12-28	WOS:000079025000013
J	Chughtai, SA; Crundwell, MC; Cruickshank, NRJ; Affie, E; Armstrong, S; Knowles, MA; Takle, LA; Kuo, M; Khan, N; Phillips, SMA; Neoptolemos, JP; Morton, DG				Chughtai, SA; Crundwell, MC; Cruickshank, NRJ; Affie, E; Armstrong, S; Knowles, MA; Takle, LA; Kuo, M; Khan, N; Phillips, SMA; Neoptolemos, JP; Morton, DG			Two novel regions of interstitial deletion on chromosome 8p in colorectal cancer	ONCOGENE			English	Article						colorectal cancer; human; chromosome 8p; loss of heterozygosity; tumour behaviour; putative TSGs	TUMOR-SUPPRESSOR GENE; HUMAN PROSTATE-CANCER; BETA-GENE; BREAST-CARCINOMA; COPY NUMBER; DNA; CLONING; HETEROZYGOSITY; MUTATION; LOCI	We have investigated interstitial deletions of chromosome 8 in 70 colorectal carcinomas and 11 colonic adenomas using 11 microsatellite markers, including eight spanning the centromeric region of chromosome 8p (p11.2-p12). Allelic loss or imbalance was observed in 38 (54%) cancers and four (36%) adenomas, Twenty-eight (40%) of the cancers had deletions of 8p11.2-p12. Two distinct and independent regions of interstitial loss were found within this region. Fluorescent in situ hybridization, using an alpha! satellite repeat probe to the centromere of 8p and two probes to the P1 region, was performed in four tumours that demonstrated allelic imbalance. Localized heterozygous deletions were confirmed in all four tumours, Eleven (16%) cancers had localized deletion in the region ANK-1 to D8S255 (P1) and a further eleven (16%) cancers had a less well localized deletion in the region defined by the markers D8S87 to D8S259 (P2), Loss of both centromeric loci was identified in a further six (9%) tumours, A functional significance for these two deletion regions was sought by correlation with primary and secondary tumour characteristics. Isolated P2 deletion was associated with 'early' T1 cancers (2p = 0.0002), and were also identified in 3/11 adenomas, Conversely, interstitial deletions of the P1 locus were more frequently seen in 'locally invasive' T3/4 cancers (2p = 0.015), and isolated P1 deletions were also associated with the presence of liver metastases (2p = 0.016). Our data provide evidence of at least two genes within the 8p11.2-p12 region, mutations in which may confer different and independent roles in the pathogenesis of colorectal cancer.	Univ Birmingham, Dept Surg, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Dept Urol, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Dept Pathol, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Dept Biol, Birmingham B15 2TT, W Midlands, England; St James Univ Hosp, Imperial Canc Res Fund, Canc Med Res Unit, Leeds LS9 7TF, W Yorkshire, England; Marie Curie Res Inst, Surrey RH8 0TL, England; Royal Liverpool Univ Hosp, Dept Surg, Liverpool L69 3GA, Merseyside, England	University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; Saint James's University Hospital; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Morton, DG (corresponding author), Univ Birmingham, Dept Surg, Birmingham B15 2TT, W Midlands, England.		Neoptolemos, John/HGU-7742-2022; Neoptolemos, John P/G-4488-2010	Knowles, Margaret/0000-0002-9363-8657; Neoptolemos, John/0000-0002-6201-7399				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; *ACS, 1990, CANC FACTS FIG, P4; Afify A, 1997, CANCER GENET CYTOGEN, V97, P101, DOI 10.1016/S0165-4608(96)00361-5; Afify A, 1996, BREAST CANCER RES TR, V38, P201, DOI 10.1007/BF01806674; BERKNER KL, 1977, J BIOL CHEM, V252, P3176; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; CANNIZZARO LA, 1987, CYTOGENET CELL GENET, V46, P589; CHYAN YJ, 1994, NUCLEIC ACIDS RES, V22, P2719, DOI 10.1093/nar/22.14.2719; Crundwell MC, 1996, INT J CANCER, V69, P295, DOI 10.1002/(SICI)1097-0215(19960822)69:4<295::AID-IJC10>3.3.CO;2-#; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; CUNNINGHAM C, 1994, BRIT J CANCER, V70, P18, DOI 10.1038/bjc.1994.243; DIB A, 1995, ONCOGENE, V10, P995; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DOBASHI Y, 1994, CANCER RES, V54, P2827; EMI M, 1992, CANCER RES, V52, P5368; Eydmann ME, 1997, CANCER GENET CYTOGEN, V93, P167, DOI 10.1016/S0165-4608(96)00200-2; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUJIWARA Y, 1993, CANCER RES, V53, P1172; FUJIWARA Y, 1995, ONCOGENE, V10, P891; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; Gustafson CE, 1996, CANCER RES, V56, P5238; Hermanek P, 1987, UICC TNM CLASSIFICAT; Ichikawa K, 1997, GENE, V189, P277, DOI 10.1016/S0378-1119(96)00863-3; Imbert A, 1996, GENOMICS, V32, P29, DOI 10.1006/geno.1996.0073; JONES TA, 1993, CYTOGENET CELL GENET, V63, P35, DOI 10.1159/000133497; KELEMEN PR, 1994, GENE CHROMOSOME CANC, V11, P195, DOI 10.1002/gcc.2870110308; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; LIPPINCOTT JB, 1992, AM JOINT COMMITTEE C; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MACOSKA JA, 1995, CANCER RES, V55, P5390; ROHEN C, 1995, CANCER GENET CYTOGEN, V80, P33, DOI 10.1016/0165-4608(94)00164-7; SHIKE M, 1990, B WORLD HEALTH ORGAN, V68, P377; Shimamoto A, 1996, P NATL ACAD SCI USA, V93, P10913, DOI 10.1073/pnas.93.20.10913; Visscher DW, 1997, GENE CHROMOSOME CANC, V18, P1; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WANG LM, 1992, CANCER RES, V52, P4824; WASYLYSHYN ML, 1991, SURGERY, V110, P265; Yamabe Y, 1997, GENOMICS, V39, P198, DOI 10.1006/geno.1996.4480; YAREMKO ML, 1994, GENE CHROMOSOME CANC, V10, P1, DOI 10.1002/gcc.2870100102; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; [No title captured]	43	29	30	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					657	665		10.1038/sj.onc.1202340	http://dx.doi.org/10.1038/sj.onc.1202340			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989816				2022-12-28	WOS:000078394400011
J	Dumont, A; Hehner, SP; Hofmann, TG; Ueffing, M; Droge, W; Schmitz, ML				Dumont, A; Hehner, SP; Hofmann, TG; Ueffing, M; Droge, W; Schmitz, ML			Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-derived reactive oxygen species and the activation of NF-kappa B	ONCOGENE			English	Article						apoptosis; hydrogen peroxide; reactive oxygen species; mitochondria; NF-kappa B	TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; GLUTATHIONE DISULFIDE; THYMOCYTE APOPTOSIS; FOREBRAIN NEURONS; CELL-DEATH; E1B 19K; PROTEIN; BCL-2; EXPRESSION	Reactive oxygen species (ROS) play an important role in cell death induced by many different stimuli. This study shows that hydrogen peroxide-induced apoptosis in T-cells did not require tyrosine kinase p56(lck), phosphatase CD45, the CD95 receptor and its associated Caspase-8, H2O2-triggered cell death led to the induced cleavage and activation of Caspase-3, Hydrogen peroxide-treatment of T-cells resulted in the formation of mitochondrial permeability transition pores, a rapid decrease of the mitochondrial transmembrane potential Delta Psi(m) and the release of Cytochrome C, Inhibition of the mitochondrial permeability transition by bongkrekic acid (BA), or interference with the mitochondrial electron transport system by rotenone or menadione prevented the cytotoxic effect of H2O2, Antimycin A, a mitochondrial inhibitor that increases the release of mitochondrial ROS (MiROS), enhanced apoptosis. Overexpression of Bcl-2 and the viral anti-apoptotic proteins BHRF-1 and E1B 19K counteracted H2O2-induced apoptosis, Pharmacological and genetic inhibition of transcription factor NF-kappa B protected cells from hydrogen peroxide-elicited cell death. This detrimental effect of NF-kappa B mediating hydrogen peroxide-induced cell death presumably relies on the induced expression of death effector genes such as p53, which was NF-kappa B-dependently upregulated in the presence of H2O2.	German Canc Res Ctr, DKFZ, Dept Immunochem, D-69120 Heidelberg, Germany; Univ Munich, Mol Eye Genet Grp, Munich, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich	Schmitz, ML (corresponding author), German Canc Res Ctr, DKFZ, Dept Immunochem, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Baeuerle PA, 1996, PATHOL BIOL, V44, P29; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bauer MKA, 1998, J BIOL CHEM, V273, P8048, DOI 10.1074/jbc.273.14.8048; Clemens JA, 1997, STROKE, V28, P1073, DOI 10.1161/01.STR.28.5.1073; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; DELCARMEN RRM, 1997, EUR J IMMUNOL, V27, P1442; Droge W, 1997, FASEB J, V11, P1077, DOI 10.1096/fasebj.11.13.9367343; DROGE W, 1994, FASEB J, V8, P1131; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; Galter Dagmar, 1994, European Journal of Biochemistry, V221, P639; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Han J, 1996, MOL CELL BIOL, V16, P5857; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hoyt KR, 1997, NEUROCHEM RES, V22, P333, DOI 10.1023/A:1022403224901; HUG H, 1994, FEBS LETT, V351, P311, DOI 10.1016/0014-5793(94)00852-3; Hug H, 1997, J BIOL CHEM, V272, P28191, DOI 10.1074/jbc.272.45.28191; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Khanim F, 1997, J GEN VIROL, V78, P2987, DOI 10.1099/0022-1317-78-11-2987; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Limbourg FP, 1996, J BIOL CHEM, V271, P20392, DOI 10.1074/jbc.271.34.20392; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x; Macho A, 1997, J IMMUNOL, V158, P4612; Mancini M, 1997, J CELL BIOL, V138, P449, DOI 10.1083/jcb.138.2.449; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Mollereau B, 1997, J IMMUNOL, V159, P2668; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Qin ZH, 1998, MOL PHARMACOL, V53, P33, DOI 10.1124/mol.53.1.33; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; SCHRAVEN B, 1995, FEBS LETT, V368, P491, DOI 10.1016/0014-5793(95)00720-T; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sha WC, 1998, J EXP MED, V187, P143, DOI 10.1084/jem.187.2.143; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; Slater AFG, 1995, TOXICOL LETT, V82-3, P149, DOI 10.1016/0378-4274(95)03474-9; SUBRAMANIAN T, 1993, GENE, V124, P173, DOI 10.1016/0378-1119(93)90391-F; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; WAUTIER JL, 1994, P NATL ACAD SCI USA, V91, P7742, DOI 10.1073/pnas.91.16.7742; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; WU HY, 1994, J BIOL CHEM, V269, P20067; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	63	286	298	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					747	757		10.1038/sj.onc.1202325	http://dx.doi.org/10.1038/sj.onc.1202325			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989825				2022-12-28	WOS:000078394400020
J	Rey, O; Baluda, MA; Park, NH				Rey, O; Baluda, MA; Park, NH			Differential gene expression in neoplastic and human papillomavirus-immortalized oral keratinocytes	ONCOGENE			English	Article						HPV; human oral keratinocytes; tumor development	PROMOTER-BINDING PROTEIN; HERPES-SIMPLEX VIRUS; SPLICING FACTOR; ADENOVIRUS E1A; CERVICAL-CARCINOMA; COMPLEMENTARY-DNA; NUCLEAR-BODIES; PML; ONCOPROTEIN; INFECTION	We have previously demonstrated that normal human oral keratinocytes immortalized by transfection with human papillomavirus type-16 Dna became tumorigenic after exposure to a chemical carcinogen, In an effort to detect differentially regulated genes associated with this transition from the immortal to the malignant phenotype, we employed representational differences analysis (a PCR-coupled subtractive hybridization technique). After analysing 50 colonies, 12 putative messages were identified. Northern analysis comparison using the identified cDNAs as probes was made between normal human oral keratinocyte, papillomavirus-immortalized human oral keratinocytes (HOK-16B), a neoplastic cell line derived from HOK-16B (HOK-16B-BaP-T) and the human oral cancer cell lines Hep-2, SCC-9 and Tu-177, We found that mRNAs encoding for cyclophilin A, c-myc binding protein 1, the heat shock protein 90 alpha and one unknown transcript were up-regulated in the oral cancer cell lines analysed as well as in HOK-16B cells. We also detected a downregulation of the mRNAs encoding the skin-derived antileukoproteinase SKALP/elafin, the translationally regulated p23 protein and one unknown transcript. Whether these messages are associated to the neoplastic conversion of human keratinocytes remains to be determined.	Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Dent Res, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Park, NH (corresponding author), Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA.			Rey, Osvaldo/0000-0003-1575-9864	NIDCR NIH HHS [DE10598, DE11728] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010598, R03DE011728, P20DE010598] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ahn JH, 1997, J VIROL, V71, P4599, DOI 10.1128/JVI.71.6.4599-4613.1997; ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; ALKEMADE HAC, 1993, AM J PATHOL, V143, P1679; ALKEMADE JAC, 1994, J CELL SCI, V107, P2335; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOHM H, 1989, BIOCHEM INT, V19, P277; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; CHANG FJ, 1990, ARCH DERMATOL RES, V282, P493, DOI 10.1007/BF00371942; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; DEBLANDRE GA, 1995, J BIOL CHEM, V270, P23860, DOI 10.1074/jbc.270.40.23860; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DILUCA D, 1990, J DENT RES, V69, P51; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GISSMANN L, 1984, J INVEST DERMATOL, V86, pS26; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; LI WZ, 1994, J BIOL CHEM, V269, P18616; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LISITYSN N, 1993, SCIENCE, V259, P949; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; MEANWELL CA, 1988, CANCER SURV, V7, P481; MIN BM, 1994, ORAL ONCOL, V30B, P338, DOI 10.1016/0964-1955(94)90036-1; MOLHUIZEN HOF, 1993, J BIOL CHEM, V268, P12028; MOROZOV A, 1995, FEBS LETT, V371, P214, DOI 10.1016/0014-5793(95)00884-C; MULLEN MA, 1995, J VIROL, V69, P476, DOI 10.1128/JVI.69.1.476-491.1995; NOTHWANG HG, 1994, BBA-GENE STRUCT EXPR, V1219, P361, DOI 10.1016/0167-4781(94)90060-4; PARK NH, 1995, ONCOGENE, V10, P2145; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; RADICE P, 1995, GENOMICS, V26, P101, DOI 10.1016/0888-7543(95)80087-3; RAY R, 1991, MOL CELL BIOL, V11, P2154, DOI 10.1128/MCB.11.4.2154; RAY RB, 1995, CELL GROWTH DIFFER, V6, P1089; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SHAFFER EL, 1980, J ORAL PATHOL MED, V9, P163, DOI 10.1111/j.1600-0714.1980.tb00373.x; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; SPITZ MR, 1988, CANCER, V61, P203, DOI 10.1002/1097-0142(19880101)61:1<203::AID-CNCR2820610134>3.0.CO;2-6; SUMMERS L, 1977, ORAL SURG, V38, P273; SUREAU A, 1992, P NATL ACAD SCI USA, V89, P11683, DOI 10.1073/pnas.89.24.11683; SYRJANEN KJ, 1983, BR J ORAL SURG, V21, P143; SYRJANEN S, 1992, SCAND J DENT RES, V100, P17; SYRJANEN SM, 1986, ORAL SURG ORAL MED O, V62, P660, DOI 10.1016/0030-4220(86)90262-8; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; YAMAZAKI M, 1989, NUCLEIC ACIDS RES, V17, P7108, DOI 10.1093/nar/17.17.7108; YEUDALL WA, 1992, ORAL ONCOL, V28B, P61, DOI 10.1016/0964-1955(92)90015-S; ZURHAUSEN H, 1977, CURR TOP MICROBIOL I, V778, P1	49	33	36	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					827	831		10.1038/sj.onc.1202328	http://dx.doi.org/10.1038/sj.onc.1202328			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989835				2022-12-28	WOS:000078394400030
J	van der Reijden, BA; Dauwerse, HG; Giles, RH; Jagmohan-Changur, S; Wijmenga, C; Liu, PP; Smit, B; Wessels, HW; Beverstock, GC; Jotterand-Bellomo, M; Martinet, D; Muhlematter, D; Lafage-Pochitaloff, M; Gabert, J; Reiffers, J; Bilhou-Nabera, C; van Ommen, GJB; Hagemeijer, A; Breuning, MH				van der Reijden, BA; Dauwerse, HG; Giles, RH; Jagmohan-Changur, S; Wijmenga, C; Liu, PP; Smit, B; Wessels, HW; Beverstock, GC; Jotterand-Bellomo, M; Martinet, D; Muhlematter, D; Lafage-Pochitaloff, M; Gabert, J; Reiffers, J; Bilhou-Nabera, C; van Ommen, GJB; Hagemeijer, A; Breuning, MH			Genomic acute myeloid leukemia-associated inv(16)(p13q22) breakpoints are tightly clustered	ONCOGENE			English	Article						inv(16)(p13q22); CBFB; MYH11; AML; genomic; breakpoints	ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE MYELOMONOCYTIC LEUKEMIA; ABNORMAL MARROW EOSINOPHILS; ACUTE MYELOGENOUS LEUKEMIA; MYOSIN HEAVY-CHAIN; MOLECULAR CHARACTERIZATION; FUSION; GENE; TRANSLOCATION; CHROMOSOME-16	The inv(16) and related t(16;16) are found in 10% of all cases with ne novo acute myeloid leukemia. In these rearrangements the core binding factor beta (CBFB) gene on 16q22 is fused to the smooth muscle myosin heavy chain gene (MYH11) on 16p13, To gain insight into the mechanisms causing the inv(16) ne have analysed 24 genomic CBFB-MYH11 breakpoints. All breakpoints in CBFB are located in a 15-Kb intron, More than 50% of the sequenced 6.2 Kb of this intron consists of human repetitive elements. Twenty-one of the 24 breakpoints in MYH11 are located in a 370-hp intron, The remaining three breakpoints in MYH11 ape located more upstream, The localization of three breakpoints adjacent to a V(D)J recombinase signal sequence in MYH11 suggests a V(D)J recombinase-mediated rearrangement in these cases, V(D)J recombinase-associated characteristics (small nucleotide deletions and insertions of random nucleotides) were detected in six other cases. CBFB and MYH11 duplications were detected in four of six cases tested.	Erasmus Univ, Inst Hematol, Dept Cell Biol & Genet, Rotterdam, Netherlands; Leiden Univ, Dept Human Genet, Sylvius Labs, NL-2300 RA Leiden, Netherlands; Natl Ctr Human Genome Res, Lab Gene Transfer, NIH, Bethesda, MD USA; Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands; CHU Vaudois, Div Autonome Genet Med, CH-1011 Lausanne, Switzerland; Inst J Paoli I Calmettes, Hematol Lab, F-13009 Marseille, France; Univ Bordeaux, Lab Univ Hematol, Bordeaux, France	Erasmus University Rotterdam; Leiden University; Leiden University - Excl LUMC; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Erasmus University Rotterdam; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Universite de Bordeaux	van der Reijden, BA (corresponding author), Erasmus Univ, Inst Hematol, Dept Cell Biol & Genet, Rotterdam, Netherlands.		Liu, Paul/A-7976-2012; Breuning, Martijn H/E-3429-2010; van der Reijden, Bert A/A-3543-2014; Wijmenga, Cisca/D-2173-2009; Wijmenga, Cisca/AAE-7719-2019	Liu, Paul/0000-0002-6779-025X; Wijmenga, Cisca/0000-0002-5635-1614; Giles, Rachel/0000-0001-9133-2008				ADRIAANSEN HJ, 1993, BLOOD, V81, P3043; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; CLAXTON DF, 1994, BLOOD, V83, P1750; DAUWERSE HG, 1989, NUCLEIC ACIDS RES, V17, P3603, DOI 10.1093/nar/17.9.3603; DAUWERSE JG, 1993, HUM MOL GENET, V2, P1527, DOI 10.1093/hmg/2.10.1527; DONG WF, 1995, LEUKEMIA, V9, P1812; GELLERT M, 1992, TRENDS GENET, V8, P408, DOI 10.1016/0168-9525(92)90322-U; HEBERT J, 1994, BLOOD, V84, P2291, DOI 10.1182/blood.V84.7.2291.bloodjournal8472291; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; JURKA J, 1992, J MOL EVOL, V35, P286, DOI 10.1007/BF00161166; KUSS BJ, 1994, LANCET, V343, P1531, DOI 10.1016/S0140-6736(94)92938-6; LEBEAU MM, 1983, NEW ENGL J MED, V309, P630, DOI 10.1056/NEJM198309153091103; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LIU PP, 1995, BLOOD, V85, P2289, DOI 10.1182/blood.V85.9.2289.bloodjournal8592289; MARLTON P, 1995, BLOOD, V85, P772, DOI 10.1182/blood.V85.3.772.bloodjournal853772; MATSUOKA R, 1993, AM J MED GENET, V46, P61, DOI 10.1002/ajmg.1320460110; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; OHNO H, 1993, LEUKEMIA, V7, P2057; PAPADOPOULOS PC, 1990, GENE CHROMOSOME CANC, V1, P233, DOI 10.1002/gcc.2870010308; POIREL H, 1995, BLOOD, V85, P1313, DOI 10.1182/blood.V85.5.1313.bloodjournal8551313; SCHICHMAN SA, 1994, CANCER RES, V54, P4277; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; SMIT AFA, 1995, NUCLEIC ACIDS RES, V23, P98, DOI 10.1093/nar/23.1.98; SMIT AFA, 1995, J MOL BIOL, V246, P401, DOI 10.1006/jmbi.1994.0095; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; VANDERREIJDEN BA, 1993, BLOOD, V82, P2948; VANDERREIJDEN BA, 1995, BLOOD, V86, P277, DOI 10.1182/blood.V86.1.277.bloodjournal861277; vanderReijden BA, 1996, LEUKEMIA, V10, P1459; VONLINDERN M, 1992, GENE CHROMOSOME CANC, V5, P227, DOI 10.1002/gcc.2870050309; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WIJMENGA C, 1993, HUM GENET, V92, P198; YANAGISAWA K, 1991, BLOOD, V78, P451	33	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					543	550		10.1038/sj.onc.1202321	http://dx.doi.org/10.1038/sj.onc.1202321			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927211				2022-12-28	WOS:000078166500027
J	Julius, MA; Rai, SD; Kitajewski, J				Julius, MA; Rai, SD; Kitajewski, J			Chimeric Wnt proteins define the amino-terminus of Wnt-1 as a transformation-specific determinant	ONCOGENE			English	Article						Wnt; chimera; transformation; beta-catenin	MAMMARY EPITHELIAL-CELLS; POLARITY GENE ARMADILLO; PROTO-ONCOGENE INT-1; XENOPUS EMBRYOS; BETA-CATENIN; WINGLESS GENE; DROSOPHILA; FAMILY; EXPRESSION; LINE	Wnt-1 induces morphological transformation of C57MG mammary epithelial cells and accumulation of cytosolic beta-catenin whereas Wnt-5a has no effect. To identify regions within the 370 amino acid Wnt-1 protein required for these functions we tested eleven chimeric genes that contained variable amounts of Wnt-1;Ind Wnt-5a sequence. Transformation and beta-catenin regulation in C57MG cells is controlled by amino acids that lie within 186 residues of the amino terminus of Wnt-1. Small substitutions between residues 186 and 292 reduced Wnt-1 activity. Replacement of the carboxy terminal 79 amino acids of Wnt-1 by Wnt-5a did not affect function. These results were supported by transient expression assays in 293 cells wherein beta-catenin accumulated in the cytoplasm in response to ectopic Wnt-1 expression. Un 293 cells, a larger region of the amino-terminus of Wnt-1 was found to be required for beta-catenin regulation. Nonfunctional chimeras that contained at least 99 amino terminal Wnt-1 residues inhibited Wnt-1 stimulation of 293 cells. One of these chimeras inhibited both Wnt-1 and Wnt-3 activity suggesting that Wnt-1 and Wnt-3 interact with a common signaling component.	Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Reprod Sci, New York, NY 10032 USA	Columbia University; Columbia University	Kitajewski, J (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.							BEJSOVEC A, 1995, GENETICS, V139, P309; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Binari RC, 1997, DEVELOPMENT, V124, P2623; BLASBAND A, 1992, ONCOGENE, V7, P153; BRADBURY JM, 1994, ONCOGENE, V9, P2597; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BROWN AMC, 1995, RETROVIRAL VECTORS, V4, P113; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CUMBERLEDGE S, 1993, NATURE, V363, P549, DOI 10.1038/363549a0; Dale TC, 1998, BIOCHEM J, V329, P209; DU SJ, 1995, MOL CELL BIOL, V15, P2625; Fagotto F, 1997, DEVELOPMENT, V124, P453; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Haerry TE, 1997, DEVELOPMENT, V124, P3055; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HINCK L, 1994, TRENDS BIOCHEM SCI, V19, P538, DOI 10.1016/0968-0004(94)90057-4; Hoang B, 1996, J BIOL CHEM, V271, P26131, DOI 10.1074/jbc.271.42.26131; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JASIN M, 1992, P NATL ACAD SCI USA, V89, P10681, DOI 10.1073/pnas.89.22.10681; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KITAJEWSKI J, 1992, MOL CELL BIOL, V12, P784, DOI 10.1128/MCB.12.2.784; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; Klymkowsky MW, 1997, BIOESSAYS, V19, P537, DOI 10.1002/bies.950190702; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Lin KM, 1997, P NATL ACAD SCI USA, V94, P11196, DOI 10.1073/pnas.94.21.11196; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; MOON RT, 1993, DEVELOPMENT, V119, P97; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PARKIN NT, 1993, GENE DEV, V7, P2181, DOI 10.1101/gad.7.11.2181; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; Schryver B, 1996, ONCOGENE, V13, P333; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; VAIDYA AB, 1978, VIROLOGY, V90, P12, DOI 10.1016/0042-6822(78)90328-8; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wang YS, 1996, J BIOL CHEM, V271, P4468; WIESCHAUS E, 1987, CELL, V49, P177, DOI 10.1016/0092-8674(87)90558-7; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	61	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					149	156		10.1038/sj.onc.1202268	http://dx.doi.org/10.1038/sj.onc.1202268			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926929				2022-12-28	WOS:000078166000016
J	Yamamoto, H; Soh, JW; Shirin, H; Xing, WQ; Lim, JT; Yao, Y; Slosberg, E; Tomita, N; Schieren, I; Weinstein, IB				Yamamoto, H; Soh, JW; Shirin, H; Xing, WQ; Lim, JT; Yao, Y; Slosberg, E; Tomita, N; Schieren, I; Weinstein, IB			Comparative effects of overexpression of p21(CKip1) and p21(Cip1/Waf1) growth and differentiation in human colon carcinoma cells	ONCOGENE			English	Article						p27(Kip1); p21(Cip1/Waf1); colon cancer; differentiation; cyclin D1	DEPENDENT KINASE INHIBITOR; BREAST-CANCER CELLS; CHAIN FATTY-ACIDS; CYCLIN D1; INCREASED EXPRESSION; SODIUM-BUTYRATE; COLORECTAL CARCINOMAS; TUMOR SUPPRESSION; ESOPHAGEAL CANCER; P53-INDEPENDENT INDUCTION	Recent studies have shown that decreased expression of p27(Kip1) is associated with high grade tumors and am unfavorable prognosis in several types of human cancer. To clarify the role of p27(Kip1) in colon cancer, we have overexpressed this protein in the HT29 colon cancer cell line. The derivatives displayed an increase in the p27(Kip1) protein in cyclin E/CDK2 immunoprecipitates and :a decrease in cyclin E-associated kinase activity when compared to vector control clones, providing evidence that the overexpressed protein was functional. Clones with a high level of p27(Kip1) displayed partial growth inhibition in monolayer culture and a decrease in plating efficiency, even though they expressed increased levels of the cyclin D1 protein. Using alkaline phosphatase expression as a marker, we found that the p27(Kip1) overexpressor clones displayed a 2-3-fold increase in sensitivity to induction of differentiation by 2 mM sodium butyrate, In contrast to these results, derivatives of HT29 cells that stably overexpressed p21(Cip1/Waf1) displayed decreased sensitivity to the induction of differentiation. These findings may explain why decreased levels of p27(Kip1) in certain human cancers is associated with high grade (poorly differentiated) tumors, and suggest that strategies that increase the level of p27(Kip1) may be useful in cancer therapy.	Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA; Osaka Univ, Sch Med, Dept Surg 2, Suita, Osaka 565, Japan	Columbia University; Columbia University; Osaka University	Weinstein, IB (corresponding author), Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, 701 W 168th St, New York, NY 10032 USA.				NATIONAL CANCER INSTITUTE [R01CA063467] Funding Source: NIH RePORTER; NCI NIH HHS [CA63467] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arber N, 1997, CANCER RES, V57, P1569; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; BASSON MD, 1996, DIGEST DIS SCI, V41, P1989; BOFFA LC, 1992, CANCER RES, V52, P5906; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chen J, 1996, J CLIN INVEST, V97, P1983, DOI 10.1172/JCI118631; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; Ciaparrone M, 1998, CANCER RES, V58, P114; CONWAY RM, 1995, ONCOL RES, V7, P289; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; CUMMINGS JH, 1981, GUT, V22, P763, DOI 10.1136/gut.22.9.763; CUNTO FD, 1998, SCIENCE, V280, P1069; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Doglioni C, 1996, J PATHOL, V179, P248, DOI 10.1002/(SICI)1096-9896(199607)179:3<248::AID-PATH571>3.0.CO;2-6; Doki Y, 1997, CARCINOGENESIS, V18, P1139, DOI 10.1093/carcin/18.6.1139; Esposito V, 1997, CANCER RES, V57, P3381; EVERS BM, 1996, AM J PHYSIOL, V271, P722; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Freemerman AJ, 1997, LEUKEMIA, V11, P504, DOI 10.1038/sj.leu.2400625; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; Goldberg Y, 1996, ONCOGENE, V12, P893; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GUO K, 1995, MOL CELL BIOL, V15, P3823; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; Harvat BL, 1997, ONCOGENE, V14, P2111, DOI 10.1038/sj.onc.1201055; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HERMAN JG, 1995, CANCER RES, V55, P4523; Hodin RA, 1996, CELL GROWTH DIFFER, V7, P647; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG W, 1992, CANCER RES, V52, P2980; Kano A, 1997, J BIOCHEM-TOKYO, V121, P677; Katayose Y, 1997, CANCER RES, V57, P5441; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAWAMATA N, 1995, CANCER RES, V55, P2266; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Kuniyasu H, 1997, CELL GROWTH DIFFER, V8, P47; LEACH FS, 1993, CANCER RES, V53, P1986; LEBLOND CP, 1948, ANAT REC, V100, P357, DOI 10.1002/ar.1091000306; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Matsushita K, 1996, INT J CANCER, V69, P259, DOI 10.1002/(SICI)1097-0215(19960822)69:4<259::AID-IJC3>3.3.CO;2-D; McDonald E, 1996, CANCER RES, V56, P2250; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; Navarro JM, 1997, EUR J CLIN INVEST, V27, P620, DOI 10.1046/j.1365-2362.1997.1510698.x; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1996, AM J PATHOL, V149, P381; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; SCHROY PC, 1994, J CELL PHYSIOL, V161, P111, DOI 10.1002/jcp.1041610114; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sgambato A, 1996, CANCER RES, V56, P1389; Sgambato A, 1997, CLIN CANCER RES, V3, P1879; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Siavoshian S, 1997, BIOCHEM BIOPH RES CO, V232, P169, DOI 10.1006/bbrc.1997.6255; Singh SP, 1998, CANCER RES, V58, P1730; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Spillare EA, 1996, MOL CARCINOGEN, V16, P53, DOI 10.1002/(SICI)1098-2744(199605)16:1<53::AID-MC7>3.0.CO;2-P; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SWAROVSKY B, 1994, PANCREAS, V9, P460, DOI 10.1097/00006676-199407000-00008; Tominaga O, 1997, JPN J CANCER RES, V88, P855, DOI 10.1111/j.1349-7006.1997.tb00461.x; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; YAMAMOTO H, 1995, BRIT J CANCER, V71, P1231, DOI 10.1038/bjc.1995.238; Yang RM, 1998, J UROLOGY, V159, P941, DOI 10.1016/S0022-5347(01)63776-5; Yasui W, 1997, PATHOL INT, V47, P470; Yoshida K, 1996, INT J HEMATOL, V65, P41; Zhang T, 1997, CANCER RES, V57, P169; ZHAR JH, 1974, BIOSTATISTICAL ANAL; ZHOU P, 1995, ONCOGENE, V11, P571	88	67	69	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					103	115		10.1038/sj.onc.1202269	http://dx.doi.org/10.1038/sj.onc.1202269			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926925				2022-12-28	WOS:000078166000012
J	Magdinier, F; Ribieras, S; Lenoir, GM; Frappart, L; Dante, R				Magdinier, F; Ribieras, S; Lenoir, GM; Frappart, L; Dante, R			Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region	ONCOGENE			English	Article						BRCA1; human breast cancers; mRNA; PCR; DNA methylation; prognostic factors	SUPPRESSOR GENE BRCA1; OVARIAN-CANCER; GERMLINE MUTATIONS; EXPRESSION; RNA; CARCINOMAS; FAMILIES; TISSUES; GROWTH; CELLS	Germ-line alterations of BRCA1 are responsible for about 50% of familial breast cancers. Although its biological function(s) has not yet been fully determined, it has been suggested that it may act as a tumor suppressor gene in breast and ovarian cancers. In sporadic breast cancers alterations of BRCA1 have not been detected and in vitro experiments have indicated that BRCA1 negatively regulates cellular proliferation, The present study was designed to identify and quantify, the BRCA1 mRNA levels, in normal and neoplasic human breast tissue, BRCA1 mRNA molecules were quantified using competitive reverse transcriptase PCR assays. DNA methylation patterns of this gene have been analysed by Southern blot experiments using methylation sensitive restriction enzymes. We found that BRCA1 mRNA levels were significantly lower in sporadic breast cancers (37 cases analysed, 24 cases of invasive ductal carcinomas not otherwise specified (NOS), two lobular carcinomas in situ two medullary carcinomas, four invasive lobular carcinomas, two invasive mucinous carcinomas and three invasive ductal carcinomas with predominantly in situ component) compared with normal breast tissues (P = 0.0003), This down-regulation of BRCA1 is observed in all histologic types analysed. In invasive ductal carcinomas NOS, this down-regulation does not correlate with any of the prognostic factors studied (tumor size, node status, histologic grade, hormone receptor status), In the samples analysed, alterations of DNA methylation patterns were not dectected in the vicinity of the major transcription start site, These data suggest the involvement of BRCA1 in the carcinogenesis of these histologic types.	CNRS, UMR 5641, Genet Lab, F-69373 Lyon, France	Centre National de la Recherche Scientifique (CNRS)	Dante, R (corresponding author), CNRS, UMR 5641, Genet Lab, Ave Rockefeller, F-69373 Lyon, France.		Magdinier, Frederique/I-4735-2016	Magdinier, Frederique/0000-0002-0159-9559				Barker DF, 1996, GENOMICS, V38, P215, DOI 10.1006/geno.1996.0618; Baylin SB, 1998, ADV CANCER RES, V72, P141; Collins N, 1997, BRIT J CANCER, V76, P1150, DOI 10.1038/bjc.1997.526; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; DANTE R, 1994, LAB INVEST, V71, P188; Dobrovic A, 1997, CANCER RES, V57, P3347; Easton D, 1997, NAT GENET, V16, P210, DOI 10.1038/ng0797-210; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; GRAFF JR, 1995, CANCER RES, V55, P5195; GUDAS JM, 1995, CANCER RES, V55, P4561; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Huynh H, 1996, CANCER RES, V56, P4865; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; POULSEN HE, 1975, INT HISTOLOGICAL CLA, P13; Rao VN, 1996, ONCOGENE, V12, P523; RIBIERAS S, 1994, J CELL BIOCHEM, V56, P86, DOI 10.1002/jcb.240560113; Ribieras S, 1997, INT J CANCER, V73, P715, DOI 10.1002/(SICI)1097-0215(19971127)73:5<715::AID-IJC17>3.0.CO;2-4; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Smith TM, 1996, GENOME RES, V6, P1029, DOI 10.1101/gr.6.11.1029; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994	33	120	123	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	1998	17	24					3169	3176		10.1038/sj.onc.1202248	http://dx.doi.org/10.1038/sj.onc.1202248			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872332	Green Published			2022-12-28	WOS:000077517400010
J	Clemens, MJ; Bushell, M; Morley, SJ				Clemens, MJ; Bushell, M; Morley, SJ			Degradation of eukaryotic polypeptide chain initiation factor (eIF) 4G in response to induction of apoptosis in human lymphoma cell lines	ONCOGENE			English	Review						apoptosis; eIF4G/initiation factors; initiation of protein synthesis	ACTIVATED PROTEIN-KINASE; MOUTH-DISEASE VIRUS; CAP-DEPENDENT TRANSLATION; UNCAPPED MESSENGER-RNAS; FAS-MEDIATED APOPTOSIS; NERVE GROWTH-FACTOR; BJA-B CELLS; FACTOR 4E; PROTEOLYTIC CLEAVAGE; PHAS-I	We have investigated the effect of inducing apoptosis in BJAB and Jurkat cells on the cellular content of several polypeptide chain initiation factors. Serum deprivation results in inhibition of protein synthesis and induction of apoptosis in BJAB cells; at early times, there is selective degradation of polypeptide initiation factor eIF4G but no major losses of other key initiation factors. The disappearance of full length eIF4G is accompanied by the appearance of smaller forms of the protein, including a major product of approximately 76 kDa. Apoptosis induced by cycloheximide results in similar effects. Both total cytoplasmic eIF4G and eIF4G associated with eIF4E are degraded with a half-life of 2-4 h under these conditions. Treatment of serum-starved or cycloheximide-treated cells with Z-VAD.FMK or Z-DEVD.FMK, which inhibit caspases required for apoptosis, protects eIF4G from degradation and blocks the appearance of the ca. 76 kDa product. Exposure of BJAB cells to rapamycin rapidly inhibits protein synthesis but does not lead to acute degradation of eIF4G. In both BJAB and Jurkat cells induction of apoptosis with anti-Fas antibody or etoposide also results in the selective loss of eIF4G, which is inhibitable by Z-VAD.FMK. These data suggest that eIF4G is selectively targeted for cleavage as cells undergo apoptosis and is a substrate for proteases activated during this process.	St George Hosp, Sch Med, Dept Biochem, Cellular & Mol Biol Grp, London SW17 0RE, England; Univ Sussex, Sch Biol Sci, Biochem Grp, Brighton BN1 9QG, E Sussex, England	St Georges University London; University of Sussex	Clemens, MJ (corresponding author), St George Hosp, Sch Med, Dept Biochem, Cellular & Mol Biol Grp, Cranmer Terrace, London SW17 0RE, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altmann M, 1997, EMBO J, V16, P1114, DOI 10.1093/emboj/16.5.1114; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Benton PA, 1996, J VIROL, V70, P5525, DOI 10.1128/JVI.70.8.5525-5532.1996; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Beretta L, 1996, J VIROL, V70, P8993, DOI 10.1128/JVI.70.12.8993-8996.1996; Berset C, 1998, P NATL ACAD SCI USA, V95, P4264, DOI 10.1073/pnas.95.8.4264; Boix J, 1998, EXP CELL RES, V238, P422, DOI 10.1006/excr.1997.3852; Borman AM, 1997, RNA, V3, P186; Brass N, 1997, HUM MOL GENET, V6, P33, DOI 10.1093/hmg/6.1.33; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COLLINS RJ, 1991, BRIT J CANCER, V64, P518, DOI 10.1038/bjc.1991.341; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; DeGracia DJ, 1996, J NEUROCHEM, V67, P2005; DEVANEY MA, 1988, J VIROL, V62, P4407, DOI 10.1128/JVI.62.11.4407-4409.1988; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Fadden P, 1997, J BIOL CHEM, V272, P10240; FEARNHEAD HO, 1995, FEBS LETT, V375, P283, DOI 10.1016/0014-5793(95)01228-7; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; GRAFF JR, 1995, INT J CANCER, V60, P255; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; Haghighat A, 1996, J VIROL, V70, P8444, DOI 10.1128/JVI.70.12.8444-8450.1996; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; HERSHEY JWB, 1994, BIOCHIMIE, V76, P847, DOI 10.1016/0300-9084(94)90186-4; Imataka H, 1997, EMBO J, V16, P817, DOI 10.1093/emboj/16.4.817; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Ishii H, 1997, INT J EXP PATHOL, V78, P123, DOI 10.1046/j.1365-2613.1997.170350.x; ISHII HH, 1995, IMMUNOL CELL BIOL, V73, P463, DOI 10.1038/icb.1995.72; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; JOSHIBARVE S, 1992, J BIOL CHEM, V267, P21038; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kamada S, 1997, ONCOGENE, V15, P285, DOI 10.1038/sj.onc.1201192; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kawanishi M, 1997, VIROLOGY, V228, P244, DOI 10.1006/viro.1996.8370; Kay JE, 1996, IMMUNOLOGY, V87, P390; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; KIRCHWEGER R, 1994, J VIROL, V68, P5677, DOI 10.1128/JVI.68.9.5677-5684.1994; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KRIEG J, 1988, J BIOL CHEM, V263, P11473; KULKARNI GV, 1994, J CELL SCI, V107, P1169; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Lavin MF, 1996, EXPERIENTIA, V52, P979, DOI 10.1007/BF01920107; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; LEDDACOLUMBANO GM, 1992, AM J PATHOL, V140, P545; LevyStrumpf N, 1997, MOL CELL BIOL, V17, P1615, DOI 10.1128/MCB.17.3.1615; Li BDL, 1997, CANCER-AM CANCER SOC, V79, P2385; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LLOYD RE, 1987, J VIROL, V61, P2480, DOI 10.1128/JVI.61.8.2480-2488.1987; LLOYD RE, 1988, J VIROL, V62, P4216, DOI 10.1128/JVI.62.11.4216-4223.1988; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; MADER S, 1995, MOL CELL BIOL, V15, P4990; MAO XH, 1992, J BIOL CHEM, V267, P20444; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; MERICK WC, 1996, TRANSLATIONAL CONTRO, P31; MERRICK WC, 1994, BIOCHIMIE, V76, P822, DOI 10.1016/0300-9084(94)90183-X; MILNER AE, 1995, APPL FLOW CYTOMETRY, P56; MIYAGI Y, 1995, CANCER LETT, V91, P247, DOI 10.1016/0304-3835(95)03737-H; MORLEY SJ, 1995, J CELL SCI, V108, P1751; Morley SJ, 1997, RNA, V3, P1085; MORLEY SJ, 1995, BIOCHEM J, V312, P627, DOI 10.1042/bj3120627; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Naranda T, 1997, MOL CELL BIOL, V17, P145, DOI 10.1128/MCB.17.1.145; Nathan CA, 1997, ONCOGENE, V15, P1087, DOI 10.1038/sj.onc.1201272; Nathan CAO, 1997, ONCOGENE, V15, P579, DOI 10.1038/sj.onc.1201216; NEUMAR RW, 1995, J NEUROCHEM, V65, P1391; Novoa I, 1997, BIOCHEMISTRY-US, V36, P7802, DOI 10.1021/bi9631172; OEHM A, 1992, J BIOL CHEM, V267, P10709; Ohlmann T, 1997, EMBO J, V16, P844, DOI 10.1093/emboj/16.4.844; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; OHLMANN T, 1995, NUCLEIC ACIDS RES, V23, P334; Ohta T, 1997, J BIOL CHEM, V272, P23111, DOI 10.1074/jbc.272.37.23111; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Perry DK, 1997, J BIOL CHEM, V272, P18530, DOI 10.1074/jbc.272.30.18530; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Rau M, 1996, J BIOL CHEM, V271, P8983, DOI 10.1074/jbc.271.15.8983; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rowan S, 1997, LEUKEMIA, V11, P457, DOI 10.1038/sj.leu.2400626; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; SINHA BK, 1995, DRUGS, V49, P11, DOI 10.2165/00003495-199549010-00002; SONENBERG N, TRANSLATIONAL CONTRO, P245; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WANG E, 1995, J CELL PHYSIOL, V163, P155, DOI 10.1002/jcp.1041630118; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yamanaka S, 1997, GENE DEV, V11, P321, DOI 10.1101/gad.11.3.321; YAN RQ, 1992, J BIOL CHEM, V267, P23226; Zakeri Z, 1996, MICROSC RES TECHNIQ, V34, P192; ZIEGLER E, 1995, VIROLOGY, V213, P549; ZIEGLER E, 1995, J VIROL, V69, P3465, DOI 10.1128/JVI.69.6.3465-3474.1995	113	109	112	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	1998	17	22					2921	2931		10.1038/sj.onc.1202227	http://dx.doi.org/10.1038/sj.onc.1202227			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879998				2022-12-28	WOS:000077286400012
J	Vonlanthen, S; Heighway, J; Tschan, MP; Borner, MM; Altermatt, HJ; Kappeler, A; Tobler, A; Fey, MF; Thatcher, N; Yarbrough, WG; Betticher, D				Vonlanthen, S; Heighway, J; Tschan, MP; Borner, MM; Altermatt, HJ; Kappeler, A; Tobler, A; Fey, MF; Thatcher, N; Yarbrough, WG; Betticher, D			Expression of p16INK4a/p16 alpha and p19ARF/p16 beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression	ONCOGENE			English	Article						CDKN2; p16INK4a/p16 alpha; p19ARF/p16 beta; p53; methylation; non-small cell lung carcinoma	TUMOR-SUPPRESSOR GENE; INK4A LOCUS; P16(INK4) PROTEIN; DNA METHYLATION; CYCLE ARREST; P16 MTS1; INACTIVATION; RB; SENESCENCE; MUTATIONS	The CDKN2 locus expresses two different mRNA transcripts, designated alpha and beta. The protein product of the or transcript is the cell cycle inhibitor and tumour suppressor p16INK4a. The beta transcript is translated in an alternate reading frame (ARF) and in humans encodes a 15 kDa protein (p19ARF). Immunohistochemical and Western analysis of p16INK4a has shown that the protein is downregulated in a significant number of tumours, but less is known on the expression of the p19ARF, We have examined the expression of p16INK4a and p19ARF in resectable non-small cell lung cancer (NSCLC) by immunostaining (n=49) and multiplex RT-PCR (n=28). In order to investigate the mechanism responsible for p16INK4a downregulation, exon 1 alpha methylation was analysed in a PCR-based assay. Of 49 tumours examined by immunostaining, 24 and 20 tumours expressed p16INK4a and p19ARF at nil to low levels, respectively, p19ARF was localized primarily to the nuclei of tumour cells, but was also seen to varying degrees in nuclei of lymphocytes, chondrocytes, fibroblasts, and epithelial cells. No tumour with normal p16INK4a had decreased p19ARF expression, Among 16 tumours with nil to low p16INK4a expression, 11 tumours exhibited full methylation of at least one site within exon 1 alpha and these tumours showed normal p19ARF expression. In contrast, no methylation of exon 1 alpha was observed in five tumours which also lacked p19ARF, In normal lung, p16INK4a and p19ARF were not expressed at detectable levels, the multiplex RT-PCR results were balanced, and sites within exon 1 alpha were strongly methylated. In tumours, imbalanced multiplex RT-PCR data (p16INK4a < p19ARF) predicted methylation of exon 1 alpha (P = 0.0006) as well as downregulation of p16INK4a, p19ARF downregulation was inversely correlated with p53 overexpression (P = 0.025), whilst negative immunostaining for p16INK4a was inversely correlated with pRb downregulation (P = 0.003) and directly correlated with p53 overexpression as assessed by immunostaining (P = 0.015), Our results show that: (1) p16INK4a and p19ARF expression are altered in almost half of resectable NSCLC; (2) methylation within exon 1 alpha is a frequent, but not the only mechanism of p16INK4a downregulation; and that (3) the inverse association of p19ARF and p53 alteration is consistent with a linked pathway.	Univ Bern, Dept Clin Res, CH-3012 Bern, Switzerland; Univ Bern, Inst Med Oncol, CH-3012 Bern, Switzerland; Univ Bern, Inst Pathol, CH-3012 Bern, Switzerland; Christie Hosp, Dept Med Oncol, Manchester, Lancs, England; Univ N Carolina, Dept Surg, Div Otorhinolaryngol, Chapel Hill, NC USA	University of Bern; University of Bern; University of Bern; Christie NHS Foundation Trust; Christie Hospital; University of North Carolina; University of North Carolina Chapel Hill	Betticher, D (corresponding author), Univ Bern, Inst Med Oncol, Inselspital, CH-3010 Bern, Switzerland.	daniel.betticher@insel.ch	Borner, Markus/B-7583-2011; Betticher, Daniel C/G-5849-2013	Tschan, Mario P./0000-0001-5897-3647				Arap W, 1997, ONCOGENE, V15, P2013, DOI 10.1038/sj.onc.1201389; Betticher DC, 1997, INT J CANCER, V74, P556, DOI 10.1002/(SICI)1097-0215(19971021)74:5<556::AID-IJC14>3.0.CO;2-4; Betticher DC, 1996, BRIT J CANCER, V73, P294, DOI 10.1038/bjc.1996.52; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BORNER MM, 1998, IN PRESS BR J CANC; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; GERADTS J, 1995, CANCER RES, V55, P6006; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GONZALEZZULUETA M, 1995, J NATL CANCER I, V87, P1383, DOI 10.1093/jnci/87.18.1383; GRUIS NA, 1995, AM J PATHOL, V146, P1199; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Hara E, 1996, MOL CELL BIOL, V16, P859; Herman JG, 1997, CANCER RES, V57, P837; HERMAN JG, 1995, CANCER RES, V55, P4525; Heyman M, 1996, BLOOD, V87, P1657, DOI 10.1182/blood.V87.4.1657.bloodjournal8741657; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; Liggett WH, 1996, CANCER RES, V56, P4119; MAO L, 1995, CANCER RES, V55, P2995; Marchetti A, 1997, J PATHOL, V181, P178, DOI 10.1002/(SICI)1096-9896(199702)181:2<178::AID-PATH741>3.0.CO;2-5; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1995, ONCOGENE, V11, P1211; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; SHAPIRO GI, 1995, CANCER RES, V55, P505; Shores C., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P277; Singer-Sam J., 1993, Experientia Supplementum (Basel), V64, P358; STONE S, 1995, ONCOGENE, V11, P987; STONE S, 1995, CANCER RES, V55, P2988; Swafford DS, 1997, MOL CELL BIOL, V17, P1366, DOI 10.1128/MCB.17.3.1366; TAM SW, 1994, CANCER RES, V54, P5816; *UICC AM JOINT COM, 1987, MAN STAG CANC; World Health Organization, 1981, HIST TYP LUNG TUM; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	46	107	113	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2779	2785		10.1038/sj.onc.1202501	http://dx.doi.org/10.1038/sj.onc.1202501			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840942				2022-12-28	WOS:000077146700011
J	Bahr, A; De Graeve, F; Kedinger, C; Chatton, B				Bahr, A; De Graeve, F; Kedinger, C; Chatton, B			Point mutations causing Bloom's syndrome abolish ATPase and DNA helicase activities of the BLM protein	ONCOGENE			English	Article						ATFa; BLM; Bloom's syndrome; helicase	HIGH-EFFICIENCY TRANSFORMATION; BASIC TRANSCRIPTION FACTOR; SYNDROME GENE-PRODUCT; WERNERS-SYNDROME; IN-VIVO; NUCLEAR-LOCALIZATION; REPAIR; CELLS; ATFA; SGS1	Bloom's syndrome (BS) is a rare human genetic disorder characterized by mutations within the BLM gene whose primary effects are excessive chromosome breakaoge and increased rates of sister chromatide interchange in somatic cells. We report the characterization of a murine protein (mBLM), highly related to the product of the human BLM gene. This protein exhibits an ATP-dependent DNA-helicase activity that unwinds DNA in a 3'-5' direction. Single aminoacid substitutions found in BS cells, abolish both ATPase and helicase activities of this protein, indicating that defects in these BLM functions may be primarily responsible for BS establishment. These results provide the first evidence suggesting that the enzymatic activities of the BLM product are implicated in the upholding of genomic integrity.	ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, CU Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Kedinger, C (corresponding author), ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, BP163, F-67404 Illkirch Graffenstaden, CU Strasbourg, France.		CHATTON, Bruno/R-3813-2019	DE GRAEVE, Fabienne/0000-0002-3455-7507; CHATTON, Bruno/0000-0003-4515-7119				AUSUBUEL FM, 1989, CURR PROTOC MOL BIOL; Bocco JL, 1996, ONCOGENE, V12, P1971; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHATTON B, 1994, ONCOGENE, V9, P375; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; ELLIS NA, 1994, AM J HUM GENET, V55, P453; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; ELLIS NA, 1995, AM J HUM GENET, V57, P1019; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; Foucault F, 1997, HUM MOL GENET, V6, P1427, DOI 10.1093/hmg/6.9.1427; Fraser RA, 1997, J BIOL CHEM, V272, P7122, DOI 10.1074/jbc.272.11.7122; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GERMAN J, 1992, GENETICS OF HEMATOLOGICAL DISORDERS, P241; GERMAN J, 1994, P NATL ACAD SCI USA, V91, P6669, DOI 10.1073/pnas.91.14.6669; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Kaneko H, 1997, BIOCHEM BIOPH RES CO, V240, P348, DOI 10.1006/bbrc.1997.7648; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; KORN R, 1995, NATURE, V378, P557, DOI 10.1038/378557a0; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; Mandel JL, 1997, NATURE, V386, P767, DOI 10.1038/386767a0; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Morozov V, 1997, TRENDS BIOCHEM SCI, V22, P417, DOI 10.1016/S0968-0004(97)01128-6; Richards RI, 1997, TRENDS BIOCHEM SCI, V22, P432, DOI 10.1016/S0968-0004(97)01108-0; ROY R, 1994, J BIOL CHEM, V269, P9826; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	43	54	55	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	1998	17	20					2565	2571		10.1038/sj.onc.1202389	http://dx.doi.org/10.1038/sj.onc.1202389			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840919				2022-12-28	WOS:000077058900003
J	Choi, SW; Park, SW; Lee, KY; Kim, KM; Chung, YJ; Rhyu, MG				Choi, SW; Park, SW; Lee, KY; Kim, KM; Chung, YJ; Rhyu, MG			Fractional allelic loss in gastric carcinoma correlates with growth patterns	ONCOGENE			English	Article						gastric carcinoma; fractional allelic loss; loss of heterozygosity; growth pattern	TUMOR-SUPPRESSOR GENES; P53; HETEROZYGOSITY; RETINOBLASTOMA; CARCINOGENESIS; DELETIONS; CANCER	To gain an insight into the genetic events underlying morphological phenotypes, we analysed 58 gastric carcinoma tissues for the genome-wide allelotype study using microsatellite markers. Based on a binomial distribution, loss of heterozygosity (LOH) that was significantly more frequent than expected (P < 0.05) thus interpreted as nonrandom LOH selected during tumorigenesis. The overall extent of chromosomes undergoing LOH i.e. fractional allelic loss (FAL, the ratio of LOH-positive markers to the total number of informative markers) was measured in each tumor patient. Nonrandom LOH was found on 17p (48.0%), 18q (38.4%), 13q (38.1%) and 9p (36.4%). Overall, there were no significant phenotypes correlated with allelic loss on specific chromosome regions. Based on a bimodal distribution of FAL values with two peaks bordered by a mean of 0.233, tumors were classified into LOH-related (> 0.233) and LOH-unrelated (< 0.233) types. Among 24 patients with LOH-related tumors, increase in the infiltrative type of growth pattern was found to correspond with a significant trend of increasing FAL values. This study shows that the growth pattern of gastric carcinoma is correlated with FAL, suggesting that a malignant phenotype is influenced by LOH event.	Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Microbiol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Clin Pathol, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Rhyu, MG (corresponding author), Catholic Univ Korea, Coll Med, Dept Internal Med, 505 Bampo Dong,Socho Gu, Seoul 137701, South Korea.							BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Barrett MT, 1996, ONCOGENE, V12, P1873; Cho JH, 1996, LAB INVEST, V74, P835; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUCHS CS, 1995, NEW ENGL J MED, V333, P32, DOI 10.1056/NEJM199507063330107; HARPER JW, 1993, CELL, V75, P805; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kerangueven F, 1997, CANCER RES, V57, P5469; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MCKIE AB, 1993, INT J CANCER, V55, P598, DOI 10.1002/ijc.2910550414; MING SC, 1977, CANCER, V39, P2475, DOI 10.1002/1097-0142(197706)39:6<2475::AID-CNCR2820390626>3.0.CO;2-L; RHYU MG, 1994, GASTROENTEROLOGY, V106, P1584, DOI 10.1016/0016-5085(94)90414-6; Schultz DC, 1996, CANCER RES, V56, P1997; TAHARA E, 1993, J CANCER RES CLIN, V119, P265, DOI 10.1007/BF01212724; Visser M, 1997, ONCOGENE, V15, P1309, DOI 10.1038/sj.onc.1201302; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850	21	37	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2655	2659		10.1038/sj.onc.1202188	http://dx.doi.org/10.1038/sj.onc.1202188			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840929				2022-12-28	WOS:000077058900013
J	Mendoza, SM; Konishi, T; Miller, CW				Mendoza, SM; Konishi, T; Miller, CW			Integration of SV40 in human osteosarcoma DNA	ONCOGENE			English	Article						SV40; integration; osteosarcoma	LARGE-T-ANTIGEN; HUMAN PLEURAL MESOTHELIOMA; PERIPHERAL-BLOOD CELLS; NORMAL HUMAN-TISSUES; LARGE-TUMOR-ANTIGEN; HUMAN BRAIN-TUMORS; SIMIAN-VIRUS 40; HEALTHY-INDIVIDUALS; HUMAN-FIBROBLASTS; CHOROID-PLEXUS	Simian virus 40 (SV40) has been demonstrated in several types of tumors, including osteosarcoma, by polymerase chain reaction (PCR), We detected SV40 sequences by PCR, followed by hybridization, in nine of 35 osteosarcoma tumors and one of 11 osteosarcoma explants, PCR can detect fewer than one virus per cell but gives little detail of the gross structure and abundance of the virus, Analysis by Southern blotting of total DNA from ten osteosarcomas, positive for SV40 by PCR, found viral integration in half of these. Analysis showed integration of one to four copies per cell of rearranged SV40. No SV40 was detectable on blots of the remaining five SV40(+) osteosarcomas, perhaps because of the lesser sensitivity of direct hybridization. Inactivation of the p53 and Rb tumor suppressors is a key activity of SV40 T-antigen, Unexpectedly, correlation of these findings with our prior studies indicated that five of ten osteosarcomas positive for SV40 DNA had mutations of p53, and two had deleted Rb, Apparently clonal integration with pre-existing alteration of a tumor suppressor gene, suggests that SV40 may play a role in the final conversion to malignant osteosarcoma.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Med,Div Hematol Oncol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Mendoza, SM (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Med,Div Hematol Oncol, Davis 5019, Los Angeles, CA 90048 USA.							BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; BOTCHAN M, 1976, CELL, V9, P269, DOI 10.1016/0092-8674(76)90118-5; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1996, ONCOGENE, V13, P527; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; CHESTERS PM, 1983, J INFECT DIS, V147, P676, DOI 10.1093/infdis/147.4.676; Damania B, 1996, GENE DEV, V10, P1369, DOI 10.1101/gad.10.11.1369; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; DEMATTEI M, 1995, INT J CANCER, V61, P756, DOI 10.1002/ijc.2910610603; DIAMANDOPOULOS GT, 1972, SCIENCE, V176, P173, DOI 10.1126/science.176.4031.173; DORRIES K, 1994, VIROLOGY, V198, P59, DOI 10.1006/viro.1994.1008; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fields BN, 1996, VIROLOGY; FOX N, 1989, SCIENCE, V244, P460, DOI 10.1126/science.2785714; HUNTER DJ, 1994, J VIROL, V68, P787, DOI 10.1128/JVI.68.2.787-796.1994; KOPROWSKI H, 1962, J CELL COMPAR PHYSL, V59, P281, DOI 10.1002/jcp.1030590308; Lednicky JA, 1997, INT J CANCER, V72, P791; LEDNICKY JA, 1995, VIROLOGY, V212, P710, DOI 10.1006/viro.1995.1529; LEWIS AM, 1979, P NATL ACAD SCI USA, V76, P299; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; Martini F, 1996, CANCER RES, V56, P4820; MILLER CW, 1990, CANCER RES, V50, P7950; Miller CW, 1997, ONCOGENE, V15, P231, DOI 10.1038/sj.onc.1201185; Miller CW, 1996, J CANCER RES CLIN, V122, P559, DOI 10.1007/BF01213553; Miller CW, 1996, CANCER GENET CYTOGEN, V86, P136, DOI 10.1016/0165-4608(95)00216-2; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; Pepper C, 1996, THORAX, V51, P1074, DOI 10.1136/thx.51.11.1074; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; ROWE WP, 1968, CANCER RES, V28, P1319; Sambrook J, 1980, Cold Spring Harb Symp Quant Biol, V44 Pt 1,, P569; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SORIANO F, 1974, NATURE, V249, P421, DOI 10.1038/249421a0; Stewart AR, 1996, VIROLOGY, V221, P355, DOI 10.1006/viro.1996.0386; Strickler H, 1997, CANCER RES, V57, P3319; Strickler HD, 1996, CANCER EPIDEM BIOMAR, V5, P473; Strickler HD, 1998, JAMA-J AM MED ASSOC, V279, P292, DOI 10.1001/jama.279.4.292	37	60	62	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2457	2462		10.1038/sj.onc.1202179	http://dx.doi.org/10.1038/sj.onc.1202179			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824156				2022-12-28	WOS:000076927300005
J	Okada, H; Watanabe, T; Niki, M; Takano, H; Chiba, N; Yanai, N; Tani, K; Hibino, H; Asano, S; Mucenski, ML; Ito, Y; Noda, T; Satake, M				Okada, H; Watanabe, T; Niki, M; Takano, H; Chiba, N; Yanai, N; Tani, K; Hibino, H; Asano, S; Mucenski, ML; Ito, Y; Noda, T; Satake, M			AML1(-/-) embryos do not express certain hematopoiesis-related gene transcripts including those of the PU.1 gene	ONCOGENE			English	Article						transcription factor; hematopoiesis; AML1; PEBP2 beta/CBF beta; PU.1; RT-PCR; gene targeting	ACUTE MYELOID-LEUKEMIA; CORE-BINDING-FACTOR; PROTEIN-PROTEIN INTERACTIONS; ACUTE LYMPHOBLASTIC-LEUKEMIA; FETAL LIVER HEMATOPOIESIS; FACTOR-RECEPTOR PROMOTER; DNA-BINDING; AML1 GENE; FUSION TRANSCRIPT; C-MYB	The AML1 and PEBP2 beta/CBF beta genes encode the DNA-binding and non-binding subunits, respectively, of the heterodimeric transcription factor, PEBP2/CBF. Targeting each gene results in an almost identical phenotype, namely the complete lack of definitive hematopoiesis in the fetal liver on embryonic day 11.5 (E11.5). We examined and compared the expression levels of various hematopoiesis-related genes in wild type embryos and in embryos mutated for AML1 or PEBP2 beta/CBF beta. The RNAs were prepared from the yolk sacs of E9.5 embryos, from the aorta-gonad- mesonephros regions of E11.5 embryos and from the livers of E11.5 embryos and RT-PCR was performed to detect various gene transcripts. Transcripts were detected for most of the hematopoiesis-related genes that encode transcription factors, cytokines and cytokine receptors, even in tissues from homozygously targeted embryos. On the other hand, PU.1 transcripts were never detected in any tissue of AML1(-/-) or PEBP2 beta/CBF beta(-/-) embryos. In addition, transcripts for the Vav, flk-2/flt-3, M-CSF receptor, G-CSF receptor and c-Myb genes were not detected in certain tissues of the (-/-) embryos. The results suggest that the expression of a particular set of hematopoiesis-related genes is closely correlated with the PEBP2/CBF function.	Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Toshima Ku, Tokyo 170, Japan; Univ Tokyo, Inst Med Sci, Dept Hematol Oncol, Minato Ku, Tokyo 108, Japan; Human Genome Sci Inc, Rockville, MD 20850 USA; Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 606, Japan	Tohoku University; Tohoku University; Japanese Foundation for Cancer Research; University of Tokyo; GlaxoSmithKline; Human Genome Sciences Inc; Kyoto University	Satake, M (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Immunol, Aoba Ku, Seiryo Machi, Sendai, Miyagi 9808575, Japan.							BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Chen HM, 1996, J BIOL CHEM, V271, P15743, DOI 10.1074/jbc.271.26.15743; CHEN HM, 1995, ONCOGENE, V11, P1549; ERICKSON P, 1992, BLOOD, V80, P1825; Frank R, 1995, ONCOGENE, V11, P2667; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KOOPMAN P, 1989, NATURE, V342, P940, DOI 10.1038/342940a0; LEIDEN JM, 1993, ANNU REV IMMUNOL, V11, P539, DOI 10.1146/annurev.iy.11.040193.002543; MACKAREHTSCHIAN K, 1995, IMMUNITY, V3, P147, DOI 10.1016/1074-7613(95)90167-1; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCCLANAHAN T, 1993, BLOOD, V81, P2903; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Mukouyama YS, 1998, IMMUNITY, V8, P105, DOI 10.1016/S1074-7613(00)80463-X; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; Nakai S, 1995, GENE DEV, V9, P3109, DOI 10.1101/gad.9.24.3109; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; Nimer S, 1996, BLOOD, V88, P66, DOI 10.1182/blood.V88.1.66.bloodjournal88166; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Ogilvy S, 1998, BLOOD, V91, P419, DOI 10.1182/blood.V91.2.419.419_419_430; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; Takahashi S, 1997, J BIOL CHEM, V272, P12611, DOI 10.1074/jbc.272.19.12611; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Zent CS, 1996, P NATL ACAD SCI USA, V93, P1044, DOI 10.1073/pnas.93.3.1044; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	53	108	113	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2287	2293		10.1038/sj.onc.1202151	http://dx.doi.org/10.1038/sj.onc.1202151			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811459				2022-12-28	WOS:000076723300002
J	Chen, L; Zhang, WJ; Fregien, N; Pierce, M				Chen, L; Zhang, WJ; Fregien, N; Pierce, M			The her-2/neu oncogene stimulates the transcription of N-acetylglucosaminyltransferase V and expression of its cell surface oligosaccharide products	ONCOGENE			English	Article						neu/her-2; oncogene; glycosyltransferase; glycosylation	HAMSTER-KIDNEY CELLS; ASPARAGINE-LINKED OLIGOSACCHARIDES; BETA-1-6 BRANCHED OLIGOSACCHARIDES; DISTINCT METASTATIC POTENTIALS; BREAST-CANCER; NEU-ONCOGENE; TRANSGENIC MICE; MEMBRANE-GLYCOPROTEINS; EPITHELIAL-CELLS; PROTO-ONCOGENE	Malignant transformation is associated with changes in the glycosylation of cell surface proteins. For example, the N-linked oligosaccharides containing the [GlcNAc beta(1,6)Man] branch are increased after transformation of many cell types by a number of tumor viruses and oncogenes which induce the expression of N-acetylglucosaminyl-transferase V (GlcNAc-T V), the enzyme that adds this branch, A large percentage of human breast carcinomas have increased N-linked beta(1,6) branches on glycoproteins, while up to 30% of breast carcinomas have amplified the oncogene her-2/neu (erb-B2), We tested the hypothesis that expression of her-2/neu stimulates GlcNAc-T V gene expression and increases the beta(1,6) branching of N-linked oligosaccharides, We found that neu-transformed NIH3T3 cells have a threefold increase in GlcNAc-T V enzyme activity and increased beta(1,6) branching on a specific set of glycoproteins. Promoter/reporter experiments showed that her-2/neu stimulates transcription from the human GlcNAc-T V promoter and that the her-2/neu response element was located about 400 bp 5' of the transcription initiation site and includes three Ets transcription factor binding sequences, Co-transfections with dominant-negative Raf and Ets expression plasmids demonstrated that the transcriptional activation of the GlcNAc-T V promoter by neu is mediated by the Ras-Raf-Ets signal transduction pathway.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Shanghai Jaio Tung Univ, Dept Biochem & Mol Biol, Inst Mol Biol, Shanghai, Peoples R China; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Shanghai Jiao Tong University; University of Miami	Pierce, M (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.				NCRR NIH HHS [RR5351] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALLRED DC, 1992, HUM PATHOL, V23, P974, DOI 10.1016/0046-8177(92)90257-4; Aperlo C, 1996, MOL CELL BIOL, V16, P6851; ARANGO J, 1988, J CELL BIOCHEM, V37, P225, DOI 10.1002/jcb.240370209; BORG A, 1991, ONCOGENE, V6, P137; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUCK CA, 1971, SCIENCE, V172, P169, DOI 10.1126/science.172.3979.169; Buckhaults P, 1997, J BIOL CHEM, V272, P19575, DOI 10.1074/jbc.272.31.19575; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CUMMINGS RD, 1982, J BIOL CHEM, V257, P13421; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1989, ONCOGENE, V4, P853; DENNIS JW, 1989, CANCER RES, V49, P945; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; DEPOTTER CR, 1990, INT J CANCER, V45, P55, DOI 10.1002/ijc.2910450112; DO KY, 1994, J BIOL CHEM, V269, P23456; FERNANDES B, 1991, CANCER RES, V51, P718; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hayes D F, 1996, Recent Results Cancer Res, V140, P101; Kang R, 1996, J BIOL CHEM, V271, P26706, DOI 10.1074/jbc.271.43.26706; KAWANO T, 1993, INT J CANCER, V53, P91, DOI 10.1002/ijc.2910530118; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEMARER N, 1992, GLYCOBIOLOGY, V2, P49, DOI 10.1093/glycob/2.1.49; Li WP, 1997, INT J CANCER, V71, P483, DOI 10.1002/(SICI)1097-0215(19970502)71:3<483::AID-IJC29>3.3.CO;2-P; LU Y, 1994, CLIN EXP METASTAS, V12, P47, DOI 10.1007/BF01784333; LU Y, 1993, MOL CELL BIOCHEM, V122, P85, DOI 10.1007/BF00925741; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PIERCE JH, 1991, ONCOGENE, V6, P1189; PIERCE M, 1986, J BIOL CHEM, V261, P772; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SAWADA R, 1994, J BIOL CHEM, V269, P1425; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STANLEY P, 1983, METHOD ENZYMOL, V96, P157; Tan M, 1997, CANCER RES, V57, P1199; TIKANNEN S, 1992, J CLIN ONCOL, V10, P1044; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260	47	81	82	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2087	2093		10.1038/sj.onc.1202124	http://dx.doi.org/10.1038/sj.onc.1202124			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798679				2022-12-28	WOS:000076540900007
J	Hall-Jackson, CA; Goedert, M; Hedge, P; Cohen, P				Hall-Jackson, CA; Goedert, M; Hedge, P; Cohen, P			Effect of SB 203580 on the activity of c-Raf in vitro and in vivo	ONCOGENE			English	Article						c-Raf; MAP kinase; SB203580; EGF; SAPK2; p38	P38 MAP KINASE; PROTEIN-KINASE; SUBSTRATE-SPECIFICITY; CELLULAR STRESSES; PLASMA-MEMBRANE; SAP KINASES; ACTIVATION; INHIBITOR; INSULIN; INTERLEUKIN-1	The inhibition of SAPK2a/p38 (a mitogen activated protein (MAP) kinase family member) by SE 203580 depends on the presence of threonine at residue 106. Nearly all other protein kinases are insensitive to this drug because a more bulky residue occupies this site (Eyers et al,, 1998), Raf is one of the few protein kinases that possesses threonine at this position, and we show that SE 203580 inhibits c-Raf with an IC50 of 2 mu M in vitro. However, SB 203580 does not suppress either growth factor or phorbol ester-induced activation of the classical MAP kinase cascade in mammalian cells. One of the reasons for this is that SE 203580 also triggers a remarkable activation of c-Raf in vivo (when measured in the absence of the drug). The SB203580-induced activation of c-Raf occurs without any increase in the GTP-loading of Ras, is not prevented by inhibitors of the MAPK cascade, protein kinase C or phosphatidylinositide 3-kinase, and is not triggered by the binding of this drug to SAPK2a/p38. The paradoxical activation of c-Raf by SE 203580 (and by another structurally unrelated c-Raf inhibitor) suggests that inhibitors of the kinase activity of c-Raf may not be effective as anti-cancer drugs.	Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Zeneca Pharmaceut, Macclesfield SK10 4TG, Cheshire, England	University of Dundee; MRC Laboratory Molecular Biology	Hall-Jackson, CA (corresponding author), Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, MSI WTB Complex,Dow St, Dundee DD1 5EH, Scotland.							ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; COHEN P, 1994, BIOCHEM J, V303, P21; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Doza YN, 1998, ONCOGENE, V17, P19, DOI 10.1038/sj.onc.1202168; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; Gum RJ, 1998, J BIOL CHEM, V273, P15605, DOI 10.1074/jbc.273.25.15605; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; LAW NM, 1996, EMERGING DRUGS PROSP, P241; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	30	131	135	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2047	2054		10.1038/sj.onc.1202603	http://dx.doi.org/10.1038/sj.onc.1202603			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321729				2022-12-28	WOS:000079346200002
J	Yue, JB; Frey, RS; Mulder, KM				Yue, JB; Frey, RS; Mulder, KM			Cross-talk between the Smad1 and Ras/MEK signaling pathways for TGF beta	ONCOGENE			English	Article						Ras/MEK; TGF beta; Smad1	GROWTH-FACTOR-BETA; FAMILY MEDIATOR SMAD1; BREAST-CANCER CELLS; EPITHELIAL-CELLS; PROTEIN; KINASE; MAD; ACTIVATION; PHOSPHORYLATION; BMP	Our previous data demonstrated that Ras activation was necessary and sufficient for transforming growth factor-p (TGF beta)-mediated Erk1 activation, and,vas required for TGF beta up-regulation of the Cdk inhibitors (CKI's) p27(Kip1) and p21(Cip1) (KM Mulder and SL Morris, J, Biol, Chem., 267, 5029-5031, 1992; MT Hartsough and KM Mulder, J, Biol, Chem., 270, 7117-7124, 1995; MT Hartsough ef nl,, J, Biol, Chem., 271, 22368-22375, 1996 and J Yue et al., Oncogene, 17, 47-55, 1998), Here we examined the role of Res in TGF beta-mediated effects on a rat homolog of Smad1 (termed RSmad1), We demonstrate that both TGF beta and bone morphogenetic protein (BMP) can induce endogenous Smad1 phosphorylation in intestinal epithelial cells (IECs), The combination of transient expression of RSmad1 and TGF beta treatment had an additive effect on induction of the TGF beta-responsive reporter 3TP-lux, Either inactivation of Ras by stable, inducible expression of a dominant-negative mutant of Ras (RasN17) or addition of MAP and ERK kinase (MEK) inhibitor PD98059 to cells significantly decreased the ability of both TGF beta and BMP to induce phosphorylation of endogenous Smad1 in IECs, Moreover, either inactivation of Ras or addition of PD98059 to IEC 4-1 cells inhibited the ability of RSmad1 to regulate 3TP luciferase activity in both the presence and absence of TGF beta, Collectively, our data indicate that TGF beta can regulate RSmad1 function in epithelial cells, and that the Ras/MEK pathway is partially required for TGF beta-mediated regulation of RSmad1.	Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Mulder, KM (corresponding author), Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA.		Yue, Jianbo/AAC-4588-2019; Yue, Jianbo/C-4463-2009; Yue, Jianbo/K-8002-2015	Yue, Jianbo/0000-0001-6384-5447	NCI NIH HHS [CA51425, CA68444, CA54816] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068444, R01CA051425, R01CA054816] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; CHEN Y, 1997, P NATL ACAD SCI USA, V94, P12939; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; Frey RS, 1997, CANCER LETT, V117, P41, DOI 10.1016/S0304-3835(97)00211-5; Frey RS, 1997, CANCER RES, V57, P628; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MULDER KM, 1993, J CELL PHYSIOL, V154, P162, DOI 10.1002/jcp.1041540120; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; RAFTERY LA, 1995, GENETICS, V139, P241; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Xu RH, 1996, P NATL ACAD SCI USA, V93, P834, DOI 10.1073/pnas.93.2.834; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; YUE J, 1999, IN PRESS J CELL PHYS; Yue JB, 1998, ONCOGENE, V17, P47, DOI 10.1038/sj.onc.1201903	29	85	92	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					2033	2037		10.1038/sj.onc.1202521	http://dx.doi.org/10.1038/sj.onc.1202521			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208426	Bronze			2022-12-28	WOS:000079191300014
J	Schmidt, M; Maurer-Gebhard, M; Groner, B; Kohler, G; Brochmann-Santos, G; Wels, W				Schmidt, M; Maurer-Gebhard, M; Groner, B; Kohler, G; Brochmann-Santos, G; Wels, W			Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors	ONCOGENE			English	Article						epidermal growth factor receptor; EGFR-vIII; monoclonal antibody 14E1; single chain Fv; immunotoxin	GROWTH-FACTOR RECEPTOR; PSEUDOMONAS EXOTOXIN; MONOCLONAL-ANTIBODIES; LUNG CARCINOMAS; TYROSINE KINASE; FV-FRAGMENTS; EXPRESSION; MUTANT; TUMORS; CELLS	Cytotoxic strategies which are directed to tumor-associated antigens might be most beneficial for cancer patients with minimal tumor load such as in an adjuvant setting after initial therapy, We have recently described a highly potent single chain antibody-toxin, scFv(14E1)-ETA, which consists of the variable domains of the antibody 14E1 genetically fused to a truncated form of Pseudomonas exotoxin A. ScFv(14E1)-ETA specifically recognizes the human epidermal growth factor receptor (EGFR) and the oncogenically activated receptor variant EGFRvIII, which have been implicated in the development of various human malignancies. Here we have investigated the antimetastatic activity of bacterially expressed scFv(14E1)-ETA and its disulfide-stabilized derivative ds-scFv(14E1)-ETA in a novel model for disseminated disease which is based on murine renal carcinoma cells subsequently transfected with the E. coli P-galactosidase gene, and human full-length or variant EGFR cDNAs, Intravenous injection of these Renca-lacZ/EGFR and Renca-lacZ/EGFRvIII cells in syngenic Balb/c mice led to the formation of pulmonary metastases which were readily detectable upon excision of the lungs and X-gal staining, Systemic treatment of mice with scFv(14E1)-ETA resulted in the complete suppression of Renca-lacZ/EGFRvIII metastasis formation and drastically reduced the number of pulmonary Renca-lacZ/EGFR tumor nodules, The ds-scFv(14E1)-ETA derivative where the antibody variable regions are connected by an artificial disulfide bond displayed improved thermal stability at physiological temperature but due to reduced cytotoxic activity was less potent than the original scFv(14E1)-ETA in metastasis suppression.	Georg Speyer Haus Inst Biomed Res, D-60596 Frankfurt, Germany; Tumor Biol Ctr, Inst Expt Canc Res, D-79106 Freiburg, Germany; Univ Freiburg, Dept Pathol, D-79104 Freiburg, Germany	University of Freiburg	Wels, W (corresponding author), Georg Speyer Haus Inst Biomed Res, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.			Wels, Winfried/0000-0001-9858-3643				Altenschmidt U, 1997, INT J CANCER, V73, P117, DOI 10.1002/(SICI)1097-0215(19970926)73:1<117::AID-IJC18>3.0.CO;2-D; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; Fan Zhen, 1998, Current Opinion in Oncology, V10, P67, DOI 10.1097/00001622-199801000-00011; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; Groner B, 1997, INT J CANCER, V70, P682, DOI 10.1002/(SICI)1097-0215(19970317)70:6<682::AID-IJC10>3.0.CO;2-C; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; HILLS D, 1995, INT J CANCER, V63, P537, DOI 10.1002/ijc.2910630414; HUMPHREY PA, 1988, CANCER RES, V48, P2231; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; Kabat EA, 1991, SEQUENCES PROTEINS I; Lorimer IAJ, 1996, P NATL ACAD SCI USA, V93, P14815, DOI 10.1073/pnas.93.25.14815; Luo Dong, 1995, Journal of Biochemistry (Tokyo), V118, P825; Maurer-Gebhard M, 1998, CANCER RES, V58, P2661; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; MURPHY GP, 1973, JNCI-J NATL CANCER I, V50, P1013, DOI 10.1093/jnci/50.4.1013; OGATA M, 1992, J BIOL CHEM, V267, P25396; Pai LH, 1996, NAT MED, V2, P350, DOI 10.1038/nm0396-350; Pantel K, 1996, CURR TOP MICROBIOL, V213, P1; PANTEL K, 1993, JNCI-J NATL CANCER I, V85, P1419, DOI 10.1093/jnci/85.17.1419; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; Reiter Y, 1996, NAT BIOTECHNOL, V14, P1239, DOI 10.1038/nbt1096-1239; Schmidt M, 1998, INT J CANCER, V75, P878, DOI 10.1002/(SICI)1097-0215(19980316)75:6<878::AID-IJC10>3.3.CO;2-U; Schmidt M, 1997, BRIT J CANCER, V75, P1575, DOI 10.1038/bjc.1997.270; Spyridonidis A, 1998, BLOOD, V91, P1820, DOI 10.1182/blood.V91.5.1820.1820_1820_1827; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; WELS W, 1995, INT J CANCER, V60, P137, DOI 10.1002/ijc.2910600120; Wels W, 1996, CURR TOP MICROBIOL, V213, P113; WELS W, 1992, CANCER RES, V52, P6310; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; YAMAZAKI H, 1990, JPN J CANCER RES, V81, P773, DOI 10.1111/j.1349-7006.1990.tb02644.x; Young NM, 1995, FEBS LETT, V377, P135, DOI 10.1016/0014-5793(95)01325-3	32	49	89	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	1999	18	9					1711	1721		10.1038/sj.onc.1202489	http://dx.doi.org/10.1038/sj.onc.1202489			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208432				2022-12-28	WOS:000079025000006
J	Yokomizo, A; Mai, M; Tindall, DJ; Cheng, L; Bostwick, DG; Naito, S; Smith, DI; Liu, WG				Yokomizo, A; Mai, M; Tindall, DJ; Cheng, L; Bostwick, DG; Naito, S; Smith, DI; Liu, WG			Overexpression of the wild type p73 gene in human bladder cancer	ONCOGENE			English	Article						p73; overexpression; allelic expression; imprinting; bladder cancer	TUMOR-SUPPRESSOR GENES; P53 MUTATIONS; NEUROBLASTOMA; CARCINOMA; PROTEIN	p73, a first p53 relative, was recently identified and shown to be monoallelically expressed in a number of different human tissues. To determine the potential role of this gene in human bladder cancer, we investigated p73 expression levels, allelic expression patterns, and analysed p73 mutations in 23 unselected primary invasive bladder cancers with matched normal tissues and in seven bladder cancer cell lines. In a comparison between normal and turner tissues using quantitative RT-PCR analysis, me found that p73 was overexpressed in 22/23 bladder cancers, sometimes as great as 20-fold. Allelic expression analysis using a C/T polymorphism in exon 2 and a newly identified T/C polymorphism in exon 5 revealed that p73 was biallelically expressed in both normal bladder and cancer tissues, suggesting that p73 is not imprinted in bladder tissue. Mutation screening of the p73 gene in bladder cancer DNAs using denaturing high-performance liquid chromatography analysis and DNA sequencing revealed no tumor-specific mutations in any coding exons of the p73 gene, These data suggest that the p73 is unlikely to be a tumor suppressor gene, but that overexpression of p73 may contribute to tumorigenesis in bladder cancer.	Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55095 USA; Mayo Clin, Dept Urol Res, Rochester, MN 55905 USA; Kyushu Univ, Fac Med, Dept Urol, Fukuoka 812, Japan	Mayo Clinic; Mayo Clinic; Kyushu University	Liu, WG (corresponding author), Mayo Clin, Dept Lab Med & Pathol, 200 1st St SW, Rochester, MN 55095 USA.				NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CordonCardo C, 1997, SEMIN DIAGN PATHOL, V14, P123; CORDONCARDO C, 1994, INT J CANCER, V56, P347, DOI 10.1002/ijc.2910560309; FUJITA J, 1985, P NATL ACAD SCI USA, V82, P3849, DOI 10.1073/pnas.82.11.3849; Goto K, 1997, MODERN PATHOL, V10, P428; JAMES CD, 1988, CANCER RES, V48, P5546; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KNOWLES MA, 1994, CANCER RES, V54, P531; Liu WG, 1998, NUCLEIC ACIDS RES, V26, P1396, DOI 10.1093/nar/26.6.1396; Mai M, 1998, CANCER RES, V58, P2347; Mai M, 1998, ONCOGENE, V17, P1739, DOI 10.1038/sj.onc.1202099; Mai M, 1998, GENOMICS, V51, P359, DOI 10.1006/geno.1998.5387; MIYAZAKI K, 1993, J BIOL CHEM, V268, P14387; Naito S, 1996, Hum Cell, V9, P49; Oefner P. J., 1995, American Journal of Human Genetics, V57, pA266; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SARKIS AS, 1993, J NATL CANCER I, V85, P53, DOI 10.1093/jnci/85.1.53; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; Tazaki H, 1988, Hum Cell, V1, P78; VERSTEEG R, 1995, EUR J CANCER, V31A, P538, DOI 10.1016/0959-8049(95)00037-J; Yokomizo A, 1998, ONCOGENE, V17, P475, DOI 10.1038/sj.onc.1201956; Yokomizo A, 1998, INT J ONCOL, V13, P101	23	124	134	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1629	1633		10.1038/sj.onc.1202474	http://dx.doi.org/10.1038/sj.onc.1202474			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102633				2022-12-28	WOS:000078770700013
J	Taylor, WR; Agarwal, ML; Agarwal, A; Stacey, DW; Stark, GR				Taylor, WR; Agarwal, ML; Agarwal, A; Stacey, DW; Stark, GR			p53 inhibits entry into mitosis when DNA synthesis is blocked	ONCOGENE			English	Article						cell cycle; checkpoint; hydroxyurea; PALA	CELL-CYCLE ARREST; WILD-TYPE P53; S-PHASE; GENE AMPLIFICATION; PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; TYROSINE PHOSPHORYLATION; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; BUDDING YEAST	Human and mouse fibroblasts with normal p53 fail to enter mitosis when DNA synthesis is blocked by aphidicolin or hydroxyurea, Isogenic p53-null fibroblasts do enter mitosis with incompletely replicated DNA, revealing that p53 contributes to a checkpoint that ensures that mitosis does not occur until DNA synthesis is complete, When treated with N-(phosphonacetyl)-L-aspartate (PALA), which inhibits pyrimidine nucleotide synthesis, leading to synthesis of damaged DNA from highly unbalanced dNTP pools, p53-null cells enter mitosis after they have completed DNA replication, but cells with wild-type p53 do not, revealing that p53 also mediates a checkpoint that monitors the quality of newly replicated DNA.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biol Mol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stark, GR (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biol Mol, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049345] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-49345] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; AGARWAL ML, 1998, IN PRESS P NATL ACAD; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Anderson GR, 1995, J SURG RES, V59, P666, DOI 10.1006/jsre.1995.1221; ATTARDI LD, 1996, EMBO J, V15, P3696; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; CHADEE DN, 1995, J BIOL CHEM, V270, P20098, DOI 10.1074/jbc.270.34.20098; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; Chen GQ, 1996, BLOOD, V88, P1052; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Di Leonardo A, 1997, CANCER RES, V57, P1013; DI LEONARDO A, 1993, COLD SPRING HARB SYM, V58, P655, DOI 10.1101/SQB.1993.058.01.073; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; HAIN J, 1993, CANCER RES, V53, P1507; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARVEY M, 1993, ONCOGENE, V8, P2457; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HERZINGER T, 1995, ONCOGENE, V11, P2151; Hughes TA, 1996, EXP CELL RES, V222, P275, DOI 10.1006/excr.1996.0035; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; JACOBBERGER J W, 1991, Methods (Orlando), V2, P207, DOI 10.1016/S1046-2023(05)80063-5; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KHANNA KK, 1993, ONCOGENE, V8, P3307; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU MJ, 1994, CHROMOSOMA, V103, P111; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MARTINEAU SN, 1995, J CELL BIOL, V131, P191, DOI 10.1083/jcb.131.1.191; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MIYASHITA T, 1995, CELL, V80, P293; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Paulson TG, 1998, MOL CELL BIOL, V18, P3089, DOI 10.1128/MCB.18.5.3089; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; POON RYC, 1996, J BIOL CHEM, V271, P13282; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; Shimizu N, 1998, J CELL BIOL, V140, P1307, DOI 10.1083/jcb.140.6.1307; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; STEWART N, 1995, ONCOGENE, V10, P109; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	82	64	66	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					283	295		10.1038/sj.onc.1202516	http://dx.doi.org/10.1038/sj.onc.1202516			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927185				2022-12-28	WOS:000078166500001
J	Vadlamudi, R; Mandal, M; Adam, L; Steinbach, G; Mendelsohn, J; Kumar, R				Vadlamudi, R; Mandal, M; Adam, L; Steinbach, G; Mendelsohn, J; Kumar, R			Regulation of cyclooxygenase-2 pathway by HER2 receptor	ONCOGENE			English	Article						NDF; COX-2; colon cancer	NEU DIFFERENTIATION FACTOR; GROWTH-FACTOR-ALPHA; HUMAN-COLON-CANCER; PROSTAGLANDIN-H SYNTHASE-2; TYROSINE KINASE-ACTIVITY; EPITHELIAL-CELLS; MONOCLONAL-ANTIBODY; COLORECTAL-CANCER; ERBB RECEPTORS; GENE-PRODUCT	Emerging lines of evidence suggest that in addition to growth factors, the process of colorectal tumorigenesis map also be driven by the upregulation of the inducible form of cyclooxygenase-2 (COX-2), an enzyme responsible for the conversion of arachidonic acid to PGEs, The present study was undertaken to investigate the expression and activation of the HER family members, and to explore the regulation of COS-2 expression by the HER2 pathway in human colorectal cancer cells. Here, rye report that human colorectal cancer cell lines express abundant levels of HER2, and HER3 receptors, and are growth-stimulated by recombinant neu-differentiation factor-beta 1 (NDF), NDF-treatment of colorectal cancer cells was accompanied by increased tyrosine phosphorylation and heterodimerization of HER3 with HER2, In addition, we demonstrated that HER2 and HER3 receptors in colorectal cancer cells are constitutively phosphorylated on tyrosine residues and form heterodimeric complexes in the absence of exogenous NDF, Inhibition of HER2/HER3 signaling by an anti-HER3 mAb against the ligand binding site resulted in a decrease in the levels of constitutively activated HER2/HER3 heterodimers, and the unexpected reduction of COS-2 expression, Activation of the HER2/HER3 pathway by NDF induced the activation of COX-2 promoter, expression of COX-2 mRNA, COX-2 protein and accumulation of prostaglandin E2 in the culture medium. Finally, we demonstrated that NDF promotes the ability of colorectal cancer cells to sur,ive in an extracellular matrix milieu, such as Matrigel, and also to invade through a 8 mu m porous membrane. These biological activities of NDF and its stimulation of cell proliferation are blocked by a specific inhibitor of COX-2, Taken together, our findings provide the first biochemical evidence of a possible role of the COS-2 pathway in the mitogenic action of NDF in colorectal cancer cells where it may be constitutively upregulated due to the autocrine/paracrine activation of HER2/HER3 heterodimers.	Univ Texas, MD Anderson Cancer Ctr, Dept Clin Invest, Cell Growth Regulat Lab, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Gastrointestinal Oncol & Digest Dis, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Clin Invest, Cell Growth Regulat Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Mandal, Mahitosh/GMW-6195-2022	Mandal, Mahitosh/0000-0003-3861-3323; Steinbach, Gideon/0000-0001-7597-0544	NATIONAL CANCER INSTITUTE [R01CA065746, U01CA065746] Funding Source: NIH RePORTER; NCI NIH HHS [CA65746] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM L, 1994, INT J CANCER, V59, P262, DOI 10.1002/ijc.2910590219; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; ANZANO MA, 1989, CANCER RES, V49, P2898; Boolbol SK, 1996, CANCER RES, V56, P2556; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Chen QR, 1997, J BIOL CHEM, V272, P5952, DOI 10.1074/jbc.272.9.5952; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Chiu CH, 1997, CANCER RES, V57, P4267; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; COFFEY RJ, 1987, CANCER RES, V47, P4590; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FANGER BO, 1989, FASEB J, V3, P71, DOI 10.1096/fasebj.3.1.2783412; Granstrom E, 1978, Adv Prostaglandin Thromboxane Res, V5, P119; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HORAN T, 1995, J BIOL CHEM, V270, P24604, DOI 10.1074/jbc.270.41.24604; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Kapitanovic S, 1997, GASTROENTEROLOGY, V112, P1103, DOI 10.1016/S0016-5085(97)70120-3; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; KUMAR R, 1996, J CELL BIOCHEM, V239, P914; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LUPU R, 1995, SEMIN CANCER BIOL, V6, P135, DOI 10.1006/scbi.1995.0016; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; MANDAL M, 1998, IN PRESS ONCOGENE; Mandel C, 1997, AM BOOK REV, V18, P29; MARTIN TE, 1987, J CELL BIOL, V105, P2069, DOI 10.1083/jcb.105.5.2069; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; RAJKUMAR T, 1993, J PATHOL, V170, P271, DOI 10.1002/path.1711700309; REIDEL H, 1988, P NATL ACAD SCI USA, V85, P1477; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Sierke SL, 1997, BIOCHEM J, V322, P757, DOI 10.1042/bj3220757; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1990, CELL, V61, P212; UNTAWALE S, 1993, CANCER RES, V53, P1630; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Yang JL, 1997, ANTICANCER RES, V17, P1023; Zhang K, 1996, J BIOL CHEM, V271, P3884	49	187	202	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					305	314		10.1038/sj.onc.1202307	http://dx.doi.org/10.1038/sj.onc.1202307			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927187				2022-12-28	WOS:000078166500003
J	Khanna, M; Park, P; Zirvi, M; Cao, WG; Picon, A; Day, J; Paty, P; Barany, F				Khanna, M; Park, P; Zirvi, M; Cao, WG; Picon, A; Day, J; Paty, P; Barany, F			Multiplex PCR/LDR for detection of K-ras mutations in primary colon tumors	ONCOGENE			English	Article						colorectal cancer; K-ras mutations; polymerase chain reaction; ligase detection reaction; thermostable ligase; microdissection	POLYMERASE CHAIN-REACTION; OLIGONUCLEOTIDE LIGATION ASSAY; SEQUENCE-CODED SEPARATION; THERMOPHILUS DNA-LIGASE; COLORECTAL-CANCER; GENE-MUTATIONS; POINT MUTATIONS; PANCREATIC ADENOCARCINOMA; MOLECULAR DIAGNOSIS; CODON-12 MUTATIONS	Point mutations in codons 12, 13, and 61 of the K-ras gene occur early in the development of colorectal cancer and are preserved throughout the course of tumor progression. These mutations can serve as biomarkers for shed or circulating tumor cells and may be useful for diagnosis of early, curable tumors and for staging of advanced cancers. We have developed a multiplex polymerase chain reaction/ligase detection reaction (PCR/LDR) method which identifies all 19 possible single-base mutations in K-ras codons 12, 13, and 61, with a sensitivity of 1 in 500 wild-type sequences. In a blinded study, 144 paraffin-embedded archival colon carcinomas were microdissected and K-ras mutations determined by both dideoxy-sequencing and multiplex PCR/LDR. Results were concordant for 134 samples. The ten discordant samples were re-evaluated using higher sensitivity uniplex PCR/LDR, and the original multiplex PCR/LDR result was confirmed in nine of these ten cases. Multiplex PCR/LDR was able to identify mutations in solid tumors or paraffin-embedded tissues containing a majority of wild-type stromal cells, with or without microdissection. The technique is well suited for large scale studies and for analysis of clinical samples containing a minority population of mutated cells.	Cornell Univ, Joan & Sanford I Weill Med Coll, Strang Canc Prevent Ctr, Hearst Microbiol Res Ctr,Dept Microbiol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, Colorectal Serv, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Barany, F (corresponding author), Cornell Univ, Joan & Sanford I Weill Med Coll, Strang Canc Prevent Ctr, Hearst Microbiol Res Ctr,Dept Microbiol, Box 62,1300 York Ave, New York, NY 10021 USA.				NCI NIH HHS [CA65930-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA065930] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARANY F, 1991, P NATL ACAD SCI USA, V88, P189, DOI 10.1073/pnas.88.1.189; BARANY F, 1991, GENE, V109, P1, DOI 10.1016/0378-1119(91)90582-V; Barany F, 1991, PCR Methods Appl, V1, P5, DOI 10.1101/gr.1.1.5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Belgrader P, 1996, GENOME SCI TECHNOLOG, V1, P77, DOI [DOI 10.1089/GST.1996.1.77, 10.1089/gst.1996.1.77]; BENHATTAR J, 1993, GASTROENTEROLOGY, V104, P1044, DOI 10.1016/0016-5085(93)90272-E; BERTHELEMY P, 1995, ANN INTERN MED, V123, P188, DOI 10.7326/0003-4819-123-3-199508010-00005; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOYLE JO, 1994, AM J SURG, V168, P429, DOI 10.1016/S0002-9610(05)80092-3; BREIVIK J, 1994, BRIT J CANCER, V69, P367, DOI 10.1038/bjc.1994.67; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CALDAS C, 1994, CANCER RES, V54, P3568; CAPELLA G, 1991, ENVIRON HEALTH PERSP, V93, P125, DOI 10.2307/3431180; Cha R S, 1992, PCR Methods Appl, V2, P14; CHEHAB FF, 1989, P NATL ACAD SCI USA, V86, P9178, DOI 10.1073/pnas.86.23.9178; CHEN J, 1991, ANAL BIOCHEM, V195, P51, DOI 10.1016/0003-2697(91)90293-3; CHEN J, 1994, ENV HLTH PERSPECT, V3, P227; Day DJ, 1996, HUM MOL GENET, V5, P2039, DOI 10.1093/hmg/5.12.2039; DAY DJ, 1995, GENOMICS, V29, P152, DOI 10.1006/geno.1995.1226; DIGIUSEPPE JA, 1994, AM J PATHOL, V144, P889; EGGERDING FA, 1995, HUM MUTAT, V5, P153, DOI 10.1002/humu.1380050209; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEERO WG, 1993, NEUROLOGY, V43, P668, DOI 10.1212/WNL.43.4.668; FINKELSTEIN SD, 1993, ARCH SURG-CHICAGO, V128, P526; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FODDE R, 1994, HUM MUTAT, V3, P83, DOI 10.1002/humu.1380030202; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GROSSMAN PD, 1994, NUCLEIC ACIDS RES, V22, P4527, DOI 10.1093/nar/22.21.4527; HALIASSOS A, 1989, NUCLEIC ACIDS RES, V17, P8093, DOI 10.1093/nar/17.20.8093; HASEGAWA H, 1995, ONCOGENE, V10, P1413; HAYASHI N, 1994, CANCER RES, V54, P3853; HAYASHI N, 1995, LANCET, V345, P1257, DOI 10.1016/S0140-6736(95)90922-2; HORN T, 1986, TETRAHEDRON LETT, V27, P4705, DOI 10.1016/S0040-4039(00)85043-1; Jacobson D R, 1992, PCR Methods Appl, V1, P299; JEN J, 1994, CANCER RES, V54, P5523; KAHN SM, 1991, ONCOGENE, V6, P1079; KHRAPKO K, 1994, NUCLEIC ACIDS RES, V22, P364, DOI 10.1093/nar/22.3.364; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KORN SH, 1993, J CLIN PATHOL, V46, P621, DOI 10.1136/jcp.46.7.621; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEVI S, 1991, CANCER RES, V51, P3497; LI HH, 1990, P NATL ACAD SCI USA, V87, P4580, DOI 10.1073/pnas.87.12.4580; LO YMD, 1991, NUCLEIC ACIDS RES, V19, P3561, DOI 10.1093/nar/19.13.3561; LOSI L, 1992, EUR J CANCER, V28A, P1115, DOI 10.1016/0959-8049(92)90468-H; LU ZB, 1993, PCR METH APPL, V3, P176; Luo JY, 1996, NUCLEIC ACIDS RES, V24, P3079, DOI 10.1093/nar/24.15.3079; Luo JY, 1996, NUCLEIC ACIDS RES, V24, P3071, DOI 10.1093/nar/24.15.3071; MANSFIELD V, 1992, PCR METH APPL, V1, P211; Mao L, 1996, SCIENCE, V271, P659, DOI 10.1126/science.271.5249.659; MAO L, 1994, CANCER RES, V54, P1634; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; MOERKERK P, 1994, CANCER RES, V54, P3376; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARK P, 1998, UNPUB; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Ravin J S, 1995, GUT, V36, P81; REDSTON MS, 1995, GASTROENTEROLOGY, V108, P383, DOI 10.1016/0016-5085(95)90064-0; RUANO G, 1989, NUCLEIC ACIDS RES, V17, P8392, DOI 10.1093/nar/17.20.8392; RUST S, 1993, NUCLEIC ACIDS RES, V21, P3623, DOI 10.1093/nar/21.16.3623; SATO Y, 1990, AM J PATHOL, V136, P267; SEYAMA T, 1992, NUCLEIC ACIDS RES, V20, P2493, DOI 10.1093/nar/20.10.2493; SHIBATA D, 1993, J NATL CANCER I, V85, P1058, DOI 10.1093/jnci/85.13.1058; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SMITH AJ, 1994, CANCER RES, V54, P5527; TADA M, 1993, CANCER RES, V53, P2472; TORIBARA NW, 1995, NEW ENGL J MED, V332, P861, DOI 10.1056/NEJM199503303321306; TRUMPER LH, 1994, BRIT J CANCER, V70, P278, DOI 10.1038/bjc.1994.292; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WESTRA WH, 1993, CANCER-AM CANCER SOC, V72, P432, DOI 10.1002/1097-0142(19930715)72:2<432::AID-CNCR2820720219>3.0.CO;2-#; WINNDEEN E, 1993, AM J HUM GENET, V53, P1512; WU DY, 1989, P NATL ACAD SCI USA, V86, P2757, DOI 10.1073/pnas.86.8.2757; WU S, 1994, EARLY DETECTION CANC, P237; Zhu D, 1997, CANCER RES, V57, P2485	80	137	161	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					27	38		10.1038/sj.onc.1202291	http://dx.doi.org/10.1038/sj.onc.1202291			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926917				2022-12-28	WOS:000078166000004
J	Korpelainen, EI; Karkkainen, M; Gunji, Y; Vikkula, M; Alitalo, K				Korpelainen, EI; Karkkainen, M; Gunji, Y; Vikkula, M; Alitalo, K			Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response	ONCOGENE			English	Article						STAT; VEGF; VEGF receptors; Tek; Tie; p21; signal transduction	EPIDERMAL GROWTH-FACTOR; CELL-GROWTH; CYTOKINE RECEPTORS; GENE-EXPRESSION; PLC-GAMMA; VEGF-C; TRANSCRIPTION; PROTEIN; BMX; PHOSPHORYLATION	Endothelial receptor tyrosine kinases (RTKs) and their signaling mechanisms are of interest because they may control tumor angiogenesis and thereby tumor growth, In this report we have examined activation of the signal transducers and activators of transcription (STATs) by the three known vascular endothelial growth factor receptors (VEGFR1-3), as well as by the endothelial Tie-1 and -2 receptors, We also studied signaling by the R849W mutant of Tie-2 (MTie-2), which has been shown to cause venous malformations. When overexpressed in 293T cells, MTie-2 activated STAT1 while the other endothelial RTKs failed to do so, In contrast, the three VEGFRs were strong activators of STAT3 and STAT5, suggesting that they activate only a specific subset of these signal transducers. STAT3 and STAT5 were also activated by Tie-2 and, more so, by MTie-2, Tyrosine phosphorylation and DNA binding of STAXs correlated with their ability to activate transcription as judged by luciferase assays. When co-expressed with STAT5, VEGFR-1 as well as both the Tie-2 receptor forms increased expression of the cell cycle inhibitor p21, Interestingly, co-expression of the Tie-2 receptors with STAT1 resulted in appearance of a novel, p21 related transcript. Taken together, these findings identify STAT proteins as novel targets for signal transduction by the endothelial RTKs, suggesting that they may be involved in the regulation of endothelial function.	Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Catholic Univ Louvain, Lab Human Mol Genet, Brussels, Belgium; Christian Duve Inst, Brussels, Belgium	University of Helsinki; Universite Catholique Louvain	Alitalo, K (corresponding author), Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland.		Alitalo, Kari K/J-5013-2014; Vikkula, Miikka/Q-1038-2018	Alitalo, Kari K/0000-0002-7331-0902; Vikkula, Miikka/0000-0002-6236-338X; Korpelainen, Eija/0000-0002-4406-5602				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Batard P, 1996, BLOOD, V87, P2212, DOI 10.1182/blood.V87.6.2212.bloodjournal8762212; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Ekman N, 1997, CIRCULATION, V96, P1729, DOI 10.1161/01.CIR.96.6.1729; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HUANG LW, 1995, ONCOGENE, V11, P2097; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kaukonen J, 1996, BRIT J HAEMATOL, V94, P455; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; May P, 1996, FEBS LETT, V394, P221, DOI 10.1016/0014-5793(96)00955-6; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; Poon RYC, 1998, ONCOGENE, V16, P1333, DOI 10.1038/sj.onc.1201897; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Saharinen P, 1997, BLOOD, V90, P4341; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; Sawano A, 1997, BIOCHEM BIOPH RES CO, V238, P487, DOI 10.1006/bbrc.1997.7327; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Tchou WW, 1996, J BIOL CHEM, V271, P29556, DOI 10.1074/jbc.271.47.29556; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; Weil D, 1997, BLOOD, V90, P4332, DOI 10.1182/blood.V90.11.4332.4332_4332_4340; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; ZIEGLER SF, 1993, ONCOGENE, V8, P663	63	100	110	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					1	8		10.1038/sj.onc.1202288	http://dx.doi.org/10.1038/sj.onc.1202288			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926914				2022-12-28	WOS:000078166000001
J	Saikumar, P; Dong, Z; Patel, Y; Hall, K; Hopfer, U; Weinberg, JM; Venkatachalam, MA				Saikumar, P; Dong, Z; Patel, Y; Hall, K; Hopfer, U; Weinberg, JM; Venkatachalam, MA			Role of hypoxia-induced Bax translocation and cytochrome c release in reoxygenation injury	ONCOGENE			English	Article						hypoxia; reoxygenation; cell death; Bax; Bcl-2; cytochrome c	INDUCED CELL-DEATH; PROXIMAL TUBULES; PROTEASE CASCADE; BCL-2; APOPTOSIS; ISCHEMIA; ACTIVATION; DAMAGE; OVEREXPRESSION; CYCLOSPORINE	We investigated mechanisms of cell death during hypoxia/reoxygenation of cultured kidney cells. During glucose-fret hypoxia, cell ATP levels declined steeply resulting in the translocation of Bas from cytosol to mitochondria. Concurrently, there was cytochrome c release and caspase activation. Cells that leaked cytochrome c underwent apoptosis after reoxygenation, ATP depletion induced by a mitochondrial uncoupler resulted in similar alterations even in the presence of oxygen. Moreover, inclusion of glucose during hypoxia prevented protein translocations and reoxygenation injury by maintaining intracellular ATP, Thus, ATP depletion, rather than hypoxia per se, was the cause of protein translocations. Overexpression of Bcl-2 prevented cytochrome c release and reoxygenation injury without ameliorating ATP depletion or Bas translocation, On the other hand, caspase inhibitors did not prevent protein translocations, but inhibited apoptosis during reoxygenation, Nevertheless, they could not confer long-term viability, since mitochondria had been damaged. Omission of glucose during reoxygenation resulted in continued failure of ATP production, and cell death,vith necrotic morphology. In contrast, cells expressing Bcl-2 had functional mitochondria and remained viable during reoxygenation even,without glucose. Therefore, Bas translocation during hypoxia is a molecular trigger for cell death during reoxygenation. If ATP is available during reoxygenation, apoptosis develops; otherwise, death occurs by necrosis. By preserving mitochondrial integrity, BCL-2 prevents both forms of cell death and ensures cell viability.	Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA	University of Texas System; University of Texas Health San Antonio; Case Western Reserve University; University of Michigan System; University of Michigan	Saikumar, P (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Hopfer, Ulrich/B-5463-2009	Hopfer, Ulrich/0000-0003-1357-0101	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK037139, R01DK054472, R01DK048417, R01DK037139] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54472, DK48417, DK37139] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; Borutaite V, 1996, J MOL CELL CARDIOL, V28, P2195, DOI 10.1006/jmcc.1996.0211; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Cotran R.S., 1998, ROBBINS PATHOLOGIC B; Dong Z, 1998, AM J PATHOL, V152, P231; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; DURAN MA, 1990, TOXICOL APPL PHARM, V105, P183, DOI 10.1016/0041-008X(90)90180-3; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; GARZAQUINTERO R, 1990, AM J PHYSIOL, V258, pF1075, DOI 10.1152/ajprenal.1990.258.4.F1075; GRIFFITHS EJ, 1995, BIOCHEM J, V307, P93, DOI 10.1042/bj3070093; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Kajstura J, 1998, AM J CARDIOL, V82, p30K, DOI 10.1016/S0002-9149(98)00535-9; Kato H, 1997, EXP NEUROL, V148, P464, DOI 10.1006/exnr.1997.6707; Kaushal GP, 1998, AM J PHYSIOL-RENAL, V274, pF587, DOI 10.1152/ajprenal.1998.274.3.F587; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li Y, 1998, J NEUROL SCI, V156, P119, DOI 10.1016/S0022-510X(98)00036-7; Lieberthal W, 1996, AM J PHYSIOL-RENAL, V271, pF477, DOI 10.1152/ajprenal.1996.271.3.F477; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOU X, 1998, CELL, V94, P481; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; MIN AJ, 1997, NATURE, V385, P353; NARO F, 1993, CARDIOSCIENCE, V4, P177; Nissim I, 1996, KIDNEY INT, V49, P684, DOI 10.1038/ki.1996.97; Noda T, 1998, AM J PHYSIOL-GASTR L, V274, pG270, DOI 10.1152/ajpgi.1998.274.2.G270; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PIPER HM, 1985, J MOL CELL CARDIOL, V17, P885, DOI 10.1016/S0022-2828(85)80102-4; Qian T, 1997, AM J PHYSIOL-CELL PH, V273, pC1783, DOI 10.1152/ajpcell.1997.273.6.C1783; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Shimizu S, 1996, ONCOGENE, V12, P2251; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Simm A, 1997, J CELL SCI, V110, P819; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; VENKATACHALAM MA, 1993, SURVIVING HYPOXIA, P473; Weinberg JM, 1997, J CLIN INVEST, V100, P713, DOI 10.1172/JCI119584; Wiegele G, 1998, NEPHROL DIAL TRANSPL, V13, P1158, DOI 10.1093/ndt/13.5.1158; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Woost PG, 1996, KIDNEY INT, V50, P125, DOI 10.1038/ki.1996.295; WYLLIE AH, 1994, PHILOS T R SOC B, V345, P237, DOI 10.1098/rstb.1994.0099; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	63	257	269	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3401	3415		10.1038/sj.onc.1202590	http://dx.doi.org/10.1038/sj.onc.1202590			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030664				2022-12-28	WOS:000078086200001
J	Hauser, PJ; Agrawal, D; Pledger, W				Hauser, PJ; Agrawal, D; Pledger, W			Primary keratinocytes have an adhesion dependent S phase checkpoint that is absent in immortalized cell lines	ONCOGENE			English	Article						keratinocyte; differentiation; S phase checkpoint; cyclin dependent kinase; p27(kip1)	CYCLIN-A; MURINE KERATINOCYTES; BALB/C-3T3 CELLS; GROWTH-FACTOR; MICE LACKING; IN-VITRO; EXPRESSION; DIFFERENTIATION; P27(KIP1); PROGRESSION	In order to understand the mechanism through which loss of anchorage inhibits growth, we have investigated the events that occur in murine keratinocytes upon substratum detachment utilizing both primary cells and established immortalized cell lines, Our data has revealed that while both primary and immortalized cells undergo growth arrest in suspension, the nature of this arrest is markedly different, Primary cells exhibit a growth arrest that is characterized by rapid cessation of DNA synthesis resulting in a static S phase population. In contrast, an immortalized non-tumorgenic cell line, Balb MK, exhibits growth arrest as measured by thymidine incorporation, but does not prevent cells that have entered S phase from continuing into G(2)/M, and accumulating as a 4N population. In contrast to both primary and MK cells, the tumorigenic SLC-1 cell line did not accumulate in a specific cell cycle interval and were able to undergo continuous growth in suspension, Examination of cyclin A protein and its associated activity revealed that cyclin A protein levels decreased in primary but not MK cells; suggesting the continued presence of cyclin A may allow continued DNA synthesis observed in MK cells. Furthermore, we demonstrate the accumulation of suspension cultured MK cells as a 4N population correlated with the loss of cyclin A/cdk2 kinase activity, which in turn occurred through the accumulation of p27(kip1), whereas neither p27(kip1) accumulation nor loss of cyclin A activity was observed in SLC-1 cells. Our results clearly reveal that the process of growth inhibition in suspension cultured cells may occur in several forms with distinct characteristics that are dependent on the status of cyclin/cdk complexes and CKI proteins. Tumor derived cells in suspension did not lose cyclin A dependent kinase activity and thus continued to grow and divide.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Med Microbiol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Vanderbilt Univ, Dept Cell Biol, Nashville, TN 37240 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Vanderbilt University	Pledger, W (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA.				NCI NIH HHS [CA73780] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073780] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGRAWAL D, 1995, CELL GROWTH DIFFER, V6, P1199; Agrawal D, 1996, MOL CELL BIOL, V16, P4327; ASSELINEAU D, 1990, DIFFERENTIATION, V45, P221, DOI 10.1111/j.1432-0436.1990.tb00476.x; DROZDOFF V, 1993, J CELL BIOL, V123, P909, DOI 10.1083/jcb.123.4.909; EICHNER R, 1984, J CELL BIOL, V98, P1388, DOI 10.1083/jcb.98.4.1388; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; FUCHS E, 1993, J CELL SCI, P197; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; JIANG HP, 1994, ONCOGENE, V9, P3397; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NELSON WG, 1983, J CELL BIOL, V97, P244, DOI 10.1083/jcb.97.1.244; OLSON JE, 1993, J CELL PHYSIOL, V154, P333, DOI 10.1002/jcp.1041540217; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROTHNAGEL JA, 1994, GENOMICS, V23, P450, DOI 10.1006/geno.1994.1522; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	30	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	1998	17	24					3083	3092		10.1038/sj.onc.1202235	http://dx.doi.org/10.1038/sj.onc.1202235			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872324				2022-12-28	WOS:000077517400002
J	Takita, J; Hayashi, Y; Nakajima, T; Adachi, J; Tanaka, T; Yamaguchi, N; Ogawa, Y; Hanada, R; Yamamoto, K; Yokota, J				Takita, J; Hayashi, Y; Nakajima, T; Adachi, J; Tanaka, T; Yamaguchi, N; Ogawa, Y; Hanada, R; Yamamoto, K; Yokota, J			The p16 (CDKN2A) gene is involved in the growth of neuroblastoma cells and its expression is associated with prognosis of neuroblastoma patients	ONCOGENE			English	Article						p16; neuroblastoma; G1 arrest; methylation; prognosis	N-MYC AMPLIFICATION; DISEASE STAGE; HUMAN GLIOMA; LUNG-CANCER; ARREST; SUPPRESSION; P16(INK4A); MUTATIONS; ARM	We previously reported that loss of heterozygosity (LOH) on chromosome 9p21 correlates with poor prognosis of neuroblastoma and the p16 gene is not expressed in approximately two thirds of neuroblastoma cell lines. Here we demonstrated that p16 expression was induced by 5-aza-2-deoxycytidine treatment in cell lines with 5' CpG island methylation but not in cell lines without methylation. Furthermore, the cell cycle of neuroblastoma cell lines significantly delayed with accumulation of cells in G1 phase by transfection of a wild-type p16 expression vector. These results indicate that p16 is inactivated in part by DNA methylation and its expression is involved in the growth of neuroblastoma cells in vitro, To assess the biological and clinical significance of p16 expression in primary tumors, we undertook immunohistochemical analysis in 74 paraffin sections of neuroblastomas. p16 protein was undetectable in 45 of 74 cases (61%) and lack of p16 expression significantly correlated with poor prognosis of patients and advanced stage of the disease. There was no correlation between loss of p16 expression and N-myc amplification in these tumors. These results indicate that inactivation of the p16 gene is involved in the progression of neuroblastoma independently of N-myc amplification.	Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 104, Japan; Natl Canc Ctr, Res Inst, Canc Informat & Epidemiol Div, Chuo Ku, Tokyo 104, Japan; Univ Tokyo, Fac Med, Dept Pediat, Bunkyo Ku, Tokyo 113, Japan; Gunma Univ, Sch Med, Dept Pathol, Maebashi, Gumma 371, Japan; Natl Kure Hosp, Clin Pediat Res Div, Kure 737, Japan; Saitama Childrens Med Ctr, Div Pathol, Iwatsuki, Saitama 339, Japan; Saitama Childrens Med Ctr, Div Hematol Oncol, Iwatsuki, Saitama 339, Japan	National Cancer Center - Japan; National Cancer Center - Japan; University of Tokyo; Gunma University; Saitama Children's Medical Center; Saitama Children's Medical Center	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1 Tsukiji 5-Chome, Tokyo 104, Japan.							Adachi J, 1997, INT J ONCOL, V10, P33; Arap W, 1997, ONCOGENE, V14, P603, DOI 10.1038/sj.onc.1200870; ARAP W, 1995, CANCER RES, V55, P1351; BELTINGER CP, 1995, CANCER RES, V55, P2053; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1995, PRINCIPLES PRACTICE, P739; Burns KL, 1998, J NEUROPATH EXP NEUR, V57, P122, DOI 10.1097/00005072-199802000-00003; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; Fueyo J, 1996, ONCOGENE, V12, P103; KRATZKE RA, 1995, J NATL CANCER I, V87, P1870, DOI 10.1093/jnci/87.24.1870; MATTHAY KTK, 1995, CA-CANCER J CLIN, V45, P179, DOI 10.3322/canjclin.45.3.179; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NAKAGAWA K, 1995, ONCOGENE, V11, P1843; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; OTTERSON GA, 1995, ONCOGENE, V11, P1211; QUELLE DE, 1995, CELL, V83, P993; REED JA, 1995, CANCER RES, V55, P2731; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; TAKITA J, 1995, ONCOGENE, V11, P1829; Takita J, 1997, CANCER RES, V57, P907; TANAKA T, 1995, CANCER-AM CANCER SOC, V76, P1086, DOI 10.1002/1097-0142(19950915)76:6<1086::AID-CNCR2820760625>3.0.CO;2-8; TONINI GP, 1993, EUR J CANCER, V29A, P802, DOI 10.1016/S0959-8049(05)80412-5; TSUDA T, 1987, CANCER, V60, P820, DOI 10.1002/1097-0142(19870815)60:4<820::AID-CNCR2820600418>3.0.CO;2-Y; Wu Q, 1996, INT J CANCER, V65, P840, DOI 10.1002/(SICI)1097-0215(19960315)65:6<840::AID-IJC22>3.0.CO;2-6	26	32	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 17	1998	17	24					3137	3143		10.1038/sj.onc.1202232	http://dx.doi.org/10.1038/sj.onc.1202232			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872329				2022-12-28	WOS:000077517400007
J	Kominsky, S; Johnson, HM; Bryan, G; Tanabe, T; Hobeika, AC; Subramaniam, PS; Torres, B				Kominsky, S; Johnson, HM; Bryan, G; Tanabe, T; Hobeika, AC; Subramaniam, PS; Torres, B			IFN gamma inhibition of cell growth in glioblastomas correlates with increased levels of the cyclin dependent kinase inhibitor p21(WAF1/CIP1)	ONCOGENE			English	Article						interferon gamma; glioblastoma; cyclin dependent kinase 2; p21(WAF1)/(CIP1)	TUMOR-SUPPRESSOR GENE; P21; P53; EXPRESSION; INDUCTION; MUTATIONS; ARREST	Glioblastoma is a highly aggressive form of brain cancer characterized by uncontrolled cell growth resulting from a loss of cell cycle regulation. In this study we determined the antiproliferative effects of interferon gamma (IFN gamma) on the glioblastoma cell lines T98G, SNB-19 and U-373, focusing on the ability of IFN gamma, to increase levels of p21(WAF1/CIP1), important negative regulator of cell cycle events. IFN gamma, was found to inhibit the growth of all cell lines, with inhibition ranging from 82.2% to 45.%.Flow cytometry analysis showed that IFN gamma treatment caused a cell cycle delay in the G(1) or S phases. The strength of this delay varied, correlating with the degree by which IFNgamma inhibited proliferation of each cell line. IFN gamma, treatment increased the production of the cyclin dependent kinase inhibitor (CKI) p21(WAF1/CIP1) in all cell lines, the level and kinetics of production of which correlated with the degree and stage of inhibition of cellular proliferation. Further, immunoprecipitation of p21(WAF1/CIP1) in complexes of p21(WAF1/CIP1)/cyclin-dependent kinase 2 (cdk2)/cyclin showed that the amount of p21(WAF1/CIP1) in the complexes and the inhibition of cdk2-cyclin kinase activity correlated with the level of p21(WAF1/CIP1) produced in the cells by IFN gamma. These results show that IFN gamma has significant antiproliferative effects on the glioblastoma cell lines and suggest that p21(WAF1/CIF1) plays a role in mediating these effects.	Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Kominsky, S (corresponding author), Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32611 USA.				NATIONAL CANCER INSTITUTE [R01CA038587] Funding Source: NIH RePORTER; NCI NIH HHS [CA38587] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; JIANG HP, 1994, ONCOGENE, V9, P3397; KASTAN MB, 1991, CANCER RES, V51, P6304; KLEIHUES P, 1995, GLIA, V15, P211, DOI 10.1002/glia.440150303; OHGAKI H, 1993, MOL CARCINOGEN, V8, P74, DOI 10.1002/mc.2940080203; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Subramaniam PS, 1997, J INTERF CYTOK RES, V17, P11, DOI 10.1089/jir.1997.17.11; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	13	62	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	1998	17	23					2973	2979		10.1038/sj.onc.1202217	http://dx.doi.org/10.1038/sj.onc.1202217			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881699				2022-12-28	WOS:000077427800004
J	Kogel, D; Plottner, O; Landsberg, G; Christian, S; Scheidtmann, KH				Kogel, D; Plottner, O; Landsberg, G; Christian, S; Scheidtmann, KH			Cloning and characterization of Dlk, a novel serine/threonine kinase that is tightly associated with chromatin and phosphorylates core histones	ONCOGENE			English	Article						serine/threonine kinase; histone phosphorylation; nuclear targeting; GFP-fusion protein; baculovirus system	SUPPRESSOR PROTEIN P53; DNA-REPLICATION; T-ANTIGEN; RETINOBLASTOMA PROTEIN; MAMMALIAN-CELLS; RAT P53; BINDING; FAMILY; DEATH; GENES	We cloned a cDNA coding for a novel serine/threonine kinase, Dlk, a protein of 448 amino acids with a predicted molecular weight of 51.3 kDa, The kinase domain shows 81% amino acid sequence identity to the recently identified DAP kinase (death associated protein kinase) (Deiss et al,, Genes & Dev,, 9, 15-30, 1995), therefore, the new kinase was called Dlk, for DAP like kinase. Northern analyses revealed a single mRNA species of 1.7 kb which was ubiquitously expressed. However, expression levels varied considerably in different cell lines and tissues. Moreover, expression was downregulated upon UV irradiation. Dlk exhibited autophosphorylation activity, predominantly towards threonine residues and phosphorylated the regulatory subunit of myosin light chain, but in this case exclusively at serine residues. Dlk seems to be tightly associated with insoluble nuclear structures, presumably chromatin, since it was resistant to various rigorous extraction procedures but it was partially released upon DNase I digestion of nuclei. Consistent with this, purified Dlk phosphorylated core histones H3, H2A and H4 as exogenous substrates and endogenous histone H3 in kinase assays with nuclear extracts. Expression as GFP-fusion protein revealed a diffuse as well as a speckled nuclear staining suggesting an association with replication or transcription centers.	Univ Bonn, Inst Genet, D-53117 Bonn, Germany	University of Bonn	Scheidtmann, KH (corresponding author), Univ Bonn, Inst Genet, Romerstr 164, D-53117 Bonn, Germany.			Kogel, Donat/0000-0003-1209-0210				BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; GRANA X, 1995, ONCOGENE, V11, P211; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lohrum M, 1996, ONCOGENE, V13, P2527; MARTIN W, 1992, EXP CELL RES, V200, P41, DOI 10.1016/S0014-4827(05)80069-2; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MULLER E, 1995, ONCOGENE, V10, P1175; MULLER E, 1993, ONCOGENE, V8, P2193; PARDOLL DM, 1980, CELL, V19, P527, DOI 10.1016/0092-8674(80)90527-9; PICKSLEY SM, 1994, CURR OPIN CELL BIOL, V6, P853, DOI 10.1016/0955-0674(94)90056-6; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scheidtmann KH, 1996, INT J ONCOL, V9, P1277; SCHIRMBECK R, 1991, J VIROL, V65, P2578, DOI 10.1128/JVI.65.5.2578-2588.1991; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SMIGHT DB, 1988, GENE, V67, P31; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401	37	94	96	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	1998	17	20					2645	2654		10.1038/sj.onc.1202204	http://dx.doi.org/10.1038/sj.onc.1202204			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840928				2022-12-28	WOS:000077058900012
J	Cohen, PA; Mani, JC; Lane, DP				Cohen, PA; Mani, JC; Lane, DP			Characterization of a new intrabody directed against the N-terminal region of human p53	ONCOGENE			English	Article						p53 tumour suppressor; single-chain antibody; transactivation	TUMOR-SUPPRESSOR PROTEIN; SINGLE-CHAIN ANTIBODY; DNA-BINDING ACTIVITY; WILD-TYPE P53; INTRACELLULAR EXPRESSION; TRANSCRIPTIONAL ACTIVATION; IMMUNOCHEMICAL ANALYSIS; PHOSPHORYLATION SITES; FILAMENTOUS PHAGE; KINETIC-ANALYSIS	Genes encoding the rearranged immunoglobulin heavy and light chain variable regions of DO-1, a monoclonal antibody directed against human p53, have been used to construct a single-chain antibody, DO-1 recognizes an N-terminal epitope in the region involved in the transactivation function of p53 and the binding of Mdm2. The DO-1 single chain scFv expressed in the periplasm of E. coli or at the surface of the filamentous phage M13 retained the immunological specificity and affinity of the full length antibody. Furthermore, the DO-1 recombinant antibody was able to inhibit the in vitro binding of Hdm2, and was shown to be a powerful protecting agent of p53's DNA binding activity at 37 degrees C. The DO-1 single-chain antibody has been used to construct single-chain intracellular antibodies (intrabodies) for expression in the cytoplasm and the nucleus of mammalian cells. These anti-p53 intrabodies were additionally modified by addition of a C-kappa domain to increase cytoplasmic and nuclear stability, Here we show that expression of the DO-1 single-chain antibody in the H1299 cell line results in an inhibition of p53's transactivation function, The DO-1 intrabody is a useful tool to study those functions of p53 driven by the N-terminal region of the protein.	Univ Dundee, Inst Med Sci, Dept Biochem, CRC,Cell Transformat Res Grp, Dundee DD1 4HN, Scotland; CNRS, UMR 9921, UFR Pharm, F-34060 Montpellier 01, France	University of Dundee; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Lane, DP (corresponding author), Univ Dundee, Inst Med Sci, Dept Biochem, CRC,Cell Transformat Res Grp, Dundee DD1 4HN, Scotland.		Cohen, Pascale/I-5875-2012; Lane, David P/C-4920-2008	Cohen, Pascale/0000-0001-7016-9598; Lane, David/0000-0003-0551-3545				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BIOCCA S, 1993, BIOCHEM BIOPH RES CO, V197, P422, DOI 10.1006/bbrc.1993.2496; BIOCCA S, 1995, BIO-TECHNOL, V13, P1110, DOI 10.1038/nbt1095-1110; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Bottger V, 1996, ONCOGENE, V13, P2141; BRAITHWAITE AW, 1989, J VIROL, V63, P1792, DOI 10.1128/JVI.63.4.1792-1799.1989; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DUAN LX, 1994, HUM GENE THER, V5, P1315, DOI 10.1089/hum.1994.5.11-1315; EL DW, 1993, CELL, V75, P817; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FISCELLA M, 1993, ONCOGENE, V8, P1519; FREUND C, 1993, FEBS LETT, V320, P97, DOI 10.1016/0014-5793(93)80070-B; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hansen S, 1996, J BIOL CHEM, V271, P3917; Harlow E., 1988, ANTIBODIES LAB MANUA; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hecker D, 1996, ONCOGENE, V12, P953; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAMAL S, 1995, ONCOGENE, V10, P2095; Jannot CB, 1997, BIOCHEM BIOPH RES CO, V230, P242, DOI 10.1006/bbrc.1996.5930; Jannot CB, 1996, ONCOGENE, V13, P275; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEONARDO AD, 1994, GENE DEV, V8, P2540; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIN YS, 1989, NATURE, V340, P656, DOI 10.1038/340656a0; Lohrum M, 1996, ONCOGENE, V13, P2527; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MACIEJEWSKI JP, 1995, NAT MED, V1, P667, DOI 10.1038/nm0795-667; Maki CG, 1996, CANCER RES, V56, P2649; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MARASCO WA, 1995, IMMUNOTECHNOLOGY, V1, P1, DOI 10.1016/1380-2933(95)00001-1; MARSTON NJ, 1994, ONCOGENE, V9, P2707; Mayo LD, 1997, CANCER RES, V57, P5013; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MHASHILKAR AM, 1995, EMBO J, V14, P1542, DOI 10.1002/j.1460-2075.1995.tb07140.x; MILLER SPL, 1992, MOL CELL BIOL, V12, P5041; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schuck P, 1996, TRENDS BIOCHEM SCI, V21, P458, DOI 10.1016/S0968-0004(96)20025-8; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VARHAVSKY A, 1992, CELL, V69, P725; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; Wright M, 1997, GENE THER, V4, P317, DOI 10.1038/sj.gt.3300372; YONEDA Y, 1992, EXP CELL RES, V201, P313, DOI 10.1016/0014-4827(92)90279-H	83	51	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	1998	17	19					2445	2456		10.1038/sj.onc.1202190	http://dx.doi.org/10.1038/sj.onc.1202190			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824155				2022-12-28	WOS:000076927300004
J	Calabro, V; Parisi, T; Di Cristofano, A; La Mantia, G				Calabro, V; Parisi, T; Di Cristofano, A; La Mantia, G			Suppression of Ras-mediated NIH3T3 transformation by p19(ARF) does not involve alterations of cell growth properties	ONCOGENE			English	Article						cellular transformation; tumor suppressor genes; cell cycle regulation; INK4a locus	CYCLE ARREST; IN-VITRO; LOCUS; P16(INK4); P16; MUTATIONS; PROTEIN; CANCER; MDM2; P53	The INK4a gene, one of the most frequently disrupted loci in human cancer, encodes two unrelated proteins, p16(INK4a) and p19(ARF), that both block cell proliferation. p16(INK4a) is a component of the Rb regulatory pathway, while p19(ARF) has been functionally related to p53, Moreover, p16(INK4a) is inactivated in many human tumors, while it has been very recently reported that p19(ARF) null mice develop tumors early in life. We show here that p19(ARF) iS able to inhibit the formation of G418-resistant colonies when transfected into human and mouse cell lines expressing wild-type p53, regardless of p16 status. Moreover its amino terminal domain encoded by exon 1 beta is still sufficient to obtain the same effect. We have analysed the ability of p19(ARF) to interfere with Ras-mediated cellular transformation in the NIH3T3 cell line. Cotransfection of p19(ARF) together with activated ras potently inhibited the formation of transformed foci in a dose-dependent manner. We have also isolated stable NIH3T3 transfectants expressing p19(ARF) and we have measured their growth properties as well as their efficiency of transformation by activated ras, Our results suggest that p19(ARF) can interfere,vith oncogene-mediated transformation, without significantly affecting NIH3T3 cell growth, at least at the levels of expression achieved in these experiments.	Univ Naples Federico II, Dept Genet Gen & Mol Biol, I-80134 Naples, Italy	University of Naples Federico II	La Mantia, G (corresponding author), Univ Naples Federico II, Dept Genet Gen & Mol Biol, Via Mezzocannone 8, I-80134 Naples, Italy.		di cristofano, antonio/AAJ-3796-2020; Calabro, Viola/H-6156-2013; Di Cristofano, Antonio/B-4148-2016	di cristofano, antonio/0000-0003-2537-3228; Calabro, Viola/0000-0002-6508-8889				Arap W, 1997, ONCOGENE, V15, P2013, DOI 10.1038/sj.onc.1201389; CALABRO V, 1996, INT J CANCER, V66, P1; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P435; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Liggett WH, 1996, CANCER RES, V56, P4119; MAO L, 1995, CANCER RES, V55, P2995; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Spillare EA, 1996, MOL CARCINOGEN, V16, P53, DOI 10.1002/(SICI)1098-2744(199605)16:1<53::AID-MC7>3.0.CO;2-P; STONE S, 1995, CANCER RES, V55, P2988; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	20	14	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2157	2162		10.1038/sj.onc.1202532	http://dx.doi.org/10.1038/sj.onc.1202532			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321741				2022-12-28	WOS:000079346200014
J	Catteau, A; Harris, WH; Xu, CF; Solomon, E				Catteau, A; Harris, WH; Xu, CF; Solomon, E			Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics	ONCOGENE			English	Article						breast cancer; ovarian cancer; BRCA1 promoter; methylation	TUMOR-SUPPRESSOR GENE; ESTROGEN-RECEPTOR GENE; DNA METHYLATION; CPG ISLAND; HYPERMETHYLATION; EXPRESSION; CARCINOMAS; RETINOBLASTOMA; MUTATIONS; IDENTIFICATION	Reduced expression of BRCA1 has been reported in sporadic breast cancer, although the mechanisms underlying this phenomenon remain unclear. Abnormal methylation leading to silencing of tumour suppressor genes has been implicated in tumorigenesis in a wide range of sporadic cancers. Therefore, we sought to determine the frequency of methylation within the BRCA1 promoter region in a large group of sporadic invasive breast (n=96) and ovarian (n=43) carcinomas using Southern analyses. Overall, methylation was detected in 11% of breast cancer cases and in 5% of ovarian tumours, Methylation of the BRCA1 promoter region was strongly correlated with lack of estrogen and progesterone receptor expression. It is clear from the frequency of abnormal methylation of the BRCA1 promoter region, that this cannot be the sole mechanism mediating the reduced expression of BRCA1 that has previously been reported to occur in the majority of invasive sporadic breast tumours, Nevertheless this study suggests that abnormal methylation of the BRCA1 promoter may be important in tumorigenesis in a subset of sporadic breast and ovarian cancers.	UMDS, Div Med & Mol Genet, Guys Hosp, London SE1 9RT, England; Guys Hosp, Hedley Atkins ICRF Breast Pathol Lab, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	Catteau, A (corresponding author), UMDS, Div Med & Mol Genet, Guys Hosp, 8th Floor,Guys Tower, London SE1 9RT, England.			Xu, Chun-Fang/0000-0002-8747-0683	Medical Research Council [G9600577] Funding Source: Medline; MRC [G9600577] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Barker DF, 1996, GENOMICS, V38, P215, DOI 10.1006/geno.1996.0618; Barnes DM, 1996, BRIT J CANCER, V74, P1445, DOI 10.1038/bjc.1996.563; BARNES DM, 1995, PROG PATHOL, V2, P89; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Brown MA, 1996, ONCOGENE, V12, P2507; CATTEAU A, 1999, IN PRESS BR J CANC; CLIBY W, 1993, CANCER RES, V53, P2393; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; CROPP CS, 1993, CANCER RES, V53, P5617; Dobrovic A, 1997, CANCER RES, V57, P3347; FERGUSON AT, 1995, CANCER RES, V55, P2279; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GRAFF JR, 1995, CANCER RES, V55, P5195; GREGER V, 1994, HUM GENET, V94, P491; Hakkarainen M, 1996, INT J CANCER, V69, P471, DOI 10.1002/(SICI)1097-0215(19961220)69:6<471::AID-IJC9>3.3.CO;2-A; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; Huang THM, 1997, CANCER RES, V57, P1030; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; READ LD, 1988, MOL ENDOCRINOL, V2, P263, DOI 10.1210/mend-2-3-263; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SAITO H, 1993, CANCER RES, V53, P3382; SAKAI T, 1991, AM J HUM GENET, V48, P880; Smith TM, 1996, GENOME RES, V6, P1029, DOI 10.1101/gr.6.11.1029; Sourvinos G, 1998, BIOCHEM BIOPH RES CO, V245, P75, DOI 10.1006/bbrc.1998.8379; TAKAHASHI H, 1995, CANCER RES, V55, P2998; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405	44	286	301	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	1999	18	11					1957	1965		10.1038/sj.onc.1202509	http://dx.doi.org/10.1038/sj.onc.1202509			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208417				2022-12-28	WOS:000079191300005
J	Walter, AO; Peng, ZY; Cartwright, CA				Walter, AO; Peng, ZY; Cartwright, CA			The Shp-2 tyrosine phosphatase activates the Src tyrosine kinase by a non-enzymatic mechanism	ONCOGENE			English	Article						Src; Shp-2; tyrosine kinase; tyrosine phosphatase	SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; FACTOR RECEPTOR-BETA; PROTEIN-KINASE; SH3 DOMAIN; C-SRC; CELL-TRANSFORMATION; BINDING-SITE; 3T3 CELLS; FAMILY; PHOSPHORYLATION	Previously, we demonstrated that the Src tyrosine kinase interacts with the Shp-2 tyrosine phosphatase. To determine whether Shp-2 regulates Src kinase activity, we measured Src activity in cells overexpressing wild-type or catalytically-inactive C463S Shp-2, We observed a 2-3-fold increase in the specific activity of Src in both cell types and the increase did not appear to be due to dephosphorylation of Tyr 527 or phosphorylation of Tyr 416 on Src. Conversely, we observed a 2-3-fold decrease in the specific activity of Src when Shp-2 expression was inhibited. Using glutathione S-transferase-fusion proteins, we demonstrated that Shp-2 binds to the SH3 domain of Src, Our findings reveal that the Shp-2 tyrosine phosphatase can regulate the Src tyrosine kinase by a non-enzymatic mechanism. We also found that the phosphatase activity of Shp-2 immunoprecipitates is downregulated in cells transformed by Src or other proteins, and that Shp-2, preferentially associates with the membrane fraction of transformed cells. We suggest that membrane-association of Shp-2 is important for regulating Shp-2 activity.	Stanford Univ, Dept Med, Sch Med, Med Sch Lab, Stanford, CA 94305 USA	Stanford University	Cartwright, CA (corresponding author), Stanford Univ, Dept Med, Sch Med, Med Sch Lab, Surge Bldg,P304, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007056, R01DK043743] Funding Source: NIH RePORTER; NIDDK NIH HHS [2R01 DK43743-07, T32 DK07056] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Cossette LJ, 1996, EXP CELL RES, V223, P459, DOI 10.1006/excr.1996.0102; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FANG KS, 1994, J BIOL CHEM, V269, P20194; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOONG AC, 1994, CANCER RES, V54, P5273; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; PARK J, 1995, MOL CELL BIOL, V15, P2374; PENG ZY, 1995, ONCOGENE, V11, P1955; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wong L, 1996, J BIOL CHEM, V271, P20981, DOI 10.1074/jbc.271.35.20981; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	48	66	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	1999	18	11					1911	1920		10.1038/sj.onc.1202513	http://dx.doi.org/10.1038/sj.onc.1202513			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208413				2022-12-28	WOS:000079191300001
J	Sekiguchi, T; Nishimoto, T; Hunter, T				Sekiguchi, T; Nishimoto, T; Hunter, T			Overexpression of D-type cyclins, E2F-1, SV40 large T antigen and HPV16 E7 rescue cell cycle arrest of tsBN462 cells caused by the CCG1/TAF(II)250 mutation	ONCOGENE			English	Article						CCG1/TAF(II)250; ELF-1; SV40; large T antigen; HPV16 E7; cyclin D; TFIID	BASAL TRANSCRIPTION FACTOR; BOX-BINDING PROTEIN; RETINOBLASTOMA PROTEIN; PROMOTER SELECTIVITY; TAF(II)250 SUBUNIT; BHK CELLS; EXPRESSION; GENE; ACTIVATION; TEMPERATURE	tsBN462 cells which have a point mutation in CCG1/TAF(11)250, a component of TFIID complex, arrest in G1 at the nonpermissive temperature of 39.5 degrees C. Overexpression of D-type cyclins rescued the cell cycle arrest of tsBN462 cells, suggesting that the cell cycle arrest was through Rb, Consistent,vith this, overexpression of E2F-1, whose function is repressed by the hypophosphorylated form of Rb, also rescued the cell cycle arrest, Moreover, expression of the viral oncoproteins SV40 large T antigen and HPV16 E7, which both bind Rb and inactivate its function, rescued the cell cycle arrest, whereas HPV16 E6 did not. Mutation of the Rb-binding motif in E7 abrogated its ability to rescue the cell cycle arrest, Expression of exogenous cyclin D1, SV40 large T antigen or CCG1/TAF(11)250 increased cyclin A expression at 39.5 degrees C. Coexpression of HPV16 E7 and adenovirus E1b19K, which blocks apoptosis, rescued the proliferation of tsBN462 cells at 38.5 degrees C. To investigate the mechanism underlying the lack of cyclin D1 expression, deletion analysis of cyclin D1 promoter was performed. The 0.15 kbp cyclin D1 core promoter region, which lacks any transcription factor binding motifs, still exhibited a temperature-sensitive phenotype in tsBN462 cells suggesting that CCG1/TAF(11)250 is critical for the function of the cyclin D1 core promoter.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA; Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 812, Japan	Salk Institute; Kyushu University	Hunter, T (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [CA39780, CA14195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIGA H, 1983, J VIROL, V48, P481, DOI 10.1128/JVI.48.2.481-491.1983; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; Boyer SN, 1996, CANCER RES, V56, P4620; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAYASHIDA T, 1994, GENE, V141, P267; HERBER B, 1994, ONCOGENE, V9, P1295; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOKUBO T, 1993, J BIOL CHEM, V268, P17554; Massimi P, 1996, ONCOGENE, V12, P2325; Massimi P, 1997, J GEN VIROL, V78, P2607, DOI 10.1099/0022-1317-78-10-2607; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NISHIMOTO T, 1982, SOMAT CELL GENET, V8, P811, DOI 10.1007/BF01543021; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; Rushton JJ, 1997, CELL GROWTH DIFFER, V8, P1099; Sekiguchi T, 1998, ONCOGENE, V16, P369, DOI 10.1038/sj.onc.1201539; SEKIGUCHI T, 1987, EXP CELL RES, V169, P395, DOI 10.1016/0014-4827(87)90200-X; SEKIGUCHI T, 1995, EXP CELL RES, V218, P490, DOI 10.1006/excr.1995.1183; Sekiguchi T, 1996, GENES CELLS, V1, P687, DOI 10.1046/j.1365-2443.1996.00259.x; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; Shao ZH, 1997, ONCOGENE, V15, P385, DOI 10.1038/sj.onc.1201204; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; Tooze J., 1980, MOL BIOL TUMOR VIR 2; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014	42	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1797	1806		10.1038/sj.onc.1202508	http://dx.doi.org/10.1038/sj.onc.1202508			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086334				2022-12-28	WOS:000079090000003
J	Desbaillets, I; Diserens, AC; de Tribolet, N; Hamou, MF; Van Meir, EG				Desbaillets, I; Diserens, AC; de Tribolet, N; Hamou, MF; Van Meir, EG			Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma	ONCOGENE			English	Article						interleukin-8; brain tumors; cytokines; hypoxia; anoxia; AP-1	ENDOTHELIAL GROWTH-FACTOR; NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; HUMAN GLIOMA-CELLS; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION; IL-8 GENE; HYPOXIA; ANGIOGENESIS	Oxygen deprivation is an important biological feature of tumor growth. We previously showed that in glioma, anoxia increases expression of IL-8, a chemokine and angiogenic factor. Here, we analysed for the first time the biochemical mechanisms inducing the IL-8 gene upon anoxia in glioma cells, and showed that they differ from those inducing the VEGF gene. Both genes are induced in biologically and genetically heterogenous glioblastoma cell lines (LN-229, LN-Z308, U87MG, T98G), whereas, in gliosarcoma cells (D247MG), only the VEGF gene is induced. The kinetics of IL-8 and VEGF mRNA inductions differ in these cells and reoxygenation experiments showed that the induction is due to the anoxic stress per se. Furthermore, in LN-229 and Z308 cell lines actinomycin D, DRB and nuclear run-on experiments showed that anoxia stimulates increased transcription of both genes. Electromobility shift assays show increased protein binding to the AP-I site on the IL-8 promoter following anoxia treatment. Finally, in situ hybridization on glioblastoma sections shows that the in vivo expression patterns of IL-8 and VEGF genes overlap, but are not identical. Since intratumoral augmentation of IL-8 and VEGF secretion, following microenvironmental decreases in oxygen pressure, may promote angiogenesis, further definition of these pathways is essential to appropriately target them for antitumoral therapy.	CHU Vaudois, Dept Neurosurg, Tumor Biol & Genet Lab, CH-1011 Lausanne, Switzerland; Emory Univ, Dept Neurosurg, Mol Neurooncol Lab, Atlanta, GA 30322 USA; Emory Univ, Winship Canc Ctr, Atlanta, GA 30322 USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Emory University; Emory University	Van Meir, EG (corresponding author), CHU Vaudois, Dept Neurosurg, Tumor Biol & Genet Lab, CH-1011 Lausanne, Switzerland.			Van Meir, Erwin G./0000-0003-2444-7707				Albertoni M, 1998, ONCOGENE, V16, P321, DOI 10.1038/sj.onc.1201544; Arenberg DA, 1996, J CLIN INVEST, V97, P2792, DOI 10.1172/JCI118734; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Colgan SP, 1996, J EXP MED, V184, P1003, DOI 10.1084/jem.184.3.1003; Damert A, 1997, CANCER RES, V57, P3860; DESBAILLETS I, 1994, INT J CANCER, V58, P240, DOI 10.1002/ijc.2910580216; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; DESBAILLETS I, 1997, THESIS U LAUSANNE SW, P189; FOLKMAN J, 1993, CANCER MED, V1, P153; Gassmann M, 1996, P NATL ACAD SCI USA, V93, P2867, DOI 10.1073/pnas.93.7.2867; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GOLDWASSER E, 1957, SCIENCE, V125, P1085, DOI 10.1126/science.125.3257.1085; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; HU DE, 1993, INFLAMMATION, V17, P135, DOI 10.1007/BF00916100; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; KLEIHUES P, 1997, PATHOLOGY GENETICS T, P255; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KUNSCH C, 1994, J IMMUNOL, V153, P153; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; MARIE S, 1993, J BIOL CHEM, V268, P23881; METINKO AP, 1992, J CLIN INVEST, V90, P791, DOI 10.1172/JCI115953; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Muller JN, 1997, J BIOL CHEM, V272, P23435, DOI 10.1074/jbc.272.37.23435; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; Russell DSRLJBDDMREBJM., 1998, RUSSELL RUBINSTEINS; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Sambrook J., 2002, MOL CLONING LAB MANU; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SINGH RK, 1994, CANCER RES, V54, P3242; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; Stevens T, 1995, ENDOTHELIUM-J ENDOTH, V3, P1, DOI [10.3109/10623329509024653, DOI 10.3109/10623329509024653]; STRIETER RM, 1992, IMMUNOL INVEST, V21, P589, DOI 10.3109/08820139209069393; SZEKANECZ Z, 1994, PATHOBIOLOGY, V62, P134, DOI 10.1159/000163891; Tanaka C, 1997, BIOCHEM BIOPH RES CO, V232, P568, DOI 10.1006/bbrc.1997.6264; VAN MEIR E, 1992, CANCER RES, V52, P4297; VAN MEIR EG, 1994, CANCER RES, V54, P649; Wakabayashi Y, 1995, JPN J CANCER RES, V86, P1189, DOI 10.1111/j.1349-7006.1995.tb03314.x; Wang GL, 1996, REDOX REP, V2, P89, DOI 10.1080/13510002.1996.11747034; YAMANAKA R, 1995, J NEURO-ONCOL, V25, P59, DOI 10.1007/BF01054723; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997; Ziesche R, 1996, P NATL ACAD SCI USA, V93, P12478, DOI 10.1073/pnas.93.22.12478	46	92	95	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1447	1456		10.1038/sj.onc.1202424	http://dx.doi.org/10.1038/sj.onc.1202424			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050881				2022-12-28	WOS:000078651600006
J	Giese, H; Dolle, MET; Hezel, A; van Steeg, H; Vijg, J				Giese, H; Dolle, MET; Hezel, A; van Steeg, H; Vijg, J			Accelerated accumulation of somatic mutations in mice deficient in the nucleotide excision repair gene XPA	ONCOGENE			English	Article						nucleotide excision repair; XPA; mutation accumulation; lacZ reporter gene; ageing	ULTRAVIOLET-B; LACKING; TUMORS; LIVER	Inheritable mutations in nucleotide excision repair (NER) genes cause cancer-prone human disorders, such as xeroderma pigmentosum, which are also characterized by symptoms of accelerated ageing. To study the impact of NER deficiency on mutation accumulation iN vivo, mutant frequencies have been determined in liver and brain of 2-16 month old NER deficient XPA(-/-), lacZ hybrid mice. While mutant frequencies in liver of 2-month old XPA(-/-), lacZ mice were comparable to XPA (+/-), lacZ and the lacZ parental strain animals, by 4 months of age mutant frequencies in the XPA-deficient mice were significantly increased by a factor of two and increased further until the age of 16 months. In brain, mutant frequencies were not found to increase with age, These results show that a deficiency in the NER gene XPA causes an accelerated accumulation of somatic mutations in Liver but not in brain. This is in keeping with a higher incidence of spontaneous liver tumors reported earlier for XPA(-/-) mice after about 15 months of age.	Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Harvard Inst Med, Boston, MA 02115 USA; Natl Inst Publ Hlth & Environm, Hlth Effects Res Lab, NL-3720 BA Bilthoven, Netherlands	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Netherlands National Institute for Public Health & the Environment	Vijg, J (corresponding author), Beth Israel Deaconess Med Ctr, 77 Ave Louis Pasteur, Boston, MA 02115 USA.				NATIONAL INSTITUTE ON AGING [P30AG013314] Funding Source: NIH RePORTER; NIA NIH HHS [P01 1801 AG10829-01, 1 P30 AG13314-01] Funding Source: Medline; NIEHS NIH HHS [1 RO1 ES/CA 08797-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bootsma D., 1998, GENETIC BASIS HUMAN, P245; BRONSON RT, 1991, GROWTH DEVELOP AGING, V55, P169; Cleaver JE, 1995, METABOLIC MOL BASES, VIII, P4393; de Vries A, 1997, CARCINOGENESIS, V18, P2327, DOI 10.1093/carcin/18.12.2327; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; deVries A, 1997, MOL CARCINOGEN, V19, P46, DOI 10.1002/(SICI)1098-2744(199705)19:1<46::AID-MC7>3.3.CO;2-O; Dolle MET, 1997, NAT GENET, V17, P431, DOI 10.1038/ng1297-431; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HART RW, 1979, MECH AGEING DEV, V9, P203, DOI 10.1016/0047-6374(79)90100-3; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0; STREHLER BL, 1980, MECH AGEING DEV, V14, P15, DOI 10.1016/0047-6374(80)90103-7; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X	13	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1257	1260		10.1038/sj.onc.1202404	http://dx.doi.org/10.1038/sj.onc.1202404			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022133				2022-12-28	WOS:000078510700016
J	Budde, A; Grummt, I				Budde, A; Grummt, I			p53 represses ribosomal gene transcription	ONCOGENE			English	Article						p53; RNA polymerase I; transcriptional repression; pre-rRNA synthesis	RNA-POLYMERASE-I; WILD-TYPE P53; DNA-BINDING; RETINOBLASTOMA PROTEIN; HUMAN FIBROBLASTS; GROWTH ARREST; PROMOTER; SPACER; IDENTIFICATION; MUTATIONS	Induction of the tumor suppressor protein p53 restricts cellular proliferation. Since actively growing cells require the ongoing synthesis of ribosomal RNA to sustain cellular biosynthesis, we studied the effect of p53 on ribosomal gene transcription by RNA polymerase I (Pol I). We have measured rDNA transcriptional activity in different cell lines which either lack or overexpress p53 and demonstrate that wild-type but not mutant p53 inhibits cellular pre-rRNA synthesis. Conversely, pre-rRNA levels are elevated both in cells which express mutant p53 and in fibroblasts from p53 knock-out mice. Transient transfection assays with a set of rDNA deletion mutants demonstrate that intergenic spacer sequences are dispensable and the minimal rDNA promoter is sufficient for p53-mediated repression of Pol I transcription, However, in a cell-free transcription system, recombinant p53 does not inhibit rDNA transcription, indicating that p53 does not directly interfere with the basal Pol I transcriptional machinery. Thus, repression of Pol I transcription by p53 may be a consequence of p53-induced growth arrest.	Deutsch Krebsforschungszentrum, Div Mol Biol Cell 2, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Grummt, I (corresponding author), Deutsch Krebsforschungszentrum, Div Mol Biol Cell 2, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.							AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GRUMMT I, 1985, CELL, V43, P801, DOI 10.1016/0092-8674(85)90253-3; GRUMMT I, 1985, P NATL ACAD SCI USA, V82, P722, DOI 10.1073/pnas.82.3.722; GRUMMT I, 1998, IN PRESS PROG NUCL A; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HALEVY O, 1991, ONCOGENE, V6, P1593; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; KASS S, 1987, MOL CELL BIOL, V7, P2891, DOI 10.1128/MCB.7.8.2891; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUHN A, 1990, P NATL ACAD SCI USA, V87, P7527, DOI 10.1073/pnas.87.19.7527; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE HB, 1993, PSYCHOANAL QUART, V62, P651; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; MICHELS S, 1990, LAB INVEST, V62, P67; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PAALMAN MH, 1995, MOL CELL BIOL, V15, P4648; PAULE MR, 1994, TRANSCRIPTION MECHAN, P83; PFLEIDERER C, 1990, NUCLEIC ACIDS RES, V18, P4727, DOI 10.1093/nar/18.16.4727; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Staib C, 1996, VIROLOGY, V219, P237, DOI 10.1006/viro.1996.0241; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	41	133	134	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1119	1124		10.1038/sj.onc.1202402	http://dx.doi.org/10.1038/sj.onc.1202402			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023689				2022-12-28	WOS:000078510600030
J	Wunder, JS; Eppert, K; Burrow, SR; Gogkoz, N; Bell, RS; Andrulis, IL				Wunder, JS; Eppert, K; Burrow, SR; Gogkoz, N; Bell, RS; Andrulis, IL			Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas	ONCOGENE			English	Article						gene amplification; CDK4; SAS; osteosarcoma	SOFT-TISSUE SARCOMAS; COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN-MALIGNANT GLIOMAS; METASTASIS SUPPRESSOR GENE; CELL-CYCLE ARREST; RING CHROMOSOMES; RETINOBLASTOMA PROTEIN; QUANTITATIVE-ANALYSIS; MAMMALIAN-CELLS; DNA-SEQUENCES	Amplification of genes in the 12q13-15 region occurs frequently in several malignancies including osteosarcoma. The products of these amplified genes are thought to provide cancer cells with a selective growth advantage; however, the specific gene(s) driving this amplicon is unknown. We have previously shown that the SAS gene is amplified in most parosteal osteosarcomas. In this study we analysed additional putative growth regulatory genes in this chromosomal region in 24 primary osteosarcoma specimens. CDK4 and SAS were coamplified in 6/6 parosteal tumors, and MDM2 was also amplified in 4/5 parosteal cases, In comparison, amplification occurred in only 2/16 classical intramedullary osteosarcomas and involved the SAS gene. Each amplified gene had a correspondingly elevated mRNA level. Four high grade intramedullary tumors had elevated mRNA expression of SAS, but did not exhibit gene amplification, Gene amplification/overexpression was not associated with metastatic disease and did not change markedly with tumor progression, as evidenced by analysis of sequential tumor specimens from eight patients. Three other genes in the 12q13-15 region (CDK2, WNT1 and WNT10b) were not amplified in any of the tumors. The different patterns of gene amplification and overexpression of CDK4, SAS and MDM2 in parosteal and intramedullary osteosarcomas may help explain the disparity in the biological behaviour of these two types of osteosarcoma.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Univ Toronto, Lab Med & Pathobiol, Toronto, ON, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Mt Sinai Hosp, Univ Musculoskeletal Oncol Unit, Toronto, ON M5G 1X5, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	Andrulis, IL (corresponding author), Univ Toronto, Dept Surg, Toronto, ON, Canada.		Andrulis, Irene L./E-7267-2013	Eppert, Kolja/0000-0001-9061-8856				Adachi M, 1996, CANCER RES, V56, P1751; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ARHEDEN K, 1988, CYTOGENET CELL GENET, V47, P86, DOI 10.1159/000132513; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Bui TD, 1997, ONCOGENE, V14, P1249, DOI 10.1038/sj.onc.1200936; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CORDONCARDO C, 1994, CANCER RES, V54, P794; DALCIN P, 1993, CANCER GENET CYTOGEN, V68, P85, DOI 10.1016/0165-4608(93)90001-3; DEMETRICK DJ, 1994, CYTOGENET CELL GENET, V66, P72, DOI 10.1159/000133669; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1996, CANCER RES, V56, P4387; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elkahloun AG, 1996, GENE CHROMOSOME CANC, V17, P205, DOI 10.1002/(SICI)1098-2264(199612)17:4<205::AID-GCC2>3.3.CO;2-#; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fischer U, 1996, HUM GENET, V98, P625, DOI 10.1007/s004390050271; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P8, DOI 10.1002/gcc.2870140103; Guo XZ, 1996, CANCER RES, V56, P4876; JANKOWSKI SA, 1994, ONCOGENE, V9, P1205; KATO J, 1993, GENE DEV, V7, P331; KHATIB ZA, 1993, CANCER RES, V53, P5535; LADANYI M, 1993, CANCER RES, V53, P16; Latham KM, 1996, MOL CELL BIOL, V16, P4445; LEACH FS, 1993, CANCER RES, V53, P2231; Lee PD, 1996, BRIT J CANCER, V74, P1046, DOI 10.1038/bjc.1996.487; LI Y, 1994, ONCOGENE, V9, P2261; Lonardo F, 1997, CANCER, V79, P1541, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1541::AID-CNCR15>3.0.CO;2-Y; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MAELANDSMO GM, 1995, BRIT J CANCER, V72, P393, DOI 10.1038/bjc.1995.344; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MELTZER PS, 1991, CELL GROWTH DIFFER, V2, P495; Miller CW, 1996, J CANCER RES CLIN, V122, P559, DOI 10.1007/BF01213553; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Mousses S, 1996, MODERN PATHOL, V9, P1; NAKAYAMA T, 1995, INT J CANCER, V64, P342, DOI 10.1002/ijc.2910640511; NILBERT M, 1995, CANCER GENET CYTOGEN, V83, P32, DOI 10.1016/S0165-4608(95)00016-X; NobleTopham SE, 1996, J ORTHOPAED RES, V14, P700, DOI 10.1002/jor.1100140504; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; ORNDAL C, 1992, CANCER GENET CYTOGEN, V60, P170, DOI 10.1016/0165-4608(92)90011-V; RAYMOND AK, 1991, CLIN ORTHOP RELAT R, P140; Reifenberger G, 1996, CANCER RES, V56, P5141; REIFENBERGER G, 1994, CANCER RES, V54, P4299; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Sambrook J., 2002, MOL CLONING LAB MANU; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH SH, 1992, CANCER RES, V52, P3746; Souhami RL, 1997, LANCET, V350, P911, DOI 10.1016/S0140-6736(97)02307-6; SU YA, 1994, P NATL ACAD SCI USA, V91, P9121, DOI 10.1073/pnas.91.19.9121; SUIJKERBUIJK RF, 1994, GENE CHROMOSOME CANC, V9, P292, DOI 10.1002/gcc.2870090410; Szymanska J, 1996, GENE CHROMOSOME CANC, V16, P31; Szymanska J, 1996, GENE CHROMOSOME CANC, V15, P89, DOI 10.1002/(SICI)1098-2264(199602)15:2<89::AID-GCC2>3.0.CO;2-#; TARKKANEN M, 1995, CANCER RES, V55, P1334; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; TSAI LH, 1993, ONCOGENE, V8, P1593; UNNI KK, 1976, CANCER, V37, P2466, DOI 10.1002/1097-0142(197605)37:5<2466::AID-CNCR2820370540>3.0.CO;2-G; VANTVEER LJ, 1984, MOL CELL BIOL, V4, P2532, DOI 10.1128/MCB.4.11.2532; Wolf M, 1997, GENE CHROMOSOME CANC, V18, P66, DOI 10.1002/(SICI)1098-2264(199701)18:1<66::AID-GCC8>3.0.CO;2-#; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659	65	122	125	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					783	788		10.1038/sj.onc.1202346	http://dx.doi.org/10.1038/sj.onc.1202346			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989829				2022-12-28	WOS:000078394400024
J	Mary, MN; Venot, C; de Fromentel, CC; Debussche, L; Conseiller, E; Cochet, O; Gruel, N; Teillaud, JL; Schweighoffer, F; Tocque, B; Bracco, L				Mary, MN; Venot, C; de Fromentel, CC; Debussche, L; Conseiller, E; Cochet, O; Gruel, N; Teillaud, JL; Schweighoffer, F; Tocque, B; Bracco, L			A tumor specific single chain antibody dependent gene expression system	ONCOGENE			English	Article						gene expression; gene therapy; scFv; p53	PHAGE DISPLAY LIBRARY; INTRACELLULAR IMMUNIZATION; HIV-1 INFECTION; 2-HYBRID SYSTEM; FV-FRAGMENTS; EGF RECEPTOR; P53; CELLS; PROMOTERS; DOMAIN	The design of conditional gene expression systems restricted to given tissues or cellular types is an important issue of gene therapy. Systems based on the targeting of molecules characteristic of the pathological state of tissues would be of interest. We have developed a synthetic transcription factor by fusing a single chain antibody (scFv) directed against p53 with the bacterial tetracycline repressor as a DNA binding domain. This hybrid protein binds to p53 and can interact with a synthetic promoter containing tetracycline-operator sequences. Gene expression can now be specifically achieved in tumor cells harboring an endogenous mutant p53 but not in a wild-type p53 containing tumor cell line or in a non-transformed cell line, Thus, a functional transactivator centered on single chain antibodies can be expressed intracellularly and induce gene expression in a scFv-mediated specific manner. This novel class of transcriptional transactivators could be referred as 'trabodies' for transcription-activating-antibodies. The trabodies technology could be useful to any cell type in which a disease related protein could be the target of specific antibodies.	Rhone Poulenc Rorer SA, Gene Med Dept, F-94403 Vitry, France; INSERM, U255, Lab Biotechnol Anticorps, F-75005 Paris, France; INSERM, U255, Inst Curie, F-75005 Paris, France	Sanofi-Aventis; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Bracco, L (corresponding author), ExonHit Therapeut SA, 65 Blvd Massena, F-75013 Paris, France.		de Fromentel, Claude Caron/Y-9715-2019	de Fromentel, Claude Caron/0000-0001-7566-3958; Teillaud, Jean-Luc/0000-0003-4442-9565				ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BIOCCA S, 1994, BIO-TECHNOL, V12, P396, DOI 10.1038/nbt0494-396; BYK G, Patent No. 9625508; Chen JD, 1996, HUM GENE THER, V7, P1515, DOI 10.1089/hum.1996.7.13-1515; CHEN X, 1995, NAT STRUCT BIOL, V2, P2; COCHET O, 1998, IN PRESS CANC RES; DaCosta LT, 1996, P NATL ACAD SCI USA, V93, P4192, DOI 10.1073/pnas.93.9.4192; deKruif J, 1996, J BIOL CHEM, V271, P7630, DOI 10.1074/jbc.271.13.7630; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; Hu SZ, 1996, CANCER RES, V56, P3055; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; Jannot CB, 1996, ONCOGENE, V13, P275; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Luo Y, 1997, BIOTECHNIQUES, V22, P350, DOI 10.2144/97222pf02; MHASHILKAR AM, 1995, EMBO J, V14, P1542, DOI 10.1002/j.1460-2075.1995.tb07140.x; MORITZ D, 1995, GENE THER, V2, P539; Nilson BHK, 1996, GENE THER, V3, P280; PACK P, 1992, BIOCHEMISTRY-US, V31, P1579, DOI 10.1021/bi00121a001; Persic L, 1997, GENE, V187, P9, DOI 10.1016/S0378-1119(96)00628-2; Persic L, 1997, GENE, V187, P1, DOI 10.1016/S0378-1119(96)00627-0; Pilkington GR, 1996, MOL IMMUNOL, V33, P439, DOI 10.1016/0161-5890(95)00153-0; REIHSAUS E, 1990, ONCOGENE, V5, P137; RICHARDSON JH, 1995, P NATL ACAD SCI USA, V92, P3137, DOI 10.1073/pnas.92.8.3137; RICHARDSON JH, 1995, TRENDS BIOTECHNOL, V13, P306, DOI 10.1016/S0167-7799(00)88970-2; Schmidt M, 1996, INT J CANCER, V65, P538, DOI 10.1002/(SICI)1097-0215(19960208)65:4<538::AID-IJC24>3.0.CO;2-4; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; WELS W, 1995, INT J CANCER, V60, P137, DOI 10.1002/ijc.2910600120	36	5	7	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					559	564		10.1038/sj.onc.1202377	http://dx.doi.org/10.1038/sj.onc.1202377			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927213				2022-12-28	WOS:000078166500029
J	Zamanian-Daryoush, M; Der, SD; Williams, BRG				Zamanian-Daryoush, M; Der, SD; Williams, BRG			Cell cycle regulation of the double stranded RNA activated protein kinase, PKR	ONCOGENE			English	Article						interferon; PKR; cell cycle	NF-KAPPA-B; SENSITIVE HEMATOPOIETIC-CELLS; C-MYC SUPPRESSION; RETINOBLASTOMA PROTEIN; ALPHA-INTERFERON; MALIGNANT TRANSFORMATION; INTERLEUKIN-6 SUPPRESS; GROWTH SUPPRESSION; INDUCED APOPTOSIS; BINDING PROTEIN	The interferon (IFN)-induced, double stranded RNA (dsRNA)-activated serine/threonine kinase, PKR, is a potent negative regulator of cell growth when overexpressed in yeast or mammalian cells. To determine whether endogenous PKR plays a role in cell growth control, we have investigated the regulation of PKR levels and activity during the cell cycle in human glioblastoma T98G cells. The steady-state level of PKR mRNA in T98G cells was highest in growth arrested cells, dropped sharply within 3h of serum stimulation then gradually increased as cells progressed through G1, reaching a plateau in early S phase. PKR protein level increased following serum stimulation reaching a peak at the G2 + M boundary and declining thereafter, In contrast, PKR kinase activity exhibited two peaks, in early G1 and at the G1/S boundary, declining sharply in early S phase. Thus, the activity profile did not follow the protein profile indicating a tight regulation of PKR at the level of activity. In T98G cells expressing the catalytically inactive PKRK296R the dsRNA-induced activation of NF-kappa B and IRF-1 was suppressed and the mutant cells exhibited resistance to stress induced apoptosis, Cell cycle distribution analysis shared that the mutant expressing cells exhibited longer G1 phase and fewer cells engaged in S phase, Furthermore, early passage mouse embryo fibroblasts derived from PKR knockout mice grew more slowly compared with the control cells. Taken together these results suggest that PKR may play a role in cell cycle progression.	Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Williams, BRG (corresponding author), Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI034039, R01AI034039] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34039] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; BURKE LC, 1992, ONCOGENE, V7, P783; BYBEE A, 1992, BIOCHIM BIOPHYS ACTA, V1137, P73, DOI 10.1016/0167-4889(92)90102-H; Carpick BW, 1997, J BIOL CHEM, V272, P9510, DOI 10.1074/jbc.272.14.9510; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Chu WM, 1998, MOL CELL BIOL, V18, P58, DOI 10.1128/MCB.18.1.58; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; FIECK A, 1992, NUCLEIC ACIDS RES, V20, P1785, DOI 10.1093/nar/20.7.1785; GALABRU J, 1985, CELL, V43, P685, DOI 10.1016/0092-8674(85)90241-7; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNIGAN G, 1986, EMBO J, V5, P1607, DOI 10.1002/j.1460-2075.1986.tb04403.x; HOVANESSIAN AG, 1993, SEMIN VIROL, V4, P237, DOI 10.1006/smvy.1993.1020; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P467, DOI 10.1111/j.1432-1033.1987.tb13360.x; Iwase S, 1997, J BIOL CHEM, V272, P12406, DOI 10.1074/jbc.272.19.12406; IWASE S, 1997, J BIOL CHEM, V272, P12414; JUDWARE R, 1991, MOL CELL BIOL, V11, P3259, DOI 10.1128/MCB.11.6.3259; JUDWARE R, 1992, J BIOL CHEM, V267, P21685; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KERR IM, 1977, NATURE, V268, P540, DOI 10.1038/268540a0; KIMCHI A, 1988, MOL CELL BIOL, V8, P2828, DOI 10.1128/MCB.8.7.2828; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MAYOL X, 1995, ONCOGENE, V11, P801; MCMILLAN NAG, 1996, CELL GROWTH REGULATI; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; Melville MW, 1997, P NATL ACAD SCI USA, V94, P97, DOI 10.1073/pnas.94.1.97; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUNDSCHAU LJ, 1992, J BIOL CHEM, V267, P23092; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; PATEL RC, 1994, J BIOL CHEM, V269, P18593; PETRYSHYN R, 1988, P NATL ACAD SCI USA, V85, P1427, DOI 10.1073/pnas.85.5.1427; Polyak SJ, 1996, J BIOL CHEM, V271, P1702, DOI 10.1074/jbc.271.3.1702; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; SAITO S, 1991, MICROBIOL IMMUNOL, V35, P1105, DOI 10.1111/j.1348-0421.1991.tb01632.x; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; Subramaniam PS, 1997, J INTERF CYTOK RES, V17, P11, DOI 10.1089/jir.1997.17.11; THOMAS NSB, 1991, ONCOGENE, V6, P317; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BRG, 1995, SEMIN VIROL, V6, P191, DOI 10.1006/smvy.1995.0024; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	65	63	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					315	326		10.1038/sj.onc.1202293	http://dx.doi.org/10.1038/sj.onc.1202293			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927188				2022-12-28	WOS:000078166500004
J	Iwata, S; Sato, Y; Asada, M; Takagi, M; Tsujimoto, A; Inaba, T; Yamada, T; Sakamoto, S; Yata, J; Shimogori, T; Igarashi, K; Mizutani, S				Iwata, S; Sato, Y; Asada, M; Takagi, M; Tsujimoto, A; Inaba, T; Yamada, T; Sakamoto, S; Yata, J; Shimogori, T; Igarashi, K; Mizutani, S			Anti-tumor activity of antizyme which targets the ornithine decarboxylase (ODC) required for cell growth and transformation	ONCOGENE			English	Article						polyamine; anti-tumor activity; cancer	TISSUE-CULTURE CELLS; POLYAMINE TRANSPORT; GENE; EXPRESSION; PROTEIN; INHIBITION; APOPTOSIS; HETEROZYGOSITY; DEGRADATION; LEUKEMIAS	Cell proliferation and transformation induced by growth factor stimulation or by carcinogens, viruses, or oncogenes are characterized by an associated increase in polyamine levels, which is mediated by increased polyamine biosynthesis and enhanced uptake of polyamines, Polyamine biosynthesis is catalyzed particularly, in the level of ornithine decarboxylase (ODC), The elevation of cellular polyamine levels on the other hand accelerates the induction of ornithine decarboxylase antizyme (antizyme), which is involved not only in ODC-degradation, but in the negative regulation of polyamine transport. Taking advantage of these characteristics of antizyme, the potential of antizyme as a factor having anti-cell growth and anti-tumor activity was investigated. We show that antizyme can induce cell death associated with a rapid decline of intracellular polyamine contents. The possible anti-tumor activities of ectopically expressed antizyme were tested in p21H-ras (Val 12)-transformed NIH3T3 cells and several human malignant cell lines including a line with loss of p53 expression, and they were shown to be as sensitive as nontransformed NIH3T3 cells in vitro. The in vivo antitumor activity was also tested using nude mice inoculated with H-vas transformed NIH3T3 cells that had been transfected with inducible antizyme expression vector and the results showed that antizyme expression in vivo blocks tumor formation in these mice. These results suggest that ectopic antizyme expression is of possible therapeutic benefit in the treatment of cancer, which is mediated by ODC inactivation and intracellular polyamine depletion.	Natl Childrens Med Res Ctr, Dept Virol, Setagaya Ku, Tokyo 154, Japan; Jichi Med Sch, Dept Mol Biol, Minami Kawachi, Tochigi, Japan; Kyoto Inst Technol, Dept Polymer Sci & Engn, Kyoto 606, Japan; Tokyo Med & Dent Univ, Dept Pediat, Tokyo 113, Japan; Chiba Univ, Fac Pharmaceut Sci, Chiba, Japan	National Center for Child Health & Development - Japan; Jichi Medical University; Kyoto Institute of Technology; Tokyo Medical & Dental University (TMDU); Chiba University	Mizutani, S (corresponding author), Natl Childrens Med Res Ctr, Dept Virol, Setagaya Ku, 3-35-31 Taishido, Tokyo 154, Japan.		Takagi, Masatoshi/F-3713-2011; Shimogori, Tomomi/L-2893-2013	Takagi, Masatoshi/0000-0002-7580-9184; Shimogori, Tomomi/0000-0002-6931-5401; Igarashi, Kazuei/0000-0003-3751-3187				AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BRUNE B, 1991, EXP CELL RES, V195, P323, DOI 10.1016/0014-4827(91)90380-D; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; DAVIS RH, 1992, MICROBIOL REV, V56, P280, DOI 10.1128/MMBR.56.2.280-290.1992; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; EVANS BD, 1982, BRIT J CANCER, V45, P466, DOI 10.1038/bjc.1982.75; FUKUCHI J, 1992, EUR J BIOCHEM, V209, P689, DOI 10.1111/j.1432-1033.1992.tb17337.x; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; HADDOX MK, 1980, CANCER RES, V40, P604; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hayashi S, 1996, TRENDS BIOCHEM SCI, V21, P27, DOI 10.1016/0968-0004(96)80882-6; HE Y, 1994, BIOCHEM BIOPH RES CO, V203, P608, DOI 10.1006/bbrc.1994.2226; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; Ichimiya A., 1994, Surface Review and Letters, V1, P1, DOI 10.1142/S0218625X94000023; IGARASHI K, 1986, J BACTERIOL, V166, P128, DOI 10.1128/jb.166.1.128-134.1986; IMAMURA Y, 1992, BIOCHIM BIOPHYS ACTA, V1132, P177, DOI 10.1016/0167-4781(92)90009-O; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kankare K, 1997, BIOCHEM J, V324, P807, DOI 10.1042/bj3240807; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; LINDBLOM A, 1993, CANCER RES, V53, P4356; MAMROUDKIDRON E, 1994, EUR J BIOCHEM, V226, P547, DOI 10.1111/j.1432-1033.1994.tb20079.x; MANDAHL N, 1989, GENE CHROMOSOME CANC, V1, P9, DOI 10.1002/gcc.2870010104; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; Matsufuji S, 1996, GENOMICS, V38, P102, DOI 10.1006/geno.1996.0601; Matsufuji S, 1996, EMBO J, V15, P1360, DOI 10.1002/j.1460-2075.1996.tb00478.x; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; MIYAZAKI Y, 1992, GENE, V113, P191, DOI 10.1016/0378-1119(92)90395-6; MOSHIER JA, 1993, CANCER RES, V53, P2618; MURAKAMI Y, 1994, BIOCHEM J, V304, P183, DOI 10.1042/bj3040183; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; OCHI H, 1986, CANCER GENET CYTOGEN, V22, P295, DOI 10.1016/0165-4608(86)90022-1; Pabst T, 1996, BLOOD, V88, P1026, DOI 10.1182/blood.V88.3.1026.bloodjournal8831026; Parchment R E, 1991, In Vivo, V5, P493; ROM E, 1994, P NATL ACAD SCI USA, V91, P3959, DOI 10.1073/pnas.91.9.3959; SATO T, 1991, CANCER RES, V51, P5118; SCALABRINO G, 1982, ADV CANCER RES, V36, P1, DOI 10.1016/S0065-230X(08)60422-4; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TEWARI DS, 1994, BBA-PROTEIN STRUCT M, V1209, P293, DOI 10.1016/0167-4838(94)90199-6; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657; Yang D, 1997, J BIOL CHEM, V272, P3376, DOI 10.1074/jbc.272.6.3376	47	72	78	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					165	172		10.1038/sj.onc.1202275	http://dx.doi.org/10.1038/sj.onc.1202275			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926931				2022-12-28	WOS:000078166000018
J	Gartel, AL; Goufman, E; Tevosian, SG; Shih, H; Yee, AS; Tyner, AL				Gartel, AL; Goufman, E; Tevosian, SG; Shih, H; Yee, AS; Tyner, AL			Activation and repression of p21(WAF1/CIP1) transcription by RB binding proteins	ONCOGENE			English	Article						p21; E2F; HBP1; Sp1	CELL-CYCLE ARREST; RETINOBLASTOMA PROTEIN; CHLORAMPHENICOL ACETYLTRANSFERASE; INHIBITOR P21(WAF1/CIP1); GENE-EXPRESSION; WAF1/CIP1 GENE; S-PHASE; INDUCTION; P21; E2F	The Cdk inhibitor p21(WAF1/CIP1) is a negative regulator of the cell cycle, although its expression is induced by a number of mitogens that promote cell proliferation. We have found that E2F1 and E2F3, transcription factors that activate genes required for cell cycle progression, are strong activators of the p21 promoter. In contrast, HBP1 (HMG-box protein-1), a novel retinoblastoma protein-binding protein, can repress the p21 promoter and inhibit induction of p21 expression by E2F, Both E2Fs and HBP1 regulate p21 transcription through cis-acting elements located between nucleotides -119 to + 16 of the p21 promoter and the DNA binding domains of each of these proteins are required for activity. Sequences between -119 and -60 basepairs containing four Spl consensus elements and two noncanonical E2F binding sites are of major importance for E2F activation, although E2F1 and E2F3 differ in the extent of their ability to activate expression when this segment is deleted. The opposing effects of E2Fs and HBP1 on p21 promoter activity suggest that interplay between these factors may determine the level of p21 transcription in vivo.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Tufts University	Tyner, AL (corresponding author), Univ Illinois, Dept Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.		Goufman, Eugene/AAG-6882-2019	Tyner, Angela/0000-0001-7448-8625	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056283, R01DK048836, P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044634] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48836, R01 DK056283-05, R01 DK056283, P30 DK-34928] Funding Source: Medline; NIGMS NIH HHS [GM44634] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; GARTEL AL, 1996, P SOC EXP BIOL MED, V213, P137; GARTEL AL, 1998, IN PRESS PROGR MOL S, V22; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; JIANG HP, 1994, ONCOGENE, V9, P3397; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Khleif SN, 1996, P NATL ACAD SCI USA, V93, P4350, DOI 10.1073/pnas.93.9.4350; Lavender P, 1997, ONCOGENE, V14, P2721, DOI 10.1038/sj.onc.1201243; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Lin SY, 1996, MOL CELL BIOL, V16, P1668; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; MICHIELI P, 1994, CANCER RES, V54, P3391; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MURRAY IA, 1991, NUCLEIC ACIDS RES, V19, P6648; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Shin EK, 1996, J BIOL CHEM, V271, P12261, DOI 10.1074/jbc.271.21.12261; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Spitkovsky D, 1997, CELL GROWTH DIFFER, V8, P699; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	52	63	64	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3463	3469		10.1038/sj.onc.1202240	http://dx.doi.org/10.1038/sj.onc.1202240			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030670				2022-12-28	WOS:000078086200007
J	Kim, JJ; Trivedi, NN; Wilson, DM; Mahalingam, S; Morrison, L; Tsai, A; Chattergoon, MA; Dang, KS; Patel, M; Ahn, L; Boyer, JD; Chalian, AA; Shoemaker, H; Kieber-Emmons, T; Agadjanyan, MA; Weiner, DB				Kim, JJ; Trivedi, NN; Wilson, DM; Mahalingam, S; Morrison, L; Tsai, A; Chattergoon, MA; Dang, KS; Patel, M; Ahn, L; Boyer, JD; Chalian, AA; Shoemaker, H; Kieber-Emmons, T; Agadjanyan, MA; Weiner, DB			Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine	ONCOGENE			English	Article						PSA; epitope mapping; DNA vaccination; immune responses; prostate cancer; immunotherapy	IMMUNODEFICIENCY-VIRUS TYPE-1; T-CELL PROLIFERATION; IMMUNE-RESPONSES; ANTITUMOR IMMUNITY; ACTIVATION ANTIGEN; CANCER STATISTICS; DNA IMMUNIZATION; MESSENGER-RNA; PROTEIN; PROTECTION	Nucleic acid immunization has been investigated as immunotherapy for infectious diseases as well as for treating specific types of cancers. In this approach, nucleic acid expression cassettes are directly inoculated into the host, whose transfected cells become the production source of novel and possibly immunologically foreign protein, We have developed a DNA vaccine construct which encodes for PSA by cloning a cDNA for PSA into a mammalian expression vector under control of a CMV promoter, We investigated and characterized the immunogenicity of PSA DNA expression cassettes in mice, PSA-specific immune responses induced in vivo by immunization were characterized by enzyme-linked immunosorbent assay (ELISA), T helper proliferation cytotoxic T lymphocyte (CTL), and flow cytometry assays, We observed a strong and persistent antibody response against PSA for at least 180 days following immunization. In addition, a significant T helper cell proliferation was observed against PSA protein, Using synthetic peptides spanning the PSA open frame, we identified four dominant T helper epitopes of PSA, Furthermore, immunization with PSA plasmid induced MHC Class I CD8+ T cell-restricted cytotoxic T lymphocyte response against tumor cell targets expressing PSA, The prostate represents a very specific functional organ critical for reproduction but not for the health and survival of the individual. Understanding the immunogenicity of PSA DNA immunization cassettes offers insight into the possible use of this tumor-associated antigen as a target for immunotherapy, These results demonstrate the ability of the genetic PSA to serve as a specific immune target capable of generating both humoral and cellular immune responses in vivo.	Univ Penn, Dept Chem Engn, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA; Centocor Inc, Malvern, PA 19355 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc	Weiner, DB (corresponding author), Univ Penn, Dept Chem Engn, Philadelphia, PA 19104 USA.		Weiner, David B/H-8579-2014	Mahalingam, Sundarasamy/0000-0003-4460-3949				AGADJANYAN MG, 1997, IN PRESS CURR TOP IM; ARMBRUSTER DA, 1993, CLIN CHEM, V39, P181; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; Boyer JD, 1997, NAT MED, V3, P526, DOI 10.1038/nm0597-526; BRIDON DP, 1995, UROLOGY, V45, P801, DOI 10.1016/S0090-4295(99)80087-9; Bright RK, 1996, CANCER RES, V56, P1126; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CONRY RM, 1994, CANCER RES, V54, P1164; COUGHLIN CM, 1995, CANCER RES, V55, P4980; DAVIS HL, 1993, HUM MOL GENET, V2, P1847, DOI 10.1093/hmg/2.11.1847; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; GARRICK MB, 1996, ANN INTERN MED, V125, P118; Geissler M, 1997, J IMMUNOL, V158, P1231; GILLILAND FD, 1995, CANCER, V75, P295, DOI 10.1002/1097-0142(19950101)75:1+<295::AID-CNCR2820751313>3.0.CO;2-U; HODGE JW, 1995, INT J CANCER, V63, P231, DOI 10.1002/ijc.2910630215; Kim JJ, 1997, J IMMUNOL, V158, P816; Kim JJ, 1997, NAT BIOTECHNOL, V15, P641; KIM JJ, 1998, SPRINGER SEMIN IMMUN, V19, P174; LABRIE F, 1993, CLIN INVEST MED, V16, P475; LABRIE F, 1992, J UROLOGY, V151, P1283; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LU S, 1995, VIROLOGY, V209, P147, DOI 10.1006/viro.1995.1238; MACGREGOR RR, 1998, IN PRESS J INF DIS; MAHALINGAM S, 1995, P NATL ACAD SCI USA, V92, P3794, DOI 10.1073/pnas.92.9.3794; Mogensen S C, 1987, Interferon, V8, P55; ODONNELL PD, 1989, J UROLOGY, V142, P1227, DOI 10.1016/S0022-5347(17)39038-9; PIENTA KJ, 1993, ANN INTERN MED, V118, P793, DOI 10.7326/0003-4819-118-10-199305150-00007; PLAUTZ GE, 1993, P NATL ACAD SCI USA, V90, P4645, DOI 10.1073/pnas.90.10.4645; RAY R, 1989, ONCOGENE, V4, P593; SANDA MG, 1994, J UROLOGY, V151, P622, DOI 10.1016/S0022-5347(17)35032-2; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SOBEL ES, 1993, J IMMUNOL, V150, P673; STACK RM, 1994, J IMMUNOL, V152, P5723; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; Tjoa B, 1996, PROSTATE, V28, P65; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; VIEWEG J, 1994, CANCER RES, V54, P1760; VIHINEN M, 1994, BIOCHEM BIOPH RES CO, V204, P1251, DOI 10.1006/bbrc.1994.2597; VILLOUTREIX BO, 1994, PROTEIN SCI, V3, P2033, DOI 10.1002/pro.5560031116; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; WANG B, 1995, HUM GENE THER, V6, P407, DOI 10.1089/hum.1995.6.4-407; WANG MC, 1982, METHOD CANCER RES, V19, P179; WATT KWK, 1986, P NATL ACAD SCI USA, V83, P3166, DOI 10.1073/pnas.83.10.3166; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; ZAGARS GK, 1995, UROLOGY, V45, P476, DOI 10.1016/S0090-4295(99)80019-3	51	66	73	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	1998	17	24					3125	3135		10.1038/sj.onc.1201736	http://dx.doi.org/10.1038/sj.onc.1201736			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872328	Bronze			2022-12-28	WOS:000077517400006
J	Tsutsumi, M; Tsai, YC; Gonzalgo, ML; Nichols, PW; Jones, PA				Tsutsumi, M; Tsai, YC; Gonzalgo, ML; Nichols, PW; Jones, PA			Early acquisition of homozygous deletions of p16/p19 during squamous cell carcinogenesis and genetic mosaicism in bladder cancer	ONCOGENE			English	Article						p16/p19; deletion; DNA methylation; 9p21; bladder cancer; squamous metaplasia	TUMOR-SUPPRESSOR GENE; HIGH-FREQUENCY; URINARY-BLADDER; CPG ISLAND; P15 GENES; IN-SITU; CARCINOMA; CHROMOSOME-9; METHYLATION; INACTIVATION	We looked for p16/p19 deletion and p16 promoter methylation, as well as loss of 9p21 heterozygosity in pure squamous cell carcinomas (SCC), and in transitional cell carcinomas (TCC) of the bladder with SCC components. Homozygous deletion of p16/p10 was detected in 11 of 21 (52%) cases of pure SCCs and in three of ten (30%) cases of TCC with SCC. Three cases of TCC with SCC had p16/p19 deletion, hypermethylation of the p16 promoter, or LOH on 9p21 only in the SCC components, suggesting that these molecular alterations occurred preferentially in SCC. Interestingly, homozygous deletion of p16/p19 was observed in squamous metaplasia from bladder cancer patients (five of 11, 45%), showing that this change occurred in preneoplastic cells. On the other hand, p16/p19 deletions were not found in squamous metaplasias from non cancerous patients. Hypermethylation of the p16 promoter was observed in two of 14 tumors (14%) and none of seven metaplasias examined. These data suggest that: (a) p16/p19 deletion is associated with early carcinogenesis of SCC of the bladder, and squamous metaplasia of the bladder cancer patient has already sustained genetic changes found in cancer, and (b) genetic mosaicism occurs in cases of TCC with SCC, with the SCC component showing more frequent 9p21 alterations than the TCC component.	Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Urol Canc Res Lab, Los Angeles, CA 90033 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Pathol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California	Jones, PA (corresponding author), Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, 1441 Eastlake Ave,Room 815, Los Angeles, CA 90033 USA.				NATIONAL CANCER INSTITUTE [R35CA049758] Funding Source: NIH RePORTER; NCI NIH HHS [5 R35 CA49758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; DURO D, 1995, ONCOGENE, V11, P21; ELMASRI WS, 1981, PARAPLEGIA, V19, P265, DOI 10.1038/sc.1981.52; Fueyo J, 1996, ONCOGENE, V13, P1615; FUJIMOTO K, 1992, CANCER RES, V52, P1393; Ghaleb AH, 1996, AM J CLIN PATHOL, V106, P234; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GONZALEZZULUETA M, 1995, J NATL CANCER I, V87, P1383, DOI 10.1093/jnci/87.18.1383; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529; Herman JG, 1997, CANCER RES, V57, P837; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAUFMAN JM, 1977, J UROLOGY, V118, P967, DOI 10.1016/S0022-5347(17)58266-X; KEEN AJ, 1994, ONCOGENE, V9, P2083; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MESSING EM, 1997, CAMPBELLS UROLOGY, P2343; MIYAO N, 1993, CANCER RES, V53, P4066; Navon JD, 1997, J UROLOGY, V157, P2109, DOI 10.1016/S0022-5347(01)64687-1; Ng MHL, 1997, BLOOD, V89, P2500, DOI 10.1182/blood.V89.7.2500; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; PACKENHAM JP, 1995, MOL CARCINOGEN, V14, P147, DOI 10.1002/mc.2940140303; QUELLE DE, 1995, CELL, V83, P993; Reed AL, 1996, CANCER RES, V56, P3630; ROSIN MP, 1995, CANCER RES, V55, P5213; RUPPERT JM, 1993, CANCER RES, V53, P5093; SAKAMOTO N, 1992, HISTOPATHOLOGY, V21, P135, DOI 10.1111/j.1365-2559.1992.tb00361.x; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Simoneau AR, 1996, CANCER RES, V56, P5039; SINGERSAM J, 1990, NUCLEIC ACIDS RES, V18, P687, DOI 10.1093/nar/18.3.687; SPRUCK CH, 1994, CANCER RES, V54, P784; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; Tamimi Y, 1996, INT J CANCER, V68, P183, DOI 10.1002/(SICI)1097-0215(19961009)68:2<183::AID-IJC7>3.0.CO;2-U; WILLIAMSON MP, 1995, HUM MOL GENET, V4, P1569, DOI 10.1093/hmg/4.9.1569; Wong DJ, 1997, CANCER RES, V57, P2619; YOUNG RH, 1991, HUM PATHOL, V22, P948, DOI 10.1016/0046-8177(91)90003-8	38	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	1998	17	23					3021	3027		10.1038/sj.onc.1202228	http://dx.doi.org/10.1038/sj.onc.1202228			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881704				2022-12-28	WOS:000077427800009
J	Zhou, J; Ng, AYN; Tymms, MJ; Jermiin, LS; Seth, AK; Thomas, RS; Kola, I				Zhou, J; Ng, AYN; Tymms, MJ; Jermiin, LS; Seth, AK; Thomas, RS; Kola, I			A novel transcription factor, ELF5, belongs to the ELF subfamily of ETS genes and maps to human chromosome 11p13-15, a region subject to LOH and rearrangement in human carcinoma cell lines	ONCOGENE			English	Article						transcription factor; epithelial cells; cancer; erbB2; transcription; LOH	MURINE LEUKEMIA-VIRUS; HUMAN PROSTATE-CANCER; HUMAN BREAST-CANCER; DNA-BINDING MOTIF; PROTEIN-KINASE-C; GM-CSF PROMOTER; T-CELLS; ONCOGENIC ACTIVITY; TRANSGENIC MICE; MESSENGER-RNAS	The ETS transcription factors are a large family implicated in the control of cellular proliferation and tumorigenesis. In addition, chromosomal translocations involving ETS family members are associated with a range of different human cancers. Given the extensive involvement of ETS factors in tumorigenesis, it becomes important to identify any additional ETS genes that may also play oncogenic roles. We identify a novel gene, ELF5, that appears to belong to the ELF (E74-like-factor) subfamily of the ETS transcription factor family, based upon similarity within the 'ETS domain'. ELF5 displays a similar, but more restricted, expression pattern to that of the newly isolated epithelium-specific ETS gene, ELF3. Unlike most other ETS family members, ELF5 is not expressed in hematopoietic compartments, but is restricted to organs such as lung, stomach, kidney, prostate, bladder and mammary gland. ELF5 is localized to human chromosome 11p13-15, a region that frequently undergoes loss of heterozygosity (LOH) in several types of carcinoma, including those of breast, kidney and prostate. We find that ELF5 expression is not detectable in a number of carcinoma cell lines, some of which display loss or rearrangement of an ELF5 allele. Similar to other ETS family members, ELF5 displays specific binding to DNA sequences containing a GGAA-core. In addition, ELF5 is able to transactivate through these ETS sequences, present upstream from a minimal promoter. Our data suggest that ELF5 may play roles in mammary, lung, prostate and/or kidney function, and possibly also in tumorigenesis.	Monash Univ, Inst Reprod & Dev, Mol Genet & Dev Grp, Melbourne, Vic 3004, Australia; Natl Vis Res Inst Australia, Melbourne, Vic, Australia; Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia; Univ Toronto, Womens Coll Hosp, Dept Pathol, Toronto, ON, Canada	Monash University; Australian National University; John Curtin School of Medical Research; University of Toronto; University Toronto Affiliates; Womens College Hospital	Kola, I (corresponding author), Monash Univ, Inst Reprod & Dev, Mol Genet & Dev Grp, Melbourne, Vic 3004, Australia.		Thomas, Ross/C-6434-2008; Jermiin, Lars Sommer/AAQ-7033-2020; Jermiin, Lars Sommer/C-2458-2009; Kola, Ismail/C-5254-2013	Jermiin, Lars Sommer/0000-0002-9619-3809; Jermiin, Lars Sommer/0000-0002-9619-3809; 				AKASHI M, 1994, BLOOD, V83, P3182; Baffa R, 1996, CANCER RES, V56, P268; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Buttice G, 1996, ONCOGENE, V13, P2297; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; Coleman WB, 1997, MOL CARCINOGEN, V19, P267, DOI 10.1002/(SICI)1098-2744(199708)19:4<267::AID-MC8>3.0.CO;2-9; COOPER JA, 1984, J BIOL CHEM, V259, P7835; Dahiya R, 1997, INT J CANCER, V72, P283, DOI 10.1002/(SICI)1097-0215(19970717)72:2<283::AID-IJC14>3.0.CO;2-H; DelannoyCourdent A, 1996, INT J DEV BIOL, V40, P1097; Doolittle RF, 1996, SCIENCE, V271, P470, DOI 10.1126/science.271.5248.470; Easteal S, 1997, J MOL EVOL, V44, pS121, DOI 10.1007/PL00000066; Feinberg AP, 1996, MED PEDIATR ONCOL, V27, P484; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; FISHER RJ, 1991, ONCOGENE, V6, P2249; Gambarotta G, 1996, ONCOGENE, V13, P1911; Gao AC, 1997, CANCER RES, V57, P846; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GRAVES BL, 1998, IN PRESS ADV CANC RE; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HART AH, 1995, ONCOGENE, V10, P1423; Hasegawa M., 1996, MOLPHY VERSION 2 3 P; HILLIS DM, 1994, NATURE, V369, P363, DOI 10.1038/369363a0; Hirose M, 1996, MED PEDIATR ONCOL, V27, P174; HUNTER T, 1982, J BIOL CHEM, V257, P4843; Ichikawa T, 1996, PROSTATE, P31; IDA K, 1995, INT J CANCER, V63, P500, DOI 10.1002/ijc.2910630407; IIZUKA M, 1995, GENE CHROMOSOME CANC, V13, P40; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kawana Y, 1997, PROSTATE, V32, P205; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; KRISTENSEN T, 1987, BIOCHEMISTRY-US, V26, P4668, DOI 10.1021/bi00389a012; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; Lee JH, 1996, J BIOL CHEM, V271, P4561; Lichy JH, 1998, AM J PATHOL, V153, P271, DOI 10.1016/S0002-9440(10)65568-X; LITTLEWOOD TD, 1994, PROTEIN PROFILE, V1, P639; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MORI S, 1989, LAB INVEST, V61, P93; Moritz Craig, 1996, P1; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PRESS MF, 1990, ONCOGENE, V5, P953; SAMBROOK J, 1997, MOL CLONING LAB MANU; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SINGLETON TP, 1992, PATHOL ANNU, V27, P165; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; THOMAS RS, 1995, ONCOGENE, V11, P2135; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRIPATHY D, 1994, HEMATOL ONCOL CLIN N, V8, P29, DOI 10.1016/S0889-8588(18)30186-2; Tymms M J, 1995, Methods Mol Biol, V37, P31; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; VANDENBUNDER B, 1994, FOLIA BIOL-PRAGUE, V40, P301; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1990, ONCOGENE, V5, P101; WELTE T, 1994, EUR J BIOCHEM, V223, P997, DOI 10.1111/j.1432-1033.1994.tb19078.x; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WERNERT N, 1992, AM J PATHOL, V140, P119; Wilson AP, 1996, BRIT J CANCER, V74, P722, DOI 10.1038/bjc.1996.428; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; Yang BS, 1996, MOL CELL BIOL, V16, P538; ZENKLUSEN JC, 1995, GENE CHROMOSOME CANC, V13, P47, DOI 10.1002/gcc.2870130108; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179	99	71	81	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	1998	17	21					2719	2732		10.1038/sj.onc.1202198	http://dx.doi.org/10.1038/sj.onc.1202198			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840936				2022-12-28	WOS:000077146700005
J	Schmid, M; Malicki, D; Nobori, T; Rosenbach, MD; Campbell, K; Carson, DA; Carrera, CJ				Schmid, M; Malicki, D; Nobori, T; Rosenbach, MD; Campbell, K; Carson, DA; Carrera, CJ			Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16(INK4A) (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC)	ONCOGENE			English	Article						non-small cell lung cancer; MTAP; p16(INK4A); cell-cycle regulation; chromosome 9p21	ACUTE LYMPHOBLASTIC-LEUKEMIA; KINASE-4 INHIBITOR GENE; IN-SITU HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; ALPHA-INTERFERON; CHROMOSOME 9P; P16/MTS1 GENE; HUMAN GLIOMAS; NECK-CANCER; P18 GENES	Homozygous deletions of the tumor suppressor gene p16(INK4A) and deficiency of methylthioadenosine phosphorylase (MTAP), both located on chromosome 9p21, have been independently reported in non-small cell lung cancer (NSCLC). To determine the frequency of co-deletion of these two genes, we investigated 50 samples of primary NSCLC using a quantitative PCR-ELISA. All specimens were fixed in formalin, paraffin embedded and stored until assayed. Histologic subtypes included 25 adenocarcinomas (50%), 21 squamous cell carcinomas (42%) and four large cell carcinomas (8%). Homozygous deletions of MTAP exon 8 could be detected in 19 of 50 NSCLC samples (38%). Adenocarcinoma (11 of 25, 44%) showed a higher deletion frequency than squamous cell carcinoma (six of 21, 29%). In contrast, homozygous p16(INK4A) deletions were detected in only nine of 50 (18%) samples using specific primers for p16(INK4A) exon 1 alpha. No difference between the histological subtypes and p16(INK4A) deletion frequency was observed. We further investigated the ten samples with MTAP deletions but intact p16(INK4A) exon 1 alpha with primers specific for p16(INK4A) exon 3, the exon nearest to MTAP exon 8. Interestingly, none of the ten samples had deletion of the p16(INK4A) exon 3 coding region. Fine mapping analysis performed in ten samples showed a frequent breakpoint between MTAP exon 4 and exon 5. In addition, p16 protein expression could not be detected in five out of six samples with intact p16 but deleted MTAP locus. These data show a high frequency of homozygous MTAP deletions in NSCLC which is associated with detectable co-deletion of p16(INK4A) only half of the cases. This result suggests the existence either of another tumor suppressor gene telomeric of p16(INK4A) or of deletions involving 3'-untranslated (3'-UTR) regulatory regions of p16(INK4A) that can interfere with its expression or function.	Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Carrera, CJ (corresponding author), Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NCI NIH HHS [R21 CA 68260, U01 CA 64926] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA068260] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barker FG, 1997, J NEURO-ONCOL, V31, P17, DOI 10.1023/A:1005768910871; Batova A, 1997, CANCER RES, V57, P832; Batova A, 1996, BLOOD, V88, P3083, DOI 10.1182/blood.V88.8.3083.bloodjournal8883083; BELLO MJ, 1990, INT J CANCER, V45, P50, DOI 10.1002/ijc.2910450111; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Carrera C. J., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P407; Carrera C J, 1986, Adv Exp Med Biol, V195 Pt B, P643; Cayuela JM, 1996, BLOOD, V87, P2180, DOI 10.1182/blood.V87.6.2180.bloodjournal8762180; Chen ZH, 1996, CANCER RES, V56, P1083; Costello JF, 1996, CANCER RES, V56, P2405; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; DREYLING MH, 1995, CANCER RES, V55, P984; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; Herman JG, 1997, CANCER RES, V57, P837; HORI H, 1996, CANCER RES, V56, P5633; Jagasia AA, 1996, CANCER LETT, V105, P77, DOI 10.1016/0304-3835(96)04273-5; KAMATANI N, 1981, BIOCHIM BIOPHYS ACTA, V675, P344, DOI 10.1016/0304-4165(81)90024-6; KAMATANI N, 1982, BLOOD, V60, P1387; KAMB A, 1994, SCIENCE, V264, P440; Kim SK, 1997, CANCER RES, V57, P400; Kratzke RA, 1996, CANCER RES, V56, P3415; KUBOTA M, 1983, J BIOL CHEM, V258, P7288; Li XS, 1996, CANCER RES, V56, P5055; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; Marchetti A, 1997, J PATHOL, V181, P178, DOI 10.1002/(SICI)1096-9896(199702)181:2<178::AID-PATH741>3.0.CO;2-5; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MERLO A, 1994, CANCER RES, V54, P2322; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1991, CANCER RES, V51, P3193; Nobori T, 1996, P NATL ACAD SCI USA, V93, P6203, DOI 10.1073/pnas.93.12.6203; NOBORI T, 1993, CANCER RES, V53, P1098; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; OHNISHI H, 1995, BLOOD, V86, P1269, DOI 10.1182/blood.V86.4.1269.bloodjournal8641269; OKAMOTO A, 1995, CANCER RES, V55, P1448; OLOPADE OI, 1995, P NATL ACAD SCI USA, V92, P6489, DOI 10.1073/pnas.92.14.6489; PEGG AE, 1969, BIOCHEM J, V115, P241, DOI 10.1042/bj1150241; Perry A, 1997, J NEUROPATH EXP NEUR, V56, P999, DOI 10.1097/00005072-199709000-00005; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rao LS, 1997, DIAGN MOL PATHOL, V6, P115, DOI 10.1097/00019606-199704000-00008; Reed AL, 1996, CANCER RES, V56, P3630; REED JA, 1995, CANCER RES, V55, P2713; Rishi AK, 1997, CANCER RES, V57, P5129; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHIMIZU T, 1995, INT J CANCER, V63, P616, DOI 10.1002/ijc.2910630503; Singh AD, 1996, OPHTHALMIC GENET, V17, P39, DOI 10.3109/13816819609057868; STADLER WM, 1994, CANCER RES, V54, P2060; STANDART N, 1994, BIOCHIMIE, V76, P867, DOI 10.1016/0300-9084(94)90189-9; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755; Tran PT, 1997, GENE, V186, P263, DOI 10.1016/S0378-1119(96)00718-4; TRAWEEK ST, 1988, BLOOD, V71, P1568; Ueki K, 1996, CANCER RES, V56, P150; VANDERRIET P, 1994, CANCER RES, V54, P1156; Waber P, 1997, ONCOGENE, V15, P1699, DOI 10.1038/sj.onc.1201336; WALKER DG, 1995, CANCER RES, V55, P20; Wiest JS, 1997, CANCER RES, V57, P1; Woloschak M, 1996, CANCER RES, V56, P2493; YOSHIDA S, 1995, CANCER RES, V55, P2756; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	63	80	83	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2669	2675		10.1038/sj.onc.1202205	http://dx.doi.org/10.1038/sj.onc.1202205			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840931				2022-12-28	WOS:000077058900015
J	Braun, K; Holzl, G; Soucek, T; Geisen, C; Moroy, T; Hengstschlager, M				Braun, K; Holzl, G; Soucek, T; Geisen, C; Moroy, T; Hengstschlager, M			Investigation of the cell cycle regulation of cdk3-associated kinase activity and the role of cdk3 in proliferation and transformation	ONCOGENE			English	Article						Cdk3; cell cycle; p27; c-Myc; E2F	DEPENDENT KINASES; THYMIDINE KINASE; C-MYC; PROTEIN-KINASES; RETINOBLASTOMA PROTEIN; GENE; COMPLEXES; FAMILY; E2F; TRANSACTIVATION	The G1-S transition in mammalian cells has been demonstrated to require the cyclin-dependent kinases cdk2, cdk3 and cdk4/6. Here we show that a novel kinase activity associated with cdk3 fluctuates throughout the cell cycle differently from the expression of cyclin D1-, E- and A-associated kinase activities. Cdk3 kinase activity is neither affected by p16 (in contrast to cdk4/6) nor by E2F-1 (in contrast to cdk2), but is downregulated upon transient p27 expression. We found cdk3 to bind to p21 and p27, We provide evidence that p27 could be involved in the regulation of the cell cycle fluctuation of cdk3 activity: cdk3 protein does not fluctuate and interaction of cdk3 with p27, but not with p21, is lost when cdk3 kinase becomes active during the cell cycle. In Myc-overexpressing cells, but not in normal Rat1 cells, constitutive ectopic expression of cdk3 induces specific upregulation of cdk3-associated kinase activity that is still cell cycle phase dependent. Ectopic cdk3, but not cdk2, enhances Myc-induced proliferation and anchorage-independent growth associated with Myc activation, without effects on cyclin D1, E- and A protein expression or kinase activities. High levels of cdk3 in Myc-overexpressing cells trigger up- and deregulation of E2F-dependent transcription without inducing the E2F-DNA binding capacity. In contrast to all other studied positive G1 regulators, cdk3 is unable to cooperate with ras in fibroblast transformation suggesting a function of cdk3 in G1 progression that is different from cyclin Dor E-associated kinase activities. Our data provide first insights into the regulation of cdk3-associated kinase activity and suggest a model how cdk3 participates in the regulation of the G1-S transition.	Univ Vienna, Dept Prenatal Diagnosis & Therapy, A-1090 Vienna, Austria; Univ Klinikum Esses, IFZ, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany	University of Vienna	Hengstschlager, M (corresponding author), Univ Vienna, Dept Prenatal Diagnosis & Therapy, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Moroy, Tarik/D-9923-2011					BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; BULLRICH F, 1995, CANCER RES, V55, P1199; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DOU QP, 1994, J BIOL CHEM, V269, P1306; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hengstschlager M, 1996, DNA CELL BIOL, V15, P41, DOI 10.1089/dna.1996.15.41; Hengstschlager M, 1996, ONCOGENE, V12, P1635; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; NEVINS JR, 1992, SCIENCE, V258, P424; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Pusch O, 1997, DNA CELL BIOL, V16, P737, DOI 10.1089/dna.1997.16.737; Pusch O, 1997, ONCOGENE, V15, P649, DOI 10.1038/sj.onc.1201236; Sherbet G.V., 1997, GENETICS CANC; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; Soucek T, 1997, ONCOGENE, V14, P2251, DOI 10.1038/sj.onc.1201061; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VLACH J, 1996, EMBO J, V15, P6596; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	38	28	30	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2259	2269		10.1038/sj.onc.1202145	http://dx.doi.org/10.1038/sj.onc.1202145			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811456				2022-12-28	WOS:000076698200011
J	Mashima, T; Naito, M; Tsuruo, T				Mashima, T; Naito, M; Tsuruo, T			Caspase-mediated cleavage of cytoskeletal actin plays a positive role in the process of morphological apoptosis	ONCOGENE			English	Article						caspase; actin; etoposide; morphology; apoptosis	INTERLEUKIN 1-BETA-CONVERTING ENZYME; AGENT-INDUCED APOPTOSIS; ICE-LIKE PROTEASES; INTERLEUKIN-1-BETA-CONVERTING ENZYME; CELL-DEATH; CYTOCHROME-C; PHOSPHATIDYLSERINE EXTERNALIZATION; DNA FRAGMENTATION; ACTIVATION; GELSOLIN	Tumors result from the imbalance between cell growth and apoptosis. One of the characteristic changes in cancers is the abnormality in cytoskeleton, which suggests some roles of cytoskeletal proteins in tumorigenesis or the maintenance of tumor cells. Previously we showed that cytoskeletal actin is the substrate of caspases, the proteases responsible for apoptosis, while the role of actin cleavage in apoptosis remained unknown. To examine the cleavage of actin in vivo, we extensively performed immunoblot analysis using actin fragment-specific antibody. Here, we showed that, in some solid tumor cells, induction of apoptosis was accompanied by caspase-dependent actin-cleavage to 15 and 31 kDa fragments in vivo. To elucidate the role of actin-cleavage further, we introduced actin cleaved-fragments. We found that ectopic expression of an actin 15 kDa fragment induces morphological changes resembling those of apoptotic cells, The expression of the actin fragment induced a dramatic change of cellular actin localization, as visualized by enhanced green fluorescent protein (EGFP)-tagged actin, while the actin fragment expression did not cause caspase activation nor the cleavage of a marker substrate protein, poly (ADP-ribose) polymerase. These results indicate that actin cleavage could play a positive role in the morphological changes of apoptosis downstream of caspase activation.	Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, Tokyo 113, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 170, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 113, Japan.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Asch HL, 1996, CANCER RES, V56, P4841; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; CHAPONNIER C, 1989, AM J PATHOL, V134, P597; Chen ZH, 1996, CANCER RES, V56, P5224; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; COTTER TG, 1992, CANCER RES, V52, P997; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Naito M, 1997, BLOOD, V89, P2060, DOI 10.1182/blood.V89.6.2060; NEAMATI N, 1995, J IMMUNOL, V154, P3788; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Shiratsuchi A, 1997, J BIOL CHEM, V272, P2354, DOI 10.1074/jbc.272.4.2354; TANAKA M, 1995, CANCER RES, V55, P3228; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VANDEKERCKHOVE J, 1980, CELL, V22, P893, DOI 10.1016/0092-8674(80)90566-8; Westphal M, 1997, CURR BIOL, V7, P176, DOI 10.1016/S0960-9822(97)70088-5; Wong WW, 1998, AGENT ACTION SUPPL, V49, P5; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	46	164	171	1	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2423	2430		10.1038/sj.onc.1202558	http://dx.doi.org/10.1038/sj.onc.1202558			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229193				2022-12-28	WOS:000079703300002
J	Sciacca, L; Costantino, A; Pandini, G; Mineo, R; Frasca, F; Scalia, P; Sbraccia, P; Goldfine, ID; Vigneri, R; Belfiore, A				Sciacca, L; Costantino, A; Pandini, G; Mineo, R; Frasca, F; Scalia, P; Sbraccia, P; Goldfine, ID; Vigneri, R; Belfiore, A			Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism	ONCOGENE			English	Article						insulin receptor; IGF-I receptor; IGF-I; IGF-II; breast cancer	HAMSTER OVARY CELLS; GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; TRANSFORMED PHENOTYPE; OVEREXPRESSION; EXPRESSION; INHIBITION; BINDING; CDNA	IGF-II, produced by breast cancer epithelial and stromal cells, enhances tumor growth by activating the IGF-I receptor (IGF-I-R) via autocrine and paracrine mechanisms. Previously we found that the insulin receptor (IR), which is related to the IGF-I-R, is overexpressed in breast cancer cells. Herein, we find that, in breast cancer the IR is activated by IGF-II, In eight human breast cancer cell lines studied there,vas high affinity ICF-II binding to the IR, with subsequent IR activation, In these lints, IGF-II had a potency up to 63% that of insulin. In contrast, in non malignant human breast cells, IGF-II was less than 1% potent as insulin. Via activation of the IR tyrosine kinase IGF-II stimulated breast cancer cell growth. However, IGF-II also activated the IR in breast cancer tissue specimens; IGF-II was 10-100% as potent as insulin. The IR occurs in two isoforms generated by alternative splicing of exon 11; these isoforms are IR-A (Ex11-) and IR-B (Ex11+). IR-A was predominantly expressed in breast cancer cells and specimens and the potency of IGF-II was correlated to the expression of this isoform (P<0.0001). These data indicate, therefore, that the IR-A, which binds IGF-II with high affinity, is predominantly expressed in breast cancer cells and represents a new autocrine/paracrine loop involved in tumor biology.	Univ Catania, Osped Garibaldi, Ist Med Interna Malattie Endocrine & Metab, I-95123 Catania, Italy; Univ La Sapienza, Policlin Umberto I, Cattedra Endocrinol 1, I-00161 Rome, Italy; Univ Calif San Francisco, Div Diabet & Endocrine Res, San Francisco, CA 94115 USA	University of Catania; Sapienza University Rome; University Hospital Sapienza Rome; University of California System; University of California San Francisco	Belfiore, A (corresponding author), Univ Catania, Osped Garibaldi, Ist Med Interna Malattie Endocrine & Metab, I-95123 Catania, Italy.		Pandini, Giuseppe/AAB-9650-2019; SCIACCA, Laura/AAS-2896-2020; Scalia, Pierluigi/AAH-8443-2019; Belfiore, Antonino/B-4652-2011; Sciacca, Laura/B-9368-2014; Frasca, Francesco/J-1332-2018; Vigneri, Riccardo/M-3968-2017	Pandini, Giuseppe/0000-0003-3747-7649; SCIACCA, Laura/0000-0002-3258-7200; Scalia, Pierluigi/0000-0002-5911-1640; Belfiore, Antonino/0000-0002-6181-4193; Sciacca, Laura/0000-0002-3258-7200; Frasca, Francesco/0000-0002-5556-3201; Vigneri, Riccardo/0000-0002-4401-3140				ARTEAGA CL, 1989, CANCER RES, V49, P6237; Belfiore A, 1996, MOL ENDOCRINOL, V10, P1318, DOI 10.1210/me.10.11.1318; CARMICHAEL J, 1987, CANCER RES, V47, P943; CULLEN K, 1997, ASSIST TECHN RES SER, V2, P1; CULLEN KJ, 1992, MOL ENDOCRINOL, V6, P91, DOI 10.1210/me.6.1.91; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ENJOH T, 1993, J CLIN ENDOCR METAB, V77, P510, DOI 10.1210/jc.77.2.510; FORSAYETH JR, 1987, J BIOL CHEM, V262, P4134; FRASCA F, 1999, IN PRESS MOL CELL BI, V19; FRITTITTA L, 1995, J CELL BIOCHEM, V57, P666, DOI 10.1002/jcb.240570411; GANDERTON RH, 1992, BIOCHEM J, V288, P195, DOI 10.1042/bj2880195; GIORGINO F, 1991, MOL ENDOCRINOL, V5, P452, DOI 10.1210/mend-5-3-452; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; JONAS HA, 1990, ENDOCRINOLOGY, V127, P1301, DOI 10.1210/endo-127-3-1301; JONAS HA, 1989, BIOCHEM J, V257, P101, DOI 10.1042/bj2570101; JONAS HA, 1992, BIOCHEM J, V266, P737; KULL FC, 1983, J BIOL CHEM, V258, P6561; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; Mathieu MC, 1997, P ASSOC AM PHYSICIAN, V109, P565; MILAZZO G, 1992, CANCER RES, V52, P3924; MILAZZO G, 1992, J CLIN INVEST, V89, P899, DOI 10.1172/JCI115670; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; OSBORNE CK, 1989, MOL ENDOCRINOL, V3, P1701, DOI 10.1210/mend-3-11-1701; PAPA V, 1990, J CLIN INVEST, V86, P1503, DOI 10.1172/JCI114868; Papa V, 1996, J ENDOCRINOL INVEST, V19, P324, DOI 10.1007/BF03347871; PODSKALNY JM, 1986, J BIOL CHEM, V261, P14076; SOOS MA, 1992, J BIOL CHEM, V267, P12955; Steller MA, 1996, CANCER RES, V56, P1761; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; YAMAGUCHI Y, 1991, ENDOCRINOLOGY, V129, P2058, DOI 10.1210/endo-129-4-2058	31	215	224	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2471	2479		10.1038/sj.onc.1202600	http://dx.doi.org/10.1038/sj.onc.1202600			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229198				2022-12-28	WOS:000079703300007
J	Jinno, S; Hung, SC; Okayama, H				Jinno, S; Hung, SC; Okayama, H			Cell cycle start from quiescence controlled by tyrosine phosphorylation of Cdk4	ONCOGENE			English	Article						Cdk4; G(0)-G(1) transition; quiescence; tyrosine phosphorylation; UV	DEPENDENT KINASES; PROTEIN-KINASE; G1 ARREST; TGF-BETA; ACTIVATION; INHIBITION; CDC25A; GROWTH; SITES; PHASE	In mammals Cdk4 (or Cdk6 in some cell types) is required for starting the cell cycle. Recently we showed that Cdk4 is regulated by tyrosine phosphorylation and dephosphorylation, and that this regulation is required for a DNA damage-induced G(1) arrest. We report here that a generic anti-phosphotyrosine antibody can detect tyrosine-phosphorylated Cdk4 and that as revealed by immunoblot detection and kinase assay, this regulation is employed for DIVA damage-responsive checkpoint control during cell cycle start from quiescence. In rat fibroblasts traversing G(1) or arrested in G(1) by deprivation of anchorage, Cdk4 does not undergo tyrosine phosphorylation, Tyrosine phosphorylation occurs only during cell's arrest in quiescence and dephosphorylation during their cell cycle start. Ultraviolet irradiation blocks dephosphorylation and concomitant activation of Cdk4, thereby preventing the start of cell cycling, Thus, unlike tyrosine phosphorylation of Cdc2, which controls phase transition in the regular cell cycle, tyrosine phosphorylation of Cdk4 is employed for controlling cell cycle start from quiescence in a rat fibroblast.	Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Grad Sch Med, Dept Orthoped Surg, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo; University of Tokyo	Okayama, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 113, Japan.							BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V5, P2981; HAN A, 1978, RADIAT RES, V74, P88, DOI 10.2307/3574759; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Iavarone A, 1997, NATURE, V387, P417; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Jung E G, 1986, Curr Probl Dermatol, V15, P117; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUME K, 1992, NEW BIOL, V4, P504; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MILLER JB, 1992, CELL, V63, P407; NAGATA A, 1991, NEW BIOL, V3, P959; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Okada S., 1970, RAD BIOCH, VI; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SEFTON BM, 1995, CURRENT PROTOCOL PRO; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; THOMPSON LH, 1970, RADIAT RES, V41, P183, DOI 10.2307/3572905; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	31	41	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					565	571		10.1038/sj.onc.1202347	http://dx.doi.org/10.1038/sj.onc.1202347			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989806				2022-12-28	WOS:000078394400001
J	Donzelli, M; Bernardi, R; Negri, C; Prosperi, E; Padovan, L; Lavialle, C; Brison, O; Scovassi, AI				Donzelli, M; Bernardi, R; Negri, C; Prosperi, E; Padovan, L; Lavialle, C; Brison, O; Scovassi, AI			Apoptosis-prone phenotype of human colon carcinoma cells with a high level amplification of the c-myc gene	ONCOGENE			English	Article						apoptosis; human colon carcinoma cells; serum starvation; c-myc; amplification; PARP proteolysis	WILD-TYPE P53; RADIATION-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR GENES; POLY(ADP-RIBOSE) POLYMERASE; MEDIATED APOPTOSIS; EPITHELIAL-CELLS; CYCLE ARREST; HELA-CELLS; IN-VIVO; DEATH	Although apoptosis can be induced by the enforced expression of exogenously introduced c-myc genes, it is not clear whether overexpression resulting from the amplification of the resident c-myc gene in tumor cells is sufficient to induce apoptosis, We have investigated the relationship between c-myc gene amplification and the propensity of tumor cells to undergo apoptosis, using the SW613-12A1 and SW613-B3 cell lines, which are representatives, respectively, of tumorigenic and nontumorigenic clones isolated from the SW613-S human colon carcinoma cell line. Tumorigenic clones are characterized by a high level of amplification and expression of the c-myc gene, whereas cells of nontumorigenic clones have a small number of copies and a lower level of expression of this gene. Analysis of c-myc mRNA level in cells cultured under low serum conditions indicated that the expression of the gene is tightly regulated by serum growth factors in non-tumorigenic B3 cells, whereas it is poorly regulated in tumorigenic 12A1 cells, the level of mRNAs remaining relatively high in serum-started 12A1 cells, Under these conditions, 12A1 cells showed clear evidence of apoptosis, whereas B3 cells were completely refractory to the induction of apoptosis, Moreover, the study of cell lines derived from nontumorigenic apoptosis-resistant clones following the introduction by transfection of exogenous c-myc gene copies showed that they have acquired an apapoptosis-prone phenotype. Altogether, our results strongly suggest that deregulated c-myc expression due to high-level amplification confers an apoptosis-prone phenotype to tumor cells. The possible consequences of these observations for cancer therapy are discussed.	CNR, Ist Genet Biochim & Evoluzionist, I-27100 Pavia, Italy; CNR, Ctr Studio Istochim, I-27100 Pavia, Italy; Univ Pavia, Dipartimento Genet, I-27100 Pavia, Italy; Inst Gustave Roussy, CNRS UMR 1599, Lab Genet Oncol, Villejuif, France	Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); University of Pavia; UNICANCER; Gustave Roussy	Scovassi, AI (corresponding author), CNR, Ist Genet Biochim & Evoluzionist, Via Abbiategrasso 207, I-27100 Pavia, Italy.		bernardi, rosa/B-1650-2013; Scovassi, Anna Ivana/F-2458-2010; Donzelli, Maddalena/ABD-3774-2020; Prosperi, Ennio/A-3439-2014; Lavialle, Christian/O-2329-2019	bernardi, rosa/0000-0002-3607-6336; Scovassi, Anna Ivana/0000-0003-3484-9881; Prosperi, Ennio/0000-0001-5391-5157; DONZELLI, MADDALENA/0000-0002-4045-0802				Alarcon RM, 1996, CANCER RES, V56, P4315; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; ASKEW DS, 1991, ONCOGENE, V6, P1915; Augenlicht LH, 1997, CANCER RES, V57, P1769; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BISHOP JM, 1995, GENE DEV, V9, P1309, DOI 10.1101/gad.9.11.1309; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BRACEY TS, 1995, ONCOGENE, V10, P2391; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; Dong JA, 1997, ONCOGENE, V15, P639, DOI 10.1038/sj.onc.1201237; El-Deiry Wafik S., 1997, Current Opinion in Oncology, V9, P79; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GALDEMARD C, 1995, ONCOGENE, V10, P2331; Guano F, 1994, Cell Death Differ, V1, P101; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hague A, 1997, BRIT J CANCER, V75, P960, DOI 10.1038/bjc.1997.167; Han JW, 1997, CANCER RES, V57, P176; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HAUPT Y, 1995, ONCOGENE, V10, P1563; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOFFMAN B, 1994, ONCOGENE, V9, P1807; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; LAMONERIE T, 1995, INT J CANCER, V61, P587, DOI 10.1002/ijc.2910610425; LAVIALLE C, 1988, ONCOGENE, V3, P335; LAVIALLE C, 1990, ONCOGENE, V5, P245; LAVIALLE C, 1989, ANTICANCER RES, V9, P1265; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARX J, 1993, SCIENCE, V259, P760, DOI 10.1126/science.8430327; MODJTAHEDI N, 1992, INT J CANCER, V52, P483, DOI 10.1002/ijc.2910520325; MODJTAHEDI N, 1985, CANCER RES, V45, P4372; Negri C, 1995, BIOCHIMIE, V77, P893, DOI 10.1016/0300-9084(95)90009-8; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PELLEGATA NS, 1994, CANCER RES, V54, P1556; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; RENAULT B, 1993, CANCER RES, V53, P2614; Rupnow BA, 1998, CELL DEATH DIFFER, V5, P141, DOI 10.1038/sj.cdd.4400328; Sakamuro D, 1995, ONCOGENE, V11, P2411; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SPENCER CA, 1991, ADV CANCER RES, V56, P1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	62	44	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					439	448		10.1038/sj.onc.1202309	http://dx.doi.org/10.1038/sj.onc.1202309			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927200				2022-12-28	WOS:000078166500016
J	Iyengar, TD; Ng, SW; Lau, CC; Welch, WR; Bell, DA; Berkowitz, RS; Mok, SC				Iyengar, TD; Ng, SW; Lau, CC; Welch, WR; Bell, DA; Berkowitz, RS; Mok, SC			Differential expression of NF1 type I and type II isoforms in sporadic borderline and invasive epithelial ovarian tumors	ONCOGENE			English	Article						ovary; cancer; NF1; retinoic acid	GTPASE-ACTIVATING PROTEIN; RETINOIC ACID; CELL-LINES; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; ALKALINE-PHOSPHATASE; GENE TRANSCRIPTS; CANCER; GROWTH; RAS; GAP	The NF1 gene, a putative tumor suppresser gene, contains a GAP related domain (GRD) which accelerates hydrolysis of ras-bound GTP to GDP, thereby converting the ras oncogene from its active to inactive form, Two forms of the NF1 GRD transcript (Type I and Type II) are differentially expressed in neuroectodermal tumor tissue relative to differentiated neural cells, and in gastric cancer cell lines relative to normal stomach mucosa, We measured relative expression of NF1 Type II and Type I isoforms in cultured normal and malignant human ovarian surface epithelial cells(HOSE) and in invasive and borderline ovarian tumor tissue. We demonstrated an Ii-fold increase in Type II: Type I ratio in 7 HOSE cultures relative to eight ovarian cancer cell lines, Our findings indicate a significant decrease in Type II isoform expression and increase in Type I expression in ovarian cancer cells and tumor tissue relative to HOSE cells. We also demonstrate an increase in Type II: Type I ratio, and a decrease in cell proliferation rate in three ovarian cancer cell lines on treatment with retinoic acid. We propose that differential expression of the NF1 Type I and Type II isoforms is related to cellular differentiation in ovarian epithelial cancer and strategies based on alteration in NF1 isoform expression may have therapeutic potential in ovarian malignancies.	Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Texas Childrens Hosp, Div Hematol Oncol, Houston, TX 77030 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Pennsylvania; Baylor College of Medicine	Mok, SC (corresponding author), Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, 75 Francis St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA069453, R01CA063381, R29CA070216] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA63381, R29CA70216, R01CA69453] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALALAWI N, 1993, MOL CELL BIOL, V13, P2497, DOI 10.1128/MCB.13.4.2497; ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; Auersperg N, 1998, SEMIN ONCOL, V25, P281; AZUMA M, 1988, CANCER RES, V48, P7219; BARKER D, 1987, SCIENCE, V236, P1100, DOI 10.1126/science.3107130; BROOKS SE, 1991, GYNECOL ONCOL, V42, P265, DOI 10.1016/0090-8258(91)90356-A; CALIARO MJ, 1994, INT J CANCER, V56, P743, DOI 10.1002/ijc.2910560522; CLIBY W, 1993, CANCER RES, V53, P2393; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; GOLDGAR DE, 1987, AM J HUM GENET, V44, P6; GUTMANN DH, 1993, J NEUROSCI RES, V36, P216, DOI 10.1002/jnr.490360212; HARANT H, 1993, BRIT J CANCER, V68, P530, DOI 10.1038/bjc.1993.381; International Federation of Gynecology and Obstetrics, 1987, AM J OBSTET GYNECOL, V156, P263; IYENGAR TD, 1996, GYNECOL ONCOL, V60, P114; Jing YK, 1997, CANCER RES, V57, P1668; LANGDON SP, 1988, CANCER RES, V48, P6161; Lu KH, 1997, CANCER RES, V57, P387; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P643; MAZARS R, 1991, ONCOGENE, V6, P1685; MCCORMICK F, 1988, COLD SPRING HARB SYM, V53, P849, DOI 10.1101/SQB.1988.053.01.097; NAKAFUKU M, 1993, P NATL ACAD SCI USA, V90, P6706, DOI 10.1073/pnas.90.14.6706; NISHI T, 1991, ONCOGENE, V6, P1555; Phillips NJ, 1996, CANCER RES, V56, P606; REESE DH, 1983, CANCER RES, V43, P5443; RICCARDI VM, 1981, ADV NEUROLOGY, V29; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; SATO T, 1991, CANCER RES, V51, P5118; SEIZINGER BR, 1987, CELL, V49, P589, DOI 10.1016/0092-8674(87)90534-4; SIDELL N, 1988, CANCER RES, V48, P2226; SKUSE GR, 1995, LANCET, V345, P902, DOI 10.1016/S0140-6736(95)90015-2; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; Tangir J, 1996, CANCER RES, V56, P2501; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; UCHIDA T, 1992, BIOCHEM BIOPH RES CO, V187, P332, DOI 10.1016/S0006-291X(05)81497-4; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; Wertheim I, 1996, ONCOGENE, V12, P2147; WERTHEIM I, 1994, J NATL CANCER I, V86, P1549, DOI 10.1093/jnci/86.20.1549; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	40	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					257	262		10.1038/sj.onc.1202294	http://dx.doi.org/10.1038/sj.onc.1202294			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926941				2022-12-28	WOS:000078166000028
J	Abujiang, P; Mori, TJ; Takahashi, T; Tanaka, F; Kasyu, I; Hitomi, S; Hiai, H				Abujiang, P; Mori, TJ; Takahashi, T; Tanaka, F; Kasyu, I; Hitomi, S; Hiai, H			Loss of heterozygosity (LOH) at 17q and 14q in human lung cancers	ONCOGENE			English	Article						pulmonary adenoma; lung cancer; LOH; tumor suppressor gene	EPITHELIAL OVARIAN-TUMORS; HUMAN PROSTATE-CANCER; CHROMOSOME 17Q; BREAST CARCINOMAS; SOMATIC MUTATIONS; SUPPRESSOR LOCI; BRCA1; GENE; ALLELOTYPE	Our recent linkage study of urethane-induced pulmonary adenomas in SMXA RI strains of mouse revealed two host resistance genes, Par1 (chromosome 11) and Par3 (chromosome 12). The map positions of Par1 and Par3 correspond to human 17q11-23 and 14q11-24, based on synteny between mouse and human. In this study, we examined the loss of heterozygosity (LOH) in these two homologous human chromosomal regions in 30 primary lung adenocarcinoma samples with matched normal DNA. Using 15 highly polymorphic markers, two commonly deleted regions were identified on human chromosomes 14 and 17, respectively. At 17q21, nine (53%) of 17 informative tumors showed LOH between D17S588 and D17S518. On the other hand, at 14q11-12, seven (32%) of 22 informative tumors showed LOH at loci between D14S261 and D14S80. Subsequently, we examined 25 squamous cell carcinomas (SQ) and 24 small cell carcinomas (SCC). At 14q11-12, six (38%) of 16 informative SQ and five (42%) of 12 informative SCC showed LOH. In contrast, at 17q11-23, one (7%) of 15 informative SQ and two (14%) of 14 SCC showed LOH. Therefore, the gene on 17q seemed to affect selectively adenocarcinomas, whereas the other gene on 14q, all three types of lung carcinomas. These observations indicate that a comparative genetic analysis provides a promising approach to survey genes involved in multifactorial process of human lung carcinogenesis.	Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068051, Japan; Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, Nagoya, Aichi 464, Japan; Kyoto Univ, Chest Dis Res Inst, Dept Thorac Surg, Sakyo Ku, Kyoto 606, Japan	Kyoto University; Aichi Cancer Center; Kyoto University	Hiai, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068051, Japan.		Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001				ABUJIANG P, 1997, CANCER RES, V57, P2904; ABUJIANG P, 1996, CANCER RES, V56, P3716; Canzian F, 1996, CANCER RES, V56, P3331; CARBONE DP, 1992, ADV INTERNAL MED, V37, P153; CHANG WYH, 1995, CANCER RES, V55, P3246; CLIBY W, 1993, CANCER RES, V53, P2393; CLIBY W, 1993, GYNECOL ONCOL, V50, P34, DOI 10.1006/gyno.1993.1160; CROPP CS, 1993, CANCER RES, V53, P5617; Dragani TA, 1995, ADV CANCER RES, V67, P83, DOI 10.1016/S0065-230X(08)60711-3; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; FONG KM, 1995, CANCER RES, V55, P4268; GAO X, 1995, CANCER RES, V55, P1002; GAO X, 1995, ONCOGENE, V11, P1241; Jandrig B, 1996, INT J CANCER, V68, P188, DOI 10.1002/(SICI)1097-0215(19961009)68:2<188::AID-IJC8>3.0.CO;2-U; MALKINSON AM, 1992, CANCER RES, V52, pS2670; Manenti G, 1997, CANCER RES, V57, P4164; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; Niederacher D, 1997, GENE CHROMOSOME CANC, V18, P181, DOI 10.1002/(SICI)1098-2264(199703)18:3<181::AID-GCC5>3.0.CO;2-Y; SATO T, 1993, GENOMICS, V17, P762, DOI 10.1006/geno.1993.1402; TAKAYAMA H, 1992, ONCOGENE, V7, P1185; THRASHBINGHAM CA, 1995, P NATL ACAD SCI USA, V92, P2854, DOI 10.1073/pnas.92.7.2854; TSUCHIYA E, 1992, CANCER RES, V52, P2478; Wertheim I, 1996, ONCOGENE, V12, P2147; ZHANG J, 1995, CHINESE MED J, V75, P211	24	47	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	1998	17	23					3029	3033		10.1038/sj.onc.1202230	http://dx.doi.org/10.1038/sj.onc.1202230			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881705				2022-12-28	WOS:000077427800010
J	Shivji, MKK; Ferrari, E; Ball, K; Hubscher, U; Wood, RD				Shivji, MKK; Ferrari, E; Ball, K; Hubscher, U; Wood, RD			Resistance of human nucleotide excision repair synthesis in vitro to p21(Cdn1)	ONCOGENE			English	Article						PCNA; DNA polymerase; nucleotide excision repair; cip1/waf1/sdi1	CELL NUCLEAR ANTIGEN; DEPENDENT KINASE INHIBITOR; DNA-POLYMERASE-EPSILON; SINGLE-STRANDED-DNA; CALF THYMUS; SACCHAROMYCES-CEREVISIAE; REPLICATION COMPLEX; PURIFIED PROTEINS; DELTA HOLOENZYME; BINDING DOMAINS	The p21(Cdn1) protein (cipl/waf1/sdi1) plays an important role as an inhibitor of mammalian cell proliferation in response to DNA damage. By interacting with and inhibiting the function of cyclin-Cdk complexes, p21 can block entry into S phase. p21 can also directly inhibit replicative DNA synthesis by binding to the DNA polymerase sliding clamp factor PCNA. When cells are damaged and p21 is induced, DNA nucleotide excision repair (NER) continues, even though this pathway is PCNA-dependent. We investigated features of p21-resistant NER using human cell extracts. A direct end-labelling approach was used to measure the excision of damaged oligonucleotides by NER and no inhibition by p21 was found. By contrast, filling of the similar to 30 nt gaps created by NER could be inhibited by pre-binding p21 to PCNA, but only when gap filling was uncoupled from incision. Binding p21 to PCNA could also inhibit filling of model similar to 30 nt gaps by both purified DNA polymerases delta and epsilon. When p21 was incubated in a cell extract before addition of PCNA, inhibition of repair synthesis was gradually relieved with time. This incubation gives p21 the opportunity to associate with other targets. As p21 blocks association of DNA polymerases with PCNA but does not prevent loading of PCNA onto DNA, repair gap filling can occur rapidly as soon as p21 dissociates from PCNA. A synthetic PCNA-binding p21 peptide was an efficient inhibitor of NER synthesis in cell extracts.	Imperial Canc Res Fund, Clare Hall Labs, Potters Bar EN6 3LD, Herts, England; Univ Zurich Irchel, Dept Vet Biochem, CH-8057 Zurich, Switzerland; Univ Dundee, Dept Biochem, CRC Labs, Dundee DD1 4HN, Scotland	University of Zurich; University of Dundee	Wood, RD (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, Potters Bar EN6 3LD, Herts, England.		Wood, Richard D/M-6319-2018	Wood, Richard D/0000-0002-9495-6892				Adams PD, 1996, MOL CELL BIOL, V16, P6623; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; BIGGERSTAFF M, 1998, IN PRESS DNA REPAIR; Budd ME, 1997, MUTAT RES-DNA REPAIR, V384, P157, DOI 10.1016/S0921-8777(97)00024-4; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gibbs E, 1997, J BIOL CHEM, V272, P2373; GOUBIN F, 1995, ONCOGENE, V10, P2281; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HARPER JW, 1993, CELL, V75, P805; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Hess MT, 1997, MOL CELL BIOL, V17, P7069, DOI 10.1128/MCB.17.12.7069; Hindges R, 1997, BIOL CHEM, V378, P345; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LEE SH, 1991, J BIOL CHEM, V266, P22707; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MAGA G, 1995, BIOCHEMISTRY-US, V34, P891, DOI 10.1021/bi00003a023; McDonald E, 1996, CANCER RES, V56, P2250; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P5003, DOI 10.1021/bi00015a011; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; Savio M, 1996, ONCOGENE, V13, P1591; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; SHIVJI MKK, 1998, IN PRESS DNA REPAIR; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WEISER T, 1991, J BIOL CHEM, V266, P10420; Wood RD, 1997, CARCINOGENESIS, V18, P605, DOI 10.1093/carcin/18.4.605; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Wood Richard D., 1995, Methods (Orlando), V7, P163, DOI 10.1006/meth.1995.1022; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x	56	65	66	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 3	1998	17	22					2827	2838		10.1038/sj.onc.1202352	http://dx.doi.org/10.1038/sj.onc.1202352			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879989				2022-12-28	WOS:000077286400003
J	Wu, SJ; Zhang, DM; Zhang, ZP; Soprano, DR; Soprano, KJ				Wu, SJ; Zhang, DM; Zhang, ZP; Soprano, DR; Soprano, KJ			Critical role of both retinoid nuclear receptors and retinoid-X-receptors in mediating growth inhibition of ovarian cancer cells by all-trans retinoic acid	ONCOGENE			English	Article						retinoids; RAR; RXR; ovarian carcinoma; LacSwitch	BREAST-CARCINOMA CELLS; ADENOCARCINOMA CELLS; CYCLE PROGRESSION; MESSENGER-RNA; SENSITIVE METHOD; THYROID-HORMONE; PROTEIN COMPLEX; LINES; PROLIFERATION; EXPRESSION	Retinoids have been shown to inhibit the growth of a number of human tumor cells, including several ovarian adenocarcinoma cell lines. All-trams retinoic acid (RA) is an effective growth suppressor of CA-OV3 cells but not SK-OV3 cells. Since the effects of RA are known to be mediated via the nuclear receptors (RARs and RXRs), we initially compared levels of the various RARs and RXRs in the CA-OV3 and SK-OV3 cell lines. The RA resistant SK-OV3 cells expressed reduced levels of RAR-alpha and RXR-alpha. Furthermore, induction of RAR-alpha by RA was impaired in the RA resistant SK-OV3 cells as was RARE binding and RARE-dependent transcriptional activity. These results suggested that changes in the amounts and/or activity of RARs and/or RXR-alpha could determine the growth response of ovarian tumor cells to RA. This was confirmed by modulating the levels of RARs and RXR-alpha in the SK-OV3 cells using the LacSwitch(TM) inducible expression system. Stably transfected clones of RA resistant SK-OV3 cells exhibited a significant inhibition of growth by RA treatment when RAR-alpha was induced. Overexpression of both RAR-alpha and RXR-alpha resulted in a level of growth inhibition nearly equal to that exhibited by the RA sensitive CA-OV3 cell line. Similar results were obtained when a combination of RXR-alpha and either RAR-beta or RAR-gamma was overexpressed in SK-OV3 cells. Our results show that the nuclear receptors and RXR-alpha play a critical role in mediating growth suppression by RA in ovarian cancer cells.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Soprano, KJ (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.				NCI NIH HHS [CA 64945] Funding Source: Medline; NICHD NIH HHS [HD 27556] Funding Source: Medline; NIDDK NIH HHS [DK 49045] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027556, R55HD027556] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA064945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049045] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERG K, 1990, APMIS, V98, P156, DOI 10.1111/j.1699-0463.1990.tb01016.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALIARO MJ, 1994, INT J CANCER, V56, P743, DOI 10.1002/ijc.2910560522; CARMICHAEL J, 1987, CANCER RES, V47, P936; CARTER R, 1991, ONCOGENE, V6, P229; COSENZA SC, 1988, J BIOL CHEM, V263, P12751; DAWSON MI, 1995, CANCER RES, V55, P4446; DE LUCA LM, 1991, FASEB J, V5, P2924; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FONTANA JA, 1988, EXP CELL BIOL, V56, P254; FONTANA JA, 1990, CANCER RES, V50, P1997; FONTANA JA, 1987, EXP CELL BIOL, V55, P136; FORMELLI F, 1993, CANCER RES, V53, P5374; GRUNT TW, 1991, J CELL SCI, V100, P657; GRUNT TW, 1992, J CELL SCI, V103, P501; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; Gudas Lorraine J., 1994, P443; HARANT H, 1993, BRIT J CANCER, V68, P530, DOI 10.1038/bjc.1993.381; HARNISH DC, 1992, DEV DYNAM, V194, P239, DOI 10.1002/aja.1001940309; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; Hoskins WJ, 1995, J CELL BIOCHEM, P189; KOGA M, 1991, J STEROID BIOCHEM, V39, P455, DOI 10.1016/0960-0760(91)90238-Z; LACROIX A, 1980, J CLIN INVEST, V65, P586, DOI 10.1172/JCI109703; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LOHNES D, 1992, J CELL SCI, P69; LOTAN R, 1990, METHOD ENZYMOL, V190, P100; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LOTAN R, 1979, CANCER RES, V39, P1014; Mangelsdorf David J., 1994, P319; MARTH C, 1985, J NATL CANCER I, V75, P871, DOI 10.1093/jnci/75.5.871; MARTH C, 1993, J STEROID BIOCHEM, V47, P123, DOI 10.1016/0960-0760(93)90065-5; MCGUIRE WP, 1995, J CLIN ONCOL, V13, P1589, DOI 10.1200/JCO.1995.13.7.1589; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; OWEN TA, 1987, J BIOL CHEM, V262, P15111; OWEN TA, 1989, J CELL PHYSIOL, V139, P424, DOI 10.1002/jcp.1041390227; OZOLS RF, 1995, SEMIN ONCOL, V22, P61; PELLEGRINI R, 1995, CELL GROWTH DIFFER, V6, P863; PENA A, 1993, J BIOL CHEM, V268, P27277; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; ROMAN SD, 1992, CANCER RES, V52, P2236; ROMAN SD, 1993, CANCER RES, V53, P5940; ROWINSKY EK, 1991, J CLIN ONCOL, V9, P1692, DOI 10.1200/JCO.1991.9.9.1692; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHAO ZM, 1995, ONCOGENE, V11, P493; SHAO ZM, 1994, INT J ONCOL, V4, P859; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; Soprano DR, 1996, ONCOGENE, V12, P577; SOPRANO DR, 1994, MECH DEVELOP, V45, P243, DOI 10.1016/0925-4773(94)90011-6; SOPRANO KJ, 1987, MOL CELL BIOCHEM, V75, P61, DOI 10.1007/BF00231609; SPORN MB, 1991, MOL ENDOCRINOL, V5, P3, DOI 10.1210/mend-5-1-3; THOMAS P, 1980, P NATL ACAD SCI USA, V77, P54205; TOSCANI A, 1987, ANAL BIOCHEM, V165, P309, DOI 10.1016/0003-2697(87)90274-0; UEDA H, 1980, CANCER-AM CANCER SOC, V46, P2203, DOI 10.1002/1097-0142(19801115)46:10<2203::AID-CNCR2820461017>3.0.CO;2-A; VANDERBURG B, 1995, MOL CELL ENDOCRINOL, V112, P143, DOI 10.1016/0303-7207(95)03600-C; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; WETHERALL NT, 1986, EUR J CANCER CLIN ON, V22, P53, DOI 10.1016/0277-5379(86)90342-1; Wilcken NRC, 1996, CELL GROWTH DIFFER, V7, P65; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; WU S, 1998, IN PRESS J CELL BIOC; Wu SJ, 1996, ONCOGENE, V12, P621; Wu SJ, 1997, EXP CELL RES, V237, P118, DOI 10.1006/excr.1997.3769; Wu SJ, 1997, EXP CELL RES, V232, P277, DOI 10.1006/excr.1997.3495; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZHAO ZR, 1995, EXP CELL RES, V219, P555, DOI 10.1006/excr.1995.1264	70	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	1998	17	22					2839	2849		10.1038/sj.onc.1202208	http://dx.doi.org/10.1038/sj.onc.1202208			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879990				2022-12-28	WOS:000077286400004
J	Fuchs, SY; Adler, V; Buschmann, T; Wu, XW; Ronai, Z				Fuchs, SY; Adler, V; Buschmann, T; Wu, XW; Ronai, Z			Mdm2 association with p53 targets its ubiquitination	ONCOGENE			English	Article						p53; ubiquitination; Mdm2; stability	HUMAN PAPILLOMAVIRUS TYPE-16; TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; E6 ONCOPROTEIN; IN-VIVO; KINASE; PHOSPHORYLATION; DEGRADATION; CELLS; STABILITY	Key to p53 ability to mediate its multiple cellular functions lies in its stability, In the present study we have elucidated the mechanism by which Mdm2 regulates p53 degradation. Using in vitro and in vivo ubiquitination assays we demonstrate that Mdm2 association with p53 targets p53 ubiquitination, Exposure of cells to UV-irradiation inhibits this targeting. Mdm2 which is deficient in p53 binding failed to target p53 ubiquitination, suggesting that the association is essential for Mdm2 targeting ability. While mdm2-p53 complex is found in non-stressed cells, the amount of p53-bound mdm2 is decreased after UV-irradiation, further pointing to the relationship between mdm2 binding and p53 level. Similar to Swiss 3T3 cells, the dissociation of mdm2-p53 complex was also found in UV-treated Scid cells, lacking functional DNA-PK, suggesting that DNA-PK is not sufficient for dissociating mdm2 from p53, Together our studies point to the role of Mdm2, as one of p53-associated proteins, in targeting p53 ubiquitination.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1 Gustave Levy Pl Box 1130, New York, NY 10029 USA.			RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA59908] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059908] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BROWN JP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CORDONCARDO C, 1994, CANCER RES, V54, P794; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; FUCHS SY, 1998, UNPUB; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Rathmell WK, 1997, CANCER RES, V57, P68; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SICILIANO JD, 1997, GENE DEV, V11, P3471; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	42	202	207	1	13	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2543	2547		10.1038/sj.onc.1202200	http://dx.doi.org/10.1038/sj.onc.1202200			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824166				2022-12-28	WOS:000076927300015
J	Rao, S; Lowe, M; Herliczek, TW; Keyomarsi, K				Rao, S; Lowe, M; Herliczek, TW; Keyomarsi, K			Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53	ONCOGENE			English	Article						lovastatin; cell cycle; cyclins; CKIs; CDKs; adaptor molecule	DEPENDENT KINASE INHIBITOR; MAMMARY EPITHELIAL-CELLS; GROWTH-FACTOR-BETA; CYCLE ARREST; RETINOBLASTOMA PROTEIN; CANCER CELLS; POTENTIAL MEDIATOR; MEVALONATE PATHWAY; RESTRICTION POINT; ACTIVATING KINASE	Previously, we reported that lovastatin, a potent inhibitor of the enzyme HMG CoA reductase also acts as an antimitogenic agent by arresting cells in the G1 phase of the cell cycle resulting in cell cycle-independent alteration of cyclin dependent kinase inhibitors (CKIs), In the present study we have investigated the nature of the CKIs (p21 and p27) alterations resulting in G1 arrest in both normal and tumor breast cell lines by lovastatin, We show that even though lovastatin treatment causes G1 arrest in a wide variety of normal and tumor breast cells irrespective of their p53 or pRb status, the p21 and p27 protein levels are not increased in all cell lines treated suggesting that the increase in p21 and p27 protein expression per se is not necessary for lovastatin mediated G1 arrest. However, the binding of p21 and p27 to CDK2 increases significantly following treatment of cells with lovastatin leading to inhibition of CDK2 activity and a subsequent arrest of cells in G1, The increased CKI binding to CDK2 is achieved by the redistribution of both p21 and p27 from CDK4 to CDK2 complexes subsequent to decreases in CDK4 and cyclin D3 expression following lovastatin treatment, Lastly, we show that lovastatin treatment of 76N-E6 breast cell line with an altered p53 pathway also results in G1 arrest and similar redistribution of CKIs from CDK4 to CDK2 as observed in other breast cell lines examined, These observations suggest that lovastatin induced G1 arrest of breast cell lines is through a p53 independent pathway and is mediated by decreased CDK2 activity through redistribution of CKIs from CDK4 to CDK2.	Wadsworth Ctr, Div Mol Med, Lab Diagnost Oncol, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12222 USA	Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Keyomarsi, K (corresponding author), Wadsworth Ctr, Div Mol Med, Lab Diagnost Oncol, Albany, NY 12201 USA.		Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849	NCI NIH HHS [R29-CA666062] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; BERNSTEIN L, 1993, EPIDEMIOL REV, V15, P48, DOI 10.1093/oxfordjournals.epirev.a036116; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DAVIGNON J, 1993, ARCH INTERN MED, V153, P1079; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fang XJ, 1998, ONCOGENE, V16, P1, DOI 10.1038/sj.onc.1201525; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GrayBablin J, 1997, CANCER RES, V57, P604; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Harper JW, 1998, GENE DEV, V12, P285, DOI 10.1101/gad.12.3.285; Harper JW, 1997, CANCER SURV, V29, P91; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HESSLING JJ, 1980, J IMMUNOL METHODS, V38, P315, DOI 10.1016/0022-1759(80)90280-X; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Jakus J, 1996, ONCOGENE, V12, P2369; JANI JP, 1993, INVAS METAST, V13, P314; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KEYOMARSI K, 1995, ONCOGENE, V11, P941; Keyomarsi Khandan, 1996, Methods in Cell Science, V18, P109, DOI 10.1007/BF00122161; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MICHIELI P, 1994, CANCER RES, V54, P3391; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Retterstol K, 1996, AM J CARDIOL, V78, P1369, DOI 10.1016/S0002-9149(96)00649-2; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOULE HD, 1990, CANCER RES, V50, P6075; TAM SW, 1994, ONCOGENE, V9, P2663; Thibault A, 1996, CLIN CANCER RES, V2, P483; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P710; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	69	171	176	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2393	2402		10.1038/sj.onc.1202322	http://dx.doi.org/10.1038/sj.onc.1202322			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811471				2022-12-28	WOS:000076723300014
J	Tanaka, M; Wang, DY; Kamo, T; Igarashi, H; Wang, Y; Xiang, YY; Tanioka, F; Naito, Y; Sugimura, H				Tanaka, M; Wang, DY; Kamo, T; Igarashi, H; Wang, Y; Xiang, YY; Tanioka, F; Naito, Y; Sugimura, H			Interaction of EphB2-tyrosine kinase receptor and its ligand conveys dorsalization signal in Xenopus laevis development	ONCOGENE			English	Article						Eph; Ephrin; dorsalization; secondary axis	PROTEIN-TYROSINE KINASE; NEURAL CREST CELLS; EPH-FAMILY; TRANSMEMBRANE LIGANDS; EXPRESSION CLONING; COMMISSURAL AXONS; SPEMANN ORGANIZER; IN-VITRO; GENE; GUIDANCE	The Eph class is the largest family of receptor tyrosine kinases and has been shown to play various roles in neural development including axon pathfinding and neural crest migration, EphB2 associates with transmembrane ligands Ephrin-B1 and -B2, which leads to tyrosine phosphorylation of both the ligands and receptor and is presumed to regulate cell-to-cell interactions by bidirectional signaling. We have investigated the biological effects of the EphB2-induced signal in the early stage of Xenopus laevis development. Xenopus EphB2 transcripts were detected maternally and were expressed at equal levels between the ventral and dorsal halves of the gastrulae, with expression increasing after the late gastrula stage. EphB2 mRNA expression in dorsal marginal zone explants from gastrulae increases during later development while that in ventral explants does not, We show here that microinjection of RNA encoding EphB2 into a ventral blastomere of embryos induced a partial secondary dorsal axis which consisted of neural tissues, notochord and somites, Analysis with molecular markers verified that the microinjected EphB2 dorsalized the mesoderm of ventral marginal zone explants, These dorsalizing effects of EphB2 in both the whole embryo and ventral explants were inhibited by the coinjection of RNA encoding the soluble form of Ephrin-B1, Furthermore, co-injection of EphB2 and Ephrin-B1 RNAs synergistically enhanced the dorsalization effect, These data show that the interaction between EphB2 and its ligands including Ephrin-B1 causes signaling events which lead to dorsal development, and strongly suggests the existence of proteins which mediate the dorsalization induced by EphB2 in early stage embryos of Xenopus laevis.	Hamamatsu Univ Sch Med, Dept Pathol 1, Hamamatsu, Shizuoka 43131, Japan	Hamamatsu University School of Medicine	Sugimura, H (corresponding author), Hamamatsu Univ Sch Med, Dept Pathol 1, 3600 Handa Cho, Hamamatsu, Shizuoka 43131, Japan.		Wang, Dong-Yu/C-6307-2019	Wang, Dong-Yu/0000-0002-5434-287X				BRANDLI AW, 1995, DEV DYNAM, V203, P119; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; EASTY DJ, 1995, CANCER RES, V55, P2528; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HARLOW E, 1988, ANTIBODIES; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; IKEGAKI N, 1995, HUM MOL GENET, V4, P2033, DOI 10.1093/hmg/4.11.2033; JONES CM, 1995, DEVELOPMENT, V121, P3651; Jones TL, 1997, ONCOGENE, V14, P2159, DOI 10.1038/sj.onc.1201082; JONES TL, 1995, ONCOGENE, V10, P1111; Jones TL, 1998, P NATL ACAD SCI USA, V95, P576, DOI 10.1073/pnas.95.2.576; KIYOKAWA E, 1994, CANCER RES, V54, P3645; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Orioli D, 1997, TRENDS GENET, V13, P354, DOI 10.1016/S0168-9525(97)01220-1; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; Sambrook J., 1989, MOL CLONING; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SCALES JB, 1995, ONCOGENE, V11, P1745; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; Tanaka M, 1997, P NATL ACAD SCI USA, V94, P4493, DOI 10.1073/pnas.94.9.4493; Weinstein DC, 1996, MECH DEVELOP, V57, P133, DOI 10.1016/0925-4773(96)00536-9; WINNING RS, 1994, MECH DEVELOP, V46, P219, DOI 10.1016/0925-4773(94)90072-8; Xu QL, 1996, NATURE, V381, P319, DOI 10.1038/381319a0; Xu QL, 1995, DEVELOPMENT, V121, P4005	41	18	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 24	1998	17	12					1509	1516		10.1038/sj.onc.1202068	http://dx.doi.org/10.1038/sj.onc.1202068			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794228	Bronze			2022-12-28	WOS:000076089900003
J	Krappmann, D; Emmerich, F; Kordes, U; Scharschmidt, E; Dorken, B; Scheidereit, C				Krappmann, D; Emmerich, F; Kordes, U; Scharschmidt, E; Dorken, B; Scheidereit, C			Molecular mechanisms of constitutive NF-kappa B/Rel activation in Hodgkin/Reed-Sternberg cells	ONCOGENE			English	Article						Hodgkin's disease; lymphoma; NF-kappa B; I kappa-B	UBIQUITIN-PROTEASOME PATHWAY; SIGNAL-INDUCED DEGRADATION; TUMOR-NECROSIS-FACTOR; B-ALPHA PROTEOLYSIS; RIBOSOMAL S6 KINASE; IN-VIVO; CYTOPLASMIC RETENTION; NUCLEAR TRANSLOCATION; INDUCED APOPTOSIS; DNA-BINDING	A common characteristic of malignant cells derived from patients wifh Hodgkin's disease (HD) is a high level of constitutive nuclear NF-kappa B/Rel activity, which stimulates proliferation and confers resistance to apoptosis, We have analysed the mechanisms that account for NF-kappa B activation in a panel of Hodgkin/Reed-Sternberg (H-RS) cell lines. Whereas two cell lines (L428 and KMH-2) expressed inactive I kappa B alpha, no significant changes in NF-kappa B or I kappa B expression were seen in other H-RS cells (L591, L1236 and HDLM-2), Constitutive NF-kappa-B was susceptible to inhibition by recombinant I kappa B alpha, suggesting that neither mutations in the NF-KB genes nor posttranslational modifications of NF-kappa B were involved. Endogenous I kappa B alpha was bound to p65 and displayed a very short half-life. I kappa B alpha. degradation could be blocked by inhibitors of the NF-kappa B activating pathway. Proteasomal inhibition caused an accumulation of phosphorylated I kappa B alpha and a reduction of NF-kappa B activity in HDLM-2 and L1236 cells. By in vitro kinase assays we demonstrate constitutive I kappa B kinase (IKK) activity in H-RS cells, indicating ongoing signal transduction, Furthermore, HRS cells secrete one or more factor(s) that were able to trigger NF-kappa B activation. We conclude that aberrant activation of IKK's, and in some cases defective I kappa Bs, lead to constitutive nuclear NF-kappa B activity, which in turn results in a growth advantage of Hodgkin's disease tumor cells.	Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Humboldt Univ, Univ Klinikum Charite, D-13122 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Scheidereit, C (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13122 Berlin, Germany.		Krappmann, Daniel/AAT-4354-2021; Krappmann, Daniel/ABF-4038-2021	Krappmann, Daniel/0000-0001-7640-3234; Krappmann, Daniel/0000-0001-7640-3234; Kordes, Uwe R./0000-0001-6375-2320				Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; ERNST MK, 1995, MOL CELL BIOL, V15, P872; FOSS HD, 1993, BRIT J HAEMATOL, V84, P627, DOI 10.1111/j.1365-2141.1993.tb03138.x; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Gilmore TD, 1997, J CLIN INVEST, V100, P2935, DOI 10.1172/JCI119843; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hirano F, 1998, MOL CELL BIOL, V18, P2596, DOI 10.1128/MCB.18.5.2596; HSU PL, 1989, AM J PATHOL, V135, P735; HSU SM, 1994, CRIT REV ONCOGENESIS, V5, P213, DOI 10.1615/CritRevOncog.v5.i2-3.60; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Kanzler H, 1996, BLOOD, V87, P3429, DOI 10.1182/blood.V87.8.3429.bloodjournal8783429; KAUFMAN D, 1992, CRIT REV ONCOL HEMAT, V13, P135, DOI 10.1016/1040-8428(92)90021-H; Krappmann D, 1997, IMMUNOBIOLOGY, V198, P3, DOI 10.1016/S0171-2985(97)80022-8; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Kuppers R, 1996, ANN ONCOL, V7, P27; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MAY MJ, 1997, SEMIN CANCER BIOL, V8, P61; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RODRIGUEZ C, 1995, YEAST, V11, P15, DOI 10.1002/yea.320110103; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Serrano D, 1997, HAEMATOLOGICA, V82, P542; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Wolf J, 1996, BLOOD, V87, P3418, DOI 10.1182/blood.V87.8.3418.bloodjournal8783418; Wood KM, 1998, ONCOGENE, V16, P2131, DOI 10.1038/sj.onc.1201735; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Wulczyn FG, 1998, NUCLEIC ACIDS RES, V26, P1724, DOI 10.1093/nar/26.7.1724; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; XERRI L, 1992, INT J CANCER, V50, P689, DOI 10.1002/ijc.2910500504; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	70	233	239	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					943	953		10.1038/sj.onc.1202351	http://dx.doi.org/10.1038/sj.onc.1202351			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023670				2022-12-28	WOS:000078510600011
J	Sweetser, DA; Froelick, GJ; Matsumoto, AM; Kafer, KE; Marck, B; Palmiter, RD; Kapur, RP				Sweetser, DA; Froelick, GJ; Matsumoto, AM; Kafer, KE; Marck, B; Palmiter, RD; Kapur, RP			Ganglioneuromas and renal anomalies are induced by activated RETMEN2B in transgenic mice	ONCOGENE			English	Article						ganglioneuroma; ret proto-oncogene; multiple endocrine neoplasia; renal agenesis; neuroblastoma; transgenic; autonomic nervous system	MEDULLARY-THYROID CARCINOMA; TYROSINE KINASE DOMAIN; ENTERIC NERVOUS-SYSTEM; NEOPLASIA TYPE 2B; RET PROTOONCOGENE; CELL-LINE; C-RET; SYMPATHOADRENAL LINEAGE; SYMPATHETIC NEUROBLASTS; KIDNEY DEVELOPMENT	Multiple endocrine neoplasia type 2B (MEN2B) is an autosomal dominant syndrome characterized by the development of medullary thyroid carcinoma, pheochromocytomas, musculoskeletal anomalies and mucosal ganglioneuromas, MEN2B is caused by a specific mutation (Met918 --> Thr) in the RET receptor tyrosine kinase, Different mutations of RET lead to other conditions including MEN2A, familial medullary thyroid carcinoma and intestinal aganglionosis (Hirschsprung disease). Transgenic mice were created using the dopamine beta-hydroxylase promoter to direct expression of RETMEN2B the developing sympathetic and enteric nervous systems and the adrenal medulla, D beta H-RETMEN2B transgenic mice developed benign neuroglial tumors, histologically identical to human ganglioneuromas, in their sympathetic nervous systems and adrenal glands. The enteric nervous system was not affected. The neoplasms in D beta H-RETMEN2B mice were similar to benign neuroglial tumors induced in transgenic mice by activated Ras expression under control of the same promoter, Levels of phoshorylated MAP kinase were not increased in the RETMEN2B-induced neurolgial proliferations, suggesting that alternative pathways may play a role in the pathogenesis of these lesions, Transgenic mice with the highest levels of D beta H-RETMEN2B expression, unexpectedly developed renal malformations analogous to those reported with loss of function mutations in the Ret gene.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98105 USA; Univ Washington, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Med Ctr, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98108 USA; Univ Washington, Sch Med, Populat Ctr Res Reprod, Seattle, WA 98108 USA; VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Sweetser, DA (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,C1-169, Seattle, WA 98105 USA.		Matsumoto, Alvin/AAH-6096-2020; Sweetser, David/ABB-9347-2021	Sweetser, David/0000-0002-1621-3284	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD012629] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009351] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052530] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA09351] Funding Source: Medline; NICHD NIH HHS [HD12629] Funding Source: Medline; NIDDK NIH HHS [R01DK52530] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; BALJET B, 1975, STAIN TECHNOL, V50, P31, DOI 10.3109/10520297509117028; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; Borrello MG, 1995, ONCOGENE, V11, P2419; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BRODEUR GM, 1997, PRINCIPLES PRACTICE; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; Califano D, 1996, P NATL ACAD SCI USA, V93, P7933, DOI 10.1073/pnas.93.15.7933; CARLSON KM, 1993, DEVELOPMENT, V119, P1005; CARNAHAN JF, 1991, DEV BIOL, V148, P552, DOI 10.1016/0012-1606(91)90273-6; DALESSIO A, 1995, CELL GROWTH DIFFER, V6, P1387; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; Durbec PL, 1996, DEVELOPMENT, V122, P349; Edery P, 1997, BIOESSAYS, V19, P389, DOI 10.1002/bies.950190506; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ForssPetter S, 1997, J NEUROSCI RES, V50, P829, DOI 10.1002/(SICI)1097-4547(19971201)50:5<829::AID-JNR19>3.0.CO;2-W; HEINICKE EA, 1987, J NEUROSCI METH, V21, P45, DOI 10.1016/0165-0270(87)90101-4; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; IKEDA I, 1990, ONCOGENE, V5, P1291; IKUNO N, 1995, PATHOL RES PRACT, V191, P92, DOI 10.1016/S0344-0338(11)80558-3; Iwashita T, 1996, ONCOGENE, V12, P481; JHIANG SM, 1992, ONCOGENE, V7, P1331; KAPUR RP, 1992, DEVELOPMENT, V116, P167; KAPUR RP, 1991, NEURON, V7, P717, DOI 10.1016/0896-6273(91)90275-5; Kusafuka T, 1996, PEDIATR SURG INT, V12, P11, DOI 10.1007/BF01194794; Lechner MS, 1997, MECH DEVELOP, V62, P105, DOI 10.1016/S0925-4773(97)00667-9; Liu ZZ, 1996, DEV BIOL, V178, P133, DOI 10.1006/dbio.1996.0204; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Rizzo C, 1996, J BIOL CHEM, V271, P29497, DOI 10.1074/jbc.271.46.29497; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Sweetser DA, 1997, ONCOGENE, V15, P2783, DOI 10.1038/sj.onc.1201452; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TSUZUKI T, 1995, ONCOGENE, V10, P191; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; WAJJWALKU W, 1992, JPN J CANCER RES, V83, P671, DOI 10.1111/j.1349-7006.1992.tb01963.x; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619	54	38	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					877	886		10.1038/sj.onc.1202376	http://dx.doi.org/10.1038/sj.onc.1202376			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023663				2022-12-28	WOS:000078510600004
J	Wenger, C; Ellenrieder, V; Alber, B; Lacher, U; Menke, A; Hameister, H; Wilda, M; Iwamura, T; Beger, HG; Adler, G; Gress, TM				Wenger, C; Ellenrieder, V; Alber, B; Lacher, U; Menke, A; Hameister, H; Wilda, M; Iwamura, T; Beger, HG; Adler, G; Gress, TM			Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells	ONCOGENE			English	Article						CTGF; pancreatic cancer; fibrosis; TGF alpha; TGF beta	FACTOR GENE-EXPRESSION; IMMEDIATE-EARLY GENE; INHIBITION; PROTEIN; LOCALIZATION; SECTIONS; PRODUCT; MATRIX; ALPHA; CYR61	CTGF is an immediate early growth responsive gene that has been shown to be a downstream mediator of TGF beta actions in fibroblasts and vascular endothelial cells, In the present study hCTGF was isolated as immediate early target gene of EGF/TGF alpha in human pancreatic cancer cells by suppression hybridization, CTGF transcripts were found in 13/15 pancreatic cancer cell lines incubated with 10% serum, In 3/7 pancreatic cancer cell lines EGF/TGF alpha induced a significant rise of CTGF transcript levels peaking 1-2 h after the start of treatment. TGF beta increased CTGF transcript levels in 2/7 pancreatic cancer cell lines after 4 h of treatment and this elevation was sustained after 24 h, Only treatment with TGF beta was accompanied by a parallel induction of collagen type I transcription. 15/19 human pancreatic cancer tissues were shown to overexpress high levels of CTGF transcripts. CTGF transcript levels in pancreatic cancer tissues and nude mouse xenograft tumors showed a good correlation to the degree of fibrosis, III situ hybridization and the nude mouse experiments revealed that in pancreatic cancer tissues, fibroblasts are the predominant site of CTGF transcription, whereas the tumor cells appear to contribute to a lesser extent. We conclude that CTGF may be of paramount importance for the development of the characteristic desmoplastic reaction in pancreatic cancer tissues.	Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Univ Ulm, Dept Med Genet, D-89070 Ulm, Germany; Univ Ulm, Dept Gen Surg, D-89070 Ulm, Germany; Miyazaki Prefectural Gen Hosp, Miyazaki 880, Japan	Ulm University; Ulm University; Ulm University	Wenger, C (corresponding author), Univ Ulm, Dept Internal Med 1, Robert Koch Str 8, D-89081 Ulm, Germany.			Gress, Thomas/0000-0002-9333-5461				Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B; BOCKMAN DE, 1992, GASTROENTEROLOGY, V103, P1883, DOI 10.1016/0016-5085(92)91448-D; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Grau AM, 1997, CANCER RES, V57, P3929; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; IGARASHI A, 1995, J INVEST DERMATOL, V105, P280, DOI 10.1111/1523-1747.ep12318465; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; LOPEZDELEON A, 1985, J HISTOCHEM CYTOCHEM, V33, P737, DOI 10.1177/33.8.2410480; Menke A, 1997, GASTROENTEROLOGY, V113, P295, DOI 10.1016/S0016-5085(97)70107-0; Oemar BS, 1997, ARTERIOSCL THROM VAS, V17, P1483, DOI 10.1161/01.ATV.17.8.1483; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Sanvito F, 1995, BIOCHEM BIOPH RES CO, V217, P1279, DOI 10.1006/bbrc.1995.2906; Schutte M, 1996, CANCER RES, V56, P2527; TANIGUCHI S, 1992, CLIN EXP METASTAS, V10, P259; VANLAETHEM JL, 1995, GASTROENTEROLOGY, V108, P1873, DOI 10.1016/0016-5085(95)90152-3; Xin LW, 1996, J CLIN PATHOL-CL MOL, V49, pM91	22	158	168	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1073	1080		10.1038/sj.onc.1202395	http://dx.doi.org/10.1038/sj.onc.1202395			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023684				2022-12-28	WOS:000078510600025
J	Lam, CW; Xie, JW; To, KF; Ng, HK; Lee, KC; Yuen, NWF; Lim, PL; Chan, LYS; Tong, SF; McCormick, F				Lam, CW; Xie, JW; To, KF; Ng, HK; Lee, KC; Yuen, NWF; Lim, PL; Chan, LYS; Tong, SF; McCormick, F			A frequent activated smoothened mutation in sporadic basal cell carcinomas	ONCOGENE			English	Article						hedgehog; patched; smoothened; basal cell carcinoma; mutation	HUMAN HOMOLOG; RECEPTOR; GENE	Basal-cell carcinomas (BCCs) are the most common cancer in Caucasians, It has been reported that the patched gene is inactivated in 30-40% sporadic BCCs and 20% sporadic medulloblastomas via loss of heterozygosity and nonsense mutations. Recently, two activating smoothened mutations have been found in the sporadic basal cell carcinomas. One, at base pair 1604 (G-to-T transversion) of exon 9, changes codon 535 from tryptophan to leucine, and the other, at base pair 1685 (G-to-A transition) of exon 10, changes codon 562 from arginine to glutamine (Xie et al,, 1998), In our study, 1604G-->T was found in 20 out of 97 (20.6%) sporadic BCCs, The high prevalence indicates that 1604G is the mutation hot spot in our tumor samples. This mutation was detected in all three histological subtypes of BCCs, suggesting that smoothened mutation is an early event during the development of the tumor. Our finding of a high smoothened mutation rate, together with high frequent patched gene mutations reported recently, indicates that activation of the hedgehog signal transduction pathway is the most common and early event in the development of sporadic BCCs, Additionally, to determine whether smoothened, like patched, is also involved in the carcinogenesis of medulloblastomas, we screened medulloblastoma samples for these two mutations by restriction analysis. We have found the 1604G-->T mutation in 1 out of 21 medulloblastomas. This result confirmed smoothened gene involvement in the carcinogenesis of medulloblastoma.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Clin Immunol Unit, Hong Kong, Peoples R China; Princess Margaret Hosp, Dept Pathol, Hong Kong, Peoples R China; United Christian Hosp, Dept Pathol, Hong Kong, Peoples R China; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; United Christian Hospital; University of California System; University of California San Francisco	Lam, CW (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Hong Kong, Peoples R China.		Ng, Ho Keung/I-3952-2015					BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HUTCHINSON F, 1994, MUTAT RES-FUND MOL M, V309, P11, DOI 10.1016/0027-5107(94)90037-X; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444; MAK ASY, 1995, SCAND J PLAST RECONS, V29, P149, DOI 10.3109/02844319509034331; Raffel C, 1997, CANCER RES, V57, P842; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Wicking C, 1997, AM J HUM GENET, V60, P21; Wong SS, 1998, J AM ACAD DERMATOL, V38, P179, DOI 10.1016/S0190-9622(98)70596-1; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	14	140	152	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					833	836		10.1038/sj.onc.1202360	http://dx.doi.org/10.1038/sj.onc.1202360			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989836				2022-12-28	WOS:000078394400031
J	Wistuba, II; Behrens, C; Milchgrub, S; Bryant, D; Hung, J; Minna, JD; Gazdar, AF				Wistuba, II; Behrens, C; Milchgrub, S; Bryant, D; Hung, J; Minna, JD; Gazdar, AF			Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma	ONCOGENE			English	Article						lung carcinoma; preneoplastic lesions; loss of heterozygosity; chromosome 3p; chromosome 9p; TP53 gene	MICROSATELLITE INSTABILITY; MUTATOR PHENOTYPE; CLONAL EVOLUTION; FORMER SMOKERS; CHROMOSOME 3P; ALLELE LOSS; FHIT GENE; CANCER; LESIONS; P53	To understand the molecular pathways involved in the pathogenesis of squamous cell lung carcinoma, we obtained DNA from 94 microdissected foci from 12 archival surgically resected tumors including histologically normal epithelium (n = 13), preneoplastic lesions (n = 54), carcinoma is situ (CIS) (n = 15) and invasive tumors (n = 12). We determined loss of heterozygosity (LOH) at 10 chromosomal regions (3p12, 3p14.2, 3p14.1-21.3, 3p21, 3p22-24, 3p25, 5q22, 9p21, 13q14 RE, and 17p13 TP53) frequently deleted in lung cancer, using 31 polymorphic microsatellite markers, including 24 that spanned the entire 3p arm. Our major findings are as follows: (1) Thirty one percent of histologically normal epithelium and 42% of mildly abnormal (hyperplasia/metaplasia) specimens had clones of cells with allelic loss at one or more regions; (2) There was a progressive increase of the overall LOH frequency within clones with increasing severity of histopathological changes; (3) The earliest and most frequent regions of allelic loss occurred at 3p21, 3p22-24, 3p25 and 9p21; (4) The size of the 3p deletions increased with progressive histologic changes; (5) TP53 allelic loss was present in many histologically advanced lesions (dysplasia and CIS); (6) Analyses of 58 normal and non-invasive foci having any molecular abnormality, indicated that 30 probably arose as independent clonal events, while 28 were potentially of the same clonal origin as the corresponding tumor; (7) Nevertheless, when the allelic losses in the 30 clonally independent lesions and their clonally unrelated tumors were compared the same parental allele was lost in 113 of 125 (90%) of comparisons. The mechanism by which this phenomenon (known as allele specific mutations) occurs is unknown; (8) Four patterns of allelic loss in clones were found. Histologically normal or mildly abnormal foci had a negative pattern (no allelic loss) or early pattern of loss while all foci of CIS and invasive tumor had an advanced pattern. However dysplasias demonstrated the entire spectrum of allelic loss patterns, and were the only histologic category having the intermediate pattern. Our findings indicate that multiple, sequentially occurring allele specific molecular changes commence in widely dispersed, apparently clonally independent foci, early in the multistage pathogenesis of squamous cell carcinomas of the lung.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Pontificia Univ Catolica Chile, Dept Pathol, Santiago, Chile	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Pontificia Universidad Catolica de Chile	Gazdar, AF (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd,NB8-106, Dallas, TX 75235 USA.				NCI NIH HHS [P50-CA70907, N01CN45580-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI J, 1995, GENE CHROMOSOME CANC, V14, P301, DOI 10.1002/gcc.2870140409; BAND PR, 1986, CANCER DETECT PREV, V9, P157; Birch DE, 1996, NATURE, V381, P445, DOI 10.1038/381445a0; CAWKWELL L, 1994, BRIT J CANCER, V70, P813, DOI 10.1038/bjc.1994.404; Chung GTY, 1995, ONCOGENE, V11, P2591; Chung GTY, 1996, CANCER RES, V56, P1609; COLBY TV, 1995, TUMORS LOWER RESP TR; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Fishel R, 1996, J NATL CANCER I, V88, P1608, DOI 10.1093/jnci/88.22.1608; FISHER JC, 1958, NATURE, V181, P651, DOI 10.1038/181651b0; FONG KM, 1995, CANCER RES, V55, P28; Fong KM, 1997, CANCER RES, V57, P2256; Franklin WA, 1997, J CLIN INVEST, V100, P2133, DOI 10.1172/JCI119748; FROST JK, 1986, J OCCUP ENVIRON MED, V28, P692, DOI 10.1097/00043764-198608000-00031; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KISHIMOTO Y, 1995, JNCI-J NATL CANCER I, V87, P1224, DOI 10.1093/jnci/87.16.1224; LOEB LA, 1991, CANCER RES, V51, P3075; LOEB LA, 1994, CANCER RES, V54, P5059; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857; MERLO A, 1994, CANCER RES, V54, P2098; Minna John D., 1997, P849; Miozzo M, 1996, CANCER RES, V56, P2285; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PARKIN DM, 1994, INT J CANCER, V59, P494, DOI 10.1002/ijc.2910590411; RISSE EKJ, 1988, ACTA CYTOL, V32, P629; SACCOMANNO G, 1974, CANCER-AM CANCER SOC, V33, P256, DOI 10.1002/1097-0142(197401)33:1<256::AID-CNCR2820330139>3.0.CO;2-G; SIEGEL S., 1956, NONPARAMETRIC STAT B; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; STRONG MS, 1984, J OTOLARYNGOL, V13, P1; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; THIBERVILLE L, 1995, CANCER RES, V55, P5133; TOGUCHIDA J, 1993, GENOMICS, V17, P535, DOI 10.1006/geno.1993.1368; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WISTUBA II, 1995, CANCER RES, V55, P2511; Wistuba II, 1998, JAMA-J AM MED ASSOC, V279, P1554, DOI 10.1001/jama.279.19.1554; Wistuba II, 1997, CANCER RES, V57, P3154; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366	42	261	273	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					643	650		10.1038/sj.onc.1202349	http://dx.doi.org/10.1038/sj.onc.1202349			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989814				2022-12-28	WOS:000078394400009
J	Walker, DR; Bond, JP; Tarone, RE; Harris, CC; Makalowski, W; Boguski, MS; Greenblatt, MS				Walker, DR; Bond, JP; Tarone, RE; Harris, CC; Makalowski, W; Boguski, MS; Greenblatt, MS			Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features	ONCOGENE			English	Article						molecular evolution; missense mutation; crystal structure; DNA binding; domain	TUMOR-SUPPRESSOR; CRYSTAL-STRUCTURE; CELL-LINES; GENE; DOMAIN; SUBSTITUTIONS; APOPTOSIS; CANCER	Missense mutations in p53 frequently occur at 'hotspot' amino acids which are highly conserved and represent regions of structural or functional importance. Using the p53 mutation database and the p53 DNA sequences for 11 species, we more precisely defined the relationships among conservation, mutation frequency and protein structure. We aligned the p53 sequences codon-by-codon and determined the degree of substitution among them. As a whole, p53 is evolving at an average rate for a mammalian protein-coding gene. As expected, the DNA binding domain is evolving more slowly than the carboxy and amino termini, A detailed map of evolutionary conservation shows that within the DNA binding domain there are repeating peaks and valleys of higher and lower evolutionary constraint, Mutation hotspots were identified by comparing the observed distribution of mutations to the pattern expected from a random multinomial distribution, Seventy-three hotspots were identified; these 19% of codons account for 88% of all reported p53 mutations. Both high evolutionary constraint and mutation hotspots are noted at amino acids close to the protein-DNA interface and at others more distant from DNA, often buried within the core of the folded protein but sometimes on its surface. The results indicate that targeting highly conserved regions for mutational and functional analysis may be efficient strategies for the study of cancer-related genes.	NCI, Natl Ctr Biotechnol Informat, Natl Lib Med, NIH, Bethesda, MD 20894 USA; NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA; NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH National Library of Medicine (NLM); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University	Greenblatt, MS (corresponding author), Univ Vermont, Coll Med, Dept Med, Hematol Oncol Unit, Patrick 534,MCHV Campus, Burlington, VT 05401 USA.		Makalowski, Wojciech/I-2843-2016	Makalowski, Wojciech/0000-0003-2303-9541	DIVISION OF BASIC SCIENCES - NCI [Z01BC005794] Funding Source: NIH RePORTER; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [Z01CP010130] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; INA Y, 1995, J MOL EVOL, V40, P190, DOI 10.1007/BF00167113; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KYTE J, 1995, MECH PROTEIN CHEM; Li W. H, 1997, MOL EVOLUTION; LI WH, 1991, FUNDAMENTALS MOL EVO, P69; MAKALOWSKI W, 1998, IN PRESS P NATL ACAD; Miller R. G., 1981, SIMULTANEOUS STAT IN, P6; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Rodin SN, 1998, INT J MOL MED, V1, P191; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SOUSSI T, 1990, ONCOGENE, V5, P945; SVED J, 1990, P NATL ACAD SCI USA, V87, P4692, DOI 10.1073/pnas.87.12.4692; TICHER A, 1989, J MOL EVOL, V28, P286, DOI 10.1007/BF02103424; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; WALKER DR, 1997, INTELL SYST MOL BIOL, V5, P333; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219	27	164	169	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					211	218		10.1038/sj.onc.1202298	http://dx.doi.org/10.1038/sj.onc.1202298			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926936				2022-12-28	WOS:000078166000023
J	Zwicker, J; Brusselbach, S; Jooss, KU; Sewing, A; Behn, M; Lucibello, FC; Muller, R				Zwicker, J; Brusselbach, S; Jooss, KU; Sewing, A; Behn, M; Lucibello, FC; Muller, R			Functional domains in cyclin D1: pRb-kinase activity is not essential for transformation	ONCOGENE			English	Article						cyclin D1; transformation; retinoblastoma protein (Rb); Ras, cooperation with cyclin D1; CDK4	RETINOBLASTOMA PROTEIN; TRANSGENIC MICE; EXPRESSION; ONCOGENE; YEAST; GENE; DNA; PHOSPHORYLATION; PHASE; CDK4	Although cyclin D1 plays a major role during cell cycle progression and is involved in human tumourigenesis, its domain structure is still poorly understood. In the present study, we have generated a series of cyclin D1 N- and C1-terminal deletion constructs. These mutants were used to define the domains required for transformation of rat embryonal fibroblasts (REF) in cooperation with activated Ha-ras and and to establish correlations with defined biochemical properties of cyclin D1, Protein binding and REF assays showed that the region of the cyclin box required for the interaction with CDK4 as well as C-terminal sequences determining protein stability were crucial for transformation. Surprisingly, however, the N-terminal deletion of 20 amino acids which impaired pRb kinase activity did not affect the transforming ability of cyclin D1, Likewise, no effect on transformation was observed with mutants defective in p21(CIP) interaction. These observations argue against a crucial role of pRb inactivation or p21(CIP) squelching in cyclin D1-mediated transformation.	Univ Marburg, Inst Mol Biol & Tumorforsch, D-35033 Marburg, Germany	Philipps University Marburg	Muller, R (corresponding author), Univ Marburg, Inst Mol Biol & Tumorforsch, Emil Mannkopff Str 2, D-35033 Marburg, Germany.		Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOUBIN F, 1995, ONCOGENE, V10, P2281; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Han EKH, 1998, PROSTATE, V35, P95, DOI 10.1002/(SICI)1097-0045(19980501)35:2<95::AID-PROS2>3.0.CO;2-F; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; JOOSS KU, 1994, EMBO J, V13, P1467, DOI 10.1002/j.1460-2075.1994.tb06401.x; KATO J, 1993, GENE DEV, V7, P331; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; Maeda K, 1998, ONCOLOGY-BASEL, V55, P145, DOI 10.1159/000011849; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; PINES J, 1994, TRENDS BIOCHEM SCI, V19, P143, DOI 10.1016/0968-0004(94)90272-0; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG CL, 1993, ONCOGENE, V8, P519; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; Sarcevic B, 1997, J BIOL CHEM, V272, P33327, DOI 10.1074/jbc.272.52.33327; SEWING A, 1994, ONCOGENE, V9, P2733; SEWING A, 1993, J CELL SCI, V104, P545; SIKORSKI RS, 1989, GENETICS, V122, P19; TAM SW, 1994, ONCOGENE, V9, P2663; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	40	41	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					19	25		10.1038/sj.onc.1202286	http://dx.doi.org/10.1038/sj.onc.1202286			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926916				2022-12-28	WOS:000078166000003
J	Jain, N; Zhang, T; Fong, SL; Lim, CP; Cao, XM				Jain, N; Zhang, T; Fong, SL; Lim, CP; Cao, XM			Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK)	ONCOGENE			English	Article						repression; Stat3 transactivation; ERK2; phosphorylation; association	EPIDERMAL GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; C-FOS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; INTERFERON-ALPHA; GENE-EXPRESSION	STAT proteins are activated by phosphorylation at specific tyrosine residue at the carboxy-terminus which is required for dimer-formation, nuclear translocation, DNA binding and transcriptional activity in cells treated with cytokines and growth factors. Recent studies have indicated that STATs are also phosphorylated by MAPK, or extracellular signal-regulated kinase (ERK) on serine, We investigated the role of ERK on the regulation of STAT activity. Here, we report that ERK2 activated by its upstream kinase, MEK1, represses Stat3 transcriptional activity induced by Src or Jak-2, To unravel the mechanism of repression, we further showed that Stat3 DNA binding activity and its tyrosine phosphorylation are also inhibited under the same conditions. ERK2 phosphorylates Stat3 on three serine-containing peptides and decreases its tyrosine phosphorylation induced by EGF treatment. We also detected an association of ERK2 and Stall in vivo which is modulated positively by activation of ERK2, but negatively by Jak2, We propose that MAP kinase cascade may negatively regulate Stat3 activities by decreasing its tyrosine phosphorylation and also possibly by association.	Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Cao, XM (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117609, Singapore.							AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAO XM, 1993, J BIOL CHEM, V268, P16949; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HELM MH, 1995, SCIENCE, V267, P1347; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jain N, 1996, J BIOL CHEM, V271, P13530, DOI 10.1074/jbc.271.23.13530; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	45	164	176	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	1998	17	24					3157	3167		10.1038/sj.onc.1202238	http://dx.doi.org/10.1038/sj.onc.1202238			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872331				2022-12-28	WOS:000077517400009
J	Reed, MF; Liu, VF; Ladha, MH; Ando, K; Griffin, JD; Weaver, DT; Ewen, ME				Reed, MF; Liu, VF; Ladha, MH; Ando, K; Griffin, JD; Weaver, DT; Ewen, ME			Enforced CDK4 expression in a hematopoietic cell line confers resistance to the G1 arrest induced by ionizing radiation	ONCOGENE			English	Article						CDK4; p53; p21; ionizing radiation	CYCLIN-DEPENDENT KINASES; P53-DEPENDENT G(1) ARREST; WILD-TYPE P53; RETINOBLASTOMA PROTEIN; HUMAN FIBROBLASTS; GROWTH ARREST; DNA-DAMAGE; ULTRAVIOLET-IRRADIATION; CANCER-CELLS; INHIBITION	In hematopoietic cells, gamma-irradiation causes a p53-dependent transient G1 phase cell cycle arrest. Various extracellular growth inhibitory signals elicit G1 arrest by targeting CDK4. Here we show that in a myeloid cell line, 32D cl 3, enforced expression of CDK4, but not cyclins D2 nor D3, overrides the gamma-irradiation-induced G1 arrest. CDK4 does not confer resistance to the radiation-induced G2 block observed in parental cells. Ectopic expression of CDK4 overcomes the ionizing radiation-induced inhibition of CDK4 and CDK2 kinase activity. The levels of CDK4 protein do not change after exposure to ionizing radiation in either parental cells or those overexpressing CDK4. Ionizing radiation induces the expression of both p53 and p21, and in cells constitutively synthesizing exogenous CDK4, the return of p53 protein levels to baseline is prolonged. Increased levels of p21 are found associated with CDK4, and not CDK2, in the lines overexpressing CDK4, compared to the parental line, after exposure to ionizing radiation. Enforced expression of CDK4 may therefore overcome a gamma-irradiation-induced G1 arrest through the titration of the CDK inhibitor p21 allowing both CDK4 and CDK2 to remain active.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Ewen, ME (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.			Reed, Michael/0000-0001-8478-8605	NATIONAL CANCER INSTITUTE [T32CA009535, R01CA065842] Funding Source: NIH RePORTER; NCI NIH HHS [CA65842, CA09535] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; ANDO K, 1995, ONCOGENE, V10, P751; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; EPPERLY M, 1995, RADIAT RES, V143, P245, DOI 10.2307/3579210; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HE J, 1994, CANCER RES, V54, P5804; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HUPPI K, 1994, ONCOGENE, V9, P3017; JIANG W, 1993, ONCOGENE, V8, P3447; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO J, 1993, GENE DEV, V7, P331; KHATIB ZA, 1993, CANCER RES, V53, P5535; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KREK W, 1995, METHOD ENZYMOL, V254, P114; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Latham KM, 1996, MOL CELL BIOL, V16, P4445; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NAKAWAKI T, 1995, BRIT J HAEMATOL, V91, P139, DOI 10.1111/j.1365-2141.1995.tb05259.x; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; QUELLE DE, 1995, ONCOGENE, V11, P635; REIFENBERGER G, 1994, CANCER RES, V54, P4299; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	65	18	20	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	1998	17	23					2961	2971		10.1038/sj.onc.1202450	http://dx.doi.org/10.1038/sj.onc.1202450			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881698				2022-12-28	WOS:000077427800003
J	Chernova, OB; Somerville, RPT; Cowell, JK				Chernova, OB; Somerville, RPT; Cowell, JK			A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors	ONCOGENE			English	Article						tumor suppressor gene; human chromosome 10; gene rearrangements; chromosome translocation; glioma; leucine-rich repeat	LEUCINE-RICH REPEATS; HUMAN GLIOMAS; DECREASED EXPRESSION; PROSTATE-CANCER; SUPPRESSOR GENE; HETEROZYGOSITY; CHROMOSOME-10; DROSOPHILA; GROWTH; MOTIF	Loss of heterozygosity for 10q23-26 is seen in over 80% of glioblastoma multiforme tumors. We have used a positional cloning strategy to isolate a novel gene, LGI1 (Leucine-rich gene-Glioma Inactivated), which is rearranged as a result of the t(10;19)(q24;q13) balanced translocation in the T98G glioblastoma cell, line lacking any normal chromosome 10. Rearrangement of the LGI1 gene was also detected in the A172 glioblastoma cell line and several glioblastoma tumors. These rearrangements lead to a complete absence of LGI1 expression in glioblastoma cells. The LGI1 gene encodes a protein with a calculated molecular mass of 60 kD and contains 3.5 leucine-rich repeats (LRR) with conserved flanking sequences. In the LRR domain, LGI1 has the highest homology with a number of transmembrane and extracellular proteins which function as receptors and adhesion proteins. LGI1 is predominantly expressed in neural tissues, especially in brain; its expression is reduced in low grade brain tumors and it is significantly reduced or absent in malignant gliomas. Its localization to the 10q24 region, and rearrangements or inactivation in malignant brain tumors, suggest that LGI1 is a candidate tumor suppressor gene involved in progression of glial tumors.	Cleveland Clin Fdn, Dept Neurosci NC30, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Cowell, JK (corresponding author), Cleveland Clin Fdn, Dept Neurosci NC30, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.			Cowell, John/0000-0002-2079-5950	NCI NIH HHS [CA76457] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076457] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albarosa R, 1996, AM J HUM GENET, V58, P1260; Asamoto M, 1997, JPN J CLIN ONCOL, V27, P22, DOI 10.1093/jjco/27.1.22; ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; BERRY R, 1995, NAT GENET, V10, P415, DOI 10.1038/ng0895-415; Bigner SH, 1990, BRAIN PATHOL, V1, P12, DOI 10.1111/j.1750-3639.1990.tb00633.x; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Buchanan SGS, 1996, PROG BIOPHYS MOL BIO, V65, P1, DOI 10.1016/S0079-6107(96)00003-X; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHANG Z, 1993, DEV BIOL, V160, P315, DOI 10.1006/dbio.1993.1310; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHERNOVA O, 1998, IN PRESS CANC GENET; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; COWELL JK, 1984, INT J CANCER, V33, P657, DOI 10.1002/ijc.2910330517; ElNaggar AK, 1997, AM J PATHOL, V151, P1767; GRAY IC, 1995, CANCER RES, V55, P4800; HALFON MS, 1995, DEV BIOL, V169, P151, DOI 10.1006/dbio.1995.1134; HERBST RA, 1994, CANCER RES, V54, P3111; JAMES CD, 1988, CANCER RES, V48, P5546; KARLBOM AE, 1993, HUM GENET, V92, P169; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Kong XT, 1997, CANCER RES, V57, P3772; KRAUS JA, 1995, J NEUROPATH EXP NEUR, V54, P91, DOI 10.1097/00005072-199501000-00011; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Marchini S, 1997, BRIT J CANCER, V76, P146, DOI 10.1038/bjc.1997.355; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Myohanen SK, 1998, CANCER RES, V58, P591; Nose A, 1997, DEVELOPMENT, V124, P1433; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PEIFFER SL, 1995, CANCER RES, V55, P1922; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; Raff T, 1997, BIOTECHNIQUES, V23, P456, DOI 10.2144/97233st02; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; Rasheed BKA, 1997, CANCER RES, V57, P4187; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Rosenberg JE, 1996, ONCOGENE, V13, P2483; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; Ryan A, 1998, GYNECOL ONCOL, V68, P14, DOI 10.1006/gyno.1997.4881; Schmidt EE, 1997, BRIT J CANCER, V75, P2, DOI 10.1038/bjc.1997.2; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; VONDEIMLING A, 1994, INT J CANCER, V57, P676, DOI 10.1002/ijc.2910570511; WINDISCH JM, 1995, BIOCHEMISTRY-US, V34, P11256, DOI 10.1021/bi00035a035; WINDISCH JM, 1995, J BIOL CHEM, V270, P28133	47	154	167	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 3	1998	17	22					2873	2881		10.1038/sj.onc.1202481	http://dx.doi.org/10.1038/sj.onc.1202481			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879993				2022-12-28	WOS:000077286400007
J	Kondo, S; Shinomura, Y; Kanayama, S; Higashimoto, Y; Kiyohara, T; Zushi, S; Kitamura, S; Ueyama, H; Matsuzawa, Y				Kondo, S; Shinomura, Y; Kanayama, S; Higashimoto, Y; Kiyohara, T; Zushi, S; Kitamura, S; Ueyama, H; Matsuzawa, Y			Modulation of apoptosis by endogenous Bcl-x(L) expression in MKN-45 human gastric cancer cells	ONCOGENE			English	Article						bcl-x(L); antisense oligonucleotides; bak; apoptosis; fas; chemotherapy	CHEMOTHERAPY-INDUCED APOPTOSIS; TUMOR-NECROSIS-FACTOR; BCL-2 HOMOLOG BAK; IN-VIVO PATTERNS; IMMUNOHISTOCHEMICAL ANALYSIS; SURFACE ANTIGEN; MONOCLONAL-ANTIBODY; ANTICANCER AGENTS; FAS ANTIGEN; DEATH	This study was designed to clarify the role of endogenous Bcl-x(L) expression in modulating apoptosis of malignant cells. Administration of bcl-x-antisense oligonucleotides decreased Bcl-x(L) protein levels in the MKN-45 human gastric cancer cell line. The decrease in Bcl-x(L) protein content resulted in increased cell death induced by serum deprivation or Fas-antibody administration. Flow cytometric analysis revealed that the increased apoptotic cell death was more prominent in bcl-x-antisense-treated cells as compared to control cells, bcl-x-sense-treated cells, or bcl-x-nonsense-treated cells. To inhibit the effect of intrinsic Bcl-x(L) protein, we overexpressed Bak, which binds Bcl-x(L) and inhibits the anti-apoptotic effect of Bcl-x(L), by transfection into MKN-45 cells. Bak-overexpressing cells showed increased apoptotic cell death induced by Fas-antibody when compared to parent cells and MKN-neo-transfected cells. Bak-overexpressing cells also showed greater sensitization to 5-fluorouracil and cisplatin than parent cells and MKN-neo-transfected cells. In conclusion, we demonstrated that administration of bcl-x-antisense oligonucleotides or overexpression of Bak protein induces sensitization to apoptosis in MKN-45 gastric cancer cells, suggesting that endogenous Bcl-x, expression in cancer cells is an important modulator of apoptosis.	Osaka Univ, Sch Med, Dept Internal Med 2, Suita, Osaka 5650871, Japan	Osaka University	Kondo, S (corresponding author), Osaka Univ, Sch Med, Dept Internal Med 2, 2-2 Yanadaoka, Suita, Osaka 5650871, Japan.							Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHERBONNELASSER.C, 1997, ONCOGENE, V13, P1489; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Decaudin D, 1997, CANCER RES, V57, P62; DOLE M, 1994, CANCER RES, V54, P3253; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Hayashi H, 1997, JPN J CANCER RES, V88, P49, DOI 10.1111/j.1349-7006.1997.tb00301.x; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAMESAKI S, 1993, CANCER RES, V53, P4251; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Kondo S, 1996, INT J CANCER, V68, P727, DOI 10.1002/(SICI)1097-0215(19961211)68:6<727::AID-IJC6>3.0.CO;2-5; Krajewska M, 1996, CANCER RES, V56, P2422; Krajewska M, 1996, AM J PATHOL, V149, P1449; Krajewski S, 1996, CANCER RES, V56, P2849; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROUQUET N, 1995, ONCOGENE, V11, P1061; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZORNIG M, 1995, ONCOGENE, V10, P2397	32	29	38	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2585	2591		10.1038/sj.onc.1202194	http://dx.doi.org/10.1038/sj.onc.1202194			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840921				2022-12-28	WOS:000077058900005
J	Soucek, L; Helmer-Citterich, M; Sacco, A; Jucker, R; Cesareni, G; Nasi, S				Soucek, L; Helmer-Citterich, M; Sacco, A; Jucker, R; Cesareni, G; Nasi, S			Design and properties of a myc derivative that efficiently homodimerizes	ONCOGENE			English	Article						myc; bHLHZip domain; molecular modelling; protein dimerization; cell proliferation	HELIX-LOOP-HELIX; C-MYC; DNA-BINDING; E-BOX; CELL-GROWTH; TRANSCRIPTIONAL ACTIVATION; RAS COTRANSFORMATION; MAX HETERODIMERS; TRANSGENIC MICE; LEUCINE ZIPPERS	bHLH and bHLHZip are highly conserved structural domains mediating DNA binding and specific protein-protein interactions. They are present in a family of transcription factors, acting as dimers, and their selective dimerization is utilized to switch on and off cell proliferation, differentiation or apoptosis, Myc is a bHLHZip protein involved in growth control and cancer, which operates in a network with the structurally related proteins Max, Mad and Mnt, It does not form homodimers, working as a heterodimer with Max; Mas, instead, forms homodimers and heterodimers with Mad and Mnt. Myc/Max dimers activate gene transcription, while Mad/Max and Mnt/Max complexes are Myc/Mas antagonists and act as repressors. Modifying the molecular recognition of dimers may provide a tool for interfering with MSc function and, in general, for directing the molecular switches operated via bHLH(Zip) proteins. By molecular modelling mutagenesis, we analysed the contribution of amino acids to the molecular recognition of Myc, creating bHLHZip domains with altered dimerization specificity. We report that Myc recognition specificity is encoded in a short region within the leucine zipper; mutation of four amino acids generates a protein, Omomyc, that homodimerizes efficiently and can still heterodimerize with wild type Myc and Max, Omomyc sequestered Myc in complexes with low DNA binding efficiency, preventing binding to Max and inhibiting Myc transcriptional activator function. Consistently with these results, Omomyc produced a proliferation arrest in NIH3T3 cells, These data demonstrate the feasibility of interfering with fundamental biological processes, such as proliferation, by modifying the dimerization selectivity of a bHLHZip protein; this may facilitate the design of peptides of potential pharmacological interest.	Univ La Sapienza, CNR, Ctr Acidi Nucl, I-00185 Rome, Italy; Univ Roma Tor Vergata, Dipartimento Biol, I-00173 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; University of Rome Tor Vergata	Nasi, S (corresponding author), Univ La Sapienza, CNR, Ctr Acidi Nucl, I-00185 Rome, Italy.		Soucek, Laura/AAG-8377-2019; Soucek, Laura/AAG-7393-2019; Cesareni, Gianni/AAW-1382-2020	Soucek, Laura/0000-0002-4750-7971; Helmer-Citterich, Manuela/0000-0001-9530-7504				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Ausiello G, 1997, PROTEINS, V28, P556, DOI 10.1002/(SICI)1097-0134(199708)28:4<556::AID-PROT9>3.3.CO;2-C; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bello-Fernandez C, 1992, Curr Top Microbiol Immunol, V182, P445; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CASTAGNOLI L, 1994, J MOL BIOL, V237, P378, DOI 10.1006/jmbi.1994.1241; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; CROUCH DH, 1990, ONCOGENE, V5, P683; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Krylov D, 1997, P NATL ACAD SCI USA, V94, P12274, DOI 10.1073/pnas.94.23.12274; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAVIGNE P, 1995, J MOL BIOL, V254, P505, DOI 10.1006/jmbi.1995.0634; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; LITTLEWOOD TD, 1994, PROTEIN PROFILE, V1, P639; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; LONGO F, 1995, BIOCHEM BIOPH RES CO, V206, P326, DOI 10.1006/bbrc.1995.1045; MARCHETTI A, 1995, J MOL BIOL, V248, P541, DOI 10.1006/jmbi.1995.0241; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Miller J.H., 1972, EXPT MOL GENETICS; MOORE KJ, 1995, TRENDS GENET, V11, P442, DOI 10.1016/S0168-9525(00)89143-X; MUHLEGOLL C, 1995, BIOCHEMISTRY-US, V34, P13554, DOI 10.1021/bi00041a035; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PENN LJZ, 1990, EMBO J, V9, P113; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZU X, 1997, GENE DEV, V11, P654	61	124	127	1	17	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2463	2472		10.1038/sj.onc.1202199	http://dx.doi.org/10.1038/sj.onc.1202199			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824157				2022-12-28	WOS:000076927300006
J	Krtolica, A; Krucher, NA; Ludlow, JW				Krtolica, A; Krucher, NA; Ludlow, JW			Hypoxia-induced pRB hypophosphorylation results from downregulation of CDK and upregulation of PP1 activities	ONCOGENE			English	Article						protein phosphatase type 1 (PP1); pRB hypoxia; cyclin-dependent kinase activity; mammalian cell cycle	CYCLIN-DEPENDENT KINASES; PROTEIN PHOSPHATASE-ACTIVITY; RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE; SUPPRESSOR PROTEIN; S-PHASE; PHOSPHORYLATION; INHIBITOR; P21; TRANSCRIPTION	Exposure of CV-1P cells to hypoxic conditions results in reversible cell cycle arrest concomitant with accumulation of pRB in the hypophosphorylated, growth suppressive form. Similar to cell cycle arrest induced by serum starvation, we show here that hypoxia-induced arrest is accompanied by a decrease in pRB-directed CDK4 and CDK2 activities, lower cyclin D and E protein levels, and by an increase in p27 protein abundance. Immunoprecipitation studies reveal an increase in p27 association with cyclin E-CDK2 complexes. In contrast to cell cycle arrest induced by serum starvation, hypoxia increases PP1-mediated pRB dephosphorylation. These data reveal that synergy between decreased pRB-directed cyclin/CDK activity and increased pRB-directed phosphatase activity contribute towards inducing and maintaining pRB in its hypophosphorylated, growth suppressive state during hypoxia.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Ludlow, JW (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA.				NCI NIH HHS [T32 CA09363, CA56940, CA11198] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198, R29CA056940, T32CA009363] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; Amellem O, 1996, EXP CELL RES, V227, P106, DOI 10.1006/excr.1996.0255; AMELLEM O, 1991, CELL PROLIFERAT, V24, P127, DOI 10.1111/j.1365-2184.1991.tb01144.x; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COHEN P, 1988, METHOD ENZYMOL, V159, P390; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Geng Y, 1996, ONCOGENE, V12, P1173; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; HALL M, 1995, ONCOGENE, V11, P1581; HARPER JW, 1993, CELL, V75, P805; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HEACOCK CS, 1990, BRIT J CANCER, V62, P217, DOI 10.1038/bjc.1990.264; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Krtolica A, 1996, CANCER RES, V56, P1168; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDLOW JW, 1993, ONCOGENE, V8, P331; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; Nelson DA, 1997, ONCOGENE, V14, P2407, DOI 10.1038/sj.onc.1201081; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; NEVINS JR, 1992, SCIENCE, V258, P424; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; VILLAMORUZZI E, 1992, FEBS LETT, V304, P211, DOI 10.1016/0014-5793(92)80621-M; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	49	69	71	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2295	2304		10.1038/sj.onc.1202159	http://dx.doi.org/10.1038/sj.onc.1202159			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811460				2022-12-28	WOS:000076723300003
J	Abdel-Rahman, WM; Georgiades, IB; Curtis, LJ; Arends, MJ; Wyllie, AH				Abdel-Rahman, WM; Georgiades, IB; Curtis, LJ; Arends, MJ; Wyllie, AH			Role of BAX mutations in mismatch repair-deficient colorectal carcinogenesis	ONCOGENE			English	Article						BAX; colorectal cancer; RER; mismatch repair	TUMOR-SUPPRESSOR P53; TGF-BETA RECEPTOR; MICROSATELLITE INSTABILITY; COLON-CANCER; IN-VIVO; GENE; BCL-2; PROGRESSION; CARCINOMAS; PHENOTYPE	BAX gene mutations occur in approximately 50% of RER+ colorectal cancers. To determine the role of these mutations in tumour progression we analysed multiple different tumour sites from RER+ colorectal cancers for BAX mutations. Sixty colorectal carcinomas were analysed for microsatellite instability at loci BAT-26, L-myc, TGF beta RII, D13S160 and D2S123. Twelve out of 60 tumours (20%) were RER+, Forty-five different tumour sites from the 12 RER+ carcinomas were analysed for BAX mutations at the [(G)8] tract in exon 3, Six out of 12 (50%) RER+ tumours showed BAX mutations, four of which showed a homogenous pattern of such mutations detected in all tumour sites. In the other two cases, BAX mutations were present in some but not all tumour sites sampled from the same patient. In contrast, TGF beta RII mutations were found in 9/12 cases (75%) and in each of these were present in all the sampled sites. Two cases showed neither BAX nor TGF beta RII mutation. These data suggest that mutations in TGF beta RII may occur at a very early stage in tumour progression, perhaps in the founder clone. BAX mutations, however, are clearly not necessary for formation of the founder clone and can occur for the first time later in tumour progression.	Univ Edinburgh, Western Gen Hosp, Mol Med Ctr, Sir Alastair Currie CRC Labs, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Wyllie, AH (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.			Abdel-Rahman, Wael/0000-0002-2149-1043				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Brown R, 1997, BRIT MED BULL, V53, P466; Bubb VJ, 1996, ONCOGENE, V12, P2641; Chung YJ, 1997, ONCOGENE, V15, P1719, DOI 10.1038/sj.onc.1201343; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; Hoang JM, 1997, CANCER RES, V57, P300; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; JACOBY RF, 1995, GASTROENTEROLOGY, V109, P73, DOI 10.1016/0016-5085(95)90270-8; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ouyang H, 1998, CLIN CANCER RES, V4, P1071; PARSONS R, 1995, CANCER RES, V55, P5548; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Samowitz WS, 1997, AM J PATHOL, V151, P33; THIBODEAU SN, 1993, AM J HUM GENET, V53, P1; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yagi OK, 1998, GASTROENTEROLOGY, V114, P268, DOI 10.1016/S0016-5085(98)70477-9; Yamamoto H, 1998, CANCER RES, V58, P997; YOUNG J, 1995, GENE CHROMOSOME CANC, V12, P251, DOI 10.1002/gcc.2870120403; Zhou XP, 1998, GENE CHROMOSOME CANC, V21, P101, DOI 10.1002/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4	24	32	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2139	2142		10.1038/sj.onc.1202589	http://dx.doi.org/10.1038/sj.onc.1202589			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321738				2022-12-28	WOS:000079346200011
J	Florenes, VA; Lu, C; Bhattacharya, N; Rak, J; Sheehan, C; Slingerland, JM; Kerbel, RS				Florenes, VA; Lu, C; Bhattacharya, N; Rak, J; Sheehan, C; Slingerland, JM; Kerbel, RS			Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21(WAF1/CIP1) is lost during progression of human malignant melanoma	ONCOGENE			English	Article						melanoma; IL-6; sensitivity; p21(WAF1/CIP1); p27(Kip1); STAT	GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR GENE; CARCINOMA CELL-LINES; TGF-BETA; MAMMALIAN-CELLS; BREAST-CANCER; POTENTIAL MEDIATOR; EPITHELIAL-CELLS; CDK INHIBITORS; IL-6 FUNCTIONS	Human melanoma cell lines derived from early stage primary tumors are particularly sensitive to growth arrest induced by interleukin-6 (IL-6), This response is lost in cell lines derived from advanced lesions, a phenomenon which may contribute to tumor aggressiveness. We sought to determine whether resistance to growth inhibition by IL-6 can be explained by oncogenic alterations in cell cycle regulators or relevant components of intracellular signaling, Our results show that IL-6 treatment of early stage melanoma cell lines caused G(1) arrest, which could not be explained by changes in levels of G1 cyclins (D1, E), cdks (cdk4, cdk2) or by loss of cyclin/cdk complex formation. Instead, IL-6 caused a marked induction of the cdk inhibitor p21(WAF1/CIP1) in three different IL-6 sensitive cell lines, two of which also showed a marked accumulation of the cdk inhibitor p27(Kip1). In contrast, IL-6 failed to induce p21(WAF1/CIP1) transcript and did not increase p21(WAF1/CIP1) Or p27(Kip1) proteins in any of the resistant lines, In fact, of five IL-6 resistant cell lines, only two expressed detectable levels of p21(WAF1/CIP1) mRNA and protein, while in three other lines, p21(WAF1/CIP1) was undetectable. IL-6 dependent upregulation of p21(WAF1/CIP1) was associated with binding of both STAT3 and STAT1 to the p21(WAF1/CIP1) promoter. Surprisingly, however, IL-6 stimulated STAT binding to this promoter in both sensitive and resistant cell lines (with one exception), suggesting that gross deregulation of this event is not the unifying cause of the defect in p21(WAF1/CIP1) induction in IL-6 resistant cells, In somatic cell hybrids of IL-6 sensitive and resistant cell lines, the resistant phenotype was dominant and IL-6 failed to induce p21(WAF1/CIP1), Thus, our results suggest that in early stage human melanoma cells, IL-6 induced growth inhibition involves induction of p21(WAF1/CIP1) which is lost in the course of tumor progression presumably as a result of a dominant oncogenic event.	Univ Toronto, Dept Med Biophys, Toronto, ON M4N 3M5, Canada; Sunnybrook Hlth Sci Ctr, Div Canc Biol Res, Toronto, ON M4N 3M5, Canada; Toronto Sunnybrook Reg Canc Ctr, Div Med Oncol, Toronto, ON M4N 3M5, Canada	University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Kerbel, RS (corresponding author), Univ Toronto, Dept Med Biophys, 2075 Bayview Ave,S-218, Toronto, ON M4N 3M5, Canada.				NCI NIH HHS [CA 41223] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARNHILL RL, 1993, AM J PATHOL, V143, P99; BORSELLINO N, 1995, CANCER RES, V55, P4633; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chiu JJ, 1996, CLIN CANCER RES, V2, P215; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORNIL I, 1991, P NATL ACAD SCI USA, V88, P6028, DOI 10.1073/pnas.88.14.6028; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EUSTACE D, 1993, GYNECOL ONCOL, V50, P15, DOI 10.1006/gyno.1993.1156; Florenes VA, 1996, ONCOGENE, V13, P2447; Florenes VA, 1998, AM J PATHOL, V153, P305, DOI 10.1016/S0002-9440(10)65572-1; Flores JF, 1996, CANCER RES, V56, P5023; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HIRAMA T, 1995, BLOOD, V86, P841; ISHIKAWA M, 1988, CANCER RES, V48, P665; ISHIKAWA M, 1988, CANCER RES, V48, P4897; JENNINGS MT, 1991, INT J CANCER, V49, P129, DOI 10.1002/ijc.2910490124; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG HP, 1995, ONCOGENE, V10, P1855; Kamb A, 1994, Nat Genet, V8, P23; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LU C, 1992, P NATL ACAD SCI USA, V89, P9215, DOI 10.1073/pnas.89.19.9215; LU C, 1993, J CELL BIOL, V120, P1281, DOI 10.1083/jcb.120.5.1281; MacDougall John R., 1993, Molecular and Cellular Differentiation, V1, P21; MACDOUGALL JR, 1995, CANCER RES, V55, P4174; Maelandsmo GM, 1996, AM J PATHOL, V149, P1813; Maelandsmo GM, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.181; Martin-Castellanos C, 1997, TRENDS CELL BIOL, V7, P95, DOI 10.1016/S0962-8924(96)10055-6; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MIKI S, 1989, FEBS LETT, V250, P607, DOI 10.1016/0014-5793(89)80805-1; MITZUTANI Y, 1995, CANCER RES, V55, P590; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Oh JW, 1997, ONCOGENE, V15, P569, DOI 10.1038/sj.onc.1201213; Okamoto M, 1997, CANCER RES, V57, P141; OTSUKI T, 1995, CANCER RES, V55, P1436; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Rak J, 1996, EUR J CANCER, V32A, P2438, DOI 10.1016/S0959-8049(96)00396-6; REED JA, 1995, CANCER RES, V55, P2713; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SHAO ZM, 1995, ONCOGENE, V11, P493; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SWOPE VB, 1991, J INVEST DERMATOL, V96, P180, DOI 10.1111/1523-1747.ep12460991; TAM SW, 1994, ONCOGENE, V9, P2663; VIDAL MJ, 1995, MELANOMA RES, V5, P243, DOI 10.1097/00008390-199508000-00006; Welch DR, 1996, MOL CELL DIFFER, V4, P91; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHANG XG, 1989, BLOOD, V74, P11	73	72	72	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1023	1032		10.1038/sj.onc.1202382	http://dx.doi.org/10.1038/sj.onc.1202382			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023678				2022-12-28	WOS:000078510600019
J	Levenberg, S; Yarden, A; Kam, Z; Geiger, B				Levenberg, S; Yarden, A; Kam, Z; Geiger, B			p27 is involved in N-cadherin-mediated contact inhibition of cell growth and S-phase entry	ONCOGENE			English	Article						cell adhesion; cadherin; cell growth; cell cycle; p27	DEPENDENT KINASE INHIBITOR; BETA-CATENIN; P27(KIP1); CYCLE; DROSOPHILA; ADHESION; PATHWAY; ARREST	In this study the direct involvement of cadherins in adhesion-mediated growth inhibition was investigated. It is shown here that overexpression of N-cadherin in CHO cells significantly suppresses their growth rate. Interaction of these cells and two additional fibroblastic lines with synthetic beads coated with N-cadherin ligands (recombinant N-cadherin ectodomain or specific antibodies) leads to growth arrest at the G1 phase of the cell cycle. The cadherin-reactive beads inhibit the entry into S phase and the reduction in the levels of cyclin-dependent kinase (cdk) inhibitors p21 and p27, following serum-stimulation of starved cells. In exponentially growing cells these beads induce G1 arrest accompanied by elevation in p27 only. We propose that cadherin-mediated signaling is involved in contact inhibition of growth by inducing cell cycle arrest at the G1 phase and elevation of p27 levels.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Geiger, B (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.			Levenberg, Shulamit/0000-0001-5471-7339				BECKER KF, 1994, CANCER RES, V54, P3845; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Deleu L, 1998, MOL CELL BIOL, V18, P409, DOI 10.1128/MCB.18.1.409; Dietrich C, 1997, ONCOGENE, V15, P2743, DOI 10.1038/sj.onc.1201439; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HOLLEY RW, 1975, NATURE, V258, P487, DOI 10.1038/258487a0; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Huttenlocher A, 1998, J CELL BIOL, V141, P515, DOI 10.1083/jcb.141.2.515; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; KAM Z, 1993, BIOIMAGING, V1, P71; Kandikonda S, 1996, CELL ADHES COMMUN, V4, P13, DOI 10.3109/15419069609010760; Kato A, 1997, J BIOL CHEM, V272, P8065, DOI 10.1074/jbc.272.12.8065; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Levenberg S, 1998, J CELL SCI, V111, P347; LEVENBERG S, 1998, IN PRESS CELL ADHE C; MILLARD S, 1997, J BIOL CHEM, V272, P7039; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VOLK T, 1986, J CELL BIOL, V103, P1451, DOI 10.1083/jcb.103.4.1451; WEISER RJ, 1986, J CELL BIOL, V103, P361; WEISER RJ, 1985, EXP CELL RES, V158, P493	30	141	147	1	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					869	876		10.1038/sj.onc.1202396	http://dx.doi.org/10.1038/sj.onc.1202396			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023662				2022-12-28	WOS:000078510600003
J	Basu, S; Kolesnick, R				Basu, S; Kolesnick, R			Stress signals for apoptosis: ceramide and c-Jun kinase	ONCOGENE			English	Article						apoptosis; stress; JNK; ceramide	N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASE; RADIATION-INDUCED APOPTOSIS; CELL-DEATH; MEDIATED ACTIVATION; GAMMA-RADIATION; BINDING PROTEIN; KAPPA-B; SPHINGOMYELINASE; PATHWAY	Mammalian systems respond to environmental stress by either adapting or undergoing programmed cell death. While there is general agreement that the caspase family of proteases serve as the effecters of the apoptotic death response, the signaling apparatus involved in the decision to activate the caspase system is less clear. In the past few years, the sphingomyelin and c-Jun Kinase (JNK)/Stress-activated Protein Kinase (SAPK) pathways have been linked to the death response in many cellular systems. These signaling systems are found throughout the animal kingdom, and ceramide signaling is conserved through yeast. Since yeast do not undergo apoptosis, the sphingomyelin pathway appears evolutionarily older than the caspase-mediated death programs. While recent reviews by several groups have broadly surveyed ceramide signaling in apoptosis, this paper examines the role of sphingomyelinases and the JNK/SAPK pathway in coordinate signaling of apoptosis.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Lab Signal Transduct, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Kolesnick, R (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Lab Signal Transduct, 1275 York Ave, New York, NY 10021 USA.				NCI NIH HHS [CA 42385] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen LJ, 1998, MOL IMMUNOL, V35, P195, DOI 10.1016/S0161-5890(98)00044-3; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Dobrowsky RT, 1998, ANN NY ACAD SCI, V845, P32, DOI 10.1111/j.1749-6632.1998.tb09660.x; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Garzotto M, 1998, CANCER RES, V58, P2260; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Goldkorn T, 1998, J CELL SCI, V111, P3209; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 1997, BIOCHEM SOC T, V25, P1171, DOI 10.1042/bst0251171; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Laethem RM, 1998, BLOOD, V91, P4350, DOI 10.1182/blood.V91.11.4350.411k27_4350_4360; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Merrill AH, 1996, ADV EXP MED BIOL, V392, P297; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Ruiz-Arguello MB, 1998, J BIOL CHEM, V273, P22977, DOI 10.1074/jbc.273.36.22977; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; SHIMENO H, 1995, BIOL PHARM BULL, V18, P1335; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wells GB, 1998, J BIOL CHEM, V273, P7235, DOI 10.1074/jbc.273.13.7235; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zha XH, 1998, J CELL BIOL, V140, P39, DOI 10.1083/jcb.140.1.39; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	75	183	192	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 24	1998	17	25					3277	3285		10.1038/sj.onc.1202570	http://dx.doi.org/10.1038/sj.onc.1202570			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916990				2022-12-28	WOS:000078048200009
J	Grana, X; Garriga, J; Mayol, X				Grana, X; Garriga, J; Mayol, X			Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth	ONCOGENE			English	Review						CDK; CKI; transcriptional regulation; cyclins; cell cycle	CYCLIN-DEPENDENT KINASE; LARGE-T-ANTIGEN; E2F TRANSCRIPTION FACTOR; RNA-POLYMERASE-III; S-PHASE ENTRY; SKELETAL-MUSCLE CELLS; LOOP-HELIX REGULATORS; A GENE-EXPRESSION; DNA-SYNTHESIS; BINDING-SITE	The retinoblastoma family of proteins, also known as pocket proteins, includes the product of the retinoblastoma susceptibility gene and the functionally and structurally related proteins p107 and p130, Pocket proteins control growth processes in many cell types, and this has been linked to the ability of pocket proteins to interact with a multitude of cellular proteins that regulate gene expression at various levels. By regulating gene expression, pocket proteins control cell cycle progression, cell cycle entry and exit, cell differentiation and apoptosis, This review will focus on the mechanisms of regulation of pocket proteins and how modulation of pocket protein levels and phosphorylation status regulate association with their cellular targets. The coordinated regulation of pocket proteins provides the cells with a competence mechanism for passage through certain cell growth and differentiation transitions.	Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Dept Biochem, Sch Med, Philadelphia, PA 19140 USA; Inst Municipal Invest Med, Unitat Biol Cellular & Mol, E-08003 Barcelona, Spain	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Grana, X (corresponding author), Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, AHP Bldg,Room 553,3307 N Broad St, Philadelphia, PA 19140 USA.		Mayol, Xavier/C-1391-2012	Grana, Xavier/0000-0001-7134-0473; Mayol, Xavier/0000-0001-7288-195X	NIGMS NIH HHS [GM54894] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054894] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; Adams PD, 1996, MOL CELL BIOL, V16, P6623; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Belbrahem A, 1996, EXP CELL RES, V225, P286, DOI 10.1006/excr.1996.0178; Botz J, 1996, MOL CELL BIOL, V16, P3401; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Chang KH, 1997, P NATL ACAD SCI USA, V94, P9040, DOI 10.1073/pnas.94.17.9040; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; Choubey D, 1997, ONCOGENE, V15, P291, DOI 10.1038/sj.onc.1201184; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; CHRISTENSEN JB, 1995, J VIROL, V69, P3945, DOI 10.1128/JVI.69.6.3945-3948.1995; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; CORBEIL HB, 1995, ONCOGENE, V11, P909; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; DYNLACHT BD, 1995, NATURE, V374, P114, DOI 10.1038/374114a0; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Geng Y, 1996, ONCOGENE, V12, P1173; GRANA X, 1995, ONCOGENE, V11, P211; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Guo K, 1997, J BIOL CHEM, V272, P791, DOI 10.1074/jbc.272.2.791; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hauser PJ, 1997, J BIOL CHEM, V272, P22954, DOI 10.1074/jbc.272.36.22954; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; HORTON LE, 1995, CELL GROWTH DIFFER, V6, P395; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HU NP, 1994, ONCOGENE, V9, P1021; Huet X, 1996, MOL CELL BIOL, V16, P3789; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG HP, 1995, ONCOGENE, V11, P1179; Johnson David G., 1998, Frontiers in Bioscience, V3, pD447; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOHNSON L F, 1992, Current Opinion in Cell Biology, V4, P149, DOI 10.1016/0955-0674(92)90025-8; Kastner A, 1998, CELL GROWTH DIFFER, V9, P857; KATO J, 1993, GENE DEV, V7, P331; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1998, ONCOGENE, V16, P1655, DOI 10.1038/sj.onc.1201682; Kobayashi M, 1998, EXP CELL RES, V239, P40, DOI 10.1006/excr.1997.3880; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KRANENBURG O, 1995, ONCOGENE, V10, P87; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; Lavender P, 1997, ONCOGENE, V14, P2721, DOI 10.1038/sj.onc.1201243; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MAYOL X, 1993, ONCOGENE, V8, P2561; Mayol X, 1996, ONCOGENE, V13, P237; Mayol X, 1997, Prog Cell Cycle Res, V3, P157; MAYOL X, 1995, ONCOGENE, V11, P801; MAYOL X, 1998, FRONT BIOSCI, V3, P11; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Mulligan GJ, 1998, MOL CELL BIOL, V18, P206, DOI 10.1128/MCB.18.1.206; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Oswald F, 1996, MOL CELL BIOL, V16, P1889; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; Philips A, 1998, ONCOGENE, V16, P1373, DOI 10.1038/sj.onc.1201655; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Puri PL, 1998, CANCER RES, V58, P1325; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rampalli AM, 1998, ONCOGENE, V16, P399, DOI 10.1038/sj.onc.1201546; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; Rawls A, 1997, CELL, V89, P5, DOI 10.1016/S0092-8674(00)80175-0; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; Riley DJ, 1997, MOL CELL BIOL, V17, P7342, DOI 10.1128/MCB.17.12.7342; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Schulze A, 1998, J VIROL, V72, P2323, DOI 10.1128/JVI.72.3.2323-2334.1998; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Shih HH, 1998, MOL CELL BIOL, V18, P4732, DOI 10.1128/MCB.18.8.4732; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; SUZUKITAKAHASHI I, 1995, ONCOGENE, V10, P1691; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAM SW, 1994, ONCOGENE, V9, P2663; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; Wang J, 1996, J CELL BIOCHEM, V62, P405; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; White RJ, 1997, TRENDS BIOCHEM SCI, V22, P77, DOI 10.1016/S0968-0004(96)10067-0; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Yee Amy S., 1998, Frontiers in Bioscience, V3, pD532; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zarkowska T, 1997, ONCOGENE, V14, P249, DOI 10.1038/sj.onc.1200824; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZHU LG, 1995, MOL CELL BIOL, V15, P3552; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	193	272	274	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 24	1998	17	25					3365	3383		10.1038/sj.onc.1202575	http://dx.doi.org/10.1038/sj.onc.1202575			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916999				2022-12-28	WOS:000078048200018
J	Chappuis-Flament, S; Pasini, A; De Vita, G; Segouffin-Cariou, C; Fusco, A; Attie, T; Lenoir, GM; Santoro, M; Billaud, M				Chappuis-Flament, S; Pasini, A; De Vita, G; Segouffin-Cariou, C; Fusco, A; Attie, T; Lenoir, GM; Santoro, M; Billaud, M			Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines	ONCOGENE			English	Article						MEN 2; Hirschsprung disease; RET receptor; tyrosine kinase	MEDULLARY-THYROID CARCINOMA; ENDOCRINE NEOPLASIA TYPE-2; TYROSINE KINASE DOMAIN; HIRSCHSPRUNGS-DISEASE; PROTOONCOGENE MUTATIONS; POINT MUTATION; BIOLOGICAL PROPERTIES; GERMLINE MUTATION; RESPONSE GENES; PHENOTYPE	The RET gene encodes a receptor tyrosine kinase whose function is essential during the development of kidney and the intestinal nervous system, Germline mutations affecting one of five cysteines (Cys609, 611, 618, 620 and 634) located in the juxtamembrane domain of the RET receptor are responsible for the vast majority of two cancer-prone disorders, multiple endocrine neoplasia type 2A (MEN 2A) and familial medullary thyroid carcinoma (FMTC). These mutations lead to the replacement of a cysteine by an alternate amino acid, Mutations of the RET gene are also the underlying genetic cause of Hirschsprung disease (HSCR), a congenital aganglionosis of the hindgut, In a fraction of kindreds, MEN 2A cosegregate with HSCR and affected individuals carry a single mutation at codons 609, 618 or 620, To examine the consequences of cysteine substitution on RET function, we have introduced a Cys to Arg mutation into the wild-type RET at either codons 609, 618, 620, 630 or 634, We now report that each mutation induces a constitutive catalytic activity due to the aberrant disulfide homodimerization of RET, However, mutations 630 and 634 activate RET more strongly than mutations 609, 618 or 620 as demonstrated by quantitative assays in rodent fibroblasts and pheochromocytoma PC12 cells, Biochemical analysis revealed that mutations 618 and 620, and to a lesser extent mutation 609, result in a marked reduction of the level of RET at the cell surface and as a consequence decrease the amount of RET covalent dimer, These findings provide a molecular basis explaining the range of phenotype engendered by alterations of RET cysteines and suggest a novel mechanism whereby mutations of cysteines 609, 618 and 620 exert both activating and inactivating effects.	CNRS UMR 5641, Genet Lab, F-69373 Lyon 08, France; Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Reggio Calabria, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Hop Necker Enfants Malad, Unite Rech Handicaps Genet Enfant, INSERM U393, F-75743 Paris, France; Hop Necker Enfants Malad, Dept Genet, F-75743 Paris, France	Centre National de la Recherche Scientifique (CNRS); University of Naples Federico II; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Billaud, M (corresponding author), CNRS UMR 5641, Genet Lab, 8 Ave Rockefeller, F-69373 Lyon 08, France.		Billaud, Marc N/M-6954-2013; ATTIE-BITACH, Tania/K-1453-2017; De Vita, Gabriella/H-4422-2011	ATTIE-BITACH, Tania/0000-0002-1155-3626; De Vita, Gabriella/0000-0002-7302-1174; Fusco, Alfredo/0000-0003-3332-5197				ANGRIST M, 1995, HUM MOL GENET, V4, P821, DOI 10.1093/hmg/4.5.821; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Berndt I, 1998, J CLIN ENDOCR METAB, V83, P770, DOI 10.1210/jc.83.3.770; Blank RD, 1996, CANCER, V78, P1996, DOI 10.1002/(SICI)1097-0142(19961101)78:9<1996::AID-CNCR22>3.3.CO;2-5; BOLINO A, 1995, ONCOGENE, V10, P2415; BORST MJ, 1995, SURGERY, V117, P386, DOI 10.1016/S0039-6060(05)80057-1; Bugalho MJ, 1997, EUR J ENDOCRINOL, V136, P423, DOI 10.1530/eje.0.1360423; CALIFANO D, 1995, ONCOGENE, V11, P107; Carlomagno F, 1997, CANCER RES, V57, P391; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Caron P, 1996, J CLIN ENDOCR METAB, V81, P2731, DOI 10.1210/jc.81.7.2731; Chakravarti A, 1996, HUM MOL GENET, V5, P303; Decker RA, 1998, HUM MOL GENET, V7, P129, DOI 10.1093/hmg/7.1.129; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; Fink M, 1996, INT J CANCER, V69, P312, DOI 10.1002/(SICI)1097-0215(19960822)69:4<312::AID-IJC13>3.0.CO;2-7; FrankRaue K, 1996, J CLIN ENDOCR METAB, V81, P1780, DOI 10.1210/jc.81.5.1780; Gershon MD, 1997, CURR OPIN NEUROBIOL, V7, P101, DOI 10.1016/S0959-4388(97)80127-4; GOODFELLOW PJ, 1995, J NATL CANCER I, V87, P1515, DOI 10.1093/jnci/87.20.1515; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hofstra RMW, 1997, J CLIN ENDOCR METAB, V82, P4176, DOI 10.1210/jc.82.12.4176; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; Isidoro C, 1996, J BIOL CHEM, V271, P26138, DOI 10.1074/jbc.271.42.26138; Ito S, 1997, CANCER RES, V57, P2870; Iwashita T, 1996, HUM MOL GENET, V5, P1577, DOI 10.1093/hmg/5.10.1577; JANSSENTIMMEN U, 1989, GENE, V80, P325, DOI 10.1016/0378-1119(89)90296-5; Kitamura Y, 1997, ONCOGENE, V14, P3103, DOI 10.1038/sj.onc.1201102; KOMMINOTH P, 1995, CANCER, V76, P479; Lindsay RM, 1996, NEURON, V17, P571, DOI 10.1016/S0896-6273(00)80189-0; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; Moers AMJ, 1996, AM J MED, V101, P635, DOI 10.1016/S0002-9343(96)00330-0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, HUM MOL GENET, V3, P2163, DOI 10.1093/hmg/3.12.2163; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; MULLIGAN LM, 1995, J CLIN ENDOCR METAB, V80, P1989, DOI 10.1210/jc.80.7.1989; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pelet A, 1998, J CLIN INVEST, V101, P1415, DOI 10.1172/JCI375; POSSENTI R, 1992, P NATL ACAD SCI USA, V89, P3815, DOI 10.1073/pnas.89.9.3815; Reynolds Lucinda F., 1995, Current Opinion in Pediatrics, V7, P702; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROSSEL M, 1995, HUM GENET, V95, P403; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUFFENECKER I, 1994, HUM MOL GENET, V3, P1939, DOI 10.1093/hmg/3.11.1939; Smith DP, 1997, ONCOGENE, V15, P1213, DOI 10.1038/sj.onc.1201481; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TANIGUCHI M, 1991, BIOCHEM BIOPH RES CO, V181, P416, DOI 10.1016/S0006-291X(05)81435-4; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; Wada M, 1996, BIOCHEM BIOPH RES CO, V218, P606, DOI 10.1006/bbrc.1996.0107	61	86	87	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	1998	17	22					2851	2861		10.1038/sj.onc.1202202	http://dx.doi.org/10.1038/sj.onc.1202202			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879991				2022-12-28	WOS:000077286400005
J	Berg, KL; Carlberg, K; Rohrschneider, LR; Siminovitch, KA; Stanley, ER				Berg, KL; Carlberg, K; Rohrschneider, LR; Siminovitch, KA; Stanley, ER			The major SHP-1-binding, tyrosine-phosphorylated protein in macrophages is a member of the KIR/LIR family and an SHP-1 substrate	ONCOGENE			English	Article						macrophage; SHP-1; KIR; LIR-1; PIR-B; PTP	CELL INHIBITORY RECEPTORS; MOTH-EATEN MICE; B-CELLS; PHOSPHATASE; STIMULATION; EXPRESSION; GROWTH; PTP1C	The SH2 domain-containing cytoplasmic protein tyrosine phosphatase, SHP-1, negatively regulates hematopoietic cell signaling, SHP-1 is associated with a tyrosine phosphorylated, plasma membrane-spanning glycoprotein, pp130, in colony stimulating factor-1 stimulated or unstimulated macrophages, This association is phosphotyrosine dependent and is mediated by the amino-terminal SH2 domain of SHP-1, pp130 behaves as a substrate of SHP-1 in vitro and is hyperphosphorylated on tyrosine in SHP-1 deficient macrophages from viable-motheaten mice. Co-immunoprecipitation data indicate that pp130 is the product of the mouse p91/PIR-B gene that encodes a member of the killer cell inhibitory receptor (KIR)/leukocyte immunoglobulin-like receptor (LIR) family. By analogy to the KIRs, p91/PIR-B may represent a novel class of macrophage receptors which act to suppress macrophage activation. These observations identify SHP-1 interactions with and regulation of p91/PIR-B as a potential mechanism for inhibiting the signaling cascades linking extracellular stimuli to macrophage activation and/or development.	Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Immunol, Toronto, ON, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Yeshiva University; Albert Einstein College of Medicine; Fred Hutchinson Cancer Center; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Stanley, ER (corresponding author), Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA.		Siminovitch, Katherine/K-1475-2013; Stanley, Evan R/J-9154-2013	Stanley, Evan R/0000-0002-2910-2065	NATIONAL CANCER INSTITUTE [T32CA009173, R37CA026504, R01CA026504] Funding Source: NIH RePORTER; NCI NIH HHS [CA 26504, 5 T32 CA09173] Funding Source: Medline; PHS HHS [P30-13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BIGNON JS, 1994, CLIN IMMUNOL IMMUNOP, V73, P168, DOI 10.1006/clin.1994.1185; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; BUSCHER D, 1993, ONCOGENE, V8, P3323; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Cosman D, 1997, IMMUNITY, V7, P273, DOI 10.1016/S1074-7613(00)80529-4; Hayami K, 1997, J BIOL CHEM, V272, P7320, DOI 10.1074/jbc.272.11.7320; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HUBBARD AL, 1975, J CELL BIOL, V64, P438, DOI 10.1083/jcb.64.2.438; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KOO GC, 1993, J IMMUNOL, V151, P6733; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; Kubagawa H, 1997, P NATL ACAD SCI USA, V94, P5261, DOI 10.1073/pnas.94.10.5261; Kuroiwa A, 1998, J BIOL CHEM, V273, P1070, DOI 10.1074/jbc.273.2.1070; LI W, 1991, J BIOL CHEM, V266, P6808; Meyaard L, 1997, IMMUNITY, V7, P283, DOI 10.1016/S1074-7613(00)80530-0; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; Siminovitch KA, 1998, SEMIN IMMUNOL, V10, P329, DOI 10.1006/smim.1998.0125; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; STANLEY ER, 1994, CYTOKINE HDB, P387; STANLEY ER, 1990, METHOD MOL BIOL, P299; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; Wagtmann N, 1997, CURR BIOL, V7, P615, DOI 10.1016/S0960-9822(06)00263-6; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; Yokoyama WM, 1997, J EXP MED, V186, P1803, DOI 10.1084/jem.186.11.1803; Yu CCK, 1996, J EXP MED, V183, P371, DOI 10.1084/jem.183.2.371	28	32	36	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2535	2541		10.1038/sj.onc.1202203	http://dx.doi.org/10.1038/sj.onc.1202203			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824165				2022-12-28	WOS:000076927300014
J	Genot, E; Reif, K; Beach, S; Kramer, I; Cantrell, D				Genot, E; Reif, K; Beach, S; Kramer, I; Cantrell, D			P21ras initiates Rac-1 but not phosphatidyl inositol 3 kinase PKB, mediated signaling pathways in T lymphocytes	ONCOGENE			English	Article						p21ras; Akt/PKB; signalling pathways; T cells	CELL ANTIGEN RECEPTOR; RAS EFFECTOR PATHWAYS; PHOSPHOINOSITIDE 3-KINASE; NEGATIVE SELECTION; REGULATED KINASE-2; PROTEIN-KINASE; ACTIVATION; DIFFERENTIATION; TRANSFORMATION; P21(RAS)	p21ras is activated by the T cell antigen receptor (TCR) and then co-ordinates important signaling pathways for T lymphocyte activation. Effector pathways for this guanine nucleotide binding protein in T cells are mediated by the serine/threonine kinase Raf-l and the Ras-related GTPase Rac-1. In fibroblasts, an important effector for the Ras oncogene is Phosphatidylinositol 3-kinase (PtdIns 3-kinase). Activation of this lipid kinase is able to induce critical Rac-1 signaling pathways and can couple p21ras to cell survival mechanisms via the serine/threonine kinase Akt/PKB, The role of PtdIns 3-kinase in Ras signaling in T cells has not been explored. In the present study, we examined the ability of PtdIns 3-kinase to initiate the Rac-1 signaling pathways important for T cell activation. We also examined the possibility that Akt/PKB is regulated by Ras signaling pathways in T lymphocytes. The results show that Ras can initiate a Rac-1 mediated pathway that regulates the transcriptional function of AP-1 complexes. PtdIns 3-kinase signals cannot mimic p21ras and induce the Rac mediated responses of AP-1 transcriptional activation. Moreover, neither TCR or Ras activation of AP-I is dependent on PtdIns 3-kinase. PKB is activated in response to triggering of the T cell antigen receptor; PtdIns 3-kinase activity is both required and sufficient for this TCR response. In contrast, p21ras signals are unable to induce Akt/PKB activity in T cell nor is Ras function required for Akt/PKB activation in response to the TCR. The present data thus highlight that PtdIns 3-kinase and Akt/PKB are not universal Ras effector molecules. Ras can initiate Rac-1 regulated signaling pathways in the context of T cell antigen receptor function independently of PtdIns 3-kinase activity.	Imperial Canc Res Fund, Lymphocyte Activat Lab, London WC2A 3PX, England; Univ London Univ Coll, Dept Pharmacol, London WC1E 6BT, England	Cancer Research UK; University of London; University College London	Genot, E (corresponding author), Hammersmith Hosp, Imperial Coll, Dept Immunol, Du Cane Rd, London W12 0NN, England.		Genot, Elisabeth/G-8031-2014; Reif, Karin/AAD-4692-2020	Reif, Karin/0000-0001-5490-8389				AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; Crompton T, 1996, CELL, V86, P243, DOI 10.1016/S0092-8674(00)80096-3; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; IZQUIERDO M, 1994, J EXP MED, V180, P401, DOI 10.1084/jem.180.1.401; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RODRIGUEZVICIAN.P, 1997, CELL, V89; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; Swat W, 1996, P NATL ACAD SCI USA, V93, P4683, DOI 10.1073/pnas.93.10.4683; Turner H, 1997, J EXP MED, V185, P43, DOI 10.1084/jem.185.1.43; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; YAN MH, 1994, NATURE, V372, P798	30	37	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	1998	17	13					1731	1738		10.1038/sj.onc.1202101	http://dx.doi.org/10.1038/sj.onc.1202101			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796702				2022-12-28	WOS:000076200100011
J	Kim, SK; Ro, JY; Kemp, BL; Lee, JS; Kwon, TJ; Hong, WK; Mao, L				Kim, SK; Ro, JY; Kemp, BL; Lee, JS; Kwon, TJ; Hong, WK; Mao, L			Identification of two distinct tumor-suppressor loci on the long arm of chromosome 10 in small cell lung cancer	ONCOGENE			English	Article						SCLC chromosome 10; LOH; tumor suppressor	PROSTATE-CANCER; HOMOZYGOUS DELETION; HUMAN GLIOBLASTOMAS; HUMAN GLIOMAS; GENE; HETEROZYGOSITY; CARCINOMA; PROTEIN; MXI1; LOCALIZATION	Recent cytogenetic studies indicated that loss of the long arm of chromosome 10 is a frequent event in small cell lung cancer (SCLC) and that a common region of the deletion is at 10q24-qter, which suggests the presence of a tumor-suppressor gene there. To map precise tumor-suppressor loci on the chromosome arm for further positional cloning efforts, we tested 46 primary SCLCs using microsatellite analysis, By analysing 11 highly polymorphic microsatellite markers located in 10q23-q26, we found that at least 78% (36/46) of the tumors exhibited loss of heterozygosity (LOH) at 10q with at least two distinct minimally deleted regions, LOH at one region (10q24) was found in at least 74% (32/43) of informative cases with a minimally deleted region between D10S198 and D10S192 (about 2 cM); LOH at another region (10q24-q25) was observed in at least 66% (29/44) of informative tumors with a minimally deleted region between D10S221 and D10S587 (about 11 cM), LOH at both regions or across both regions was observed in at least 52% (24/46) of the tumors tested, However, no mutations or homozygous deletions were found in the coding region of MXI1, a candidate tumor suppressor gene at 10q24-q25, in a panel of SCLC cell lines. Our data demonstrate that at least two tumor-suppressor loci exist on 10q and that they may play an important role in SCLC tumorigenesis.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mao, L (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358	NCI NIH HHS [CA 16672, CA 70907, U19 CA 68437] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA068437, P30CA016672, P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albarosa R, 1996, AM J HUM GENET, V58, P1260; AYER DE, 1993, CELL, V72, P1; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GARDNER E, 1991, GENOMICS, V11, P475, DOI 10.1016/0888-7543(91)90162-8; GRAY IC, 1995, CANCER RES, V55, P4800; HERBST RA, 1994, CANCER RES, V54, P3111; HOSOE S, 1994, CANCER RES, V54, P1787; Kim SK, 1997, CANCER RES, V57, P400; Kim SK, 1998, ONCOGENE, V16, P89, DOI 10.1038/sj.onc.1201512; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MERLO A, 1994, CANCER RES, V54, P2322; MILLER CW, 1992, CANCER RES, V52, P1695; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; MORI N, 1990, ONCOGENE, V5, P1713; MORITA R, 1991, CANCER RES, V51, P5817; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PEIFFER SL, 1995, CANCER RES, V55, P1922; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; RASHEED BKA, 1995, ONCOGENE, V10, P2243; REMPEL SA, 1993, CANCER RES, V53, P2386; RIED T, 1994, CANCER RES, V54, P1801; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SPEAKS SL, 1992, GENE CHROMOSOME CANC, V5, P239, DOI 10.1002/gcc.2870050311; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; WECHSLER DS, 1994, GENOMICS, V21, P669, DOI 10.1006/geno.1994.1336; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	33	45	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1749	1753		10.1038/sj.onc.1202073	http://dx.doi.org/10.1038/sj.onc.1202073			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796705				2022-12-28	WOS:000076200100014
